<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">1761</journal-id><journal-id journal-id-type="pmc-domain">tp</journal-id><journal-title-group><journal-title>Translational Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2158-3188</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501013</article-id><article-id pub-id-type="pmcid-ver">PMC12501013.1</article-id><article-id pub-id-type="pmcaid">12501013</article-id><article-id pub-id-type="pmcaiid">12501013</article-id><article-id pub-id-type="pmid">41052975</article-id><article-id pub-id-type="doi">10.1038/s41398-025-03561-7</article-id><article-id pub-id-type="publisher-id">3561</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Using blood methylomes to predict response to amisulpride in the first-episode psychosis in the OPTiMiSE cohort</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4579-6607</contrib-id><name name-style="western"><surname>Lokmer</surname><given-names initials="A">Ana</given-names></name><address><email>ana.lokmer@inserm.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Troudet</surname><given-names initials="R">R&#233;jane</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bacq-Daian</surname><given-names initials="D">Delphine</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boland-Auge</surname><given-names initials="A">Anne</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barau</surname><given-names initials="C">Caroline</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="IAu1"><collab>the OPTiMiSE study group<contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5473-3697</contrib-id><name name-style="western"><surname>Leboyer</surname><given-names initials="M">Marion</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4321-4100</contrib-id><name name-style="western"><surname>Jamain</surname><given-names initials="S">St&#233;phane</given-names></name><address><email>stephane.jamain@inserm.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib></contrib-group></collab></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deleuze</surname><given-names initials="JF">Jean-Fran&#231;ois</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5473-3697</contrib-id><name name-style="western"><surname>Leboyer</surname><given-names initials="M">Marion</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4321-4100</contrib-id><name name-style="western"><surname>Jamain</surname><given-names initials="S">St&#233;phane</given-names></name><address><email>stephane.jamain@inserm.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04qe59j94</institution-id><institution-id institution-id-type="GRID">grid.462410.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0386 3258</institution-id><institution>Univ Paris Est Cr&#233;teil, INSERM, IMRB, </institution><institution>Translational Neuropsychiatry, </institution></institution-wrap>Cr&#233;teil, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rrhf939</institution-id><institution-id institution-id-type="GRID">grid.484137.d</institution-id><institution>Fondation FondaMental, </institution></institution-wrap>Cr&#233;teil, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/004yvsb77</institution-id><institution-id institution-id-type="GRID">grid.418135.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0641 3404</institution-id><institution>Universit&#233; Paris-Saclay, CEA, </institution><institution>Centre National de Recherche en G&#233;nomique Humaine (CNRGH), </institution></institution-wrap>Evry, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033yb0967</institution-id><institution-id institution-id-type="GRID">grid.412116.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2292 1474</institution-id><institution>AP-HP, H&#244;pitaux Universitaires H. Mondor, </institution><institution>Plateforme de Ressources Biologiques, </institution></institution-wrap>Cr&#233;teil, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033yb0967</institution-id><institution-id institution-id-type="GRID">grid.412116.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2292 1474</institution-id><institution>AP-HP, H&#244;pitaux Universitaires H. Mondor, </institution><institution>DMU IMPACT, </institution></institution-wrap>Cr&#233;teil, France </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478532</issue-id><elocation-id>369</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41398_2025_Article_3561.pdf"/><abstract id="Abs1"><p id="Par1">Treatment of schizophrenia relies heavily on the use of antipsychotic drugs. Their efficacy is at present determined by lengthy trial-and-error approach, calling for more efficient strategies based on personalized medicine. Here, we present a prospective study of 116 first-episode-psychosis (FEP) patients from the OPTiMiSE cohort, aiming to identify blood epigenomic biomarkers predicting response to amisulpride and to shed light on involved mechanisms by linking the observed methylation patterns to genetic variation and gene expression. The analysis of 210 paired (baseline and follow-up) blood methylomes revealed 67 regions stably differentially methylated between good and bad responders and 197 regions with response-specific dynamics. The former were primarily enriched in functions related to neurotransmission and synapse assembly, the latter in immunity and inflammation. Baseline methylation values of three of these candidate regions, situated within <italic toggle="yes">HOXA, HTR2A</italic> and <italic toggle="yes">PRR5</italic> genes, were selected as good predictors (10x cross-validated Matthews correlation coefficient&#8201;=&#8201;0.81) of amisulpride response in our cohort. Screening for associations between the methylation of the selected regions and the genetic variants (SNPs) in a 1MBp surroundings revealed a high degree of genetic control for <italic toggle="yes">HTR2A</italic>, but not for <italic toggle="yes">HOXA</italic> or <italic toggle="yes">PRR5</italic> regions. Whereas we detected multiple correlations between methylation and gene expression, few were temporally stable, such as the correlation between <italic toggle="yes">HOXA5</italic> and <italic toggle="yes">SKAP2</italic> expression, a gene affecting susceptibility to schizophrenia. Our findings demonstrate the strengths of prospective design in response-biomarker research and suggest that epigenetic variation associated with antipsychotic response is shaped by both the environmental and genetic factors.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Personalized medicine</kwd><kwd>Predictive markers</kwd><kwd>Schizophrenia</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche (French National Research Agency)</institution></institution-wrap></funding-source><award-id>ANR-11-IDEX-0004-02</award-id><award-id>ANR-11-IDEX-0004-02</award-id><award-id>ANR-11-IDEX-0004-02</award-id><award-id>ANR-11-IDEX-0004-02</award-id><award-id>ANR-11-IDEX-0004-02</award-id><award-id>ANR-11-IDEX-0004-02</award-id><award-id>ANR-11-IDEX-0004-02</award-id><award-id>ANR-11-IDEX-0004-02</award-id><principal-award-recipient><name name-style="western"><surname>Lokmer</surname><given-names>Ana</given-names></name><name name-style="western"><surname>Troudet</surname><given-names>R&#233;jane</given-names></name><name name-style="western"><surname>Bacq-Daian</surname><given-names>Delphine</given-names></name><name name-style="western"><surname>Boland-Auge</surname><given-names>Anne</given-names></name><name name-style="western"><surname>Barau</surname><given-names>Caroline</given-names></name><name name-style="western"><surname>Deleuze</surname><given-names>Jean-Fran&#231;ois</given-names></name><name name-style="western"><surname>Leboyer</surname><given-names>Marion</given-names></name><name name-style="western"><surname>Jamain</surname><given-names>St&#233;phane</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Institut National pour la Sant&#233; et la Recherche M&#233;dicale (INSERM) Fondation Fondamental Commissariat a l'energie atomique et aux energies alternatives (CEA) Fondation pour la Recherche Medicale (FRM Espoirs de la Rechereche 2015, FDM20151234954) Paris School of Neurosciences (ENP) Bio-Psy Laboratory of Excellence</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000780</institution-id><institution>European Commission (EC)</institution></institution-wrap></funding-source><award-id>HEALTH-F2-2010-242114</award-id><award-id>HEALTH-F2-2010-242114</award-id><award-id>HEALTH-F2-2010-242114</award-id><principal-award-recipient><name name-style="western"><surname>Deleuze</surname><given-names>Jean-Fran&#231;ois</given-names></name><name name-style="western"><surname>Leboyer</surname><given-names>Marion</given-names></name><name name-style="western"><surname>Jamain</surname><given-names>St&#233;phane</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Schizophrenia (SCZ) affects only around 0.3% of the global population [<xref ref-type="bibr" rid="CR1">1</xref>], but its severity, chronicity and frequent comorbidities result in a disproportionate effect on health and economic systems [<xref ref-type="bibr" rid="CR2">2</xref>]. Schizophrenia is mainly treated by antipsychotics, whose efficacy is highly variable and unpredictable [<xref ref-type="bibr" rid="CR3">3</xref>]. Considering the severity of disease symptoms and frequent side effects of antipsychotics [<xref ref-type="bibr" rid="CR4">4</xref>], substituting current time-consuming switching strategies [<xref ref-type="bibr" rid="CR5">5</xref>] with a biomarker-based, precision.medicine approach, would benefit both patients and healthcare systems.</p><p id="Par3">Genetic polymorphisms represent a natural first choice in the quest for straightforward and accessible biomarkers. However, none of the variants that have been associated with antipsychotic response and adverse effects, many of which involved in neurotransmission and xenobiotics metabolism, reliably predict treatment response [<xref ref-type="bibr" rid="CR6">6</xref>]. Similar to the etiology of schizophrenia [<xref ref-type="bibr" rid="CR7">7</xref>], the treatment response variability seems to arise through an interplay of genetic and environmental factors and probably also mirrors clinical heterogeneity [<xref ref-type="bibr" rid="CR8">8</xref>]. Gene expression and epigenetic marks reflect all these levels of variation, potentially providing more specific biomarkers than polymorphisms [<xref ref-type="bibr" rid="CR9">9</xref>]. Although numerous studies examined the link between antipsychotic response and gene expression [<xref ref-type="bibr" rid="CR10">10</xref>] or epigenetic variation (review in e.g. Burghardt et al. [<xref ref-type="bibr" rid="CR11">11</xref>]), very few [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>] utilized a prospective design, the most suitable choice for the predictive-biomarker discovery. Inconsistent findings of these studies can be explained by differences in genomic coverage, methodological choices and variability of the examined populations and antipsychotics. Neither Rukova et al. [<xref ref-type="bibr" rid="CR12">12</xref>] nor Lokmer et al. [<xref ref-type="bibr" rid="CR13">13</xref>] succeeded in predicting treatment response from baseline methylation values, although Lokmer et al. [<xref ref-type="bibr" rid="CR13">13</xref>] were able to predict the response to risperidone from the combined baseline and follow-up methylation of four CpGs in an Indian cohort. Tang et al. [<xref ref-type="bibr" rid="CR14">14</xref>] focused exclusively on immunity-related genes and reported three CpGs as response biomarkers in Han population, none of which could be associated with gene expression variation.</p><p id="Par4">Here, we present a prospective, repeated-measures study of blood genome-wide methylation of 116 first-episode psychosis patients from the OPTiMiSE clinical trial [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], aiming, firstly, to predict the response to amisulpride after four weeks of treatment using baseline methylation, and secondly, to identify stable and treatment-induced epigenetic differences between the good and bad responders. In addition, we combined epigenetic, genetic and gene expression data from OPTiMiSE cohort with the knowledge from the public databases to examine how genetic, epigenetic and low-level phenotypic variation interact to shape response to antipsychotic treatment (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Flowchart of the analysis workflow performed in the study with the first phase of the OPTiMiSE study flowchart in the inset.</title><p>Response trajectories for individual patients showing total PANSS scores at baseline and follow-up visits are shown on the top of the figure. The rectangles are colored according to study stages or type of data as indicated on the left side of the figure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e390" position="float" orientation="portrait" xlink:href="41398_2025_3561_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Ethics approval and consent to participate</title><p id="Par5">All methods were performed in accordance with relevant guidelines and regulations. The cohort is a subset of patients from the first phase of the OPTiMiSE (Optimization of Treatment and Management of Schizophrenia in Europe, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01248195">NCT01248195</ext-link>) clinical trial [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. A written informed consent was obtained from all participants prior their inclusion in the study. All inclusion sites obtained local ethical approval and this research was approved by an Institutional Review Board.</p></sec><sec id="Sec4"><title>Participant characteristics and study design</title><p id="Par6">The cohort comprises 116 adults (41 women and 75 men) from twelve European countries, experiencing first episode psychosis (FEP) for less than two years. Only individuals whose gender identity corresponded with their genetic sex were included. The participants had either been antipsychotic-naive or minimally treated at baseline, when they were prescribed 200&#8211;800&#8201;mg/day amisulpride orally. Compliance was confirmed by amisulpride concentration blood measurements. Amisulpride was chosen based on its comparatively good efficacy and relatively narrow side-effects profile [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par7">Symptom severity was assessed using total Positive and Negative Syndrome Scale (PANSS) score at baseline and four weeks later at follow-up. Patients with at least 20% reduction of PANSS score at follow-up were classified as (good) responders, while those with PANSS reduction below this threshold were considered as bad or non-responders (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par8">Blood for genetic, epigenetic, gene expression and immune parameter analysis was collected during both visits. Genotyping revealed 104 patients were of European, eight of Asian and four of African ancestry. No further data regarding ethnicity were collected. Cytokine levels were measured due to their potential involvement in antipsychotic response [<xref ref-type="bibr" rid="CR21">21</xref>]. Additional details regarding genotyping, gene expression and cytokine measurements can be found in [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec5"><title>Generation and quality control of blood methylome data</title><p id="Par9">Laboratory protocols, data generation and quality control procedures have been previously published [<xref ref-type="bibr" rid="CR13">13</xref>] and detailed methods are also described in <xref rid="MOESM1" ref-type="media">Supplementary Materials and Methods</xref>. All analyses have been conducted in R statistical framework version 4.1.3 [<xref ref-type="bibr" rid="CR23">23</xref>]. Briefly, genome-wide methylation of bisulphite-converted blood DNA was assessed using Infinium Methylation EPIC v1.0 BeadChip Illumina Inc., USA) according to the manufacturer&#8217;s protocol. Quality control and normalization were conducted following published recommendations [<xref ref-type="bibr" rid="CR24">24</xref>] and included background, dye- and design-bias normalization, preceded by the exclusion of cross-reactive [<xref ref-type="bibr" rid="CR25">25</xref>] and undetected (background intensity) probes and low-quality samples (i.e. samples with low median intensity, many undetected probes or genotype of sex mismatch between paired samples).</p></sec><sec id="Sec6"><title>Detection and functional characterization of differentially methylated regions</title><p id="Par10">To increase statistical power and reproducibility, we performed a region-based analysis. Regions were identified with the unsupervised method implemented in the <italic toggle="yes">coMethDMR</italic> v.1.2.0 package [<xref ref-type="bibr" rid="CR26">26</xref>] with default parameters. To identify response-associated regions, we used random coefficient mixed effects beta family models [<xref ref-type="bibr" rid="CR27">27</xref>], with amisulpride response defined either as categorical variable or as %PANSS reduction. As methylation is measured by beta values, i.e. by the proportion/percentage of methylated sites, we used beta family (a distribution restricted to 0&#8211;1 interval) with logit link for modelling. We were interested in both stable methylome differences between the good and bad responders (main effect of response) and in response-specific temporal shifts following antipsychotic treatment (response x visit interaction or response-specific treatment effects). The models included following covariates: age, sex, smoking, alcohol use, body mass index (BMI), duration of untreated psychosis (DUP), leukocyte composition (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>), and covariates accounting for population genetic diversity and batch effects. Patient, sample and probe IDs, included as random effects, accounted for repeated measures design, and for the within-region methylation variability, respectively [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par11">We investigated functional enrichment of differentially methylated regions compared to the universe comprising all tested regions [<xref ref-type="bibr" rid="CR13">13</xref>]. In addition, we checked for any associations with psychiatric, neurodevelopmental or neurodegenerative disorders in the public databases.</p><p id="Par12">We conducted expression quantitative trait methylation (eQTM) analysis by calculating repeated-measures (rmcorr, to account for the CpG-level variability within a region [<xref ref-type="bibr" rid="CR28">28</xref>]) and Spearman&#8217;s rho (for the region mean and individual CpG-level) between methylation and gene expression [<xref ref-type="bibr" rid="CR20">20</xref>] for all the <italic toggle="yes">cis</italic> region-gene pairs. We did this for both visits together and for each one separately and kept only correlations with the lower 95% confidence interval&#8201;&gt;&#8201;0.1, followed by enrichment analysis.</p></sec><sec id="Sec7"><title>Response prediction from differentially methylated regions</title><p id="Par13">We used generalized additive modelling fitted by gradient boosting (<italic toggle="yes">mboost</italic> v. 2.9&#8211;5 package [<xref ref-type="bibr" rid="CR29">29</xref>]) to predict treatment response from the covariate-corrected baseline methylation values of the regions selected as described above. We performed the analysis for dichotomous response and for reduction of total PANSS and its subscores, for all individuals and for the indivduals of European ancestry only. False positive rate was minimized by stability variable selection procedure [<xref ref-type="bibr" rid="CR30">30</xref>], with 0.75 selection probability cutoff and upper bound for the per-family error-rate PFER&#8201;=&#8201;1. The regions surviving these cutoffs were used to build the final 10x cross-validated predictive models. We used R2 for assessing the performances of PANSS reduction models, and Matthews correlation coefficient (MCC) for dichotomous response, a performance measure suitable for the unbalanced designs [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec8"><title>Detection of methylation quantitative trait loci (mQTLs) associated with the response-predicting regions</title><p id="Par14">To identify methylation quantitative trait loci (mQTLs) in a 1MBp window surrounding the response-predicting regions, we genotyped patients using the OmniExpressExome 8v1-4 A1 BeadChip (Illumina Inc., USA) and performed quality control and imputation following published procedures [<xref ref-type="bibr" rid="CR32">32</xref>]. We analyzed a single representative from each group of perfectly collinear SNPs (linkage R<sup>2</sup>&#8201;=&#8201;1) by linear modelling, with genotype as an explanatory variable and covariate-corrected methylation value as a dependent variable. We ran models for both the mean methylation value of a region and for each CpG in the region separately. We considered only SNPs with Benjamini-Hochberg-adjusted p-values&#8201;&lt;&#8201;0.05 and used R-squared as a measure of effect size. We queried public databases using the LDlink tools [<xref ref-type="bibr" rid="CR33">33</xref>] to search for published associations between our mQTLs and psychiatric diseases and nervous system functioning in &#8220;EUR&#8221; superpopulation, as 90% participants were of European origin. We then used Fisher&#8217;s exact test to find GWAS traits over-represented in our mQTL set as compared to those associated with any SNP in the queried 1MBp window.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Good response correlates with leukocyte composition and immunological factors</title><p id="Par15">We observed no differences in sex ratio, BMI, substance abuse or baseline PANSS score between the good (<italic toggle="yes">N</italic>&#8201;=&#8201;83, 72%) and bad (<italic toggle="yes">N</italic>&#8201;=&#8201;33, 28%) responders (Supplementary Table <xref rid="MOESM2" ref-type="media">S1</xref>). However, good responders were older (t&#8201;=&#8201;&#8722;2.09, df&#8201;=&#8201;63. 82, <italic toggle="yes">p</italic>&#8201;=&#8201;0.041, effect size&#8201;=&#8201;0. 25) and had shorter duration of untreated psychosis (DUP, U&#8201;=&#8201;2.26, df&#8201;=&#8201;49.10, <italic toggle="yes">p</italic>&#8201;=&#8201;0.024, effect size&#8201;=&#8201;0.21). They also had a higher blood concentration of the CCL22 chemokine (t&#8201;=&#8201;&#8722;2.65, df&#8201;=&#8201;70.52, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01, effect size&#8201;=&#8201;0.30) and a lower NK-cell relative abundance (t&#8201;=&#8201;2.561 df&#8201;=&#8201;48.10, <italic toggle="yes">p</italic>&#8201;=&#8201;0.014, effect size&#8201;=&#8201;0.35) at baseline. Amisulpride dose and blood concentration tended towards lower values in good responders (dose: t&#8201;=&#8201;1.874 df&#8201;=&#8201;43.21, <italic toggle="yes">p</italic>&#8201;=&#8201;0.068; concentration: t&#8201;=&#8201;1.892 df&#8201;=&#8201;43.77, <italic toggle="yes">p</italic>&#8201;=&#8201;0.065). Furthermore, we detected a weak genetic effect (genetic PC1, distinguishing individuals of African ancestry from the rest, t&#8201;=&#8201;1.98, df =113.52, <italic toggle="yes">p</italic>&#8201;=&#8201;0.05, effect size&#8201;=&#8201;0.18). Finally, the distribution of good and bad responders varied across collection centres (Fisher&#8217;s exact test, <italic toggle="yes">p</italic>&#8201;=&#8201;0.021), largely due to the absence of good responders in the centre 17 in Spain.</p></sec><sec id="Sec11"><title>Amisulpride response is associated with methylation in regions involved in development, neurotransmission, inflammation and other signaling and immunity-related processes</title><p id="Par16">Multiple-comparison-corrected analysis of 210 paired samples that passed quality control revealed 67 regions with average methylation differences between good and bad responders (main effect of response, Supplementary Table <xref rid="MOESM3" ref-type="media">S2</xref>) and 197 regions with response-specific treatment effect (visit x response interaction, Supplementary Table <xref rid="MOESM4" ref-type="media">S3</xref>), with three regions found in both groups (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>). The regions associated with a positive response defined as PANSS reduction, were mostly distinct from those significant for the dichotomous response (Supplementary Table <xref rid="MOESM5" ref-type="media">S4</xref>, Supplementary Table <xref rid="MOESM6" ref-type="media">S5</xref>, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>). However, since the magnitude of coefficient estimates from dichotomous and continuous models were strongly correlated (response main effect: r [95%CI]&#8201;=&#8201;0.84 [0.83, 0.85], visit x response interaction: r [95%CI]&#8201;=&#8201;0.86 [0.85, 0.87]) when disregarding the statistical significance, we assumed that the differences arose due to technical rather than to biological reasons and we therefore focus primarily on the dichotomous response here, with quantitative-response analysis available in the supplement.</p><p id="Par17">The processes enriched in the regions differentially methylated between the good and bad responders included morphogenesis, synapse assembly and neurotransmission, whereas the regions with a response-specific treatment effect were mostly involved in inflammation, cell signaling and development (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, Supplementary Table <xref rid="MOESM7" ref-type="media">S6</xref>). Some identified genes have known links with psychiatric, neurodevelopmental and neurodegenerative conditions, including schizophrenia (Fig. <xref rid="Fig3" ref-type="fig">3</xref>, Supplementary Table <xref rid="MOESM8" ref-type="media">S7</xref>, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref>). This included the genes explicitly involved in neuronal development and neurotransmission (e.g. <italic toggle="yes">MDGA1</italic> and <italic toggle="yes">SHANK2</italic> in synapse assembly), but also those annotated to less specific terms (e.g. <italic toggle="yes">CHN2</italic> in small GTPase signal transduction or <italic toggle="yes">EXOC2</italic> in cytokinesis).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Enriched biological processes (BP) in differentially methylated regions.</title><p>Regions with average methylation differences between the good and bad responders (<bold>A</bold>) and in those with response-specific treatment effect <bold>(B)</bold>. Terms were filtered to reduce redundancy and grouped by semantic similarity, with similar terms represented by shades of the same colour, and the rectangle size inversely proportional to the term&#8217;s p-value.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e624" position="float" orientation="portrait" xlink:href="41398_2025_3561_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Differentially methylated genes associated with the enriched biological processes (BP).</title><p>Regions with average methylation differences between good and bad responders are shown in <bold>A</bold> and those with response-specific treatment effect in <bold>B</bold>. Genes annotation at the top of the heatmaps show if the gene has previously been associated with schizophrenia, other psychiatric disorders or neurodevelopmental and neurodegenerative conditions based on the ClinVar, OMIM, MedGen and GWAS catalog databases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e639" position="float" orientation="portrait" xlink:href="41398_2025_3561_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec12"><title>Methylation in response-associated regions correlates with the expression of schizophrenia and antipsychotic drug response-associated genes</title><p id="Par18">Expression level of 1141 genes correlated with methylation in at least one response-related region on at least one sampling date (Supplementary Table <xref rid="MOESM9" ref-type="media">S8</xref>). Of these, 149 genes were influenced by a single region or a CpG site, the rest with at least two sites (median [IQR]&#8201;=&#8201;5 [4, 7]). Both CpG and region-level analysis revealed the enrichment of purine biosynthesis-related processes for the genes whose expression correlated with methylation in the regions significant for the main effect of response. Conversely, the terms enriched in the response-specific treatment effect group, varied depending on the analysis level (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S4</xref>, Supplementary Table <xref rid="MOESM10" ref-type="media">S9</xref>), suggesting that a multilevel analysis could uncover complementary mechanisms of antipsychotic response. Finally, 519 of these gene overlapped with the genes dysregulated in either autism, schizophrenia, bipolar disorder, depression or alcoholism [<xref ref-type="bibr" rid="CR34">34</xref>], with a marginally significant overrepresentation for the schizophrenia group (Fisher&#8217;s exact test OR [95%CI]&#8201;=&#8201;1.3 [1.04, Inf], <italic toggle="yes">p</italic>&#8201;=&#8201;0.02, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S5</xref>).</p></sec><sec id="Sec13"><title>Baseline methylation patterns of HOXA, HTR2A and PRR5 genes predict amisulpride response</title><p id="Par19">Variable selection procedure including baseline methylation patterns of the 467 candidate regions and response-associated patient traits (Supplementary Table <xref rid="MOESM2" ref-type="media">S1</xref>) retained only methylation values of three regions, located in <italic toggle="yes">HOXA, HTR2A</italic> and <italic toggle="yes">PRR5</italic> genes, as predictors of amisulpride response (model performance: 10&#215; cross-validated Kappa&#8201;=&#8201;0.81, MCC&#8201;=&#8201;0.81, AUC&#8201;=&#8201;0.89). Note that the results for total and PANSS subscores reduction models were similar (Supplementary Table <xref rid="MOESM11" ref-type="media">S10</xref>, Fig. <xref rid="Fig4" ref-type="fig">4</xref>), but characterized by poorer model performance (R2&#8201;=&#8201;0.29&#8211;0.47, Supplementary Table <xref rid="MOESM12" ref-type="media">S11</xref>). Excluding the individuals of non-European ancestry yielded similar results, with an additional <italic toggle="yes">HOXA-</italic>associated region selected as an antipsychotic response predictor and a slightly higher performance (MCC&#8201;=&#8201;0.85, Kappa&#8201;=&#8201;0.84, AUC&#8201;=&#8201;0.90, Supplementary Table <xref rid="MOESM12" ref-type="media">S11</xref>). Further details, including the confusion matrix for binary response and correlation between the observed and predicted values for PANSS reduction can be found in Supplementary Figs. <xref rid="MOESM1" ref-type="media">S6</xref>&#8211;<xref rid="MOESM1" ref-type="media">S8</xref> and Supplementary Table <xref rid="MOESM11" ref-type="media">S10</xref>.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Heatmap showing the selection probabilities for the regions with baseline methylation values predicting different components of treatment response.</title><p>Probabilities &gt;= 0.75 were considered significant and are shown in bold. Region coordinates are based on GRCh37.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e709" position="float" orientation="portrait" xlink:href="41398_2025_3561_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec14"><title>Influence of genetic factors on the epigenetic biomarkers varies between the regions</title><p id="Par20">We identified mQTLs within 1MBp window around each of the three response-predicting regions, ranging from two mQTLs affecting a single CpG in the <italic toggle="yes">PRR5</italic> region, to 62 mQTLs and a majority of CpGs influenced by multiple polymorphisms in the <italic toggle="yes">HTR2A</italic> region (Fig. <xref rid="Fig5" ref-type="fig">5</xref>, Supplementary Table <xref rid="MOESM13" ref-type="media">S12</xref>). Two <italic toggle="yes">HTR2A</italic> SNPs, rs6313 and rs6311 (here in complete LD), have been previously linked with variation in antipsychotic response [<xref ref-type="bibr" rid="CR35">35</xref>]. Although we found no deviation from the expected number of mQTLs given the number of tested SNPs in either <italic toggle="yes">HTR2A</italic> or <italic toggle="yes">HOXA</italic> region (Fisher&#8217;s exact p-values&#8201;=&#8201;0.233), the number of CpGs affected by the mQTLs and the number of mQTLs affecting each CpG varied considerably between the two regions. In <italic toggle="yes">HTR2A</italic>, CpGs were affected by a median of 23 mQTLs (IQR 7.5&#8211;36.5), compared to 3.5 mQTLs (IQR 0.3&#8211;4.8) for the <italic toggle="yes">HOXA</italic> region. Correspondingly, a single mQTL affected a median of 4.5 CpGs in <italic toggle="yes">HTR2A</italic> region (IQR 1&#8211;12), and a single mQTL (IQR 1-1) per CpG in <italic toggle="yes">HOXA</italic> region. Characterization of these mQTLs or linked SNPs (R2&#8201;&gt;&#8201;=&#8201;0.8) using the LDlink database revealed two over-represented traits: &#8220;pulse pressure&#8221; and &#8220;waist circumference adjusted for body mass index&#8221; (BH-corrected Fisher&#8217;s exact test p-value&#8201;&lt;&#8201;0.05), with other high-ranked traits also related to weight and circulatory system (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S9</xref>, Supplementary Table <xref rid="MOESM14" ref-type="media">S13</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Association (R<sup>2</sup>) between the methylation in the response predicting regions and their corresponding mQTLs.</title><p><bold>A</bold>
<italic toggle="yes">HOXA</italic>, <bold>B</bold>
<italic toggle="yes">HTR2A</italic> and <bold>C</bold>
<italic toggle="yes">PRR5</italic>. The association was calculated for each CpG in a region separately and for the mean region methylation value. LD&#8201;=&#8201;1 shows the number of SNPs in complete linkage for each mQTL, LD&#8201;&gt;&#8201;1 shows the number of linked SNPs (LD&#8201;&gt;&#8201;0.8) excluding those in complete linkage. &#8220;mQTL in the region&#8221; shows if a particular SNP is located in the response-related co-methylated region, &#8220;mQTL in the same gene as the region?&#8221; marks the SNPs that are annotated to the same gene as the corresponding co-methylated region. Counts in annotation columns are capped at 7 and 35 (based on 75% quantile) for clarity. Genomic coordinates are based on GRCh37. SNP rs6313 in <bold>B</bold> is shown in bold.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e790" position="float" orientation="portrait" xlink:href="41398_2025_3561_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>Genetic and epigenetic variation of response-predicting regions correlates with expression of genes involved in nervous system functioning</title><p id="Par21">For each response-predicting region, we identified at least two genes whose expression covaried with either whole (mean) region methylation or with the methylation at its constitutive CpG sites (Supplementary Table <xref rid="MOESM10" ref-type="media">S9</xref>, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S10</xref>). However, these correlations were mostly weak and unstable over time and across individual CpGs. For example, a weak negative correlation (rmcorr [95%CI]&#8201;=&#8201;&#8722;0.07 [&#8722;0.12, &#8722;0.03], not shown) between the expression and methylation of <italic toggle="yes">HTR2A</italic> gene at baseline turned into a positive correlation at follow-up (rmcorr [95%CI]&#8201;=&#8201;0.14 [0.08, 0.22]). In addition, mean methylation of this region, and the CpG cg23881368 in particular, were negatively correlated with the expression of <italic toggle="yes">LRCH1</italic>, a regulator of microglia-mediated neuroinflammation, at baseline only (rmcorr [95%CI]&#8201;=&#8201;&#8722;0.13 [&#8722;0.17, &#8722;0.06] and Spearman&#8217;s rho [95%CI]&#8201;=&#8201;&#8722;0.22 [&#8722;0.39, &#8722;0.07], respectively). Methylation of <italic toggle="yes">HOXA</italic> region correlated with the expression of several <italic toggle="yes">HOXA</italic> genes, varying in magnitude and direction, contrary to rather stable negative correlations with <italic toggle="yes">SKAP2</italic> expression, a gene involved in src signaling &#8211; implicated, among other, in neuroinflammation [<xref ref-type="bibr" rid="CR36">36</xref>]. Finally, the correlations in the <italic toggle="yes">PRR5</italic> region were more consistent, especially at the mean region methylation level, reveiling a stable positive correlation with the expression of <italic toggle="yes">LDOC1L</italic> and a negative one with the expression of <italic toggle="yes">NUP50</italic>, a gene predicting the risk of Alzheimer disease [<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p id="Par22">The ability to predict response to antipsychotic treatment in individual cases would help reduce patients&#8217; suffering and alleviate pressure on the healthcare systems. A way to increase our odds in the search for reliable biomarkers is to improve our understanding of how levels of biological variation interact to shape the treatment response. Our analysis of blood methylomes of amisulpride-treated first-episode psychosis patients revealed multiple associations between methylation on one side and antipsychotic response and gene expression on the other. Moreover, we were able to predict the response from the baseline methylation of three regions with good reliability in our cohort. Finally, by integrating ours and publicly available data from genetic to gene expression level, we could show that these candidate epigenetic biomarkers were under varying degree of genetic control and that many of the response-associated genes were involved in psychiatric disorders or neurodevelopment. Our results suggest that variation in treatment response arises through an interplay of genetic, developmental and environmental factors. Whereas this conclusion corroborates the results of previous studies based on genetic [<xref ref-type="bibr" rid="CR38">38</xref>] and epigenetic data [<xref ref-type="bibr" rid="CR13">13</xref>] or their combination [<xref ref-type="bibr" rid="CR39">39</xref>], the identified genes and regions mostly differ, likely due to differences between the cohorts, tested antipsychotics and experimental designs [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par23">Schizophrenia manifests itself by a wide spectrum of symptoms, occurring with variable intensities and in different combinations and antipsychotics may differ in efficacy against particular symptom subgroups [<xref ref-type="bibr" rid="CR40">40</xref>]. Although the regions predicting improvement of specific symptom groups mostly overlapped, we did observe some differences. For example, only negative PANSS reduction was predicted by methylation in <italic toggle="yes">LINC00612</italic>, a non-coding RNA involved in inflammation and apoptosis [<xref ref-type="bibr" rid="CR41">41</xref>], but not by <italic toggle="yes">HTR2A</italic> methylation. However, non-significant selection probabilities were mostly close to the threshold in all models and the candidate regions were selected based on their link with total response in univariate analysis, and therefore we might have missed regions specific for individual subscores. Still, positive correlations between the PANSS subscores observed here (not shown) and elsewhere [<xref ref-type="bibr" rid="CR14">14</xref>] suggest pseudospecificity [<xref ref-type="bibr" rid="CR42">42</xref>] and therefore biological explanation for the observed overlap.</p><p id="Par24">The major response predictor, for both overall response and symptom subgroups, was a region annotated to several <italic toggle="yes">HOXA</italic> genes, vital for the development of nervous system [<xref ref-type="bibr" rid="CR43">43</xref>], but also involved in neurodegeneration [<xref ref-type="bibr" rid="CR44">44</xref>]. Interestingly, <italic toggle="yes">HOXA3</italic> gene was associated with response to risperidone in our previous study [<xref ref-type="bibr" rid="CR13">13</xref>]. <italic toggle="yes">HOXA</italic> methylation may reflect both genetic factors and early life environment. Here, we observed little evidence of <italic toggle="yes">cis</italic> genetic control of <italic toggle="yes">HOXA</italic> methylation, which, together with the evidence of its environmentally-driven methylation in the adulthood [<xref ref-type="bibr" rid="CR45">45</xref>] and a life-long influence of <italic toggle="yes">HOXA</italic> genes on synaptogenesis [<xref ref-type="bibr" rid="CR46">46</xref>], suggests that this region may also tag lifestyle or other environmental determinants of treatment response. This is in contrast with <italic toggle="yes">HTR2A</italic> region, where methylation patterns were largely attributable to genetic polymorphisms.</p><p id="Par25">The association between treatment response and <italic toggle="yes">HTR2A</italic> methylation here may seem surprising, given the very low affinity of amisulpride for serotonin receptors [<xref ref-type="bibr" rid="CR47">47</xref>]. Nevertheless, monoaminergic neurotransmitter systems interact with each other [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and <italic toggle="yes">HTR2A</italic> can modulate effects of dopamine antagonists, such as haloperidol [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Similarly, interaction of <italic toggle="yes">DRD2</italic> (rs1076560) and <italic toggle="yes">HTR2A</italic> (rs6314) polymorphisms affects response to olanzapine [<xref ref-type="bibr" rid="CR52">52</xref>]. Of note, although our sample size was insufficient to test this interaction, none of the good responders was a homozygote for a minor rs6314 allele (Fisher&#8217;s exact text <italic toggle="yes">p</italic>&#8201;=&#8201;0.03). In addition, although we could not link rs6314 to methylation here, two other <italic toggle="yes">HTR2A</italic> SNPs, rs6311 and rs6313, associated with response to haloperidol [<xref ref-type="bibr" rid="CR53">53</xref>], amisulpride [<xref ref-type="bibr" rid="CR54">54</xref>], risperidone and olanzapine [<xref ref-type="bibr" rid="CR35">35</xref>], acted as mQTLs in our cohort, suggesting that methylation may mediate their effects. However, further steps along the cascade leading to phenotypic variation remain unclear, with the unstable correlation between <italic toggle="yes">HTR2A</italic> methylation and expression in our study mirroring previously reported inconsistent relationship between the <italic toggle="yes">HTR2A</italic> mRNA and protein levels in the blood [<xref ref-type="bibr" rid="CR53">53</xref>]. Furthermore, whereas methylation in the <italic toggle="yes">HTR2A</italic> region predicted reduction of total, general and positive, but not negative symptoms in our cohort, these <italic toggle="yes">HTR2A</italic> mQTLs (rs6311 and rs6313) have been usually linked to the improvement of positive and negative symptoms [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. These incongruences may reflect epistatic [<xref ref-type="bibr" rid="CR55">55</xref>] or <italic toggle="yes">trans</italic> epigenetic mechanisms, but also the complexity and interactions within neurotransmission systems [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par26"><italic toggle="yes">HTR2A</italic> affects not only various aspects of mood and behaviour, but also cardiac function and digestive system [<xref ref-type="bibr" rid="CR56">56</xref>]. Luo et al. [<xref ref-type="bibr" rid="CR57">57</xref>] observed lower weight gain for rs6313 CC genotype carriers following antipsychotic treatment, unlike us (but we did observe high weight gain for rs6314 TT homozygotes, not shown). This pleiotropy may help explain high prevalence of antipsychotic-related side effects or schizophrenia-related comorbidities. Interestingly, the third identified region, in the <italic toggle="yes">PRR5</italic> gene is involved in mTORC2 signalling [<xref ref-type="bibr" rid="CR58">58</xref>], a pathway mediating dopamine-dependent behaviours [<xref ref-type="bibr" rid="CR59">59</xref>], but also the side-effects of antipsychotic drugs [<xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par27">At least some forms of schizophrenia can be linked to inflammatory processes [<xref ref-type="bibr" rid="CR61">61</xref>] and antipsychotics can affect innate immunity [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Although the only difference in plasma protein levels observed here was a lower concentration of the cytokine CCL22 in bad responders, the treatment-affected methylation predominantly in the regions involved in immunity and inflammation, supporting a link between antipsychotic response and immunity. Differential expression of the genes attributable to methylation shifts in our study and the indirect evidence linking our mQTLs to gene expression from the public databases, strengthen this conclusion. These genes include: alphamacroglobulin <italic toggle="yes">A2M</italic>, a peripheral marker of neuroinflammation affecting susceptibility to major depressive disorder [<xref ref-type="bibr" rid="CR64">64</xref>]; <italic toggle="yes">A2ML1</italic>, discriminating schizophrenic from bipolar patients and healthy controls [<xref ref-type="bibr" rid="CR65">65</xref>], and <italic toggle="yes">PZP</italic>, a chaperone linked with Alzheimer&#8217;s disease [<xref ref-type="bibr" rid="CR66">66</xref>].</p><p id="Par28">Regarding the limitations of our study, we are aware that amisulpride is unavailable in the USA, limiting clinical utility of our findings there. However, it is approved and used to treat schizophrenia in Europe and 50 other countries. In addition, amisulpride ranks among top antipsychotics in terms of both symptom improvement (including the negative ones) and side-effects profiles according to multiple studies [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR67">67</xref>&#8211;<xref ref-type="bibr" rid="CR69">69</xref>]. This, with its good cost-effectiveness [<xref ref-type="bibr" rid="CR70">70</xref>], makes it a good candidate for a broader use in the future, especially in low- and middle-income countries. Furthermore, although blood has a high clinical potential as a source of biomarkers due to easy accessibility, it remains unclear if and how methylation and expression in the blood reflect processes in the central nervous system. However, although methylation in blood and the brain co-varies only at few sites [<xref ref-type="bibr" rid="CR71">71</xref>], blood methylome can still tag psychiatric disorders, as these co-occur with alterations in lymphocyte functions and abundances [<xref ref-type="bibr" rid="CR72">72</xref>&#8211;<xref ref-type="bibr" rid="CR74">74</xref>], and these are characterized by specific methylation profiles [<xref ref-type="bibr" rid="CR75">75</xref>]. Comparing the methylation-based leukocyte composition estimates with those obtained from direct measurements could provide more insight into relative contributions of cell composition shifts and (de)methylation to methylation patterns observed in the blood. Furthermore, we did not examine <italic toggle="yes">trans</italic> regulation of epigenetic variation and gene expression. As <italic toggle="yes">trans</italic> correlations could account for non-negligible portion of genetically controlled methylation differences [<xref ref-type="bibr" rid="CR76">76</xref>], we may have missed additional response-related processes. Regarding our cohort, 90% of the individuals are of European ancestry and the prediction models may not be straightforwardly transferable to non-European populations. For example, Ota et al. [<xref ref-type="bibr" rid="CR15">15</xref>] have found very little overlap of the risperidone-response associated differentially methylated sites between the Brazilian and Indian cohorts. In addition, a matching validation cohort would provide a stronger support for the results than the model cross-validation we performed here. Finally, a larger cohort would have improved the robustness of the findings and increased statistical power [<xref ref-type="bibr" rid="CR77">77</xref>] and should be preferred especially when studying multiple antipsychotics and heterogeneous populations. Still, our work represents one of the rare prospective studies aiming to identify epigenomic biomarkers of antipsychotic response by genome-wide analysis. Our approach combining a focus on a single antipsychotic, a prospective study design and a narrowly delineated cohort including only first-episode psychosis patients, with the analysis protocol accounting for all major sources of epigenetic variation (sex, tobacco use, ancestry, age) and biochemically confirmed adherence, allowed us not only to identify epigenetic biomarkers of the response to amisulpride in our cohort and shed some light on the involved pathways, but also to provide a well-defined reference for future comparisons.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary methods and figures</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM2_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Table S1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM3_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM4_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM5_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S4</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM6_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S5</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM7_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S6</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM8_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S7</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM9" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM9_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S8</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM10" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM10_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S9</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM11" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM11_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S10</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM12" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM12_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S11</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM13" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM13_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S12</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM14" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3561_MOESM14_ESM.xls" position="float" orientation="portrait"><caption><p>Supplementary Table S13</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>A list of authors and their affiliations appears at the end of the paper.</p></fn><fn><p>A list of members and their affiliations appears in the Supplementary Information.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41398-025-03561-7.</p></sec><ack><title>Acknowledgements</title><p>We are very grateful to patients for their participation. We thank Aur&#233;lie Krol, Claire Mulot, Magali Nacfer, Aurore Hattabi, Stefanie Wojciech, the Centre universitaire des Saints-P&#232;res (Prof. P Beaune), and the Biological Resources Platform (Dr. C Barau) of Mondor Hospital for technical assistance.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>SJ and AL designed the study. RT, CB, DBD, ABA and JFD generated methylome data. AL and SJ conducted methylome analyses and AL performed statistical analyses. ML and the OPTiMiSE study group designed, collected and analysed clinical data, with the help of SJ, RT and AL for biological samples collection. AL and SJ wrote the article and all the authors corrected and approved it.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the European Commission Seventh Framework Program (HEALTH-F2-2010-242114) and the Investissements d&#8217;Avenir program managed by the Agence Nationale pour la Recherche (ANR) under reference ANR-11-IDEX-0004-02 (Labex BioPsy). This work also received financial support from the Institut National pour la Sant&#233; et la Recherche M&#233;dicale (Inserm); the Fondation FondaMental; the Commissariat &#224; l&#8217;&#233;nergie atomique et aux &#233;nergies alternatives (CEA) and the Fondation pour la Recherche M&#233;dicale (FRM Espoirs de la Recherche 2015, FDM20151234954 to RT). The Jamain&#8217;s team is affiliated with the Paris School of Neuroscience (ENP) and the Bio-Psy Laboratory of Excellence.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Raw methylation intensity data are deposited in the ArrayExpress repository (accession number: E-MTAB-13006). Methods are described in detail in <xref rid="MOESM1" ref-type="media">Supplementary Materials and Methods</xref>. All other data and scripts are available on Figshare or upon request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par29">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charlson</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Santomauro</surname><given-names>DF</given-names></name><name name-style="western"><surname>Diminic</surname><given-names>S</given-names></name><name name-style="western"><surname>Stockings</surname><given-names>E</given-names></name><name name-style="western"><surname>Scott</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Global epidemiology and burden of schizophrenia: findings from the global burden of disease Study 2016</article-title><source>Schizophr Bull</source><year>2018</year><volume>44</volume><fpage>1195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1093/schbul/sby058</pub-id><pub-id pub-id-type="pmid">29762765</pub-id><pub-id pub-id-type="pmcid">PMC6192504</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease Study 2016. Schizophr Bull. 2018;44:1195&#8211;203.<pub-id pub-id-type="pmid">29762765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/schbul/sby058</pub-id><pub-id pub-id-type="pmcid">PMC6192504</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>HY</given-names></name><name name-style="western"><surname>Teoh</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wu</surname><given-names>DB-C</given-names></name><name name-style="western"><surname>Kotirum</surname><given-names>S</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>C-F</given-names></name><name name-style="western"><surname>Chaiyakunapruk</surname><given-names>N</given-names></name></person-group><article-title>Global economic burden of schizophrenia: a systematic review</article-title><source>Neuropsychiatr Dis Treat</source><year>2016</year><volume>12</volume><fpage>357</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">26937191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S96649</pub-id><pub-id pub-id-type="pmcid">PMC4762470</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Chong HY, Teoh SL, Wu DB-C, Kotirum S, Chiou C-F, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357&#8211;73.<pub-id pub-id-type="pmid">26937191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S96649</pub-id><pub-id pub-id-type="pmcid">PMC4762470</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjornestad</surname><given-names>J</given-names></name><name name-style="western"><surname>Lavik</surname><given-names>KO</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>L</given-names></name><name name-style="western"><surname>Hjeltnes</surname><given-names>A</given-names></name><name name-style="western"><surname>Moltu</surname><given-names>C</given-names></name><name name-style="western"><surname>Veseth</surname><given-names>M</given-names></name></person-group><article-title>Antipsychotic treatment &#8211; a systematic literature review and meta-analysis of qualitative studies</article-title><source>J Ment Health</source><year>2020</year><volume>29</volume><fpage>513</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1080/09638237.2019.1581352</pub-id><pub-id pub-id-type="pmid">30862219</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bjornestad J, Lavik KO, Davidson L, Hjeltnes A, Moltu C, Veseth M. Antipsychotic treatment &#8211; a systematic literature review and meta-analysis of qualitative studies. J Ment Health. 2020;29:513&#8211;23.<pub-id pub-id-type="pmid">30862219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09638237.2019.1581352</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Gallego</surname><given-names>JA</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>DG</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kane</surname><given-names>JM</given-names></name><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name></person-group><article-title>Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis</article-title><source>Int J Neuropsychopharmacol</source><year>2013</year><volume>16</volume><fpage>1205</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1017/S1461145712001277</pub-id><pub-id pub-id-type="pmid">23199972</pub-id><pub-id pub-id-type="pmcid">PMC3594563</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Zhang J-P, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205&#8211;18.<pub-id pub-id-type="pmid">23199972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1461145712001277</pub-id><pub-id pub-id-type="pmcid">PMC3594563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>PF</given-names></name><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name></person-group><article-title>Strategies for dosing and switching antipsychotics for optimal clinical management</article-title><source>J Clin Psychiatry</source><year>2008</year><volume>69</volume><fpage>4</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">18484804</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69:4&#8211;17.<pub-id pub-id-type="pmid">18484804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>DJ</given-names></name></person-group><article-title>Pharmacogenetics of antipsychotic drug treatment: update and clinical implications</article-title><source>Complex Psychiatry</source><year>2019</year><volume>5</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1159/000492332</pub-id><pub-id pub-id-type="pmcid">PMC7206586</pub-id><pub-id pub-id-type="pmid">32399466</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Yoshida K, M&#252;ller DJ. Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Complex Psychiatry. 2019;5:1&#8211;26.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000492332</pub-id><pub-id pub-id-type="pmcid">PMC7206586</pub-id><pub-id pub-id-type="pmid">32399466</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orsolini</surname><given-names>L</given-names></name><name name-style="western"><surname>Pompili</surname><given-names>S</given-names></name><name name-style="western"><surname>Volpe</surname><given-names>U</given-names></name></person-group><article-title>Schizophrenia: a narrative review of etiopathogenetic, diagnostic and treatment aspects</article-title><source>J Clin Med</source><year>2022</year><volume>11</volume><fpage>5040</fpage><pub-id pub-id-type="doi">10.3390/jcm11175040</pub-id><pub-id pub-id-type="pmid">36078967</pub-id><pub-id pub-id-type="pmcid">PMC9457502</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Orsolini L, Pompili S, Volpe U. Schizophrenia: a narrative review of etiopathogenetic, diagnostic and treatment aspects. J Clin Med. 2022;11:5040.<pub-id pub-id-type="pmid">36078967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm11175040</pub-id><pub-id pub-id-type="pmcid">PMC9457502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carbon</surname><given-names>M</given-names></name><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name></person-group><article-title>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</article-title><source>Dialogues Clin Neurosci</source><year>2014</year><volume>16</volume><fpage>505</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.31887/DCNS.2014.16.4/mcarbon</pub-id><pub-id pub-id-type="pmid">25733955</pub-id><pub-id pub-id-type="pmcid">PMC4336920</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16:505&#8211;24.<pub-id pub-id-type="pmid">25733955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31887/DCNS.2014.16.4/mcarbon</pub-id><pub-id pub-id-type="pmcid">PMC4336920</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Gim&#233;nez</surname><given-names>JL</given-names></name><name name-style="western"><surname>Seco-Cervera</surname><given-names>M</given-names></name><name name-style="western"><surname>Tollefsbol</surname><given-names>TO</given-names></name><name name-style="western"><surname>Rom&#225;-Mateo</surname><given-names>C</given-names></name><name name-style="western"><surname>Peir&#243;-Chova</surname><given-names>L</given-names></name><name name-style="western"><surname>Lapunzina</surname><given-names>P</given-names></name><etal/></person-group><article-title>Epigenetic biomarkers: current strategies and future challenges for their use in the clinical laboratory</article-title><source>Crit Rev Clin Lab Sci</source><year>2017</year><volume>54</volume><fpage>529</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1080/10408363.2017.1410520</pub-id><pub-id pub-id-type="pmid">29226748</pub-id><pub-id pub-id-type="pmcid">PMC6733278</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Garc&#237;a-Gim&#233;nez JL, Seco-Cervera M, Tollefsbol TO, Rom&#225;-Mateo C, Peir&#243;-Chova L, Lapunzina P, et al. Epigenetic biomarkers: current strategies and future challenges for their use in the clinical laboratory. Crit Rev Clin Lab Sci. 2017;54:529&#8211;50.<pub-id pub-id-type="pmid">29226748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408363.2017.1410520</pub-id><pub-id pub-id-type="pmcid">PMC6733278</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagh</surname><given-names>VV</given-names></name><name name-style="western"><surname>Vyas</surname><given-names>P</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></name><name name-style="western"><surname>Pachpor</surname><given-names>TA</given-names></name><name name-style="western"><surname>Paralikar</surname><given-names>V</given-names></name><name name-style="western"><surname>Khare</surname><given-names>SP</given-names></name></person-group><article-title>Peripheral blood-based gene expression studies in schizophrenia: a systematic review</article-title><source>Front Genet</source><year>2021</year><volume>12</volume><fpage>736483</fpage><pub-id pub-id-type="doi">10.3389/fgene.2021.736483</pub-id><pub-id pub-id-type="pmid">34721526</pub-id><pub-id pub-id-type="pmcid">PMC8548640</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wagh VV, Vyas P, Agrawal S, Pachpor TA, Paralikar V, Khare SP. Peripheral blood-based gene expression studies in schizophrenia: a systematic review. Front Genet. 2021;12:736483.<pub-id pub-id-type="pmid">34721526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2021.736483</pub-id><pub-id pub-id-type="pmcid">PMC8548640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burghardt</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Khoury</surname><given-names>AS</given-names></name><name name-style="western"><surname>Msallaty</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Seyoum</surname><given-names>B</given-names></name></person-group><article-title>Antipsychotic medications and DNA methylation in schizophrenia and bipolar disorder: a systematic review</article-title><source>Pharmacotherapy</source><year>2020</year><volume>40</volume><fpage>331</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/phar.2375</pub-id><pub-id pub-id-type="pmid">32058614</pub-id><pub-id pub-id-type="pmcid">PMC7152563</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Burghardt KJ, Khoury AS, Msallaty Z, Yi Z, Seyoum B. Antipsychotic medications and DNA methylation in schizophrenia and bipolar disorder: a systematic review. Pharmacotherapy. 2020;40:331&#8211;42.<pub-id pub-id-type="pmid">32058614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.2375</pub-id><pub-id pub-id-type="pmcid">PMC7152563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rukova</surname><given-names>B</given-names></name><name name-style="western"><surname>Staneva</surname><given-names>R</given-names></name><name name-style="western"><surname>Hadjidekova</surname><given-names>S</given-names></name><name name-style="western"><surname>Stamenov</surname><given-names>G</given-names></name><name name-style="western"><surname>Milanova</surname><given-names>V</given-names></name><name name-style="western"><surname>Toncheva</surname><given-names>D</given-names></name></person-group><article-title>Whole genome methylation analyses of schizophrenia patients before and after treatment</article-title><source>Biotechnol Biotechnol Equip.</source><year>2014</year><volume>28</volume><fpage>518</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1080/13102818.2014.933501</pub-id><pub-id pub-id-type="pmid">26019538</pub-id><pub-id pub-id-type="pmcid">PMC4434134</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Rukova B, Staneva R, Hadjidekova S, Stamenov G, Milanova V, Toncheva D. Whole genome methylation analyses of schizophrenia patients before and after treatment. Biotechnol Biotechnol Equip. 2014;28:518&#8211;24.<pub-id pub-id-type="pmid">26019538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13102818.2014.933501</pub-id><pub-id pub-id-type="pmcid">PMC4434134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lokmer</surname><given-names>A</given-names></name><name name-style="western"><surname>Alladi</surname><given-names>CG</given-names></name><name name-style="western"><surname>Troudet</surname><given-names>R</given-names></name><name name-style="western"><surname>Bacq-Daian</surname><given-names>D</given-names></name><name name-style="western"><surname>Boland-Auge</surname><given-names>A</given-names></name><name name-style="western"><surname>Latapie</surname><given-names>V</given-names></name><etal/></person-group><article-title>Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems</article-title><source>Epigenomics</source><year>2023</year><volume>15</volume><fpage>21</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.2217/epi-2023-0017</pub-id><pub-id pub-id-type="pmid">36919681</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lokmer A, Alladi CG, Troudet R, Bacq-Daian D, Boland-Auge A, Latapie V, et al. Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems. Epigenomics. 2023;15:21&#8211;38. 10.2217/epi-2023-0017<pub-id pub-id-type="pmid">36919681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/epi-2023-0017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Palaniyappan</surname><given-names>L</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Epigenetic profile of the immune system associated with symptom severity and treatment response in schizophrenia</article-title><source>J Psychiatry Neurosci</source><year>2024</year><volume>49</volume><fpage>E45</fpage><lpage>E58</lpage><pub-id pub-id-type="doi">10.1503/jpn.230099</pub-id><pub-id pub-id-type="pmid">38359932</pub-id><pub-id pub-id-type="pmcid">PMC10890792</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Tang Y, Tan Y, Palaniyappan L, Yao Y, Luo Q, Li Y. Epigenetic profile of the immune system associated with symptom severity and treatment response in schizophrenia. J Psychiatry Neurosci. 2024;49:E45&#8211;E58.<pub-id pub-id-type="pmid">38359932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/jpn.230099</pub-id><pub-id pub-id-type="pmcid">PMC10890792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>VK</given-names></name><name name-style="western"><surname>Spindola</surname><given-names>LM</given-names></name><name name-style="western"><surname>Stavrum</surname><given-names>A-K</given-names></name><name name-style="western"><surname>Costa</surname><given-names>GO</given-names></name><name name-style="western"><surname>Bugiga</surname><given-names>AVG</given-names></name><name name-style="western"><surname>Noto</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Longitudinal DNA methylation and cell-type proportions alterations in risperidone treatment response in first-episode psychosis</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2025</year><volume>139</volume><fpage>111402</fpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2025.111402</pub-id><pub-id pub-id-type="pmid">40393579</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Ota VK, Spindola LM, Stavrum A-K, Costa GO, Bugiga AVG, Noto MN, et al. Longitudinal DNA methylation and cell-type proportions alterations in risperidone treatment response in first-episode psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2025;139:111402 10.1016/j.pnpbp.2025.111402<pub-id pub-id-type="pmid">40393579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pnpbp.2025.111402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leucht</surname><given-names>S</given-names></name><name name-style="western"><surname>Winter-van Rossum</surname><given-names>I</given-names></name><name name-style="western"><surname>Heres</surname><given-names>S</given-names></name><name name-style="western"><surname>Arango</surname><given-names>C</given-names></name><name name-style="western"><surname>Fleischhacker</surname><given-names>WW</given-names></name><name name-style="western"><surname>Glenth&#248;j</surname><given-names>B</given-names></name><etal/></person-group><article-title>The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics</article-title><source>Schizophr Bull</source><year>2015</year><volume>41</volume><fpage>549</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbv019</pub-id><pub-id pub-id-type="pmid">25786408</pub-id><pub-id pub-id-type="pmcid">PMC4393704</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, Glenth&#248;j B, et al. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015;41:549&#8211;58.<pub-id pub-id-type="pmid">25786408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/schbul/sbv019</pub-id><pub-id pub-id-type="pmcid">PMC4393704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahn</surname><given-names>RS</given-names></name><name name-style="western"><surname>Winter van Rossum</surname><given-names>I</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S</given-names></name><name name-style="western"><surname>Mcguire</surname><given-names>P</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>SW</given-names></name><name name-style="western"><surname>Leboyer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study</article-title><source>Lancet Psychiatry</source><year>2018</year><volume>5</volume><fpage>797</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(18)30252-9</pub-id><pub-id pub-id-type="pmid">30115598</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Kahn RS, Winter van Rossum I, Leucht S, Mcguire P, Lewis SW, Leboyer M, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5:797&#8211;807.<pub-id pub-id-type="pmid">30115598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(18)30252-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahn</surname><given-names>RS</given-names></name><name name-style="western"><surname>Fleischhacker</surname><given-names>WW</given-names></name><name name-style="western"><surname>Boter</surname><given-names>H</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>M</given-names></name><name name-style="western"><surname>Vergouwe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Keet</surname><given-names>IP</given-names></name><etal/></person-group><article-title>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>1085</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60486-9</pub-id><pub-id pub-id-type="pmid">18374841</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085&#8211;97.<pub-id pub-id-type="pmid">18374841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)60486-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leucht</surname><given-names>S</given-names></name><name name-style="western"><surname>Cipriani</surname><given-names>A</given-names></name><name name-style="western"><surname>Spineli</surname><given-names>L</given-names></name><name name-style="western"><surname>Mavridis</surname><given-names>D</given-names></name><name name-style="western"><surname>&#214;rey</surname><given-names>D</given-names></name><name name-style="western"><surname>Richter</surname><given-names>F</given-names></name><etal/></person-group><article-title>Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis</article-title><source>Lancet</source><year>2013</year><volume>382</volume><fpage>951</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60733-3</pub-id><pub-id pub-id-type="pmid">23810019</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Leucht S, Cipriani A, Spineli L, Mavridis D, &#214;rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951&#8211;62.<pub-id pub-id-type="pmid">23810019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)60733-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troudet</surname><given-names>R</given-names></name><name name-style="western"><surname>Ali</surname><given-names>WBH</given-names></name><name name-style="western"><surname>Bacq-Daian</surname><given-names>D</given-names></name><name name-style="western"><surname>Rossum</surname><given-names>IWV</given-names></name><name name-style="western"><surname>Boland-Auge</surname><given-names>A</given-names></name><name name-style="western"><surname>Battail</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses</article-title><source>Neuropsychopharmacology</source><year>2020</year><volume>45</volume><fpage>1637</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/s41386-020-0703-2</pub-id><pub-id pub-id-type="pmid">32450569</pub-id><pub-id pub-id-type="pmcid">PMC7421408</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Troudet R, Ali WBH, Bacq-Daian D, Rossum IWV, Boland-Auge A, Battail C, et al. Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses. Neuropsychopharmacology. 2020;45:1637&#8211;44.<pub-id pub-id-type="pmid">32450569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-020-0703-2</pub-id><pub-id pub-id-type="pmcid">PMC7421408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fond</surname><given-names>G</given-names></name><name name-style="western"><surname>d&#8217;Albis</surname><given-names>M-A</given-names></name><name name-style="western"><surname>Jamain</surname><given-names>S</given-names></name><name name-style="western"><surname>Tamouza</surname><given-names>R</given-names></name><name name-style="western"><surname>Arango</surname><given-names>C</given-names></name><name name-style="western"><surname>Fleischhacker</surname><given-names>WW</given-names></name><etal/></person-group><article-title>The promise of biological markers for treatment response in first-episode psychosis: a systematic review</article-title><source>Schizophr Bull</source><year>2015</year><volume>41</volume><fpage>559</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbv002</pub-id><pub-id pub-id-type="pmid">25759473</pub-id><pub-id pub-id-type="pmcid">PMC4393702</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Fond G, d&#8217;Albis M-A, Jamain S, Tamouza R, Arango C, Fleischhacker WW, et al. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull. 2015;41:559&#8211;73.<pub-id pub-id-type="pmid">25759473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/schbul/sbv002</pub-id><pub-id pub-id-type="pmcid">PMC4393702</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinuzzi</surname><given-names>E</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>S</given-names></name><name name-style="western"><surname>Daoudlarian</surname><given-names>D</given-names></name><name name-style="western"><surname>Bel Haj Ali</surname><given-names>W</given-names></name><name name-style="western"><surname>Gilet</surname><given-names>C</given-names></name><name name-style="western"><surname>Fillatre</surname><given-names>L</given-names></name><etal/></person-group><article-title>Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study</article-title><source>Transl Psychiatry</source><year>2019</year><volume>9</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">30655509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-018-0366-5</pub-id><pub-id pub-id-type="pmcid">PMC6336802</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Martinuzzi E, Barbosa S, Daoudlarian D, Bel Haj Ali W, Gilet C, Fillatre L, et al. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatry. 2019;9:1&#8211;13.<pub-id pub-id-type="pmid">30655509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-018-0366-5</pub-id><pub-id pub-id-type="pmcid">PMC6336802</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="book"><person-group person-group-type="author"><collab>R Core Team.</collab></person-group><source>R: a language and environment for statistical computing</source><year>2020</year><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name></element-citation><mixed-citation id="mc-CR23" publication-type="book">R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dedeurwaerder</surname><given-names>S</given-names></name><name name-style="western"><surname>Defrance</surname><given-names>M</given-names></name><name name-style="western"><surname>Bizet</surname><given-names>M</given-names></name><name name-style="western"><surname>Calonne</surname><given-names>E</given-names></name><name name-style="western"><surname>Bontempi</surname><given-names>G</given-names></name><name name-style="western"><surname>Fuks</surname><given-names>F</given-names></name></person-group><article-title>A comprehensive overview of Infinium HumanMethylation450 data processing</article-title><source>Brief Bioinform</source><year>2014</year><volume>15</volume><fpage>929</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1093/bib/bbt054</pub-id><pub-id pub-id-type="pmid">23990268</pub-id><pub-id pub-id-type="pmcid">PMC4239800</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. A comprehensive overview of Infinium HumanMethylation450 data processing. Brief Bioinform. 2014;15:929&#8211;41.<pub-id pub-id-type="pmid">23990268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbt054</pub-id><pub-id pub-id-type="pmcid">PMC4239800</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pidsley</surname><given-names>R</given-names></name><name name-style="western"><surname>Zotenko</surname><given-names>E</given-names></name><name name-style="western"><surname>Peters</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>MG</given-names></name><name name-style="western"><surname>Risbridger</surname><given-names>GP</given-names></name><name name-style="western"><surname>Molloy</surname><given-names>P</given-names></name><etal/></person-group><article-title>Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling</article-title><source>Genome Biol</source><year>2016</year><volume>17</volume><fpage>208</fpage><pub-id pub-id-type="doi">10.1186/s13059-016-1066-1</pub-id><pub-id pub-id-type="pmid">27717381</pub-id><pub-id pub-id-type="pmcid">PMC5055731</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016;17:208.<pub-id pub-id-type="pmid">27717381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-016-1066-1</pub-id><pub-id pub-id-type="pmcid">PMC5055731</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez</surname><given-names>L</given-names></name><name name-style="western"><surname>Odom</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Young</surname><given-names>JI</given-names></name><name name-style="western"><surname>Martin</surname><given-names>ER</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>coMethDMR: accurate identification of co-methylated and differentially methylated regions in epigenome-wide association studies with continuous phenotypes</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><fpage>e98</fpage><pub-id pub-id-type="doi">10.1093/nar/gkz590</pub-id><pub-id pub-id-type="pmid">31291459</pub-id><pub-id pub-id-type="pmcid">PMC6753499</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Gomez L, Odom GJ, Young JI, Martin ER, Liu L, Chen X, et al. coMethDMR: accurate identification of co-methylated and differentially methylated regions in epigenome-wide association studies with continuous phenotypes. Nucleic Acids Res. 2019;47:e98<pub-id pub-id-type="pmid">31291459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkz590</pub-id><pub-id pub-id-type="pmcid">PMC6753499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>ME</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>K</given-names></name><name name-style="western"><surname>van Benthem</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>A</given-names></name><name name-style="western"><surname>Berg</surname><given-names>CW</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>A</given-names></name><etal/></person-group><article-title>glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling</article-title><source>R J</source><year>2017</year><volume>9</volume><fpage>378</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.32614/RJ-2017-066</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Brooks ME, Kristensen K, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R J. 2017;9:378&#8211;400.</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakdash</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Marusich</surname><given-names>LR</given-names></name></person-group><article-title>Repeated measures correlation</article-title><source>Front Psychol</source><year>2017</year><volume>8</volume><fpage>456</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2017.00456</pub-id><pub-id pub-id-type="pmid">28439244</pub-id><pub-id pub-id-type="pmcid">PMC5383908</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Bakdash JZ, Marusich LR. Repeated measures correlation. Front Psychol. 2017;8:456.<pub-id pub-id-type="pmid">28439244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2017.00456</pub-id><pub-id pub-id-type="pmcid">PMC5383908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hothorn</surname><given-names>T</given-names></name><name name-style="western"><surname>Buehlmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Kneib</surname><given-names>T</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>M</given-names></name><name name-style="western"><surname>Hofner</surname><given-names>B</given-names></name></person-group><article-title>Model-based boosting 2.0</article-title><source>JMLR</source><year>2010</year><volume>11</volume><fpage>2109</fpage><lpage>2113</lpage></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hothorn T, Buehlmann P, Kneib T, Schmid M, Hofner B. Model-based boosting 2.0. JMLR. 2010;11:2109&#8211;2113.</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meinshausen</surname><given-names>N</given-names></name><name name-style="western"><surname>B&#252;hlmann</surname><given-names>P</given-names></name></person-group><article-title>Stability selection</article-title><source>J R Stat Soc Ser B Stat Methodol</source><year>2010</year><volume>72</volume><fpage>417</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1467-9868.2010.00740.x</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Meinshausen N, B&#252;hlmann P. Stability selection. J R Stat Soc Ser B Stat Methodol. 2010;72:417&#8211;73.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chicco</surname><given-names>D</given-names></name><name name-style="western"><surname>Jurman</surname><given-names>G</given-names></name></person-group><article-title>The Matthews correlation coefficient (MCC) should replace the ROC AUC as the standard metric for assessing binary classification</article-title><source>BioData Min</source><year>2023</year><volume>16</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13040-023-00322-4</pub-id><pub-id pub-id-type="pmid">36800973</pub-id><pub-id pub-id-type="pmcid">PMC9938573</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Chicco D, Jurman G. The Matthews correlation coefficient (MCC) should replace the ROC AUC as the standard metric for assessing binary classification. BioData Min. 2023;16:4.<pub-id pub-id-type="pmid">36800973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13040-023-00322-4</pub-id><pub-id pub-id-type="pmcid">PMC9938573</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ter Hark</surname><given-names>SE</given-names></name><name name-style="western"><surname>Jamain</surname><given-names>S</given-names></name><name name-style="western"><surname>Schijven</surname><given-names>D</given-names></name><name name-style="western"><surname>Lin</surname><given-names>BD</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>MK</given-names></name><name name-style="western"><surname>Boland-Auge</surname><given-names>A</given-names></name><etal/></person-group><article-title>A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)</article-title><source>J Psychopharmacol</source><year>2020</year><volume>34</volume><fpage>524</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1177/0269881120907972</pub-id><pub-id pub-id-type="pmid">32126890</pub-id><pub-id pub-id-type="pmcid">PMC7222287</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">ter Hark SE, Jamain S, Schijven D, Lin BD, Bakker MK, Boland-Auge A, et al. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). J Psychopharmacol. 2020;34:524&#8211;31.<pub-id pub-id-type="pmid">32126890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0269881120907972</pub-id><pub-id pub-id-type="pmcid">PMC7222287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machiela</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>SJ</given-names></name></person-group><article-title>LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><fpage>3555</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv402</pub-id><pub-id pub-id-type="pmid">26139635</pub-id><pub-id pub-id-type="pmcid">PMC4626747</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555&#8211;7.<pub-id pub-id-type="pmid">26139635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btv402</pub-id><pub-id pub-id-type="pmcid">PMC4626747</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandal</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Haney</surname><given-names>JR</given-names></name><name name-style="western"><surname>Parikshak</surname><given-names>NN</given-names></name><name name-style="western"><surname>Leppa</surname><given-names>V</given-names></name><name name-style="western"><surname>Ramaswami</surname><given-names>G</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>C</given-names></name><etal/></person-group><article-title>Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>693</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1126/science.aad6469</pub-id><pub-id pub-id-type="pmid">29439242</pub-id><pub-id pub-id-type="pmcid">PMC5898828</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science. 2018;359:693&#8211;7.<pub-id pub-id-type="pmid">29439242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad6469</pub-id><pub-id pub-id-type="pmcid">PMC5898828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maffioletti</surname><given-names>E</given-names></name><name name-style="western"><surname>Valsecchi</surname><given-names>P</given-names></name><name name-style="western"><surname>Minelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Magri</surname><given-names>C</given-names></name><name name-style="western"><surname>Bonvicini</surname><given-names>C</given-names></name><name name-style="western"><surname>Barlati</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients</article-title><source>Drug Dev Res</source><year>2020</year><volume>81</volume><fpage>754</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1002/ddr.21686</pub-id><pub-id pub-id-type="pmid">32462699</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Maffioletti E, Valsecchi P, Minelli A, Magri C, Bonvicini C, Barlati S, et al. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug Dev Res. 2020;81:754&#8211;61.<pub-id pub-id-type="pmid">32462699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ddr.21686</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Src inhibition attenuates neuroinflammation and protects dopaminergic neurons in Parkinson&#8217;s disease models</article-title><source>Front Neurosci</source><year>2020</year><volume>14</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.3389/fnins.2020.00045</pub-id><pub-id pub-id-type="pmid">32132891</pub-id><pub-id pub-id-type="pmcid">PMC7040487</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Yang H, Wang L, Zang C, Wang Y, Shang J, Zhang Z, et al. Src inhibition attenuates neuroinflammation and protects dopaminergic neurons in Parkinson&#8217;s disease models. Front Neurosci. 2020;14:45.<pub-id pub-id-type="pmid">32132891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00045</pub-id><pub-id pub-id-type="pmcid">PMC7040487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Megat</surname><given-names>S</given-names></name><name name-style="western"><surname>Mora</surname><given-names>N</given-names></name><name name-style="western"><surname>Sanogo</surname><given-names>J</given-names></name><name name-style="western"><surname>Roman</surname><given-names>O</given-names></name><name name-style="western"><surname>Catanese</surname><given-names>A</given-names></name><name name-style="western"><surname>Alami</surname><given-names>NO</given-names></name><etal/></person-group><article-title>Integrative genetic analysis illuminates ALS heritability and identifies risk genes</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>342</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-35724-1</pub-id><pub-id pub-id-type="pmid">36670122</pub-id><pub-id pub-id-type="pmcid">PMC9860017</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Megat S, Mora N, Sanogo J, Roman O, Catanese A, Alami NO, et al. Integrative genetic analysis illuminates ALS heritability and identifies risk genes. Nat Commun. 2023;14:342.<pub-id pub-id-type="pmid">36670122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-35724-1</pub-id><pub-id pub-id-type="pmcid">PMC9860017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruderfer</surname><given-names>DM</given-names></name><name name-style="western"><surname>Charney</surname><given-names>AW</given-names></name><name name-style="western"><surname>Readhead</surname><given-names>B</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>BA</given-names></name><name name-style="western"><surname>K&#228;hler</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach</article-title><source>Lancet Psychiatry</source><year>2016</year><volume>3</volume><fpage>350</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(15)00553-2</pub-id><pub-id pub-id-type="pmid">26915512</pub-id><pub-id pub-id-type="pmcid">PMC4982509</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ruderfer DM, Charney AW, Readhead B, Kidd BA, K&#228;hler AK, Kenny PJ, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry. 2016;3:350&#8211;7.<pub-id pub-id-type="pmid">26915512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(15)00553-2</pub-id><pub-id pub-id-type="pmcid">PMC4982509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L-K</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y-Y-N</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>W-Q</given-names></name><etal/></person-group><article-title>Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis</article-title><source>Mil Med Res</source><year>2023</year><volume>10</volume><fpage>24</fpage><pub-id pub-id-type="pmid">37269009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40779-023-00459-7</pub-id><pub-id pub-id-type="pmcid">PMC10236828</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Guo L-K, Su Y, Zhang Y-Y-N, Yu H, Lu Z, Li W-Q, et al. Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis. Mil Med Res. 2023;10:24.<pub-id pub-id-type="pmid">37269009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40779-023-00459-7</pub-id><pub-id pub-id-type="pmcid">PMC10236828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huhn</surname><given-names>M</given-names></name><name name-style="western"><surname>Nikolakopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Schneider-Thoma</surname><given-names>J</given-names></name><name name-style="western"><surname>Krause</surname><given-names>M</given-names></name><name name-style="western"><surname>Samara</surname><given-names>M</given-names></name><name name-style="western"><surname>Peter</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis</article-title><source>Lancet</source><year>2019</year><volume>394</volume><fpage>939</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31135-3</pub-id><pub-id pub-id-type="pmid">31303314</pub-id><pub-id pub-id-type="pmcid">PMC6891890</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939&#8211;51.<pub-id pub-id-type="pmid">31303314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)31135-3</pub-id><pub-id pub-id-type="pmcid">PMC6891890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>LINC00612/miR-31-5p/Notch1 axis regulates apoptosis, inflammation, and oxidative stress in human pulmonary microvascular endothelial cells induced by cigarette smoke extract</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2020</year><volume>15</volume><fpage>2049</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.2147/COPD.S255696</pub-id><pub-id pub-id-type="pmid">32921999</pub-id><pub-id pub-id-type="pmcid">PMC7457876</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Luo J, Li L, Hu D, Zhang X. LINC00612/miR-31-5p/Notch1 axis regulates apoptosis, inflammation, and oxidative stress in human pulmonary microvascular endothelial cells induced by cigarette smoke extract. Int J Chron Obstruct Pulmon Dis. 2020;15:2049&#8211;60.<pub-id pub-id-type="pmid">32921999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/COPD.S255696</pub-id><pub-id pub-id-type="pmcid">PMC7457876</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopkins</surname><given-names>SC</given-names></name><name name-style="western"><surname>Ogirala</surname><given-names>A</given-names></name><name name-style="western"><surname>Loebel</surname><given-names>A</given-names></name><name name-style="western"><surname>Koblan</surname><given-names>KS</given-names></name></person-group><article-title>Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia</article-title><source>Schizophr Bull</source><year>2018</year><volume>44</volume><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbx101</pub-id><pub-id pub-id-type="pmid">28981857</pub-id><pub-id pub-id-type="pmcid">PMC5890480</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Hopkins SC, Ogirala A, Loebel A, Koblan KS. Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia. Schizophr Bull. 2018;44:593&#8211;602.<pub-id pub-id-type="pmid">28981857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/schbul/sbx101</pub-id><pub-id pub-id-type="pmcid">PMC5890480</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philippidou</surname><given-names>P</given-names></name><name name-style="western"><surname>Dasen</surname><given-names>JS</given-names></name></person-group><article-title>Hox genes: choreographers in neural development, architects of circuit organization</article-title><source>Neuron</source><year>2013</year><volume>80</volume><fpage>12</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.09.020</pub-id><pub-id pub-id-type="pmid">24094100</pub-id><pub-id pub-id-type="pmcid">PMC3835187</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Philippidou P, Dasen JS. Hox genes: choreographers in neural development, architects of circuit organization. Neuron. 2013;80:12&#8211;34.<pub-id pub-id-type="pmid">24094100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2013.09.020</pub-id><pub-id pub-id-type="pmcid">PMC3835187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Jager</surname><given-names>P</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>G</given-names></name><name name-style="western"><surname>Lunnon</surname><given-names>K</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>J</given-names></name><name name-style="western"><surname>Schalkwyk</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Alzheimery&#8217;s disease pathology is associated with early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci</article-title><source>Nat Neurosci</source><year>2014</year><volume>17</volume><fpage>1156</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nn.3786</pub-id><pub-id pub-id-type="pmid">25129075</pub-id><pub-id pub-id-type="pmcid">PMC4292795</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">De Jager P, Srivastava G, Lunnon K, Burgess J, Schalkwyk L, Yu L, et al. Alzheimery&#8217;s disease pathology is associated with early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17:1156&#8211;63.<pub-id pub-id-type="pmid">25129075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.3786</pub-id><pub-id pub-id-type="pmcid">PMC4292795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>DC</given-names></name><name name-style="western"><surname>Gorski</surname><given-names>PP</given-names></name><name name-style="western"><surname>Maasar</surname><given-names>MF</given-names></name><name name-style="western"><surname>Seaborne</surname><given-names>RA</given-names></name><name name-style="western"><surname>Baumert</surname><given-names>P</given-names></name><name name-style="western"><surname>Brown</surname><given-names>AD</given-names></name><etal/></person-group><article-title>DNA methylation across the genome in aged human skeletal muscle tissue and muscle-derived cells: the role of HOX genes and physical activity</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>15360</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-72730-z</pub-id><pub-id pub-id-type="pmid">32958812</pub-id><pub-id pub-id-type="pmcid">PMC7506549</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Turner DC, Gorski PP, Maasar MF, Seaborne RA, Baumert P, Brown AD, et al. DNA methylation across the genome in aged human skeletal muscle tissue and muscle-derived cells: the role of HOX genes and physical activity. Sci Rep. 2020;10:15360.<pub-id pub-id-type="pmid">32958812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-72730-z</pub-id><pub-id pub-id-type="pmcid">PMC7506549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gofflot</surname><given-names>F</given-names></name><name name-style="western"><surname>Lizen</surname><given-names>B</given-names></name></person-group><article-title>Emerging roles for HOX proteins in synaptogenesis</article-title><source>Int J Dev Biol</source><year>2018</year><volume>62</volume><fpage>807</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1387/ijdb.180299fg</pub-id><pub-id pub-id-type="pmid">30604850</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Gofflot F, Lizen B. Emerging roles for HOX proteins in synaptogenesis. Int J Dev Biol. 2018;62:807&#8211;18.<pub-id pub-id-type="pmid">30604850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1387/ijdb.180299fg</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name></person-group><article-title>From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics</article-title><source>Eur Psychiatry</source><year>2010</year><volume>25</volume><fpage>S12</fpage><lpage>S21</lpage><pub-id pub-id-type="doi">10.1016/S0924-9338(10)71701-6</pub-id><pub-id pub-id-type="pmid">20620881</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25:S12&#8211;S21.<pub-id pub-id-type="pmid">20620881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0924-9338(10)71701-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masana</surname><given-names>M</given-names></name><name name-style="western"><surname>Santana</surname><given-names>N</given-names></name><name name-style="western"><surname>Artigas</surname><given-names>F</given-names></name><name name-style="western"><surname>Bortolozzi</surname><given-names>A</given-names></name></person-group><article-title>Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review</article-title><source>Curr Top Med Chem</source><year>2012</year><volume>12</volume><fpage>2357</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.2174/156802612805289872</pub-id><pub-id pub-id-type="pmid">23279176</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Masana M, Santana N, Artigas F, Bortolozzi A. Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review. Curr Top Med Chem. 2012;12:2357&#8211;74.<pub-id pub-id-type="pmid">23279176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156802612805289872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hensler</surname><given-names>JG</given-names></name><name name-style="western"><surname>Artigas</surname><given-names>F</given-names></name><name name-style="western"><surname>Bortolozzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Daws</surname><given-names>LC</given-names></name><name name-style="western"><surname>Deurwaerd&#232;re</surname><given-names>PD</given-names></name><name name-style="western"><surname>Milan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Catecholamine/Serotonin interactions: systems thinking for brain function and disease</article-title><source>Adv Pharmacol</source><year>2013</year><volume>68</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1016/B978-0-12-411512-5.00009-9</pub-id><pub-id pub-id-type="pmid">24054145</pub-id><pub-id pub-id-type="pmcid">PMC3902978</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Hensler JG, Artigas F, Bortolozzi A, Daws LC, Deurwaerd&#232;re PD, Milan L, et al. Catecholamine/Serotonin interactions: systems thinking for brain function and disease. Adv Pharmacol. 2013;68:167.<pub-id pub-id-type="pmid">24054145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-411512-5.00009-9</pub-id><pub-id pub-id-type="pmcid">PMC3902978</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benaliouad</surname><given-names>F</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>S</given-names></name><name name-style="western"><surname>Rompr&#233;</surname><given-names>P-P</given-names></name></person-group><article-title>Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward</article-title><source>Neuropsychopharmacology</source><year>2007</year><volume>32</volume><fpage>551</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1301136</pub-id><pub-id pub-id-type="pmid">16794561</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Benaliouad F, Kapur S, Rompr&#233; P-P. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology. 2007;32:551&#8211;61.<pub-id pub-id-type="pmid">16794561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.npp.1301136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charron</surname><given-names>A</given-names></name><name name-style="western"><surname>Hage</surname><given-names>CE</given-names></name><name name-style="western"><surname>Servonnet</surname><given-names>A</given-names></name><name name-style="western"><surname>Samaha</surname><given-names>A-N</given-names></name></person-group><article-title>5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity</article-title><source>Eur Neuropsychopharmacol</source><year>2015</year><volume>25</volume><fpage>2381</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.10.002</pub-id><pub-id pub-id-type="pmid">26508706</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Charron A, Hage CE, Servonnet A, Samaha A-N. 5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity. Eur Neuropsychopharmacol. 2015;25:2381&#8211;93.<pub-id pub-id-type="pmid">26508706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euroneuro.2015.10.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blasi</surname><given-names>G</given-names></name><name name-style="western"><surname>Selvaggi</surname><given-names>P</given-names></name><name name-style="western"><surname>Fazio</surname><given-names>L</given-names></name><name name-style="western"><surname>Antonucci</surname><given-names>LA</given-names></name><name name-style="western"><surname>Taurisano</surname><given-names>P</given-names></name><name name-style="western"><surname>Masellis</surname><given-names>R</given-names></name><etal/></person-group><article-title>Variation in Dopamine D2 and Serotonin 5-HT2A receptor genes is associated with working memory processing and response to treatment with antipsychotics</article-title><source>Neuropsychopharmacology</source><year>2015</year><volume>40</volume><fpage>1600</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/npp.2015.5</pub-id><pub-id pub-id-type="pmid">25563748</pub-id><pub-id pub-id-type="pmcid">PMC4915265</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Blasi G, Selvaggi P, Fazio L, Antonucci LA, Taurisano P, Masellis R, et al. Variation in Dopamine D2 and Serotonin 5-HT2A receptor genes is associated with working memory processing and response to treatment with antipsychotics. Neuropsychopharmacology. 2015;40:1600&#8211;8.<pub-id pub-id-type="pmid">25563748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2015.5</pub-id><pub-id pub-id-type="pmcid">PMC4915265</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabotina</surname><given-names>AM</given-names></name><name name-style="western"><surname>Belinskaya</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zhuravlev</surname><given-names>AS</given-names></name><name name-style="western"><surname>Nasyrova</surname><given-names>RF</given-names></name><name name-style="western"><surname>Sosin</surname><given-names>DN</given-names></name><name name-style="western"><surname>Ershov</surname><given-names>EE</given-names></name><etal/></person-group><article-title>The influence of Rs6311 and Rs6313 polymorphisms of serotonin 2a receptor gene (HTR2A) on its mRNA and protein levels in peripheral blood leukocytes in treatment with antipsychotics</article-title><source>Cell Tissue Biol</source><year>2018</year><volume>12</volume><fpage>382</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1134/S1990519X18050115</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Zabotina AM, Belinskaya MA, Zhuravlev AS, Nasyrova RF, Sosin DN, Ershov EE, et al. The influence of Rs6311 and Rs6313 polymorphisms of serotonin 2a receptor gene (HTR2A) on its mRNA and protein levels in peripheral blood leukocytes in treatment with antipsychotics. Cell Tissue Biol. 2018;12:382&#8211;90.</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdani</surname><given-names>N</given-names></name><name name-style="western"><surname>Bonni&#232;re</surname><given-names>M</given-names></name><name name-style="western"><surname>Ad&#232;s</surname><given-names>J</given-names></name><name name-style="western"><surname>Hamon</surname><given-names>M</given-names></name><name name-style="western"><surname>Boni</surname><given-names>C</given-names></name><name name-style="western"><surname>Gorwood</surname><given-names>P</given-names></name></person-group><article-title>Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics</article-title><source>Neurosci Lett</source><year>2005</year><volume>377</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2004.11.070</pub-id><pub-id pub-id-type="pmid">15722190</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hamdani N, Bonni&#232;re M, Ad&#232;s J, Hamon M, Boni C, Gorwood P. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett. 2005;377:69&#8211;74.<pub-id pub-id-type="pmid">15722190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2004.11.070</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myers</surname><given-names>RL</given-names></name><name name-style="western"><surname>Airey</surname><given-names>DC</given-names></name><name name-style="western"><surname>Manier</surname><given-names>DH</given-names></name><name name-style="western"><surname>Shelton</surname><given-names>RC</given-names></name><name name-style="western"><surname>Sanders-Bush</surname><given-names>E</given-names></name></person-group><article-title>Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression</article-title><source>Biol Psychiatry</source><year>2007</year><volume>61</volume><fpage>167</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2005.12.018</pub-id><pub-id pub-id-type="pmid">16697352</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Myers RL, Airey DC, Manier DH, Shelton RC, Sanders-Bush E. Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol Psychiatry. 2007;61:167&#8211;73.<pub-id pub-id-type="pmid">16697352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2005.12.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>M</given-names></name><name name-style="western"><surname>Gray</surname><given-names>JA</given-names></name><name name-style="western"><surname>Roth</surname><given-names>BL</given-names></name></person-group><article-title>The expanded biology of serotonin</article-title><source>Annu Rev Med</source><year>2009</year><volume>60</volume><fpage>355</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.60.042307.110802</pub-id><pub-id pub-id-type="pmid">19630576</pub-id><pub-id pub-id-type="pmcid">PMC5864293</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355&#8211;66.<pub-id pub-id-type="pmid">19630576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.med.60.042307.110802</pub-id><pub-id pub-id-type="pmcid">PMC5864293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Pharmacogenetic correlates of antipsychotic-induced weight gain in the Chinese population</article-title><source>Neurosci Bull</source><year>2019</year><volume>35</volume><fpage>561</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s12264-018-0323-6</pub-id><pub-id pub-id-type="pmid">30607769</pub-id><pub-id pub-id-type="pmcid">PMC6527659</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Luo C, Liu J, Wang X, Mao X, Zhou H, Liu Z. Pharmacogenetic correlates of antipsychotic-induced weight gain in the Chinese population. Neurosci Bull. 2019;35:561&#8211;80.<pub-id pub-id-type="pmid">30607769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12264-018-0323-6</pub-id><pub-id pub-id-type="pmcid">PMC6527659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D-H</given-names></name><name name-style="western"><surname>Jun</surname><given-names>C-B</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y-M</given-names></name><name name-style="western"><surname>Haar</surname><given-names>EV</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><etal/></person-group><article-title>PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>25604</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1074/jbc.M704343200</pub-id><pub-id pub-id-type="pmid">17599906</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Woo S-Y, Kim D-H, Jun C-B, Kim Y-M, Haar EV, Lee S, et al. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem. 2007;282:25604&#8211;12.<pub-id pub-id-type="pmid">17599906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M704343200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dadalko</surname><given-names>OI</given-names></name><name name-style="western"><surname>Siuta</surname><given-names>M</given-names></name><name name-style="western"><surname>Poe</surname><given-names>A</given-names></name><name name-style="western"><surname>Erreger</surname><given-names>K</given-names></name><name name-style="western"><surname>Matthies</surname><given-names>HJG</given-names></name><name name-style="western"><surname>Niswender</surname><given-names>K</given-names></name><etal/></person-group><article-title>mTORC2/Rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission</article-title><source>J Neurosci</source><year>2015</year><volume>35</volume><fpage>8843</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0887-15.2015</pub-id><pub-id pub-id-type="pmid">26063917</pub-id><pub-id pub-id-type="pmcid">PMC4461689</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Dadalko OI, Siuta M, Poe A, Erreger K, Matthies HJG, Niswender K, et al. mTORC2/Rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission. J Neurosci. 2015;35:8843&#8211;54.<pub-id pub-id-type="pmid">26063917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0887-15.2015</pub-id><pub-id pub-id-type="pmcid">PMC4461689</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuo</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hou</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Mechanistic/mammalian target of rapamycin and side effects of antipsychotics: insights into mechanisms and implications for therapy</article-title><source>Transl Psychiatry</source><year>2022</year><volume>12</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41398-021-01778-w</pub-id><pub-id pub-id-type="pmid">35013125</pub-id><pub-id pub-id-type="pmcid">PMC8748807</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Zhuo C, Xu Y, Hou W, Chen J, Li Q, Liu Z, et al. Mechanistic/mammalian target of rapamycin and side effects of antipsychotics: insights into mechanisms and implications for therapy. Transl Psychiatry. 2022;12:1&#8211;8.<pub-id pub-id-type="pmid">35013125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-021-01778-w</pub-id><pub-id pub-id-type="pmcid">PMC8748807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>DR</given-names></name></person-group><article-title>Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology</article-title><source>Biomark Neuropsychiatry</source><year>2019</year><volume>1</volume><fpage>100006</fpage><pub-id pub-id-type="doi">10.1016/j.bionps.2019.100006</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Miller BJ, Goldsmith DR. Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology. Biomark Neuropsychiatry. 2019;1:100006.</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Amin</surname><given-names>MM</given-names></name><name name-style="western"><surname>Nasir Uddin</surname><given-names>MM</given-names></name><name name-style="western"><surname>Mahmud Reza</surname><given-names>H</given-names></name></person-group><article-title>Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures</article-title><source>Clin Psychopharmacol Neurosci</source><year>2013</year><volume>11</volume><fpage>144</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.9758/cpn.2013.11.3.144</pub-id><pub-id pub-id-type="pmid">24465251</pub-id><pub-id pub-id-type="pmcid">PMC3897763</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Al-Amin MM, Nasir Uddin MM, Mahmud Reza H. Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures. Clin Psychopharmacol Neurosci. 2013;11:144&#8211;51.<pub-id pub-id-type="pmid">24465251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.9758/cpn.2013.11.3.144</pub-id><pub-id pub-id-type="pmcid">PMC3897763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X-S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Altered peripheral immune profiles in first-episode, drug-free patients with schizophrenia: response to antipsychotic medications</article-title><source>Front Med</source><year>2021</year><volume>8</volume><fpage>757655</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.757655</pub-id><pub-id pub-id-type="pmcid">PMC8652082</pub-id><pub-id pub-id-type="pmid">34901070</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Chen L, Zheng W-H, Du Y, Li X-S, Yu Y, Wang H, et al. Altered peripheral immune profiles in first-episode, drug-free patients with schizophrenia: response to antipsychotic medications. Front Med. 2021;8:757655.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2021.757655</pub-id><pub-id pub-id-type="pmcid">PMC8652082</pub-id><pub-id pub-id-type="pmid">34901070</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Association between FoxO1, A2M, and TGF-&#946;1, environmental factors, and major depressive disorder</article-title><source>Front Psychiatry</source><year>2020</year><volume>11</volume><fpage>675</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2020.00675</pub-id><pub-id pub-id-type="pmid">32792993</pub-id><pub-id pub-id-type="pmcid">PMC7394695</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Zhao M, Chen L, Qiao Z, Zhou J, Zhang T, Zhang W, et al. Association between FoxO1, A2M, and TGF-&#946;1, environmental factors, and major depressive disorder. Front Psychiatry. 2020;11:675.<pub-id pub-id-type="pmid">32792993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2020.00675</pub-id><pub-id pub-id-type="pmcid">PMC7394695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smirnova</surname><given-names>L</given-names></name><name name-style="western"><surname>Seregin</surname><given-names>A</given-names></name><name name-style="western"><surname>Boksha</surname><given-names>I</given-names></name><name name-style="western"><surname>Dmitrieva</surname><given-names>E</given-names></name><name name-style="western"><surname>Simutkin</surname><given-names>G</given-names></name><name name-style="western"><surname>Kornetova</surname><given-names>E</given-names></name><etal/></person-group><article-title>The difference in serum proteomes in schizophrenia and bipolar disorder</article-title><source>BMC Genomics</source><year>2019</year><volume>20</volume><fpage>535</fpage><pub-id pub-id-type="doi">10.1186/s12864-019-5848-1</pub-id><pub-id pub-id-type="pmid">31291891</pub-id><pub-id pub-id-type="pmcid">PMC6620192</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Smirnova L, Seregin A, Boksha I, Dmitrieva E, Simutkin G, Kornetova E, et al. The difference in serum proteomes in schizophrenia and bipolar disorder. BMC Genomics. 2019;20:535.<pub-id pub-id-type="pmid">31291891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12864-019-5848-1</pub-id><pub-id pub-id-type="pmcid">PMC6620192</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cater</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kumita</surname><given-names>JR</given-names></name><name name-style="western"><surname>Zeineddine Abdallah</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Bernardo-Gancedo</surname><given-names>A</given-names></name><name name-style="western"><surname>Henry</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human pregnancy zone protein stabilizes misfolded proteins including preeclampsia- and Alzheimer&#8217;s-associated amyloid beta peptide</article-title><source>Proc Natl Acad Sci USA</source><year>2019</year><volume>116</volume><fpage>6101</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1073/pnas.1817298116</pub-id><pub-id pub-id-type="pmid">30850528</pub-id><pub-id pub-id-type="pmcid">PMC6442606</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Cater JH, Kumita JR, Zeineddine Abdallah R, Zhao G, Bernardo-Gancedo A, Henry A, et al. Human pregnancy zone protein stabilizes misfolded proteins including preeclampsia- and Alzheimer&#8217;s-associated amyloid beta peptide. Proc Natl Acad Sci USA. 2019;116:6101&#8211;10.<pub-id pub-id-type="pmid">30850528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1817298116</pub-id><pub-id pub-id-type="pmcid">PMC6442606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komossa</surname><given-names>K</given-names></name><name name-style="western"><surname>Rummel&#8208;Kluge</surname><given-names>C</given-names></name><name name-style="western"><surname>Hunger</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>F</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>S</given-names></name><name name-style="western"><surname>Silveira da Mota Neto</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Amisulpride versus other atypical antipsychotics for schizophrenia</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><volume>2010</volume><fpage>CD006624</fpage><pub-id pub-id-type="pmid">20091599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD006624.pub2</pub-id><pub-id pub-id-type="pmcid">PMC4164462</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Komossa K, Rummel&#8208;Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;2010:CD006624.<pub-id pub-id-type="pmid">20091599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD006624.pub2</pub-id><pub-id pub-id-type="pmcid">PMC4164462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnsen</surname><given-names>E</given-names></name><name name-style="western"><surname>Kroken</surname><given-names>RA</given-names></name><name name-style="western"><surname>L&#248;berg</surname><given-names>E-M</given-names></name><name name-style="western"><surname>Rettenbacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Joa</surname><given-names>I</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial</article-title><source>Lancet Psychiatry</source><year>2020</year><volume>7</volume><fpage>945</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(20)30341-2</pub-id><pub-id pub-id-type="pmid">33069317</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Johnsen E, Kroken RA, L&#248;berg E-M, Rettenbacher M, Joa I, Larsen TK, et al. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. Lancet Psychiatry. 2020;7:945&#8211;54.<pub-id pub-id-type="pmid">33069317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30341-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name></person-group><article-title>Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study</article-title><source>Neuropsychiatr Dis Treat</source><year>2017</year><volume>13</volume><fpage>1703</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.2147/NDT.S140905</pub-id><pub-id pub-id-type="pmid">28721051</pub-id><pub-id pub-id-type="pmcid">PMC5499925</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Liang Y, Yu X. Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study. Neuropsychiatr Dis Treat. 2017;13:1703&#8211;12.<pub-id pub-id-type="pmid">28721051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S140905</pub-id><pub-id pub-id-type="pmcid">PMC5499925</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>Z-M</given-names></name><name name-style="western"><surname>Men</surname><given-names>P</given-names></name><name name-style="western"><surname>Qu</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>S</given-names></name></person-group><article-title>Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China</article-title><source>Expert Rev. Pharmacoecon Outcomes Res</source><year>2020</year><volume>20</volume><fpage>313</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1080/14737167.2020.1752670</pub-id><pub-id pub-id-type="pmid">32293194</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Yi Z-M, Men P, Qu S, Li C, Yu X, Zhai S. Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. Expert Rev. Pharmacoecon Outcomes Res. 2020;20:313&#8211;20.<pub-id pub-id-type="pmid">32293194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737167.2020.1752670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hannon</surname><given-names>E</given-names></name><name name-style="western"><surname>Lunnon</surname><given-names>K</given-names></name><name name-style="western"><surname>Schalkwyk</surname><given-names>L</given-names></name><name name-style="western"><surname>Mill</surname><given-names>J</given-names></name></person-group><article-title>Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes</article-title><source>Epigenetics</source><year>2015</year><volume>10</volume><fpage>1024</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1080/15592294.2015.1100786</pub-id><pub-id pub-id-type="pmid">26457534</pub-id><pub-id pub-id-type="pmcid">PMC4844197</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Hannon E, Lunnon K, Schalkwyk L, Mill J. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics. 2015;10:1024&#8211;32.<pub-id pub-id-type="pmid">26457534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15592294.2015.1100786</pub-id><pub-id pub-id-type="pmcid">PMC4844197</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gladkevich</surname><given-names>A</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>HF</given-names></name><name name-style="western"><surname>Korf</surname><given-names>J</given-names></name></person-group><article-title>Lymphocytes as a neural probe: potential for studying psychiatric disorders</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2004</year><volume>28</volume><fpage>559</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2004.01.009</pub-id><pub-id pub-id-type="pmid">15093964</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:559&#8211;76.<pub-id pub-id-type="pmid">15093964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pnpbp.2004.01.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Mierlo</surname><given-names>HC</given-names></name><name name-style="western"><surname>Broen</surname><given-names>JCA</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>RS</given-names></name><name name-style="western"><surname>de Witte</surname><given-names>LD</given-names></name></person-group><article-title>B-cells and schizophrenia: a promising link or a finding lost in translation?</article-title><source>Brain Behav Immun</source><year>2019</year><volume>81</volume><fpage>52</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2019.06.043</pub-id><pub-id pub-id-type="pmid">31271869</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">van Mierlo HC, Broen JCA, Kahn RS, de Witte LD. B-cells and schizophrenia: a promising link or a finding lost in translation? Brain Behav Immun. 2019;81:52&#8211;62.<pub-id pub-id-type="pmid">31271869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2019.06.043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Sandberg AA, Steen VM, Torsvik A. Is elevated neutrophil count and neutrophil-to-lymphocyte ratio a cause or consequence of schizophrenia?&#8212;a scoping review. Front Psychiatry. 2021;12. 10.3389/fpsyt.2021.728990.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.728990</pub-id><pub-id pub-id-type="pmcid">PMC8483576</pub-id><pub-id pub-id-type="pmid">34603107</pub-id></mixed-citation></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaffe</surname><given-names>AE</given-names></name><name name-style="western"><surname>Irizarry</surname><given-names>RA</given-names></name></person-group><article-title>Accounting for cellular heterogeneity is critical in epigenome-wide association studies</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><fpage>R31</fpage><pub-id pub-id-type="doi">10.1186/gb-2014-15-2-r31</pub-id><pub-id pub-id-type="pmid">24495553</pub-id><pub-id pub-id-type="pmcid">PMC4053810</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Jaffe AE, Irizarry RA. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol. 2014;15:R31.<pub-id pub-id-type="pmid">24495553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2014-15-2-r31</pub-id><pub-id pub-id-type="pmcid">PMC4053810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaunt</surname><given-names>TR</given-names></name><name name-style="western"><surname>Shihab</surname><given-names>HA</given-names></name><name name-style="western"><surname>Hemani</surname><given-names>G</given-names></name><name name-style="western"><surname>Min</surname><given-names>JL</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>G</given-names></name><name name-style="western"><surname>Lyttleton</surname><given-names>O</given-names></name><etal/></person-group><article-title>Systematic identification of genetic influences on methylation across the human life course</article-title><source>Genome Biol</source><year>2016</year><volume>17</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s13059-016-0926-z</pub-id><pub-id pub-id-type="pmid">27036880</pub-id><pub-id pub-id-type="pmcid">PMC4818469</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Gaunt TR, Shihab HA, Hemani G, Min JL, Woodward G, Lyttleton O, et al. Systematic identification of genetic influences on methylation across the human life course. Genome Biol. 2016;17:61.<pub-id pub-id-type="pmid">27036880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-016-0926-z</pub-id><pub-id pub-id-type="pmcid">PMC4818469</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Takata</surname><given-names>A</given-names></name></person-group><article-title>The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research</article-title><source>Mol Psychiatry</source><year>2023</year><volume>28</volume><fpage>1868</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/s41380-023-02005-2</pub-id><pub-id pub-id-type="pmid">36878965</pub-id><pub-id pub-id-type="pmcid">PMC10575785</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Nakamura T, Takata A. The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research. Mol Psychiatry. 2023;28:1868&#8211;89.<pub-id pub-id-type="pmid">36878965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02005-2</pub-id><pub-id pub-id-type="pmcid">PMC10575785</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501336</article-id><article-id pub-id-type="pmcid-ver">PMC12501336.1</article-id><article-id pub-id-type="pmcaid">12501336</article-id><article-id pub-id-type="pmcaiid">12501336</article-id><article-id pub-id-type="pmid">40750515</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100317</article-id><article-id pub-id-type="pii">S2274-5807(25)00260-2</article-id><article-id pub-id-type="publisher-id">100317</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Psychiatry meets neurodegeneration &#8211; A collaborative approach to dementia prevention<sup><xref ref-type="fn" rid="d36e29">&#9734;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Kurz</surname><given-names initials="C">Carolin</given-names></name><email>carolin.kurz@med.uni-muenchen.de</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Haupt</surname><given-names initials="M">Martin</given-names></name><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Auer</surname><given-names initials="S">Stefanie</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Lautenschlager</surname><given-names initials="N">Nicola</given-names></name><xref rid="aff0005" ref-type="aff">e</xref><xref rid="aff0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Kurz</surname><given-names initials="A">Alexander</given-names></name><xref rid="aff0007" ref-type="aff">g</xref></contrib><aff id="aff0001"><label>a</label>Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany</aff><aff id="aff0002"><label>b</label>Department of the History, Philosophy and Ethics of Medicine, Heinrich Heine University, D&#252;sseldorf, Germany</aff><aff id="aff0003"><label>c</label>Teaching practice of the Clinic and Polyclinic for Psychiatry and Psychotherapy of the Heinrich Heine University, D&#252;sseldorf, Germany</aff><aff id="aff0004"><label>d</label>Department for Dementia Research and Care Science, University for Continuing Education Krems, Austria</aff><aff id="aff0005"><label>e</label>Department of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia</aff><aff id="aff0006"><label>f</label>Royal Melbourne Hospital Mental Health Services, Royal Melbourne Hospital, Parkville, Victoria, Australia</aff><aff id="aff0007"><label>g</label>Department of Psychiatry and Psychotherapy, Centre for Cognitive Disorders, School of Medicine, Technical University of Munich, Munich, Germany</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nu&#223;baumstr. 7, 80336 Munich, Germany. <email>carolin.kurz@med.uni-muenchen.de</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>7</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100317</elocation-id><history><date date-type="received"><day>12</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>5</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Crown Copyright &#169; 2025 Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><p>The advent of amyloid-targeting therapies and biomarker-based risk stratification has transformed the understanding of Alzheimer&#8217;s disease and related disorders. These conditions are now recognized as chronic, detectable and modifiable, often presenting decades before clinical symptoms appear. While this paradigm shift enables earlier intervention, it also raises ethical and psychological challenges that necessitate a redefined role for psychiatry. Instead of merely supporting late-stage care, psychiatry is well-placed to facilitate risk communication, promote resilience, and encourage adaptive behavior in individuals navigating preclinical or prodromal neurodegeneration. This article outlines an ethical, stepwise communication framework, clarifies the distinction between diagnosis and probabilistic risk, and explores psychiatric contributions&#8212;from motivational models to lifestyle-based prevention&#8212;that bridge the gap between biological insight and subjective experience. By reinterpreting risk as a chance for intervention rather than resignation, psychiatry broadens the therapeutic scope and helps safeguard independence, dignity and quality of life&#8212;making it a pivotal participant in dementia prevention and individualized, person-centered care.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Patient-centered care</kwd><kwd>Quality of life</kwd><kwd>Neurodegenerative diseases</kwd><kwd>Cognitive dysfunction/prevention &amp; control</kwd><kwd>Dementia/prevention &amp; control</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction &#8211; from organic psychoses to precision psychiatry</title><p id="para0002">Historically classified as &#8216;organic psychoses&#8217;, Alzheimer&#8217;s disease (AD) has held a unique position in psychiatry due to its clearly identifiable neuropathological features, which have profoundly shaped psychiatry&#8217;s emphasis on brain-based mechanisms in the understanding and treatment of mental illness [<xref rid="bib0001" ref-type="bibr">1</xref>]. With the advent of amyloid-targeting therapies and a shift towards a biologically based definition of Alzheimer's disease (AD), the historical arc comes full circle &#8211; linking past biological concepts to current approaches that emphasize pathology-driven interventions even before clinical symptoms emerge [<xref rid="bib0002" ref-type="bibr">2</xref>,<xref rid="bib0003" ref-type="bibr">3</xref>]. Psychiatry is faced with the task of not only interpreting pathological findings, but also contributing to prevention, emotional adaptation, and lifestyle change starting at the presymptomatic stage -empowering individuals to engage actively in their own brain health. Early diagnosis is becoming not only medically but also psychologically and ethically relevant, redefining psychiatry&#8217;s role from late-stage support to early intervention.</p></sec><sec id="sec0002"><label>2</label><title>Conceptual foundations: bridging risk and diagnosis</title><p id="para0003">Increased screening and recognition of neurodegeneration as a chronic disease with a long latency period - often 10 to 20 years - create valuable opportunities for early prevention, intervention, and informed decision-making [<xref rid="bib0004" ref-type="bibr">4</xref>]. The growing use of biomarkers in preclinical stages raises fundamental questions: when pathology is present without symptoms, is it disease or an at-risk state? [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0006" ref-type="bibr">6</xref>]. Communicating probabilistic information demands care: without explanation, individuals may feel falsely reassured or needlessly alarmed. Ethical, value-based communication is essential to empower rather than to harm [<xref rid="bib0007" ref-type="bibr">7</xref>]. While the public health benefits of early detection are compelling, they must be weighed against ethical and practical challenges [<xref rid="bib0008" ref-type="bibr">8</xref>].</p></sec><sec id="sec0003"><label>3</label><title>Presymptomatic screening &#8211; chance or risk?</title><p id="para0004">Advances in biomarkers and therapies have sparked debate on how to define and communicate presymptomatic stages, highlighting tensions between identifying biological risk and avoiding premature diagnostic labels [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0006" ref-type="bibr">6</xref>]. At the same time, defining early symptoms in neurodegenerative diseases remains a major challenge. Initial changes&#8212;such as apathy, anxiety, irritability, or subtle changes in personality - are often nuanced and gradual, and are increasingly conceptualized under the term <italic toggle="yes">mild behavioral impairment</italic> [<xref rid="bib0009" ref-type="bibr">9</xref>,<xref rid="bib0010" ref-type="bibr">10</xref>]. These symptoms can be difficult to distinguish from normal variation, adding complexity to early detection strategies. Nonetheless, biomarker-based approaches primarily target Alzheimer&#8217;s disease but frequently detect non-AD disorders - especially in ageing populations, where 30&#8211;50 % with early symptoms have alternative or mixed aetiologies [<xref rid="bib0011" ref-type="bibr">11</xref>]. Furthermore, a considerable number of people with preclinical AD may be excluded from amyloid-targeting therapies due to strict trial or treatment criteria [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>]. These realities call for early identification not only as a treatment precursor but as a public health opportunity to provide prevention and reduce future burden [<xref rid="bib0014" ref-type="bibr">14</xref>]. The debate surrounding the early diagnosis of Alzheimer's disease (AD), particularly in the presymptomatic or at-risk stages, requires careful consideration of the potential individual benefits and risks, as well as integration into an evidence-based, ethically sound framework.</p></sec><sec id="sec0004"><label>4</label><title>Psychiatry&#8217;s role in prevention of dementia</title><p id="para0005">Earlier recognition opens a window for pro-active self-management&#8212;something long hindered by delayed diagnosis [<xref rid="bib0015" ref-type="bibr">15</xref>]. Given that 20&#8211;47 % of people over 60 express concern about developing dementia, many are motivated to take preventive action [<xref rid="bib0016" ref-type="bibr">16</xref>]. Mental health professionals offer unique expertise in communicating risk, managing uncertainty, and supporting emotional resilience&#8212;key to enabling behavior change and long-term motivation [<xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>, <xref rid="bib0019" ref-type="bibr">[19]</xref>]. Psychiatry plays a direct role in reducing modifiable risk factors by offering targeted interventions that integrate psychosocial and somatic care. These include promoting healthy behaviors such as physical activity, smoking cessation, weight management, and controlling vascular risk factors like hypertension and hypercholesterolemia [<xref rid="bib0020" ref-type="bibr">[20]</xref>, <xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>]. Additionally, the treatment of depression, anxiety, and sleep disturbances can further enhance cognitive outcomes and quality of life [<xref rid="bib0023" ref-type="bibr">23</xref>]. Despite methodological challenges&#8212;such as reliance on observational data, confounding variables, and heterogeneous study designs&#8212;prevention remains a cornerstone of dementia strategy. Early, structured, and inclusive interventions show great potential, particularly in underserved populations. To ensure effectiveness, it is crucial to investigate which modifiable risk factors, in which combinations and at which stages, yield the greatest benefit for specific dementia subtypes. Dementia prevention should be considered a collective societal responsibility, with psychiatry playing an integral role in fostering sustainable, interdisciplinary approaches.</p></sec><sec id="sec0005"><label>5</label><title>Challenges and ethical considerations of early diagnosis</title><p id="para0006">The growing focus on early detection must be balanced with consideration of the potential risks. Early diagnosis can cause anxiety and stigmatization, particularly since it is estimated that 20&#8211;30 % of individuals with positive AD biomarkers will never exhibit clinical symptoms [<xref rid="bib0024" ref-type="bibr">[24]</xref>, <xref rid="bib0025" ref-type="bibr">[25]</xref>, <xref rid="bib0026" ref-type="bibr">[26]</xref>]. Consequently, full-scale population screening is problematic and a targeted case-finding strategy - focusing on individuals with early symptoms or defined risk factors - offers a more effective, ethical, and resource-efficient approach &#8211; and also justifies initiating diagnostic steps [<xref rid="bib0015" ref-type="bibr">15</xref>,<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0027" ref-type="bibr">27</xref>].</p><p id="para0007">The <italic toggle="yes">psychiatric middle ground</italic> offers a conceptual and clinical framework for navigating the presymptomatic and transitional stages of neurodegenerative diseases such as AD (see <xref rid="fig0001" ref-type="fig">Fig. 1</xref>). It advocates for clear, ethically sound nomenclature that distinguishes between risk states, prodromal stages, and clinical diagnoses&#8212;ensuring transparent communication while minimizing harm [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>].<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Navigating the Stages of Alzheimer&#8217;s Disease by a stepwise approach.</p><p>Schematic overview of the clinical trajectory in Alzheimer&#8217;s disease, from normal ageing to dementia. The diagram integrates biological and clinical indicators with psychiatric roles and public health strategies. It distinguishes between at-risk and diagnostic stages and emphasizes proactive, ethically sound approaches to risk communication, prevention, and support. The model highlights the <italic toggle="yes">psychiatric middle ground</italic> - bridging biological changes and lived experience&#8212;thereby supporting person-centered care across all stages of the disease [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0006" ref-type="bibr">6</xref>] ADL &#8211; activities of daily living.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0006"><label>6</label><title>Risk communication and behavior change</title><p id="para0008">Psychiatry plays a key role in promoting sustained behavioral change by communicating risk, fostering motivation and resilience, and applying strategies such as self-regulation, motivation techniques, and habit formation to support long-term adherence to risk-reduction. Early identification through biomarkers can open a critical window for enabling individuals to adopt lifestyle changes that have a beneficial effect on brain plasticity and stress response [<xref rid="bib0007" ref-type="bibr">7</xref>,<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>,<xref rid="bib0023" ref-type="bibr">23</xref>,<xref rid="bib0029" ref-type="bibr">29</xref>].</p></sec><sec id="sec0007"><label>7</label><title>From risk to resilience &#8211; A new preventive paradigm</title><p id="para0009">Understanding why some individuals remain symptom-free despite biomarker-positive profiles points to resilience as a modifiable construct that can be actively promoted [<xref rid="bib0030" ref-type="bibr">[30]</xref>, <xref rid="bib0031" ref-type="bibr">[31]</xref>, <xref rid="bib0032" ref-type="bibr">[32]</xref>, <xref rid="bib0033" ref-type="bibr">[33]</xref>]. Resilience factors such as optimism, emotional regulation, social connectedness, structured routines, and relationship building carry biological significance and may mitigate the impact of progressive neurobiological alterations [<xref rid="bib0030" ref-type="bibr">30</xref>]. Effective dementia prevention requires more than awareness - it depends on enabling and sustaining meaningful behavior change across individual and societal levels. Key principles include the promotion of acceptance, the equipping of individuals with practical skills and the encouragement of a mindset that is adaptive rather than merely reactive [<xref rid="bib0034" ref-type="bibr">34</xref>].</p></sec><sec id="sec0008"><label>8</label><title>Shifting the focus toward quality of life and personhood</title><p id="para0010">Independent of eligibility for amyloid-targeting therapies, treatment should prioritize factors that affect quality of life rather than focusing solely on cognitive decline. Effective medical treatment goes beyond pathology and should include supporting functional abilities, compensating for difficulties, improving communication and promoting overall well-being while maintaining hope, self-determination and a sense of purpose to help individuals adapt to their changing circumstances and counters age-related stereotypes [<xref rid="bib0035" ref-type="bibr">[35]</xref>, <xref rid="bib0036" ref-type="bibr">[36]</xref>, <xref rid="bib0037" ref-type="bibr">[37]</xref>]. Recognizing the potential of individuals at every stage of life is essential to fostering a culture of respect, equity and inclusion in health care [<xref rid="bib0038" ref-type="bibr">38</xref>]. Tailoring therapies to cognitive and emotional changes, engaging caregivers as partners in care, and providing structured, accessible interventions enhance equitable and effective treatment [<xref rid="bib0039" ref-type="bibr">39</xref>,<xref rid="bib0040" ref-type="bibr">40</xref>].</p></sec><sec id="sec0009"><label>9</label><title>Expanding psychiatric impact through public health strategies</title><p id="para0011">To shift dementia care toward prevention, early diagnostics must be embedded in public health infrastructures across diverse populations and settings. Access to healthcare via community-based, low-threshold formal resources such as pharmacies, or via telehealth, should be promototed [<xref rid="bib0041" ref-type="bibr">41</xref>,<xref rid="bib0042" ref-type="bibr">42</xref>]. Task shifting within multidisciplinary teams allows nurses and community health workers to conduct screening, monitoring, and education, easing pressure on specialists. Psychiatry plays a central role: equipping individuals with coping skills, training professionals in ethical communication, and embedding mental health into dementia outreach, but requires long-term investment in decentralized infrastructure.</p></sec><sec id="sec0010"><label>10</label><title>Addressing gaps in early detection and communication</title><p id="para0012">Psychiatry, as part of a preventive approach to dementia, must evolve - and has much to offer. It fills a critical gap in dementia care by contributing structured, ethically grounded frameworks for early identification and communication. Psychiatry ensures that information is conveyed clearly, culturally sensitively, and in an empowering way&#8212;helping vulnerable individuals navigate uncertainty and engage in proactive health decisions [<xref rid="bib0014" ref-type="bibr">14</xref>]. When at-risk identification is framed not as a deterministic outcome but as an opportunity for action, individuals are more likely to assume responsibility, pursue personalized preventive steps, and potentially influence the course of disease [<xref rid="bib0007" ref-type="bibr">7</xref>]. As cognitive decline affects multiple dimensions of life, including identity, relationships and emotions, an individualized approach that emphasizes dignity, strengths and individual history is required [<xref rid="bib0043" ref-type="bibr">43</xref>]. This approach goes beyond symptom management and focuses on preserving individuality and incorporating coping strategies [<xref rid="bib0043" ref-type="bibr">[43]</xref>, <xref rid="bib0044" ref-type="bibr">[44]</xref>, <xref rid="bib0045" ref-type="bibr">[45]</xref>, <xref rid="bib0046" ref-type="bibr">[46]</xref>].</p></sec><sec id="sec0011"><label>11</label><title>Conclusion</title><p id="para0013">In AD and related disorders the focus has shifted are from being defined primarily by dementia as an end-stage symptom of brain pathology towards maintaining independence, quality of life, and participation. By aligning biological insights with psychological adaptation, psychiatry bridges the gap between pathology and personhood, where psychiatry meets neurodegeneration.<table-wrap position="float" id="utbl0001" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Key Contributions and Addressed Gaps in Dementia Prevention</bold><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0014"><bold>Procative role of psychiatry:</bold> Repositions psychiatry from late-stage support to an early, preventive role in neurodegeneration &#8211; addressing risk communication, emotional adaptation, and lifestyle guidance.</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0015"><bold>Bridging biological and psychosocial models:</bold> Connects biomarker-based diagnostics with behavioral and psychological interventions</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0016"><bold>Clarification of diagnosis vs. at-risk:</bold> Frames biomarker findings not as deterministic diagnoses, but as modifiable risks&#8212;highlighting the need for psychiatric support in communicating uncertainty.</p></list-item><list-item id="celistitem0004"><label>&#8226;</label><p id="para0017"><bold>Risk factors as targets for intervention:</bold> Emphasizes modifiable risk factors positioning psychiatry to address mental health-related risks across the life course that influence brain health.</p></list-item><list-item id="celistitem0005"><label>&#8226;</label><p id="para0018"><bold>Resilience as an intervention target:</bold> Redefines resilience not just as an individual trait but as a biopsychosocial resource that can be promoted through psychiatric techniques.</p></list-item><list-item id="celistitem0006"><label>&#8226;</label><p id="para0019"><bold>Concrete behavioral frameworks:</bold> Introduces evidence-based behavior change models into dementia prevention&#8212;an area often overlooked.</p></list-item><list-item id="celistitem0007"><label>&#8226;</label><p id="para0020"><bold>Focus on quality of life:</bold> Shifts attention from pathology to personhood&#8212;emphasizing autonomy, and inclusion across all stages of cognitive decline.</p></list-item><list-item id="celistitem0008"><label>&#8226;</label><p id="para0021"><bold>Public health relevance:</bold> Proposes scalable, low-threshold, and ethically sound approaches that extend psychiatric impact beyond specialty clinics.</p></list-item><list-item id="celistitem0009"><label>&#8226;</label><p id="para0022"><bold>Ethical communication in early detection:</bold> Promotes clear, value-sensitive communication of probabilistic risk&#8212;empowering individuals to take preventive action without inducing unnecessary distress.</p></list-item></list></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0012"><title>Statements relating to our ethics and integrity policies</title><p id="para0023">This manuscript is a personal perspective and does not involve original research, clinical trials, patient data, or external funding. As such, no data availability statement, funding statement, conflict of interest disclosure, ethics approval statement, or patient consent statement is applicable. Additionally, there is no material reproduced from other sources that would require permission, nor is this work associated with any clinical trial registration. The authors affirm that there are no ethical concerns related to this manuscript and no conflicts of interest to disclose.</p></sec><sec id="sec0012a"><title>CRediT authorship contribution statement</title><p id="para0023a"><bold>Carolin Kurz:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Conceptualization. <bold>Martin Haupt:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Conceptualization. <bold>Stefanie Auer:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Conceptualization. <bold>Nicola Lautenschlager:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Conceptualization. <bold>Alexander Kurz:</bold> Writing &#8211; original draft, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0024">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Beer</surname><given-names>M.D.</given-names></name></person-group><article-title>History of psychiatry and the psychiatric profession</article-title><source>Curr Opin Psychiatry</source><volume>22</volume><issue>6</issue><year>2009</year><fpage>594</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1097/YCO.0b013e328330c3c2</pub-id><comment>Nov</comment><pub-id pub-id-type="pmid">19644373</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title><source>Alzheimers Dement</source><volume>7</volume><issue>3</issue><year>2011</year><fpage>280</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.003</pub-id><comment>May</comment><pub-id pub-id-type="pmid">21514248</pub-id><pub-id pub-id-type="pmcid">PMC3220946</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Boxer</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name></person-group><article-title>Accelerating Alzheimer's therapeutic development: the past and future of clinical trials</article-title><source>Cell</source><volume>186</volume><issue>22</issue><year>2023</year><fpage>4757</fpage><lpage>4772</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.09.023</pub-id><comment>Oct 26</comment><pub-id pub-id-type="pmid">37848035</pub-id><pub-id pub-id-type="pmcid">PMC10625460</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Biomarker changes during 20 years preceding Alzheimer's disease</article-title><source>N Engl J Med</source><volume>390</volume><issue>8</issue><year>2024</year><fpage>712</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2310168</pub-id><comment>Feb 22</comment><pub-id pub-id-type="pmid">38381674</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><etal/></person-group><article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>8</issue><year>Aug 2024</year><fpage>5143</fpage><lpage>5169</lpage><pub-id pub-id-type="doi">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Villain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><etal/></person-group><article-title>Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group</article-title><source>Lancet Neurol</source><volume>20</volume><issue>6</issue><year>2021</year><fpage>484</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00066-1</pub-id><comment>Jun</comment><pub-id pub-id-type="pmid">33933186</pub-id><pub-id pub-id-type="pmcid">PMC8339877</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Goldfarb</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sheard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shaughnessy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Atri</surname><given-names>A.</given-names></name></person-group><article-title>Disclosure of Alzheimer's disease and Dementia: patient- and care partner-centric decision-making and communication</article-title><source>J Clin Psychiatry</source><volume>80</volume><issue>2</issue><year>2019</year><pub-id pub-id-type="doi">10.4088/JCP.MS18002BR1C</pub-id><comment>Mar 19</comment><pub-id pub-id-type="pmid">30900850</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bryce</surname><given-names>R.</given-names></name><name name-style="western"><surname>Albanese</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wimo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ferri</surname><given-names>C.P.</given-names></name></person-group><article-title>The global prevalence of dementia: a systematic review and metaanalysis</article-title><source>Alzheimers Dement</source><volume>9</volume><issue>1</issue><year>2013</year><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2012.11.007</pub-id><comment>Jane2</comment><pub-id pub-id-type="pmid">23305823</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>L.</given-names></name><name name-style="western"><surname>O'Bryant</surname><given-names>S.E</given-names></name></person-group><article-title>Plasma total tau and neurobehavioral symptoms of cognitive decline in cognitively normal older adults</article-title><source>Front Psychol</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">774049</object-id><pub-id pub-id-type="doi">10.3389/fpsyg.2021.774049</pub-id><pub-id pub-id-type="pmcid">PMC8603823</pub-id><pub-id pub-id-type="pmid">34803857</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The prevalence of mild behavioral impairment in older adults with mild cognitive impairment: a systematic review and meta-analysis</article-title><source>J Alzheimers Dis</source><volume>105</volume><issue>2</issue><year>2025</year><fpage>351</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1177/13872877251328712</pub-id><comment>May</comment><pub-id pub-id-type="pmid">40151921</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Arvanitakis</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name></person-group><article-title>Mixed brain pathologies account for most dementia cases in community-dwelling older persons</article-title><source>Neurology</source><volume>69</volume><issue>24</issue><year>2007</year><fpage>2197</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000271090.28148.24</pub-id><comment>Dec 11</comment><pub-id pub-id-type="pmid">17568013</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Defrancesco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gizewski</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Mangesius</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population</article-title><source>BJPsych Open</source><volume>10</volume><issue>5</issue><year>2024</year><fpage>e160</fpage><pub-id pub-id-type="doi">10.1192/bjo.2024.747</pub-id><comment>Sep 23</comment><pub-id pub-id-type="pmid">39308280</pub-id><pub-id pub-id-type="pmcid">PMC11457211</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Connolly</surname><given-names>E.</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dolphin</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Projected annual Lecanemab treatment eligibility in an Irish regional specialist memory clinic</article-title><source>Int J Geriatr Psychiatry</source><volume>39</volume><issue>10</issue><year>2024</year><fpage>e6157</fpage><pub-id pub-id-type="doi">10.1002/gps.6157</pub-id><comment>Oct</comment><pub-id pub-id-type="pmid">39384333</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Porteri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Albanese</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scerri</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues</article-title><source>Neurobiol Aging</source><volume>52</volume><year>2017</year><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.07.011</pub-id><comment>Apr</comment><pub-id pub-id-type="pmid">28317644</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Mate</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Magin</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H.</given-names></name><etal/></person-group><article-title>An evaluation of the additional benefit of population screening for dementia beyond a passive case-finding approach</article-title><source>Int J Geriatr Psychiatry</source><volume>32</volume><issue>3</issue><year>2017</year><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1002/gps.4466</pub-id><comment>Mar</comment><pub-id pub-id-type="pmid">26988976</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Cutler</surname><given-names>S.J.</given-names></name></person-group><article-title>Worries about getting Alzheimer's: who's concerned?</article-title><source>Am J Alzheimers Dis Other Demen</source><volume>30</volume><issue>6</issue><year>2015</year><fpage>591</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1177/1533317514568889</pub-id><comment>Sep</comment><pub-id pub-id-type="pmid">25657292</pub-id><pub-id pub-id-type="pmcid">PMC10852650</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Purcher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hofler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auer</surname><given-names>S.</given-names></name></person-group><article-title>Attitudes towards dementia prevention in Austria-results of an exploratory study</article-title><source>Z Gerontol Geriatr</source><year>2025</year><pub-id pub-id-type="doi">10.1007/s00391-025-02433-5</pub-id><comment>Apr 2Einstellungen zur Demenzpravention in Osterreich - Ergebnisse einer explorativen Studie</comment><pub-id pub-id-type="pmcid">PMC12238080</pub-id><pub-id pub-id-type="pmid">40175617</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><mixed-citation publication-type="other" id="sbref0018">Rajan D.R.K, Winkelmann J., Kringos D., Jakab M., Khalid F. Implementing the Primary Health Care approach: a primer. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://extranet.who.int/uhcpartnership/sites/default/files/reports/PHC%20primer.pdf?utm_source=chatgpt.com" id="interref0001">https://extranet.who.int/uhcpartnership/sites/default/files/reports/PHC%20primer.pdf?utm_source=chatgpt.com</ext-link>.</mixed-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Albanese</surname><given-names>E.</given-names></name><name name-style="western"><surname>Launer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Egger</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Body mass index in midlife and dementia: systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies</article-title><source>Alzheimers Dement (Amst)</source><volume>8</volume><year>2017</year><fpage>165</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2017.05.007</pub-id><pub-id pub-id-type="pmid">28761927</pub-id><pub-id pub-id-type="pmcid">PMC5520956</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Iwagami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qizilbash</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gregson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Blood cholesterol and risk of dementia in more than 1.8 million people over two decades: a retrospective cohort study</article-title><source>Lancet Healthy Longev</source><volume>2</volume><issue>8</issue><year>2021</year><fpage>e498</fpage><lpage>e506</lpage><pub-id pub-id-type="doi">10.1016/S2666-7568(21)00150-1</pub-id><comment>Aug</comment><pub-id pub-id-type="pmid">36097999</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Iso-Markku</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kujala</surname><given-names>U.M.</given-names></name><name name-style="western"><surname>Knittle</surname><given-names>K.</given-names></name><name name-style="western"><surname>Polet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vuoksimaa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Waller</surname><given-names>K.</given-names></name></person-group><article-title>Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies</article-title><source>Br J Sports Med</source><volume>56</volume><issue>12</issue><year>2022</year><fpage>701</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1136/bjsports-2021-104981</pub-id><comment>Jun</comment><pub-id pub-id-type="pmid">35301183</pub-id><pub-id pub-id-type="pmcid">PMC9163715</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.M.</given-names></name></person-group><article-title>Effect of smoking cessation on the risk of dementia: a longitudinal study</article-title><source>Ann Clin Transl Neurol.</source><volume>5</volume><issue>10</issue><year>2018</year><fpage>1192</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1002/acn3.633</pub-id><comment>Oct</comment><pub-id pub-id-type="pmid">30349854</pub-id><pub-id pub-id-type="pmcid">PMC6186929</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.Y.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission</article-title><source>Lancet</source><volume>404</volume><issue>10452</issue><year>2024</year><fpage>572</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01296-0</pub-id><comment>Aug 10</comment><pub-id pub-id-type="pmid">39096926</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pichet Binette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Groot</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline</article-title><source>Nat Med.</source><volume>28</volume><issue>11</issue><year>2022</year><fpage>2381</fpage><lpage>2387</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-02049-x</pub-id><comment>Nov</comment><pub-id pub-id-type="pmid">36357681</pub-id><pub-id pub-id-type="pmcid">PMC9671808</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia</article-title><source>Nat Med.</source><volume>26</volume><issue>3</issue><year>2020</year><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0755-1</pub-id><comment>Mar</comment><pub-id pub-id-type="pmid">32123385</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Parnetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chipi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salvadori</surname><given-names>N.</given-names></name><name name-style="western"><surname>D'Andrea</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eusebi</surname><given-names>P.</given-names></name></person-group><article-title>Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis</article-title><source>Alzheimers Res Ther</source><volume>11</volume><issue>1</issue><year>2019</year><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s13195-018-0459-7</pub-id><comment>Jan 15</comment><pub-id pub-id-type="pmid">30646955</pub-id><pub-id pub-id-type="pmcid">PMC6334406</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Iliffe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Primary care and dementia: 1. diagnosis, screening and disclosure</article-title><source>Int J Geriatr Psychiatry</source><volume>24</volume><issue>9</issue><year>2009</year><fpage>895</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1002/gps.2204</pub-id><comment>Sep</comment><pub-id pub-id-type="pmid">19226529</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Apostolova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>Lecanemab: appropriate use recommendations</article-title><source>J Prev Alzheimers Dis</source><volume>10</volume><issue>3</issue><year>2023</year><fpage>362</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.14283/jpad.2023.30</pub-id><pub-id pub-id-type="pmid">37357276</pub-id><pub-id pub-id-type="pmcid">PMC10313141</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Grasset</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bis</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Selected social and lifestyle correlates of brain health markers: the Cross-Cohort Collaboration Consortium</article-title><source>Alzheimers Dement</source><volume>21</volume><issue>4</issue><year>2025</year><object-id pub-id-type="publisher-id">e70148</object-id><pub-id pub-id-type="doi">10.1002/alz.70148</pub-id><comment>Apr</comment><pub-id pub-id-type="pmcid">PMC11982914</pub-id><pub-id pub-id-type="pmid">40207408</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Kunzler</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Chmitorz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bagusat</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Construct validity and population-based norms of the German Brief resilience scale (BRS)</article-title><source>Eur J Health Psychol</source><volume>25</volume><issue>3</issue><year>2018</year><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1027/2512-8442/a000016</pub-id><pub-id pub-id-type="pmid">32671321</pub-id><pub-id pub-id-type="pmcid">PMC7357822</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Lesuis</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Hoeijmakers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Korosi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Vulnerability and resilience to Alzheimer's disease: early life conditions modulate neuropathology and determine cognitive reserve</article-title><source>Alzheimers Res Ther</source><volume>10</volume><issue>1</issue><year>2018</year><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s13195-018-0422-7</pub-id><comment>Sep 19</comment><pub-id pub-id-type="pmid">30227888</pub-id><pub-id pub-id-type="pmcid">PMC6145191</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Hye</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leckey</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Plasma REST: a novel candidate biomarker of Alzheimer's disease is modified by psychological intervention in an at-risk population</article-title><source>Transl Psychiatry</source><volume>7</volume><issue>6</issue><year>2017</year><fpage>e1148</fpage><pub-id pub-id-type="doi">10.1038/tp.2017.113</pub-id><comment>Jun 6</comment><pub-id pub-id-type="pmid">28585932</pub-id><pub-id pub-id-type="pmcid">PMC5537638</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Herrman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Diaz-Granados</surname><given-names>N.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>T.</given-names></name></person-group><article-title>What is resilience?</article-title><source>The Canadian Journal of Psychiatry</source><volume>56</volume><issue>5</issue><year>2011</year><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1177/070674371105600504</pub-id><pub-id pub-id-type="pmid">21586191</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Janitra</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.C.</given-names></name><etal/></person-group><article-title>Efficacy of resilience-related psychological interventions in patients with long-term diseases: a meta-analysis of randomised controlled trials</article-title><source>Int J Ment Health Nurs</source><volume>33</volume><issue>5</issue><year>2024</year><fpage>1388</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1111/inm.13334</pub-id><comment>Oct</comment><pub-id pub-id-type="pmid">38651215</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name></person-group><article-title>Living well with dementia&#8211;development of the national dementia strategy for England</article-title><source>Int J Geriatr Psychiatry</source><volume>25</volume><issue>9</issue><year>2010</year><fpage>917</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1002/gps.2598</pub-id><comment>Sep</comment><pub-id pub-id-type="pmid">20803721</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Joosten-Weyn Banningh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vernooij-Dassen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rikkert</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Teunisse</surname><given-names>J.P</given-names></name></person-group><article-title>Mild cognitive impairment: coping with an uncertain label</article-title><source>Int J Geriatr Psychiatry</source><volume>23</volume><issue>2</issue><year>2008</year><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1002/gps.1855</pub-id><comment>Feb</comment><pub-id pub-id-type="pmid">17578843</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Arhiri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gherman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Holman</surname><given-names>A.C.</given-names></name></person-group><article-title>Ageism against older patients in nursing: conceptual differentiations and the role of moral sensitivity</article-title><source>J Elder Abuse Negl</source><volume>34</volume><issue>3</issue><year>2022</year><fpage>198</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1080/08946566.2022.2086957</pub-id><comment>Jun</comment><pub-id pub-id-type="pmid">35686299</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Chary</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ordonez</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A scoping review of geriatric emergency medicine research transparency in diversity, equity, and inclusion reporting</article-title><source>J Am Geriatr Soc.</source><volume>72</volume><issue>11</issue><year>2024</year><fpage>3551</fpage><lpage>3566</lpage><pub-id pub-id-type="doi">10.1111/jgs.19052</pub-id><comment>Nov</comment><pub-id pub-id-type="pmid">38994587</pub-id><pub-id pub-id-type="pmcid">PMC11560720</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Bakker</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Duivenvoorden</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>van der Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olde Rikkert</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Beekman</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Ribbe</surname><given-names>M.W</given-names></name></person-group><article-title>Integrative psychotherapeutic nursing home program to reduce multiple psychiatric symptoms of cognitively impaired patients and caregiver burden: randomized controlled trial</article-title><source>Am J Geriatr Psychiatry</source><volume>19</volume><issue>6</issue><year>2011</year><fpage>507</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1097/JGP.0b013e3181eafdc6</pub-id><comment>Jun</comment><pub-id pub-id-type="pmid">20808147</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Chand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grossberg</surname><given-names>G.</given-names></name></person-group><article-title>How to adapt cognitive-behavioral therapy for older adults</article-title><source>Curr Psychiatry</source><volume>12</volume><year>2013</year><fpage>10</fpage><lpage>14</lpage><comment>03/01</comment></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Auer</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Span</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reisberg</surname><given-names>B.</given-names></name></person-group><article-title>Dementia service centres in Austria: a comprehensive support and early detection model for persons with dementia and their caregivers - theoretical foundations and model description</article-title><source>Dementia (London)</source><volume>14</volume><issue>4</issue><year>2015</year><fpage>513</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1177/1471301213502214</pub-id><comment>Jul</comment><pub-id pub-id-type="pmid">24339114</pub-id><pub-id pub-id-type="pmcid">PMC4514820</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Moores</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rutter</surname><given-names>P.</given-names></name></person-group><article-title>The Wessex Dementia Friendly Pharmacy Framework</article-title><source>Int J Pharm Pract</source><volume>29</volume><issue>2</issue><year>2021</year><fpage>134</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1093/ijpp/riaa001</pub-id><comment>Mar 17</comment><pub-id pub-id-type="pmid">33729518</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.</given-names></name></person-group><article-title>Effectiveness of person-centered care on people with dementia: a systematic review and meta-analysis</article-title><source>Clin Interv Aging</source><volume>12</volume><year>2017</year><fpage>381</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.2147/CIA.S117637</pub-id><pub-id pub-id-type="pmid">28255234</pub-id><pub-id pub-id-type="pmcid">PMC5322939</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Fulford</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Stanghellini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Broome</surname><given-names>M.</given-names></name></person-group><article-title>What can philosophy do for psychiatry?</article-title><source>World Psychiatry</source><volume>3</volume><issue>3</issue><year>2004</year><fpage>130</fpage><lpage>135</lpage><comment>Oct</comment><pub-id pub-id-type="pmid">16633476</pub-id><pub-id pub-id-type="pmcid">PMC1414692</pub-id></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Stockwell-Smith</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moyle</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kellett</surname><given-names>U.</given-names></name></person-group><article-title>The impact of early-stage dementia on community-dwelling care recipient/carer dyads' capacity to self-manage</article-title><source>J Clin Nurs</source><volume>28</volume><issue>3&#8211;4</issue><year>2019</year><fpage>629</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1111/jocn.14657</pub-id><comment>Feb</comment><pub-id pub-id-type="pmid">30182488</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Oken</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gallegos</surname><given-names>A.M.</given-names></name></person-group><article-title>Contributions of loneliness to cognitive impairment and dementia in older adults are independent of other risk factors and Alzheimer's pathology: a narrative review</article-title><source>Front Hum Neurosci</source><volume>18</volume><year>2024</year><object-id pub-id-type="publisher-id">1380002</object-id><pub-id pub-id-type="doi">10.3389/fnhum.2024.1380002</pub-id><pub-id pub-id-type="pmcid">PMC11169707</pub-id><pub-id pub-id-type="pmid">38873650</pub-id></element-citation></ref></ref-list><ack id="ack0001"><title>Acknowledgements</title><p id="para0025">The authors declare that no funding was received for this work and no conflicts of interest exist.</p></ack><fn-group><fn id="d36e29"><label>&#9734;</label><p id="notep0001">Sadly, Alexander Kurz passed away on 29th January 2023, and the co-authors completed the manuscript, which was well advanced, on his behalf.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="fsn371024" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Food Sci Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Food Sci Nutr</journal-id><journal-id journal-id-type="pmc-domain-id">2357</journal-id><journal-id journal-id-type="pmc-domain">fsn</journal-id><journal-id journal-id-type="publisher-id">FSN3</journal-id><journal-title-group><journal-title>Food Science &amp; Nutrition</journal-title></journal-title-group><issn pub-type="epub">2048-7177</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501769</article-id><article-id pub-id-type="pmcid-ver">PMC12501769.1</article-id><article-id pub-id-type="pmcaid">12501769</article-id><article-id pub-id-type="pmcaiid">12501769</article-id><article-id pub-id-type="doi">10.1002/fsn3.71024</article-id><article-id pub-id-type="publisher-id">FSN371024</article-id><article-id pub-id-type="other">FSN3-2025-06-1906.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Functional Foods Enriched With Bioactive Compounds: Therapeutic Potential and Technological Innovations</article-title></title-group><contrib-group><contrib id="fsn371024-cr-0001" contrib-type="author"><name name-style="western"><surname>Arshad</surname><given-names initials="Z">Zargull</given-names></name><xref rid="fsn371024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="fsn371024-cr-0002" contrib-type="author"><name name-style="western"><surname>Shahid</surname><given-names initials="S">Shafa</given-names></name><xref rid="fsn371024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="fsn371024-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Hasnain</surname><given-names initials="A">Ammarah</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6318-5653</contrib-id><xref rid="fsn371024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>ammarahhasnain3@gmail.com</email></address></contrib><contrib id="fsn371024-cr-0004" contrib-type="author"><name name-style="western"><surname>Yaseen</surname><given-names initials="E">Esha</given-names></name><xref rid="fsn371024-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="fsn371024-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Rahimi</surname><given-names initials="M">Mehdi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5625-3275</contrib-id><xref rid="fsn371024-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fsn371024-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>mehdi83ra@gmail.com</email></address></contrib></contrib-group><aff id="fsn371024-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Biotechnology, Faculty of Biological Sciences</named-content>
<institution>Lahore University of Biological and Applied Sciences</institution>
<city>Lahore</city>
<country country="PK">Pakistan</country>
</aff><aff id="fsn371024-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences</named-content>
<institution>Graduate University of Advanced Technology</institution>
<city>Kerman</city>
<country country="IR">Iran</country>
</aff><aff id="fsn371024-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Microbiology, College of Science</named-content>
<institution>Knowledge University</institution>
<city>Erbil</city>
<country country="IQ">Iraq</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Ammarah Hasnain (<email>ammarahhasnain3@gmail.com</email>)<break/>
Mehdi Rahimi (<email>mehdi83ra@gmail.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>13</volume><issue seq="670">10</issue><issue-id pub-id-type="pmc-issue-id">497558</issue-id><issue-id pub-id-type="doi">10.1002/fsn3.v13.10</issue-id><elocation-id>e71024</elocation-id><history><date date-type="rev-recd"><day>03</day><month>9</month><year>2025</year></date><date date-type="received"><day>23</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Food Science &amp; Nutrition</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="FSN3-13-e71024.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:FSN3-13-e71024.pdf"/><abstract><title>ABSTRACT</title><p>Functional foods have gained increasing attention for their dual role in providing essential nutrition and promoting health through the presence of bioactive compounds. These compounds, naturally found in a variety of plant and animal sources, include polyphenols, carotenoids, omega&#8208;3 fatty acids, probiotics, prebiotics, alkaloids, and terpenoids. They exhibit a wide range of therapeutic effects, mediated through mechanisms such as antioxidant activity, anti&#8208;inflammatory responses, modulation of gut microbiota, and enzyme inhibition. This review offers a comprehensive classification of these key bioactive compounds, detailing their natural origins with an emphasis on their mechanisms of action. Additionally, it explores their incorporation into diverse functional food matrices, including fortified beverages, dairy products, snack items, and dietary supplements. Modern biotechnological and AI&#8208;driven approaches have revolutionized the precision, efficacy, and characterization of functional food products by enabling high&#8208;throughput screening of bioactive compounds, predictive modeling for formulation, and large&#8208;scale data mining to identify novel ingredient interactions and health correlations. Despite the growing popularity of functional foods, challenges persist in terms of the stability and bioavailability of bioactive compounds, regulatory hurdles, and consumer acceptance. Addressing these issues is critical to ensuring the efficacy and safety of functional food products. The review also highlights future perspectives in the field, emphasizing the need for innovative delivery systems and multidisciplinary research to enhance the bioavailability, functionality, and accessibility of these products. By highlighting the challenges and proposing possible solutions, this review serves as a foundational reference for bridging the gap among researchers, healthcare professionals, and stakeholders.</p></abstract><abstract abstract-type="graphical"><p>Functional foods enriched with bioactive compounds such as polyphenols, carotenoids, omega&#8208;3 fatty acids, and probiotics provide therapeutic benefits through antioxidant, anti&#8208;inflammatory, and gut&#8208;modulating mechanisms. Advances in biotechnology and AI have improved screening, formulation, and delivery of these compounds in diverse food matrices including dairy, beverages, and supplements. Despite challenges in stability, bioavailability, and regulation, innovative strategies and multidisciplinary research offer promising solutions to enhance efficacy, safety, and consumer acceptance of functional foods.<boxed-text position="anchor" content-type="graphic" id="fsn371024-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="FSN3-13-e71024-g007.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="fsn371024-kwd-0001">bioactive compounds</kwd><kwd id="fsn371024-kwd-0002">biotechnological and AI&#8208;driven approaches</kwd><kwd id="fsn371024-kwd-0003">carotenoids</kwd><kwd id="fsn371024-kwd-0004">gut microbiome modulation</kwd><kwd id="fsn371024-kwd-0005">omega 3&#8208;fatty acids</kwd><kwd id="fsn371024-kwd-0006">polyphenols</kwd><kwd id="fsn371024-kwd-0007">probiotics and prebiotics</kwd></kwd-group><counts><fig-count count="11"/><table-count count="7"/><page-count count="25"/><word-count count="12700"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="fsn371024-cit-1001"><string-name name-style="western"><surname>Arshad</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Shahid</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Hasnain</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Yaseen</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Rahimi</surname></string-name>. <year>2025</year>. &#8220;<article-title>Functional Foods Enriched With Bioactive Compounds: Therapeutic Potential and Technological Innovations</article-title>.&#8221; <source>Food Science &amp; Nutrition</source><volume>13</volume>, no. <issue>10</issue>: <elocation-id>e71024</elocation-id>. <pub-id pub-id-type="doi">10.1002/fsn3.71024</pub-id>.</mixed-citation>
</p><fn-group id="fsn371024-ntgp-0001"><fn fn-type="funding" id="fsn371024-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="fsn371024-body-0001"><sec id="fsn371024-sec-0001"><label>1</label><title>Introduction</title><p>Functional foods are dietary compounds that provide health benefits beyond basic nutrition due to the presence of crucial bioactive compounds such as polyphenols, carotenoids, omega&#8208;3 fatty acids, alkaloids, isothiocyanates, plant stanols, sterols, flavonoids, polyols, soy protein, fatty acids, prebiotics, probiotics, phytoestrogens, as well as various minerals and vitamins (Shaikh&#160;<xref rid="fsn371024-bib-0109" ref-type="bibr">2022</xref>; Topolska et&#160;al.&#160;<xref rid="fsn371024-bib-0118" ref-type="bibr">2021</xref>). The concept of functional food originated in Japan during the 1980s, when government agencies began approving foods with verified health benefits (Arshad et&#160;al.&#160;<xref rid="fsn371024-bib-0012" ref-type="bibr">2021</xref>). The idea of functional foods has its roots in traditional dietary practices and has developed into scientifically formulated products designed to improve overall health and prevent diseases (Vignesh et&#160;al.&#160;<xref rid="fsn371024-bib-0124" ref-type="bibr">2024</xref>) (Figure&#160;<xref rid="fsn371024-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Functional food: types, activities, and future challenges.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="FSN3-13-e71024-g009.jpg"/></fig><p>In contrast to the conventional food that provides basic nutrition, functional foods are enriched with compounds that contribute to specific physiological effects (Table&#160;<xref rid="fsn371024-tbl-0001" ref-type="table">1</xref>). Conventional foods provide essential nutrients required for survival while functional foods are enriched with bioactive ingredients that actively contribute to physiological well&#8208;being (Hasler&#160;<xref rid="fsn371024-bib-0046" ref-type="bibr">2002</xref>; Victoria Obayomi et&#160;al.&#160;<xref rid="fsn371024-bib-0123" ref-type="bibr">2024</xref>).</p><table-wrap position="float" id="fsn371024-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Comparison of conventional vs. functional foods based on formulation, regulation, and health benefits.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Feature</th><th align="center" valign="bottom" rowspan="1" colspan="1">Conventional food</th><th align="center" valign="bottom" rowspan="1" colspan="1">Functional food</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary role</td><td align="center" valign="top" rowspan="1" colspan="1">Provides essential nutrition</td><td align="center" valign="top" rowspan="1" colspan="1">Offers health benefits beyond nutrition</td><td align="center" valign="top" rowspan="1" colspan="1">Frumuzachi et&#160;al.&#160;(<xref rid="fsn371024-bib-0038" ref-type="bibr">2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Formulation</td><td align="center" valign="top" rowspan="1" colspan="1">Basic nutrients</td><td align="center" valign="top" rowspan="1" colspan="1">Basic nutrients + bioactive compounds</td><td align="center" valign="top" rowspan="1" colspan="1">Temple&#160;(<xref rid="fsn371024-bib-0117" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Health claims</td><td align="center" valign="top" rowspan="1" colspan="1">General</td><td align="center" valign="top" rowspan="1" colspan="1">Specific</td><td align="center" valign="top" rowspan="1" colspan="1">McClements and Xiao&#160;(<xref rid="fsn371024-bib-0080" ref-type="bibr">2014</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Regulation</td><td align="center" valign="top" rowspan="1" colspan="1">Standard food safety laws</td><td align="center" valign="top" rowspan="1" colspan="1">Additional oversight for health&#8208;related claims</td><td align="center" valign="top" rowspan="1" colspan="1">Frumuzachi et&#160;al.&#160;(<xref rid="fsn371024-bib-0038" ref-type="bibr">2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Examples</td><td align="center" valign="top" rowspan="1" colspan="1">Rice, milk, bread</td><td align="center" valign="top" rowspan="1" colspan="1">Probiotc yogurt, fortified cereals, omega&#8208;3&#8208;eggs</td><td align="center" valign="top" rowspan="1" colspan="1">Tafese Awulachew&#160;(<xref rid="fsn371024-bib-0116" ref-type="bibr">2024</xref>)</td></tr></tbody></table></table-wrap><p>Key stages that involve in developing functional food are identification of beneficial compounds, their extraction from natural sources, and their incorporation into food matrices while ensuring stability, bioavailability, and efficacy (Rezagholizade&#8208;shirvan et&#160;al.&#160;<xref rid="fsn371024-bib-0103" ref-type="bibr">2024</xref>). In addition to the key stages the ultimate step in developing functional food ensures that the food is palatable and acceptable to the consumers and this requires careful consideration of sensory properties, cost and convenience (Jones and Jew&#160;<xref rid="fsn371024-bib-0056" ref-type="bibr">2007</xref>; Vlaicu et&#160;al.&#160;<xref rid="fsn371024-bib-0127" ref-type="bibr">2023</xref>).</p><p>According to recent research, the bioactive compounds that are potentially found in food play a significant role in lowering the risk of chronic diseases, promoting gut health, reducing inflammation, boosting immune function, enhancing cognitive abilities, and assisting in weight management (Essa et&#160;al.&#160;<xref rid="fsn371024-bib-0034" ref-type="bibr">2023</xref>; Rivero&#8208;Pino and Montserrat&#8208;de la Paz&#160;<xref rid="fsn371024-bib-0104" ref-type="bibr">2024</xref>). The bioactive compounds, derived from plant&#8208;based, marine, and microbial sources, have demonstrated great potential in addressing prevalent health concerns such as obesity, diabetes, cardiovascular diseases, and neurodegenerative disorders (Ud Din et&#160;al.&#160;<xref rid="fsn371024-bib-0119" ref-type="bibr">2023</xref>; Vignesh et&#160;al.&#160;<xref rid="fsn371024-bib-0124" ref-type="bibr">2024</xref>). The growing body of evidence supporting the health benefits of functional foods has led to their incorporation into dietary guidelines and health policies on a global scale (Xavier et&#160;al.&#160;<xref rid="fsn371024-bib-0133" ref-type="bibr">2024</xref>). The regulatory landscape for functional foods varies regionally, with some countries having established guidelines. Effectiveness relies on scientific validation, quality control, and labeling, requiring collaboration between food scientists, nutritionists, and regulatory agencies (Martirosyan and Alvarado&#160;<xref rid="fsn371024-bib-0077" ref-type="bibr">2023</xref>).</p><p>Recent meta&#8208;analytic evidence indicates that polyphenols can significantly improve muscle mass in sarcopenic individuals, highlighting their therapeutic potential (Medoro et&#160;al. <xref rid="fsn371024-bib-0142" ref-type="bibr">2024</xref>). Omega&#8208;3 fatty acid supplementation (0.8&#8211;1.2&#8201;g/day) significantly reduces the risk of major cardiovascular events, heart attacks, and cardiovascular death, especially in patients with coronary heart disease according to the meta&#8208;analysis by Shen et&#160;al. (<xref rid="fsn371024-bib-0143" ref-type="bibr">2022</xref>). Probiotic efficacy has been evaluated through meta&#8208;analyses across conditions like irritable bowel syndrome (IBS), allergic rhinitis, and pediatric atopic dermatitis, offering stronger evidence on their therapeutic and preventive benefits (Farahmandi et&#160;al. <xref rid="fsn371024-bib-0144" ref-type="bibr">2022</xref>; Lee et&#160;al. <xref rid="fsn371024-bib-0145" ref-type="bibr">2008</xref>).</p><p>The development of functional foods encounters several challenges, such as consumer perception, affordability, and the sustainability of sourcing bioactive ingredients. Some consumers are still doubtful about the health benefits associated with functional foods, highlighting the need for public education and clear scientific communication (Baker et&#160;al.&#160;<xref rid="fsn371024-bib-0013" ref-type="bibr">2022</xref>). Furthermore, it is important to ensure the sustainable production of bioactive compounds while keeping costs manageable to make functional foods accessible to a wide range of populations (Yuan et&#160;al.&#160;<xref rid="fsn371024-bib-0137" ref-type="bibr">2024</xref>).</p><p>In this review, crucial bioactive compounds, their natural origins, and their contribution to the creation of functional foods have been studied. By comprehending the characteristics and mechanisms of these bioactive compounds, researchers and food technologists can develop innovative functional foods that promote health and well&#8208;being. Ongoing progress in food technology and nutrigenomics offers promising opportunities to enhance the effectiveness of functional foods, leading to a healthier future.</p></sec><sec id="fsn371024-sec-0002"><label>2</label><title>Key Bioactive Compounds and Their Sources</title><sec id="fsn371024-sec-0003"><label>2.1</label><title>Polyphenols as Potent Antioxidants and Disease Modulators</title><p>Polyphenols are one of the most prevalent classes of bioactive metabolites in plants, which are important for the human body through their impactful antioxidant, anti&#8208;inflammatory, and antimicrobial activities. Such secondary metabolites are found in a wide range of dietary sources that include fruits, such as berries, apples, and grapes; vegetables, such as spinach, onions, and kale; tea and coffee; and whole grains (Table&#160;<xref rid="fsn371024-tbl-0001" ref-type="table">1</xref>) (Pandey and Rizvi&#160;<xref rid="fsn371024-bib-0094" ref-type="bibr">2009</xref>).</p><p>Recent studies highlight the role of nanoencapsulation in enhancing the bioavailability and therapeutic effectiveness of polyphenols. Encapsulation techniques improve stability, protect polyphenols from degradation, and enhance absorption in the body, making them more effective in disease prevention and treatment (Ali Redha et&#160;al.&#160;<xref rid="fsn371024-bib-0008" ref-type="bibr">2024</xref>; Pugazhendhi et&#160;al.&#160;<xref rid="fsn371024-bib-0100" ref-type="bibr">2025</xref>).</p></sec><sec id="fsn371024-sec-0004"><label>2.2</label><title>Carotenoids as Pigments With Nutritional and Therapeutic Potential</title><p>Carotenoids are lipophilic pigments widely distributed in nature, known for their dual significance in human health. They can act as both provitamin A carotenoids and preformed vitamin A, playing essential roles in human nutrition and disease prevention. Provitamin carotenoids are found in plant&#8208;based sources like fruits and vegetables such as carrots, tomatoes, bell peppers, and leafy greens (Table&#160;<xref rid="fsn371024-tbl-0002" ref-type="table">2</xref>) (Dumay and Moran&#231;ais <xref rid="fsn371024-bib-0146" ref-type="bibr">2016</xref>). They contribute to the essential physiological functions including vision, immune response, and cellular growth (Huang et&#160;al. <xref rid="fsn371024-bib-0147" ref-type="bibr">2022</xref>). On the contrary, preformed vitamin A is found in foods from animal sources, including dairy products, eggs, fish, and organ meats. They contribute to potential pharmacological properties, particularly antioxidant, anti&#8208;inflammatory, and anticancer activities, although these effects are still under investigation and not yet fully established for clinical trials (NIH&#160;<xref rid="fsn371024-bib-0149" ref-type="bibr">2025</xref>).</p><table-wrap position="float" id="fsn371024-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Overview of bioactive compounds, their sources, key health benefits, daily intake threshold vs. pharmacological doses (mg/day).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Bioactive compounds</th><th align="center" valign="bottom" rowspan="1" colspan="1">Examples/key functions</th><th align="center" valign="bottom" rowspan="1" colspan="1">Major food sources</th><th align="center" valign="bottom" rowspan="1" colspan="1">Key health benefits</th><th align="center" valign="bottom" rowspan="1" colspan="1">Daily intake threshold (mg/day)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pharmacological doses (mg/day)</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="7" valign="top" rowspan="1">Polyphenols</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Flavonoids</td><td align="center" valign="top" rowspan="1" colspan="1">Quercetin, catechins, anthocyanins, kaempferol</td><td align="center" valign="top" rowspan="1" colspan="1">Berries, apples, onions, green tea, cocoa, citrus fruits</td><td align="center" valign="top" rowspan="1" colspan="1">Cardiovascular protection, anti&#8208;inflammatory effects, antioxidant properties, improved blood circulation</td><td align="center" valign="top" rowspan="1" colspan="1">300&#8211;600</td><td align="center" valign="top" rowspan="1" colspan="1">500&#8211;1000</td><td align="center" valign="top" rowspan="1" colspan="1">Ullah et&#160;al. (<xref rid="fsn371024-bib-0150" ref-type="bibr">2020</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Phenolic Acids</td><td align="center" valign="top" rowspan="1" colspan="1">Caffeic acid, ferulic acid, gallic acid</td><td align="center" valign="top" rowspan="1" colspan="1">Coffee, whole grains, berries, spices (e.g., cinnamon), olive oil</td><td align="center" valign="top" rowspan="1" colspan="1">Neuroprotection, antioxidant activity, reduced inflammation, skin health benefits</td><td align="center" valign="top" rowspan="1" colspan="1">200&#8211;500</td><td align="center" valign="top" rowspan="1" colspan="1">100&#8211;250</td><td align="center" valign="top" rowspan="1" colspan="1">Mihaylova et&#160;al. (<xref rid="fsn371024-bib-0151" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lignans</td><td align="center" valign="top" rowspan="1" colspan="1">Secoisolarici&#8208; &#8208;resinol, matairesinol</td><td align="center" valign="top" rowspan="1" colspan="1">Flaxseeds, sesame seeds, whole grains, legumes</td><td align="center" valign="top" rowspan="1" colspan="1">Hormone regulation, cancer prevention, improved gut microbiota, cardiovascular benefits</td><td align="center" valign="top" rowspan="1" colspan="1">~1</td><td align="center" valign="top" rowspan="1" colspan="1">50&#8211;600</td><td align="center" valign="top" rowspan="1" colspan="1">Gass and Khan (<xref rid="fsn371024-bib-0152" ref-type="bibr">2013</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Stilbens</td><td align="center" valign="top" rowspan="1" colspan="1">Resveratrol, pterostilbene</td><td align="center" valign="top" rowspan="1" colspan="1">Red wine, grapes, peanuts, blueberries</td><td align="center" valign="top" rowspan="1" colspan="1">Anti&#8208;aging effects, cardiovascular protection, anticancer properties, cognitive health improvement</td><td align="center" valign="top" rowspan="1" colspan="1">~1</td><td align="center" valign="top" rowspan="1" colspan="1">150&#8211;500</td><td align="center" valign="top" rowspan="1" colspan="1">Kaur et&#160;al. (<xref rid="fsn371024-bib-0153" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Carotenoids</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Beta&#8208;carotene</td><td align="center" valign="top" rowspan="1" colspan="1">Provitamin A compound</td><td align="center" valign="top" rowspan="1" colspan="1">Carrots, sweet potatoes, spinach, mangoes, pumpkin</td><td align="center" valign="top" rowspan="1" colspan="1">Supports immune function, enhances vision, promotes skin health</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8211;7</td><td align="center" valign="top" rowspan="1" colspan="1">15&#8211;30</td><td align="center" valign="top" rowspan="1" colspan="1">Sharma et&#160;al.&#160;(<xref rid="fsn371024-bib-0110" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Luten</td><td align="center" valign="top" rowspan="1" colspan="1">Eye health, blue light filtration</td><td align="center" valign="top" rowspan="1" colspan="1">Kale, spinach, broccoli, corn, egg yolk</td><td align="center" valign="top" rowspan="1" colspan="1">Protects against age&#8208;related macular degeneration (AMD), reduces eye strain</td><td align="center" valign="top" rowspan="1" colspan="1">1&#8211;3&#8201;mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">10&#8211;20&#8201;mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">Mrowicka et&#160;al. (<xref rid="fsn371024-bib-0154" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Zeaxanthin</td><td align="center" valign="top" rowspan="1" colspan="1">Ocular protection, antioxidant properties</td><td align="center" valign="top" rowspan="1" colspan="1">Orange bell peppers, corn, goji berries, eggs</td><td align="center" valign="top" rowspan="1" colspan="1">Reduces the risk of cataracts and AMD, improves visual function</td><td align="center" valign="top" rowspan="1" colspan="1">0.3&#8211;1.0&#8201;mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8211;10&#8201;mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">Mrowicka et&#160;al. (<xref rid="fsn371024-bib-0154" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alpha&#8208;linolenic acid (ALA)</td><td align="center" valign="top" rowspan="1" colspan="1">Precursor to EPA &amp; DHA, supports metabolic functions</td><td align="center" valign="top" rowspan="1" colspan="1">Flaxseeds, chia seeds, walnuts, soybeans</td><td align="center" valign="top" rowspan="1" colspan="1">Cardiovascular protection, anti&#8208;inflammatory effects</td><td align="center" valign="top" rowspan="1" colspan="1">1.1&#8201;g/day (women) 1.6&#8201;g/day (men) as per US Institute of Medicine</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8211;5&#8201;g/day</td><td align="center" valign="top" rowspan="1" colspan="1">Rajaram (<xref rid="fsn371024-bib-0156" ref-type="bibr">2014</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Eicosapentaenoic acid (EPA)</td><td align="center" valign="top" rowspan="1" colspan="1">Reduces systemic inflammation, regulates blood clotting</td><td align="center" valign="top" rowspan="1" colspan="1">Fatty fish (salmon, mackerel, sardines), krill oil, algae&#8208;based supplements</td><td align="center" valign="top" rowspan="1" colspan="1">Lowers triglyceride levels, reduces risk of hypertension &amp; atherosclerosis</td><td align="center" valign="top" rowspan="1" colspan="1">~100&#8211;250&#8201;mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">500&#8211;4000&#8201;mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">Nassar et&#160;al. (<xref rid="fsn371024-bib-0157" ref-type="bibr">2023</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Docosahexaenoic acid (DHA)</td><td align="center" valign="top" rowspan="1" colspan="1">Essential for brain &amp; retinal development, supports cognitive function</td><td align="center" valign="top" rowspan="1" colspan="1">Fatty fish, fish oil, algae oil</td><td align="center" valign="top" rowspan="1" colspan="1">Protects against neurodegenerative disorders (e.g., Alzheimer's), enhances memory &amp; learning</td><td align="center" valign="top" rowspan="1" colspan="1">~100&#8211;200&#8201;mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">300&#8211;2000&#8201;mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">Ahmad et&#160;al. (<xref rid="fsn371024-bib-0158" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Alkaloids and terpenoids</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alkaloids</td><td align="center" valign="top" rowspan="1" colspan="1">Caffeine, theobromine, morphine, nicotine, berberine</td><td align="center" valign="top" rowspan="1" colspan="1">Tea, coffee, cocoa, opium poppy, berberis, tobacco</td><td align="center" valign="top" rowspan="1" colspan="1">Antimicrobial, analgesic, neuroprotective, anti&#8208;inflammatory, CNS stimulation</td><td align="center" valign="top" rowspan="1" colspan="1">Usually low or trace</td><td align="center" valign="top" rowspan="1" colspan="1">Moderate to high (1&#8211;1500&#8201;mg/day)</td><td align="center" valign="top" rowspan="1" colspan="1">Behl et&#160;al. (<xref rid="fsn371024-bib-0159" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Terpenoids</td><td align="center" valign="top" rowspan="1" colspan="1">Limonene, curcumin, menthol, linalool, artemisinin</td><td align="center" valign="top" rowspan="1" colspan="1">Citrus peels, turmeric, rosemary, mint, lavender, artemisia</td><td align="center" valign="top" rowspan="1" colspan="1">Antioxidant, anti&#8208;inflammatory, antimicrobial, anticancer, neuroprotective</td><td align="center" valign="top" rowspan="1" colspan="1">Low via diet (&lt;&#8201;1&#8211;10&#8201;mg/day)</td><td align="center" valign="top" rowspan="1" colspan="1">100&#8211;1000+ mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">Sharma et&#160;al. (<xref rid="fsn371024-bib-0160" ref-type="bibr">2017</xref>)</td></tr></tbody></table></table-wrap><p>Modification of carotenoid content in staple crops through genetic modification is one of the biofortification strategies that have been explored to overcome vitamin A deficiency in susceptible populations (Naik et&#160;al. <xref rid="fsn371024-bib-0162" ref-type="bibr">2024</xref>). For instance, Golden Rice, a genetically modified crop developed to combat vitamin A deficiency (VAD) by producing provitamin A (&#946;&#8208;carotene) in the edible endosperm through the insertion of psy (from maize) and crtI (from Pantoea ananatis) genes. The &#946;&#8208;carotene in Golden Rice is efficiently converted to vitamin A in humans. It has been declared safe for human consumption by major regulatory agencies including US FDA and Health Canada based on assessments from the International Rice Research Institute (IRRI) (IRRI&#160;<xref rid="fsn371024-bib-0051" ref-type="bibr">2025</xref>; ISAAA&#160;<xref rid="fsn371024-bib-0052" ref-type="bibr">2018</xref>). The World Health Organization (WHO) considers biofortification, including genetic modification, a promising and sustainable strategy to combat micronutrient deficiencies in populations with limited dietary diversity. However, WHO highlights the need for rigorous safety assessments, adherence to Codex Alimentarius standards, long&#8208;term monitoring, and community acceptance before issuing formal recommendations (WHO&#160;<xref rid="fsn371024-bib-0131" ref-type="bibr">2023</xref>).</p></sec><sec id="fsn371024-sec-0005"><label>2.3</label><title>Omega&#8208;3 Fatty Acids as Essential Lipids for Brain and Heart Health</title><p>Omega&#8208;3 fatty acids, a class of essential polyunsaturated fatty acids (PUFAs), are well recognized for their profound impact on cardiovascular, cognitive, and metabolic health (Figure&#160;<xref rid="fsn371024-fig-0002" ref-type="fig">2</xref>). These bioactive lipids are predominantly found in fatty fish such as salmon, mackerel, and sardines, as well as in plant&#8208;based sources like flaxseeds, chia seeds, and walnuts (Table&#160;<xref rid="fsn371024-tbl-0003" ref-type="table">3</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Sources and health benefits of omega&#8208;3 fatty acids.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="FSN3-13-e71024-g011.jpg"/></fig><table-wrap position="float" id="fsn371024-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Overview of probiotics, prebiotics, and synbiotics, their sources, and key health benefits.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Category</th><th align="center" valign="bottom" rowspan="1" colspan="1">Key microorganisms/components</th><th align="center" valign="bottom" rowspan="1" colspan="1">Major food sources</th><th align="center" valign="bottom" rowspan="1" colspan="1">Health benefits</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Probiotics</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Lactobacillus</italic>, <italic toggle="yes">Bifidobacterium</italic>, <italic toggle="yes">Saccharomyces boulardii</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Yogurt, kefir, sauerkraut, kimchi, miso, kombucha</td><td align="center" valign="top" rowspan="1" colspan="1">Improves digestion, enhances immune response, reduces risk of IBS and IBD, restores gut flora after antibiotic use</td><td align="center" valign="top" rowspan="1" colspan="1">Kothari et&#160;al.&#160;(<xref rid="fsn371024-bib-0064" ref-type="bibr">2019</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prebiotics</td><td align="center" valign="top" rowspan="1" colspan="1">Inulin, fructooligosaccharides (FOS), galactooligosaccharides (GOS), resistant starch</td><td align="center" valign="top" rowspan="1" colspan="1">Garlic, onions, bananas, whole grains, asparagus, chicory root</td><td align="center" valign="top" rowspan="1" colspan="1">Promotes growth of probiotics, enhances gut microbiota diversity, supports digestive health, reduces inflammation</td><td align="center" valign="top" rowspan="1" colspan="1">Victoria Obayomi et&#160;al.&#160;(<xref rid="fsn371024-bib-0123" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Synbiotics</td><td align="center" valign="top" rowspan="1" colspan="1">Probiotic strains + Prebiotic fibers</td><td align="center" valign="top" rowspan="1" colspan="1">Fermented dairy with added prebiotics, functional foods, dietary supplements</td><td align="center" valign="top" rowspan="1" colspan="1">Improves microbiota composition, enhances nutrient absorption, potential role in mental health via gut&#8208;brain axis</td><td align="center" valign="top" rowspan="1" colspan="1">Markowiak and &#346;li&#380;ewska&#160;(<xref rid="fsn371024-bib-0076" ref-type="bibr">2017</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="fsn371024-sec-0006"><label>2.4</label><title>Alkaloids and Terpenoids as Bioactive Compounds With Medicinal Properties</title><p>Alkaloids and terpenoids are two significant classes of bioactive compounds found in plants, each with diverse pharmacological properties. Alkaloids are nitrogen&#8208;containing secondary metabolites that exhibit antimicrobial, analgesic, neuroprotective, and anti&#8208;inflammatory activities. These compounds are prevalent in various medicinal plants, as well as in widely consumed beverages such as tea, coffee, and cocoa (Heinrich et&#160;al. <xref rid="fsn371024-bib-0163" ref-type="bibr">2021</xref>). Notable alkaloids include caffeine, theobromine, and morphine, each of which exerts distinct physiological effects. Caffeine, for instance, acts as a central nervous system stimulant, enhancing alertness and cognitive function, while morphine is a potent analgesic used in pain management (Evans et&#160;al.&#160;<xref rid="fsn371024-bib-0035" ref-type="bibr">2025</xref>) (Table&#160;<xref rid="fsn371024-tbl-0002" ref-type="table">2</xref>).</p><p>Terpenoids, also known as isoprenoids, represent the largest class of plant&#8208;derived natural compounds with extensive medicinal and nutritional applications. These lipophilic compounds contribute to the aroma, flavor, and pigmentation of many plants and are commonly found in essential oils, citrus fruits, and herbs such as rosemary and mint (Ludwiczuk et&#160;al.&#160;<xref rid="fsn371024-bib-0072" ref-type="bibr">2017</xref>). Terpenoids possess antioxidant, anti&#8208;inflammatory, antimicrobial, and anticancer properties, making them valuable in pharmaceutical and nutraceutical industries (Siddiqui et&#160;al.&#160;<xref rid="fsn371024-bib-0112" ref-type="bibr">2024</xref>). Compounds such as limonene, found in citrus peels, have been studied for their potential role in cancer prevention, while curcumin, a bioactive terpenoid from turmeric, exhibits strong anti&#8208;inflammatory and neuroprotective effects. With the rising interest in plant&#8208;based medicines, the extraction, synthesis, and bioavailability enhancement of alkaloids and terpenoids remain key research areas for developing novel therapeutic agents (Koolaji et&#160;al.&#160;<xref rid="fsn371024-bib-0063" ref-type="bibr">2020</xref>) (Table&#160;<xref rid="fsn371024-tbl-0002" ref-type="table">2</xref>).</p></sec><sec id="fsn371024-sec-0007"><label>2.5</label><title>Probiotics, Prebiotics, and Their Role in Gut Microbiota</title><p>The gut microbiome plays a pivotal role in human health, and probiotics and prebiotics are essential modulators of microbial diversity and function (Table&#160;<xref rid="fsn371024-tbl-0003" ref-type="table">3</xref>).</p><p>Recent research highlights the gut&#8208;brain axis as a key area of interest, suggesting that probiotics and prebiotics may influence mental health by modulating neurotransmitter production and reducing inflammation.</p></sec></sec><sec id="fsn371024-sec-0008"><label>3</label><title>Mechanism of Action</title><sec id="fsn371024-sec-0009"><label>3.1</label><title>Antioxidant Activity</title><p>Antioxidant activity is an ability of a molecule to prevent the oxidation of other useful molecules in the body, which results in the generation of harmful free radicals. Antioxidants are capable of donating electrons to free radicals, thus neutralizing these radicals and averting them from causing cellular and tissue damage (Figure&#160;<xref rid="fsn371024-fig-0003" ref-type="fig">3</xref>) (Lu et&#160;al.&#160;<xref rid="fsn371024-bib-0071" ref-type="bibr">2021</xref>; Munteanu and Apetrei&#160;<xref rid="fsn371024-bib-0087" ref-type="bibr">2021</xref>). In functional foods, antioxidants are predominately phenolic in nature, such as flavonoids, polyphenols, and omega&#8208;3 fatty acids, which chelate pro&#8208;oxidant ionic metals and scavenge reactive oxidative species (ROS), thus reducing inflammation and oxidative stress (Abeyrathne et&#160;al.&#160;<xref rid="fsn371024-bib-0002" ref-type="bibr">2022</xref>; Uro&#8208;Chukwu et&#160;al.&#160;<xref rid="fsn371024-bib-0121" ref-type="bibr">2025</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Principal mode of action of antioxidants.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="FSN3-13-e71024-g005.jpg"/></fig><sec id="fsn371024-sec-0010"><label>3.1.1</label><title>Role of Dietary Antioxidants in Different Body Mechanisms</title><p>The inhibition of oxidative stress is achieved by some common dietary antioxidants such as vitamin C and E, carotenoids, and polyphenols that donate electrons to stabilize free radicals, including peroxyl radicals (ROO&#183;), superoxide anions (<mml:math id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">O</mml:mi><mml:mn>2</mml:mn><mml:mo>&#8722;</mml:mo></mml:msubsup></mml:mrow></mml:mrow></mml:math>) and hydroxyl radicals (OH&#183;) (Hossain et&#160;al.&#160;<xref rid="fsn371024-bib-0048" ref-type="bibr">2022</xref>; Vignesh et&#160;al.&#160;<xref rid="fsn371024-bib-0124" ref-type="bibr">2024</xref>). Tomato&#8208;based products that are enriched with carotenoid lycopene lower cardiovascular disease risk by reducing oxidative stress. Dietary fibers modulate enzymatic defense systems endogenously, such as superoxide dismutase (SOD), which catalyzes dismutation of superoxide radicals into hydrogen peroxide, which is broken down into oxygen and water (Figure&#160;<xref rid="fsn371024-fig-0004" ref-type="fig">4</xref>) (Eddaikra and Eddaikra&#160;<xref rid="fsn371024-bib-0031" ref-type="bibr">2021</xref>; Islam et&#160;al.&#160;<xref rid="fsn371024-bib-0053" ref-type="bibr">2022</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Dismutation of superoxide radicals into hydrogen peroxide by superoxide dismutase encapsulated in dietary fibers. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/design/DAGjAUUKI40/WR2xVIX22XTqa6P0mVlX-g/edit?utm_content=DAGjAUUKI40&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton" ext-link-type="uri">https://www.canva.com/design/DAGjAUUKI40/WR2xVIX22XTqa6P0mVlX&#8208;g/edit?utm_content=DAGjAUUKI40&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="FSN3-13-e71024-g001.jpg"/></fig><p>Although antioxidants play a crucial role in reducing excessive reactive oxygen species (ROS) and preventing oxidative damage, it is important to recognize that moderate ROS levels are physiologically essential. ROS act as signaling molecules in pathways regulating cell proliferation, differentiation, immune responses, and stress adaptation. Complete elimination of ROS can disrupt these redox&#8208;sensitive signaling cascades, impair adaptive responses, and compromise cellular homeostasis. Therefore, the aim of antioxidant&#8208;based interventions should be to maintain redox balance, preserving beneficial ROS&#8208;mediated functions while preventing harmful oxidative stress (Hasanuzzaman et&#160;al. <xref rid="fsn371024-bib-0164" ref-type="bibr">2020</xref>; Poljsak et&#160;al. <xref rid="fsn371024-bib-0165" ref-type="bibr">2013</xref>).</p></sec></sec><sec id="fsn371024-sec-0011"><label>3.2</label><title>Anti&#8208;Inflammatory Effects</title><p>Inflammation is a complicated physiological response that arises when the human body reacts to different adverse stimuli, such as toxic agents, cellular injury, and pathogenic microbes. Chronic inflammation significantly leads to cancer, diabetes, cardiovascular disease, and neurodegenerative diseases (Elbandy&#160;<xref rid="fsn371024-bib-0033" ref-type="bibr">2022</xref>; Ma et&#160;al.&#160;<xref rid="fsn371024-bib-0073" ref-type="bibr">2025</xref>). Functional foods have bioactive compounds that exert anti&#8208;inflammatory benefits through several molecular mechanisms (Martirosyan et&#160;al.&#160;<xref rid="fsn371024-bib-0078" ref-type="bibr">2022</xref>; Mondal et&#160;al.&#160;<xref rid="fsn371024-bib-0086" ref-type="bibr">2021</xref>).</p><sec id="fsn371024-sec-0012"><label>3.2.1</label><title>Pro&#8208;Inflammatory Cytokines Inhibition</title><p>Pro&#8208;inflammatory cytokines such as interleukin&#8208;1&#946; (IL&#8208;1&#946;), interleukin&#8208;6 (IL&#8208;6), and tumor necrosis factor&#8208;alpha (TNF&#8208;&#945;) play an important role in the inflammatory response, which is being suppressed by functional food bioactives (Coutinho&#8208;Wolino et&#160;al.&#160;<xref rid="fsn371024-bib-0023" ref-type="bibr">2022</xref>). Different bioactive compounds are known for their anti&#8208;inflammatory responses in various reports. According to previous studies on <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Curcuma longa</italic>
</styled-content> (common name: turmeric), its bioactive compound curcumin, also known as diferuloylmethane, possesses anti&#8208;inflammatory properties. The study reveals that 10&#8211;20&#8201;&#956;M of curcumin concentrations significantly reduce IL&#8208;6 and TNF&#8208;&#945; secretion in lipopolysaccharides (LPS)&#8208;stimulated macrophages by inhibiting NF&#8208;&#954;B pathway and toll&#8208;like receptors (TLR4) activation (Guimar&#227;es et&#160;al.&#160;<xref rid="fsn371024-bib-0044" ref-type="bibr">2013</xref>).</p><p>Moreover, omega&#8208;3 fatty acids are also known to suppress inflammatory responses in living cells. Meta&#8208;analytic data reported that daily intake of 30&#8201;mg of omega&#8208;3 fatty acids for 12&#8201;weeks significantly reduced IL&#8208;6 levels by 1.87&#8201;pg/mL and TNF&#8208;&#945; by 2.11&#8201;pg/mL in a clinical trial on mice models (Djuricic and Calder <xref rid="fsn371024-bib-0166" ref-type="bibr">2021</xref>; Kavyani et&#160;al. <xref rid="fsn371024-bib-0167" ref-type="bibr">2022</xref>; Ro&#351;ian et&#160;al. <xref rid="fsn371024-bib-0168" ref-type="bibr">2025</xref>). In another clinical study on humans, omega&#8208;3 fatty acid supplementation (2&#8211;4&#8201;g/day EPA and DHA) led to a 24%&#8211;36% reduction in serum IL&#8208;6 and TNF&#8208;&#945; in patients with rheumatoid arthritis and cardiovascular disease (Table&#160;<xref rid="fsn371024-tbl-0004" ref-type="table">4</xref>) (Banaszak et&#160;al.&#160;<xref rid="fsn371024-bib-0014" ref-type="bibr">2024</xref>; Bodur et&#160;al.&#160;<xref rid="fsn371024-bib-0075" ref-type="bibr">2025</xref>).</p><table-wrap position="float" id="fsn371024-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Mechanism of action of various functional food bioactives in the inhibition of pro&#8208;inflammatory cytokines.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Bioactive compound</th><th align="center" valign="bottom" rowspan="1" colspan="1">Food sources</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mechanism of action</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="top" rowspan="1" colspan="1">Turmeric</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibits ofNLRP3 and NF&#8208;&#954;BInflammasome (10&#8211;20&#8201;&#956;M)</td><td align="center" valign="top" rowspan="1" colspan="1">Barakat et&#160;al.&#160;(<xref rid="fsn371024-bib-0015" ref-type="bibr">2023</xref>), Guimar&#227;es et&#160;al.&#160;(<xref rid="fsn371024-bib-0044" ref-type="bibr">2013</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="top" rowspan="1" colspan="1">Onions, garlic</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibits NF&#8208;&#954;B and NLRP3 inflammasome activation (5&#8208;50&#8201;&#956;M)</td><td align="center" valign="top" rowspan="1" colspan="1">Chojnacka and Lewandowska&#160;(<xref rid="fsn371024-bib-0022" ref-type="bibr">2023</xref>), Djuricic and Calder (<xref rid="fsn371024-bib-0166" ref-type="bibr">2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Resveratrol</td><td align="center" valign="top" rowspan="1" colspan="1">Berries, grapes</td><td align="center" valign="top" rowspan="1" colspan="1">Activation of SIRT1 for inhibiting cytokine expression</td><td align="center" valign="top" rowspan="1" colspan="1">Zhang et&#160;al.&#160;(<xref rid="fsn371024-bib-0138" ref-type="bibr">2022</xref>), Banaszak et&#160;al.&#160;(<xref rid="fsn371024-bib-0014" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Omega&#8208;3 fatty acids</td><td align="center" valign="top" rowspan="1" colspan="1">Fatty fish</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibition of NF&#8208;&#954;B signaling by activation of PPAR&#8208;&#947; (2&#8211;4&#8201;g/day)</td><td align="center" valign="top" rowspan="1" colspan="1">Sharma et&#160;al.&#160;(<xref rid="fsn371024-bib-0110" ref-type="bibr">2024</xref>), Cui et&#160;al.&#160;(<xref rid="fsn371024-bib-0024" ref-type="bibr">2019</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Flavonoids</td><td align="center" valign="top" rowspan="1" colspan="1">Fruits and vegetables</td><td align="center" valign="top" rowspan="1" colspan="1">Modulation of NF&#8208;&#954;B, AP&#8208;1, PPAR, Nrf2, and MAPK pathways</td><td align="center" valign="top" rowspan="1" colspan="1">Behl et&#160;al.&#160;(<xref rid="fsn371024-bib-0016" ref-type="bibr">2021</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Terpenes</td><td align="center" valign="top" rowspan="1" colspan="1">Mushrooms</td><td align="center" valign="top" rowspan="1" colspan="1">Inhibition of TLR4 activation (50&#8211;100&#8201;&#956;g/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">Spano et&#160;al.&#160;(<xref rid="fsn371024-bib-0114" ref-type="bibr">2022</xref>), Fakhri et&#160;al.&#160;(<xref rid="fsn371024-bib-0036" ref-type="bibr">2022</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="fsn371024-sec-0013"><label>3.2.2</label><title>
<styled-content style="fixed-case" toggle="no">NF</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">&#954;Bsignaling</styled-content> Pathway Modulation</title><p>NF&#8208;&#954;B pathway plays an important role in regulating inflammation, with its sustained activation associated with various ailments like neuroinflammation, cancer, and cardiovascular disease (Kannan et&#160;al.&#160;<xref rid="fsn371024-bib-0057" ref-type="bibr">2025</xref>). According to a recent study, 10&#8201;&#956;&#924; of curcumin was found to inhibit I&#954;B kinase in murine macrophage cell lines (RAW264.7), thus preventing phosphorylation and degradation of I&#954;B, hence blocking nuclear translocation of NF&#8208;&#954;B (Figure&#160;<xref rid="fsn371024-fig-0005" ref-type="fig">5</xref>). Similarly, 25&#8201;&#956;M of resveratrol inhibited NF&#8208;&#954;B activation in LPS&#8208;stimulated THP&#8208;1 human monocytes, leading to a significant decrease in TNF&#8208;&#945; by 40% (Fakhri et&#160;al.&#160;<xref rid="fsn371024-bib-0036" ref-type="bibr">2022</xref>; Patel et&#160;al.&#160;<xref rid="fsn371024-bib-0097" ref-type="bibr">2020</xref>). A polyphenolic compound, resveratrol that is found in grapes and red wine, averts activation of NF&#8208;&#954;b in monocytes, which results in reduced secretion of IL&#8208;1&#946; and TNF&#8208;&#945; (Chojnacka and Lewandowska&#160;<xref rid="fsn371024-bib-0022" ref-type="bibr">2023</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Inhibition of NF&#8208;&#954;Bby curcumin. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/design/DAGjFRImsNo/qR00qEtcxaAihr-QyFuf4w/edit?utm_content=DAGjFRImsNo&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton" ext-link-type="uri">https://www.canva.com/design/DAGjFRImsNo/qR00qEtcxaAihr&#8208;QyFuf4w/edit?utm_content=DAGjFRImsNo&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="FSN3-13-e71024-g004.jpg"/></fig><p>A well&#8208;controlled study in mice fed a high&#8208;fat diet (HFD) with resveratrol supplementation (30&#8201;mg/kg/day) demonstrated significant metabolic and anti&#8208;inflammatory benefits, including decreased hepatic mRNA expression of NF&#8208;&#954;B, IL&#8208;6, TNF&#8208;&#945;, and IL&#8208;1&#946;, increased SIRT1 expression, improved lipid metabolism, and reduced markers of NAFLD (e.g., liver triglycerides and steatosis) (Andrade et&#160;al.&#160;<xref rid="fsn371024-bib-0011" ref-type="bibr">2014</xref>; Yasmin et&#160;al.&#160;<xref rid="fsn371024-bib-0135" ref-type="bibr">2025</xref>; Zhou et&#160;al.&#160;<xref rid="fsn371024-bib-0141" ref-type="bibr">2019</xref>).</p></sec><sec id="fsn371024-sec-0014"><label>3.2.3</label><title>
<styled-content style="fixed-case" toggle="no">MAPK</styled-content> Pathway Regulation</title><p>Mitogen&#8208;activated protein kinase (MAPK) pathway is vital for cytokine synthesis by transmitting inflammatory signals (Ganguly et&#160;al.&#160;<xref rid="fsn371024-bib-0039" ref-type="bibr">2023</xref>). According to research, epigallocatechin gallate (EGCG) from green tea (25&#8211;50&#8201;&#956;M) inhibits phosphorylation of p38 MAPK in macrophages, resulting in reduced IL&#8208;1&#946; and TNF&#8208;&#945; levels (Behl et&#160;al.&#160;<xref rid="fsn371024-bib-0016" ref-type="bibr">2021</xref>). Quercitin (30&#8201;&#956;M) present in onions and apples inhibits the activation of JNK signaling in LPS&#8208;stimulated RAW264.7 macrophages, contributing to decreased iNOS and COX&#8208;2 expression (Cui et&#160;al.&#160;<xref rid="fsn371024-bib-0024" ref-type="bibr">2019</xref>; Sahu and Rawal&#160;<xref rid="fsn371024-bib-0107" ref-type="bibr">2024</xref>).</p></sec></sec><sec id="fsn371024-sec-0015"><label>3.3</label><title>Gut Microbiome Modulation</title><p>Functional nutrients can modulate the gut microbiome by selectively promoting the growth of beneficial microbes, thereby influencing metabolic homeostasis. These nutrients play an important role in preventing gut microbiome imbalance by inhibiting pathogenic microbes and promoting the proliferation of bioactive microbial metabolites (Dahiya and Nigam&#160;<xref rid="fsn371024-bib-0025" ref-type="bibr">2022</xref>; Green et&#160;al.&#160;<xref rid="fsn371024-bib-0041" ref-type="bibr">2020</xref>). Prebiotics, including resistant starch, fructans, and galactooligosaccharides, act as substrates for beneficial gut bacteria such as <italic toggle="yes">Lactobacillus</italic> and <italic toggle="yes">Bifidobacterium</italic>. These bacteria produce short&#8208;chain fatty acids (SCFA) such as butyrate, acetate, and propionate that maintain intestinal barriers (Zhang et&#160;al.&#160;<xref rid="fsn371024-bib-0139" ref-type="bibr">2023</xref>). Dietary fiber fermentation lowers oxidative stress and inflammation by strengthening the intestinal barrier and enhancing the integrity of tight junctions (Gao et&#160;al.&#160;<xref rid="fsn371024-bib-0040" ref-type="bibr">2022</xref>).</p><sec id="fsn371024-sec-0016"><label>3.3.1</label><title>Role of Dietary Polyphenols in Balancing Gut Microbiota</title><p>Polyphenol&#8208;rich foods such as blueberries, cranberries, tea, and cocoa enhance the proliferation of <italic toggle="yes">Akkermansia muciniphila, Lactobacillus</italic> sp., and <italic toggle="yes">Bifidobacterium bifidum as</italic> a prebiotic effect while suppressing obesity&#8208;associated microorganisms and enhancing short&#8208;chain fatty acid levels (Liu et&#160;al.&#160;<xref rid="fsn371024-bib-0069" ref-type="bibr">2020</xref>). They also play a significant role in suppressing harmful bacteria by inhibiting PBP2 and PBP4, which lead to a reduction in peptidoglycan cross&#8208;linking and an increase in lysine, as well as the creation of an acidic environment in the gut by the deletion of H&#8201;+&#8201;&#8208;ATPase5, proton donation, and proton pump impairment (Figure&#160;<xref rid="fsn371024-fig-0006" ref-type="fig">6</xref>). Flavonoids from citrus fruits and polyphenols from green tea have been shown to modulate bile acid metabolism and improve cholesterol homeostasis. In addition, omega&#8208;3 fatty acids lead to bile acid conversion and gut microbial diversity, thus promoting inflammation&#8208;free microbial diversity (Wang et&#160;al.&#160;<xref rid="fsn371024-bib-0129" ref-type="bibr">2024</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Impact of dietary polyphenols on gut microbiome. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/design/DAGjG9xB8F4/0e6SeBhsRr3rbnbZKMw39g/edit?utm_content=DAGjG9xB8F4&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton" ext-link-type="uri">https://www.canva.com/design/DAGjG9xB8F4/0e6SeBhsRr3rbnbZKMw39g/edit?utm_content=DAGjG9xB8F4&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="FSN3-13-e71024-g002.jpg"/></fig></sec></sec><sec id="fsn371024-sec-0017"><label>3.4</label><title>Enzyme Inhibition</title><p>Enzymes are essential for human survival; any malfunction in them can cause overexpression or underexpression of enzymes necessary for normal functioning. This can be stopped by the formation of an enzyme&#8208;inhibitor complex that inhibits aberrant enzyme functioning (Phull et&#160;al.&#160;<xref rid="fsn371024-bib-0099" ref-type="bibr">2022</xref>; Saleem et&#160;al.&#160;<xref rid="fsn371024-bib-0108" ref-type="bibr">2024</xref>). Functional food phytochemical constituents regulate crucial enzymes, thus lowering the risk of diseases and promoting improved health. A number of functional foods contain key bioactive components that exert therapeutic effects by obstructing enzymes involved in carbohydrate metabolism, digestion of lipids, oxidative stress, and inflammatory pathways (Hou et&#160;al.&#160;<xref rid="fsn371024-bib-0049" ref-type="bibr">2024</xref>).</p><sec id="fsn371024-sec-0018"><label>3.4.1</label><title>Pancreatic Lipase Inhibition</title><p>Pancreatic lipase plays a crucial role in managing weight and the breakdown of dietary fats (Lim et&#160;al.&#160;<xref rid="fsn371024-bib-0068" ref-type="bibr">2022</xref>). Control of obesity and dyslipidemia can be managed via pancreatic lipase inhibition by functional bioactives, which is an effective approach. Grapes contain proanthocyanidins that bind to the active site of this enzyme, limiting its ability to break down into free fatty acids (Figure&#160;<xref rid="fsn371024-fig-0007" ref-type="fig">7</xref>). Likewise, saponins in fenugreek and different legumes form insoluble complexes by interacting with dietary lipids, thereby restraining the bioavailability of fats (Jamai et&#160;al.&#160;<xref rid="fsn371024-bib-0054" ref-type="bibr">2024</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>Inhibitory potential of pancreatic lipase by grape polyphenols. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/design/DAGjLT3ibvs/AsxAmVlj7ADpCuFB5rULCg/edit?utm_content=DAGjLT3ibvs&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton" ext-link-type="uri">https://www.canva.com/design/DAGjLT3ibvs/AsxAmVlj7ADpCuFB5rULCg/edit?utm_content=DAGjLT3ibvs&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-15" orientation="portrait" xlink:href="FSN3-13-e71024-g003.jpg"/></fig></sec><sec id="fsn371024-sec-0019"><label>3.4.2</label><title>Inhibition of Butyryl Cholinesterase (<styled-content style="fixed-case" toggle="no">BChE</styled-content>) and Acetyl Cholinesterase (<styled-content style="fixed-case" toggle="no">AChE</styled-content>)</title><p>Inhibition of butyryl cholinesterase and acetyl cholinesterase, enzymes linked to Alzheimer's disease pathology, is derived from functional food bioactives. According to research, about 12 active ingredients from <italic toggle="yes">Ganoderma amboinense</italic>, such as lucidenic acid F and ganoderic acid, exhibit AChE inhibition for Alzheimer's management. Enzymatic hydrolysates present in yellow field pea proteins, particularly those treated with flavourzyme, pepsin, and alcalase, resulted in inhibition of AChE activity by 20%&#8211;30% (Hou et&#160;al.&#160;<xref rid="fsn371024-bib-0049" ref-type="bibr">2024</xref>). Similarly, extracts of <italic toggle="yes">Limonium spathulatum</italic> showed substantial inhibitory action against BChE, with IC<sub>50</sub> values of about as low as 0.03&#8201;mg/mL (Grzelczyk et&#160;al.&#160;<xref rid="fsn371024-bib-0043" ref-type="bibr">2023</xref>). However, despite promising in&#160;vitro enzyme inhibition, it is important to note that many phytochemicals face limited permeability across the blood&#8211;brain barrier, which can restrict their therapeutic efficacy in neurological disorders like Alzheimer's disease (Paramanick et&#160;al.&#160;<xref rid="fsn371024-bib-0096" ref-type="bibr">2022</xref>).</p></sec><sec id="fsn371024-sec-0020"><label>3.4.3</label><title>Inhibition of Carbohydrate Digesting Enzymes</title><p>&#945;&#8208;Amylase and &#945;&#8208;glucosidase are carbohydrate&#8208;digesting enzymes that are mandatory for the digestion and absorption of nutrients. However, their overexpression may lead to several metabolic issues (Vyas et&#160;al.&#160;<xref rid="fsn371024-bib-0128" ref-type="bibr">2024</xref>). Their inhibition is a strategy for controlling postprandial hyperglycemia, which is the major risk for type 2 diabetes. Plant polyphenols such as diosmin, curcumin, and morin have the ability to constrain carbohydrate&#8208;digesting enzymes. The extract of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Gardenia jasminoides</italic>
</styled-content> plays an important role in impeding &#945;&#8208;amylase and &#945;&#8208;glucosidase, thus reducing the fasting blood glucose level and high&#8208;fat diet lipids. Epigallocatechin gallate (EGCG) and quercetin have the potential to reduce starch digestion by inhibition of &#945;&#8208;amylase activity (Li et&#160;al.&#160;<xref rid="fsn371024-bib-0067" ref-type="bibr">2025</xref>; Wu et&#160;al.&#160;<xref rid="fsn371024-bib-0132" ref-type="bibr">2024</xref>).</p></sec><sec id="fsn371024-sec-0021"><label>3.4.4</label><title>Angiotensin&#8208;Converting Enzyme (<styled-content style="fixed-case" toggle="no">ACE</styled-content>) Inhibition</title><p>Angiotensin&#8208;converting enzyme converts angiotensin I to angiotensin II, a strong vasoconstrictor that is vital for the maintenance of blood pressure (Khurana and Goswami&#160;<xref rid="fsn371024-bib-0062" ref-type="bibr">2022</xref>). Peptides that are derived from fish proteins, fermented dairy, and soy emulate the action of pharmacological ACE inhibitors, thus inhibiting the active site of the enzyme and preventing the synthesis of angiotensin II synthesis (Figure&#160;<xref rid="fsn371024-fig-0008" ref-type="fig">8</xref>). Flavonoids from green tea, cocoa, and grapes increase nitric oxide inhibition along with the inhibition of ACE, leading to improved endothelial function by vasodilation. Meta&#8208;analytical evidence suggests that 3&#8211;5&#8201;g peptide/day may be effective in exerting antihypertensive effects without adverse outcomes (Ahmad et&#160;al.&#160;<xref rid="fsn371024-bib-0004" ref-type="bibr">2023</xref>; Hadi et&#160;al.&#160;<xref rid="fsn371024-bib-0045" ref-type="bibr">2022</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0008" orientation="portrait"><label>FIGURE 8</label><caption><p>Anti&#8208;hypertensive mechanism of bioactive peptides in functional food. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/design/DAGjY-O9P98/9cm2hhhkbeAAimd3Tzvs6A/edit?utm_content=DAGjY-O9P98&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton" ext-link-type="uri">https://www.canva.com/design/DAGjY&#8208;O9P98/9cm2hhhkbeAAimd3Tzvs6A/edit?utm_content=DAGjY&#8208;O9P98&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-17" orientation="portrait" xlink:href="FSN3-13-e71024-g006.jpg"/></fig></sec></sec></sec><sec id="fsn371024-sec-0022"><label>4</label><title>Applications in Functional Food Development</title><sec id="fsn371024-sec-0023"><label>4.1</label><title>Fortified Beverages</title><p>Beverage is a liquid drink meant for human consumption in order to quench one's thirst, and it constitutes human culture. Fortified beverages, also known as designer beverages, are one of the major advancements in the development of functional food, and they provide increased nutritional advantages by incorporating different bioactive ingredients (Ajeeshkumar et&#160;al.&#160;<xref rid="fsn371024-bib-0005" ref-type="bibr">2021</xref>). These drinks are made to meet certain health needs, such as boosting probiotic viability, improving antioxidant activity, and supplementing essential nutrients. Functional ingredients, including probiotics, dietary fibers, omega&#8208;3 fatty acids, and vitamins, are most commonly used in the fortification of beverages (Afzal et&#160;al.&#160;<xref rid="fsn371024-bib-0003" ref-type="bibr">2022</xref>).</p><sec id="fsn371024-sec-0024"><label>4.1.1</label><title>Examples and Applications</title><p>Emmer&#8208;based fermented beverages enriched with fruit juices (e.g., blueberry, aronia) are non&#8208;dairy probiotic alternatives, especially suitable for lactose&#8208;intolerant individuals. These beverages, when fortified with <italic toggle="yes">Lactiplantibacillus plantarum</italic> and fruit juices like blueberry or aronia, deliver total phenolic contents and antioxidant capacities while maintaining probiotic viability above during refrigerated storage (Dimitrellou et&#160;al.&#160;<xref rid="fsn371024-bib-0029" ref-type="bibr">2021</xref>; Pannerchelvan et&#160;al.&#160;<xref rid="fsn371024-bib-0095" ref-type="bibr">2023</xref>). Fortified juices are the valuable alternatives that can be consumed by lactose&#8208;intolerant individuals. Evolus from Valio Finland is a commercial beverage that is supplemented with bioactive peptides from <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Lactobacillus helveticus</italic>
</styled-content> (Jauhiainen et&#160;al.&#160;<xref rid="fsn371024-bib-0055" ref-type="bibr">2005</xref>). Synbiotic beverages that are fortified with prebiotics and cereal sprouts demonstrate enhanced sensory acceptance and probiotic viability, catering to health&#8208;conscious consumers (Kheto et&#160;al.&#160;<xref rid="fsn371024-bib-0061" ref-type="bibr">2025</xref>).</p></sec></sec><sec id="fsn371024-sec-0025"><label>4.2</label><title>Functional Dairy Products</title><p>Functional dairy products have become an essential component of the food industry, which contributes to human health beyond mere nutrition. The adaptability of dairy ingredients, along with advancements in the dairy industry, has enabled the development of a diverse array of functional dairy products (Khalaf et&#160;al.&#160;<xref rid="fsn371024-bib-0060" ref-type="bibr">2021</xref>). These products can easily be incorporated with essential bioactive components, including bioactive peptides, prebiotics, probiotics, and other functional ingredients, that make a versatile dairy products in health&#8208;promoting foods (Lamsar and Abhilasha&#160;<xref rid="fsn371024-bib-0066" ref-type="bibr">2023</xref>).</p><sec id="fsn371024-sec-0026"><label>4.2.1</label><title>Probiotics and Prebiotics Dairy Products</title><p>The dairy matrix offers a protective milieu for probiotic bacteria along with prebiotics, enhancing their survival during storage and processing (Ali et&#160;al.&#160;<xref rid="fsn371024-bib-0007" ref-type="bibr">2022</xref>). According to studies, yogurt is fortified with <italic toggle="yes">Bifidobacterium bifidum, <styled-content style="fixed-case" toggle="no">Lactobacillus acidophilus</styled-content>
</italic>, and <italic toggle="yes">Streptococcus thermophiles</italic> to balance the gut microbiome.</p><p>
<bold>Activia</bold> by Danone's yogurt, which is a functional food, contains probiotic strain <italic toggle="yes">Bifidobacterium animalis</italic> DN&#8208;173010 and insulin. Clinical studies report faster intestinal transit and symptom relief in individuals with IBS.</p><p>
<bold>Yakult</bold>, a fermented dairy drink, delivers <italic toggle="yes">Lacticaseibacillus paracasei</italic> strain Shirota (LcS) to improve digestion (according to Yakult Philippines <xref rid="fsn371024-bib-0169" ref-type="bibr">2019</xref>). Studies show regular intake reduces constipation episodes, improves gut immunity, and is consumed in over 40 countries (Lamsar and Abhilasha&#160;<xref rid="fsn371024-bib-0066" ref-type="bibr">2023</xref>).</p></sec><sec id="fsn371024-sec-0027"><label>4.2.2</label><title>Fortified Dairy Based Bioactive Peptides and Other Dairy Functional Products</title><p>The philosophy of science aims to enhance the quality of human life, and for many years, bioactive peptides have been used as a component of functional food to improve this quality. Bioactive peptides are biological entities that are buried inside precursor proteins and become functional during cleavage of that protein (Akbarian et&#160;al.&#160;<xref rid="fsn371024-bib-0006" ref-type="bibr">2022</xref>). Peptides derived from casein and whey have shown to inhibit ACE; therefore, reducing blood pressure.</p><p>
<bold>Calpis</bold>, from Japan, contains Val&#8208;Pro&#8208;Pro (VPP) and Ile&#8208;Pro&#8208;Pro (IPP) tripeptides, which inhibit ACE activity and are clinically shown to reduce systolic blood pressure in mildly hypertensive individuals (Table&#160;<xref rid="fsn371024-tbl-0005" ref-type="table">5</xref>).</p><table-wrap position="float" id="fsn371024-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Some commercially available functional dairy products.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Brand/product name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Type of product</th><th align="center" valign="bottom" rowspan="1" colspan="1">Active ingredient</th><th align="center" valign="bottom" rowspan="1" colspan="1">Nutrient content/serving</th><th align="center" valign="bottom" rowspan="1" colspan="1">Consumer outcomes</th><th align="center" valign="bottom" rowspan="1" colspan="1">Manufacturer</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="7" valign="top" rowspan="1">Probiotics</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yakult</td><td align="center" valign="top" rowspan="1" colspan="1">Fermented milk</td><td align="center" valign="top" rowspan="1" colspan="1">
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Lactobacillus casei</italic>
</styled-content> Shirota</td><td align="center" valign="top" rowspan="1" colspan="1">160&#8201;cal, 1&#8201;g protein, 14&#8201;g carbohydrates</td><td align="center" valign="top" rowspan="1" colspan="1">Prevents constipation and gastrointestinal infections</td><td align="center" valign="top" rowspan="1" colspan="1">Yakult Honsha Co., Japan</td><td align="center" valign="top" rowspan="1" colspan="1">Mellentin (<xref rid="fsn371024-bib-0170" ref-type="bibr">2023</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Biobalance</td><td align="center" valign="top" rowspan="1" colspan="1">Fermented milk</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Bifidobacteriumlactis</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">7&#8201;cal, 1&#8201;g of total carbohydrates</td><td align="center" valign="top" rowspan="1" colspan="1">Facilitates intestinal transit</td><td align="center" valign="top" rowspan="1" colspan="1">Dos Pinos R.L., Costa Rica</td><td align="center" valign="top" rowspan="1" colspan="1">Ali et&#160;al.&#160;(<xref rid="fsn371024-bib-0007" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Activia</td><td align="center" valign="top" rowspan="1" colspan="1">Yogurt</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Bifidobacteriumanimalis</italic> DN&#8208;173, <italic toggle="yes">Bifidusregularis</italic>, <italic toggle="yes">Bifidusactivo</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">90&#8201;cal, 1.5&#8201;g of total fats, 1&#8201;g of saturated fats, 5&#8201;mg of cholesterol, 55&#8201;mg of sodium, 15&#8201;g of carbohydrates, 12&#8201;g of total sugars, 4&#8201;g of proteins</td><td align="center" valign="top" rowspan="1" colspan="1">Controls irritable bowel syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">Groupe Danone, France</td><td align="center" valign="top" rowspan="1" colspan="1">Ali et&#160;al.&#160;(<xref rid="fsn371024-bib-0007" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Prebiotics</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Orafti</td><td align="center" valign="top" rowspan="1" colspan="1">Soluble powder</td><td align="center" valign="top" rowspan="1" colspan="1">Inulin/oligofructose</td><td align="center" valign="top" rowspan="1" colspan="1">101&#8201;kcal, 1.5&#8201;g total fat, 1&#8201;g saturated fats, 5&#8201;mg cholesterol, 55&#8201;mg sodium, 20&#8201;g total carbohydrates, 12&#8201;g total sugars, 4&#8201;g proteins</td><td align="center" valign="top" rowspan="1" colspan="1">Improves intestinal flora</td><td align="center" valign="top" rowspan="1" colspan="1">BENEO Group, Belgium</td><td align="center" valign="top" rowspan="1" colspan="1">Kumar et&#160;al. (<xref rid="fsn371024-bib-0172" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hilma</td><td align="center" valign="top" rowspan="1" colspan="1">Fiber + enzyme supplement</td><td align="center" valign="top" rowspan="1" colspan="1">Acacia gum, psyllium husk</td><td align="center" valign="top" rowspan="1" colspan="1">20&#8201;cal, 6&#8201;g total carbohydrates; 6&#8201;g dietary fiber, 100&#8201;mg enzyme blend</td><td align="center" valign="top" rowspan="1" colspan="1">Supports bowel regularity, reduces bloating, improves digestion for sensitive stomachs; prebiotic support for gut microbiome</td><td align="center" valign="top" rowspan="1" colspan="1">Hilma, USA</td><td align="center" valign="top" rowspan="1" colspan="1">Hilma&#160;(<xref rid="fsn371024-bib-0047" ref-type="bibr">2020</xref>)</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Bioactive peptides</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Recaldent</td><td align="center" valign="top" rowspan="1" colspan="1">Ingredient</td><td align="center" valign="top" rowspan="1" colspan="1">Caseinophosphopeptides and amorphous calcium phosphate</td><td align="center" valign="top" rowspan="1" colspan="1">18.6&#8201;kcal per 8 pastilles (10.4&#8201;g)</td><td align="center" valign="top" rowspan="1" colspan="1">Anti&#8208;cariogenic activity</td><td align="center" valign="top" rowspan="1" colspan="1">Cadbury Co. UK</td><td align="center" valign="top" rowspan="1" colspan="1">Ali et&#160;al.&#160;(<xref rid="fsn371024-bib-0007" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Calpis</td><td align="center" valign="top" rowspan="1" colspan="1">Sour milk</td><td align="center" valign="top" rowspan="1" colspan="1">Hypotensive tripeptides</td><td align="center" valign="top" rowspan="1" colspan="1">~50&#8201;kcal, ~12&#8201;g carbohydrates/sugars, ~15&#8201;mg sodium, ~20&#8201;mg calcium</td><td align="center" valign="top" rowspan="1" colspan="1">Reduces blood pressure</td><td align="center" valign="top" rowspan="1" colspan="1">Calpis Co., Japan</td><td align="center" valign="top" rowspan="1" colspan="1">Peighambardoust et&#160;al.&#160;(<xref rid="fsn371024-bib-0098" ref-type="bibr">2021</xref>)</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Animal&#8208;Derived Functional Compounds from By&#8208;products</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Collagen peptides (from fish)</td><td align="center" valign="top" rowspan="1" colspan="1">Animal&#8208;derived (waste&#8208;based)</td><td align="center" valign="top" rowspan="1" colspan="1">Marine collagen peptides</td><td align="center" valign="top" rowspan="1" colspan="1">369&#8201;cals, 90&#8201;g of proteins</td><td align="center" valign="top" rowspan="1" colspan="1">Enhances skin elasticity, supports joint health</td><td align="center" valign="top" rowspan="1" colspan="1">Vital proteins (marine collagen)</td><td align="center" valign="top" rowspan="1" colspan="1">Steele&#160;(<xref rid="fsn371024-bib-0115" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chitosan&#8208;based drinks</td><td align="center" valign="top" rowspan="1" colspan="1">Functional animal product</td><td align="center" valign="top" rowspan="1" colspan="1">Chitosan (from shrimp/crab shells)</td><td align="center" valign="top" rowspan="1" colspan="1">3&#8201;kcal, 0.5&#8201;g total carbohydrates, 0.5&#8201;g dietary fiber</td><td align="center" valign="top" rowspan="1" colspan="1">Fat&#8208;binding, cholesterol&#8208;lowering, weight management, digestive health</td><td align="center" valign="top" rowspan="1" colspan="1">Various nutraceutical companies</td><td align="center" valign="top" rowspan="1" colspan="1">Ylitalo et&#160;al.&#160;(<xref rid="fsn371024-bib-0136" ref-type="bibr">2002</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Eggshell membrane hydrolysates</td><td align="center" valign="top" rowspan="1" colspan="1">Nutraceutical capsule/drink</td><td align="center" valign="top" rowspan="1" colspan="1">Collagen, glycosaminoglycans</td><td align="center" valign="top" rowspan="1" colspan="1">66&#8201;mg of collagen and 100&#8201;mg of hyaluronic acid</td><td align="center" valign="top" rowspan="1" colspan="1">Joint support, reduces inflammation, improves connective tissue health</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple nutraceutical brands</td><td align="center" valign="top" rowspan="1" colspan="1">Ruff et&#160;al.&#160;(<xref rid="fsn371024-bib-0106" ref-type="bibr">2009</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">BioPURE&#8208;GMP</td><td align="center" valign="top" rowspan="1" colspan="1">Nutraceutical capsule/drink</td><td align="center" valign="top" rowspan="1" colspan="1">Glycomacropeptides (GMP)</td><td align="center" valign="top" rowspan="1" colspan="1">100 cals, 16&#8201;g of proteins, 3&#8201;g of fats, and 2&#8201;g of carbohydrates, 75&#8201;mg of cholesterol</td><td align="center" valign="top" rowspan="1" colspan="1">Enhances gut barrier function, exhibits anti&#8208;carcinogenic properties</td><td align="center" valign="top" rowspan="1" colspan="1">Davisco Foods International, USA</td><td align="center" valign="top" rowspan="1" colspan="1">Rackerby et&#160;al.&#160;(<xref rid="fsn371024-bib-0102" ref-type="bibr">2024</xref>)</td></tr></tbody></table></table-wrap><p>Research also proved that consumption of <bold>omega&#8208;3 fortified milk</bold> for approximately 12&#8201;weeks led to improved brain function in older individuals. In Canada and the US, milk is supplemented with vitamin D to prevent osteoporosis and rickets (Peighambardoust et&#160;al.&#160;<xref rid="fsn371024-bib-0098" ref-type="bibr">2021</xref>).</p></sec><sec id="fsn371024-sec-0028"><label>4.2.3</label><title>Functional Animal&#8208;Derived Products From Wastes</title><p>Bioactive compounds from animal waste streams and by&#8208;products are being recycled into functional foods and nutraceuticals in response to concerns about sustainability and the circular economy. These include:</p><p>
<bold>Fish&#8208;derived collagen peptides</bold> (from skin, scales, and bones) have been added to drinks, jellies, and capsules to promote healthy joints and skin. Research shows that consistent consumption improves skin elasticity and lessens joint pain (Steele&#160;<xref rid="fsn371024-bib-0115" ref-type="bibr">2022</xref>).</p><p>
<bold>Chitosan</bold> (from shrimp and crab shells) has been used in fat&#8208;binding drinks, antimicrobial packaging, and dietary supplements that lower cholesterol and help in weight management (Ylitalo et&#160;al.&#160;<xref rid="fsn371024-bib-0136" ref-type="bibr">2002</xref>).</p><p>
<bold>Eggshell membrane hydrolysates</bold>, enriched with collagen and glycosaminoglycans, are used in functional drinks and capsules to support connective tissue and joints (Ruff et&#160;al.&#160;<xref rid="fsn371024-bib-0106" ref-type="bibr">2009</xref>).</p><p>
<bold>Glycomacropeptides (GMP)</bold> from cheese whey are present in products like <bold>BioPURE&#8208;GMP</bold>. It shows anti&#8208;carcinogenic properties and enhances gut barrier function (Rackerby et&#160;al.&#160;<xref rid="fsn371024-bib-0102" ref-type="bibr">2024</xref>).</p><p>These innovations demonstrate how animal&#8208;derived by&#8208;products are being transformed into high&#8208;value health&#8208;promoting ingredients, reducing waste and enhancing sustainability in the food sector.</p></sec></sec><sec id="fsn371024-sec-0029"><label>4.3</label><title>Poultry as a Source of Functional Compounds</title><p>Poultry products (e.g., ducks, chickens, and turkeys), beyond providing basic nutrition, are a significant source of functional compounds that include antioxidants, bioactive peptides, and vital nutrients like omega&#8208;3 fatty acids and amino acids (Romero&#8208;Garay et&#160;al.&#160;<xref rid="fsn371024-bib-0105" ref-type="bibr">2022</xref>).</p><p>The cardiovascular benefits of <bold>omega&#8208;3&#8208;enriched eggs</bold> have recently drawn the attention of the researchers. It has been reported that hens supplemented with flaxseed or fish oil exhibited enhanced content of alpha&#8208;linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) in their eggs. This provides a practical way to raise omega&#8208;3 intake in the general population (Vlaicu et&#160;al.&#160;<xref rid="fsn371024-bib-0126" ref-type="bibr">2021</xref>).</p><p>Additionally, <bold>carotenoids</bold> like lutein and zeaxanthin, which are critical for eye health, can be delivered through poultry products. Adding carotenoid&#8208;rich feed ingredients, such as algae or marigold extract, improves carotenoid content and yolk color of eggs (Dansou et&#160;al.&#160;<xref rid="fsn371024-bib-0027" ref-type="bibr">2023</xref>).</p><p>
<bold>Antioxidant capacity and vitamin enrichment</bold> in poultry can be manipulated through dietary strategies. For example, the inclusion of plant&#8208;derived polyphenols or vitamin E in poultry feed not only improves the oxidative stability of meat and eggs but also potentially enhances their health&#8208;promoting properties for consumers (Matumoto&#8208;Pintro et&#160;al.&#160;<xref rid="fsn371024-bib-0079" ref-type="bibr">2017</xref>).</p></sec><sec id="fsn371024-sec-0030"><label>4.4</label><title>Snack Foods</title><p>The increased demand for healthy, on&#8208;the&#8208;go food options has fueled innovation in formulations of functional snacks, thus integrating scientifically validated ingredients to boost nutritional profile (Kr&#252;ger et&#160;al.&#160;<xref rid="fsn371024-bib-0065" ref-type="bibr">2022</xref>). Researchers formulated a snack bar which contained a blend of 25% oats, 15% banana peel powder, and 60% amaranth grain, involving all the essential components like phenolics, antioxidants, &#946;&#8208;glucan, and minerals. Thermogravimetric analysis revealed that its active components are stable at high temperatures, thus preserving functional capabilities. Sensory evaluations of indicated that this bar could be stored for about 60&#8201;days without being contaminated and also has both nutritional and economic benefits (Boukid et&#160;al.&#160;<xref rid="fsn371024-bib-0018" ref-type="bibr">2022</xref>).</p><p>Although using banana peels provides a nutrient&#8208;rich and sustainable alternative, there are certain limitations associated with its use (Deb et&#160;al.&#160;<xref rid="fsn371024-bib-0028" ref-type="bibr">2022</xref>). Potential issues include the indigestibility of some fibrous components and the presence of heavy metals (such as lead and cadmium) from environmental exposure, which require careful regulatory review to guarantee food safety and consumer acceptance. These factors must be addressed for the commercialization of functional innovations (Yasin et&#160;al.&#160;<xref rid="fsn371024-bib-0134" ref-type="bibr">2025</xref>).</p><sec id="fsn371024-sec-0031"><label>4.4.1</label><title>Bioactive Components Containing Functional Food Snacks</title><p>Residues of <italic toggle="yes">Hibiscus sabdariffa</italic>, significantly containing flavonoids and phenolics, were incorporated into snack crackers to boost their antioxidant potential DPPH scavenging activity potential (Chew et&#160;al.&#160;<xref rid="fsn371024-bib-0020" ref-type="bibr">2024</xref>). For example, Dang coconut chips contain magnesium and selenium as minerals that activate glutathione peroxidase, which combats oxidative stress. Similarly, Sunroot (Jerusalem artichoke) is supplemented with snack foods due to its rich content of antioxidants and insulin (Nazzaro et&#160;al.&#160;<xref rid="fsn371024-bib-0090" ref-type="bibr">2025</xref>). <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Cannabis sativa</italic>
</styled-content> contains a bioactive component, cannabinoids, as a functional component, and the inclusion of this plant seed in the dough of gluten&#8208;free bread and crackers that is rich in iron contributes toward reducing disease risk (Kr&#252;ger et&#160;al.&#160;<xref rid="fsn371024-bib-0065" ref-type="bibr">2022</xref>).</p><p>However, it's crucial to note that only hemp&#8208;derived strains of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Cannabis sativa</italic>
</styled-content> with low optimized levels of tetrahydrocannabinol (THC) are utilized in culinary applications. There is no risk of psychosis or addiction because these hemp seeds don't contain large amounts of cannabinoids like CBD or THC (EFSA&#160;<xref rid="fsn371024-bib-0032" ref-type="bibr">2022</xref>; FDA&#160;<xref rid="fsn371024-bib-0037" ref-type="bibr">2024</xref>). Strict regulations govern the use of hemp&#8208;derived food ingredients; for example, the European Food Safety Authority (EFSA) and the US Food and Drug Authority (FDA) permit the use of hemp seeds in food products as long as the THC content stays below predetermined limits (usually &#8804;&#8201;0.3%) and no cannabinoid extraction is done (EFSA&#160;<xref rid="fsn371024-bib-0032" ref-type="bibr">2022</xref>; FDA&#160;<xref rid="fsn371024-bib-0037" ref-type="bibr">2024</xref>).</p></sec></sec><sec id="fsn371024-sec-0032"><label>4.5</label><title>Dietary Supplements</title><p>The global rise in chronic ailments, consumer demands for health&#8208;promoting foods, and nutrient deficiencies has resulted in the expansion of dietary supplement&#8208;enriched functional foods. According to the 1994 Dietary Supplement and Education Act, nutritional additives include vitamins, minerals, amino acids, proteins, fatty acids, and fiber, which are known as dietary supplements (Alongi and Anese&#160;<xref rid="fsn371024-bib-0009" ref-type="bibr">2021</xref>). Vitamin D dairy products have been demonstrated to improve immunological and bone health. Iron&#8208;supplemented cereals have been developed to fight anemia, especially in populations where iron deficiency is highly prevalent. PUFA &#42935;&#8208;3 and &#42935;&#8208;6 and MUFA &#42935;&#8208;9 in functional foods reduce the chance of inflammatory disease and coronary heart disease. Coenzyme Q&#8208;10 is an internal lipophilic that is effective as a dietary supplement in functional food effective for human fitness and skin smoothness (Figure&#160;<xref rid="fsn371024-fig-0009" ref-type="fig">9</xref>). Resveratrol is a polyphenol that is found in grapes, integrated into beverages for longevity&#8208;promoting properties (Boggia et&#160;al.&#160;<xref rid="fsn371024-bib-0017" ref-type="bibr">2020</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0009" orientation="portrait"><label>FIGURE 9</label><caption><p>Functional food&#8208;based dietary supplements. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/design/DAGjZEHPiwM/moppQ8cF6fhMfJcCjyhp-g/edit?utm_content=DAGjZEHPiwM&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton" ext-link-type="uri">https://www.canva.com/design/DAGjZEHPiwM/moppQ8cF6fhMfJcCjyhp&#8208;g/edit?utm_content=DAGjZEHPiwM&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-19" orientation="portrait" xlink:href="FSN3-13-e71024-g008.jpg"/></fig><table-wrap position="float" id="fsn371024-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 6</label><caption><p>Global market value of functional foods.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Category</th><th align="center" valign="bottom" rowspan="1" colspan="1">Market highlights</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="3" valign="top" rowspan="1">Global market shares</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Global market value (2021)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>USD 177.4B</bold>, Projected <bold>USD 219.5B by 2026</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">S&#248;rensen et&#160;al.&#160;(<xref rid="fsn371024-bib-0113" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pandemic impact</td><td align="center" valign="top" rowspan="1" colspan="1">Growth rose from <bold>0.3% (2019&#8211;20)</bold> to <bold>5% (2020&#8211;21)</bold>, driven by health awareness (e.g., vitamin D fortification)</td><td align="center" valign="top" rowspan="1" colspan="1">S&#248;rensen et&#160;al.&#160;(<xref rid="fsn371024-bib-0113" ref-type="bibr">2022</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Europe (2021)</td><td align="center" valign="top" rowspan="1" colspan="1">Western Europe: <bold>USD 23B</bold>, Eastern Europe: <bold>USD 5.2B</bold>. UK (20% of EU), Germany (14%), France (13%), Spain (12%), Italy (11%)</td><td align="center" valign="top" rowspan="1" colspan="1">S&#248;rensen et&#160;al.&#160;(<xref rid="fsn371024-bib-0113" ref-type="bibr">2022</xref>), Vicentini et&#160;al.&#160;(<xref rid="fsn371024-bib-0122" ref-type="bibr">2016</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Latin America</td><td align="center" valign="top" rowspan="1" colspan="1">Mexico: <bold>USD 12.7B (2011)</bold>&#8201;&#8594;&#8201;<bold>USD 16.3B (2015)</bold>, Rapid expansion: <bold>Brazil +10% annually</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">S&#248;rensen et&#160;al.&#160;(<xref rid="fsn371024-bib-0113" ref-type="bibr">2022</xref>), Vicentini et&#160;al.&#160;(<xref rid="fsn371024-bib-0122" ref-type="bibr">2016</xref>)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other regions</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Saudi Arabia, Israel, and South Africa show higher functional food potential</p>
<p>Eastern Europe has fragmented functional food market</p>
<p>Within the region, Russia dominates the market, accounting for 51% of all functional food sales in Eastern Europe</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">S&#248;rensen et&#160;al.&#160;(<xref rid="fsn371024-bib-0113" ref-type="bibr">2022</xref>), Vicentini et&#160;al.&#160;(<xref rid="fsn371024-bib-0122" ref-type="bibr">2016</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="fsn371024-note-0003"><p>
<italic toggle="yes">Note:</italic> Bold values highlight key market sizes, growth rates, and dominant regional contributions.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="fsn371024-tbl-0007" content-type="TABLE" orientation="portrait"><label>TABLE 7</label><caption><p>Types of beneficial functional foods available in the market with brand names.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Product/functional food</th><th align="center" valign="bottom" rowspan="1" colspan="1">Type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Key bioactive compound(s)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Company/brand</th><th align="center" valign="bottom" rowspan="1" colspan="1">Regional availability</th><th align="center" valign="bottom" rowspan="1" colspan="1">Retail price range (USD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Reported health benefits</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Activia (probiotic yogurt)</td><td align="center" valign="top" rowspan="1" colspan="1">Dairy/yogurt</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Bifidobacteriumanimalis</italic> subsp. <italic toggle="yes">Lactis</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Danone (Dannon)</td><td align="center" valign="top" rowspan="1" colspan="1">USA, EU, APAC</td><td align="center" valign="top" rowspan="1" colspan="1">$1.0&#8211;$2.5 (single cup)</td><td align="center" valign="top" rowspan="1" colspan="1">Supports digestive health; reduces minor GI discomfort</td><td align="center" valign="top" rowspan="1" colspan="1">Danone&#160;(<xref rid="fsn371024-bib-0026" ref-type="bibr">2023</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yakult (probiotic drink)</td><td align="center" valign="top" rowspan="1" colspan="1">Fermented beverage</td><td align="center" valign="top" rowspan="1" colspan="1">
<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Lactobacillus casei</italic>
</styled-content> Shirota</td><td align="center" valign="top" rowspan="1" colspan="1">Yakult Honsha</td><td align="center" valign="top" rowspan="1" colspan="1">Global (major markets)</td><td align="center" valign="top" rowspan="1" colspan="1">$0.8&#8211;$1.8 (single bottle)</td><td align="center" valign="top" rowspan="1" colspan="1">Supports gut microbiota and regularity</td><td align="center" valign="top" rowspan="1" colspan="1">Kato&#8208;Kataoka et&#160;al.&#160;(<xref rid="fsn371024-bib-0058" ref-type="bibr">2016</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DanActive/Actimel</td><td align="center" valign="top" rowspan="1" colspan="1">Fermented beverage</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">L. casei</italic> strains + vitamins D/B6</td><td align="center" valign="top" rowspan="1" colspan="1">Danone</td><td align="center" valign="top" rowspan="1" colspan="1">USA, EU, APAC</td><td align="center" valign="top" rowspan="1" colspan="1">$1.0&#8211;$2.0 (single bottle)</td><td align="center" valign="top" rowspan="1" colspan="1">Immune support; digestive health</td><td align="center" valign="top" rowspan="1" colspan="1">Danone&#160;(<xref rid="fsn371024-bib-0026" ref-type="bibr">2023</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Special K (fortified cereal)</td><td align="center" valign="top" rowspan="1" colspan="1">Cereals</td><td align="center" valign="top" rowspan="1" colspan="1">Added vitamins &amp; minerals (iron, B vitamins)</td><td align="center" valign="top" rowspan="1" colspan="1">Kellogg's</td><td align="center" valign="top" rowspan="1" colspan="1">Global</td><td align="center" valign="top" rowspan="1" colspan="1">$3&#8211;$6 (box)</td><td align="center" valign="top" rowspan="1" colspan="1">General micronutrient fortification</td><td align="center" valign="top" rowspan="1" colspan="1">kelloggs.co.uk, <xref rid="fsn371024-bib-0059" ref-type="bibr">n.d.</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Eggland's Best (Omega3 EGGS)</td><td align="center" valign="top" rowspan="1" colspan="1">Eggs</td><td align="center" valign="top" rowspan="1" colspan="1">Omega3 fatty acids (ALA, EPA/DHA)</td><td align="center" valign="top" rowspan="1" colspan="1">Eggland's Best</td><td align="center" valign="top" rowspan="1" colspan="1">USA, EU markets</td><td align="center" valign="top" rowspan="1" colspan="1">$3.5&#8211;$6.5 (dozen)</td><td align="center" valign="top" rowspan="1" colspan="1">Increased omega3 intake for CV health</td><td align="center" valign="top" rowspan="1" colspan="1">Michella and Slaugh&#160;(<xref rid="fsn371024-bib-0084" ref-type="bibr">2000</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GT's SYNERGY Kombucha</td><td align="center" valign="top" rowspan="1" colspan="1">Kombucha</td><td align="center" valign="top" rowspan="1" colspan="1">Live cultures, tea polyphenols</td><td align="center" valign="top" rowspan="1" colspan="1">GT's Living Foods</td><td align="center" valign="top" rowspan="1" colspan="1">USA, EU, APAC (selected)</td><td align="center" valign="top" rowspan="1" colspan="1">$3&#8211;$5 (bottle)</td><td align="center" valign="top" rowspan="1" colspan="1">Gut health, antioxidants</td><td align="center" valign="top" rowspan="1" colspan="1">GT's Living Foods</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beyond Burger (plant based patty)</td><td align="center" valign="top" rowspan="1" colspan="1">Plant based meat</td><td align="center" valign="top" rowspan="1" colspan="1">Pea/rice proteins; fortified iron</td><td align="center" valign="top" rowspan="1" colspan="1">Beyond Meat</td><td align="center" valign="top" rowspan="1" colspan="1">Global (major retailers)</td><td align="center" valign="top" rowspan="1" colspan="1">$4&#8211;$8 (pack)</td><td align="center" valign="top" rowspan="1" colspan="1">Protein alternative with lower sat fat</td><td align="center" valign="top" rowspan="1" colspan="1">Beyond Meat&#160;(<xref rid="fsn371024-bib-0081" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quest protein bars</td><td align="center" valign="top" rowspan="1" colspan="1">Snack bar</td><td align="center" valign="top" rowspan="1" colspan="1">High protein (whey/milk isolates), fiber</td><td align="center" valign="top" rowspan="1" colspan="1">Quest Nutrition</td><td align="center" valign="top" rowspan="1" colspan="1">USA, EU</td><td align="center" valign="top" rowspan="1" colspan="1">$1.8&#8211;$3.5 (bar)</td><td align="center" valign="top" rowspan="1" colspan="1">Muscle maintenance, satiety</td><td align="center" valign="top" rowspan="1" colspan="1">Quest Nutrition&#160;(<xref rid="fsn371024-bib-0101" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Manitoba harvest hemp hearts</td><td align="center" valign="top" rowspan="1" colspan="1">Seeds/toppings</td><td align="center" valign="top" rowspan="1" colspan="1">&#8208;Omega3 &amp; omega6 fatty acids, plant protein</td><td align="center" valign="top" rowspan="1" colspan="1">Manitoba Harvest</td><td align="center" valign="top" rowspan="1" colspan="1">North America, EU (selected)</td><td align="center" valign="top" rowspan="1" colspan="1">$6&#8211;$12 (8&#8201;oz)</td><td align="center" valign="top" rowspan="1" colspan="1">Plant protein &amp; essential fatty acids</td><td align="center" valign="top" rowspan="1" colspan="1">Manitoba Harvest Hemp Foods (<xref rid="fsn371024-bib-0171" ref-type="bibr">2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Huel (meal replacement)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8208;Meal replacement Powder/ready to drink</td><td align="center" valign="top" rowspan="1" colspan="1">Balanced macros +27 essential vitamins &amp; minerals</td><td align="center" valign="top" rowspan="1" colspan="1">Huel Ltd.</td><td align="center" valign="top" rowspan="1" colspan="1">Global (online + retailers)</td><td align="center" valign="top" rowspan="1" colspan="1">$2.0&#8211;$4.5 per meal equivalent</td><td align="center" valign="top" rowspan="1" colspan="1">Complete nutrition/weight management</td><td align="center" valign="top" rowspan="1" colspan="1">HuelLimited&#160;(<xref rid="fsn371024-bib-0050" ref-type="bibr">2015&#8211;2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ensure (clinical nutrition)</td><td align="center" valign="top" rowspan="1" colspan="1">Nutrition shake</td><td align="center" valign="top" rowspan="1" colspan="1">Proteins, vitamins &amp; minerals (27+), ALA in some formulations</td><td align="center" valign="top" rowspan="1" colspan="1">Abbott Nutrition</td><td align="center" valign="top" rowspan="1" colspan="1">Global</td><td align="center" valign="top" rowspan="1" colspan="1">$1.5&#8211;$3.5 (bottle)</td><td align="center" valign="top" rowspan="1" colspan="1">Clinical nutritional support; elderly nutrition</td><td align="center" valign="top" rowspan="1" colspan="1">Abbott&#160;(<xref rid="fsn371024-bib-0001" ref-type="bibr">2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oatly (fortified oat milk)</td><td align="center" valign="top" rowspan="1" colspan="1">Plant based milk</td><td align="center" valign="top" rowspan="1" colspan="1">Added calcium, vitamin D, B12</td><td align="center" valign="top" rowspan="1" colspan="1">Oatly</td><td align="center" valign="top" rowspan="1" colspan="1">Global (major markets)</td><td align="center" valign="top" rowspan="1" colspan="1">$2.5&#8211;$5 (carton)</td><td align="center" valign="top" rowspan="1" colspan="1">Dairy alternative with fortification</td><td align="center" valign="top" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://oatly.com" ext-link-type="uri">oatly.com</ext-link>, <xref rid="fsn371024-bib-0092" ref-type="bibr">n.d.</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chobani (probiotic yogurt lines)</td><td align="center" valign="top" rowspan="1" colspan="1">Dairy/yogurt</td><td align="center" valign="top" rowspan="1" colspan="1">Live cultures (probiotics)</td><td align="center" valign="top" rowspan="1" colspan="1">Chobani</td><td align="center" valign="top" rowspan="1" colspan="1">USA, select international</td><td align="center" valign="top" rowspan="1" colspan="1">$1.0&#8211;$2.5 (cup)</td><td align="center" valign="top" rowspan="1" colspan="1">Digestive health; protein&#8208;rich yogurt</td><td align="center" valign="top" rowspan="1" colspan="1">Chobani&#160;(<xref rid="fsn371024-bib-0021" ref-type="bibr">2024</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alpro (fortified plant drinks)</td><td align="center" valign="top" rowspan="1" colspan="1">Plant based beverage</td><td align="center" valign="top" rowspan="1" colspan="1">Vitamins &amp; minerals (Ca, B12, D)</td><td align="center" valign="top" rowspan="1" colspan="1">Alpro (Danone)</td><td align="center" valign="top" rowspan="1" colspan="1">EU, UK, APAC</td><td align="center" valign="top" rowspan="1" colspan="1">$2&#8211;$4 (carton)</td><td align="center" valign="top" rowspan="1" colspan="1">Dairy alternative with micronutrients</td><td align="center" valign="top" rowspan="1" colspan="1">Alpro&#160;(<xref rid="fsn371024-bib-0010" ref-type="bibr">2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nature's Bounty Omega3 (supplement)</td><td align="center" valign="top" rowspan="1" colspan="1">Dietary supplement</td><td align="center" valign="top" rowspan="1" colspan="1">EPA/DHA fish oil</td><td align="center" valign="top" rowspan="1" colspan="1">Nature's Bounty</td><td align="center" valign="top" rowspan="1" colspan="1">Global</td><td align="center" valign="top" rowspan="1" colspan="1">$8&#8211;$20 (bottle)</td><td align="center" valign="top" rowspan="1" colspan="1">Cardiovascular &amp; cognitive support</td><td align="center" valign="top" rowspan="1" colspan="1">Bounty&#160;(<xref rid="fsn371024-bib-0019" ref-type="bibr">2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Optimum Nutrition Gold Standard Whey (Protein)</td><td align="center" valign="top" rowspan="1" colspan="1">Sports nutrition</td><td align="center" valign="top" rowspan="1" colspan="1">Whey protein isolate/concentrate</td><td align="center" valign="top" rowspan="1" colspan="1">Optimum Nutrition (Glanbia)</td><td align="center" valign="top" rowspan="1" colspan="1">Global</td><td align="center" valign="top" rowspan="1" colspan="1">$1.0&#8211;$2.5 per serving</td><td align="center" valign="top" rowspan="1" colspan="1">Muscle recovery and performance</td><td align="center" valign="top" rowspan="1" colspan="1">Optimum Nutrition&#160;(<xref rid="fsn371024-bib-0093" ref-type="bibr">2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">S&#8208;26 Probiotic Infant Formula</td><td align="center" valign="top" rowspan="1" colspan="1">Infant nutrition</td><td align="center" valign="top" rowspan="1" colspan="1">Probiotic strains (varies by formulation)</td><td align="center" valign="top" rowspan="1" colspan="1">Wyeth/Nestl&#233;/Mead Johnson variations</td><td align="center" valign="top" rowspan="1" colspan="1">Selected regions</td><td align="center" valign="top" rowspan="1" colspan="1">$20&#8211;$60 (tin)</td><td align="center" valign="top" rowspan="1" colspan="1">Gut health in infants (formulation&#8208;specific claims)</td><td align="center" valign="top" rowspan="1" colspan="1">Nestl&#233;&#160;(<xref rid="fsn371024-bib-0091" ref-type="bibr">2025</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Olly (multivitamin gummies)</td><td align="center" valign="top" rowspan="1" colspan="1">Dietary supplement/gummies</td><td align="center" valign="top" rowspan="1" colspan="1">Vitamins (multi blends)</td><td align="center" valign="top" rowspan="1" colspan="1">Olly</td><td align="center" valign="top" rowspan="1" colspan="1">USA, online global</td><td align="center" valign="top" rowspan="1" colspan="1">$8&#8211;$18 (bottle)</td><td align="center" valign="top" rowspan="1" colspan="1">General wellness, sleep/beauty formulations</td><td align="center" valign="top" rowspan="1" colspan="1">Unilever&#160;(<xref rid="fsn371024-bib-0120" ref-type="bibr">2025</xref>)</td></tr></tbody></table></table-wrap></sec></sec><sec id="fsn371024-sec-0033"><label>5</label><title>Market of Different Types of Functional Foods</title><p>The global functional food market has emerged as one of the fastest&#8208;growing sectors in the food industry, driven by consumer demand for preventive health solutions, rising healthcare costs, and increasing awareness of diet&#8208;related diseases. According to Euromonitor, the global market for functional foods is estimated to be worth USD 177.4 billion in 2021 and expected to be USD 219.5 billion by 2026 (S&#248;rensen et&#160;al.&#160;<xref rid="fsn371024-bib-0113" ref-type="bibr">2022</xref>; Tables&#160;<xref rid="fsn371024-tbl-0006" ref-type="table">6</xref> and <xref rid="fsn371024-tbl-0007" ref-type="table">7</xref>). This discrepancy reflects differences in the classification of functional foods rather than an actual decline in market size.</p></sec><sec id="fsn371024-sec-0034"><label>6</label><title>Challenges Associated With Functional Foods</title><p>With compromised living standards and life expectancy, along with a high frequency of illnesses, nutrition plays an important role in maintaining human health. Scientists are working in collaboration to meet various food demands with associated therapeutic advantages, popularly known as functional food, promising in ensuring human well&#8208;being and lowering the risk of illnesses (Lobine et&#160;al.&#160;<xref rid="fsn371024-bib-0070" ref-type="bibr">2022</xref>). The utilization of bioactive components and natural products in functional food development is a quickly expanding research area, providing significant health benefits beyond basic nutrition. However, multiple challenges must be addressed to secure their safety, efficacy, and commercial viability.</p><sec id="fsn371024-sec-0035"><label>6.1</label><title>Bioavailability and Stability Issues</title><p>Bioavailability and stability are essential components in the development of functional foods, influencing their efficacy and shelf life (Mihociu et&#160;al.&#160;<xref rid="fsn371024-bib-0085" ref-type="bibr">2024</xref>).</p><p>Functional bioactive compounds like polyphenols, probiotics, peptides, and omega&#8208;3 fatty acids often exhibit weak solubility, low permeability, and susceptibility to enzymatic destruction. Molecular size, hydrophobicity, and interaction with food matrices can also impede absorption (Mafe et&#160;al.&#160;<xref rid="fsn371024-bib-0074" ref-type="bibr">2025</xref>; Mihociu et&#160;al.&#160;<xref rid="fsn371024-bib-0085" ref-type="bibr">2024</xref>). Functional ingredients are susceptible to deterioration due to environmental variables such as temperature, pH, light, and oxygen. Oxidation, hydrolysis, and microbial contamination can all impair their structural integrity and efficacy. Stability is also a major concern during processing, storage, and digestion, requiring advanced delivery systems (e.g., nanoencapsulation, liposomes) (Mafe et&#160;al.&#160;<xref rid="fsn371024-bib-0074" ref-type="bibr">2025</xref>; Mihociu et&#160;al.&#160;<xref rid="fsn371024-bib-0085" ref-type="bibr">2024</xref>).</p></sec><sec id="fsn371024-sec-0036"><label>6.2</label><title>Standardization and Quality Control</title><p>Standardization and quality control are difficult for the formation of functional foods because of the complexity of bioactive substances, the unpredictability of raw materials, and inconsistent regulations. Exact analytical methods such as mass spectrometry and HPLC are necessary to guarantee consistent constituent composition; however, consistency is hampered by natural variances. Regional differences in regulations lead to discrepancies in safety evaluations, health claims, and labeling (Wani et&#160;al.&#160;<xref rid="fsn371024-bib-0130" ref-type="bibr">2023</xref>).</p></sec><sec id="fsn371024-sec-0037"><label>6.3</label><title>Regulatory and Safety Concerns</title><p>Functional foods are at the nexus of food and medicines, which presents challenges for their development due to complicated regulatory frameworks and safety issues. Regulatory agencies like the FDA and EFSA enforce strict rules on labeling, ingredient approval, and health claims; yet, regional variations make it difficult for products to be accepted on the international market. It takes sophisticated analytical techniques, such as mass spectrometry and microbiological testing, to guarantee the absence of pollutants, allergies, and poisons. It is also necessary to assess the long&#8208;term consequences of intake through toxicological and clinical research (Vilas&#8208;Boas et&#160;al.&#160;<xref rid="fsn371024-bib-0125" ref-type="bibr">2021</xref>).</p></sec><sec id="fsn371024-sec-0038"><label>6.4</label><title>Consumer Acceptances</title><p>Consumer acceptability and marketability, which are impacted by sensory qualities, perceived health advantages, and cost, are critical to the success of functional foods. Customers frequently reject functional food because of unfavorable flavor, texture, or appearance brought on by the addition of bioactive ingredients. Acceptance is further hampered by false information and mistrust over health claims, which makes open communication and claims supported by science necessary. Furthermore, market penetration is restricted by premium pricing brought on by expensive R&amp;D and sophisticated processing methods (Grinberga&#8208;Zalite et&#160;al.&#160;<xref rid="fsn371024-bib-0042" ref-type="bibr">2024</xref>).</p></sec><sec id="fsn371024-sec-0039"><label>6.5</label><title>Cost&#8211;Benefit Analysis of Functional Food Versus Regular Food</title><p>In addition to regulatory and safety concerns, economic feasibility remains a critical challenge influencing the widespread adoption of functional foods as they may carry a higher price point due to added bioactive components and enhanced processing. A comparative cost&#8211;benefit analysis indicates that preventive intake of functional foods could outweigh the initial cost when weighed against medical expenses for managing lifestyle&#8208;related disorders; however, several studies suggest their long&#8208;term cost&#8208;effectiveness in reducing healthcare burdens associated with chronic diseases (Mehboob&#160;<xref rid="fsn371024-bib-0082" ref-type="bibr">2025</xref>; Michaud et&#160;al.&#160;<xref rid="fsn371024-bib-0083" ref-type="bibr">2017</xref>; Musich et&#160;al.&#160;<xref rid="fsn371024-bib-0088" ref-type="bibr">2016</xref>). Nonetheless, affordability and equitable access remain key barriers to consumer adoption, especially in low&#8208; to middle&#8208;income populations (Zheng&#160;<xref rid="fsn371024-bib-0140" ref-type="bibr">2022</xref>).</p></sec><sec id="fsn371024-sec-0040"><label>6.6</label><title>Advancement in Biotechnology and Omics Approaches</title><p>The &#8220;omics technologies and biotechnology&#8221; have revolutionized the discovery, characterization, precision, and application of bioactive compounds and natural products in the functional food development. Various approaches are being used, including &#8220;omics&#8221;, synthetic biology, genetic engineering, and gene&#8208;editing (Figure&#160;<xref rid="fsn371024-fig-0010" ref-type="fig">10</xref>). These approaches provide a deeper knowledge of complex interactions between human biology and bioactive molecules, opening ways to ward targeted, validated, and effective functional foods (Nayak et&#160;al.&#160;<xref rid="fsn371024-bib-0089" ref-type="bibr">2021</xref>).</p><fig position="float" fig-type="FIGURE" id="fsn371024-fig-0010" orientation="portrait"><label>FIGURE 10</label><caption><p>Advancements in biotechnological and omics approaches.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-21" orientation="portrait" xlink:href="FSN3-13-e71024-g010.jpg"/></fig></sec><sec id="fsn371024-sec-0041"><label>6.7</label><title>Development of Smart Delivery Systems</title><p>Smart delivery system in functional food development enhancing the bioavailability, stability, and targeted release of sensitive bioactive compounds. Techniques such as liposomes, biopolymer&#8208;based carriers, and nano&#8208;emulsions protect bioactive compounds and improve their absorption. Additionally, smart packaging with intelligent and active features helps maintain product quality and increase shelf life, ensuring efficacy from production to consumption (Shishir et&#160;al.&#160;<xref rid="fsn371024-bib-0111" ref-type="bibr">2021</xref>).</p></sec><sec id="fsn371024-sec-0042"><label>6.8</label><title>Personalized Nutrition and Functional Foods</title><p>Personalized nutrition in the development of functional food offers tailored dietary solutions based on an individual's metabolism, lifestyle, and genetics. Researchers can develop customized functional food products by using tools such as nutrigenomics, microbiome analysis, and metabolomics that effectively target specific health conditions. Advancements in digital health and AI technologies further enable personalized recommendations and real&#8208;time monitoring, enhancing the effectiveness, accessibility, and precision of functional nutrition (Dj Nevena et&#160;al.&#160;<xref rid="fsn371024-bib-0030" ref-type="bibr">2022</xref>).</p></sec><sec id="fsn371024-sec-0043"><label>6.9</label><title>Expanded Clinical Research and Regulatory Harmonization</title><p>Expanded clinical research and regulatory harmonization are crucial for advancing functional foods derived from natural products and bioactives. Strict clinical trials are essential to establish the safety, efficacy, and health benefits of these foods, paving the way for personalized nutrition and improved consumer acceptance. Meanwhile, regulatory harmonization creates global standards that ensure product quality and safety, facilitating innovation and international trade. By promoting collaboration among regulatory bodies, researchers, and industry stakeholders, these efforts will increase the development and trust in functional foods, ultimately meeting the growing consumer demand for health&#8208;promoting products (Alongi and Anese&#160;<xref rid="fsn371024-bib-0009" ref-type="bibr">2021</xref>).</p></sec></sec><sec id="fsn371024-sec-0044"><label>7</label><title>Future Prospect and Conclusion</title><p>Bioactive compounds obtained from natural food products and plant extracts possess incredible supplementary and medicinal properties. These biologically active components such as carotenoids, probiotics, prebiotics, and omega&#8208;3 fatty acids have diverse health benefits such as anti&#8208;inflammatory, antioxidant, enzyme inhibition activities, and gut microbiome modulation. Modern biotechnological and bioinformatics approaches have revolutionized the development, characterization, and targeted delivery of these therapeutically and nutritionally significant natural compounds.</p><p>In the future, integrating precision nutrition strategies (&#8220;omics&#8221; technologies and machine learning) may accelerate the discovery of new bioactive compounds and customized therapeutics. Sustainable sourcing, enhanced bioavailability through nanotechnology, and thorough clinical validation of these compounds will ensure their effectiveness, safety, and widespread adoption. To bridge the gap between conventional approaches and contemporary healthcare innovations, these natural compounds must also be transformed from research to mainstream health solutions in the market.</p></sec><sec id="fsn371024-sec-0045"><title>Author Contributions</title><p>A.H. and Z.A.: Conceived and designed the project; Z.A., S.S., A.H., E.Y., and M.R.: analyzed, wrote, revised, and proofread the manuscript. All authors contributed to the article and read and approved the final manuscript.</p></sec><sec id="fsn371024-sec-0047"><title>Ethics Statement</title><p>The authors have nothing to report.</p></sec><sec sec-type="conclusions" id="fsn371024-sec-0048"><title>Consent</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="fsn371024-sec-0049"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="fsn371024-sec-0046"><title>Acknowledgments</title><p>The authors acknowledge the support provided by the Department of Biotechnology, Lahore University of Biological and Applied Sciences. All assistance and guidance were provided by the corresponding author, Dr. A.H.</p></ack><sec sec-type="data-availability" id="fsn371024-sec-0051"><title>Data Availability Statement</title><p>Data used during the preparation of this manuscript is available within the article.</p></sec><ref-list content-type="cited-references" id="fsn371024-bibl-0001"><title>References</title><ref id="fsn371024-bib-0001"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0001"><string-name name-style="western"><surname>Abbott</surname></string-name>. <year>2025</year>. <article-title>&#8220;Ensure&#174; Original Vanilla Nutrition Powder.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ensure.com" ext-link-type="uri">https://www.ensure.com</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0002"><mixed-citation publication-type="journal" id="fsn371024-cit-0002"><string-name name-style="western"><surname>Abeyrathne</surname>, <given-names>E. D. N. S.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Nam</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Huang</surname></string-name>, and <string-name name-style="western"><given-names>D. U.</given-names><surname>Ahn</surname></string-name>. <year>2022</year>. &#8220;<article-title>Plant&#8208; and Animal&#8208;Based Antioxidants' Structure, Efficacy, Mechanisms, and Applications: A Review</article-title>.&#8221; <source>Antioxidants</source><volume>11</volume>, no. <issue>5</issue>: <elocation-id>1025</elocation-id>.<pub-id pub-id-type="pmid">35624889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11051025</pub-id><pub-id pub-id-type="pmcid">PMC9137533</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0003"><mixed-citation publication-type="journal" id="fsn371024-cit-0003"><string-name name-style="western"><surname>Afzal</surname>, <given-names>M. F.</given-names></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Khalid</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Akram</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Bioactive Profile and Functional Food Applications of Banana in Food Sectors and Health: A Review</article-title>.&#8221; <source>International Journal of Food Properties</source><volume>25</volume>, no. <issue>1</issue>: <fpage>2286</fpage>&#8211;<lpage>2300</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0004"><mixed-citation publication-type="journal" id="fsn371024-cit-0004"><string-name name-style="western"><surname>Ahmad</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Haque</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ahmad</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Srivastava</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Khan</surname></string-name>. <year>2023</year>. &#8220;<article-title>Angiotensin&#8208;Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension</article-title>.&#8221; <source>Journal of the Renin&#8208;Angiotensin&#8208;Aldosterone System</source><volume>2023</volume>: <elocation-id>7890188</elocation-id>.<pub-id pub-id-type="pmid">37389408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2023/7890188</pub-id><pub-id pub-id-type="pmcid">PMC10307051</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0158"><mixed-citation publication-type="journal" id="fsn371024-cit-0158"><string-name name-style="western"><surname>Ahmad</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Ali</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Khardali</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Incredible Use of Omega&#8208;3 Fatty Acids: A Review on Current Use and Future Prospective</article-title>.&#8221; <source>Journal of Young Pharmacists</source>. <pub-id pub-id-type="doi">10.5530/jyp.2024.16.24</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0005"><mixed-citation publication-type="journal" id="fsn371024-cit-0005"><string-name name-style="western"><surname>Ajeeshkumar</surname>, <given-names>K. K.</given-names></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Aneesh</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Raju</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Suseela</surname></string-name>, <string-name name-style="western"><given-names>C. N.</given-names><surname>Ravishankar</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Benjakul</surname></string-name>. <year>2021</year>. &#8220;<article-title>Advancements in Liposome Technology: Preparation Techniques and Applications in Food, Functional Foods, and Bioactive Delivery: A Review</article-title>.&#8221; <source>Comprehensive Reviews in Food Science and Food Safety</source><volume>20</volume>, no. <issue>2</issue>: <fpage>1280</fpage>&#8211;<lpage>1306</lpage>.<pub-id pub-id-type="pmid">33665991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1541-4337.12725</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0006"><mixed-citation publication-type="journal" id="fsn371024-cit-0006"><string-name name-style="western"><surname>Akbarian</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Khani</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Eghbalpour</surname></string-name>, and <string-name name-style="western"><given-names>V. N.</given-names><surname>Uversky</surname></string-name>. <year>2022</year>. &#8220;<article-title>Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>23</volume>, no. <issue>3</issue>: <elocation-id>1445</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijms23031445</pub-id>.<pub-id pub-id-type="pmid">35163367</pub-id><pub-id pub-id-type="pmcid">PMC8836030</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0007"><mixed-citation publication-type="journal" id="fsn371024-cit-0007"><string-name name-style="western"><surname>Ali</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Kamal</surname></string-name>, <string-name name-style="western"><given-names>M. H.</given-names><surname>Rahman</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Functional Dairy Products as a Source of Bioactive Peptides and Probiotics: Current Trends and Future Prospectives</article-title>.&#8221; <source>Journal of Food Science and Technology</source><volume>59</volume>, no. <issue>4</issue>: <fpage>1263</fpage>&#8211;<lpage>1279</lpage>.<pub-id pub-id-type="pmid">35250052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13197-021-05091-8</pub-id><pub-id pub-id-type="pmcid">PMC8882518</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0008"><mixed-citation publication-type="journal" id="fsn371024-cit-0008"><string-name name-style="western"><surname>Ali Redha</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Kodikara</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Cozzolino</surname></string-name>. <year>2024</year>. &#8220;<article-title>Does Encapsulation Improve the Bioavailability of Polyphenols in Humans? A Concise Review Based on In&#160;Vivo Human Studies</article-title>.&#8221; <source>Nutrients</source><volume>16</volume>, no. <issue>21</issue>: <elocation-id>3625</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2072-6643/16/21/3625" ext-link-type="uri">https://www.mdpi.com/2072&#8208;6643/16/21/3625</ext-link>.<pub-id pub-id-type="pmid">39519458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu16213625</pub-id><pub-id pub-id-type="pmcid">PMC11547751</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0009"><mixed-citation publication-type="journal" id="fsn371024-cit-0009"><string-name name-style="western"><surname>Alongi</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Anese</surname></string-name>. <year>2021</year>. &#8220;<article-title>Re&#8208;Thinking Functional Food Development Through a Holistic Approach</article-title>.&#8221; <source>Journal of Functional Foods</source><volume>81</volume>: <elocation-id>104466</elocation-id>.</mixed-citation></ref><ref id="fsn371024-bib-0010"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0010"><collab collab-type="authors">Alpro</collab>
. <year>2025</year>. <article-title>&#8220;Fortified Plant Drinks.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alpro.com/uk" ext-link-type="uri">https://www.alpro.com/uk</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0011"><mixed-citation publication-type="journal" id="fsn371024-cit-0011"><string-name name-style="western"><surname>Andrade</surname>, <given-names>J. M.</given-names></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Para&#237;so</surname></string-name>, <string-name name-style="western"><given-names>M. V.</given-names><surname>de Oliveira</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Resveratrol Attenuates Hepatic Steatosis in High&#8208;Fat Fed Mice by Decreasing Lipogenesis and Inflammation</article-title>.&#8221; <source>Nutrition</source><volume>30</volume>, no. <issue>7&#8211;8</issue>: <fpage>915</fpage>&#8211;<lpage>919</lpage>. <pub-id pub-id-type="doi">10.1016/j.nut.2013.11.016</pub-id>.<pub-id pub-id-type="pmid">24985011</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0012"><mixed-citation publication-type="book" id="fsn371024-cit-0012"><string-name name-style="western"><surname>Arshad</surname>, <given-names>M. S.</given-names></string-name>, <string-name name-style="western"><given-names>M. H.</given-names><surname>Ahmad</surname></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Khan</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<part-title>Functional Foods and Human Health: An Overview</part-title>.&#8221; In <source>Functional Foods &#8208; Phytochemicals and Health Promoting Potential</source>, edited by <person-group person-group-type="editor"><string-name name-style="western"><given-names>M. S.</given-names><surname>Arshad</surname></string-name></person-group> and <person-group person-group-type="editor"><string-name name-style="western"><given-names>M. H.</given-names><surname>Ahmad</surname></string-name></person-group>. <publisher-name>IntechOpen</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0013"><mixed-citation publication-type="journal" id="fsn371024-cit-0013"><string-name name-style="western"><surname>Baker</surname>, <given-names>M. T.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Parrella</surname></string-name>, and <string-name name-style="western"><given-names>H. R.</given-names><surname>Leggette</surname></string-name>. <year>2022</year>. &#8220;<article-title>Consumer Acceptance Toward Functional Foods: A Scoping Review</article-title>.&#8221; <source>International Journal of Environmental Research and Public Health</source><volume>19</volume>, no. <issue>3</issue>: <elocation-id>1217</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijerph19031217</pub-id>.<pub-id pub-id-type="pmid">35162240</pub-id><pub-id pub-id-type="pmcid">PMC8835010</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0014"><mixed-citation publication-type="journal" id="fsn371024-cit-0014"><string-name name-style="western"><surname>Banaszak</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Dobrzy&#324;ska</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Kawka</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Role of Omega&#8208;3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) as Modulatory and Anti&#8208;Inflammatory Agents in Noncommunicable Diet&#8208;Related Diseases&#8211;Reports From the Last 10&#8201;Years</article-title>.&#8221; <source>Clinical Nutrition ESPEN</source><volume>63</volume>: <fpage>240</fpage>&#8211;<lpage>258</lpage>.<pub-id pub-id-type="pmid">38980796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnesp.2024.06.053</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0015"><mixed-citation publication-type="journal" id="fsn371024-cit-0015"><string-name name-style="western"><surname>Barakat</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>N. K.</given-names><surname>Syed</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Hasen</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>The Effect of Natural Products on Inflammatory Cytokines Production and Secretion</article-title>.&#8221; <source>Phytomedicine Plus</source><volume>3</volume>, no. <issue>4</issue>: <elocation-id>100488</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.phyplu.2023.100488</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0159"><mixed-citation publication-type="journal" id="fsn371024-cit-0159"><string-name name-style="western"><surname>Behl</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Singh</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Sharma</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends</article-title>.&#8221; <source>Molecules</source><volume>27</volume>, no. <issue>12</issue>. <pub-id pub-id-type="doi">10.3390/molecules27123705</pub-id>.<pub-id pub-id-type="pmcid">PMC9229453</pub-id><pub-id pub-id-type="pmid">35744831</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0016"><mixed-citation publication-type="journal" id="fsn371024-cit-0016"><string-name name-style="western"><surname>Behl</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Upadhyay</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Singh</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Polyphenols Targeting MAPK Mediated Oxidative Stress and Inflammation in Rheumatoid Arthritis</article-title>.&#8221; <source>Molecules</source><volume>26</volume>, no. <issue>21</issue>: <elocation-id>6570</elocation-id>.<pub-id pub-id-type="pmid">34770980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules26216570</pub-id><pub-id pub-id-type="pmcid">PMC8588006</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0075"><mixed-citation publication-type="journal" id="fsn371024-cit-0075"><string-name name-style="western"><surname>Bodur</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Yilmaz</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>A&#287;ag&#252;nd&#252;z</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Ozogul</surname></string-name>. <year>2025</year>. &#8220;<article-title>Immunomodulatory Effects of Omega&#8208;3 Fatty Acids: Mechanistic Insights and Health Implications</article-title>.&#8221; <source>Molecular Nutrition &amp; Food Research</source><volume>69</volume>, no. <issue>10</issue>: <elocation-id>e202400752</elocation-id>. <pub-id pub-id-type="doi">10.1002/mnfr.202400752</pub-id>.<pub-id pub-id-type="pmid">40159804</pub-id><pub-id pub-id-type="pmcid">PMC12087734</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0017"><mixed-citation publication-type="journal" id="fsn371024-cit-0017"><string-name name-style="western"><surname>Boggia</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Zunin</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Turrini</surname></string-name>. <year>2020</year>. &#8220;<article-title>Functional Foods and Food Supplements</article-title>.&#8221; <source>Applied Sciences</source><volume>10</volume>, no. <issue>23</issue>: <elocation-id>8538</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2076-3417/10/23/8538" ext-link-type="uri">https://www.mdpi.com/2076&#8208;3417/10/23/8538</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0018"><mixed-citation publication-type="journal" id="fsn371024-cit-0018"><string-name name-style="western"><surname>Boukid</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Klerks</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Pellegrini</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Current and Emerging Trends in Cereal Snack Bars: Implications for New Product Development</article-title>.&#8221; <source>International Journal of Food Sciences and Nutrition</source><volume>73</volume>, no. <issue>5</issue>: <fpage>610</fpage>&#8211;<lpage>629</lpage>.<pub-id pub-id-type="pmid">35184668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09637486.2022.2042211</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0019"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0019"><string-name name-style="western"><surname>Bounty</surname>, <given-names>N. S.</given-names></string-name><year>2025</year>. <article-title>&#8220;Nature's Bounty.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://naturesbounty.com/" ext-link-type="uri">https://naturesbounty.com/</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0020"><mixed-citation publication-type="journal" id="fsn371024-cit-0020"><string-name name-style="western"><surname>Chew</surname>, <given-names>L. Y.</given-names></string-name>, <string-name name-style="western"><given-names>S. K.</given-names><surname>Teng</surname></string-name>, <string-name name-style="western"><given-names>Y. P.</given-names><surname>Neo</surname></string-name>, <string-name name-style="western"><given-names>Y. Y.</given-names><surname>Sim</surname></string-name>, and <string-name name-style="western"><given-names>S. C.</given-names><surname>Chew</surname></string-name>. <year>2024</year>. &#8220;<article-title>The Potential of Roselle (<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Hibiscus sabdariffa</italic>
</styled-content>) Plant in Industrial Applications: A Promising Source of Functional Compounds</article-title>.&#8221; <source>Journal of Oleo Science</source><volume>73</volume>, no. <issue>3</issue>: <fpage>275</fpage>&#8211;<lpage>292</lpage>.<pub-id pub-id-type="pmid">38432993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5650/jos.ess23111</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0021"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0021"><collab collab-type="authors">Chobani</collab>
. <year>2024</year>. <article-title>&#8220;High Protein.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chobani.com/" ext-link-type="uri">https://www.chobani.com/</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0022"><mixed-citation publication-type="journal" id="fsn371024-cit-0022"><string-name name-style="western"><surname>Chojnacka</surname>, <given-names>K.</given-names></string-name>, and <string-name name-style="western"><given-names>U.</given-names><surname>Lewandowska</surname></string-name>. <year>2023</year>. &#8220;<article-title>Inhibition of Pro&#8208;Inflammatory Cytokine Secretion by Polyphenol&#8208;Rich Extracts in Macrophages via NF&#8208;&#954;B Pathway</article-title>.&#8221; <source>Food Reviews International</source><volume>39</volume>, no. <issue>8</issue>: <fpage>5459</fpage>&#8211;<lpage>5478</lpage>. <pub-id pub-id-type="doi">10.1080/87559129.2022.2071936</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0023"><mixed-citation publication-type="journal" id="fsn371024-cit-0023"><string-name name-style="western"><surname>Coutinho&#8208;Wolino</surname>, <given-names>K. S.</given-names></string-name>, <string-name name-style="western"><given-names>P. P.</given-names><surname>Almeida</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Mafra</surname></string-name>, and <string-name name-style="western"><given-names>M. B.</given-names><surname>Stockler&#8208;Pinto</surname></string-name>. <year>2022</year>. &#8220;<article-title>Bioactive Compounds Modulating Toll&#8208;Like 4 Receptor (TLR4)&#8208;Mediated Inflammation: Pathways Involved and Future Perspectives</article-title>.&#8221; <source>Nutrition Research</source><volume>107</volume>: <fpage>96</fpage>&#8211;<lpage>116</lpage>.<pub-id pub-id-type="pmid">36209684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nutres.2022.09.001</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0024"><mixed-citation publication-type="journal" id="fsn371024-cit-0024"><string-name name-style="western"><surname>Cui</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Qian</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Li</surname></string-name>. <year>2019</year>. &#8220;<article-title>Quercetin Inhibits LPS&#8208;Induced Macrophage Migration by Suppressing the iNOS/FAK/Paxillin Pathway and Modulating the Cytoskeleton</article-title>.&#8221; <source>Cell Adhesion &amp; Migration</source><volume>13</volume>, no. <issue>1</issue>: <fpage>1</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1080/19336918.2018.1486142</pub-id>.<pub-id pub-id-type="pmid">29945484</pub-id><pub-id pub-id-type="pmcid">PMC6527387</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0025"><mixed-citation publication-type="journal" id="fsn371024-cit-0025"><string-name name-style="western"><surname>Dahiya</surname>, <given-names>D.</given-names></string-name>, and <string-name name-style="western"><given-names>P. S.</given-names><surname>Nigam</surname></string-name>. <year>2022</year>. &#8220;<article-title>The Gut Microbiota Influenced by the Intake of Probiotics and Functional Foods With Prebiotics Can Sustain Wellness and Alleviate Certain Ailments Like Gut&#8208;Inflammation and Colon&#8208;Cancer</article-title>.&#8221; <source>Microorganisms</source><volume>10</volume>, no. <issue>3</issue>: <elocation-id>665</elocation-id>.<pub-id pub-id-type="pmid">35336240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/microorganisms10030665</pub-id><pub-id pub-id-type="pmcid">PMC8954736</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0026"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0026"><collab collab-type="authors">Danone</collab>
. <year>2023</year>. <article-title>&#8220;Danone Launches New Science&#8208;Based Probiotic Supplement to Support Breastfeeding Experiences.&#8221;</article-title> [Press Release].</mixed-citation></ref><ref id="fsn371024-bib-0027"><mixed-citation publication-type="journal" id="fsn371024-cit-0027"><string-name name-style="western"><surname>Dansou</surname>, <given-names>D. M.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yu</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Carotenoid Enrichment in Eggs: From Biochemistry Perspective</article-title>.&#8221; <source>Animal Nutrition</source><volume>14</volume>: <fpage>315</fpage>&#8211;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1016/j.aninu.2023.05.012</pub-id>.<pub-id pub-id-type="pmid">37635928</pub-id><pub-id pub-id-type="pmcid">PMC10448277</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0028"><mixed-citation publication-type="journal" id="fsn371024-cit-0028"><string-name name-style="western"><surname>Deb</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kumar</surname></string-name>, and <string-name name-style="western"><given-names>D. C.</given-names><surname>Saxena</surname></string-name>. <year>2022</year>. &#8220;<article-title>Functional, Thermal and Structural Properties of Fractionated Protein From Waste Banana Peel</article-title>.&#8221; <source>Food Chemistry: X</source><volume>13</volume>: <elocation-id>100205</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.fochx.2022.100205</pub-id>.<pub-id pub-id-type="pmid">35498999</pub-id><pub-id pub-id-type="pmcid">PMC9039918</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0029"><mixed-citation publication-type="journal" id="fsn371024-cit-0029"><string-name name-style="western"><surname>Dimitrellou</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Kandylis</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Kokkinomagoulos</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hatzikamari</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Bekatorou</surname></string-name>. <year>2021</year>. &#8220;<article-title>Emmer&#8208;Based Beverage Fortified With Fruit Juices</article-title>.&#8221; <source>Applied Sciences</source><volume>11</volume>, no. <issue>7</issue>: <elocation-id>3116</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2076-3417/11/7/3116" ext-link-type="uri">https://www.mdpi.com/2076&#8208;3417/11/7/3116</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0030"><mixed-citation publication-type="book" id="fsn371024-cit-0030"><string-name name-style="western"><surname>Dj Nevena</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Hippe</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Lilja</surname></string-name>, and <string-name name-style="western"><given-names>A. G.</given-names><surname>Haslberger</surname></string-name>. <year>2022</year>. &#8220;<part-title>Precise Nutrition and Functional Foods</part-title>.&#8221; In <source>Advances in Precision Nutrition, Personalization and Healthy Aging</source>, <fpage>231</fpage>&#8211;<lpage>267</lpage>. <publisher-name>Springer</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0166"><mixed-citation publication-type="journal" id="fsn371024-cit-0166"><string-name name-style="western"><surname>Djuricic</surname>, <given-names>I.</given-names></string-name>, and <string-name name-style="western"><given-names>P. C.</given-names><surname>Calder</surname></string-name>. <year>2021</year>. &#8220;<article-title>Beneficial Outcomes of omega&#8208;6 and omega&#8208;3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021</article-title>.&#8221; <source>Nutrients</source><volume>13</volume>, no. <issue>7</issue>: <elocation-id>2421</elocation-id>.<pub-id pub-id-type="pmid">34371930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu13072421</pub-id><pub-id pub-id-type="pmcid">PMC8308533</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0146"><mixed-citation publication-type="book" id="fsn371024-cit-0146"><string-name name-style="western"><surname>Dumay</surname>, <given-names>J.</given-names></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Moran&#231;ais</surname></string-name>. <year>2016</year>. &#8220;<part-title>Chapter&#160;9 &#8208; Proteins and Pigments</part-title>.&#8221; In <source>Seaweed in Health and Disease Prevention</source>, edited by <person-group person-group-type="editor"><string-name name-style="western"><given-names>J.</given-names><surname>Fleurence</surname></string-name></person-group> and <person-group person-group-type="editor"><string-name name-style="western"><given-names>I.</given-names><surname>Levine</surname></string-name></person-group>, <fpage>275</fpage>&#8211;<lpage>318</lpage>. <publisher-name>Academic Press</publisher-name>. <pub-id pub-id-type="doi">10.1016/B978-0-12-802772-1.00009-9</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0031"><mixed-citation publication-type="book" id="fsn371024-cit-0031"><string-name name-style="western"><surname>Eddaikra</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Eddaikra</surname></string-name>. <year>2021</year>. &#8220;<part-title>Endogenous Enzymatic Antioxidant Defense and Pathologies</part-title>.&#8221; In <source>Antioxidants&#8208;Benefits, Sources, Mechanisms of Action</source>. <publisher-name>IntechOpen</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0032"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0032"><collab collab-type="authors">EFSA, E. F. S. A</collab>
. <year>2022</year>. <article-title>&#8220;Cannabinoids in Food: Applications and Data Requirements.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.efsa.europa.eu/en/news/cannabinoids-food-applications-and-data-requirements" ext-link-type="uri">https://www.efsa.europa.eu/en/news/cannabinoids&#8208;food&#8208;applications&#8208;and&#8208;data&#8208;requirements</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0033"><mixed-citation publication-type="journal" id="fsn371024-cit-0033"><string-name name-style="western"><surname>Elbandy</surname>, <given-names>M.</given-names></string-name><year>2022</year>. &#8220;<article-title>Anti&#8208;Inflammatory Effects of Marine Bioactive Compounds and Their Potential as Functional Food Ingredients in the Prevention and Treatment of Neuroinflammatory Disorders</article-title>.&#8221; <source>Molecules</source><volume>28</volume>, no. <issue>1</issue>: <elocation-id>2</elocation-id>.<pub-id pub-id-type="pmid">36615197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28010002</pub-id><pub-id pub-id-type="pmcid">PMC9822486</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0034"><mixed-citation publication-type="journal" id="fsn371024-cit-0034"><string-name name-style="western"><surname>Essa</surname>, <given-names>M. M.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bishir</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bhat</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Functional Foods and Their Impact on Health</article-title>.&#8221; <source>Journal of Food Science and Technology</source><volume>60</volume>, no. <issue>3</issue>: <fpage>820</fpage>&#8211;<lpage>834</lpage>. <pub-id pub-id-type="doi">10.1007/s13197-021-05193-3</pub-id>.<pub-id pub-id-type="pmid">36908338</pub-id><pub-id pub-id-type="pmcid">PMC9998796</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0035"><mixed-citation publication-type="book" id="fsn371024-cit-0035"><string-name name-style="western"><surname>Evans</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Richards</surname></string-name>, and <string-name name-style="western"><given-names>A. S.</given-names><surname>Battisti</surname></string-name>. <year>2025</year>. <source>Caffeine</source>. <publisher-name>StatPearls</publisher-name>. Treasure Island (FL) Ineligible Companies. Disclosure: John Richards Declares No Relevant Financial Relationships With Ineligible Companies. Disclosure: Amanda Battisti Declares No Relevant Financial Relationships With Ineligible Companies. StatPearls Publishing Copyright &#169; 2025, StatPearls Publishing LLC.</mixed-citation></ref><ref id="fsn371024-bib-0036"><mixed-citation publication-type="journal" id="fsn371024-cit-0036"><string-name name-style="western"><surname>Fakhri</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>S. Z.</given-names><surname>Moradi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Yarmohammadi</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Narimani</surname></string-name>, <string-name name-style="western"><given-names>C. E.</given-names><surname>Wallace</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Bishayee</surname></string-name>. <year>2022</year>. &#8220;<article-title>Modulation of TLR/NF&#8208;&#954;B/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy</article-title>.&#8221; <source>Frontiers in Oncology</source><volume>12</volume>: <elocation-id>834072</elocation-id>.<pub-id pub-id-type="pmid">35299751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.834072</pub-id><pub-id pub-id-type="pmcid">PMC8921560</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0144"><mixed-citation publication-type="journal" id="fsn371024-cit-0144"><string-name name-style="western"><surname>Farahmandi</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>A. E.</given-names><surname>Mohr</surname></string-name>, and <string-name name-style="western"><given-names>L. V.</given-names><surname>McFarland</surname></string-name>. <year>2022</year>. &#8220;<article-title>Effects of Probiotics on Allergic Rhinitis: A Systematic Review and Meta&#8208;Analysis of Randomized Clinical Trials</article-title>.&#8221; <source>American Journal of Rhinology &amp; Allergy</source><volume>36</volume>, no. <issue>4</issue>: <fpage>440</fpage>&#8211;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1177/19458924211073550</pub-id>.<pub-id pub-id-type="pmid">35099301</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0037"><mixed-citation publication-type="book" id="fsn371024-cit-0037"><collab collab-type="authors">FDA, U. S</collab>
. <year>2024</year>. <source>FDA Regulation of Cannabis and Cannabis&#8208;Derived Products, Including Cannabidiol (CBD)</source>. <publisher-name>FDA, U. S</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0171"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0171"><string-name name-style="western"><surname>Foods</surname>, <given-names>M. H. H.</given-names></string-name><year>2025</year>. <article-title>&#8220;Hemp Hearts.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://manitobaharvest.com" ext-link-type="uri">https://manitobaharvest.com</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0038"><mixed-citation publication-type="journal" id="fsn371024-cit-0038"><string-name name-style="western"><surname>Frumuzachi</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Flanagan</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Rohn</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Mocan</surname></string-name>. <year>2025</year>. &#8220;<article-title>The Dichotomy Between Functional and Functionalized Foods &#8211; A Critical Characterization of Concepts</article-title>.&#8221; <source>Food Research International</source><volume>208</volume>: <elocation-id>116173</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.foodres.2025.116173</pub-id>.<pub-id pub-id-type="pmid">40263787</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0039"><mixed-citation publication-type="journal" id="fsn371024-cit-0039"><string-name name-style="western"><surname>Ganguly</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Macleod</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wong</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Harland</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>McGonagle</surname></string-name>. <year>2023</year>. &#8220;<article-title>Revisiting p38 Mitogen&#8208;Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK&#8208;Activated Protein Kinase Inhibitors (MK2i)</article-title>.&#8221; <source>Pharmaceuticals</source><volume>16</volume>, no. <issue>9</issue>: <elocation-id>1286</elocation-id>.<pub-id pub-id-type="pmid">37765094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph16091286</pub-id><pub-id pub-id-type="pmcid">PMC10537904</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0040"><mixed-citation publication-type="journal" id="fsn371024-cit-0040"><string-name name-style="western"><surname>Gao</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>R.&#8208;J.</given-names><surname>Song</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>S.&#8208;F.</given-names><surname>Han</surname></string-name>. <year>2022</year>. &#8220;<article-title>Oat Fiber Supplementation Alleviates Intestinal Inflammation and Ameliorates Intestinal Mucosal Barrier via Acting on Gut Microbiota&#8208;Derived Metabolites in LDLR<sup>&#8722;/&#8722;</sup> Mice</article-title>.&#8221; <source>Nutrition</source><volume>95</volume>: <elocation-id>111558</elocation-id>.<pub-id pub-id-type="pmid">34998028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nut.2021.111558</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0152"><mixed-citation publication-type="book" id="fsn371024-cit-0152"><string-name name-style="western"><surname>Gass</surname>, <given-names>M. L. S.</given-names></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Khan</surname></string-name>. <year>2013</year>. &#8220;<part-title>Chapter&#160;77 &#8208; Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis</part-title>.&#8221; In <source>Osteoporosis</source>, edited by <person-group person-group-type="editor"><string-name name-style="western"><given-names>R.</given-names><surname>Marcus</surname></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><given-names>D.</given-names><surname>Feldman</surname></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><given-names>D. W.</given-names><surname>Dempster</surname></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><given-names>M.</given-names><surname>Luckey</surname></string-name></person-group>, and <person-group person-group-type="editor"><string-name name-style="western"><given-names>J. A.</given-names><surname>Cauley</surname></string-name></person-group>, <edition>Fourth ed.</edition>, <fpage>1805</fpage>&#8211;<lpage>1825</lpage>. <publisher-name>Academic Press</publisher-name>. <pub-id pub-id-type="doi">10.1016/B978-0-12-415853-5.00077-7</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0041"><mixed-citation publication-type="journal" id="fsn371024-cit-0041"><string-name name-style="western"><surname>Green</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Arora</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Prakash</surname></string-name>. <year>2020</year>. &#8220;<article-title>Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>21</volume>, no. <issue>8</issue>: <elocation-id>2890</elocation-id>.<pub-id pub-id-type="pmid">32326175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21082890</pub-id><pub-id pub-id-type="pmcid">PMC7215979</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0042"><mixed-citation publication-type="journal" id="fsn371024-cit-0042"><string-name name-style="western"><surname>Grinberga&#8208;Zalite</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Zvirbule</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Hernik</surname></string-name>. <year>2024</year>. &#8220;<article-title>Fostering a Link Between Creativity and Consumer Acceptance: Essential Factors for Advancing Innovations in Food Industry</article-title>.&#8221; <source>Creativity Studies</source><volume>17</volume>, no. <issue>1</issue>: <fpage>309</fpage>&#8211;<lpage>322</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0043"><mixed-citation publication-type="journal" id="fsn371024-cit-0043"><string-name name-style="western"><surname>Grzelczyk</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Szwajgier</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Baranowska&#8208;W&#243;jcik</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Effect of Inhibiting Butyrylcholinesterase Activity Using Fractionated Coffee Extracts Digested In&#160;Vitro in Gastrointestinal Tract: Docking Simulation and Calorimetric and Studies</article-title>.&#8221; <source>Nutrients</source><volume>15</volume>, no. <issue>10</issue>: <elocation-id>2366</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2072-6643/15/10/2366" ext-link-type="uri">https://www.mdpi.com/2072&#8208;6643/15/10/2366</ext-link>.<pub-id pub-id-type="pmid">37242249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu15102366</pub-id><pub-id pub-id-type="pmcid">PMC10224059</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0044"><mixed-citation publication-type="journal" id="fsn371024-cit-0044"><string-name name-style="western"><surname>Guimar&#227;es</surname>, <given-names>M. R.</given-names></string-name>, <string-name name-style="western"><given-names>F. R.</given-names><surname>Leite</surname></string-name>, <string-name name-style="western"><given-names>L. C.</given-names><surname>Spolidorio</surname></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>Kirkwood</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Rossa</surname><suffix>Jr.</suffix></string-name><year>2013</year>. &#8220;<article-title>Curcumin Abrogates LPS&#8208;Induced Pro&#8208;Inflammatory Cytokines in RAW 264.7 Macrophages. Evidence for Novel Mechanisms Involving SOCS&#8208;1, &#8208;3 and p38 MAPK</article-title>.&#8221; <source>Archives of Oral Biology</source><volume>58</volume>, no. <issue>10</issue>: <fpage>1309</fpage>&#8211;<lpage>1317</lpage>. <pub-id pub-id-type="doi">10.1016/j.archoralbio.2013.07.005</pub-id>.<pub-id pub-id-type="pmid">24011306</pub-id><pub-id pub-id-type="pmcid">PMC4030384</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0045"><mixed-citation publication-type="journal" id="fsn371024-cit-0045"><string-name name-style="western"><surname>Hadi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pourmasoumi</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kazemi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Najafgholizadeh</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Marx</surname></string-name>. <year>2022</year>. &#8220;<article-title>Efficacy of Synbiotic Interventions on Blood Pressure: A Systematic Review and Meta&#8208;Analysis of Clinical Trials</article-title>.&#8221; <source>Critical Reviews in Food Science and Nutrition</source><volume>62</volume>, no. <issue>20</issue>: <fpage>5582</fpage>&#8211;<lpage>5591</lpage>.<pub-id pub-id-type="pmid">33612008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2021.1888278</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0164"><mixed-citation publication-type="journal" id="fsn371024-cit-0164"><string-name name-style="western"><surname>Hasanuzzaman</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bhuyan</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Zulfiqar</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Reactive Oxygen Species and Antioxidant Defense in Plants under Abiotic Stress: Revisiting the Crucial Role of a Universal Defense Regulator</article-title>.&#8221; <source>Antioxidants (Basel)</source><volume>9</volume>, no. <issue>8</issue>. <pub-id pub-id-type="doi">10.3390/antiox9080681</pub-id>.<pub-id pub-id-type="pmcid">PMC7465626</pub-id><pub-id pub-id-type="pmid">32751256</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0046"><mixed-citation publication-type="journal" id="fsn371024-cit-0046"><string-name name-style="western"><surname>Hasler</surname>, <given-names>C. M.</given-names></string-name><year>2002</year>. &#8220;<article-title>Functional Foods: Benefits, Concerns and Challenges&#8212;A Position Paper From the American Council on Science and Health</article-title>.&#8221; <source>Journal of Nutrition</source><volume>132</volume>, no. <issue>12</issue>: <fpage>3772</fpage>&#8211;<lpage>3781</lpage>. <pub-id pub-id-type="doi">10.1093/jn/132.12.3772</pub-id>.<pub-id pub-id-type="pmid">12468622</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0163"><mixed-citation publication-type="journal" id="fsn371024-cit-0163"><string-name name-style="western"><surname>Heinrich</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Mah</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Amirkia</surname></string-name>. <year>2021</year>. &#8220;<article-title>Alkaloids Used as Medicines: Structural Phytochemistry Meets Biodiversity&#8208;An Update and Forward Look</article-title>.&#8221; <source>Molecules</source><volume>26</volume>, no. <issue>7</issue>. <pub-id pub-id-type="doi">10.3390/molecules26071836</pub-id>.<pub-id pub-id-type="pmcid">PMC8036335</pub-id><pub-id pub-id-type="pmid">33805869</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0047"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0047"><collab collab-type="authors">Hilma</collab>
. <year>2020</year>. <article-title>&#8220;Hilma Daily Pre + Probiotic + Herbs.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hilma.co/products/digestive-essentials?srsltid=AfmBOopxutY7YwqhRxZ8D8BDXTRCKLyyxBDSqUXlp0fZUQ6h5xWhLo97" ext-link-type="uri">https://www.hilma.co/products/digestive&#8208;essentials?srsltid=AfmBOopxutY7YwqhRxZ8D8BDXTRCKLyyxBDSqUXlp0fZUQ6h5xWhLo97</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0048"><mixed-citation publication-type="journal" id="fsn371024-cit-0048"><string-name name-style="western"><surname>Hossain</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Yeo</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Dave</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Shahidi</surname></string-name>. <year>2022</year>. &#8220;<article-title>Phenolic Compounds and Antioxidant Capacity of Sea Cucumber (<italic toggle="yes">Cucumaria frondosa</italic>) Processing Discards as Affected by High&#8208;Pressure Processing (HPP)</article-title>.&#8221; <source>Antioxidants</source><volume>11</volume>, no. <issue>2</issue>: <elocation-id>337</elocation-id>.<pub-id pub-id-type="pmid">35204219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11020337</pub-id><pub-id pub-id-type="pmcid">PMC8868223</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0049"><mixed-citation publication-type="journal" id="fsn371024-cit-0049"><string-name name-style="western"><surname>Hou</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Liu</surname></string-name>. <year>2024</year>. &#8220;<article-title>In&#8208;Depth Analysis of the Acetylcholinesterase Inhibitors of Ganoderma Amboinense Based Receptor&#8208;Ligand Affinity Coupled With Complex Chromatography</article-title>.&#8221; <source>Journal of Food Composition and Analysis</source><volume>125</volume>: <elocation-id>105776</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jfca.2023.105776</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0147"><mixed-citation publication-type="journal" id="fsn371024-cit-0147"><string-name name-style="western"><surname>Huang</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Hu</surname></string-name>. <year>2022</year>. &#8220;<article-title>Make Your Packaging Colorful and Multifunctional: The Molecular Interaction and Properties Characterization of Natural Colorant&#8208;Based Films and Their Applications in Food Industry</article-title>.&#8221; <source>Trends in Food Science &amp; Technology</source><volume>124</volume>: <fpage>259</fpage>&#8211;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.tifs.2022.04.028</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0050"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0050"><collab collab-type="authors">HuelLimited</collab>
. <year>2015</year>&#8211;2025. <article-title>&#8220;Huel: Ready&#8208;to&#8208;Drink, On&#8208;the&#8208;Go Complete Meal.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://huel.com" ext-link-type="uri">https://huel.com</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0051"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0051"><collab collab-type="authors">IRRI</collab>
. <year>2025</year>. <article-title>&#8220;Golden Rice Meets Food Safety Standards in Three Global Leading Regulatory Agencies.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.irri.org/" ext-link-type="uri">https://www.irri.org/</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0052"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0052"><collab collab-type="authors">ISAAA</collab>
. <year>2018</year>. <article-title>&#8220;Golden Rice Gets Approval From US FDA.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.isaaa.org/default.asp" ext-link-type="uri">https://www.isaaa.org/default.asp</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0053"><mixed-citation publication-type="journal" id="fsn371024-cit-0053"><string-name name-style="western"><surname>Islam</surname>, <given-names>M. N.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Rauf</surname></string-name>, <string-name name-style="western"><given-names>F. I.</given-names><surname>Fahad</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Superoxide Dismutase: An Updated Review on Its Health Benefits and Industrial Applications</article-title>.&#8221; <source>Critical Reviews in Food Science and Nutrition</source><volume>62</volume>, no. <issue>26</issue>: <fpage>7282</fpage>&#8211;<lpage>7300</lpage>.<pub-id pub-id-type="pmid">33905274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2021.1913400</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0054"><mixed-citation publication-type="journal" id="fsn371024-cit-0054"><string-name name-style="western"><surname>Jamai</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>N. E.</given-names><surname>Daoudi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Elrherabi</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Bnouham</surname></string-name>. <year>2024</year>. &#8220;<article-title>Medicinal Plants and Natural Products to Treat Obesity Through Inhibiting Pancreatic Lipase: A Review (2020&#8211;2022)</article-title>.&#8221; <source>Letters in Drug Design &amp; Discovery</source><volume>21</volume>, no. <issue>11</issue>: <fpage>1936</fpage>&#8211;<lpage>1955</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0055"><mixed-citation publication-type="journal" id="fsn371024-cit-0055"><string-name name-style="western"><surname>Jauhiainen</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Vapaatalo</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Poussa</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kyr&#246;npalo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Rasmussen</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Korpela</surname></string-name>. <year>2005</year>. &#8220;<article-title>
<italic toggle="yes">Lactobacillus helveticus</italic> Fermented Milk Lowers Blood Pressure in Hypertensive Subjects in 24&#8208;h Ambulatory Blood Pressure Measurement</article-title>.&#8221; <source>American Journal of Hypertension</source><volume>18</volume>, no. <issue>12 Pt 1</issue>: <fpage>1600</fpage>&#8211;<lpage>1605</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjhyper.2005.06.006</pub-id>.<pub-id pub-id-type="pmid">16364832</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0056"><mixed-citation publication-type="journal" id="fsn371024-cit-0056"><string-name name-style="western"><surname>Jones</surname>, <given-names>P. J.</given-names></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Jew</surname></string-name>. <year>2007</year>. &#8220;<article-title>Functional Food Development: Concept to Reality</article-title>.&#8221; <source>Trends in Food Science &amp; Technology</source><volume>18</volume>, no. <issue>7</issue>: <fpage>387</fpage>&#8211;<lpage>390</lpage>. <pub-id pub-id-type="doi">10.1016/j.tifs.2007.03.008</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0057"><mixed-citation publication-type="journal" id="fsn371024-cit-0057"><string-name name-style="western"><surname>Kannan</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Paul</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Thangaraj</surname></string-name>. <year>2025</year>. &#8220;<article-title>Stimulation, Regulation, and Inflammaging Interventions of Natural Compounds on Nuclear Factor Kappa B (NF&#8208;kB) Pathway: A Comprehensive Review</article-title>.&#8221; <source>Inflammopharmacology</source><volume>33</volume>, no. <issue>1</issue>: <fpage>145</fpage>&#8211;<lpage>162</lpage>.<pub-id pub-id-type="pmid">39776026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10787-024-01635-4</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0058"><mixed-citation publication-type="journal" id="fsn371024-cit-0058"><string-name name-style="western"><surname>Kato&#8208;Kataoka</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Nishida</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Takada</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Fermented Milk Containing <italic toggle="yes">Lactobacillus casei</italic> Strain Shirota Preserves the Diversity of the Gut Microbiota and Relieves Abdominal Dysfunction in Healthy Medical Students Exposed to Academic Stress</article-title>.&#8221; <source>Applied and Environmental Microbiology</source><volume>82</volume>, no. <issue>12</issue>: <fpage>3649</fpage>&#8211;<lpage>3658</lpage>. <pub-id pub-id-type="doi">10.1128/aem.04134-15</pub-id>.<pub-id pub-id-type="pmid">27208120</pub-id><pub-id pub-id-type="pmcid">PMC4959178</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0153"><mixed-citation publication-type="journal" id="fsn371024-cit-0153"><string-name name-style="western"><surname>Kaur</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Kaur</surname></string-name>, <string-name name-style="western"><given-names>G. K.</given-names><surname>Sodhi</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Stilbenes: A Journey from Folklore to Pharmaceutical Innovation</article-title>.&#8221; <source>Archives of Microbiology</source><volume>206</volume>, no. <issue>5</issue>: <fpage>229</fpage>. <pub-id pub-id-type="doi">10.1007/s00203-024-03939-z</pub-id>.<pub-id pub-id-type="pmid">38647675</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0167"><mixed-citation publication-type="journal" id="fsn371024-cit-0167"><string-name name-style="western"><surname>Kavyani</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Musazadeh</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Fathi</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Faghfouri</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Dehghan</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Sarmadi</surname></string-name>. <year>2022</year>. &#8220;<article-title>Efficacy of the Omega&#8208;3 Fatty Acids Supplementation on Inflammatory Biomarkers: An Umbrella Meta&#8208;Analysis</article-title>.&#8221; <source>International Immunopharmacology</source><volume>111</volume>: <elocation-id>109104</elocation-id>.<pub-id pub-id-type="pmid">35914448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2022.109104</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0059"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0059"><collab collab-type="authors">kelloggs.co.uk</collab>
. n.d. <article-title>&#8220;kelloggs.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kelloggs.co.uk/en_GB/nutrition/adding-vitamins-and-minerals.html#:~:text=%C2%A9%202025%20Kellanova.%20All%20rights%20reserved" ext-link-type="uri">https://www.kelloggs.co.uk/en_GB/nutrition/adding&#8208;vitamins&#8208;and&#8208;minerals.html#:~:text=%C2%A9%202025%20Kellanova.%20All%20rights%20reserved</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0060"><mixed-citation publication-type="journal" id="fsn371024-cit-0060"><string-name name-style="western"><surname>Khalaf</surname>, <given-names>A. T.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>S. J. A.</given-names><surname>Alneamah</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>What Is New in the Preventive and Therapeutic Role of Dairy Products as Nutraceuticals and Functional Foods?</article-title>&#8221; <source>BioMed Research International</source><volume>2021</volume>, no. <issue>1</issue>: <elocation-id>8823222</elocation-id>.<pub-id pub-id-type="pmid">33681381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/8823222</pub-id><pub-id pub-id-type="pmcid">PMC7925044</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0061"><mixed-citation publication-type="journal" id="fsn371024-cit-0061"><string-name name-style="western"><surname>Kheto</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Adhikary</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dhua</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>A Review on Advancements in Emerging Processing of Whey Protein: Enhancing Functional and Nutritional Properties for Functional Food Applications</article-title>.&#8221; <source>Food Safety and Health</source><volume>3</volume>, no. <issue>1</issue>: <fpage>23</fpage>&#8211;<lpage>45</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0062"><mixed-citation publication-type="journal" id="fsn371024-cit-0062"><string-name name-style="western"><surname>Khurana</surname>, <given-names>V.</given-names></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Goswami</surname></string-name>. <year>2022</year>. &#8220;<article-title>Angiotensin Converting Enzyme (ACE)</article-title>.&#8221; <source>Clinica Chimica Acta</source><volume>524</volume>: <fpage>113</fpage>&#8211;<lpage>122</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2021.10.029</pub-id><pub-id pub-id-type="pmid">34728179</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0063"><mixed-citation publication-type="journal" id="fsn371024-cit-0063"><string-name name-style="western"><surname>Koolaji</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Shammugasamy</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Schindeler</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Dong</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Dehghani</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Valtchev</surname></string-name>. <year>2020</year>. &#8220;<article-title>Citrus Peel Flavonoids as Potential Cancer Prevention Agents</article-title>.&#8221; <source>Current Developments in Nutrition</source><volume>4</volume>, no. <issue>5</issue>: <elocation-id>nzaa025</elocation-id>. <pub-id pub-id-type="doi">10.1093/cdn/nzaa025</pub-id>.<pub-id pub-id-type="pmid">32391511</pub-id><pub-id pub-id-type="pmcid">PMC7199889</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0064"><mixed-citation publication-type="journal" id="fsn371024-cit-0064"><string-name name-style="western"><surname>Kothari</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Patel</surname></string-name>, and <string-name name-style="western"><given-names>S.&#8208;K.</given-names><surname>Kim</surname></string-name>. <year>2019</year>. &#8220;<article-title>Probiotic Supplements Might Not Be Universally&#8208;Effective and Safe: A Review</article-title>.&#8221; <source>Biomedicine &amp; Pharmacotherapy</source><volume>111</volume>: <fpage>537</fpage>&#8211;<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.104</pub-id>.<pub-id pub-id-type="pmid">30597307</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0065"><mixed-citation publication-type="journal" id="fsn371024-cit-0065"><string-name name-style="western"><surname>Kr&#252;ger</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>van Eeden</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Beswa</surname></string-name>. <year>2022</year>. &#8220;<article-title>
<italic toggle="yes">Cannabis sativa</italic> Cannabinoids as Functional Ingredients in Snack Foods&#8212;Historical and Developmental Aspects</article-title>.&#8221; <source>Plants</source><volume>11</volume>, no. <issue>23</issue>: <elocation-id>3330</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2223-7747/11/23/3330" ext-link-type="uri">https://www.mdpi.com/2223&#8208;7747/11/23/3330</ext-link>.<pub-id pub-id-type="pmid">36501366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/plants11233330</pub-id><pub-id pub-id-type="pmcid">PMC9739163</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0172"><mixed-citation publication-type="journal" id="fsn371024-cit-0172"><string-name name-style="western"><surname>Kumar</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Lal</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dutt</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Functional Fermented Probiotics, Prebiotics, and Synbiotics from Non&#8208;Dairy Products: A Perspective from Nutraceutical</article-title>.&#8221; <source>Molecular Nutrition &amp; Food Research</source><volume>66</volume>, no. <issue>14</issue>: <elocation-id>2101059</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mnfr.202101059</pub-id><pub-id pub-id-type="pmid">35616160</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0066"><mixed-citation publication-type="book" id="fsn371024-cit-0066"><string-name name-style="western"><surname>Lamsar</surname>, <given-names>H.</given-names></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Abhilasha</surname></string-name>. <year>2023</year>. &#8220;<part-title>Chapter Four &#8211; Dairy&#8208;Based Functional Food Products</part-title>.&#8221; In <source>Industrial Application of Functional Foods, Ingredients and Nutraceuticals</source>, edited by <person-group person-group-type="editor"><string-name name-style="western"><given-names>C.</given-names><surname>Anandharamakrishnan</surname></string-name></person-group> and <person-group person-group-type="editor"><string-name name-style="western"><given-names>P.</given-names><surname>Subramanian</surname></string-name></person-group>, <fpage>127</fpage>&#8211;<lpage>170</lpage>. <publisher-name>Academic Press</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0145"><mixed-citation publication-type="journal" id="fsn371024-cit-0145"><string-name name-style="western"><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Seto</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Bielory</surname></string-name>. <year>2008</year>. &#8220;<article-title>Meta&#8208;Analysis of Clinical Trials of Probiotics for Prevention and Treatment of Pediatric Atopic Dermatitis</article-title>.&#8221; <source>Journal of Allergy and Clinical Immunology</source><volume>121</volume>, no. <issue>1</issue>: <fpage>116</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2007.10.043</pub-id>.<pub-id pub-id-type="pmid">18206506</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0067"><mixed-citation publication-type="journal" id="fsn371024-cit-0067"><string-name name-style="western"><surname>Li</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Zeng</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Ming</surname></string-name>. <year>2025</year>. &#8220;<article-title>Lowering Glycemic Levels via Gastrointestinal Tract Factors: The Roles of Dietary Fiber, Polyphenols, and Their Combination</article-title>.&#8221; <source>Critical Reviews in Food Science and Nutrition</source><volume>65</volume>, no. <issue>3</issue>: <fpage>575</fpage>&#8211;<lpage>611</lpage>.<pub-id pub-id-type="pmid">37966135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2023.2278169</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0068"><mixed-citation publication-type="journal" id="fsn371024-cit-0068"><string-name name-style="western"><surname>Lim</surname>, <given-names>S. Y.</given-names></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Steiner</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Cridge</surname></string-name>. <year>2022</year>. &#8220;<article-title>Lipases: It's Not Just Pancreatic Lipase!</article-title>&#8221; <source>American Journal of Veterinary Research</source><volume>83</volume>, no. <issue>8</issue>. <pub-id pub-id-type="doi">10.2460/ajvr.22.03.0048</pub-id>.<pub-id pub-id-type="pmid">35895796</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0069"><mixed-citation publication-type="journal" id="fsn371024-cit-0069"><string-name name-style="western"><surname>Liu</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Ma</surname></string-name>, and <string-name name-style="western"><given-names>Z.&#8208;Y.</given-names><surname>Chen</surname></string-name>. <year>2020</year>. &#8220;<article-title>Beneficial Effects of Dietary Polyphenols on High&#8208;Fat Diet&#8208;Induced Obesity Linking With Modulation of Gut Microbiota</article-title>.&#8221; <source>Journal of Agricultural and Food Chemistry</source><volume>68</volume>, no. <issue>1</issue>: <fpage>33</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.9b06817</pub-id>.<pub-id pub-id-type="pmid">31829012</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0070"><mixed-citation publication-type="journal" id="fsn371024-cit-0070"><string-name name-style="western"><surname>Lobine</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>K. R.</given-names><surname>Rengasamy</surname></string-name>, and <string-name name-style="western"><given-names>M. F.</given-names><surname>Mahomoodally</surname></string-name>. <year>2022</year>. &#8220;<article-title>Functional Foods and Bioactive Ingredients Harnessed From the Ocean: Current Status and Future Perspectives</article-title>.&#8221; <source>Critical Reviews in Food Science and Nutrition</source><volume>62</volume>, no. <issue>21</issue>: <fpage>5794</fpage>&#8211;<lpage>5823</lpage>.<pub-id pub-id-type="pmid">33724095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2021.1893643</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0071"><mixed-citation publication-type="journal" id="fsn371024-cit-0071"><string-name name-style="western"><surname>Lu</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Wang</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Antioxidant Activity and Healthy Benefits of Natural Pigments in Fruits: A Review</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>, no. <issue>9</issue>: <elocation-id>4945</elocation-id>.<pub-id pub-id-type="pmid">34066601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22094945</pub-id><pub-id pub-id-type="pmcid">PMC8125642</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0072"><mixed-citation publication-type="book" id="fsn371024-cit-0072"><string-name name-style="western"><surname>Ludwiczuk</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Skalicka&#8208;Wo&#378;niak</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Georgiev</surname></string-name>. <year>2017</year>. &#8220;<part-title>Terpenoids</part-title>.&#8221; In <source>Pharmacognosy: Fundamentals, Applications and Strategies</source>, edited by <person-group person-group-type="editor"><string-name name-style="western"><given-names>S.</given-names><surname>Badal</surname></string-name></person-group> and <person-group person-group-type="editor"><string-name name-style="western"><given-names>R.</given-names><surname>Delgoda</surname></string-name></person-group>, <fpage>233</fpage>&#8211;<lpage>266</lpage>. <publisher-name>Academic Press</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0073"><mixed-citation publication-type="journal" id="fsn371024-cit-0073"><string-name name-style="western"><surname>Ma</surname>, <given-names>Z. F.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Fu</surname></string-name>, and <string-name name-style="western"><given-names>Y. Y.</given-names><surname>Lee</surname></string-name>. <year>2025</year>. &#8220;<article-title>The Modulatory Role of Bioactive Compounds in Functional Foods on Inflammation and Metabolic Pathways in Chronic Diseases</article-title>.&#8221; <source>Food</source><volume>14</volume>, no. <issue>5</issue>: <elocation-id>821</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/foods14050821</pub-id><pub-id pub-id-type="pmcid">PMC11899172</pub-id><pub-id pub-id-type="pmid">40077524</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0074"><mixed-citation publication-type="journal" id="fsn371024-cit-0074"><string-name name-style="western"><surname>Mafe</surname>, <given-names>A. N.</given-names></string-name>, <string-name name-style="western"><given-names>G. I.</given-names><surname>Edo</surname></string-name>, <string-name name-style="western"><given-names>O. S.</given-names><surname>Majeed</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>A Review on Probiotics and Dietary Bioactives: Insights on Metabolic Well&#8208;Being, Gut Microbiota, and Inflammatory Responses</article-title>.&#8221; <source>Food Chemistry Advances</source><volume>6</volume>: <elocation-id>100919</elocation-id>.</mixed-citation></ref><ref id="fsn371024-bib-0076"><mixed-citation publication-type="journal" id="fsn371024-cit-0076"><string-name name-style="western"><surname>Markowiak</surname>, <given-names>P.</given-names></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>&#346;li&#380;ewska</surname></string-name>. <year>2017</year>. &#8220;<article-title>Effects of Probiotics, Prebiotics, and Synbiotics on Human Health</article-title>.&#8221; <source>Nutrients</source><volume>9</volume>, no. <issue>9</issue>: <elocation-id>1021</elocation-id>. <pub-id pub-id-type="doi">10.3390/nu9091021</pub-id>.<pub-id pub-id-type="pmid">28914794</pub-id><pub-id pub-id-type="pmcid">PMC5622781</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0077"><mixed-citation publication-type="journal" id="fsn371024-cit-0077"><string-name name-style="western"><surname>Martirosyan</surname>, <given-names>D.</given-names></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Alvarado</surname></string-name>. <year>2023</year>. &#8220;<article-title>Functional Foods Regulation System: Proposed Regulatory Paradigm by Functional Food Center</article-title>.&#8221; <source>Functional Food Science</source><volume>3</volume>: <elocation-id>275</elocation-id>. <pub-id pub-id-type="doi">10.31989/ffs.v3i11.1265</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0078"><mixed-citation publication-type="journal" id="fsn371024-cit-0078"><string-name name-style="western"><surname>Martirosyan</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Lampert</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Lee</surname></string-name>. <year>2022</year>. &#8220;<article-title>A Comprehensive Review on the Role of Food Bioactive Compounds in Functional Food Science</article-title>.&#8221; <source>Functional Food Science</source><volume>2</volume>, no. <issue>3</issue>: <fpage>64</fpage>&#8211;<lpage>78</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0079"><mixed-citation publication-type="journal" id="fsn371024-cit-0079"><string-name name-style="western"><surname>Matumoto&#8208;Pintro</surname>, <given-names>P. T.</given-names></string-name>, <string-name name-style="western"><given-names>A. E.</given-names><surname>Murakami</surname></string-name>, <string-name name-style="western"><given-names>A. C. P.</given-names><surname>Vital</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Effects of Storage Time and Temperature on Lipid Oxidation of Egg Powders Enriched With Natural Antioxidants</article-title>.&#8221; <source>Food Chemistry</source><volume>228</volume>: <fpage>463</fpage>&#8211;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1016/j.foodchem.2017.02.044</pub-id>.<pub-id pub-id-type="pmid">28317750</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0080"><mixed-citation publication-type="journal" id="fsn371024-cit-0080"><string-name name-style="western"><surname>McClements</surname>, <given-names>D.</given-names></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Xiao</surname></string-name>. <year>2014</year>. &#8220;<article-title>Excipient Foods: Designing Food Matrices That Improve the Oral Bioavailability of Pharmaceuticals and Nutraceuticals</article-title>.&#8221; <source>Food &amp; Function</source><volume>5</volume>: <fpage>1320</fpage>&#8211;<lpage>1333</lpage>. <pub-id pub-id-type="doi">10.1039/c4fo00100a</pub-id>.<pub-id pub-id-type="pmid">24760211</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0081"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0081"><string-name name-style="western"><surname>Meat</surname>, <given-names>B.</given-names></string-name><year>2024</year>. <article-title>&#8220;New Beyond Burger.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.beyondmeat.com/en-US/" ext-link-type="uri">https://www.beyondmeat.com/en&#8208;US/</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0142"><mixed-citation publication-type="journal" id="fsn371024-cit-0142"><string-name name-style="western"><surname>Medoro</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Scapagnini</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Davinelli</surname></string-name>. <year>2024</year>. &#8220;<article-title>Polyphenol Supplementation and Sarcopenia: A Systematic Review and Meta&#8208;Analysis of Clinical Trials</article-title>.&#8221; <source>Journal of Frailty &amp; Aging</source><volume>13</volume>, no. <issue>4</issue>: <fpage>432</fpage>&#8211;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.14283/jfa.2024.73</pub-id>.<pub-id pub-id-type="pmid">39574264</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0082"><mixed-citation publication-type="journal" id="fsn371024-cit-0082"><string-name name-style="western"><surname>Mehboob</surname>, <given-names>K.</given-names></string-name><year>2025</year>. &#8220;<article-title>Cost&#8208;Benefit Analysis of Preventive Healthcare Programs</article-title>.&#8221; <source>Pakistan Journal of Health Sciences</source><volume>6</volume>, no. <issue>4</issue>: <elocation-id>01</elocation-id>. <pub-id pub-id-type="doi">10.54393/pjhs.v6i4.3068</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0170"><mixed-citation publication-type="journal" id="fsn371024-cit-0170"><string-name name-style="western"><surname>Mellentin</surname>, <given-names>J.</given-names></string-name><year>2023</year>. &#8220;<article-title>Key Trends in Functional Foods for 2024: Young People in Particular Are Hungry for Health Benefits from Food. As Nutrition&#8217;rules&#8217; Change and Consumer Need&#8208;States Evolve, New Business Opportunities Emerge</article-title>.&#8221; <source>Nutraceuticals World</source><volume>26</volume>, no. <issue>9</issue>: <fpage>36</fpage>&#8211;<lpage>40</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0083"><mixed-citation publication-type="journal" id="fsn371024-cit-0083"><string-name name-style="western"><surname>Michaud</surname>, <given-names>T. L.</given-names></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>You</surname></string-name>, <string-name name-style="western"><given-names>K. E.</given-names><surname>Wilson</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Cost Effectiveness and Return on Investment of a Scalable Community Weight Loss Intervention</article-title>.&#8221; <source>Preventive Medicine</source><volume>105</volume>: <fpage>295</fpage>&#8211;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/j.ypmed.2017.10.011</pub-id>.<pub-id pub-id-type="pmid">28987334</pub-id><pub-id pub-id-type="pmcid">PMC5918290</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0084"><mixed-citation publication-type="journal" id="fsn371024-cit-0084"><string-name name-style="western"><surname>Michella</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Slaugh</surname></string-name>. <year>2000</year>. &#8220;<article-title>Producing and Marketing a Specialty Egg</article-title>.&#8221; <source>Poultry Science</source><volume>79</volume>: <fpage>975</fpage>&#8211;<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1093/ps/79.7.975</pub-id>.<pub-id pub-id-type="pmid">10901196</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0151"><mixed-citation publication-type="journal" id="fsn371024-cit-0151"><string-name name-style="western"><surname>Mihaylova</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Dimitrova&#8208;Dimova</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Popova</surname></string-name>. <year>2024</year>. &#8220;<article-title>Dietary Phenolic Compounds&#8208;Wellbeing and Perspective Applications</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>25</volume>, no. <issue>9</issue>. <pub-id pub-id-type="doi">10.3390/ijms25094769</pub-id>.<pub-id pub-id-type="pmcid">PMC11084633</pub-id><pub-id pub-id-type="pmid">38731987</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0085"><mixed-citation publication-type="journal" id="fsn371024-cit-0085"><string-name name-style="western"><surname>Mihociu</surname>, <given-names>T. E.</given-names></string-name>, <string-name name-style="western"><given-names>D. G.</given-names><surname>Cimponeriu</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Mustatea</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Belc</surname></string-name>. <year>2024</year>. &#8220;<article-title>Bioaccessibility and Stability of Phytochemical Compounds, Essential Features in the Design of Functional Foods: A Review</article-title>.&#8221; <source>Journal of Hygienic Engineering and Design</source><volume>46</volume>, no. <issue>1</issue>: <fpage>179</fpage>&#8211;<lpage>191</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0086"><mixed-citation publication-type="journal" id="fsn371024-cit-0086"><string-name name-style="western"><surname>Mondal</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>N. P. P.</given-names><surname>Soumya</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mini</surname></string-name>, and <string-name name-style="western"><given-names>S. K.</given-names><surname>Sivan</surname></string-name>. <year>2021</year>. &#8220;<article-title>Bioactive Compounds in Functional Food and Their Role as Therapeutics</article-title>.&#8221; <source>Bioactive Compounds in Health and Disease</source><volume>4</volume>, no. <issue>3</issue>: <fpage>24</fpage>&#8211;<lpage>39</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0154"><mixed-citation publication-type="journal" id="fsn371024-cit-0154"><string-name name-style="western"><surname>Mrowicka</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Mrowicki</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Kucharska</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Majsterek</surname></string-name>. <year>2022</year>. &#8220;<article-title>Lutein and Zeaxanthin and Their Roles in Age&#8208;Related Macular Degeneration&#8208;Neurodegenerative Disease</article-title>.&#8221; <source>Nutrients</source><volume>14</volume>, no. <issue>4</issue>. <pub-id pub-id-type="doi">10.3390/nu14040827</pub-id>.<pub-id pub-id-type="pmcid">PMC8874683</pub-id><pub-id pub-id-type="pmid">35215476</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0087"><mixed-citation publication-type="journal" id="fsn371024-cit-0087"><string-name name-style="western"><surname>Munteanu</surname>, <given-names>I. G.</given-names></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Apetrei</surname></string-name>. <year>2021</year>. &#8220;<article-title>Analytical Methods Used in Determining Antioxidant Activity: A Review</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume>, no. <issue>7</issue>: <elocation-id>3380</elocation-id>.<pub-id pub-id-type="pmid">33806141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22073380</pub-id><pub-id pub-id-type="pmcid">PMC8037236</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0088"><mixed-citation publication-type="journal" id="fsn371024-cit-0088"><string-name name-style="western"><surname>Musich</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hawkins</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Klemes</surname></string-name>. <year>2016</year>. &#8220;<article-title>The Impact of Personalized Preventive Care on Health Care Quality, Utilization, and Expenditures</article-title>.&#8221; <source>Population Health Management</source><volume>19</volume>, no. <issue>6</issue>: <fpage>389</fpage>&#8211;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1089/pop.2015.0171</pub-id>.<pub-id pub-id-type="pmid">26871762</pub-id><pub-id pub-id-type="pmcid">PMC5296930</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0162"><mixed-citation publication-type="journal" id="fsn371024-cit-0162"><string-name name-style="western"><surname>Naik</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Kumar</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Rizwanuddin</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Biofortification as a Solution for Addressing Nutrient Deficiencies and Malnutrition</article-title>.&#8221; <source>Heliyon</source><volume>10</volume>, no. <issue>9</issue>: <elocation-id>e30595</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e30595</pub-id>.<pub-id pub-id-type="pmid">38726166</pub-id><pub-id pub-id-type="pmcid">PMC11079288</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0157"><mixed-citation publication-type="journal" id="fsn371024-cit-0157"><string-name name-style="western"><surname>Nassar</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Jaffery</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Ibrahim</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Baraka</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Abosheaishaa</surname></string-name>. <year>2023</year>. &#8220;<article-title>The Multidimensional Benefits of Eicosapentaenoic Acid: From Heart Health to Inflammatory Control</article-title>.&#8221; <source>Egyptian Journal of Internal Medicine</source><volume>35</volume>, no. <issue>1</issue>: <fpage>81</fpage>. <pub-id pub-id-type="doi">10.1186/s43162-023-00265-6</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0089"><mixed-citation publication-type="journal" id="fsn371024-cit-0089"><string-name name-style="western"><surname>Nayak</surname>, <given-names>S. N.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Aravind</surname></string-name>, <string-name name-style="western"><given-names>S. S.</given-names><surname>Malavalli</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Omics Technologies to Enhance Plant Based Functional Foods: An Overview</article-title>.&#8221; <source>Frontiers in Genetics</source><volume>12</volume>: <elocation-id>742095</elocation-id>.<pub-id pub-id-type="pmid">34858472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2021.742095</pub-id><pub-id pub-id-type="pmcid">PMC8631721</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0090"><mixed-citation publication-type="journal" id="fsn371024-cit-0090"><string-name name-style="western"><surname>Nazzaro</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Uliano</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Lerro</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Stanco</surname></string-name>. <year>2025</year>. &#8220;<article-title>From Claims to Choices: How Health Information Shapes Consumer Decisions in the Functional Food Market</article-title>.&#8221; <source>Food</source><volume>14</volume>, no. <issue>4</issue>: <elocation-id>699</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/foods14040699</pub-id><pub-id pub-id-type="pmcid">PMC11854803</pub-id><pub-id pub-id-type="pmid">40002141</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0091"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0091"><collab collab-type="authors">Nestl&#233;</collab>
. <year>2025</year>. <article-title>&#8220;S&#8208;26&#174; GOLD Promise Stage 4 Formula Milk Powder.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.wyethnutrition.com.sg/" ext-link-type="uri">https://www.wyethnutrition.com.sg/</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0149"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0149"><collab collab-type="authors">NIH, N. I. o. H</collab>
. <year>2025</year>. <article-title>&#8220;Vitamin A and Carotenoids; Fact Sheet for Health Professionals.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ods.od.nih.gov/factsheets/VitaminA-HealthProfessional/" ext-link-type="uri">https://ods.od.nih.gov/factsheets/VitaminA&#8208;HealthProfessional/</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0092"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0092"><collab collab-type="authors">oatly.com</collab>
. n.d. <article-title>&#8220;Oat Drink.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.oatly.com/products/oat-drink/oat-drink-1l" ext-link-type="uri">https://www.oatly.com/products/oat&#8208;drink/oat&#8208;drink&#8208;1l</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0093"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0093"><collab collab-type="authors">Optimum Nutrition</collab>
. <year>2025</year>. <article-title>&#8220;Gold Standard 100% Whey&#8482;.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.optimumnutrition.com/en-us" ext-link-type="uri">https://www.optimumnutrition.com/en&#8208;us</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0094"><mixed-citation publication-type="journal" id="fsn371024-cit-0094"><string-name name-style="western"><surname>Pandey</surname>, <given-names>K. B.</given-names></string-name>, and <string-name name-style="western"><given-names>S. I.</given-names><surname>Rizvi</surname></string-name>. <year>2009</year>. &#8220;<article-title>Plant Polyphenols as Dietary Antioxidants in Human Health and Disease</article-title>.&#8221; <source>Oxidative Medicine and Cellular Longevity</source><volume>2</volume>, no. <issue>5</issue>: <fpage>270</fpage>&#8211;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.4161/oxim.2.5.9498</pub-id>.<pub-id pub-id-type="pmid">20716914</pub-id><pub-id pub-id-type="pmcid">PMC2835915</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0095"><mixed-citation publication-type="journal" id="fsn371024-cit-0095"><string-name name-style="western"><surname>Pannerchelvan</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Rios&#8208;Solis</surname></string-name>, <string-name name-style="western"><given-names>F. W. F.</given-names><surname>Wong</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>Strategies for Improvement of Gamma&#8208;Aminobutyric Acid (GABA) Biosynthesis via Lactic Acid Bacteria (LAB) Fermentation</article-title>.&#8221; <source>Food &amp; Function</source><volume>14</volume>, no. <issue>9</issue>: <fpage>3929</fpage>&#8211;<lpage>3948</lpage>.<pub-id pub-id-type="pmid">36951915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2fo03936b</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0096"><mixed-citation publication-type="journal" id="fsn371024-cit-0096"><string-name name-style="western"><surname>Paramanick</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>V. D.</given-names><surname>Singh</surname></string-name>, and <string-name name-style="western"><given-names>V. K.</given-names><surname>Singh</surname></string-name>. <year>2022</year>. &#8220;<article-title>Neuroprotective Effect of Phytoconstituents via Nanotechnology for Treatment of Alzheimer Diseases</article-title>.&#8221; <source>Journal of Controlled Release</source><volume>351</volume>: <fpage>638</fpage>&#8211;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2022.09.058</pub-id>.<pub-id pub-id-type="pmid">36191675</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0097"><mixed-citation publication-type="journal" id="fsn371024-cit-0097"><string-name name-style="western"><surname>Patel</surname>, <given-names>S. S.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Acharya</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Ray</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Agrawal</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Raghuwanshi</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Jain</surname></string-name>. <year>2020</year>. &#8220;<article-title>Cellular and Molecular Mechanisms of Curcumin in Prevention and Treatment of Disease</article-title>.&#8221; <source>Critical Reviews in Food Science and Nutrition</source><volume>60</volume>, no. <issue>6</issue>: <fpage>887</fpage>&#8211;<lpage>939</lpage>.<pub-id pub-id-type="pmid">30632782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2018.1552244</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0098"><mixed-citation publication-type="journal" id="fsn371024-cit-0098"><string-name name-style="western"><surname>Peighambardoust</surname>, <given-names>S. H.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Karami</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pateiro</surname></string-name>, and <string-name name-style="western"><given-names>J. M.</given-names><surname>Lorenzo</surname></string-name>. <year>2021</year>. &#8220;<article-title>A Review on Health&#8208;Promoting, Biological, and Functional Aspects of Bioactive Peptides in Food Applications</article-title>.&#8221; <source>Biomolecules</source><volume>11</volume>, no. <issue>5</issue>: <elocation-id>631</elocation-id>.<pub-id pub-id-type="pmid">33922830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom11050631</pub-id><pub-id pub-id-type="pmcid">PMC8145060</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0169"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0169"><string-name name-style="western"><surname>Philippines</surname>, <given-names>Y.</given-names></string-name><year>2019</year>. <article-title>&#8220;Yakult; Facts.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.yakult.com.ph/facts" ext-link-type="uri">https://www.yakult.com.ph/facts</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0099"><mixed-citation publication-type="journal" id="fsn371024-cit-0099"><string-name name-style="western"><surname>Phull</surname>, <given-names>A.&#8208;R.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ahmed</surname></string-name>, and <string-name name-style="western"><given-names>H.&#8208;J.</given-names><surname>Park</surname></string-name>. <year>2022</year>. &#8220;<article-title>Cordyceps Militaris as a Bio Functional Food Source: Pharmacological Potential, Anti&#8208;Inflammatory Actions and Related Molecular Mechanisms</article-title>.&#8221; <source>Microorganisms</source><volume>10</volume>, no. <issue>2</issue>: <elocation-id>405</elocation-id>.<pub-id pub-id-type="pmid">35208860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/microorganisms10020405</pub-id><pub-id pub-id-type="pmcid">PMC8875674</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0165"><mixed-citation publication-type="journal" id="fsn371024-cit-0165"><string-name name-style="western"><surname>Poljsak</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>&#352;uput</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Milisav</surname></string-name>. <year>2013</year>. &#8220;<article-title>Achieving the Balance Between ROS and Antioxidants: When to Use the Synthetic Antioxidants</article-title>.&#8221; <source>Oxidative Medicine and Cellular Longevity</source><volume>2013</volume>: <elocation-id>956792</elocation-id>. <pub-id pub-id-type="doi">10.1155/2013/956792</pub-id>.<pub-id pub-id-type="pmid">23738047</pub-id><pub-id pub-id-type="pmcid">PMC3657405</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0100"><mixed-citation publication-type="journal" id="fsn371024-cit-0100"><string-name name-style="western"><surname>Pugazhendhi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Alshehri</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kandasamy</surname></string-name>, <string-name name-style="western"><given-names>P. K.</given-names><surname>Sarangi</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Sharma</surname></string-name>. <year>2025</year>. &#8220;<article-title>Deciphering the Importance of Nanoencapsulation to Improve the Availability of Bioactive Molecules in Food Sources to the Human Body</article-title>.&#8221; <source>Food Chemistry</source><volume>464</volume>: <elocation-id>141762</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.foodchem.2024.141762</pub-id>.<pub-id pub-id-type="pmid">39509889</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0101"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0101"><collab collab-type="authors">Quest Nutrition Inc</collab>
. <year>2024</year>. <article-title>&#8220;Protein Bars.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.questnutrition.com/" ext-link-type="uri">https://www.questnutrition.com/</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0102"><mixed-citation publication-type="journal" id="fsn371024-cit-0102"><string-name name-style="western"><surname>Rackerby</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><given-names>H. N. M.</given-names><surname>Le</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Haymowicz</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Dallas</surname></string-name>, and <string-name name-style="western"><given-names>S. H.</given-names><surname>Park</surname></string-name>. <year>2024</year>. &#8220;<article-title>Potential Prebiotic Properties of Whey Protein and Glycomacropeptide in Gut Microbiome</article-title>.&#8221; <source>Food Science of Animal Resources</source><volume>44</volume>, no. <issue>2</issue>: <fpage>299</fpage>&#8211;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.5851/kosfa.2024.e12</pub-id>.<pub-id pub-id-type="pmid">38764509</pub-id><pub-id pub-id-type="pmcid">PMC11097032</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0156"><mixed-citation publication-type="journal" id="fsn371024-cit-0156"><string-name name-style="western"><surname>Rajaram</surname>, <given-names>S.</given-names></string-name><year>2014</year>. &#8220;<article-title>Health Benefits of Plant&#8208;Derived &#945;&#8208;Linolenic acid123</article-title>.&#8221; <source>American Journal of Clinical Nutrition</source><volume>100</volume>: <fpage>443S</fpage>&#8211;<lpage>448S</lpage>. <pub-id pub-id-type="doi">10.3945/ajcn.113.071514</pub-id>.<pub-id pub-id-type="pmid">24898228</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0103"><mixed-citation publication-type="journal" id="fsn371024-cit-0103"><string-name name-style="western"><surname>Rezagholizade&#8208;shirvan</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Soltani</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Shokri</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Radfar</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Arab</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Shamloo</surname></string-name>. <year>2024</year>. &#8220;<article-title>Bioactive Compound Encapsulation: Characteristics, Applications in Food Systems, and Implications for Human Health</article-title>.&#8221; <source>Food Chemistry: X</source><volume>24</volume>: <elocation-id>101953</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.fochx.2024.101953</pub-id>.<pub-id pub-id-type="pmid">39582652</pub-id><pub-id pub-id-type="pmcid">PMC11584689</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0104"><mixed-citation publication-type="journal" id="fsn371024-cit-0104"><string-name name-style="western"><surname>Rivero&#8208;Pino</surname>, <given-names>F.</given-names></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Montserrat&#8208;de la Paz</surname></string-name>. <year>2024</year>. &#8220;<article-title>The Role of Bioactive Compounds in Immunonutrition</article-title>.&#8221; <source>Nutrients</source><volume>16</volume>, no. <issue>20</issue>: <elocation-id>3432</elocation-id>. <pub-id pub-id-type="doi">10.3390/nu16203432</pub-id>.<pub-id pub-id-type="pmid">39458428</pub-id><pub-id pub-id-type="pmcid">PMC11510454</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0105"><mixed-citation publication-type="journal" id="fsn371024-cit-0105"><string-name name-style="western"><surname>Romero&#8208;Garay</surname>, <given-names>M. G.</given-names></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Montalvo&#8208;Gonz&#225;lez</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Hern&#225;ndez&#8208;Gonz&#225;lez</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Soto&#8208;Dom&#237;nguez</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Becerra&#8208;Verd&#237;n</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>De Lourdes Garc&#237;a&#8208;Maga&#241;a</surname></string-name>. <year>2022</year>. &#8220;<article-title>Bioactivity of Peptides Obtained From Poultry By&#8208;Products: A Review</article-title>.&#8221; <source>Food Chemistry: X</source><volume>13</volume>: <elocation-id>100181</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.fochx.2021.100181</pub-id>.<pub-id pub-id-type="pmid">35498958</pub-id><pub-id pub-id-type="pmcid">PMC9039914</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0168"><mixed-citation publication-type="journal" id="fsn371024-cit-0168"><string-name name-style="western"><surname>Ro&#351;ian</surname>, <given-names>&#350;. H.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Boarescu</surname></string-name>, and <string-name name-style="western"><given-names>P.&#8208;M.</given-names><surname>Boarescu</surname></string-name>. <year>2025</year>. &#8220;<article-title>Antioxidant and Anti&#8208;Inflammatory Effects of Bioactive Compounds in Atherosclerosis</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>26</volume>, no. <issue>3</issue>: <fpage>1379</fpage>.<pub-id pub-id-type="pmid">39941147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26031379</pub-id><pub-id pub-id-type="pmcid">PMC11818840</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0106"><mixed-citation publication-type="journal" id="fsn371024-cit-0106"><string-name name-style="western"><surname>Ruff</surname>, <given-names>K. J.</given-names></string-name>, <string-name name-style="western"><given-names>D. P.</given-names><surname>DeVore</surname></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Leu</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Robinson</surname></string-name>. <year>2009</year>. &#8220;<article-title>Eggshell Membrane: A Possible New Natural Therapeutic for Joint and Connective Tissue Disorders. Results From Two Open&#8208;Label Human Clinical Studies</article-title>.&#8221; <source>Clinical Interventions in Aging</source><volume>4</volume>: <fpage>235</fpage>&#8211;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.2147/cia.s5797</pub-id>.<pub-id pub-id-type="pmid">19554094</pub-id><pub-id pub-id-type="pmcid">PMC2697588</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0107"><mixed-citation publication-type="journal" id="fsn371024-cit-0107"><string-name name-style="western"><surname>Sahu</surname>, <given-names>R.</given-names></string-name>, and <string-name name-style="western"><given-names>R. K.</given-names><surname>Rawal</surname></string-name>. <year>2024</year>. &#8220;<article-title>Modulation of the c&#8208;JNK/p38&#8208;MAPK Signaling Pathway: Investigating the Therapeutic Potential of Natural Products in Hypertension</article-title>.&#8221; <source>Phytomedicine Plus</source><volume>4</volume>: <elocation-id>100564</elocation-id>.</mixed-citation></ref><ref id="fsn371024-bib-0108"><mixed-citation publication-type="journal" id="fsn371024-cit-0108"><string-name name-style="western"><surname>Saleem</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Yaqub</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Rafique</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Nutritional and Medicinal Plants as Potential Sources of Enzyme Inhibitors Toward the Bioactive Functional Foods: An Updated Review</article-title>.&#8221; <source>Critical Reviews in Food Science and Nutrition</source><volume>64</volume>, no. <issue>27</issue>: <fpage>9805</fpage>&#8211;<lpage>9828</lpage>.<pub-id pub-id-type="pmid">37255100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2023.2217264</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0109"><mixed-citation publication-type="book" id="fsn371024-cit-0109"><string-name name-style="western"><surname>Shaikh</surname>, <given-names>S.</given-names></string-name><year>2022</year>. &#8220;<part-title>Sources and Health Benefits of Functional Food Components</part-title>.&#8221; In <source>Current Topics in Functional Food</source>, edited by <person-group person-group-type="editor"><string-name name-style="western"><given-names>N.</given-names><surname>Shiomi</surname></string-name></person-group> and <person-group person-group-type="editor"><string-name name-style="western"><given-names>A.</given-names><surname>Savitskaya</surname></string-name></person-group>. <publisher-name>IntechOpen</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0110"><mixed-citation publication-type="journal" id="fsn371024-cit-0110"><string-name name-style="western"><surname>Sharma</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Vidhya</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Ojha</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>The Role of Functional Foods and Nutraceuticals in Disease Prevention and Health Promotion</article-title>.&#8221; <source>European Journal of Nutrition &amp; Food Safety</source><volume>16</volume>: <fpage>61</fpage>&#8211;<lpage>83</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0160"><mixed-citation publication-type="journal" id="fsn371024-cit-0160"><string-name name-style="western"><surname>Sharma</surname>, <given-names>S. H.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Thulasingam</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Nagarajan</surname></string-name>. <year>2017</year>. &#8220;<article-title>Terpenoids as Anti&#8208;Colon Cancer Agents &#8211; a Comprehensive Review on Its Mechanistic Perspectives</article-title>.&#8221; <source>European Journal of Pharmacology</source><volume>795</volume>: <fpage>169</fpage>&#8211;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2016.12.008</pub-id>.<pub-id pub-id-type="pmid">27940056</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0143"><mixed-citation publication-type="journal" id="fsn371024-cit-0143"><string-name name-style="western"><surname>Shen</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gong</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Xiao</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Ma</surname></string-name>. <year>2022</year>. &#8220;<article-title>Omega&#8208;3 Fatty Acid Supplementation and Coronary Heart Disease Risks: A Meta&#8208;Analysis of Randomized Controlled Clinical Trials</article-title>.&#8221; <source>Frontiers in Nutrition</source><volume>9</volume>: <elocation-id>809311</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnut.2022.809311</pub-id>.<pub-id pub-id-type="pmid">35187035</pub-id><pub-id pub-id-type="pmcid">PMC8850984</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0111"><mixed-citation publication-type="journal" id="fsn371024-cit-0111"><string-name name-style="western"><surname>Shishir</surname>, <given-names>M. R. I.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Gowd</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Suo</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Advances in Smart Delivery of Food Bioactive Compounds Using Stimuli&#8208;Responsive Carriers: Responsive Mechanism, Contemporary Challenges, and Prospects</article-title>.&#8221; <source>Comprehensive Reviews in Food Science and Food Safety</source><volume>20</volume>, no. <issue>6</issue>: <fpage>5449</fpage>&#8211;<lpage>5488</lpage>.<pub-id pub-id-type="pmid">34668321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1541-4337.12851</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0112"><mixed-citation publication-type="journal" id="fsn371024-cit-0112"><string-name name-style="western"><surname>Siddiqui</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>M. U.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Sharma</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Gupta</surname></string-name>. <year>2024</year>. &#8220;<article-title>Terpenoids in Essential Oils: Chemistry, Classification, and Potential Impact on Human Health and Industry</article-title>.&#8221; <source>Phytomedicine Plus</source><volume>4</volume>, no. <issue>2</issue>: <elocation-id>100549</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.phyplu.2024.100549</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0113"><mixed-citation publication-type="journal" id="fsn371024-cit-0113"><string-name name-style="western"><surname>S&#248;rensen</surname>, <given-names>H. M.</given-names></string-name>, <string-name name-style="western"><given-names>K. D.</given-names><surname>Rochfort</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Maye</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Exopolysaccharides of Lactic Acid Bacteria: Production, Purification and Health Benefits Towards Functional Food</article-title>.&#8221; <source>Nutrients</source><volume>14</volume>, no. <issue>14</issue>: <elocation-id>2938</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2072-6643/14/14/2938" ext-link-type="uri">https://www.mdpi.com/2072&#8208;6643/14/14/2938</ext-link>.<pub-id pub-id-type="pmid">35889895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu14142938</pub-id><pub-id pub-id-type="pmcid">PMC9319976</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0114"><mixed-citation publication-type="journal" id="fsn371024-cit-0114"><string-name name-style="western"><surname>Spano</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Di Matteo</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ingallina</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Modulatory Properties of Food and Nutraceutical Components Targeting NLRP3 Inflammasome Activation</article-title>.&#8221; <source>Nutrients</source><volume>14</volume>, no. <issue>3</issue>: <elocation-id>490</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2072-6643/14/3/490" ext-link-type="uri">https://www.mdpi.com/2072&#8208;6643/14/3/490</ext-link>.<pub-id pub-id-type="pmid">35276849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu14030490</pub-id><pub-id pub-id-type="pmcid">PMC8840562</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0115"><mixed-citation publication-type="journal" id="fsn371024-cit-0115"><string-name name-style="western"><surname>Steele</surname>, <given-names>C.</given-names></string-name><year>2022</year>. &#8220;<article-title>Collagen: A Review of Clinical Use and Efficacy</article-title>.&#8221; <source>Nutritional Medicine Journal</source><volume>1</volume>, no. <issue>2</issue>: <fpage>12</fpage>&#8211;<lpage>36</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0116"><mixed-citation publication-type="book" id="fsn371024-cit-0116"><string-name name-style="western"><surname>Tafese Awulachew</surname>, <given-names>M. T.</given-names></string-name><year>2024</year>. &#8220;<part-title>Functional Foods: Functional Ingredients, Sources and Classification, Health Claims, Food Intolerance, and Allergy</part-title>.&#8221; In <source>Functional Food &#8208; Upgrading Natural and Synthetic Sources</source>, edited by <person-group person-group-type="editor"><string-name name-style="western"><given-names>A.</given-names><surname>Novo Barros</surname></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><given-names>J.</given-names><surname>Campos</surname></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><given-names>A.</given-names><surname>Vilela</surname></string-name></person-group>, and <person-group person-group-type="editor"><string-name name-style="western"><given-names>R.</given-names><surname>Fernandes</surname></string-name></person-group>. <publisher-name>IntechOpen</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0117"><mixed-citation publication-type="journal" id="fsn371024-cit-0117"><string-name name-style="western"><surname>Temple</surname>, <given-names>N. J.</given-names></string-name><year>2022</year>. &#8220;<article-title>A Rational Definition for Functional Foods: A Perspective</article-title>.&#8221; <source>Frontiers in Nutrition</source><volume>9</volume>: <elocation-id>957516</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnut.2022.957516</pub-id>.<pub-id pub-id-type="pmid">36245478</pub-id><pub-id pub-id-type="pmcid">PMC9559824</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0118"><mixed-citation publication-type="journal" id="fsn371024-cit-0118"><string-name name-style="western"><surname>Topolska</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Florkiewicz</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Filipiak&#8208;Florkiewicz</surname></string-name>. <year>2021</year>. &#8220;<article-title>Functional Food&#8212;Consumer Motivations and Expectations</article-title>.&#8221; <source>International Journal of Environmental Research and Public Health</source><volume>18</volume>, no. <issue>10</issue>: <elocation-id>5327</elocation-id>.<pub-id pub-id-type="pmid">34067768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph18105327</pub-id><pub-id pub-id-type="pmcid">PMC8156986</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0119"><mixed-citation publication-type="journal" id="fsn371024-cit-0119"><string-name name-style="western"><surname>Ud Din</surname>, <given-names>S. R.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Saeed</surname></string-name>, <string-name name-style="western"><given-names>S. U.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>F. A.</given-names><surname>Kiani</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Alsuhaibani</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Zhong</surname></string-name>. <year>2023</year>. &#8220;<article-title>Bioactive Compounds (BACs): A Novel Approach to Treat and Prevent Cardiovascular Diseases</article-title>.&#8221; <source>Current Problems in Cardiology</source><volume>48</volume>, no. <issue>7</issue>: <elocation-id>101664</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.cpcardiol.2023.101664</pub-id>.<pub-id pub-id-type="pmid">36841315</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0150"><mixed-citation publication-type="journal" id="fsn371024-cit-0150"><string-name name-style="western"><surname>Ullah</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Munir</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Badshah</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Important Flavonoids and Their Role as a Therapeutic Agent</article-title>.&#8221; <source>Molecules</source><volume>25</volume>, no. <issue>22</issue>. <pub-id pub-id-type="doi">10.3390/molecules25225243</pub-id>.<pub-id pub-id-type="pmcid">PMC7697716</pub-id><pub-id pub-id-type="pmid">33187049</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0120"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0120"><collab collab-type="authors">Unilever</collab>
. <year>2025</year>. <article-title>&#8220;Women's Multi.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.olly.com/" ext-link-type="uri">https://www.olly.com/</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0121"><mixed-citation publication-type="journal" id="fsn371024-cit-0121"><string-name name-style="western"><surname>Uro&#8208;Chukwu</surname>, <given-names>H. C.</given-names></string-name>, <string-name name-style="western"><given-names>F. C.</given-names><surname>Uro&#8208;Chukwu</surname></string-name>, and <string-name name-style="western"><given-names>F. C.</given-names><surname>Uro&#8208;Chukwu</surname></string-name>. <year>2025</year>. &#8220;<article-title>Biological Activities and Mechanisms of Actions of Bioactive Compounds (BACS) Identified in Pure and Ternary Blends of Cocoyam, Soya Bean and Bambara Groundnut Flour Using Gas Chromatography&#8208;Mass Spectrometry (GC&#8208;MS) Technique: A Review</article-title>.&#8221; <source>Journal of Drug Delivery &amp; Therapeutics</source><volume>15</volume>, no. <issue>1</issue>: <fpage>177</fpage>&#8211;<lpage>186</lpage>.</mixed-citation></ref><ref id="fsn371024-bib-0122"><mixed-citation publication-type="journal" id="fsn371024-cit-0122"><string-name name-style="western"><surname>Vicentini</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Liberatore</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Mastrocola</surname></string-name>. <year>2016</year>. &#8220;<article-title>Functional Foods: Trends and Development of the Global Market</article-title>.&#8221; <source>Italian Journal of Food Science</source><volume>28</volume>, no. <issue>2</issue>: <fpage>338</fpage>&#8211;<lpage>351</lpage>. <pub-id pub-id-type="doi">10.14674/1120-1770/ijfs.v211</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0123"><mixed-citation publication-type="journal" id="fsn371024-cit-0123"><string-name name-style="western"><surname>Victoria Obayomi</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Folakemi Olaniran</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Olugbemiga Owa</surname></string-name>. <year>2024</year>. &#8220;<article-title>Unveiling the Role of Functional Foods With Emphasis on Prebiotics and Probiotics in Human Health: A Review</article-title>.&#8221; <source>Journal of Functional Foods</source><volume>119</volume>: <elocation-id>106337</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jff.2024.106337</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0124"><mixed-citation publication-type="journal" id="fsn371024-cit-0124"><string-name name-style="western"><surname>Vignesh</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>T. C.</given-names><surname>Amal</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sarvalingam</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Vasanth</surname></string-name>. <year>2024</year>. &#8220;<article-title>A Review on the Influence of Nutraceuticals and Functional Foods on Health</article-title>.&#8221; <source>Food Chemistry Advances</source><volume>5</volume>: <elocation-id>100749</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.focha.2024.100749</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0125"><mixed-citation publication-type="journal" id="fsn371024-cit-0125"><string-name name-style="western"><surname>Vilas&#8208;Boas</surname>, <given-names>A. A.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pintado</surname></string-name>, and <string-name name-style="western"><given-names>A. L.</given-names><surname>Oliveira</surname></string-name>. <year>2021</year>. &#8220;<article-title>Natural Bioactive Compounds From Food Waste: Toxicity and Safety Concerns</article-title>.&#8221; <source>Food</source><volume>10</volume>, no. <issue>7</issue>: <elocation-id>1564</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/foods10071564</pub-id><pub-id pub-id-type="pmcid">PMC8304211</pub-id><pub-id pub-id-type="pmid">34359434</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0126"><mixed-citation publication-type="journal" id="fsn371024-cit-0126"><string-name name-style="western"><surname>Vlaicu</surname>, <given-names>P. A.</given-names></string-name>, <string-name name-style="western"><given-names>T. D.</given-names><surname>Panaite</surname></string-name>, and <string-name name-style="western"><given-names>R. P.</given-names><surname>Turcu</surname></string-name>. <year>2021</year>. &#8220;<article-title>Enriching Laying Hens Eggs by Feeding Diets With Different Fatty Acid Composition and Antioxidants</article-title>.&#8221; <source>Scientific Reports</source><volume>11</volume>, no. <issue>1</issue>: <fpage>20707</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-00343-1</pub-id>.<pub-id pub-id-type="pmid">34667227</pub-id><pub-id pub-id-type="pmcid">PMC8526598</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0127"><mixed-citation publication-type="journal" id="fsn371024-cit-0127"><string-name name-style="western"><surname>Vlaicu</surname>, <given-names>P. A.</given-names></string-name>, <string-name name-style="western"><given-names>A. E.</given-names><surname>Untea</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Varzaru</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Saracila</surname></string-name>, and <string-name name-style="western"><given-names>A. G.</given-names><surname>Oancea</surname></string-name>. <year>2023</year>. &#8220;<article-title>Designing Nutrition for Health&#8212;Incorporating Dietary By&#8208;Products Into Poultry Feeds to Create Functional Foods With Insights Into Health Benefits, Risks, Bioactive Compounds, Food Component Functionality and Safety Regulations</article-title>.&#8221; <source>Food</source><volume>12</volume>, no. <issue>21</issue>: <elocation-id>4001</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2304-8158/12/21/4001" ext-link-type="uri">https://www.mdpi.com/2304&#8208;8158/12/21/4001</ext-link>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/foods12214001</pub-id><pub-id pub-id-type="pmcid">PMC10650119</pub-id><pub-id pub-id-type="pmid">37959120</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0128"><mixed-citation publication-type="journal" id="fsn371024-cit-0128"><string-name name-style="western"><surname>Vyas</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Prabaker</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Prabhu</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Study of an Inhibitory Effect of Plant Polyphenolic Compounds Against Digestive Enzymes Using Bench&#8208;Working Experimental Evidence Predicted by Molecular Docking and Dynamics</article-title>.&#8221; <source>International Journal of Biological Macromolecules</source><volume>259</volume>: <elocation-id>129222</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.129222</pub-id>.<pub-id pub-id-type="pmid">38185307</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0129"><mixed-citation publication-type="journal" id="fsn371024-cit-0129"><string-name name-style="western"><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Reinventing Gut Health: Leveraging Dietary Bioactive Compounds for the Prevention and Treatment of Diseases</article-title>.&#8221; <source>Frontiers in Nutrition</source><volume>11</volume>: <elocation-id>1491821</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnut.2024.1491821</pub-id>.<pub-id pub-id-type="pmid">39502877</pub-id><pub-id pub-id-type="pmcid">PMC11534667</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0130"><mixed-citation publication-type="book" id="fsn371024-cit-0130"><string-name name-style="western"><surname>Wani</surname>, <given-names>S. A.</given-names></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Elshikh</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Al&#8208;Wahaibi</surname></string-name>, and <string-name name-style="western"><given-names>H. R.</given-names><surname>Naik</surname></string-name>. <year>2023</year>. <source>Functional Foods: Technological Challenges and Advancement in Health Promotion</source>. <publisher-name>CRC Press</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0131"><mixed-citation publication-type="book" id="fsn371024-cit-0131"><collab collab-type="authors">WHO</collab>
. <year>2023</year>. <source>Biofortification of Crops With Minerals and Vitamins</source>. <publisher-name>WHO</publisher-name>.</mixed-citation></ref><ref id="fsn371024-bib-0132"><mixed-citation publication-type="journal" id="fsn371024-cit-0132"><string-name name-style="western"><surname>Wu</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Jia</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Ren</surname></string-name>. <year>2024</year>. &#8220;<article-title>Formation and Application of Starch&#8211;Polyphenol Complexes: Influencing Factors and Rapid Screening Based on Chemometrics</article-title>.&#8221; <source>Food</source><volume>13</volume>, no. <issue>10</issue>: <elocation-id>1557</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/foods13101557</pub-id><pub-id pub-id-type="pmcid">PMC11121577</pub-id><pub-id pub-id-type="pmid">38790857</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0133"><mixed-citation publication-type="journal" id="fsn371024-cit-0133"><string-name name-style="western"><surname>Xavier</surname>, <given-names>J. R.</given-names></string-name>, <string-name name-style="western"><given-names>B. S.</given-names><surname>Sanjay</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Gupta</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mehta</surname></string-name>, and <string-name name-style="western"><given-names>O. P.</given-names><surname>Chauhan</surname></string-name>. <year>2024</year>. &#8220;<article-title>Bioactive Compounds of Foods: Phytochemicals and Peptides</article-title>.&#8221; <source>Food and Humanity</source><volume>3</volume>: <elocation-id>100354</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.foohum.2024.100354</pub-id>.</mixed-citation></ref><ref id="fsn371024-bib-0134"><mixed-citation publication-type="journal" id="fsn371024-cit-0134"><string-name name-style="western"><surname>Yasin</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Gangan</surname></string-name>, and <string-name name-style="western"><given-names>S. K.</given-names><surname>Panchal</surname></string-name>. <year>2025</year>. &#8220;<article-title>Banana Peels: A Genuine Waste or a Wonderful Opportunity?</article-title>&#8221; <source>Applied Sciences</source><volume>15</volume>, no. <issue>6</issue>: <elocation-id>3195</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2076-3417/15/6/3195" ext-link-type="uri">https://www.mdpi.com/2076&#8208;3417/15/6/3195</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0135"><mixed-citation publication-type="journal" id="fsn371024-cit-0135"><string-name name-style="western"><surname>Yasmin</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>S. N.</given-names><surname>Menon</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Pandey</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>Resveratrol Attenuates Hepatic Oxidative Stress and Preserves Gut Mucosal Integrity in High&#8208;Fat Diet&#8208;Fed Rats by Modulating Antioxidant and Anti&#8208;Inflammatory Pathways</article-title>.&#8221; <source>Scientific Reports</source><volume>15</volume>, no. <issue>1</issue>: <elocation-id>25162</elocation-id>. <pub-id pub-id-type="doi">10.1038/s41598-025-08450-z</pub-id>.<pub-id pub-id-type="pmid">40645973</pub-id><pub-id pub-id-type="pmcid">PMC12254242</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0136"><mixed-citation publication-type="journal" id="fsn371024-cit-0136"><string-name name-style="western"><surname>Ylitalo</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Lehtinen</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Wuolijoki</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Ylitalo</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Lehtim&#228;ki</surname></string-name>. <year>2002</year>. &#8220;<article-title>Cholesterol&#8208;Lowering Properties and Safety of Chitosan</article-title>.&#8221; <source>Arzneimittel&#8208;Forschung</source><volume>52</volume>: <fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1055/s-0031-1299848</pub-id>.<pub-id pub-id-type="pmid">11838268</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0137"><mixed-citation publication-type="journal" id="fsn371024-cit-0137"><string-name name-style="western"><surname>Yuan</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Zhong</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Hussain</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ren</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Xie</surname></string-name>. <year>2024</year>. &#8220;<article-title>Industrial Production of Functional Foods for Human Health and Sustainability</article-title>.&#8221; <source>Food</source><volume>13</volume>, no. <issue>22</issue>: <elocation-id>3546</elocation-id>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/2304-8158/13/22/3546" ext-link-type="uri">https://www.mdpi.com/2304&#8208;8158/13/22/3546</ext-link>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/foods13223546</pub-id><pub-id pub-id-type="pmcid">PMC11593949</pub-id><pub-id pub-id-type="pmid">39593962</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0138"><mixed-citation publication-type="journal" id="fsn371024-cit-0138"><string-name name-style="western"><surname>Zhang</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Si</surname></string-name>. <year>2022</year>. &#8220;<article-title>Synergistic Anti&#8208;Inflammatory Effects and Mechanisms of the Combination of Resveratrol and Curcumin in Human Vascular Endothelial Cells and Rodent Aorta</article-title>.&#8221; <source>Journal of Nutritional Biochemistry</source><volume>108</volume>: <elocation-id>109083</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2022.109083</pub-id>.<pub-id pub-id-type="pmid">35691595</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0139"><mixed-citation publication-type="journal" id="fsn371024-cit-0139"><string-name name-style="western"><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhou</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Guan</surname></string-name>. <year>2023</year>. &#8220;<article-title>Dietary Components Regulate Chronic Diseases Through Gut Microbiota: A Review</article-title>.&#8221; <source>Journal of the Science of Food and Agriculture</source><volume>103</volume>, no. <issue>14</issue>: <fpage>6752</fpage>&#8211;<lpage>6766</lpage>.<pub-id pub-id-type="pmid">37225671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jsfa.12732</pub-id></mixed-citation></ref><ref id="fsn371024-bib-0140"><mixed-citation publication-type="miscellaneous" id="fsn371024-cit-0140"><string-name name-style="western"><surname>Zheng</surname>, <given-names>Y.</given-names></string-name><year>2022</year>. <article-title>&#8220;Functional Food VS Health Food: The Different Raceways Under the Big Health Industry.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cirs-group.com/en/food/functional-food-vs-health-food-the-different-raceways-under-the-big-health-industry" ext-link-type="uri">https://www.cirs&#8208;group.com/en/food/functional&#8208;food&#8208;vs&#8208;health&#8208;food&#8208;the&#8208;different&#8208;raceways&#8208;under&#8208;the&#8208;big&#8208;health&#8208;industry</ext-link>.</mixed-citation></ref><ref id="fsn371024-bib-0141"><mixed-citation publication-type="journal" id="fsn371024-cit-0141"><string-name name-style="western"><surname>Zhou</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Xiao</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zheng</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Deng</surname></string-name>. <year>2019</year>. &#8220;<article-title>Deciphering the Anti&#8208;Obesity Benefits of Resveratrol: The &#8216;Gut Microbiota&#8208;Adipose Tissue&#8217; Axis</article-title>.&#8221; <source>Frontiers in Endocrinology</source><volume>10</volume>: <elocation-id>413</elocation-id>. <pub-id pub-id-type="doi">10.3389/fendo.2019.00413</pub-id>.<pub-id pub-id-type="pmid">31316465</pub-id><pub-id pub-id-type="pmcid">PMC6610334</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70695" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504049</article-id><article-id pub-id-type="pmcid-ver">PMC12504049.1</article-id><article-id pub-id-type="pmcaid">12504049</article-id><article-id pub-id-type="pmcaiid">12504049</article-id><article-id pub-id-type="pmid">41057914</article-id><article-id pub-id-type="doi">10.1002/alz.70695</article-id><article-id pub-id-type="publisher-id">ALZ70695</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>White matter hyperintensities precede other biomarkers in <italic toggle="yes">GRN</italic> frontotemporal dementia</article-title><alt-title alt-title-type="left-running-head">SOLTANINEJAD <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70695-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Soltaninejad</surname><given-names initials="M">Mahdie</given-names></name><xref rid="alz70695-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>Mahdie.soltaninejad@mail.mcgill.ca</email></address></contrib><contrib id="alz70695-cr-0002" contrib-type="author"><name name-style="western"><surname>Dadar</surname><given-names initials="M">Mahsa</given-names></name><xref rid="alz70695-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70695-cr-0003" contrib-type="author"><name name-style="western"><surname>Collins</surname><given-names initials="DL">D. Louis</given-names></name><xref rid="alz70695-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70695-cr-0004" contrib-type="author"><name name-style="western"><surname>Rajabli</surname><given-names initials="R">Reza</given-names></name><xref rid="alz70695-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70695-cr-0005" contrib-type="author"><name name-style="western"><surname>Venkatraghavan</surname><given-names initials="V">Vikram</given-names></name><xref rid="alz70695-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70695-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70695-cr-0006" contrib-type="author"><name name-style="western"><surname>Bouzigues</surname><given-names initials="A">Arabella</given-names></name><xref rid="alz70695-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70695-cr-0007" contrib-type="author"><name name-style="western"><surname>Russell</surname><given-names initials="LL">Lucy L.</given-names></name><xref rid="alz70695-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70695-cr-0008" contrib-type="author"><name name-style="western"><surname>Foster</surname><given-names initials="PH">Phoebe H.</given-names></name><xref rid="alz70695-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70695-cr-0009" contrib-type="author"><name name-style="western"><surname>Ferry&#8208;Bolder</surname><given-names initials="E">Eve</given-names></name><xref rid="alz70695-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70695-cr-0010" contrib-type="author"><name name-style="western"><surname>van Swieten</surname><given-names initials="JC">John C.</given-names></name><xref rid="alz70695-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70695-cr-0011" contrib-type="author"><name name-style="western"><surname>Jiskoot</surname><given-names initials="LC">Lize C.</given-names></name><xref rid="alz70695-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70695-cr-0012" contrib-type="author"><name name-style="western"><surname>Seelaar</surname><given-names initials="H">Harro</given-names></name><xref rid="alz70695-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70695-cr-0013" contrib-type="author"><name name-style="western"><surname>Sanchez&#8208;Valle</surname><given-names initials="R">Raquel</given-names></name><xref rid="alz70695-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz70695-cr-0014" contrib-type="author"><name name-style="western"><surname>Laforce</surname><given-names initials="R">Robert</given-names></name><xref rid="alz70695-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz70695-cr-0015" contrib-type="author"><name name-style="western"><surname>Graff</surname><given-names initials="C">Caroline</given-names></name><xref rid="alz70695-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="alz70695-cr-0016" contrib-type="author"><name name-style="western"><surname>Galimberti</surname><given-names initials="D">Daniela</given-names></name><xref rid="alz70695-aff-0010" ref-type="aff">
<sup>10</sup>
</xref><xref rid="alz70695-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz70695-cr-0017" contrib-type="author"><name name-style="western"><surname>Vandenberghe</surname><given-names initials="R">Rik</given-names></name><xref rid="alz70695-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="alz70695-cr-0018" contrib-type="author"><name name-style="western"><surname>de Mendon&#231;a</surname><given-names initials="A">Alexandre</given-names></name><xref rid="alz70695-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="alz70695-cr-0019" contrib-type="author"><name name-style="western"><surname>Tiraboschi</surname><given-names initials="P">Pietro</given-names></name><xref rid="alz70695-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="alz70695-cr-0020" contrib-type="author"><name name-style="western"><surname>Santana</surname><given-names initials="I">Isabel</given-names></name><xref rid="alz70695-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="alz70695-cr-0021" contrib-type="author"><name name-style="western"><surname>Gerhard</surname><given-names initials="A">Alexander</given-names></name><xref rid="alz70695-aff-0016" ref-type="aff">
<sup>16</sup>
</xref><xref rid="alz70695-aff-0017" ref-type="aff">
<sup>17</sup>
</xref><xref rid="alz70695-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="alz70695-cr-0022" contrib-type="author"><name name-style="western"><surname>Levin</surname><given-names initials="J">Johannes</given-names></name><xref rid="alz70695-aff-0019" ref-type="aff">
<sup>19</sup>
</xref><xref rid="alz70695-aff-0020" ref-type="aff">
<sup>20</sup>
</xref><xref rid="alz70695-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="alz70695-cr-0023" contrib-type="author"><name name-style="western"><surname>Nacmias</surname><given-names initials="B">Benedetta</given-names></name><xref rid="alz70695-aff-0022" ref-type="aff">
<sup>22</sup>
</xref><xref rid="alz70695-aff-0023" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib id="alz70695-cr-0024" contrib-type="author"><name name-style="western"><surname>Otto</surname><given-names initials="M">Markus</given-names></name><xref rid="alz70695-aff-0024" ref-type="aff">
<sup>24</sup>
</xref></contrib><contrib id="alz70695-cr-0025" contrib-type="author"><name name-style="western"><surname>Bertoux</surname><given-names initials="M">Maxime</given-names></name><xref rid="alz70695-aff-0025" ref-type="aff">
<sup>25</sup>
</xref></contrib><contrib id="alz70695-cr-0026" contrib-type="author"><name name-style="western"><surname>Lebouvier</surname><given-names initials="T">Thibaud</given-names></name><xref rid="alz70695-aff-0025" ref-type="aff">
<sup>25</sup>
</xref></contrib><contrib id="alz70695-cr-0027" contrib-type="author"><name name-style="western"><surname>Butler</surname><given-names initials="CR">Chris R.</given-names></name><xref rid="alz70695-aff-0026" ref-type="aff">
<sup>26</sup>
</xref></contrib><contrib id="alz70695-cr-0028" contrib-type="author"><name name-style="western"><surname>Ber</surname><given-names initials="IL">Isabelle Le</given-names></name><xref rid="alz70695-aff-0027" ref-type="aff">
<sup>27</sup>
</xref></contrib><contrib id="alz70695-cr-0029" contrib-type="author"><name name-style="western"><surname>Finger</surname><given-names initials="E">Elizabeth</given-names></name><xref rid="alz70695-aff-0028" ref-type="aff">
<sup>28</sup>
</xref></contrib><contrib id="alz70695-cr-0030" contrib-type="author"><name name-style="western"><surname>Tartaglia</surname><given-names initials="MC">Maria Carmela</given-names></name><xref rid="alz70695-aff-0029" ref-type="aff">
<sup>29</sup>
</xref></contrib><contrib id="alz70695-cr-0031" contrib-type="author"><name name-style="western"><surname>Masellis</surname><given-names initials="M">Mario</given-names></name><xref rid="alz70695-aff-0030" ref-type="aff">
<sup>30</sup>
</xref></contrib><contrib id="alz70695-cr-0032" contrib-type="author"><name name-style="western"><surname>Rowe</surname><given-names initials="JB">James B.</given-names></name><xref rid="alz70695-aff-0031" ref-type="aff">
<sup>31</sup>
</xref></contrib><contrib id="alz70695-cr-0033" contrib-type="author"><name name-style="western"><surname>Synofzik</surname><given-names initials="M">Matthis</given-names></name><xref rid="alz70695-aff-0032" ref-type="aff">
<sup>32</sup>
</xref></contrib><contrib id="alz70695-cr-0034" contrib-type="author"><name name-style="western"><surname>Moreno</surname><given-names initials="F">Fermin</given-names></name><xref rid="alz70695-aff-0033" ref-type="aff">
<sup>33</sup>
</xref></contrib><contrib id="alz70695-cr-0035" contrib-type="author"><name name-style="western"><surname>Borroni</surname><given-names initials="B">Barbara</given-names></name><xref rid="alz70695-aff-0034" ref-type="aff">
<sup>34</sup>
</xref><xref rid="alz70695-aff-0035" ref-type="aff">
<sup>35</sup>
</xref></contrib><contrib id="alz70695-cr-0036" contrib-type="author"><name name-style="western"><surname>Rohrer</surname><given-names initials="JD">Jonathan D.</given-names></name><xref rid="alz70695-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70695-cr-0037" contrib-type="author"><name name-style="western"><surname>Iturria&#8208;Medina</surname><given-names initials="Y">Yasser</given-names></name><xref rid="alz70695-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70695-cr-0038" contrib-type="author"><name name-style="western"><surname>Ducharme</surname><given-names initials="S">Simon</given-names></name><xref rid="alz70695-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70695-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70695-cr-0039" contrib-type="author"><collab collab-type="authors">GENFI Consortium</collab></contrib></contrib-group><aff id="alz70695-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">McConnell Brain Imaging Centre</named-content>
<named-content content-type="organisation-division">Montreal Neurological Institute</named-content>
<institution>McGill University</institution>
<city>Montr&#233;al</city>
<named-content content-type="country-part">Qu&#233;bec</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70695-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Douglas Mental Health University Institute</named-content>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>McGill University</institution>
<city>Montr&#233;al</city>
<named-content content-type="country-part">Qu&#233;bec</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70695-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Biomedical Engineering and Physics</named-content>
<named-content content-type="organisation-division">Amsterdam University Medical Center</named-content>
<institution>University of Amsterdam</institution>
<city>Amsterdam</city>
<country country="NL">the Netherlands</country>
</aff><aff id="alz70695-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Informatics Institute</named-content>
<institution>University of Amsterdam</institution>
<city>Amsterdam</city>
<country country="NL">the Netherlands</country>
</aff><aff id="alz70695-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Dementia Research Centre</named-content>
<named-content content-type="organisation-division">Department of Neurodegenerative Disease</named-content>
<institution>UCL Queen Square Institute of Neurology</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz70695-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Erasmus Medical Centre</institution>
<city>Rotterdam</city>
<country country="NL">Netherlands</country>
</aff><aff id="alz70695-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Cl&#237;nic</named-content>
<named-content content-type="organisation-division">Institut d'Investigaci&#243;ns Biom&#232;diques August Pi I Sunyer</named-content>
<institution>University of Barcelona</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70695-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Clinique Interdisciplinaire de M&#233;moire</named-content>
<named-content content-type="organisation-division">D&#233;partement des Sciences Neurologiques</named-content>
<named-content content-type="organisation-division">CHU de Qu&#233;bec, and Facult&#233; de M&#233;decine</named-content>
<institution>Universit&#233; Laval</institution>
<city>Qu&#233;bec</city>
<country country="CA">Canada</country>
</aff><aff id="alz70695-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Neurobiology</named-content>
<named-content content-type="organisation-division">Care Sciences and Society</named-content>
<named-content content-type="organisation-division">Center for Alzheimer Research</named-content>
<named-content content-type="organisation-division">Division of Neurogeriatrics</named-content>
<named-content content-type="organisation-division">Bioclinicum</named-content>
<institution>Karolinska Institutet</institution>
<city>Solna</city>
<country country="SE">Sweden</country>
</aff><aff id="alz70695-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Fondazione Ca&#8217; Granda</named-content>
<institution>IRCCS Ospedale Policlinico</institution>
<city>Milano</city>
<country country="IT">Italy</country>
</aff><aff id="alz70695-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Department of Biomedical</named-content>
<named-content content-type="organisation-division">Surgical and Dental Sciences</named-content>
<institution>University of Milan</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="alz70695-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Laboratory for Cognitive Neurology</named-content>
<named-content content-type="organisation-division">Department of Neurosciences</named-content>
<institution>KU Leuven</institution>
<city>Leuven</city>
<country country="BE">Belgium</country>
</aff><aff id="alz70695-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>University of Lisbon</institution>
<city>Lisbon</city>
<country country="PT">Portugal</country>
</aff><aff id="alz70695-aff-0014">
<label>
<sup>14</sup>
</label>
<institution>Fondazione IRCCS Istituto Neurologico Carlo Besta</institution>
<city>Milano</city>
<country country="IT">Italy</country>
</aff><aff id="alz70695-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">University Hospital of Coimbra (HUC)</named-content>
<named-content content-type="organisation-division">Neurology Service</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>University of Coimbra</institution>
<city>Coimbra</city>
<country country="PT">Portugal</country>
</aff><aff id="alz70695-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Division of Psychology Communication and Human Neuroscience</named-content>
<named-content content-type="organisation-division">Wolfson Molecular Imaging Centre</named-content>
<institution>University of Manchester</institution>
<city>Manchester</city>
<country country="GB">UK</country>
</aff><aff id="alz70695-aff-0017">
<label>
<sup>17</sup>
</label>
<named-content content-type="organisation-division">Department of Nuclear Medicine</named-content>
<named-content content-type="organisation-division">Center for Translational Neuro&#8208; and Behavioral Sciences</named-content>
<institution>University Hospital Essen</institution>
<city>Essen</city>
<country country="DE">Germany</country>
</aff><aff id="alz70695-aff-0018">
<label>
<sup>18</sup>
</label>
<institution>Department of Geriatric Medicine</institution>
<city>Arnsberg</city>
<country country="DE">Germany</country>
</aff><aff id="alz70695-aff-0019">
<label>
<sup>19</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>LMU University Hospital</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="alz70695-aff-0020">
<label>
<sup>20</sup>
</label>
<institution>Germany Center for Neurodegenerative Diseases</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="alz70695-aff-0021">
<label>
<sup>21</sup>
</label>
<institution>Munich Cluster for Systems Neurology (SyNergy)</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="alz70695-aff-0022">
<label>
<sup>22</sup>
</label>
<named-content content-type="organisation-division">Department of Neuroscience</named-content>
<named-content content-type="organisation-division">Psychology</named-content>
<named-content content-type="organisation-division">Drug Research and Child Health</named-content>
<institution>University of Florence</institution>
<city>Florence</city>
<country country="IT">Italy</country>
</aff><aff id="alz70695-aff-0023">
<label>
<sup>23</sup>
</label>
<institution>IRCCS Fondazione Don Carlo Gnocchi</institution>
<city>Florence</city>
<country country="IT">Italy</country>
</aff><aff id="alz70695-aff-0024">
<label>
<sup>24</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University of Ulm</institution>
<city>Ulm</city>
<country country="DE">Germany</country>
</aff><aff id="alz70695-aff-0025">
<label>
<sup>25</sup>
</label>
<institution>Centre Hospitalier Universitaire de Lille, Nord d&#233;partement</institution>
<city>Lille</city>
<country country="FR">France</country>
</aff><aff id="alz70695-aff-0026">
<label>
<sup>26</sup>
</label>
<named-content content-type="organisation-division">Nuffield Department of Clinical Neurosciences, Medical Sciences Division</named-content>
<institution>University of Oxford</institution>
<city>Oxford</city>
<country country="GB">UK</country>
</aff><aff id="alz70695-aff-0027">
<label>
<sup>27</sup>
</label>
<named-content content-type="organisation-division">Sorbonne Universit&#233;</named-content>
<named-content content-type="organisation-division">Paris Brain Institute &#8211; Institut du Cerveau &#8211; ICM</named-content>
<institution>H&#244;pital Piti&#233;</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="alz70695-aff-0028">
<label>
<sup>28</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Neurological Sciences</named-content>
<named-content content-type="organisation-division">London Health Sciences Centre</named-content>
<named-content content-type="organisation-division">University Hospital</named-content>
<institution>University of Western Ontario</institution>
<city>London</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70695-aff-0029">
<label>
<sup>29</sup>
</label>
<named-content content-type="organisation-division">Tanz Centre for Research in Neurodegenerative Diseases</named-content>
<institution>University of Toronto</institution>
<city>Toronto</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70695-aff-0030">
<label>
<sup>30</sup>
</label>
<named-content content-type="organisation-division">Sunnybrook Health Sciences Centre</named-content>
<named-content content-type="organisation-division">Sunnybrook Research Institute</named-content>
<institution>University of Toronto</institution>
<city>Toronto</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70695-aff-0031">
<label>
<sup>31</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Neurosciences</named-content>
<named-content content-type="organisation-division">Cambridge University Hospitals NHS Trust, and MRC Cognition and Brain Sciences Unit</named-content>
<institution>University of Cambridge</institution>
<city>Cambridge</city>
<country country="GB">UK</country>
</aff><aff id="alz70695-aff-0032">
<label>
<sup>32</sup>
</label>
<named-content content-type="organisation-division">Department of Neurodegenerative Diseases</named-content>
<institution>Hertie&#8208;Institute for Clinical Brain Research and Center of Neurology, University of T&#252;bingen</institution>
<city>T&#252;bingen</city>
<country country="DE">Germany</country>
</aff><aff id="alz70695-aff-0033">
<label>
<sup>33</sup>
</label>
<named-content content-type="organisation-division">Cognitive Disorders Unit</named-content>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Donostia Universitary Hospital</institution>
<city>Donostia</city>
<named-content content-type="country-part">Gipuzkoa</named-content>
<country country="ES">Spain</country>
</aff><aff id="alz70695-aff-0034">
<label>
<sup>34</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical and Experimental Sciences</named-content>
<institution>University of Brescia</institution>
<city>Brescia</city>
<country country="IT">Italy</country>
</aff><aff id="alz70695-aff-0035">
<label>
<sup>35</sup>
</label>
<named-content content-type="organisation-division">Molecular Markers Laboratory</named-content>
<institution>IRCCS Istituto Centro San Giovanni di Di</institution>
<city>Brescia</city>
<country country="IT">Italy</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Mahdie Soltaninejad, Montreal Neurological Institute, McGill University, 3801 University Street, Montr&#233;al, H3A2B4 Qu&#233;bec, Canada.<break/> Email: <email>Mahdie.soltaninejad@mail.mcgill.ca</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="380">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70695</elocation-id><history><date date-type="rev-recd"><day>15</day><month>8</month><year>2025</year></date><date date-type="received"><day>14</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70695.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70695.pdf"/><abstract><title>Abstract</title><sec id="alz70695-sec-0010"><title>INTRODUCTION</title><p>Increased white matter hyperintensities (WMHs) have been reported in genetic frontotemporal dementia (FTD) in small studies, but the sequence of WMH abnormalities relative to other biomarkers is unclear.</p></sec><sec id="alz70695-sec-0020"><title>METHODS</title><p>Using a large dataset (<italic toggle="yes">n</italic>&#160;=&#160;763 GENFI2 participants), we measured WMHs and examined them across genetic FTD variants and stages. Cortical and subcortical volumes were parcellated, and serum neurofilament light chain (NfL) levels were measured. Biomarker progression was assessed with discriminative event&#8208;based and regression modeling.</p></sec><sec id="alz70695-sec-0030"><title>RESULTS</title><p>Symptomatic <italic toggle="yes">GRN</italic> carriers showed elevated WMHs, primarily in the frontal lobe, while no significant increase was observed in symptomatic <italic toggle="yes">C9orf72</italic> or <italic toggle="yes">MAPT</italic> carriers. WMH abnormalities preceded NfL elevation, ventricular enlargement, and cortical atrophy. Longitudinally, baseline WMHs predicted subcortical changes, while subcortical volumes did not predict WMH changes, suggesting WMHs may precede neurodegeneration.</p></sec><sec id="alz70695-sec-0040"><title>DISCUSSION</title><p>WMHs are elevated in a subset of <italic toggle="yes">GRN</italic>&#8208;associated FTD. When present, they appear early and should be considered in disease progression models.</p></sec><sec id="alz70695-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70695-list-0001"><list-item><p>Elevated WMH volumes are found predominantly in symptomatic <italic toggle="yes">GRN</italic>.</p></list-item><list-item><p>WMH accumulation is mostly observed in the frontal lobe.</p></list-item><list-item><p>WMH abnormalities appear early in <italic toggle="yes">GRN</italic>&#8208;associated FTD, before NfL, atrophy, and ventriculomegaly.</p></list-item><list-item><p>Longitudinally, WMH volumes can predict subcortical changes, but not vice versa.</p></list-item><list-item><p>WMHs are key early markers in <italic toggle="yes">GRN</italic>&#8208;associated FTD and should be included in progression models.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70695-kwd-0001">biomarker sequence</kwd><kwd id="alz70695-kwd-0002">C9orf72</kwd><kwd id="alz70695-kwd-0003">dementia</kwd><kwd id="alz70695-kwd-0004">disease progression</kwd><kwd id="alz70695-kwd-0005">early marker</kwd><kwd id="alz70695-kwd-0006">event&#8208;based modeling</kwd><kwd id="alz70695-kwd-0007">FTD</kwd><kwd id="alz70695-kwd-0008">GRN</kwd><kwd id="alz70695-kwd-0009">MAPT</kwd><kwd id="alz70695-kwd-0010">magnetic resonance imaging</kwd><kwd id="alz70695-kwd-0011">neurodegeneration</kwd><kwd id="alz70695-kwd-0012">neurofilament light chain</kwd><kwd id="alz70695-kwd-0013">neuroimaging</kwd><kwd id="alz70695-kwd-0014">progranulin</kwd><kwd id="alz70695-kwd-0015">white matter
</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Weston Brain Institute</institution><institution-id institution-id-type="doi">10.13039/100012479</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>NIHR Cambridge Biomedical Research Centre</institution><institution-id institution-id-type="doi">10.13039/501100018956</institution-id></institution-wrap></funding-source><award-id>NIHR203312</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Wellcome Trust</institution><institution-id institution-id-type="doi">10.13039/100010269</institution-id></institution-wrap></funding-source><award-id>220258</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Medical Research Council</institution><institution-id institution-id-type="doi">10.13039/501100000265</institution-id></institution-wrap></funding-source><award-id>MC_UU_00030/14</award-id><award-id>MR/T033371/1</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Canadian Institutes of Health Research</institution><institution-id institution-id-type="doi">10.13039/501100000024</institution-id></institution-wrap></funding-source><award-id>MOP&#8208;327387</award-id><award-id>PJT&#8208;175242</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Fonds de Recherche du Qu&#233;bec &#8208; Sant&#233;</institution><institution-id institution-id-type="doi">10.13039/501100000156</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="14"/><word-count count="8392"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70695-cite-0001"><string-name name-style="western"><surname>Soltaninejad</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DL</given-names></string-name>, et&#160;al. <article-title>White matter hyperintensities precede other biomarkers in <italic toggle="yes">GRN</italic> frontotemporal dementia</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70695</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70695</pub-id><pub-id pub-id-type="pmid">41057914</pub-id><pub-id pub-id-type="pmcid">PMC12504049</pub-id></mixed-citation>
</p><fn-group><fn id="alz70695-note-0001"><p>The list of GENFI consortium members is provided in Appendix.</p></fn></fn-group></notes></front><body><sec id="alz70695-sec-0060"><label>1</label><title>BACKGROUND</title><p>Frontotemporal dementia (FTD) presents as a multifaceted neurodegenerative disorder marked by progressive deterioration in behavior, personality, and/or language, ranking as the second most prevalent cause of early onset dementia following Alzheimer's disease.<xref rid="alz70695-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Approximately 30% of FTD cases exhibit a robust familial dementia history, often linked to specific genetic mutations. The majority of FTD's heritability stems from autosomal dominant mutations within three primary genes: <italic toggle="yes">C9orf72</italic> (chromosome 9 open reading frame 72), <italic toggle="yes">GRN</italic> (progranulin), and <italic toggle="yes">MAPT</italic> (microtubule&#8208;associated protein tau).<xref rid="alz70695-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Despite symptomatic overlap across these gene mutations, the molecular mechanisms driving the emergence of phenotypic outcomes are inherently distinct.</p><p>White matter hyperintensities (WMHs) have garnered significant attention due to their clinicopathologic contributions in a range of neurodegenerative conditions and their deleterious effect on cognition.<xref rid="alz70695-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70695-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> These lesions manifest as hyperintensities on specific sequences of magnetic resonance imaging (MRI), signaling abnormalities within the brain's white matter. These anomalies can indicate areas of demyelination, gliosis, and/or small vessel disease. WMH <italic toggle="yes">post mortem</italic> histopathology reveals non&#8208;specific brain alterations, such as gliosis, myelin and axon loss attributed to arteriosclerosis, tissue rarefaction, and lipohyalinosis. These changes may be caused by various factors, including hypoxia, hypoperfusion, blood&#8211;brain barrier leakage, inflammation, degeneration, and amyloid angiopathy.<xref rid="alz70695-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Moreover, increasing evidence suggests that WMHs in neurodegeneration are not solely driven by vascular pathology but may also reflect intrinsic disease processes, including amyloidosis and gray matter degeneration, as shown in Alzheimer's disease, where WMHs have been linked to cerebral amyloid angiopathy and neurodegeneration rather than traditional vascular risk factors.<xref rid="alz70695-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>The overwhelming majority of neuroimaging research in FTD has centered on changes in gray matter, with less attention given to the role of WMHs. Sudre et&#160;al.<xref rid="alz70695-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> reported increased WMH burden in FTD patients with symptomatic <italic toggle="yes">GRN</italic> mutations, but not in those carrying <italic toggle="yes">MAPT</italic> or <italic toggle="yes">C9orf72</italic> mutations. This investigation did not find significant WMH changes during the presymptomatic phase. A follow&#8208;up longitudinal study from the same group showed variations among <italic toggle="yes">GRN</italic> cases, with 25% of individuals displaying either no WMHs or only mild WMHs during the symptomatic phase and only 9% of those in the presymptomatic phase already exhibiting severe WMH involvement.<xref rid="alz70695-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Despite its reliance on a small sample size, this study has exerted a significant influence on the research landscape concerning the association between FTD and WMHs being tied to <italic toggle="yes">GRN</italic> cases. Another study<xref rid="alz70695-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> employing diffusion tensor imaging revealed microstructural white matter changes among individuals with <italic toggle="yes">C9orf72</italic> repeat expansions and <italic toggle="yes">MAPT</italic> mutations during presymptomatic stages, highlighting the impact that genetic FTD has on white matter.</p><p>Despite these results, WMHs were not factored into recent disease models aiming to guide clinical trials.<xref rid="alz70695-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In our study, we aimed to address these gaps in knowledge by investigating the prevalence of WMH across distinct genetic groups and different stages of FTD, leveraging a later version of the GENFI2 dataset with a larger sample to assess the validity of previous WMH studies. We further undertook a temporal analysis of WMH compared to other markers in the course of the progression of the disease.</p></sec><sec id="alz70695-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70695-sec-0080"><label>2.1</label><title>Data</title><p>Data for this study were obtained from the fifth data freeze of GENFI2 (Genetic Frontotemporal dementia Initiative), a large international study involving 25 centers in Europe and Canada. GENFI collects longitudinal data on genetic FTD and aims to gather multimodal neuroimaging, cognitive, and fluid biomarkers to develop markers for early&#8208;stage FTD identification, track disease progression, and gain insight into the presymptomatic phase of the disease.</p><p>Participants included in GENFI2 were known symptomatic carriers of pathogenic mutations in <italic toggle="yes">C9orf72</italic>, <italic toggle="yes">GRN</italic>, or <italic toggle="yes">MAPT</italic>, as well as their first&#8208;degree relatives who were at risk of carrying a mutation. Genotyping was performed at local sites, and all participants underwent a standard clinical evaluation, including medical and family history assessments, as well as physical examinations. Symptomatic carriers met clinical criteria for behavioral variant of frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), frontotemporal dementia with amyotrophic lateral sclerosis (FTD&#8208;ALS) or other rare presentations, while presymptomatic carriers did not fulfill clinical criteria. The non&#8208;carrier group comprised healthy first&#8208;degree relatives of symptomatic carriers who tested negative for the reported family mutation. Detailed inclusion and exclusion criteria can be found elsewhere.<xref rid="alz70695-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>T1&#8208;weighted and T2&#8208;weighted MRI scans were acquired across multiple sites using 3T scanners from Siemens (Trio, Skyra, Prisma), Philips, and General Electric. Imaging followed harmonized acquisition protocols established by the GENFI study to ensure inter&#8208;site consistency.<xref rid="alz70695-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> For T1&#8208;weighted imaging, sagittal 3D MPRAGE or equivalent sequences were used. Acquisition parameters (median [range]) included an inversion time (TI) of 850&#160;ms (400 to 960&#160;ms), repetition time (TR) of 2000&#160;ms (6.6 to 2200&#160;ms), echo time (TE) of 2.9&#160;ms (2.2 to 9.0&#160;ms), flip angle of 8&#176; (8&#176; to 11&#176;), slice thickness of 1.1&#160;mm, and 208 slices (200 to 208). For T2&#8208;weighted imaging, sagittal 3D fast spin echo sequences were used. Acquisition parameters (median [range]) included TR of 3200&#160;ms (2200 to 3200&#160;ms), effective TE (TEeff) of 105&#160;ms (50 to 105&#160;ms), slice thickness of 1.1&#160;mm, and 176 slices (176 to 208).</p><p>Serum levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were longitudinally measured using the single&#8208;molecule array technique (Simoa).<xref rid="alz70695-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70695-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70695-list-0002"><list-item><p>
<bold>Systematic review</bold>: We systematically reviewed the literature on WMHs in FTD using PubMed. While a few small studies reported increased WMHs in <italic toggle="yes">GRN</italic> mutation carriers, their sample sizes were limited, and they did not assess the timing of WMHs within disease progression or their temporal relationship to other biomarkers.</p></list-item><list-item><p>
<bold>Interpretation</bold>: We identified a sequence of key biomarkers in <italic toggle="yes">GRN</italic>&#8208;associated FTD and demonstrated that WMHs were among the earliest biomarkers, preceding cortical and subcortical atrophy as well as blood biomarkers. This aligns with neuropathological evidence of early white matter involvement in FTLD&#8208;<italic toggle="yes">GRN</italic>. Additionally, using a larger dataset, we validated previous reports of elevated WMHs in <italic toggle="yes">GRN</italic> carriers, confirming their reliability.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future studies should integrate WMHs into FTD progression models to enhance early diagnosis. Understanding why only a subset of <italic toggle="yes">GRN</italic> carriers exhibit high WMH volumes remains a key research priority.</p></list-item></list>
</p></sec></boxed-text><p>GENFI is a longitudinal dataset with multiple visits available for some participants. In this study, we first used a cross&#8208;sectional design to maximize the number of subjects, selecting only one visit per participant (except in our final analysis, which incorporated a longitudinal approach). To ensure consistency in data selection, we prioritized visits with both blood and imaging biomarkers available. Where participants had multiple eligible visits, we chose the most recent one to better capture a broader spectrum of disease severity. Longitudinal visits were used to test for the temporal relationship of biomarker changes.</p></sec><sec id="alz70695-sec-0100"><label>2.2</label><title>Image processing</title><sec id="alz70695-sec-0110"><label>2.2.1</label><title>White matter hyperintensities segmentation</title><p>The segmentation of WMH was performed using BISON,<xref rid="alz70695-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> integrating data from T1&#8208;weighted (T1w) and T2&#8208;weighted (T2w) imaging modalities. The workflow employed a random forest classifier trained with location, intensity parameters, and manually labeled data to generate participant&#8208;specific WMH maps. Before WMH segmentation, T1w and T2w scans underwent preprocessing steps including image denoising, intensity non&#8208;uniformity correction, and intensity normalization within a range of 0&#8208;100. T1w images were linearly registered and subsequently nonlinearly registered to the ICBM152 template. T1w and T2w images were linearly co&#8208;registered using a six&#8208;parameter rigid registration. All stereotaxic space priors and averages for WMH segmentation were resampled onto the native T1w volume using the inverse of the estimated non&#8208;linear registration transformation. Quality control was performed via visual inspection of WMH segmentations and corresponding structural MRI scans using Qrater.<xref rid="alz70695-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Eleven of the 778 participants were excluded due to segmentation errors or major image artifacts. This included cases in which visible hyperintensities were not captured by the segmentation, as well as cases with substantial over&#8208;segmentation (Figure&#160;<xref rid="alz70695-fig-0001" ref-type="fig">1</xref>). The WMH lesion maps were then linearly registered to the ICBM152 template, and Hammers' atlas was used to quantify WMH volumes in each of the eight lobes.<xref rid="alz70695-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70695-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70695-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Flowchart of inclusion and exclusion criteria in study. QC, quality control; WMH, white matter hyperintensity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70695-g003.jpg"/></fig></sec><sec id="alz70695-sec-0120"><label>2.2.2</label><title>Brain parcellation</title><p>In this study, gray matter volumes were obtained with the Geodesic Information Flow (GIF) algorithm,<xref rid="alz70695-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> a multi&#8208;atlas segmentation approach, for accurate and robust cortical and subcortical volume parcellation. GIF utilizes spatially&#8208;variant graph structures, connecting morphologically similar participants for gradual information diffusion amid large&#8208;scale morphological variability. From the parcellated regions, we considered the volumes of cortical and subcortical areas most closely associated with FTD, as identified in previous studies,<xref rid="alz70695-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70695-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70695-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="alz70695-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> including the frontal lobe, temporal lobe, insula, basal ganglia (nucleus accumbens, caudate, putamen, and globus pallidus), cerebellum, cingulate cortex, ventricle, amygdala, hippocampus, and thalamus. The summed volumes of left and right regions were then utilized for further analysis. Additionally, to address individual variations in brain size, the volumes were standardized by dividing them by the intracranial volume.</p></sec></sec><sec id="alz70695-sec-0130"><label>2.3</label><title>Statistical tests</title><p>Statistical analyses were conducted using RStudio Version 4.3.1. To achieve a normal distribution of the WMH volumes, a log transformation was applied. A linear regression model was employed to adjust the WMH volumes of mutation carriers, with age and sex being taken into account. The model was specified as follows:
<disp-formula id="alz70695-disp-0001"><label>(1)</label><mml:math id="jats-math-1" display="block"><mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mi>WMH</mml:mi><mml:mspace width="0.33em"/><mml:mi>volume</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#8764;</mml:mo><mml:mspace width="0.33em"/><mml:mi>Age</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Sex</mml:mi><mml:mspace width="0.33em"/></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>The model was fitted using data from the healthy control cohort. Subsequently, the difference between the actual log&#8208;transformed WMH volumes and the predicted values derived from this model was calculated for each person. These differences, referred to as adjusted WMH values, represent the residual WMH volume after accounting for demographic variables.</p><p>During this stage of the analysis, four participants were excluded due to missing demographic data, which made adjustment impossible (Figure&#160;<xref rid="alz70695-fig-0001" ref-type="fig">1</xref>). Detailed information regarding the exact number of participants and their demographic characteristics is provided in Table&#160;<xref rid="alz70695-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="alz70695-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographic characteristics of participants.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">
<italic toggle="yes">C9orf72</italic> expansion carriers</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">
<italic toggle="yes">GRN</italic> mutation carriers</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1">
<italic toggle="yes">MAPT</italic> mutation carriers</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Non&#8208;carriers (Healthy control)</th><th align="left" rowspan="1" colspan="1">Presymptomatic</th><th align="left" rowspan="1" colspan="1">Symptomatic</th><th align="left" rowspan="1" colspan="1">Presymptomatic</th><th align="left" rowspan="1" colspan="1">Symptomatic</th><th align="left" rowspan="1" colspan="1">Presymptomatic</th><th align="left" rowspan="1" colspan="1">Symptomatic</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">298</td><td align="left" rowspan="1" colspan="1">129</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">47.3 <mml:math id="jats-math-2" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 13.6</td><td align="left" rowspan="1" colspan="1">44.9 <mml:math id="jats-math-3" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 11.1<sup>a,b,c,d</sup>
</td><td align="left" rowspan="1" colspan="1">65.0 <mml:math id="jats-math-4" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 7.6<sup>a,b,e,f,g</sup>
</td><td align="left" rowspan="1" colspan="1">47.3 <mml:math id="jats-math-5" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 12.3<sup>a,f,h,i</sup>
</td><td align="left" rowspan="1" colspan="1">63.8 <mml:math id="jats-math-6" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 8.4<sup>a,b,c,j,k</sup>
</td><td align="left" rowspan="1" colspan="1">41.4 <mml:math id="jats-math-7" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 11.2<sup>a,b,g,i,k</sup>
</td><td align="left" rowspan="1" colspan="1">57.1 <mml:math id="jats-math-8" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 9.6<sup>a,b,d,e,h,j</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean WMH <mml:math id="jats-math-9" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> SD WMH (mL)</td><td align="left" rowspan="1" colspan="1">6.105 <mml:math id="jats-math-10" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 15.06</td><td align="left" rowspan="1" colspan="1">7.587<sup>c</sup>
<mml:math id="jats-math-11" display="inline"><mml:mrow><mml:mrow><mml:mspace width="0.33em"/><mml:mo>&#177;</mml:mo></mml:mrow></mml:mrow></mml:math> 15.31</td><td align="left" rowspan="1" colspan="1">8.673<sup>b</sup>
<mml:math id="jats-math-12" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 8.84</td><td align="left" rowspan="1" colspan="1">6.376<sup>a</sup>
<mml:math id="jats-math-13" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 15.72</td><td align="left" rowspan="1" colspan="1">14.446<sup>a,b,c</sup>
<mml:math id="jats-math-14" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 18.77</td><td align="left" rowspan="1" colspan="1">11.182 <mml:math id="jats-math-15" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 27.02</td><td align="left" rowspan="1" colspan="1">16.839 <mml:math id="jats-math-16" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 34.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Median WMH (mL)</td><td align="left" rowspan="1" colspan="1">15.060</td><td align="left" rowspan="1" colspan="1">15.313</td><td align="left" rowspan="1" colspan="1">8.836</td><td align="left" rowspan="1" colspan="1">15.718</td><td align="left" rowspan="1" colspan="1">18.773</td><td align="left" rowspan="1" colspan="1">27.019</td><td align="left" rowspan="1" colspan="1">34.213</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean Log<sub>10</sub> WMH (mm3)</td><td align="left" rowspan="1" colspan="1">3.469</td><td align="left" rowspan="1" colspan="1">3.535</td><td align="left" rowspan="1" colspan="1">3.751</td><td align="left" rowspan="1" colspan="1">3.487</td><td align="left" rowspan="1" colspan="1">3.921</td><td align="left" rowspan="1" colspan="1">3.542</td><td align="left" rowspan="1" colspan="1">3.766</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, male (%)</td><td align="left" rowspan="1" colspan="1">40.9</td><td align="left" rowspan="1" colspan="1">40.3</td><td align="left" rowspan="1" colspan="1">64.9</td><td align="left" rowspan="1" colspan="1">36.5</td><td align="left" rowspan="1" colspan="1">42.2</td><td align="left" rowspan="1" colspan="1">38.0</td><td align="left" rowspan="1" colspan="1">59.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years)</td><td align="left" rowspan="1" colspan="1">14.4 <mml:math id="jats-math-17" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 3.2</td><td align="left" rowspan="1" colspan="1">14.3 <mml:math id="jats-math-18" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 2.9<sup>a,c</sup>
</td><td align="left" rowspan="1" colspan="1">12.9 <mml:math id="jats-math-19" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 3.7<sup>a,b,f</sup>
</td><td align="left" rowspan="1" colspan="1">14.8 <mml:math id="jats-math-20" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 3.4<sup>a,f,h</sup>
</td><td align="left" rowspan="1" colspan="1">11.9 <mml:math id="jats-math-21" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 3.5<sup>a,b,c,k</sup>
</td><td align="left" rowspan="1" colspan="1">14.0 <mml:math id="jats-math-22" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 3.4<sup>k</sup>
</td><td align="left" rowspan="1" colspan="1">13.3 <mml:math id="jats-math-23" display="inline"><mml:mrow><mml:mo>&#177;</mml:mo></mml:mrow></mml:math> 3.5<sup>h</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NfL availability</td><td align="left" rowspan="1" colspan="1">77.8%</td><td align="left" rowspan="1" colspan="1">77.5%</td><td align="left" rowspan="1" colspan="1">67.5%</td><td align="left" rowspan="1" colspan="1">83.9%</td><td align="left" rowspan="1" colspan="1">80.0%</td><td align="left" rowspan="1" colspan="1">86.0%</td><td align="left" rowspan="1" colspan="1">81.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">GFAP availability</td><td align="left" rowspan="1" colspan="1">61.1%</td><td align="left" rowspan="1" colspan="1">63.6%</td><td align="left" rowspan="1" colspan="1">57.1%</td><td align="left" rowspan="1" colspan="1">61.3%</td><td align="left" rowspan="1" colspan="1">66.6%</td><td align="left" rowspan="1" colspan="1">64.0%</td><td align="left" rowspan="1" colspan="1">66.6%</td></tr></tbody></table><table-wrap-foot><fn id="alz70695-tbl1-note-0001"><p>WMH values include raw volumes (reported as mean&#160;&#177;&#160;SD in mL, and median in mL) and log10&#8208;transformed mean volumes (in cubic millimeters [mm<sup>3</sup>]). These values are not adjusted for age or sex. Significant differences are indicated by letters: <bold>a</bold> (between symptomatic and presymptomatic of that mutation group), <bold>b</bold> (between healthy control and this group), <bold>c</bold> (between presymptomatic <italic toggle="yes">C9orf72</italic> and symptomatic <italic toggle="yes">GRN</italic>), <bold>d</bold> (between presymptomatic <italic toggle="yes">C9orf72</italic> and symptomatic <italic toggle="yes">MAPT</italic>), <bold>e</bold> (between symptomatic <italic toggle="yes">C9orf72</italic> and symptomatic <italic toggle="yes">MAPT</italic>), <bold>f</bold> (between symptomatic <italic toggle="yes">C9orf72</italic> and presymptomatic <italic toggle="yes">GRN</italic>), <bold>g</bold> (between symptomatic <italic toggle="yes">C9orf72</italic> and presymptomatic <italic toggle="yes">MAPT</italic>), <bold>h</bold> (between presymptomatic <italic toggle="yes">GRN</italic> and symptomatic <italic toggle="yes">MAPT</italic>), <bold>i</bold> (between presymptomatic <italic toggle="yes">GRN</italic> and presymptomatic <italic toggle="yes">MAPT</italic>), <bold>j</bold> (between symptomatic <italic toggle="yes">GRN</italic> and symptomatic <italic toggle="yes">MAPT</italic>), and <bold>k</bold> (between symptomatic <italic toggle="yes">GRN</italic> and presymptomatic <italic toggle="yes">MAPT</italic>).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Kruskal&#8211;Wallis variance analysis was performed to compare adjusted WMH values across the three mutation cohorts and different disease stages (symptomatic and presymptomatic). Dunn's post&#8208;hoc test, a nonparametric pairwise multiple comparison test, was conducted to determine significant differences in adjusted WMH volume between mutation groups. A similar analysis was performed for adjusted WMH volumes in each of the eight lobes. All <italic toggle="yes">p</italic>&#8208;values reported in the manuscript are corrected for multiple comparisons with Bonferroni's method.</p><p>To rule out confounding influences on WMH, cardiovascular risk factors (stroke, hypertension, hypercholesterolemia, and diabetes) and history of traumatic brain injury were compared across mutation groups and controls (Table <xref rid="alz70695-supinfo-0001" ref-type="">S1</xref>). Since no significant differences were found, these risk factor variables were not included as covariates in the model.</p></sec><sec id="alz70695-sec-0140"><label>2.4</label><title>Temporal relationship analysis</title><p>After investigating the prevalence of WMH across distinct genetic groups, we aimed to determine the temporal sequence of WMH accumulation in relation to other key imaging biomarkers in groups exhibiting substantial WMH burden. In addition to lobar WMH and WMH of the whole brain, we included essential gray matter volumes and subcortical measures in FTD, i.e., frontal and temporal gray matter, cingulate, insula, cerebellum, basal ganglia (nucleus accumbens, caudate, putamen, and globus pallidus), hippocampus, amygdala, and thalamus, alongside additional biomarkers like ventricle volume, GFAP, and NfL for ranking.</p><sec id="alz70695-sec-0150"><label>2.4.1</label><title>Cross&#8208;sectional analysis using discriminative event&#8208;based modeling</title><p>We utilized the Discriminative Event&#8208;Based Modeling (DEBM) approach<xref rid="alz70695-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70695-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> to investigate the order of biomarker abnormalities in presymptomatic and symptomatic FTD. DEBM was well suited for our purpose because it requires only cross&#8208;sectional data and effectively handles missing values. In DEBM, an &#8220;event&#8221; refers to the transition of a biomarker from a normal to an abnormal state, with the total number of events in disease progression corresponding to the number of biomarkers. To ensure a more normalized distribution, blood biomarkers (NfL and GFAP), ventricle volume, and WMHs were log&#8208;transformed, effectively reducing skewness in their distributions. To control for confounding factors, the DEBM analysis incorporated sex and age by adjusting biomarker values based on these factors prior to Gaussian Mixture Modeling (GMM).</p><p>The DEBM procedure initially determines the distribution of normal and abnormal biomarker values through GMM. Using these distributions, it computes the probability for each participant that the biomarker is abnormal. This probability signifies the progression of that biomarker. Therefore, based on these probabilities, we create an approximate sequence of biomarker abnormality for each participant, which is aggregated across participants to create a robust central biomarker ordering that minimizes the sum of distances to all participant&#8208;wise orderings.</p><p>Healthy controls, presymptomatic carriers, and symptomatic carriers were treated as distinct diagnoses to effectively model the progression. The degree of uncertainty in biomarker ordering was assessed by estimating it for 100 independently sampled datasets using bootstrap resampling with replacement. The analysis included 480 participants with verified imaging biomarkers.</p><p>For the DEBM approach to be effectively applied, two key assumptions must be considered when selecting biomarkers:
<list list-type="order" id="alz70695-list-0003"><list-item><p>The biomarker must exhibit a statistically significant difference between the FTD and healthy control groups.</p></list-item><list-item><p>The Gaussian mixture model must be fitted appropriately, which we verified by calculating the mean squared error of the fitted distribution for each biomarker.</p></list-item></list>
</p><p>We rigorously assessed the accuracy of the Gaussian mixture model by calculating the mean squared error and visually inspecting the distribution. The limited sample size constrained the applicability of the DEBM approach to certain biomarkers. Biomarkers that did not meet these criteria were excluded from the DEBM analysis and subsequently evaluated using the longitudinal approach. This ensured the incorporation of only reliable biomarkers into the DEBM while allowing further investigation of excluded biomarkers through complementary methods. This integrated approach enabled us to maximize the utility of both cross&#8208;sectional and longitudinal data, providing a comprehensive understanding of biomarker dynamics.</p><p>To validate the accuracy of the model, we assessed the disease stage that the DEBM estimated for each individual. This was done by comparing the abnormality probabilities of biomarkers for each participant with the central biomarker ordering derived from the model. Two validation approaches were employed. First, we evaluated the model's performance by calculating the area under the curve (AUC) to differentiate between symptomatic carriers and healthy controls based on estimated disease stage using 10&#8208;fold cross&#8208;validation. Secondly, as a construct validation metric, we examined the correlation between the estimated disease stages and key clinical scores commonly used in FTD assessment. These included the Clinical Dementia Rating&#8208;Frontotemporal Lobar Degeneration Sum&#8208;of&#8208;Boxes (CDR&#8208;FTLD SoB), Mini&#8208;Mental State Examination (MMSE), Trail Making Test Part B (TMT&#8208;B), Boston Naming Test, Digit Symbol substitution test, and Verbal Fluency test. Non&#8208;parametric Spearman's rank correlation analyses were conducted to assess the relationships between the estimated disease stages and key clinical scores, given the non&#8208;normal distribution of the overall population on these metrics. These validation metrics allowed us to assess both the discriminative power and clinical relevance of the estimated disease stages.</p></sec><sec id="alz70695-sec-0160"><label>2.4.2</label><title>Longitudinal analysis using linear regression modeling</title><p>Subsequently, we conducted a longitudinal assessment focusing on the interplay between WMHs and other neuroimaging biomarkers that were not evaluated through DEBM analysis, specifically in <italic toggle="yes">GRN</italic> mutation carriers. These biomarkers include the insula, basal ganglia (nucleus accumbens, caudate, putamen, and globus pallidus), thalamus, hippocampus, amygdala, and cingulate volumes. The process involved standardizing each biomarker to a <italic toggle="yes">z</italic>&#8208;score by subtracting its mean and dividing by its standard deviation across the full dataset and employing linear regression models to predict the shift in each biomarker between baseline and follow&#8208;up measurements, with WMHs serving as either the predictor or the response biomarker in each model. This approach aimed to explore directional associations between WMH and atrophy, rather than to maximize prediction accuracy. The models were designed to account for potential influences from age, sex, education, NfL, and the baseline value of the response biomarker. NfL was included to control for individual differences in global disease activity that may confound MRI&#8208;based associations. The analysis was represented by Equation&#160;<xref rid="alz70695-disp-0002" ref-type="disp-formula">2</xref>:
<disp-formula id="alz70695-disp-0002"><label>(2)</label><mml:math id="jats-math-24" display="block"><mml:mrow><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mspace width="0.33em"/><mml:mi>Response</mml:mi><mml:mspace width="0.33em"/><mml:mi>biomarker</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mspace width="0.33em"/></mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mi>Predictor</mml:mi><mml:mspace width="0.33em"/><mml:mi>biomarke</mml:mi></mml:mrow><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mi>baseline</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo linebreak="badbreak">+</mml:mo><mml:mspace width="0.33em"/><mml:mrow><mml:mi>Age</mml:mi><mml:mspace width="0.33em"/></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mrow><mml:mspace width="0.33em"/><mml:mi>Sex</mml:mi></mml:mrow><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>NfL</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Education</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo linebreak="badbreak">+</mml:mo><mml:mspace width="0.33em"/><mml:mrow><mml:mi>Response</mml:mi><mml:mspace width="0.33em"/><mml:mi>biomarke</mml:mi></mml:mrow><mml:msub><mml:mi mathvariant="normal">r</mml:mi><mml:mi>baseline</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>Here, <mml:math id="jats-math-25" display="inline"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mspace width="0.33em"/><mml:mrow><mml:mi>Response</mml:mi><mml:mspace width="0.33em"/><mml:mi>biomarker</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mspace width="0.33em"/><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math> represents the predicted rate of change in the response biomarker between the baseline measurement and all subsequent follow&#8208;up evaluations. In our analysis, WMH volumes and NfL biomarkers were log&#8208;transformed to achieve a normal distribution.</p></sec></sec></sec><sec id="alz70695-sec-0170"><label>3</label><title>RESULTS</title><sec id="alz70695-sec-0180"><label>3.1</label><title>Participant demographics and clinical information</title><p>Table&#160;<xref rid="alz70695-tbl-0001" ref-type="table">1</xref> provides an overview of demographic and clinical data. The research included 298 family controls who did not carry the mutation. Among the 465 participants identified with mutations, <italic toggle="yes">C9orf72</italic> mutations were the most prevalent, affecting 44.3% of the group, followed by <italic toggle="yes">GRN</italic> mutations at 39.1% and <italic toggle="yes">MAPT</italic> mutations at 16.6%. Notably, 68% of these individuals were in the asymptomatic stage across the genetic variants mentioned. Among symptomatic participants, the predominant diagnosis was bvFTD, representing 66.4% of cases, with PPA at 16.8%, and amyotrophic lateral sclerosis (ALS) or FTD&#8208;ALS at 10.7%. The remaining 6.1% of cases were diagnosed with other clinical syndromes.</p><p>Demographic analyses confirmed that symptomatic mutation carriers were older and had received fewer years of education than both presymptomatic mutation carriers and control groups (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). <italic toggle="yes">MAPT</italic> mutation carriers and the control group were younger than those with the <italic toggle="yes">GRN</italic> mutation (<italic toggle="yes">MAPT</italic>: <italic toggle="yes">p</italic>&#160;=&#160;0.01; controls: <italic toggle="yes">p</italic>&#160;=&#160;0.001) and those carrying the <italic toggle="yes">C9orf72</italic> mutation (<italic toggle="yes">MAPT</italic>: <italic toggle="yes">p&#160;</italic>=&#160;0.002; controls: <italic toggle="yes">p&#160;</italic>&lt;&#160;0.001). Additionally, symptomatic <italic toggle="yes">C9orf72</italic> mutation carriers had fewer years of education compared to the control group (<italic toggle="yes">p</italic>&#160;=&#160;0.03). The gender ratio among symptomatic carriers also showed a higher proportion of males compared to the presymptomatic (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) and control groups (<italic toggle="yes">p</italic>&#160;=&#160;0.002). Moreover, the <italic toggle="yes">C9orf72</italic> symptomatic carrier cohort included a significantly higher proportion of males compared to <italic toggle="yes">GRN</italic> symptomatic carriers (<italic toggle="yes">p</italic>&#160;=&#160;0.02). Other demographic characteristics remained consistent across all groups. NfL samples were obtained from 78.64% of participants, and GFAP data were available for 61.86%.</p></sec><sec id="alz70695-sec-0190"><label>3.2</label><title>White matter hyperintensities across genetic groups</title><p>The WMH distribution maps in Figure&#160;<xref rid="alz70695-fig-0002" ref-type="fig">2</xref> depict the absolute prevalence and regional distribution of WMH across mutation groups on a voxel&#8208;wise basis. As expected, in all participants (including controls), WMHs are predominantly located in the periventricular regions, with a visually wider spatial extent in symptomatic participants.</p><fig position="float" fig-type="FIGURE" id="alz70695-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Voxel&#8208;wise distribution of white matter hyperintensity (WMH) prevalence in mutation groups. The color bar represents the proportion of participants within each cohort exhibiting WMHs at specific voxel locations.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70695-g005.jpg"/></fig><p>Figure&#160;<xref rid="alz70695-fig-0003" ref-type="fig">3</xref> presents the statistical comparisons of adjusted volumes of WMH, as described in the methods section. These values are log&#8208;transformed initially and then controlled for age and sex. For precise measures, refer to Tables <xref rid="alz70695-supinfo-0001" ref-type="">S2</xref> and <xref rid="alz70695-supinfo-0001" ref-type="">S3</xref> in the supplementary materials; these values depict the contrast of each cohort compared to the control group. Adjusted WMH volumes were significantly higher among all&#8208;group symptomatic mutation carriers as a group compared to controls (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;&lt;&#160;0.001, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.215). Specifically, post hoc testing showed that the effect was driven by symptomatic carriers with <italic toggle="yes">GRN</italic> mutations who exhibited markedly elevated whole&#8208;brain WMH volumes compared to controls (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;&lt;&#160;0.001, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.389), while the difference was not present for symptomatic <italic toggle="yes">C9orf72</italic> and <italic toggle="yes">MAPT</italic>. As illustrated in Figure <xref rid="alz70695-supinfo-0001" ref-type="">S1</xref>, some individuals in the <italic toggle="yes">MAPT</italic> group exhibited elevated WMH volumes; however, these values did not translate into statistically or clinically meaningful group&#8208;level effects. Among symptomatic cases, <italic toggle="yes">GRN</italic> carriers also showed higher WMH volumes compared to those with <italic toggle="yes">C9orf72</italic> mutations (<italic toggle="yes">p</italic>&#160;=&#160;0.035); however, this difference did not remain significant after Bonferroni correction. Within the <italic toggle="yes">GRN</italic> mutation carriers, a distinctive pattern emerged, as symptomatic cases exhibited higher WMH volumes than presymptomatic <italic toggle="yes">GRN</italic> cases (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.001, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.341), underscoring the progressive nature of WMH accumulation over the disease course. Aside from the <italic toggle="yes">GRN</italic> mutation carriers, no other significant differences in whole&#8208;brain adjusted WMH volumes were observed between the other mutation groups and controls or presymptomatic carriers.</p><fig position="float" fig-type="FIGURE" id="alz70695-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Regional and total white matter hyperintensity (WMH) volume across genetic groups. (A) Heatmap showing mean age&#8208; and sex&#8208;adjusted WMH volume (log&#8208;transformed) across brain regions and clinical/genetic subgroups. Values represent group&#8208;level averages of residualized WMH volumes. (B) Violin plots of total age&#8208; and sex&#8208;adjusted WMH volume (log&#8208;transformed) across mutation groups and controls, stratified by clinical status. Black horizontal bars indicate group means. Among symptomatic individuals, <italic toggle="yes">GRN</italic> carriers exhibited significantly higher WMH volumes compared to controls (<italic toggle="yes">P</italic>
<sub>Bonferroni&#160;</sub>&lt;&#160;0.001); no other between&#8208;group differences reached statistical significance. Full statistical results are reported in Tables <xref rid="alz70695-supinfo-0001" ref-type="">S4</xref> and <xref rid="alz70695-supinfo-0001" ref-type="">S5</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70695-g006.jpg"/></fig><p>Examination of WMH volumes per lobe revealed that the frontal lobe was the most prominent site of accumulation. Notably, symptomatic carriers demonstrated a marked increase in adjusted WMHs compared to healthy controls in both the left frontal lobe (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;&lt;&#160;0.001, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.26) and the right frontal lobe (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;&lt;&#160;0.001, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.214). Symptomatic <italic toggle="yes">GRN</italic> carriers exhibited substantially elevated WMHs in the left frontal lobe compared to controls (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;&lt;&#160;0.001, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.469) and symptomatic <italic toggle="yes">C9orf72</italic> (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.019, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.299). Additionally, WMH volumes in the left frontal lobe were significantly higher in symptomatic <italic toggle="yes">GRN</italic> carriers than in their presymptomatic counterparts (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;&lt;&#160;0.001, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.406).</p><p>A stepwise pattern of WMH increase was observed in the left frontal lobe across disease progression: presymptomatic carriers had higher WMH volumes than controls (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.036, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.118), and symptomatic carriers showed higher volumes than presymptomatic carriers (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.035, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.147). Moreover, presymptomatic <italic toggle="yes">C9orf72</italic> carriers exhibited slightly higher WMH volumes in the left frontal lobe compared to controls (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.027, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.164).</p><p>The pattern was also present in the right frontal lobe, where symptomatic <italic toggle="yes">GRN</italic> mutation carriers exhibited heightened WMHs compared to controls (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;&lt;&#160;0.001, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.341) and presymptomatic <italic toggle="yes">GRN</italic> carriers (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.009, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.297). There was an unexpected trend for high WMHs in the left occipital lobe of presymptomatic individuals across all genetic groups compared to controls (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.039, <italic toggle="yes">&#948;&#160;</italic>=&#160;0.115). This effect was primarily driven by presymptomatic <italic toggle="yes">C9orf72</italic> carriers (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.039, <italic toggle="yes">&#948;&#160;</italic>=&#160;0.15). Elevated WMH volumes were also detected in the right parietal lobe of symptomatic carriers compared to controls (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.017, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.157), particularly among those with <italic toggle="yes">GRN</italic> mutations (<italic toggle="yes">P</italic>
<sub>Bonferroni</sub>&#160;=&#160;0.028, <italic toggle="yes">&#948;</italic>&#160;=&#160;0.242). A complete list of these comparisons is provided in Tables <xref rid="alz70695-supinfo-0001" ref-type="">S4</xref> and <xref rid="alz70695-supinfo-0001" ref-type="">S5</xref> of the supplementary materials.</p><p>We found no significant differences in adjusted WMH volume across clinical phenotypes (bvFTD, PPA, and ALS); see Tables <xref rid="alz70695-supinfo-0001" ref-type="">S6</xref> and&#160;<xref rid="alz70695-sec-0240" ref-type="sec">S7</xref> and Figure <xref rid="alz70695-supinfo-0001" ref-type="">S2</xref> for details. As a final step, we explored the possibility of testing per <italic toggle="yes">GRN</italic> mutation subtype. The number of cases per subtype of <italic toggle="yes">GRN</italic> mutation was too small to compare prevalence across them, but we provide the adjusted level of WMH per mutation subtype in Figure <xref rid="alz70695-supinfo-0001" ref-type="">S3</xref>.</p></sec><sec id="alz70695-sec-0200"><label>3.3</label><title>Biomarker dynamics in <italic toggle="yes">GRN</italic> cohort</title><sec id="alz70695-sec-0210"><label>3.3.1</label><title>Temporal cascade of biomarker abnormalities</title><p>Since <italic toggle="yes">GRN</italic> mutation carriers were clearly the most prominent group with a significant amount of WMHs, particularly in the frontal lobe, we focused our analysis on this cohort. We examined the temporal relationships among WMHs in the frontal lobe, WMHs in the temporal lobe, WMHs in the parietal lobe, total WMHs, and other key neuroimaging biomarkers in FTD. These included frontal and temporal gray matter, insula, cerebellum, basal ganglia, thalamus, hippocampus, amygdala, and cingulate, as well as additional biomarkers, including ventricle volume, GFAP, and NfL. All of these biomarkers exhibited significant differences between FTD and control groups (as reported in Table <xref rid="alz70695-supinfo-0001" ref-type="">S8</xref>). Of these, nine biomarkers met the criteria for DEBM analysis, which required both significant group differences and adequate Gaussian mixture model fitting as assessed by the mean squared error of the Gaussian mixture model distributions (Table <xref rid="alz70695-supinfo-0001" ref-type="">S9</xref>). These nine biomarkers included WMHs in the frontal lobe, WMHs in the temporal lobe, total WMHs, ventricle volume, cerebellum, frontal and temporal gray matter, and levels of GFAP and NfL. The DEBM analysis was performed on this subset of biomarkers to delineate their sequence of abnormalities and associated uncertainties in <italic toggle="yes">GRN</italic>&#8208;associated FTD, as depicted in Figure&#160;<xref rid="alz70695-fig-0004" ref-type="fig">4</xref>. This variability was measured through 100 bootstrapping iterations (with replacement).</p><fig position="float" fig-type="FIGURE" id="alz70695-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Sequence of biomarker abnormalities. The positional variance diagram for the <italic toggle="yes">GRN</italic> cohort illustrates the most probable sequence of biomarker abnormalities along with their corresponding uncertainties. The <italic toggle="yes">y</italic>&#8208;axis (from top to bottom) orders the biomarkers by the most likely sequence as estimated by the Discriminative Event&#8208;Based Modeling model, while the <italic toggle="yes">x</italic>&#8208;axis indicates the position of each biomarker in the sequence, ranging from one to the total number of biomarkers. The color intensity of each square represents the frequency with which a biomarker was placed at a specific position during bootstrap resampling. The spread from bootstrap resampling reflects the standard error of the distribution, representing the uncertainty in the estimated ordering. GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; WMH, white matter hyperintensity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70695-g001.jpg"/></fig><p>According to the findings depicted in Figure&#160;<xref rid="alz70695-fig-0004" ref-type="fig">4</xref>, WMH abnormalities emerged at earlier disease stages compared to other studied neuroimaging biomarkers. This initial phase of WMH changes was followed by abnormalities in ventricular size and NfL levels, which were subsequently succeeded by gray matter atrophy in the temporal and frontal lobes.</p></sec><sec id="alz70695-sec-0220"><label>3.3.2</label><title>Validation of disease stage estimation</title><p>The accuracy of estimated event ordering, validated through disease stage differentiation between symptomatic carriers and healthy controls, demonstrates robust clustering ability. This was reflected in high AUC values for distinguishing controls from <italic toggle="yes">GRN</italic> mutation carriers, with an AUC of 0.92&#160;&#177;&#160;0.05. Further validation is provided by the strong correlation between estimated disease stages and clinical scores (including CDR&#8208;FTLD SoB, MMSE, TMT&#8208;B, Boston Naming Test, Digit Symbol, and VF), as detailed in Table <xref rid="alz70695-supinfo-0001" ref-type="">S10</xref>.</p></sec></sec><sec id="alz70695-sec-0230"><label>3.4</label><title>Longitudinal study in <italic toggle="yes">GRN</italic> mutation carriers</title><p>To further investigate the temporal relationships among biomarkers that were not included in the DEBM analysis, we conducted a longitudinal assessment focusing on <italic toggle="yes">GRN</italic> mutation carriers. This analysis explored the dynamic interplay between WMHs and other neuroimaging biomarkers, including the insula, basal ganglia (nucleus accumbens, caudate, putamen, and globus pallidus), thalamus, hippocampus, amygdala, and cingulate volumes. By quantifying <italic toggle="yes">z</italic>&#8208;scores for each biomarker and employing linear regression models, we assessed whether changes in WMHs predicted alterations in these subcortical regions or vice versa over time. The longitudinal analysis encompassed 83 participants (70 presymptomatic and 13 symptomatic <italic toggle="yes">GRN</italic> carriers) who had follow&#8208;up scans, enabling us to better understand how WMH changes correlate with downstream neurodegeneration. Demographic and biomarker characteristics of the longitudinal cohort are summarized in Table <xref rid="alz70695-supinfo-0001" ref-type="">S11</xref>.</p><p>The estimated parameters of each model are reported in Table <xref rid="alz70695-supinfo-0001" ref-type="">S12</xref> and <xref rid="alz70695-supinfo-0001" ref-type="">S13</xref>. Figure&#160;<xref rid="alz70695-fig-0005" ref-type="fig">5A</xref>, generated using the circlize package in R,<xref rid="alz70695-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> displays the <italic toggle="yes">t</italic>&#8208;statistics for all associations, regardless of significance, among the neuroimaging biomarkers identified in our analysis. Figure&#160;<xref rid="alz70695-fig-0005" ref-type="fig">5B</xref> focuses on significant associations (FDR corrected <italic toggle="yes">p</italic>&#8208;value&#160;&lt;&#160;0.05), where a line connecting the baseline of a predictor biomarker on the left to the rate of change of a response biomarker on the right indicates that the predictor biomarker has predictive value for explaining variations in the response biomarker over time.</p><fig position="float" fig-type="FIGURE" id="alz70695-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Associations between white matter hyperintensity (WMH) and subcortical biomarkers and predictability of longitudinal variations. Diagrams illustrate the associations between predictor biomarkers (left side) and the rate of change of response biomarkers (right side). The width of the connecting lines represents the <italic toggle="yes">t</italic>&#8208;statistic, indicating the strength of the predictive association. (A) Chord diagram showing <italic toggle="yes">t</italic>&#8208;statistics for all tests, including both significant and non&#8208;significant associations. (B) Diagram displaying only the significant associations (FDR&#8208;corrected <italic toggle="yes">p</italic> value&#160;&lt;&#160;0.05). Higher baseline WMH volumes are associated with faster volume decline in the amygdala, hippocampus, and cingulate cortex.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ALZ-21-e70695-g002.jpg"/></fig><p>The results shown in Figure&#160;<xref rid="alz70695-fig-0005" ref-type="fig">5B</xref> indicate that baseline WMH volumes predict subsequent brain changes. Higher baseline WMH volumes were associated with a more rapid decrease in amygdala volume (<italic toggle="yes">p</italic>&#160;=&#160;0.006, FDR&#8208;corrected <italic toggle="yes">p</italic>&#160;=&#160;0.038), accelerated hippocampal atrophy (<italic toggle="yes">p</italic>&#160;=&#160;0.023, FDR&#8208;corrected <italic toggle="yes">p</italic>&#160;=&#160;0.050), and faster cingulate volume reduction (<italic toggle="yes">p</italic>&#160;=&#160;0.025, FDR&#8208;corrected <italic toggle="yes">p</italic>&#160;=&#160;0.050). Figure&#160;<xref rid="alz70695-fig-0006" ref-type="fig">6</xref> presents scatter plots for these significant associations, showing the relationship between baseline WMH burden and rates of subcortical volume decline, with regression lines and 95% confidence intervals highlighting the observed trends. Interestingly, none of the studied subcortical biomarkers (thalamus, basal ganglia, amygdala, hippocampus, cingulate, and insula) were found to predict variations in WMH volumes. Our results underscore that WMHs are significant predictors of greater gray matter loss over time, emphasizing the impactful role of WMHs on brain structure changes.</p><fig position="float" fig-type="FIGURE" id="alz70695-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Relationship of baseline WMH volume to subsequent subcortical atrophy progression. Each scatter plot corresponds to one of the significant associations identified in Figure&#160;<xref rid="alz70695-fig-0005" ref-type="fig">5B</xref>, with baseline WMH volume (log&#8208;transformed and <italic toggle="yes">z</italic>&#8208;scored across the full cohort) on the <italic toggle="yes">x</italic>&#8208;axis and the annualized rate of change in subcortical volume (total intracranial volume&#8208;normalized and <italic toggle="yes">z</italic>&#8208;scored prior to slope estimation) on the <italic toggle="yes">y</italic>&#8208;axis. Linear regression lines with 95% confidence intervals illustrate the relationships.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ALZ-21-e70695-g004.jpg"/></fig></sec></sec><sec id="alz70695-sec-0240"><label>4</label><title>DISCUSSION</title><p>Our investigation into WMHs across genetic groups in the context of FTD revealed intriguing patterns. Notably, symptomatic <italic toggle="yes">GRN</italic> mutation carriers exhibited the most pronounced WMH burden after adjusting for age and sex, with a spatial distribution concentrated in the frontal lobes and, secondarily, in parietal areas. While not present in all patients, WMHs in the <italic toggle="yes">GRN</italic> cohort followed a consistent temporal pattern, emerging early in the disease course and preceding frontal and temporal cortical atrophy. Additionally, we observed modest but significant WMH increases in the left frontal and occipital lobes of presymptomatic <italic toggle="yes">C9orf72</italic> carriers, suggesting subtle early changes in this group, but these did not translate into increased WMH burden at the symptomatic stage. Finally, although some individuals with <italic toggle="yes">MAPT</italic> mutations showed elevated WMHs, these did not result in significant group&#8208;level effects. Collectively, our findings emphasize the distinct prominence of WMHs in <italic toggle="yes">GRN</italic>&#8208;associated FTD.</p><p>Our results underscore the specific association of WMHs with the <italic toggle="yes">GRN</italic> mutation in genetic FTD. This finding is in line with Sudre et&#160;al.,<xref rid="alz70695-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70695-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> who also observed a similar association in a study conducted on the previous smaller GENFI data release. Patients with <italic toggle="yes">GRN</italic> mutations are deficient in progranulin, a protein that plays a crucial role in regulating the growth and survival of brain cells. There is a well&#8208;documented link between progranulin deficiency and neuroinflammation,<xref rid="alz70695-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70695-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> and neuroinflammation is implicated in the pathogenesis of WMHs.<xref rid="alz70695-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> This observation prompts a deeper exploration of how neuroinflammation contributes to the formation of WMH in the context of <italic toggle="yes">GRN</italic>&#8208;associated FTD, providing a potential avenue for targeted therapeutic interventions.</p><p>Our DEBM analysis elucidates a sequential pattern of biomarker abnormalities in <italic toggle="yes">GRN</italic>&#8208;associated FTD, beginning with abnormalities in WMHs. These early indicators of disease progression are subsequently followed by ventricular abnormalities and alterations in NfL levels, eventually leading to measurable temporal and frontal gray matter atrophy in later stages. This trajectory highlights the pivotal role of WMHs in understanding <italic toggle="yes">GRN</italic>&#8208;associated FTD progression.</p><p>Our longitudinal analysis of <italic toggle="yes">GRN</italic> carriers reveals a noteworthy association between the initial volume of WMHs and subsequent reductions in gray matter volume across several critical brain regions, including the amygdala, hippocampus, and cingulate. This observation underscores the association between baseline WMHs and future neurological deterioration, characterized by pronounced atrophy within these areas. Conversely, our study found no evidence to suggest that alterations in subcortical biomarkers could serve as predictors for changes in WMH volume. Given the directional relationship observed, our study suggests that WMHs might precede the atrophy of gray matter, a conclusion that finds resonance in what was found in several studies of Alzheimer's disease.<xref rid="alz70695-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70695-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz70695-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</p><p>Furthermore, our analysis indicates that NfL abnormalities precede frontal and temporal lobe atrophy, echoing the findings of Panman et&#160;al.<xref rid="alz70695-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> and Staffaroni et&#160;al.,<xref rid="alz70695-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> who identified NfL as an early abnormal biomarker in the <italic toggle="yes">GRN</italic> mutation group, preceding changes in gray matter volumes, white matter microstructures, and cognitive markers. While Panman et&#160;al.<xref rid="alz70695-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> identified NfL as the earliest biomarker among the key markers they investigated in FTD, their study did not include WMHs. In contrast, our findings suggest that WMHs may precede even NfL abnormalities, indicating that WMHs could represent the earliest detectable biomarker in <italic toggle="yes">GRN</italic>&#8208;associated FTD.</p><p>We also observed that abnormalities in GFAP manifested in the late stages of the disease, while abnormalities in NfL appeared earlier. This finding is consistent with the sequence of fluid biomarkers in FTD reported by van der Ende et&#160;al.<xref rid="alz70695-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>The current paradigm for modeling disease progression in genetic FTD due to <italic toggle="yes">GRN</italic> mutation may benefit from integrating WMHs into existing frameworks. Our DEBM and longitudinal analysis findings indicate early white matter disruption in FTD. A prior study by McKenna et&#160;al.<xref rid="alz70695-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> highlighted alterations in white matter as relatively precise and early radiological markers, particularly effective in differentiating presymptomatic mutation carriers from healthy controls. Incorporating WMHs into disease models may offer a more comprehensive understanding of the progression from presymptomatic to symptomatic stages, shedding light on the nuanced temporal dynamics of WMH accumulation in the context of genetic FTD.</p><p>Our findings align with neuropathological evidence showing early white matter involvement in FTLD&#8208;<italic toggle="yes">GRN</italic>. A recent study found severe frontal myelin loss in <italic toggle="yes">GRN</italic> mutation carriers, independent of axonal degeneration, suggesting a primary myelin defect.<xref rid="alz70695-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> This supports our observation that WMHs appear earlier than cortical atrophy and NfL changes. Their findings also implicate microglial dysfunction and TMEM106B pathology, highlighting distinct pathogenic mechanisms and reinforcing the value of white matter biomarkers in disease staging and therapy monitoring.</p><p>In our analyses, we did not find laterality differences in <italic toggle="yes">GRN</italic> mutations at the group level (Table <xref rid="alz70695-supinfo-0001" ref-type="">S14</xref>). However, it is likely that at the individual level, some subjects have predominant right&#8208; or left&#8208;sided changes, which might relate to symptomatic presentation.<xref rid="alz70695-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>It is essential to acknowledge certain limitations in our study. One limitation is that we used cortical volume as a measure of gray matter atrophy, which might not be as sensitive to subtle gray matter changes as cortical surface&#8208;based measures. Additionally, the age difference between groups, where presymptomatic cases were generally younger than symptomatic ones, represents a limitation that could bias our comparisons. Given the small size of FTD datasets, balancing our groups by exclusion was not feasible. However, we accounted for age in all our analyses and modeling as a confounding factor and attempted to regress out its impact. By doing so, we aimed to minimize potential age&#8208;related biases in our results. To further address this concern, we performed two complementary sensitivity analyses to improve age comparability between symptomatic carriers and controls. These analyses (detailed in Tables <xref rid="alz70695-supinfo-0001" ref-type="">S15</xref> and <xref rid="alz70695-supinfo-0001" ref-type="">S16</xref>) used both nearest&#8208;neighbor matching and group&#8208;level age restriction approaches. In both cases, <italic toggle="yes">GRN</italic> carriers continued to show significantly elevated WMH volumes compared to age&#8208;matched controls, confirming that this key result is not driven by age imbalance.</p><p>Another limitation involves scanner&#8208;related variability inherent in multisite studies such as GENFI. Despite efforts to harmonize acquisition protocols across sites, residual differences in scanner hardware, software, or upgrades may still influence WMH quantification. We were not able to fully account for this variability due to small sample sizes at many sites; however, unmeasured scanner&#8208;specific effects may persist and could partially impact our results.</p><p>It should be mentioned that presymptomatic cases in GENFI could include some participants with minimal or ambiguous symptoms compatible with a prodrome of FTD; however, 79.3% of cases had a confirmed CDR&#8208;FTLD SoB of 0.</p><p>Another important limitation is the relatively small number of symptomatic cases, particularly when compared to studies applying DEBM to diseases such as Alzheimer's disease. This smaller sample size may contribute to challenges in GMM, including occasional instability in biomarker modeling. Such instability is influenced, in part, by the overlap between normal and abnormal Gaussian distributions, which becomes more pronounced when samples with abnormal biomarker values are limited. However, our study represents one of the largest cohorts available for FTD research, surpassing the size of previous reports and enhancing the reliability and generalizability of our findings.</p><p>Our DEBM results in <italic toggle="yes">GRN</italic> suggest that WMHs may precede, on average, changes in other biomarkers such as NfL or atrophy. While we did not perform detailed analyses of presymptomatic trajectories for biomarkers other than WMHs, these findings highlight the potential challenge of identifying presymptomatic <italic toggle="yes">GRN</italic> carriers at imminent risk of phenoconversion for clinical trials. This pattern contrasts with some prior models in other diseases, such as Alzheimer's disease, and underscores the heterogeneity in biomarker dynamics across neurodegenerative syndromes.</p><p>While many neuroimaging biomarkers could be explored, we focused on a curated list identified in the literature as relevant to FTD. Notably, in DEBM, adding more biomarkers can reduce certainty in the event order, emphasizing the need for deliberate selection.</p><p>Our study boasts several strengths that contribute to the robustness of our findings in addition to the larger number of participants compared to previous reports. The quality of our WMH pipeline, which remains robust across multisite data acquisition and functions effectively without the need for Fluid&#8208;Attenuated Inversion Recovery MRI modality, further solidifies the reliability of our WMH measurements. The application of a robust event&#8208;based modeling approach, resilient to missing values, provides a comprehensive understanding of the sequencing of biomarker abnormalities across different mutation groups.</p><p>In conclusion, our study not only contributes valuable insights into the distribution and dynamics of WMH in genetic FTD but also highlights the potential role of WMHs in refining disease progression models in <italic toggle="yes">GRN</italic> mutations. It will be important to uncover the pathological differences explaining why some <italic toggle="yes">GRN</italic> carriers develop more WMHs than others. Further research in this direction may uncover novel avenues for therapeutic interventions targeting neuroinflammatory processes associated with WMHs in genetic FTD.</p></sec><sec sec-type="COI-statement" id="alz70695-sec-0260"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors report no conflicts of interest. Author disclosures are available in the <xref rid="alz70695-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70695-sec-0270"><title>CONSENT STATEMENT</title><p>This study received the approval of the McGill University Health Centre review ethics board (MP&#8208;20&#8208;2016&#8208;2500), and all data&#8208;collecting sites obtained their local board approval. Written informed consent was obtained from all participants, and the research was conducted according to the ethical principles outlined in the Declaration of Helsinki.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70695-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70695-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70695-s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70695-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70695-s002.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70695-sec-0250"><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank all participants and their families for taking part in the GENFI study. This study was supported by multiple funding sources. S.D. receives salary funding from the Fond de Recherche du Qu&#233;bec&#8212;Sant&#233; (FRQS). GENFI2 is funded by the Canadian Institutes for Health Research. J.B.R. is supported by the Medical Research Council (MC_UU_00030/14; MR/T033371/1), Wellcome Trust (220258), and the National Institute for Health and Care Research Cambridge Biomedical Research Centre (NIHR203312: the views expressed are those of the authors and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care). M.M., E.F., S.D., and R.L. Jr. have received funding from two Canadian Institutes of Health Research project grants (MOP&#8208;327387 and PJT&#8208;175242) and from the Weston Brain Institute for the conduct of this study.</p></ack><sec sec-type="data-availability" id="alz70695-sec-0290"><title>DATA AVAILABILITY STATEMENT</title><p>The data used in this study are part of the GENFI dataset and can be accessed upon reasonable request through the study website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.genfi.org" ext-link-type="uri" specific-use="software is-supplemented-by">www.genfi.org</ext-link>), subject to review and approval by the GENFI data access committee.</p></sec><ref-list id="alz70695-bibl-0001"><title>REFERENCES</title><ref id="alz70695-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70695-cite-0002"><string-name name-style="western"><surname>Ratnavalli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Brayne</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hodges</surname><given-names>JR</given-names></string-name>. <article-title>The prevalence of frontotemporal dementia</article-title>. <source>Neurology</source>. <year>2002</year>;<volume>58</volume>(<issue>11</issue>):<fpage>1615</fpage>&#8208;<lpage>1621</lpage>. .<pub-id pub-id-type="pmid">12058088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.58.11.1615</pub-id></mixed-citation></ref><ref id="alz70695-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70695-cite-0003"><string-name name-style="western"><surname>Greaves</surname><given-names>CV</given-names></string-name>, <string-name name-style="western"><surname>Rohrer</surname><given-names>JD</given-names></string-name>. <article-title>An update on genetic frontotemporal dementia</article-title>. <source>J Neurol</source>. <year>2019</year>;<volume>266</volume>(<issue>8</issue>):<fpage>2075</fpage>&#8208;<lpage>2086</lpage>. .<pub-id pub-id-type="pmid">31119452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-019-09363-4</pub-id><pub-id pub-id-type="pmcid">PMC6647117</pub-id></mixed-citation></ref><ref id="alz70695-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70695-cite-0004"><string-name name-style="western"><surname>Alber</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alladi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>HJ</given-names></string-name>, et&#160;al. <article-title>White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): knowledge gaps and opportunities</article-title>. <source>Alzheimer's Dement (N Y)</source>. <year>2019</year>;<volume>5</volume>:<fpage>107</fpage>&#8208;<lpage>117</lpage>. .<pub-id pub-id-type="pmid">31011621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2019.02.001</pub-id><pub-id pub-id-type="pmcid">PMC6461571</pub-id></mixed-citation></ref><ref id="alz70695-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70695-cite-0005"><string-name name-style="western"><surname>Hu</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>YN</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>XN</given-names></string-name>, et&#160;al. <article-title>White matter hyperintensities and risks of cognitive impairment and dementia: a systematic review and meta&#8208;analysis of 36 prospective studies</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2021</year>;<volume>120</volume>:<fpage>16</fpage>&#8208;<lpage>27</lpage>.<pub-id pub-id-type="pmid">33188821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2020.11.007</pub-id></mixed-citation></ref><ref id="alz70695-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70695-cite-0006"><string-name name-style="western"><surname>Abraham</surname><given-names>HMA</given-names></string-name>, <string-name name-style="western"><surname>Wolfson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Moscufo</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Guttmann</surname><given-names>CRG</given-names></string-name>, <string-name name-style="western"><surname>Kaplan</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>WB</given-names></string-name>. <article-title>Cardiovascular risk factors and small vessel disease of the brain: blood pressure, white matter lesions, and functional decline in older persons</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2016</year>;<volume>36</volume>(<issue>1</issue>):<fpage>132</fpage>&#8208;<lpage>142</lpage>.<pub-id pub-id-type="pmid">26036933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2015.121</pub-id><pub-id pub-id-type="pmcid">PMC4758547</pub-id></mixed-citation></ref><ref id="alz70695-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70695-cite-0007"><string-name name-style="western"><surname>Shirzadi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Yau</surname><given-names>WYW</given-names></string-name>, et&#160;al. <article-title>Etiology of white matter hyperintensities in autosomal dominant and sporadic Alzheimer disease</article-title>. <source>JAMA Neurol</source>. <year>2023</year>;<volume>80</volume>(<issue>12</issue>):<fpage>1353</fpage>&#8208;<lpage>1363</lpage>.<pub-id pub-id-type="pmid">37843849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.3618</pub-id><pub-id pub-id-type="pmcid">PMC10580156</pub-id></mixed-citation></ref><ref id="alz70695-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70695-cite-0008"><string-name name-style="western"><surname>Sudre</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Bocchetta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cash</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort</article-title>. <source>NeuroImage Clin</source>. <year>2017</year>;<volume>15</volume>:<fpage>171</fpage>&#8208;<lpage>180</lpage>.<pub-id pub-id-type="pmid">28529873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2017.04.015</pub-id><pub-id pub-id-type="pmcid">PMC5429247</pub-id></mixed-citation></ref><ref id="alz70695-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70695-cite-0009"><string-name name-style="western"><surname>Sudre</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Bocchetta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Heller</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>White matter hyperintensities in progranulin&#8208;associated frontotemporal dementia: a longitudinal GENFI study</article-title>. <source>NeuroImage Clin</source>. <year>2019</year>;<volume>24</volume>:<elocation-id>102077</elocation-id>.<pub-id pub-id-type="pmid">31835286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2019.102077</pub-id><pub-id pub-id-type="pmcid">PMC6911860</pub-id></mixed-citation></ref><ref id="alz70695-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70695-cite-0010"><string-name name-style="western"><surname>Panman</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Jiskoot</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Bouts</surname><given-names>MJRJ</given-names></string-name>, et&#160;al. <article-title>Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study</article-title>. <source>Neurobiol Aging</source>. <year>2019</year>;<volume>76</volume>:<fpage>115</fpage>&#8208;<lpage>124</lpage>. .<pub-id pub-id-type="pmid">30711674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2018.12.017</pub-id></mixed-citation></ref><ref id="alz70695-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70695-cite-0011"><string-name name-style="western"><surname>Staffaroni</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Quintana</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wendelberger</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Temporal order of clinical and biomarker changes in familial frontotemporal dementia</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>(<issue>10</issue>):<fpage>2194</fpage>&#8208;<lpage>2206</lpage>. .<pub-id pub-id-type="pmid">36138153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01942-9</pub-id><pub-id pub-id-type="pmcid">PMC9951811</pub-id></mixed-citation></ref><ref id="alz70695-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70695-cite-0012"><string-name name-style="western"><surname>Rohrer</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Nicholas</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Cash</surname><given-names>DM</given-names></string-name>, et&#160;al. <article-title>Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross&#8208;sectional analysis</article-title>. <source>Lancet Neurol</source>. <year>2015</year>;<volume>14</volume>(<issue>3</issue>):<fpage>253</fpage>&#8208;<lpage>262</lpage>..<pub-id pub-id-type="pmid">25662776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(14)70324-2</pub-id><pub-id pub-id-type="pmcid">PMC6742501</pub-id></mixed-citation></ref><ref id="alz70695-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70695-cite-0013"><string-name name-style="western"><surname>Wilke</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Reich</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van Swieten</surname><given-names>JC</given-names></string-name>, et&#160;al. <article-title>Stratifying the presymptomatic phase of genetic frontotemporal dementia by serum NfL and pNfH: a longitudinal multicentre study</article-title>. <source>Ann Neurol</source>. <year>2022</year>;<volume>91</volume>(<issue>1</issue>):<fpage>33</fpage>&#8208;<lpage>47</lpage>.<pub-id pub-id-type="pmid">34743360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26265</pub-id></mixed-citation></ref><ref id="alz70695-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70695-cite-0014"><string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DL</given-names></string-name>. <article-title>BISON: brain tissue segmentation pipeline using T1 &#8208;weighted magnetic resonance images and a random forest classifier</article-title>. <source>Magn Reson Med</source>. <year>2021</year>;<volume>85</volume>(<issue>4</issue>):<fpage>1881</fpage>&#8208;<lpage>1894</lpage>.<pub-id pub-id-type="pmid">33040404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.28547</pub-id></mixed-citation></ref><ref id="alz70695-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70695-cite-0015"><string-name name-style="western"><surname>Fernandez&#8208;Lozano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>QRATER: a collaborative and centralized imaging quality control web&#8208;based application</article-title>. <source>Aperture Neuro</source>. <year>2024</year>;<volume>4</volume>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.52294/001c.118616</pub-id><pub-id pub-id-type="pmcid">PMC12363495</pub-id><pub-id pub-id-type="pmid">40837456</pub-id></mixed-citation></ref><ref id="alz70695-bib-0015"><label>15</label><mixed-citation publication-type="miscellaneous" id="alz70695-cite-0016"><string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <article-title>Hammers Atlas Registered to ICBM</article-title>. Published online <year>2023</year>. doi:<pub-id pub-id-type="doi">10.5281/zenodo.7930159</pub-id></mixed-citation></ref><ref id="alz70695-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70695-cite-0017"><string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maranzano</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Misquitta</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Performance comparison of 10 different classification techniques in segmenting white matter hyperintensities in aging</article-title>. <source>NeuroImage</source>. <year>2017</year>;<volume>157</volume>:<fpage>233</fpage>&#8208;<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.06.009</pub-id><pub-id pub-id-type="pmid">28602597</pub-id><pub-id pub-id-type="pmcid">PMC6469398</pub-id></mixed-citation></ref><ref id="alz70695-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70695-cite-0018"><string-name name-style="western"><surname>Cardoso</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Modat</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wolz</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Geodesic information flows: spatially&#8208;variant graphs and their application to segmentation and fusion</article-title>. <source>IEEE Trans Med Imaging</source>. <year>2015</year>;<volume>34</volume>(<issue>9</issue>):<fpage>1976</fpage>&#8208;<lpage>1988</lpage>. doi:<pub-id pub-id-type="doi">10.1109/TMI.2015.2418298</pub-id><pub-id pub-id-type="pmid">25879909</pub-id></mixed-citation></ref><ref id="alz70695-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70695-cite-0019"><string-name name-style="western"><surname>Meeter</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Kaat</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Rohrer</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>van Swieten</surname><given-names>JC</given-names></string-name>. <article-title>Imaging and fluid biomarkers in frontotemporal dementia</article-title>. <source>Nat Rev Neurol</source>. <year>2017</year>;<volume>13</volume>(<issue>7</issue>):<fpage>406</fpage>&#8208;<lpage>419</lpage>.<pub-id pub-id-type="pmid">28621768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2017.75</pub-id></mixed-citation></ref><ref id="alz70695-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70695-cite-0020"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kumfor</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Landin&#8208;Romero</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Irish</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Piguet</surname><given-names>O</given-names></string-name>. <article-title>The cerebellum in frontotemporal dementia: a meta&#8208;analysis of neuroimaging studies</article-title>. <source>Neuropsychol Rev</source>. <year>2019</year>;<volume>29</volume>(<issue>4</issue>):<fpage>450</fpage>&#8208;<lpage>464</lpage>. .<pub-id pub-id-type="pmid">31428914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11065-019-09414-7</pub-id></mixed-citation></ref><ref id="alz70695-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70695-cite-0021"><string-name name-style="western"><surname>Bocchetta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Todd</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Peakman</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Differential early subcortical involvement in genetic FTD within the GENFI cohort</article-title>. <source>NeuroImage Clin</source>. <year>2021</year>;<volume>30</volume>:<elocation-id>102646</elocation-id>. .<pub-id pub-id-type="pmid">33895632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2021.102646</pub-id><pub-id pub-id-type="pmcid">PMC8099608</pub-id></mixed-citation></ref><ref id="alz70695-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70695-cite-0022"><string-name name-style="western"><surname>Kamalian</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Khodadadifar</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Saberi</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Convergent regional brain abnormalities in behavioral variant frontotemporal dementia: a neuroimaging meta&#8208;analysis of 73 studies</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<elocation-id>e12318</elocation-id>. .<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12318</pub-id><pub-id pub-id-type="pmcid">PMC9148620</pub-id><pub-id pub-id-type="pmid">35664889</pub-id></mixed-citation></ref><ref id="alz70695-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70695-cite-0023"><string-name name-style="western"><surname>Venkatraghavan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bron</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Niessen</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>S</given-names></string-name>. <article-title>Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling</article-title>. <source>NeuroImage</source>. <year>2019</year>;<volume>186</volume>:<fpage>518</fpage>&#8208;<lpage>532</lpage>. .<pub-id pub-id-type="pmid">30471388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2018.11.024</pub-id></mixed-citation></ref><ref id="alz70695-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70695-cite-0024"><string-name name-style="western"><surname>Panman</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Venkatraghavan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>van der Ende</surname><given-names>EL</given-names></string-name>, et&#160;al. <article-title>Modelling the cascade of biomarker changes in <italic toggle="yes">GRN</italic> &#8208;related frontotemporal dementia</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2021</year>;<volume>92</volume>(<issue>5</issue>):<fpage>494</fpage>&#8208;<lpage>501</lpage>. .<pub-id pub-id-type="pmid">33452053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2020-323541</pub-id><pub-id pub-id-type="pmcid">PMC8053353</pub-id></mixed-citation></ref><ref id="alz70695-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70695-cite-0025"><string-name name-style="western"><surname>Gu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Eils</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schlesner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brors</surname><given-names>B</given-names></string-name>. <article-title>circlize Implements and enhances circular visualization in R</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>(<issue>19</issue>):<fpage>2811</fpage>&#8208;<lpage>2812</lpage>.<pub-id pub-id-type="pmid">24930139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btu393</pub-id></mixed-citation></ref><ref id="alz70695-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70695-cite-0026"><string-name name-style="western"><surname>Ahmed</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Mackenzie</surname><given-names>IR</given-names></string-name>, <string-name name-style="western"><surname>Hutton</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></string-name>. <article-title>Progranulin in frontotemporal lobar degeneration and neuroinflammation</article-title>. <source>J Neuroinflammation</source>. <year>2007</year>;<volume>4</volume>(<issue>1</issue>):<fpage>7</fpage>. .<pub-id pub-id-type="pmid">17291356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-4-7</pub-id><pub-id pub-id-type="pmcid">PMC1805428</pub-id></mixed-citation></ref><ref id="alz70695-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70695-cite-0027"><string-name name-style="western"><surname>Amin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Carling</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>L</given-names></string-name>. <article-title>New insights and therapeutic opportunities for progranulin&#8208;deficient frontotemporal dementia</article-title>. <source>Curr Opin Neurobiol</source>. <year>2022</year>;<volume>72</volume>:<fpage>131</fpage>&#8208;<lpage>139</lpage>. .<pub-id pub-id-type="pmid">34826653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.conb.2021.10.001</pub-id></mixed-citation></ref><ref id="alz70695-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70695-cite-0028"><string-name name-style="western"><surname>Huang</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Contribution of inflammation and hypoperfusion to white matter hyperintensities&#8208;related cognitive impairment</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>12</volume>:<elocation-id>786840</elocation-id>.<pub-id pub-id-type="pmid">35058875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.786840</pub-id><pub-id pub-id-type="pmcid">PMC8763977</pub-id></mixed-citation></ref><ref id="alz70695-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70695-cite-0029"><string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Camicioli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Duchesne</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>DL</given-names></string-name>. <article-title>Initiative for the ADN. The temporal relationships between white matter hyperintensities, neurodegeneration, amyloid beta, and cognition</article-title>. <source>Alzheimer's Dement (Amst)</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>e12091</elocation-id>.<pub-id pub-id-type="pmid">33083512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12091</pub-id><pub-id pub-id-type="pmcid">PMC7552231</pub-id></mixed-citation></ref><ref id="alz70695-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70695-cite-0030"><string-name name-style="western"><surname>Brickman</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Provenzano</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Muraskin</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community</article-title>. <source>Arch Neurol</source>. <year>2012</year>;<volume>69</volume>(<issue>12</issue>):<fpage>1621</fpage>&#8208;<lpage>1627</lpage>. .<pub-id pub-id-type="pmid">22945686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2012.1527</pub-id><pub-id pub-id-type="pmcid">PMC3597387</pub-id></mixed-citation></ref><ref id="alz70695-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70695-cite-0031"><string-name name-style="western"><surname>Tosto</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zimmerman</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Carmichael</surname><given-names>OT</given-names></string-name>, <string-name name-style="western"><surname>Brickman</surname><given-names>AM</given-names></string-name>. <article-title>Alzheimer's Disease Neuroimaging Initiative. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment</article-title>. <source>Alzheimer's Dement</source>. <year>2015</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1510</fpage>&#8208;<lpage>1519</lpage>.<pub-id pub-id-type="pmid">26079417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2015.05.014</pub-id><pub-id pub-id-type="pmcid">PMC4677059</pub-id></mixed-citation></ref><ref id="alz70695-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70695-cite-0032"><string-name name-style="western"><surname>Van der Ende</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Bron</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Poos</surname><given-names>JM</given-names></string-name>, et&#160;al. <article-title>A data&#8208;driven disease progression model of fluid biomarkers in genetic frontotemporal dementia</article-title>. <source>Brain</source>. <year>2022</year>;<volume>145</volume>(<issue>5</issue>):<fpage>1805</fpage>&#8208;<lpage>1817</lpage>.<pub-id pub-id-type="pmid">34633446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab382</pub-id><pub-id pub-id-type="pmcid">PMC9166533</pub-id></mixed-citation></ref><ref id="alz70695-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70695-cite-0033"><string-name name-style="western"><surname>McKenna</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Lope</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Bede</surname><given-names>P</given-names></string-name>. <article-title>Pre&#8208;symptomatic radiological changes in frontotemporal dementia: propagation characteristics, predictive value and implications for clinical trials</article-title>. <source>Brain Imaging Behav</source>. <year>2022</year>;<volume>16</volume>(<issue>6</issue>):<fpage>2755</fpage>&#8208;<lpage>2767</lpage>.<pub-id pub-id-type="pmid">35920960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-022-00711-z</pub-id><pub-id pub-id-type="pmcid">PMC9712335</pub-id></mixed-citation></ref><ref id="alz70695-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70695-cite-0034"><string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cheung</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Perneel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rademakers</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hsiung</surname><given-names>GYR</given-names></string-name>, <string-name name-style="western"><surname>Mackenzie</surname><given-names>IRA</given-names></string-name>. <article-title>White matter pathology in FTLD caused by GRN mutations</article-title>. <source>Acta Neuropathol</source>. <year>2025</year>;<volume>149</volume>(<issue>1</issue>):<fpage>7</fpage>.<pub-id pub-id-type="pmid">39812821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-025-02847-w</pub-id></mixed-citation></ref><ref id="alz70695-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70695-cite-0035"><string-name name-style="western"><surname>Borrego&#8208;Ecija</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Junc&#224;&#8208;Parella</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vandebergh</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Association of initial side of brain atrophy with clinical features and disease progression in patients with GRN frontotemporal dementia</article-title>. <source>Neurology</source>. <year>2024</year>;<volume>103</volume>(<issue>11</issue>):<elocation-id>e209944</elocation-id>.<pub-id pub-id-type="pmid">39527772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000209944</pub-id><pub-id pub-id-type="pmcid">PMC11558542</pub-id></mixed-citation></ref></ref-list><app-group><app id="alz70695-app-0001" content-type="APPENDIX"><sec id="alz70695-sec-0300"><title>FURTHER DETAILS ARE PROVIDED IN THE SUPPLEMENTARY MATERIALS</title><sec id="alz70695-sec-0310"><title>GENFI consortium members</title><p>Annabel Nelson, Martina Bocchetta, David Cash, David L. Thomas, Emily Todd, Hanya Benotmane, Jennifer Nicholas, Kiran Samra, Rachelle Shafei, Carolyn Timberlake, Thomas Cope, Timothy Rittman, Antonella Alberici, Enrico Premi, Roberto Gasparotti, Valentina Cantoni, Emanuele Buratti, Andrea Arighi, Chiara Fenoglio, Elio Scarpini, Giorgio Fumagalli, Vittoria Borracci, Giacomina Rossi, Giorgio Giaccone, Giuseppe Di Fede, Paola Caroppo, Pietro Tiraboschi, Sara Prioni, Veronica Redaelli, David Tang&#8208;Wai, Ekaterina Rogaeva, Miguel Castelo&#8208;Branco, Morris Freedman, Ron Keren, Sandra Black, Sara Mitchell, Christen Shoesmith, Robart Bartha, Rosa Rademakers, Janne M. Papma, Lucia Giannini, Rick van Minkelen, Yolande Pijnenburg, Benedetta Nacmias, Camilla Ferrari, Cristina Polito, Gemma Lombardi, Valentina Bessi, Michele Veldsman, Christin Andersson, Hakan Thonberg, Linn &#214;ijerstedt, Vesna Jelic, Paul Thompson, Tobias Langheinrich, Albert Llad&#243;, Anna Antonell, Jaume Olives, Mircea Balasa, Nuria Bargall&#243;, Sergi Borrego&#8208;Ecija, Ana Verdelho, Ana Gorostidi, Jorge Villanua, Marta Ca&#241;ada, Mikel Tainta, Miren Zulaica, Myriam Barandiaran, Patricia Alves, Benjamin Bender, Lisa Graf, Annick Vogels, Mathieu Vandenbulcke, Philip Van Damme, Rose Bruffaerts, Koen Poesen, Pedro Rosa&#8208;Neto, Serge Gauthier, Anne Bertrand, Aur&#233;lie Funkiewiez, Daisy Rinaldi, Dario Saracino, Olivier Colliot, Sabrina Sayah, Catharina Prix, Elisabeth Wlasich, Olivia Wagemann, Sandra Loosli, Sonja Sch&#246;necker, Tobias Hoegen, Jolina Lombardi, Sarah Anderl&#8208;Straub, Adeline Rollin, Gregory Kuchcinski, Maxime Bertoux, Thibaud Lebouvier, Vincent Deramecour, Beatriz Santiago, Diana Duro, Maria Jo&#227;o Leit&#227;o, Maria Rosario Almeida, Miguel T&#225;buas&#8208;Pereira, S&#243;nia Afonso</p></sec></sec></app></app-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">1239</journal-id><journal-id journal-id-type="pmc-domain">frontagineuro</journal-id><journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Aging Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1663-4365</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501983</article-id><article-id pub-id-type="pmcid-ver">PMC12501983.1</article-id><article-id pub-id-type="pmcaid">12501983</article-id><article-id pub-id-type="pmcaiid">12501983</article-id><article-id pub-id-type="doi">10.3389/fnagi.2025.1622816</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Aging Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Music elicits different gene expression responses in the buccal cavity of age-related cognitive disorders patients and healthy controls</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>G&#243;mez-Carballa</surname><given-names initials="A">Alberto</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1286656/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Navarro</surname><given-names initials="L">Laura</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mallah</surname><given-names initials="NEZ">Nour El Zahraa</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3184885/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bello</surname><given-names initials="X">Xabier</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pischedda</surname><given-names initials="S">Sara</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1652296/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Viz-Lasheras</surname><given-names initials="S">Sandra</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Curr&#225;s</surname><given-names initials="MJ">Mar&#237;a Jos&#233;</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ferreir&#243;s-Vidal</surname><given-names initials="I">Isabel</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mallah</surname><given-names initials="N">Narmeen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/811919/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Montoto-Louzao</surname><given-names initials="J">Juli&#225;n</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Camino-Mera</surname><given-names initials="A">Alba</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Castelo-Mart&#237;nez</surname><given-names initials="L">L&#250;a</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rey-V&#225;zquez</surname><given-names initials="S">Sara</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Redondo</surname><given-names initials="L">Lorenzo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dacosta-Urbieta</surname><given-names initials="A">Ana</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rivero-Calle</surname><given-names initials="I">Irene</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rodr&#237;guez-Tenreiro</surname><given-names initials="C">Carmen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin&#243;n-Torres</surname><given-names initials="F">Federico</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Salas</surname><given-names initials="A">Antonio</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1021428/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><on-behalf-of>Sensogenomics Working Group</on-behalf-of></contrib-group><aff id="aff1"><sup>1</sup><institution>Genetics, Vaccines and Infections Research Group (GenViP), Instituto de Investigaci&#243;n Sanitaria de Santiago, Universidade de Santiago de Compostela</institution>, <addr-line>Santiago de Compostela</addr-line>, <country>Spain</country></aff><aff id="aff2"><sup>2</sup><institution>Facultade de Medicina, GenPoB Research Group, Unidade de Xen&#233;tica, Instituto de Ciencias Forenses, Universidade de Santiago de Compostela, Instituto de Investigaci&#243;n Sanitaria (IDIS), Hospital Cl&#237;nico Universitario de Santiago (SERGAS)</institution>, <addr-line>Santiago de Compostela</addr-line>, <country>Spain</country></aff><aff id="aff3"><sup>3</sup><institution>Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Respiratorias (CIBERES)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Pediatrics, Translational Pediatrics and Infectious Diseases, Hospital Cl&#237;nico Universitario de Santiago de Compostela</institution>, <addr-line>Santiago de Compostela</addr-line>, <country>Spain</country></aff><author-notes><fn fn-type="edited-by" id="fn0002"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/48263/overview" ext-link-type="uri">Elizabeta Blagoja Mukaetova-Ladinska</ext-link>, University of Leicester, United Kingdom</p></fn><fn fn-type="edited-by" id="fn0003"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/606704/overview" ext-link-type="uri">Ruma Raha-Chowdhury</ext-link>, University of Cambridge, United Kingdom</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2626704/overview" ext-link-type="uri">Rafaela Lacerda</ext-link>, National Health Institute Doutor Ricardo Jorge (INSA), Portugal</p></fn><corresp id="c001">*Correspondence: Antonio Salas, <email>antonio.salas@usc.es</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">481075</issue-id><elocation-id>1622816</elocation-id><history><date date-type="received"><day>06</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 10:25:16.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 G&#243;mez-Carballa, Navarro, Mallah, Bello, Pischedda, Viz-Lasheras, Curr&#225;s, Ferreir&#243;s-Vidal, Mallah, Montoto-Louzao, Camino-Mera, Castelo-Mart&#237;nez, Rey-V&#225;zquez, Redondo, Dacosta-Urbieta, Rivero-Calle, Rodr&#237;guez-Tenreiro, Martin&#243;n-Torres and Salas.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>G&#243;mez-Carballa, Navarro, Mallah, Bello, Pischedda, Viz-Lasheras, Curr&#225;s, Ferreir&#243;s-Vidal, Mallah, Montoto-Louzao, Camino-Mera, Castelo-Mart&#237;nez, Rey-V&#225;zquez, Redondo, Dacosta-Urbieta, Rivero-Calle, Rodr&#237;guez-Tenreiro, Martin&#243;n-Torres and Salas</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnagi-17-1622816.pdf"/><abstract><sec id="sec1001"><title>Introduction</title><p>Recent evidence suggests that external stimuli can shape transcriptomes, a field emerging as sensogenomics. Specifically, the analysis of capillary blood samples has shown that musical stimuli can modulate gene expression patterns, not only in healthy individuals but also in those with age-related cognitive disorders (ACD).</p></sec><sec id="sec2001"><title>Methods</title><p>Using targeted transcriptomics with Nanostring nCounter, we present groundbreaking evidence indicating that brief exposure to music can also impact the buccal transcriptome in both healthy donors and ACD patients.</p></sec><sec id="sec3001"><title>Results</title><p>Our findings reveal that music elicits stronger transcriptomic effect on patients compared to controls, driving global upregulation in ACD patients but downregulation in controls. The most significantly dysregulated genes in ACD patients include <italic toggle="yes">LGALS3</italic> (downregulated) and <italic toggle="yes">CXCL8</italic> (upregulated), whereas in controls, <italic toggle="yes">THOP1</italic> was the top significant gene (downregulated). These genes play important roles in normal brain functions and are also altered in neurodegenerative conditions. Weighted Gene Co-expression network analysis reveals relevant and significant modules, both positive and negative correlated with music, implicated in neurodegenerative (e.g., autophagy) and immunological processes (e.g., IL-1, MHC).</p></sec><sec id="sec4001"><title>Discussion</title><p>Collectively, these results suggest a complex interplay between music and molecular responses in the human body, and highlight the potential of musical stimuli to influence gene expression patterns outside systemic circulation, paving the way for further exploration of music&#8217;s therapeutic applications.</p></sec></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>dementia</kwd><kwd>saliva</kwd><kwd>mild cognitive impairment</kwd><kwd>music stimuli</kwd><kwd>RNA-Seq</kwd><kwd>transcriptome</kwd><kwd>sensogenomics</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This study received support from Grupos de Referencia Competitiva GRC GAIN (IN607A2023/02) and Programa de Cooperaci&#243;n Interreg-VI POCTEP (0313_EUTERPE_ADN_1_E) [AS], IIN607A2021/05 [FM-T]) and IN677D 2024/06 [AG-C]).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="0"/><equation-count count="0"/><ref-count count="89"/><page-count count="13"/><word-count count="11386"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neurocognitive Aging and Behavior</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Little is known about how musical stimuli impact on our gene expression. <xref rid="ref53" ref-type="bibr">Navarro et al. (2021)</xref> have recently highlighted the importance of deeper exploration into this still poorly understood field of biological science [sensogenomics (<xref rid="ref53" ref-type="bibr">Navarro et al., 2021</xref>; <xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>, <xref rid="ref9003" ref-type="bibr">2025</xref>; <xref rid="ref52" ref-type="bibr">Navarro et al., 2023</xref>; <xref rid="ref9004" ref-type="bibr">Salas et al., In press</xref>; <xref rid="ref9002" ref-type="bibr">Cavenaghi et al., 2025</xref>; <xref rid="ref9001" ref-type="bibr">Castelo-Mart&#237;nez et al., 2025</xref>)], taking advantage of new technologies emerging in the &#8216;-omic&#8217; sciences, including genomics and transcriptomics. There have been only a few attempts to understand the gene expression mechanisms activated during music stimulation; the initial ones were carried out on healthy controls and professional musicians, with results indicating a few genes differentially expressed after exposure to classical music stimuli (<xref rid="ref39" ref-type="bibr">Kanduri et al., 2015</xref>; <xref rid="ref38" ref-type="bibr">J&#228;rvel&#228;, 2018</xref>). Recently, the exploratory study by <xref rid="ref52" ref-type="bibr">Navarro et al. (2023)</xref> provided suggestive evidence of the potential impact of music in the context of Alzheimer&#8217;s disease (AD) and reviewed the current evidence overall, concurring on the beneficial effect of music on neurodegenerative diseases. To the best of our knowledge, our most recent study, <xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al. (2023)</xref>, is the only attempt to date to examine the impact of music in a disease context, specifically in capillary blood samples collected from age-related cognitive disorder (ACD) patients. This study found an increased effect of music in ACD patients compared to healthy controls, but most interestingly, it revealed that brief musical stimuli can modify the way patients express genes typically altered in this condition, but in the opposite direction.</p><p>Building upon previous findings, the present study represents the first attempt to analyze the impact of music in ACD patients, but this time exploring salivary instead of blood transcriptomes. The interest in analyzing saliva stems from the growing importance of this non-invasive biological source in biomedical studies, with several salivary biomarkers being explored as proxies for diagnosing and monitoring brain health, stress, mental disorders, and neurological diseases (<xref rid="ref22" ref-type="bibr">Farah et al., 2018</xref>; <xref rid="ref5" ref-type="bibr">Bauduin et al., 2021</xref>; <xref rid="ref2" ref-type="bibr">Ali and Nater, 2020</xref>; <xref rid="ref21" ref-type="bibr">Engeland et al., 2019</xref>; <xref rid="ref69" ref-type="bibr">Schepici et al., 2020</xref>). Saliva is primarily produced and secreted by the parotid, submandibular, and sublingual salivary glands and regulated by the autonomous nervous system (<xref rid="ref17" ref-type="bibr">Chibly et al., 2022</xref>). These major salivary glands are innervated by both sympathetic and parasympathetic nerves, with compact fibers encircled by Schwann cells (<xref rid="ref28" ref-type="bibr">Garrett and Kidd, 1993</xref>). The submandibular and sublingual glands are responsible for most unstimulated saliva production, whereas most of parotid gland saliva secretion occurs in response to stimuli. Previous studies have reported the presence of neurotransmitters in salivary glands extracted from mice and rats (<xref rid="ref49" ref-type="bibr">Murai et al., 1998</xref>; <xref rid="ref50" ref-type="bibr">Murai et al., 1995</xref>). Parasympathetic stimulation promotes the release of the neurotransmitter acetylcholine whereas sympathetic activation releases noradrenaline stimulating the secretion of proteins (<xref rid="ref51" ref-type="bibr">Nakamura et al., 2004</xref>; <xref rid="ref60" ref-type="bibr">Proctor and Carpenter, 2007</xref>). Given this connection between the salivary glands and the nervous system, the existence of a bidirectional oral-brain axis has been suggested (<xref rid="ref67" ref-type="bibr">Sansores-Espana et al., 2021</xref>), through which an inflammatory response in the oral cavity may impact brain homeostasis and vice-versa. Since there is growing evidence indicating an impact of music on blood transcriptomes as well as its beneficial effects on many disease conditions, it seems imperative to explore if musical stimuli have also the potential to regulate salivary transcriptomes.</p><p>Here, we propose exploring gene expression patterns in saliva obtained from ACD patients and healthy controls before and after brief musical stimuli. The samples analyzed in this study partially overlap with those used in <xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al. (2023)</xref>; and all of them were collected during the same experimental concerts. Therefore, this scenario offers a unique opportunity to evaluate the potential of saliva analysis in capturing expression changes triggered by music, and to undertake a comparative analysis with the capillary blood signatures reported in our previous study (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>).</p></sec><sec sec-type="methods" id="sec2"><title>Methods</title><sec id="sec3"><title>Participants and <italic toggle="yes">n</italic>Counter assay</title><p>Written informed consent was obtained from all the participants in the present study. The Ethics Committee of Xunta de Galicia approved the present project (Registration code: 2020/021), and the study was conducted in accordance to the guidelines of the Helsinki Declaration. We have followed the same experimental procedures described in <xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al. (2023)</xref> and within the framework of the Sensogenomics project (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.sensogenomics.com/" ext-link-type="uri">www.sensogenomics.com</ext-link>).<xref rid="fn0001" ref-type="fn"><sup>1</sup></xref> Briefly, we collected saliva samples at two timepoints: before and after an experimental concert of classical music; (see Figure 1 of <xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>) for a schematic representation of the sampling and analysis procedures. Saliva samples were collected in <italic toggle="yes">Oragene DNA</italic> devices (ORE-100; DNAgenotek), comprising 10 ACD patients [aged 84&#8211;92&#8239;years old (mean 84); 5/5 male/female] and 14 healthy donors [aged 18&#8211;88 (mean 57); 3/11 male/female]. Nearly all the ACD patients (9/10; 90%) and more than half of the controls (8/14; 57%) from the present study overlap with those included in the capillary blood experiment (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>).</p><p>RNA from saliva was isolated using 500&#8239;&#956;L of sample and the RNeasy microkit (Qiagen). We slightly modified the protocol provided by the extraction kit as recommended by the Oragene tubes supplier. RNA concentration step and an additional DNase treatment were undertaken using an RNA clean &amp; concentrator kit (Zymo Research). RNA amount and integrity were checked using TapeStation 4200 (Agilent), and DV200 values were calculated to ensure that &gt;50% of the RNA fragments were above 200&#8239;nt and to estimate the optimal sample input.</p><p>Gene expression was evaluated through the <italic toggle="yes">n</italic>Counter <italic toggle="yes">MAX</italic> (NanoString Technologies) and the <italic toggle="yes">n</italic>Counter Host Response Panel, which includes 785 genes. We opted for NanoString over other methods such as RNAseq due to the intrinsic difficulties associated to sequencing endogenous RNA from saliva samples. Bacteria are naturally present in human saliva, making it challenging to analyze only the human component of the salivary transcriptome (<xref rid="ref31" ref-type="bibr">Gosch et al., 2024</xref>). We followed standard protocols; including 12&#8239;&#215;&#8239;RNA hybridization with 5&#8239;&#956;L of RNA as input, and hybridization time of 18&#8239;h for all samples. We also mixed controls and ACD patient samples in the same runs to avoid technical sample bias and batch effects. After filtering out genes expressing below the background (maximum expression value &lt; background), we detected a total of 566 and 672 genes (out of the total 785 in the NanoString panel) in ACD patients and healthy controls, respectively. In addition, 553 out of 566 genes in ACD and 648 out of 672 genes in healthy controls overlap with those detected in capillary blood samples from our previous study (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>).</p></sec><sec id="sec4"><title>Statistical analysis</title><p>First, we carried out a quality control (QC) of the raw expression data checking technical parameters following manufacturer recommendations. Samples that did not pass technical QC, or with low number of genes detected, were excluded for downstream analysis.</p><p>Genes with counts below the background (defined as the mean + 2 standard deviations [SD] of the negative control spikes in the code set, disregarding negative control C, which typically yields a higher number of counts) were excluded from both normalization and the differential expression analysis.</p><p>Data normalization was performed through an iterative strategy that combines both <italic toggle="yes">DESeq2</italic> (<xref rid="ref46" ref-type="bibr">Love et al., 2014</xref>) and <italic toggle="yes">RUVSeq</italic> (<xref rid="ref65" ref-type="bibr">Risso et al., 2014</xref>) packages as described in (<xref rid="ref10" ref-type="bibr">Bhattacharya et al., 2021</xref>). Control reference genes for data normalization were detected by selecting invariable genes [<italic toggle="yes">p</italic>-value &gt; 0.1, BaseMean &gt; 100 and |log<sub>2</sub> Fold Change (FC)|&#8239;&lt;&#8239;0.2] after a na&#239;ve differential expression analysis between timepoint 1 (TP1) and timepoint 2 (TP2) in both ACD and healthy controls separately. Genes expressed below the background were removed. We used a paired-sampling design to carry out analysis of transcriptome differences before the musical stimuli (Pretest; TP1) and after the musical stimuli (Posttest; TP2). Additionally, we evaluated if differentially expressed genes (DEGs) detected in saliva are also altered in ACD patients due to the condition by contrasting DEGs between TP1 and TP2 against DEGs that are altered in AD and mild cognitive impairment (MCI) patients. For this purpose, we downloaded from GEO (gene expression omnibus) microarray blood gene expression data from three independent microarray datasets analyzing MCI and AD patients and healthy controls, as done previously (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>). Data were processed and merged as explained in (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>; <xref rid="ref52" ref-type="bibr">Navarro et al., 2023</xref>).</p><p>We used the Weighted Gene Co-expression Network Analysis (<italic toggle="yes">WGCNA</italic>) R package (<xref rid="ref44" ref-type="bibr">Langfelder and Horvath, 2008</xref>) to investigate clusters of co-expressed genes potentially correlated to the musical stimuli in ACD patients and the healthy control groups separately. Normalized and corrected gene expression data, adjusted for patient-to-patient variability, served as input to construct a signed weighted correlation network. Following the package developers&#8217; recommendations and considering the number of samples per group, we chose a soft-thresholding power of 18. We computed the Topological Overlap Matrix (TOM) and the corresponding dissimilarity (1&#8211;TOM) values. We set a minimum module size of 30, and a dendrogram cut height threshold of 0.2 for module merging. Initially labeled by colors, the detected modules of co-expressed genes were later renamed using the name of the genes showing the highest connectivity within each module (hub genes). We identified modules of interest significantly associated with the musical stimuli by correlating module eigengenes with the timepoint (TP1 and TP2) data; and measuring gene significance (GS), a value that quantifies the biological significance of genes in modules. For each gene, Module Membership (MM) quantifies its intramodular connectivity within the module. Multiple test adjustment was carried out using the FDR method by Benjamini-Hochberg (<xref rid="ref8" ref-type="bibr">Benjamini and Hochberg, 1995</xref>).</p><p>Functional analysis of significantly correlated modules was carried out through an over-representation analysis with the <italic toggle="yes">Clusterprofiler</italic> R package (<xref rid="ref79" ref-type="bibr">Wu et al., 2021</xref>). The biological processes from the Gene Ontology (GO) and Reactome were used as reference databases for the analysis. The pool of genes included in the <italic toggle="yes">n</italic>Counter NanoString Host Response gene expression panel was employed as the gene universe for statistical calculations. To facilitate the interpretation of the results, redundant terms (similarity &gt; 0.7) were detected and removed after calculating the terms similarity matrix.</p><p>Different R packages were used to generate volcano plots [<italic toggle="yes">EnhancedVolcano</italic> (<xref rid="ref11" ref-type="bibr">Blighe et al., 2020</xref>)] and heatmaps [<italic toggle="yes">ComplexHeatmap</italic> (<xref rid="ref33" ref-type="bibr">Gu et al., 2016</xref>)]. Statistical significance was assessed using the Wilcoxon test.</p><p>Statistical analyses were performed using R version 4.2.2 (<xref rid="ref61" ref-type="bibr">R Core Team, 2019</xref>).</p></sec></sec><sec sec-type="results" id="sec5"><title>Results</title><sec id="sec6"><title>Differentially expression in saliva in response to music</title><p>To assess the impact of the musical stimuli on the transcriptomes of donors, we first conducted a paired TP1 <italic toggle="yes">vs</italic>. TP2 transcriptome analysis for the two groups of donors separately.</p><p>First, we observed a higher number of DEGs in ACD patients compared to controls. Specifically, we detected 31 (adjusted <italic toggle="yes">p</italic>-value &lt; 0.05) DEGs in the ACD group out of a total of 566 detected genes. In contrast, we found 7 adjusted DEGs in healthy controls out of a total of 672 detected genes. These different proportions (31/566 <italic toggle="yes">vs</italic>. 7/672) were statistically significant under a two-sample proportion test (<italic toggle="yes">p</italic>-value&#8239;=&#8239;1&#8239;&#215;&#8239;10<sup>&#8722;05</sup>); <xref rid="SM1" ref-type="supplementary-material">Supplementary Tables S1, S2</xref>; <xref rid="fig1" ref-type="fig">Figure 1A</xref>.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p><bold>(A)</bold> Volcano plot showing the DEGs between TP1 and TP2 in both ADC and control donors (HC). Names of DEGs with |log<sub>2</sub>FC| value &gt; 0.5 and adjusted <italic toggle="yes">p</italic>-value &lt; 0.01 are displayed. <bold>(B)</bold> Density plots of log<sub>2</sub>FC; dashed lines indicate Log<sub>2</sub>FC&#8239;=&#8239;0; vertical solid lines indicate median values; <bold>(C)</bold> Principal components analysis (PCA) using DEGs with <italic toggle="yes">p</italic>-value &lt; 0.05. <bold>(D)</bold> Heatmap and cluster analysis of the DEGs (adjusted <italic toggle="yes">p</italic>-value &lt; 0.05) in ADC and HC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1622816-g001.jpg"><alt-text content-type="machine-generated">(A) Two volcano plots displaying differential expression between TP1 and TP2 in ACD and healthy controls (HC), highlighting significant genes like LGALS3, CXCL8, CD59 and THOP1. (B) Two density plots comparing log2FC distributions for ACD and HC, showing medians. (C) Principal component analysis plot from expression profiles of DEGs with P-value &lt; 0.05, comparing timepoints TP1 and TP2 in ACD and HC samples. (D) Heatmap with hierarchical clustering of gene expression from DEGs (adjusted P-value &lt; 0.05) in ACD and HC over two timepoints, shown in different colors.</alt-text></graphic></fig><p>Secondly, the musical stimuli drive the transcriptome of ACD patients toward upregulation when compared to controls. Notably, there are more upregulated adjusted DEGs in ACD donors (11/31&#8239;=&#8239;0.35) compared to the lower proportion observed in the healthy controls (0/7). Moreover, upregulation appears to be the predominant overall response to music in the transcriptome of ACD patients (median log<sub>2</sub> Fold Change (log<sub>2</sub>FC)&#8239;=&#8239;0.032 of non-adjusted DEGs with <italic toggle="yes">p</italic>-value &lt; 0.05), whereas downregulation predominates in the transcriptome of healthy donors (median log<sub>2</sub>FC&#8239;=&#8239;&#8722;0.037 of DEGs with non-adjusted <italic toggle="yes">p</italic>-value &lt; 0.05); <xref rid="fig1" ref-type="fig">Figure 1B</xref>. While these figures are inadequate for a two-sample proportion test (as it is an incorrect approximation to a Chi-square), we conducted the test using the observed non-adjusted DEGs, with proportions 52/97&#8239;=&#8239;0.54 in ACD patients <italic toggle="yes">vs</italic>. 45/128&#8239;=&#8239;0.35 in healthy controls; these different proportions were statistically significant with <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.009.</p><p>The transcriptome profiles of non-adjusted DEGs reveal a segregation of samples into their two timepoints (TP1 and TP2) in ACD patients, as evidenced by Principal Component Analysis (PCA). This differentiation is particularly noticeable in Principal Component 1 (PC1), which account for most of the variation (79%); PC2 contributes minimally to this primary PC1 clustering, representing only 8% of the variation; <xref rid="fig1" ref-type="fig">Figure 1C</xref>. However, the differentiation between TP1 and TP2 is less pronounced in the healthy cohort, with PC1 and PC2 accounting for only 58 and 9% of the variation, respectively; <xref rid="fig1" ref-type="fig">Figure 1C</xref>. A heatmap of DEGs (adjusted <italic toggle="yes">p</italic>-value &lt; 0.05) in ACD clearly demonstrates a clear distinction between TP1 and TP2 in ACD patients. Despite the limited number of DEGs observed in healthy donors (<italic toggle="yes">n</italic>&#8239;=&#8239;7), the heatmap efficiently separates most of the transcriptomes into the two timepoints; <xref rid="fig1" ref-type="fig">Figure 1D</xref>.</p><p>The top downregulated gene in ACD was <italic toggle="yes">LGALS3</italic> (log<sub>2</sub>FC&#8239;=&#8239;&#8722;0.83; adjusted <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.007) whereas the DEG showing the lowest adjusted <italic toggle="yes">p</italic>-value was <italic toggle="yes">CXCL8</italic> (log<sub>2</sub>FC&#8239;=&#8239;0.78; adjusted <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.004). In control samples, the top DEG, namely <italic toggle="yes">THOP1</italic>, was downregulated in TP2 with respect to TP1 (log<sub>2</sub>FC&#8239;=&#8239;&#8722; 0.73; adjusted <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.007); <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>.</p><p>Using a pathways enrichment approach and DEGs (adjusted <italic toggle="yes">p</italic>-value &lt; 0.05) a single GO significant term was detected in ACD patients: &#8220;unsaturated fatty acid metabolic process&#8221; (adjusted <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.03), involving the DEGs <italic toggle="yes">IL1B</italic>, <italic toggle="yes">PTGS2</italic>, <italic toggle="yes">ACOX1</italic>, <italic toggle="yes">MIF</italic> and <italic toggle="yes">ALOX12</italic>. Nonsignificant pathway resulted from the analysis in control donors, most likely due to the low number of DEGs detected.</p></sec><sec id="sec7"><title>Comparative transcriptomic response to music in capillary blood and saliva</title><p>We observed few similarities between transcriptomic response in the capillary blood and saliva of donors exposed to musical stimuli comparing the values mentioned above with results reported in (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>; see also <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>); namely: (i) There is a statistically significant higher number of DEGs in ACD patients compared to controls, (ii) Global upregulation is the predominant reaction to music in the transcriptome of ACD patients, while downregulation predominates in the transcriptome of healthy donors, and (iii) The transcriptome profile of DEGs shows a clear distinct differentiation between TP1 and TP2 in both healthy controls and, even more marked, in ACD patients.</p><p>However, there are also a few differences between the transcriptomes in saliva and capillary blood of patients and controls that are worth highlighting.</p><p>Firstly, the most notable finding is that the proportion of adjusted DEGs is substantially higher in saliva than in blood (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>), for both ACD patients and healthy controls. When referred to the total number of transcripts captured by the different techniques [NanoString in saliva and RNAseq in capillary blood (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>)], the proportions are as follows: (i) in ACD patients: 31/566&#8239;=&#8239;0.05 [saliva] vs. 328/36155&#8239;=&#8239;0.01 [capillary blood]; and (ii) in healthy controls: 7/672&#8239;=&#8239;0.01 [saliva] vs. 1/35865&#8239;=&#8239;0.00 [capillary blood]. For these comparisons, the two-sample proportion test is highly significant, p-value &lt; 2&#8239;&#215;&#8239;10<sup>&#8722;16</sup>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>. In addition, to mitigate potential bias arising from the different techniques employed to generate salivary and capillary blood transcriptomes, we can consider only the common genes in both studies (553 in ACD patients and 648 in healthy controls; see Material and Methods). Although the proportions are more attenuated, they remain consistent: (i) in ACD patients: 30/553&#8239;=&#8239;0.05 [saliva] vs. 21/553&#8239;=&#8239;0.04 [capillary blood], and (ii) in healthy controls: 7/648&#8239;=&#8239;0.01[saliva] <italic toggle="yes">vs</italic>. 0/648&#8239;=&#8239;0.00 [capillary blood]. This difference is statistically significant in healthy controls (<italic toggle="yes">p</italic>-value&#8239;=&#8239;0.02); but it is highly significant in both groups when computing proportions using non-adjusted DEGs; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>.</p><p>Secondly, we observed a significant proportion of genes that express in different directions in capillary blood and saliva. Specifically, there are 24 common (non-adjusted) DEGs in the two tissues for ACD patients, and 7 in healthy controls. Among these, 11/24&#8239;=&#8239;0.46 [ACD patients], and 2/7&#8239;=&#8239;0.29 [controls] were found to be negatively correlated (<xref rid="fig2" ref-type="fig">Figure 2</xref>). Additionally, there are only two DEGs (adjusted <italic toggle="yes">p</italic>-value &lt; 0.05) in ACD patients (none in controls), namely <italic toggle="yes">KDM6B</italic> and <italic toggle="yes">TIMP2,</italic> that overlap between saliva and blood transcriptomes. While <italic toggle="yes">TIMP2</italic> expressed similarly in saliva and capillary blood, <italic toggle="yes">KDM6B</italic> is upregulated in saliva but downregulated in blood (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Correlation between gene expression changes observed in capillary blood and saliva samples after musical stimulation in ACD and control donors (HC). Blue dots indicate positive correlation whereas red dots indicate negative correlation between tissues. Only common DEGs (<italic toggle="yes">p</italic>-value &lt; 0.05) in both saliva and capillary blood samples are being displayed. Ranked values refer to the value of the test statistic for a gene obtained from <italic toggle="yes">DESeq2</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1622816-g002.jpg"><alt-text content-type="machine-generated">Scatter plots comparing ranked gene expressions in saliva versus blood for two conditions, ACD and HC. In ACD, genes like KDM6B and TIMP2 are highlighted. Blue dots indicate positive correlation whereas red dots indicate negative correlation between tissues. Only common DEGs (P-value &lt; 0.05) in both saliva and capillary blood samples are being displayed. Ranked values refer to the value of the test statistic for a gene obtained from DESeq2.</alt-text></graphic></fig></sec><sec id="sec8"><title>Music-related DEGs in saliva from ACD patients compared to DEGs in AD/MCI condition</title><p>To investigate if some of the genes affected by musical stimuli in ACD were also dysregulated in AD/MCI patients due to their condition, we contrasted the DEGs detected in ACD after the musical stimuli with DEGs resulted from comparing transcriptomes from AD/MCI patients and healthy controls. We observed that some genes targeted by music were also affected in both neurodegenerative conditions. However, music appeared to impact more significantly on genes dysregulated in MCI (<italic toggle="yes">n</italic>&#8239;=&#8239;13) than in genes dysregulated in AD (<italic toggle="yes">n</italic>&#8239;=&#8239;8); <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>. There were few genes that showed a negative correlation in these contrasts, more in MCI (<italic toggle="yes">n</italic>&#8239;=&#8239;7) than in AD (<italic toggle="yes">n</italic>&#8239;=&#8239;3); suggesting that music has a compensatory effect for those altered in the two disease conditions.</p><p>Interestingly, the only significant genes altered by music in both capillary blood and saliva (see above) were also differentially expressed in AD and MCI, namely <italic toggle="yes">KDM6B</italic> and <italic toggle="yes">TIMP2</italic> (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>). Both genes showed a significant higher expression in MCI and AD compared to healthy controls. However, music induced opposite expression changes in saliva for the <italic toggle="yes">KDM6B</italic> (over-expression as in MCI/AD) and <italic toggle="yes">TIMP2</italic> (under-expression) genes.</p></sec><sec id="sec9"><title>Co-expression modules in response to the musical stimuli in ACD</title><p>The <italic toggle="yes">WGCNA</italic> analysis generated six modules of co-expressed genes from the ACD expression data (<xref rid="fig3" ref-type="fig">Figure 3A</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S2A,B</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>). Correlation of the modules eigengenes with TP1 and TP2 revealed four modules significantly correlated with the expression changes produced by the music stimuli (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). Three of them were positively correlated: <italic toggle="yes">PIK3CD</italic> [(blue) <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.004], <italic toggle="yes">NOTCH1</italic> [(brown) <italic toggle="yes">p</italic>-value&#8239;=&#8239;5&#8239;&#215;&#8239;10<sup>&#8722;06</sup>], and <italic toggle="yes">CXCR1</italic> [(green) <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.002]; whereas the module <italic toggle="yes">CD59</italic> [(turquoise) <italic toggle="yes">p</italic>-value&#8239;=&#8239;7&#8239;&#215;&#8239;10<sup>&#8722;05</sup>] showed a negative correlation. <italic toggle="yes">NOTCH1</italic> and <italic toggle="yes">CD59</italic> modules showed the highest correlation with the musical stimuli (<italic toggle="yes">R</italic>&#8239;=&#8239;0.83 and <italic toggle="yes">R</italic>&#8239;=&#8239;&#8722;0.77, respectively).</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Co-expression analysis in ACD patients. <bold>(A)</bold> Correlation and <italic toggle="yes">p</italic>-values values heatmap obtained from the co-expression analysis. Upper value corresponds to the correlation with musical stimuli and <italic toggle="yes">p</italic>-values are shown in brackets <bold>(B)</bold> Boxplots of samples eigengenes values between TP1 and TP2 from <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">CD59</italic> and <italic toggle="yes">PIK3CD</italic> modules. <bold>(C)</bold> Pathways enrichment analysis results using GO and Reactome databases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1622816-g003.jpg"><alt-text content-type="machine-generated">Co-expression analysis in ACD patients. Panel A displays a heatmap showing correlations values and significance between TP1-TP2 comparison and NOTCH1, PIK3CD, CXCR1, CD59, CREBBP, and CFLAR co-expression modules. Panel B shows box plots for NOTCH1, PIK3CD, and CD59 modules eigengenes values in TP1 and TP2, with p-values indicating statistical significance. Panel C presents a dot plot for GO and Reactome pathways significantly associated with CD59 and NOTCH1 co-expression modules, with gene ratios and adjusted p-values, focusing on intracellular transport and immune system processes.</alt-text></graphic></fig><p>The highly significant correlation values of these four modules suggest a functional role of these gene sets in the buccal molecular response to music in ACD patients. This functional relevance is likewise visible by examining the global correlation between gene MM and gene-trait correlation values for the individual genes within each module, indicating that genes with higher trait-correlation values are also important functional drivers of the modules (high MM values) (<italic toggle="yes">R</italic>&#8239;=&#8239;0.73 and <italic toggle="yes">p</italic>-value&#8239;=&#8239;9&#8239;&#215;&#8239;10<sup>&#8722;34</sup> for <italic toggle="yes">CD59</italic> module; <italic toggle="yes">R</italic>&#8239;=&#8239;0.74 and <italic toggle="yes">p</italic>-value&#8239;=&#8239;3&#8239;&#215;&#8239;10<sup>&#8722;14</sup> for <italic toggle="yes">NOTCH1</italic> module); <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S2C</xref>. Modules <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">CD59</italic> and <italic toggle="yes">PIK3CD</italic> are the ones showing the most significant expression changes between TP1 and TP2 <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S2D</xref>; this is particularly clear when examining their module eigengene values (<xref rid="fig3" ref-type="fig">Figure 3B</xref>).</p><p>Pathways enrichment analysis of the significant modules identified relevant biological routes involved in the musical stimuli for three of the modules; <italic toggle="yes">CD59</italic>, <italic toggle="yes">NOTCH1</italic> and <italic toggle="yes">PIK3CD</italic> (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S4</xref>; <xref rid="fig3" ref-type="fig">Figure 3C</xref>). The most relevant pathways detected for the downregulated <italic toggle="yes">CD59</italic> module were related to intracellular protein transport and localization (in GO) and, most remarkable, autophagic machinery/vacuole organization (in GO and Reactome; <xref rid="fig3" ref-type="fig">Figure 3C</xref>). Genes from the upregulated <italic toggle="yes">NOTCH1</italic> and <italic toggle="yes">PIK3CD</italic> modules were involved in the detection of biotic stimulus (<italic toggle="yes">NOTCH1</italic> in GO) and innate immune system (<italic toggle="yes">PIK3CD</italic> in Reactome; <xref rid="fig3" ref-type="fig">Figure 3C</xref>).</p></sec><sec id="sec10"><title>Co-expression modules in response to the musical stimuli in controls</title><p>The co-expression module analysis in control donors also detected significant modules altered in response to music, but the correlations were generally lower than those reported for the ACD patients (<xref rid="fig4" ref-type="fig">Figure 4A</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S3A,B</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>). Three modules yielded positive correlation values [<italic toggle="yes">LTF</italic> &#8211; (yellow) <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.002, <italic toggle="yes">GZMA</italic> &#8211; (brown) <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.004, <italic toggle="yes">CCR2</italic> &#8211; (red) <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.01], indicating upregulation after receiving musical stimuli (in TP2), whereas two of them showed negative correlation values [<italic toggle="yes">SERPINA1</italic> &#8211; (turquoise) <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.0002, <italic toggle="yes">NCF4</italic> &#8211; (green) <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.005], indicating downregulation after listening to music; all of them survived adjustment for multiple test (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>). Among the topmost significant modules (<italic toggle="yes">SERPINA1</italic>, <italic toggle="yes">GZMA</italic> and <italic toggle="yes">LTF</italic>), the most significant one was also the most negatively correlated with musical stimulation (<italic toggle="yes">SERPINA1</italic>; <italic toggle="yes">R</italic>&#8239;=&#8239;&#8722;0.64), and the module displaying the most extreme differences in eigengenes values between both timepoints (<italic toggle="yes">p</italic>-value&#8239;=&#8239;0.0002; <xref rid="fig4" ref-type="fig">Figure 4B</xref>). Although the overall gene expression profiles of the top three modules clustered reasonably well the samples into TP1 and TP2 (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S3C</xref>), this separation by TP was not as optimal as in the case of the modules from ACD patients. The importance of the <italic toggle="yes">SERPINA1</italic> module and its core genes in the gene expression response of control donors can also be noted in the high correlation and low significance values observed when contrasting gene MMs with GSs individual values (<italic toggle="yes">R</italic>&#8239;=&#8239;0.70; <italic toggle="yes">p</italic>-value&#8239;=&#8239;1&#8239;&#215;&#8239;10<sup>&#8722;34</sup>) in comparison to the values obtained for the other modules (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S3D</xref>).</p><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Co-expression analysis in control donors. <bold>(A)</bold> Correlation and <italic toggle="yes">p</italic>-values values heatmap obtained from the co-expression analysis. Upper value corresponds to the correlation with musical stimuli and <italic toggle="yes">p</italic>-values are shown in brackets <bold>(B)</bold> Boxplots of samples eigengenes values between TP1 and TP2 from <italic toggle="yes">GZMA</italic>, <italic toggle="yes">LTF</italic> and <italic toggle="yes">SERPINA1</italic> modules. <bold>(C)</bold> Pathways enrichment analysis results using GO and Reactome databases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1622816-g004.jpg"><alt-text content-type="machine-generated">Co-expression analysis in control donors. Panel A displays a heatmap showing correlations values and significance between TP1-TP2 comparison and HLA-A, GZMA, NCF4, CCR2, LTF and SERPINA1 co-expression modules. Panel B shows box plots for GZMA, LTF, and SERPINA1 modules eigengenes values in TP1 and TP2 with with p-values indicating statistical significance. Panel C presents a dot plot for GO and Reactome pathways significantly associated with co-expression modules GZMA and SERPINA1, showing gene ratios and p-values, with pathways like immune response and signaling highlighted.</alt-text></graphic></fig><p>Several pathways were found to be related to <italic toggle="yes">GZMA</italic>, <italic toggle="yes">SERPINA1</italic> and <italic toggle="yes">LTF</italic> modules after a functional assessment of each of the significantly correlated modules (<xref rid="fig4" ref-type="fig">Figure 4C</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S4</xref>). The <italic toggle="yes">GZMA</italic> module showed a strong involvement of the adaptative immune system. Thus, most significant pathways can be condensed into three sets of adaptive immune-related processes: antigen processing and presentation <italic toggle="yes">via</italic> MHC class II, cell adhesion, and T-cell metabolism routes (activation, proliferation, regulation, differentiation). Consistently, enrichment analysis with Reactome database yielded equivalent results, with MHC class II antigen presentation as the top significant pathway, and other pathways with a key role modulating T-cell activity (CD28, PD-1 signaling) or triggering downstream cascades after T-cell receptor activation (ZAP-70); (<xref rid="fig4" ref-type="fig">Figure 4C</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>). GO enrichment analysis of <italic toggle="yes">SERPINA1</italic> module resulted in intracellular protein transport and related terms significantly associated with this module. However, Reactome enrichment analysis found several significant pathways engaged in the innate immune system, locating at the top different Toll-Like Receptors (TLR) cascades and related pathways, such as IL-1 signaling, MyD88: MAL (TIRAP) cascade or TRAF6 mediated induction of NFkB and MAP kinases. Most noticeable, autophagy pathways were also significantly associated with the <italic toggle="yes">SERPINA1</italic> module (autophagy, macro-autophagy and ER-Phagosome pathways) suggesting functional similarities with the negatively correlated module <italic toggle="yes">CD59</italic> detected in ACD patients (see above). Processes associated with the <italic toggle="yes">LTF</italic> module were only detected in Reactome; related to the GPCR signal transduction events, and more specifically to the sub-family A/1 (Rhodopsin-like) receptors.</p></sec></sec><sec sec-type="discussion" id="sec11"><title>Discussion</title><p>Musical stimulation is a multifaceted cognitive phenomenon that intricately engages various brain regions, eliciting a spectrum of cognitive, emotional, and physiological responses. Elucidating the molecular changes triggered by music can help to understanding its effect on brain function and mental health in the general population, as well as its therapeutic potential in the context of various neurological and psychiatric conditions. Moreover, disentangling the complexity of gene networks (and molecular pathways involved in these networks) could reveal new targets for pharmacological interventions or provide guidance to develop new personalized music-based therapies.</p><p>Recently, we demonstrated that musical stimuli have an important impact on the capillary blood transcriptomes of ACD patients and healthy individuals, providing insights into the systemic gene expression response to music. We reported that music stimulation in ACD patients compensates for the expression of genes and pathways dysregulated due to cognitive impairment. Elaborating on this groundwork and given the known connection between the oral cavity and the brain, namely oral-brain axis, we aimed for the first time to investigate gene expression changes elicited by music in saliva samples in healthy donors and ACD patients. For this purpose, we have followed the same experimental design that has already been successfully used in our previous study on capillary blood samples, but this time employing a specific saliva collection device and a hybridization-based and PCR-free <italic toggle="yes">n</italic>Counter assay from NanoString. Currently, this is the most appropriate technology to deal with transcriptomes isolated from saliva samples, which are usually enriched with abundant genetic material from microbial species and poor in terms of quantity/quality.</p><p>Overall, the results suggest that music significantly impacts on the salivary transcriptomes of patients and controls; with this impact being higher than in the capillary blood transcriptomes of donors (as evidenced by the number of DEGs captured, both non-adjusted and adjusted; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>). This finding highlights, for the first time, the relevance of the host transcriptome response to music in saliva. Additionally, the results indicate that the relative impact of music on individual genes may vary considerably between tissues, leading to specific genes being upregulated in one tissue but downregulated in another; this differential behavior between tissues is consistent with responses to other significant external stimuli in the host, such as an infection (<xref rid="ref30" ref-type="bibr">G&#243;mez-Carballa et al., 2022</xref>).</p><p>Three significant observations from the present study on the impact of music on salivary transcriptomes have already been reported for capillary blood transcriptomes (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>), namely, music elicits: (i) greater transcriptomic changes in ACD patients than in controls, (ii) a transcriptomic response toward upregulation in ACD patients compared to healthy donors, and (iii) music modifies the salivary expression of a few genes that are known to be altered in AD/MCI conditions. Despite the relatively low overlap existing between DEGs from saliva and blood capillary samples, <italic toggle="yes">KDM6B</italic> (Lysine Demethylase 6B) and <italic toggle="yes">TIMP2</italic> (TIMP Metallopeptidase Inhibitor 2) genes emerged as the only common DEGs (adjusted <italic toggle="yes">p</italic>-value &lt; 0.05) in both tissues from ACD patients. <italic toggle="yes">TIMP2</italic> was downregulated in both tissues whereas <italic toggle="yes">KDM6B</italic> showed opposite regulation patterns between tissues after musical stimuli. Furthermore, these genes were also found significantly upregulated in MCI/AD patients compared to healthy controls (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>). As reported in the literature, both <italic toggle="yes">KDM6B</italic> and <italic toggle="yes">TIMP2</italic> are required for a normal brain function, as alterations in these genes might lead to neurological conditions. <italic toggle="yes">TIMP2</italic> protein regulates extracellular matrix (ECM) remodeling and is particularly enriched in the hippocampus in comparison to other TIMP proteins (<xref rid="ref15" ref-type="bibr">Castellano et al., 2017</xref>). In the adult brain, <italic toggle="yes">TIMP2</italic> participates in neurogenesis, neuronal differentiation and in hippocampus-dependent memory (<xref rid="ref23" ref-type="bibr">Ferreira et al., 2023</xref>; <xref rid="ref58" ref-type="bibr">Perez-Martinez and Jaworski, 2005</xref>). Moreover, TIMP2 level disturbances were found across several neurodegenerative disorders such as AD (<xref rid="ref45" ref-type="bibr">Lorenzl et al., 2003</xref>; <xref rid="ref76" ref-type="bibr">Wang et al., 2020</xref>; <xref rid="ref1" ref-type="bibr">Aksnes et al., 2023</xref>). <italic toggle="yes">KDM6B</italic> cooperates with Tau in regulating synaptic plasticity and cognitive function (<xref rid="ref77" ref-type="bibr">Wang et al., 2022</xref>) and is present in excitatory neurons. Deleting <italic toggle="yes">KDM6B</italic> in neurons led to impaired synaptic activity, resulting in learning and memory deficits in mice (<xref rid="ref77" ref-type="bibr">Wang et al., 2022</xref>). Indeed, <italic toggle="yes">KDM6B</italic> has been recently reported as a risk gene for intellectual disability (<xref rid="ref73" ref-type="bibr">Stolerman et al., 2019</xref>), highlighting its importance for an adequate brain activity.</p><p>In ACD patients, the <italic toggle="yes">CXCL8</italic> and <italic toggle="yes">LGALS3</italic> genes emerged as the most upregulated and downregulated genes in TP2, respectively. <italic toggle="yes">CXCL8</italic> gene encodes the pro-inflammatory IL-8 cytokine and is primarily expressed in neurons, astrocytes, and microglia in the nervous system. Chronic inflammation has been reported to be a pivotal factor in AD development (<xref rid="ref80" ref-type="bibr">Xia and Hyman, 1999</xref>), even from an early stage of the disease progression (MCI) and potentially preceding clinical symptoms. Significantly higher levels of CXCL8 have been reported in cerebrospinal fluid (CSF), brain and plasma from AD patients in comparison to levels from healthy controls (<xref rid="ref3" ref-type="bibr">Alsadany et al., 2013</xref>; <xref rid="ref4" ref-type="bibr">Ashutosh et al., 2011</xref>; <xref rid="ref18" ref-type="bibr">Correa et al., 2011</xref>; <xref rid="ref27" ref-type="bibr">Galimberti et al., 2006</xref>), suggesting a probable detrimental role of CXCL8 in AD. <italic toggle="yes">CXCL8</italic> has been negatively correlated with cognitive scores from AD patients (<xref rid="ref3" ref-type="bibr">Alsadany et al., 2013</xref>), and positively correlated with CSF amyloid beta (A&#946;) levels (<xref rid="ref18" ref-type="bibr">Correa et al., 2011</xref>). However, a neuro-protective role of CXCL8 in AD has also been suggested. While stimulation with A&#946; triggers <italic toggle="yes">CXCL8</italic> production, it exhibits neuroprotective effects against A&#946;-induced toxicity, possibly through a <italic toggle="yes">CXCL8</italic>-induced intracellular signaling and the production of neurotrophic factors, such as brain-derived neurotrophic factor (<xref rid="ref4" ref-type="bibr">Ashutosh et al., 2011</xref>). Thus, it is tempting to interpret that the upregulation of the <italic toggle="yes">CXCL8</italic> gene observed in saliva might represent a neuroprotective response triggered by music in the brains of ACD patients. Nevertheless, the specific role of <italic toggle="yes">CXCL8</italic> in AD pathogenesis is still unclear, and the disparity in results reporting both neuroprotective and detrimental effects may reflect issues related to, e.g., different experimental conditions and tissues.</p><p>The main pathological characteristics of AD include the formation of A&#946; plaques and neurofibrillary tangles, neuronal loss, inflammation, oxidative stress, and microglial activation. Galectin-3, encoded by <italic toggle="yes">LGALS3</italic> gene, has been extensively associated with the activation of microglial cells around A&#946; plaques in AD, indicating a major involvement in disease pathogenesis (<xref rid="ref12" ref-type="bibr">Boza-Serrano et al., 2019</xref>; <xref rid="ref36" ref-type="bibr">Holtman et al., 2015</xref>; <xref rid="ref43" ref-type="bibr">Krasemann et al., 2017</xref>). Molecular signatures of microglial activation in AD and aging have been described <italic toggle="yes">LGALS3</italic> as one of the most upregulated genes (<xref rid="ref43" ref-type="bibr">Krasemann et al., 2017</xref>; <xref rid="ref40" ref-type="bibr">Keren-Shaul et al., 2017</xref>). Although there are no data on the Galectin-3 measurements in microglia from MCI patients, elevated galectin levels have also been reported in the serum of both AD and MCI patients (<xref rid="ref37" ref-type="bibr">Ijsselstijn et al., 2013</xref>; <xref rid="ref47" ref-type="bibr">Ma et al., 2020</xref>; <xref rid="ref82" ref-type="bibr">Yazar et al., 2021</xref>; <xref rid="ref78" ref-type="bibr">Wang et al., 2015</xref>), suggesting a role of Galectin-3 in the disease and/or a risk factor for disease development. These pieces of evidence support the usefulness of Galectin-3 as a biomarker for AD, and its inhibition could have significant therapeutic benefits (<xref rid="ref12" ref-type="bibr">Boza-Serrano et al., 2019</xref>). Therefore, the under-expression of <italic toggle="yes">LGALS3</italic> might suggest a beneficial effect of music in ACD by compensating for the pathological effect of <italic toggle="yes">LGALS3</italic> over-expression due to the disease condition.</p><p>The top DEG in healthy controls, the Thimet Oligopeptidase (<italic toggle="yes">THOP1</italic>) gene, showed a significantly lower expression after the musical stimuli. <italic toggle="yes">THOP1</italic> is responsible for encoding a metallopeptidase, which participates in the metabolism of different neuropeptides expressed in neurons and glial cells, and plays a role in the brain neuropeptide degradation (<xref rid="ref41" ref-type="bibr">Kim et al., 2003</xref>). Dysregulation of <italic toggle="yes">THOP1</italic> has been associated with an unbalance in dopamine and serotonin turnover (<xref rid="ref24" ref-type="bibr">Ferro et al., 2020</xref>) and it is widely understood that listening to music can influence both dopaminergic and serotoninergic pathways. Thus, under-expression observed in the <italic toggle="yes">THOP1</italic> gene may be indicative of a music-mediated regulation of these neurotransmission systems. In addition, some studies have reported an over-regulation of <italic toggle="yes">THOP1</italic> in brain and CSF of AD patients (<xref rid="ref20" ref-type="bibr">Del Campo et al., 2023</xref>; <xref rid="ref71" ref-type="bibr">Shi et al., 2020</xref>), indicating a potential association with A&#946;-mediated toxicity. However, this over-expression of <italic toggle="yes">THOP1</italic> in AD patients has been attributed to a protective response against A&#946; toxicity (<xref rid="ref59" ref-type="bibr">Pollio et al., 2008</xref>).</p><p>Pathways analysis of DEGs suggests an influence of musical stimuli on unsaturated fatty acid metabolism in ACD patients. The brain, predominantly composed of lipids, necessitates proper lipid homeostasis for a normal brain function and development. Within the brain, unsaturated fatty acids, particularly polyunsaturated fatty acids (PUFAs) govern critical processes such as cell survival, neurogenesis, brain inflammation and synaptic function (<xref rid="ref6" ref-type="bibr">Bazinet and Laye, 2014</xref>). With normal aging, there is a decline in cholesterol and PUFAs levels in lipid rafts, affecting cell&#8211;cell communication, signal transduction, and synaptic plasticity. However, this reduction is significantly more prominent in AD and other neurodegenerative diseases, leading to dysregulation in unsaturated fatty acid metabolism, increased Amyloid Precursor Protein (APP) processing, and rapid formation of A&#946; aggregates (<xref rid="ref32" ref-type="bibr">Grassi et al., 2020</xref>; <xref rid="ref72" ref-type="bibr">Snowden et al., 2017</xref>). Reduced levels of unsaturated fatty acids have been detected in the brain and plasma of AD patients (<xref rid="ref72" ref-type="bibr">Snowden et al., 2017</xref>; <xref rid="ref19" ref-type="bibr">Cunnane et al., 2012</xref>). Interestingly, various therapeutic approaches targeting lipid metabolism are being considered in the context of AD (<xref rid="ref75" ref-type="bibr">Tong et al., 2024</xref>); our finding indicating a role of music in lipid homeostasis deserves further exploration.</p><p>Co-expression modules analysis pointed out to an impact of music on the salivary transcriptomes, higher in ACD than in healthy controls (both in correlation values and lower <italic toggle="yes">p</italic>-values). Overall, the molecular response to music was characterized by a stronger involvement of both adaptative and innate immune systems in healthy controls than in ACD patients. Specifically, the over-regulated <italic toggle="yes">GZMA</italic> module was found to be engaged in several T-cell adaptative related responses whereas the under-regulated <italic toggle="yes">SERPINA1</italic> module participates in different innate processes, such as IL-1 and TLR signaling. Interactions between the immune and nervous systems are bidirectional, with each directly influencing the behavior of the other. Furthermore, both the adaptive and innate immune systems play complex and dynamic roles in learning and memory, brain function, and neurostimulation and collaborate closely to preserve immune homeostasis (<xref rid="ref25" ref-type="bibr">Filiano et al., 2015</xref>). Dysregulation of these immune components can have significant repercussions on brain function and development, underscoring the importance of proper immune regulation in maintaining neurological health. For instance, microglia are macrophage-like innate resident immune cells of the central nervous system (CNS) with essential functions in the brain, ranging from immune surveillance and response to synaptic pruning and neuroprotection (<xref rid="ref56" ref-type="bibr">Paolicelli et al., 2011</xref>; <xref rid="ref16" ref-type="bibr">Chen et al., 2014</xref>; <xref rid="ref63" ref-type="bibr">Ransohoff and Cardona, 2010</xref>). Microglia interact with neurons modulating synaptic transmissions and, therefore, directly influencing synaptic plasticity and neuronal excitability (<xref rid="ref57" ref-type="bibr">Pascual et al., 2012</xref>; <xref rid="ref84" ref-type="bibr">Zhan et al., 2014</xref>). Dysregulation of microglial activity has been implicated in neurological and neurodegenerative disorders, such as AD (<xref rid="ref68" ref-type="bibr">Scheltens et al., 2021</xref>). Another innate immune component, the TLR family, is expressed in microglia, astrocytes and oligodendrocytes, but neurons also express TLRs, regulating proliferation, differentiation, outgrowth and neuron survival (<xref rid="ref55" ref-type="bibr">Okun et al., 2011</xref>). TLRs cascades are involved in different brain-related functions contributing to neurogenesis, modulation of CNS plasticity and learning (<xref rid="ref66" ref-type="bibr">Rolls et al., 2007</xref>; <xref rid="ref54" ref-type="bibr">Okun et al., 2010</xref>). Disturbances in TLR signaling might have either a negative or positive impact on nervous system homeostasis. Studies also provide evidence of the important role of cytokines considered pro-inflammatory, such as the innate immunity mediators IL-1 and TNF, for normal synaptic function (<xref rid="ref7" ref-type="bibr">Ben Menachem-Zidon et al., 2011</xref>; <xref rid="ref83" ref-type="bibr">Yirmiya and Goshen, 2011</xref>). Similarly, adaptative immunity T-cells have showed to be important for normal brain functioning with a beneficial role in cognition and behavior (<xref rid="ref42" ref-type="bibr">Kipnis et al., 2012</xref>; <xref rid="ref14" ref-type="bibr">Brynskikh et al., 2008</xref>; <xref rid="ref62" ref-type="bibr">Radjavi et al., 2014</xref>). A decreased number or dysfunction of T-cells may contribute to the etiology of different neurological disorders like autism or AD.</p><p>Notably, <italic toggle="yes">CD59</italic> gene emerged as both one of the top downregulated DEGs and the hub gene of the under-regulated module in ACD patients. CD59 is a glycoprotein that plays a crucial role in regulating the complement system by preventing the formation of the Membrane Attack Complex (MAC). In the brain, complement proteins regulate neurodevelopment, neural migration, proliferation and synaptic pruning. Downregulation of <italic toggle="yes">CD59</italic> (<xref rid="ref81" ref-type="bibr">Yang et al., 2000</xref>) and upregulation of the complement system have been reported in several studies involving AD mouse models and brain tissue from AD patients (<xref rid="ref34" ref-type="bibr">Hammond et al., 2019</xref>; <xref rid="ref70" ref-type="bibr">Shi et al., 2017</xref>; <xref rid="ref64" ref-type="bibr">Reichwald et al., 2009</xref>). However, it is still unclear if the changes in complement activity observed in AD are harmful or beneficial, as studies report both neuroprotective and neurodegenerative roles (<xref rid="ref70" ref-type="bibr">Shi et al., 2017</xref>; <xref rid="ref48" ref-type="bibr">Maier et al., 2008</xref>; <xref rid="ref9" ref-type="bibr">Benoit et al., 2013</xref>; <xref rid="ref74" ref-type="bibr">Toledo et al., 2014</xref>; <xref rid="ref13" ref-type="bibr">Brucato and Benjamin, 2020</xref>). Therefore, the biological interpretation of the expression changes induced by music is complex. The two downregulated modules in ACD patients and controls (<italic toggle="yes">CD59</italic> and <italic toggle="yes">SERPINA1</italic>) showed some functional commonalities, with intracellular transport and autophagic pathways emerging as common processes associated with the musical stimuli in both modules. Autophagy promotes the clearance of misfolded proteins and pathological aggregates, and in the brain, helps to maintain neuronal cellular morphology and physiological activities for a proper CNS function, prevents cellular toxicity and plays a crucial role in synaptic plasticity (<xref rid="ref35" ref-type="bibr">Haynes et al., 2015</xref>). In fact, deficient autophagic machinery is one of the most relevant hallmarks found in neurodegenerative diseases like AD (<xref rid="ref26" ref-type="bibr">Filippone et al., 2022</xref>; <xref rid="ref85" ref-type="bibr">Zhang et al., 2021</xref>). The effect of music on the downregulation of modules involved in autophagy could be related to a local response, as these pathways are crucial for the homeostasis of most, if not all, tissues. However, this issue deserves further investigation in future studies due to the significant role of autophagy in neurodegenerative processes.</p><p>After our initial and recent attempt to investigate the impact of music on neurodegenerative diseases, the present follow-up study is pioneering in revealing several aspects: (i) It demonstrates that music has the ability to influence the expression patterns captured from saliva donors, (ii) It establishes parallels between gene expression observed in saliva and blood; (iii) It highlights that music has a stronger impact on the transcriptome of ACD patients compared to healthy individuals, as, e.g., measured by the number of DEGs altered by music, and (iv) It reveals that music overall triggers the upregulation of gene expression in patients compared to healthy controls.</p><p>Among the limitations of the present study, we echo those already discussed in our previous study on sensogenomics22 experimental concerts carried out on capillary blood samples (<xref rid="ref29" ref-type="bibr">G&#243;mez-Carballa et al., 2023</xref>). Additionally, we acknowledge the challenge posed by the analysis of saliva in RNAseq analysis. Fortunately, the methodology employed in the present study, although it evaluates a lower number of genes for expression, offers the advantage of being a gold standard for gene expression studies. Therefore, the high quality of the gene expression results provided by NanoString compensates somewhat for the limitation of analyzing fewer genes.</p><p>The present study has demonstrated the power of short-duration musical stimuli in modifying the salivary transcriptome of ACD patients and healthy donors. The impact of music on saliva tissue is comparable to, or even greater than, that observed in blood with a more pronounced effect seen in patients than in healthy controls. Of note is the discovery that music influences the expression of genes and modules commonly altered in neurodegenerative diseases, a finding that may help to elucidate the known beneficial effects of music as reported by specialists in neuroscience and cognitive sciences. Further efforts to validate these findings in larger cohorts and other disease scenarios and to explore the impact of music not only on the gene expression level but also on other &#8216;-omic&#8217; layers are warranted.</p></sec></body><back><ack><p>We would like to kindly acknowledge all participants in the present study, the AGADEA association of Alzheimer disease patients, and the musicians of SANARTE, who kindly agreed to participate in this project. We would also like to acknowledge the Real Filharmon&#237;a de Galicia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.rfgalicia.org" ext-link-type="uri">www.rfgalicia.org</ext-link>; and Sabela Garc&#237;a Fonte in particular), and the Auditorio de Galicia for their support.</p></ack><fn-group><fn id="fn0001"><p>
<sup>1</sup>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://sensogenomics.com" ext-link-type="uri">http://sensogenomics.com</ext-link>
</p></fn></fn-group><sec sec-type="data-availability" id="sec12"><title>Data availability statement</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/geo/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE268683">GSE268683</ext-link>.</p></sec><sec sec-type="ethics-statement" id="sec13"><title>Ethics statement</title><p>The studies involving humans were approved by the Ethics Committee of Xunta de Galicia approved the present project (Registration code: 2020/021), and the study was conducted in accordance to the guidelines of the Helsinki Declaration. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#8217; legal guardians/next of kin. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec><sec sec-type="author-contributions" id="sec14"><title>Author contributions</title><p>AG-C: Conceptualization, Methodology, Writing &#8211; original draft, Data curation, Investigation, Visualization, Supervision, Validation, Writing &#8211; review &amp; editing, Formal analysis, Software. LN: Writing &#8211; review &amp; editing, Conceptualization. NoM: Writing &#8211; review &amp; editing, Software, Formal analysis. XB: Writing &#8211; review &amp; editing, Data curation, Methodology. SP: Writing &#8211; review &amp; editing, Data curation, Methodology. SV-L: Methodology, Writing &#8211; review &amp; editing, Data curation. MC: Writing &#8211; review &amp; editing, Methodology. IF-V: Writing &#8211; review &amp; editing, Supervision. NaM: Writing &#8211; review &amp; editing, Methodology. JM-L: Writing &#8211; review &amp; editing, Methodology. AC-M: Writing &#8211; review &amp; editing. LC-M: Writing &#8211; review &amp; editing, Methodology. SR-V: Methodology, Writing &#8211; original draft. LR: Writing &#8211; original draft, Methodology. AD-U: Methodology, Writing &#8211; review &amp; editing. IR-C: Methodology, Writing &#8211; review &amp; editing. CR-T: Writing &#8211; review &amp; editing, Methodology, FM-T: Project administration, Resources, Writing &#8211; review &amp; editing, Funding acquisition. AS: Supervision, Validation, Conceptualization, Investigation, Project administration, Funding acquisition, Writing &#8211; review &amp; editing, Resources, Methodology, Software, Formal analysis, Writing &#8211; original draft, Visualization.</p></sec><sec id="sec15"><title>Group member of sensogenomics working group</title><p>Antonio Salas Ellacuriaga &#8211; PI; Federico Martin&#243;n-Torres &#8211; PI; Laura Navarro Ram&#243;n &#8211; Coordinator. <italic toggle="yes">GenPoB/GenVip - Instituto de Investigaci&#243;n Sanitaria (IDIS) (alphabetic order)</italic>. Alba Camino Mera, Albert Pad&#237;n Villar, Alberto G&#243;mez Carballa, Alejandro P&#233;rez L&#243;pez, Alicia Carballal Fern&#225;ndez, Ana Cotovad Bellas, Ana Isabel Dacosta Urbieta, Narmeen Mallah, Ana Mar&#237;a Pastoriza Mourelle, Ana Mar&#237;a Sen&#237;n Ferreiro, Andr&#233;s Muy P&#233;rez, Ant&#237;a Rivas Oural, Antonio Justicia Grande, Antonio Pi&#241;eiro Garc&#237;a, Anxela Cristina Delgado Garc&#237;a, Bel&#233;n Mosquera P&#233;rez, Blanca D&#237;az Esteban, Carlos Dur&#225;n Su&#225;rez, Carmen Curros Novo, Carmen G&#243;mez Vieites, Carmen Rodr&#237;guez-Tenreiro S&#225;nchez, Celia Varela P&#225;jaro, Claudia Navarro Gonzalo, Cristina Ser&#233;n Trasorras, Cristina Talavero Gonz&#225;lez, Ein&#233;s Monteagudo Vilavedra, Estefan&#237;a Rey Campos, Esther Montero Campos, Fernando &#193;lvez Gonz&#225;lez, Fernando Caama&#241;o Vi&#241;as, Francisco Garc&#237;a Iglesias, Gloria <italic toggle="yes">Viz</italic> Rodr&#237;guez, Hugo Alberto Tovar Velasco, Irene &#193;lvarez Rodr&#237;guez, Irene Garc&#237;a Zuazola, Irene Rivero Calle, Iria Afonso Carrasco, Isabel Ferreir&#243;s Vidal, Isabel Lista Garc&#237;a, Isabel Rego Lijo, Iv&#225;n Prieto G&#243;mez, Iv&#225;n Quintana Cepedal, Jacobo Pardo Seco, Jes&#250;s Eir&#237;s Pu&#241;al, Jos&#233; G&#243;mez Rial, Jos&#233; Manuel Fern&#225;ndez Garc&#237;a, Jos&#233; Mar&#237;a Martin&#243;n Mart&#237;nez, Julia Cela Mosquera, Julia Garc&#237;a Curr&#225;s, Juli&#225;n Montoto Louzao, Lara Mart&#237;nez Mart&#237;nez, Laura Navarro Marr&#243;n, Lidia Pi&#241;eiro Rodr&#237;guez, Lorenzo Redondo Collazo, L&#250;a Castelo Mart&#237;nez, Luc&#237;a Company Arciniegas, Luis Crego Rodr&#237;guez, Luisa Garc&#237;a Vicente, Manuel V&#225;zquez Donsi&#243;n, Mar&#237;a Dolores Mart&#237;nez Garc&#237;a, Mar&#237;a Elena Gamborino Caram&#233;s, Mar&#237;a Elena Sobrino Fern&#225;ndez, Mar&#237;a Jos&#233; Curr&#225;s Tuala, Mar&#237;a Mart&#237;nez Leis, Mar&#237;a Soledad Vilas Iglesias, Mar&#237;a Sol Rodriguez Calvo, Mar&#237;a Teresa Autran Garc&#237;a, Marina Casas P&#233;rez, Marta Aldonza Torres, Marta Bouz&#243;n Alejandro, Marta Lendoiro Fuentes, Miriam Ben Garc&#237;a, Miriam Cebey L&#243;pez, Montserrat L&#243;pez Franco, Nour El Zahraa Mallah, Narmeen Mallah, Natalia Garc&#237;a S&#225;nchez, Natalia Vieito Perez, Patricia Regueiro Casuso, Ricardo Su&#225;rez Camacho, Rita Garc&#237;a Fern&#225;ndez, Rita Varela Est&#233;vez, Rosaura Pic&#225;ns Leis, Ruth Barral Arca, Sandra Carnota Antonio, Sandra <italic toggle="yes">Viz</italic> Lasheras, Sara Pischedda, Sara Rey V&#225;zquez, Sonia Marcos Alonso, Sonia Ser&#233;n Fern&#225;ndez, Susana Rey Garc&#237;a, Vanesa &#193;lvarez Iglesias, Victoria Redondo Cervantes, Vanesa &#193;lvarez Iglesias, Wiktor Dominik Nowak, Xabier Bello Paderne, and Xabier Mazaira L&#243;pez. <italic toggle="yes">Nursing volunteers (alphabetic order)</italic>. Alejandra Fern&#225;ndez M&#233;ndez, Ana Isabel Abad&#237;n Campa&#241;a, Ana Mar&#237;a Le&#243;n Caama&#241;o, Ana Mar&#237;a Buide Illobre, &#193;ngeles Mera Cores, Carmen Nieves Vastro, Carolina Suarez Crego, Concepci&#243;n Rey Iglesias, Cristina Candal Regueira, Dolores Barreiro Puente, Elvira Rodr&#237;guez Rodr&#237;guez, Eugenia Gonz&#225;lez Budi&#241;o, Eva Rey &#193;lvarez, Fernando Rodr&#237;guez Gerpe, Gemma Albela Silva, Isabel Castro P&#233;rez, Isabel Dom&#237;nguez R&#237;os, Jos&#233; &#193;ngel Fern&#225;ndez de la Iglesia, Jos&#233; Cruces V&#225;zquez, Jos&#233; Luis Cambeiro Quintela, Jos&#233; Ram&#243;n Magari&#241;os Iglesias, Julia Rey Brandariz, Julio Abel Fern&#225;ndez L&#243;pez, Luisa Garc&#237;a Vicente, Manuel Gonz&#225;lez Lito, Manuel Gonz&#225;lez Lij&#243;, Manuela P&#233;rez Rivas, Margarita Turnes Paredes, Mar&#237;a Aurora M&#233;ndez L&#243;pez, Mar&#237;a Bego&#241;a Tom&#233; Arufe, Mar&#237;a Campos Torres, Mar&#237;a del Carmen Baloira Nogueira, Mar&#237;a del Carmen Garc&#237;a juan, Mar&#237;a Esther Moricosa Garc&#237;a, Mar&#237;a Luz Chao Jarel, Mar&#237;a Mart&#237;nez Leis, Mar&#237;a Mercedes Jim&#233;nez Santos, Mar&#237;a Salom&#233; Buide Illobre, Mar&#237;a Victoria L&#243;pez Pereira, Mercedes Jorge Gonz&#225;lez, Mercedes Isolina Rodr&#237;guez Rodr&#237;guez, Miren Payo Puente, Natalia Carter Dom&#237;nguez, Olga Mar&#237;a Reyes Gonz&#225;lez, Pilar Mera Rodr&#237;guez, Purificaci&#243;n Sebio Brandariz, Salom&#233; Quint&#225;ns lago, Yolanda Rodr&#237;guez Taboada, and Mar&#237;a Pereira Grau. <italic toggle="yes">Other volunteers (alphabetic order)</italic>. Alba Arias G&#243;mez, Alejandro Moreno D&#237;az, Ana Arca Mar&#225;n, Astro Gonz&#225;lez Guirado, Brais Garc&#237;a Iglesias, Carlos S&#225;nchez Rub&#237;n, Carmen Otero de Andr&#233;s, Clara P&#233;rez Errazquin Barrera, Claudia Rey Posse, Cristina Rojas Garc&#237;a, Eduardo Xavier Gim&#233;nez Bargiela, Elena Gloria Morales Garc&#237;a, Fabio Izquierdo Garc&#237;a Escribano, Gabriel Guisande Garc&#237;a, Jaime L&#243;pez Mart&#237;n, Lara Pais Ramiro, Luc&#237;a Rico Montero, Lu&#237;s Est&#233;vez Mart&#237;nez, Manuel Est&#233;vez Casal, Mar&#237;a Ar&#225;nzazu Palomino Ca&#241;o, Mar&#237;a Rubio Vald&#233;s, Marisol Nogales Ben&#237;tez, Miryam Tilve P&#233;rez, Nuria Villar Mui&#241;os, Pablo Del Cerro Rodr&#237;guez, Pablo Pozuelo Mart&#237;nez Carde&#241;oso, Salma Ouahabi El Ouahabi, and Santiago V&#225;zquez Calvache.</p></sec><sec sec-type="COI-statement" id="sec17"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec18"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec19"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec20"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fnagi.2025.1622816/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnagi.2025.1622816/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_1.XLSX" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_2.XLSX" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM3" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_3.XLSX" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM4" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_4.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image_1.TIF" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM6" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image_2.TIF" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM7" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image_3.TIF" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aksnes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edwin</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Saltvedt</surname><given-names>I.</given-names></name><name name-style="western"><surname>Eldholm</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Chaudhry</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Halaas</surname><given-names>N. B.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Sex-specific associations of matrix metalloproteinases in Alzheimer's disease</article-title>. <source>Biol. Sex Differ.</source><volume>14</volume>:<fpage>35</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13293-023-00514-x</pub-id>, PMID: <pub-id pub-id-type="pmid">37221606</pub-id><pub-id pub-id-type="pmcid">PMC10207710</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nater</surname><given-names>U. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Salivary alpha-amylase as a biomarker of stress in behavioral medicine</article-title>. <source>Int. J. Behav. Med.</source><volume>27</volume>, <fpage>337</fpage>&#8211;<lpage>342</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12529-019-09843-x</pub-id>, PMID: <pub-id pub-id-type="pmid">31900867</pub-id><pub-id pub-id-type="pmcid">PMC7250801</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsadany</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Shehata</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Mohamad</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Mahfouz</surname><given-names>R. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease</article-title>. <source>Am. J. Alzheimers Dis. Other Dement.</source><volume>28</volume>, <fpage>54</fpage>&#8211;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1533317512467680</pub-id>, PMID: <pub-id pub-id-type="pmid">23242124</pub-id><pub-id pub-id-type="pmcid">PMC10697231</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashutosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cotter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Borgmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Persidsky</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>CXCL8 protects human neurons from amyloid-beta-induced neurotoxicity: relevance to Alzheimer's disease</article-title>. <source>Biochem. Biophys. Res. Commun.</source><volume>412</volume>, <fpage>565</fpage>&#8211;<lpage>571</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2011.07.127</pub-id><pub-id pub-id-type="pmid">21840299</pub-id><pub-id pub-id-type="pmcid">PMC3236067</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauduin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bauduin</surname><given-names>S. E. E. C.</given-names></name><name name-style="western"><surname>Giltay</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>van Noorden</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>der Werff</surname><given-names>S. J. A.</given-names></name><name name-style="western"><surname>de Leeuw</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Salivary markers of stress system activation and social withdrawal in humans</article-title>. <source>J. Psychiatr. Res.</source><volume>136</volume>, <fpage>435</fpage>&#8211;<lpage>443</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpsychires.2020.10.017</pub-id>, PMID: <pub-id pub-id-type="pmid">33160608</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bazinet</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Laye</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Polyunsaturated fatty acids and their metabolites in brain function and disease</article-title>. <source>Nat. Rev. Neurosci.</source><volume>15</volume>, <fpage>771</fpage>&#8211;<lpage>785</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrn3820</pub-id>, PMID: <pub-id pub-id-type="pmid">25387473</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben Menachem-Zidon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Avital</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ben-Menahem</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Goshen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kreisel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shmueli</surname><given-names>E. M.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Astrocytes support hippocampal-dependent memory and long-term potentiation via interleukin-1 signaling</article-title>. <source>Brain Behav. Immun.</source><volume>25</volume>, <fpage>1008</fpage>&#8211;<lpage>1016</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbi.2010.11.007</pub-id>, PMID: <pub-id pub-id-type="pmid">21093580</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamini</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hochberg</surname><given-names>Y.</given-names></name></person-group> (<year>1995</year>). <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J. R. Stat. Soc. Ser. B Stat Methodol.</source><volume>57</volume>, <fpage>289</fpage>&#8211;<lpage>300</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benoit</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>M. X.</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Benavente</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vasquez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tenner</surname><given-names>A. J.</given-names></name></person-group> (<year>2013</year>). <article-title>C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-beta neurotoxicity</article-title>. <source>J. Biol. Chem.</source><volume>288</volume>, <fpage>654</fpage>&#8211;<lpage>665</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M112.400168</pub-id>, PMID: <pub-id pub-id-type="pmid">23150673</pub-id><pub-id pub-id-type="pmcid">PMC3537064</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Furberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pietzak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Purdue</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Troester</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>An approach for normalization and quality control for NanoString RNA expression data</article-title>. <source>Brief. Bioinform.</source><volume>22</volume>. doi: <pub-id pub-id-type="doi">10.1093/bib/bbaa163</pub-id>, PMID: <pub-id pub-id-type="pmid">32789507</pub-id><pub-id pub-id-type="pmcid">PMC8138885</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Blighe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <italic toggle="yes">EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling. Version 180, R package</italic>.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boza-Serrano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sanchez-Varo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garc&#237;a-Revilla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jimenez-Ferrer</surname><given-names>I.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's disease</article-title>. <source>Acta Neuropathol.</source><volume>138</volume>, <fpage>251</fpage>&#8211;<lpage>273</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-019-02013-z</pub-id>, PMID: <pub-id pub-id-type="pmid">31006066</pub-id><pub-id pub-id-type="pmcid">PMC6660511</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brucato</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>D. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Synaptic pruning in Alzheimer's disease: role of the complement system</article-title>. <source>Glob. J. Med. Res.</source><volume>20</volume>. doi: <pub-id pub-id-type="doi">10.34257/gjmrfvol20is6pg1</pub-id>, PMID: <pub-id pub-id-type="pmid">32982106</pub-id><pub-id pub-id-type="pmcid">PMC7518506</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brynskikh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kipnis</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Adaptive immunity affects learning behavior in mice</article-title>. <source>Brain Behav. Immun.</source><volume>22</volume>, <fpage>861</fpage>&#8211;<lpage>869</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbi.2007.12.008</pub-id>, PMID: <pub-id pub-id-type="pmid">18249087</pub-id></mixed-citation></ref><ref id="ref9001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castelo-Mart&#237;nez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mallah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cavenaghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martin&#243;n-Torres</surname><given-names>F.</given-names></name><name name-style="western"><surname>G&#243;mez-Carballa</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Harmonizing the oral-brain axis: Music-induced microbiota shifts in age-related cognitive disorders and healthy aging</article-title>. <source>medRxiv</source>. doi: <pub-id pub-id-type="doi">10.1101/2025.07.29.25332408</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellano</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Mosher</surname><given-names>K. I.</given-names></name><name name-style="western"><surname>Abbey</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>James</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Berdnik</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Human umbilical cord plasma proteins revitalize hippocampal function in aged mice</article-title>. <source>Nature</source><volume>544</volume>, <fpage>488</fpage>&#8211;<lpage>492</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature22067</pub-id>, PMID: <pub-id pub-id-type="pmid">28424512</pub-id><pub-id pub-id-type="pmcid">PMC5586222</pub-id></mixed-citation></ref><ref id="ref9002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavenaghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mallah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martin&#243;n-Torres</surname><given-names>F.</given-names></name></person-group>, <person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Carballa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>A.</given-names></name></person-group> (<year>2025</year>). <article-title>Decoding the peripheral transcriptomic and meta-genomic response to music in Autism Spectrum Disorder via saliva-based RNA sequencing</article-title>. <source>BioRxiv</source>. doi: <pub-id pub-id-type="doi">10.1101/2025.07.04.663204</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jalabi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>G. J.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain</article-title>. <source>Nat. Commun.</source><volume>5</volume>:<fpage>4486</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms5486</pub-id>, PMID: <pub-id pub-id-type="pmid">25047355</pub-id><pub-id pub-id-type="pmcid">PMC4109015</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chibly</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Aure</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V. N.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>M. P.</given-names></name></person-group> (<year>2022</year>). <article-title>Salivary gland function, development, and regeneration</article-title>. <source>Physiol. Rev.</source><volume>102</volume>, <fpage>1495</fpage>&#8211;<lpage>1552</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00015.2021</pub-id>, PMID: <pub-id pub-id-type="pmid">35343828</pub-id><pub-id pub-id-type="pmcid">PMC9126227</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correa</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Starling</surname><given-names>D.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Caramelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>T. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Chemokines in CSF of Alzheimer's disease patients</article-title>. <source>Arq. Neuropsiquiatr.</source><volume>69</volume>, <fpage>455</fpage>&#8211;<lpage>459</lpage>. doi: <pub-id pub-id-type="doi">10.1590/s0004-282x2011000400009</pub-id>, PMID: <pub-id pub-id-type="pmid">21755121</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunnane</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Tangney</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tremblay-Mercier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fortier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D. A.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease</article-title>. <source>J. Alzheimers Dis.</source><volume>29</volume>, <fpage>691</fpage>&#8211;<lpage>697</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-2012-110629</pub-id>, PMID: <pub-id pub-id-type="pmid">22466064</pub-id><pub-id pub-id-type="pmcid">PMC3409580</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Campo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vermunt</surname><given-names>L.</given-names></name><name name-style="western"><surname>CFW</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sieben</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hok-A-Hin</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Lle&#243;</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer s disease</article-title>. <source>Nat. Commun.</source><volume>14</volume>:<fpage>5635</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-023-41122-y</pub-id>, PMID: <pub-id pub-id-type="pmid">37704597</pub-id><pub-id pub-id-type="pmcid">PMC10499811</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engeland</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Rohleder</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>Salivary biomarkers in psychoneuroimmunology</article-title>. <source>Curr. Opin. Behav. Sci.</source><volume>28</volume>, <fpage>58</fpage>&#8211;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cobeha.2019.01.007</pub-id>, PMID: <pub-id pub-id-type="pmid">32215283</pub-id><pub-id pub-id-type="pmcid">PMC7094032</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Haraty</surname><given-names>H.</given-names></name><name name-style="western"><surname>Salame</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fares</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ojcius</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Said Sadier</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Salivary biomarkers for the diagnosis and monitoring of neurological diseases</article-title>. <source>Biom. J.</source><volume>41</volume>, <fpage>63</fpage>&#8211;<lpage>87</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bj.2018.03.004</pub-id>, PMID: <pub-id pub-id-type="pmid">29866603</pub-id><pub-id pub-id-type="pmcid">PMC6138769</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Philippi</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Grau-Perales</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Rosenstadt</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Neuronal TIMP2 regulates hippocampus-dependent plasticity and extracellular matrix complexity</article-title>. <source>Mol. Psychiatry</source><volume>28</volume>, <fpage>3943</fpage>&#8211;<lpage>3954</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41380-023-02296-5</pub-id>, PMID: <pub-id pub-id-type="pmid">37914840</pub-id><pub-id pub-id-type="pmcid">PMC10730400</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferro</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Gewehr</surname><given-names>M. C. F.</given-names></name><name name-style="western"><surname>Navon</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Thimet Oligopeptidase biochemical and biological significances: past, present, and future directions</article-title>. <source>Biomolecules</source><volume>10</volume>. doi: <pub-id pub-id-type="doi">10.3390/biom10091229</pub-id>, PMID: <pub-id pub-id-type="pmid">32847123</pub-id><pub-id pub-id-type="pmcid">PMC7565970</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filiano</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Gadani</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Kipnis</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Interactions of innate and adaptive immunity in brain development and function</article-title>. <source>Brain Res.</source><volume>1617</volume>, <fpage>18</fpage>&#8211;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainres.2014.07.050</pub-id>, PMID: <pub-id pub-id-type="pmid">25110235</pub-id><pub-id pub-id-type="pmcid">PMC4320678</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filippone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mannino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lyssenko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pratico</surname><given-names>D.</given-names></name></person-group> (<year>2022</year>). <article-title>The contribution of altered neuronal autophagy to neurodegeneration</article-title>. <source>Pharmacol. Ther.</source><volume>238</volume>:<fpage>108178</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pharmthera.2022.108178</pub-id>, PMID: <pub-id pub-id-type="pmid">35351465</pub-id><pub-id pub-id-type="pmcid">PMC9510148</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galimberti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schoonenboom</surname><given-names>N.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fenoglio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouwman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Venturelli</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease</article-title>. <source>Arch. Neurol.</source><volume>63</volume>, <fpage>538</fpage>&#8211;<lpage>543</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archneur.63.4.538</pub-id>, PMID: <pub-id pub-id-type="pmid">16606766</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrett</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>A.</given-names></name></person-group> (<year>1993</year>). <article-title>The innervation of salivary glands as revealed by morphological methods</article-title>. <source>Microsc. Res. Tech.</source><volume>26</volume>, <fpage>75</fpage>&#8211;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jemt.1070260108</pub-id>, PMID: <pub-id pub-id-type="pmid">8219376</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Carballa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pardo-Seco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pischedda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Viz-Lasheras</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Music compensates for altered gene expression in age-related cognitive disorders</article-title>. <source>Sci. Rep.</source><volume>13</volume>:<fpage>21259</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-48094-5</pub-id>, PMID: <pub-id pub-id-type="pmid">38040763</pub-id><pub-id pub-id-type="pmcid">PMC10692168</pub-id></mixed-citation></ref><ref id="ref9003"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Carballa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pischedda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mallah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>W.</given-names></name><name name-style="western"><surname>Martin&#243;n-Torres</surname><given-names>F.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2025</year>). <source>Can music modulate gene expression involved in traumatic brain injury?</source><publisher-loc>An integrative transcriptomic and epigenomic proof of concept</publisher-loc>. <publisher-name>BioRxiv</publisher-name>. doi: <pub-id pub-id-type="doi">10.1101/2025.07.02.662815</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Carballa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rivero-Calle</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pardo-Seco</surname><given-names>J.</given-names></name><name name-style="western"><surname>G&#243;mez-Rial</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rivero-Velasco</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-N&#250;&#241;ez</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity</article-title>. <source>Environ. Res.</source><volume>210</volume>:<fpage>112890</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.envres.2022.112890</pub-id>, PMID: <pub-id pub-id-type="pmid">35202626</pub-id><pub-id pub-id-type="pmcid">PMC8861187</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gosch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Banemann</surname><given-names>R.</given-names></name><name name-style="western"><surname>D&#248;rum</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hadrys</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haenggi</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Spitting in the wind?-the challenges of RNA sequencing for biomarker discovery from saliva</article-title>. <source>Int. J. Legal Med.</source><volume>138</volume>, <fpage>401</fpage>&#8211;<lpage>412</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00414-023-03100-3</pub-id>, PMID: <pub-id pub-id-type="pmid">37847308</pub-id><pub-id pub-id-type="pmcid">PMC10861700</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grassi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giussani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mauri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Prioni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sonnino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prinetti</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases</article-title>. <source>J. Lipid Res.</source><volume>61</volume>, <fpage>636</fpage>&#8211;<lpage>654</lpage>. doi: <pub-id pub-id-type="doi">10.1194/jlr.TR119000427</pub-id>, PMID: <pub-id pub-id-type="pmid">31871065</pub-id><pub-id pub-id-type="pmcid">PMC7193971</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Eils</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schlesner</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title>. <source>Bioinformatics</source><volume>32</volume>, <fpage>2847</fpage>&#8211;<lpage>2849</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btw313</pub-id>, PMID: <pub-id pub-id-type="pmid">27207943</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammond</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>B.</given-names></name></person-group> (<year>2019</year>). <article-title>Immune Signaling in Neurodegeneration</article-title>. <source>Immunity</source><volume>50</volume>, <fpage>955</fpage>&#8211;<lpage>974</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.016</pub-id>, PMID: <pub-id pub-id-type="pmid">30995509</pub-id><pub-id pub-id-type="pmcid">PMC6822103</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Hegde</surname><given-names>A. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Proteasome inhibition augments new protein accumulation early in long-term synaptic plasticity and rescues adverse Abeta effects on protein synthesis</article-title>. <source>ACS Chem. Neurosci.</source><volume>6</volume>, <fpage>695</fpage>&#8211;<lpage>700</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acschemneuro.5b00068</pub-id>, PMID: <pub-id pub-id-type="pmid">25775404</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holtman</surname><given-names>I. R.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Schaafsma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis</article-title>. <source>Acta Neuropathol. Commun.</source><volume>3</volume>:<fpage>31</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40478-015-0203-5</pub-id>, PMID: <pub-id pub-id-type="pmid">26001565</pub-id><pub-id pub-id-type="pmcid">PMC4489356</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ijsselstijn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Papma</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Calame</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stingl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koudstaal</surname><given-names>P. J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Serum proteomics in amnestic mild cognitive impairment</article-title>. <source>Proteomics</source><volume>13</volume>, <fpage>2526</fpage>&#8211;<lpage>2533</lpage>. doi: <pub-id pub-id-type="doi">10.1002/pmic.201200190</pub-id>, PMID: <pub-id pub-id-type="pmid">23868823</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#228;rvel&#228;</surname><given-names>I.</given-names></name></person-group> (<year>2018</year>). <article-title>Genomics studies on musical aptitude, music perception, and practice</article-title>. <source>Ann. N. Y. Acad. Sci.</source><volume>1423</volume>, <fpage>82</fpage>&#8211;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1111/nyas.13620</pub-id>, PMID: <pub-id pub-id-type="pmid">29570792</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanduri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Raijas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ahvenainen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Philips</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Ukkola-Vuoti</surname><given-names>L.</given-names></name><name name-style="western"><surname>L&#228;hdesm&#228;ki</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>The effect of listening to music on human transcriptome</article-title>. <source>PeerJ</source><volume>3</volume>:<fpage>e830</fpage>. doi: <pub-id pub-id-type="doi">10.7717/peerj.830</pub-id>, PMID: <pub-id pub-id-type="pmid">25789207</pub-id><pub-id pub-id-type="pmcid">PMC4362302</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keren-Shaul</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spinrad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matcovitch-Natan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dvir-Szternfeld</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ulland</surname><given-names>T. K.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>A unique microglia type associated with restricting development of Alzheimer's disease</article-title>. <source>Cell</source><volume>169</volume>, <fpage>1276</fpage>&#8211;<lpage>1290.e17</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2017.05.018</pub-id>, PMID: <pub-id pub-id-type="pmid">28602351</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Grum-Tokars</surname><given-names>V.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Cotter</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Cahill</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J. L.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Novel roles of neuropeptide processing enzymes: EC3.4.24.15 in the neurome</article-title>. <source>J. Neurosci. Res.</source><volume>74</volume>, <fpage>456</fpage>&#8211;<lpage>467</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jnr.10779</pub-id>, PMID: <pub-id pub-id-type="pmid">14598322</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kipnis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gadani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Derecki</surname><given-names>N. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Pro-cognitive properties of T cells</article-title>. <source>Nat. Rev. Immunol.</source><volume>12</volume>, <fpage>663</fpage>&#8211;<lpage>669</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri3280</pub-id>, PMID: <pub-id pub-id-type="pmid">22903149</pub-id><pub-id pub-id-type="pmcid">PMC4032225</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krasemann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Madore</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cialic</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baufeld</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calcagno</surname><given-names>N.</given-names></name><name name-style="western"><surname>el Fatimy</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases</article-title>. <source>Immunity</source><volume>47</volume>, <fpage>566</fpage>&#8211;<lpage>581.e9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2017.08.008</pub-id>, PMID: <pub-id pub-id-type="pmid">28930663</pub-id><pub-id pub-id-type="pmcid">PMC5719893</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langfelder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>WGCNA: an R package for weighted correlation network analysis</article-title>. <source>BMC Bioinformatics</source><volume>9</volume>:<fpage>559</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id>, PMID: <pub-id pub-id-type="pmid">19114008</pub-id><pub-id pub-id-type="pmcid">PMC2631488</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Albers</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>LeWitt</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Chirichigno</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Hilgenberg</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Cudkowicz</surname><given-names>M. E.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases</article-title>. <source>J. Neurol. Sci.</source><volume>207</volume>, <fpage>71</fpage>&#8211;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0022-510x(02)00398-2</pub-id>, PMID: <pub-id pub-id-type="pmid">12614934</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol.</source><volume>15</volume>:<fpage>550</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>, PMID: <pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level</article-title>. <source>J. Diabetes Investig.</source><volume>11</volume>, <fpage>1295</fpage>&#8211;<lpage>1302</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jdi.13256</pub-id>, PMID: <pub-id pub-id-type="pmid">32196999</pub-id><pub-id pub-id-type="pmcid">PMC7477520</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seabrook</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Lemere</surname><given-names>C. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice</article-title>. <source>J. Neurosci.</source><volume>28</volume>, <fpage>6333</fpage>&#8211;<lpage>6341</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0829-08.2008</pub-id>, PMID: <pub-id pub-id-type="pmid">18562603</pub-id><pub-id pub-id-type="pmcid">PMC3329761</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>T.</given-names></name></person-group> (<year>1998</year>). <article-title>Sex-dependent differences in the concentrations of the principal neurotransmitters, noradrenaline and acetylcholine, in the three major salivary glands of mice</article-title>. <source>Arch. Oral Biol.</source><volume>43</volume>, <fpage>9</fpage>&#8211;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0003-9969(97)00088-5</pub-id>, PMID: <pub-id pub-id-type="pmid">9569985</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Itsukaichi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>T.</given-names></name></person-group> (<year>1995</year>). <article-title>Basal levels of noradrenaline, dopamine, 5-hydroxytryptamine, and acetylcholine in the submandibular, parotid, and sublingual glands of mice and rats</article-title>. <source>Arch. Oral Biol.</source><volume>40</volume>, <fpage>663</fpage>&#8211;<lpage>668</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0003-9969(95)00023-i</pub-id>, PMID: <pub-id pub-id-type="pmid">7575239</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Futatsugi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kusakawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice</article-title>. <source>J. Physiol.</source><volume>558</volume>, <fpage>561</fpage>&#8211;<lpage>575</lpage>. doi: <pub-id pub-id-type="doi">10.1113/jphysiol.2004.064626</pub-id>, PMID: <pub-id pub-id-type="pmid">15146045</pub-id><pub-id pub-id-type="pmcid">PMC1664962</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarro</surname><given-names>L.</given-names></name><name name-style="western"><surname>G&#243;mez-Carballa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pischedda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montoto-Louzao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Viz-Lasheras</surname><given-names>S.</given-names></name><name name-style="western"><surname>Camino-Mera</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Sensogenomics of music and Alzheimer's disease: An interdisciplinary view from neuroscience, transcriptomics, and epigenomics</article-title>. <source>Front. Aging Neurosci.</source><volume>15</volume>:<fpage>1063536</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2023.1063536</pub-id>, PMID: <pub-id pub-id-type="pmid">36819725</pub-id><pub-id pub-id-type="pmcid">PMC9935844</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martinon-Torres</surname><given-names>F.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Sensogenomics and the biological background underlying musical stimuli: perspectives for a new era of musical research</article-title>. <source>Genes (Basel)</source><volume>12</volume>. doi: <pub-id pub-id-type="doi">10.3390/genes12091454</pub-id>, PMID: <pub-id pub-id-type="pmid">34573436</pub-id><pub-id pub-id-type="pmcid">PMC8472585</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okun</surname><given-names>E.</given-names></name><name name-style="western"><surname>Griffioen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pita</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>107</volume>, <fpage>15625</fpage>&#8211;<lpage>15630</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1005807107</pub-id>, PMID: <pub-id pub-id-type="pmid">20713712</pub-id><pub-id pub-id-type="pmcid">PMC2932590</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okun</surname><given-names>E.</given-names></name><name name-style="western"><surname>Griffioen</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>M. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Toll-like receptor signaling in neural plasticity and disease</article-title>. <source>Trends Neurosci.</source><volume>34</volume>, <fpage>269</fpage>&#8211;<lpage>281</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tins.2011.02.005</pub-id>, PMID: <pub-id pub-id-type="pmid">21419501</pub-id><pub-id pub-id-type="pmcid">PMC3095763</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paolicelli</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Bolasco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Scianni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Panzanelli</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Synaptic pruning by microglia is necessary for normal brain development</article-title>. <source>Science</source><volume>333</volume>, <fpage>1456</fpage>&#8211;<lpage>1458</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1202529</pub-id>, PMID: <pub-id pub-id-type="pmid">21778362</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascual</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ben Achour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rostaing</surname><given-names>P.</given-names></name><name name-style="western"><surname>Triller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bessis</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>109</volume>, <fpage>E197</fpage>&#8211;<lpage>E205</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1111098109</pub-id>, PMID: <pub-id pub-id-type="pmid">22167804</pub-id><pub-id pub-id-type="pmcid">PMC3268269</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Martinez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jaworski</surname><given-names>D. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal</article-title>. <source>J. Neurosci.</source><volume>25</volume>, <fpage>4917</fpage>&#8211;<lpage>4929</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5066-04.2005</pub-id>, PMID: <pub-id pub-id-type="pmid">15901773</pub-id><pub-id pub-id-type="pmcid">PMC1282460</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hoozemans</surname><given-names>J. J. M.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Roncarati</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosi</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>van Haastert</surname><given-names>E. S.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicity</article-title>. <source>Neurobiol. Dis.</source><volume>31</volume>, <fpage>145</fpage>&#8211;<lpage>158</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2008.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">18571100</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proctor</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>G. H.</given-names></name></person-group> (<year>2007</year>). <article-title>Regulation of salivary gland function by autonomic nerves</article-title>. <source>Auton. Neurosci.</source><volume>133</volume>, <fpage>3</fpage>&#8211;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.autneu.2006.10.006</pub-id>, PMID: <pub-id pub-id-type="pmid">17157080</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab id="coll2">R Core Team</collab></person-group> (<year>2019</year>). <source>R: A language and Enviroment for statistical computing R foundation for statistical computing</source>. <publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Core Team</publisher-name>.</mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radjavi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kipnis</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Brain antigen-reactive CD4+ T cells are sufficient to support learning behavior in mice with limited T cell repertoire</article-title>. <source>Brain Behav. Immun.</source><volume>35</volume>, <fpage>58</fpage>&#8211;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbi.2013.08.013</pub-id>, PMID: <pub-id pub-id-type="pmid">24012647</pub-id><pub-id pub-id-type="pmcid">PMC3858511</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ransohoff</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>A. E.</given-names></name></person-group> (<year>2010</year>). <article-title>The myeloid cells of the central nervous system parenchyma</article-title>. <source>Nature</source><volume>468</volume>, <fpage>253</fpage>&#8211;<lpage>262</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature09615</pub-id>, PMID: <pub-id pub-id-type="pmid">21068834</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichwald</surname><given-names>J.</given-names></name><name name-style="western"><surname>Danner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiederhold</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Expression of complement system components during aging and amyloid deposition in APP transgenic mice</article-title>. <source>J. Neuroinflammation</source><volume>6</volume>:<fpage>35</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1742-2094-6-35</pub-id>, PMID: <pub-id pub-id-type="pmid">19917141</pub-id><pub-id pub-id-type="pmcid">PMC2784442</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Risso</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ngai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Speed</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Dudoit</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Normalization of RNA-seq data using factor analysis of control genes or samples</article-title>. <source>Nat. Biotechnol.</source><volume>32</volume>, <fpage>896</fpage>&#8211;<lpage>902</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nbt.2931</pub-id>, PMID: <pub-id pub-id-type="pmid">25150836</pub-id><pub-id pub-id-type="pmcid">PMC4404308</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rolls</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shechter</surname><given-names>R.</given-names></name><name name-style="western"><surname>London</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ziv</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ronen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Toll-like receptors modulate adult hippocampal neurogenesis</article-title>. <source>Nat. Cell Biol.</source><volume>9</volume>, <fpage>1081</fpage>&#8211;<lpage>1088</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ncb1629</pub-id>, PMID: <pub-id pub-id-type="pmid">17704767</pub-id></mixed-citation></ref><ref id="ref9004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martin&#243;n-Torres</surname><given-names>F.</given-names></name><name name-style="western"><surname>G&#243;mez-Carballa</surname><given-names>A.</given-names></name></person-group> (<year>In press</year>). <article-title>Beyond behavioral studies: Exploring the multi-omics impact of music on human health: Comment on Can arts-based interventions improve health? A conceptual and methodological critique by Martin Skov and Marcos Nadal</article-title>. <source>Physics of Life Reviews</source>. doi: <pub-id pub-id-type="doi">10.1016/j.plrev.2025.09.002</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sansores-Espana</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Melgar-Rodr&#237;guez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olivares-Sagredo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cafferata</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Aguilar</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Vernal</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Oral-gut-brain Axis in experimental models of periodontitis: associating gut Dysbiosis with neurodegenerative diseases</article-title>. <source>Front Aging</source><volume>2</volume>:<fpage>781582</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fragi.2021.781582</pub-id>, PMID: <pub-id pub-id-type="pmid">35822001</pub-id><pub-id pub-id-type="pmcid">PMC9261337</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holstege</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C. E.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Alzheimer's disease</article-title>. <source>Lancet</source><volume>397</volume>, <fpage>1577</fpage>&#8211;<lpage>1590</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(20)32205-4</pub-id>, PMID: <pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schepici</surname><given-names>G.</given-names></name><name name-style="western"><surname>Silvestro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trubiani</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bramanti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mazzon</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Salivary biomarkers: future approaches for early diagnosis of neurodegenerative diseases</article-title>. <source>Brain Sci.</source><volume>10</volume>. doi: <pub-id pub-id-type="doi">10.3390/brainsci10040245</pub-id>, PMID: <pub-id pub-id-type="pmid">32326227</pub-id><pub-id pub-id-type="pmcid">PMC7226627</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.</given-names></name><name name-style="western"><surname>le</surname><given-names>K. X.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caldarone</surname><given-names>B. J.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice</article-title>. <source>Sci. Transl. Med.</source><volume>9</volume>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.aaf6295</pub-id>, PMID: <pub-id pub-id-type="pmid">28566429</pub-id><pub-id pub-id-type="pmcid">PMC6936623</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Transcriptomic analyses for identification and prioritization of genes associated with Alzheimer's disease in humans</article-title>. <source>Front. Bioeng. Biotechnol.</source><volume>8</volume>:<fpage>31</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fbioe.2020.00031</pub-id>, PMID: <pub-id pub-id-type="pmid">32154224</pub-id><pub-id pub-id-type="pmcid">PMC7047416</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snowden</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Ebshiana</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Hye</surname><given-names>A.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pletnikova</surname><given-names>O.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: a nontargeted metabolomic study</article-title>. <source>PLoS Med.</source><volume>14</volume>:<fpage>e1002266</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.1002266</pub-id>, PMID: <pub-id pub-id-type="pmid">28323825</pub-id><pub-id pub-id-type="pmcid">PMC5360226</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stolerman</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Francisco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stallworth</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Monaghan</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Keller&#8208;Ramey</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Genetic variants in the KDM6B gene are associated with neurodevelopmental delays and dysmorphic features</article-title>. <source>Am. J. Med. Genet. A</source><volume>179</volume>, <fpage>1276</fpage>&#8211;<lpage>1286</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ajmg.a.61173</pub-id>, PMID: <pub-id pub-id-type="pmid">31124279</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toledo</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Korff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J. Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment</article-title>. <source>Alzheimer's Res Ther</source><volume>6</volume>:<fpage>36</fpage>. doi: <pub-id pub-id-type="doi">10.1186/alzrt266</pub-id>, PMID: <pub-id pub-id-type="pmid">25478014</pub-id><pub-id pub-id-type="pmcid">PMC4255518</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Su</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: current advancements and future prospects</article-title>. <source>Neurobiol. Dis.</source><volume>196</volume>:<fpage>106505</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2024.106505</pub-id>, PMID: <pub-id pub-id-type="pmid">38642715</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>The MMP-2/TIMP-2 system in Alzheimer disease</article-title>. <source>CNS Neurol. Disord. Drug Targets</source><volume>19</volume>, <fpage>402</fpage>&#8211;<lpage>416</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1871527319666200812223007</pub-id>, PMID: <pub-id pub-id-type="pmid">32787764</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J. E.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>KDM6B cooperates with tau and regulates synaptic plasticity and cognition via inducing VGLUT1/2</article-title>. <source>Mol. Psychiatry</source><volume>27</volume>, <fpage>5213</fpage>&#8211;<lpage>5226</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41380-022-01750-0</pub-id>, PMID: <pub-id pub-id-type="pmid">36028572</pub-id><pub-id pub-id-type="pmcid">PMC10108576</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Elevated Galectin-3 levels in the serum of patients with Alzheimer's disease</article-title>. <source>Am. J. Alzheimers Dis. Other Dement.</source><volume>30</volume>, <fpage>729</fpage>&#8211;<lpage>732</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1533317513495107</pub-id>, PMID: <pub-id pub-id-type="pmid">23823143</pub-id><pub-id pub-id-type="pmcid">PMC10852776</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title>. <source>Innovation</source><volume>2</volume>:<fpage>100141</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id>, PMID: <pub-id pub-id-type="pmid">34557778</pub-id><pub-id pub-id-type="pmcid">PMC8454663</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>M. Q.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B. T.</given-names></name></person-group> (<year>1999</year>). <article-title>Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease</article-title>. <source>J. Neurovirol.</source><volume>5</volume>, <fpage>32</fpage>&#8211;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.3109/13550289909029743</pub-id>, PMID: <pub-id pub-id-type="pmid">10190688</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name></person-group> (<year>2000</year>). <article-title>Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease</article-title>. <source>J. Neurosci.</source><volume>20</volume>, <fpage>7505</fpage>&#8211;<lpage>7509</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-20-07505.2000</pub-id>, PMID: <pub-id pub-id-type="pmid">11027207</pub-id><pub-id pub-id-type="pmcid">PMC6772855</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Olgun Yazar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cihan</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report</article-title>. <source>Acta Neurol. Belg.</source><volume>121</volume>, <fpage>949</fpage>&#8211;<lpage>954</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13760-020-01477-1</pub-id>, PMID: <pub-id pub-id-type="pmid">32852752</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yirmiya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goshen</surname><given-names>I.</given-names></name></person-group> (<year>2011</year>). <article-title>Immune modulation of learning, memory, neural plasticity and neurogenesis</article-title>. <source>Brain Behav. Immun.</source><volume>25</volume>, <fpage>181</fpage>&#8211;<lpage>213</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbi.2010.10.015</pub-id>, PMID: <pub-id pub-id-type="pmid">20970492</pub-id></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Paolicelli</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Sforazzini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weinhard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bolasco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior</article-title>. <source>Nat. Neurosci.</source><volume>17</volume>, <fpage>400</fpage>&#8211;<lpage>406</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nn.3641</pub-id>, PMID: <pub-id pub-id-type="pmid">24487234</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y. Q.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Autophagy in Alzheimer's disease pathogenesis: therapeutic potential and future perspectives</article-title>. <source>Ageing Res. Rev.</source><volume>72</volume>:<fpage>101464</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.arr.2021.101464</pub-id>, PMID: <pub-id pub-id-type="pmid">34551326</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="trc270161" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement (N Y)</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement (N Y)</journal-id><journal-id journal-id-type="pmc-domain-id">3303</journal-id><journal-id journal-id-type="pmc-domain">trci</journal-id><journal-id journal-id-type="publisher-id">TRC2</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia : Translational Research &amp; Clinical Interventions</journal-title></journal-title-group><issn pub-type="epub">2352-8737</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504043</article-id><article-id pub-id-type="pmcid-ver">PMC12504043.1</article-id><article-id pub-id-type="pmcaid">12504043</article-id><article-id pub-id-type="pmcaiid">12504043</article-id><article-id pub-id-type="doi">10.1002/trc2.70161</article-id><article-id pub-id-type="publisher-id">TRC270161</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug</article-title><alt-title alt-title-type="left-running-head">MOXON <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="trc270161-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Moxon</surname><given-names initials="R">Robyn</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-9494-5447</contrib-id><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>Rmoxon@acumenpharm.com</email></address></contrib><contrib id="trc270161-cr-0002" contrib-type="author"><name name-style="western"><surname>Feaster</surname><given-names initials="T">Todd</given-names></name><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270161-cr-0003" contrib-type="author"><name name-style="western"><surname>Sethuraman</surname><given-names initials="G">Gopalan</given-names></name><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270161-cr-0004" contrib-type="author"><name name-style="western"><surname>Carroll</surname><given-names initials="A">Alyssa</given-names></name><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270161-cr-0005" contrib-type="author"><name name-style="western"><surname>Gan</surname><given-names initials="ST">Siew Tin</given-names></name><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270161-cr-0006" contrib-type="author"><name name-style="western"><surname>Skljarevski</surname><given-names initials="V">Vladimir</given-names></name><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270161-cr-0007" contrib-type="author"><name name-style="western"><surname>Sundell</surname><given-names initials="K">Karen</given-names></name><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270161-cr-0008" contrib-type="author"><name name-style="western"><surname>Hitchcock</surname><given-names initials="J">Janice</given-names></name><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="trc270161-cr-0009" contrib-type="author"><name name-style="western"><surname>Siemers</surname><given-names initials="E">Eric</given-names></name><xref rid="trc270161-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="trc270161-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Acumen Pharmaceuticals, Inc.</institution>
<city>Newton</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Robyn Moxon, Acumen Pharmaceuticals, Inc., 1210&#8208;1220 Washington St., STE 210, Newton, MA 02465, USA.<break/> Email: <email>Rmoxon@acumenpharm.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Oct-Dec</season><year>2025</year></pub-date><volume>11</volume><issue seq="20">4</issue><issue-id pub-id-type="pmc-issue-id">498507</issue-id><issue-id pub-id-type="doi">10.1002/trc2.v11.4</issue-id><elocation-id>e70161</elocation-id><history><date date-type="rev-recd"><day>08</day><month>9</month><year>2025</year></date><date date-type="received"><day>22</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="TRC2-11-e70161.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:TRC2-11-e70161.pdf"/><abstract><title>Abstract</title><sec id="trc270161-sec-0010"><title>INTRODUCTION</title><p>Historically underrepresented racial and ethnic groups may face a higher risk and burden of dementia but continue to be underrepresented in Alzheimer's disease (AD) clinical research. Recent efforts have been insufficient to identify and address race&#8208;related disparities in recruitment and eligibility for AD clinical trials.</p></sec><sec id="trc270161-sec-0020"><title>METHODS</title><p>INTERCEPT&#8208;AD was a Phase 1 randomized, placebo&#8208;controlled, double&#8208;blind, first&#8208;in&#8208;human study of sabirnetug (ACU193) in participants with early symptomatic AD (mild cognitive impairment [MCI] or mild dementia due to AD). Participants were referred through seven site&#8208;selected recruitment strategies across 17 study sites in the United States (June 2021&#8211;January 2023). Numbers of pre&#8208;screened (<italic toggle="yes">n</italic> = 1025), screened (<italic toggle="yes">n</italic> = 260), and eligible (<italic toggle="yes">n</italic> = 70) participants were compared by recruitment strategy. Recruitment strategy effectiveness (percentage of eligible participants among screened participants) and reasons for screening ineligibility were compared between non&#8208;Hispanic White participants and participants from other racial and ethnic groups (i.e., participants who self&#8208;identified as American Indian or Alaska Native, Asian, Black or African American, or Hispanic or Latino).</p></sec><sec id="trc270161-sec-0030"><title>RESULTS</title><p>Local site databases were used at 13 of 17 sites (76%) and accounted for the most screened (<italic toggle="yes">n</italic> = 107, 41%) and eligible (<italic toggle="yes">n</italic> = 32, 46%) participants. Non&#8208;Hispanic White participants were recruited from all seven recruitment strategies, whereas participants of other racial and ethnic groups were recruited primarily from site databases. Significantly more participants of other racial and ethnic groups were ineligible for the study after screening, largely due to ineligible amyloid positron emission tomography (PET) scans (+13.9%).</p></sec><sec id="trc270161-sec-0040"><title>DISCUSSION</title><p>Diverse recruitment tactics, customized to capabilities of study sites and patient populations, may be more successful in recruiting diverse populations than a one&#8208;size&#8208;fits&#8208;all approach. Although a diverse pool of potential participants was screened, a less diverse group was enrolled, largely due to race&#8208; and ethnicity&#8208;related disparities in screening eligibility rates. Further investigation is needed to assess equitable screening methods for AD clinical trials.</p></sec><sec id="trc270161-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="trc270161-list-0001"><list-item><p>Site databases recruited the most screened and enrolled participants.</p></list-item><list-item><p>Diverse participants were primarily recruited from site databases.</p></list-item><list-item><p>The diversity of enrolled participants was lower than screened participants.</p></list-item><list-item><p>More ineligible participants were from diverse racial and ethnic groups.</p></list-item><list-item><p>No approach was observed to be a one&#8208;size&#8208;fits&#8208;all method to recruit and enroll a diverse pool of participants.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="trc270161-kwd-0001">ACU193</kwd><kwd id="trc270161-kwd-0002">Alzheimer's disease</kwd><kwd id="trc270161-kwd-0003">clinical trial eligibility</kwd><kwd id="trc270161-kwd-0004">racial and ethnic groups</kwd><kwd id="trc270161-kwd-0005">racial disparities</kwd><kwd id="trc270161-kwd-0006">recruitment</kwd><kwd id="trc270161-kwd-0007">sabirnetug</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Acumen Pharmaceuticals, Inc</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="10"/><word-count count="5928"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October-December 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="trc270161-cite-0001"><string-name name-style="western"><surname>Moxon</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Feaster</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sethuraman</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>11</volume>:<elocation-id>e70161</elocation-id>. <pub-id pub-id-type="doi">10.1002/trc2.70161</pub-id></mixed-citation>
</p></notes></front><body><sec id="trc270161-sec-0060"><label>1</label><title>BACKGROUND</title><p>Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects an estimated 6.9 million people in the United States.<xref rid="trc270161-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> With an aging and growing global population, the number of individuals with AD is expected to rise substantially.<xref rid="trc270161-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="trc270161-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="trc270161-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="trc270161-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Early intervention to delay the onset or progression of AD could substantially reduce the global burden on health care systems<xref rid="trc270161-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> and provide benefits to patients and families. Although disease&#8208;modifying therapies have been approved for the treatment of AD,<xref rid="trc270161-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="trc270161-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> advances in treatment and prevention strategies have been hindered by slow participant accrual in clinical trials and the underrepresentation of racial and ethnic groups historically underrepresented in the United States, including Black or African American, Hispanic or Latino, American Indian or Alaska Native, and Asian populations.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270161-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> In response, the AD research community has focused efforts to increase diversity in clinical trials, a goal further emphasized by the draft guidance of the U.S. Food and Drug Administration (FDA) on the inclusion of more representative populations in clinical trials.<xref rid="trc270161-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>Recruitment of participants to AD clinical trials is often low due to upstream barriers that prevent potential participants from finding clinical trials and volunteering.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270161-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> These upstream barriers include limited awareness of early asymptomatic and symptomatic stages of AD, limited access to diagnostics, lack of awareness of clinical trials among participants and caregivers, stigma surrounding the disease, cultural or linguistic barriers, and distrust in medical researchers.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270161-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="trc270161-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Recent efforts have aimed to assess the efficacy of common recruitment strategies,<xref rid="trc270161-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="trc270161-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> including the use of social media.<xref rid="trc270161-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="trc270161-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> These strategies differ in effectiveness for participants of different racial and ethnic backgrounds, but due to poor reporting and underrepresentation of racial and ethnic groups in AD clinical trials, it is unclear which strategies might best prioritize a diverse participant pool.<xref rid="trc270161-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Moreover, many AD clinical trials recruit potential participants across multiple sites with unique populations, suggesting that a one&#8208;size&#8208;fits&#8208;all recruitment strategy may not be feasible.<xref rid="trc270161-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="trc270161-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>A high percentage of potential participants are excluded from AD clinical trials during pre&#8208;screening and screening processes, contributing to slow accrual of participants to AD clinical trials.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270161-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> High rates of ineligibility after screening may be the result of downstream barriers to participation, such as restrictive criteria for study inclusion and subjective or racially biased cutoff values for cognitive scores used to determine screen failures.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270161-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Because the incidence and prevalence of AD increases with aging, many potential participants have other age&#8208;related conditions that cause them to be ineligible, such as cerebrovascular disease or cardiovascular disease.<xref rid="trc270161-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> However, comorbidities used to exclude potential participants may be more prevalent in certain racial and ethnic groups, likely due to structural risk factors associated with historical marginalization.<xref rid="trc270161-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="trc270161-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> For example, increased prevalence of cardiovascular disease and cardiovascular risk has been reported not only among African Americans, compared to non&#8208;Hispanic White Americans, but also in communities with high levels of neighborhood social disadvantage and poverty, which are common in historically segregated cities.<xref rid="trc270161-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Exclusions based on these comorbidities may lead to sampling bias that may disproportionately exclude participants of underrepresented racial and ethnic groups.<xref rid="trc270161-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="trc270161-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> In addition, due to inherent challenges in working with adults with cognitive impairment, potential participants are often excluded or withdraw from studies due to logistical issues, such as lack of access to transportation, impaired ability to consent to participation, or lack of a qualifying study partner who can be enrolled in the trial alongside the participant.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270161-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="trc270161-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>Many racial and ethnic groups are still underrepresented in AD clinical research, despite recent efforts to increase racial and ethnic diversity among clinical trial participants.<xref rid="trc270161-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="trc270161-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="trc270161-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Substantial differences among racial and ethnic groups have been found in recruitment rates and referral sources, as well as in ineligibility rates and reasons for ineligibility during screening.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270161-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="trc270161-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="trc270161-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Studies with low participant racial diversity lack both the statistical power to compare differences among racial groups and the inferential power to apply the results to a broader, more representative population of individuals with AD.<xref rid="trc270161-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Considering that the prevalence of AD and related dementias may be higher for Black and Hispanic Americans than for White Americans, underrepresentation of these racial and ethnic groups in AD clinical studies could pose major challenges to developing strategies to reduce the burden of AD nationwide.<xref rid="trc270161-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> However, recent studies using biomarkers to confirm AD pathology have presented mixed support for race&#8208; and ethnicity&#8208;related differences in AD prevalence and risk.<xref rid="trc270161-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="trc270161-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> For example, the Imaging Dementia&#8208;Evidence for Amyloid Scanning (IDEAS) study found that despite disproportionately higher rates of dementia and clinical AD, Black and Hispanic participants showed lower odds of amyloid positron emission tomography (PET) positivity compared to White participants.<xref rid="trc270161-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> As a result, there is an overall lack of consensus in the literature as to what extent mixed results may be due to poor reporting of patient demographics, low inclusion of diverse participants, or inconsistent results from varying methodologies.<xref rid="trc270161-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="trc270161-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The need for more representative participant populations should be a high priority for research on treatments and interventions for AD.<xref rid="trc270161-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>Our primary aim was to develop a better understanding of the outcome of recruitment strategies and the reasons for ineligibility for participants from different racial and ethnic groups during the Phase 1 Placebo&#8208;Controlled, Single&#8208; and Multiple&#8208;Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravensou ACU193 in Mild Cognitive Impairment or Mild Dementia due to Alzheimer's Disease (INTERCEPT&#8208;AD) clinical trial. INTERCEPT&#8208;AD was a Phase 1, randomized, double&#8208;blind, placebo&#8208;controlled, first&#8208;in&#8208;human study of sabirnetug (ACU193) in participants with early AD (i.e., mild cognitive impairment [MCI] or mild dementia due to AD). We assessed recruitment strategies based on the numbers and percentages of participants pre&#8208;screened, screened, and eligible for participation in the study. We acknowledge that the terms &#8220;race&#8221; and &#8220;ethnicity&#8221; have no biological meaning, but we use these terms throughout to describe groups that have significant social meaning and are associated with socioeconomic and health disparities in the United States.<xref rid="trc270161-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</p></sec><sec id="trc270161-sec-0070"><label>2</label><title>METHODS</title><sec id="trc270161-sec-0080"><label>2.1</label><title>Study design</title><p>The INTERCEPT&#8208;AD study (Study ACU&#8208;001; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04931459">NCT04931459</ext-link>) was a randomized, placebo&#8208;controlled, double&#8208;blind Phase 1 study designed to assess the safety and tolerability of single and multiple intravenous doses of sabirnetug in participants with MCI or mild dementia due to AD. Participants were recruited by 17 study sites in the United States, and the clinical trial was conducted with eligible participants at 15 of those study sites in accordance with the protocol, International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP), the Declaration of Helsinki (2008), and all other applicable regulatory requirements. The study design and primary results from INTERCEPT&#8208;AD have been reported previously.<xref rid="trc270161-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="trc270161-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="trc270161-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="trc270161-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors reviewed (using PubMed) publications related to recruitment and screening in Alzheimer's disease (AD) clinical trials, prioritizing reviews and original research that included participant race and ethnicity data.</p></list-item><list-item><p>
<bold>Interpretation</bold>: The INTERCEPT&#8208;AD trial screened a diverse pool of potential participants, primarily through site databases. Consistent with the literature, the trial enrolled a less diverse group, largely due to more ineligible participants from historically underrepresented racial and ethnic groups than from non&#8208;Hispanic White participants. The most common reason for ineligibility was a negative visual read of amyloid positron emission tomography scans.</p></list-item><list-item><p>
<bold>Future directions</bold>: Using multiple recruitment strategies, customized to a study site's capabilities and patient population, may be more successful in recruiting diverse populations than a one&#8208;size&#8208;fits&#8208;all approach. Future efforts to improve representation in AD clinical trials should evaluate eligibility criteria for efficacy and equity across racial and ethnic groups.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="trc270161-sec-0100"><label>2.2</label><title>Study recruitment</title><p>Sites screened potential participants identified through multiple recruitment strategies, including three sponsor&#8208;initiated campaigns (A, B, and C). Recruitment strategies were selected through a collaborative process between the individual site and the sponsor to prioritize site&#8208;specific needs, including patient population, local communities, and availability of staff. Recruitment strategies used were grouped post hoc into seven categories: (1) site database (patients in the local site's database or referred by clinical staff; these patients are often already in communication with the site and sometimes have been pre&#8208;screened prior to joining a study); (2) external referral (patients referred by friends, family, or self&#8208;referrals); (3) physician referral (patients referred by physicians not affiliated with the study site; these are referrals that come in from outside physicians such as primary care physicians or other specialists); (4) site campaign (site&#8208;led ads, events, and databases not specific to INTERCEPT&#8208;AD; many trial sites have social media campaigns, digital ads, or participate in local events within the community in order to spread awareness about clinical trials, often with free memory screening events); (5) Campaign A (the sponsor employed a vendor who used digital ads linking to a study website with a pre&#8208;screening questionnaire; this vendor employed paid advertising campaigns through social media and search engines, which led users to the study website in order to learn more and take the pre&#8208;screener. If users passed the pre&#8208;screener, they would be able to schedule a call back from the vendor, who would go through a more thorough phone screen and connect them with a local study site if they were qualified); (6) Campaign B (the sponsor employed a vendor who used the vendor's patient identification system to pre&#8208;screen and refer participants to the site. This vendor used medical records and database searches to find potential participants who met certain eligibility criteria predetermined in partnership with the sponsor. Potential participants who met these criteria were then contacted and pre&#8208;screened further via digital or phone&#8208;based assessments. Potential participants&#8217; health records within the vendor's national database were also verified by artificial intelligence and trained reviewers. Qualified participants were then put in contact with their local study site); and (7) Campaign C (the sponsor employed a vendor who used social media interest groups to recruit, using generic ads and an INTERCEPT&#8208;AD pre&#8208;screener; this vendor had social media groups already created for various diseases and was able to post about clinical trial opportunities within these groups. If users were interested, they could click a link and take a pre&#8208;screening questionnaire; those who passed would be contacted by a call center with the vendor for further pre&#8208;qualification before their contact information was passed on to the clinical study site).</p></sec><sec id="trc270161-sec-0110"><label>2.3</label><title>Pre&#8208;screening process</title><p>Pre&#8208;screening occurred through online questionnaires, phone interviews, or in&#8208;person interviews at the study site. All pre&#8208;screening processes asked whether the potential participant was 55&#8208; to 90&#8208;years&#8208;old, had been experiencing memory problems, had a possible study partner who could attend visits with them, and had been diagnosed with AD or MCI. (Note that diagnosis was not a study criterion; however, the information was collected during pre&#8208;screening.) Some pre&#8208;screening processes also collected more in&#8208;depth health history and/or further demographic information.</p></sec><sec id="trc270161-sec-0120"><label>2.4</label><title>Screening process and eligibility criteria</title><p>Eligibility requirements for INTERCEPT&#8208;AD have been described previously.<xref rid="trc270161-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Briefly, participants were required to be 55 to 90 years of age, to meet the National Institute on Aging&#8212;Alzheimer's Association criteria for MCI or mild dementia due to AD, and to have evidence of brain amyloid assessed by amyloid PET scan. The primary reason for ineligibility was recorded for each ineligible participant; in the instances where more than one reason for ineligibility was recorded by the site, the sponsor requested the that principal investigator confirm which should be considered the primary reason.</p></sec><sec id="trc270161-sec-0130"><label>2.5</label><title>Recruitment strategy effectiveness</title><p>The effectiveness of these recruitment strategies was assessed by comparing, for each strategy, the number of potential participants screened with the number found to be eligible for trial enrollment. Thus the strategy with the highest percentage of screened patients who were eligible for enrollment was considered the most effective.</p></sec><sec id="trc270161-sec-0140"><label>2.6</label><title>Statistical analysis by race and ethnicity</title><p>To assess whether participant race and ethnicity impacted recruitment or eligibility, participants were split into two categories: participants who self&#8208;identified as non&#8208;Hispanic White and participants who self&#8208;identified as American Indian or Alaska Native, Asian, Black or African American, or Hispanic or Latino (hereafter referred to as participants from diverse racial and ethnic groups). Group differences in recruitment sources were calculated. Group differences in the percentage of ineligible participants were compared between groups using a chi&#8208;square test and among primary reasons for ineligibility using percent differences. Post hoc analyses were conducted using a chi&#8208;square test if the percent difference between groups was &gt;5% for any primary reason for ineligibility. Statistical significance was defined as p&#8804;0.050.</p></sec></sec><sec id="trc270161-sec-0150"><label>3</label><title>RESULTS</title><sec id="trc270161-sec-0160"><label>3.1</label><title>Patient demographics and study participants</title><p>Across all sites, 1025 potential participants were pre&#8208;screened, of whom 260 participants (25.4%) completed the screening process (Figures&#160;<xref rid="trc270161-fig-0001" ref-type="fig">1</xref> and&#160;<xref rid="trc270161-fig-0002" ref-type="fig">2</xref>). After screening, 70 participants (26.9%) were eligible for the INTERCEPT&#8208;AD trial, whereas 190 participants (73.1%) were ineligible due to screen failures. Of 260 screened participants, 52.7% identified as non&#8208;Hispanic White, 31.5% as Hispanic or Latino, 14.2% as Black or African American, 1.2% as American Indian or Alaska Native, and 0.4% as Asian (Figure&#160;<xref rid="trc270161-fig-0001" ref-type="fig">1</xref>). Of 70 eligible participants, 78.6% identified as non&#8208;Hispanic White, 15.7% as Hispanic or Latino, 4.3% as Black or African American, 1.4% as American Indian or Alaska Native, and 0% as Asian (Figure&#160;<xref rid="trc270161-fig-0001" ref-type="fig">1</xref>). In the INTERCEPT&#8208;AD trial, 65 eligible participants were randomized into treatment groups; 62 participants received sabirnetug or placebo, and 3 participants discontinued prior to receiving the study drug.</p><fig position="float" fig-type="FIGURE" id="trc270161-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Race and ethnicity of participants screened (<italic toggle="yes">n</italic> = 260) and eligible (<italic toggle="yes">n</italic> = 70) for enrollment in the INTERCEPT&#8208;AD trial. AD, Alzheimer's disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="TRC2-11-e70161-g003.jpg"/></fig><fig position="float" fig-type="FIGURE" id="trc270161-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Participant funnels by recruitment strategy, associated with Table&#160;<xref rid="trc270161-tbl-0001" ref-type="table">1</xref>. The percentage of screened participants out of pre&#8208;screened participants and the percentage of eligible participants out of pre&#8208;screened participants are reported for each recruitment strategy. The total study participants category (<italic toggle="yes">n</italic> = 1025) includes 43 pre&#8208;screened participants with an unknown recruitment strategy (i.e., referral source). AD, Alzheimer's disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="TRC2-11-e70161-g004.jpg"/></fig></sec><sec id="trc270161-sec-0170"><label>3.2</label><title>Recruitment Strategies Across Sites</title><p>Study sites typically used multiple recruitment strategies, and no single recruitment strategy was used at all sites (Table&#160;<xref rid="trc270161-tbl-0001" ref-type="table">1</xref>). Campaign A (digital ads linking to a study website with a pre&#8208;screening questionnaire) was the most effective strategy, with 15 eligible of 47 screened participants (31.9%) (Table&#160;<xref rid="trc270161-tbl-0001" ref-type="table">1</xref>; Figure&#160;<xref rid="trc270161-fig-0003" ref-type="fig">3</xref>). The next most effective strategies were Campaign B (vendor&#8208;specific patient identification system to pre&#8208;screen and refer participants to site), with 9 eligible of 30 screened participants (30.0%) and site database, with 32 eligible of 107 screened participants (29.9%). Site database was also the most frequently used recruitment strategy (13 of 17 sites [76.5%]) and led to the highest total number of screened participants (107 of 260, 41.2%) and eligible study participants (32 of 70, 45.7%) of any recruitment strategy (Table&#160;<xref rid="trc270161-tbl-0001" ref-type="table">1</xref>; Figure&#160;<xref rid="trc270161-fig-0002" ref-type="fig">2</xref>). The least used and least effective strategy was Campaign C (recruitment through social media interest groups), used by 2 of 17 sites (11.8%) and yielding the lowest percentage of eligible participants (0 of 7, 0%) of screened participants per strategy (Table&#160;<xref rid="trc270161-tbl-0001" ref-type="table">1</xref>; Figure&#160;<xref rid="trc270161-fig-0002" ref-type="fig">2</xref>).</p><table-wrap position="float" id="trc270161-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Pre&#8208;screened, screened, and eligible participants and effectiveness rate by recruitment strategy.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Recruitment strategy</th><th align="left" rowspan="1" colspan="1">Sites (%<xref rid="trc270161-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>) (<italic toggle="yes">n</italic> = 17)</th><th align="left" rowspan="1" colspan="1">
<p>Participants, pre&#8208;screened</p>
<p>(<italic toggle="yes">n</italic> = 1025<xref rid="trc270161-tbl1-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Participants, screened</p>
<p>(<italic toggle="yes">n</italic> = 260)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Participants, eligible, <italic toggle="yes">n</italic> (%<xref rid="trc270161-tbl1-note-0003" ref-type="table-fn">
<sup>c</sup>
</xref>)</p>
<p>(<italic toggle="yes">n</italic> = 70)</p>
</th><th align="left" rowspan="1" colspan="1">Effectiveness rate<xref rid="trc270161-tbl1-note-0004" ref-type="table-fn">
<sup>d</sup>
</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Site database</td><td align="left" rowspan="1" colspan="1">13 (76)</td><td align="left" rowspan="1" colspan="1">243</td><td align="left" rowspan="1" colspan="1">107</td><td align="left" rowspan="1" colspan="1">32 (45.7)</td><td align="left" rowspan="1" colspan="1">29.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">External referral</td><td align="left" rowspan="1" colspan="1">8 (47)</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">6 (8.6)</td><td align="left" rowspan="1" colspan="1">25.0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Physician referral</td><td align="left" rowspan="1" colspan="1">4 (24)</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">3 (4.3)</td><td align="left" rowspan="1" colspan="1">21.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Site campaign</td><td align="left" rowspan="1" colspan="1">7 (41)</td><td align="left" rowspan="1" colspan="1">356</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">5 (7.1)</td><td align="left" rowspan="1" colspan="1">16.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Campaign A</td><td align="left" rowspan="1" colspan="1">5 (29)</td><td align="left" rowspan="1" colspan="1">107</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">15 (21.4)</td><td align="left" rowspan="1" colspan="1">31.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">Campaign B</td><td align="left" rowspan="1" colspan="1">7 (41)</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">9 (12.9)</td><td align="left" rowspan="1" colspan="1">30.0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Campaign C</td><td align="left" rowspan="1" colspan="1">2 (12)</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">0%</td></tr></tbody></table><table-wrap-foot><fn id="trc270161-tbl1-note-0001"><label>
<sup>a</sup>
</label><p>The percentage of sites that used each recruitment strategy does not sum to 100% because each site could use multiple strategies.</p></fn><fn id="trc270161-tbl1-note-0002"><label>
<sup>b</sup>
</label><p>Includes 43 pre&#8208;screened participants with unknown recruitment strategy.</p></fn><fn id="trc270161-tbl1-note-0003"><label>
<sup>c</sup>
</label><p>Percentage of eligible participants per recruitment strategy out of total eligible participants.</p></fn><fn id="trc270161-tbl1-note-0004"><label>
<sup>d</sup>
</label><p>&#8220;Effectiveness rate&#8221; indicates the percentage of screened participants who were ultimately eligible for the trial, reported per recruitment strategy.</p></fn><fn id="trc270161-tbl1-note-0005"><p>Campaign A, the vendor used digital ads linking to a study website with a pre&#8208;screening questionnaire; Campaign B, the vendor used their own patient identification system to pre&#8208;screen and refer participants to the site; Campaign C, the vendor used social media interest groups to recruit, using generic ads and an INTERCEPT&#8208;AD pre&#8208;screening questionnaire.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="trc270161-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Participants screened (left) and enrolled (right) in the INTERCEPT&#8208;AD trial per site (<italic toggle="yes">n</italic> = 15) per recruitment strategy. Values represent the mean number of participants screened and enrolled for each of the recruitment strategies across trial sites. AD, Alzheimer's disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="TRC2-11-e70161-g001.jpg"/></fig><p>After accounting for variation in how many sites used each recruitment strategy, the strategies with the highest numbers of screened and eligible participants per site were Campaign A (9.4 and 3, respectively) and the site database (8.2 and 2.5) (Figure&#160;<xref rid="trc270161-fig-0003" ref-type="fig">3</xref>).</p></sec><sec id="trc270161-sec-0180"><label>3.3</label><title>Recruitment strategies by race and ethnicity</title><p>The main sources of recruitment varied significantly between the two racial and ethnic categories designated in this study (Figure&#160;<xref rid="trc270161-fig-0004" ref-type="fig">4</xref>). Participants who went through the screening process and identified as non&#8208;Hispanic White (<italic toggle="yes">n</italic> = 137) were recruited through a combination of strategies: site database (29.2%), Campaign A (23.4%), site campaign (18.2%), Campaign B (13.9%), external referrals (8.0%), Campaign C (4.4%), and physician referrals (2.9%). Screened participants from diverse racial and ethnic groups (i.e., participants who self&#8208;identified as American Indian or Alaska Native, Asian, Black or African American, or Hispanic or Latino) (n = 123) were mostly recruited from the local site's database (54.5%), followed by Campaign A (12.2%), external referrals (10.6%), Campaign B (8.9%), physician referrals (8.1%), site campaign (4.9%), and Campaign C (0.8%).</p><fig position="float" fig-type="FIGURE" id="trc270161-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Screened participants for the INTERCEPT&#8208;AD trial by recruitment strategy and race and ethnicity. Pie charts depicting proportions of participants self&#8208;identified as non&#8208;Hispanic White (left) versus self&#8208;identified as other racial and ethnic groups (right), including American Indian or Alaska Native, Black or African American, or Hispanic or Latino. The total number of screened participants per group (<italic toggle="yes">n</italic>) is shown in the center of the pie chart. AD, Alzheimer's disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="TRC2-11-e70161-g002.jpg"/></fig></sec><sec id="trc270161-sec-0190"><label>3.4</label><title>Reasons for study ineligibility by race and ethnicity</title><p>The percentage of ineligible participants differed significantly between participants who identified as non&#8208;Hispanic White (59.9%) and participants from diverse racial and ethnic groups (87.8%; &#967;<sup>2</sup> = 25.74, <italic toggle="yes">p</italic> &lt; 0.001). The most common reason for ineligibility overall was amyloid&#8208;negative PET scans, accounting for the majority of ineligible participants who identified as non&#8208;Hispanic White (53.7%) or from diverse racial and ethnic groups (67.6%; Table&#160;<xref rid="trc270161-tbl-0002" ref-type="table">2</xref>). Compared to non&#8208;Hispanic White participants, significantly more participants from diverse racial and ethnic groups were ineligible due to PET scans (+13.9%; &#967;<sup>2</sup> = 3.83, <italic toggle="yes">p</italic> = 0.050), and significantly fewer were ineligible due to Clinical Dementia Rating (CDR) scale scores (&#8722;8.9%; &#967;<sup>2</sup> = 8.05, <italic toggle="yes">p</italic> = 0.005; Table&#160;<xref rid="trc270161-tbl-0002" ref-type="table">2</xref>). All other reasons for ineligibility were similar between racial and ethnic groups (i.e., &lt;5% difference in ineligible participants). The second most common reason for ineligibility overall was withdrawing consent; all other reasons occurred in &lt;10% of participants (Table&#160;<xref rid="trc270161-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="trc270161-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Reasons for study ineligibility by race and ethnicity.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Reason for ineligibility</th><th align="left" rowspan="1" colspan="1">
<p>Potential participants, non&#8208;Hispanic White, <italic toggle="yes">n</italic> (%)</p>
<p>(<italic toggle="yes">N</italic> = 82)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Potential participants, diverse racial and ethnic groups,<xref rid="trc270161-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
<italic toggle="yes">n</italic> (%)</p>
<p>(<italic toggle="yes">N</italic> = 108)</p>
</th><th align="left" rowspan="1" colspan="1">Percent difference<xref rid="trc270161-tbl2-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PET negative</td><td align="left" rowspan="1" colspan="1">44 (53.7)</td><td align="left" rowspan="1" colspan="1">73 (67.6)</td><td align="left" rowspan="1" colspan="1">+13.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Withdrew consent</td><td align="left" rowspan="1" colspan="1">9 (11.0)</td><td align="left" rowspan="1" colspan="1">14 (13.0)</td><td align="left" rowspan="1" colspan="1">+2.0</td></tr><tr><td align="left" rowspan="1" colspan="1">CDR</td><td align="left" rowspan="1" colspan="1">8 (9.8)</td><td align="left" rowspan="1" colspan="1">1 (0.9)</td><td align="left" rowspan="1" colspan="1">&#8722;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">MRI abnormal</td><td align="left" rowspan="1" colspan="1">5 (6.1)</td><td align="left" rowspan="1" colspan="1">3 (2.8)</td><td align="left" rowspan="1" colspan="1">&#8722;3.3</td></tr><tr><td align="left" rowspan="1" colspan="1">MRI contraindication</td><td align="left" rowspan="1" colspan="1">3 (3.7)</td><td align="left" rowspan="1" colspan="1">5 (4.6)</td><td align="left" rowspan="1" colspan="1">+0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">MMSE</td><td align="left" rowspan="1" colspan="1">3 (3.7)</td><td align="left" rowspan="1" colspan="1">3 (2.8)</td><td align="left" rowspan="1" colspan="1">&#8722;0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Unstable illness</td><td align="left" rowspan="1" colspan="1">3 (3.7)</td><td align="left" rowspan="1" colspan="1">1 (0.9)</td><td align="left" rowspan="1" colspan="1">&#8722;2.8</td></tr><tr><td align="left" rowspan="1" colspan="1">ECG</td><td align="left" rowspan="1" colspan="1">2 (2.4)</td><td align="left" rowspan="1" colspan="1">4 (3.7)</td><td align="left" rowspan="1" colspan="1">+1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">History of cardiac disease</td><td align="left" rowspan="1" colspan="1">1 (1.2)</td><td align="left" rowspan="1" colspan="1">2 (1.9)</td><td align="left" rowspan="1" colspan="1">+0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Other neurological diseases</td><td align="left" rowspan="1" colspan="1">1 (1.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">&#8722;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">No caregiver</td><td align="left" rowspan="1" colspan="1">1 (1.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">&#8722;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurological illness</td><td align="left" rowspan="1" colspan="1">1 (1.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">&#8722;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Lab abnormality</td><td align="left" rowspan="1" colspan="1">1 (1.2)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">&#8722;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Use of anticoagulants</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (1.9)</td><td align="left" rowspan="1" colspan="1">+1.9</td></tr></tbody></table><table-wrap-foot><fn id="trc270161-tbl2-note-0001"><p>Abbreviations: CDR, Clinical Dementia Rating; ECG, electrocardiography; MMSE, Mini&#8208;Mental State Examination; MRI, magnetic resonance imaging; PET, positron emission tomography.</p></fn><fn id="trc270161-tbl2-note-0002"><label>
<sup>a</sup>
</label><p>&#8220;Diverse racial and ethnic groups&#8221; include participants self&#8208;identifying as American Indian or Alaska Native, Asian, Black or African American, or Hispanic or Latino.</p></fn><fn id="trc270161-tbl2-note-0003"><label>
<sup>b</sup>
</label><p>&#8220;Percent difference&#8221; is the simple difference in the percentage of ineligible participants for a given reason out of the total number of ineligible participants per racial and ethnic group category.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="trc270161-sec-0200"><label>4</label><title>DISCUSSION</title><p>In clinical trials for early AD and MCI, an average of 78% of potential participants do not fully meet study criteria.<xref rid="trc270161-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> In INTERCEPT&#8208;AD, this percentage was 73.1%. Understanding the effectiveness of recruitment strategies for AD clinical trials is essential to improving the recruitment process and ensuring the recruitment of a diverse population of study participants. Our results suggest that clinical trials may find success with a customized approach addressing the unique capabilities of individual sites and patient populations. A combination of site&#8208;led and sponsor&#8208;driven recruitment strategies appeared to maximize enrollment. The two strategies that recruited the highest percentage of eligible patients were local site databases and Campaign A, a sponsor&#8208;driven initiative that used digital ads to direct potential participants to a pre&#8208;screening questionnaire on the study website. Most participants from racial and ethnic groups that have been traditionally underrepresented in AD clinical research were recruited from site databases; other strategies were much less effective at recruiting these participants. The success of site databases for recruiting participants from underrepresented racial and ethnic groups is consistent with the importance of considering the trustworthiness of the referral source in designing recruitment strategies.<xref rid="trc270161-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Previous studies have attributed effective strategies for recruiting participants from diverse racial and ethnic groups to local&#8208;level efforts, such as involving community organizations and tailoring recruitment to specific populations.<xref rid="trc270161-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Thus, site selection and feasibility may play an important role in recruiting a diverse and representative pool of participants to AD clinical trials.</p><p>The INTERCEPT&#8208;AD trial screened a diverse population of potential study participants but randomized a much less diverse participant population. Significantly more potential participants from racial and ethnic groups that have been traditionally underrepresented in AD clinical trials were ineligible after screening (88%) compared to non&#8208;Hispanic White participants (60%), largely due to more negative PET scans (+13.9%). Similar disparities have been attributed to racial biases in screen failures associated with race&#8208;related factors, such as differences in excluded comorbidities and access to study sites.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>CDR and Mini&#8208;Mental State Examination (MMSE) scores have been associated previously with racial biases and disparities in screen failures for AD clinical trials.<xref rid="trc270161-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="trc270161-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> However, participants from traditionally underrepresented racial and ethnic groups in the INTERCEPT&#8208;AD trial were significantly less likely than non&#8208;Hispanic White participants to be ineligible due to CDR scores (&#8722;8.9%) and were numerically less likely to be ineligible due to MMSE scores (&#8722;0.9%). In addition, ineligibility due to no caregiver was infrequent (1.2% of non&#8208;Hispanic White participants and 0% of participants from diverse racial and ethnic groups). These results suggest that cognitive impairment scores and the caregiver requirement may be less of an issue with screening disparities and that future efforts to improve the diversity of enrolled study participants should focus on the assessment of PET scans. Understanding this discrepancy is a topic for future research because diverse populations may have more comorbidities and thus would be more likely to have other causes for cognitive impairment. Considering that in the INTERCEPT&#8208;AD trial, more participants from diverse racial and ethnic groups were recruited from local site databases than non&#8208;Hispanic White participants, the difference in ineligibility may also be due to differences in the pre&#8208;screening processes associated with each recruitment strategy.<xref rid="trc270161-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Participants from racial and ethnic groups that have been historically underrepresented in clinical research may be less likely to enroll in AD and dementia clinical trials due to mistrust of medical professionals and groups.<xref rid="trc270161-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Thus, recruitment strategies involving trusted health care teams at local sites might be more successful at recruiting diverse participants who may already meet the trial inclusion criteria.</p><p>Recruiting underrepresented groups in Phase 1 studies presents challenges similar to those observed in later&#8208;phase trials, particularly due to inclusion and exclusion criteria, which frequently require evidence of amyloid and AD pathology. In our study, although recruitment tactics were not specifically tailored to prioritize underrepresented groups, they did result in a diverse pool of individuals screened. However, this initial diversity did not carry through to those meeting criteria for study enrollment. This highlights a broader challenge in AD clinical research, regardless of study phase, in that inclusion and exclusion criteria now typically include a requirement for amyloid positivity, which may unintentionally limit diversity by excluding individuals who meet clinical but not biomarker criteria for an AD diagnosis.</p><p>Americans from racial and ethnic groups who have been historically underrepresented in AD clinical trials<xref rid="trc270161-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> may also face a higher risk and higher predicted burden of dementia, which may be clinically attributed to AD but may not have biomarker confirmation of AD pathology.<xref rid="trc270161-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="trc270161-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="trc270161-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="trc270161-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Race&#8208;related disparities in AD clinical trial representation have been attributed to overall health and socioeconomic disparities produced by historic and continued marginalization of non&#8208;White people in the United States.<xref rid="trc270161-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> The influence of the apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 genetic risk factor for AD may differ among racial or ethnic groups, and this may affect responses to novel AD treatments.<xref rid="trc270161-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="trc270161-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="trc270161-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> The reasons underlying these disparities are still unclear, due to poor reporting of patient demographics and inadequate recruitment and retention data.<xref rid="trc270161-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> According to a meta&#8208;analysis of eligibility criteria across 101 AD clinical trials, less than half of all AD clinical trials provided race and ethnicity data for participants (45.5%), and, of these studies, the median reported percentage of White participants was 94.7%.<xref rid="trc270161-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Investing in site&#8208;specific recruitment strategies will likely be an effective strategy both to improve overall recruitment and to increase the racial and ethnic diversity of participants, both of which could help accelerate research for novel treatments and interventions. Even a small delay in the onset of AD could substantially decrease the worldwide burden of AD.<xref rid="trc270161-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Improving the diversity of participants in this research is imperative.</p><sec id="trc270161-sec-0210"><label>4.1</label><title>Strengths and limitations</title><p>Although conclusions are limited by the relatively small sample size of a Phase 1 study, findings are consistent with those of larger studies. The small sample size also prevented us from analyzing results for individual racial and ethnic groups. Analysis of recruitment strategies did not capture site expenditures or staff effort. Certain site&#8208;specific factors were not accounted for but may have affected the number of participants recruited from underrepresented groups, such as staff demographics, services available in non&#8208;English languages, and overall diversity of patients in each site's local area. In addition, the least effective strategy, Campaign C, was used by the fewest sites, suggesting that the low efficacy of this strategy could have been related to site&#8208;specific factors. However, the most&#8208;used strategy, local site databases, was also among the most effective strategies, suggesting that study sites can use their knowledge of their patient populations to select appropriate and effective strategies for recruiting participants. Many previous AD clinical trials have not reported participant demographics or have not reported recruitment rates and eligibility rates separately by racial or ethnic groups.<xref rid="trc270161-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> The present study provides detailed evidence to analyze the recruitment of underrepresented groups in AD clinical trials.</p><p>In conclusion, sites that used their internal patient databases had higher numbers of screened and eligible participants, suggesting that a combination of site&#8208;led and sponsor&#8208;driven recruitment initiatives could maximize enrollment. Although INTERCEPT&#8208;AD pre&#8208;screened a diverse pool of potential participants, after screening, the trial enrolled a less diverse group of participants. These disparities between recruited and enrolled participants were driven by differences in ineligibility, particularly PET scan results, during the screening process between participants who identified as non&#8208;Hispanic White and participants who identified as diverse racial and ethnic groups (i.e., American Indian or Alaska Native, Black or African American, Asian, or Hispanic or Latino). A better understanding of the rates of comorbidity in diverse populations is needed. Use of diverse recruitment tactics customized to each study site's capabilities and patient population may be a more successful strategy than a one&#8208;size&#8208;fits&#8208;all approach. Further research is needed to better understand the challenges for diverse participants throughout the screening and eligibility process and to ensure greater inclusion in clinical trials.</p></sec></sec><sec sec-type="COI-statement" id="trc270161-sec-0230"><title>CONFLICT OF INTEREST STATEMENT</title><p>R.M., T.F., G.S., A.C., S.T.G., K.S., J.H., and E.S. are employees of and hold equity in Acumen Pharmaceuticals, Inc. V.S. receives consultant fees from Acumen Pharmaceuticals, Inc. Author disclosures are available in the <xref rid="trc270161-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="trc270161-sec-0240"><title>CONSENT STATEMENT</title><p>All participants provided written informed consent before screening procedures were initiated.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="trc270161-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="trc270161-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TRC2-11-e70161-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="trc270161-sec-0220"><title>ACKNOWLEDGMENTS</title><p>Medical writing assistance was provided by Lauren Benedict and Jennie G. Jacobson of Jacobson Medical Writing, Inc. and funded by Acumen Pharmaceuticals. The INTERCEPT&#8208;AD study and this study were funded by Acumen Pharmaceuticals, Inc.</p></ack><ref-list id="trc270161-bibl-0001"><title>REFERENCES</title><ref id="trc270161-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="trc270161-cite-0002"><article-title>2024 Alzheimer's disease facts and figures</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>5</issue>):<fpage>3708</fpage>&#8208;<lpage>3821</lpage>.<pub-id pub-id-type="pmid">38689398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13809</pub-id><pub-id pub-id-type="pmcid">PMC11095490</pub-id></mixed-citation></ref><ref id="trc270161-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="trc270161-cite-0003"><string-name name-style="western"><surname>Brookmeyer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Abdalla</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kawas</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Corrada</surname><given-names>MM</given-names></string-name>. <article-title>Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>2</issue>):<fpage>121</fpage>&#8208;<lpage>129</lpage>.<pub-id pub-id-type="pmid">29233480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2017.10.009</pub-id><pub-id pub-id-type="pmcid">PMC5803316</pub-id></mixed-citation></ref><ref id="trc270161-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="trc270161-cite-0004"><collab collab-type="authors">GBD 2019 Dementia Forecasting Collaborators</collab>
. <article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet Public Health</source>. <year>2022</year>;<volume>7</volume>(<issue>2</issue>):<fpage>e105</fpage>&#8208;<lpage>e125</lpage>.<pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></mixed-citation></ref><ref id="trc270161-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="trc270161-cite-0005"><string-name name-style="western"><surname>Rajan</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Weuve</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>McAninch</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DA</given-names></string-name>. <article-title>Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020&#8208;2060)</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>12</issue>):<fpage>1966</fpage>&#8208;<lpage>1975</lpage>.<pub-id pub-id-type="pmid">34043283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12362</pub-id><pub-id pub-id-type="pmcid">PMC9013315</pub-id></mixed-citation></ref><ref id="trc270161-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="trc270161-cite-0006"><article-title>Lecanemab&#8208;irmb package insert 2023</article-title>Accessed October 4, 2024. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf</ext-link></mixed-citation></ref><ref id="trc270161-bib-0006"><label>6</label><mixed-citation publication-type="miscellaneous" id="trc270161-cite-0007"><article-title>Donanemab&#8208;azbt package insert 2024</article-title>Accessed October 4, 2024. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761248s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761248s000lbl.pdf</ext-link></mixed-citation></ref><ref id="trc270161-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="trc270161-cite-0008"><string-name name-style="western"><surname>Langbaum</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Zissimopoulos</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Au</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials</article-title>. <source>Alzheimer's Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>2</issue>):<fpage>696</fpage>&#8208;<lpage>707</lpage>.<pub-id pub-id-type="pmid">35946590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12737</pub-id><pub-id pub-id-type="pmcid">PMC9911558</pub-id></mixed-citation></ref><ref id="trc270161-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="trc270161-cite-0009"><string-name name-style="western"><surname>Ritchie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gillen</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Grill</surname><given-names>JD</given-names></string-name>. <article-title>Recruitment across two decades of NIH&#8208;funded Alzheimer's disease clinical trials</article-title>. <source>Alzheimer's Res Ther</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>28</fpage>.<pub-id pub-id-type="pmid">36732846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01177-x</pub-id><pub-id pub-id-type="pmcid">PMC9893207</pub-id></mixed-citation></ref><ref id="trc270161-bib-0009"><label>9</label><mixed-citation publication-type="miscellaneous" id="trc270161-cite-0010"><article-title>Enhancing the diversity of clinical trial populations &#8212; Eligibility criteria, enrollment practices, and trial designs guidance for industry 2020</article-title>Accessed February 7, 2025. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://regulations.gov/document/FDA-2019-D-1264-0094" ext-link-type="uri">https://regulations.gov/document/FDA&#8208;2019&#8208;D&#8208;1264&#8208;0094</ext-link></mixed-citation></ref><ref id="trc270161-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="trc270161-cite-0011"><string-name name-style="western"><surname>Grill</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Karlawish</surname><given-names>J</given-names></string-name>. <article-title>Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials</article-title>. <source>Alzheimers Res Ther</source>. <year>2010</year>;<volume>2</volume>(<issue>6</issue>):<fpage>34</fpage>.<pub-id pub-id-type="pmid">21172069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt58</pub-id><pub-id pub-id-type="pmcid">PMC3031880</pub-id></mixed-citation></ref><ref id="trc270161-bib-0011"><label>11</label><mixed-citation publication-type="book" id="trc270161-cite-0012"><string-name name-style="western"><surname>Gauthier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rosa&#8208;Neto</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Morais</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Webster</surname><given-names>C</given-names></string-name>. <source>World Alzheimer Report 2021: Journey Through the Diagnosis of Dementia</source>. <publisher-name>Alzheimer's Disease International</publisher-name>; <year>2021</year>. Accessed October 4, 2024. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alzint.org/resource/world-alzheimer-report-2021/" ext-link-type="uri">https://www.alzint.org/resource/world&#8208;alzheimer&#8208;report&#8208;2021/</ext-link></mixed-citation></ref><ref id="trc270161-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="trc270161-cite-0013"><string-name name-style="western"><surname>Raman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Quiroz</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Langford</surname><given-names>O</given-names></string-name>, et&#160;al. <article-title>Disparities by race and ethnicity among adults recruited for a preclinical Alzheimer disease trial</article-title>. <source>JAMA Network Open</source>. <year>2021</year>;<volume>4</volume>(<issue>7</issue>):<fpage>e2114364</fpage>&#8208;<lpage>e</lpage>.<pub-id pub-id-type="pmid">34228129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.14364</pub-id><pub-id pub-id-type="pmcid">PMC8261604</pub-id></mixed-citation></ref><ref id="trc270161-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="trc270161-cite-0014"><string-name name-style="western"><surname>Szabo&#8208;Reed</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Vidoni</surname><given-names>ED</given-names></string-name>, et&#160;al. <article-title>Recruitment methods and yield rates for a multisite clinical trial exploring risk reduction for Alzheimer's disease (rrAD)</article-title>. <source>Alzheimer's Dement: Transl Res Clin Interv</source>. <year>2023</year>;<volume>9</volume>(<issue>4</issue>):<elocation-id>e12422</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12422</pub-id><pub-id pub-id-type="pmcid">PMC10576444</pub-id><pub-id pub-id-type="pmid">37841653</pub-id></mixed-citation></ref><ref id="trc270161-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="trc270161-cite-0015"><string-name name-style="western"><surname>Teano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gipson</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Social media programs for outreach and recruitment supporting aging and Alzheimer disease and related dementias research: longitudinal descriptive study</article-title>. <source>JMIR Aging</source>. <year>2024</year>;<volume>7</volume>:<elocation-id>e51520</elocation-id>.<pub-id pub-id-type="pmid">38981112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/51520</pub-id><pub-id pub-id-type="pmcid">PMC11267090</pub-id></mixed-citation></ref><ref id="trc270161-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="trc270161-cite-0016"><string-name name-style="western"><surname>Gilmore&#8208;Bykovskyi</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gleason</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review</article-title>. <source>Alzheimer's Dement Trans Res Clin Interv</source>. <year>2019</year>;<volume>5</volume>(<issue>1</issue>):<fpage>751</fpage>&#8208;<lpage>770</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2019.09.018</pub-id><pub-id pub-id-type="pmcid">PMC6944728</pub-id><pub-id pub-id-type="pmid">31921966</pub-id></mixed-citation></ref><ref id="trc270161-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="trc270161-cite-0017"><string-name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></string-name>. <article-title>Alzheimer disease in African American individuals: increased incidence or not enough data?</article-title><source>Nature Rev Neurolog</source>. <year>2022</year>;<volume>18</volume>(<issue>1</issue>):<fpage>56</fpage>&#8208;<lpage>62</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-021-00589-3</pub-id><pub-id pub-id-type="pmcid">PMC8647782</pub-id><pub-id pub-id-type="pmid">34873310</pub-id></mixed-citation></ref><ref id="trc270161-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="trc270161-cite-0018"><string-name name-style="western"><surname>Franzen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>van den Berg</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria</article-title>. <source>Alzheimer's Dement</source>. <year>2022</year>;<volume>18</volume>(<issue>4</issue>):<fpage>810</fpage>&#8208;<lpage>823</lpage>.<pub-id pub-id-type="pmid">34590409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12433</pub-id><pub-id pub-id-type="pmcid">PMC8964823</pub-id></mixed-citation></ref><ref id="trc270161-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="trc270161-cite-0019"><string-name name-style="western"><surname>Indorewalla</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>O'Connor</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Budson</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Guess</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>J</given-names></string-name>. <article-title>Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in Alzheimer's disease research</article-title>. <source>J Alzheimer's Dis</source>. <year>2021</year>;<volume>80</volume>:<fpage>927</fpage>&#8208;<lpage>940</lpage>.<pub-id pub-id-type="pmid">33612540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201081</pub-id><pub-id pub-id-type="pmcid">PMC8150544</pub-id></mixed-citation></ref><ref id="trc270161-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="trc270161-cite-0020"><string-name name-style="western"><surname>Shepherd</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Joyce</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Improving the inclusion of an under&#8208;served group in trials: development and implementation of the INCLUDE Impaired Capacity to Consent Framework</article-title>. <source>Trials</source>. <year>2024</year>;<volume>25</volume>(<issue>1</issue>):<fpage>83</fpage>.<pub-id pub-id-type="pmid">38273417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13063-024-07944-x</pub-id><pub-id pub-id-type="pmcid">PMC10809528</pub-id></mixed-citation></ref><ref id="trc270161-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="trc270161-cite-0021"><string-name name-style="western"><surname>Padala</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Yarns</surname><given-names>BC</given-names></string-name>. <article-title>Under&#8208;represented populations left out of Alzheimer's disease treatment with aducanumab: commentary on ethics</article-title>. <source>J Alzheimer's Dis Rep</source>. <year>2022</year>;<volume>6</volume>:<fpage>345</fpage>&#8208;<lpage>348</lpage>.<pub-id pub-id-type="pmid">35891635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/ADR-220023</pub-id><pub-id pub-id-type="pmcid">PMC9277694</pub-id></mixed-citation></ref><ref id="trc270161-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="trc270161-cite-0022"><string-name name-style="western"><surname>Wilkins</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Windon</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Dilworth&#8208;Anderson</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the imaging dementia&#8208;evidence for amyloid scanning (IDEAS) cohort study</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>11</issue>):<fpage>1139</fpage>&#8208;<lpage>1147</lpage>.<pub-id pub-id-type="pmid">36190710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2022.3157</pub-id><pub-id pub-id-type="pmcid">PMC9531087</pub-id></mixed-citation></ref><ref id="trc270161-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="trc270161-cite-0023"><string-name name-style="western"><surname>Flanagin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Frey</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Christiansen</surname><given-names>SL</given-names></string-name>, AMA Manual of Style <collab collab-type="authors">Committee</collab>
. <article-title>Updated guidance on the reporting of race and ethnicity in medical and science journals</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>326</volume>(<issue>7</issue>):<fpage>621</fpage>&#8208;<lpage>627</lpage>.<pub-id pub-id-type="pmid">34402850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.13304</pub-id></mixed-citation></ref><ref id="trc270161-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="trc270161-cite-0024"><string-name name-style="western"><surname>Siemers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Feaster</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sethuraman</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>INTERCEPT&#8208;AD, a phase 1 study of intravenous Sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease</article-title>. <source>J Prev Alzheimer's Dis</source>. <year>2025</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>100005</elocation-id>.<pub-id pub-id-type="pmid">39800458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tjpad.2024.100005</pub-id><pub-id pub-id-type="pmcid">PMC12184067</pub-id></mixed-citation></ref><ref id="trc270161-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="trc270161-cite-0025"><string-name name-style="western"><surname>Siemers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hitchcock</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sundell</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>ACU193, a monoclonal antibody that selectively binds soluble A&#223; oligomers: development rationale, phase 1 trial design, and clinical development plan</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2023</year>;<volume>10</volume>(<issue>1</issue>):<fpage>19</fpage>&#8208;<lpage>24</lpage>.<pub-id pub-id-type="pmid">36641606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.93</pub-id></mixed-citation></ref><ref id="trc270161-bib-0025"><label>25</label><mixed-citation publication-type="miscellaneous" id="trc270161-cite-0026"><string-name name-style="western"><surname>Goldman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Malzbender</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lavin&#8208;Mena</surname><given-names>MS</given-names></string-name>, et&#160;al. <article-title>Key barriers for clinical trials for Alzheimer's disease 2020</article-title>Accessed October 4, 2024. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://healthpolicy.usc.edu/research/key-barriers-for-clinical-trials-for-alzheimers-disease/" ext-link-type="uri">https://healthpolicy.usc.edu/research/key&#8208;barriers&#8208;for&#8208;clinical&#8208;trials&#8208;for&#8208;alzheimers&#8208;disease/</ext-link></mixed-citation></ref><ref id="trc270161-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="trc270161-cite-0027"><string-name name-style="western"><surname>Brookmeyer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Hebert</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>National estimates of the prevalence of Alzheimer's disease in the United States</article-title>. <source>Alzheimer's Dement</source>. <year>2011</year>;<volume>7</volume>(<issue>1</issue>):<fpage>61</fpage>&#8208;<lpage>73</lpage>.<pub-id pub-id-type="pmid">21255744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2010.11.007</pub-id><pub-id pub-id-type="pmcid">PMC3052294</pub-id></mixed-citation></ref><ref id="trc270161-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="trc270161-cite-0028"><string-name name-style="western"><surname>Brookmeyer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ziegler&#8208;Graham</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Arrighi</surname><given-names>HM</given-names></string-name>. <article-title>Forecasting the global burden of Alzheimer's disease</article-title>. <source>Alzheimer's Dement</source>. <year>2007</year>;<volume>3</volume>(<issue>3</issue>):<fpage>186</fpage>&#8208;<lpage>191</lpage>.<pub-id pub-id-type="pmid">19595937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2007.04.381</pub-id></mixed-citation></ref><ref id="trc270161-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="trc270161-cite-0029"><string-name name-style="western"><surname>Belloy</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Le Guen</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>APOE genotype and Alzheimer disease risk across age, sex, and population ancestry</article-title>. <source>JAMA Neurolog</source>. <year>2023</year>;<volume>80</volume>(<issue>12</issue>):<fpage>1284</fpage>&#8208;<lpage>1294</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.3599</pub-id><pub-id pub-id-type="pmcid">PMC10628838</pub-id><pub-id pub-id-type="pmid">37930705</pub-id></mixed-citation></ref><ref id="trc270161-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="trc270161-cite-0030"><string-name name-style="western"><surname>Granot&#8208;Hershkovitz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tarraf</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kurniansyah</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>APOE alleles' association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos&#8208;investigation of neurocognitive aging (HCHS/SOL)</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>3</issue>):<fpage>466</fpage>&#8208;<lpage>474</lpage>.<pub-id pub-id-type="pmid">33155766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12205</pub-id><pub-id pub-id-type="pmcid">PMC8016734</pub-id></mixed-citation></ref><ref id="trc270161-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="trc270161-cite-0031"><string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>BB</given-names></string-name>, et&#160;al. <article-title>Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences</article-title>. <source>Neurolog Sci</source>. <year>2024</year>;<volume>45</volume>(<issue>3</issue>):<fpage>1041</fpage>&#8208;<lpage>1050</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10072-023-07076-1</pub-id><pub-id pub-id-type="pmid">37759100</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">1761</journal-id><journal-id journal-id-type="pmc-domain">tp</journal-id><journal-title-group><journal-title>Translational Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2158-3188</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501003</article-id><article-id pub-id-type="pmcid-ver">PMC12501003.1</article-id><article-id pub-id-type="pmcaid">12501003</article-id><article-id pub-id-type="pmcaiid">12501003</article-id><article-id pub-id-type="pmid">41052979</article-id><article-id pub-id-type="doi">10.1038/s41398-025-03589-9</article-id><article-id pub-id-type="publisher-id">3589</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Salivary mitochondrial DNA is associated with biomarkers of Alzheimer&#8217;s disease in cognitively normal older adults</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2628-7076</contrib-id><name name-style="western"><surname>Cantero</surname><given-names initials="JL">Jose L.</given-names></name><address><email>jlcanlor@upo.es</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Atienza</surname><given-names initials="M">Mercedes</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Podlesniy</surname><given-names initials="P">Petar</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7891-5919</contrib-id><name name-style="western"><surname>Puigr&#242;s</surname><given-names initials="M">Margalida</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7951-9881</contrib-id><name name-style="western"><surname>Trullas</surname><given-names initials="R">Ramon</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02z749649</institution-id><institution-id institution-id-type="GRID">grid.15449.3d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2200 2355</institution-id><institution>Laboratory of Functional Neuroscience, </institution><institution>Pablo de Olavide University, </institution></institution-wrap>Seville, Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ca2c886</institution-id><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution>Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), </institution><institution>Instituto de Salud Carlos III, </institution></institution-wrap>28029 Madrid, Spain </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02ysayy16</institution-id><institution-id institution-id-type="GRID">grid.420258.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1794 1077</institution-id><institution>Neurobiology Unit, Institut d&#8217;Investigacions Biom&#232;diques de Barcelona, </institution><institution>Consejo Superior de Investigaciones Cient&#237;ficas (IIBB-CSIC-IDIBAPS), </institution></institution-wrap>08036 Barcelona, Spain </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478532</issue-id><elocation-id>355</elocation-id><history><date date-type="received"><day>23</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>31</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41398_2025_Article_3589.pdf"/><abstract id="Abs1"><p id="Par1">A significant body of evidence suggests that mitochondrial dysfunction plays a key role in the development and progression of Alzheimer&#8217;s disease (AD). However, the absence of peripheral biomarkers for mitochondrial dysfunction limits its clinical applicability. Mitochondrial DNA (mtDNA) copy number, a proxy for mitochondrial function, has shown promise in detecting early stages of AD and predicting AD risk in cerebrospinal fluid (CSF) and blood, respectively. Surprisingly, recent studies have identified mtDNA molecules in human saliva, but their relationship with AD remains unexplored. Here, we investigated potential associations between salivary mtDNA copy number and cortical amyloid-&#946; (A&#946;) load measured with PET, and blood AD markers measured with ultrasensitive single molecule array (SIMOA) assays, in cognitively normal older adults. We found that salivary mtDNA copy number was positively correlated with cortical A&#946; burden and plasma levels of tau phosphorylated at threonine 181 (pTau-181), and negatively correlated with general cognitive ability. It is worth noting that salivary mtDNA was not significantly associated with other blood-based AD biomarkers, including A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, neurofilament-light chain (NfL), or glial fibrillary acidic protein (GFAP). Additionally, plasma pTau-181 levels moderated the association between salivary mtDNA and A&#946; accumulation in the inferior temporal lobe, while A&#946; load in the occipital cortex mediated the association between plasma pTau-181 and salivary mtDNA. Together, these findings represent the first evidence linking salivary mtDNA to well-established AD biomarkers in normal aging, suggesting that salivary mtDNA may serve as a potential non-invasive biomarker for identifying individuals at risk for developing AD in the general population.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Prognostic markers</kwd><kwd>Molecular neuroscience</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003329</institution-id><institution>Ministerio de Econom&#237;a y Competitividad (Ministry of Economy and Competitiveness)</institution></institution-wrap></funding-source><award-id>PID2023-149270OB-I00</award-id><award-id>PID2023-153168OB-I00</award-id><principal-award-recipient><name name-style="western"><surname>Cantero</surname><given-names>Jose L.</given-names></name><name name-style="western"><surname>Trullas</surname><given-names>Ramon</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Mitochondria are cellular organelles that play a pivotal role in energy production and oxidative balance in most eukaryotic cells. Beyond their metabolic functions, they serve as major regulatory centers involved in programmed cell death, immune response modulation, macromolecule synthesis, calcium homeostasis, and both intracellular and endocrine signaling pathways [<xref ref-type="bibr" rid="CR1">1</xref>]. Mitochondrial function and mitophagy declines with age, leading to alterations in cellular physiology that may contribute to the development of aging-related chronic diseases [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par3">Mitochondria contain their own DNA (mtDNA), which encodes proteins critical for mitochondrial function. Recent studies have identified mtDNA in different body fluids, either as unprotected circulating cell-free mtDNA (cf-mtDNA) or encapsulated in extracellular vesicles [<xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. Notably, these forms of mtDNA appear to be resistant to nuclease degradation. While the cellular origins and physiological roles of cf-mtDNA remain unclear, latest findings suggest its potential as a biomarker for Alzheimer&#8217;s disease (AD) in CSF [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], as well as its predictive value for AD-related risk in blood [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par4">Saliva is attracting considerable attention as a suitable biofluid for identifying biomarkers of complex systemic diseases, due to its easy accessibility, minimally invasive collection procedures and low patient compliance demands. Furthermore, saliva-based analyses offer a potentially cost-effective strategy for screening of large-scale population and longitudinal follow-up studies [<xref ref-type="bibr" rid="CR11">11</xref>]. Although mtDNA has been previously detected in human saliva [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>], research examining its potential as a surrogate biomarker for AD in cognitively normal older adults is lacking. In this study, we first explored whether variations in salivary mtDNA levels were associated with changes in cognitive function. Next, we investigated potential associations between salivary mtDNA levels and cortical A&#946; load measured with PET, as well as its relationship with a panel of blood-based AD biomarkers measured with ultrasensitive SIMOA assays. Finally, we assessed whether these variables acted as moderators or mediators in the observed associations.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Participants</title><p id="Par5">Ninety-one cognitively normal older adults participated in the study. To rule out the presence of mild cognitive impairment or dementia, each participant underwent a complete neurological evaluation. Individuals with conditions such as stroke, epilepsy, head trauma, neurodevelopmental disorders, intellectual disability, alcohol abuse, hydrocephalus, or intracranial tumors, were excluded from participation.</p><p id="Par6">Inclusion criteria were: i) normal cognitive performance on cognitive tests, based on age- and education-adjusted reference values; ii) Clinical Dementia Rating score of 0, indicating no evidence of dementia; iii) autonomy in daily life; and iv) a score lower than 5 on the short form of the Geriatric Depression Scale, indicating no symptoms of depression.</p><p id="Par7">All participants provided their informed consent before taking part in the study. The protocol was approved by the Ethical Committee for Clinical Research of the Junta de Andaluc&#237;a, following the ethical standards outlined in the Declaration of Helsinki.</p></sec><sec id="Sec4"><title>Neuropsychological assessment</title><p id="Par8">Participants completed a comprehensive neuropsychological assessment. The assessment included the Spanish version of the memory binding test [<xref ref-type="bibr" rid="CR19">19</xref>], the face-name associative memory test [<xref ref-type="bibr" rid="CR20">20</xref>], the D2 attention test, as well as the letter-number sequencing and digit span subtests from the Wechsler Adult Intelligence Scale-III. Additionally, the spatial span subtest of the Wechsler Memory Scale-III was administered together with the short form of the Boston Naming Test, and semantic and phonological fluency tasks based on the &#8220;Animal&#8221; and letter &#8220;P&#8221; naming categories. Processing speed was assessed using the Symbol Digit Modalities Test. To evaluate executive function, both forms of the Trail Making Test (A and B) were administered, along with the Tower of London test, which measures planning and problem-solving abilities.</p></sec><sec id="Sec5"><title>Saliva collection</title><p id="Par9">Unstimulated whole saliva samples were collected into 50&#8201;ml sterile polypropylene conical tubes, which had been previously treated with a 2% sodium azide solution. Immediately after collection, samples were placed on ice and subjected to an initial centrifugation at 162 x g (1000&#8201;rpm) for 10&#8201;min at 4&#8201;&#176;C. The supernatant was then centrifuged again at 2287 x g (4500&#8201;rpm) for 15&#8201;min at 4&#8201;&#176;C. Following centrifugation, a protease inhibitor cocktail (cOmplete&#8482; Ultra Tablets Mini, Roche, Basel, Switzerland) was added at a concentration of 1X. The resulting sample was aliquoted into 1.5&#8201;ml polypropylene tubes and stored at &#8722;80&#8201;&#176;C until analysis.</p></sec><sec id="Sec6"><title>Measurement of mtDNA copy number and nuclear genomes in saliva</title><p id="Par10">Quantification of mtDNA and nuclear DNA (nDNA) was carried out directly in saliva samples without performing nucleic acid extraction following a modified protocol [<xref ref-type="bibr" rid="CR21">21</xref>]. Saliva was mixed with the 100ST DNA/RNA/protein solubilization reagent (DirectQuant) in a 4:1 ratio (v:v) and heated at 90&#8201;&#176;C for 3&#8201;min with continuous shaking at 750&#8201;rpm. The resulting solubilized saliva was then diluted 1:20 using double-distilled water for mtDNA quantification. The mtDNA was amplified using the primer pair mt92-CYTB, which targets the region from base pairs 15427 to 15518 of the mtDNA reference sequence <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NC_012920.1">NC_012920.1</ext-link> (Forward, 5&#8217;-AGACGCCCTCGGCTTACTTC-3&#8217;; Reverse, 5&#8217;-GGGTATAATTGTCTGGGTCGCC-3&#8217;). For nDNA measurement, the TBP1-73 primer pair, targeting the <italic toggle="yes">TBP1</italic> gene, was used (Forward, 5&#8217;-CACCACAGCTCTTCCACTCA-3&#8217;; Reverse, 5&#8217;-GGGGAGGGATACAGTGGAGT-3&#8217;). The digital PCR (dPCR) reaction for both mtDNA and nDNA quantification was prepared in a 20&#8201;&#181;l final volume, consisting of 5&#8201;&#181;l of saliva (diluted for mtDNA or undiluted for nDNA), 10&#8201;&#181;l of 2X QX200&#8482; dPCR&#8482; EvaGreen Supermix (Bio-Rad, #1864033), 1&#8201;&#181;l of either 2.7&#8201;&#181;M mt92-CYTB primers (135&#8201;nM final concentration) or 1&#8201;&#181;l of 1.9&#8201;&#181;M TBP1-73 primers (95&#8201;nM final concentration), 1&#8201;&#181;l of restriction enzyme AluI (#FD0014, Thermo Scientific) for mtDNA analysis, or 0.5&#8201;&#181;l of SaqAI (#FD2174, Thermo Scientific) and 0.5&#8201;&#181;l of BsuRI (#FD0154, Thermo Scientific) for nDNA. The final reaction volume was adjusted to 20&#8201;&#181;l with double-distilled water. Enzyme digestion was performed at 37&#8201;&#176;C for 15&#8201;min before partitioning the reaction mixture into droplets using the Bio-Rad QX200&#8482; Droplet Reader.</p><p id="Par11">The dPCR amplification conditions were as follows: initial denaturation at 95&#8201;&#176;C for 5&#8201;min, followed by 40 cycles of denaturation at 95&#8201;&#176;C for 30&#8201;s, and annealing at 60&#8201;&#176;C for 1&#8201;min, with a final extension at 4&#8201;&#176;C for 5&#8201;min, 90&#8201;&#176;C for 5&#8201;min, and cooling at 4&#8201;&#176;C for 10&#8201;min. The quantification of the amplified PCR products was performed with the Bio-Rad QX200&#8482; Droplet Reader. The number of mtDNA copies per sample was calculated by the formula: (mtDNA copies per &#181;l saliva) / (nuclear DNA copies per &#181;l saliva / 2).</p></sec><sec id="Sec7"><title>Blood biomarkers of AD</title><p id="Par12">Blood samples were collected after an overnight fast, immediately processed, and stored at &#8722;80&#8201;&#176;C until analysis. Plasma levels of A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, and pTau-181 along with serum levels of NfL and GFAP, were measured in duplicate using SIMOA assays (Quanterix, MA, USA) on a SR-X analyzer according to the manufacturer&#8217;s instructions. The average of the two measurements (pg/ml) was used for statistical analysis. To ensure measurement accuracy and consistency, samples with coefficients of variation greater than 20% were repeated.</p></sec><sec id="Sec8"><title>Acquisition and preprocessing of MRI scans</title><p id="Par13">Structural brain images were acquired on a Philips Ingenia 3.0&#8201;T CX MRI scanner equipped with a 32-channel receive-only radio-frequency (RF) head coil (Philips, Best, Netherlands). A high-resolution 3D T1-weighted magnetization prepared rapid gradient echo (MPRAGE) sequence was obtained in the sagittal plane with no inter-slice gaps using the following parameters: repetition time/echo time = 2600&#8201;ms/4.7&#8201;ms, flip angle = 9&#176;, acquisition matrix = 384 &#215;384, and isotropic voxel resolution of 0.65&#8201;mm&#179;.</p><p id="Par14">T1-weighted (T1w) images were processed using Freesurfer version 6.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://surfer.nmr.mgh.harvard.edu/">https://surfer.nmr.mgh.harvard.edu/</ext-link>), which involved a series of preprocessing steps: brain extraction, automated segmentation of tissue types, and the creation of white matter (WM) and pial surfaces. Additional corrections for surface topology and inflation, as well as co-registration and spherical projection of cortical surfaces, were applied to establish a surface-based coordinate system [<xref ref-type="bibr" rid="CR22">22</xref>]. Manual adjustments were made by a trained technician on a slice-by-slice basis to correct misalignments in the pial surface and inaccuracies in WM segmentation. Visual inspection was performed at each stage to ensure quality control and accuracy of the processing pipeline.</p></sec><sec id="Sec9"><title>Acquisition and preprocessing of amyloid PET scans</title><p id="Par15">Participants received an injection of 300 MBq of 18F-Florbetaben (FBB, NeuraCeq&#8482;, Curium Pharma) 90&#8201;min prior to imaging with a Philips Gemini 16 PET/CT scanner (Philips, Best, Netherlands). A dynamic 20-min FBB-PET scan was conducted, consisting of four 5-min frames. Each frame was reviewed for excessive motion artifacts. As no significant head movements were observed, the four frames were averaged to generate a single static FBB brain image for subsequent quantitative analysis. Amyloid PET images were corrected for radioactive decay, dead time, attenuation, and scatter, and were then reconstructed with an iterative algorithm, yielding an isotropic voxel resolution of 2&#8201;mm&#179;.</p><p id="Par16">Partial volume correction (PVC) of the FBB-PET images was performed with the PetSurfer tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://surfer.nmr.mgh.harvard.edu/fswiki/PetSurfer">https://surfer.nmr.mgh.harvard.edu/fswiki/PetSurfer</ext-link>), employing a region-based voxel-wise method derived from the geometric transfer matrix [<xref ref-type="bibr" rid="CR23">23</xref>]. This method assumes a uniform 6&#8201;mm point spread function. Initial alignment of the cerebral FBB images to T1w scans was followed by transformation of the PVC-corrected FBB cortical images into a standardized uptake value ratio (SUVR) format, with the mean PVC uptake in the cerebellar grey matter serving as the reference region. The resulting cortical-to-cerebellum SUVR images were then mapped to individual cortical surfaces and smoothed with non-linear spherical wavelet-based denoising techniques [<xref ref-type="bibr" rid="CR24">24</xref>]. The global A&#946; load was computed by obtaining a composite FBB measure for each participant [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par17">Scores of cognitive tests were transformed into Z-scores for each participant. Z-scores were reversed if a higher score indicates a worse test performance. General cognitive ability was estimated in principal component analysis using the g-factor score, which was derived from the first unrotated component with the highest eigenvalue. Higher values in the g-factor score indicated better cognitive performance. The analysis was performed with R Statistical Software v3.0.1 (R Foundation for Statistical Computing, Vienna, Austria), applying the <italic toggle="yes">prcomp</italic> function.</p><p id="Par18">Before conducting statistical analyses, we applied a Box-Cox transformation to dependent variables in order to address non-normality and reduce heteroscedasticity [<xref ref-type="bibr" rid="CR26">26</xref>]. Multiple linear regression models were used to assess the relationships between salivary mtDNA and variables such as age, cognitive performance, and blood biomarkers for AD, including A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>1-42</sub>/A&#946;<sub>1-40</sub> ratio, pTau-181, NfL, and GFAP. Additionally, we examined differences in salivary mtDNA as a function of sex, APOE4 genotype, and family history of AD. Age and sex were included as covariates in all models.</p><p id="Par19">To explore variations in cortical A&#946; load with respect to salivary mtDNA and plasma pTau-181, we conducted vertex-wise multiple linear regression analyses on cortical surface data. These statistical models were adjusted for age and sex, and dependent variables underwent Box-Cox transformation. We also investigated the interaction between plasma pTau-181 and salivary mtDNA on cortical A&#946; load. This statistical approach was similarly adjusted for age and sex.</p><p id="Par20">Cortical surface-based analyses were performed using the SurfStat tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.math.mcgill.ca/keith/surfstat/">https://www.math.mcgill.ca/keith/surfstat/</ext-link>). Multiple comparisons were controlled for by applying a hierarchical statistical model [<xref ref-type="bibr" rid="CR27">27</xref>], which first adjusted for family-wise error rate within significant clusters over smoothed statistical maps using random field theory, followed by false discovery rate control within vertices of significant clusters on unsmoothed maps. The anatomical locations of corrected clusters were identified using the peak vertex positions on the Desikan-Killiany brain atlas [<xref ref-type="bibr" rid="CR28">28</xref>]. After confirming significant effects, standardized local effect sizes (f<sup>2</sup><sub>local</sub> or rho<sub>local</sub>) were calculated for the regression models [<xref ref-type="bibr" rid="CR29">29</xref>]. To estimate the precision of effect sizes, 95% confidence intervals (CI<sub>95%</sub>) were determined using the <italic toggle="yes">bootci</italic> function in Matlab with 10,000 bootstrap samples, applying a normal approximation to the interval based on bootstrapped bias and standard error.</p><p id="Par21">In order to mitigate issues related to multiple comparisons, Bayesian linear regression was also performed on the peak vertex for each significant cortical cluster using JASP v0.12.2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://jasp-stats.org/">https://jasp-stats.org/</ext-link>). Bayesian models were specified using the Jeffreys-Zellner-Siow prior with an r scale of 0.354 [<xref ref-type="bibr" rid="CR30">30</xref>]. The Bayes factor (BF<sub>10</sub>) was calculated to compare models with and without the predictor of interest (experimental <italic toggle="yes">versus</italic> null models). To interpret results, we follow the classification scheme by Lee and Wagenmakers [<xref ref-type="bibr" rid="CR31">31</xref>]. Results were only reported when they met the following criteria: (i) the p-value from the frequentist analysis was &lt;0.05 after correction for multiple comparisons, (ii) the local effect size was at least moderate, with the CI<sub>95%</sub> excluding zero, and (iii) there was at least moderate evidence in favor of the alternative hypothesis (BF<sub>10</sub>&#8201;&#8805;&#8201;10).</p><p id="Par22">Finally, we conducted simple mediation analyses with bootstrapping, using the R mediation package, to determine whether the relationship between salivary mtDNA and plasma pTau-181 was mediated by cortical A&#946; load. We specifically tested whether A&#946; burden in the region where pTau-181 was associated with salivary mtDNA acted as the mediator. The indirect effects were considered significant if the bootstrapped CI<sub>95%</sub> did not include zero. To ensure that spurious effects did not influence the hypothesized pathway, we also examined alternative models where cortical A&#946; was the predictor, pTau-181 the mediator, and salivary mtDNA the outcome variable. Lastly, we assessed whether the relationship between salivary mtDNA and cortical A&#946; burden was mediated by global A&#946; or by other regions where pTau-181 might influence the A&#946;-mtDNA association.</p></sec></sec><sec id="Sec11" sec-type="results"><title>Results</title><sec id="Sec12"><title>Sample characteristics</title><p id="Par23">Table <xref rid="Tab1" ref-type="table">1</xref> shows demographics, blood-based AD biomarkers, and global A&#946; load. Table <xref rid="Tab2" ref-type="table">2</xref> shows results of cognitive testing. Salivary mtDNA was not associated with age, sex, APOE4 genotype, first-degree family history of AD, plasma A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>1-42</sub>/A&#946;<sub>1-40</sub> ratio, serum NfL or GFAP (Figure <xref rid="MOESM2" ref-type="media">S1</xref>). However, salivary mtDNA was significantly correlated with general cognitive ability (F<sub>3,87</sub>&#8201;=&#8201;4.1, p&#8201;=&#8201;0.04; R<sup>2</sup>&#8201;=&#8201;0.06, &#946;&#8201;=&#8201;&#8722;26.3, p&#8201;=&#8201;0.04) and plasma pTau-181 (F<sub>3,87</sub>&#8201;=&#8201;4.6, p&#8201;=&#8201;0.03; R<sup>2</sup>&#8201;=&#8201;0.06, &#946;&#8201;=&#8201;6.5, p&#8201;=&#8201;0.03) adjusted for age and sex. The correlation with general cognitive ability was negative (r&#8201;=&#8201;&#8722;0.21, p&#8201;=&#8201;0.04; Fig. <xref rid="Fig1" ref-type="fig">1A</xref>), while the correlation with plasma pTau-181 was positive (r&#8201;=&#8201;0.22, p&#8201;=&#8201;0.03; Fig. <xref rid="Fig1" ref-type="fig">1B</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographics, blood-based AD biomarkers, and global A&#946; load of the study sample.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="1" rowspan="1">Age (years)</td><td colspan="1" rowspan="1">66.9&#8201;&#177;&#8201;5.9</td></tr><tr><td colspan="1" rowspan="1">Sex (F/M)</td><td colspan="1" rowspan="1">62/29</td></tr><tr><td colspan="1" rowspan="1">Education years</td><td colspan="1" rowspan="1">11.6&#8201;&#177;&#8201;5</td></tr><tr><td colspan="1" rowspan="1">ApoE4 (yes/no)</td><td colspan="1" rowspan="1">26/65</td></tr><tr><td colspan="1" rowspan="1">FH (yes/no)</td><td colspan="1" rowspan="1">29/62</td></tr><tr><td colspan="1" rowspan="1">Salivary mtDNA</td><td colspan="1" rowspan="1">413.2&#8201;&#177;&#8201;430.6</td></tr><tr><td colspan="1" rowspan="1">A&#946;<sub>1-40</sub> (pg/ml)</td><td colspan="1" rowspan="1">165.7&#8201;&#177;&#8201;44.1</td></tr><tr><td colspan="1" rowspan="1">A&#946;<sub>1-42</sub> (pg/ml)</td><td colspan="1" rowspan="1">7.0&#8201;&#177;&#8201;1.7</td></tr><tr><td colspan="1" rowspan="1">A&#946;<sub>1-42</sub>/A&#946;<sub>1-40</sub> ratio</td><td colspan="1" rowspan="1">0,044&#8201;&#177;&#8201;0.014</td></tr><tr><td colspan="1" rowspan="1">pTau-181 (pg/ml)</td><td colspan="1" rowspan="1">22.4&#8201;&#177;&#8201;9.7</td></tr><tr><td colspan="1" rowspan="1">NfL (pg/ml)</td><td colspan="1" rowspan="1">15.3&#8201;&#177;&#8201;7.6</td></tr><tr><td colspan="1" rowspan="1">GFAP (pg/ml)</td><td colspan="1" rowspan="1">279.6&#8201;&#177;&#8201;115.3</td></tr><tr><td colspan="1" rowspan="1">Global A&#946; load</td><td colspan="1" rowspan="1">1.21&#8201;&#177;&#8201;0.36</td></tr></tbody></table><table-wrap-foot><p>Results are expressed as mean&#8201;&#177;&#8201;standard deviation unless otherwise stated. F/M: females/males; FH: first-degree family history of AD. Global A&#946; load was computed using an 18F-Florbetaben (FBB) composite extracted across four large bilateral cortical regions [<xref ref-type="bibr" rid="CR25">25</xref>].</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Cognitive profile of the study sample.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="1" rowspan="1">MMSE</td><td colspan="1" rowspan="1">28.8&#8201;&#177;&#8201;1.3</td></tr><tr><td colspan="2" rowspan="1">Memory Binding Test</td></tr><tr><td colspan="1" rowspan="1">&#8195;Total free recall</td><td colspan="1" rowspan="1">14.9&#8201;&#177;&#8201;5</td></tr><tr><td colspan="1" rowspan="1">&#8195;Total paired recall</td><td colspan="1" rowspan="1">23.9&#8201;&#177;&#8201;4.9</td></tr><tr><td colspan="1" rowspan="1">&#8195;Total delayed-free recall</td><td colspan="1" rowspan="1">15.3&#8201;&#177;&#8201;5.9</td></tr><tr><td colspan="1" rowspan="1">&#8195;Total delayed paired recall</td><td colspan="1" rowspan="1">23.3&#8201;&#177;&#8201;5.4</td></tr><tr><td colspan="1" rowspan="1">S-FNAME</td><td colspan="1" rowspan="1">31.1&#8201;&#177;&#8201;16</td></tr><tr><td colspan="1" rowspan="1">Boston Naming Test</td><td colspan="1" rowspan="1">12.2&#8201;&#177;&#8201;2.2</td></tr><tr><td colspan="1" rowspan="1">Phonological fluency</td><td colspan="1" rowspan="1">15.9&#8201;&#177;&#8201;4.9</td></tr><tr><td colspan="1" rowspan="1">Semantic fluency</td><td colspan="1" rowspan="1">21.6&#8201;&#177;&#8201;15.6</td></tr><tr><td colspan="1" rowspan="1">Trail Making Test-A (seconds)</td><td colspan="1" rowspan="1">47.6&#8201;&#177;&#8201;21.6</td></tr><tr><td colspan="1" rowspan="1">Trail Making Test-B (seconds)</td><td colspan="1" rowspan="1">129.5&#8201;&#177;&#8201;88.1</td></tr><tr><td colspan="1" rowspan="1">Tower of London (seconds)</td><td colspan="1" rowspan="1">324.3&#8201;&#177;&#8201;118.1</td></tr><tr><td colspan="1" rowspan="1">D2</td><td colspan="1" rowspan="1">340.7&#8201;&#177;&#8201;103.1</td></tr><tr><td colspan="1" rowspan="1">Letter-number sequencing</td><td colspan="1" rowspan="1">9.0&#8201;&#177;&#8201;2.7</td></tr><tr><td colspan="1" rowspan="1">Digit span</td><td colspan="1" rowspan="1">13.8&#8201;&#177;&#8201;3.1</td></tr><tr><td colspan="1" rowspan="1">Symbol digit modalities test</td><td colspan="1" rowspan="1">39.8&#8201;&#177;&#8201;15.6</td></tr></tbody></table><table-wrap-foot><p>Results are expressed as mean&#8201;&#177;&#8201;standard deviation. MMSE: Mini-Mental State Examination; S-FNAME: Spanish validation of the Face Name Associative Memory Exam.</p></table-wrap-foot></table-wrap><fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Associations between salivary mtDNA and cognitive and blood-based AD biomarker.</title><p><bold>A</bold> Correlations between salivary mtDNA and general cognitive ability (i.e., the g factor). <bold>B</bold> Correlations between salivary mtDNA and plasma pTau-181 levels. These analyses were adjusted for age and sex.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e654" position="float" orientation="portrait" xlink:href="41398_2025_3589_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Associations between salivary mtDNA and cortical A&#946; load</title><p id="Par24">Salivary mtDNA was not significantly correlated with global A&#946; load, but it was associated with FBB binding to A&#946; deposits over posterior cortical regions (F<sub>5,85</sub>&#8201;=&#8201;15.7; p&#8201;=&#8201;0.00002, f<sup>2</sup><sub>local</sub>&#8201;=&#8201;0.22 (moderate), CI<sub>95%</sub> [0.08 &#8211; 0.48]). Results are illustrated in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. Specifically, salivary mtDNA levels were positively correlated with A&#946; load in lateral occipital regions (r&#8201;=&#8201;0.43, p&#8201;=&#8201;0.0001) of the left hemisphere. The Bayesian analysis showed extreme evidence in favor of the alternative hypothesis (BF<sub>10</sub>&#8201;=&#8201;882).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Association between salivary mtDNA levels and <sup>18</sup>F-Florbetaben (FBB)-PET binding to A&#946; deposits in the neocortex.</title><p>(<bold>A</bold>) Significant results projected onto the cortical surface. (<bold>B)</bold> The scatter plot shows the relationship between salivary mtDNA levels and the peak vertex of cortical FBB binding, adjusted for age and sex. L: left.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e689" position="float" orientation="portrait" xlink:href="41398_2025_3589_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec14"><title>Associations between plasma pTau-181 and cortical A&#946; load</title><p id="Par25">Plasma pTau-181 levels were significantly correlated with global A&#946; load (F<sub>3,87</sub>&#8201;=&#8201;3.2, p&#8201;=&#8201;0.027; R<sup>2</sup>&#8201;=&#8201;0.1, &#946;&#8201;=&#8201;0.01, p&#8201;=&#8201;0.01). Bayesian analysis also provided very strong evidence in favor of the alternative hypothesis (BF<sub>10</sub>&#8201;=&#8201;60.6). This association was particularly noticeable over parieto-occipital regions in both hemispheres (left: F<sub>5,85</sub>&#8201;=&#8201;16.6; p&#8201;=&#8201;0.001, f<sup>2</sup><sub>local</sub>&#8201;=&#8201;0.23 (moderate), CI<sub>95%</sub> [0.06 &#8211; 0.46]; right: F<sub>5,85</sub>&#8201;=&#8201;15.7; p&#8201;=&#8201;0.003, f<sup>2</sup><sub>local</sub>&#8201;=&#8201;0.23 (moderate), CI<sub>95%</sub> [0.07 &#8211; 0.62]). In both cases, evidence favoring the alternative hypothesis was high (left BF<sub>10</sub>&#8201;&gt;&#8201;2800; right BF<sub>10</sub>&#8201;&gt;&#8201;500). These results are displayed in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. We also analyzed associations between plasma A&#946;<sub>1-42</sub>, A&#946;<sub>1-40</sub> levels and FBB binding. Plasma A&#946;<sub>1-42</sub>, but not A&#946;<sub>1-40</sub>, correlated negatively with A&#946; load in both cortical hemispheres, affecting canonical AD regions such as posterior cingulate, inferior parietal, and insular cortex (Figure <xref rid="MOESM3" ref-type="media">S2</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Association between plasma pTau-181 levels and <sup>18</sup>F-Florbetaben (FBB)-PET binding to A&#946; deposits in the neocortex.</title><p>(<bold>A</bold>) Significant results projected onto the cortical surface. (<bold>B</bold>) Scatter plots showing the associations between plasma pTau-181 levels and the peak vertex of cortical FBB binding, adjusted for age and sex. L: left, R: Right.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e752" position="float" orientation="portrait" xlink:href="41398_2025_3589_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>Moderating effect of plasma pTau-181 on the relationship between salivary mtDNA and cortical A&#946; load</title><p id="Par26">Multiple regression analyses showed that the association between salivary mtDNA and cortical A&#946; load was significantly moderated by plasma pTau-181 over regions of the temporal lobe in the left (F<sub>9,81</sub>&#8201;=&#8201;16.53; p&#8201;=&#8201;0.0006, rho<sub>local</sub>&#8201;=&#8201;0.73 (large), CI<sub>95%</sub> [0.44 &#8211; 1.10]) and right hemisphere (F<sub>9,81</sub>&#8201;=&#8201;12.16; p&#8201;=&#8201;0.00002, rho<sub>local</sub>&#8201;=&#8201;0.51 (large), CI<sub>95%</sub> [0.19 &#8211; 0.84]) (Fig. <xref rid="Fig4" ref-type="fig">4A</xref>). Evidence in favor of the alternative hypothesis was very strong for the left (BF<sub>10</sub>&#8201;=&#8201;87.4) and moderate for the right hemisphere (BF<sub>10</sub>&#8201;=&#8201;6.2). <italic toggle="yes">Post hoc</italic> analyses revealed that only those participants showing high plasma pTau-181 levels exhibited a positive association of salivary mtDNA with A&#946; load in the left parahippocampal (r&#8201;=&#8201;0.61, p&#8201;=&#8201;0.0003) and right fusiform gyri (r&#8201;=&#8201;0.39, p&#8201;=&#8201;0.032) (Fig. <xref rid="Fig4" ref-type="fig">4B</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Moderating role of plasma pTau-181 in the relationship between salivary mtDNA and <sup>18</sup>F-Florbetaben (FBB)-PET binding to A&#946; deposits in the neocortex.</title><p>(<bold>A</bold>) Significant results projected onto the cortical surface. (<bold>B</bold>) Scatter plots depicting partial correlations between salivary mtDNA and peak vertices of cortical FBB binding in participants showing high (pink) and low (green) plasma pTau-181 levels, adjusted for age and sex. L: left, R: Right.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e801" position="float" orientation="portrait" xlink:href="41398_2025_3589_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec16"><title>Mediation analyses</title><p id="Par27">We conducted several mediation models to assess the hypothesis that cortical A&#946; load mediates the association between plasma pTau-181 and salivary mtDNA. Results showed that this association was specifically mediated by FBB binding to A&#946; deposits in the left lateral occipital cortex (Fig. <xref rid="Fig5" ref-type="fig">5</xref>), but not by global A&#946; load (Figure <xref rid="MOESM4" ref-type="media">S3A</xref>) or by A&#946; burden in the temporal lobe (Figure <xref rid="MOESM4" ref-type="media">S3</xref>,<xref rid="MOESM1" ref-type="media">B</xref>). As illustrated in Fig. <xref rid="Fig5" ref-type="fig">5</xref>, mediation analysis revealed that plasma pTau-181 was indirectly related to salivary mtDNA through its relationship with A&#946; accumulation in the left lateral occipital cortex, adjusted for age and sex. In this model, increased plasma pTau-181 was associated with increased A&#946; (standardized &#946; = 0.38, p&#8201;=&#8201;0.0005), and increased A&#946; was subsequently related to increased levels of salivary mtDNA (standardized &#946; = 0.40, p&#8201;=&#8201;0.0002). A 95% CI based on 10,000 bootstrapped samples of the indirect effect was entirely above zero (1.4 &#8211; 8.05), strengthening the significance of the hypothesized mediation pathway. There was no direct effect of plasma pTau-181 on lateral occipital A&#946; load (standardized &#946; = 0.08, p&#8201;=&#8201;0.47). Similar results were found when salivary mtDNA was included as independent variable and pTau-181 as dependent variable in the model. In this case, the mediation effect was also significant (standardized &#946; = 0.005, p&#8201;=&#8201;0.004), contrary to the direct effect (standardized &#946; = 0.003, p&#8201;=&#8201;0.49). However, the reverse mediation, with plasma pTau-181 as mediator and temporal A&#946; load as independent variable, was not significant (indirect effect&#8201;=&#8201;0.03 [&#8722;84.2 &#8211; 180.5]) (Figure <xref rid="MOESM4" ref-type="media">S3</xref>,<xref rid="MOESM1" ref-type="media">C</xref>), confirming the A&#946;-mediated effect.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Mediation model assessing the role of cortical A&#946; burden in linking plasma pTau-181 to salivary mtDNA.</title><p>Schematic representation of a simple mediation model exploring the relationship between FBB binding to A&#946; deposits over the left lateral occipital cortex (i.e., the significant cluster displayed in Fig. <xref rid="Fig2" ref-type="fig">2A</xref>) as mediator variable, plasma pTau-181 levels as independent variable, and salivary mtDNA levels as dependent variable. Numbers along paths are standardized regression coefficients with the corresponding <italic toggle="yes">p</italic> value.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e842" position="float" orientation="portrait" xlink:href="41398_2025_3589_Fig5_HTML.jpg"/></fig></p></sec></sec><sec id="Sec17" sec-type="discussion"><title>Discussion</title><p id="Par28">Previous studies have reported the presence of mtDNA in human saliva [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>], but its relationship with AD biomarkers has remained unexplored so far. Here, we showed that higher levels of salivary mtDNA were associated with greater A&#946; burden in occipital regions, higher plasma pTau-181 levels, and lower cognitive ability in cognitively normal older adults. Remarkably, plasma pTau-181 levels moderated the association between salivary mtDNA and A&#946; accumulation in regions of the inferior temporal lobe. In contrast, the relationship between salivary mtDNA and plasma pTau-181 was mediated by A&#946; accumulation in occipital regions. Together, these results provide new evidence linking salivary mtDNA to well-established AD biomarkers, highlighting associations between salivary mtDNA and AD pathology before the onset of clinical symptoms.</p><p id="Par29">Extensive research has supported mitochondrial dysfunction as an early feature of AD, either contributing to the development of A&#946; pathology or mediating pathologic molecular cascades [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Our results suggest that cortical A&#946; load is accompanied by increased levels of salivary mtDNA. High concentrations of circulating mtDNA have been reported in a variety of pathological conditions, such as diabetes, cancer, myocardial infarction and major depressive disorder [<xref ref-type="bibr" rid="CR3">3</xref>], suggesting that high mtDNA levels may be a potential biomarker and/or predictor of outcome in a variety of diseases. However, the positive correlation between salivary mtDNA and cerebral A&#946; load found in our study differs from previous work showing decreased cf-mtDNA levels in asymptomatic patients with pathological levels of A&#946;<sub>1-42</sub> in CSF samples [<xref ref-type="bibr" rid="CR8">8</xref>]. The source of cf-mtDNA in the CSF is likely circumscribed to brain parenchyma, while the content of mtDNA in saliva may originate from diverse cell types. We speculate that low levels of cf-mtDNA in CSF are the result of a blunted physiological release of byproducts of mitochondrial quality control due to A&#946; aggregation, whereas high levels of salivary mtDNA may be due to increased systemic inflammation. Our mediation analyses supported the two hypotheses as the A&#946;-mediated effect remained significant regardless of whether mtDNA was included as a dependent or independent variable in the model. Consequently, salivary mtDNA may hold promise as a non-invasive biomarker of A&#946; accumulation in the brain. However, its diagnostic utility remains to be determined through future studies with larger cohorts, along the AD continuum.</p><p id="Par30">In the present study, pTau-181 was the only blood-based AD biomarker that exhibited significant associations with salivary mtDNA. Although plasma A&#946; species are commonly used as AD biomarkers, their concentrations are strongly influenced by peripheral production and binding interactions with blood components, which can obscure brain-derived signals and reduce their specificity for central A&#946; pathology [<xref ref-type="bibr" rid="CR34">34</xref>]. Our results are consistent with evidence that plasma pTau-181 is among the most AD-specific plasma biomarkers [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], showing progressive increases across the AD continuum and accurately predicting tau and amyloid pathology in the brain [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], while other plasma AD biomarkers do not perform as well as pTau181 in identifying A&#946; pathology [<xref ref-type="bibr" rid="CR39">39</xref>]. Interestingly, participants with the highest levels of plasma pTau-181 showed the strongest association between salivary mtDNA and cortical A&#946; accumulation, consistent with evidence of a synergistic effect of A&#946; and tau pathology on disease progression [<xref ref-type="bibr" rid="CR40">40</xref>]. Indeed, A&#946; can promote tau phosphorylation and aggregation [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], and A&#946;<sub>1-42</sub>-induced neurotoxicity depends on tau levels through the activation of glycogen synthase kinase-3 (GSK-3) [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], while both pathologies disrupt mitochondrial integrity and function in a feed-forward loop [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Conversely, increased mtDNA mutations have been shown to accelerate A&#946; accumulation and propagation [<xref ref-type="bibr" rid="CR47">47</xref>], worsening mitochondrial dynamics [<xref ref-type="bibr" rid="CR48">48</xref>]. Despite these plausible mechanisms, we acknowledge that our data do not allow us to conclusively determine why associations with salivary mtDNA were selective for pTau-181. Further studies are needed to confirm this association and to clarify whether the preference for pTau-181 reflects biological mechanisms (e.g., tau-mediated mitochondrial stress and release of cell-free mtDNA) or methodological factors (e.g., differential assay sensitivity).</p><p id="Par31">The biological origin of salivary mtDNA remains unclear [<xref ref-type="bibr" rid="CR16">16</xref>]. While saliva contains buccal epithelial and white blood cells that could release mtDNA during isolation, previous studies have rule out cellular content as a major contributor to salivary mtDNA [<xref ref-type="bibr" rid="CR16">16</xref>]. Alternatively, a fraction of salivary mtDNA may originate from blood, given that blood components can passively diffuse into the gingival crevicular fluid, which is in direct contact with saliva [<xref ref-type="bibr" rid="CR49">49</xref>]. Indeed, many blood-derived compounds are detectable in saliva, as shown by comparative proteomic analysis [<xref ref-type="bibr" rid="CR50">50</xref>]. Moreover, unprotected extracellular mtDNA passively released into the bloodstream [<xref ref-type="bibr" rid="CR51">51</xref>] due to blood-brain barrier (BBB) leakage may act as an endogenous damage-associated molecular pattern (DAMP), triggering innate immune responses and potentially contributing to neuroinflammatory cascades [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Future studies should clarify whether systemic inflammatory processes underlie the observed associations between salivary mtDNA and plasma pTau-181 levels.</p><p id="Par32">This study has several limitations that should be considered. First, the sample size was relatively small, which may limit the generalizability of our findings. To address this limitation, we only reported results that satisfied both frequentist and Bayesian statistical thresholds and exhibited at least moderate local effect sizes. Future studies with larger and more diverse cohorts are needed to validate and extend these findings to broader contexts. Second, the cross-sectional design of this study precludes any assessment of the prognostic value of salivary mtDNA for AD progression. Follow-up studies are required to determine whether baseline salivary mtDNA levels are able to predict AD progression in cognitively normal older adults, and to examine whether salivary mtDNA levels change along the AD continuum. Finally, we only assessed correlations between salivary mtDNA and plasma pTau-181, limiting our ability to compare with other phosphorylated forms of tau (e.g., pTau-217) that have demonstrated superior accuracy in detecting A&#946; pathology [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par33">To conclude, the results of the present study provide the first evidence of an association between salivary mtDNA and well-established AD biomarkers in cognitively normal older adults. These results open new avenues for using salivary mtDNA as a potential biomarker to identify individuals at risk for developing AD before the onset of clinical symptoms.</p></sec><sec id="Sec18" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3589_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Figure legends SM</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3589_MOESM2_ESM.tif" position="float" orientation="portrait"><caption><p>Figure S1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3589_MOESM3_ESM.tif" position="float" orientation="portrait"><caption><p>Figure S2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41398_2025_3589_MOESM4_ESM.tif" position="float" orientation="portrait"><caption><p>Figure S3</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41398-025-03589-9.</p></sec><ack><title>Acknowledgements</title><p>This work was supported by the Spanish Ministry of Economy and Competitiveness, grants PID2023-149270OB-I00 (JLC), PID2023-151095NB-I00 (MA), and PID2023-153168OB-I00 (RT, PP); Instituto de Salud Carlos III &#8220;European Union NextGenerationEU/PRTR&#8221;, grant PMP22/00100 (RT), and CIBERNED (JLC, RT). We also thank the participants and their family for their collaboration in this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>JLC conceived the study and wrote the first draft. MA and JLC collected data, performed analysis, and prepared figures and tables. PP, MP and RT measured mtDNA content in saliva. All authors contributed to data interpretation and discussion of results, revised the article for important intellectual content, and approved the final version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data used for this study are available upon reasonable request to the corresponding author.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par34">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name></person-group><article-title>Aging: all roads lead to mitochondria</article-title><source>Semin Cell Dev Biol</source><year>2021</year><volume>116</volume><fpage>160</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2021.02.006</pub-id><pub-id pub-id-type="pmid">33741252</pub-id><pub-id pub-id-type="pmcid">PMC9774040</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Son JM, Lee C. Aging: all roads lead to mitochondria. Semin Cell Dev Biol. 2021;116:160&#8211;8. 10.1016/j.semcdb.2021.02.006<pub-id pub-id-type="pmid">33741252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcdb.2021.02.006</pub-id><pub-id pub-id-type="pmcid">PMC9774040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>DR</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Mitochondria and the autophagy-inflammation-cell death axis in organismal aging</article-title><source>Science</source><year>2011</year><volume>333</volume><fpage>1109</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1126/science.120194</pub-id><pub-id pub-id-type="pmid">21868666</pub-id><pub-id pub-id-type="pmcid">PMC3405151</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science. 2011;333:1109&#8211;12. 10.1126/science.120194<pub-id pub-id-type="pmid">21868666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1201940</pub-id><pub-id pub-id-type="pmcid">PMC3405151</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miliotis</surname><given-names>S</given-names></name><name name-style="western"><surname>Nicolalde</surname><given-names>B</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>M</given-names></name><name name-style="western"><surname>Yepez</surname><given-names>J</given-names></name><name name-style="western"><surname>Caicedo</surname><given-names>A</given-names></name></person-group><article-title>Forms of extracellular mitochondria and their impact in health</article-title><source>Mitochondrion</source><year>2019</year><volume>48</volume><fpage>16</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2019.02.002</pub-id><pub-id pub-id-type="pmid">30771504</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Miliotis S, Nicolalde B, Ortega M, Yepez J, Caicedo A. Forms of extracellular mitochondria and their impact in health. Mitochondrion. 2019;48:16&#8211;30. 10.1016/j.mito.2019.02.002<pub-id pub-id-type="pmid">30771504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mito.2019.02.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picard</surname><given-names>M</given-names></name></person-group><article-title>Blood mitochondrial DNA copy number: What are we counting?</article-title><source>Mitochondrion</source><year>2021</year><volume>60</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2021.06.010</pub-id><pub-id pub-id-type="pmid">34157430</pub-id><pub-id pub-id-type="pmcid">PMC8464495</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Picard M. Blood mitochondrial DNA copy number: What are we counting? Mitochondrion. 2021;60:1&#8211;11. 10.1016/j.mito.2021.06.010<pub-id pub-id-type="pmid">34157430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mito.2021.06.010</pub-id><pub-id pub-id-type="pmcid">PMC8464495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caicedo</surname><given-names>A</given-names></name><name name-style="western"><surname>Benavides-Almeida</surname><given-names>A</given-names></name><name name-style="western"><surname>Haro-Vinueza</surname><given-names>A</given-names></name><name name-style="western"><surname>Pe&#241;a-Cisneros</surname><given-names>J</given-names></name><name name-style="western"><surname>P&#233;rez-Meza</surname><given-names>&#193;A</given-names></name><name name-style="western"><surname>Michelson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Decoding the nature and complexity of extracellular mtDNA: types and implications for health and disease</article-title><source>Mitochondrion</source><year>2024</year><volume>75</volume><fpage>101848.</fpage><pub-id pub-id-type="doi">10.1016/j.mito.2024.101848</pub-id><pub-id pub-id-type="pmid">38246335</pub-id><pub-id pub-id-type="pmcid">PMC11939008</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Caicedo A, Benavides-Almeida A, Haro-Vinueza A, Pe&#241;a-Cisneros J, P&#233;rez-Meza &#193;A, Michelson J, et al. Decoding the nature and complexity of extracellular mtDNA: types and implications for health and disease. Mitochondrion. 2024;75:101848. 10.1016/j.mito.2024.101848<pub-id pub-id-type="pmid">38246335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mito.2024.101848</pub-id><pub-id pub-id-type="pmcid">PMC11939008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michelson</surname><given-names>J</given-names></name><name name-style="western"><surname>Rausser</surname><given-names>S</given-names></name><name name-style="western"><surname>Peng</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Sturm</surname><given-names>G</given-names></name><name name-style="western"><surname>Trumpff</surname><given-names>C</given-names></name><etal/></person-group><article-title>MitoQuicLy: A high-throughput method for quantifying cell-free DNA from human plasma, serum, and saliva</article-title><source>Mitochondrion</source><year>2023</year><volume>71</volume><fpage>26</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2023.05.001</pub-id><pub-id pub-id-type="pmid">37172669</pub-id><pub-id pub-id-type="pmcid">PMC10524316</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Michelson J, Rausser S, Peng A, Yu T, Sturm G, Trumpff C, et al. MitoQuicLy: A high-throughput method for quantifying cell-free DNA from human plasma, serum, and saliva. Mitochondrion. 2023;71:26&#8211;39. 10.1016/j.mito.2023.05.001<pub-id pub-id-type="pmid">37172669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mito.2023.05.001</pub-id><pub-id pub-id-type="pmcid">PMC10524316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puigr&#242;s</surname><given-names>M</given-names></name><name name-style="western"><surname>Calderon</surname><given-names>A</given-names></name><name name-style="western"><surname>Mart&#237;n-Ruiz</surname><given-names>D</given-names></name><name name-style="western"><surname>Serradell</surname><given-names>M</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>M</given-names></name><name name-style="western"><surname>Mu&#241;oz-Lopetegi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder</article-title><source>EBioMedicine</source><year>2024</year><volume>102</volume><fpage>105065.</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2024.105065</pub-id><pub-id pub-id-type="pmid">38502973</pub-id><pub-id pub-id-type="pmcid">PMC10963194</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Puigr&#242;s M, Calderon A, Mart&#237;n-Ruiz D, Serradell M, Fern&#225;ndez M, Mu&#241;oz-Lopetegi A, et al. Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder. EBioMedicine. 2024;102:105065. 10.1016/j.ebiom.2024.105065<pub-id pub-id-type="pmid">38502973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2024.105065</pub-id><pub-id pub-id-type="pmcid">PMC10963194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podlesniy</surname><given-names>P</given-names></name><name name-style="western"><surname>Figueiro-Silva</surname><given-names>J</given-names></name><name name-style="western"><surname>Llado</surname><given-names>A</given-names></name><name name-style="western"><surname>Antonell</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanchez-Valle</surname><given-names>R</given-names></name><name name-style="western"><surname>Alcolea</surname><given-names>D</given-names></name><etal/></person-group><article-title>Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease</article-title><source>Ann Neurol</source><year>2013</year><volume>74</volume><fpage>655</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1002/ana.23955</pub-id><pub-id pub-id-type="pmid">23794434</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Podlesniy P, Figueiro-Silva J, Llado A, Antonell A, Sanchez-Valle R, Alcolea D, et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol. 2013;74:655&#8211;68. 10.1002/ana.23955<pub-id pub-id-type="pmid">23794434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.23955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podlesniy</surname><given-names>P</given-names></name><name name-style="western"><surname>Llorens</surname><given-names>F</given-names></name><name name-style="western"><surname>Puigr&#242;s</surname><given-names>M</given-names></name><name name-style="western"><surname>Serra</surname><given-names>N</given-names></name><name name-style="western"><surname>Sep&#250;lveda-Falla</surname><given-names>D</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid mitochondrial DNA in rapid and slow progressive forms of Alzheimer&#8217;s disease</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>6298.</fpage><pub-id pub-id-type="doi">10.3390/ijms21176298</pub-id><pub-id pub-id-type="pmid">32878083</pub-id><pub-id pub-id-type="pmcid">PMC7503553</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Podlesniy P, Llorens F, Puigr&#242;s M, Serra N, Sep&#250;lveda-Falla D, Schmidt C, et al. Cerebrospinal fluid mitochondrial DNA in rapid and slow progressive forms of Alzheimer&#8217;s disease. Int J Mol Sci. 2020;21:6298. 10.3390/ijms21176298<pub-id pub-id-type="pmid">32878083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21176298</pub-id><pub-id pub-id-type="pmcid">PMC7503553</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorham</surname><given-names>IK</given-names></name><name name-style="western"><surname>Reid</surname><given-names>DM</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Barber</surname><given-names>RC</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>NR</given-names></name></person-group><article-title>Blood-based mtDNA quantification indicates population-specific differences associated with Alzheimer&#8217;s disease-related risk</article-title><source>J Alzheimers Dis</source><year>2024</year><volume>97</volume><fpage>1407</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.3233/JAD-230880</pub-id><pub-id pub-id-type="pmid">38250773</pub-id><pub-id pub-id-type="pmcid">PMC11315371</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Gorham IK, Reid DM, Sun J, Zhou Z, Barber RC, Phillips NR. Blood-based mtDNA quantification indicates population-specific differences associated with Alzheimer&#8217;s disease-related risk. J Alzheimers Dis. 2024;97:1407&#8211;19. 10.3233/JAD-230880<pub-id pub-id-type="pmid">38250773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230880</pub-id><pub-id pub-id-type="pmcid">PMC11315371</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>E</given-names></name><name name-style="western"><surname>Lamster</surname><given-names>IB</given-names></name></person-group><article-title>The diagnostic applications of saliva&#8211;a review</article-title><source>Crit Rev Oral Biol Med</source><year>2002</year><volume>13</volume><fpage>197</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1177/154411130201300209</pub-id><pub-id pub-id-type="pmid">12097361</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kaufman E, Lamster IB. The diagnostic applications of saliva&#8211;a review. Crit Rev Oral Biol Med. 2002;13:197&#8211;212. 10.1177/154411130201300209<pub-id pub-id-type="pmid">12097361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/154411130201300209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>N</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Molecular signatures of major depression</article-title><source>Curr Biol</source><year>2015</year><volume>25</volume><fpage>1146</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2015.03.008</pub-id><pub-id pub-id-type="pmid">25913401</pub-id><pub-id pub-id-type="pmcid">PMC4425463</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Cai N, Chang S, Li Y, Li Q, Hu J, Liang J, et al. Molecular signatures of major depression. Curr Biol. 2015;25:1146&#8211;56. 10.1016/j.cub.2015.03.008<pub-id pub-id-type="pmid">25913401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2015.03.008</pub-id><pub-id pub-id-type="pmcid">PMC4425463</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hill</surname><given-names>HZ</given-names></name><name name-style="western"><surname>Lange</surname><given-names>G</given-names></name><name name-style="western"><surname>Falvo</surname><given-names>MJ</given-names></name></person-group><article-title>Salivary mitochondrial DNA copy number is associated with exercise ventilatory efficiency</article-title><source>J Strength Cond Res</source><year>2017</year><volume>31</volume><fpage>2000</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1519/JSC.0000000000001932</pub-id><pub-id pub-id-type="pmid">28640773</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Chen Y, Hill HZ, Lange G, Falvo MJ. Salivary mitochondrial DNA copy number is associated with exercise ventilatory efficiency. J Strength Cond Res. 2017;31:2000&#8211;4. 10.1519/JSC.0000000000001932<pub-id pub-id-type="pmid">28640773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1519/JSC.0000000000001932</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>WW</given-names></name><name name-style="western"><surname>Rosenbaum</surname><given-names>E</given-names></name><name name-style="western"><surname>Mambo</surname><given-names>E</given-names></name><name name-style="western"><surname>Zahurak</surname><given-names>M</given-names></name><name name-style="western"><surname>Masayesva</surname><given-names>B</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>1564</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1471</pub-id><pub-id pub-id-type="pmid">16533782</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Jiang WW, Rosenbaum E, Mambo E, Zahurak M, Masayesva B, Carvalho AL, et al. Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res. 2006;12:1564&#8211;9. 10.1158/1078-0432.CCR-05-1471<pub-id pub-id-type="pmid">16533782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-05-1471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HR</given-names></name><name name-style="western"><surname>Shim</surname><given-names>JY</given-names></name></person-group><article-title>Association between salivary mitochondrial DNA copy number and chronic fatigue according to combined symptoms in Korean adults</article-title><source>Korean J Fam Med</source><year>2017</year><volume>38</volume><fpage>206</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.4082/kjfm.2017.38.4.206</pub-id><pub-id pub-id-type="pmid">28775810</pub-id><pub-id pub-id-type="pmcid">PMC5541168</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Shin J, Kim KC, Lee DC, Lee HR, Shim JY. Association between salivary mitochondrial DNA copy number and chronic fatigue according to combined symptoms in Korean adults. Korean J Fam Med. 2017;38:206&#8211;12. 10.4082/kjfm.2017.38.4.206<pub-id pub-id-type="pmid">28775810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4082/kjfm.2017.38.4.206</pub-id><pub-id pub-id-type="pmcid">PMC5541168</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trumpff</surname><given-names>C</given-names></name><name name-style="western"><surname>Rausser</surname><given-names>S</given-names></name><name name-style="western"><surname>Haahr</surname><given-names>R</given-names></name><name name-style="western"><surname>Karan</surname><given-names>KR</given-names></name><name name-style="western"><surname>Gouspillou</surname><given-names>G</given-names></name><name name-style="western"><surname>Puterman</surname><given-names>E</given-names></name><etal/></person-group><article-title>Dynamic behavior of cell-free mitochondrial DNA in human saliva</article-title><source>Psychoneuroendocrinology</source><year>2022</year><volume>143</volume><fpage>105852.</fpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2022.105852</pub-id><pub-id pub-id-type="pmid">35834882</pub-id><pub-id pub-id-type="pmcid">PMC9880596</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Trumpff C, Rausser S, Haahr R, Karan KR, Gouspillou G, Puterman E, et al. Dynamic behavior of cell-free mitochondrial DNA in human saliva. Psychoneuroendocrinology. 2022;143:105852. 10.1016/j.psyneuen.2022.105852<pub-id pub-id-type="pmid">35834882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2022.105852</pub-id><pub-id pub-id-type="pmcid">PMC9880596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tymofiyeva</surname><given-names>O</given-names></name><name name-style="western"><surname>Henje Blom</surname><given-names>E</given-names></name><name name-style="western"><surname>Ho</surname><given-names>TC</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>CG</given-names></name><name name-style="western"><surname>Lindqvist</surname><given-names>D</given-names></name><name name-style="western"><surname>Wolkowitz</surname><given-names>OM</given-names></name><etal/></person-group><article-title>High levels of mitochondrial DNA are associated with adolescent brain structural hypoconnectivity and increased anxiety but not depression</article-title><source>J Affect Disord</source><year>2018</year><volume>232</volume><fpage>283</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2018.02.024</pub-id><pub-id pub-id-type="pmid">29500956</pub-id><pub-id pub-id-type="pmcid">PMC5864120</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Tymofiyeva O, Henje Blom E, Ho TC, Connolly CG, Lindqvist D, Wolkowitz OM, et al. High levels of mitochondrial DNA are associated with adolescent brain structural hypoconnectivity and increased anxiety but not depression. J Affect Disord. 2018;232:283&#8211;90. 10.1016/j.jad.2018.02.024<pub-id pub-id-type="pmid">29500956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2018.02.024</pub-id><pub-id pub-id-type="pmcid">PMC5864120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayal</surname><given-names>L</given-names></name><name name-style="western"><surname>Hamadah</surname><given-names>O</given-names></name><name name-style="western"><surname>Almasri</surname><given-names>A</given-names></name><name name-style="western"><surname>Idrees</surname><given-names>M</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>P</given-names></name><name name-style="western"><surname>Kujan</surname><given-names>O</given-names></name></person-group><article-title>Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers have promising screening and early detection role</article-title><source>J Oral Pathol Med</source><year>2023</year><volume>52</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1111/jop.13392</pub-id><pub-id pub-id-type="pmid">36459078</pub-id><pub-id pub-id-type="pmcid">PMC10108294</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Sayal L, Hamadah O, Almasri A, Idrees M, Thomson P, Kujan O. Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers have promising screening and early detection role. J Oral Pathol Med. 2023;52:29&#8211;36. 10.1111/jop.13392<pub-id pub-id-type="pmid">36459078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jop.13392</pub-id><pub-id pub-id-type="pmcid">PMC10108294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gramunt</surname><given-names>N</given-names></name><name name-style="western"><surname>S&#225;nchez-Benavides</surname><given-names>G</given-names></name><name name-style="western"><surname>Buschke</surname><given-names>H</given-names></name><name name-style="western"><surname>Di&#233;guez-Vide</surname><given-names>F</given-names></name><name name-style="western"><surname>Pe&#241;a-Casanova</surname><given-names>J</given-names></name><name name-style="western"><surname>Masramon</surname><given-names>X</given-names></name><etal/></person-group><article-title>The memory binding test: development of two alternate forms into Spanish and Catalan</article-title><source>J Alzheimers Dis</source><year>2016</year><volume>52</volume><fpage>283</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.3233/JAD-151175</pub-id><pub-id pub-id-type="pmid">27060959</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gramunt N, S&#225;nchez-Benavides G, Buschke H, Di&#233;guez-Vide F, Pe&#241;a-Casanova J, Masramon X, et al. The memory binding test: development of two alternate forms into Spanish and Catalan. J Alzheimers Dis. 2016;52:283&#8211;93. 10.3233/JAD-151175<pub-id pub-id-type="pmid">27060959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-151175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alegret</surname><given-names>M</given-names></name><name name-style="western"><surname>Valero</surname><given-names>S</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>G</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanabria</surname><given-names>A</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>I</given-names></name><etal/></person-group><article-title>Validation of the Spanish version of the Face Name Associative Memory Exam (S-FNAME) in cognitively normal older individuals</article-title><source>Arch Clin Neuropsychol</source><year>2015</year><volume>30</volume><fpage>712</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1093/arclin/acv050</pub-id><pub-id pub-id-type="pmid">26289054</pub-id><pub-id pub-id-type="pmcid">PMC4751234</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Alegret M, Valero S, Ortega G, Espinosa A, Sanabria A, Hern&#225;ndez I, et al. Validation of the Spanish version of the Face Name Associative Memory Exam (S-FNAME) in cognitively normal older individuals. Arch Clin Neuropsychol. 2015;30:712&#8211;20. 10.1093/arclin/acv050<pub-id pub-id-type="pmid">26289054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acv050</pub-id><pub-id pub-id-type="pmcid">PMC4751234</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puigr&#242;s</surname><given-names>M</given-names></name><name name-style="western"><surname>Calderon</surname><given-names>A</given-names></name><name name-style="western"><surname>P&#233;rez-Soriano</surname><given-names>A</given-names></name><name name-style="western"><surname>de Dios</surname><given-names>C</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>M</given-names></name><name name-style="western"><surname>Colell</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson&#8217;s disease</article-title><source>Neurobiol Dis</source><year>2022</year><volume>174</volume><fpage>105885.</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2022.105885</pub-id><pub-id pub-id-type="pmid">36208866</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Puigr&#242;s M, Calderon A, P&#233;rez-Soriano A, de Dios C, Fern&#225;ndez M, Colell A, et al. Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson&#8217;s disease. Neurobiol Dis. 2022;174:105885. 10.1016/j.nbd.2022.105885<pub-id pub-id-type="pmid">36208866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2022.105885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name><name name-style="western"><surname>Dale</surname><given-names>AM</given-names></name></person-group><article-title>Measuring the thickness of the human cerebral cortex from magnetic resonance images</article-title><source>Proc Natl Acad Sci USA</source><year>2010</year><volume>97</volume><fpage>11050</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.200033797</pub-id><pub-id pub-id-type="pmcid">PMC27146</pub-id><pub-id pub-id-type="pmid">10984517</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA. 2010;97:11050&#8211;5. 10.1073/pnas.200033797<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.200033797</pub-id><pub-id pub-id-type="pmcid">PMC27146</pub-id><pub-id pub-id-type="pmid">10984517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greve</surname><given-names>DN</given-names></name><name name-style="western"><surname>Salat</surname><given-names>DH</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Izquierdo-Garcia</surname><given-names>D</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>AP</given-names></name><name name-style="western"><surname>Catana</surname><given-names>C</given-names></name><etal/></person-group><article-title>Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging</article-title><source>Neuroimage</source><year>2016</year><volume>132</volume><fpage>334</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.02.042</pub-id><pub-id pub-id-type="pmid">26915497</pub-id><pub-id pub-id-type="pmcid">PMC4851886</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Greve DN, Salat DH, Bowen SL, Izquierdo-Garcia D, Schultz AP, Catana C, et al. Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging. Neuroimage. 2016;132:334&#8211;43. 10.1016/j.neuroimage.2016.02.042<pub-id pub-id-type="pmid">26915497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2016.02.042</pub-id><pub-id pub-id-type="pmcid">PMC4851886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernal-Rusiel</surname><given-names>JL</given-names></name><name name-style="western"><surname>Atienza</surname><given-names>M</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>JL</given-names></name></person-group><article-title>Detection of focal changes in human cortical thickness: spherical wavelets versus Gaussian smoothing</article-title><source>Neuroimage</source><year>2008</year><volume>41</volume><fpage>1278</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.03.022</pub-id><pub-id pub-id-type="pmid">18474434</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Bernal-Rusiel JL, Atienza M, Cantero JL. Detection of focal changes in human cortical thickness: spherical wavelets versus Gaussian smoothing. Neuroimage. 2008;41:1278&#8211;92. 10.1016/j.neuroimage.2008.03.022<pub-id pub-id-type="pmid">18474434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2008.03.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mormino</surname><given-names>EC</given-names></name><name name-style="western"><surname>Betensky</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hedden</surname><given-names>T</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>AP</given-names></name><name name-style="western"><surname>Ward</surname><given-names>A</given-names></name><name name-style="western"><surname>Huijbers</surname><given-names>W</given-names></name><etal/></person-group><article-title>Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease</article-title><source>Neurology</source><year>2014</year><volume>82</volume><fpage>1760</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000431</pub-id><pub-id pub-id-type="pmid">24748674</pub-id><pub-id pub-id-type="pmcid">PMC4035706</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82:1760&#8211;7. 10.1212/WNL.0000000000000431<pub-id pub-id-type="pmid">24748674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000431</pub-id><pub-id pub-id-type="pmcid">PMC4035706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Box</surname><given-names>GEP</given-names></name><name name-style="western"><surname>Cox</surname><given-names>DR</given-names></name></person-group><article-title>An analysis of transformations</article-title><source>J R Stat Soc Ser B</source><year>1964</year><volume>26</volume><fpage>211</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1964.tb00553.x</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Box GEP, Cox DR. An analysis of transformations. J R Stat Soc Ser B. 1964;26:211&#8211;43. 10.1111/j.2517-6161.1964.tb00553.x</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernal-Rusiel</surname><given-names>JL</given-names></name><name name-style="western"><surname>Atienza</surname><given-names>M</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>JL</given-names></name></person-group><article-title>Determining the optimal level of smoothing in cortical thickness analysis: a hierarchical approach based on sequential statistical thresholding</article-title><source>Neuroimage</source><year>2010</year><volume>52</volume><fpage>158</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.03.074</pub-id><pub-id pub-id-type="pmid">20362677</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Bernal-Rusiel JL, Atienza M, Cantero JL. Determining the optimal level of smoothing in cortical thickness analysis: a hierarchical approach based on sequential statistical thresholding. Neuroimage. 2010;52:158&#8211;71. 10.1016/j.neuroimage.2010.03.074<pub-id pub-id-type="pmid">20362677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2010.03.074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desikan</surname><given-names>RS</given-names></name><name name-style="western"><surname>S&#233;gonne</surname><given-names>F</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>BT</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>BC</given-names></name><name name-style="western"><surname>Blacker</surname><given-names>D</given-names></name><etal/></person-group><article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title><source>Neuroimage</source><year>2006</year><volume>31</volume><fpage>968</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.02</pub-id><pub-id pub-id-type="pmid">16530430</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Desikan RS, S&#233;gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#8211;80. 10.1016/j.neuroimage.2006.01.02<pub-id pub-id-type="pmid">16530430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2006.01.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JE</given-names></name></person-group><source>Statistical Power Analysis for the Behavioral Sciences</source><year>1988</year><publisher-loc>Hillsdale, New Jersey</publisher-loc><publisher-name>Lawrence Erlbaum Associates</publisher-name></element-citation><mixed-citation id="mc-CR29" publication-type="book">Cohen JE. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1988.</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>F</given-names></name><name name-style="western"><surname>Paulo</surname><given-names>R</given-names></name><name name-style="western"><surname>Molina</surname><given-names>G</given-names></name><name name-style="western"><surname>Clyde</surname><given-names>MA</given-names></name><name name-style="western"><surname>Berger</surname><given-names>JO</given-names></name></person-group><article-title>Mixtures of g priors for Bayesian variable selection</article-title><source>J Am Stat Assoc.</source><year>2008</year><volume>103</volume><fpage>410</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1198/016214507000001337</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Liang F, Paulo R, Molina G, Clyde MA, Berger JO. Mixtures of g priors for Bayesian variable selection. J Am Stat Assoc. 2008;103:410&#8211;23. 10.1198/016214507000001337</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>MD</given-names></name><name name-style="western"><surname>Wagenmakers</surname><given-names>EJ</given-names></name></person-group><source>Bayesian Cognitive Modeling: A Practical Course</source><year>2013</year><publisher-name>Cambridge University Press</publisher-name></element-citation><mixed-citation id="mc-CR31" publication-type="book">Lee MD, Wagenmakers EJ. Bayesian Cognitive Modeling: A Practical Course. Cambridge University Press; 2013.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swerdlow</surname><given-names>RH</given-names></name></person-group><article-title>Mitochondria and mitochondrial cascades in Alzheimer&#8217;s disease</article-title><source>J Alzheimers Dis</source><year>2018</year><volume>62</volume><fpage>1403</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3233/JAD-170585</pub-id><pub-id pub-id-type="pmid">29036828</pub-id><pub-id pub-id-type="pmcid">PMC5869994</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer&#8217;s disease. J Alzheimers Dis. 2018;62:1403&#8211;16. 10.3233/JAD-170585<pub-id pub-id-type="pmid">29036828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170585</pub-id><pub-id pub-id-type="pmcid">PMC5869994</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name></person-group><article-title>Mitochondria dysfunction in the pathogenesis of Alzheimer&#8217;s disease: recent advances</article-title><source>Mol Neurodegener</source><year>2020</year><volume>15</volume><fpage>30.</fpage><pub-id pub-id-type="doi">10.1186/s13024-020-00376-6</pub-id><pub-id pub-id-type="pmid">32471464</pub-id><pub-id pub-id-type="pmcid">PMC7257174</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer&#8217;s disease: recent advances. Mol Neurodegener. 2020;15:30. 10.1186/s13024-020-00376-6<pub-id pub-id-type="pmid">32471464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-020-00376-6</pub-id><pub-id pub-id-type="pmcid">PMC7257174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcello</surname><given-names>A</given-names></name><name name-style="western"><surname>Wirths</surname><given-names>O</given-names></name><name name-style="western"><surname>Schneider-Axmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Degerman-Gunnarsson</surname><given-names>M</given-names></name><name name-style="western"><surname>Lannfelt</surname><given-names>L</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>TA</given-names></name></person-group><article-title>Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer&#8217;s disease</article-title><source>J Neural Transm</source><year>2009</year><volume>116</volume><fpage>913</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s00702-009-0224-y</pub-id><pub-id pub-id-type="pmid">19415450</pub-id><pub-id pub-id-type="pmcid">PMC2700872</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA. Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer&#8217;s disease. J Neural Transm. 2009;116:913&#8211;20. 10.1007/s00702-009-0224-y<pub-id pub-id-type="pmid">19415450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-009-0224-y</pub-id><pub-id pub-id-type="pmcid">PMC2700872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Plasma P-tau181 in Alzheimer&#8217;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#8217;s dementia</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><fpage>379</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0755-1</pub-id><pub-id pub-id-type="pmid">32123385</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer&#8217;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#8217;s dementia. Nat Med. 2020;26:379&#8211;86. 10.1038/s41591-020-0755-1<pub-id pub-id-type="pmid">32123385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0755-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></name><name name-style="western"><surname>Pascoal</surname><given-names>TA</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Blood phosphorylated tau 181 as a biomarker for Alzheimer&#8217;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts</article-title><source>Lancet Neurol</source><year>2020</year><volume>19</volume><fpage>422</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30071-5</pub-id><pub-id pub-id-type="pmid">32333900</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&#8217;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#8211;33. 10.1016/S1474-4422(20)30071-5<pub-id pub-id-type="pmid">32333900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30071-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chai</surname><given-names>X</given-names></name><name name-style="western"><surname>Vemuri</surname><given-names>P</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>VJ</given-names></name><etal/></person-group><article-title>Plasma phospho-tau181 increases with Alzheimer&#8217;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography</article-title><source>Alzheimers Dement</source><year>2018</year><volume>14</volume><fpage>989</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.013</pub-id><pub-id pub-id-type="pmid">29626426</pub-id><pub-id pub-id-type="pmcid">PMC6097897</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer&#8217;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14:989&#8211;97. 10.1016/j.jalz.2018.02.013<pub-id pub-id-type="pmid">29626426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.013</pub-id><pub-id pub-id-type="pmcid">PMC6097897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thijssen</surname><given-names>EH</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>A</given-names></name><name name-style="western"><surname>Strom</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></name><etal/></person-group><article-title>Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#8217;s disease and frontotemporal lobar degeneration</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><fpage>387</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0762-2</pub-id><pub-id pub-id-type="pmid">32123386</pub-id><pub-id pub-id-type="pmcid">PMC7101073</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#8217;s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387&#8211;97. 10.1038/s41591-020-0762-2<pub-id pub-id-type="pmid">32123386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0762-2</pub-id><pub-id pub-id-type="pmcid">PMC7101073</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>HS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Park</surname><given-names>HH</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers</article-title><source>Alzheimers Dement (Amst)</source><year>2023</year><volume>15</volume><fpage>e12502.</fpage><pub-id pub-id-type="doi">10.1002/dad2.12502</pub-id><pub-id pub-id-type="pmid">38026758</pub-id><pub-id pub-id-type="pmcid">PMC10654468</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kwon HS, Lee EH, Kim HJ, Park SH, Park HH, Jeong JH, et al. Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers. Alzheimers Dement (Amst). 2023;15:e12502. 10.1002/dad2.12502<pub-id pub-id-type="pmid">38026758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12502</pub-id><pub-id pub-id-type="pmcid">PMC10654468</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascoal</surname><given-names>TA</given-names></name><name name-style="western"><surname>Mathotaarachchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Shin</surname><given-names>M</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Mohades</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Synergistic interaction between amyloid and tau predicts the progression to dementia</article-title><source>Alzheimers Dement</source><year>2017</year><volume>13</volume><fpage>644</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.11.005</pub-id><pub-id pub-id-type="pmid">28024995</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, et al. Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement. 2017;13:644&#8211;53. 10.1016/j.jalz.2016.11.005<pub-id pub-id-type="pmid">28024995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.11.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>M</given-names></name><name name-style="western"><surname>Shepardson</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>D</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>5819</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1073/pnas.1017033108</pub-id><pub-id pub-id-type="pmid">21421841</pub-id><pub-id pub-id-type="pmcid">PMC3078381</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA. 2011;108:5819&#8211;24. 10.1073/pnas.1017033108<pub-id pub-id-type="pmid">21421841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1017033108</pub-id><pub-id pub-id-type="pmcid">PMC3078381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Felice</surname><given-names>FG</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>MP</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Velasco</surname><given-names>PT</given-names></name><name name-style="western"><surname>Lacor</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers</article-title><source>Neurobiol Aging</source><year>2008</year><volume>29</volume><fpage>1334</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.02.029</pub-id><pub-id pub-id-type="pmid">17403556</pub-id><pub-id pub-id-type="pmcid">PMC3142933</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al. Alzheimer&#8217;s disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobiol Aging. 2008;29:1334&#8211;47. 10.1016/j.neurobiolaging.2007.02.029<pub-id pub-id-type="pmid">17403556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2007.02.029</pub-id><pub-id pub-id-type="pmcid">PMC3142933</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takashima</surname><given-names>A</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Michel</surname><given-names>G</given-names></name><name name-style="western"><surname>Mercken</surname><given-names>M</given-names></name><name name-style="western"><surname>Hoshi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>K</given-names></name><etal/></person-group><article-title>Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta</article-title><source>Neurosci Lett</source><year>1996</year><volume>203</volume><fpage>33</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(95)12257-5</pub-id><pub-id pub-id-type="pmid">8742040</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, et al. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett. 1996;203:33&#8211;6. 10.1016/0304-3940(95)12257-5<pub-id pub-id-type="pmid">8742040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0304-3940(95)12257-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>SH</given-names></name><name name-style="western"><surname>Noh</surname><given-names>MY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name></person-group><article-title>Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3</article-title><source>Brain Res</source><year>2008</year><volume>1188</volume><fpage>254</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2007.10.064</pub-id><pub-id pub-id-type="pmid">18031715</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Koh SH, Noh MY, Kim SH. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 2008;1188:254&#8211;62. 10.1016/j.brainres.2007.10.064<pub-id pub-id-type="pmid">18031715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2007.10.064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ittner</surname><given-names>LM</given-names></name><name name-style="western"><surname>G&#246;tz</surname><given-names>J</given-names></name></person-group><article-title>Amyloid-&#946; and tau&#8211;a toxic pas de deux in Alzheimer&#8217;s disease</article-title><source>Nat Rev Neurosci</source><year>2011</year><volume>12</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/nrn2967</pub-id><pub-id pub-id-type="pmid">21193853</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Ittner LM, G&#246;tz J. Amyloid-&#946; and tau&#8211;a toxic pas de deux in Alzheimer&#8217;s disease. Nat Rev Neurosci. 2011;12:65&#8211;72. 10.1038/nrn2967<pub-id pub-id-type="pmid">21193853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>AK</given-names></name><name name-style="western"><surname>Jara</surname><given-names>C</given-names></name><name name-style="western"><surname>Park-Kang</surname><given-names>HS</given-names></name><name name-style="western"><surname>Polanco</surname><given-names>CM</given-names></name><name name-style="western"><surname>Tapia</surname><given-names>D</given-names></name><name name-style="western"><surname>Alarc&#243;n</surname><given-names>F</given-names></name><etal/></person-group><article-title>Synaptic mitochondria: an early target of amyloid-&#946; and tau in Alzheimer&#8217;s disease</article-title><source>J Alzheimers Dis</source><year>2021</year><volume>84</volume><fpage>1391</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.3233/JAD-215139</pub-id><pub-id pub-id-type="pmid">34719499</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Torres AK, Jara C, Park-Kang HS, Polanco CM, Tapia D, Alarc&#243;n F, et al. Synaptic mitochondria: an early target of amyloid-&#946; and tau in Alzheimer&#8217;s disease. J Alzheimers Dis. 2021;84:1391&#8211;414. 10.3233/JAD-215139<pub-id pub-id-type="pmid">34719499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kukreja</surname><given-names>L</given-names></name><name name-style="western"><surname>Kujoth</surname><given-names>GC</given-names></name><name name-style="western"><surname>Prolla</surname><given-names>TA</given-names></name><name name-style="western"><surname>Van Leuven</surname><given-names>F</given-names></name><name name-style="western"><surname>Vassar</surname><given-names>R</given-names></name></person-group><article-title>Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><year>2014</year><volume>9</volume><fpage>16.</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-9-16</pub-id><pub-id pub-id-type="pmid">24885175</pub-id><pub-id pub-id-type="pmcid">PMC4028006</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Kukreja L, Kujoth GC, Prolla TA, Van Leuven F, Vassar R. Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer&#8217;s disease. Mol Neurodegener. 2014;9:16. 10.1186/1750-1326-9-16<pub-id pub-id-type="pmid">24885175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1750-1326-9-16</pub-id><pub-id pub-id-type="pmcid">PMC4028006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manczak</surname><given-names>M</given-names></name><name name-style="western"><surname>Calkins</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>PH</given-names></name></person-group><article-title>Impaired mitochondrial dynamics and abnormal interaction of amyloid &#946; with mitochondrial protein Drp1 in neurons from patients with Alzheimer&#8217;s disease: implications for neuronal damage</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><fpage>2495</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr139</pub-id><pub-id pub-id-type="pmid">21459773</pub-id><pub-id pub-id-type="pmcid">PMC3109997</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid &#946; with mitochondrial protein Drp1 in neurons from patients with Alzheimer&#8217;s disease: implications for neuronal damage. Hum Mol Genet. 2011;20:2495&#8211;509. 10.1093/hmg/ddr139<pub-id pub-id-type="pmid">21459773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddr139</pub-id><pub-id pub-id-type="pmcid">PMC3109997</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbarao</surname><given-names>KC</given-names></name><name name-style="western"><surname>Nattuthurai</surname><given-names>GS</given-names></name><name name-style="western"><surname>Sundararajan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sujith</surname><given-names>I</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>J</given-names></name><name name-style="western"><surname>Syedshah</surname><given-names>YP</given-names></name></person-group><article-title>Gingival crevicular fluid: An overview</article-title><source>J Pharm Bioallied Sci</source><year>2019</year><volume>11</volume><fpage>S135</fpage><lpage>S139</lpage><pub-id pub-id-type="doi">10.4103/JPBS.JPBS_56_19</pub-id><pub-id pub-id-type="pmid">31198325</pub-id><pub-id pub-id-type="pmcid">PMC6555362</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Subbarao KC, Nattuthurai GS, Sundararajan SK, Sujith I, Joseph J, Syedshah YP. Gingival crevicular fluid: An overview. J Pharm Bioallied Sci. 2019;11:S135&#8211;S139. 10.4103/JPBS.JPBS_56_19<pub-id pub-id-type="pmid">31198325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/JPBS.JPBS_56_19</pub-id><pub-id pub-id-type="pmcid">PMC6555362</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loo</surname><given-names>JA</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W</given-names></name><name name-style="western"><surname>Ramachandran</surname><given-names>P</given-names></name><name name-style="western"><surname>Wong</surname><given-names>DT</given-names></name></person-group><article-title>Comparative human salivary and plasma proteomes</article-title><source>J Dent Res</source><year>2010</year><volume>89</volume><fpage>1016</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1177/0022034510380414</pub-id><pub-id pub-id-type="pmid">20739693</pub-id><pub-id pub-id-type="pmcid">PMC3144065</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res. 2010;89:1016&#8211;23. 10.1177/0022034510380414<pub-id pub-id-type="pmid">20739693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0022034510380414</pub-id><pub-id pub-id-type="pmcid">PMC3144065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambardella</surname><given-names>S</given-names></name><name name-style="western"><surname>Limanaqi</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferese</surname><given-names>R</given-names></name><name name-style="western"><surname>Biagioni</surname><given-names>F</given-names></name><name name-style="western"><surname>Campopiano</surname><given-names>R</given-names></name><name name-style="western"><surname>Centonze</surname><given-names>D</given-names></name><etal/></person-group><article-title>ccf-mtDNA as a potential link between the brain and immune system in neuro-immunological disorders</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1064.</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01064</pub-id><pub-id pub-id-type="pmid">31143191</pub-id><pub-id pub-id-type="pmcid">PMC6520662</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Gambardella S, Limanaqi F, Ferese R, Biagioni F, Campopiano R, Centonze D, et al. ccf-mtDNA as a potential link between the brain and immune system in neuro-immunological disorders. Front Immunol. 2019;10:1064. 10.3389/fimmu.2019.01064<pub-id pub-id-type="pmid">31143191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01064</pub-id><pub-id pub-id-type="pmcid">PMC6520662</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>MO</given-names></name></person-group><article-title>Circulating cell-free DNA differentiates severity of inflammation</article-title><source>Biol Res Nurs</source><year>2016</year><volume>18</volume><fpage>477</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1177/1099800416642571</pub-id><pub-id pub-id-type="pmid">27067611</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Frank MO. Circulating cell-free DNA differentiates severity of inflammation. Biol Res Nurs. 2016;18:477&#8211;88. 10.1177/1099800416642571<pub-id pub-id-type="pmid">27067611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1099800416642571</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>LE</given-names></name><name name-style="western"><surname>Shadel</surname><given-names>GS</given-names></name></person-group><article-title>Mitochondrial DNA release in innate immune signaling</article-title><source>Annu Rev Biochem</source><year>2023</year><volume>92</volume><fpage>299</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-032620-104401</pub-id><pub-id pub-id-type="pmid">37001140</pub-id><pub-id pub-id-type="pmcid">PMC11058562</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Newman LE, Shadel GS. Mitochondrial DNA release in innate immune signaling. Annu Rev Biochem. 2023;92:299&#8211;332. 10.1146/annurev-biochem-032620-104401<pub-id pub-id-type="pmid">37001140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biochem-032620-104401</pub-id><pub-id pub-id-type="pmcid">PMC11058562</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Wiste</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Algeciras-Schimnich</surname><given-names>A</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>SD</given-names></name><name name-style="western"><surname>Figdore</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>VJ</given-names></name><etal/></person-group><article-title>Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><fpage>2143</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/alz.13651</pub-id><pub-id pub-id-type="pmid">38265198</pub-id><pub-id pub-id-type="pmcid">PMC10984437</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Jack CR Jr, Wiste HJ, Algeciras-Schimnich A, Weigand SD, Figdore DJ, Lowe VJ, et al. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals. Alzheimers Dement. 2024;20:2143&#8211;54. 10.1002/alz.13651<pub-id pub-id-type="pmid">38265198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13651</pub-id><pub-id pub-id-type="pmcid">PMC10984437</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendes</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ribaldi</surname><given-names>F</given-names></name><name name-style="western"><surname>Lathuiliere</surname><given-names>A</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><etal/></person-group><article-title>Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort</article-title><source>J Neurol</source><year>2024</year><volume>271</volume><fpage>2053</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s00415-023-12148-5</pub-id><pub-id pub-id-type="pmid">38195896</pub-id><pub-id pub-id-type="pmcid">PMC10972950</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H, et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol. 2024;271:2053&#8211;66. 10.1007/s00415-023-12148-5<pub-id pub-id-type="pmid">38195896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-023-12148-5</pub-id><pub-id pub-id-type="pmcid">PMC10972950</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ccr371073" xml:lang="en" article-type="case-study" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Clin Case Rep</journal-id><journal-id journal-id-type="pmc-domain-id">2542</journal-id><journal-id journal-id-type="pmc-domain">ccr</journal-id><journal-id journal-id-type="publisher-id">CCR3</journal-id><journal-title-group><journal-title>Clinical Case Reports</journal-title></journal-title-group><issn pub-type="epub">2050-0904</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501107</article-id><article-id pub-id-type="pmcid-ver">PMC12501107.1</article-id><article-id pub-id-type="pmcaid">12501107</article-id><article-id pub-id-type="pmcaiid">12501107</article-id><article-id pub-id-type="doi">10.1002/ccr3.71073</article-id><article-id pub-id-type="publisher-id">CCR371073</article-id><article-id pub-id-type="other">CCR3-2024-05-1444.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Case Series</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Series</subject></subj-group></article-categories><title-group><article-title>Increased Brain Activity Associated With Improved Metabolic Biomarkers: A Case Series</article-title></title-group><contrib-group><contrib id="ccr371073-cr-0001" contrib-type="author"><name name-style="western"><surname>McCallen</surname><given-names initials="JA">J. A.</given-names></name><xref rid="ccr371073-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ccr371073-cr-0002" contrib-type="author"><name name-style="western"><surname>Oakley</surname><given-names initials="DS">D. S.</given-names></name><xref rid="ccr371073-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ccr371073-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Towers</surname><given-names initials="GE">G. E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8429-520X</contrib-id><xref rid="ccr371073-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>grace.towers@wavimed.com</email></address></contrib></contrib-group><aff id="ccr371073-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Cenegenics Medical Institute</institution>
<city>Denver</city>
<named-content content-type="country-part">Colorado</named-content>
<country country="US">USA</country>
</aff><aff id="ccr371073-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>WAVi Research</institution>
<city>Denver</city>
<named-content content-type="country-part">Colorado</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
G. E. Towers (<email>grace.towers@wavimed.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>13</volume><issue seq="2170">10</issue><issue-id pub-id-type="pmc-issue-id">497443</issue-id><issue-id pub-id-type="doi">10.1002/ccr3.v13.10</issue-id><elocation-id>e71073</elocation-id><history><date date-type="rev-recd"><day>01</day><month>3</month><year>2025</year></date><date date-type="received"><day>18</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Clinical Case Reports</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CCR3-13-e71073.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CCR3-13-e71073.pdf"/><abstract><title>ABSTRACT</title><p>This case series highlights the potential of combining dietary, exercise, and hormonal interventions to improve metabolic health markers (HbA1C, insulin, body fat) and enhance cognitive function (P300 amplitude, IAF). EEG&#8208;based brain monitoring offers a valuable tool for tracking cognitive risk and guiding preventative strategies in aging populations.</p></abstract><abstract abstract-type="graphical"><p>Bold values represent improvement. <italic toggle="yes">Note: P300&#8201;V also shown as topographs of evoked voltage across the scalp (box illustrations represent regions of interest)</italic>.<boxed-text position="anchor" content-type="graphic" id="ccr371073-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CCR3-13-e71073-g001.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ccr371073-kwd-0001">body fat</kwd><kwd id="ccr371073-kwd-0002">electroencephalogram (EEG)</kwd><kwd id="ccr371073-kwd-0003">event related potential (ERP)</kwd><kwd id="ccr371073-kwd-0004">hemoglobin A1C</kwd><kwd id="ccr371073-kwd-0005">individual peak frequency (IAF)</kwd><kwd id="ccr371073-kwd-0006">insulin</kwd></kwd-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="6"/><word-count count="4000"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ccr371073-cit-1001"><string-name name-style="western"><given-names>J. A.</given-names><surname>McCallen</surname></string-name>, <string-name name-style="western"><given-names>D. S.</given-names><surname>Oakley</surname></string-name>, and <string-name name-style="western"><given-names>G. E.</given-names><surname>Towers</surname></string-name>, &#8220;<article-title>Increased Brain Activity Associated With Improved Metabolic Biomarkers: A Case Series</article-title>,&#8221; <source>Clinical Case Reports</source><volume>13</volume>, no. <issue>10</issue> (<year>2025</year>): <elocation-id>e71073</elocation-id>, <pub-id pub-id-type="doi">10.1002/ccr3.71073</pub-id>.</mixed-citation>
</p><fn-group id="ccr371073-ntgp-0001"><fn fn-type="funding" id="ccr371073-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="ccr371073-body-0001"><sec id="ccr371073-sec-0001"><label>1</label><title>Introduction</title><p>Dementing diseases affect 5.6 million Americans and cost more than $300 billion annually [<xref rid="ccr371073-bib-0001" ref-type="bibr">1</xref>, <xref rid="ccr371073-bib-0002" ref-type="bibr">2</xref>]. People of all ages are concerned about mental decline in the aging process and often cite Alzheimer's as their greatest health concern [<xref rid="ccr371073-bib-0003" ref-type="bibr">3</xref>]. Dementia notwithstanding, general declines in mental performance that are a part of normal aging are also a concern and brain&#8208;function optimization is a focus of a growing number of clinics. Risk factors for age&#8208;related cognitive decline have been well studied and while this information can be used in clinic, insurance does not typically reimburse for preventive brain health services. Patients are therefore required to seek clinics offering a self&#8208;pay model in order to receive preventive&#8208;focused care offering health screenings that include physiologic measurements of brain activity&#8212;measurements which are otherwise not reimbursed except for neurologic diagnosis. The goal of this study is to present case studies, including patients at risk for future cognitive decline, on preventive health outcomes that include direct measures of brain function obtained alongside standard health measures.</p></sec><sec id="ccr371073-sec-0002"><label>2</label><title>Detailed Case Description</title><sec id="ccr371073-sec-0003"><label>2.1</label><title>Patient Profiles and Clinical Measures</title><p>We present a case series of three male patients who are executives, under stress, who entered a clinical program for wellness and disease prevention. These patients were cognitively symptom&#8208;free, but their cases were selected because their initial evaluation revealed elevated hemoglobin A1C and fasting insulin, low free testosterone, and excess body fat.</p><p>We focus on these markers because they have also been perceived to be important in brain health. Hemoglobin A1C (HbA1C) is a stable marker of glycation and reflects average glucose levels over time. Values at or above 5.7 are considered pre&#8208;diabetic/diabetic and are strongly correlated with a higher incidence of vascular disease. HbA1C levels &#8805;&#8201;6.5% are associated with a 2.8&#8208;fold increased risk of dementia. HbA1C levels &#8805;&#8201;7% are associated with a 5&#8208;fold increased risk of dementia [<xref rid="ccr371073-bib-0004" ref-type="bibr">4</xref>]. Likewise, elevated fasting serum insulin is associated with higher rates of dementia [<xref rid="ccr371073-bib-0005" ref-type="bibr">5</xref>]. Low testosterone levels are associated with higher rates of cardiovascular mortality, obesity, insulin resistance, and dementia [<xref rid="ccr371073-bib-0006" ref-type="bibr">6</xref>]. Finally, obesity is a primary driver of cognitive decline and can be directly measured by dual x&#8208;ray absorptiometry as a percentage of body fat [<xref rid="ccr371073-bib-0007" ref-type="bibr">7</xref>].</p><p>The wellness program being studied focuses on three primary interventional strategies to lower vascular disease risk and improve health:
<list list-type="order" id="ccr371073-list-0001"><list-item id="ccr371073-li-0001"><p>
<italic toggle="yes">Protein&#8208;adequate low&#8208;glycemic diet</italic> to reduce excess glycation and fasting insulin secretion. Dietary protein intake was increased to 150&#8211;180&#8201;g per day and dietary intake of high glycemic carbohydrates was minimized per individual to achieve a hemoglobin A1C at or below 5.1.</p></list-item><list-item id="ccr371073-li-0002"><p>
<italic toggle="yes">Weightlifting and high intensity interval training</italic> to decrease insulin resistance, and increase muscle mass, cardiovascular fitness, and cranial blood flow.</p></list-item><list-item id="ccr371073-li-0003"><p>
<italic toggle="yes">Physiologic levels of testosterone supplementation</italic> to reverse bone loss, improve muscle mass and function, reduce fat mass, and improve mood. While many myths persist about the dangers of testosterone supplementation, studies over the past 20&#8201;years have demonstrated its safety, specifically in the areas of cardiovascular and prostate health [<xref rid="ccr371073-bib-0008" ref-type="bibr">8</xref>, <xref rid="ccr371073-bib-0009" ref-type="bibr">9</xref>, <xref rid="ccr371073-bib-0010" ref-type="bibr">10</xref>, <xref rid="ccr371073-bib-0011" ref-type="bibr">11</xref>, <xref rid="ccr371073-bib-0012" ref-type="bibr">12</xref>]. These patients were given twice weekly intramuscular testosterone cypionate to achieve a free serum testosterone level of 160&#8208;200&#8201;pg/mL.</p></list-item></list>
</p></sec><sec id="ccr371073-sec-0004"><label>2.2</label><title>
<styled-content style="fixed-case" toggle="no">EEG</styled-content>/<styled-content style="fixed-case" toggle="no">ERP</styled-content> Measures</title><p>Here we focus on measures relevant to age&#8208;related cognitive decline: EEG alpha peak frequency, and an EEG event&#8208;related potential (ERP) comprising the audio oddball P300 amplitude and latency (speed). While other EEG frequencies and other ERP metrics have also been found to be important to the task, alpha band analyses and audio P300 protocols are the most facile and accessible clinically.</p><p>The dominant frequency of the electroencephalogram (EEG) occurs in what is defined as the alpha band between 8 and 12&#8201;Hz [<xref rid="ccr371073-bib-0013" ref-type="bibr">13</xref>, <xref rid="ccr371073-bib-0014" ref-type="bibr">14</xref>]. It typically is strongest occipitally in the eyes&#8208;closed condition. The alpha band can provide information on cognitive functioning where frequency slowing, a reduction in alpha power, and a shift of strength from posterior&#8208;to&#8208;anterior has been observed in both normal aging and in dementia [<xref rid="ccr371073-bib-0005" ref-type="bibr">5</xref>, <xref rid="ccr371073-bib-0015" ref-type="bibr">15</xref>, <xref rid="ccr371073-bib-0016" ref-type="bibr">16</xref>, <xref rid="ccr371073-bib-0017" ref-type="bibr">17</xref>, <xref rid="ccr371073-bib-0018" ref-type="bibr">18</xref>, <xref rid="ccr371073-bib-0019" ref-type="bibr">19</xref>, <xref rid="ccr371073-bib-0020" ref-type="bibr">20</xref>, <xref rid="ccr371073-bib-0021" ref-type="bibr">21</xref>, <xref rid="ccr371073-bib-0022" ref-type="bibr">22</xref>, <xref rid="ccr371073-bib-0023" ref-type="bibr">23</xref>, <xref rid="ccr371073-bib-0024" ref-type="bibr">24</xref>, <xref rid="ccr371073-bib-0025" ref-type="bibr">25</xref>, <xref rid="ccr371073-bib-0026" ref-type="bibr">26</xref>, <xref rid="ccr371073-bib-0027" ref-type="bibr">27</xref>, <xref rid="ccr371073-bib-0028" ref-type="bibr">28</xref>, <xref rid="ccr371073-bib-0029" ref-type="bibr">29</xref>, <xref rid="ccr371073-bib-0030" ref-type="bibr">30</xref>, <xref rid="ccr371073-bib-0031" ref-type="bibr">31</xref>, <xref rid="ccr371073-bib-0032" ref-type="bibr">32</xref>, <xref rid="ccr371073-bib-0033" ref-type="bibr">33</xref>, <xref rid="ccr371073-bib-0034" ref-type="bibr">34</xref>, <xref rid="ccr371073-bib-0035" ref-type="bibr">35</xref>, <xref rid="ccr371073-bib-0036" ref-type="bibr">36</xref>, <xref rid="ccr371073-bib-0037" ref-type="bibr">37</xref>]. On an individual level, an individual's peak alpha frequency (IAF) is a stable marker and can provide longitudinal patient information [<xref rid="ccr371073-bib-0038" ref-type="bibr">38</xref>, <xref rid="ccr371073-bib-0039" ref-type="bibr">39</xref>, <xref rid="ccr371073-bib-0040" ref-type="bibr">40</xref>, <xref rid="ccr371073-bib-0041" ref-type="bibr">41</xref>, <xref rid="ccr371073-bib-0042" ref-type="bibr">42</xref>, <xref rid="ccr371073-bib-0043" ref-type="bibr">43</xref>, <xref rid="ccr371073-bib-0044" ref-type="bibr">44</xref>]. Given its high stability in the absence of neuropathological processes, IAF can provide information on neuropathological changes and can be a valuable tool to track healthy individuals for early changes, perhaps even before symptoms arise [<xref rid="ccr371073-bib-0042" ref-type="bibr">42</xref>].</p><p>ERPs are EEG measurements time&#8208;locked to the onset of a given stimulus. They are named according to their polarity (P for positive or N for negative) and their time of occurrence after the stimulus in milliseconds (e.g., P300). The auditory oddball protocol delivers standard repeated tones which are periodically interrupted by a different tone, or the oddball tone. This is one of the most widely studied protocols and utilizes measurements of amplitude and latency to assess the brain's cognitive ability to recognize the odd tone as different. In a healthy person this recognition occurs reliably near 300&#8201;ms post stimulus, hence the name P300. The amplitude (P300V) is thought to be proportional to the amount of attentional resources devoted to the task where the latency (P300T, the delay between stimulus delivery and recognition of the oddball tone as different) is a measure of stimulus classification speed [<xref rid="ccr371073-bib-0045" ref-type="bibr">45</xref>]. An increase in the P300T and/or a decrease in P300V has been observed in many conditions accompanied by a decline in cognitive function and as such can be considered a non&#8208;specific measure for aging, dementia, mild traumatic brain injury (mTBI), pre&#8208;Alzheimer's and many others [<xref rid="ccr371073-bib-0045" ref-type="bibr">45</xref>, <xref rid="ccr371073-bib-0046" ref-type="bibr">46</xref>, <xref rid="ccr371073-bib-0047" ref-type="bibr">47</xref>]. These metrics have also been linked to cardio health in wellness settings such as this [<xref rid="ccr371073-bib-0048" ref-type="bibr">48</xref>].</p></sec><sec id="ccr371073-sec-0005"><label>2.3</label><title>Procedure</title><p>After clinical interviews and assessments, including blood samples, vascular ultrasound, VO2 max and CNS Vital Signs neurocognitive testing [<xref rid="ccr371073-bib-0049" ref-type="bibr">49</xref>], the patients received an EEG scan with an oddball P300 using the WAVi system. Details of the scan, system, procedure, and EEG extraction has been detailed elsewhere and include a 4&#8208;min oddball audio ERP [<xref rid="ccr371073-bib-0050" ref-type="bibr">50</xref>, <xref rid="ccr371073-bib-0051" ref-type="bibr">51</xref>, <xref rid="ccr371073-bib-0052" ref-type="bibr">52</xref>]. The EEG study was approved by the Solutions Institutional Review Board and written informed consent was obtained from the participant before scanning.</p><p>Patients in the program are prescribed individualized treatments based upon their testing results. These patients received twice weekly intramuscular testosterone cypionate to achieve a serum free testosterone in the 75th&#8211;100th percentile for a 30&#8211;35yo man; a heavy weightlifting program 4&#8201;days weekly combined with a high intensity interval program to achieve their peak heart rate based upon VO2 Max testing; careful instruction in low&#8208;glycemic diet sufficient to lower HbgA1C to or below 5.1%; as well as general micronutrient supplementation consisting of pharmaceutical grade multi&#8208;vitamin/mineral, fish oil at a dose sufficient to lower hs&#8208;CRP below 1.0&#8201;mg/L (typically 4&#8211;8&#8201;g/day) [<xref rid="ccr371073-bib-0053" ref-type="bibr">53</xref>, <xref rid="ccr371073-bib-0054" ref-type="bibr">54</xref>], thyroid replacement in both T4 and T3 forms to lower TSH below 2.0mIU/L, and place freeT3 above the 50th percentile; and vitamin D optimization to a serum level of 60&#8208;80&#8201;ng/mL [<xref rid="ccr371073-bib-0055" ref-type="bibr">55</xref>, <xref rid="ccr371073-bib-0056" ref-type="bibr">56</xref>]. Patients' labs were then retested on a routine quarterly schedule, with full testing including (but not limited to) body composition, WAVi, and neurocognitive function annually.</p></sec></sec><sec sec-type="results" id="ccr371073-sec-0006"><label>3</label><title>Results</title><p>The pre&#8208; and post&#8208;treatment results for the four patients involved in this study are shown in Table&#160;<xref rid="ccr371073-tbl-0001" ref-type="table">1</xref>. Changes in cognitive performance or risk are reported by changes in the average of the percentile rank of the 12 domains in the CNS test, and by changes in P300 and IAF which are compared to the expected test&#8208;variances reported for a reference population comprising 2000 subjects as a control [<xref rid="ccr371073-bib-0051" ref-type="bibr">51</xref>, <xref rid="ccr371073-bib-0052" ref-type="bibr">52</xref>]. After intervention, all of the patient's blood markers moved toward or within the clinical targets of Table&#160;<xref rid="ccr371073-tbl-0001" ref-type="table">1</xref>, and all experienced a reduction in body fat. These improvements were accompanied by improved cognition. While we see marginally improved CNS scores, P300 amplitudes increased well above the normal expectation of &#177;2&#8201;&#956;V (Table&#160;<xref rid="ccr371073-tbl-0001" ref-type="table">1</xref>, Figure&#160;<xref rid="ccr371073-fig-0001" ref-type="fig">1</xref>).</p><table-wrap position="float" id="ccr371073-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Clinical markers and cognitive outcomes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Marker (range)</th><th align="center" colspan="2" valign="bottom" rowspan="1">Patient 1</th><th align="center" colspan="2" valign="bottom" rowspan="1">Patient 2</th><th align="center" colspan="2" valign="bottom" rowspan="1">Patient 3</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">74.5&#8201;years</th><th align="center" valign="bottom" rowspan="1" colspan="1">75.8&#8201;years</th><th align="center" valign="bottom" rowspan="1" colspan="1">62.6&#8201;years</th><th align="center" valign="bottom" rowspan="1" colspan="1">64.8&#8201;years</th><th align="center" valign="bottom" rowspan="1" colspan="1">61.2&#8201;years</th><th align="center" valign="bottom" rowspan="1" colspan="1">62.8&#8201;years</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1C (&lt;&#8201;5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">5.7</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>5.3</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td><td align="center" valign="top" rowspan="1" colspan="1">5.8</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>5.1</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insulin (&lt;&#8201;5)</td><td align="center" valign="top" rowspan="1" colspan="1">13.5</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>2.8</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">7.1</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>3.4</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">9.3</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>4.8</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Free test (155&#8211;220)</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>152</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>298</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>140</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body fat</td><td align="center" valign="top" rowspan="1" colspan="1">37%</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>24%</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">42%</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>30%</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">42%</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>33%</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNS VS percentile</td><td align="center" valign="top" rowspan="1" colspan="1">35%</td><td align="center" valign="top" rowspan="1" colspan="1">36%</td><td align="center" valign="top" rowspan="1" colspan="1">56%</td><td align="center" valign="top" rowspan="1" colspan="1">63%</td><td align="center" valign="top" rowspan="1" colspan="1">49%</td><td align="center" valign="top" rowspan="1" colspan="1">52%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P300V (6&#8211;16&#8201;&#956;V), &#916;P300V&#8201;&#177;&#8201;2&#8201;&#956;V</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>6&#8201;&#956;V</p>
<p>
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="image" xlink:href="CCR3-13-e71073-g008.jpg"/>
</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>
<bold>15&#8201;&#956;V</bold>
</p>
<p>
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="image" xlink:href="CCR3-13-e71073-g006.jpg"/>
</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>6&#8201;&#956;V</p>
<p>
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="image" xlink:href="CCR3-13-e71073-g009.jpg"/>
</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>
<bold>19&#8201;&#956;V</bold>
</p>
<p>
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="image" xlink:href="CCR3-13-e71073-g004.jpg"/>
</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>9&#8201;&#956;V</p>
<p>
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="image" xlink:href="CCR3-13-e71073-g003.jpg"/>
</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>
<bold>15&#8201;&#956;V</bold>
</p>
<p>
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="image" xlink:href="CCR3-13-e71073-g002.jpg"/>
</p>
</td></tr></tbody></table><table-wrap-foot id="ccr371073-ntgp-0002"><fn id="ccr371073-note-0002"><p>
<italic toggle="yes">Note:</italic> Bold values represent improvement. P300V also shown as topographs of evoked voltage across the scalp (box illustrations represent regions of interest).</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="ccr371073-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Improvement in P300 amplitudes measured pre&#8208; and post&#8208;intervention. Error lines represent test&#8211;retest expectation [<xref rid="ccr371073-bib-0051" ref-type="bibr">51</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CCR3-13-e71073-g005.jpg"/></fig><p>None of the patients showed changes beyond expectation for the other cognitive&#8208;decline risk markers of IAF and P300 latency, except the oldest patient (Patient 1; Figure&#160;<xref rid="ccr371073-fig-0002" ref-type="fig">2</xref>) who ironically had the lowest CNS improvement. While he was symptom free and within the normal range for most CNS domains, his IAF on initial evaluation was 8.8&#8201;Hz (age&#8208;matched target range 9.0&#8211;10.5&#8201;Hz) and his P300T was 408&#8201;ms (310&#8211;402&#8201;ms target). Changes in these trait&#8208;based markers are early warning signs of decline that may not be apparent in neurocognitive tests as evidenced here. After intervention, his IAF sped up to a healthy 10.5&#8201;Hz and his P300T to 300&#8201;ms, both beyond expected within&#8208;person variances (Figure&#160;<xref rid="ccr371073-fig-0002" ref-type="fig">2</xref>). Alongside his 15&#8201;&#956;V P300 amplitude, these are values expected for a typical 20&#8208;year&#8208;old.</p><fig position="float" fig-type="FIGURE" id="ccr371073-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Reduction in cognitive risk markers for Patient 1. IAF increase (top graph) and a P300T decrease (bottom graph, increased speed). Dashed lines show test&#8211;retest expectation [<xref rid="ccr371073-bib-0051" ref-type="bibr">51</xref>, <xref rid="ccr371073-bib-0052" ref-type="bibr">52</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CCR3-13-e71073-g007.jpg"/></fig></sec><sec sec-type="discussion" id="ccr371073-sec-0007"><label>4</label><title>Discussion</title><p>These 3 patients entered the program with no disease symptoms but had elevated A1VC, insulin, and body fat with low testosterone and low/normal evoked cognitive responses. Following treatment programs that focused on testosterone replacement, weightlifting, and low&#8208;glycemic diet, these patients showed major improvement in most of the blood markers and body fat with an increase in cognitive resources as measured by the P300 amplitude. It is also interesting to note that the only the oldest patient had low baseline scores on other cognitive&#8208;risk markers of P300 latency and IAF even though his CNS was normal. Following treatment these markers also showed dramatic improvement well beyond expectation to values typically seen in 20&#8201;year&#8208;old patients.</p><p>While correlation is not causation and this case study is not designed to tease out which of the interventions, or something else, most affected cognition for each patient, these results demonstrate the need to include brain monitoring in routine evaluations. As more data are collected we can begin to answer the questions posed here, such as the importance of body fat reduction to brain longevity, an intervention that accessible to many people, versus glycemic control or less&#8208;common interventions such as testosterone replacement. It has been known for many decades that blood pressure, for example, is a risk factor that can be modified and we now routinely measure blood pressure in otherwise symptom&#8208;free patients in order to prescribe or test interventions. Likewise as we learn more about dementia risk factors, some of which discussed here, the measurement of brain function through oft&#8208;reimbursable tests such as EEG/ERP can help guide prescriptions and/or track these interventions to modify these risks.</p></sec><sec sec-type="conclusions" id="ccr371073-sec-0008"><label>5</label><title>Conclusion</title><p>In these cases, we show how measures of brain function, as measured both by CNS and EEG with evoked response potentials in this instance, can be used alongside other physiological markers such as HbA1C, insulin, free testosterone, and body fat. In this case series, all patients clearly showed improved cardiometabolic health accompanied by improved cognition. In one case, the patient showed improvement in all EEG/ERP&#8208;based cognitive&#8208;risk markers discussed here&#8212;a cognitive risk that was not flagged by neurocognitive testing. All of these measures are readily accessible and can enable clinicians to better track preventative programs including cognition. Our goal, with this small case series, is to demonstrate that an aggressive program of hormonal, nutritional, and exercise optimization can have a powerful effect on the improvement of cognitive function with aging. We suggest that objective measures of brain function become standard in the assessment of the aging patient, long before symptoms of cognitive decline begin to appear, in order to initiate a broad range of effective strategies to reduce the incidence of cognitive decline in the general population.</p></sec><sec id="ccr371073-sec-0014"><title>Author Contributions</title><p>
<bold>D. S. Oakley:</bold> formal analysis, investigation, methodology, resources, software, validation, writing &#8211; original draft. <bold>J. A. McCallen:</bold> conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, validation, writing &#8211; original draft. <bold>G. E. Towers:</bold> writing &#8211; review and editing.</p></sec><sec id="ccr371073-sec-0009"><title>Ethics Statement</title><p>This study was approved by the Solutions Institutional Review Board. Informed consent was obtained from all participants prior to their involvement in the study, and measures were taken to ensure confidentiality and privacy throughout the research process.</p></sec><sec sec-type="conclusions" id="ccr371073-sec-0010"><title>Consent</title><p>Written consent for the publication of their case details and accompanying results was obtained from the patients involved in this study.</p></sec><sec sec-type="COI-statement" id="ccr371073-sec-0013"><title>Conflicts of Interest</title><p>David Oakley and Grace Towers are paid consultants or employees of WAVi Co. (providers of the EEG equipment). The other author declares no conflicts of interest.</p></sec></body><back><sec sec-type="data-availability" id="ccr371073-sec-0012"><title>Data Availability Statement</title><p>Access to these data can be requested by qualified researchers engaging in independent scientific research and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a Data Sharing Agreement. For more information or to submit a request, please contact David Oakley, <email>davido@wavimed.com</email>.</p></sec><ref-list content-type="cited-references" id="ccr371073-bibl-0001"><title>References</title><ref id="ccr371073-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="ccr371073-cit-0001"><article-title>&#8220;Alzheimer's Disease and Dementia,&#8221;</article-title> (<year>2019</year>), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://alz.org/alzheimers-dementia/facts-figures" ext-link-type="uri">https://alz.org/alzheimers&#8208;dementia/facts&#8208;figures</ext-link>.</mixed-citation></ref><ref id="ccr371073-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ccr371073-cit-0002"><string-name name-style="western"><given-names>L. O.</given-names><surname>Nichols</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lummus</surname></string-name>, et&#160;al., &#8220;<article-title>The Cost&#8208;Effectiveness of a Behavior Intervention With Caregivers of Patients With Alzheimer's Disease</article-title>,&#8221; <source>Journal of the American Geriatrics Society</source><volume>56</volume>, no. <issue>3</issue> (<year>2008</year>): <fpage>413</fpage>&#8211;<lpage>420</lpage>.<pub-id pub-id-type="pmid">18179480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2007.01569.x</pub-id><pub-id pub-id-type="pmcid">PMC2575686</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ccr371073-cit-0003"><string-name name-style="western"><given-names>L. A.</given-names><surname>Anderson</surname></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>Day</surname></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Beard</surname></string-name>, <string-name name-style="western"><given-names>P. S.</given-names><surname>Reed</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Wu</surname></string-name>, &#8220;<article-title>The Public's Perceptions About Cognitive Health and Alzheimer's Disease Among the U.S. Population: A National Review</article-title>,&#8221; <source>Gerontologist</source><volume>49</volume> (<year>2009</year>): <fpage>S3</fpage>&#8211;<lpage>S11</lpage>.<pub-id pub-id-type="pmid">19525214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geront/gnp088</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ccr371073-cit-0004"><string-name name-style="western"><given-names>A.</given-names><surname>Ramirez</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wolfsgruber</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Lange</surname></string-name>, et&#160;al., &#8220;<article-title>Elevated HbA1c Is Associated With Increased Risk of Incident Dementia in Primary Care Patients</article-title>,&#8221; <source>Journal of Alzheimer's Disease</source><volume>44</volume>, no. <issue>4</issue> (<year>2015</year>): <fpage>1203</fpage>&#8211;<lpage>1212</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-141521</pub-id><pub-id pub-id-type="pmid">25524954</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ccr371073-cit-0005"><string-name name-style="western"><given-names>Q. X.</given-names><surname>Pan</surname></string-name>, <string-name name-style="western"><given-names>X. J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Y. Y.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Relationship Between Insulin Levels and Nonpsychotic Dementia: A Systematic Review and Meta&#8208;Analysis</article-title>,&#8221; <source>Neural Plasticity</source><volume>2017</volume> (<year>2017</year>): <elocation-id>1230713</elocation-id>, <pub-id pub-id-type="doi">10.1155/2017/1230713</pub-id>.<pub-id pub-id-type="pmid">29445549</pub-id><pub-id pub-id-type="pmcid">PMC5763205</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ccr371073-cit-0006"><string-name name-style="western"><given-names>P. M.</given-names><surname>Oskui</surname></string-name>, <string-name name-style="western"><given-names>W. J.</given-names><surname>French</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Herring</surname></string-name>, <string-name name-style="western"><given-names>G. S.</given-names><surname>Mayeda</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Burstein</surname></string-name>, and <string-name name-style="western"><given-names>R. A.</given-names><surname>Kloner</surname></string-name>, &#8220;<article-title>Testosterone and the Cardiovascular System: A Comprehensive Review of the Clinical Literature</article-title>,&#8221; <source>Journal of the American Heart Association</source><volume>2</volume>, no. <issue>6</issue> (<year>2013</year>): <elocation-id>272</elocation-id>, <pub-id pub-id-type="doi">10.1161/JAHA.113.000272</pub-id>.<pub-id pub-id-type="pmcid">PMC3886770</pub-id><pub-id pub-id-type="pmid">24242682</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ccr371073-cit-0007"><string-name name-style="western"><given-names>X.</given-names><surname>Tang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Lu</surname></string-name>, et&#160;al., &#8220;<article-title>Relationship Between Central Obesity and the Incidence of Cognitive Impairment and Dementia From Cohort Studies Involving 5,060,687 Participants</article-title>,&#8221; <source>Neuroscience and Biobehavioral Reviews</source><volume>130</volume> (<year>2021</year>): <fpage>301</fpage>&#8211;<lpage>313</lpage>.<pub-id pub-id-type="pmid">34464646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2021.08.028</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ccr371073-cit-0008"><string-name name-style="western"><given-names>A.</given-names><surname>Morgentaler</surname></string-name>, &#8220;<article-title>Testosterone Replacement Therapy and Prostate Cancer</article-title>,&#8221; <source>Urologic Clinics of North America</source><volume>34</volume> (<year>2007</year>): <fpage>555</fpage>&#8211;<lpage>563</lpage>.<pub-id pub-id-type="pmid">17983895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ucl.2007.08.002</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ccr371073-cit-0009"><string-name name-style="western"><given-names>A.</given-names><surname>Morgentaler</surname></string-name> and <string-name name-style="western"><given-names>A. M.</given-names><surname>Traish</surname></string-name>, &#8220;<article-title>Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen&#8208;Dependent Growth</article-title>,&#8221; <source>European Urology</source><volume>55</volume> (<year>2009</year>): <fpage>310</fpage>&#8211;<lpage>321</lpage>.<pub-id pub-id-type="pmid">18838208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2008.09.024</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ccr371073-cit-0010"><string-name name-style="western"><given-names>A.</given-names><surname>Morgentaler</surname></string-name> and <string-name name-style="western"><given-names>W. P.</given-names><surname>Conners</surname>, <suffix>III</suffix></string-name>, &#8220;<article-title>Testosterone Therapy in Men With Prostate Cancer: Literature Review, Clinical Experience, and Recommendations</article-title>,&#8221; <source>Asian Journal of Andrology</source><volume>17</volume> (<year>2015</year>): <fpage>206</fpage>&#8211;<lpage>211</lpage>.<pub-id pub-id-type="pmid">25652633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1008-682X.148067</pub-id><pub-id pub-id-type="pmcid">PMC4650486</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ccr371073-cit-0011"><string-name name-style="western"><given-names>R.</given-names><surname>Ravi Kacker</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hult</surname></string-name>, <string-name name-style="western"><given-names>I. F.</given-names><surname>San Francisco</surname></string-name>, et&#160;al., &#8220;<article-title>Can Testosterone Therapy Be Offered to Men on Active Surveillance for Prostate Cancer? Preliminary Results</article-title>,&#8221; <source>Asian Journal of Andrology</source><volume>18</volume> (<year>2016</year>): <fpage>16</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">26306850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1008-682X.160270</pub-id><pub-id pub-id-type="pmcid">PMC4736350</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ccr371073-cit-0012"><string-name name-style="western"><given-names>J.</given-names><surname>Ory</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Flannigan</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Lundeen</surname></string-name>, <string-name name-style="western"><given-names>J. G.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Pommerville</surname></string-name>, and <string-name name-style="western"><given-names>S. L.</given-names><surname>Goldenberg</surname></string-name>, &#8220;<article-title>Testosterone Therapy in Patients With Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes</article-title>,&#8221; <source>Journal of Urology</source><volume>196</volume> (<year>2016</year>): <fpage>1082</fpage>&#8211;<lpage>1089</lpage>.<pub-id pub-id-type="pmid">27131465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.juro.2016.04.069</pub-id><pub-id pub-id-type="pmcid">PMC5025358</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ccr371073-cit-0013"><string-name name-style="western"><given-names>H.</given-names><surname>Aurlien</surname></string-name>, <string-name name-style="western"><given-names>I. O.</given-names><surname>Gjerde</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Aarseth</surname></string-name>, et&#160;al., &#8220;<article-title>EEG Background Activity Described by a Large Computerized Database</article-title>,&#8221; <source>Clinical Neurophysiology</source><volume>115</volume> (<year>2004</year>): <fpage>665</fpage>&#8211;<lpage>673</lpage>.<pub-id pub-id-type="pmid">15036063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2003.10.019</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ccr371073-cit-0014"><string-name name-style="western"><given-names>A. K.</given-names><surname>Chiang</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Rennie</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Robinson</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>van Albada</surname></string-name>, and <string-name name-style="western"><given-names>C. C.</given-names><surname>Kerr</surname></string-name>, &#8220;<article-title>Age Trends and Sex Differences of Alpha Rhythms Including Split Alpha Peaks</article-title>,&#8221; <source>Clinical Neurophysiology</source><volume>122</volume> (<year>2011</year>): <fpage>1505</fpage>&#8211;<lpage>1517</lpage>.<pub-id pub-id-type="pmid">21349761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2011.01.040</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ccr371073-cit-0015"><string-name name-style="western"><given-names>M. G.</given-names><surname>Knyazeva</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Barzegaran</surname></string-name>, <string-name name-style="western"><given-names>V. Y.</given-names><surname>Vildavski</surname></string-name>, and <string-name name-style="western"><given-names>J. F.</given-names><surname>Demonet</surname></string-name>, &#8220;<article-title>Aging of Human Alpha Rhythm</article-title>,&#8221; <source>Neurobiology of Aging</source><volume>69</volume> (<year>2018</year>): <fpage>261</fpage>&#8211;<lpage>273</lpage>.<pub-id pub-id-type="pmid">29920435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2018.05.018</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ccr371073-cit-0016"><string-name name-style="western"><given-names>E.</given-names><surname>Basar</surname></string-name>, &#8220;<article-title>A Review of Alpha Activity in Integrative Brain Function: Fundamental Physiology, Sensory Coding, Cognition and Pathology</article-title>,&#8221; <source>International Journal of Psychophysiology</source><volume>86</volume> (<year>2012</year>): <fpage>1</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">22820267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpsycho.2012.07.002</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ccr371073-cit-0017"><string-name name-style="western"><given-names>Z. A.</given-names><surname>Ga&#225;l</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Boha</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Stam</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Moln&#225;r</surname></string-name>, &#8220;<article-title>Age&#8208;Dependent Features of EEG Reactivity: Spectral, Complexity, and Network Characteristics</article-title>,&#8221; <source>Neuroscience Letters</source><volume>479</volume> (<year>2010</year>): <fpage>79</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">20560166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2010.05.037</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ccr371073-cit-0018"><string-name name-style="western"><given-names>O.</given-names><surname>Hubbard</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Sunde</surname></string-name>, and <string-name name-style="western"><given-names>E. S.</given-names><surname>Goldensohn</surname></string-name>, &#8220;<article-title>The EEG in Centenarians</article-title>,&#8221; <source>Electroencephalography and Clinical Neurophysiology</source><volume>40</volume> (<year>1976</year>): <fpage>407</fpage>&#8211;<lpage>417</lpage>.<pub-id pub-id-type="pmid">56267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0013-4694(76)90192-9</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ccr371073-cit-0019"><string-name name-style="western"><given-names>S. S.</given-names><surname>Lodder</surname></string-name> and <string-name name-style="western"><given-names>M. J.</given-names><surname>van Putten</surname></string-name>, &#8220;<article-title>Automated EEG Analysis: Characterizing the Posterior Dominant Rhythm</article-title>,&#8221; <source>Journal of Neuroscience Methods</source><volume>200</volume> (<year>2011</year>): <fpage>86</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">21722667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneumeth.2011.06.008</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ccr371073-cit-0020"><string-name name-style="western"><given-names>O. N.</given-names><surname>Markand</surname></string-name>, &#8220;<article-title>Electroencephalogram in Dementia</article-title>,&#8221; <source>American Journal of EEG Technology</source><volume>26</volume> (<year>1986</year>): <fpage>3</fpage>&#8211;<lpage>17</lpage>.</mixed-citation></ref><ref id="ccr371073-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ccr371073-cit-0021"><string-name name-style="western"><given-names>C. B.</given-names><surname>Peltz</surname></string-name>, <string-name name-style="western"><given-names>H. L.</given-names><surname>Kim</surname></string-name>, and <string-name name-style="western"><given-names>C. H.</given-names><surname>Kawas</surname></string-name>, &#8220;<article-title>Abnormal EEGs in Cognitively and Physically Healthy Oldest&#8208;Old: Findings From the 90+ Study</article-title>,&#8221; <source>Journal of Clinical Neurophysiology</source><volume>27</volume> (<year>2010</year>): <fpage>292</fpage>&#8211;<lpage>295</lpage>.<pub-id pub-id-type="pmid">20634708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNP.0b013e3181eaad7d</pub-id><pub-id pub-id-type="pmcid">PMC2928050</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ccr371073-cit-0022"><string-name name-style="western"><given-names>O.</given-names><surname>Vysata</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kukal</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Prochazka</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Pazdera</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Valis</surname></string-name>, &#8220;<article-title>Age&#8208;Related Changes in the Energy and Spectral Composition of EEG</article-title>,&#8221; <source>Neurophysiology</source><volume>44</volume> (<year>2012</year>): <fpage>63</fpage>&#8211;<lpage>67</lpage>.</mixed-citation></ref><ref id="ccr371073-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ccr371073-cit-0023"><string-name name-style="western"><given-names>C.</given-names><surname>Babiloni</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Binetti</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Cassarino</surname></string-name>, et&#160;al., &#8220;<article-title>Sources of Cortical Rhythms in Adults During Physiological Aging: A Multicentric EEG Study</article-title>,&#8221; <source>Human Brain Mapping</source><volume>27</volume> (<year>2006</year>): <fpage>162</fpage>&#8211;<lpage>172</lpage>.<pub-id pub-id-type="pmid">16108018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.20175</pub-id><pub-id pub-id-type="pmcid">PMC6871339</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ccr371073-cit-0024"><string-name name-style="western"><given-names>E.</given-names><surname>Niedermeyer</surname></string-name>, &#8220;<article-title>Alpha Rhythms as Physiological and Abnormal Phenomena</article-title>,&#8221; <source>International Journal of Psychophysiology</source><volume>26</volume> (<year>1997</year>): <fpage>31</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">9202993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0167-8760(97)00754-x</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ccr371073-cit-0025"><string-name name-style="western"><given-names>P.</given-names><surname>Rossini</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Del Percio</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Pasqualetti</surname></string-name>, et&#160;al., &#8220;<article-title>Conversion From Mild Cognitive Impairment to Alzheimer's Disease Is Predicted by Sources and Coherence of Brain Electroencephalography Rhythms</article-title>,&#8221; <source>Neuroscience</source><volume>143</volume> (<year>2006</year>): <fpage>793</fpage>&#8211;<lpage>803</lpage>.<pub-id pub-id-type="pmid">17049178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2006.08.049</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ccr371073-cit-0026"><string-name name-style="western"><given-names>J. L.</given-names><surname>Cantero</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Atienza</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Gomez&#8208;Herrero</surname></string-name>, et&#160;al., &#8220;<article-title>Functional Integrity of Thalamocortical Circuits Differentiates Normal Aging From Mild Cognitive Impairment</article-title>,&#8221; <source>Human Brain Mapping</source><volume>30</volume> (<year>2009</year>): <fpage>3944</fpage>&#8211;<lpage>3957</lpage>.<pub-id pub-id-type="pmid">19449329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.20819</pub-id><pub-id pub-id-type="pmcid">PMC6871053</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ccr371073-cit-0027"><string-name name-style="western"><given-names>F.</given-names><surname>d'Onofrio</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Salvia</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Petretta</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Bonavita</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Rodriguez</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Tedeschi</surname></string-name>, &#8220;<article-title>Quantified&#8208;EEG in Normal Aging and Dementias</article-title>,&#8221; <source>Acta Neurologica Scandinavica</source><volume>93</volume> (<year>1996</year>): <fpage>336</fpage>&#8211;<lpage>345</lpage>.<pub-id pub-id-type="pmid">8800344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0404.1996.tb00006.x</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ccr371073-cit-0028"><string-name name-style="western"><given-names>M.</given-names><surname>Gawel</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Zalewska</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Szmidt&#8208;Salkowska</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Kowalski</surname></string-name>, &#8220;<article-title>Does EEG (Visual and Quantitative) Reflect Mental Impairment in Subcortical Vascular Dementia?</article-title>,&#8221; <source>Journal of the Neurological Sciences</source><volume>257</volume> (<year>2007</year>): <fpage>11</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">17337009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2007.01.046</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ccr371073-cit-0029"><string-name name-style="western"><given-names>V.</given-names><surname>Jelic</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Johansson</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Almkvist</surname></string-name>, et&#160;al., &#8220;<article-title>Quantitative Electroencephalography in Mild Cognitive Impairment: Longitudinal Changes and Possible Prediction of Alzheimer's Disease</article-title>,&#8221; <source>Neurobiology of Aging</source><volume>21</volume> (<year>2000</year>): <fpage>533</fpage>&#8211;<lpage>540</lpage>.<pub-id pub-id-type="pmid">10924766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(00)00153-6</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ccr371073-cit-0030"><string-name name-style="western"><given-names>T.</given-names><surname>Montez</surname></string-name>, <string-name name-style="western"><given-names>S. S.</given-names><surname>Poil</surname></string-name>, <string-name name-style="western"><given-names>B. F.</given-names><surname>Jones</surname></string-name>, et&#160;al., &#8220;<article-title>Altered Temporal Correlations in Parietal Alpha and Prefrontal Theta Oscillations in Early&#8208;Stage Alzheimer Disease</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>106</volume> (<year>2009</year>): <fpage>1614</fpage>&#8211;<lpage>1619</lpage>.<pub-id pub-id-type="pmid">19164579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0811699106</pub-id><pub-id pub-id-type="pmcid">PMC2635782</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ccr371073-cit-0031"><string-name name-style="western"><given-names>D. V.</given-names><surname>Moretti</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Babiloni</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Binetti</surname></string-name>, et&#160;al., &#8220;<article-title>Individual Analysis of EEG Frequency and Band Power in Mild Alzheimer's Disease</article-title>,&#8221; <source>Clinical Neurophysiology</source><volume>115</volume> (<year>2004</year>): <fpage>299</fpage>&#8211;<lpage>308</lpage>.<pub-id pub-id-type="pmid">14744569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1388-2457(03)00345-6</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ccr371073-cit-0032"><string-name name-style="western"><given-names>C.</given-names><surname>Babiloni</surname></string-name>, <string-name name-style="western"><given-names>G. B.</given-names><surname>Frisoni</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pievani</surname></string-name>, et&#160;al., &#8220;<article-title>White&#8208;Matter Vascular Lesions Correlate With Alpha EEG Sources in Mild Cognitive Impairment</article-title>,&#8221; <source>Neuropsychologia</source><volume>46</volume> (<year>2008</year>): <fpage>1707</fpage>&#8211;<lpage>1720</lpage>.<pub-id pub-id-type="pmid">18440574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2008.03.021</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ccr371073-cit-0033"><string-name name-style="western"><given-names>D. V.</given-names><surname>Moretti</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Miniussi</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Frisoni</surname></string-name>, et&#160;al., &#8220;<article-title>Vascular Damage and EEG Markers in Subjects With Mild Cognitive Impairment</article-title>,&#8221; <source>Clinical Neurophysiology</source><volume>118</volume> (<year>2007</year>): <fpage>1866</fpage>&#8211;<lpage>1876</lpage>.<pub-id pub-id-type="pmid">17576096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2007.05.009</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="ccr371073-cit-0034"><string-name name-style="western"><given-names>L. S.</given-names><surname>Prichep</surname></string-name>, &#8220;<article-title>Quantitative EEG and Electromagnetic Brain Imaging in Aging and in the Evolution of Dementia</article-title>,&#8221; <source>Annals of the New York Academy of Sciences</source><volume>1097</volume> (<year>2007</year>): <fpage>156</fpage>&#8211;<lpage>167</lpage>.<pub-id pub-id-type="pmid">17413018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1379.008</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="ccr371073-cit-0035"><string-name name-style="western"><given-names>E.</given-names><surname>Stomrud</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Hansson</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Minthon</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Blennow</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Rosen</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Londos</surname></string-name>, &#8220;<article-title>Slowing of EEG Correlates With CSF Biomarkers and Reduced Cognitive Speed in Elderly With Normal Cognition Over 4&#8201;Years</article-title>,&#8221; <source>Neurobiology of Aging</source><volume>31</volume> (<year>2010</year>): <fpage>215</fpage>&#8211;<lpage>223</lpage>.<pub-id pub-id-type="pmid">18462837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2008.03.025</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="ccr371073-cit-0036"><string-name name-style="western"><given-names>B.</given-names><surname>Szelies</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Grond</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Herholz</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kessler</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Wullen</surname></string-name>, and <string-name name-style="western"><given-names>W. D.</given-names><surname>Heiss</surname></string-name>, &#8220;<article-title>Quantitative EEG Mapping and PET in Alzheimer's Disease</article-title>,&#8221; <source>Journal of the Neurological Sciences</source><volume>110</volume> (<year>1992</year>): <fpage>46</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">1506868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-510x(92)90008-9</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="ccr371073-cit-0037"><string-name name-style="western"><given-names>B.</given-names><surname>Szelies</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Mielke</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kessler</surname></string-name>, and <string-name name-style="western"><given-names>W. D.</given-names><surname>Heiss</surname></string-name>, &#8220;<article-title>EEG Power Changes Are Related to Regional Cerebral Glucose Metabolism in Vascular Dementia</article-title>,&#8221; <source>Clinical Neurophysiology</source><volume>110</volume> (<year>1999</year>): <fpage>615</fpage>&#8211;<lpage>620</lpage>.<pub-id pub-id-type="pmid">10378729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1388-2457(98)00052-2</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="ccr371073-cit-0038"><string-name name-style="western"><given-names>J. F. W.</given-names><surname>Deakin</surname></string-name> and <string-name name-style="western"><given-names>K. A.</given-names><surname>Exley</surname></string-name>, &#8220;<article-title>Personality and Male&#8208;Female Influences on the EEG Alpha Rhythm</article-title>,&#8221; <source>Biological Psychology</source><volume>8</volume> (<year>1979</year>): <fpage>285</fpage>&#8211;<lpage>290</lpage>.<pub-id pub-id-type="pmid">486627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0301-0511(79)90010-3</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="ccr371073-cit-0039"><string-name name-style="western"><given-names>T.</given-names><surname>Gasser</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>B&#228;cher</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Steinberg</surname></string-name>, &#8220;<article-title>Test&#8208;Retest Reliability of Spectral Parameters of the EEG</article-title>,&#8221; <source>Electroencephalography and Clinical Neurophysiology</source><volume>60</volume> (<year>1985</year>): <fpage>312</fpage>&#8211;<lpage>319</lpage>.<pub-id pub-id-type="pmid">2579798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0013-4694(85)90005-7</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="ccr371073-cit-0040"><string-name name-style="western"><given-names>A.</given-names><surname>Kondacs</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Szab&#243;</surname></string-name>, &#8220;<article-title>Long&#8208;Term Intra&#8208;Individual Variability of the Background EEG in Normals</article-title>,&#8221; <source>Clinical Neurophysiology</source><volume>110</volume> (<year>1999</year>): <fpage>1708</fpage>&#8211;<lpage>1716</lpage>.<pub-id pub-id-type="pmid">10574286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1388-2457(99)00122-4</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="ccr371073-cit-0041"><string-name name-style="western"><given-names>M. C.</given-names><surname>Salinsky</surname></string-name>, <string-name name-style="western"><given-names>B. S.</given-names><surname>Oken</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Morehead</surname></string-name>, &#8220;<article-title>Test&#8208;Retest Reliability in EEG Frequency Analysis</article-title>,&#8221; <source>Electroencephalography and Clinical Neurophysiology</source><volume>79</volume> (<year>1991</year>): <fpage>382</fpage>&#8211;<lpage>392</lpage>.<pub-id pub-id-type="pmid">1718711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0013-4694(91)90203-g</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="ccr371073-cit-0042"><string-name name-style="western"><given-names>M.</given-names><surname>Doppelmayr</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Klimesch</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Pachinger</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Ripper</surname></string-name>, &#8220;<article-title>Individual Differences in Brain Dynamics: Important Implications for the Calculation of Event&#8208;Related Band Power</article-title>,&#8221; <source>Biological Cybernetics</source><volume>79</volume> (<year>1998</year>): <fpage>49</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">9742677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s004220050457</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="ccr371073-cit-0043"><string-name name-style="western"><given-names>W.</given-names><surname>Klimesch</surname></string-name>, &#8220;<article-title>Memory Processes, Brain Oscillations and EEG Synchronization</article-title>,&#8221; <source>International Journal of Psychophysiology</source><volume>24</volume> (<year>1996</year>): <fpage>61</fpage>&#8211;<lpage>100</lpage>.<pub-id pub-id-type="pmid">8978436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0167-8760(96)00057-8</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="ccr371073-cit-0044"><string-name name-style="western"><given-names>W.</given-names><surname>Klimesch</surname></string-name>, &#8220;<article-title>EEG&#8208;Alpha Rhythms and Memory Processes</article-title>,&#8221; <source>International Journal of Psychophysiology</source><volume>26</volume> (<year>1997</year>): <fpage>319</fpage>&#8211;<lpage>340</lpage>.<pub-id pub-id-type="pmid">9203012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0167-8760(97)00773-3</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="ccr371073-cit-0045"><string-name name-style="western"><given-names>J.</given-names><surname>Polich</surname></string-name>, &#8220;<article-title>Clinical Application of the P300 Event&#8208;Related Brain Potential</article-title>,&#8221; <source>Physical Medicine and Rehabilitation Clinics of North America</source><volume>15</volume>, no. <issue>1</issue> (<year>2004</year>): <fpage>133</fpage>&#8211;<lpage>161</lpage>.<pub-id pub-id-type="pmid">15029903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1047-9651(03)00109-8</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="ccr371073-cit-0046"><string-name name-style="western"><given-names>E. J.</given-names><surname>Golob</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Ringman</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Irimajiri</surname></string-name>, et&#160;al., &#8220;<article-title>Cortical Event&#8208;Related Potentials in Preclinical Familial Alzheimer Disease</article-title>,&#8221; <source>Neurology</source><volume>73</volume>, no. <issue>20</issue> (<year>2009</year>): <fpage>1649</fpage>&#8211;<lpage>1655</lpage>.<pub-id pub-id-type="pmid">19917987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181c1de77</pub-id><pub-id pub-id-type="pmcid">PMC2788802</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="ccr371073-cit-0047"><string-name name-style="western"><given-names>S. A.</given-names><surname>Gordeev</surname></string-name>, &#8220;<article-title>The Use of Endogenous P300 Event&#8208;Related Potentials of the Brain for Assessing Cognitive Functions in Healthy Subjects and in Clinical Practice</article-title>,&#8221; <source>Fiziologiia Cheloveka</source><volume>33</volume>, no. <issue>2</issue> (<year>2007</year>): <fpage>121</fpage>&#8211;<lpage>133</lpage>.<pub-id pub-id-type="pmid">17486999</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="ccr371073-cit-0048"><string-name name-style="western"><given-names>J.</given-names><surname>Boone</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Davids</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Joffe</surname></string-name>, et&#160;al., &#8220;<article-title>In&#8208;Clinic Measurements of Vascular Risk and Brain Activity</article-title>,&#8221; <source>Journal of Ageing and Longevity</source><volume>2</volume> (<year>2022</year>): <fpage>240</fpage>&#8211;<lpage>251</lpage>, <pub-id pub-id-type="doi">10.3390/jal2030020</pub-id>.</mixed-citation></ref><ref id="ccr371073-bib-0049"><label>49</label><mixed-citation publication-type="miscellaneous" id="ccr371073-cit-0049"><collab collab-type="authors">CNS Vital Signs</collab>
, <article-title>&#8220;CNS Vital Signs Academic Research Users,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cnsvs.com/" ext-link-type="uri">https://www.cnsvs.com/</ext-link>.</mixed-citation></ref><ref id="ccr371073-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="ccr371073-cit-0050"><string-name name-style="western"><given-names>G.</given-names><surname>Clayton</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Davis</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Holliday</surname></string-name>, et&#160;al., &#8220;<article-title>In&#8208;Clinic Event Related Potentials After Sports Concussion: A 4&#8208;Year Study</article-title>,&#8221; <source>Journal of Pediatric Rehabilitation Medicine</source><volume>13</volume> (<year>2020</year>): <fpage>81</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">32176669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/PRM-190620</pub-id><pub-id pub-id-type="pmcid">PMC7242851</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0051"><label>51</label><mixed-citation publication-type="miscellaneous" id="ccr371073-cit-0051"><string-name name-style="western"><given-names>D. S.</given-names><surname>Oakley</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Fosse</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Gerwick</surname></string-name>, et&#160;al., <article-title>&#8220;P300 Parameters Over the Lifespan: Validating Target Ranges on an In&#8208;Clinic Platform,&#8221;</article-title> bioRxiv, (<year>2021</year>), <pub-id pub-id-type="doi">10.1101/2021.10.25.465715</pub-id>.</mixed-citation></ref><ref id="ccr371073-bib-0052"><label>52</label><mixed-citation publication-type="miscellaneous" id="ccr371073-cit-0052"><string-name name-style="western"><given-names>D.</given-names><surname>Joffe</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Oakley</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Arese Lucini</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Palermo</surname></string-name>, <article-title>&#8220;Measurements of EEG Alpha Peak Frequencies Over the Lifespan: Validating Target Ranges on an In&#8208;Clinic Platform,&#8221;</article-title> bioRxiv, (<year>2021</year>), <pub-id pub-id-type="doi">10.1101/2021.10.06.463353</pub-id>.</mixed-citation></ref><ref id="ccr371073-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="ccr371073-cit-0053"><string-name name-style="western"><given-names>H.</given-names><surname>Tokuda</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ito</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Sueyasu</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of Combining Exercise With Long&#8208;Chain Polyunsaturated Fatty Acid Supplementation on Cognitive Function in the Elderly: A Randomized Controlled Trial</article-title>,&#8221; <source>Scientific Reports</source><volume>10</volume> (<year>2020</year>): <elocation-id>12906</elocation-id>, <pub-id pub-id-type="doi">10.1038/s41598-020-69560-4</pub-id>.<pub-id pub-id-type="pmid">32737350</pub-id><pub-id pub-id-type="pmcid">PMC7395090</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="ccr371073-cit-0054"><string-name name-style="western"><given-names>L. K.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Shahar</surname></string-name>, <string-name name-style="western"><given-names>A. V.</given-names><surname>Chin</surname></string-name>, and <string-name name-style="western"><given-names>N. A.</given-names><surname>Yusoff</surname></string-name>, &#8220;<article-title>Docosahexaenoic Acid&#8208;Concentrated Fish Oil Supplementation in Subjects With Mild Cognitive Impairment (MCI): A 12&#8208;Month Randomised, Double&#8208;Blind, Placebo&#8208;Controlled Trial</article-title>,&#8221; <source>Psychopharmacology</source><volume>225</volume> (<year>2013</year>): <fpage>605</fpage>&#8211;<lpage>612</lpage>, <pub-id pub-id-type="doi">10.1007/s00213-012-2848-0</pub-id>.<pub-id pub-id-type="pmid">22932777</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="ccr371073-cit-0055"><string-name name-style="western"><given-names>E.</given-names><surname>Mavraki</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Ioannidis</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Tripsianis</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Gioka</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kolousi</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Vadikolias</surname></string-name>, &#8220;<article-title>Vitamin D in Mild Cognitive Impairment and Alzheimer's Disease. A Study in Older Greek Adults</article-title>,&#8221; <source>Hippokratia</source><volume>24</volume>, no. <issue>3</issue> (<year>2020</year>): <fpage>120</fpage>&#8211;<lpage>126</lpage>.<pub-id pub-id-type="pmid">34239289</pub-id><pub-id pub-id-type="pmcid">PMC8256783</pub-id></mixed-citation></ref><ref id="ccr371073-bib-0056"><label>56</label><mixed-citation publication-type="book" id="ccr371073-cit-0056"><string-name name-style="western"><given-names>A.</given-names><surname>Lauer</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Janitschke</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Hartmann</surname></string-name>, <string-name name-style="western"><given-names>H. S.</given-names><surname>Grimm</surname></string-name>, and <string-name name-style="western"><given-names>M. O. W.</given-names><surname>Grimm</surname></string-name>, &#8220;<part-title>The Effects of Vitamin D Deficiency on Neurodegenerative Diseases</part-title>,&#8221; in <source>Vitamin D Deficiency</source> (<publisher-name>IntechOpen</publisher-name>, <year>2019</year>), <pub-id pub-id-type="doi">10.5772/intechopen.89160</pub-id>.</mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501341</article-id><article-id pub-id-type="pmcid-ver">PMC12501341.1</article-id><article-id pub-id-type="pmcaid">12501341</article-id><article-id pub-id-type="pmcaiid">12501341</article-id><article-id pub-id-type="pmid">40829975</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100326</article-id><article-id pub-id-type="pii">S2274-5807(25)00269-9</article-id><article-id pub-id-type="publisher-id">100326</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Dementia risk prediction: A comparative analysis of the ANU-ADRI, CAIDE, CogDrisk, LIBRA, and LIBRA2 indices in the HUNT study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Stubs</surname><given-names initials="J">Josephine</given-names></name><email>josephine.stuebs@aldringoghelse.no</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0003" ref-type="aff">c</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Langballe</surname><given-names initials="EM">Ellen Melbye</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Livingston</surname><given-names initials="G">Gill</given-names></name><xref rid="aff0004" ref-type="aff">d</xref><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Anstey</surname><given-names initials="KJ">Kaarin J.</given-names></name><xref rid="aff0006" ref-type="aff">f</xref><xref rid="aff0007" ref-type="aff">g</xref><xref rid="aff0008" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Deckers</surname><given-names initials="K">Kay</given-names></name><xref rid="aff0009" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Mathews</surname><given-names initials="FE">Fiona E.</given-names></name><xref rid="aff0010" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Kivim&#228;ki</surname><given-names initials="M">Mika</given-names></name><xref rid="aff0004" ref-type="aff">d</xref><xref rid="aff0011" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Strand</surname><given-names initials="BH">Bj&#248;rn Heine</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0012" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Rokstad</surname><given-names initials="AM">Anne-Marie</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0013" ref-type="aff">m</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Krokstad</surname><given-names initials="S">Steinar</given-names></name><xref rid="aff0014" ref-type="aff">n</xref><xref rid="aff0015" ref-type="aff">o</xref></contrib><contrib contrib-type="author" id="au0011"><name name-style="western"><surname>Selb&#230;k</surname><given-names initials="G">Geir</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0003" ref-type="aff">c</xref></contrib><aff id="aff0001"><label>a</label>Norwegian National Centre for Ageing and Health, Vestfold Hospital Trust, Aldring og helse, 103 T&#248;nsberg, Norway</aff><aff id="aff0002"><label>b</label>Department of Geriatric Medicine, Oslo University Hospital, Kirkeveien 166, 0450 Oslo Norway</aff><aff id="aff0003"><label>c</label>Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway</aff><aff id="aff0004"><label>d</label>Division of Psychiatry, 149 Tottenham Court Rd, University College London, London, W1W 7EJ UK</aff><aff id="aff0005"><label>e</label>North London NHS Foundation Trust, St Pancras Hospital, London, NW1 0PE UK</aff><aff id="aff0006"><label>f</label>School of Psychology, University of New South Wales, Sydney, Australia</aff><aff id="aff0007"><label>g</label>Neuroscience Research Australia, Sydney, Australia</aff><aff id="aff0008"><label>h</label>UNSW Ageing Futures Institute, University of New South Wales, Sydney, Australia</aff><aff id="aff0009"><label>i</label>Alzheimer Centrum Limburg, Department of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Dr. Tanslaan 12, 6229 ET, Maastricht, The Netherlands</aff><aff id="aff0010"><label>j</label>Institute for Clinical and Applied Health Research, University of Hull, Cottingham Road, Hull, HU6 7RX, UK</aff><aff id="aff0011"><label>k</label>Department of Public Health, Faculty of Medicine, University of Helsinki, Tukholmankatu 8 B, FI-00014 University of Helsinki, Finland</aff><aff id="aff0012"><label>l</label>Department of Physical Health and Ageing, Norwegian Institute of Public Health, Oslo, Norway</aff><aff id="aff0013"><label>m</label>Faculty of Health Sciences and Social Care, Molde University College, Postboks 2110, 6402 Molde, Norway</aff><aff id="aff0014"><label>n</label>Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, HUNT Research Centre, Norwegian University of Science and Technology, Trondheim, Norway</aff><aff id="aff0015"><label>o</label>Levanger Hospital, Nord-Tr&#248;ndelag Hospital Trust, Levanger, Norway</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. <email>josephine.stuebs@aldringoghelse.no</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>18</day><month>8</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100326</elocation-id><history><date date-type="received"><day>3</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>6</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0001">5 dementia risk scores and a demographics-only model were compared longitudinally.</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0002">CogDrisk and LIBRA showed the best overall accuracy in predicting dementia risk.</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0003">ANU-ADRI showed moderate predictive performance.</p></list-item><list-item id="celistitem0004"><label>&#8226;</label><p id="para0004">CAIDE and LIBRA2 performed weakest across models and subgroups.</p></list-item><list-item id="celistitem0005"><label>&#8226;</label><p id="para0005">No index outperformed age and education alone in predicting dementia.</p></list-item></list></p></abstract><abstract id="abs0002"><sec><title>Background/Objective</title><p>Dementia is a major global health concern, necessitating effective risk assessment tools and early intervention. This study compared the performance of five modifiable dementia risk indices &#8211; ANU-ADRI, CAIDE, CogDrisk, LIBRA, and LIBRA2 and a &#8220;demographics-only&#8221; (age, education) model.</p></sec><sec><title>Methods</title><p>We analyzed data from 5247 Norwegian participants in the Tr&#248;ndelag Health Study (HUNT4 70+, 2017&#8211;2019) and dementia risk indices from baseline data in HUNT3 (2006&#8211;2008). Logistic regression models assessed associations between standardized index scores and all-cause dementia and Alzheimer&#8217;s disease (AD) across age group (&lt;65 vs. &#8805;65 years), sex, and APOE4 status.</p></sec><sec><title>Results</title><p>During the mean follow-up of 10.6 (9.3&#8211;12.3) years (SD=0.74), all indices significantly predicted dementia and AD, though none outperformed the demographics-only model. CogDrisk showed significantly better discriminative ability than all other indices (0.76, 95 % CI:0.74&#8211;0.78; DeLong <italic toggle="yes">p</italic> &lt; 0.05), followed by LIBRA (0.75, 95 % CI:0.72&#8211;0.77) and ANU-ADRI (0.74, 95 % CI:0.72&#8211;0.76). LIBRA2 (0.69, 95 % CI:0.66&#8211;0.71) and CAIDE (0.59, 95 % CI:0.56&#8211;0.61) had significantly lower accuracy (DeLong <italic toggle="yes">p</italic> &lt; 0.001). Removing demographics maintained rank order but reduced accuracy across all indices. Stratified analyses showed stronger performance in those &#8805;65 years and females at HUNT3, while APOE4 status did not affect performance.</p></sec><sec><title>Conclusion</title><p>All indices were associated with dementia risk, with CogDrisk performing best across all conditions, and LIBRA2 and CAIDE performing weakest. No index outperformed a model including age and education only. Future research should refine risk indices for age- and sex-specific applications and assess whether simpler demographic models may suffice in some contexts.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Dementia</kwd><kwd>Risk index</kwd><kwd>Modifiable risk factors</kwd><kwd>HUNT</kwd><kwd>Lifestyle</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0010">Dementia is a major global health challenge, affecting over 57 million people worldwide, with prevalence projected to rise to 153 million by 2050 [<xref rid="bib0001" ref-type="bibr">1</xref>]. Beyond its devastating personal and societal cost, dementia presents a serious economic burden, with global costs exceeding $1 trillion annually [<xref rid="bib0002" ref-type="bibr">2</xref>]. Delaying dementia onset by just five years is estimated to reduce its incidence by 33 % [<xref rid="bib0003" ref-type="bibr">3</xref>]. Furthermore, increasing the years individuals live independently or with low support needs, would substantially alleviate both financial and emotional pressures on individuals, families, and healthcare systems [<xref rid="bib0003" ref-type="bibr">3</xref>]. This may be possible through improvements in risk reduction, intervention, and early identification of dementia pathology &#8211; avenues that have seen large strides in recent years, for example with new low-cost and minimally invasive diagnostic tests [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0005" ref-type="bibr">5</xref>], increased knowledge on modifiable dementia risk factors [<xref rid="bib0006" ref-type="bibr">6</xref>], and potentially emerging anti-amyloid antibody treatments [<xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>, <xref rid="bib0009" ref-type="bibr">[9]</xref>].</p><p id="para0011">The Lancet Commission on Dementia Prevention, Intervention, and Care has estimated that 14 modifiable risk factors account for roughly 45 % of dementia risk [<xref rid="bib0006" ref-type="bibr">6</xref>]. This finding underscores the potential for targeted lifestyle interventions to reduce the global dementia burden and can be tackled jointly by individuals, physicians, researchers, and policymakers. Multiple tools have been developed and validated over the past decade, enabling the mapping of modifiable dementia risk and protective factors in individuals and populations. Among the most well-studied are the Australian National University Alzheimer&#8217;s Disease Risk Index (ANU-ADRI) [<xref rid="bib0010" ref-type="bibr">10</xref>], the Cardiovascular Risk Factors, Aging, and Dementia Study (CAIDE) [<xref rid="bib0011" ref-type="bibr">11</xref>], the LIfestyle for BRAin Health (LIBRA) index [<xref rid="bib0012" ref-type="bibr">12</xref>] and its updated version (LIBRA2) [<xref rid="bib0013" ref-type="bibr">13</xref>], and the more recently developed CogDrisk Index [<xref rid="bib0014" ref-type="bibr">14</xref>]. These indices focus on modifiable risk factors, which are combined into a single dementia risk score.</p><p id="para0012">While most of these indices were originally developed to support prevention and user guidance, they have the potential to play a crucial role in a collaborative approach to dementia risk reduction and are increasingly used across a broad spectrum of applications. For individuals, they highlight modifiable risk factors and enable early lifestyle changes, as well as low-cost, accessible self-assessment &#8211; especially for those who lack regular health care accessibility. Each index now has an app or website allowing individuals to self-assess at home [<xref rid="bib0015" ref-type="bibr">15</xref>]. Physicians may use them to stratify risk, guide personalized risk reduction plans, and improve communication about risk with patients. Researchers benefit from standardized frameworks for measuring risk, selecting high-risk participants for trials, and using indices as surrogate outcomes when direct dementia diagnoses are impractical [<xref rid="bib0015" ref-type="bibr">15</xref>]. Policymakers can benefit from aggregated data to identify high-risk populations, design targeted public health initiatives and monitor intervention impact over time.</p><p id="para0013">Despite their potential, further studies are needed to assess their validity and limitations in different contexts to ensure appropriate application. Given their resource-intensive computational and data collection demands, thorough validation and optimization are crucial to avoid placing an undue burden on overtaxed healthcare systems or imposing computational strain in research and clinical settings, particularly in contexts where simpler models, such as those based on age, sex, and education, may suffice. While each index has been tested and validated across diverse cohorts, results show varying predictive performance [<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>, <xref rid="bib0019" ref-type="bibr">[19]</xref>, <xref rid="bib0020" ref-type="bibr">[20]</xref>, <xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>, <xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>, <xref rid="bib0025" ref-type="bibr">[25]</xref>, <xref rid="bib0026" ref-type="bibr">[26]</xref>, <xref rid="bib0027" ref-type="bibr">[27]</xref>]. ANU-ADRI, developed through evidence synthesis, has shown low-to-moderate accuracy (AUC=0.52&#8211;0.75) [<xref rid="bib0024" ref-type="bibr">24</xref>,<xref rid="bib0026" ref-type="bibr">26</xref>,<xref rid="bib0028" ref-type="bibr">28</xref>], performing well in the Rotterdam Study (AUC=0.75) [<xref rid="bib0016" ref-type="bibr">16</xref>] but less so in the UK Biobank (AUC=0&#8211;58&#8211;0.59) [<xref rid="bib0027" ref-type="bibr">27</xref>,<xref rid="bib0028" ref-type="bibr">28</xref>] which has a younger age range than many cohorts. CAIDE, derived from Finnish population data, has demonstrated strong performance in studies with extended follow-ups, achieving AUCs as high as 0.78 [<xref rid="bib0011" ref-type="bibr">11</xref>,<xref rid="bib0016" ref-type="bibr">16</xref>], but its accuracy is lower in other cohorts (AUC=0.50&#8211;0.68) [<xref rid="bib0024" ref-type="bibr">24</xref>,<xref rid="bib0026" ref-type="bibr">26</xref>,<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0029" ref-type="bibr">29</xref>]. LIBRA, developed through evidence synthesis focused on midlife modifiable risk and protective factors, shows low to moderate accuracy (AUC=0.52&#8211;0.75) [<xref rid="bib0030" ref-type="bibr">30</xref>], and is less reliable in very old cohorts (75+ years) [<xref rid="bib0031" ref-type="bibr">31</xref>]. However, comparability between different studies is problematic as some studies include age as a covariate while others do not. Recently developed CogDrisk performs with moderate accuracy across populations, with AUCs ranging from 0.66 to 0.77 [<xref rid="bib0024" ref-type="bibr">24</xref>]. Notably, age alone often performs as well as or better than full indices [<xref rid="bib0032" ref-type="bibr">32</xref>], underscoring the challenge of improving prediction models beyond demographic factors such as age, gender, and education.</p><p id="para0014">Most risk factors in these indices are well-validated individually and offer value for users assessing how their lifestyle affects dementia risk. However, their growing use in research and other settings necessitates assessing their effectiveness beyond their original intent. Moreover, the growing number of indices calls for a comprehensive comparison of their performance in different contexts. Particularly, subgroup comparisons based on age, sex, and genetic risk (Apolipoprotein epsilon 4 allele (APOE4) status) are warranted, as these variables are known to moderate the association between lifestyle factors and dementia risk [<xref rid="bib0006" ref-type="bibr">6</xref>,<xref rid="bib0032" ref-type="bibr">[32]</xref>, <xref rid="bib0033" ref-type="bibr">[33]</xref>, <xref rid="bib0034" ref-type="bibr">[34]</xref>]. Despite widespread use of these indices individually, directly comparing their predictive performance within the same cohort remains rare. Only one other study to date has compared all five of the most commonly used dementia risk indices [<xref rid="bib0024" ref-type="bibr">24</xref>]. Therefore, this study aims to compare the predictive performance of these dementia risk indices (ANU-ADRI, CAIDE, CogDrisk, LIBRA and LIBRA2) against each other and a simpler demographic model (age and education), across all eligible participants of the Tr&#248;ndelag Health Study (HUNT) and within subgroups stratified by age, self-reported sex, and APOE4 status.</p></sec><sec id="sec0002"><label>2</label><title>Method</title><sec id="sec0003"><label>2.1</label><title>Study population</title><p id="para0015">This study used data from the HUNT Study, a population-based cohort in Tr&#248;ndelag, Norway, ongoing since 1984. HUNT includes four surveys conducted every 10&#8211;11 years, collecting health, lifestyle, and disease data via clinical exams, interviews, questionnaires, and biological samples [<xref rid="bib0035" ref-type="bibr">35</xref>]. Participants also consented to data linkage with national health registries. Beyond informed consent given by HUNT participants, the Regional Committee for Medical and Health Research Ethics in Norway (REK Southeast 251,687) and the Norwegian Center for Research Data (NSD 571,736), evaluated and approved this project and data linkage between the different registries.</p><p id="para0016">This study focused on participants from HUNT4 70+, a sub-study of the fourth HUNT survey (HUNT4, 2017&#8211;2019) targeting individuals aged 70 and older. Lifestyle and health data for these participants were collected about 11 years earlier during HUNT3 (2006&#8211;2008), enabling longitudinal risk factor analysis. HUNT3 was selected as baseline because it includes nearly all variables used in the dementia risk indices and aligns with the start of available registry data from the Norwegian Patient Registry (NPR) in 2007. Additional linkage to data from Statistics Norway (SSB) and NPR provided access to education records and disease diagnoses (3-digit ICD-10 codes, recorded in specialized health care settings) between 2007 and 2009. Of 9930 individuals who participated in HUNT4 70+ (representing 51.2 % of the local population aged 70 and older in Tr&#248;ndelag [<xref rid="bib0036" ref-type="bibr">36</xref>]), 9726 (98.0 %) provided sufficient information to inform dementia status and constituted the eligible follow-up sample for outcome classification in this study. Among these, 8397 (86.3 %) had also participated in HUNT3 and were eligible for risk score calculation. The main analysis excluded participants with incomplete risk score data (<italic toggle="yes">n</italic> = 3268, 32.9 %) that could not be supplemented with registry data (NPR/SSB), yielding a final analytical sample of 5247 individuals.</p></sec><sec id="sec0004"><label>2.2</label><title>Materials</title><p id="para0017">We compared the predictive performance of ANU-ADRI, CAIDE, CogDrisk, and LIBRA, and LIBRA2. <xref rid="tbl0001" ref-type="table">Table 1</xref> provides the variables and weights included in these indices. ANU-ADRI was developed to estimate AD risk in public health settings for adults 65 and older [<xref rid="bib0010" ref-type="bibr">10</xref>]. It developed through literature reviews and meta-analyses identifying 11 risk factors, and 4 protective factors associated with AD. Risk ratios were converted into point-based scores, and summed to provide individual risk scores. This index includes pesticide exposure, which has been excluded in this study, due to limited data availability. CAIDE, focuses on midlife risk assessment and was developed in a Finnish cohort aged 39 to 64 years, followed for 20 years to assess dementia outcomes [<xref rid="bib0011" ref-type="bibr">11</xref>]. It incorporates vascular risk factors, age, sex, education, and APOE4 status. The score derived using logistic regression coefficients from baseline risk factors. CogDrisk assess dementia risk in adults aged 65 years and older, incorporating 17 risk factors identified through systematic reviews and meta-analyses [<xref rid="bib0014" ref-type="bibr">14</xref>]. Risk ratios for each factor were converted into points and summed to create an individual risk score. LIBRA, now validated in over 25 cohorts [<xref rid="bib0021" ref-type="bibr">21</xref>], was developed based on a systematic review and Delphi consensus, focusing on twelve modifiable dementia risk factors such as diet, physical activity, cardiovascular-, and psychosocial risks [<xref rid="bib0012" ref-type="bibr">12</xref>]. Relative risk estimates from meta-analyses were used to derive weights which are summed to yield a total score. LIBRA2, a recently modified version, incorporates three additional variables (sleep, social contact, and hearing impairment) [<xref rid="bib0013" ref-type="bibr">13</xref>]. Neither version includes non-modifiable factors (such as age, sex, and education), reflecting their focus on lifestyle-based risk reduction. However, to aide comparability to other indices, previous studies have commonly included these variables in the index [<xref rid="bib0037" ref-type="bibr">37</xref>]. In line with previous studies [<xref rid="bib0024" ref-type="bibr">24</xref>], the current study includes age, sex, and education into the LIBRA score using ANU-ADRI&#8217;s scoring. Additionally, this study also compared all indices without age, sex, and education. The LIBRA Index includes chronic kidney disease; however, this item was omitted in this study as this data was not accessible.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Descriptive table displaying all variables and their weights included in each index, as well profile of included and missing population.</p></caption><alt-text id="alt0002">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Variable</th><th valign="top" colspan="1" rowspan="1">Level</th><th valign="top" colspan="1" rowspan="1">N included</th><th valign="top" colspan="1" rowspan="1">N missing</th><th valign="top" colspan="1" rowspan="1">ANU-ADRI</th><th valign="top" colspan="1" rowspan="1">CAIDE</th><th valign="top" colspan="1" rowspan="1">CogDrisk</th><th valign="top" colspan="1" rowspan="1">LIBRA</th><th valign="top" colspan="1" rowspan="1">LIBRA2</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Sex</bold></td><td valign="top" colspan="1" rowspan="1">Women</td><td valign="top" colspan="1" rowspan="1">2768 (52.8 %)</td><td valign="top" colspan="1" rowspan="1">2525 (56.4 %) ***</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Men</td><td valign="top" colspan="1" rowspan="1">2479 (47.2 %)</td><td valign="top" colspan="1" rowspan="1">1954 (43.6 %) ***</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Age Baseline (HUNT3)</bold></td><td valign="top" colspan="1" rowspan="1">57.8&#8211;90.0; M:66.6 (SD: 5.8)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Age Follow-up (HUNT4 70+)</bold></td><td valign="top" colspan="1" rowspan="1">70.0&#8211;100.4; M:77.2 (SD: 5.8)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Dementia</bold></td><td valign="top" colspan="1" rowspan="1">No Dementia</td><td valign="top" colspan="1" rowspan="1">4681 (89.2 %)</td><td valign="top" colspan="1" rowspan="1">3538 (79.0 %)***</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">All Type Dementia</td><td valign="top" colspan="1" rowspan="1">566 (10.8 %)</td><td valign="top" colspan="1" rowspan="1">941 (21.0 %)***</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Age (Males)</bold></td><td valign="top" colspan="1" rowspan="1">&lt;47</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">47&#8211;53</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&gt;53</td><td valign="top" colspan="1" rowspan="1">2479 (100 %)</td><td valign="top" colspan="1" rowspan="1">1316 (100 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Age (Males)</bold></td><td valign="top" colspan="1" rowspan="1">&lt;65</td><td valign="top" colspan="1" rowspan="1">1251 (50.5 %)</td><td valign="top" colspan="1" rowspan="1">546 (41.5 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">(0)<xref rid="tb1fn1" ref-type="table-fn">a</xref></td><td valign="top" colspan="1" rowspan="1">(0) <xref rid="tb1fn1" ref-type="table-fn">a</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">65&#8211;69</td><td valign="top" colspan="1" rowspan="1">651 (26.3 %)</td><td valign="top" colspan="1" rowspan="1">342 (26.0 %)***</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">(0.4)</td><td valign="top" colspan="1" rowspan="1">(0.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">70&#8211;74</td><td valign="top" colspan="1" rowspan="1">366 (14.8 %)</td><td valign="top" colspan="1" rowspan="1">230 (17.5 %)***</td><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">8</td><td valign="top" colspan="1" rowspan="1">(5.2)</td><td valign="top" colspan="1" rowspan="1">(5.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">75&#8211;79</td><td valign="top" colspan="1" rowspan="1">143 (5.8 %)</td><td valign="top" colspan="1" rowspan="1">136 (10.3 %)***</td><td valign="top" colspan="1" rowspan="1">18</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">13</td><td valign="top" colspan="1" rowspan="1">(6.8)</td><td valign="top" colspan="1" rowspan="1">(6.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">80&#8211;84</td><td valign="top" colspan="1" rowspan="1">61 (2.5 %)</td><td valign="top" colspan="1" rowspan="1">53 (4.0 %)***</td><td valign="top" colspan="1" rowspan="1">26</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">17</td><td valign="top" colspan="1" rowspan="1">(11.2)</td><td valign="top" colspan="1" rowspan="1">(11.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">85&#8211;89</td><td valign="top" colspan="1" rowspan="1">7 (0.3 %)</td><td valign="top" colspan="1" rowspan="1">9 (0.7 %)***</td><td valign="top" colspan="1" rowspan="1">33</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">20</td><td valign="top" colspan="1" rowspan="1">(14.1)</td><td valign="top" colspan="1" rowspan="1">(14.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&gt;90</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">38</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">22</td><td valign="top" colspan="1" rowspan="1">(16.4)</td><td valign="top" colspan="1" rowspan="1">(16.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Age (Females)</bold></td><td valign="top" colspan="1" rowspan="1">&lt;47</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">47&#8211;53</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">0 (0.0 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&gt;53</td><td valign="top" colspan="1" rowspan="1">2768 (100 %)</td><td valign="top" colspan="1" rowspan="1">1831 (100 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Age (Females)</bold></td><td valign="top" colspan="1" rowspan="1">&lt;65</td><td valign="top" colspan="1" rowspan="1">1318 (47.6 %)</td><td valign="top" colspan="1" rowspan="1">689 (37.6 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">(0)</td><td valign="top" colspan="1" rowspan="1">(0)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">65&#8211;69</td><td valign="top" colspan="1" rowspan="1">699 (25.2 %)</td><td valign="top" colspan="1" rowspan="1">453 (24.8 %)***</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">(2.1)</td><td valign="top" colspan="1" rowspan="1">(2.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">70&#8211;74</td><td valign="top" colspan="1" rowspan="1">421 (15.2 %)</td><td valign="top" colspan="1" rowspan="1">307 (16.8 %)***</td><td valign="top" colspan="1" rowspan="1">14</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">7</td><td valign="top" colspan="1" rowspan="1">(6.2)</td><td valign="top" colspan="1" rowspan="1">(6.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">75&#8211;79</td><td valign="top" colspan="1" rowspan="1">239 (8.6 %)</td><td valign="top" colspan="1" rowspan="1">230 (12.6 %)***</td><td valign="top" colspan="1" rowspan="1">21</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">11</td><td valign="top" colspan="1" rowspan="1">(9.2)</td><td valign="top" colspan="1" rowspan="1">(9.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">80&#8211;84</td><td valign="top" colspan="1" rowspan="1">67 (2.4 %)</td><td valign="top" colspan="1" rowspan="1">127 (6.9 %)***</td><td valign="top" colspan="1" rowspan="1">29</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">15</td><td valign="top" colspan="1" rowspan="1">(12.4)</td><td valign="top" colspan="1" rowspan="1">(12.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">85&#8211;89</td><td valign="top" colspan="1" rowspan="1">23 (0.8 %)</td><td valign="top" colspan="1" rowspan="1">21 (1.2 %)***</td><td valign="top" colspan="1" rowspan="1">35</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">19</td><td valign="top" colspan="1" rowspan="1">(15.3)</td><td valign="top" colspan="1" rowspan="1">(15.3)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&gt;90</td><td valign="top" colspan="1" rowspan="1">1 (0.04 %)</td><td valign="top" colspan="1" rowspan="1">4 (0.2 %)***</td><td valign="top" colspan="1" rowspan="1">41</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">23</td><td valign="top" colspan="1" rowspan="1">(17.6)</td><td valign="top" colspan="1" rowspan="1">(17.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">&lt;8 years / Low</td><td valign="top" colspan="1" rowspan="1">3 (0.06 %)</td><td valign="top" colspan="1" rowspan="1">2 (0.04 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">(2.7)</td><td valign="top" colspan="1" rowspan="1">(2.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">8&#8211;11 years / Medium</td><td valign="top" colspan="1" rowspan="1">3376 (64.3 %)</td><td valign="top" colspan="1" rowspan="1">3172 (70.9 %)***</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">(1.4)</td><td valign="top" colspan="1" rowspan="1">(1.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&gt;11 years / High</td><td valign="top" colspan="1" rowspan="1">1868 (35.6 %)</td><td valign="top" colspan="1" rowspan="1">1305 (29.1 %)***</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">(0)</td><td valign="top" colspan="1" rowspan="1">(0)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Alcohol Use</bold></td><td valign="top" colspan="1" rowspan="1">None</td><td valign="top" colspan="1" rowspan="1">3924 (74.8 %)</td><td valign="top" colspan="1" rowspan="1">1710 (69.9 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Light&#8211;Moderate (1&#8211;14 units/wk)</td><td valign="top" colspan="1" rowspan="1">1295 (24.7 %)</td><td valign="top" colspan="1" rowspan="1">711 (29.1 %)***</td><td valign="top" colspan="1" rowspan="1">&#8722;3</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8722;1</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Excessive (&#8805;14 units/wk)</td><td valign="top" colspan="1" rowspan="1">28 (0.5 %)</td><td valign="top" colspan="1" rowspan="1">26 (1.1 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">3.1</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>APOE &#949;4 Carrier</bold></td><td valign="top" colspan="1" rowspan="1">Non-carrier</td><td valign="top" colspan="1" rowspan="1">3848 (73.3 %)</td><td valign="top" colspan="1" rowspan="1">3183 (72.7 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Carrier<xref rid="tb1fn2" ref-type="table-fn">b</xref></td><td valign="top" colspan="1" rowspan="1">1399 (26.7 %)</td><td valign="top" colspan="1" rowspan="1">1195 (27.3 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>BMI</bold></td><td valign="top" colspan="1" rowspan="1">Underweight (&lt;18.5)</td><td valign="top" colspan="1" rowspan="1">21 (0.4 %)</td><td valign="top" colspan="1" rowspan="1">9 (0.3 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Normal (18.5&#8211;24.99)</td><td valign="top" colspan="1" rowspan="1">1272 (24.2 %)</td><td valign="top" colspan="1" rowspan="1">780 (25.1 %)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Overweight (25&#8211;29.99)</td><td valign="top" colspan="1" rowspan="1">2662 (50.7 %)</td><td valign="top" colspan="1" rowspan="1">1545 (49.7 %)</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Obese (&#8805;30)</td><td valign="top" colspan="1" rowspan="1">1292 (24.6 %)</td><td valign="top" colspan="1" rowspan="1">777 (25.0 %)</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">1.6</td><td valign="top" colspan="1" rowspan="1">7</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Cognitive Activity</bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">1428 (27.2 %)</td><td valign="top" colspan="1" rowspan="1">941 (42.6 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">9.4</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Medium</td><td valign="top" colspan="1" rowspan="1">1874 (35.7 %)</td><td valign="top" colspan="1" rowspan="1">743 (33.7 %)***</td><td valign="top" colspan="1" rowspan="1">&#8722;6</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;4</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">High</td><td valign="top" colspan="1" rowspan="1">1945 (37.1 %)</td><td valign="top" colspan="1" rowspan="1">524 (23.7 %)***</td><td valign="top" colspan="1" rowspan="1">&#8722;7</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;5</td><td valign="top" colspan="1" rowspan="1">&#8722;3.2</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Coronary Heart Disease</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">4376 (83.4 %)</td><td valign="top" colspan="1" rowspan="1">3802 (84.9 %)*</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">871 (16.6 %)</td><td valign="top" colspan="1" rowspan="1">677 (15.1 %)*</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">8.3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Depression</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">4733 (90.2 %)</td><td valign="top" colspan="1" rowspan="1">4224 (94.3 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">514 (9.8 %)</td><td valign="top" colspan="1" rowspan="1">255 (5.7 %)***</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">2.1</td><td valign="top" colspan="1" rowspan="1">13</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Diabetes</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">4804 (91.6 %)</td><td valign="top" colspan="1" rowspan="1">4040 (90.2 %)*</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0 (M), 0 (F)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">443 (8.4 %)</td><td valign="top" colspan="1" rowspan="1">439 (9.8 %)*</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2 (M), 3 (F)</td><td valign="top" colspan="1" rowspan="1">1.3</td><td valign="top" colspan="1" rowspan="1">6.8</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Diet: Fish Intake</bold></td><td valign="top" colspan="1" rowspan="1">0&#8211;0.25 servings/week</td><td valign="top" colspan="1" rowspan="1">1205 (23.0 %)</td><td valign="top" colspan="1" rowspan="1">569 (19.6 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.26&#8211;2 servings/week</td><td valign="top" colspan="1" rowspan="1">3600 (68.6 %)</td><td valign="top" colspan="1" rowspan="1">1993 (68.7 %)***</td><td valign="top" colspan="1" rowspan="1">&#8722;3</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8722;0.25</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">2.1&#8211;4 servings/week</td><td valign="top" colspan="1" rowspan="1">321 (6.1 %)</td><td valign="top" colspan="1" rowspan="1">245 (8.5 %)***</td><td valign="top" colspan="1" rowspan="1">&#8722;4</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8722;0.25</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&gt;4.1 servings/week</td><td valign="top" colspan="1" rowspan="1">121 (2.3 %)</td><td valign="top" colspan="1" rowspan="1">93 (3.2 %)***</td><td valign="top" colspan="1" rowspan="1">&#8722;5</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8722;0.25</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Diet: Mediterranean</bold></td><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">3031 (57.8 %)</td><td valign="top" colspan="1" rowspan="1">1621 (55.9 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8722;1.7</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">2216 (42.2 %)</td><td valign="top" colspan="1" rowspan="1">1278 (44.1 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">3.8</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Hearing Impairment</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">2882 (54.9 %)</td><td valign="top" colspan="1" rowspan="1">2795 (62.4 %)***</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">2365 (45.1 %)</td><td valign="top" colspan="1" rowspan="1">1684 (37.6 %)***</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">7.6</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Hypercholesterolemia</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">3928 (74.9 %)</td><td valign="top" colspan="1" rowspan="1">2213 (74.8 %)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">1319 (25.1 %)</td><td valign="top" colspan="1" rowspan="1">746 (25.2 %)</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">1.4</td><td valign="top" colspan="1" rowspan="1">8.2</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Hypertension</bold></td><td valign="top" colspan="1" rowspan="1">No (Systolic &lt;140 mm Hg)</td><td valign="top" colspan="1" rowspan="1">2788 (53.1 %)</td><td valign="top" colspan="1" rowspan="1">1624 (36.3 %)***</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes (Systolic &#8805;140 mm Hg)</td><td valign="top" colspan="1" rowspan="1">2459 (46.9 %)</td><td valign="top" colspan="1" rowspan="1">2855 (63.7 %)***</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">1.6</td><td valign="top" colspan="1" rowspan="1">3.5</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Physical Activity</bold></td><td valign="top" colspan="1" rowspan="1">Low</td><td valign="top" colspan="1" rowspan="1">943 (18.0 %)</td><td valign="top" colspan="1" rowspan="1">464 (24.8 %)***</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1.1</td><td valign="top" colspan="1" rowspan="1">6</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Medium</td><td valign="top" colspan="1" rowspan="1">42 (0.8 %)</td><td valign="top" colspan="1" rowspan="1">23 (1.2 %)***</td><td valign="top" colspan="1" rowspan="1">&#8722;2</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8722;3</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">High</td><td valign="top" colspan="1" rowspan="1">4262 (81.2 %)</td><td valign="top" colspan="1" rowspan="1">1388 (74.0 %)***</td><td valign="top" colspan="1" rowspan="1">&#8722;3</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8722;3</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Traumatic Brain Injury</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">4906 (93.5 %)</td><td valign="top" colspan="1" rowspan="1">4201 (93.8 %)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">341 (6.5 %)</td><td valign="top" colspan="1" rowspan="1">278 (6.2 %)</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Sleep Problems</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">3590 (68.4 %)</td><td valign="top" colspan="1" rowspan="1">1472 (67.4 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">1657 (31.6 %)</td><td valign="top" colspan="1" rowspan="1">713 (32.6 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">3.3</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Smoking</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">2216 (42.2 %)</td><td valign="top" colspan="1" rowspan="1">1197 (41.7 %)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Former Smoker</td><td valign="top" colspan="1" rowspan="1">2224 (42.4 %)</td><td valign="top" colspan="1" rowspan="1">1179 (41.1 %)</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">807 (15.4 %)</td><td valign="top" colspan="1" rowspan="1">492 (17.2 %)</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">1.5</td><td valign="top" colspan="1" rowspan="1">7.9</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Social Activity</bold></td><td valign="top" colspan="1" rowspan="1">Lowest</td><td valign="top" colspan="1" rowspan="1">1245 (23.7 %)</td><td valign="top" colspan="1" rowspan="1">604 (25.0 %)</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Low to Medium</td><td valign="top" colspan="1" rowspan="1">1344 (25.6 %)</td><td valign="top" colspan="1" rowspan="1">576 (23.9 %)</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Medium to High</td><td valign="top" colspan="1" rowspan="1">1344 (25.6 %)</td><td valign="top" colspan="1" rowspan="1">630 (26.1 %)</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Highest</td><td valign="top" colspan="1" rowspan="1">1314 (25.0 %)</td><td valign="top" colspan="1" rowspan="1">602 (25.0 %)</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">6.5</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Social: Loneliness</bold></td><td valign="top" colspan="1" rowspan="1">Not Lonely</td><td valign="top" colspan="1" rowspan="1">4302 (82.0 %)</td><td valign="top" colspan="1" rowspan="1">2002 (79.4 %)**</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Lonely</td><td valign="top" colspan="1" rowspan="1">945 (18.0 %)</td><td valign="top" colspan="1" rowspan="1">521 (80.7 %)**</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Stroke History</bold></td><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">5044 (96.1 %)</td><td valign="top" colspan="1" rowspan="1">3011 (95.8 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">203 (3.9 %)</td><td valign="top" colspan="1" rowspan="1">132 (4.2 %)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Pesticide Exposure</bold><xref rid="tbl0001n13" ref-type="table-fn">c</xref></td><td valign="top" colspan="1" rowspan="1">Never</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Ever</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Chronic Kidney Disease</bold><xref rid="tbl0001n13" ref-type="table-fn">c</xref></td><td valign="top" colspan="1" rowspan="1">Yes</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">1.1</td><td valign="top" colspan="1" rowspan="1">5.7</td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">No</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">0</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Total Score (min - max; M; (SD))</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&#8722;14&#8211;53; M: 5.9 (SD: 10.0)</td><td valign="top" colspan="1" rowspan="1">5.0&#8211;16.0; M:9.2 (SD: 2.0)</td><td valign="top" colspan="1" rowspan="1">&#8722;8.25&#8211;31.75; M:3.5 (SD: 7.0)</td><td valign="top" colspan="1" rowspan="1">&#8722;5.9&#8211;23.1; M:3.0 (SD: 5.0)</td><td valign="top" colspan="1" rowspan="1">0 &#8211; 82.5; M:29.1 (SD: 13.7)</td><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Notes: Chi&#178; tests assessed differences in variable distributions between included and excluded participants. Missing refers to participants eligible for dementia classification but excluded from main analysis due to missing HUNT3 data or incomplete risk factor information. Significance levels: *** <italic toggle="yes">p</italic> &lt; 0.001, ** <italic toggle="yes">p</italic> &lt; 0.005, * <italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn1"><label>a</label><p id="notep0002">LIBRA and LIBRA2 were originally developed without assigning points for age, and education, therefore these variables are in parentheses. To aid comparability many studies, including this one have assigned age and education weights.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn2"><label>b</label><p id="notep0003">APOE4 Carrier: heterozygotes=1261, homozygotes=138.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl0001n13"><label>c</label><p id="ntparaJDMijal4AX">Pesticide exposure and chronic kidney disease are omitted from all analyses as this data was not available.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0005"><label>2.3</label><title>Data preparation and index generation</title><p id="para0018">All variables were derived from participant responses and measurements collected during HUNT3 (2006&#8211;2008), and supplemented by HUNT1 (1984&#8211;1986), HUNT2 (1995&#8211;1997), SSB (2007) and NPR (2007&#8211;2009) to address missing data. All data were harmonized and recoded to align with the definitions and requirements of each risk index. This harmonization ensured variables across indices were consistently defined, categorized, and scored according to their respective scoring systems (see <xref rid="tbl0001" ref-type="table">Table 1</xref>), enabling meaningful comparisons.</p><sec id="sec0006"><label>2.3.1</label><title>Dementia status</title><p id="para0019">Dementia diagnoses in HUNT4 70+ were established by a Diagnostic Consensus Committee of nine medical doctors with expertise in geriatrics, neurology, and old-age psychiatry, combining clinical and research experience [<xref rid="bib0038" ref-type="bibr">38</xref>]. Diagnoses followed Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, classifying participants into one of the following categories: (1) no cognitive impairment, (2) amnestic- and (3) nonamnestic mild cognitive impairment, and (4) dementia. Participants with dementia were further categorized as having AD or other dementia types (see [<xref rid="bib0035" ref-type="bibr">35</xref>]). In this study, dementia was coded as &#8220;No Dementia&#8221; (no or mild cognitive impairment) and &#8220;Dementia&#8221; (any dementia diagnosis). We also ran supplementary analyses including AD status only, defined as &#8220;no dementia&#8221; vs. &#8220;AD,&#8221; with other dementias coded as missing.</p></sec><sec id="sec0007"><label>2.3.2</label><title>Education</title><p id="para0020">Education was obtained from Statistics Norway (SSB, 2007) and categorized into three levels primary, secondary, tertiary (&lt;8 years, 8&#8211;12 years, and &gt;12 years of formal education) [<xref rid="bib0010" ref-type="bibr">10</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>,<xref rid="bib0024" ref-type="bibr">24</xref>].</p></sec><sec id="sec0008"><label>2.3.3</label><title>Alcohol consumption</title><p id="para0021">Alcohol intake was based on HUNT3 self-reported weekly units and categorized as: none (0 units/week), low/moderate (1&#8211;14), and high (&#8805;14) [<xref rid="bib0010" ref-type="bibr">10</xref>,<xref rid="bib0030" ref-type="bibr">30</xref>].</p></sec><sec id="sec0009"><label>2.3.4</label><title>APOE4 status</title><p id="para0022">DNA from HUNT participants was analyzed using Illumina HumanCoreExome arrays. APOE genotyping used rs429358 and rs7412 single nucleotide polymorphisms to determine &#949;4 allele presence <xref rid="bib52" ref-type="bibr">[39]</xref>. Following CAIDE protocol, participants were classified as having &#8220;no &#949;4 allele&#8221; or &#8220;at least one &#949;4 allele.&#8221;</p></sec><sec id="sec0010"><label>2.3.5</label><title>Body mass index (BMI)</title><p id="para0023">BMI was calculated using the standard formula (kg/m&#178;), based on participants&#8217; weight (in kilograms, rounded to one decimal) and height (in meters, rounded to two decimals). Measurements were taken on the HUNT3 participation day, with participants wearing light clothing and no shoes. BMI was categorized as underweight (&lt;18.5), normal weight (18.5&#8211;24.99), overweight (25&#8211;29.99), and obese (&#8805;30) [<xref rid="bib0039" ref-type="bibr">40</xref>].</p></sec><sec id="sec0011"><label>2.3.6</label><title>Cognitive activity</title><p id="para0024">Cognitive activity was assessed using a composite score from self-reported work and leisure activities selected for closely resembling questions included in ANU-ADRI and CogDrisk [<xref rid="bib0010" ref-type="bibr">10</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>]. These included hours using a computer at work, computer use for leisure, and frequency of attending museums, concerts, or participating in music and theatre. The combined score was grouped into tertiles: low, medium, and high cognitive activity.</p></sec><sec id="sec0012"><label>2.3.7</label><title>Cholesterol</title><p id="para0025">Serum total cholesterol levels were obtained from non-fasting blood samples taken at HUNT3 and categorized as normal (&lt;6.5 mmol/L) or high (&#8805;6.5 mmol/L) [<xref rid="bib0011" ref-type="bibr">11</xref>].</p></sec><sec id="sec0013"><label>2.3.8</label><title>Depression</title><p id="para0026">Depression was measured using the Hospital Anxiety and Depression Scale [<xref rid="bib0040" ref-type="bibr">41</xref>], with scores &#8805;8 classified as depression [<xref rid="bib0040" ref-type="bibr">41</xref>]. Where HUNT3 data were missing, NPR data (ICD10 F32&#8211;33) was used for participants who had been diagnosed with depression by their health care provider between 2007 and 2009.</p></sec><sec id="sec0014"><label>2.3.9</label><title>Diabetes</title><p id="para0027">Diabetes status was determined using self-reported diagnoses or non-fasting glucose levels (&#8805;9 mmol/L) from HUNT3. HUNT3 data were validated and, if missing, supplemented using earlier HUNT surveys and NPR (ICD10 E10&#8211;E14). A self-reported diabetes diagnosis or elevated non-fasting glucose levels (&#8805;9 mmol/L) [<xref rid="bib0041" ref-type="bibr">42</xref>] were considered a risk factor.</p></sec><sec id="sec0015"><label>2.3.10</label><title>Fish consumption and healthy diet</title><p id="para0028">Fish consumption was self-reported in HUNT3 and categorized into four groups: 0&#8211;3 times/month, 1&#8211;3 times/week, 4&#8211;6 times/week, and &#8805;1 time/day. A healthy diet score was based on the frequency of fruit, vegetable, and fish consumption. Points from 1 to 4 (1=&#8220;0&#8211;3 times/month&#8221;, 4=&#8220;every day or more&#8221;) were assigned to each food group, summed, and classified as healthy (&#8805;10 points) or unhealthy (&lt;10) [<xref rid="bib0010" ref-type="bibr">10</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>].</p></sec><sec id="sec0016"><label>2.3.11</label><title>Hearing loss</title><p id="para0029">Hearing loss was determined using self-reported data from HUNT1, 2, and 3. Participants were asked if they had hearing loss/impaired hearing they were aware of (yes/no) [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>]. Hearing loss in HUNT1 or HUNT2 was carried forward to HUNT3.</p></sec><sec id="sec0017"><label>2.3.12</label><title>Heart disease</title><p id="para0030">The LIBRA index includes coronary heart disease [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>], while CogDrisk [<xref rid="bib0014" ref-type="bibr">14</xref>] includes arterial fibrillation. A proxy variable for heart disease was created, incorporating diagnoses of angina pectoris, heart failure, myocardial infarction, and other specified heart diseases, to capture participants with potential cardiovascular issues. Participants reporting any of these conditions were categorized as having heart disease. NPR data (ICD10 I11, I20&#8211;I25, I50&#8211;I51) supplemented missing HUNT3 data.</p></sec><sec id="sec0018"><label>2.3.13</label><title>Hypertension</title><p id="para0031">Blood pressure was measured in a seated position following standardized protocols at HUNT3. After two minutes of rest, three automatic oscillometric readings were taken at one-minute intervals, with the mean of the second and third used in analyses. Systolic and diastolic pressures were recorded to the nearest 2 mm Hg. In line with all indices, hypertension was defined as a mean systolic blood pressure &#8805;140 mm Hg [<xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>]. If HUNT3 data were missing, NPR diagnoses (ICD10 I10, I15) were used to classify participants as hypertensive.</p></sec><sec id="sec0019"><label>2.3.14</label><title>Physical activity</title><p id="para0032">Physical activity was measured as total weekly minutes of moderate-to-vigorous physical activity (MVPA) based on self-reported levels in HUNT3. Participants engaging in &#8805;150 min per week were categorized as &#8220;highly active,&#8221; 30&#8211;149 min as &#8220;medium active,&#8221; and &#8804;29 min as &#8220;inactive&#8221; in the ANU-ADRI [<xref rid="bib0010" ref-type="bibr">10</xref>], CogDrisk [<xref rid="bib0014" ref-type="bibr">14</xref>], and LIBRA [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>] indices. Instead of three levels, the CAIDE Index used a dichotomous variable (active/inactive). In line with CAIDE&#8217;s scoring criteria [<xref rid="bib0011" ref-type="bibr">11</xref>], &#8220;active&#8221; was defined as at least 30 min, at least twice per week.</p></sec><sec id="sec0020"><label>2.3.15</label><title>Smoking status</title><p id="para0033">Self-reported smoking status at HUNT3 was categorized into three groups: current smoker, ex-smoker, and non-smoker. Current smoking was consistently classified as a risk factor across all indices [<xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>, <xref rid="bib0014" ref-type="bibr">[14]</xref>]. While ANU-ADRI assigned risk points to ex-smokers [<xref rid="bib0010" ref-type="bibr">10</xref>], the other indices grouped them with non-smokers into a single category.</p></sec><sec id="sec0021"><label>2.3.16</label><title>Social activity</title><p id="para0034">In line with cognitive activity, social activity was assessed using a composite score derived from multiple self-reported social life measures, selected to imitate the ANU-ADRI [<xref rid="bib0010" ref-type="bibr">10</xref>] survey as closely as HUNT3 data allowed. ANU-ADRI considers five factors: (1) marital status, (2) social network size, (3) social network quality, (4) level of social activities, and (5) living arrangements. Marital status and living arrangements were based on whether participants lived with a spouse or domestic partner (yes/no). Social network quality was evaluated using responses to: "Has friends who provide help" and "Has friends to talk to confidentially" (yes/no). Participants also rated agreement with: "I feel a strong sense of community with the people who live here," "We trust each other here," and "People like living here," on a 1 (strongly disagree) to 5 (strongly agree) scale. Level of social activity was measured by frequency of participation in social activities such as associations or church services, rated from 1 (never) to 5 (very frequent). A composite score was created by standardizing and aggregating these measures, then dividing participants into quartiles: low, low-medium, high-medium, and high. The lowest quartile was also categorized as "low social activity" in the LIBRA index. CogDrisk measures social activity as &#8220;lonely&#8221;, &#8220;not lonely&#8221; [<xref rid="bib0014" ref-type="bibr">14</xref>] which is a survey question in HUNT and could be used directly by coding participants who reported some to strong loneliness as &#8220;lonely&#8221; and others as &#8220;not lonely&#8221;.</p></sec><sec id="sec0022"><label>2.3.17</label><title>Sleep disturbance</title><p id="para0035">HUNT3 sleep disturbance was defined as experiencing difficulties falling asleep, staying asleep, or waking early &#8220;several times a week.&#8221; Participants reporting frequent disturbances of at least one category were categorized as having sleep disturbance [<xref rid="bib0013" ref-type="bibr">13</xref>].</p></sec><sec id="sec0023"><label>2.3.18</label><title>Stroke</title><p id="para0036">Stroke history was determined using self-reported data (yes/no) [<xref rid="bib0014" ref-type="bibr">14</xref>] from HUNT3, supplemented with data from NPR (ICD10 I60&#8211;I69) and earlier HUNT surveys if stroke data for HUNT3 was missing.</p></sec><sec id="sec0024"><label>2.3.19</label><title>Traumatic brain injury (TBI)</title><p id="para0037">TBI was assessed using self-reported data from HUNT2, asking whether participants had ever been hospitalized for a head injury [<xref rid="bib0010" ref-type="bibr">10</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>]. Additionally, data from NPR (ICD10 S06&#8211;S07, S09) was used to account for participants treated for head injuries in the years 2007&#8211;2009.</p></sec></sec><sec id="sec0025"><label>2.4</label><title>Statistical analysis</title><p id="para0038">Stata 18 (StataCorp) was used for all analyses. Descriptive statistics summarized baseline characteristics and examined missing data for the dementia risk indices. Differences between participants with complete and incomplete data were assessed using chi-squared tests, with statistical significance set at <italic toggle="yes">p</italic> &lt; 0.05 .</p><p id="para0039">Logistic regression models were employed to evaluate the association between each risk index and dementia status (dementia vs. no dementia), and AD status (AD vs. no dementia). All indices were analyzed in two forms: (i) including age, sex, and education weights, and (ii) excluding them. This was done to compare both the complete indices like they are commonly used, and to compare just the lifestyle risk factors aspects of each index. Additionally, this aided in comparison with the LIBRA indices, which were originally developed without demographic variables. Though similar in distributional shape, the original indices varied substantially in scale and dispersion (<xref rid="tbl0001" ref-type="table">Table 1</xref>). To account for these differences and facilitate comparison across indices with varying scoring systems, all risk indices were standardized to z-scores (Mean=0, SD=1) prior to analysis. Additional logistic regression models were run to predict dementia using (i) age, sex, and education, and (ii) age and education. Sex did not significantly contribute to the model (<italic toggle="yes">p</italic> = 0.827) and was therefore excluded from further analyses. The final demographics only model (age and education) was used as the reference model for evaluating the predictive performance of the risk indices using the receiver operating characteristic curve (AUC). To enable meaningful comparison of predictive performance and statistical AUC testing, all primary analyses were conducted on the same sample of participants with complete data across all indices. To minimize the inflation of Type I error from multiple comparisons, we first conducted a global DeLong test [<xref rid="bib0042" ref-type="bibr">43</xref>] comparing the AUCs of all indices. Only if the global comparison reached statistical significance (<italic toggle="yes">p</italic> &#8804; 0.05) did we proceed with pairwise ROC comparisons between indices. AUC values were interpreted using standard thresholds: 0.5&#8211;0.6=&#8220;fail&#8221;, 0.6&#8211;0.7=&#8220;poor&#8221;, 0.7&#8211;0.8=&#8220;moderate&#8221;, and 0.8&#8211;0.9=&#8220;good&#8221; [<xref rid="bib0043" ref-type="bibr">44</xref>]. Finally, we conducted stratified analyses by sex (male/female), baseline age group (&#8804;65 vs. &gt;65), and APOE4 status (non-carrier vs. at least one &#949;4 allele).</p><sec id="sec0026"><label>2.4.1</label><title>Sensitivity analysis</title><p id="para0040">To address missing data and evaluate the robustness of our findings, sensitivity analyses were conducted using joint multivariate normal imputation [<xref rid="bib0044" ref-type="bibr">45</xref>]. A total of 100 imputed datasets were generated using age, sex, education, and dementia status as predictors. Logistic regression models were run within each imputed dataset, and pooled estimates were derived using Rubin&#8217;s rules. The imputed results were compared with the complete case analysis, focusing on coefficients, significance levels, Relative Variance Increase (RVI) and Fraction of Missing Information (FMI). Additionally, to assess whether restricting the main analyses to complete cases influenced findings, we reran each index-specific model using all participants with available data for that specific index, regardless of missingness in other indices.</p></sec></sec></sec><sec id="sec0027"><label>3</label><title>Results</title><sec id="sec0028"><label>3.1</label><title>Summary statistics</title><p id="para0041">The study included 5247 participants (52.8 % women), with a mean age of 66.6 years (SD=5.8, range: 57.8&#8211;90.0) at baseline (HUNT3), and 77.2 years (SD=5.8, range: 70.0&#8211;100.4) at follow-up (HUNT4). Dementia was present in 10.8 % of participants, with AD (6.3 %) being the most prevalent subtype (<xref rid="tbl0001" ref-type="table">Table 1</xref>).</p><p id="para0042">Participants with missing data were significantly older, more often female, and had lower educational attainment. Dementia, diabetes, hypertension, physical inactivity, and smoking were significantly more prevalent in this group, while depression was significantly less common. No significant differences were found for coronary heart disease, BMI, or sleep problems (<xref rid="tbl0001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec0029"><label>3.2</label><title>Dementia risk indices</title><p id="para0043">All dementia risk indices were associated with dementia status (<xref rid="tbl0002" ref-type="table">Table 2</xref>). CogDrisk showed the strongest association (OR=2.57, 95 %CI: 2.35&#8211;2.81) and the highest discriminatory ability (AUC=0.761), followed by LIBRA (OR=2.51, 95 %CI: 2.30&#8211;2.74; AUC=0.746; <xref rid="tbl0003" ref-type="table">Table 3</xref>) and ANU-ADRI (OR=2.39, 95 %CI: 2.20&#8211;2.60; AUC=0.738). LIBRA2 demonstrated moderate performance (OR=1.93, 95 %CI: 1.77&#8211;2.11; AUC=0.686), while CAIDE had the weakest predictive ability (OR=1.35, 95 %CI: 1.24&#8211;1.47; AUC=0.587). However, none of the indices outperformed a demographics-only model (age, education; AUC=0.762; DeLong&#8217;s <italic toggle="yes">p</italic> &gt; 0.05). Moreover, ANU-ADRI (<italic toggle="yes">p</italic> = 0.015), CAIDE (<italic toggle="yes">p</italic> &lt; 0.001), and LIBRA2 (<italic toggle="yes">p</italic> &lt; 0.001) performed significantly worse (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>).<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Table showing all logistic regression models, for ANU-ADRI, CAIDE, CogDrisk, LIBRA, LIBRA2, and a demographics only model.</p></caption><alt-text id="alt0003">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="1" rowspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">ANU-ADRI<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">CAIDE<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">CogDrisk<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">LIBRA<hr/></th><th colspan="2" align="left" valign="top" rowspan="1">LIBRA 2<hr/></th><th colspan="3" align="left" valign="top" rowspan="1">Demographics<hr/></th></tr><tr><th align="left" valign="top" colspan="1" rowspan="1">Model</th><th align="left" valign="top" colspan="1" rowspan="1">Odds Ratio (95 %CI)</th><th align="left" valign="top" colspan="1" rowspan="1">Pseudo r-squared</th><th align="left" valign="top" colspan="1" rowspan="1">Odds Ratio (95 %CI)</th><th align="left" valign="top" colspan="1" rowspan="1">Pseudo r-squared</th><th align="left" valign="top" colspan="1" rowspan="1">Odds Ratio (95 %CI)</th><th align="left" valign="top" colspan="1" rowspan="1">Pseudo r-squared</th><th align="left" valign="top" colspan="1" rowspan="1">Odds Ratio (95 %CI)</th><th align="left" valign="top" colspan="1" rowspan="1">Pseudo r-squared</th><th align="left" valign="top" colspan="1" rowspan="1">Odds Ratio (95 %CI)</th><th align="left" valign="top" colspan="1" rowspan="1">Pseudo r-squared</th><th valign="top" colspan="1" rowspan="1">Variable</th><th valign="top" colspan="1" rowspan="1">Odds Ratio</th><th valign="top" colspan="1" rowspan="1">Pseudo r-squared</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>Dementia</bold></td><td rowspan="2" align="left" valign="top" colspan="1">2.39 (2.20, 2.60)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.13***</td><td rowspan="2" align="left" valign="top" colspan="1">1.35 (1.24, 1.47)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.01***</td><td rowspan="2" align="left" valign="top" colspan="1">2.57 (2.35, 2.81)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.14***</td><td rowspan="2" align="left" valign="top" colspan="1">2.51 (2.30, 2.74)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.13***</td><td rowspan="2" align="left" valign="top" colspan="1">1.93 (1.77, 2.11)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.06***</td><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">1.16 (1.14, 1.18)***</td><td valign="top" colspan="1" rowspan="1">0.14***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">0.62 (0.50, 0.78)***</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>Dementia No Demographics</bold></td><td rowspan="2" align="left" valign="top" colspan="1">1.32 (1.21, 1.44)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.01***</td><td rowspan="2" align="left" valign="top" colspan="1">1.17 (1.08, 1.28)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.00***</td><td rowspan="2" align="left" valign="top" colspan="1">1.72 (1.58, 1.87)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.05***</td><td rowspan="2" align="left" valign="top" colspan="1">1.59 (1.45, 1.74)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.03***</td><td rowspan="2" align="left" valign="top" colspan="1">1.54 (1.41, 1.68)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.03***</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>AD</bold></td><td rowspan="2" align="left" valign="top" colspan="1">2.45 (2.21, 2.72)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.12***</td><td rowspan="2" align="left" valign="top" colspan="1">1.33 (1.19, 1.48)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.01***</td><td rowspan="2" align="left" valign="top" colspan="1">2.55 (2.29, 2.85)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.12***</td><td rowspan="2" align="left" valign="top" colspan="1">2.56 (2.29, 2.86)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.12***</td><td rowspan="2" align="left" valign="top" colspan="1">1.90 (1.70, 2.12)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.05***</td><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">1.17 (1.15, 1.19)***</td><td valign="top" colspan="1" rowspan="1">0.14***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">0.58 (0.44, 0.78)***</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>AD No Demographics</bold></td><td rowspan="2" align="left" valign="top" colspan="1">1.24 (1.11, 1.39)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.00***</td><td rowspan="2" align="left" valign="top" colspan="1">1.14 (1.02, 1.27)*</td><td rowspan="2" align="left" valign="top" colspan="1">0.00*</td><td rowspan="2" align="left" valign="top" colspan="1">1.61 (1.45, 1.79)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.03***</td><td rowspan="2" align="left" valign="top" colspan="1">1.50 (1.34, 1.68)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.02***</td><td rowspan="2" align="left" valign="top" colspan="1">1.48 (1.33, 1.65)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.02***</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>Female</bold></td><td rowspan="2" align="left" valign="top" colspan="1">2.62 (2.34, 2.93)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.16***</td><td rowspan="2" align="left" valign="top" colspan="1">1.49 (1.32, 1.68)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.02***</td><td rowspan="2" align="left" valign="top" colspan="1">2.74 (2.43, 3.09)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.16***</td><td rowspan="2" align="left" valign="top" colspan="1">2.75 (2.44, 3.09)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.17***</td><td rowspan="2" align="left" valign="top" colspan="1">2.17 (1.93, 2.45)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.09***</td><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">1.19 (1.16, 1.21)***</td><td valign="top" colspan="1" rowspan="1">0.17***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">0.79 (0.57, 1.08)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>Male</bold></td><td rowspan="2" align="left" valign="top" colspan="1">2.17 (1.9, 2.48)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.08***</td><td rowspan="2" align="left" valign="top" colspan="1">1.25 (1.10, 1.43)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.01***</td><td rowspan="2" align="left" valign="top" colspan="1">2.36 (2.07, 2.69)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.11***</td><td rowspan="2" align="left" valign="top" colspan="1">2.28 (1.98, 2.63)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.08***</td><td rowspan="2" align="left" valign="top" colspan="1">1.66 (1.46, 1.89)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.04***</td><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">1.13 (1.11, 1.16)***</td><td valign="top" colspan="1" rowspan="1">0.10***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">0.50 (0.369, 0.687)***</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>&#8804; 64 Years</bold></td><td rowspan="2" align="left" valign="top" colspan="1">1.74 (1.24, 2.46)**</td><td rowspan="2" align="left" valign="top" colspan="1">0.01**</td><td rowspan="2" align="left" valign="top" colspan="1">1.30 (1.07, 1.57)*</td><td rowspan="2" align="left" valign="top" colspan="1">0.01*</td><td rowspan="2" align="left" valign="top" colspan="1">2.24 (1.63, 3.07)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.03***</td><td rowspan="2" align="left" valign="top" colspan="1">2.01 (1.46, 2.77)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.02***</td><td rowspan="2" align="left" valign="top" colspan="1">1.61 (1.32, 1.96)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.03***</td><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">1.08 (0.96, 1.22)</td><td valign="top" colspan="1" rowspan="1">0.01**</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">0.51 (0.33, 0.79)**</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>&#8805; 65 Years</bold></td><td rowspan="2" align="left" valign="top" colspan="1">2.05 (1.86, 2.27)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.09***</td><td rowspan="2" align="left" valign="top" colspan="1">1.32 (1.19, 1.47)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.01***</td><td rowspan="2" align="left" valign="top" colspan="1">2.31 (2.05, 2.59)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.09***</td><td rowspan="2" align="left" valign="top" colspan="1">2.14 (1.93, 2.39)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.09***</td><td rowspan="2" align="left" valign="top" colspan="1">1.74 (1.57, 1.92)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.05***</td><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">1.16 (1.13, 1.18)***</td><td valign="top" colspan="1" rowspan="1">0.09***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">0.67 (0.52, 0.87)**</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>APOE4 Negative</bold></td><td rowspan="2" align="left" valign="top" colspan="1">2.32 (2.10, 2.56)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.12***</td><td rowspan="2" align="left" valign="top" colspan="1">1.31 (1.16, 1.48)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.01***</td><td rowspan="2" align="left" valign="top" colspan="1">2.54 (2.28, 2.83)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.14***</td><td rowspan="2" align="left" valign="top" colspan="1">2.46 (2.21, 2.74)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.13***</td><td rowspan="2" align="left" valign="top" colspan="1">2.01 (1.81, 2.24)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.07***</td><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">1.15 (1.13, 1.18)***</td><td valign="top" colspan="1" rowspan="1">0.14***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">0.61 (0.46, 0.80)***</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1"><bold>APOE4 Positive</bold></td><td rowspan="2" align="left" valign="top" colspan="1">2.84 (2.49, 3.37)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.15***</td><td rowspan="2" align="left" valign="top" colspan="1">1.28 (1.08, 1.51)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.01***</td><td rowspan="2" align="left" valign="top" colspan="1">2.95 (2.48, 3.52)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.16***</td><td rowspan="2" align="left" valign="top" colspan="1">2.96 (2.47, 3.53)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.15***</td><td rowspan="2" align="left" valign="top" colspan="1">1.81 (1.54, 2.12)***</td><td rowspan="2" align="left" valign="top" colspan="1">0.05***</td><td valign="top" colspan="1" rowspan="1"><bold>Age</bold></td><td valign="top" colspan="1" rowspan="1">1.19 (1.15, 1.22)***</td><td valign="top" colspan="1" rowspan="1">0.17***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Education</bold></td><td valign="top" colspan="1" rowspan="1">0.58 (0.40, 0.85)**</td><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Notes: Logistic Regression models of all dementia risk indices and a simple demographics model across all-case dementia and Alzheimer&#8217;s Disease (AD). Stratified analyses have only been performed for all-case dementia. Model significance are indicated as *** <italic toggle="yes">p</italic> &lt; 0.001, ** <italic toggle="yes">p</italic> &lt; 0.005, * <italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot></table-wrap><fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>ROC curves for all indices under different conditions.</p><p>Notes: ROC curves for models including age and education weighting (see <xref rid="tbl0003" ref-type="table">Table 3</xref> for full model info) Legends display AUC values for each curve.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0030"><label>3.3</label><title>Dementia risk indices without demographics</title><p id="para0044">Excluding demographic variables resulted in a reduction in predictive power across all indices (<xref rid="tbl0002" ref-type="table">Table 2</xref>). CogDrisk remained the strongest predictor (AUC=0.654), followed by LIBRA (AUC=0.631) and LIBRA2 (AUC=0.628;<xref rid="tbl0003" ref-type="table">Table 3</xref>). CAIDE had the weakest association (OR=1.17, 95 %CI: 1.08&#8211;1.28; AUC=0.547). All indices performed significantly worse than the demographics-only model (all <italic toggle="yes">p</italic> &lt; 0.001, <xref rid="fig0001" ref-type="fig">Fig. 1</xref>; <xref rid="tbl0003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec0031"><label>3.4</label><title>Alzheimer&#8217;s disease and risk indices</title><p id="para0045">All risk indices were associated with AD status (<xref rid="tbl0002" ref-type="table">Table 2</xref>). CogDrisk (OR=2.55, 95 %CI: 2.29&#8211;2.85; AUC=0.759), and LIBRA (OR=2.56, 95 %CI: 2.29&#8211;2.86; AUC=0.751) demonstrated the highest predictive performance. LIBRA2 exhibited moderate performance (OR=1.90, 95 %CI: 1.70&#8211;2.12; AUC=0.683), while CAIDE had the lowest predictive ability (OR=1.33, 95 %CI: 1.19&#8211;1.48; AUC=0.581). The demographics-only model achieved an AUC of 0.774. ANU-ADRI (<italic toggle="yes">p</italic> = 0.026), CAIDE (<italic toggle="yes">p</italic> &lt; 0.001), and LIBRA2 (<italic toggle="yes">p</italic> &lt; 0.001) performed significantly worse than the demographics-only model (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>). Excluding demographic variables resulted in a reduction in predictive power across all indices, with results closely mirroring those observed for dementia prediction (<xref rid="tbl0003" ref-type="table">Table 3</xref>).<table-wrap position="float" id="tbl0003" orientation="portrait"><label>Table 3</label><caption><p>Table showing AUC values for each logistic regression model predicting all-case dementia and AD.</p></caption><alt-text id="alt0004">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Index</th><th valign="top" colspan="1" rowspan="1">N</th><th valign="top" colspan="1" rowspan="1">Demographics</th><th valign="top" colspan="1" rowspan="1">ANU_ADRI</th><th valign="top" colspan="1" rowspan="1">CAIDE</th><th valign="top" colspan="1" rowspan="1">CogDrisk</th><th valign="top" colspan="1" rowspan="1">LIBRA</th><th valign="top" colspan="1" rowspan="1">LIBRA2</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>Model</bold></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">AUC (95 % CI)</td><td valign="top" colspan="1" rowspan="1">AUC (95 % CI)</td><td valign="top" colspan="1" rowspan="1">AUC (95 % CI)</td><td valign="top" colspan="1" rowspan="1">AUC (95 % CI)</td><td valign="top" colspan="1" rowspan="1">AUC (95 % CI)</td><td valign="top" colspan="1" rowspan="1">AUC (95 % CI)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Dementia</bold></td><td valign="top" colspan="1" rowspan="1">5247</td><td valign="top" colspan="1" rowspan="1">0.76 (0.74&#8211;0.78)</td><td valign="top" colspan="1" rowspan="1">0.74 (0.72&#8211;0.76)**</td><td valign="top" colspan="1" rowspan="1">0.59 (0.56&#8211;0.61)***</td><td valign="top" colspan="1" rowspan="1">0.76 (0.74&#8211;0.78)</td><td valign="top" colspan="1" rowspan="1">0.75 (0.72&#8211;0.77)*</td><td valign="top" colspan="1" rowspan="1">0.69 (0.66&#8211;0.71)***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Dementia No Demographics</bold></td><td valign="top" colspan="1" rowspan="1">5247</td><td valign="top" colspan="1" rowspan="1">0.76 (0.74&#8211;0.78)</td><td valign="top" colspan="1" rowspan="1">0.58 (0.56&#8211;0.61)***</td><td valign="top" colspan="1" rowspan="1">0.55 (0.52&#8211;0.57)***</td><td valign="top" colspan="1" rowspan="1">0.65 (0.63&#8211;0.68)***</td><td valign="top" colspan="1" rowspan="1">0.63 (0.61&#8211;0.66)***</td><td valign="top" colspan="1" rowspan="1">0.63 (0.60&#8211;0.65)***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>AD</bold></td><td valign="top" colspan="1" rowspan="1">5009</td><td valign="top" colspan="1" rowspan="1">0.77 (0.75&#8211;0.80)</td><td valign="top" colspan="1" rowspan="1">0.75 (0.72&#8211;0.78)*</td><td valign="top" colspan="1" rowspan="1">0.58 (0.55&#8211;0.61)***</td><td valign="top" colspan="1" rowspan="1">0.76 (0.73&#8211;0.79)</td><td valign="top" colspan="1" rowspan="1">0.75 (0.72&#8211;0.78)</td><td valign="top" colspan="1" rowspan="1">0.68 (0.65&#8211;0.71)***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>AD No Demographics</bold></td><td valign="top" colspan="1" rowspan="1">5009</td><td valign="top" colspan="1" rowspan="1">0.77 (0.75&#8211;0.80)</td><td valign="top" colspan="1" rowspan="1">0.56 (0.53&#8211;0.60)***</td><td valign="top" colspan="1" rowspan="1">0.54 (0.51&#8211;0.57)***</td><td valign="top" colspan="1" rowspan="1">0.63 (0.60&#8211;0.67)***</td><td valign="top" colspan="1" rowspan="1">0.62 (0.59&#8211;0.65)***</td><td valign="top" colspan="1" rowspan="1">0.62 (0.59&#8211;0.65)***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Female</bold></td><td valign="top" colspan="1" rowspan="1">2768</td><td valign="top" colspan="1" rowspan="1">0.78 (0.76&#8211;0.81)</td><td valign="top" colspan="1" rowspan="1">0.78 (0.75&#8211;0.81)</td><td valign="top" colspan="1" rowspan="1">0.61 (0.58&#8211;0.64)***</td><td valign="top" colspan="1" rowspan="1">0.78 (0.75&#8211;0.81)</td><td valign="top" colspan="1" rowspan="1">0.78 (0.75&#8211;0.81)</td><td valign="top" colspan="1" rowspan="1">0.72 (0.69&#8211;0.75)***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Male</bold></td><td valign="top" colspan="1" rowspan="1">2479</td><td valign="top" colspan="1" rowspan="1">0.73 (0.70&#8211;0.77)</td><td valign="top" colspan="1" rowspan="1">0.69 (0.66&#8211;0.73)*</td><td valign="top" colspan="1" rowspan="1">0.57 (0.53&#8211;0.60)***</td><td valign="top" colspan="1" rowspan="1">0.74 (0.71&#8211;0.77)</td><td valign="top" colspan="1" rowspan="1">0.70 (0.67&#8211;0.74)</td><td valign="top" colspan="1" rowspan="1">0.65 (0.61&#8211;0.68)***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>&#8804;64 Years</bold></td><td valign="top" colspan="1" rowspan="1">2569</td><td valign="top" colspan="1" rowspan="1">0.59 (0.53&#8211;0.64)</td><td valign="top" colspan="1" rowspan="1">0.60 (0.54&#8211;0.65)</td><td valign="top" colspan="1" rowspan="1">0.58 (0.53&#8211;0.63)</td><td valign="top" colspan="1" rowspan="1">0.63 (0.57&#8211;0.68)</td><td valign="top" colspan="1" rowspan="1">0.63 (0.57&#8211;0.68)</td><td valign="top" colspan="1" rowspan="1">0.63 (0.58&#8211;0.69)</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>&#8805; 65 Years</bold></td><td valign="top" colspan="1" rowspan="1">2678</td><td valign="top" colspan="1" rowspan="1">0.71 (0.68&#8211;0.74)</td><td valign="top" colspan="1" rowspan="1">0.70 (0.67&#8211;0.73)</td><td valign="top" colspan="1" rowspan="1">0.58 (0.55&#8211;0.60)***</td><td valign="top" colspan="1" rowspan="1">0.70 (0.67&#8211;0.73)</td><td valign="top" colspan="1" rowspan="1">0.70 (0.67&#8211;0.73)</td><td valign="top" colspan="1" rowspan="1">0.65 (0.63&#8211;0.68)***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>APOE4 Negative</bold></td><td valign="top" colspan="1" rowspan="1">3729</td><td valign="top" colspan="1" rowspan="1">0.76 (0.73&#8211;0.78)</td><td valign="top" colspan="1" rowspan="1">0.73 (0.70&#8211;0.76)*</td><td valign="top" colspan="1" rowspan="1">0.57 (0.54&#8211;0.60)***</td><td valign="top" colspan="1" rowspan="1">0.76 (0.73&#8211;0.79)</td><td valign="top" colspan="1" rowspan="1">0.74 (0.71&#8211;0.77)</td><td valign="top" colspan="1" rowspan="1">0.70 (0.67&#8211;0.73)***</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>APOE4 Positive</bold></td><td valign="top" colspan="1" rowspan="1">1355</td><td valign="top" colspan="1" rowspan="1">0.79 (0.75&#8211;0.82)</td><td valign="top" colspan="1" rowspan="1">0.76 (0.72&#8211;0.80)</td><td valign="top" colspan="1" rowspan="1">0.57 (0.53&#8211;0.61)***</td><td valign="top" colspan="1" rowspan="1">0.78 (0.74&#8211;0.81)</td><td valign="top" colspan="1" rowspan="1">0.76 (0.72&#8211;0.80)</td><td valign="top" colspan="1" rowspan="1">0.67 (0.63&#8211;0.71)***</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: The simple demographics model comprising age and education has been set as the gold standard in a gold standard analysis, *** <italic toggle="yes">p</italic> &lt; 0.001, ** <italic toggle="yes">p</italic> &lt; 0.005, * <italic toggle="yes">p</italic> &lt; 0.05 indicate where indices significantly deviate from the demographics model in predicative ability.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0032"><label>3.5</label><title>Stratified analysis</title><p id="para0046">When stratified by sex, all indices showed stronger predictive ability in females than males. In females, LIBRA (AUC=0.782), CogDrisk (AUC=0.778), and ANU-ADRI (AUC=0.776) performed similarly to each other (<italic toggle="yes">p</italic> &gt; 0.05) and significantly better than LIBRA2 (AUC=0.715) and CAIDE (AUC=0.608) (<italic toggle="yes">p</italic> &lt; 0.001). In males, CogDrisk (AUC=0.738) significantly outperformed all other indices (<italic toggle="yes">p</italic> &lt; 0.001), while LIBRA2 (AUC=0.648) and CAIDE (AUC=0.566) performed significantly worse than all other indices (<italic toggle="yes">p</italic> &lt; 0.005). Age was a strong predictor in both sexes (AUC=0.784 in females, 0.734 in males), while education was a significant predictor in males (<italic toggle="yes">p</italic> &lt; 0.001) but not in females (<italic toggle="yes">p</italic> = 0.134).</p><p id="para0047">Among age groups, all indices performed better in individuals aged &#8805;65 at baseline (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>). In individuals under 65 years at baseline, all indices performed similarly with no significant differences between them (<italic toggle="yes">p</italic> &gt; 0.05, <xref rid="tbl0003" ref-type="table">Table 3</xref> and <xref rid="fig0001" ref-type="fig">Fig. 1</xref>). In older adults (&#8805;65), ANU-ADRI (AUC=0.699), CogDrisk (AUC=0.701), and LIBRA (AUC=0.699) performed similarly (<italic toggle="yes">p</italic> &gt; 0.05), while LIBRA2 (AUC=0.653) and CAIDE (AUC=0.576) were significantly weaker (<italic toggle="yes">p</italic> &lt; 0.001). Between APOE4 carriers, CogDrisk (AUC=0.775), LIBRA (AUC=0.762), and ANU-ADRI (AUC=0.760) performed similarly to each other and the demographics only model (AUC=0.79; <italic toggle="yes">p</italic> &gt; 0.05), while LIBRA2 (AUC=0.668) CAIDE (AUC=0.567) performed significantly weaker (<italic toggle="yes">p</italic> &lt; 0.001). In non-carriers, the same ranking was observed but with slightly lower performance (see <xref rid="tbl0002" ref-type="table">Table 2</xref>, <xref rid="tbl0003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec0033"><label>3.6</label><title>Sensitivity analysis</title><p id="para0048">Joint multivariate normal imputation was conducted to assess the robustness of the findings. Results remained consistent with the complete case analysis, with all indices retaining their significant associations with dementia. Effect sizes were slightly attenuated, but comparable, with CogDrisk and LIBRA maintaining the highest predictive accuracy. Relative Variance Increase (RVI) values were modest (0.10&#8211;0.28, <xref rid="tbl0004" ref-type="table">Table 4</xref>), indicating that missing data had minimal impact on results. The Fraction of Missing Information (FMI) was highest for LIBRA2 (0.35; <xref rid="tbl0004" ref-type="table">Table 4</xref>) but remained within an acceptable range across indices. Additionally, an analysis using all available cases without adjusting for missing data produced comparable results, with only minor variations in effect sizes and AUC values (see <xref rid="tbl0004" ref-type="table">Table 4</xref>)<table-wrap position="float" id="tbl0004" orientation="portrait"><label>Table 4</label><caption><p>Sensitivity analysis using Multiple Imputation, and index-specific complete case analysis.</p></caption><alt-text id="alt0005">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="8" align="left" valign="top" rowspan="1">Sensitivity Analysis with Imputed Data</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Variable</td><td valign="top" colspan="1" rowspan="1">Coeficient</td><td valign="top" colspan="1" rowspan="1">(95 % Conf. Interval)</td><td valign="top" colspan="1" rowspan="1">F-test</td><td valign="top" colspan="1" rowspan="1">Average RVI</td><td valign="top" colspan="1" rowspan="1">Largest FMI</td><td valign="top" colspan="1" rowspan="1">Observations</td><td valign="top" colspan="1" rowspan="1">Imputed Cases</td></tr><tr><td valign="top" colspan="1" rowspan="1">ANU-ADRI</td><td valign="top" colspan="1" rowspan="1">0.91***</td><td valign="top" colspan="1" rowspan="1">(0.84, 0.97)</td><td valign="top" colspan="1" rowspan="1">688.62***</td><td valign="top" colspan="1" rowspan="1">0.10</td><td valign="top" colspan="1" rowspan="1">0.15</td><td valign="top" colspan="1" rowspan="1">8379</td><td valign="top" colspan="1" rowspan="1">2750</td></tr><tr><td valign="top" colspan="1" rowspan="1">CAIDE</td><td valign="top" colspan="1" rowspan="1">0.32***</td><td valign="top" colspan="1" rowspan="1">(0.25, 0.39)</td><td valign="top" colspan="1" rowspan="1">81.98***</td><td valign="top" colspan="1" rowspan="1">0.12</td><td valign="top" colspan="1" rowspan="1">0.19</td><td valign="top" colspan="1" rowspan="1">8379</td><td valign="top" colspan="1" rowspan="1">1488</td></tr><tr><td valign="top" colspan="1" rowspan="1">CogDrisk</td><td valign="top" colspan="1" rowspan="1">0.94***</td><td valign="top" colspan="1" rowspan="1">(0.87, 1.02)</td><td valign="top" colspan="1" rowspan="1">697.83***</td><td valign="top" colspan="1" rowspan="1">0.11</td><td valign="top" colspan="1" rowspan="1">0.16</td><td valign="top" colspan="1" rowspan="1">8379</td><td valign="top" colspan="1" rowspan="1">2805</td></tr><tr><td valign="top" colspan="1" rowspan="1">LIBRA</td><td valign="top" colspan="1" rowspan="1">0.94***</td><td valign="top" colspan="1" rowspan="1">(0.87, 1.01)</td><td valign="top" colspan="1" rowspan="1">660.99***</td><td valign="top" colspan="1" rowspan="1">0.13</td><td valign="top" colspan="1" rowspan="1">0.18</td><td valign="top" colspan="1" rowspan="1">8379</td><td valign="top" colspan="1" rowspan="1">2749</td></tr><tr><td valign="top" colspan="1" rowspan="1">LIBRA2</td><td valign="top" colspan="1" rowspan="1">0.71***</td><td valign="top" colspan="1" rowspan="1">(0.63, 0.79)</td><td valign="top" colspan="1" rowspan="1">297.97***</td><td valign="top" colspan="1" rowspan="1">0.28</td><td valign="top" colspan="1" rowspan="1">0.35</td><td valign="top" colspan="1" rowspan="1">8379</td><td valign="top" colspan="1" rowspan="1">2861</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="8" align="left" valign="top" rowspan="1">Sensitivity Analysis with Index-Specific Complete Cases</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Variable</td><td valign="top" colspan="1" rowspan="1">Odds Ratio</td><td valign="top" colspan="1" rowspan="1">(95 % Conf Interval)</td><td valign="top" colspan="1" rowspan="1">Pseudo r-squared</td><td valign="top" colspan="1" rowspan="1">Chi2</td><td valign="top" colspan="1" rowspan="1">AIC</td><td valign="top" colspan="1" rowspan="1">ROC</td><td valign="top" colspan="1" rowspan="1">Observations</td></tr><tr><td valign="top" colspan="1" rowspan="1">ANU-ADRI</td><td valign="top" colspan="1" rowspan="1">2.43***</td><td valign="top" colspan="1" rowspan="1">(2.24, 2.63)</td><td valign="top" colspan="1" rowspan="1">0.13</td><td valign="top" colspan="1" rowspan="1">527.92***</td><td valign="top" colspan="1" rowspan="1">1746.07</td><td valign="top" colspan="1" rowspan="1">0.74</td><td valign="top" colspan="1" rowspan="1">5629</td></tr><tr><td valign="top" colspan="1" rowspan="1">CAIDE</td><td valign="top" colspan="1" rowspan="1">1.38***</td><td valign="top" colspan="1" rowspan="1">(1.28, 1.48)</td><td valign="top" colspan="1" rowspan="1">0.02</td><td valign="top" colspan="1" rowspan="1">80.58***</td><td valign="top" colspan="1" rowspan="1">2630.22</td><td valign="top" colspan="1" rowspan="1">0.59</td><td valign="top" colspan="1" rowspan="1">6891</td></tr><tr><td valign="top" colspan="1" rowspan="1">CogDrisk</td><td valign="top" colspan="1" rowspan="1">2.56***</td><td valign="top" colspan="1" rowspan="1">(2.36, 2.78)</td><td valign="top" colspan="1" rowspan="1">0.14</td><td valign="top" colspan="1" rowspan="1">539.34***</td><td valign="top" colspan="1" rowspan="1">1700.92</td><td valign="top" colspan="1" rowspan="1">0.76</td><td valign="top" colspan="1" rowspan="1">5574</td></tr><tr><td valign="top" colspan="1" rowspan="1">LIBRA</td><td valign="top" colspan="1" rowspan="1">2.56***</td><td valign="top" colspan="1" rowspan="1">(2.36, 2.79)</td><td valign="top" colspan="1" rowspan="1">0.14</td><td valign="top" colspan="1" rowspan="1">544.5***</td><td valign="top" colspan="1" rowspan="1">1737.90</td><td valign="top" colspan="1" rowspan="1">0.75</td><td valign="top" colspan="1" rowspan="1">5630</td></tr><tr><td valign="top" colspan="1" rowspan="1">LIBRA2</td><td valign="top" colspan="1" rowspan="1">1.99***</td><td valign="top" colspan="1" rowspan="1">(1.83, 2.16)</td><td valign="top" colspan="1" rowspan="1">0.07</td><td valign="top" colspan="1" rowspan="1">265.21***</td><td valign="top" colspan="1" rowspan="1">1806.53</td><td valign="top" colspan="1" rowspan="1">0.69</td><td valign="top" colspan="1" rowspan="1">5518</td></tr><tr><td valign="top" colspan="1" rowspan="1">Age</td><td valign="top" colspan="1" rowspan="1">1.15***</td><td valign="top" colspan="1" rowspan="1">(1.14, 1.16)</td><td valign="top" colspan="1" rowspan="1">0.14</td><td valign="top" colspan="1" rowspan="1">941.84***</td><td valign="top" colspan="1" rowspan="1">2867.25</td><td valign="top" colspan="1" rowspan="1">0.76</td><td valign="top" colspan="1" rowspan="1">8379</td></tr><tr><td valign="top" colspan="1" rowspan="1">Education</td><td valign="top" colspan="1" rowspan="1">0.64***</td><td valign="top" colspan="1" rowspan="1">(0.54, 0.76)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Notes: Significance is set as *** <italic toggle="yes">p</italic> &lt; 0.001, ** <italic toggle="yes">p</italic> &lt; 0.005, * <italic toggle="yes">p</italic> &lt; 0.05. Imputed sensitivity analyses using joint multivariate normal imputation (100 datasets; predictors: age, sex, education, dementia status); index-specific complete case sensitivity analyses using all participants with available data for each individual index irrespective of their inclusion in other indices.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec0034"><label>4</label><title>Discussion</title><p id="para0049">This study aimed to compare the predictive accuracy of ANU-ADRI, CAIDE, CogDrisk, LIBRA, and LIBRA2 over an 11-year follow-up in a representative Norwegian population cohort. Their predictive performance was evaluated against a simple demographics model comprising age and education. Our results show that while all indices predicted all-cause dementia and AD statistically significantly, none outperformed the demographics model. Of all indices, CogDrisk emerged as the strongest predictor, demonstrating the highest coefficients and AUC across most analyses and subgroups. Along with LIBRA, it was the only index that did not perform significantly worse than the demographics model. This is in line with previous reports that demographic variables alone often achieve similar discriminative power as any index [<xref rid="bib0016" ref-type="bibr">16</xref>,<xref rid="bib0021" ref-type="bibr">21</xref>,<xref rid="bib0028" ref-type="bibr">28</xref>]. Consistent with previous findings [<xref rid="bib0024" ref-type="bibr">24</xref>,<xref rid="bib0026" ref-type="bibr">26</xref>], CAIDE consistently demonstrated the weakest predictive performance, followed by LIBRA2, which performed significantly worse than the demographics model and CogDrisk in almost all analyses, except in individuals under 65 years at baseline, where no significant differences were observed between indices.</p><p id="para0050">Beyond our findings showing that demographics alone achieve better or similar AUC values to all tested indices, our results, also consistent with previous studies [<xref rid="bib0024" ref-type="bibr">24</xref>], show that removing demographic data greatly diminishes index accuracy. This suggests that age and education account for most of the predictive power within the indices, while other variables contribute little additional accuracy; possibly because they serve as proxies for a broad range of latent exposures or because the indices lack sufficiently refined weighting to capture risk differentials across subgroups.</p><p id="para0051">When stratifying by sex, indices showed stronger predictive accuracy in females than in males. Among females, LIBRA, CogDrisk, and ANU-ADRI performed similarly and significantly better than LIBRA2 and CAIDE. Among males, CogDrisk outperformed all others, and LIBRA2 and CAIDE had the weakest performance. The indices explained 50 %&#8211;140 % more variance in dementia risk in females, revealing more pronounced sex disparities than previous studies, which often reported minimal sex differences or better index performance in males [<xref rid="bib0024" ref-type="bibr">24</xref>,<xref rid="bib0045" ref-type="bibr">46</xref>]. Although sex was not independently linked to dementia, stratifying by sex significantly impacted each index&#8217;s accuracy, implying that sex not only modulates individual risk factor expression [<xref rid="bib0032" ref-type="bibr">32</xref>,<xref rid="bib0033" ref-type="bibr">33</xref>], but also risk indices overall. These findings further underscore the importance of refining weighting, and future research should explore whether sex differences persist in other cohorts and whether more precise adjustments could improve predictive accuracy.</p><p id="para0052">Predictive accuracy varied across age groups and was generally lower in younger participants (&lt;65), likely due to lower dementia prevalence (4.0 % vs. 17.3 % in older adults), which limits model discrimination. However, it was unexpected that all indices performed equally poorly in this group, with no significant differences between them. CAIDE and LIBRA were designed to capture midlife risk factors [<xref rid="bib0011" ref-type="bibr">11</xref>,<xref rid="bib0012" ref-type="bibr">12</xref>] and were anticipated to outperform indices developed on older populations [<xref rid="bib0014" ref-type="bibr">14</xref>,<xref rid="bib0016" ref-type="bibr">16</xref>]. Notably, CAIDE performed similarly in both age groups, despite prior evidence that it performs worse in older age groups, likely due to it attributing the same weights to everyone over 53 years [<xref rid="bib0011" ref-type="bibr">11</xref>].</p><p id="para0053">Interestingly, LIBRA performed significantly better in the older age group, despite its midlife orientation. LIBRA performed similar to ANU-ADRI and CogDrisk, which were developed with broader age applicability. These indices assign zero weight to BMI and hypertension in those over 60, as those risk factors are known to reverse their association with dementia risk in late life [<xref rid="bib0046" ref-type="bibr">47</xref>,<xref rid="bib0047" ref-type="bibr">48</xref>]. However, this approach is coarse and does not fully capture the complex, age-dependent nature of dementia risk; for instance, none of the indices assign risk to underweight, which is a well-established late-life risk factor [<xref rid="bib0048" ref-type="bibr">49</xref>]. Future research should explore more nuanced, age-stratified weighting reflecting the dynamic relationship between risk factors and dementia across the lifespan. Additionally, longer follow-up periods may be necessary to adequately evaluate risk prediction in younger age groups.</p><p id="para0054">Stratification of APOE4-carries showed the same patterns as the other analyses with CogDrisk, LIBRA, and ANU-ADRI performing similarly, and LIBRA2 and CAIDE showing significantly weaker performance. In non-carriers, the same ranking was observed but with slightly lower performance. This indicates that the predictive performance of the indices is largely consistent irrespective of APOE4 status, and stratification by genetic risk does not significantly enhance their discriminatory ability compared to the unstratified analysis.</p><sec id="sec0035"><label>4.1</label><title>Strengths and limitations</title><p id="para0055">This study has several strengths. By using data from 5247 participants in the HUNT4 70+ study, representing over one-quarter of the regional population aged 70+, our findings are based on a large, representative cohort, enhancing external validity. With 566 dementia cases, the study had sufficient power [<xref rid="bib0049" ref-type="bibr">50</xref>] to compare and validate five dementia risk indices across multiple stratifications, including age, sex, and APOE4 status. Additionally, the 11-year follow-up period is as long or longer than in most previous validation studies [<xref rid="bib0021" ref-type="bibr">21</xref>], providing a more comprehensive assessment of long-term dementia risk prediction and reduced likelihood of reverse causality, as the follow-up period exceeds the average duration of the pre-clinical stage of dementia measured at age 70 [<xref rid="bib0050" ref-type="bibr">51</xref>].</p><p id="para0056">The availability of genetic data and linkage to public health registries further strengthened the analysis by allowing for near-complete index construction and supplementation with validated patient information, thereby minimizing missing data. Dementia diagnoses were rigorously established by a multidisciplinary team using DSM-5 criteria, ensuring greater diagnostic accuracy compared to studies relying on self-reports, Mini Mental State Examination scores, or hospital records [<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0027" ref-type="bibr">27</xref>]. This study is also the largest to date to provide a direct, side-by-side comparison of ANU-ADRI, CAIDE, CogDrisk, LIBRA, and LIBRA2 under identical conditions. While previous research has validated individual indices or smaller subsets, this study offers an evaluation of all five tools within the same large cohort. Additionally, it is one of the few studies to compare index performance in late mid-life and late life. Sensitivity analyses confirmed the robustness of findings, reinforcing the reliability of index predictions despite missing data.</p><p id="para0057">Despite these strengths, several limitations should be noted. The relatively low dementia prevalence in those who were under 65 years at HUNT3 (4.0 % vs. 17.3 % in those &#8805;65 at HUNT3) likely contributed to lower AUCs in younger participants, as low case numbers inherently limit model discrimination. While the follow-up period was substantial, it may not fully capture long-term cumulative risk trajectories, particularly for midlife-focused indices. Additionally, several variables, including physical activity, smoking, and social/cognitive engagement, hearing loss, and some medical conditions were self-reported, potentially introducing potential measurement errors. The sensitivity of the thresholds of some of the risk factors was not established, which may have reduced the predictive accuracy. The HUNT dataset also lacks information on pesticide exposure and chronic kidney disease, limiting full validation of ANU-ADRI and LIBRA, which include these factors. Kidney disease, however, is a frequently missing variable [<xref rid="bib0013" ref-type="bibr">13</xref>], making this study comparable to many other LIBRA validation studies. Like other validation studies, this analysis was limited by the availability of variables in the dataset. The original CAIDE, LIBRA, ANU-ADRI, and CogDrisk indices have published questionnaires, but direct evaluation of these instruments is not feasible in most retrospective cohort studies. Instead, we constructed approximations based on available data, reflecting the conceptual structure and intended variable weighting of each index. As such, this study evaluates the statistical implementation of these indices within the HUNT dataset, and the feasibility of their real-life applicability as practical tools in research settings. While the degree of measurement error introduced by these approximations has not been formally assessed, this approach reflects the way these tools are likely to be implemented in retrospective and cohort based research [<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0016" ref-type="bibr">16</xref>,<xref rid="bib0018" ref-type="bibr">[18]</xref>, <xref rid="bib0019" ref-type="bibr">[19]</xref>, <xref rid="bib0020" ref-type="bibr">[20]</xref>,<xref rid="bib0024" ref-type="bibr">[24]</xref>, <xref rid="bib0025" ref-type="bibr">[25]</xref>, <xref rid="bib0026" ref-type="bibr">[26]</xref>, <xref rid="bib0027" ref-type="bibr">[27]</xref>].</p><p id="para0058">Our study reports a prevalence of dementia of 10.8 % which is similar to- or better than previous studies in terms of sample representativeness [<xref rid="bib0016" ref-type="bibr">16</xref>,<xref rid="bib0024" ref-type="bibr">24</xref>,<xref rid="bib0027" ref-type="bibr">27</xref>]. Despite this, prevalence in our sample was 26 % lower than general estimates of dementia prevalence in those above 70 years in Norway (14.6 % [<xref rid="bib0038" ref-type="bibr">38</xref>]). While sensitivity analyses suggest that missingness did not substantially impact results, missing data were systematically associated with demographic and health characteristics, introducing the possibility of bias. Prior research found that dementia diagnoses were relatively higher among non-participants [<xref rid="bib0035" ref-type="bibr">35</xref>]. This selective attrition likely led to an underestimation of the associations between risk indices and dementia outcomes, as individuals at higher risk were disproportionately lost to follow-up. This underestimation may have further been amplified by healthy survivor bias and lack of information on competing risks due to death occurring between HUNT3 and HUNT4. Future work should address this more formally using registry-linked mortality and diagnosis data and methods such as inverse probability weighting or competing risk models based on the full HUNT3 cohort. Furthermore, dementia diagnoses were not confirmed via biomarkers, which may introduce some misclassification bias [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0051" ref-type="bibr">52</xref>].</p></sec><sec id="sec0036"><label>4.2</label><title>Conclusion</title><p id="para0059">The current study found that, among five commonly used dementia risk indices, CogDrisk and LIBRA performed best, while CAIDE and LIBRA2 showed the weakest predictive ability. However, no dementia risk index outperformed a demographics-only model, underlining the central role of age and education in risk prediction. These findings highlight the need to evaluate whether risk indices provide meaningful improvements over demographics-only models in research settings. Given the extensive validation of the individual risk factors included in all indices, these indices still provide valuable insight for individuals and in clinical settings however, it is unclear how valuable the risk score is beyond providing a checklist of presence or absence of each risk factor. This study underlines that different applications may call for different methods: while demographics-based models are useful for broad risk estimation, indices like CogDrisk and LIBRA remain valuable for risk reduction strategies in clinical and policy settings due to their emphasis on modifiable risk and protective factors. Age- and sex-stratified analyses suggest that refining weighting could improve predictive accuracy, and future research should optimize indices for different age groups and explore possible sex-specific adjustments.</p></sec></sec><sec id="sec0037"><title>Funding</title><p id="para0060">This project is funded by the Norwegian Research Council (303,419).</p><p id="para0061">The genotyping was financed by the National Institute of health (NIH), University of Michigan, The Norwegian Research council, and Central Norway Regional Health Authority and the Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU). The genotype quality control and imputation has been conducted by the K. G. Jebsen center for genetic epidemiology, Department of public health and nursing, Faculty of medicine and health sciences, Norwegian University of Science and Technology (NTNU). GCF is funded by the Faculty of Medicine and Health Sciences at NTNU and Central Norway Regional Health Authority.</p><p id="para0062">MK was supported by the Wellcome Trust (221,854/Z/20/Z), the UK Medical Research Council (MR/Y014154/1), and the Research Council of Finland (350,426). KJA is funded by ARC Laureate Fellowship FL190100011.</p></sec><sec id="sec0038"><title>Data sharing</title><p id="para0063">The data used in this study is owned by the HUNT research center, Statistics Norway, the Norwegian Patient Registry and the Norwegian Cause of Death Registry. Access requires approval from the Regional Ethics Committees and the data owners. The authors are not permitted to share the data with third parties but can be contacted with questions.</p></sec><sec id="sec0039"><title>Declaration of generative AI and AI-Assisted technologies in the writing process</title><p id="para0064">During the preparation of this work, the author(s) used ChatGPT (OpenAI) and Microsoft Copilot to provide critical feedback on clarity and language. No AI-generated content was inserted directly, and the author(s) take full responsibility for the content of the publication.</p></sec><sec id="sec0039a"><title>CRediT authorship contribution statement</title><p id="para0064a"><bold>Josephine Stubs:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Project administration, Methodology, Formal analysis, Data curation, Conceptualization. <bold>Ellen Melbye Langballe:</bold> Writing &#8211; review &amp; editing, Supervision, Resources, Project administration, Methodology, Formal analysis, Conceptualization. <bold>Gill Livingston:</bold> Writing &#8211; review &amp; editing, Supervision, Funding acquisition, Conceptualization. <bold>Kaarin J. Anstey:</bold> Writing &#8211; review &amp; editing, Funding acquisition, Conceptualization. <bold>Kay Deckers:</bold> Writing &#8211; review &amp; editing. <bold>Fiona E. Mathews:</bold> Writing &#8211; review &amp; editing, Methodology, Funding acquisition, Conceptualization. <bold>Mika Kivim&#228;ki:</bold> Writing &#8211; review &amp; editing, Funding acquisition, Conceptualization. <bold>Bj&#248;rn Heine Strand:</bold> Writing &#8211; review &amp; editing, Methodology, Funding acquisition, Conceptualization. <bold>Anne-Marie Rokstad:</bold> Writing &#8211; review &amp; editing, Funding acquisition, Conceptualization. <bold>Steinar Krokstad:</bold> Writing &#8211; review &amp; editing, Funding acquisition, Conceptualization. <bold>Geir Selb&#230;k:</bold> Writing &#8211; review &amp; editing, Supervision, Resources, Project administration, Methodology, Funding acquisition, Formal analysis, Data curation, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0065">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>E.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Vollset</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Fukutaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chalek</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet Public Health</source><volume>7</volume><issue>2</issue><year>2022</year><fpage>e105</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wimo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guerchet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gemma-Claire</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.-T.</given-names></name><etal/></person-group><article-title>World Alzheimer Report 2015: the Global Impact of Dementia - an analysis of prevalence, incidence, cost and trends</article-title><source>Alzheimer's Disease International</source><year>2015</year><pub-id pub-id-type="doi">10.1111/j.0963-7214.2004.00293.x</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><mixed-citation publication-type="other" id="sbref0003">Lewis, F., Karlsberg Schaffer, S., Sussex, J., O'neill, P. and Cockcroft, L. (2014). The trajectory of dementia in the UK &#8211; Making a difference. OHE contract research. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ohe.org/publications/trajectory-dementia-uk-making-difference/" id="interref0001">https://www.ohe.org/publications/trajectory-dementia-uk-making-difference/</ext-link>.</mixed-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tideman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Blood biomarkers to detect Alzheimer disease in primary care and secondary care</article-title><source>JAMA</source><volume>332</volume><issue>15</issue><year>2024</year><fpage>1245</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1001/jama.2024.13855</pub-id><pub-id pub-id-type="pmid">39068545</pub-id><pub-id pub-id-type="pmcid">PMC11284636</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Barth&#233;lemy</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Salvad&#243;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Highly accurate blood test for Alzheimer&#8217;s disease is similar or superior to clinical cerebrospinal fluid tests</article-title><source>Nat Med</source><volume>30</volume><issue>4</issue><year>2024</year><fpage>1085</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-02869-z</pub-id><pub-id pub-id-type="pmid">38382645</pub-id><pub-id pub-id-type="pmcid">PMC11031399</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Costafreda</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Selb&#230;k</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission</article-title><source>The Lancet</source><volume>404</volume><issue>10452</issue><year>2024</year><fpage>572</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01296-0</pub-id><pub-id pub-id-type="pmid">39096926</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hossen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>M.F.I.</given-names></name><name name-style="western"><surname>Bari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tamanna</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Aducanumab for the treatment of Alzheimer's disease: a systematic review</article-title><source>Psychogeriatrics</source><volume>23</volume><issue>3</issue><year>2023</year><fpage>512</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1111/psyg.12944</pub-id><pub-id pub-id-type="pmid">36775284</pub-id><pub-id pub-id-type="pmcid">PMC11578022</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ardayfio</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial</article-title><source>JAMA</source><volume>330</volume><issue>6</issue><year>2023</year><fpage>512</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Lecanemab in early Alzheimer's Disease</article-title><source>N Engl J Med</source><volume>388</volume><issue>1</issue><year>2023</year><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2212948</pub-id><pub-id pub-id-type="pmid">36449413</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Cherbuin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herath</surname><given-names>P.M.</given-names></name></person-group><article-title>Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention</article-title><source>Prev Sci</source><volume>14</volume><issue>4</issue><year>2013</year><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1007/s11121-012-0313-2</pub-id><pub-id pub-id-type="pmid">23319292</pub-id><pub-id pub-id-type="pmcid">PMC3696462</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ngandu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Laatikainen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soininen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study</article-title><source>Lancet Neurology</source><volume>5</volume><issue>9</issue><year>2006</year><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(06)70537-3</pub-id><pub-id pub-id-type="pmid">16914401</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Deckers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Van Boxtel</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Schiepers</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>De Vugt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mu&#241;oz S&#225;nchez</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies</article-title><source>Int J Geriatr Psychiatry</source><volume>30</volume><issue>3</issue><year>2015</year><fpage>234</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1002/gps.4245</pub-id><pub-id pub-id-type="pmid">25504093</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Rosenau</surname><given-names>C.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Boxtel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tange</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deckers</surname><given-names>K.</given-names></name></person-group><article-title>Validation of the updated "LIfestyle for BRAin health" (LIBRA) Index in the English Longitudinal Study of ageing and Maastricht aging study</article-title><source>J Alzheimers Dis</source><volume>101</volume><issue>4</issue><year>2024</year><fpage>1237</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.3233/jad-240666</pub-id><pub-id pub-id-type="pmid">39302374</pub-id><pub-id pub-id-type="pmcid">PMC11492037</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Kootar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huque</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Eramudugolla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>R.</given-names></name></person-group><article-title>Development of the CogDrisk tool to assess risk factors for dementia</article-title><source>Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</source><volume>14</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">e12336</object-id><pub-id pub-id-type="doi">10.1002/dad2.12336</pub-id><pub-id pub-id-type="pmcid">PMC9275658</pub-id><pub-id pub-id-type="pmid">35845259</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Anstey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kootar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barbera</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Dementia risk scores and their role in the implementation of risk reduction guidelines</article-title><source>Front Neurol</source><volume>12</volume><issue>January 2022</issue><year>2022</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.3389/fneur.2021.765454</pub-id><pub-id pub-id-type="pmcid">PMC8764151</pub-id><pub-id pub-id-type="pmid">35058873</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Licher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leening</surname><given-names>M.J.G.</given-names></name><name name-style="western"><surname>Wolters</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Vernooij</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>External validation of four dementia prediction models for use in the general community-dwelling population: a comparative analysis from the Rotterdam Study</article-title><source>Eur J Epidemiol</source><year>2018</year><pub-id pub-id-type="doi">10.1007/s10654-018-0403-y</pub-id><pub-id pub-id-type="pmcid">PMC6061119</pub-id><pub-id pub-id-type="pmid">29740780</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Kaffashian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dugravot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elbaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shipley</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sabia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Predicting cognitive decline: a dementia risk score vs the framingham vascular risk scores</article-title><source>Neurology</source><year>2013</year><pub-id pub-id-type="doi">10.1212/WNL.0b013e31828ab370</pub-id><pub-id pub-id-type="pmcid">PMC3656460</pub-id><pub-id pub-id-type="pmid">23547265</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Exalto</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Quesenberry</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Midlife risk score for the prediction of dementia four decades later</article-title><source>Alzheimer's and Dementia</source><year>2014</year><pub-id pub-id-type="doi">10.1016/j.jalz.2013.05.1772</pub-id><pub-id pub-id-type="pmid">24035147</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Vuorinen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spulber</surname><given-names>G.</given-names></name><name name-style="western"><surname>Damangir</surname><given-names>S.</given-names></name><name name-style="western"><surname>Niskanen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ngandu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Midlife CAIDE dementia risk score and dementia-related brain changes up to 30 years later on magnetic resonance imaging</article-title><source>J Alzheimer's Disease</source><year>2015</year><pub-id pub-id-type="doi">10.3233/JAD-140924</pub-id><pub-id pub-id-type="pmid">25190628</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Hooshmand</surname><given-names>B.</given-names></name><name name-style="western"><surname>Polvikoski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Myllykangas</surname><given-names>L.</given-names></name><etal/></person-group><article-title>CAIDE Dementia Risk Score, Alzheimer and cerebrovascular pathology: a population-based autopsy study</article-title><source>J Intern Med</source><year>2018</year><pub-id pub-id-type="doi">10.1111/joim.12736</pub-id><pub-id pub-id-type="pmid">29411449</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Van Asbroeck</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lipnicki</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Castro-Costa</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Lifestyle and incident dementia: a COSMIC individual participant data meta-analysis</article-title><source>Alzheimer&#8217;s and Dementia</source><volume>20</volume><issue>6</issue><year>2024</year><fpage>3972</fpage><lpage>3986</lpage><pub-id pub-id-type="doi">10.1002/alz.13846</pub-id><pub-id pub-id-type="pmcid">PMC11180928</pub-id><pub-id pub-id-type="pmid">38676366</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Vos</surname><given-names>S.J.B.</given-names></name></person-group><article-title>Modifiable risk factors for prevention of dementia in midlife, late life and the oldest-old: validation of the LIBRA index</article-title><source>J Alzheimer's Disease</source><volume>58</volume><issue>2</issue><year>2017</year><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.3233/JAD-161208</pub-id><pub-id pub-id-type="pmid">28453475</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Reuben</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moffitt</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Ambler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Improving risk indexes for Alzheimer's disease and related dementias for use in midlife</article-title><source>Brain Commun</source><volume>4</volume><issue>5</issue><year>2022</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/braincomms/fcac223</pub-id><pub-id pub-id-type="pmcid">PMC9535507</pub-id><pub-id pub-id-type="pmid">36213312</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Huque</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kootar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eramudugolla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>CogDrisk, ANU-ADRI, CAIDE, and LIBRA risk scores for estimating dementia risk</article-title><source>JAMA Netw Open</source><volume>6</volume><issue>8</issue><year>2023</year><object-id pub-id-type="publisher-id">E2331460</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.31460</pub-id><pub-id pub-id-type="pmcid">PMC10469268</pub-id><pub-id pub-id-type="pmid">37647064</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Deckers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barbera</surname><given-names>M.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ngandu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Van Boxtel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-term dementia risk prediction by the LIBRA score: a 30-year follow-up of the CAIDE study</article-title><source>Int J Geriatr Psychiatry</source><volume>35</volume><issue>2</issue><year>2020</year><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1002/gps.5235</pub-id><pub-id pub-id-type="pmid">31736136</pub-id><pub-id pub-id-type="pmcid">PMC7003764</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Geethadevi</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Peel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Validity of three risk prediction models for dementia or cognitive impairment in Australia</article-title><source>Age Ageing</source><volume>51</volume><issue>12</issue><year>2022</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/ageing/afac307</pub-id><pub-id pub-id-type="pmcid">PMC9804251</pub-id><pub-id pub-id-type="pmid">36585910</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Anat&#252;rk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ebmeier</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Georgiopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Newby</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Development and validation of a dementia risk score in the UK Biobank and Whitehall II cohorts</article-title><source>BMJ Mental Health</source><volume>26</volume><issue>1</issue><year>2023</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1136/bmjment-2023-300719</pub-id><pub-id pub-id-type="pmcid">PMC10577770</pub-id><pub-id pub-id-type="pmid">37603383</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Kivim&#228;ki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Singh-Manoux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mars</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lindbohm</surname><given-names>J.V.</given-names></name><etal/></person-group><article-title>Estimating dementia risk using multifactorial prediction models</article-title><source>JAMA Netw Open</source><volume>6</volume><issue>6</issue><year>2023</year><object-id pub-id-type="publisher-id">e2318132</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.18132</pub-id><pub-id pub-id-type="pmcid">PMC10265307</pub-id><pub-id pub-id-type="pmid">37310738</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Chosy</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Edland</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>N.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.Y.</given-names></name><etal/></person-group><article-title>The CAIDE dementia risk Score and the Honolulu-Asia Aging Study</article-title><source>Dement Geriatr Cogn Disord</source><volume>48</volume><issue>3&#8211;4</issue><year>2020</year><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1159/000504801</pub-id><pub-id pub-id-type="pmcid">PMC9620982</pub-id><pub-id pub-id-type="pmid">31968337</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Schiepers</surname><given-names>O.J.G.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deckers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Irving</surname><given-names>K.</given-names></name><name name-style="western"><surname>O&#8217;donnell</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Lifestyle for Brain Health (LIBRA): a new model for dementia prevention</article-title><source>Int J Geriatr Psychiatry</source><volume>33</volume><issue>1</issue><year>2018</year><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1002/gps.4700</pub-id><pub-id pub-id-type="pmid">28247500</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Deckers</surname><given-names>K.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Boxtel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verhey</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Lack of associations between modifiable risk factors and dementia in the very old: findings from the Cambridge City over-75s cohort study</article-title><source>Aging and Mental Health</source><volume>22</volume><issue>10</issue><year>2018</year><fpage>1272</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1080/13607863.2017.1280767</pub-id><pub-id pub-id-type="pmid">28151002</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lipnicki</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Castro-Costa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lima-Costa</surname><given-names>M.F.</given-names></name><etal/></person-group><article-title>Sex differences in dementia risk and risk factors: individual-participant data analysis using 21 cohorts across six continents from the COSMIC consortium</article-title><source>Alzheimers Dement</source><volume>19</volume><issue>8</issue><year>2023</year><fpage>3365</fpage><lpage>3378</lpage><pub-id pub-id-type="doi">10.1002/alz.12962</pub-id><pub-id pub-id-type="pmid">36790027</pub-id><pub-id pub-id-type="pmcid">PMC10955774</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="book" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Sindi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Toopchiani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barbera</surname><given-names>M.</given-names></name><name name-style="western"><surname>H&#229;kansson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lehtisalo</surname><given-names>J.</given-names></name><etal/></person-group><part-title>Chapter 10 - sex and gender differences in genetic and lifestyle risk and protective factors for dementia</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Ferretti</surname><given-names>M.T.</given-names></name><etal/></person-group><source>Sex and gender differences in alzheimer's disease</source><year>2021</year><publisher-name>Academic Press</publisher-name><fpage>269</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-819344-0.00013-2</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Licher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karamuji&#263;-&#268;omi&#263;</surname><given-names>H.</given-names></name><name name-style="western"><surname>Voortman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Leening</surname><given-names>M.J.G.</given-names></name><etal/></person-group><article-title>Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population</article-title><source>Nat Med</source><volume>25</volume><issue>9</issue><year>2019</year><fpage>1364</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0547-7</pub-id><pub-id pub-id-type="pmid">31451782</pub-id><pub-id pub-id-type="pmcid">PMC6739225</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>&#197;svold</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Langhammer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rehn</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Kjelvik</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gr&#248;ntvedt</surname><given-names>T.V.</given-names></name><etal/></person-group><article-title>Cohort profile update: the HUNT Study, Norway</article-title><source>Int J Epidemiol</source><volume>52</volume><issue>1</issue><year>2023</year><fpage>e80</fpage><lpage>e91</lpage><pub-id pub-id-type="doi">10.1093/ije/dyac095</pub-id><pub-id pub-id-type="pmid">35578897</pub-id><pub-id pub-id-type="pmcid">PMC9908054</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><mixed-citation publication-type="other" id="sbref0036">Gj&#248;ra, L., Kjelvik, G., Strand, B.H., Kvello-Alme, M., &amp; Selbaek, G. (2020). <italic toggle="yes">Forekomst av demens i Norge</italic>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bk.no" id="interref0002">www.bk.no</ext-link>.</mixed-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Van Middelaar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hoevenaar-Blom</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Van Gool</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Moll Van Charante</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Van Dalen</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Modifiable dementia risk score to study heterogeneity in treatment effect of a dementia prevention trial: a post hoc analysis in the preDIVA trial using the LIBRA index</article-title><source>Alzheimers Res Ther</source><volume>10</volume><issue>1</issue><year>2018</year><fpage>62</fpage><pub-id pub-id-type="doi">10.1186/s13195-018-0389-4</pub-id><pub-id pub-id-type="pmid">29960597</pub-id><pub-id pub-id-type="pmcid">PMC6026510</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Gj&#248;ra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Bergh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Borza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Br&#230;khus</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Current and Future Prevalence Estimates of Mild Cognitive Impairment, Dementia, and Its Subtypes in a Population-Based Sample of People 70 Years and Older in Norway: The HUNT Study</article-title><source>J Alzheimers Dis</source><volume>79</volume><issue>3</issue><year>2021</year><fpage>1213</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.3233/jad-201275</pub-id><pub-id pub-id-type="pmid">33427745</pub-id><pub-id pub-id-type="pmcid">PMC7990439</pub-id></element-citation></ref><ref id="bib52"><label>39</label><element-citation publication-type="journal" id="optz9sKRhEtOR"><person-group person-group-type="author"><name name-style="western"><surname>N&#230;ss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kval&#248;y</surname><given-names>K.</given-names></name><name name-style="western"><surname>S&#248;rgjerd</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>S&#230;termo</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Nor&#248;y</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Data Resource Profile: The HUNT Biobank</article-title><source>Int J Epidemi</source><volume>53</volume><issue>3</issue><year>2024</year><pub-id pub-id-type="doi">10.1093/ije/dyae073</pub-id><pub-id pub-id-type="pmcid">PMC11150882</pub-id><pub-id pub-id-type="pmid">38836303</pub-id></element-citation></ref><ref id="bib0039"><label>40</label><mixed-citation publication-type="other" id="tboref0001">Weir C.B., Jan A. In: Publishing S., editor. BMI Classification Percentile And Cut Off Points. BMI Classification Percentile And Cut Off Points, 2025. StatPearls Treasure Island; 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK541070/" id="interref0003">https://www.ncbi.nlm.nih.gov/books/NBK541070/</ext-link>.</mixed-citation></ref><ref id="bib0040"><label>41</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Hinz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Br&#228;hler</surname><given-names>E.</given-names></name></person-group><article-title>Normative values for the Hospital Anxiety and Depression Scale (HADS) in the general German population</article-title><source>Journal of Psychosomatic Research</source><volume>71</volume><issue>2</issue><year>2011</year><fpage>74</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychores.2011.01.005</pub-id><pub-id pub-id-type="pmid">21767686</pub-id></element-citation></ref><ref id="bib0041"><label>42</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Akbar</surname><given-names>D.H.</given-names></name></person-group><article-title>Sub-optimal postprandial blood glucose level in diabetics attending the outpatient clinic of a University Hospital</article-title><source>Saudi Med J</source><volume>24</volume><issue>10</issue><year>2003</year><fpage>1109</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">14578979</pub-id></element-citation></ref><ref id="bib0042"><label>43</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Delong</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Delong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Clarke-Pearson</surname><given-names>D.L.</given-names></name></person-group><article-title>Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach</article-title><source>Biometrics</source><volume>44</volume><issue>3</issue><year>1988</year><fpage>837</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">3203132</pub-id></element-citation></ref><ref id="bib0043"><label>44</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>&#199;orbac&#305;o&#287;lu</surname><given-names>&#350;.K.</given-names></name><name name-style="western"><surname>Aksel</surname><given-names>G.</given-names></name></person-group><article-title>Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value</article-title><source>Turk J Emerg Med</source><volume>23</volume><issue>4</issue><year>2023</year><fpage>195</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.4103/tjem.tjem_182_23</pub-id><pub-id pub-id-type="pmid">38024184</pub-id><pub-id pub-id-type="pmcid">PMC10664195</pub-id></element-citation></ref><ref id="bib0044"><label>45</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Huque</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Carlin</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.J.</given-names></name></person-group><article-title>A comparison of multiple imputation methods for missing data in longitudinal studies</article-title><source>BMC Med Res Methodol</source><volume>18</volume><issue>1</issue><year>2018</year><fpage>168</fpage><pub-id pub-id-type="doi">10.1186/s12874-018-0615-6</pub-id><pub-id pub-id-type="pmid">30541455</pub-id><pub-id pub-id-type="pmcid">PMC6292063</pub-id></element-citation></ref><ref id="bib0045"><label>46</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Kootar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huque</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Eramudugolla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rizzuto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Validation of the CogDrisk Instrument as predictive of dementia in four general community-dwelling populations</article-title><source>J Prevent Alzheimer's Disease</source><volume>10</volume><issue>3</issue><year>2023</year><fpage>478</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.14283/jpad.2023.38</pub-id><pub-id pub-id-type="pmcid">PMC10449369</pub-id><pub-id pub-id-type="pmid">37357288</pub-id></element-citation></ref><ref id="bib0046"><label>47</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Kivim&#228;ki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luukkonen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Batty</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Ferrie</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Pentti</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Body mass index and risk of dementia: analysis of individual-level data from 1.3 million individuals</article-title><source>Alzheimers Dement</source><volume>14</volume><issue>5</issue><year>2018</year><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2017.09.016</pub-id><pub-id pub-id-type="pmid">29169013</pub-id><pub-id pub-id-type="pmcid">PMC5948099</pub-id></element-citation></ref><ref id="bib0047"><label>48</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Selbaek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stuebs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Engedal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hachinski</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hestad</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Blood pressure trajectories over 35 years and dementia risk: a retrospective study: the HUNT study</article-title><source>Front Aging Neurosci</source><volume>14</volume><year>2022</year><object-id pub-id-type="publisher-id">931715</object-id><pub-id pub-id-type="doi">10.3389/fnagi.2022.931715</pub-id><pub-id pub-id-type="pmcid">PMC9522576</pub-id><pub-id pub-id-type="pmid">36185489</pub-id></element-citation></ref><ref id="bib0048"><label>49</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Albanese</surname><given-names>E.</given-names></name><name name-style="western"><surname>Launer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Egger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Giannakopoulos</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Body mass index in midlife and dementia: systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies</article-title><source>Alzheimers Dement</source><volume>8</volume><year>2017</year><fpage>165</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2017.05.007</pub-id><pub-id pub-id-type="pmcid">PMC5520956</pub-id><pub-id pub-id-type="pmid">28761927</pub-id></element-citation></ref><ref id="bib0049"><label>50</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Debray</surname><given-names>T.P.A.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ensor</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Minimum sample size for external validation of a clinical prediction model with a binary outcome</article-title><source>Stat Med</source><volume>40</volume><issue>19</issue><year>2021</year><fpage>4230</fpage><lpage>4251</lpage><pub-id pub-id-type="doi">10.1002/sim.9025</pub-id><pub-id pub-id-type="pmid">34031906</pub-id></element-citation></ref><ref id="bib0050"><label>51</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Vermunt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sikkes</surname><given-names>S.A.M.</given-names></name><name name-style="western"><surname>Van Den Hout</surname><given-names>A.</given-names></name><name name-style="western"><surname>Handels</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bos</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Duration of preclinical, prodromal, and dementia stages of Alzheimer&#8217;s disease in relation to age, sex, and APOE genotype</article-title><source>Alzheimers Dement</source><volume>15</volume><issue>7</issue><year>2019</year><fpage>888</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2019.04.001</pub-id><pub-id pub-id-type="pmid">31164314</pub-id><pub-id pub-id-type="pmcid">PMC6646097</pub-id></element-citation></ref><ref id="bib0051"><label>52</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fransquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wrigglesworth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lacaze</surname><given-names>P.</given-names></name></person-group><article-title>Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies [Perspective]</article-title><source>Front Public Health</source><volume>6</volume><year>2018</year><pub-id pub-id-type="doi">10.3389/fpubh.2018.00181</pub-id><pub-id pub-id-type="pmcid">PMC6018385</pub-id><pub-id pub-id-type="pmid">29971228</pub-id></element-citation></ref></ref-list><ack id="ack0001"><title>Acknowledgments</title><p id="para0066">The Tr&#248;ndelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology NTNU), Tr&#248;ndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health.</p><p id="para0067">The genetic investigations of the HUNT Study, is a collaboration between researchers from the K.G. Jebsen center for genetic epidemiology and University of Michigan Medical School and the University of Michigan School of Public Health. The K.G. Jebsen Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norway</p><p id="para0068">The SNP genotyping was performed by the Genomics Core Facility (GCF), Norwegian University of Science and Technology (NTNU).</p></ack></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">1239</journal-id><journal-id journal-id-type="pmc-domain">frontagineuro</journal-id><journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Aging Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1663-4365</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12500553</article-id><article-id pub-id-type="pmcid-ver">PMC12500553.1</article-id><article-id pub-id-type="pmcaid">12500553</article-id><article-id pub-id-type="pmcaiid">12500553</article-id><article-id pub-id-type="doi">10.3389/fnagi.2025.1648561</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Aging Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Quantitative analysis of serum metabolites in a rat model of Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Smolentsev</surname><given-names initials="AA">Anton A.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Telegina</surname><given-names initials="DV">Darya V.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn0002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/583131/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kolosova</surname><given-names initials="NG">Nataliya G.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/157115/overview"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsentalovich</surname><given-names initials="YP">Yuri P.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1080526/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Snytnikova</surname><given-names initials="OA">Olga A.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3079508/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>International Tomography Center, Siberian Branch of the Russian Academy of Sciences</institution>, <addr-line>Novosibirsk</addr-line>, <country>Russia</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Natural Sciences, Novosibirsk State University</institution>, <addr-line>Novosibirsk</addr-line>, <country>Russia</country></aff><aff id="aff3"><sup>3</sup><institution>The Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences</institution>, <addr-line>Novosibirsk</addr-line>, <country>Russia</country></aff><author-notes><fn fn-type="edited-by" id="fn0003"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/80392/overview" ext-link-type="uri">Ilya Bezprozvanny</ext-link>, Peter the Great St.Petersburg Polytechnic University, Russia</p></fn><fn fn-type="edited-by" id="fn0004"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/39645/overview" ext-link-type="uri">Antonio Giuliano Zippo</ext-link>, National Research Council (CNR), Italy</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2196199/overview" ext-link-type="uri">Christoph Trautwein</ext-link>, Werner Siemens Imaging Centre, Germany</p></fn><corresp id="c001">*Correspondence: Olga A. Snytnikova, <email>snytnikova_olga@tomo.nsc.ru</email></corresp><fn fn-type="equal" id="fn0002"><p><sup>&#8224;</sup>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">481075</issue-id><elocation-id>1648561</elocation-id><history><date date-type="received"><day>17</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Smolentsev, Telegina, Kolosova, Tsentalovich and Snytnikova.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Smolentsev, Telegina, Kolosova, Tsentalovich and Snytnikova</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnagi-17-1648561.pdf"/><abstract><sec id="sec1"><title>Objective</title><p>OXYS rats are a unique animal model of sporadic Alzheimer&#8217;s disease (AD) that demonstrates all the key signs of AD in humans. Studying metabolic processes in OXYS rats in comparison with control Wistar rats can contribute to understanding the mechanisms of AD development, as well as to establishing metabolomic biomarkers of AD. The main goals of the work are to establish differences in the metabolomic profiles of OXYS and Wistar rat serum at different stages of AD-like pathology (presymptomatic, early and late).</p></sec><sec id="sec2"><title>Methods</title><p>NMR-based metabolomics was applied for metabolomic profiling of blood serum of OXYS and Wistar rats at the age of 20&#8239;days (presymptomatic period), 4&#8239;months (first manifestation of signs of AD) and 16&#8239;months (active development of signs).</p></sec><sec id="sec3"><title>Results</title><p>We determined the concentrations of 55 metabolites present in rat serum. We found that age-related changes in both rat strains reflect animal maturation (20&#8239;days to 4&#8239;months) and aging (4&#8239;months to 16&#8239;months), and correspond mainly to amino acid metabolism, purine metabolism, and energy pathways. Potential AD blood biomarkers include lysine, BCAAs, alanine, ornithine, creatine, glutamine and pyruvate.</p></sec><sec id="sec4"><title>Conclusion</title><p>The most significant differences between OXYS and Wistar blood metabolomes were found for 20-day-old animals, which corresponds to the preclinical period of AD development in humans. Metabolomic changes observed in the brain and blood are different and often opposite in sign. Blood serum is potentially promising fluid for AD diagnosis.</p></sec></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>aging</kwd><kwd>OXYS rats</kwd><kwd>serum</kwd><kwd>metabolomic profile</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This research was funded by the Russian Science Foundation (grant no. 25&#8211;14-00035).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="0"/><ref-count count="69"/><page-count count="12"/><word-count count="10093"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Alzheimer's Disease and Related Dementias</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><label>1</label><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) is the most common neurodegenerative disorder and the leading cause of senile dementia that have no effective treatment. Age is the most significant risk factor for sporadic form of disease (more than 95% of cases), in which the first signs of cognitive impairment appear over the age of 65&#8239;years against the background of irreversible neurodegenerative changes that develop asymptomatically over many years. As life expectancy increases, by 2050 the number of people worldwide with dementia will exceed 150 million (<xref rid="ref3" ref-type="bibr">Alzheimer's Association Report, 2023</xref>). Alzheimer&#8217;s disease is characterized by abnormal deposition of beta-amyloid (A&#946;), hyperphosphorylated tau proteins, and mitochondrial dysfunction in the brain. All this, together with such phenomena as reactive astrogliosis and neurodegeneration, contributes to the occurrence of cognitive impairment and ultimately leads to dementia (<xref rid="ref59" ref-type="bibr">Swerdlow, 2020</xref>). The need to prevent these processes by taking measures aimed at combating AD at the earliest stages of its development is actively discussed (<xref rid="ref48" ref-type="bibr">Ritchie et al., 2017</xref>). Research over the last decade using new technologies has shown that the preclinical period of AD can last for decades. The question of the initial moment of development of AD disease and what contributes to it remains still open. There is a pressing need for early diagnosis of AD which is driving the search of new approaches. Neuroimaging and cerebrospinal fluid biomarkers could help detect and diagnose the disease, but unfortunately, the clinical implementation of these methods is limited by their availability, cost, and invasiveness. Therefore, the search for blood-based biomarkers that would allow earlier and faster diagnosis, and could also help in risk assessment, early detection, prognosis, and treatment of AD is currently becoming an urgent task. However, a recent compelling international study has shown that assessing plasma levels of the traditional AD markers amyloid and phospho&#8211;tau can only confirm doctors&#8217; conclusions, increasing their confidence in the diagnosis, but have a little impact on its establishing (<xref rid="ref2" ref-type="bibr">Altomare et al., 2024</xref>). It can be assumed that in the future, such plasma biomarkers could significantly improve the efficiency of monitoring AD progression or treatment response, but are unlikely to be useful as early markers of the disease, unlike metabolomic markers (<xref rid="ref18" ref-type="bibr">Gonz&#225;lez-Dom&#237;nguez et al., 2015</xref>; <xref rid="ref67" ref-type="bibr">Weng et al., 2022</xref>; <xref rid="ref40" ref-type="bibr">Nielsen et al., 2024</xref>).</p><p>Metabolic dysfunction is one of the risk factors for AD, which appears to contribute or perhaps even trigger pathological molecular cascades of AD-pathology in conjunction with changes in various metabolites in the body. It is noteworthy, that a metabolomic analysis of blood in amyloid-positive individuals identified metabolites the levels of which differed between individuals with progressive cognitive decline and those whose cognitive abilities remained unchanged 3&#8239;years before cognitive decline (<xref rid="ref60" ref-type="bibr">Tremblay-Franco et al., 2024</xref>). It is suggested that pathological changes in the brain may be reflected in blood metabolites which are expected to be candidate biomarkers.</p><p>However, it is unclear to what extent changes in the blood metabolome reflect changes in the brain at the preclinical stage of AD. Research progress in this direction can be facilitated by the use of quantitative metabolomics methods, a high-throughput technology that allows for the simultaneous detection and cataloging of a large number of metabolites, which can be a useful tool in studying the pathogenesis of the disease, identifying its predictors and biomarkers that reflect the rate of AD progression and response to therapy (<xref rid="ref10" ref-type="bibr">Dong and Brewer, 2019</xref>; <xref rid="ref24" ref-type="bibr">Huo et al., 2020</xref>; <xref rid="ref39" ref-type="bibr">Niedzwiecki et al., 2020</xref>; <xref rid="ref44" ref-type="bibr">Ozaki et al., 2022</xref>; <xref rid="ref27" ref-type="bibr">Jaramillo-Jimenez et al., 2023</xref>; <xref rid="ref28" ref-type="bibr">Judd et al., 2023</xref>; <xref rid="ref45" ref-type="bibr">Pandey et al., 2024</xref>). At the same time, the study of preclinical stages of the disease in humans, the manifestation of which occurs later than the formation of neurodegenerative changes and the development of deep events at the molecular level, is problematic. The aim of this study is to compare changes in serum metabolomes in the dynamic of AD-like pathology development in senescence-accelerated OXYS rats, a unique model of the sporadic form of the disease. These animals spontaneously develop all the main hallmarks of Alzheimer&#8217;s disease: structural neurodegenerative changes, neuronal loss, synaptic failure, disturbances in neurotrophic supply, cerebrovascular changes, accumulation of A&#946;<sub>1&#8211;42</sub> and hyperphosphorylation of tau protein in the hippocampus, as well as cognitive impairment against the background of increasing mitochondrial dysfunction with age (<xref rid="ref32" ref-type="bibr">Kolosova et al., 2014</xref>, <xref rid="ref31" ref-type="bibr">2022</xref>; <xref rid="ref57" ref-type="bibr">Stefanova et al., 2014</xref>). In our recent work (<xref rid="ref55" ref-type="bibr">Snytnikova et al., 2024</xref>), we studied the metabolomic composition of the hippocampus of OXYS and Wistar rats and found sets of differential metabolites for different ages. In particular, we found increased accumulation of scyllo-inositol and decreased hypotaurine content in the brain of OXYS rats compared to Wistar rats. In this work, we studied the serum metabolome of OXYS rats at different stages of development of pathology similar to Alzheimer&#8217;s disease, including presymptomatic stage, using Wistar rats as a control. The results of the study were compared with data on the hippocampal metabolome of these animals (<xref rid="ref55" ref-type="bibr">Snytnikova et al., 2024</xref>).</p></sec><sec sec-type="materials|methods" id="sec6"><label>2</label><title>Materials and methods</title><sec id="sec7"><label>2.1</label><title>Chemicals</title><p>All reagents were purchased from Sigma-Aldrich (St. Louis, Michigan, USA) with the following exceptions: phosphate-buffered saline was purchased from Biolot (Moscow, Russia), D<sub>2</sub>O 99.9% and sodium 4,4-dimethyl-4-silapentane-1-sulfonate (DSS) were purchased from Cambridge Isotope Laboratories Inc. (Tewkesbury, Massachusetts, USA). Water was deionized to a quality of 18.2&#8239;M&#937; using an ultrapure water system (SG water, Munich, Germany).</p></sec><sec id="sec8"><label>2.2</label><title>Animals</title><p>In this work, we used the genetic model of senescence-accelerated OXYS rats. This strain is characterized by accelerated aging and spontaneous development of all the key features of Alzheimer&#8217;s disease. OXYS rats develop the manifestation of behavioral alterations and learning and memory deficits at the same time with the hyperphosphorylation of the tau protein in the hippocampus and cortex, impaired long-term potentiation and first signs of neurodegeneration at about 3&#8211;5&#8239;months. With age, neurodegenerative changes in the brain of OXYS rats become amplified against the background of overproduction of amyloid precursor protein (A<italic toggle="yes">&#946;</italic>PP), accumulation of &#946;-amyloid, and by the age of 16&#8211;18&#8239;months reach the well-pronounced stages of the AD-like pathology (<xref rid="ref32" ref-type="bibr">Kolosova et al., 2014</xref>). The study was performed using rat males from three age groups: age 20&#8239;days, which corresponds to the &#8220;presymptomatic&#8221; period without the development of AD signs; 4&#8239;months - with manifestations of signs, and 16&#8239;months with the active progression of AD signs (&#8220;early&#8221; and &#8220;late&#8221; stages, respectively) (<xref rid="ref32" ref-type="bibr">Kolosova et al., 2014</xref>; <xref rid="ref57" ref-type="bibr">Stefanova et al., 2014</xref>). Age-matched Wistar rats were used as control. The keeping of animals as described in <xref rid="ref55" ref-type="bibr">Snytnikova et al. (2024)</xref> and all experiments with animals were carried out in accordance with the regulation on the ethics of using animals in research supported by the Russian Science Foundation,<xref rid="fn0001" ref-type="fn"><sup>1</sup></xref> as well as with the European Union Directive 2010/63/EU and approved by the Commission on Bioethics at the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (Protocol no. 85/1 dated June 18, 2021).</p></sec><sec id="sec9"><label>2.3</label><title>Sample collection, metabolite extraction and NMR spectroscopy</title><p>Euthanasia of the animal was performed by introducing 100% carbon dioxide into an unlined cage initially containing room air with the lid closed at a rate sufficient to produce rapid anesthesia. Death occurred within 1&#8239;min. The rat was immediately decapitated and blood was collected from the body. To prepare the serum, the blood was allowed to clot for 15&#8239;min and then centrifuged for 15&#8239;min at 3000&#8239;g. The supernatant was collected and frozen in liquid nitrogen. All collected serum samples were stored at &#8722;70 &#176;C until analyzed.</p><p>The extraction of water-soluble metabolites from the rat blood serum was performed by the sample preparation protocol earlier evaluated in our lab (<xref rid="ref56" ref-type="bibr">Snytnikova et al., 2022</xref>). A cold methanol-chloroform extraction was chosen as the most efficient method for extracting metabolites from blood serum. The volumes of serum and extracting solution were used at the ratio: serum/methanol/chloroform&#8239;=&#8239;1/1/1. In this work, 300&#8239;&#956;L of cold methanol (&#8722;20 &#176;C) and 300&#8239;&#956;L of cold chloroform (&#8722;20 &#176;C) were added to 300&#8239;&#956;L of serum. Samples were mixed on a mini-vortex centrifuge and placed in a shaker for 30&#8239;min at 1300&#8239;rpm. The samples were kept in a freezer at &#8722;20 &#176;C for 30&#8239;min, then centrifuged at 12,000 rpm at 4 &#176;C for 30&#8239;min, and the supernatant was taken. The top hydrophilic fraction was collected and dried on a vacuum evaporator. The dried extracts were dissolved in 600&#8239;&#956;L deuterated phosphate buffer (0.01&#8239;M, pH&#8239;=&#8239;7.4) containing 6&#8239;&#956;M DSS as an internal standard.</p><p>The metabolomic composition of the obtained extracts was analyzed by the method of nuclear magnetic resonance using an AVANCE III HD 700&#8239;MHz NMR spectrometer (Bruker BioSpin, Ettlingen, Germany) at the Center of Collective Use &#8220;Mass spectrometric investigations&#8221; SB RAS. The <sup>1</sup>H spectra were recorded using the 5&#8239;mm TXI <sup>1</sup>H-<sup>13</sup>C/<sup>15</sup>N/D ZGR probehead. The spectra were acquired at using a single pulse zgpr sequence (detection pulse was 90 degrees) with the water signal suppression (saturation of the water signal with low power (20&#8239;&#956;W) continuous RF during the delay between repetitions), 14&#8239;ppm spectral width, 5&#8239;s relaxation delay, 6.7&#8239;s acquisition time. For each sample, the total spectrum of the sample was obtained by the sum of the 64 accumulated spectra. The temperature of the sample during the recording of the spectrum was maintained at 25.0&#8239;&#177;&#8239;0.1 &#176;C, the magnetic field homogeneity was shimmed with a Topshim procedure, and the sample volume in 5&#8239;mm NMR tubes was 0.6&#8239;mL. The parameters of the spectra recording were the same as described in the works (<xref rid="ref17" ref-type="bibr">Glinskikh et al., 2021</xref>; <xref rid="ref56" ref-type="bibr">Snytnikova et al., 2022</xref>, <xref rid="ref55" ref-type="bibr">2024</xref>). The chemical shift of metabolites were determined relatively DSS (chemical shift 0.00&#8239;ppm). The assignment of the metabolite resonances was carried out by comparing the obtained data with the data in Human Metabolome Database<xref rid="fn00002" ref-type="fn"><sup>1</sup></xref> and <xref rid="ref69" ref-type="bibr">Wishart et al. (2022)</xref>, or by adding reference compounds whenever needed, and also based on our own experience in the metabolomic profiling (<xref rid="ref54" ref-type="bibr">Snytnikova et al., 2017</xref>, <xref rid="ref53" ref-type="bibr">2019</xref>, <xref rid="ref56" ref-type="bibr">2022</xref>, <xref rid="ref55" ref-type="bibr">2024</xref>; <xref rid="ref17" ref-type="bibr">Glinskikh et al., 2021</xref>). We compared the resonances of individual substances with the resonances observed in the spectrum of the sample, which is actually a superposition of the spectra of individual substances. The concentrations of the metabolite were determined by signals which do not overlap in the spectrum with signals from other metabolites. To determine the metabolite concentrations we used the same metabolite list with resonances published earlier in the <xref rid="SM1" ref-type="supplementary-material">Supplementary material</xref> of study (<xref rid="ref56" ref-type="bibr">Snytnikova et al., 2022</xref>). The phases and baselines of the collected spectra were manually corrected using MestReNova V.12 (Mestrelab Research S. L.) software. The absolute concentrations of metabolites in the samples were calculated by the integration of the peak area of the metabolite signals relatively to the DSS signal. A detailed description of the concentration determination was published in the works (<xref rid="ref17" ref-type="bibr">Glinskikh et al., 2021</xref>; <xref rid="ref56" ref-type="bibr">Snytnikova et al., 2022</xref>).</p></sec><sec id="sec10"><label>2.4</label><title>Analysis of metabolite concentrations</title><p>The normalized metabolite concentration data were used to reveal the general metabolomic differences. PCA and sPLS-DA were performed using autoscaled (mean-centered and divided by the standard deviation of each variable) quantitative metabolomic data. To analyze the contributions of all metabolites into metabolic fingerprints we apply the principal component analysis (PCA) and sparse partial least squares discriminant analysis (sPLS-DA). To determine the meaningful patterns of metabolite concentration differences, the Metabolite Set Enrichment Analysis (MSEA) and Metabolite Pathway Analysis (MetPA) using the Kyoto Encyclopedia of Genes and Genomes database [KEGG; (<xref rid="ref29" ref-type="bibr">Kanehisa et al., 2014</xref>)] were applied. These analyzes were performed using the MetaboAnalyst 6.0 web-platform MetaboAnalyst<xref rid="fn00003" ref-type="fn"><sup>1</sup></xref> (<xref rid="ref46" ref-type="bibr">Pang et al., 2021</xref>). The Statistical Analysis (one factor) module was used to construct the PCA scores and Volcano plots. The MSEA plots were constructed with the Enrichment Analysis module.</p></sec><sec id="sec11"><label>2.5</label><title>Statistical analysis</title><p>The obtained data of metabolite concentration were analyzed by one-way and two-way analysis of variance (ANOVA) using the Google Colaboratory<xref rid="fn00004" ref-type="fn"><sup>1</sup></xref> and the Python library of the Numpy and Scipy Documentation<xref rid="fn00005" ref-type="fn"><sup>1</sup></xref>, graphs were built using the Matplotlib: Visualization with Python<xref rid="fn00006" ref-type="fn"><sup>1</sup></xref>. The Shapiro&#8211;Wilk test was used to check the normality of distributions. The Levene&#8217;s test was used to assess the homogeneity of dispersions. <italic toggle="yes">Post hoc</italic> multiple comparisons test was used with ANOVA analysis of variance. The genotype (Wistar, OXYS) and age of the animals (20&#8239;days, 4&#8239;months, and 16&#8239;months) were considered as independent factors in two-way ANOVA. The results were considered statistically significant at <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05 with FDR adjustment. Statistical calculation values are presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary information</xref>.</p></sec></sec><sec sec-type="results" id="sec12"><label>3</label><title>Results</title><sec id="sec13"><label>3.1</label><title>Quantitative metabolomic profiling of serum</title><p>The performed metabolomic profiling of rat serum revealed a total of 55 metabolites. For each sample group studied, the range of variation and the average value of the metabolite concentrations were determined. The determined concentrations of metabolites ranged from 0.3&#8239;&#956;M to 7.6&#8239;mM. The most abundant metabolites in the blood serum (the concentration above 300&#8239;&#956;M) were lactate, glucose, alanine, glutamine, 3-hydroxybutyrate, glycine, creatine and lysine. <xref rid="tab1" ref-type="table">Table 1</xref> shows the concentrations of metabolites with the most significant differences between rat strains. Tables with concentrations of all metabolites measured in this work are presented in the <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>&#8212;Wistar rats, <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>&#8212;OXYS rats.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Concentrations of rat serum metabolites with the most significant interstrain differences (indicated by asterisk).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Metabolite</th><th align="center" valign="top" colspan="2" rowspan="1">20&#8239;days</th><th align="center" valign="top" colspan="2" rowspan="1">4&#8239;months</th><th align="center" valign="top" colspan="2" rowspan="1">16&#8239;months</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Wistar</th><th align="center" valign="top" rowspan="1" colspan="1">OXYS</th><th align="center" valign="top" rowspan="1" colspan="1">Wistar</th><th align="center" valign="top" rowspan="1" colspan="1">OXYS</th><th align="center" valign="top" rowspan="1" colspan="1">Wistar</th><th align="center" valign="top" rowspan="1" colspan="1">OXYS</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">2-Ketoisovalerate</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.1&#8239;&#177;&#8239;2.5</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.6&#8239;&#177;&#8239;1.0</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.4&#8239;&#177;&#8239;0.9</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.0&#8239;&#177;&#8239;0.9</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.9&#8239;&#177;&#8239;0.9</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.9&#8239;&#177;&#8239;1.3<sup>
<bold>*</bold>
</sup></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">3-Methyl-2-oxovalerate</td><td align="center" valign="bottom" rowspan="1" colspan="1">14&#8239;&#177;&#8239;5</td><td align="center" valign="bottom" rowspan="1" colspan="1">11.2&#8239;&#177;&#8239;2.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">10.6&#8239;&#177;&#8239;1.8</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.1&#8239;&#177;&#8239;1.2<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">15&#8239;&#177;&#8239;4</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.4&#8239;&#177;&#8239;2.5<sup>
<bold>*</bold>
</sup></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Allantoin</td><td align="center" valign="bottom" rowspan="1" colspan="1">39&#8239;&#177;&#8239;9</td><td align="center" valign="bottom" rowspan="1" colspan="1">52&#8239;&#177;&#8239;7<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">73&#8239;&#177;&#8239;10</td><td align="center" valign="bottom" rowspan="1" colspan="1">64&#8239;&#177;&#8239;5</td><td align="center" valign="bottom" rowspan="1" colspan="1">50&#8239;&#177;&#8239;7</td><td align="center" valign="bottom" rowspan="1" colspan="1">51&#8239;&#177;&#8239;6</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Ascorbate</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.9&#8239;&#177;&#8239;0.4</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.4&#8239;&#177;&#8239;0.4</td><td align="center" valign="bottom" rowspan="1" colspan="1">19&#8239;&#177;&#8239;7</td><td align="center" valign="bottom" rowspan="1" colspan="1">20&#8239;&#177;&#8239;7</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.8&#8239;&#177;&#8239;2.9</td><td align="center" valign="bottom" rowspan="1" colspan="1">15.9&#8239;&#177;&#8239;2.0<sup>
<bold>*</bold>
</sup></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Citrate</td><td align="center" valign="bottom" rowspan="1" colspan="1">280&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">270&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">238&#8239;&#177;&#8239;28</td><td align="center" valign="bottom" rowspan="1" colspan="1">174&#8239;&#177;&#8239;21<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">210&#8239;&#177;&#8239;50</td><td align="center" valign="bottom" rowspan="1" colspan="1">180&#8239;&#177;&#8239;40</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Creatine</td><td align="center" valign="bottom" rowspan="1" colspan="1">180&#8239;&#177;&#8239;30</td><td align="center" valign="bottom" rowspan="1" colspan="1">264&#8239;&#177;&#8239;15<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">296&#8239;&#177;&#8239;30</td><td align="center" valign="bottom" rowspan="1" colspan="1">330&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">350&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">360&#8239;&#177;&#8239;50</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Cytidine</td><td align="center" valign="bottom" rowspan="1" colspan="1">35&#8239;&#177;&#8239;8</td><td align="center" valign="bottom" rowspan="1" colspan="1">35&#8239;&#177;&#8239;12</td><td align="center" valign="bottom" rowspan="1" colspan="1">68&#8239;&#177;&#8239;8</td><td align="center" valign="bottom" rowspan="1" colspan="1">58.0&#8239;&#177;&#8239;1.5<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">60&#8239;&#177;&#8239;7</td><td align="center" valign="bottom" rowspan="1" colspan="1">61&#8239;&#177;&#8239;6</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Glutamine</td><td align="center" valign="bottom" rowspan="1" colspan="1">600&#8239;&#177;&#8239;70</td><td align="center" valign="bottom" rowspan="1" colspan="1">490&#8239;&#177;&#8239;60<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">550&#8239;&#177;&#8239;70</td><td align="center" valign="bottom" rowspan="1" colspan="1">540&#8239;&#177;&#8239;50</td><td align="center" valign="bottom" rowspan="1" colspan="1">750&#8239;&#177;&#8239;90</td><td align="center" valign="bottom" rowspan="1" colspan="1">670&#8239;&#177;&#8239;60</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Glycerol</td><td align="center" valign="bottom" rowspan="1" colspan="1">135&#8239;&#177;&#8239;22</td><td align="center" valign="bottom" rowspan="1" colspan="1">160&#8239;&#177;&#8239;30</td><td align="center" valign="bottom" rowspan="1" colspan="1">120&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">120&#8239;&#177;&#8239;70</td><td align="center" valign="bottom" rowspan="1" colspan="1">143&#8239;&#177;&#8239;29</td><td align="center" valign="bottom" rowspan="1" colspan="1">77&#8239;&#177;&#8239;16<sup>
<bold>*</bold>
</sup></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Glycine</td><td align="center" valign="bottom" rowspan="1" colspan="1">219&#8239;&#177;&#8239;16</td><td align="center" valign="bottom" rowspan="1" colspan="1">280&#8239;&#177;&#8239;40<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">290&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">315&#8239;&#177;&#8239;24</td><td align="center" valign="bottom" rowspan="1" colspan="1">330&#8239;&#177;&#8239;50</td><td align="center" valign="bottom" rowspan="1" colspan="1">310&#8239;&#177;&#8239;30</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Histidine</td><td align="center" valign="bottom" rowspan="1" colspan="1">45&#8239;&#177;&#8239;7</td><td align="center" valign="bottom" rowspan="1" colspan="1">60&#8239;&#177;&#8239;7<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">60&#8239;&#177;&#8239;11</td><td align="center" valign="bottom" rowspan="1" colspan="1">67&#8239;&#177;&#8239;3</td><td align="center" valign="bottom" rowspan="1" colspan="1">68&#8239;&#177;&#8239;9</td><td align="center" valign="bottom" rowspan="1" colspan="1">70&#8239;&#177;&#8239;6</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Isoleucine</td><td align="center" valign="bottom" rowspan="1" colspan="1">84&#8239;&#177;&#8239;13</td><td align="center" valign="bottom" rowspan="1" colspan="1">63&#8239;&#177;&#8239;10<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">82&#8239;&#177;&#8239;13</td><td align="center" valign="bottom" rowspan="1" colspan="1">88&#8239;&#177;&#8239;9</td><td align="center" valign="bottom" rowspan="1" colspan="1">101&#8239;&#177;&#8239;15</td><td align="center" valign="bottom" rowspan="1" colspan="1">99&#8239;&#177;&#8239;16</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Leucine</td><td align="center" valign="bottom" rowspan="1" colspan="1">140&#8239;&#177;&#8239;30</td><td align="center" valign="bottom" rowspan="1" colspan="1">103&#8239;&#177;&#8239;11<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">133&#8239;&#177;&#8239;21</td><td align="center" valign="bottom" rowspan="1" colspan="1">151&#8239;&#177;&#8239;25</td><td align="center" valign="bottom" rowspan="1" colspan="1">151&#8239;&#177;&#8239;23</td><td align="center" valign="bottom" rowspan="1" colspan="1">151&#8239;&#177;&#8239;22</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Lysine</td><td align="center" valign="bottom" rowspan="1" colspan="1">127&#8239;&#177;&#8239;25</td><td align="center" valign="bottom" rowspan="1" colspan="1">250&#8239;&#177;&#8239;80<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">240&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">245&#8239;&#177;&#8239;29</td><td align="center" valign="bottom" rowspan="1" colspan="1">310&#8239;&#177;&#8239;30</td><td align="center" valign="bottom" rowspan="1" colspan="1">270&#8239;&#177;&#8239;40</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Mannose</td><td align="center" valign="bottom" rowspan="1" colspan="1">22.5&#8239;&#177;&#8239;2.6</td><td align="center" valign="bottom" rowspan="1" colspan="1">29&#8239;&#177;&#8239;4<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">33&#8239;&#177;&#8239;10</td><td align="center" valign="bottom" rowspan="1" colspan="1">31&#8239;&#177;&#8239;6</td><td align="center" valign="bottom" rowspan="1" colspan="1">30&#8239;&#177;&#8239;3</td><td align="center" valign="bottom" rowspan="1" colspan="1">31&#8239;&#177;&#8239;3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Proline</td><td align="center" valign="bottom" rowspan="1" colspan="1">180&#8239;&#177;&#8239;70</td><td align="center" valign="bottom" rowspan="1" colspan="1">164&#8239;&#177;&#8239;19</td><td align="center" valign="bottom" rowspan="1" colspan="1">164&#8239;&#177;&#8239;29</td><td align="center" valign="bottom" rowspan="1" colspan="1">140&#8239;&#177;&#8239;10</td><td align="center" valign="bottom" rowspan="1" colspan="1">190&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">131&#8239;&#177;&#8239;21<sup>
<bold>*</bold>
</sup></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Sarcosine</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.2&#8239;&#177;&#8239;1.9</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.4&#8239;&#177;&#8239;0.8</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.97&#8239;&#177;&#8239;0.19</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.1&#8239;&#177;&#8239;0.6<sup>
<bold>*</bold>
</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">2.7&#8239;&#177;&#8239;0.5</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.4&#8239;&#177;&#8239;1.1</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Threonine</td><td align="center" valign="bottom" rowspan="1" colspan="1">160&#8239;&#177;&#8239;50</td><td align="center" valign="bottom" rowspan="1" colspan="1">182&#8239;&#177;&#8239;21</td><td align="center" valign="bottom" rowspan="1" colspan="1">230&#8239;&#177;&#8239;40</td><td align="center" valign="bottom" rowspan="1" colspan="1">219&#8239;&#177;&#8239;18</td><td align="center" valign="bottom" rowspan="1" colspan="1">350&#8239;&#177;&#8239;90</td><td align="center" valign="bottom" rowspan="1" colspan="1">210&#8239;&#177;&#8239;30<sup>
<bold>*</bold>
</sup></td></tr></tbody></table><table-wrap-foot><p>Data presented in &#956;M as Mean &#177; SD.</p></table-wrap-foot></table-wrap></sec><sec id="sec14"><label>3.2</label><title>Age-related changes in the metabolomic profiles</title><p>Age-related changes in the serum metabolome were evaluated based on the score values of multivariate principal component analysis (PCA). A comparison was made of age-related changes in the blood metabolomic profiles during physiological aging of Wistar rats and senescence-accelerated OXYS rats. Age-related differences for Wistar and OXYS rats in terms of the totality of all metabolites are shown in <xref rid="fig1" ref-type="fig">Figure 1</xref> by PCA scores plots, where the number of points corresponds to the number of studied samples in a group.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Principal component analysis of metabolomic profile of blood serum from Wistar <bold>(A)</bold> and OXYS <bold>(B)</bold> rats of various ages. Colored ovals indicate 95% confidence regions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1648561-g001.jpg"><alt-text content-type="machine-generated">Scatter plots labeled A and B display age-related clustering of data for Wistar and OXYS subjects, respectively. Plot A shows clusters for 16 months, 4 months, and 20 days, with percentages on PC1 and PC2 axes. Plot B similarly shows clusters for the same age points with different percentages on PC1 and PC2 axes. Ellipses indicate groupings.</alt-text></graphic></fig><p>For both Wistar and OXYS rats, the serum metabolomic profile at 20&#8239;days of age differs significantly from that of 4- and 16-month-old animals. The separation of the sample populations depending on age occurs mainly along the first principal component (38.0% for Wistar and 46.1% for OXYS). The group difference is best visualized by the sPLS&#8211;DA plot presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>, where the separation between 4- and 16-month-old animals occurs along the second component. Age-related changes for all 55 metabolites detected in this work are shown in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S2</xref>, and statistical analysis of age-related changes is presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Tables S3, S4</xref>.</p><p>To analyze age-related changes in rat serum metabolomic profiles in more detail, we constructed PCA score plots, Volcano plots, and performed MSEA for 20&#8239;days and 4&#8239;months of age, and separately for 4&#8239;months and 16&#8239;months of age. The analyses were performed for both Wistar and OXYS rats (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S3.1&#8211;S3.4</xref>). Since age-related differences were significant, we reduced the number of differential metabolites identified by using relatively high cutoff values: fold change above 1.3, <italic toggle="yes">p</italic>-value below 0.05. This way, we identified 20 differential metabolites (concentration of 8 compounds decreased and 12 compounds increased) when comparing 20-day-old and 4-month-old Wistar, 32 differential metabolites (19 decreased and 13 increased) when comparing 20-days and 4-months OXYS rats (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S3.1 and S3.2</xref>, respectively; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>). In the comparison of 4-month-old and 16-month-old animals, the list of significantly different metabolites is much shorter: 14 compounds (5 decreased and 9 increased) for Wistar and only 2 metabolites (1 decreased and 1 increased) for OXYS (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S3.3 and S3.4</xref>, respectively; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>).</p><p>Venn diagram (<xref rid="fig2" ref-type="fig">Figure 2A</xref>) demonstrates the metabolic shift at 20&#8239;days versus 4&#8239;months of age and at 4&#8239;months versus 16&#8239;months of age in Wistar and OXYS rats. Since metabolomic changes between 20&#8239;days and 4&#8239;months are more significant, we also constructed a detailed Venn diagram for these ages, which indicates the directions of metabolomic changes (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). <xref rid="fig2" ref-type="fig">Figure 2B</xref> also contains a list of differential metabolites common for both OXYS and Wistar rats. <xref rid="fig2" ref-type="fig">Figure 2C</xref> presents an example of metabolite concentration changes with age in the rat serum: the level of dimethylglycine decreases between 20&#8239;days and 4&#8239;months of age, and then increases for both OXYS and Wistar rats. In addition to dimethylglycine, codirectional changes were found for 15 metabolites from 20&#8239;days to 4&#8239;months of age (8 decreased and 8 increased, as shown in <xref rid="fig2" ref-type="fig">Figure 2B</xref>) and a decrease in phosphocholine concentration from 4&#8239;months to 16&#8239;months of age in both Wistar and OXYS rats (<xref rid="SM1" ref-type="supplementary-material">Supplementary Tables S1, S2</xref>). In the age period from 20&#8239;days to 4&#8239;months, an increase in the concentration of allantoin, creatine, glycine and lysine was observed specifically for Wistar rats, whereas in OXYS rats there was a change in the concentration of 16 metabolites (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). In the period from 4 to 16&#8239;months of age, the concentration of dimethylglycine increased and phosphocholine decreased in the blood serum of rats of both lines. The concentration of methionine increased unidirectionally in all periods of the study and the concentration of scyllo-inositol decreased in Wistar rats (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>). At the same time, the level of 5 metabolites in the blood serum of Wistar rats changed in different directions: the concentration of allantoin and ascorbate increased at the age of 4&#8239;months and decreased at the age of 16&#8239;months, whereas dimethylglycine, methionine sulfoxide and sarcosine demonstrated opposite directions of concentration change (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>). From 4 to 16&#8239;months, the levels of 6 metabolites changed specifically for Wistar rats, of which only the concentration of betaine decreased, whereas the concentration of 2-ketoisovalerate, arginine, glutamine, ketoleucine and threonine increased (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>).</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Comparison of age-related changes of metabolite concentrations (Fold Change &gt; 1.3, <italic toggle="yes">p</italic>-value &lt; 0.05) in OXYS and Wistar rats using a Venn diagram: overall changes from 20&#8239;days to 4&#8239;months and from 4&#8239;months to 16&#8239;months <bold>(A)</bold>; detailed analysis of data from 20&#8239;days to 4&#8239;months <bold>(B)</bold> (red and blue indicate increased and decreased concentration, respectively). <bold>(C)</bold> Serum dimethylglycine concentrations in Wistar and OXYS rats; data are presented as mean &#177; SD. Significant differences: # <italic toggle="yes">p</italic>-value &lt; 0.05 with previous age. The sign 20d in the figure corresponds to the age of 20&#8239;days, 4&#8239;m and 16&#8239;m - 4 and 16&#8239;months, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1648561-g002.jpg"><alt-text content-type="machine-generated">Venn diagrams and line graph comparing metabolic changes in Wistar and OXYS rats. Panel A shows metabolite overlap between ages 20 days to 4 months and 4 to 16 months, highlighting dimethylglycine and allantoin. Panel B details metabolites with changes labeled as up or down in both rat types from 20 days to 4 months. Panel C displays a line graph of dimethylglycine concentration over with aging, with both rat types showing similar trends.</alt-text></graphic></fig></sec><sec id="sec15"><label>3.3</label><title>The effect of the AD-like pathology on the serum metabolome</title><p>To assess metabolome changes as AD develops and progresses, we compared serum metabolome profiles of age-matched Wistar and OXYS rats (<xref rid="fig3" ref-type="fig">Figure 3</xref>). PCA demonstrates that interstrain differences are greatest at 20&#8239;days of age, when AD signs have not yet been detected in OXYS rats, and are lowest during the period of active AD manifestation at 4&#8239;months of age. In 20-day-old OXYS rats, the levels of three metabolites (leucine, isoleucine and glutamine) are reduced and the levels of nine metabolites (creatine, histidine, glycine, mannose, allantoin, serine, lysine, pyruvate and ascorbate) are increased compared to Wistar rats. In 4-month-old OXYS rats, the levels of citrate, 3-methyl-2-oxovalerate, betaine, glutamate, lactate, phosphocholine, and pyruvate are decreased, and there is only one increased metabolite, sarcosine. At the age of 16&#8239;months, the levels of glycerol, 2-ketoisovalerate, 3-methyl-2-oxovalerate, threonine, proline, ketoleucine, ornithine, methionine, and pyruvate are reduced in OXYS rats, while the levels of ascorbate, dimethylamine, and formate are increased compared to Wistar rats. The graphs in <xref rid="fig4" ref-type="fig">Figure 4</xref> show examples of metabolites with the greatest differences between age-matched OXYS and Wistar rats.</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>PCA scores plots (left), Volcano plots (middle) and enriched metabolite sets (p-value &lt; 0.05) for serum metabolites from age-matched Wistar and OXYS rats at different ages: 20&#8239;days <bold>(A)</bold>, 4&#8239;months <bold>(B)</bold>, 16&#8239;months <bold>(C)</bold>. In Volcano plots, the <italic toggle="yes">x</italic>-axis displays the fold change (FC), the horizontal line depicts the cut-off of <italic toggle="yes">p</italic>-value&#8239;=&#8239;0.1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1648561-g003.jpg"><alt-text content-type="machine-generated">Three panels show comparison of OXYS and Wistar rats at different ages with PCA and enrichment analysis. Panel A shows data at 20 days with the most distinct metabolites creatine and lysine and significant enrichment in purine metabolism. Panel B covers 4 months with key changes like citrate and sarcosine, and alterations in TCA cycle. Panel C presents 16 months of data, showing significant enrichment in amino acid biosynthesis and degradation pathways. Enrichment plots illustrate the most significant pathways reflecting metabolic changes with aging.</alt-text></graphic></fig><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Venn diagram for differential metabolites in blood of OXYS and Wistar rats at 20&#8239;days, 4&#8239;months, and 16&#8239;months. Red and blue letter indicate increased and decreased concentration, respectively. Comparison of metabolite concentrations in Wistar (blue circle) and OXYS (red square) rat serum during the development of AD signs: presymptomatic (at 20&#8239;days of age), early (4&#8239;months) and late (16&#8239;months) stages. Data are presented as mean &#177; SD. Significant differences: *<italic toggle="yes">p</italic>-value &lt; 0.05 between rat strains. (S)-OMV, 3-Methyl-2-oxovalerate. The sign 20d on the x-axis displays data corresponding to the age of 20&#8239;days, 4&#8239;m and 16&#8239;m - 4 and 16&#8239;months, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1648561-g004.jpg"><alt-text content-type="machine-generated">Venn diagram and graphs showing metabolite concentrations over time for Wistar and OXYS rats. The Venn diagram lists affected metabolites at different ages: 20 days, 4 months, and 16 months, with overlaps for ascorbate and (S)-OMV. Graphs for each metabolite show concentration trends at 20 days, 4 months, and 16 months, with significant differences marked by symbols.</alt-text></graphic></fig><p>We found three metabolites the concentrations of which changed significantly for at least two ages. The concentration of pyruvate was increased in OXYS rats at 20&#8239;days of age, and decreased at 4&#8239;months and 16&#8239;months of age. Serum ascorbate levels were significantly higher in OXYS rats than in Wistar rats at 20&#8239;days and 16&#8239;months of age and were similar at 4&#8239;months of age. The metabolite 3-methyl-2-oxovalerate was significantly lower in OXYS at 4&#8239;months and 16&#8239;months of age.</p><p>MSEA performed for age-matched OXYS and Wistar rats indicates metabolic pathways with the largest and statistically significant differences between the strains (<xref rid="fig3" ref-type="fig">Figure 3</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Tables S5&#8211;S7</xref>). At the age of 20&#8239;days, 22 pathways comprising 31 metabolites detected in this work were statistically different with <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05. For 4-month-old rats, a significant difference was found for five pathways (18 metabolites), and for 16-month-old animals for six pathways (15 metabolites). For 20&#8239;days and 4&#8239;months of ages, two pathways were common. These pathways are &#8220;Glycine, serine and threonine metabolism,&#8221; which includes the metabolites serine, choline, betaine, dimethylglycine, glycine, sarcosine, threonine, creatine, and pyruvate, and &#8220;Glyoxylate and dicarboxylate metabolism,&#8221; which includes citrate, serine, glycine, acetate, pyruvate, formate, and glutamine. For 20&#8239;days and 16&#8239;months of ages, the common pathways are &#8220;Arginine and proline metabolites,&#8221; &#8220;Valine, leucine and isoleucine biosynthesis,&#8221; and &#8220;Valine, leucine and isoleucine degradation.&#8221; None of metabolic pathways found at 16&#8239;months of age matched those observed in 4-month-old animals.</p></sec></sec><sec sec-type="discussion" id="sec16"><label>4</label><title>Discussion</title><p>The first aim of our study was to investigate the changes in the serum metabolome during aging and the development of AD signs in rats and, secondly, to validate blood-based biomarkers to aid in AD diagnosis, especially at the early, presymptomatic stage. To gain deeper insight into the pathophysiology of dementia and to identify new potential diagnostic serum markers for AD, we analyzed the serum metabolome profile of Wistar and OXYS rats at different stages of AD signs development and compared these data with previously obtained metabolomic profiles in the rat hippocampus (<xref rid="ref55" ref-type="bibr">Snytnikova et al., 2024</xref>). The main function of blood is to deliver nutrients and remove waste products, so it is important to recognize that different levels of metabolites in the blood may result from different biological processes occurring in the body. Thus, with the development of a pathological process, an increase in a particular metabolite may be observed, but at the same time, overproduction of this compound may reflect the physiological response of the body to suppress the disease. Although elucidating metabolic mechanisms is a complex task, this does not prevent their use for clinical assessments, thus bringing practical benefits (<xref rid="ref67" ref-type="bibr">Weng et al., 2022</xref>).</p><p>In rat serum, the greatest age-related differences in the metabolic profile were found between 20&#8239;days and 4&#8239;months of age, while the difference between 4&#8239;months and 16&#8239;months was less pronounced (<xref rid="fig1" ref-type="fig">Figure 1</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S1, S3.1&#8211;S3.4</xref>). The differential metabolite lists in Wistar and OXYS rats between 20&#8239;days and 4&#8239;months of age were similar (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S3.1, S3.2</xref>). MSEA showed that the most affected metabolic pathways during this time period were &#8220;Alanine, aspartate, and glutamate metabolism,&#8221; &#8220;Cysteine and methionine metabolism,&#8221; &#8220;Glycine, serine, and threonine metabolism,&#8221; &#8220;Glycolysis/gluconeogenesis,&#8221; and &#8220;Pyruvate metabolism&#8221; for both rat strains (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S3.1, S3.2</xref>). Apparently, these age-related metabolomic changes observed in both Wistar and OXYS rats appear to be related to the maturation of the animals. The metabolomic changes reflecting animal aging (4&#8239;months vs. 16&#8239;months) and common to both strains correspond to &#8220;Purine metabolism,&#8221; &#8220;Nitrogen metabolism&#8221; and &#8220;Arginine biosynthesis&#8221; (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S3.3, S3.4</xref>). Metabolomic studies in other animal models have also demonstrated age-related changes in similar metabolites and associated pathways (<xref rid="ref71" ref-type="bibr">Yin et al., 2023</xref>). Interestingly, we found only one metabolite, dimethylglycine, the level of which changes with aging in both rat strains (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). This is an intermediate metabolite in the metabolism of choline to glycine that exhibits antioxidant activity, most likely through free radical scavenging with a minor contribution to the respiratory chain (<xref rid="ref14" ref-type="bibr">Finsterer and Bindu, 2015</xref>). On the other hand, elevated plasma dimethylglycine levels have been shown to be associated with an increased risk of acute myocardial infarction and coronary heart disease (<xref rid="ref66" ref-type="bibr">Wei and Wang, 2021</xref>). Thus, it can be assumed that the increase in dimethylglycine levels by 16&#8239;months in Wistar and OXYS rats reflects increasing vascular dysfunction, which is characteristic of both normal and accelerated aging.</p><p>To search for potential AD biomarkers in blood, we examined the interstrain differences in the serum metabolomic profiles during the development of AD signs in OXYS rats. According to modern studies (<xref rid="ref8" ref-type="bibr">De-Paula et al., 2012</xref>), three clinical phases of AD can be defined: (1) pre-symptomatic (or preclinical) AD; (2) pre-dementia phase of AD (compatible with the definition of progressive, amnestic mild cognitive impairment); (3) phase of clinically defined dementia in AD. It is clear that there is no biological model that completely reproduces all the features of human AD. However, non-transgenic OXYS rats largely reproduce the stages of the disease (<xref rid="ref57" ref-type="bibr">Stefanova et al., 2014</xref>, <xref rid="ref58" ref-type="bibr">2015</xref>; <xref rid="ref50" ref-type="bibr">Rudnitskaya et al., 2021</xref>; <xref rid="ref31" ref-type="bibr">Kolosova et al., 2022</xref>). The age of 20&#8239;days corresponds to the presymptomatic stage of AD, when OXYS rats do not show signs of the disease. At the age of 3&#8211;5&#8239;months, against the background of mitochondrial dysfunction OXYS rats manifest signs of AD such as hyperphosphorylation of tau-protein, disruption of long-term post-tetanic potentiation, synaptic deficiency, destructive neuron changes, behavioral disorders and reduction of cognitive functions. This stage we can define as the pre-dementia phase of AD. By 16&#8239;months, OXYS rats shows active progression of AD signs against the background of increased APP levels, enhanced accumulation of A&#946; and formation of amyloid plaques in the brain, and a transition to the stage of disease occurs, which can be defined as an analogue of the dementia phase of AD in humans.</p><p>For 20-day-old rats, the highest and statistically significant interstrain differences were found for several amino acids, organic acids, and sugars (<xref rid="fig2" ref-type="fig">Figures 2</xref>, <xref rid="fig4" ref-type="fig">4</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>), and the most affected metabolic pathways are &#8220;Purine metabolism,&#8221; &#8220;Glyoxylate and dicarboxylate metabolism,&#8221; &#8220;Arginine and proline metabolism,&#8221; and &#8220;Glycine, serine and threonine metabolism&#8221; (<xref rid="fig3" ref-type="fig">Figure 3</xref>). This is in a good agreement with the results obtained for the human blood from AD patients (<xref rid="ref61" ref-type="bibr">Trushina et al., 2013</xref>; <xref rid="ref62" ref-type="bibr">Trushina and Mielke, 2014</xref>; <xref rid="ref41" ref-type="bibr">Nielsen et al., 2021</xref>, <xref rid="ref40" ref-type="bibr">2024</xref>; <xref rid="ref68" ref-type="bibr">Whiley et al., 2021</xref>; <xref rid="ref67" ref-type="bibr">Weng et al., 2022</xref>; <xref rid="ref5" ref-type="bibr">Berezhnoy et al., 2023</xref>; <xref rid="ref72" ref-type="bibr">Yu et al., 2023</xref>). In particular, changes in glycolysis, the Krebs cycle, and the urea cycle in the human blood under AD development were found in study (<xref rid="ref67" ref-type="bibr">Weng et al., 2022</xref>), while Nielsen et al. reported that the most affected pathways were &#8220;Purine metabolism,&#8221; &#8220;Metabolism of branched-chain amino acids,&#8221; &#8220;Glycolysis and gluconeogenesis,&#8221; and &#8220;Lysine metabolism&#8221; (<xref rid="ref41" ref-type="bibr">Nielsen et al., 2021</xref>, <xref rid="ref40" ref-type="bibr">2024</xref>). In the work (<xref rid="ref61" ref-type="bibr">Trushina et al., 2013</xref>), alternations in &#8220;Lysine metabolism,&#8221; &#8220;TCA cycle,&#8221; &#8220;Pyruvate metabolism,&#8221; and &#8220;Valine, leucine and isoleucine metabolism&#8221; were detected in the blood of AD patients.</p><p>An analysis of the literature data on human blood metabolomics related to Alzheimer&#8217;s disease shows that lysine is the metabolite most often proposed as a potential biomarker of AD (<xref rid="ref61" ref-type="bibr">Trushina et al., 2013</xref>; <xref rid="ref74" ref-type="bibr">Zetterberg and Burnham, 2019</xref>; <xref rid="ref44" ref-type="bibr">Ozaki et al., 2022</xref>; <xref rid="ref40" ref-type="bibr">Nielsen et al., 2024</xref>). Other potential biomarkers include BCAAs, alanine, ornithine, creatine, glutamine and pyruvate (<xref rid="ref61" ref-type="bibr">Trushina et al., 2013</xref>; <xref rid="ref30" ref-type="bibr">Kelley and Andersson, 2014</xref>; <xref rid="ref74" ref-type="bibr">Zetterberg and Burnham, 2019</xref>; <xref rid="ref41" ref-type="bibr">Nielsen et al., 2021</xref>, <xref rid="ref40" ref-type="bibr">2024</xref>; <xref rid="ref44" ref-type="bibr">Ozaki et al., 2022</xref>; <xref rid="ref67" ref-type="bibr">Weng et al., 2022</xref>; <xref rid="ref5" ref-type="bibr">Berezhnoy et al., 2023</xref>; <xref rid="ref72" ref-type="bibr">Yu et al., 2023</xref>). Most of these potential biomarkers were detected in the present work as differential metabolites between OXYS and Wistar rats. We found a decrease in the level of leucine, isoleucine and glutamine and an increase in the level of nine metabolites (creatine, histidine, glycine, mannose, allantoin, serine, lysine, pyruvate and ascorbate) in 20-day-old OXYS rats compared to Wistar rats. The most statistically significant difference is observed for creatine, the concentration of which in the blood serum of OXYS rats is higher, 260&#8239;&#956;M versus 180&#8239;&#956;M in Wistar. Creatine is a nitrogen-containing carboxylic acid involved in metabolic pathways of energy metabolism, and it is an important source of energy for the body. Elevated levels of this metabolite may indicate disturbances in guanidinoacetate metabolism (<xref rid="ref5" ref-type="bibr">Berezhnoy et al., 2023</xref>), as well as disturbances in the Krebs cycle and modification of creatine kinase enzyme (<xref rid="ref6" ref-type="bibr">Castegna et al., 2002</xref>; <xref rid="ref65" ref-type="bibr">Wang et al., 2020</xref>). In a recent study, creatine was proposed as one of the biomarkers for diagnosing Alzheimer&#8217;s disease in humans (<xref rid="ref40" ref-type="bibr">Nielsen et al., 2024</xref>). It should also be noted that other differential metabolites identified in the present work have been earlier observed at the preclinical stage of the disease. These metabolites include glutamine and BCAAs (leucine and isoleucine), which are reduced in OXYS rats. A link between low levels of BCAAs and AD has been previously reported (<xref rid="ref38" ref-type="bibr">Morabito et al., 2014</xref>; <xref rid="ref18" ref-type="bibr">Gonz&#225;lez-Dom&#237;nguez et al., 2015</xref>; <xref rid="ref26" ref-type="bibr">Ikeuchi et al., 2022</xref>; <xref rid="ref52" ref-type="bibr">Siddik et al., 2022</xref>). Some researchers have suggested that decreased level of BCAAs can be considered as a potential marker for predicting the transition from mild cognitive impairment to AD (<xref rid="ref41" ref-type="bibr">Nielsen et al., 2021</xref>, <xref rid="ref40" ref-type="bibr">2024</xref>; <xref rid="ref70" ref-type="bibr">Xiong et al., 2022</xref>). <xref rid="ref72" ref-type="bibr">Yu et al. (2023)</xref> suggested that the concentration of BCAAs in the blood of AD patients is significantly reduced because brain cells use the carbon skeleton of BCAAs as an auxiliary fuel to support the impaired energy metabolism in Alzheimer&#8217;s disease. However, another randomized study found elevated BCAAs concentrations in the serum of patients with Alzheimer&#8217;s disease (<xref rid="ref34" ref-type="bibr">Li et al., 2018</xref>). These largely opposite results are most likely due to the fact that the BCAAs concentration in blood often directly reflects dietary consumption levels, as they are mainly poorly metabolized in the liver (<xref rid="ref20" ref-type="bibr">Griffin and Bradshaw, 2017</xref>). Thus, decreased blood concentrations of essential amino acids may indicate underlying nutritional deficiencies in preclinical human dementia (<xref rid="ref51" ref-type="bibr">Sato et al., 2021</xref>). BCAAs and glutamine are closely related to glutamate metabolism. Glutamine is converted to glutamate, acting as the main excitatory neurotransmitter in the CNS (<xref rid="ref7" ref-type="bibr">Chaudhry et al., 2002</xref>). As noted in Nielsen&#8217;s work (<xref rid="ref41" ref-type="bibr">Nielsen et al., 2021</xref>), a decrease in BCAA levels can affect the conversion of glutamine and glutamate, and thereby lead to decreased neurotransmission. This is supported by the finding of lower glutamine levels in people with cognitive impairment, as well as in a study of patients with AD, which also reported decreased glutamate levels (<xref rid="ref12" ref-type="bibr">Fayed et al., 2011</xref>). Glutamine and BCAAs contribute to the Krebs cycle (<xref rid="ref10" ref-type="bibr">Dong and Brewer, 2019</xref>). Therefore, changes in glutamine and BCAA levels will also affect the functioning of the TCA cycle. Although decreased serum leucine and isoleucine levels were only detected in OXYS rats at 20&#8239;days of age, we found decreased levels of the downstream BCAA metabolite 3-methyl-2-oxavalerate during the manifestation and progression of AD. We suggest that the decreased level of 3-methyl-2-oxavalerate may indicate BCAA dysregulation, which in turn may be a cause and/or consequence of mitochondrial dysfunction (<xref rid="ref36" ref-type="bibr">Menni et al., 2013</xref>). Indeed, we have previously shown that the development of AD signs in OXYS rats occurs against the background of mitochondrial dysfunction from an early age (<xref rid="ref31" ref-type="bibr">Kolosova et al., 2022</xref>). It can be assumed that the decrease in the level of 3-methyl-2-oxavalerate in OXYS rats reflects disturbances in mitochondrial metabolism at the early and late stages of the development of AD-like degeneration. Thus, the set of differential metabolites found in young OXYS versus Wistar rats is similar to that in AD patients versus healthy controls, and the same metabolic pathways are affected. Differential metabolites found in the blood of 20-day-old rats can be considered as potential early biomarkers of neurodegeneration.</p><p>According to our data, the only metabolite that differed in OXYS compared to Wistar rats at all stages of AD-like pathology development was pyruvate, the end product of glycolysis and a substrate for the synthesis of mitochondrial adenosine triphosphate. Decreased level of pyruvate was observed in the blood of patients with mild to moderate AD (<xref rid="ref40" ref-type="bibr">Nielsen et al., 2024</xref>), but increased pyruvate levels were observed in CSF of patients with AD (<xref rid="ref47" ref-type="bibr">Parnetti et al., 1995</xref>). However, we believe that changes in pyruvate levels reflect disturbances in energy metabolism that are characteristic of the development of neurodegenerative diseases in human and OXYS rats. This is also supported by data obtained from patients with Parkinson&#8217;s disease (decreased pyruvate levels were found in blood samples) (<xref rid="ref1" ref-type="bibr">Ahmed et al., 2009</xref>), which makes it questionable to use pyruvate as a specific biomarker of AD.</p><p>A common feature of old (16&#8239;months) OXYS rats and humans with developed AD is mitochondrial dysfunction (<xref rid="ref63" ref-type="bibr">Tyumentsev et al., 2018</xref>), which alters the energy metabolism. Indeed, the differential metabolites and the most affected pathways found in 16-month-old OXYS rats compared to Wistar rats are mainly related to energy metabolism. These pathways include glycolysis, pyruvate metabolism, and BCAAs biosynthesis and degradation (<xref rid="fig3" ref-type="fig">Figure 3</xref>). Other metabolites whose concentrations differ significantly from the control group are threonine, ornithine and 2-ketoisovalerate. The concentrations of these metabolites in the serum of 16-month-old OXYS rats are significantly lower. A similar observation was reported in works (<xref rid="ref44" ref-type="bibr">Ozaki et al., 2022</xref>; <xref rid="ref5" ref-type="bibr">Berezhnoy et al., 2023</xref>); ornithine and threonine levels in the serum of patients with AD were reduced. Interestingly, we found high levels of ascorbate (vitamin C in humans) in the serum of aged OXYS rats. In humans, the association between vitamin C and Alzheimer&#8217;s disease has been reported to be controversial (<xref rid="ref25" ref-type="bibr">Ide et al., 2016</xref>; <xref rid="ref64" ref-type="bibr">Ulstein and B&#248;hmer, 2016</xref>; <xref rid="ref33" ref-type="bibr">Lanyau-Dom&#237;nguez et al., 2020</xref>; <xref rid="ref21" ref-type="bibr">Hamid et al., 2022</xref>; <xref rid="ref4" ref-type="bibr">Appiah et al., 2024</xref>). For example, a recent study shows that extremely high serum ascorbate concentrations above 2.3&#8239;mg/dL correlates with a higher risk of AD in humans (<xref rid="ref4" ref-type="bibr">Appiah et al., 2024</xref>). Unlike humans and other primates, mice and rats are able to synthesize ascorbate from d-glucuronate in liver (<xref rid="ref16" ref-type="bibr">Gabbay et al., 2010</xref>). Unfortunately, we have to note that the exact mechanism that could explain the association between very high ascorbate levels and Alzheimer&#8217;s disease progression is unknown.</p><p>In our recent paper (<xref rid="ref55" ref-type="bibr">Snytnikova et al., 2024</xref>), we analyzed the metabolomic differences between the hippocampi of OXYS and Wistar rats. It is interesting to compare the metabolomic changes characteristic of the blood and brain of rats. It should be noted that the brain samples in the work (<xref rid="ref55" ref-type="bibr">Snytnikova et al., 2024</xref>) were collected within 3&#8239;min after death. Therefore, significant metabolomic changes could have occurred due to rapid anaerobic reactions in the brain (<xref rid="ref9" ref-type="bibr">Dienel, 2021</xref>; <xref rid="ref15" ref-type="bibr">Fomenko et al., 2022</xref>). However, these changes concern mainly energetic metabolites (such as ATP, ADP, AMP, glucose and lactate) and Krebs cycle compounds. For other metabolites, the influence of postmortem processes is less pronounced (<xref rid="ref15" ref-type="bibr">Fomenko et al., 2022</xref>). Considering that the postmortem intervals for all animals in the work (<xref rid="ref55" ref-type="bibr">Snytnikova et al., 2024</xref>) were approximately equal, the data presented for non-energetic compounds of the hippocampus can be used, at least, for qualitative comparison with the data obtained for the blood metabolome in the present work. The comparison shows that some differential metabolites and affected pathways are common for blood and hippocampus, including &#8220;Purine metabolism&#8221; and &#8220;Glyoxylate and dicarboxylate metabolism&#8221; for 20-day-old rats, &#8220;Pyrimidine metabolism&#8221; for 4-month-old rats, and &#8220;Valine, leucine and isoleucine biosynthesis&#8221; in 16-month-old animals. However, the majority of differential metabolites in the blood and brain differ, and the metabolomic changes in the blood and brain are often in opposite directions. Such contradirectional behavior is observed for several other metabolites, including acetate, cytidine, histidine, and isoleucine. The comparison of age-related changes in the blood and brain of OXYS and Wistar rats for all detected metabolites is presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S4</xref>. Therefore, it is obvious that both metabolomic age-related changes and changes induced by neurodegenerative processes in the brain and blood are different.</p><p>The development of blood-based biomarkers for Alzheimer&#8217;s disease faces challenges such as the unknown ability of the molecule to cross the blood&#8211;brain barrier (BBB) and the lack of direct association of peripheral markers with brain processes (<xref rid="ref11" ref-type="bibr">Enche Ady et al., 2017</xref>). It is believed that BBB disruption occurring with aging play a key role in the early stages of AD (<xref rid="ref73" ref-type="bibr">Yu et al., 2024</xref>). Moreover, with increasing cognitive impairment, BBB disruption increases, implying an increased relationship between blood and brain metabolite concentrations (<xref rid="ref22" ref-type="bibr">Henriksen et al., 2014</xref>). Thus, the observed opposite behavior for a number of metabolites found in this study can be explained by the function of the BBB. Indeed, we have previously found altered BBB permeability in the hippocampus in OXYS rats during the first 3&#8239;weeks of life (<xref rid="ref49" ref-type="bibr">Rudnitskaya et al., 2023</xref>). In the present study, we found that in 20-day-old OXYS rats (that corresponds the presymptomatic stage of AD), levels of two metabolites, allantoin and histidine, were increased in serum and decreased in the hippocampus (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S4</xref>). These metabolites are associated with oxidative stress and energy metabolism disorders and are altered in the serum and urine of Alzheimer&#8217;s disease patients (<xref rid="ref5" ref-type="bibr">Berezhnoy et al., 2023</xref>; <xref rid="ref71" ref-type="bibr">Yin et al., 2023</xref>; <xref rid="ref40" ref-type="bibr">Nielsen et al., 2024</xref>). In late stage Alzheimer&#8217;s disease, we observed decreased threonine levels in both the blood and hippocampus of aged OXYS rats, and we suggest that this metabolite could potentially be considered as a biomarker. Thus, extensive studies have identified metabolite and pathway changes specific to dementia and prediagnostic dementia, in particular altered threonine catabolism in the prediagnostic stage, which extends to several threonine-related pathways in the dementia stage (<xref rid="ref13" ref-type="bibr">Figueira et al., 2019</xref>).</p></sec><sec id="sec17"><label>5</label><title>Limitations of this study</title><p>In this study, we measured metabolomic composition of rat serum and compared it with the metabolomic profile of rat hippocampus reported in <xref rid="ref55" ref-type="bibr">Snytnikova et al. (2024)</xref>. In both studies, animals were anesthetized by asphyxiation with 100% CO<sub>2</sub> followed by decapitation. It has been noted (<xref rid="ref43" ref-type="bibr">Overmyer et al., 2015</xref>) that anesthesia by CO<sub>2</sub> can induce tissue-specific changes in the metabolome due to anaerobic reactions. Therefore, the quantitative data obtained in the present study may be dependent on the method of sacrifice.</p></sec><sec sec-type="conclusions" id="sec18"><label>6</label><title>Conclusion</title><p>In this study, we investigated the changes in blood metabolites during development of AD signs in OXYS rats. Noteworthy, the most significant changes of the metabolome were found in 20-day-old OXYS rats compared to control Wistar rats, which corresponds to the preclinical period of AD development in humans. Metabolomic changes observed in the brain and blood are different and often opposite in sign, but the presence of common differential metabolites suggests that blood serum is potentially promising fluid for the diagnosis of AD.</p></sec></body><back><ack><p>We thank the Ministry of Science and Higher Education of the RF for the access to scientific equipment. The animals were kindly provided by the Breeding Experimental Animal Laboratory of the ICG SB RAS (Novosibirsk, Russia). Animal maintenance was supported by the Budget Project no. FWNR-2022-0016.</p></ack><fn-group><fn id="fn0001"><p>
<sup>1</sup>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rscf.ru/" ext-link-type="uri">https://www.rscf.ru/</ext-link>
</p></fn><fn id="fn00002"><p><sup>1</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.hmdb.ca" ext-link-type="uri">http://www.hmdb.ca</ext-link> (Accessed December 12, 2023).</p></fn><fn id="fn00003"><p><sup>1</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.metaboanalyst.ca" ext-link-type="uri">www.metaboanalyst.ca</ext-link> (Accessed February 12, 2024).</p></fn><fn id="fn00004"><p><sup>1</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://colab.google/" ext-link-type="uri">https://colab.google</ext-link> (Accessed December 12, 2023).</p></fn><fn id="fn00005"><p><sup>1</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://docs.scipy.org" ext-link-type="uri">https://docs.scipy.org</ext-link> (Accessed December 12, 2023).</p></fn><fn id="fn00006"><p><sup>1</sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://matplotlib.org" ext-link-type="uri">https://matplotlib.org</ext-link> (Accessed December 12, 2023).</p></fn></fn-group><sec sec-type="data-availability" id="sec19"><title>Data availability statement</title><p>The datasets presented in this study can be found in online repositories. Raw NMR spectra, description of samples and metabolite concentrations are available at the Animal Metabolite Database repository, Experiment ID 299 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://amdb.online/amdb/experiments/299/" ext-link-type="uri">https://amdb.online/amdb/experiments/299/</ext-link>, accessed on 29 May 2025). All obtained data are available from the corresponding author upon request.</p></sec><sec sec-type="ethics-statement" id="sec20"><title>Ethics statement</title><p>The animal study was approved by the Commission on Bioethics at the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (Protocol No. 85/1 dated June 18, 2021). The study was conducted in accordance with the local legislation and institutional requirements.</p></sec><sec sec-type="author-contributions" id="sec21"><title>Author contributions</title><p>AS: Visualization, Writing &#8211; original draft, Formal analysis, Data curation, Writing &#8211; review &amp; editing, Investigation. DT: Methodology, Data curation, Writing &#8211; review &amp; editing, Visualization, Formal analysis, Writing &#8211; original draft. NK: Validation, Conceptualization, Writing &#8211; review &amp; editing, Methodology, Writing &#8211; original draft, Formal analysis. YT: Funding acquisition, Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Methodology, Conceptualization. OS: Conceptualization, Writing &#8211; review &amp; editing, Supervision, Formal analysis, Writing &#8211; original draft, Methodology, Project administration, Investigation, Visualization, Validation.</p></sec><sec sec-type="COI-statement" id="sec23"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="ai-statement" id="sec24"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec25"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec26"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fnagi.2025.1648561/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnagi.2025.1648561/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Supplementary_file_1.DOCX" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Santosh</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Christlet</surname><given-names>H. T. T.</given-names></name></person-group> (<year>2009</year>). <article-title>Metabolic profiling of Parkinson&#8217;s disease: evidence of biomarker from gene expression analysis and rapid neural network detection</article-title>. <source>J. Biomed. Sci.</source><volume>16</volume>:<fpage>63</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1423-0127-16-63</pub-id>, PMID: <pub-id pub-id-type="pmid">19594911</pub-id><pub-id pub-id-type="pmcid">PMC2720938</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altomare</surname><given-names>D.</given-names></name><name name-style="western"><surname>Libri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alberici</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rivolta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Padovani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>N. J.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Plasma biomarkers increase diagnostic confidence in patients with Alzheimer&#8217;s disease or frontotemporal lobar degeneration</article-title>. <source>Alzheimer's Res Ther</source><volume>16</volume>:<fpage>107</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-024-01474-z</pub-id>, PMID: <pub-id pub-id-type="pmid">38734612</pub-id><pub-id pub-id-type="pmcid">PMC11088144</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab id="coll1">Alzheimer's Association Report</collab></person-group> (<year>2023</year>). <article-title>Alzheimer&#8217;s disease facts and figures (2023)</article-title>. <source>Alzheimers Dement.</source><volume>19</volume>, <fpage>1598</fpage>&#8211;<lpage>1695</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.13016</pub-id><pub-id pub-id-type="pmid">36918389</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appiah</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ingabire-Gasana</surname><given-names>E.</given-names></name><name name-style="western"><surname>Appiah</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name></person-group> (<year>2024</year>). <article-title>The relation of serum vitamin C concentrations with Alzheimer&#8217;s disease mortality in a National Cohort of community-dwelling elderly adults</article-title>. <source>Nutrients</source><volume>16</volume>:<fpage>1672</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu16111672</pub-id>, PMID: <pub-id pub-id-type="pmid">38892605</pub-id><pub-id pub-id-type="pmcid">PMC11174700</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berezhnoy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Laske</surname><given-names>C.</given-names></name><name name-style="western"><surname>Trautwein</surname><given-names>C.</given-names></name></person-group> (<year>2023</year>). <article-title>Metabolomic profiling of CSF and blood serum elucidates general and sex-specific patterns for mild cognitive impairment and Alzheimer&#8217;s disease patients</article-title>. <source>Front. Aging Neurosci.</source><volume>15</volume>:<fpage>1219718</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2023.1219718</pub-id>, PMID: <pub-id pub-id-type="pmid">37693649</pub-id><pub-id pub-id-type="pmcid">PMC10483152</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castegna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aksenov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aksenova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thongboonkerd</surname><given-names>V.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>W. M.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Proteomic identification of oxidatively modified proteins in Alzheimer&#8217;s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1</article-title>. <source>Free Radic. Biol. Med.</source><volume>33</volume>, <fpage>562</fpage>&#8211;<lpage>571</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0891-5849(02)00914-0</pub-id>, PMID: <pub-id pub-id-type="pmid">12160938</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhry</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reimer</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Glutamine uptake by neurons: interaction of protons with system a transporters</article-title>. <source>J. Neurosci.</source><volume>22</volume>, <fpage>62</fpage>&#8211;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-01-00062.2002</pub-id>, PMID: <pub-id pub-id-type="pmid">11756489</pub-id><pub-id pub-id-type="pmcid">PMC6757603</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De-Paula</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Radanovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diniz</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Forlenza</surname><given-names>O. V.</given-names></name></person-group> (<year>2012</year>). <article-title>Alzheimer&#8217;s disease</article-title>. <source>Subcell. Biochem.</source><volume>65</volume>, <fpage>329</fpage>&#8211;<lpage>352</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-94-007-5416-4_14</pub-id><pub-id pub-id-type="pmid">23225010</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dienel</surname><given-names>G. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Stop the rot. Enzyme inactivation at brain harvest prevents artifacts</article-title>. <source>J. Neurochem.</source><volume>158</volume>, <fpage>1007</fpage>&#8211;<lpage>1031</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jnc.15293</pub-id>, PMID: <pub-id pub-id-type="pmid">33636013</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>G. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Global metabolic shifts in age and Alzheimer&#8217;s disease mouse brains pivot at NAD+/NADH redox sites</article-title>. <source>J Alzheimer's Dis</source><volume>71</volume>, <fpage>119</fpage>&#8211;<lpage>140</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-190408</pub-id>, PMID: <pub-id pub-id-type="pmid">31356210</pub-id><pub-id pub-id-type="pmcid">PMC6839468</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enche Ady</surname><given-names>C. N. A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Teh</surname><given-names>L. K.</given-names></name><name name-style="western"><surname>Salleh</surname><given-names>M. Z.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>M. P.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Metabolomic-guided discovery of Alzheimer&#8217;s disease biomarkers from body fluid</article-title>. <source>J. Neurosci. Res.</source><volume>95</volume>, <fpage>2005</fpage>&#8211;<lpage>2024</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jnr.24048</pub-id>, PMID: <pub-id pub-id-type="pmid">28301062</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Modrego</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Rojas-Salinas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>Brain glutamate levels are decreased in Alzheimer&#8217;s disease: a magnetic resonance spectroscopy study</article-title>. <source>Am. J. Alzheimers Dis. Other Dement.</source><volume>26</volume>, <fpage>450</fpage>&#8211;<lpage>456</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1533317511421780</pub-id>, PMID: <pub-id pub-id-type="pmid">21921084</pub-id><pub-id pub-id-type="pmcid">PMC10845671</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figueira</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adolfsson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nordin Adolfsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nyberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>&#214;hman</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Serum metabolite markers of dementia through quantitative NMR analysis: the importance of threonine-linked metabolic pathways</article-title>. <source>J Alzheimer's Dis</source><volume>69</volume>, <fpage>763</fpage>&#8211;<lpage>774</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-181189</pub-id>, PMID: <pub-id pub-id-type="pmid">31127768</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finsterer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bindu</surname><given-names>P. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Therapeutic strategies for mitochondrial disorders</article-title>. <source>Pediatr. Neurol.</source><volume>52</volume>, <fpage>302</fpage>&#8211;<lpage>313</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2014.06.023</pub-id>, PMID: <pub-id pub-id-type="pmid">25701186</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fomenko</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Yanshole</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Tsentalovich</surname><given-names>Y. P.</given-names></name></person-group> (<year>2022</year>). <article-title>Stability of Metabolomic content during sample preparation: blood and brain tissues</article-title>. <source>Meta</source><volume>12</volume>:<fpage>811</fpage>. doi: <pub-id pub-id-type="doi">10.3390/metabo12090811</pub-id>, PMID: <pub-id pub-id-type="pmid">36144215</pub-id><pub-id pub-id-type="pmcid">PMC9505456</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabbay</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Bohren</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Morello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bertin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Ascorbate synthesis pathway</article-title>. <source>J. Biol. Chem.</source><volume>285</volume>, <fpage>19510</fpage>&#8211;<lpage>19520</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M110.110247</pub-id>, PMID: <pub-id pub-id-type="pmid">20410296</pub-id><pub-id pub-id-type="pmcid">PMC2885230</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glinskikh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Snytnikova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zelentsova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Borisova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsentalovich</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akulov</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>The effect of blood contained in the samples on the Metabolomic profile of mouse brain tissue: a study by NMR spectroscopy</article-title>. <source>Molecules</source><volume>26</volume>:<fpage>3096</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules26113096</pub-id>, PMID: <pub-id pub-id-type="pmid">34067246</pub-id><pub-id pub-id-type="pmcid">PMC8196876</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Dom&#237;nguez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garc&#237;a-Barrera</surname><given-names>T.</given-names></name><name name-style="western"><surname>G&#243;mez-Ariza</surname><given-names>J. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Metabolite profiling for the identification of altered metabolic pathways in Alzheimer&#8217;s disease</article-title>. <source>J. Pharm. Biomed. Anal.</source><volume>107</volume>, <fpage>75</fpage>&#8211;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpba.2014.10.010</pub-id>, PMID: <pub-id pub-id-type="pmid">25575172</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffin</surname><given-names>J. W. D.</given-names></name><name name-style="western"><surname>Bradshaw</surname><given-names>P. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Amino acid catabolism in Alzheimer&#8217;s disease brain: friend or foe?</article-title><source>Oxidative Med. Cell. Longev.</source><volume>2017</volume>:<fpage>5472792</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2017/5472792</pub-id>, PMID: <pub-id pub-id-type="pmid">28261376</pub-id><pub-id pub-id-type="pmcid">PMC5316456</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mansoor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zahid</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>A quantitative meta-analysis of vitamin C in the pathophysiology of Alzheimer&#8217;s disease</article-title>. <source>Front. Aging Neurosci.</source><volume>14</volume>:<fpage>970263</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2022.970263</pub-id>, PMID: <pub-id pub-id-type="pmid">36158537</pub-id><pub-id pub-id-type="pmcid">PMC9490219</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriksen</surname><given-names>K.</given-names></name><name name-style="western"><surname>O&#8217;Bryant</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J. Q.</given-names></name><name name-style="western"><surname>Montine</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Jeromin</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>The future of blood-based biomarkers for Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement.</source><volume>10</volume>, <fpage>115</fpage>&#8211;<lpage>131</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2013.01.013</pub-id><pub-id pub-id-type="pmid">23850333</pub-id><pub-id pub-id-type="pmcid">PMC4128378</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Brain and blood metabolome for Alzheimer&#8217;s dementia: findings from a targeted metabolomics analysis</article-title>. <source>Neurobiol. Aging</source><volume>86</volume>, <fpage>123</fpage>&#8211;<lpage>133</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.10.014</pub-id>, PMID: <pub-id pub-id-type="pmid">31785839</pub-id><pub-id pub-id-type="pmcid">PMC6995427</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ide</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>N.</given-names></name><name name-style="western"><surname>Katsuyama</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Peripheral vitamin C levels in Alzheimer&#8217;s disease: a cross-sectional study</article-title>. <source>J. Nutr. Sci. Vitaminol.</source><volume>62</volume>, <fpage>432</fpage>&#8211;<lpage>436</lpage>. doi: <pub-id pub-id-type="doi">10.3177/jnsv.62.432</pub-id><pub-id pub-id-type="pmid">28202849</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikeuchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kanda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Toru</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Decreased circulating branched-chain amino acids are associated with development of Alzheimer&#8217;s disease in elderly individuals with mild cognitive impairment</article-title>. <source>Front. Nutr.</source><volume>9</volume>:<fpage>1040476</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnut.2022.1040476</pub-id>, PMID: <pub-id pub-id-type="pmid">36590218</pub-id><pub-id pub-id-type="pmcid">PMC9794986</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaramillo-Jimenez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giil</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Borda</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Tovar-Rios</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Kristiansen</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Bruheim</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Serum TCA cycle metabolites in Lewy bodies dementia and Alzheimer&#8217;s disease: network analysis and cognitive prognosis</article-title>. <source>Mitochondrion</source><volume>71</volume>, <fpage>17</fpage>&#8211;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mito.2023.05.002</pub-id>, PMID: <pub-id pub-id-type="pmid">37172667</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Judd</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Jasbi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Winslow</surname><given-names>W.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T. G.</given-names></name><name name-style="western"><surname>Klein-Seetharaman</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Inflammation and the pathological progression of Alzheimer&#8217;s disease are associated with low circulating choline levels</article-title>. <source>Acta Neuropathol.</source><volume>146</volume>, <fpage>565</fpage>&#8211;<lpage>583</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-023-02616-7</pub-id>, PMID: <pub-id pub-id-type="pmid">37548694</pub-id><pub-id pub-id-type="pmcid">PMC10499952</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Furumichi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Data, information, knowledge and principle: back to metabolism in KEGG</article-title>. <source>Nucleic Acids Res.</source><volume>42</volume>, <fpage>D199</fpage>&#8211;<lpage>D205</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkt1076</pub-id>, PMID: <pub-id pub-id-type="pmid">24214961</pub-id><pub-id pub-id-type="pmcid">PMC3965122</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelley</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>H. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Disorders of purines and pyrimidines</article-title>. <source>Handb. Clin. Neurol.</source><volume>120</volume>, <fpage>827</fpage>&#8211;<lpage>838</lpage>. doi: <pub-id pub-id-type="doi">10.1016/B978-0-7020-4087-0.00055-3</pub-id><pub-id pub-id-type="pmid">24365355</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolosova</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Kozhevnikova</surname><given-names>O. S.</given-names></name><name name-style="western"><surname>Muraleva</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Rudnitskaya</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Rumyantseva</surname><given-names>Y. V.</given-names></name><name name-style="western"><surname>Stefanova</surname><given-names>N. A.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>SkQ1 as a tool for controlling accelerated senescence program: experiments with OXYS rats</article-title>. <source>Biochem. Mosc.</source><volume>87</volume>, <fpage>1552</fpage>&#8211;<lpage>1562</lpage>. doi: <pub-id pub-id-type="doi">10.1134/S0006297922120124</pub-id>, PMID: <pub-id pub-id-type="pmid">36717446</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolosova</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Stefanova</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Korbolina</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Fursova</surname><given-names>A. Z.</given-names></name><name name-style="western"><surname>Kozhevnikova</surname><given-names>O. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Senescence-accelerated OXYS rats: a genetic model of premature aging and age-related diseases</article-title>. <source>Adv. Gerontol.</source><volume>4</volume>, <fpage>294</fpage>&#8211;<lpage>298</lpage>. doi: <pub-id pub-id-type="doi">10.1134/S2079057014040146</pub-id><pub-id pub-id-type="pmid">25306668</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanyau-Dom&#237;nguez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mac&#237;as-Matos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Llibre-Rodr&#237;guez</surname><given-names>J. D. J.</given-names></name><name name-style="western"><surname>Pita-Rodr&#237;guez</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Su&#225;rez-Medina</surname><given-names>R.</given-names></name><name name-style="western"><surname>Quintero-Alejo</surname><given-names>M. E.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Levels of vitamins and homocysteine in older adults with Alzheimer disease or mild cognitive impairment in Cuba</article-title>. <source>MEDICC Rev.</source><volume>22</volume>:<fpage>40</fpage>. doi: <pub-id pub-id-type="doi">10.37757/MR2020.V22.N4.14</pub-id>, PMID: <pub-id pub-id-type="pmid">33295319</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Defect of branched-chain amino acid metabolism promotes the development of Alzheimer&#8217;s disease by targeting the mTOR signaling</article-title>. <source>Biosci. Rep.</source><volume>38</volume>:<fpage>BSR20180127</fpage>. doi: <pub-id pub-id-type="doi">10.1042/BSR20180127</pub-id>, PMID: <pub-id pub-id-type="pmid">29802157</pub-id><pub-id pub-id-type="pmcid">PMC6028749</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fauman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Erte</surname><given-names>I.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>J. R. B.</given-names></name><name name-style="western"><surname>Kastenm&#252;ller</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.-Y.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach</article-title>. <source>Diabetes</source><volume>62</volume>, <fpage>4270</fpage>&#8211;<lpage>4276</lpage>. doi: <pub-id pub-id-type="doi">10.2337/db13-0570</pub-id>, PMID: <pub-id pub-id-type="pmid">23884885</pub-id><pub-id pub-id-type="pmcid">PMC3837024</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morabito</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leibel</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Small</surname><given-names>S. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Hyperleucinemia causes hippocampal retromer deficiency linking diabetes to Alzheimer&#8217;s disease</article-title>. <source>Neurobiol. Dis.</source><volume>65</volume>, <fpage>188</fpage>&#8211;<lpage>192</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2013.12.017</pub-id>, PMID: <pub-id pub-id-type="pmid">24440570</pub-id><pub-id pub-id-type="pmcid">PMC4235335</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niedzwiecki</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>G. W.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>High-resolution metabolomic profiling of Alzheimer&#8217;s disease in plasma</article-title>. <source>Ann. Clin. Transl. Neurol.</source><volume>7</volume>, <fpage>36</fpage>&#8211;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1002/acn3.50956</pub-id>, PMID: <pub-id pub-id-type="pmid">31828981</pub-id><pub-id pub-id-type="pmcid">PMC6952314</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Andreassen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gotfredsen</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Vestergaard</surname><given-names>K.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>J. S.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Serum metabolic signatures for Alzheimer&#8217;s disease reveal alterations in amino acid composition: a validation study</article-title>. <source>Metabolomics</source><volume>20</volume>:<fpage>12</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s11306-023-02078-8</pub-id>, PMID: <pub-id pub-id-type="pmid">38180611</pub-id><pub-id pub-id-type="pmcid">PMC10770204</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Maltesen</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Havelund</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>F&#230;rgeman</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Gotfredsen</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Vesterg&#229;rd</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Characterising Alzheimer&#8217;s disease through integrative NMR- and LC-MS-based metabolomics</article-title>. <source>Metabol. Open</source><volume>12</volume>:<fpage>100125</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.metop.2021.100125</pub-id>, PMID: <pub-id pub-id-type="pmid">34622190</pub-id><pub-id pub-id-type="pmcid">PMC8479251</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overmyer</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Thonusin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Burant</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>C. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Impact of anesthesia and euthanasia on metabolomics of mammalian tissues: studies in a C57BL/6J mouse model</article-title>. <source>PLoS One</source><volume>10</volume>:<fpage>e0117232</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0117232</pub-id>, PMID: <pub-id pub-id-type="pmid">25658945</pub-id><pub-id pub-id-type="pmcid">PMC4319778</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer&#8217;s disease (from the Nakayama study)</article-title>. <source>Sci. Rep.</source><volume>12</volume>:<fpage>15205</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-022-19670-y</pub-id>, PMID: <pub-id pub-id-type="pmid">36075959</pub-id><pub-id pub-id-type="pmcid">PMC9458733</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>M.</given-names></name><name name-style="western"><surname>Batra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Krumsiek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kotredes</surname><given-names>K. P.</given-names></name><name name-style="western"><surname>Garceau</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Metabolomics profiling reveals distinct, sex-specific signatures in serum and brain metabolomes in mouse models of Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement.</source><volume>20</volume>, <fpage>3987</fpage>&#8211;<lpage>4001</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.13851</pub-id>, PMID: <pub-id pub-id-type="pmid">38676929</pub-id><pub-id pub-id-type="pmcid">PMC11180854</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>de Lima Morais</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Barrette</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights</article-title>. <source>Nucleic Acids Res.</source><volume>49</volume>, <fpage>W388</fpage>&#8211;<lpage>W396</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkab382</pub-id>, PMID: <pub-id pub-id-type="pmid">34019663</pub-id><pub-id pub-id-type="pmcid">PMC8265181</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parnetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gaiti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Polidori</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Brunetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chionne</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>1995</year>). <article-title>Increased cerebrospinal fluid pyruvate levels in Alzheimer&#8217;s disease</article-title>. <source>Neurosci. Lett.</source><volume>199</volume>, <fpage>231</fpage>&#8211;<lpage>233</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0304-3940(95)12058-C</pub-id>, PMID: <pub-id pub-id-type="pmid">8577405</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ropacki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Albala</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Recommended cognitive outcomes in preclinical Alzheimer&#8217;s disease: consensus statement from the European prevention of Alzheimer&#8217;s dementia project</article-title>. <source>Alzheimers Dement.</source><volume>13</volume>, <fpage>186</fpage>&#8211;<lpage>195</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2016.07.154</pub-id>, PMID: <pub-id pub-id-type="pmid">27702619</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudnitskaya</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kozlova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Burnyasheva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peunov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tyumentsev</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stefanova</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Postnatal maturation of the blood&#8211;brain barrier in senescence-accelerated OXYS rats, which are prone to an Alzheimer&#8217;s disease-like pathology</article-title>. <source>Int. J. Mol. Sci.</source><volume>24</volume>:<fpage>15649</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms242115649</pub-id>, PMID: <pub-id pub-id-type="pmid">37958635</pub-id><pub-id pub-id-type="pmcid">PMC10648128</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudnitskaya</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Kozlova</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Burnyasheva</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Stefanova</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Kolosova</surname><given-names>N. G.</given-names></name></person-group> (<year>2021</year>). <article-title>Glia not neurons: uncovering brain Dysmaturation in a rat model of Alzheimer&#8217;s disease</article-title>. <source>Biomedicine</source><volume>9</volume>:<fpage>823</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biomedicines9070823</pub-id>, PMID: <pub-id pub-id-type="pmid">34356887</pub-id><pub-id pub-id-type="pmcid">PMC8301397</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takado</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsukamoto-Yasui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Minatohara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takuwa</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Neurodegenerative processes accelerated by protein malnutrition and decelerated by essential amino acids in a tauopathy mouse model</article-title>. <source>Sci. Adv.</source><volume>7</volume>:<fpage>eabd5046</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.abd5046</pub-id>, PMID: <pub-id pub-id-type="pmid">34678069</pub-id><pub-id pub-id-type="pmcid">PMC8535828</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddik</surname><given-names>M. A. B.</given-names></name><name name-style="western"><surname>Mullins</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gannaban</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Zabet-Moghaddam</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Branched-chain amino acids are linked with Alzheimer&#8217;s disease-related pathology and cognitive deficits</article-title>. <source>Cells</source><volume>11</volume>:<fpage>3523</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells11213523</pub-id>, PMID: <pub-id pub-id-type="pmid">36359919</pub-id><pub-id pub-id-type="pmcid">PMC9658564</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snytnikova</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Khlichkina</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Sagdeev</surname><given-names>R. Z.</given-names></name><name name-style="western"><surname>Tsentalovich</surname><given-names>Y. P.</given-names></name></person-group> (<year>2019</year>). <article-title>Evaluation of sample preparation protocols for quantitative NMR-based metabolomics</article-title>. <source>Metabolomics</source><volume>15</volume>:<fpage>84</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s11306-019-1545-y</pub-id>, PMID: <pub-id pub-id-type="pmid">31127446</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snytnikova</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Khlichkina</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Yanshole</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Yanshole</surname><given-names>V. V.</given-names></name><name name-style="western"><surname>Iskakov</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Egorova</surname><given-names>E. V.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Metabolomics of the human aqueous humor</article-title>. <source>Metabolomics</source><volume>13</volume>:<fpage>5</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s11306-016-1144-0</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snytnikova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Telegina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Savina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsentalovich</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kolosova</surname><given-names>N.</given-names></name></person-group> (<year>2024</year>). <article-title>Quantitative Metabolomic analysis of the rat Hippocampus: effects of age and of the development of Alzheimer&#8217;s disease-like pathology</article-title>. <source>J Alzheimer's Dis</source><volume>99</volume>, <fpage>S327</fpage>&#8211;<lpage>S344</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-230706</pub-id>, PMID: <pub-id pub-id-type="pmid">37980669</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snytnikova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tsentalovich</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sagdeev</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kolosova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kozhevnikova</surname><given-names>O.</given-names></name></person-group> (<year>2022</year>). <article-title>Quantitative Metabolomic analysis of changes in the rat blood serum during autophagy modulation: a focus on accelerated senescence</article-title>. <source>Int. J. Mol. Sci.</source><volume>23</volume>:<fpage>12720</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms232112720</pub-id>, PMID: <pub-id pub-id-type="pmid">36361511</pub-id><pub-id pub-id-type="pmcid">PMC9658531</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kozhevnikova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vitovtov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maksimova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Logvinov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rudnitskaya</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease</article-title>. <source>Cell Cycle</source><volume>13</volume>, <fpage>898</fpage>&#8211;<lpage>909</lpage>. doi: <pub-id pub-id-type="doi">10.4161/cc.28255</pub-id>, PMID: <pub-id pub-id-type="pmid">24552807</pub-id><pub-id pub-id-type="pmcid">PMC3984313</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanova</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Muraleva</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Korbolina</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Kiseleva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maksimova</surname><given-names>K. Y.</given-names></name><name name-style="western"><surname>Kolosova</surname><given-names>N. G.</given-names></name></person-group> (<year>2015</year>). <article-title>Amyloid accumulation is a late event in sporadic Alzheimer&#8217;s disease-like pathology in nontransgenic rats</article-title>. <source>Oncotarget</source><volume>6</volume>, <fpage>1396</fpage>&#8211;<lpage>1413</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.2751</pub-id>, PMID: <pub-id pub-id-type="pmid">25595891</pub-id><pub-id pub-id-type="pmcid">PMC4359302</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swerdlow</surname><given-names>R. H.</given-names></name></person-group> (<year>2020</year>). <article-title>The mitochondrial hypothesis: dysfunction, bioenergetic defects, and the metabolic link to Alzheimer&#8217;s disease</article-title>. <source>Int. Rev. Neurobiol.</source><volume>154</volume>, <fpage>207</fpage>&#8211;<lpage>233</lpage>. doi: <pub-id pub-id-type="doi">10.1016/bs.irn.2020.01.008</pub-id>, PMID: <pub-id pub-id-type="pmid">32739005</pub-id><pub-id pub-id-type="pmcid">PMC8493961</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tremblay-Franco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Canlet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carriere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakhle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Galinier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Portais</surname><given-names>J.-C.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Integrative multimodal metabolomics to early predict cognitive decline among amyloid positive community-dwelling older adults</article-title>. <source>J. Gerontol. A Biol. Sci. Med. Sci.</source><volume>79</volume>:<fpage>glae077</fpage>. doi: <pub-id pub-id-type="doi">10.1093/gerona/glae077</pub-id>, PMID: <pub-id pub-id-type="pmid">38452244</pub-id><pub-id pub-id-type="pmcid">PMC11000317</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trushina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Persson</surname><given-names>X.-M. T.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer&#8217;s disease using metabolomics</article-title>. <source>PLoS One</source><volume>8</volume>:<fpage>e63644</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0063644</pub-id>, PMID: <pub-id pub-id-type="pmid">23700429</pub-id><pub-id pub-id-type="pmcid">PMC3658985</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trushina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>M. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Recent advances in the application of metabolomics to Alzheimer&#8217;s disease</article-title>. <source>Biochim. Biophys. Acta Mol. basis Dis.</source><volume>1842</volume>, <fpage>1232</fpage>&#8211;<lpage>1239</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbadis.2013.06.014</pub-id>, PMID: <pub-id pub-id-type="pmid">23816564</pub-id><pub-id pub-id-type="pmcid">PMC3842412</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyumentsev</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Stefanova</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Muraleva</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Rumyantseva</surname><given-names>Y. V.</given-names></name><name name-style="western"><surname>Kiseleva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vavilin</surname><given-names>V. A.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Mitochondrial dysfunction as a predictor and driver of Alzheimer&#8217;s disease-like pathology in OXYS rats</article-title>. <source>J Alzheimer's Dis</source><volume>63</volume>, <fpage>1075</fpage>&#8211;<lpage>1088</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-180065</pub-id>, PMID: <pub-id pub-id-type="pmid">29710722</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulstein</surname><given-names>I.</given-names></name><name name-style="western"><surname>B&#248;hmer</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Normal vitamin levels and nutritional indices in Alzheimer&#8217;s disease patients with mild cognitive impairment or dementia with Normal body mass indexes</article-title>. <source>J Alzheimer's Dis</source><volume>55</volume>, <fpage>717</fpage>&#8211;<lpage>725</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-160393</pub-id>, PMID: <pub-id pub-id-type="pmid">27716664</pub-id><pub-id pub-id-type="pmcid">PMC5147482</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Mitochondria dysfunction in the pathogenesis of Alzheimer&#8217;s disease: recent advances</article-title>. <source>Mol. Neurodegener.</source><volume>15</volume>:<fpage>30</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13024-020-00376-6</pub-id>, PMID: <pub-id pub-id-type="pmid">32471464</pub-id><pub-id pub-id-type="pmcid">PMC7257174</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name></person-group> (<year>2021</year>). <article-title>The expression levels of plasma dimethylglycine (DMG), human maternally expressed gene 3 (MEG3), and Apelin-12 in patients with acute myocardial infarction and their clinical significance</article-title>. <source>Ann. Palliat. Med.</source><volume>10</volume>, <fpage>2175</fpage>&#8211;<lpage>2183</lpage>. doi: <pub-id pub-id-type="doi">10.21037/apm-21-122</pub-id>, PMID: <pub-id pub-id-type="pmid">33725773</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muti</surname><given-names>I. H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Kivis&#228;kk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S. E.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>A nuclear magnetic resonance spectroscopy method in characterization of blood metabolomics for Alzheimer&#8217;s disease</article-title>. <source>Meta</source><volume>12</volume>:<fpage>181</fpage>. doi: <pub-id pub-id-type="doi">10.3390/metabo12020181</pub-id>, PMID: <pub-id pub-id-type="pmid">35208255</pub-id><pub-id pub-id-type="pmcid">PMC8878886</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whiley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>D&#8217;Hondt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Jim&#233;nez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Snowden</surname><given-names>S. G.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer&#8217;s disease</article-title>. <source>Alzheimer's Res Ther</source><volume>13</volume>:<fpage>20</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-020-00741-z</pub-id>, PMID: <pub-id pub-id-type="pmid">33422142</pub-id><pub-id pub-id-type="pmcid">PMC7797094</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Anjum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>HMDB 5.0: the human metabolome database for 2022</article-title>. <source>Nucleic Acids Res.</source><volume>50</volume>, <fpage>D622</fpage>&#8211;<lpage>D631</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkab1062</pub-id>, PMID: <pub-id pub-id-type="pmid">34986597</pub-id><pub-id pub-id-type="pmcid">PMC8728138</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Therriault</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name></person-group> (<year>2022</year>). <article-title>The associations of serum valine with mild cognitive impairment and Alzheimer&#8217;s disease</article-title>. <source>Aging Clin. Exp. Res.</source><volume>34</volume>, <fpage>1807</fpage>&#8211;<lpage>1817</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40520-022-02120-0</pub-id>, PMID: <pub-id pub-id-type="pmid">35362856</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Hankemeier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kindt</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>E. C. M.</given-names></name></person-group> (<year>2023</year>). <article-title>Status of Metabolomic measurement for insights in Alzheimer&#8217;s disease progression&#8212;what is missing?</article-title><source>Int. J. Mol. Sci.</source><volume>24</volume>:<fpage>4960</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms24054960</pub-id>, PMID: <pub-id pub-id-type="pmid">36902391</pub-id><pub-id pub-id-type="pmcid">PMC10003384</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Alteration of metabolic profiles during the progression of Alzheimer&#8217;s disease</article-title>. <source>Brain Sci.</source><volume>13</volume>:<fpage>1459</fpage>. doi: <pub-id pub-id-type="doi">10.3390/brainsci13101459</pub-id>, PMID: <pub-id pub-id-type="pmid">37891827</pub-id><pub-id pub-id-type="pmcid">PMC10605479</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Revealing the mechanisms of blood&#8211;brain barrier in chronic neurodegenerative disease: an opportunity for therapeutic intervention</article-title>. <source>Rev. Neurosci.</source><volume>35</volume>, <fpage>895</fpage>&#8211;<lpage>916</lpage>. doi: <pub-id pub-id-type="doi">10.1515/revneuro-2024-0040</pub-id>, PMID: <pub-id pub-id-type="pmid">38967133</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>S. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Blood-based molecular biomarkers for Alzheimer&#8217;s disease</article-title>. <source>Mol. Brain</source><volume>12</volume>:<fpage>26</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13041-019-0448-1</pub-id>, PMID: <pub-id pub-id-type="pmid">30922367</pub-id><pub-id pub-id-type="pmcid">PMC6437931</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501334</article-id><article-id pub-id-type="pmcid-ver">PMC12501334.1</article-id><article-id pub-id-type="pmcaid">12501334</article-id><article-id pub-id-type="pmcaiid">12501334</article-id><article-id pub-id-type="pmid">40887393</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100362</article-id><article-id pub-id-type="pii">S2274-5807(25)00304-8</article-id><article-id pub-id-type="publisher-id">100362</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Early Alzheimer&#8217;s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Hsu</surname><given-names initials="JL">Jung-Lung</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Park</surname><given-names initials="KH">Kee Hyung</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Panegyres</surname><given-names initials="PK">Peter K.</given-names></name><xref rid="aff0003" ref-type="aff">c</xref><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Huang</surname><given-names initials="YH">Yao Hsien</given-names></name><email>huang.yh@lilly.com</email><xref rid="aff0005" ref-type="aff">e</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Eom</surname><given-names initials="YI">Young In</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Prusty</surname><given-names initials="V">Vinay</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Tan</surname><given-names initials="LS">Lolita Stephanie</given-names></name><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Shea</surname><given-names initials="YF">Yat Fung</given-names></name><xref rid="aff0006" ref-type="aff">f</xref></contrib><aff id="aff0001"><label>a</label>Department of Neurology, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan</aff><aff id="aff0002"><label>b</label>Department of Neurology, College of Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea</aff><aff id="aff0003"><label>c</label>Neurodegenerative Disorders Research Pty Ltd, West Perth, Australia</aff><aff id="aff0004"><label>d</label>The University of Western Australia, Nedlands, WA, Australia</aff><aff id="aff0005"><label>e</label>Eli Lilly And Company, Indianapolis, IN,USA</aff><aff id="aff0006"><label>f</label>Division of Geriatrics, Department of Medicine, Queen Mary Hospital, Hong Kong</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Eli Lilly and Company (Taiwan) Inc., 14th Floor, No. 9 and 11 Songgao Road, Xinyi District, Taipei City, Taiwan. <email>huang.yh@lilly.com</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>8</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100362</elocation-id><history><date date-type="received"><day>17</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>18</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><p>Early diagnosis of mild cognitive impairment (MCI) and Alzheimer&#8217;s disease (AD) with mild dementia is becoming increasingly important to enable patients to receive appropriate treatment with available amyloid-targeting therapies. Reviews of AD prevalence and diagnostic and treatment patterns typically focus on global or western populations, but the situation in Asia, Australasia, and Pacific Nations (AAPN) countries is less clear. We performed a narrative review of literature for AD in several AAPN countries, focusing on patients with MCI or mild dementia who may benefit from early treatment. Published information regarding AD incidence and prevalence and current practice in AAPN countries is limited and the nature of available information differs between countries. However, AAPN countries include some of the most rapidly aging populations and show the associated increasing trend of all-cause dementia prevalence observed globally. Although lecanemab and donanemab are now approved for AD with MCI and mild dementia in several AAPN countries, the most appropriate diagnostic pathway for patients with MCI and early AD is not established. Even though the AAPN region includes countries with routine access to advanced technologies, concerns have already been raised about the ability of healthcare systems in Australia, New Zealand, and Korea to respond to approvals of new AD therapies, including the need to ensure availability of biomarker testing and dementia specialists to allow patients to receive the early diagnosis required to enable appropriate treatment. Guidelines and national policies also need updating to differentiate between dementia subtypes and include amyloid-targeting therapies for eligible patients with early AD.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Diagnosis</kwd><kwd>Early Alzheimer&#8217;s disease</kwd><kwd>Mild cognitive impairment</kwd><kwd>Asia-Pacific</kwd><kwd>Treatment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0001">Alzheimer&#8217;s disease (AD) biomarkers are being explored as potential targets for treatment options for early AD and may provide opportunities for clinical monitoring of treatment [<xref rid="bib0001" ref-type="bibr">1</xref>]. Lecanemab received accelerated United States approval for AD in January 2023, followed by traditional approval in July 2023, with the indication stating that treatment should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stages of AD [<xref rid="bib0002" ref-type="bibr">2</xref>]. Subsequent Asia, Australasia, and Pacific Nations (AAPN) country approvals were Japan in September 2023 (launched in December 2023) [<xref rid="bib0003" ref-type="bibr">3</xref>], China in January 2024 (launched in June 2024) [<xref rid="bib0004" ref-type="bibr">4</xref>], Korea in May 2024 [<xref rid="bib0005" ref-type="bibr">5</xref>], Hong Kong in July 2024 [<xref rid="bib0006" ref-type="bibr">6</xref>], Macau in January 2025 [<xref rid="bib0007" ref-type="bibr">7</xref>], and Taiwan in March 2025 [<xref rid="bib0008" ref-type="bibr">8</xref>].</p><p id="para0002">Appropriate use recommendations for lecanemab have also been issued for Japan and Korea [<xref rid="bib0009" ref-type="bibr">9</xref>,<xref rid="bib0010" ref-type="bibr">10</xref>]. The Australian Therapeutic Goods Administration (TGA) recently (March 2025) confirmed its decision (from October 2024) not to register lecanemab, following a sponsor request for reconsideration [<xref rid="bib0011" ref-type="bibr">11</xref>].</p><p id="para0003">There are currently no approved targeted treatments for AD in New Zealand or Pacific nations. Donanemab received approval for MCI and AD with mild dementia in the United States in July 2024, followed by AAPN approvals in Japan (September 2024), China (December 2024), Taiwan (April 2025) [<xref rid="bib0012" ref-type="bibr">12</xref>], and Australia (May 2025) [<xref rid="bib0013" ref-type="bibr">13</xref>], after showing a significant slowing of clinical progression in patients with early symptomatic AD (MCI or AD with mild dementia) and amyloid or tau pathology, versus placebo, in the randomized phase 3 TRAILBLAZER-ALZ 2 trial [<xref rid="bib0001" ref-type="bibr">1</xref>,<xref rid="bib0003" ref-type="bibr">3</xref>,<xref rid="bib0014" ref-type="bibr">[14]</xref>, <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>]. Clinical progression at 76 weeks was significantly slowed in those with low/medium tau and in the combined low/medium and high tau pathology population, and <italic toggle="yes">post-hoc</italic> analyses suggested a greater benefit for patients who begin treatment at an earlier disease stage [<xref rid="bib0001" ref-type="bibr">1</xref>].</p><p id="para0004">As targeted therapies become available, early diagnosis is becoming increasingly important to enable patients with AD to receive appropriate treatment. Reviews of the available data for AD prevalence and diagnostic and treatment patterns typically focus on global or western populations, but the situation in AAPN countries is less clear.</p><p id="para0005">Here we provide a narrative review of the literature available for patients with AD in several countries in the AAPN region, focusing on patients with MCI or mild dementia who may benefit from early treatment.</p></sec><sec id="sec0002"><label>2</label><title>Prevalence of AD with MCI or mild dementia in AAPN countries</title><p id="para0006">The prevalence of AD and all-cause dementia is increasing in AAPN countries and globally, which is generally attributed to an aging population [<xref rid="bib0019" ref-type="bibr">[19]</xref>, <xref rid="bib0020" ref-type="bibr">[20]</xref>, <xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>, <xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>], and health and social care systems will need to adapt to provide appropriate support for patients and care partners. However, most published data for AAPN countries are based on all-cause dementia or AD dementia of any severity, and data specifically on AD with MCI or mild dementia and the incidence and characteristics of new cases are lacking. As variation in the type of data presented and methods used prevent direct comparisons between countries, a narrative summary of the available literature is presented here. Reported prevalences for individual countries also vary between sources, reflecting differences in study design and focus; for example, in terms of the populations studied, methodology, and sources used. AD prevalence estimates may also be affected by the availability and accuracy of diagnostic biomarker tests in different countries, along with access limitations due to the costs and expertise required to evaluate results [<xref rid="bib0025" ref-type="bibr">25</xref>]. Improving access to routine biomarker testing should be an urgent priority for all countries.</p><sec id="sec0003"><label>2.1</label><title>Australia</title><p id="para0007">AD affects up to 10 % of Australians aged &gt;65 years, rising to &#8764;30 % in those aged &gt;85 years [<xref rid="bib0026" ref-type="bibr">26</xref>]. Dementia Australia estimates that approximately 433,300 people in Australia were estimated to be living with all-cause dementia in 2025; this is expected to increase to &#8764;812,500 by 2054 [<xref rid="bib0027" ref-type="bibr">27</xref>]. The Australian Institute of Health and Welfare previously published a 2023 all-cause dementia prevalence rate of 411,100, with this rate estimated to be 3- to 5-times higher among first nation people [<xref rid="bib0028" ref-type="bibr">28</xref>].</p><p id="para0008">The Australian Dementia Network (ADNeT) registry was designed to measure the quality of clinical care received by people newly diagnosed with dementia or MCI [<xref rid="bib0029" ref-type="bibr">29</xref>]. Of the 2,369 patients within the Clinical Quality registry (CQR) in 2022, 68 % had a dementia diagnosis (median age 79 years, median Mini-Mental State Exam (MMSE) score 22) and 32 % had MCI (median age 77 years, median MMSE score 27) [<xref rid="bib0029" ref-type="bibr">29</xref>]. AD was the most common dementia subtype (53 %), followed by mixed AD and vascular dementia (23 %). Vascular dementia alone accounted for 10 % of dementia cases and 14 % of cases were of other etiologies [<xref rid="bib0029" ref-type="bibr">29</xref>].</p></sec><sec id="sec0004"><label>2.2</label><title>China</title><p id="para0009">The China Alzheimer report of 2024 provided a comprehensive review of AD and related dementias, including epidemiological trends, economic burden, diagnosis and treatment status, and public health and societal impact [<xref rid="bib0020" ref-type="bibr">20</xref>].</p><p id="para0010">A national cross-sectional study of 46,011 adults aged &#8805;60 years between 2015 and 2018 estimated the overall age- and sex-adjusted prevalence of AD in China to be 3.9 % (95 % confidence interval (CI) 3.8&#8211;4.1), corresponding to 9.83 million people (95 % CI 9.39&#8211;10.29) [<xref rid="bib0030" ref-type="bibr">30</xref>]. Respective estimates for all-cause dementia were 6.0 % (95 % CI 5.8&#8211;6.3), 15.07 (95 % CI 14.53&#8211;15.62) million people. Overall MCI prevalence was estimated at 15.5 % (95 % CI 15.2&#8211;15.9), 38.77 (37.95&#8211;39.62) million people, although AD-specific data were not reported for MCI [<xref rid="bib0030" ref-type="bibr">30</xref>]. The authors called for authorities to develop dementia prevention strategies for people with MCI and to establish an appropriate MCI and dementia management policy given the growing health and economic burden in China and worldwide [<xref rid="bib0030" ref-type="bibr">30</xref>]. Survey data from 2023 have also suggested a growing trend for younger people being diagnosed with AD, with 21.3 % of patients in the survey being &lt;60 years old, compared with previous reports of 5&#8211;10 % [<xref rid="bib0031" ref-type="bibr">31</xref>]. The China Health and Retirement Longitudinal Study (CHARLS 2018) of adults aged &#8805;50 years also showed all-cause dementia prevalence varied across provinces, highlighting the need for targeted strategies for dementia prevention and treatment [<xref rid="bib0032" ref-type="bibr">32</xref>].</p></sec><sec id="sec0005"><label>2.3</label><title>Hong Kong</title><p id="para0011">&#8220;Dementia and AD&#8221; was rated as the most feared disease category by Chinese patients aged &#8805;65 years old in a cross-sectional survey in Hong Kong [<xref rid="bib0021" ref-type="bibr">21</xref>]. In 2018, the Hong Kong Alzheimer&#8217;s Disease Association Social Welfare Department estimated that &#8764;100,000 people in Hong Kong were living with dementia [<xref rid="bib0033" ref-type="bibr">33</xref>]. The Big Data Analytics Platform identified 23,467 people aged &#8805;65 years old diagnosed with AD in Hong Kong between January 2007 and December 2017 [<xref rid="bib0034" ref-type="bibr">34</xref>]. Of these, 71 % were female and the median age at diagnosis was 84 years old (range 77&#8211;91) [<xref rid="bib0034" ref-type="bibr">34</xref>].</p><p id="para0012">The number of patients with all-cause dementia receiving treatment at public hospitals in Hong Kong increased from 72,900 in 2018 to 84,100 in 2022 [<xref rid="bib0035" ref-type="bibr">35</xref>]. The Hong Kong mental morbidity survey for older people, conducted between 2019 and 2023, examined the cognitive and mental health care needs of 4,368 adults aged &#8805;60 years living at home and 503 residents of residential care homes (RCHEs) [<xref rid="bib0036" ref-type="bibr">36</xref>]. One-fifth (22 %) of older adults living in the community were found to have mild neurocognitive disorder, with 7.4 % classed as having &#8220;major neurocognitive disorders (dementia).&#8221; The prevalence of dementia in older adults residing in RCHEs was estimated at around 70 %. Previously reported underlying etiologies of dementia (in 2006) were 73.5 % for AD and 22.4 % for vascular dementia [<xref rid="bib0037" ref-type="bibr">37</xref>].</p></sec><sec id="sec0006"><label>2.4</label><title>Japan</title><p id="para0013">A 2021 report estimated that &gt;5 million people in Japan were living with all-cause dementia and estimated the global cost of dementia at &gt;14.5 trillion yen (&#8764;133 billion US dollars) [<xref rid="bib0038" ref-type="bibr">38</xref>]. Nationwide dementia prevalence in Japan is expected to exceed 25 % in people aged &#8805;65 years by 2045 [<xref rid="bib0039" ref-type="bibr">39</xref>].</p><p id="para0014">The most recent national survey (published in 2012) identified from a systematic review of articles published between January 2000 and November 2015 reported a mean dementia prevalence of 15.75 % (95 % CI 12.4&#8211;22.2) in people aged &#8805;65 years, although the population in most cities studied was older than the national average [<xref rid="bib0040" ref-type="bibr">40</xref>,<xref rid="bib0041" ref-type="bibr">41</xref>]. AD was the most common cause of dementia, comprising 65.8 % of cases [<xref rid="bib0040" ref-type="bibr">40</xref>,<xref rid="bib0041" ref-type="bibr">41</xref>].</p></sec><sec id="sec0007"><label>2.5</label><title>New Zealand</title><p id="para0015">Routinely collected health data from the New Zealand Integrated Data Infrastructure between 2016 and 2020 suggested a crude diagnosed all-cause dementia prevalence of 3.8&#8211;4.0 % in people aged &#8805;60 years and 13.7&#8211;14.4 % in those aged &#8805;80 years [<xref rid="bib0042" ref-type="bibr">42</xref>]. Age-sex standardized prevalence in 2019&#8211;2020 was higher in M&#257;ori (5.4 % aged &#8805;60 years; 17.5 % aged &#8805;80 years) and Pacific Islander populations (6.3 % aged &#8805;60 years; 22.2 % aged &#8805;80 years) than in European (3.7 % aged &#8805;60 years; 13.6 % aged &#8805;80 years) and Asian (3.4 % aged &#8805;60 years; 13.5 % aged &#8805;80 years) populations [<xref rid="bib0042" ref-type="bibr">42</xref>]. Another study using data from the New Zealand Health Survey from 2011/12 to 2018/19 estimated an all-cause dementia incidence of 19.2 per person-years in people aged &#8805;60 years, with incidence rates being lower in Asian people versus Europeans [<xref rid="bib0043" ref-type="bibr">43</xref>]. The Neurological Foundation estimates the dementia prevalence in New Zealand will be &gt;170,000 people by 2050 [<xref rid="bib0044" ref-type="bibr">44</xref>].</p></sec><sec id="sec0008"><label>2.6</label><title>Republic of Korea</title><p id="para0016">Data from the National Health Insurance Service Senior Cohort showed that both the annual standardized incidence and prevalence of all-cause dementia in Korea increased steadily from 2003 to 2015 [<xref rid="bib0045" ref-type="bibr">45</xref>].</p><p id="para0017">Prevalences of AD and MCI in Korea have been estimated at around 7 % and 22 %, respectively. Data from the Nationwide Survey on Dementia Epidemiology of Korea (NaSDEK) 2016 showed a standardized AD prevalence in the total population of 7.1 % and a standardized MCI prevalence of 22.3 % [<xref rid="bib0045" ref-type="bibr">45</xref>]. Data from the Korea Dementia Observatory (KDO) 2020 showed an estimated AD prevalence in the total population of 7.7 % and an MCI prevalence of 22.7 % [<xref rid="bib0046" ref-type="bibr">46</xref>].</p><p id="para0018">NaSDEK 2016 reported a standardized all-cause dementia prevalence of 6.9 % in people aged &#8805;60 years and 9.5 % in those aged &#8805;65 years [<xref rid="bib0045" ref-type="bibr">45</xref>]. Another population-based study estimated that the prevalence of dementia in people aged &#8805;65 years in Korea increased from 5.9 % in 2015 to 7.3 % in 2019, with further increases expected in future [<xref rid="bib0023" ref-type="bibr">23</xref>]. The Ministry of Health and Welfare and Korean National Institute of Dementia reported an estimated prevalence of dementia of 886,173 in people aged &#8805;65 years in 2021, which may be expected to increase to 1.42 million in 2030 and 3.15 million in 2050 [<xref rid="bib0047" ref-type="bibr">47</xref>].</p><p id="para0019">NaSDEK data also indicated an increase in the AD dementia subtype from 70.7 % to 74.4 % of dementia cases between 2008 and 2016, along with a decrease in vascular dementia from 24.4 % to 8.7 % [<xref rid="bib0045" ref-type="bibr">45</xref>].</p><p id="para0020">The total health economic cost of all-cause dementia in Korea increased by approximately 1.5 times between 2015 and 2019, to an estimated 4,218 million US dollars in 2019, a cost per capita of &#8764;6,957 US dollars [<xref rid="bib0023" ref-type="bibr">23</xref>].</p></sec><sec id="sec0009"><label>2.7</label><title>Taiwan</title><p id="para0021">Data from the Taiwan National Health Insurance Research Database from 2004 to 2010 showed an increase in age&#8211;sex standardized AD prevalence from 2.3 % to 3.5 % (P&lt;0.0001) [<xref rid="bib0048" ref-type="bibr">48</xref>]. However, standardized incidence rates for both all-cause dementia and AD over this time period showed a non-significant decline, with AD incidence falling from 4.9 to 4.6 per thousand person-years. Nonetheless, both incidence and prevalence increased with age and were higher in females than males [<xref rid="bib0048" ref-type="bibr">48</xref>]. The increase in dementia prevalence with age likely explains the expectation that it will exceed 460,000 by 2031 [<xref rid="bib0049" ref-type="bibr">49</xref>]. The first national population-based survey of MCI and dementia (2011&#8211;2013) in people aged &#8805;65 years in Taiwan found an age-adjusted MCI prevalence of 18.8 % and an all-cause dementia prevalence of 8.0 %, with rates of both MCI and dementia being higher in females than males [<xref rid="bib0050" ref-type="bibr">50</xref>]. Another study showed an increase in the annual incidence of all-cause dementia in Taiwan from 30,606 in 2004 to 50,651 in 2017, with a particularly pronounced increase in females [<xref rid="bib0051" ref-type="bibr">51</xref>]. The increase in dementia incidence was accompanied by increases in other comorbidities, further impacting on healthcare resources [<xref rid="bib0051" ref-type="bibr">51</xref>].</p></sec><sec id="sec0010"><label>2.8</label><title>Pacific Nations</title><p id="para0022">There is very little published information on MCI, AD, and related dementias among Pacific Islanders and Native Hawaiians [<xref rid="bib0052" ref-type="bibr">52</xref>,<xref rid="bib0053" ref-type="bibr">53</xref>]. The countries include those of Melanesia (e.g., Papua New Guinea, Solomon Islands, Vanuatu, New Caledonia, Fiji, Nauru, Tuvalu, Wallis and Fortuna, Tonga); Micronesia (Northern Mariana Islands, Guam, Palau, Marshall Islands, Kiribati); and Polynesia (Samoa, American Samoa, Tokelau, Mua, Cook Islands, French Polynesia, Pitcairn Islands, Easter Island, Hawaii). These countries are some of the poorest in the world and most heavily impacted by climate change, particularly rising sea levels [<xref rid="bib0054" ref-type="bibr">54</xref>], which is associated with negative health effects including an increased risk of neurodegenerative disorders [<xref rid="bib0055" ref-type="bibr">55</xref>].</p><p id="para0023">There are limited prevalence data for AD or all-cause dementia in this region, although 2004 data for Chamorros people aged &#8805;65 years in Guam showed an all-cause dementia prevalence of 12.2 % [<xref rid="bib0056" ref-type="bibr">56</xref>,<xref rid="bib0057" ref-type="bibr">57</xref>]. The absence of data for most Pacific Island countries is concerning as it represents an unknown area of great potential need. Furthermore, ethnicity is associated with AD pathogenesis, and studying the genetic predisposition to AD in these populations may help to enable early diagnosis, especially in people with young-onset AD [<xref rid="bib0058" ref-type="bibr">58</xref>].</p></sec></sec><sec id="sec0011"><label>3</label><title>Current guidelines plus diagnostic and treatment patterns in AAPN countries</title><p id="para0024">The 2024 Alzheimer&#8217;s Association revised criteria for diagnosis and staging of AD for research purposes now include the use of biomarkers in the diagnosis of AD [<xref rid="bib0059" ref-type="bibr">59</xref>], and International Working Group recommendations include the appropriate use of biomarkers in the context of other evaluations for AD diagnosis in a clinical setting [<xref rid="bib0060" ref-type="bibr">60</xref>,<xref rid="bib0061" ref-type="bibr">61</xref>]. However, a recent systematic review of international and country-specific clinical practice guidelines for AD (53 overall, 15 published between 2018 and 2022) found recommendations had remained largely consistent and unchanged across several countries and global regions over the past 20 years [<xref rid="bib0062" ref-type="bibr">62</xref>].</p><p id="para0025">AD gene testing was reported as not being included in any guidelines, although <italic toggle="yes">Apolipoprotein E</italic> (<italic toggle="yes">APOE</italic>) genotyping is now included in the 2021 revised Korean guidelines [<xref rid="bib0063" ref-type="bibr">63</xref>] and traditional Chinese medicine guidelines (2019) recommend genetic testing of people with a family history [<xref rid="bib0064" ref-type="bibr">64</xref>]. None of the guidelines in the 2022 review recommended screening or biomarker testing for asymptomatic populations [<xref rid="bib0059" ref-type="bibr">59</xref>,<xref rid="bib0062" ref-type="bibr">62</xref>], although the Taiwan Dementia Society recently issued recommendations for the use of blood-based biomarkers for symptomatic patients (alongside other clinical evaluations), biochemistry, and neuroimaging [<xref rid="bib0065" ref-type="bibr">65</xref>], and a Chinese expert consensus recommended population screening to identify people at high risk for AD [<xref rid="bib0066" ref-type="bibr">66</xref>].</p><p id="para0026">Pharmacological treatment for cognitive symptoms was only recommended for people with AD dementia; no severity level was stated for this, but medication was not recommended for people with MCI [<xref rid="bib0062" ref-type="bibr">62</xref>]. AAPN guidelines included in the systematic review were from Australia (2018/2019, but these were for deprescribing cholinesterase inhibitors and memantine; [<xref rid="bib0067" ref-type="bibr">67</xref>,<xref rid="bib0068" ref-type="bibr">68</xref>]), China (2019, traditional Chinese medicine; [<xref rid="bib0064" ref-type="bibr">64</xref>]), Korea (2021; [<xref rid="bib0063" ref-type="bibr">63</xref>]) and Taiwan (2021; [<xref rid="bib0069" ref-type="bibr">69</xref>]); those from Korea and Taiwan were reported to cover both AD and MCI but only the 2017 American Academy of Neurology guidelines [<xref rid="bib0070" ref-type="bibr">70</xref>] were reported to clearly refer to &#8220;MCI due to AD&#8221; [<xref rid="bib0062" ref-type="bibr">62</xref>]. A screening flowchart for MCI has been proposed by researchers from Australia and China, aimed at enabling timely subsequent investigation and disease differentiation [<xref rid="bib0071" ref-type="bibr">71</xref>].</p><p id="para0027">A systematic review and meta-analysis of AD diagnostic test accuracy in developed and developing countries found that accessibility of some biomarkers varies between countries, with the associated costs and expertise required limiting their use in developing countries [<xref rid="bib0025" ref-type="bibr">25</xref>]. However, China and Australia were the only AAPN countries included in the analysis; of the 84 studies analyzed, four were from China and the number from Australia was not stated (categorized as &#8220;low&#8221;).</p><p id="para0028">A summary of AAPN country recommendations relevant to early AD identified during this review is provided in <xref rid="tbl0001" ref-type="table">Table 1</xref>. As the guidelines vary between countries in terms of the level of detail and focus, it was not possible to perform further direct comparisons. Details of the guidance available for individual countries is therefore summarized narratively throughout this section.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Overview of AAPN country-specific guidelines relevant to early Alzheimer&#8217;s disease.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Guideline</th><th valign="top" colspan="1" rowspan="1">Countries recommending this point (Ref number)</th></tr></thead><tbody><tr><td colspan="2" align="left" valign="top" rowspan="1"><bold><italic toggle="yes">Clinical assessment</italic></bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Neuropsychological assessment, followed by blood biomarkers and imaging for population screening to identify people at high risk for AD</td><td valign="top" colspan="1" rowspan="1">China [<xref rid="bib0066" ref-type="bibr">66</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Follow up patients with subjective cognitive decline every 1&#8211;2 years</td><td valign="top" colspan="1" rowspan="1">Korea [<xref rid="bib0063" ref-type="bibr">63</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Review of patients with MCI (e.g., after 6&#8211;18 months)</td><td valign="top" colspan="1" rowspan="1">Australia [<xref rid="bib0072" ref-type="bibr">72</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mini-Mental State Examination for screening and diagnosis of dementia</td><td valign="top" colspan="1" rowspan="1">Korea [<xref rid="bib0063" ref-type="bibr">63</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Neurological examination for differentiating between dementia subtypes in patients with MCI or dementia</td><td valign="top" colspan="1" rowspan="1">Korea [<xref rid="bib0063" ref-type="bibr">63</xref>]</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><bold><italic toggle="yes">Standard evaluation</italic></bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Use of PET scan or CSF testing for population screening to identify people at high risk for AD (if an individual is undiagnosed after neuropsychological assessment, followed by blood biomarkers)</td><td valign="top" colspan="1" rowspan="1">China (66</td></tr><tr><td valign="top" colspan="1" rowspan="1">Brain MRI scan</td><td valign="top" colspan="1" rowspan="1">Australia [<xref rid="bib0072" ref-type="bibr">72</xref>], Korea [<xref rid="bib0063" ref-type="bibr">63</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">PET scan</td><td valign="top" colspan="1" rowspan="1">Australia [<xref rid="bib0072" ref-type="bibr">72</xref>], Korea [<xref rid="bib0063" ref-type="bibr">63</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">CT scan</td><td valign="top" colspan="1" rowspan="1">Australia<xref rid="tb1fn1" ref-type="table-fn">*</xref> [<xref rid="bib0072" ref-type="bibr">72</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Blood biochemistry analysis</td><td valign="top" colspan="1" rowspan="1">Australia [<xref rid="bib0072" ref-type="bibr">72</xref>]</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><bold><italic toggle="yes">AD biomarker analysis</italic></bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">Use of blood biomarkers for population screening to identify people at high risk for AD (if an individual is undiagnosed after neuropsychological assessment)</td><td valign="top" colspan="1" rowspan="1">China [<xref rid="bib0066" ref-type="bibr">66</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Use of CSF A&#946;, total tau, and phosphorylated tau tests to differentiate between AD and other dementias</td><td valign="top" colspan="1" rowspan="1">Korea [<xref rid="bib0063" ref-type="bibr">63</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">General &#8220;biomarker&#8221; testing recommendation</td><td valign="top" colspan="1" rowspan="1">Australia<xref rid="tb1fn2" ref-type="table-fn">&#8224;</xref> [<xref rid="bib0072" ref-type="bibr">72</xref>], Japan [<xref rid="bib0041" ref-type="bibr">41</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Use of blood-based biomarkers for symptomatic patients, alongside other clinical evaluations, biochemistry, and neuroimaging</td><td valign="top" colspan="1" rowspan="1">Taiwan [<xref rid="bib0065" ref-type="bibr">65</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Patients with a dementia diagnosis who are suspected of having MCI or mild dementia due to AD should receive appropriate fluid biomarker testing or amyloid PET</td><td valign="top" colspan="1" rowspan="1">Japan [<xref rid="bib0090" ref-type="bibr">90</xref>], Dementia Japan [<xref rid="bib0091" ref-type="bibr">91</xref>]</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><bold><italic toggle="yes">Genetic testing</italic></bold></td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">Apolipoprotein E</italic> genotyping</td><td valign="top" colspan="1" rowspan="1">Korea [<xref rid="bib0063" ref-type="bibr">63</xref>]</td></tr><tr><td valign="top" colspan="1" rowspan="1">Genetic testing of people with a family history of AD</td><td valign="top" colspan="1" rowspan="1">China [<xref rid="bib0064" ref-type="bibr">64</xref>], Hong Kong [<xref rid="bib0085" ref-type="bibr">85</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="tb1fn1"><label>&#8270;</label><p id="notep0001">Single-photon emission CT scanning is not considered accurate enough for use.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb1fn2"><label>&#8224;</label><p id="notep0002">For patients with a persistent history of clear cognitive degeneration over 6&#8211;12 months if PET scan unavailable.</p><p id="notep0003">AAPN: Asia, Australasia, and Pacific nations; AD: Alzheimer&#8217;s disease; CT: computed tomography; MCI: mild cognitive impairment; MRI: magnetic resonance imaging; PET, positron emission tomography.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec0012"><label>3.1</label><title>Australia</title><p id="para0029">Nationally informed recommendations for the detection, assessment and management of MCI were published in 2022 [<xref rid="bib0072" ref-type="bibr">72</xref>]. These guidelines are not specific to MCI in AD but recommend a computed tomography (CT) scan (along with blood biochemistry) at a minimum, along with magnetic resonance imaging (MRI) where available. The 2024 Australia Dementia Network Memory and Cognition Clinic Guidelines included practice points (aspirational criteria) regarding the use of advanced neuroimaging (e.g., positron emission tomography (PET)) and cerebrospinal fluid (CSF) biomarkers where further diagnostic information is needed [<xref rid="bib0073" ref-type="bibr">73</xref>]. Future guidelines are expected to include analysis of blood-based biomarkers to aid in the early detection of AD.</p><p id="para0030">Increased numbers of people presenting with possible MCI, notably to General Practitioners (GPs), is expected to rise dramatically in the coming years. GPs are recommended to consider referring patients for secondary consultation as &#8764;40 % of clinical MCI cases may be due to non-AD neurodegenerative diseases or psychiatric conditions. Patients with a persistent history of clear cognitive degeneration over 6&#8211;12 months should be offered other biomarker testing if PET scanning (fluorodeoxyglucose or amyloid) is unavailable [<xref rid="bib0072" ref-type="bibr">72</xref>]. Patients with MCI should ideally be reviewed at 6&#8211;12 months but certainly within 18 months, and earlier review may be needed if concerns are identified [<xref rid="bib0072" ref-type="bibr">72</xref>].</p><p id="para0031">Most patients with dementia are diagnosed in hospital, with only &#8764;15 % of patients diagnosed in memory clinics [<xref rid="bib0074" ref-type="bibr">74</xref>]. However, GPs and other non-dementia-specialist clinicians are expected to refer patients to specialists such as geriatricians and neurologists for management and treatment, which may take place at a public or private memory clinic.</p><p id="para0032">Dementia experts are calling for changes to Australasian healthcare systems to allow the appropriate use and monitoring of new AD treatments and provide diagnostic and healthcare professional (HCP) training facilities [<xref rid="bib0075" ref-type="bibr">75</xref>], following concerns about the preparedness to deal with the costs and potential safety events associated with new treatments [<xref rid="bib0074" ref-type="bibr">74</xref>]. PET and CSF AD biomarker testing, required for the prescription of monoclonal antibody therapies, are not currently available on universal healthcare in Australia [<xref rid="bib0074" ref-type="bibr">74</xref>]. Early dementia screening is recommended to help enable timely access to appropriate treatment [<xref rid="bib0076" ref-type="bibr">76</xref>].</p><p id="para0033">New clinical practice guidelines and diagnostic biomarkers guidelines for AD in Australia are due to be published between 2024 and 2026 and are expected to highlight the need for a considerable change in healthcare infrastructure to aid in the early detection of AD.</p></sec><sec id="sec0013"><label>3.2</label><title>China</title><p id="para0034">MRI and CT are regarded as important in distinguishing AD from other dementias [<xref rid="bib0020" ref-type="bibr">20</xref>]. MRI is the first choice for routine imaging due to its high resolution, with CT used when MRI is contraindicated [<xref rid="bib0020" ref-type="bibr">20</xref>]. Use of PET is restricted due to cost and the historical lack of effective targeted therapies, and a comprehensive evaluation is needed to consider the economic costs versus potential health benefits [<xref rid="bib0020" ref-type="bibr">20</xref>]. A 2024 expert consensus recommended neuropsychological assessment, followed by blood biomarkers and imaging for population screening to identify people at high risk for AD, with future work needed to validate low-cost accessible methods [<xref rid="bib0066" ref-type="bibr">66</xref>].</p><p id="para0035">A 2023 expert consensus recommended that A&#946;-PET results (with a binary positive/negative interpretation) should be used in combination with other clinical and neuropsychological characteristics, other imaging data, and other biological markers for the diagnosis of AD [<xref rid="bib0077" ref-type="bibr">77</xref>]. Although A&#946;-PET is considered important to provide qualitative and semi-quantitative measurement of &#946;-amyloid in the brain <italic toggle="yes">in vivo</italic>, there are ethical concerns about disclosing a positive A&#946;-PET result to people with preclinical AD and their relatives [<xref rid="bib0020" ref-type="bibr">20</xref>]. Fluid biomarkers (e.g., blood, urine, CSF) are not widely used in clinical practice; the main limitation with CSF biomarkers is that an invasive lumbar puncture procedure is required that cannot be performed in most memory clinics in China [<xref rid="bib0020" ref-type="bibr">20</xref>].</p><p id="para0036">Memory clinics are increasingly being used to diagnose and treat patients with AD presenting with MCI early in the disease course [<xref rid="bib0020" ref-type="bibr">20</xref>]. Both pharmaceutical and non-pharmaceutical interventions are used in the treatment of AD, with most pharmacotherapies aimed at improving cognition and relieving neuropsychiatric symptoms [<xref rid="bib0020" ref-type="bibr">20</xref>]. Traditional Chinese medicine still features in many AD clinical trials in China, although other trials are evaluating anti-A&#946; therapy, neuromodulation therapy, and stem cell-based therapy [<xref rid="bib0020" ref-type="bibr">20</xref>].</p><p id="para0037">General practitioner (GP) attitudes and knowledge are important in the early management of MCI; a cross-sectional study of 1,253 GPs in Shanghai found MCI knowledge was low, with &gt;12 % of GPs having no knowledge and 28 % not considering MCI as a disease. However, most respondents agreed or strongly agreed with MCI management as a strategy to delay AD occurrence (68.8 %) and to support MCI screening (67.5 %) and timely diagnosis (63.1 %) [<xref rid="bib0078" ref-type="bibr">78</xref>]. Compliance with relevant guidelines was higher for GPs with more training and knowledge and more favorable attitudes towards MCI. The authors recommended further study of factors affecting GP attitudes [<xref rid="bib0078" ref-type="bibr">78</xref>].</p></sec><sec id="sec0014"><label>3.3</label><title>Hong Kong</title><p id="para0038">The importance of early diagnosis of dementia is being increasingly recognized by HCPs and patients in Hong Kong and a cross-sectional survey indicated that patients would like to be told about their diagnosis early to enable them to access treatment and support [<xref rid="bib0021" ref-type="bibr">21</xref>]. Diagnosis and management of AD is mostly undertaken by geriatricians, followed by neurologists and psychogeriatricians. Plain CT remains the initial neuroimaging of choice. MRI, amyloid PET imaging, and fluorodeoxyglucose (FDG)-PET scans are commonly utilized in patients with diagnostic difficulties [<xref rid="bib0079" ref-type="bibr">79</xref>,<xref rid="bib0080" ref-type="bibr">80</xref>]. Although some cut-off values for CSF biomarkers (p-tau 181, total tau, amyloid &#946;42 and their ratios) have been validated for AD diagnosis in Hong Kong [<xref rid="bib0081" ref-type="bibr">81</xref>], acceptance of CSF analysis remains low because of its invasiveness and need for clinical admission. Blood-based biomarkers for AD (p-tau 181, p-tau 217, and PlasmarkAD (proteomics platform)) are available locally via private laboratories for the early detection of MCI or AD [<xref rid="bib0082" ref-type="bibr">[82]</xref>, <xref rid="bib0083" ref-type="bibr">[83]</xref>, <xref rid="bib0084" ref-type="bibr">[84]</xref>]. Genetic testing for familial AD may be offered for people with a strong family history, a family history of early-onset AD or for those with suspected early-onset AD; genetic testing for hereditary dementias is available at local laboratories of public hospitals after consulting medical biochemists [<xref rid="bib0085" ref-type="bibr">85</xref>,<xref rid="bib0086" ref-type="bibr">86</xref>].</p><p id="para0039">The Hong Kong Geriatrics Society reports an annual conversion rate of amnestic MCI to AD dementia of &#8764;5&#8211;10 % [<xref rid="bib0085" ref-type="bibr">85</xref>]. The Society recognizes the pre-MCI stage, including transitional cognitive decline (TCD), subjective cognitive decline (SCD) and mild behavioral impairment (MBI); people with TCD, SCD, MBI, or MCI may progress to AD [<xref rid="bib0085" ref-type="bibr">85</xref>,<xref rid="bib0087" ref-type="bibr">87</xref>]. In a study of 88 people from a memory clinic in Hong Kong, the prevalence of MBI was 7 % in the cognitively normal/SCD group (n=43) and 11.1 % in the MCI group (n=45), as assessed by the MBI-checklist [<xref rid="bib0088" ref-type="bibr">88</xref>]. The International Working Group (IWG)-2, Diagnostic and Statistical Manual of Mental Disorder (DSM)-5 and the National Institute on Aging and Alzheimer&#8217;s Association (NIA-AA) criteria are used in the diagnosis of AD [<xref rid="bib0085" ref-type="bibr">85</xref>].</p><p id="para0040">Drugs used in treating dementia include donepezil, rivastigmine, galantamine, and memantine [<xref rid="bib0033" ref-type="bibr">33</xref>], although lecanemab was approved for AD with MCI or mild dementia in Hong Kong in July 2024 [<xref rid="bib0006" ref-type="bibr">6</xref>]. Other drugs may be used to treat associated disorders such as depression, anxiety or sleeping disorders, and non-pharmacological treatments are also encouraged [<xref rid="bib0033" ref-type="bibr">33</xref>]. A study of people with AD between 2007 and 2017 reported that 39.9 % of people were receiving dementia medication, with other medication classes including antipsychotics (50.7 % had used these at least once), antidepressants (40.3 %), and hypnotics (29.1 %); However, the data were not stratified by stage of AD [<xref rid="bib0034" ref-type="bibr">34</xref>].</p></sec><sec id="sec0015"><label>3.4</label><title>Japan</title><p id="para0041">Clinical practice guidelines for dementia management were developed in 2010 by six major Japanese societies and provided specific guidance for AD [<xref rid="bib0041" ref-type="bibr">41</xref>]. These guidelines recommend that AD diagnosis should be based on psychiatric and neurological signs, imaging, and biomarker presence. Donepezil was the only recommended medication approved and indicated for AD dementia in these guidelines, but galantamine, rivastigmine, and memantine were subsequently recommended in 2012 based on meta-analyses. The evidence for non-pharmacotherapies was considered weak, although non-pharmacological interventions and patient care programs are used to help control the behavioral and psychological symptoms of dementia and improve quality of life for patients and their care partners. The guidelines were updated in 2017; there were no significant changes to the AD treatment algorithm but the need for more data on real-world clinical practice for AD in Japan was highlighted [<xref rid="bib0041" ref-type="bibr">41</xref>,<xref rid="bib0089" ref-type="bibr">89</xref>].</p><p id="para0042">In 2023, guidelines for the use of PET and fluid biomarkers recommended that patients should first receive a clinical assessment for dementia as per the 2017 guidelines [<xref rid="bib0089" ref-type="bibr">[89]</xref>, <xref rid="bib0090" ref-type="bibr">[90]</xref>, <xref rid="bib0091" ref-type="bibr">[91]</xref>]. Those who subsequently receive a dementia diagnosis and are suspected as having MCI or mild dementia due to AD should then undergo further testing using appropriate fluid biomarkers or amyloid PET to determine whether they are eligible for targeted treatments that require confirmation of amyloid pathology evidence [<xref rid="bib0090" ref-type="bibr">90</xref>,<xref rid="bib0091" ref-type="bibr">91</xref>].</p></sec><sec id="sec0016"><label>3.5</label><title>New Zealand</title><p id="para0043">Most patients are diagnosed with dementia in memory clinics and dementia is mainly treated in the primary care setting [<xref rid="bib0074" ref-type="bibr">74</xref>]. As reported for Australia, changes to New Zealand healthcare systems will be required to address concerns about the preparedness to deal with the costs and potential safety events associated with new AD treatments [<xref rid="bib0074" ref-type="bibr">74</xref>]. Amyloid PET or CSF AD biomarker testing&#8212;required for the prescription of monoclonal antibody therapies&#8212;are also not currently available on universal healthcare in New Zealand [<xref rid="bib0074" ref-type="bibr">74</xref>] and will require the use of secondary care centers.</p><p id="para0044">The strategy for registration of a new medication in New Zealand is typically based on it first being approved in Australia, simplifying its approval in New Zealand. This can lead to inequalities in access to medications in New Zealand compared with other countries. Inequalities in access to currently available dementia medications have also been reported within New Zealand [<xref rid="bib0092" ref-type="bibr">92</xref>]. A retrospective population study found dementia medications were less likely to be dispensed to people of M&#257;ori, Pacific, Middle Eastern, Latin American, or African ethnicities, versus those of European ethnicity. People aged 65&#8211;79 years were more likely to receive dementia medication than those aged &lt;65 years or &#8805;80 years, although there were no statistically significant differences between males and females [<xref rid="bib0092" ref-type="bibr">92</xref>].</p></sec><sec id="sec0017"><label>3.6</label><title>Republic of Korea</title><p id="para0045">The 2021 revised Korean clinical practice guideline for dementia (diagnosis and evaluation) includes a description of &#8220;SCD regarded as a preclinical stage of AD,&#8221; along with the inclusion of amyloid PET to identify amyloid-&#946; protein <italic toggle="yes">in vivo</italic> [<xref rid="bib0063" ref-type="bibr">63</xref>]. The guideline notes that elderly patients with SCD have a higher risk of future progression to dementia (or AD dementia) versus those without SCD and therefore recommends these patients are followed up every 1&#8211;2 years. A Clinical Dementia Rating is recommended as a diagnostic tool for dementia (moderate level of evidence, strong grade of recommendation); MMSE is recommended for dementia screening (high level of evidence, strong grade of recommendation), and diagnosis (high level of evidence, weak grade of recommendation). Neurological examination is then recommended for differentiating between dementia subtypes in patients with MCI or dementia (moderate level of evidence, strong grade of recommendation). CSF amyloid-&#946;, total tau, and phosphorylated tau tests are recommended to increase the accuracy of the diagnosis (high level of evidence, weak grade of recommendation) and <italic toggle="yes">APOE</italic> genotyping can be helpful in prognostic evaluation as well as diagnosis (moderate level of evidence, weak grade of recommendation). Assessing the degree of medial temporal lobe atrophy with brain MRI (moderate level of evidence, strong grade of recommendation) and use of amyloid PET scans (high level of evidence, weak grade of recommendation) are also recommended to increase diagnostic accuracy of AD [<xref rid="bib0063" ref-type="bibr">63</xref>].</p><p id="para0046">Donepezil, rivastigmine, galantamine, and memantine are approved for the treatment of dementia, although no medications are approved for managing the associated behavioral and psychological symptoms [<xref rid="bib0093" ref-type="bibr">93</xref>]. However, evidence-based clinical practice guidelines for the pharmacological treatment of behavioral and psychological symptoms of dementia were recently published by the Korean Dementia Association [<xref rid="bib0117" ref-type="bibr">117</xref>]. The guidelines provide conditional recommendations for the use of antipsychotics (e.g., risperidone, brexpiprazole), antidepressants (e.g., citalopram), cognitive enhancers (e.g., donepezil, memantine), and pimavanserin, depending on symptom presentation and dementia subtype. Emphasizing individualized treatment strategies, the guidelines balance therapeutic efficacy with potential risks, with all recommendations graded according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology [<xref rid="bib0117" ref-type="bibr">117</xref>].</p><p id="para0047">In response to the recent availability of lecanemab in South Korea, the Korean Dementia Association has issued clinical recommendations aimed at guiding physicians in the safe and effective implementation of this disease-modifying therapy in routine practice [<xref rid="bib0118" ref-type="bibr">118</xref>].</p><p id="para0048">The introduction of further targeted therapies for AD is expected but, as for other countries, concerns have been raised regarding the ability of the healthcare system to enable blood biomarker testing in a timely manner [<xref rid="bib0094" ref-type="bibr">94</xref>].</p></sec><sec id="sec0018"><label>3.7</label><title>Taiwan</title><p id="para0049">The Taiwan Dementia Society recently issued consensus recommendations for the use of blood-based biomarkers for patients with symptoms of AD to aid with a differential diagnosis of AD from other dementias [<xref rid="bib0065" ref-type="bibr">65</xref>]. The use was recommended to assist with clinical diagnosis and prognosis of patients with cognitive symptoms, although the results need to be interpreted by dementia specialists alongside other clinical evaluations, biochemistry, and neuropsychological and neuroimaging information [<xref rid="bib0065" ref-type="bibr">65</xref>].</p><p id="para0050">The Taiwan Dementia Treatment Guideline is focused on treatment options for AD and other dementias [<xref rid="bib0069" ref-type="bibr">69</xref>]. Although the guideline advises treating AD dementia at an early stage, it does not recommend pharmacological therapy for patients with MCI but reviews supporting evidence for non-pharmacological interventions, such as exercise [<xref rid="bib0069" ref-type="bibr">69</xref>].</p></sec><sec id="sec0019"><label>3.8</label><title>Pacific Nations</title><p id="para0051">There are no known guidelines for the diagnosis or treatment of dementia in the Pacific nations.</p></sec></sec><sec id="sec0020"><label>4</label><title>Dementia and AD policies in AAPN countries</title><p id="para0052">Hong Kong, Japan, Korea, and Taiwan were included in a recent review of all-cause dementia care and policy in five Asian regions (also including Thailand); this review did not focus on MCI or AD specifically but highlighted the need to establish a dementia committee for Asia regions [<xref rid="bib0095" ref-type="bibr">95</xref>].</p><sec id="sec0021"><label>4.1</label><title>Australia</title><p id="para0053">Australia was one of the first countries to develop a national comprehensive dementia policy initiative [<xref rid="bib0096" ref-type="bibr">96</xref>]. The first initiative was the National Plan for Dementia Care 1992&#8211;1997, and dementia is now established as a key priority in the national aged care agenda. Initiatives and recommendations include improved early intervention assistance, with a localized dementia-specific pathway for use by GPs. The new 10-year National Dementia Action Plan 2024&#8211;2034 states eight high-level actions focused on improving the lives people living with dementia and their care partners [<xref rid="bib0097" ref-type="bibr">97</xref>].</p><p id="para0054">Australia&#8217;s recently increased funding for AD and dementia research has allowed the country to play a leading role in related international and Asia&#8211;Pacific research projects [<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0096" ref-type="bibr">96</xref>].</p></sec><sec id="sec0022"><label>4.2</label><title>China</title><p id="para0055">The Healthy China 2030 Planning Outline and Healthy China Action Plan (2019&#8211;2030) are national policies launched in 2016 and 2019, respectively, that focus on the importance of caring for and preventing AD in an aging population, with the goal of decreasing the growth rate of AD in the population by 2030 [<xref rid="bib0020" ref-type="bibr">20</xref>]. The Chinese National Healthcare Commission also launched a notice on the Promotion of Dementia Prevalence and Treatment (2023&#8211;2025), which includes emphasis on increasing public awareness, early screening and intervention for AD, with the capability of building collaboration between professional service providers [<xref rid="bib0032" ref-type="bibr">32</xref>].</p><p id="para0056">In 2024, the Chinese expert consensus on the diagnosis and treatment of MCI due to AD issued a framework and recommendations for the diagnosis and treatment of MCI due to AD encompassing seven key aspects: epidemiology; pathogenesis; clinical manifestations; diagnosis; differential diagnosis, treatment strategies and guidance for medical professionals; risk factors; and preventive measures. The initiative aims to facilitate early diagnosis, timely intervention, and precise treatment of AD, addressing the escalating challenges posed by the aging population and the associated rise in AD prevalence [<xref rid="bib0098" ref-type="bibr">98</xref>].</p></sec><sec id="sec0023"><label>4.3</label><title>Hong Kong</title><p id="para0057">A 2017 report from the Hong Kong Government Review Committee on Mental Health made 10 suggestions regarding the provision of nursing care and support for people with dementia [<xref rid="bib0099" ref-type="bibr">99</xref>]. Suggestions included improving public education, supporting HCPs and care partners, strengthening specialist services, and improving health and social care services.</p><p id="para0058">Project Sunrise was initiated by the Hong Kong Alzheimer&#8217;s Disease Association to train GPs in the diagnosis of early AD, including increasing awareness of unusual presentations [<xref rid="bib0100" ref-type="bibr">100</xref>]. In September 2018, the Hong Kong Alzheimer&#8217;s Disease Association Social Welfare Department launched the &#8220;Dementia Friendly Community Campaign&#8221; aimed at raising public awareness and understanding of dementia [<xref rid="bib0033" ref-type="bibr">33</xref>]. The Dementia Community Support Scheme has been in place since 2019 to provide dementia community support services to elderly persons with mild or moderate dementia and their care partners in the community through the participation of District Elderly Community Centres [<xref rid="bib0101" ref-type="bibr">101</xref>].</p></sec><sec id="sec0024"><label>4.4</label><title>Japan</title><p id="para0059">Japan has a National Dementia Plan (NDP) that includes the availability of diagnostic services and Medical Centers for Dementia to promote diagnosis and includes early dementia diagnosis as a target [<xref rid="bib0102" ref-type="bibr">102</xref>]. The &#8220;National Framework for Promotion of Dementia Policies&#8221; was adopted in 2019; it focuses on improving inclusivity of people with dementia and risk reduction by delaying the onset or progression of dementia [<xref rid="bib0103" ref-type="bibr">103</xref>]. A Basic Plan for the Promotion of Policies on Dementia was subsequently approved in December 2024, further dedicated to improving understanding, independence, and support for people with dementia [<xref rid="bib0104" ref-type="bibr">104</xref>].</p></sec><sec id="sec0025"><label>4.5</label><title>New Zealand</title><p id="para0060">The Alzheimer&#8217;s NZ Dementia Services and Standards model was developed to align strategies, policies, and evidence of effective approaches so that services can be developed accordingly [<xref rid="bib0105" ref-type="bibr">105</xref>].</p></sec><sec id="sec0026"><label>4.6</label><title>Republic of Korea</title><p id="para0061">Korea has an NDP that is legislated under the Dementia Management Act [<xref rid="bib0102" ref-type="bibr">102</xref>,<xref rid="bib0106" ref-type="bibr">106</xref>]. There is also a National Dementia Initiative, included as a complementary plan to the third NDP [<xref rid="bib0102" ref-type="bibr">102</xref>]. Korea&#8217;s NDP includes early dementia diagnosis as a target. Currently, 256 Dementia Reassurance Centers are operating to promote early diagnosis of people with dementia and provide support for both patients and care partners [<xref rid="bib0102" ref-type="bibr">102</xref>].</p></sec><sec id="sec0027"><label>4.7</label><title>Taiwan</title><p id="para0062">The Taiwan Government Ministry of Health and Welfare published a &#8220;Framework for Dementia Prevention and Care&#8221; in 2013, which raised seven areas of dementia care policy. A second version of the framework, announced in 2017 and adopted in 2018, listed seven strategies relating to diagnosis, treatment, management, raising awareness, and family support for dementia care, aligned with the World Health Organization Global Plan of Action for Dementia [<xref rid="bib0049" ref-type="bibr">49</xref>,<xref rid="bib0107" ref-type="bibr">107</xref>].</p><p id="para0063">The Dementia Care Policy in Taiwan commenced in 2018, leading to the establishment of dementia integrated care centers (DICCs) and dementia community service sites (DCSSs) and upgrading dementia diagnosis, treatment, and care management [<xref rid="bib0049" ref-type="bibr">49</xref>]. The policy also aims to create a dementia-friendly society [<xref rid="bib0049" ref-type="bibr">49</xref>].</p></sec><sec id="sec0028"><label>4.8</label><title>Pacific Nations</title><p id="para0064">No information on dementia or AD policies in Pacific nations was identified during this review. However, in 2021, Natives Engaged in Alzheimer&#8217;s Research was awarded a National Institute of Aging grant aimed at reducing disparities associated with AD and other dementias in American Indian, Native Alaskan, Native Hawaiian, and Pacific Islander groups [<xref rid="bib0108" ref-type="bibr">108</xref>,<xref rid="bib0109" ref-type="bibr">109</xref>]. The resulting information is expected to help improve access to dementia diagnosis, care, and treatment.</p></sec></sec><sec id="sec0029"><label>5</label><title>Conclusions and future perspectives</title><p id="para0065">This narrative review summarizes the prevalence of MCI and AD in AAPN countries and the associated diagnostic and treatment patterns. The global prevalence of all-cause dementia is expected to increase to more than 150 million in 2050 (from 57 million in 2019), with half of the affected people living in the Western Pacific Region, and there is an urgent need for public health planning to provide the necessary resources to support patients and care partners [<xref rid="bib0024" ref-type="bibr">24</xref>,<xref rid="bib0110" ref-type="bibr">[110]</xref>, <xref rid="bib0111" ref-type="bibr">[111]</xref>, <xref rid="bib0112" ref-type="bibr">[112]</xref>]. AAPN countries include some of the most rapidly aging populations in the world and show the associated increasing trend of all-cause dementia prevalence observed globally. However, the most appropriate diagnostic pathway for patients with MCI and early AD is not established and the infrastructure for diagnosis and access to new targeted treatments is not necessarily readily available. Pacific Island nations also include some of the poorest countries, where access to basic dementia diagnosis and management may be limited. A recent review called for urgent intergovernmental collaboration and investment across Western Pacific countries to help enable equitable access to new diagnostic methods and amyloid-targeting therapies as they become available [<xref rid="bib0111" ref-type="bibr">111</xref>]. Another report highlighted the need for comprehensive national plans to ensure availability of resources and improve education and training [<xref rid="bib0112" ref-type="bibr">112</xref>].</p><p id="para0066">Published information regarding AD incidence and prevalence and current practice regarding early AD in AAPN countries is meagre and the amount and nature of the available information also differs between studies and countries. We were therefore able to provide a narrative summary of the information but were unable to perform direct comparisons between sources. Available information is mostly based on all-cause dementia or AD of any severity and further information is needed to allow countries to plan accordingly.</p><p id="para0067">Although the AAPN region includes countries with routine access to advanced technologies, concerns have already been raised about the ability of healthcare systems in Australia, New Zealand, and Korea to respond to approvals of new AD therapies, including the need to ensure the availability of biomarker testing and dementia specialists to allow patients to receive the early diagnosis required to enable appropriate treatment and avoid long waiting lists. Training will also be required to upskill HCPs in the use of new imaging technologies and interpretation of biomarker results for the diagnosis and staging of AD.</p><p id="para0068">Many current AAPN guidelines focus on all-cause dementia and updates are needed to differentiate between dementia subtypes and include amyloid-targeting therapies for eligible patients with early AD. National policies and healthcare systems also need to adapt to accommodate the increasing AD prevalence as, even if disease modifying therapies become available, the current policies, guidelines, and infrastructure may mean that appropriate patients may not get access. It will also be important to identify any inequalities in treatment access (e.g., according to ethnicity or age, as reported for currently available medications [<xref rid="bib0092" ref-type="bibr">92</xref>]) to ensure all eligible patients receive the appropriate treatment. Further research may help identify other factors associated with increased dementia risk and possible reasons for any conflicting data [<xref rid="bib0113" ref-type="bibr">113</xref>]. For example, although most reports in AAPN and other countries show a higher risk/prevalence in females [<xref rid="bib0045" ref-type="bibr">45</xref>,<xref rid="bib0048" ref-type="bibr">48</xref>,<xref rid="bib0095" ref-type="bibr">95</xref>,<xref rid="bib0114" ref-type="bibr">114</xref>], male sex was among factors associated with increased dementia risk in a nationwide survey in Korea [<xref rid="bib0115" ref-type="bibr">115</xref>]. Policies and planning also need to consider the psychological and socioeconomic effects of AD on patients, care partners, and the general population, as well as the resources needed for comorbidities in an aging population [<xref rid="bib0051" ref-type="bibr">51</xref>].</p><p id="para0069">Further knowledge and understanding regarding the epidemiology of early AD in different countries will help healthcare systems to plan appropriate treatment patterns and resources. The inclusion of biomarkers in the 2024 Alzheimer&#8217;s Association revised criteria for diagnosis and staging of AD for research purposes [<xref rid="bib0059" ref-type="bibr">59</xref>] and International Working Group recommendations for appropriate use of biomarkers in a clinical setting [<xref rid="bib0060" ref-type="bibr">60</xref>,<xref rid="bib0061" ref-type="bibr">61</xref>] reflects the need to distinguish between AD and other dementias at an early stage to enable patients to receive optimal treatment; this will become increasingly important once targeted therapies become available and urgent action is needed to ensure that the required staff training and resources are available to support their introduction and routine use. We therefore recommend that future revisions of AAPN guidelines follow the lead of these guidelines. Biomarker screening and imaging for people with MCI will also help to distinguish between those in a predementia stage of AD or other dementias and those who may return to a normal MMSE score [<xref rid="bib0116" ref-type="bibr">116</xref>]. The ability to provide early diagnosis and treatment of those with AD, while reassuring and avoiding inappropriate diagnosis of those with temporarily reduced MMSE scores may also help to encourage people with symptoms to come forward for early testing. More studies are required to help support and monitor the use of different AD biomarkers in individual countries, including those in poorer Pacific nations.</p></sec><sec id="sec0030"><title>Funding</title><p id="para0070">This review and medical writing support was funded by <funding-source id="gs0001">Eli Lilly and Company</funding-source>.</p></sec><sec id="sec0031"><title>Declaration of Generative AI and AI-assisted technologies in the writing process</title><p id="para0071">No Generative AI and AI-assisted technologies were used in the writing process for this manuscript.</p></sec><sec id="sec0031a"><title>CRediT authorship contribution statement</title><p id="para0071a"><bold>Jung-Lung Hsu:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Investigation, Data curation. <bold>Kee Hyung Park:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Investigation, Conceptualization. <bold>Peter K. Panegyres:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Investigation, Formal analysis, Data curation. <bold>Yao Hsien Huang:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Investigation, Data curation, Conceptualization. <bold>Young In Eom:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. <bold>Vinay Prusty:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Formal analysis, Conceptualization. <bold>Lolita Stephanie Tan:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Investigation, Data curation. <bold>Yat Fung Shea:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Investigation, Formal analysis, Data curation, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0073">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical Trial</article-title><source>JAMA</source><volume>330</volume><year>2023</year><fpage>512</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><mixed-citation publication-type="other" id="sbref0002">Lecanemab Prescribing Information. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.leqembi.com/-/media/Files/Leqembi/Prescribing-Information.pdf" id="interref0001">https://www.leqembi.com/-/media/Files/Leqembi/Prescribing-Information.pdf</ext-link>. Accessed January 2024.</mixed-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="other" id="sbref0003"><person-group person-group-type="author"><collab>Japan PMDA</collab></person-group><article-title>List of approved products</article-title><comment>Available at</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html" id="interref0002">https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html</ext-link><year>2024</year><comment>Accessed September 2024</comment></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="other" id="sbref0004"><person-group person-group-type="author"><collab>China National Medical Products Administration</collab></person-group><article-title>Lecanemab injection approved for marketing by China NMPA</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://english.nmpa.gov.cn/2024-01/09/c_986552.htm" id="interref0003">https://english.nmpa.gov.cn/2024-01/09/c_986552.htm</ext-link><year>2024</year><comment>Accessed September 2024</comment></element-citation></ref><ref id="bib0005"><label>5</label><mixed-citation publication-type="other" id="sbref0005">Eisai. &#8220;LEQEMBI&#174;&#8221; (lecanemab) approved for the treatment of Alzheimer&#8217;s disease in South Korea. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.eisai.com/news/2024/news202436.html" id="interref0004">https://www.eisai.com/news/2024/news202436.html</ext-link>. Accessed July 2024.</mixed-citation></ref><ref id="bib0006"><label>6</label><mixed-citation publication-type="other" id="sbref0006">Eisai. &#8220;LEQEMBI&#174;&#8221; (lecanemab) approved for the treatment of Alzheimer&#8217;s disease in Hong Kong. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.eisai.com/news/2024/news202449.html" id="interref0005">https://www.eisai.com/news/2024/news202449.html</ext-link>. Accessed January 2025.</mixed-citation></ref><ref id="bib0007"><label>7</label><mixed-citation publication-type="other" id="sbref0007">Eisai. Update on regulatory review of lecanemab for early Alzheimer&#8217;s disease by the European commission. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.eisai.com/news/2025/news202531.html" id="interref0006">https://www.eisai.com/news/2025/news202531.html</ext-link>. Accessed June 2025.</mixed-citation></ref><ref id="bib0008"><label>8</label><mixed-citation publication-type="other" id="sbref0008">Taiwan Food and Drug Administration. Lecanemab. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://lmspiq.fda.gov.tw/web/DRPIQ/DRPIQ1000Result?licBaseId=CC7DDD77-4B0D-4DF5-BD9C-95CD54F721BA" id="interref0007">https://lmspiq.fda.gov.tw/web/DRPIQ/DRPIQ1000Result?licBaseId=CC7DDD77-4B0D-4DF5-BD9C-95CD54F721BA</ext-link>. Accessed 25 June 2025.</mixed-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="other" id="sbref0009"><person-group person-group-type="author"><collab>PMDA</collab></person-group><article-title>Optimized usage guideline for lecanemab</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/files/000265885.pdf" id="interref0008">https://www.pmda.go.jp/files/000265885.pdf</ext-link><year>2023</year><comment>Accessed December 2024</comment></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C-H</given-names></name><etal/></person-group><article-title>Lecanemab: appropriate use recommendations by Korean dementia association</article-title><source>Dement Neurocogn Disord</source><volume>23</volume><year>2024</year><fpage>165</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.12779/dnd.2024.23.4.165</pub-id><pub-id pub-id-type="pmid">39512702</pub-id><pub-id pub-id-type="pmcid">PMC11538855</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><mixed-citation publication-type="other" id="sbref0011">Australian Government 2025. TGA confirms decision to not register lecanemab (LEQEMBI) published March 3 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.tga.gov.au/news/news/tga-confirms-decision-not-register-lecanemab-leqembi" id="interref0009">https://www.tga.gov.au/news/news/tga-confirms-decision-not-register-lecanemab-leqembi</ext-link>. Accessed May 2025.</mixed-citation></ref><ref id="bib0012"><label>12</label><mixed-citation publication-type="other" id="sbref0012">Taiwan Food and Drug Administration. Donanemab. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://lmspiq.fda.gov.tw/web/DRPIQ/DRPIQ1000Result?licBaseId=21025D05-6A85-4BD2-B491-218987607AA0" id="interref0010">https://lmspiq.fda.gov.tw/web/DRPIQ/DRPIQ1000Result?licBaseId=21025D05-6A85-4BD2-B491-218987607AA0</ext-link> Accessed 25 June 2025.</mixed-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="other" id="sbref0013"><person-group person-group-type="author"><collab>Australian Government</collab></person-group><article-title>KISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vial (420194)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.tga.gov.au/resources/artg/420194" id="interref0011">https://www.tga.gov.au/resources/artg/420194</ext-link><year>2025</year><comment>Accessed 25 June 2025</comment></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="other" id="sbref0014"><person-group person-group-type="author"><collab>Donanemab PI (UAE, Qatar, Bahrain)</collab></person-group><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gulf.lilly.com/mealabels/kisunla" id="interref0012">https://gulf.lilly.com/mealabels/kisunla</ext-link><year>2024</year><comment>Accessed 29 January 2025</comment></element-citation></ref><ref id="bib0015"><label>15</label><mixed-citation publication-type="other" id="sbref0015">Eli Lilly. Donanemab prescribing information. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pi.lilly.com/us/kisunla-uspi.pdf" id="interref0013">https://pi.lilly.com/us/kisunla-uspi.pdf</ext-link>. Accessed July 2024.</mixed-citation></ref><ref id="bib0016"><label>16</label><mixed-citation publication-type="other" id="sbref0016">United Arab Emirates Ministry of Health and Prevention. Product marketing authorization approval: Kisunla&#8482; 350 mg/20 mL. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://smartservices.moh.gov.ae/eReports/downloadCertificate?appNumber=0F6A88C55CC68BAD01E74FB0611B9875" id="interref0014">https://smartservices.moh.gov.ae/eReports/downloadCertificate?appNumber=0F6A88C55CC68BAD01E74FB0611B9875</ext-link>. Accessed January 2025.</mixed-citation></ref><ref id="bib0017"><label>17</label><mixed-citation publication-type="other" id="sbref0017">Donanemab SmPC. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mhraproducts4853.blob.core.windows.net/docs/023d485b567facc9afc0b4f131b92e36e3696cdd" id="interref0015">https://mhraproducts4853.blob.core.windows.net/docs/023d485b567facc9afc0b4f131b92e36e3696cdd</ext-link> Accessed November 2024.</mixed-citation></ref><ref id="bib0018"><label>18</label><mixed-citation publication-type="other" id="sbref0018">Eli Lilly. Lilly's Kisunla&#8482; (donanemab-azbt) approved in China for the treatment of early symptomatic Alzheimer's disease. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-china-treatment-early#:~:text=17%2C%202024%20%2FPRNewswire%2F%20%2D%2D,treatment%20for%20adults%20with%20early" id="interref0016">https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-china-treatment-early#:~:text=17%2C%202024%20%2FPRNewswire%2F%20%2D%2D,treatment%20for%20adults%20with%20early</ext-link>. Accessed January 2025.</mixed-citation></ref><ref id="bib0019"><label>19</label><mixed-citation publication-type="other" id="sbref0019">Alzheimer&#8217;s Disease International. Dementia statistics. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/#:~:text=Numbers%20of%20people%20with%20dementia,will%20be%20in%20developing%20countries" id="interref0017">https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/#:~:text=Numbers%20of%20people%20with%20dementia,will%20be%20in%20developing%20countries</ext-link>. Accessed November 2023.</mixed-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>China Alzheimer Report</article-title><comment>2024</comment><source>Zhenduanxue lilun yu shijian</source><volume>23</volume><issue>3</issue><year>2024</year><fpage>219</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.16150/j.1671-2870.2024.03.001</pub-id><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doaj.org/article/f0f05b3fdcca43cb86f66229d4306f3f" id="interref0018">https://doaj.org/article/f0f05b3fdcca43cb86f66229d4306f3f</ext-link><comment>Accessed June 2025</comment></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Sanson-Fisher</surname><given-names>R.</given-names></name></person-group><article-title>Perceptions of Chinese towards dementia in Hong Kong&#8212;Diagnosis, symptoms and impacts</article-title><source>Int J Env Res Public Health</source><volume>16</volume><year>2019</year><fpage>128</fpage><pub-id pub-id-type="doi">10.3390/ijerph16010128</pub-id><pub-id pub-id-type="pmid">30621271</pub-id><pub-id pub-id-type="pmcid">PMC6339208</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sugimura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>T.</given-names></name></person-group><article-title>The Japanese MCI screen for early detection of Alzheimer's disease and related disorders</article-title><source>Am J Alzheimers Dis Other Demen</source><volume>23</volume><year>2008</year><fpage>162</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1177/1533317507312624</pub-id><pub-id pub-id-type="pmid">18223126</pub-id><pub-id pub-id-type="pmcid">PMC10846169</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Shon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.</given-names></name></person-group><article-title>Health-economic burden of dementia in South Korea</article-title><source>BMC Geriatr</source><year>2021</year><fpage>549</fpage><pub-id pub-id-type="doi">10.1186/s12877-021-02526-x</pub-id><pub-id pub-id-type="pmid">34645415</pub-id><pub-id pub-id-type="pmcid">PMC8515696</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><collab>GBD 2019 Dementia Forecasting Collaborators</collab></person-group><article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global burden of disease study 2019</article-title><source>Lancet Public Health</source><volume>7</volume><year>2022</year><fpage>e105</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Ch&#225;vez-Fumagalli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aguilar-Pineda</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Diagnosis of Alzheimer's disease in developed and developing countries: systematic review and meta-analysis of diagnostic test accuracy</article-title><source>J Alzheimers Dis Rep</source><volume>5</volume><year>2021</year><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3233/ADR-200263</pub-id><pub-id pub-id-type="pmid">33681713</pub-id><pub-id pub-id-type="pmcid">PMC7902992</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="book" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sanson-Fisher</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>Mansfield E</given-names></name></person-group><series>Dementia is the second most feared condition among Australian health service consumers: results of a cross-sectional survey</series><volume>23</volume><year>2023</year><publisher-name>BMC Public Health</publisher-name><fpage>876</fpage><pub-id pub-id-type="doi">10.1186/s12889-023-15772-y</pub-id><pub-id pub-id-type="pmcid">PMC10176813</pub-id><pub-id pub-id-type="pmid">37173717</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="other" id="sbref0027"><person-group person-group-type="author"><collab>Dementia Australia</collab></person-group><article-title>Dementia facts and figures</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dementia.org.au/about-dementia/dementia-facts-and-figures" id="interref0019">https://www.dementia.org.au/about-dementia/dementia-facts-and-figures</ext-link><year>2025</year><comment>Accessed 25 June 2025</comment></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="other" id="sbref0028"><person-group person-group-type="author"><collab>Australian Institute of Health and Welfare</collab></person-group><article-title>Dementia in Australia</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/about" id="interref0020">https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/about</ext-link><year>2024</year><comment>Accessed July 2024</comment></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="book" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><etal/></person-group><part-title>The Australian Dementia Network (ADNeT) Registry 2022 Annual report</part-title><year>2023</year><publisher-name>Monash University, School of Public Health and Preventive Medicine</publisher-name><comment>May</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://australiandementianetwork.org.au/wp-content/uploads/2023/05/ADNeT22_Report_F1_Web-1.pdf" id="interref0021">https://australiandementianetwork.org.au/wp-content/uploads/2023/05/ADNeT22_Report_F1_Web-1.pdf</ext-link><comment>Accessed January 2024</comment></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study</article-title><source>Lancet Public Health</source><volume>5</volume><year>2020</year><fpage>e661</fpage><lpage>e671</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(20)30185-7</pub-id><pub-id pub-id-type="pmid">33271079</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>2023 China Alzheimer&#8217;s disease: facts and figures</article-title><source>Hum Brain</source><volume>2</volume><year>2023</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.37819/hb.3.1771</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Geographical variation in dementia prevalence across China: a geospatial analysis</article-title><source>Lancet</source><volume>47</volume><year>2024</year><object-id pub-id-type="publisher-id">10117</object-id><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.thelancet.com/action/showPdf?pii=S2666-6065%2824%2900111-1" id="interref0022">https://www.thelancet.com/action/showPdf?pii=S2666-6065%2824%2900111-1</ext-link><comment>Accessed 25 June 2025</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanwpc.2024.101117</pub-id><pub-id pub-id-type="pmcid">PMC11225804</pub-id><pub-id pub-id-type="pmid">38974661</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="book" id="sbref0033"><person-group person-group-type="author"><collab>Hong Kong Alzheimer&#8217;s Disease Association Social Welfare Department</collab></person-group><part-title>Dementia Friendly Community Campaign</part-title><year>2018</year><publisher-name>Dementia Awareness Kit</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.swd.gov.hk/dementiacampaign/en/doc/Dementia_Awareness_kit_en.pdf" id="interref0023">https://www.swd.gov.hk/dementiacampaign/en/doc/Dementia_Awareness_kit_en.pdf</ext-link><comment>Accessed January 2024</comment></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Demographics and medication use of patients with late-onset Alzheimer&#8217;s disease in Hong Kong</article-title><source>J Alzheimers Dis</source><volume>87</volume><year>2022</year><fpage>1205</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.3233/JAD-215312</pub-id><pub-id pub-id-type="pmid">35466936</pub-id><pub-id pub-id-type="pmcid">PMC9198724</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="other" id="sbref0035"><person-group person-group-type="author"><collab>South China Morning Post</collab></person-group><article-title>Hong Kong elderly with dementia should receive early care before diagnosis, mental health advisory chief says</article-title><comment>Published 20 May 2024</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.scmp.com/news/hong-kong/health-environment/article/3263257/hong-kong-elderly-dementia-should-receive-early-care-diagnosis-mental-health-advisory-chief-says#" id="interref0024">https://www.scmp.com/news/hong-kong/health-environment/article/3263257/hong-kong-elderly-dementia-should-receive-early-care-diagnosis-mental-health-advisory-chief-says#</ext-link><year>2024</year><comment>Accessed May 2024</comment></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="other" id="sbref0036"><person-group person-group-type="author"><collab>CU Medicine Hong Kong</collab></person-group><article-title>CUHK announces survey results on the mental health of local child, adolescent and elderly populations</article-title><comment>Press Release 29 November 2023</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.med.cuhk.edu.hk/press-releases/cuhk-announces-survey-results-on-the-mental-health-of-local-child-adolescent-and-elderly-populations" id="interref0025">https://www.med.cuhk.edu.hk/press-releases/cuhk-announces-survey-results-on-the-mental-health-of-local-child-adolescent-and-elderly-populations</ext-link><year>2023</year><comment>Accessed May 2024</comment></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="other" id="sbref0037"><person-group person-group-type="author"><collab>Hong Kong Department of Health</collab></person-group><article-title>Dementia care seminar cum kick-off ceremony for Dementia Care Campaign, 13 October 2006</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dh.gov.hk/english/press/2006/061013.html" id="interref0026">https://www.dh.gov.hk/english/press/2006/061013.html</ext-link><year>2006</year></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Iwatsubo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Niimi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>H.</given-names></name></person-group><article-title>Editorial: Alzheimer's disease research in Japan: A short history, current status and future perspectives toward prevention</article-title><source>J Prev Alzheimers Dis</source><volume>8</volume><year>2021</year><fpage>462</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.14283/jpad.2021.38</pub-id><pub-id pub-id-type="pmid">34585221</pub-id><pub-id pub-id-type="pmcid">PMC12280777</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Nakahori</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sekine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tatsuse</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kido</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name></person-group><article-title>Future projections of the prevalence of dementia in Japan: results from the Toyama dementia survey</article-title><source>BMC Geriatr</source><volume>21</volume><year>2021</year><fpage>602</fpage><pub-id pub-id-type="doi">10.1186/s12877-021-02540-z</pub-id><pub-id pub-id-type="pmid">34702187</pub-id><pub-id pub-id-type="pmcid">PMC8546941</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Asada</surname><given-names>T.</given-names></name></person-group><article-title>Prevalence of dementia in Japan: past, present and future</article-title><source>Rinsho Shinkeigaku</source><volume>52</volume><year>2012</year><fpage>962</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.5692/clinicalneurol.52.962</pub-id><comment>Japanese</comment><pub-id pub-id-type="pmid">23196483</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Montgomery</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stathis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name></person-group><article-title>Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan</article-title><source>Clin Outcomes Res</source><volume>10</volume><year>2017</year><fpage>13</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.2147/CEOR.S146788</pub-id><pub-id pub-id-type="pmcid">PMC5749549</pub-id><pub-id pub-id-type="pmid">29343976</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>G.</given-names></name><name name-style="western"><surname>To</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rivera-Rodriguez</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dementia prevalence estimation among the main ethnic groups in New Zealand: a population-based descriptive study of routinely collected health data</article-title><source>BMJ Open</source><volume>12</volume><year>2022</year><object-id pub-id-type="publisher-id">e062304</object-id><pub-id pub-id-type="doi">10.1136/bmjopen-2022-062304</pub-id><pub-id pub-id-type="pmcid">PMC9454053</pub-id><pub-id pub-id-type="pmid">36691174</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="other" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Ma&#8217;u</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cullum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mukadam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rivera-Rodriguez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>G.</given-names></name></person-group><article-title>Estimating the incidence of dementia in New Zealand: a cohort study applying capture-recapture modelling to routinely collected linked health datasets</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.thelancet.com/action/showPdf?pii=S2666-6065%2824%2900210-4" id="interref0027">https://www.thelancet.com/action/showPdf?pii=S2666-6065%2824%2900210-4</ext-link><year>2024</year><comment>Accessed 25 June 2025</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanwpc.2024.101216</pub-id><pub-id pub-id-type="pmcid">PMC11535379</pub-id><pub-id pub-id-type="pmid">39502411</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="other" id="sbref0044"><person-group person-group-type="author"><collab>Neurological Foundation</collab></person-group><article-title>Alzheimer&#8217;s disease and Dementia</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://neurological.org.nz/conditions/brain-disorders-and-support/alzheimers-disease-and-dementia/" id="interref0028">https://neurological.org.nz/conditions/brain-disorders-and-support/alzheimers-disease-and-dementia/</ext-link><year>2019</year><comment>Accessed November 2023</comment></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>J-W</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y-J.</given-names></name></person-group><article-title>Prevalence and incidence of dementia in South Korea: a nationwide analysis of the national health insurance service senior cohort</article-title><source>J Clin Neurol</source><volume>17</volume><year>2021</year><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.3988/jcn.2021.17.2.249</pub-id><pub-id pub-id-type="pmid">33835746</pub-id><pub-id pub-id-type="pmcid">PMC8053535</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>J-H.</given-names></name></person-group><article-title>Dementia epidemiology fact Sheet 2022</article-title><source>Ann Rehabil Med</source><volume>46</volume><year>2022</year><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.5535/arm.22027</pub-id><pub-id pub-id-type="pmid">35508924</pub-id><pub-id pub-id-type="pmcid">PMC9081392</pub-id></element-citation></ref><ref id="bib0047"><label>47</label><element-citation publication-type="other" id="sbref0047"><person-group person-group-type="author"><collab>Korean Dementia Observatory</collab></person-group><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nid.or.kr/main/main.aspx" id="interref0029">https://www.nid.or.kr/main/main.aspx</ext-link><year>2022</year><comment>Accessed September 2024</comment></element-citation></ref><ref id="bib0048"><label>48</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Li</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>SC.</given-names></name></person-group><article-title>Gender and age differences and the trend in the incidence and prevalence of dementia and Alzheimer's disease in Taiwan: A 7-year national population-based study</article-title><source>Biomed Res Int</source><year>2019</year><object-id pub-id-type="publisher-id">5378540</object-id><pub-id pub-id-type="doi">10.1155/2019/5378540</pub-id><pub-id pub-id-type="pmcid">PMC6878786</pub-id><pub-id pub-id-type="pmid">31815145</pub-id></element-citation></ref><ref id="bib0049"><label>49</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>C-J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M-C.</given-names></name></person-group><article-title>Integrated care for dementia in Taiwan: policy, system and services</article-title><source>Int J Gerontol Spec Issue</source><year>2019</year><fpage>S73</fpage><lpage>S77</lpage></element-citation></ref><ref id="bib0050"><label>50</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S-C</given-names></name><etal/></person-group><article-title>A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e100303</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0100303</pub-id><pub-id pub-id-type="pmcid">PMC4062510</pub-id><pub-id pub-id-type="pmid">24940604</pub-id></element-citation></ref><ref id="bib0051"><label>51</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>S-T</given-names></name><name name-style="western"><surname>Loh</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>F-Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L-K.</given-names></name></person-group><article-title>Trends in dementia incidence and mortality, and dynamic changes in comorbidity and healthcare utilization from 2004 to 2017: A Taiwan national cohort study</article-title><source>Arch Gerontol Geriatr</source><volume>121</volume><year>2024</year><object-id pub-id-type="publisher-id">105330</object-id><pub-id pub-id-type="doi">10.1016/j.archger.2024.105330</pub-id><pub-id pub-id-type="pmid">38341955</pub-id></element-citation></ref><ref id="bib0052"><label>52</label><element-citation publication-type="other" id="sbref0052"><person-group person-group-type="author"><collab>Alzheimer&#8217;s Disease International</collab></person-group><article-title>Dementia in the Asia Pacific region</article-title><comment>2014</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.alzint.org/u/Dementia-Asia-Pacific-2014.pdf" id="interref0030">https://www.alzint.org/u/Dementia-Asia-Pacific-2014.pdf</ext-link><year>2014</year><comment>Accessed June 2024</comment></element-citation></ref><ref id="bib0053"><label>53</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohaimin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Min</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease and its related dementias among Asian Americans, Native Hawaiians, and Pacific Islanders: A scoping review</article-title><source>J Alzheimer 19s Dis</source><volume>77</volume><year>2020</year><fpage>523</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.3233/JAD-200509</pub-id><pub-id pub-id-type="pmcid">PMC8638681</pub-id><pub-id pub-id-type="pmid">32675416</pub-id></element-citation></ref><ref id="bib0054"><label>54</label><element-citation publication-type="other" id="sbref0054"><person-group person-group-type="author"><collab>US National Science Foundation</collab></person-group><article-title>The Pacific Islands: The front line in the battle against climate change (May 2022)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://new.nsf.gov/science-matters/pacific-islands-front-line-battle-against-climate" id="interref0031">https://new.nsf.gov/science-matters/pacific-islands-front-line-battle-against-climate</ext-link><year>2022</year><comment>Accessed June 2024</comment></element-citation></ref><ref id="bib0055"><label>55</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Teasdale</surname><given-names>N.</given-names></name><name name-style="western"><surname>Panegyres</surname><given-names>PK.</given-names></name></person-group><article-title>Climate change in Western Australia and its potential impact on human health</article-title><source>J Clim Change Health</source><volume>12</volume><year>2023</year><object-id pub-id-type="publisher-id">100243</object-id><pub-id pub-id-type="doi">10.1016/j.joclim.2023.100243</pub-id></element-citation></ref><ref id="bib0056"><label>56</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Galasko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garnst</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE</article-title><source>Neurology</source><volume>68</volume><year>2007</year><fpage>1772</fpage><lpage>1781</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000262028.16738.64</pub-id><pub-id pub-id-type="pmid">17515539</pub-id></element-citation></ref><ref id="bib0057"><label>57</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>GW.</given-names></name></person-group><article-title>Systematic review of dementia prevalence and incidence in United States race/ethnic populations</article-title><source>Alzheimers Dement</source><volume>13</volume><year>2017</year><fpage>72</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.06.2360</pub-id><pub-id pub-id-type="pmid">27599209</pub-id></element-citation></ref><ref id="bib0058"><label>58</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Panegyres</surname><given-names>PK.</given-names></name></person-group><article-title>The role of ethnicity in Alzheimer&#8217;s disease: findings from the C-PATH Online Data repository</article-title><source>J Alzheimers Dis</source><volume>51</volume><year>2016</year><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.3233/JAD-151089</pub-id><pub-id pub-id-type="pmid">26890783</pub-id></element-citation></ref><ref id="bib0059"><label>59</label><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><etal/></person-group><article-title>Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer&#8217;s Association Workgroup</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>8</issue><year>2024</year><fpage>5143</fpage><lpage>5169</lpage><pub-id pub-id-type="doi">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></element-citation></ref><ref id="bib0060"><label>60</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Villain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><etal/></person-group><article-title>Clinical diagnosis of Alzheimer&#8217;s disease: recommendations of the International working group</article-title><source>Lancet Neurol</source><volume>20</volume><year>2021</year><fpage>484</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00066-1</pub-id><pub-id pub-id-type="pmid">33933186</pub-id><pub-id pub-id-type="pmcid">PMC8339877</pub-id></element-citation></ref><ref id="bib0061"><label>61</label><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Villain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Alzheimer disease as a clinical-biological construct-an International Working Group recommendation</article-title><source>JAMA Neurol</source><volume>1</volume><issue>12</issue><year>2024</year><fpage>1304</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2024.3770</pub-id><pub-id pub-id-type="pmcid">PMC12010406</pub-id><pub-id pub-id-type="pmid">39483064</pub-id></element-citation></ref><ref id="bib0062"><label>62</label><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name name-style="western"><surname>Monfared</surname><given-names>A.A.T.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>N.T.N.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>I.</given-names></name><etal/></person-group><article-title>A systematic review of clinical practice guidelines for Alzheimer&#8217;s disease and strategies for future advancements</article-title><source>Neurol Ther</source><volume>12</volume><year>2023</year><fpage>1257</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1007/s40120-023-00504-6</pub-id><pub-id pub-id-type="pmid">37261607</pub-id><pub-id pub-id-type="pmcid">PMC10310649</pub-id></element-citation></ref><ref id="bib0063"><label>63</label><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H-J</given-names></name><etal/></person-group><article-title>Clinical Practice Guideline for dementia (Diagnosis and Evaluation): 2021 revised edition</article-title><source>Dement Neurocogn Disord</source><volume>21</volume><year>2022</year><fpage>42</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.12779/dnd.2022.21.1.42</pub-id><pub-id pub-id-type="pmid">35154339</pub-id><pub-id pub-id-type="pmcid">PMC8811204</pub-id></element-citation></ref><ref id="bib0064"><label>64</label><element-citation publication-type="journal" id="sbref0064"><article-title>Xinjiang uygur autonomous region hospital of traditional Chinese Medicine, et al. International clinical practice guideline of Chinese medicine Alzheimer</article-title><source>World J Tradit Chin Med</source><volume>7</volume><issue>2</issue><year>2021</year><fpage>265</fpage><lpage>275</lpage></element-citation></ref><ref id="bib0065"><label>65</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y-W</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y-J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y-S</given-names></name><etal/></person-group><article-title>Application of blood-based biomarkers of Alzheimer&#8217;s disease in clinical practice: recommendations from Taiwan Dementia society</article-title><source>J Formos Med Assoc</source><volume>123</volume><year>2024</year><fpage>1210</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2024.01.018</pub-id><pub-id pub-id-type="pmid">38296698</pub-id></element-citation></ref><ref id="bib0066"><label>66</label><element-citation publication-type="journal" id="sbref0066"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Consensus on rapid screening for prodromal Alzheimer&#8217;s disease in China</article-title><source>Gen Psychiatr</source><volume>37</volume><year>2024</year><object-id pub-id-type="publisher-id">e101310</object-id><pub-id pub-id-type="doi">10.1136/gpsych-2023-101310</pub-id><pub-id pub-id-type="pmcid">PMC10836380</pub-id><pub-id pub-id-type="pmid">38313393</pub-id></element-citation></ref><ref id="bib0067"><label>67</label><element-citation publication-type="book" id="sbref0067"><person-group person-group-type="author"><name name-style="western"><surname>Reeve</surname><given-names>E.</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>W.</given-names></name><etal/></person-group><part-title>Evidence-Based Clinical Practice Guideline For Deprescribing Cholinesterase Inhibitors And Memantine: Recommendations</part-title><year>2018</year><publisher-name>The University of Sydney</publisher-name><publisher-loc>Sydney</publisher-loc><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cdpc.sydney.edu.au/wp-content/uploads/2019/06/deprescribing-guideline.pdf" id="interref0032">https://cdpc.sydney.edu.au/wp-content/uploads/2019/06/deprescribing-guideline.pdf</ext-link><comment>Accessed November 2023</comment></element-citation></ref><ref id="bib0068"><label>68</label><element-citation publication-type="journal" id="sbref0068"><person-group person-group-type="author"><name name-style="western"><surname>Reeve</surname><given-names>E.</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary</article-title><source>Med J Aust</source><volume>210</volume><year>2019</year><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.5694/mja2.50015</pub-id><pub-id pub-id-type="pmid">30771226</pub-id></element-citation></ref><ref id="bib0069"><label>69</label><element-citation publication-type="journal" id="sbref0069"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L-K</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>P-Y</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>Y-C</given-names></name><etal/></person-group><article-title>Taiwan Dementia Treatment Guideline</article-title><source>Int J Gerontol</source><volume>15</volume><year>2021</year><fpage>292</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.6890/IJGE.202110_15(4).0001</pub-id></element-citation></ref><ref id="bib0070"><label>70</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Getchius</surname><given-names>T.S.D.</given-names></name><name name-style="western"><surname>Ganguli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gloss</surname><given-names>D.</given-names></name></person-group><article-title>Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology</article-title><source>Neurology</source><volume>90</volume><year>2018</year><fpage>126</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004826</pub-id><pub-id pub-id-type="pmid">29282327</pub-id><pub-id pub-id-type="pmcid">PMC5772157</pub-id></element-citation></ref><ref id="bib0071"><label>71</label><element-citation publication-type="journal" id="sbref0071"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Cognitive assessment tools for mild cognitive impairment screening</article-title><source>J Neurol</source><volume>268</volume><year>2021</year><fpage>1615</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09506-7</pub-id><pub-id pub-id-type="pmid">31414193</pub-id></element-citation></ref><ref id="bib0072"><label>72</label><element-citation publication-type="journal" id="sbref0072"><person-group person-group-type="author"><name name-style="western"><surname>Woodward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brodaty</surname><given-names>H.</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Nationally informed recommendations on approaching the detection, assessment, and management of mild cognitive impairment</article-title><source>J Alzheimers Dis</source><volume>89</volume><year>2022</year><fpage>803</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.3233/JAD-220288</pub-id><pub-id pub-id-type="pmid">35964184</pub-id><pub-id pub-id-type="pmcid">PMC9535556</pub-id></element-citation></ref><ref id="bib0073"><label>73</label><element-citation publication-type="other" id="sbref0073"><person-group person-group-type="author"><collab>Australia Dementia Network</collab></person-group><comment>Version 2</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://memoryandcognitionclinic.com.au/wp-content/uploads/2024/05/ADNeT_MC_Clinic_Guidelines_Version_2.pdf" id="interref0033">https://memoryandcognitionclinic.com.au/wp-content/uploads/2024/05/ADNeT_MC_Clinic_Guidelines_Version_2.pdf</ext-link><year>2024</year><comment>Accessed 25 June 2025</comment></element-citation></ref><ref id="bib0074"><label>74</label><element-citation publication-type="journal" id="sbref0074"><person-group person-group-type="author"><name name-style="western"><surname>Brodtmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Darby</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oboudiyat</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems</article-title><source>Med J Aust</source><volume>218</volume><year>2023</year><fpage>247</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.5694/mja2.51880</pub-id><pub-id pub-id-type="pmid">36934371</pub-id></element-citation></ref><ref id="bib0075"><label>75</label><element-citation publication-type="other" id="sbref0075"><person-group person-group-type="author"><collab>Monash University</collab></person-group><article-title>Time for action in Alzheimer&#8217;s disease as new treatments advance</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.monash.edu/medicine/news/latest/2023-articles/time-for-action-in-alzheimers-disease-as-new-treatments-advance" id="interref0034">https://www.monash.edu/medicine/news/latest/2023-articles/time-for-action-in-alzheimers-disease-as-new-treatments-advance</ext-link><year>2023</year><comment>Accessed November 2023</comment></element-citation></ref><ref id="bib0076"><label>76</label><element-citation publication-type="journal" id="sbref0076"><person-group person-group-type="author"><name name-style="western"><surname>Panegyres</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>R.</given-names></name><name name-style="western"><surname>Burchell</surname><given-names>J.</given-names></name></person-group><article-title>Early dementia screening</article-title><source>Diagnostics</source><volume>6</volume><year>2016</year><fpage>6</fpage><pub-id pub-id-type="doi">10.3390/diagnostics6010006</pub-id><pub-id pub-id-type="pmid">26838803</pub-id><pub-id pub-id-type="pmcid">PMC4808821</pub-id></element-citation></ref><ref id="bib0077"><label>77</label><element-citation publication-type="journal" id="sbref0077"><person-group person-group-type="author"><collab>Chinese Society of Dementia and Cognitive lmpairment and Chinese Society of Nuclear Medicine</collab></person-group><article-title>Expert consensus on the application of amyloid-PET imaging in the diagnosis of Alzheimer's disease</article-title><source>Zhonghua Yi Xue Za Zhi</source><volume>103</volume><year>2023</year><fpage>3615</fpage><lpage>3626</lpage><pub-id pub-id-type="doi">10.3760/cma.j.cn112137-20230909-00433</pub-id><comment>[Chinese]</comment><pub-id pub-id-type="pmid">38018060</pub-id></element-citation></ref><ref id="bib0078"><label>78</label><element-citation publication-type="journal" id="sbref0078"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fawkes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wand</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name></person-group><article-title>Knowledge, attitudes, and practice of general practitioners toward community detection and management of mild cognitive impairment: a cross-sectional study in Shanghai, China</article-title><source>BMC Prim Care</source><volume>23</volume><year>2022</year><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/s12875-022-01716-9</pub-id><pub-id pub-id-type="pmid">35545764</pub-id><pub-id pub-id-type="pmcid">PMC9092880</pub-id></element-citation></ref><ref id="bib0079"><label>79</label><element-citation publication-type="journal" id="sbref0079"><person-group person-group-type="author"><name name-style="western"><surname>Shea</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>LW.</given-names></name></person-group><article-title>Impact of <sup>18</sup>FDG PET and <sup>11</sup>C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong</article-title><source>Hong Kong Med J</source><volume>22</volume><year>2016</year><fpage>327</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.12809/hkmj154707</pub-id><pub-id pub-id-type="pmid">27313272</pub-id></element-citation></ref><ref id="bib0080"><label>80</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Mak</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Combination of MRI hippocampal volumetry and arterial spin labeling MR perfusion at 3-tesla improves the efficacy in discriminating Alzheimer's disease from cognitively normal elderly adults</article-title><source>J Alzheimers Dis</source><volume>41</volume><year>2014</year><fpage>749</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.3233/JAD-131868</pub-id><pub-id pub-id-type="pmid">24670395</pub-id></element-citation></ref><ref id="bib0081"><label>81</label><element-citation publication-type="journal" id="sbref0081"><person-group person-group-type="author"><name name-style="western"><surname>Shea</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study</article-title><source>Am J Alzheimers Dis Other Demen</source><volume>28</volume><year>2013</year><fpage>769</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1177/1533317513504615</pub-id><pub-id pub-id-type="pmid">24085246</pub-id><pub-id pub-id-type="pmcid">PMC10852804</pub-id></element-citation></ref><ref id="bib0082"><label>82</label><element-citation publication-type="journal" id="sbref0082"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Uhm</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ip</surname><given-names>F.C.</given-names></name><etal/></person-group><article-title>A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups</article-title><source>Alzheimers Dement</source><volume>20</volume><year>2024</year><fpage>2000</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1002/alz.13676</pub-id><pub-id pub-id-type="pmid">38183344</pub-id><pub-id pub-id-type="pmcid">PMC10984431</pub-id></element-citation></ref><ref id="bib0083"><label>83</label><element-citation publication-type="other" id="sbref0083"><person-group person-group-type="author"><collab>Hong Kong Center for Neurodegenerative Diseases</collab></person-group><article-title>Cognitact launches PlasmarkAD blood test service for early detection of Alzheimer&#8217;s disease</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.hkcend.org/news/cognitact-launches-plasmarkad-blood-test-service-for-early-detection-of-alzheimers-disease/" id="interref0035">https://www.hkcend.org/news/cognitact-launches-plasmarkad-blood-test-service-for-early-detection-of-alzheimers-disease/</ext-link><year>2023</year><comment>Accessed July 2024</comment></element-citation></ref><ref id="bib0084"><label>84</label><element-citation publication-type="other" id="sbref0084"><person-group person-group-type="author"><collab>Hong Kong Center for Neurodegenerative Diseases</collab></person-group><article-title>HKUST neuroscientists develop highly accurate universal diagnostic blood test for Alzheimer&#8217;s disease and mild cognitive impairment</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.hkcend.org/news/hkust-neuroscientists-develop-highly-accurate-universal-diagnostic-blood-test-for-alzheimers-disease-and-mild-cognitive-impairment/" id="interref0036">https://www.hkcend.org/news/hkust-neuroscientists-develop-highly-accurate-universal-diagnostic-blood-test-for-alzheimers-disease-and-mild-cognitive-impairment/</ext-link><year>2024</year><comment>Accessed July 2024</comment></element-citation></ref><ref id="bib0085"><label>85</label><element-citation publication-type="book" id="sbref0085"><person-group person-group-type="author"><collab>The Hong Kong Geriatrics Society</collab></person-group><part-title>Practical Manual of Dementia in Older Adults</part-title><edition>3rd edn.</edition><year>2022</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://hkgs.org/image/files/%5bWeb_0623(ALL)%5dHKGS%20Booklet%202022(2).pdf" id="interref0037">https://hkgs.org/image/files/%5bWeb_0623(ALL)%5dHKGS%20Booklet%202022(2).pdf</ext-link><comment>Accessed January 2024</comment></element-citation></ref><ref id="bib0086"><label>86</label><element-citation publication-type="journal" id="sbref0086"><person-group person-group-type="author"><name name-style="western"><surname>Shea</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>AO.</given-names></name></person-group><article-title>The first case series of Chinese patients in Hong Kong with familial Alzheimer's disease compared with those with biomarker-confirmed sporadic late-onset Alzheimer's disease</article-title><source>Hong Kong Med J</source><volume>23</volume><year>2017</year><fpage>579</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.12809/hkmj176845</pub-id><pub-id pub-id-type="pmid">29123074</pub-id></element-citation></ref><ref id="bib0087"><label>87</label><element-citation publication-type="journal" id="sbref0087"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>Z.</given-names></name><name name-style="western"><surname>McGirr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Forkert</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EE.</given-names></name></person-group><article-title>Mild behavioral impairment and subjective cognitive decline predict cognitive and functional decline</article-title><source>J Alzheimers Dis</source><volume>80</volume><year>2021</year><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.3233/JAD-201184</pub-id><pub-id pub-id-type="pmid">33554909</pub-id><pub-id pub-id-type="pmcid">PMC8075401</pub-id></element-citation></ref><ref id="bib0088"><label>88</label><element-citation publication-type="other" id="sbref0088"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y-Q</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Shea</surname><given-names>Y-F.</given-names></name></person-group><article-title>Prevalence of mild behavioral impairment among a Chinese cohort of elderly with mild cognitive impairment and subjective cognitive impairment</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2023.06.10.23291238v1" id="interref0038">https://www.medrxiv.org/content/10.1101/2023.06.10.23291238v1</ext-link><year>2023</year><comment>Accessed May 2024</comment></element-citation></ref><ref id="bib0089"><label>89</label><element-citation publication-type="other" id="sbref0089"><person-group person-group-type="author"><collab>Japanese Society of Neurology 2017</collab></person-group><article-title>Clinical practice guideline for dementia</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.neurology-jp.org/guidelinem/dementia/documents/preface.pdf" id="interref0039">https://www.neurology-jp.org/guidelinem/dementia/documents/preface.pdf</ext-link><year>2017</year><comment>Accessed February 2024</comment></element-citation></ref><ref id="bib0090"><label>90</label><element-citation publication-type="other" id="sbref0090"><person-group person-group-type="author"><collab>Dementia Japan</collab></person-group><article-title>Guideline for the proper use of amyloid PET imaging agents</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dementia-japan.org/wp-content/uploads/2023/12/amyloid_pet_guideline_3rd.pdf" id="interref0040">https://dementia-japan.org/wp-content/uploads/2023/12/amyloid_pet_guideline_3rd.pdf</ext-link><year>2023</year><comment>Accessed September 2024</comment></element-citation></ref><ref id="bib0091"><label>91</label><element-citation publication-type="other" id="sbref0091"><person-group person-group-type="author"><collab>Dementia Japan</collab></person-group><article-title>Guidelines for the proper use of cerebrospinal fluid and blood biomarkers and APOE tests for dementia</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dementia-japan.org/wp-content/uploads/2023/12/biomarker_guideline20230930.pdf" id="interref0041">https://dementia-japan.org/wp-content/uploads/2023/12/biomarker_guideline20230930.pdf</ext-link><year>2023</year><comment>Accessed September 2024</comment></element-citation></ref><ref id="bib0092"><label>92</label><element-citation publication-type="journal" id="sbref0092"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>A.H.Y.</given-names></name><name name-style="western"><surname>Hikaka</surname><given-names>J.</given-names></name><name name-style="western"><surname>To</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Anti-dementia medication use in Aotearoa New Zealand: an exploratory study using health data from the Integrated Data Infrastructure (IDI)</article-title><source>Aust N Z J Psychiatr</source><volume>57</volume><year>2023</year><fpage>895</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1177/00048674221121091</pub-id><pub-id pub-id-type="pmid">36053008</pub-id></element-citation></ref><ref id="bib0093"><label>93</label><element-citation publication-type="journal" id="sbref0093"><person-group person-group-type="author"><name name-style="western"><surname>Youn</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H-G.</given-names></name></person-group><article-title>Pharmacotherapy for dementia</article-title><source>J Korean Med Assoc</source><volume>61</volume><issue>12</issue><year>2018</year><fpage>758</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.5124/jkma.2018.61.12.758</pub-id></element-citation></ref><ref id="bib0094"><label>94</label><element-citation publication-type="journal" id="sbref0094"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Yoong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mattke</surname><given-names>S.</given-names></name></person-group><article-title>Is Korea prepared for an Alzheimer&#8217;s disease-modifying therapy? Assessing the Korean healthcare system infrastructure and the effect of blood-based biomarker tests</article-title><source>Ann Geriatr Med Res</source><volume>25</volume><year>2021</year><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.4235/agmr.20.0082</pub-id><pub-id pub-id-type="pmid">33550774</pub-id><pub-id pub-id-type="pmcid">PMC8024173</pub-id></element-citation></ref><ref id="bib0095"><label>95</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>A comparison of dementia care and policy in five Asian regions: A literature review</article-title><source>J Korean Gerontol Nurs</source><volume>25</volume><year>2023</year><fpage>174</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.17079/jkgn.2303.16001</pub-id></element-citation></ref><ref id="bib0096"><label>96</label><mixed-citation publication-type="other" id="sbref0096">Australian Institute of Health and Welfare. Dementia in Australia. National policy response to dementia. Last updated September 13 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/national-policy-response-to-dementia" id="interref0042">https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/national-policy-response-to-dementia</ext-link>. Accessed May 2025.</mixed-citation></ref><ref id="bib0097"><label>97</label><element-citation publication-type="book" id="sbref0097"><person-group person-group-type="author"><collab>Australian Institute of Health and Welfare</collab></person-group><part-title>Dementia in Australia</part-title><year>2024</year><publisher-name>Care partners</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/national-policy-response-to-dementia" id="interref0043">https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/national-policy-response-to-dementia</ext-link></element-citation></ref><ref id="bib0098"><label>98</label><element-citation publication-type="journal" id="sbref0098"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>2024 Chinese expert consensus on the diagnosis and treatment of mild cognitive impairment due to AD</article-title><source>Chin J Neurol</source><volume>57</volume><year>2024</year><fpage>715</fpage><lpage>736</lpage></element-citation></ref><ref id="bib0099"><label>99</label><mixed-citation publication-type="other" id="sbref0099">The Government of the Hong Kong Special Administrative Region. Press release. June 2022. LCQ18: policy on support for dementia patients. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.info.gov.hk/gia/general/202206/01/P2022060100384.htm" id="interref0044">https://www.info.gov.hk/gia/general/202206/01/P2022060100384.htm</ext-link>. Accessed May 2024.</mixed-citation></ref><ref id="bib0100"><label>100</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name name-style="western"><surname>Yee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsui</surname><given-names>N.B.Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.N.</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease: insights for risk evaluation and prevention in the Chinese population and the need for a comprehensive programme in Hong Kong/China</article-title><source>Hong Kong Med J</source><volume>24</volume><year>2018</year><fpage>492</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.12809/hkmj187244</pub-id><pub-id pub-id-type="pmid">30232267</pub-id></element-citation></ref><ref id="bib0101"><label>101</label><element-citation publication-type="other" id="sbref0101"><person-group person-group-type="author"><collab>Health Bureau</collab></person-group><article-title>Other publications: Dementia Community Support Scheme</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.healthbureau.gov.hk/en/press_and_publications/otherinfo/180500_dcss/dcss_background.html" id="interref0045">https://www.healthbureau.gov.hk/en/press_and_publications/otherinfo/180500_dcss/dcss_background.html</ext-link><year>2019</year><comment>Accessed May 2024</comment></element-citation></ref><ref id="bib0102"><label>102</label><element-citation publication-type="journal" id="sbref0102"><person-group person-group-type="author"><name name-style="western"><surname>Seong</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW.</given-names></name></person-group><article-title>Comparative analysis on the policy approaches in the national dementia plans of G7 countries and Korea and their implementation</article-title><source>J Korean Med Sci</source><volume>38</volume><year>2023</year><fpage>e227</fpage><pub-id pub-id-type="doi">10.3346/jkms.2023.38.e227</pub-id><pub-id pub-id-type="pmid">37527910</pub-id><pub-id pub-id-type="pmcid">PMC10396431</pub-id></element-citation></ref><ref id="bib0103"><label>103</label><element-citation publication-type="journal" id="sbref0103"><person-group person-group-type="author"><name name-style="western"><surname>Ishihara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>U-I.</given-names></name></person-group><article-title>A policy overview of Japan's progress on dementia care in a super aged society and future challenges</article-title><source>J Glob Health Med</source><volume>6</volume><issue>1</issue><year>2024</year><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.35772/ghm.2023.01047</pub-id><pub-id pub-id-type="pmcid">PMC10912804</pub-id><pub-id pub-id-type="pmid">38450108</pub-id></element-citation></ref><ref id="bib0104"><label>104</label><element-citation publication-type="other" id="sbref0104"><person-group person-group-type="author"><collab>Science Japan</collab></person-group><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sj.jst.go.jp/stories/2025/s0225-01p.html" id="interref0046">https://sj.jst.go.jp/stories/2025/s0225-01p.html</ext-link><year>2025</year><comment>Accessed 25 June 2025</comment></element-citation></ref><ref id="bib0105"><label>105</label><element-citation publication-type="other" id="sbref0105"><person-group person-group-type="author"><collab>Alzheimers New Zealand</collab></person-group><article-title>Services and standards</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://alzheimers.org.nz/explore/dementia-friendly-nz/services-and-standards/" id="interref0047">https://alzheimers.org.nz/explore/dementia-friendly-nz/services-and-standards/</ext-link><year>2024</year><comment>Accessed January 2024</comment></element-citation></ref><ref id="bib0106"><label>106</label><mixed-citation publication-type="other" id="sbref0106">Ministry of Health and Welfare. The 3rd national dementia plan. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.alzint.org/u/Republic-of-Korea-The-3rd-National-Dementia-Plan.pdf" id="interref0048">https://www.alzint.org/u/Republic-of-Korea-The-3rd-National-Dementia-Plan.pdf</ext-link>. Accessed November 2023.</mixed-citation></ref><ref id="bib0107"><label>107</label><mixed-citation publication-type="other" id="sbref0107">Taiwan Government Ministry of Health and Welfare. Promoting the &#8220;Taiwan dementia policy: a framework for prevention and care 2.0&#8221; to jointly create a &#8220;dementia-friendly Taiwan!&#8221; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mohw.gov.tw/cp-3775-43174-2.html" id="interref0049">https://www.mohw.gov.tw/cp-3775-43174-2.html</ext-link> Accessed May 2024.</mixed-citation></ref><ref id="bib0108"><label>108</label><element-citation publication-type="other" id="sbref0108"><person-group person-group-type="author"><collab>NIA</collab></person-group><article-title>Natives Engaged in Alzheimer&#8217;s Research (NEAR) website</article-title><comment>November</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nia.nih.gov/research/alzheimers-dementia-outreach-recruitment-engagement-resources/natives-engaged-alzheimers" id="interref0050">https://www.nia.nih.gov/research/alzheimers-dementia-outreach-recruitment-engagement-resources/natives-engaged-alzheimers</ext-link><year>2023</year><comment>Accessed June 2024</comment></element-citation></ref><ref id="bib0109"><label>109</label><mixed-citation publication-type="other" id="sbref0109">IREACH. Battling dementia in Native and Pacific Islander communities. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ireach.wsu.edu/near/" id="interref0051">https://ireach.wsu.edu/near/</ext-link>. Accessed June 2024.</mixed-citation></ref><ref id="bib0110"><label>110</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name name-style="western"><surname>Devenney</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>Q.A.N.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Kiernan</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>RH.</given-names></name></person-group><article-title>A scoping review of the unique landscape and challenges associated with dementia in the Western Pacific region</article-title><source>Lancet Reg Health West Pac</source><volume>50</volume><year>2024</year><object-id pub-id-type="publisher-id">101192</object-id><pub-id pub-id-type="doi">10.1016/j.lanwpc.2024.101192</pub-id><pub-id pub-id-type="pmcid">PMC11471059</pub-id><pub-id pub-id-type="pmid">39399870</pub-id></element-citation></ref><ref id="bib0111"><label>111</label><element-citation publication-type="journal" id="sbref0111"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Callaghan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Michaelian</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Aihara</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies</article-title><source>Lancet Reg Health West Pac</source><volume>50</volume><year>2024</year><object-id pub-id-type="publisher-id">101183</object-id><pub-id pub-id-type="doi">10.1016/j.lanwpc.2024.101183</pub-id><pub-id pub-id-type="pmcid">PMC11471058</pub-id><pub-id pub-id-type="pmid">39399864</pub-id></element-citation></ref><ref id="bib0112"><label>112</label><element-citation publication-type="journal" id="sbref0112"><person-group person-group-type="author"><name name-style="western"><surname>Timmins</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>V.C.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Regional health priorities for dementia: a roadmap for the Western Pacific</article-title><source>Lancet</source><volume>50</volume><year>2024</year><object-id pub-id-type="publisher-id">101179</object-id><pub-id pub-id-type="doi">10.1016/j.lanwpc.2024.101179</pub-id><pub-id pub-id-type="pmcid">PMC11471056</pub-id><pub-id pub-id-type="pmid">39399866</pub-id></element-citation></ref><ref id="bib0113"><label>113</label><element-citation publication-type="journal" id="sbref0113"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L-Y</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>M-J.</given-names></name></person-group><article-title>Rural-urban disparities in the prevalence of mild cognitive impairment and dementia in Taiwan: A door-to-door nationwide study</article-title><source>J Epidemiol</source><volume>32</volume><year>2022</year><fpage>502</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.2188/jea.JE20200602</pub-id><pub-id pub-id-type="pmid">33840652</pub-id><pub-id pub-id-type="pmcid">PMC9551297</pub-id></element-citation></ref><ref id="bib0114"><label>114</label><element-citation publication-type="journal" id="sbref0114"><person-group person-group-type="author"><collab>Alzheimer&#8217;s Association Report</collab></person-group><article-title>Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement</source><volume>19</volume><year>2023</year><fpage>1598</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1002/alz.13016</pub-id><pub-id pub-id-type="pmid">36918389</pub-id></element-citation></ref><ref id="bib0115"><label>115</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M-H</given-names></name><etal/></person-group><article-title>A nationwide survey on the prevalence of dementia and mild cognitive impairment in South Korea</article-title><source>J Alzheimers Dis</source><volume>23</volume><year>2011</year><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-101221</pub-id><pub-id pub-id-type="pmid">21178286</pub-id></element-citation></ref><ref id="bib0116"><label>116</label><element-citation publication-type="journal" id="sbref0116"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>M.</given-names></name></person-group><article-title>Mild cognitive impairment in a population-based epidemiological study</article-title><source>Psychogeriatrics</source><volume>7</volume><year>2007</year><fpage>104</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1111/j.1479-8301.2007.00197.x</pub-id></element-citation></ref><ref id="bib0117"><label>117</label><element-citation publication-type="journal" id="sbref0117"><person-group person-group-type="author"><name name-style="western"><surname>Byeon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Clinical Practice Guidelines for dementia: recommendations for the pharmacological treatment of behavioral and psychological symptoms</article-title><source>Dement Neurocogn Disord</source><volume>24</volume><issue>1</issue><year>2025</year><fpage>24</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.12779/dnd.2025.24.1.24</pub-id><pub-id pub-id-type="pmid">39944528</pub-id><pub-id pub-id-type="pmcid">PMC11813557</pub-id></element-citation></ref><ref id="bib0118"><label>118</label><element-citation publication-type="journal" id="sbref0118"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C-h</given-names></name><etal/></person-group><article-title>Lecanemab: appropriate use recommendations by Korean Dementia Association</article-title><source>Dement Neurocogn Disord</source><volume>23</volume><issue>4</issue><year>2024</year><fpage>165</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.12779/dnd.2024.23.4.165</pub-id><pub-id pub-id-type="pmid">39512702</pub-id><pub-id pub-id-type="pmcid">PMC11538855</pub-id></element-citation></ref></ref-list><ack id="ack0001"><title>Acknowledgments</title><p id="para0074">The authors wish to thank Shuang Cai and Taka Matsumura of Eli Lilly and Company for their review of the information specific to China and Japan, and Frances-Catherine Quevenco, John Sims, Jim Hendrix, and Eric Edgell of Eli Lilly and Company for providing medical review of this manuscript. The authors thank Ji Sun Kim M.D. for her editorial support and oversight during this work.</p><p id="para0075">Medical writing support was provided by Claire Lavin and Sarah Birch on behalf of Rx Communications, (Mold, UK) funded by Eli Lilly and Company.</p></ack></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501338</article-id><article-id pub-id-type="pmcid-ver">PMC12501338.1</article-id><article-id pub-id-type="pmcaid">12501338</article-id><article-id pub-id-type="pmcaiid">12501338</article-id><article-id pub-id-type="pmid">40750513</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100311</article-id><article-id pub-id-type="pii">S2274-5807(25)00254-7</article-id><article-id pub-id-type="publisher-id">100311</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Association of sugar intake with incident dementia in the UK Biobank: a prospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Che</surname><given-names initials="Y">Yue</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Wei</surname><given-names initials="W">Wenming</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Mao</surname><given-names initials="T">Tingting</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Qin</surname><given-names initials="L">Lina</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Wang</surname><given-names initials="H">Hanchi</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yijia</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Da</surname><given-names initials="W">Weixuan</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Feng</surname><given-names initials="J">Jin</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Liu</surname><given-names initials="L">Li</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Cheng</surname><given-names initials="B">Bolun</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0011"><name name-style="western"><surname>Liu</surname><given-names initials="H">Huan</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0012"><name name-style="western"><surname>Wen</surname><given-names initials="Y">Yan</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0013"><name name-style="western"><surname>Jia</surname><given-names initials="Y">Yumeng</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0014"><name name-style="western"><surname>Zhang</surname><given-names initials="F">Feng</given-names></name><email>fzhxjtu@mail.xjtu.edu.cn</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><aff id="aff0001"><label>a</label>NHC Key Laboratory of Environment and Endemic Diseases, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi&#8217;an, Shaanxi, 710061, China</aff><aff id="aff0002"><label>b</label>Collaborative Innovation Center of Endemic Diseases and Health Promotion in Silk Road Region, Xi&#8217;an, Shaanxi, 710061, China</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, School of Public Health, Health Science Center of Xi'an Jiaotong University, No.76 Yan Ta West Road, Xi&#8217;an, Shaanxi, 710061. PR China. <email>fzhxjtu@mail.xjtu.edu.cn</email></corresp><fn id="fn1"><label>1</label><p id="notep0001">Marker present with author but regarding author notes is missing.</p></fn></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>8</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100311</elocation-id><history><date date-type="received"><day>23</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>10</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><sec><title>Background</title><p>Excessive sugar intake has been implicated in increased dementia risk; however, existing studies are constrained by small sample sizes and a primary focus on total sugar, with limited investigation into specific sugar subtypes. This study explores the relationship between sugar intake, its subtypes, and the incidence of dementia.</p></sec><sec><title>Methods</title><p>We analyzed 172,516 participants from the UK Biobank who completed at least one 24-hour dietary recall (Oxford WebQ). Cox proportional hazards models estimated the hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) for total sugar and its subtypes (free sugar, fructose, glucose, sucrose, maltose, lactose, and other sugars) about the risk of dementia. Sex-stratified analyses were also performed.</p></sec><sec><title>Results</title><p>Higher intakes of total sugar (HR = 1.292, 95 % CI = 1.148&#8211;-1.453) and free sugar intake (HR = 1.254, 95 % CI = 1.117&#8211;-1.408) were significantly associated with increased dementia risk. Positive associations were also observed for non-milk extrinsic sugars (HR = 1.321, 95 % CI = 1.175&#8211;-1.486) and sucrose (HR = 1.291, 95 % CI = 1.147&#8211;-1.452). These associations were evident in women, with higher intakes of total sugars, free sugars, glucose, sucrose, and non-milk extrinsic sugars independently linked to increased dementia risk, whereas no significant associations were found in men.</p></sec><sec><title>Conclusion</title><p>Higher consumption of total sugars, free sugars, sucrose, and non-milk extrinsic sugars confers increased dementia risk, particularly among women.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Dementia</kwd><kwd>Sugar intake</kwd><kwd>Sugar subtypes</kwd><kwd>Sex differences</kwd><kwd>Cox proportional hazards model</kwd><kwd>UK Biobank</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0007">Dementia is a clinical syndrome that primarily affects cognitive functions, including attention, memory, language, executive function, and processing speed [<xref rid="bib0001" ref-type="bibr">1</xref>]. Given the global acceleration of population aging, the prevalence of dementia is expected to rise significantly. The number of people affected by dementia worldwide is projected to increase from 57.4 million in 2019 to more than 150 million by 2050, representing a 166 % increase. Dementia has become one of the major threats to the health and quality of life of older individuals [<xref rid="bib0002" ref-type="bibr">2</xref>]. Although recent advances in the early treatment of dementia, particularly those targeting amyloid-associated lesions, have provided hope for patients, preventive measures aimed at delaying the onset of dementia remain a critical and cost-effective approach [<xref rid="bib0003" ref-type="bibr">3</xref>].</p><p id="para0008">Sugar, classified into monosaccharides, disaccharides, and polysaccharides based on its chemical structure, is the body&#8217;s primary source of energy [<xref rid="bib0004" ref-type="bibr">4</xref>]. The brain, being one of the most energy-demanding organs, relies almost exclusively on glucose to fuel its complex physiological functions [<xref rid="bib0005" ref-type="bibr">5</xref>]. Excessive sugar consumption has been linked to cardiovascular diseases, metabolic disorders, and systemic inflammation [<xref rid="bib0006" ref-type="bibr">6</xref>].</p><p id="para0009">Recent epidemiological studies have found that sugar intake may be closely associated with the development of dementia [<xref rid="bib0007" ref-type="bibr">7</xref>]. Excessive sugar consumption damages neurons in the brain, impairs cognitive function, increases the risk of dementia, and may contribute to cerebrovascular diseases [<xref rid="bib0008" ref-type="bibr">8</xref>]. Additionally, excessive sugar intake is linked to chronic conditions such as diabetes and obesity, which are known risk factors for dementia [<xref rid="bib0009" ref-type="bibr">[9]</xref>, <xref rid="bib0010" ref-type="bibr">[10]</xref>, <xref rid="bib0011" ref-type="bibr">[11]</xref>]. Based on these findings, we hypothesize that excessive sugar intake and its subtypes may increase the risk of dementia compared to low sugar intake.</p><p id="para0010">However, significant controversies and limitations remain in the current research on the relationship between sugar intake and the risk of dementia [<xref rid="bib0012" ref-type="bibr">12</xref>]. Most previous studies were based on small sample sizes and primarily focused on a single type of sugar, overlooking the complexity of sugar&#8217;s presence in food as multiple subtypes. This narrow focus has led to certain limitations and uncertainties in the study results [<xref rid="bib0013" ref-type="bibr">13</xref>,<xref rid="bib0014" ref-type="bibr">14</xref>].</p><p id="para0011">In this study, we examined the relationship between sugar intake and its subtypes with the incidence of dementia using a large dataset from the UK Biobank. This provides new insights into the treatment and prevention of dementia.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Study design and study population</title><p id="para0012">The UK Biobank (UKB) is a large-scale, population-based cohort study that recruited over 500,000 participants aged 37 to 73 years between 2006 and 2010 in the United Kingdom (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ukbiobank.ac.uk/about-biobank-uk/" id="interref0001">http://www.ukbiobank.ac.uk/about-biobank-uk/</ext-link>). The following exclusion criteria were applied in this study: (1) participants who did not complete at least one 24-hour dietary recall; (2) participants who reported implausible energy intakes (&lt;500 or &gt;3,500 kcal/day for women; &lt;800 or &gt;4,000 kcal/day for men); (3) individuals with missing data on covariates; and (4) participants diagnosed with dementia at baseline.</p><p id="para0013">After data cleaning and screening, a total of 172,516 eligible participants were included in the final analysis. The UK Biobank received ethical approval from the National Information Governance Board for Health and Social Care and the National Health Service (NHS) North West Centre for Research Ethics Committee (Ref: 11/NW/0382). All participants provided informed consent via electronic signature.</p></sec><sec id="sec0004"><label>2.2</label><title>Sugar intake measurement</title><p id="para0014">Dietary data in the UK Biobank were collected using the Oxford WebQ, a web-based questionnaire designed to assess participants&#8217; dietary intake over the previous 24 h. For each food or beverage item, consumption was calculated by multiplying the reported number of servings by a standard portion size. Built-in algorithms analyzed food composition and calculated specific nutrient intakes, including total sugar intake <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>. The validity of the Oxford WebQ has been demonstrated through comparisons with traditional interviewer-led 24-hour dietary recalls, particularly when multiple questionnaires are completed [<xref rid="bib0018" ref-type="bibr">18</xref>].</p><p id="para0015">In this study, data on total sugar intake (g/day) and sugar subtypes (free sugar, fructose, glucose, sucrose, maltose, lactose, and other sugars) were extracted and analyzed. Participants were categorized into tertiles based on their daily intake of each sugar type, forming three groups: Q1 (lowest intake), Q2, and Q3 (highest intake), with Q1 serving as the reference group for analysis.</p></sec><sec id="sec0005"><label>2.3</label><title>Outcome ascertainment</title><p id="para0016">The primary outcome variable for this study, referred to as all-cause dementia (hereafter &#8220;dementia&#8221;), was defined by an algorithm provided by the UK Biobank. This algorithm determined the date of dementia diagnosis based on linked data from hospital admission records, death registries, and self-reported medical conditions at baseline. Additionally, first-occurrence data from primary care visits were included to complement the algorithm-defined dementia outcomes. To enhance the accuracy of dementia diagnosis, individuals diagnosed with dementia at baseline were excluded. Follow-up time was defined as the period from the first dietary assessment to the earliest of the following events: the first dementia diagnosis, loss to follow-up, death, or the end of the study review [<xref rid="bib0019" ref-type="bibr">19</xref>,<xref rid="bib0020" ref-type="bibr">20</xref>]. Dementia diagnoses were made using the International Classification of Diseases (ICD-10) codes F00-F03, G30, G310, G311, and G318.</p></sec><sec id="sec0006"><label>2.4</label><title>Covariates</title><p id="para0017">Covariates were selected based on previously established risk factors for dementia and included sex (female/male), baseline age, race (White/non-White, including mixed race, Black, Asian, and other ethnic groups), body mass index (BMI), Townsend Deprivation Index (TDI), education level (Degree level or professional education, Other levels, and Missing value), smoking status, alcohol consumption, use of vitamin or mineral supplements, physical activity level (assessed using the International Physical Activity Questionnaire [IPAQ] and categorized as low, medium, or high), and medical conditions including diabetes, hypertension, and obesity [<xref rid="bib0021" ref-type="bibr">21</xref>].</p></sec><sec id="sec0007"><label>2.5</label><title>Data analysis</title><p id="para0018">Baseline characteristics were summarized according to tertiles of total sugar intake. Continuous variables were presented as means with standard deviations (SD), while categorical variables were reported as counts and percentages.</p><p id="para0019">A Cox proportional hazards regression model was employed to assess the association between sugar intake and dementia risk. Sugar intake was categorized into tertiles (Q1 to Q3), with Q1 serving as the reference group. Covariates were adjusted in three models: Model 1 included sociodemographic factors (age, sex, ethnicity, education level, and TDI); Model 2 additionally incorporated behavioral factors, including BMI, smoking status, alcohol consumption, IPAQ score, and supplement use; and Model 3 further adjusted for medical conditions, including diabetes, cancer, hypertension, and cardiovascular disease. The proportional hazards (PH) assumption was thoroughly evaluated for all Cox regression models included in our study. Specifically, we assessed this assumption using Schoenfeld residuals via the cox.zph function in R.</p><p id="para0020">Hazard ratios (HRs) and 95 % confidence intervals (CIs) were calculated, and p-values for trend were computed using the median value of each tertile as a quasi-continuous variable in the model. Stratified analyses were conducted by sex to explore potential sex-specific associations. To further assess whether sex modifies the association between sugar intake and dementia risk, we included interaction terms between sex and sugar intake variables in the Cox proportional hazards models. We tested the significance and consistency of these interactions across different model specifications and subsamples to evaluate the potential effect modification by sex and the robustness of the interaction effects.</p><p id="para0021">All statistical analyses were performed using the R programming language, with a significance threshold set at <italic toggle="yes">p</italic> &lt; 0.05. Given that ten independent tests were conducted, Bonferroni correction was applied, resulting in an adjusted significance level of 0.005 (0.05 / 10). Only results with <italic toggle="yes">p</italic>-values &lt; 0.005 were considered statistically significant.</p></sec></sec><sec id="sec0008"><label>3</label><title>Results</title><sec id="sec0009"><label>3.1</label><title>Baseline characteristics of UK Biobank participants</title><p id="para0022">Based on tertiles of total sugar intake (Q1 to Q3, representing progressively higher intake), the characteristics of the study population are summarized in <xref rid="tbl0001" ref-type="table">Table 1</xref>. The number of participants in the Q1, Q2, and Q3 groups was 57,506, 57,505, and 57,505, respectively. Notably, the mean age of participants increased across tertiles: 55.0 &#177; 8.0 years in Q1, 56.1 &#177; 7.9 years in Q2, and 56.6 &#177; 7.9 years in Q3, suggesting a trend of higher mean age with increasing sugar intake. Regarding sex distribution, females were fewer than males in the Q1 group, whereas females outnumbered males in both the Q2 and Q3 groups.<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of the study population.</p></caption><alt-text id="alt0003">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1">Characteristics</th><th colspan="3" align="left" valign="top" rowspan="1">Total sugar intake<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1">Q1</th><th valign="top" colspan="1" rowspan="1">Q2</th><th valign="top" colspan="1" rowspan="1">Q3</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Number</td><td valign="top" colspan="1" rowspan="1">57,506</td><td valign="top" colspan="1" rowspan="1">57,505</td><td valign="top" colspan="1" rowspan="1">57,505</td></tr><tr><td valign="top" colspan="1" rowspan="1">Age</td><td valign="top" colspan="1" rowspan="1">55.0 (8.0)</td><td valign="top" colspan="1" rowspan="1">56.1 (7.9)</td><td valign="top" colspan="1" rowspan="1">56.6(7.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sex</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Female</td><td valign="top" colspan="1" rowspan="1">27,990 (48.7)</td><td valign="top" colspan="1" rowspan="1">32,294 (56.2)</td><td valign="top" colspan="1" rowspan="1">32,130 (55.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Male</td><td valign="top" colspan="1" rowspan="1">29,516 (51.3)</td><td valign="top" colspan="1" rowspan="1">25,211 (43.8)</td><td valign="top" colspan="1" rowspan="1">25,375 (44.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Racial</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;white</td><td valign="top" colspan="1" rowspan="1">55,298 (96.2)</td><td valign="top" colspan="1" rowspan="1">55,443 (96.4)</td><td valign="top" colspan="1" rowspan="1">54,750 (95.2)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Non-white</td><td valign="top" colspan="1" rowspan="1">2208 (3.8)</td><td valign="top" colspan="1" rowspan="1">2062 (3.6)</td><td valign="top" colspan="1" rowspan="1">2755 (4.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">TDI</td><td valign="top" colspan="1" rowspan="1">&#8722;1.50 (2.9)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.70 (2.8)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.63 (2.9)</td></tr><tr><td valign="top" colspan="1" rowspan="1">BMI</td><td valign="top" colspan="1" rowspan="1">27.28 (4.7)</td><td valign="top" colspan="1" rowspan="1">26.65 (4.5)</td><td valign="top" colspan="1" rowspan="1">26.65 (4.5)</td></tr><tr><td valign="top" colspan="1" rowspan="1">IPAQ</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Low</td><td valign="top" colspan="1" rowspan="1">12,208 (21.2)</td><td valign="top" colspan="1" rowspan="1">10,369 (18.0)</td><td valign="top" colspan="1" rowspan="1">8996 (15.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Moderate</td><td valign="top" colspan="1" rowspan="1">24,816 (43.2)</td><td valign="top" colspan="1" rowspan="1">24,947 (43.4)</td><td valign="top" colspan="1" rowspan="1">23,458 (40.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;High</td><td valign="top" colspan="1" rowspan="1">20,482 (35.6)</td><td valign="top" colspan="1" rowspan="1">22,189 (38.6)</td><td valign="top" colspan="1" rowspan="1">25,051 (43.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Education level</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Degree/Professional</td><td valign="top" colspan="1" rowspan="1">31,538 (54.8)</td><td valign="top" colspan="1" rowspan="1">32,070 (55.8)</td><td valign="top" colspan="1" rowspan="1">31,058 (54.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Other</td><td valign="top" colspan="1" rowspan="1">21,824 (38.0)</td><td valign="top" colspan="1" rowspan="1">21,257 (37.0)</td><td valign="top" colspan="1" rowspan="1">21,763 (37.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Missing value</td><td valign="top" colspan="1" rowspan="1">4144 (7.2)</td><td valign="top" colspan="1" rowspan="1">4178 (7.3)</td><td valign="top" colspan="1" rowspan="1">4684 (8.1)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Alcohol intake, Yes</td><td valign="top" colspan="1" rowspan="1">56,493 (98.2)</td><td valign="top" colspan="1" rowspan="1">55,947 (97.3)</td><td valign="top" colspan="1" rowspan="1">54,861 (95.4)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Smoking, Yes</td><td valign="top" colspan="1" rowspan="1">27,685 (48.1)</td><td valign="top" colspan="1" rowspan="1">24,280 (42.2)</td><td valign="top" colspan="1" rowspan="1">23,013 (40.0)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Supplementation, Yes</td><td valign="top" colspan="1" rowspan="1">24,584 (42.8)</td><td valign="top" colspan="1" rowspan="1">29,014 (50.5)</td><td valign="top" colspan="1" rowspan="1">31,471 (54.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Medical history</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Hypertension, Yes</td><td valign="top" colspan="1" rowspan="1">15,633 (27.2)</td><td valign="top" colspan="1" rowspan="1">15,093 (26.2)</td><td valign="top" colspan="1" rowspan="1">15,920 (27.7)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;CVD,Yes</td><td valign="top" colspan="1" rowspan="1">10,042 (17.5)</td><td valign="top" colspan="1" rowspan="1">9857 (17.1)</td><td valign="top" colspan="1" rowspan="1">10,708 (18.6)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Cancer, Yes</td><td valign="top" colspan="1" rowspan="1">4945 (8.6)</td><td valign="top" colspan="1" rowspan="1">5414 (9.4)</td><td valign="top" colspan="1" rowspan="1">5657 (9.8)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Diabetes, Yes</td><td valign="top" colspan="1" rowspan="1">4654 (8.1)</td><td valign="top" colspan="1" rowspan="1">3485 (6.1)</td><td valign="top" colspan="1" rowspan="1">3330 (5.8)</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Data is presented as mean (SD) for continuous variables and as frequency (percentage) for categorical variables. BMI, body mass index; TDI, Townsend Deprivation Index; IPAQ, International Physical Activity Questionnaire.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0010"><label>3.2</label><title>Sugar intake and dementia</title><p id="para0023">The PH assumption showed <italic toggle="yes">p</italic>-values &gt; 0.05, and the residual plots demonstrated approximately flat trend lines over time, providing further support for the validity of the PH assumption. The detailed results of the PH assumption tests are provided in Supplementary Table 1.</p><p id="para0024">In a series of analyses examining the effects of total and free sugar intake on dementia incidence, three models (Model 1, Model 2, and Model 3) were constructed for in-depth evaluation. The results indicated that the highest intake levels of both total and free sugars were significantly associated with increased risk of dementia. Specifically, the hazard ratio (HR) and 95 % confidence interval (CI) for the highest total sugar intake group were 1.292 (1.148, 1.453). Similarly, the highest free sugar intake group had an HR of 1.254 (1.117, 1.408). Moreover, the highest intake groups of non-milk extrinsic sugars and sucrose were also significantly associated with elevated dementia risk, with HRs (95 % CIs) of 1.321 (1.175, 1.486) and 1.291 (1.147, 1.452), respectively. In this study, only the results from Model 3 are presented in <xref rid="tbl0002" ref-type="table">Table 2</xref>, as they best represent the final specification and key findings of the analysis.<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Associations between sugar intake and dementia.</p></caption><alt-text id="alt0004">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Sugar</th><th valign="top" colspan="1" rowspan="1">Quartile</th><th valign="top" colspan="1" rowspan="1">Model 1</th><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Model 2</th><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Model 3</th><th valign="top" colspan="1" rowspan="1"/></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">HR (95 %CI)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-Value</th><th valign="top" colspan="1" rowspan="1">HR (95 %CI)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-Value</th><th valign="top" colspan="1" rowspan="1">HR (95 %CI)</th><th valign="top" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-Value</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Total sugars</td><td valign="top" colspan="1" rowspan="1">Q1</td><td valign="top" colspan="1" rowspan="1">Ref</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">0.953 (0.840, 1.080)</td><td valign="top" colspan="1" rowspan="1">4.49 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.965(0.850, 1.095)</td><td valign="top" colspan="1" rowspan="1">5.77 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.980(0.863, 1.112)</td><td valign="top" colspan="1" rowspan="1">7.50 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.266(1.127, 1.422)</td><td valign="top" colspan="1" rowspan="1">6.85 &#215; 10<sup>&#8211;5</sup></td><td valign="top" colspan="1" rowspan="1">1.291(1.148, 1.452)</td><td valign="top" colspan="1" rowspan="1">2.08 &#215; 10<sup>&#8211;5</sup></td><td valign="top" colspan="1" rowspan="1">1.292(1.148, 1.453)</td><td valign="top" colspan="1" rowspan="1">2.02 &#215; 10<sup>&#8211;5</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Free sugar</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">1.033(0.916, 1.165)</td><td valign="top" colspan="1" rowspan="1">5.99 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.037(0.919, 1.170)</td><td valign="top" colspan="1" rowspan="1">5.56 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.073(0.951, 1.211)</td><td valign="top" colspan="1" rowspan="1">2.50 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.224(1.091, 1.374)</td><td valign="top" colspan="1" rowspan="1">5.90 &#215; 10<sup>&#8211;4</sup></td><td valign="top" colspan="1" rowspan="1">1.228(1.094, 1.379)</td><td valign="top" colspan="1" rowspan="1">4.96 &#215; 10<sup>&#8211;4</sup></td><td valign="top" colspan="1" rowspan="1">1.254(1.117, 1.408)</td><td valign="top" colspan="1" rowspan="1">1.31 &#215; 10<sup>&#8211;4</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Fructose</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">0.865 (0.764, 0.979)</td><td valign="top" colspan="1" rowspan="1">2.19 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">0.875(0.772, 0.991)</td><td valign="top" colspan="1" rowspan="1">3.57 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">0.879(0.776, 0.995)</td><td valign="top" colspan="1" rowspan="1">4.22 &#215; 10<sup>&#8211;2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.115(0.993, 1.252)</td><td valign="top" colspan="1" rowspan="1">6.49 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">1.138(1.012, 1.280)</td><td valign="top" colspan="1" rowspan="1">3.06 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">1.150(1.023, 1.294)</td><td valign="top" colspan="1" rowspan="1">1.97 &#215; 10<sup>&#8211;2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Glucose</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">0.936(0.827, 1.059)</td><td valign="top" colspan="1" rowspan="1">2.94 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.946(0.835, 1.070)</td><td valign="top" colspan="1" rowspan="1">3.76 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.955(0.844, 1.081)</td><td valign="top" colspan="1" rowspan="1">4.70 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.133(1.009, 1.273)</td><td valign="top" colspan="1" rowspan="1">3.50 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">1.155(1.026, 1.299)</td><td valign="top" colspan="1" rowspan="1">1.67 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">1.167(1.037, 1.313)</td><td valign="top" colspan="1" rowspan="1">1.04 &#215; 10<sup>&#8211;2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Lactose</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">0.901(0.797, 1.019)</td><td valign="top" colspan="1" rowspan="1">9.56 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">0.907(0.803, 1.026)</td><td valign="top" colspan="1" rowspan="1">1.21 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.920(0.814, 1.040)</td><td valign="top" colspan="1" rowspan="1">1.82 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.101(0.981, 1.235)</td><td valign="top" colspan="1" rowspan="1">1.03 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.114(0.993, 1.251)</td><td valign="top" colspan="1" rowspan="1">6.65 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">1.117(0.995, 1.253)</td><td valign="top" colspan="1" rowspan="1">6.14 &#215; 10<sup>&#8211;2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Maltose</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">0.973(0.866, 1.093)</td><td valign="top" colspan="1" rowspan="1">6.44 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.974(0.866, 1.095)</td><td valign="top" colspan="1" rowspan="1">6.56 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.967(0.861, 1.088)</td><td valign="top" colspan="1" rowspan="1">5.79 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.000(0.889, 1.125)</td><td valign="top" colspan="1" rowspan="1">9.96 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.995(0.884, 1.119)</td><td valign="top" colspan="1" rowspan="1">9.30 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.982(0.873, 1.104)</td><td valign="top" colspan="1" rowspan="1">7.60 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Intrinsic and milk sugars</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">0.969(0.855, 1.098)</td><td valign="top" colspan="1" rowspan="1">6.20 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.982(0.867, 1.113)</td><td valign="top" colspan="1" rowspan="1">7.79 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">0.986(0.870, 1.118)</td><td valign="top" colspan="1" rowspan="1">8.24 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.145(1.017, 1.290)</td><td valign="top" colspan="1" rowspan="1">2.55 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">1.170(1.037, 1.320)</td><td valign="top" colspan="1" rowspan="1">1.06 &#215; 10<sup>&#8211;2</sup></td><td valign="top" colspan="1" rowspan="1">1.157(1.025, 1.305)</td><td valign="top" colspan="1" rowspan="1">1.81 &#215; 10<sup>&#8211;2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Non-milk extrinsic sugars</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">1.086(0.961,1.226)</td><td valign="top" colspan="1" rowspan="1">1.84 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.094(0.968, 1.1236)</td><td valign="top" colspan="1" rowspan="1">1.49 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.132(1.002, 1.279)</td><td valign="top" colspan="1" rowspan="1">4.65 &#215; 10<sup>&#8211;2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.285(1.144,1.444)</td><td valign="top" colspan="1" rowspan="1">2.30 &#215; 10<sup>&#8211;5</sup></td><td valign="top" colspan="1" rowspan="1">1.294(1.151, 1.454)</td><td valign="top" colspan="1" rowspan="1">1.50 &#215; 10<sup>&#8211;5</sup></td><td valign="top" colspan="1" rowspan="1">1.321(1.175, 1.486)</td><td valign="top" colspan="1" rowspan="1">3.11 &#215; 10<sup>&#8211;6</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Sucrose</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">1.088(0.962, 1.230)</td><td valign="top" colspan="1" rowspan="1">1.79 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.099(0.972, 1.243)</td><td valign="top" colspan="1" rowspan="1">1.31 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.108(0.980, 1.254)</td><td valign="top" colspan="1" rowspan="1">1.02 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.278(1.137, 1.436)</td><td valign="top" colspan="1" rowspan="1">4.05 &#215; 10<sup>&#8211;5</sup></td><td valign="top" colspan="1" rowspan="1">1.290(1.147, 1.451)</td><td valign="top" colspan="1" rowspan="1">2.18 &#215; 10<sup>&#8211;5</sup></td><td valign="top" colspan="1" rowspan="1">1.291(1.147, 1.452)</td><td valign="top" colspan="1" rowspan="1">2.21 &#215; 10<sup>&#8211;5</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Other Sugars</td><td valign="top" colspan="1" rowspan="1">Q2</td><td valign="top" colspan="1" rowspan="1">1.024(0.908, 1.154)</td><td valign="top" colspan="1" rowspan="1">7.04 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.028(0.912, 1.160)</td><td valign="top" colspan="1" rowspan="1">6.50 &#215; 10<sup>&#8211;1</sup></td><td valign="top" colspan="1" rowspan="1">1.051(0.931, 1.185)</td><td valign="top" colspan="1" rowspan="1">4.21 &#215; 10<sup>&#8211;1</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">Q3</td><td valign="top" colspan="1" rowspan="1">1.189(1.057, 1.337)</td><td valign="top" colspan="1" rowspan="1">3.95 &#215; 10<sup>&#8211;3</sup></td><td valign="top" colspan="1" rowspan="1">1.190(1.058, 1.339)</td><td valign="top" colspan="1" rowspan="1">3.75 &#215; 10<sup>&#8211;3</sup></td><td valign="top" colspan="1" rowspan="1">1.180(1.049, 1.328)</td><td valign="top" colspan="1" rowspan="1">5.83 &#215; 10<sup>&#8211;3</sup></td></tr></tbody></table><table-wrap-foot><fn id="spara008"><p>Notes:</p></fn><fn id="spara009"><p>Model 1: Adjusted for sociodemographic factors, including age, sex, ethnicity, education level, and TDI.</p></fn><fn id="spara010"><p>Model 2: Additionally adjusted for behavioral factors, including BMI, smoking status, alcohol consumption, IPAQ, and supplement use.</p></fn><fn id="spara011"><p>Model 3: Further adjusted for medical conditions, including diabetes, cancer, hypertension, and cardiovascular disease.</p></fn><fn id="spara012"><p>Abbreviations: HR, hazards ratio; CI, confidence interval; Ref, reference; Q, quartile.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0011"><label>3.3</label><title>Stratified analyses</title><p id="para0025">We stratified the population by sex and observed significant associations between sugar intake and dementia risk among females. Specifically, higher intakes of total sugars (HR = 1.516, 95 % CI: 1.250&#8211;1.838), free sugars (HR = 1.410, 95 % CI: 1.177&#8211;1.690), glucose (HR = 1.341, 95 % CI: 1.104&#8211;1.630), sucrose (HR = 1.485, 95 % CI: 1.226&#8211;1.798), and non-milk extrinsic sugars (HR = 1.494, 95 % CI: 1.241&#8211;1.798) were significantly associated with increased dementia risk. In contrast, no significant associations were found between total or subtype-specific sugar intake and dementia risk in males. However, after incorporating the sugar &#215; sex interaction terms into the Cox models, the interaction effects were not statistically significant, indicating no meaningful difference in the associations between sexes. These findings are presented in <xref rid="fig0001" ref-type="fig">Fig. 1</xref>, <xref rid="fig0002" ref-type="fig">Fig. 2</xref>, while the interaction results are provided in Fig. S1.<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Association between sugar intake and the risk of dementia in the female subgroup</p><p>Notes: Blue dots indicate the hazard ratio (HR), and the connecting line represents the 95 % confidence interval (CI).</p></caption><alt-text id="alt0001">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Association between sugar intake and the risk of dementia in the male subgroup</p><p>Notes: Red dots indicate the hazard ratio (HR), and the connecting line represents the 95 % confidence interval (CI).</p></caption><alt-text id="alt0002">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec></sec><sec id="sec0012"><label>4</label><title>Discussion</title><p id="para0026">This study examined the association between sugar intake and dementia risk using data from a large UK Biobank cohort. Higher consumption of total sugars, free sugars, non-milk extrinsic sugars, and sucrose was independently associated with an increased risk of dementia. Stratified analyses revealed significant associations between dementia risk and the intake of total sugars, free sugars, glucose, sucrose, and non-milk extrinsic sugars, particularly among females. These results align with previous research and support the hypothesis that a high-sugar diet constitutes a significant risk factor for dementia [<xref rid="bib0022" ref-type="bibr">22</xref>].</p><p id="para0027">To our knowledge, this is the first prospective cohort study in a general population to systematically investigate the dose-response relationship between total sugar intake, its subtypes&#8212;including free sugars, fructose, glucose, sucrose, lactose, and other sugars&#8212;and incident dementia. Current evidence on dietary sugars and dementia risk remains limited and primarily focuses on composite dietary patterns. For example, Zhang et al. reported a positive association between high-sugar dietary patterns and dementia risk in a prospective cohort study, but their analysis did not differentiate among sugar subtypes, leaving unclear whether specific sugars (e.g., free sugars, fructose, glucose, sucrose, maltose, milk extrinsic sugars) contribute differently to dementia risk [<xref rid="bib0023" ref-type="bibr">23</xref>]. In contrast, our study not only reaffirmed the significant association between high sugar intake and dementia risk but also made an important analytical advance by carefully distinguishing sugar subtypes&#8212;including free sugars, fructose, and sucrose&#8212;and examining their distinct effects on dementia risk. This novel approach overcomes previous limitations and establishes a robust foundation for further mechanistic research.</p><p id="para0028">Although a significant association between sugar intake and dementia risk was observed, the underlying mechanisms remain incompletely understood. Existing studies suggest several pathways through which a high-sugar diet may increase dementia risk, including insulin resistance, oxidative stress, inflammatory responses, and alterations in the gut microbiome <xref rid="bib0024" ref-type="bibr">[24]</xref>, <xref rid="bib0025" ref-type="bibr">[25]</xref>, <xref rid="bib0026" ref-type="bibr">[26]</xref>, <xref rid="bib0027" ref-type="bibr">[27]</xref>. Insulin resistance, a hallmark of metabolic dysfunction commonly associated with high sugar consumption, has been increasingly implicated in the development and progression of dementia. Chronic consumption of high-sugar diets may lead to systemic insulin resistance, which not only impairs peripheral metabolic regulation but also disrupts insulin signaling in the brain. This disruption leads to synaptic dysfunction, reduced neuronal plasticity, and ultimately, cognitive decline. Neuronal insulin signaling plays a critical role in maintaining cognitive function, and its impairment may hinder amyloid-&#946; (A&#946;) clearance, promote abnormal tau phosphorylation, and induce synaptic damage&#8212;hallmarks of Alzheimer&#8217;s disease and related dementias. Although the present study did not directly examine these biological pathways, the observed associations at the population level are consistent with existing mechanistic research. These findings provide indirect support for the role of metabolic dysregulation in dementia and contribute additional epidemiological evidence regarding the potential impact of dietary sugar intake on cognitive health [<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0029" ref-type="bibr">29</xref>]. Furthermore, high sugar consumption may exacerbate neuronal damage by increasing oxidative stress. Oxidative stress contributes to mitochondrial dysfunction, lipid peroxidation, and neuronal apoptosis, all of which are central features of neurodegeneration. It may also damage the cerebral vascular endothelium, disrupt the blood&#8211;brain barrier, and initiate neuroinflammatory responses, thereby accelerating cognitive decline [<xref rid="bib0030" ref-type="bibr">30</xref>,<xref rid="bib0031" ref-type="bibr">31</xref>]. A high-sugar diet may also alter gut microbiota composition by increasing harmful bacteria, which can affect brain function via systemic circulation and exacerbate neuropathological changes [<xref rid="bib0032" ref-type="bibr">32</xref>,<xref rid="bib0033" ref-type="bibr">33</xref>]. Despite these insights, further experimental and mechanistic studies are needed to fully elucidate how sugar intake influences dementia risk.</p><p id="para0029">Furthermore, our stratified analyses revealed a sex-specific association between sugar intake and dementia risk. Previous research shows that women differ from men in neuroendocrine regulation, metabolic profiles, and behavior, potentially increasing their vulnerability to impaired glucose metabolism and neurodegenerative diseases [<xref rid="bib0034" ref-type="bibr">34</xref>,<xref rid="bib0035" ref-type="bibr">35</xref>]. For instance, estrogen decline after menopause may exacerbate the harmful effects of a high-sugar diet on hippocampal glucose metabolism by reducing insulin sensitivity [<xref rid="bib0036" ref-type="bibr">36</xref>]. Metabolomics studies in Alzheimer&#8217;s disease (AD) mouse models have found that female mice display more severe impairments in glucose clearance, whereas male mice sometimes show improved clearance at certain ages [<xref rid="bib0037" ref-type="bibr">37</xref>]. Epidemiological data also indicate that women generally consume more sugar daily than men, and chronic sugar exposure may promote abnormal tau protein phosphorylation through the advanced glycation end products&#8211;receptor for advanced glycation end products (AGEs&#8211;RAGE) pathway, aggravating neurodegeneration [<xref rid="bib0038" ref-type="bibr">38</xref>,<xref rid="bib0039" ref-type="bibr">39</xref>]. These sex-related biological differences provide valuable insights into how sugar intake influences dementia risk, underscoring sex as a critical factor in glucose metabolism and dementia development. Further analysis of the sex &#215; sugar intake interaction did not reach statistical significance, indicating that although stratified analyses revealed significant effects in females, the moderating role of sex in this association remains statistically inconclusive. This outcome may be due to the stringent significance threshold (<italic toggle="yes">p</italic> &lt; 0.005) employed in this study to mitigate the risk of false positives arising from multiple testing. Although some stratified analyses showed significant associations, the interaction test did not meet this strict criterion, suggesting that sex differences in the effect warrant confirmation through larger sample sizes or independent cohorts.</p><p id="para0030">Despite these important findings, several limitations warrant consideration and suggest directions for future research. First, dietary assessment limitations must be acknowledged. Although combining the Oxford WebQ and 24-hour dietary recalls improved data reliability, sugar intake was ultimately self-reported, which is subject to systematic underreporting of high-sugar foods due to social desirability bias [<xref rid="bib0040" ref-type="bibr">40</xref>]. Despite data adjustments (e.g., portion size correction, frequency conversion, nutrient algorithm calculations), changes in dietary habits during follow-up (e.g., voluntary sugar reduction) may not have been fully captured. Future studies integrating objective biomarkers, such as urinary glucose metabolites, could enhance exposure measurement accuracy. Second, due to the non-random availability of dietary recall data in the UK Biobank, concerns about the generalizability of the study findings arise. Participants who completed the dietary assessments may differ systematically from those who did not, potentially introducing selection bias. Additionally, a &#8220;healthy volunteer&#8221; selection bias within the UK Biobank cohort may have contributed to an underestimation of the observed positive associations, as participants tend to be healthier than nonparticipants [<xref rid="bib0041" ref-type="bibr">41</xref>]. Moreover, the majority of participants in the UK Biobank were White British, which may limit the generalizability of our findings to more ethnically diverse populations [<xref rid="bib0023" ref-type="bibr">23</xref>]. Third, this study did not directly investigate key mechanistic mediators linking sugar intake to dementia. Although sugar subtypes were distinguished for the first time, crucial molecular markers like advanced glycation end products (AGEs) were not measured [<xref rid="bib0042" ref-type="bibr">42</xref>,<xref rid="bib0043" ref-type="bibr">43</xref>], limiting subtype-specific neurotoxicity analysis. The absence of insulin resistance indices (e.g., HOMA-IR) and systemic inflammatory markers (e.g., IL-6, CRP) also precluded a comprehensive multi-omics framework [<xref rid="bib0044" ref-type="bibr">44</xref>]. Fourth, although participants with baseline dementia were excluded, individuals with other neurological disorders, such as stroke and Parkinson&#8217;s disease, were neither excluded nor adjusted for in the analyses, which may have introduced residual confounding. This represents a limitation of our study. Future research should consider addressing this issue to better clarify the relationship between exposure and dementia risk. Fifth, to ensure data quality, participants with physiologically implausible energy intakes&#8212;defined as less than 500 or more than 3500 kcal/day for women, and less than 800 or more than 4000 kcal/day for men&#8212;were excluded based on established criteria. Extremely low or high reported energy intakes often reflect reporting errors, recall bias, or technical issues during data entry. Including such implausible dietary records can distort dose&#8211;response relationships and increase measurement error, thereby reducing the statistical power of the analysis. Future studies using objective biomarkers of dietary intake could help overcome these limitations.</p></sec><sec id="sec0013"><label>5</label><title>Conclusions</title><p id="para0031">The present study confirmed a significant association between a high-sugar diet and dementia risk through prospective cohort analysis, revealing notable sex differences. Specifically, the association was more pronounced among women. These findings underscore the importance of developing targeted dietary intervention strategies and suggest that public health policies should prioritize stricter restrictions on high-sugar diets, particularly for the female population. Future research should further investigate the biological mechanisms underlying the relationship between sugar intake and dementia risk, incorporating multi-omics approaches and neuroimaging data to establish a more comprehensive scientific foundation for dementia prevention and treatment.</p></sec><sec id="sec0014"><title>Statement of ethics</title><p id="para0032">Ethical approval of the UKB study was granted by the National Health Service National Research Ethics Service (reference 11/NW/0382).</p></sec><sec id="sec0015"><title>Funding</title><p id="para0033">The Natural Science Basic Research Plan in Shaanxi Province of China [2021JCW-08].</p></sec><sec id="sec0015a"><title>CRediT authorship contribution statement</title><p id="para0033a"><bold>Yue Che:</bold> Writing &#8211; original draft, Methodology, Conceptualization. <bold>Wenming Wei:</bold> Writing &#8211; original draft, Visualization. <bold>Tingting Mao:</bold> Visualization. <bold>Lina Qin:</bold> Writing &#8211; original draft. <bold>Hanchi Wang:</bold> Methodology. <bold>Yijia Li:</bold> Methodology. <bold>Weixuan Da:</bold> Conceptualization. <bold>Jin Feng:</bold> Supervision. <bold>Li Liu:</bold> Methodology, Conceptualization. <bold>Bolun Cheng:</bold> Methodology, Formal analysis. <bold>Huan Liu:</bold> Supervision, Data curation. <bold>Yan Wen:</bold> Supervision. <bold>Yumeng Jia:</bold> Supervision, Data curation. <bold>Feng Zhang:</bold> Writing &#8211; review &amp; editing, Methodology, Funding acquisition.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0037">The authors have stated that they have no conflict of interest.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.-R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.-F.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Y.-N.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Modifiable risk factors for incident dementia and cognitive impairment: an umbrella review of evidence</article-title><source>J Affect Disord</source><volume>314</volume><year>2022</year><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2022.07.008</pub-id><pub-id pub-id-type="pmid">35863541</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>E.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Vollset</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Fukutaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chalek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abd-Allah</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet Public Health</source><volume>7</volume><issue>2</issue><year>2022</year><fpage>e105</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Hammond</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Crane</surname><given-names>P.K.</given-names></name><etal/></person-group><article-title>&#946;-amyloid and tau drive early Alzheimer&#8217;s disease decline while glucose hypometabolism drives late decline</article-title><source>Commun Biol</source><volume>3</volume><issue>1</issue><year>2020</year><fpage>352</fpage><pub-id pub-id-type="doi">10.1038/s42003-020-1079-x</pub-id><pub-id pub-id-type="pmid">32632135</pub-id><pub-id pub-id-type="pmcid">PMC7338410</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eichner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fasshauer</surname><given-names>M.</given-names></name></person-group><article-title>Association of sugar intake from different sources with incident dementia in the prospective cohort of UK Biobank participants</article-title><source>Nutr J</source><volume>22</volume><issue>1</issue><year>2023</year><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s12937-023-00871-8</pub-id><pub-id pub-id-type="pmid">37661278</pub-id><pub-id pub-id-type="pmcid">PMC10476309</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Mergenthaler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lindauer</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dienel</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Meisel</surname><given-names>A.</given-names></name></person-group><article-title>Sugar for the brain: the role of glucose in physiological and pathological brain function</article-title><source>Trend Neurosci</source><volume>36</volume><issue>10</issue><year>2013</year><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2013.07.001</pub-id><pub-id pub-id-type="pmid">23968694</pub-id><pub-id pub-id-type="pmcid">PMC3900881</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>T.F.A.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Midlife lipid and glucose levels are associated with Alzheimer&#8217;s disease</article-title><source>Alzheimer Dement</source><volume>19</volume><issue>1</issue><year>2023</year><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1002/alz.12641</pub-id><pub-id pub-id-type="pmcid">PMC10078665</pub-id><pub-id pub-id-type="pmid">35319157</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The relationship between diabetes and the dementia risk: a meta-analysis</article-title><source>Diabetol Metab Syndr</source><volume>16</volume><issue>1</issue><year>2024</year><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/s13098-024-01346-4</pub-id><pub-id pub-id-type="pmid">38745237</pub-id><pub-id pub-id-type="pmcid">PMC11092065</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Muth</surname><given-names>A.-K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.Q.</given-names></name></person-group><article-title>The impact of dietary macronutrient intake on cognitive function and the brain</article-title><source>Clin Nutrit</source><volume>40</volume><issue>6</issue><year>2021</year><fpage>3999</fpage><lpage>4010</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2021.04.043</pub-id><pub-id pub-id-type="pmid">34139473</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease</article-title><source>J Biolog Chem</source><volume>282</volume><issue>50</issue><year>2007</year><fpage>36275</fpage><lpage>36282</lpage><pub-id pub-id-type="doi">10.1074/jbc.M703561200</pub-id><pub-id pub-id-type="pmid">17942401</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Robison</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Salinero</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Abi-Ghanem</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Tyagi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>High-fat diet exacerbates cognitive decline in mouse models of Alzheimer&#8217;s disease and mixed dementia in a sex-dependent manner</article-title><source>J Neuroinflammation</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>110</fpage><pub-id pub-id-type="doi">10.1186/s12974-022-02466-2</pub-id><pub-id pub-id-type="pmid">35568928</pub-id><pub-id pub-id-type="pmcid">PMC9107741</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>K.</given-names></name></person-group><article-title>Risk of incident dementia according to Glycemic status and comorbidities of hyperglycemia: a nationwide population-based cohort study</article-title><source>Diabet Care</source><volume>45</volume><issue>1</issue><year>2022</year><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.2337/dc21-0957</pub-id><pub-id pub-id-type="pmid">34711638</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Volpe</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Van Bockstaele</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>H.J.</given-names></name></person-group><article-title>Dietary sugar intake and risk of Alzheimer&#8217;s disease in older women</article-title><source>Nutr Neurosci</source><volume>25</volume><issue>11</issue><year>2022</year><fpage>2302</fpage><lpage>2313</lpage><pub-id pub-id-type="doi">10.1080/1028415X.2021.1959099</pub-id><pub-id pub-id-type="pmid">34328409</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Sugary beverages and genetic risk in relation to brain structure and incident dementia: a prospective cohort study</article-title><source>Am J Clin Nutr</source><volume>117</volume><issue>4</issue><year>2023</year><fpage>672</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.ajcnut.2023.01.015</pub-id><pub-id pub-id-type="pmid">36781080</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Haroon</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Austin</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>G.L.</given-names></name></person-group><article-title>Risk of dementia in seniors with newly diagnosed diabetes: a population-based study</article-title><source>Diabet Care</source><volume>38</volume><issue>10</issue><year>2015</year><fpage>1868</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.2337/dc15-0491</pub-id><pub-id pub-id-type="pmid">26216873</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eichner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fasshauer</surname><given-names>M.</given-names></name></person-group><article-title>Association of sugar intake from different sources with cardiovascular disease incidence in the prospective cohort of UK Biobank participants</article-title><source>Nutr J</source><volume>23</volume><issue>1</issue><year>2024</year><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/s12937-024-00926-4</pub-id><pub-id pub-id-type="pmid">38383449</pub-id><pub-id pub-id-type="pmcid">PMC10882929</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Different dietary carbohydrate component intakes and long-term outcomes in patients with NAFLD: results of longitudinal analysis from the UK Biobank</article-title><source>Nutr J</source><volume>22</volume><issue>1</issue><year>2023</year><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/s12937-023-00897-y</pub-id><pub-id pub-id-type="pmid">38062487</pub-id><pub-id pub-id-type="pmcid">PMC10704713</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Kaiser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Behrendt</surname><given-names>I.</given-names></name><name name-style="western"><surname>Eichner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fasshauer</surname><given-names>M.</given-names></name></person-group><article-title>Association of all-cause mortality with sugar intake from different sources in the prospective cohort of UK Biobank participants</article-title><source>Br J Nutr</source><volume>130</volume><issue>2</issue><year>2023</year><fpage>294</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1017/S0007114522003233</pub-id><pub-id pub-id-type="pmid">36204988</pub-id><pub-id pub-id-type="pmcid">PMC10277665</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Wark</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hardie</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Alwan</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Validity of an online 24-h recall tool (myfood24) for dietary assessment in population studies: comparison with biomarkers and standard interviews</article-title><source>BMC Med</source><volume>16</volume><issue>1</issue><year>2018</year><fpage>136</fpage><pub-id pub-id-type="doi">10.1186/s12916-018-1113-8</pub-id><pub-id pub-id-type="pmid">30089491</pub-id><pub-id pub-id-type="pmcid">PMC6083628</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Plasma metabolomic profiles of dementia: a prospective study of 110,655 participants in the UK Biobank</article-title><source>BMC Med</source><volume>20</volume><issue>1</issue><year>2022</year><fpage>252</fpage><pub-id pub-id-type="doi">10.1186/s12916-022-02449-3</pub-id><pub-id pub-id-type="pmid">35965319</pub-id><pub-id pub-id-type="pmcid">PMC9377110</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Collister</surname><given-names>J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Ku&#378;ma</surname><given-names>E.</given-names></name><name name-style="western"><surname>Littlejohns</surname><given-names>T.</given-names></name></person-group><article-title>Association between metabolic syndrome and risk of incident dementia in UK Biobank</article-title><source>Alzheimer Dement</source><volume>20</volume><issue>1</issue><year>2024</year><fpage>447</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1002/alz.13439</pub-id><pub-id pub-id-type="pmcid">PMC10916994</pub-id><pub-id pub-id-type="pmid">37675869</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Lacy</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gilsanz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Karter</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Quesenberry</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Pletcher</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Whitmer</surname><given-names>R.A.</given-names></name></person-group><article-title>Long-term glycemic control and dementia risk in type 1 diabetes</article-title><source>Diabet Care</source><volume>41</volume><issue>11</issue><year>2018</year><fpage>2339</fpage><lpage>2345</lpage><pub-id pub-id-type="doi">10.2337/dc18-0073</pub-id><pub-id pub-id-type="pmcid">PMC6196833</pub-id><pub-id pub-id-type="pmid">30181165</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>The association between sugar-sweetened beverages and cognitive function in middle-aged and older people: a meta-analysis</article-title><source>J Prevent Alzheimer Dis</source><volume>9</volume><issue>2</issue><year>2022</year><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.14283/jpad.2021.71</pub-id><pub-id pub-id-type="pmid">35543006</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Associations of sugar intake, high-sugar dietary pattern, and the risk of dementia: a prospective cohort study of 210,832 participants</article-title><source>BMC Med</source><volume>22</volume><issue>1</issue><year>2024</year><fpage>298</fpage><pub-id pub-id-type="doi">10.1186/s12916-024-03525-6</pub-id><pub-id pub-id-type="pmid">39020335</pub-id><pub-id pub-id-type="pmcid">PMC11256505</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>S.H.-H.</given-names></name><name name-style="western"><surname>Shie</surname><given-names>F.-S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.-K.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>P.-C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-H.</given-names></name><etal/></person-group><article-title>A high-sucrose diet aggravates Alzheimer&#8217;s disease pathology, attenuates hypothalamic leptin signaling, and impairs food-anticipatory activity in APPswe/PS1dE9 mice</article-title><source>Neurobiol Aging</source><volume>90</volume><year>2020</year><fpage>60</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.11.018</pub-id><pub-id pub-id-type="pmid">31879131</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.A.</given-names></name></person-group><article-title>Oxidative stress in diabetes and Alzheimer&#8217;s disease. Bierhaus A, editor</article-title><source>JAD</source><volume>16</volume><issue>4</issue><year>2009</year><fpage>763</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.3233/JAD-2009-1013</pub-id><pub-id pub-id-type="pmid">19387111</pub-id><pub-id pub-id-type="pmcid">PMC2765716</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Gardener</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rainey-Smith</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>R.N.</given-names></name></person-group><article-title>Diet and inflammation in Alzheimer&#8217;s disease and related chronic diseases: a review</article-title><source>J Alzheimers Dis</source><volume>50</volume><issue>2</issue><year>2016</year><fpage>301</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.3233/JAD-150765</pub-id><pub-id pub-id-type="pmid">26682690</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Naval&#243;n-Monllor</surname><given-names>V.</given-names></name><name name-style="western"><surname>Soriano-Roman&#237;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Las Hazas</surname><given-names>M.-C.L.</given-names></name><name name-style="western"><surname>Hernando-Quintana</surname><given-names>N.</given-names></name><name name-style="western"><surname>Su&#225;rez Di&#233;guez</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Microbiota dysbiosis caused by dietetic patterns as a promoter of Alzheimer&#8217;s disease through metabolic syndrome mechanisms</article-title><source>Food Funct</source><volume>14</volume><issue>16</issue><year>2023</year><fpage>7317</fpage><lpage>7334</lpage><pub-id pub-id-type="doi">10.1039/D3FO01257C</pub-id><pub-id pub-id-type="pmid">37470232</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Berlanga-Acosta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guill&#233;n-Nieto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Rodr&#237;guez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bringas-Vega</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Garc&#237;a-del-Barco-Herrera</surname><given-names>D.</given-names></name><name name-style="western"><surname>Berlanga-Saez</surname><given-names>J.O.</given-names></name><etal/></person-group><article-title>Insulin resistance at the crossroad of Alzheimer Disease pathology: a review</article-title><source>Front Endocrinol</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">560375</object-id><pub-id pub-id-type="doi">10.3389/fendo.2020.560375</pub-id><pub-id pub-id-type="pmcid">PMC7674493</pub-id><pub-id pub-id-type="pmid">33224105</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Barone</surname><given-names>E.</given-names></name><name name-style="western"><surname>Di Domenico</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perluigi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>D.A.</given-names></name></person-group><article-title>The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease</article-title><source>Free Radic Biol Med</source><volume>176</volume><year>2021</year><fpage>16</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.09.006</pub-id><pub-id pub-id-type="pmid">34530075</pub-id><pub-id pub-id-type="pmcid">PMC8595768</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Hahm</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>MO</surname><given-names>Kim</given-names></name></person-group><article-title>Metabolic stress alters antioxidant systems, suppresses the adiponectin receptor 1 and induces Alzheimer&#8217;s like pathology in mice brain</article-title><source>Cells</source><volume>9</volume><issue>1</issue><year>2020</year><fpage>249</fpage><pub-id pub-id-type="doi">10.3390/cells9010249</pub-id><pub-id pub-id-type="pmid">31963819</pub-id><pub-id pub-id-type="pmcid">PMC7016950</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Hydrogen attenuates cognitive impairment in rat models of vascular dementia by inhibiting oxidative stress and NLRP3 inflammasome activation</article-title><source>Adv Healthc Mater</source><volume>13</volume><issue>20</issue><year>2024</year><object-id pub-id-type="publisher-id">2400400</object-id><pub-id pub-id-type="doi">10.1002/adhm.202400400</pub-id><pub-id pub-id-type="pmid">38769944</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Noble</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Schade</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Gut microbial taxa elevated by dietary sugar disrupt memory function</article-title><source>Transl Psychiatry</source><volume>11</volume><issue>1</issue><year>2021</year><fpage>194</fpage><pub-id pub-id-type="doi">10.1038/s41398-021-01309-7</pub-id><pub-id pub-id-type="pmid">33790226</pub-id><pub-id pub-id-type="pmcid">PMC8012713</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Frausto</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Forsyth</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Keshavarzian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Voigt</surname><given-names>R.M.</given-names></name></person-group><article-title>Dietary regulation of gut-brain axis in Alzheimer&#8217;s Disease: importance of microbiota metabolites</article-title><source>Front Neurosci</source><volume>15</volume><year>2021</year><object-id pub-id-type="publisher-id">736814</object-id><pub-id pub-id-type="doi">10.3389/fnins.2021.736814</pub-id><pub-id pub-id-type="pmcid">PMC8639879</pub-id><pub-id pub-id-type="pmid">34867153</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Subramaniapillai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Almey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Natasha Rajah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Einstein</surname><given-names>G.</given-names></name></person-group><article-title>Sex and gender differences in cognitive and brain reserve: implications for Alzheimer&#8217;s disease in women</article-title><source>Front Neuroendocrinol</source><volume>60</volume><year>2021</year><object-id pub-id-type="publisher-id">100879</object-id><pub-id pub-id-type="doi">10.1016/j.yfrne.2020.100879</pub-id><pub-id pub-id-type="pmid">33137359</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>A.</given-names></name></person-group><article-title>The relationship between gender differences in dietary habits, neuroinflammation, and Alzheimer&#8217;s disease</article-title><source>Front Aging Neurosci</source><volume>16</volume><year>2024</year><object-id pub-id-type="publisher-id">1395825</object-id><pub-id pub-id-type="doi">10.3389/fnagi.2024.1395825</pub-id><pub-id pub-id-type="pmcid">PMC11061392</pub-id><pub-id pub-id-type="pmid">38694261</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kamble</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Hetty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fanni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vranic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarsenbayeva</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Role of estrogen and its receptors in adipose tissue glucose metabolism in pre- and postmenopausal women</article-title><source>J Clin Endocrinol Metabol</source><volume>107</volume><issue>5</issue><year>2022</year><fpage>e1879</fpage><lpage>e1889</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgac042</pub-id><pub-id pub-id-type="pmcid">PMC9016422</pub-id><pub-id pub-id-type="pmid">35084504</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lasher</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Nagarajan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.Y.</given-names></name></person-group><article-title>Sexual dimorphism in the peripheral metabolic homeostasis and behavior in the <sc>TgF344-AD</sc> rat model of Alzheimer&#8217;s disease</article-title><source>Aging Cell</source><volume>22</volume><issue>7</issue><year>2023</year><object-id pub-id-type="publisher-id">e13854</object-id><pub-id pub-id-type="doi">10.1111/acel.13854</pub-id><pub-id pub-id-type="pmcid">PMC10352566</pub-id><pub-id pub-id-type="pmid">37095621</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Alhusseini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ramadan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aljarayhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arnous</surname><given-names>W.</given-names></name><name name-style="western"><surname>Abdelaal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dababo</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Added sugar intake among the saudi population. Abd El-Hack ME, editor</article-title><source>PLoS ONE</source><volume>18</volume><issue>9</issue><year>2023</year><object-id pub-id-type="publisher-id">e0291136</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0291136</pub-id><pub-id pub-id-type="pmcid">PMC10490978</pub-id><pub-id pub-id-type="pmid">37682946</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>L.R.</given-names></name></person-group><article-title>AGE-RAGE axis culminates into multiple pathogenic processes: a central road to neurodegeneration</article-title><source>Front Mol Neurosci</source><volume>16</volume><year>2023</year><object-id pub-id-type="publisher-id">1155175</object-id><pub-id pub-id-type="doi">10.3389/fnmol.2023.1155175</pub-id><pub-id pub-id-type="pmcid">PMC10230046</pub-id><pub-id pub-id-type="pmid">37266370</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Leurgans</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>T.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dhana</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Dietary sugar intake associated with a higher risk of dementia in community-dwelling older adults. Rong S, editor</article-title><source>JAD</source><volume>95</volume><issue>4</issue><year>2023</year><fpage>1417</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.3233/JAD-230013</pub-id><pub-id pub-id-type="pmid">37694364</pub-id><pub-id pub-id-type="pmcid">PMC10921393</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Fry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Littlejohns</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Sudlow</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>N.</given-names></name><name name-style="western"><surname>Adamska</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sprosen</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population</article-title><source>Am J Epidemiol</source><volume>186</volume><issue>9</issue><year>2017</year><fpage>1026</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1093/aje/kwx246</pub-id><pub-id pub-id-type="pmid">28641372</pub-id><pub-id pub-id-type="pmcid">PMC5860371</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kulsange</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kazi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chirmade</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kale</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mote</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Behavioral and proteomic studies reveal methylglyoxal activate pathways associated with Alzheimer&#8217;s disease</article-title><source>ACS Pharmacol Transl Sci</source><volume>6</volume><issue>1</issue><year>2022</year><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.2c00143</pub-id><pub-id pub-id-type="pmid">36654748</pub-id><pub-id pub-id-type="pmcid">PMC9841776</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Mietelska-Porowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doma&#324;ska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Want</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wi&#281;ckowska-Gacek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chutora&#324;ski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koperski</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Induction of brain insulin resistance and Alzheimer&#8217;s molecular changes by western diet</article-title><source>IJMS</source><volume>23</volume><issue>9</issue><year>2022</year><fpage>4744</fpage><pub-id pub-id-type="doi">10.3390/ijms23094744</pub-id><pub-id pub-id-type="pmid">35563135</pub-id><pub-id pub-id-type="pmcid">PMC9102094</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><mixed-citation publication-type="other" id="tboref0001">Huber H, Ashton NJ, Weinhold L, Schmid M, Coenen M, Stoffel-Wagner B, et al. 1518-P: Plasma Biomarker Concentrations of Alzheimer&#8217;s Disease Are Associated with Insulin Resistance&#8212;Results from a Pilot RCT in Adults with Diabetes Risk. Diabetes. 2023 Jun 20;72(Supplement_1):1518-P. <pub-id pub-id-type="doi">10.2337/db23-1518-P</pub-id>.</mixed-citation></ref></ref-list><sec id="sec0018" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0035a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><sec sec-type="data-availability" id="refdata001"><title>Data availability</title><p id="para9001">The data supporting the findings of this study are available from the UK Biobank. Access to the UK Biobank resource is available to qualified researchers through an application process via their official website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ukbiobank.ac.uk/about-biobank-uk/" id="PC_linkcezTuqNpmn">http://www.ukbiobank.ac.uk/about-biobank-uk/</ext-link>).</p></sec><ack id="ack0001"><title>Acknowledgements</title><p id="para0036">This study was conducted using the <funding-source id="gs0001">UK Biobank Resource</funding-source> (application number <award-id award-type="grant" rid="gs0001">46478</award-id>). We thank the research subjects who participated in this study.</p></ack><fn-group><fn id="sec0017" fn-type="supplementary-material"><p id="para0007a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100311" id="interref0002">doi:10.1016/j.tjpad.2025.100311</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-id journal-id-type="pmc-domain-id">943</journal-id><journal-id journal-id-type="pmc-domain">alzreth</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12502172</article-id><article-id pub-id-type="pmcid-ver">PMC12502172.1</article-id><article-id pub-id-type="pmcaid">12502172</article-id><article-id pub-id-type="pmcaiid">12502172</article-id><article-id pub-id-type="pmid">41053874</article-id><article-id pub-id-type="doi">10.1186/s13195-025-01868-7</article-id><article-id pub-id-type="publisher-id">1868</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Regional tau PET patterns predict prospective domain-specific cognitive decline in early symptomatic Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Malpetti</surname><given-names initials="M">Maura</given-names></name><address><email>mm2243@medschl.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Rathore</surname><given-names initials="S">Saima</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iaccarino</surname><given-names initials="L">Leonardo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>La Joie</surname><given-names initials="R">Renaud</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tronchin</surname><given-names initials="G">Giulia</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wessels</surname><given-names initials="AM">Alette M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sims</surname><given-names initials="JR">John R.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pontecorvo</surname><given-names initials="MJ">Michael J.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shcherbinin</surname><given-names initials="S">Sergey</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rabinovici</surname><given-names initials="GD">Gil D.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013meh722</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>Department of Clinical Neurosciences, </institution><institution>Cambridge University Hospitals NHS Trust, University of Cambridge, </institution></institution-wrap>Herchel Smith Building, Forvie Site Robinson Way, Cambridge Biomedical Campus, CB2 0SZ Cambridge, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02wedp412</institution-id><institution-id institution-id-type="GRID">grid.511435.7</institution-id><institution-id institution-id-type="ISNI">0000 0005 0281 4208</institution-id><institution>UK Dementia Research Institute at University of Cambridge, </institution></institution-wrap>Cambridge, CB2 0XY UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01qat3289</institution-id><institution-id institution-id-type="GRID">grid.417540.3</institution-id><institution-id institution-id-type="ISNI">0000 0000 2220 2544</institution-id><institution>Eli Lilly and Company, </institution></institution-wrap>Indianapolis, USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043mz5j54</institution-id><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>Memory and Aging Center, Department of Neurology, Department of Neurology, Weill Institute for Neurosciences, </institution><institution>University of California, San Francisco, </institution></institution-wrap>San Francisco, CA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043mz5j54</institution-id><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>Department of Radiology and Biomedical Imaging, </institution><institution>University of California, San Francisco, </institution></institution-wrap>San Francisco, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">478170</issue-id><elocation-id>220</elocation-id><history><date date-type="received"><day>6</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 10:25:16.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13195_2025_Article_1868.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Tau-PET binding patterns are heterogenous, with regional binding showing strong cross-sectional correlations with domain-specific cognitive performance and longitudinal correlations with prospective neurodegeneration. Here we evaluated whether regional patterns of baseline tau-PET predict prospective longitudinal decline in specific cognitive domains in early symptomatic Alzheimer&#8217;s disease (AD), including participants from clinical trial cohorts.</p></sec><sec><title>Methods</title><p id="Par2">731 amyloid-positive participants with a clinical diagnosis of mild cognitive impairment (MCI) or mild AD dementia underwent a flortaucipir F 18 PET (FTP-PET), structural MRI, and neuropsychological testing with the AD Assessment Scale-Cognitive Subscale (ADAS-Cog). Cognitive assessment was repeated after 9&#8211;18 or 12&#8211;24 months. Sub-scale annualized w-scores at each time point were combined as composite scores according to domains, including episodic memory, semantic memory, executive function, language and praxis. Latent growth curve models were applied to longitudinal composite scores to estimate the rate of annual decline (slope) in each participant. Standardized uptake value ratio (SUVR) images were created using cerebellar crus as the reference region. Regional and voxel-wise correlation analyses were implemented to identify baseline FTP-PET patterns and MRI grey matter volumes associated with longitudinal changes in each cognitive domain, and to evaluate whether MRI mediates the association between FTP-PET and cognitive decline.</p></sec><sec><title>Results</title><p id="Par3">Differential FTP-PET signal patterns showed significant negative associations with domain-specific annual rates of decline. Higher temporo-parietal FTP-PET SUVR was associated with faster decline in episodic memory, while higher left anterior temporal SUVR was associated with faster decline in semantic memory. FTP-PET signal in a left-dominant fronto-temporal pattern was associated with faster decline in language, while FTP-PET signal in a right-dominant fronto-parietal pattern was associated with faster decline in praxis. Executive decline showed limited spatial associations with FTP-PET. Overall, regional and voxel-wise analyses identified similar pairwise associations between FTP-PET signal and domain-specific longitudinal decline. Baseline MRI showed weaker associations with domain-specific cognitive decline than FTP-PET, and did not mediate the predictive effect of the latter.</p></sec><sec><title>Conclusion</title><p id="Par4">Differential regional tau-PET signal patterns were associated with domain-specific cognitive decline in MCI and early AD dementia. Tau-PET may be a useful precision medicine tool to support individualized predictions of cognitive decline trajectories in early symptomatic AD.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13195-025-01868-7.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Tau PET</kwd><kwd>Prognosis</kwd><kwd>Cognitive domains</kwd><kwd>Early AD</kwd></kwd-group><funding-group><award-group><funding-source><institution>Race Against Dementia Alzheimer&#8217;s Research UK</institution></funding-source><award-id>ARUK-RADF2021A-010</award-id><principal-award-recipient><name name-style="western"><surname>Malpetti</surname><given-names>Maura</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Parke Davis Exchange Fellowship in Biomedical Sciences</institution></funding-source><award-id>PD/2020/02</award-id><principal-award-recipient><name name-style="western"><surname>Malpetti</surname><given-names>Maura</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100018956</institution-id><institution>NIHR Cambridge Biomedical Research Centre</institution></institution-wrap></funding-source><award-id>NIHR203312</award-id><principal-award-recipient><name name-style="western"><surname>Malpetti</surname><given-names>Maura</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>NIH/NIA</institution></funding-source><award-id>P30-AG062422, R35 AG072362, U01-AG057195, U01-AG082350</award-id><principal-award-recipient><name name-style="western"><surname>Rabinovici</surname><given-names>Gil D.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Alzheimer&#8217;s Association</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>American College of Radiology</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100016608</institution-id><institution>Rainwater Charitable Foundation</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Laurel Foundation</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Shenandoah Foundation</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">The new era of disease modifying therapies for Alzheimer&#8217;s disease (AD) has been made possible by the utilization of biomarkers &#8211; highlighting that it is crucial to continue to validate these tools for more accurate prognosis and stratification of patients to advance disease-modifying treatments through clinical trials. Several biomarkers have emerged to quantify and track AD pathological hallmarks, including positron emission tomography (PET) radiotracers that bind selectively to amyloid-&#946; plaques and tau neurofibrillary tangles. Whereas in vivo amyloid PET, as well as amyloid neuropathology at postmortem, correlate only weakly with cognitive impairment cross-sectionally, tau load assessed by tau-PET strongly correlates with clinical progression and the extent of neurodegeneration [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">Cross-sectional studies show that tau-PET uptake topography overlaps with patterns of brain atrophy and hypometabolism as measured by magnetic resonance imaging (MRI) or FDG-PET [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Tau-PET is also associated with domain-specific cognitive deficits [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>] and distinct clinical variants of AD [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Longitudinally, strong associations between baseline tau-PET and cognitive changes over time have been described across the AD clinical spectrum. Tau-PET uptake in temporo-parietal regions outperforms amyloid-PET, structural MRI measures and fluid biomarkers in predicting cognitive decline on global scales [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. This has been replicated in several single- and multi-center studies, with different tau-PET tracers and participants at different stages of the disease course. These converging findings suggest that tau-PET is a promising prognostic tool for predicting cognitive decline.</p><p id="Par7">Current disease-modifying treatment trials commonly rely on global/composite measures of cognitive and functional decline to assess the efficacy of the intervention. While being useful and easily implementable, this approach may not take into account the variety of AD-related clinical presentations, with non-amnestic syndromes and individual decline profiles in potentially different cognitive domains. Similarly, most previous evidence on the prognostic value of tau-PET has focused on global or summary metrics of tracer uptake or regional uptake in a single region (e.g., temporal meta-ROI) to predict global measures of cognitive decline or changes in the memory domain specifically. This approach captures initial tau accumulation, linking mesial temporal structures with memory performance, however neglects relevant information about differential spatial patterns that tau-PET can reveal. Identifying more granular associations between tau PET patterns and domain-specific decline has the potential to complement traditional global tau-cognition associations and support both disease staging and prognosis as well as potentially serve as potential outcome measure in clinical trials.</p><p id="Par8">Here, we aim to test whether tau-PET spatial patterns are useful to <italic toggle="yes">track</italic> and <italic toggle="yes">predict</italic> differential cognitive trajectories on the AD spectrum in clinical-trial cohorts. Specifically, we evaluated whether regional patterns of baseline tau-PET predict prospective longitudinal decline in specific cognitive domains in early symptomatic AD. Our study focused on 18F flortaucipir (FTP-PET), which is to date the only tau-PET tracer to have received FDA and EMA-approval for clinical use in the U.S./EU. In a cohort of 731 patients with AD, we tested whether (i) baseline differential tau-PET patterns correlate with domain-specific cognitive performance cross-sectionally; (ii) similar tau-PET patterns at baseline predict cognitive decline in specific domains over time; (iii) structural brain changes over time mediate the prognostic value of tau PET. Establishing tau-PET as a tool for tracking in vivo disease and predicting clinical progression would improve patient prognostication and management, also potentially enriching screening and outcome evaluation in clinical trials.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study participants</title><p id="Par9">We included participants enrolled either in observational flortaucipir clinical development studies (AV1451-A05: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02016560">NCT02016560</ext-link> [<xref ref-type="bibr" rid="CR2">2</xref>]) or in interventional clinical trials (EXPEDITION-3: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01900665">NCT01900665</ext-link> [<xref ref-type="bibr" rid="CR16">16</xref>], and AMARANTH: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02245737">NCT02245737</ext-link> [<xref ref-type="bibr" rid="CR17">17</xref>]) conducted at Eli Lilly and Company. Seven hundreds thirty-one (<italic toggle="yes">N</italic>&#8201;=&#8201;731) participants were included in our analyses, as they: (i) had a clinical diagnosis of mild cognitive impairment (MCI) due to AD, or AD with mild dementia based on NIA-AA criteria ; (ii) had a positive florbetapir PET scan (assessed via visual interpretation with adjunct quantitative information - the VisQ method [<xref ref-type="bibr" rid="CR18">18</xref>] - evaluating cortical A&#946; levels); (iii) underwent a FTP-PET PETscan at baseline; (iv) had available clinical and neuropsychological assessment data. Out of 731 participants, 221 had a diagnosis of MCI due to AD, and 510 had a diagnosis of AD with mild dementia.</p><p id="Par10">For longitudinal analyses, we included all participants from the observational study (AV1451-A05; <italic toggle="yes">n</italic>&#8201;=&#8201;108), and participants in placebo arms only from the two clinical trials (EXPEDITION-3 <italic toggle="yes">n</italic>&#8201;=&#8201;82, and AMARANTH <italic toggle="yes">n</italic>&#8201;=&#8201;31), while participants in treatment arms were excluded.</p></sec><sec id="Sec4"><title>Image acquisition and processing</title><p id="Par11">In study A05, flortaucipir PET images were acquired across four 5-min frames (20&#160;min total) beginning 80&#160;min after IV injection of 370 MBq flortaucipir F18 as described in previous publications. In Expedition 3 and Amaranth images were acquired across six 5-min frames (30&#160;min total) beginning 75&#160;min after IV injection of 240 MBq flortaucipir F18. Other aspects of image acquisition and processing were comparable across the three studies and methods have been described in earlier publications [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Briefly, all FTP-PET scans were motion- and time-corrected, followed by summing into a single scan. After a series of pre-processing steps [<xref ref-type="bibr" rid="CR2">2</xref>], the summed FTP-PET scans were transformed to Montreal Neurologic Institute (MNI) atlas space. Automated anatomical labelling (AAL) atlas was used to partition the spatially-normalized FTP-PET images into 92 anatomical regions. Voxel-wise maps and regional SUVR values were created using subject-specific cerebellum crus as reference region. Cortical surface maps were created for baseline and follow-up FTP-PET scans of each participant. Cortical reconstruction program provided by FreeSurfer (version 6.0.0w) was applied on the baseline T1-weighted MRI scans to segregate white matter and pial surfaces and to calculate subject-specific subcortical segmentations. The cortical reconstructions with macroscopically failed segmentations and/or surface errors were removed from further analysis after manual inspection. The motion- and time-corrected baseline and follow-up FTP-PET scans were registered to the bias-corrected T1-weighted MRI scans generated by FreeSurfer using Linear Image Registration Tool with 6 degrees-of-freedom. The FTP-PET uptake halfway between the pial and white surfaces was projected onto FreeSurfer&#8217;s average template and smoothed by a white surface Gaussian filter with a full width at half maximum (FWHM) of 5&#160;mm. The smoothed surface maps were then normalized by each subject&#8217;s cerebellum crus reference value to produce FTP-PET reflecting standardized uptake volume ratio (SUVR) surface. Unlike conventional approaches that rely on atlas-based inferior cerebellar gray matter or whole cerebellum regions, our method uses a subject-specific cerebellar crus reference region derived from each individual&#8217;s T1-weighted MRI. The inferior cerebellar gray matter is located at the bottom of the PET field of view, thus attenuation correction and spatial normalization can be more prone to error. Our approach allowed for an accurate placement of the reference region, especially in cases with severe atrophy, while maintaining consistency across participants.</p></sec><sec id="Sec5"><title>Cognitive assessment and domains</title><p id="Par12">At baseline, all participants underwent the ADAS-Cog cognitive assessment, which evaluates episodic and semantic memory, language, executive and praxis functions (higher scores indicate worse performance in each of these domains). The same cognitive assessment was repeated after 9 and 18 months in A05 and EXPEDITION-3 trials, and after 1 year and 2 years in AMARANTH. Sub-scores for episodic memory were calculated including the recall, recognition, orientation, and remembering instructions items from the ADAS-Cog cognitive scale. Semantic memory was measured using the naming objects and fingers ADAS-Cog sub-scores, while the language sub-score included scores in difficulty in finding words and following commands. Executive functions were evaluated with the number of cancellations from ADAS-Cog13, and available for the AMARANTH and EXPEDITION-3 studies but not in the A05 study. Finally, the ideational and constructional praxis subscores were used to assess the praxis domain.</p><p id="Par13">To obtain comparable scores across domains, we calculated patient-specific W-scores (age-corrected z-scores) for each ADAS-Cog sub-score against a group of 68 cognitively unimpaired, amyloid-negative controls (recruited as part of the A05 study; female: 46.3%; apoe4-carriers: 20%; percentage white: 75%; mean (SD) age: 58.94 (18.68); mean years of education: 15.83; all with a Mini-Mental State Examination (MMSE)&#8201;&gt;&#8201;28, average MMSE (SD): 29.50 (0.50); average ADAS-Cog11 (SD): 5.34 (3.28)). Notably, this group included 15 young controls with a mean age of 29.0. Next, patient-specific W-scores of single ADAS-Cog sub-tests were averaged within each cognitive domain. None of the patients included had missing cognitive assessment data. The executive domain was evaluated only in the AMARANTH and EXPEDITION-3 studies, as the respective test of number of cancellations from ADAS-Cog13 was not available in A05 study. Moreover, since the normal controls were not available in AMARANTH and EXPEDITION-3 for calculating w-scores, raw scores were used for the executive domain.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par14">First, ROI-based Pearson correlation analyses were performed to identify the cross-sectional associations between left and right regional tau-PET SUVR values and domain-specific cognitive impairment at baseline. Second, we applied latent growth curve models (LGCM) to longitudinal domain-specific scores to estimate the rate of annual decline (slope) for each participant. Worse cognitive performance is reflected in higher scores on the ADAS test over time. Domain-specific scores at follow-up were annualized to the nearest whole year for A05 and EXPEDITION3 studies, using the absolute difference in scores between the baseline and the following visits, divided by the time interval in days between tests and multiplied by 365 (9 months converted to 1 year) and 730 (18 months converted to 2 years). This allowed us to run the models across all cohorts using equidistant and comparable time intervals between visits, and to calculate slopes that are interpretable as &#8216;annual rate of change&#8217; in each cognitive domain. LGCM were fitted on longitudinal annualized domain-specific scores across all patients, and linear slopes for domain-specific scores were estimated, and used in further analyses. LGCM was implemented in Lavaan software using full information maximum likelihood estimation with robust standard errors for missingness and non-normality. We considered three indices of good model fit [<xref ref-type="bibr" rid="CR20">20</xref>]: (1) the root-mean-square error of approximation (RMSEA, acceptable fit: &lt; 0.08, good fit: &lt; 0.05), (2) the comparative fit index (CFI, acceptable fit: 0.95&#8211;0.97, good fit: &gt;0.97), and (3) the standardized root mean-square residual (SRMR, acceptable fit: 0.05&#8211;0.10, good fit: &lt; 0.05). From the model fitting, variables &#8220;intercept&#8221; and &#8220;slope&#8221; were created extracting the individual estimated values for each subject in the model. Baseline tau-PET SUVR regional values were included in region-specific correlation analyses with the annual rate of domain-specific decline (slope). Associations between tau-PET and domain-specific cognitive impairments, cross-sectionally and longitudinally, were also tested with voxel-wise regression analyses. Both ROI-based and voxel-wise analyses were performed across all patients, and within each diagnostic group (MCI, dementia). Results were considered statistically significant with a <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 with Family Wise Error (FWE) correction, and cluster extent k&#8201;=&#8201;100 was used for voxel-wise regression analyses. Covariates were not included as the approach already accounted for age (calculating w-scores) and baseline clinical severity (LGCM account for intercept and slope covariance). Analyses adjusting for sex as covariate led to the same results, thus we did not include this in the final analyses.</p><p id="Par15">Next, we tested whether the relationship between baseline tau-PET and longitudinal domain-specific cognitive decline was mediated by atrophy in the same brain regions. First, we tested for associations between gray-matter regional volumes and cognitive change slope. Second, we undertook mediation analyses within specific brain regions where cognitive impairment showed associations with both tau-PET SUVR and grey matter volume. Our analysis was restricted to those regions where imaging-cognition correlations with both imaging modalities, thus ensuring an impartial assessment without favoring one modality over the other. Utilizing the &#8216;mediation&#8217; R package, we computed the average direct effect (ADE) and the average causal mediation effect (ACME). These effects were estimated as population averages through non-parametric bootstrapping comprising 5000 simulations, with a significance level set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par16">Table&#160;<xref rid="Tab1" ref-type="table">1</xref> shows demographics and summaries of patient w-scores across various cognitive domains of participants included in cross-sectional analyses. Nearly half of the sample (374/731) were female, and 66% of the sample (478/720; data for 11 patients was not available) were APOE-&#949;4 carriers. One-sample t-tests reveal significant impairment in all cognitive domains, suggesting poorer performance compared to controls. Specifically, these differences were observed in episodic memory [t&#8201;=&#8201;24.56, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001], semantic memory [t&#8201;=&#8201;12.24, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001], language [t&#8201;=&#8201;18.16, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001], executive [t&#8201;=&#8201;27.40, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001], and praxis [t&#8201;=&#8201;15.96, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001]. Domain-specific cognitive performance did not differ significantly across study cohorts at the statistical threshold of <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. Table&#160;<xref rid="Tab2" ref-type="table">2</xref> shows the demographics and clinical/cognitive assessment summaries for participants (<italic toggle="yes">n</italic>&#8201;=&#8201;221; 65% with mild AD dementia, 35% with MCI due to AD) included in the longitudinal analyses. The average age of the cohort was 74 years; 51% were male, 64% were APOE-&#949;4 carriers, and the average follow-up time was 19 months.</p><p id="Par17">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Clinical, demographics, and genetic characteristics of the 731 participants included in cross-sectional analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinical and Genetic<break/>Characteristics</th><th align="left" colspan="1" rowspan="1">Complete Dataset<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;731)</th><th align="left" colspan="1" rowspan="1">A05<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;173)</th><th align="left" colspan="1" rowspan="1">AMARANTH<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;365)</th><th align="left" colspan="1" rowspan="1">EXPEDITION-3<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;193)</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age in years, mean (SD) [min-max]</td><td align="left" colspan="1" rowspan="1"><p>73.0 (8.0)</p><p>[MCI: 50&#8211;97,</p><p>AD: 54&#8211;95]</p></td><td align="left" colspan="1" rowspan="1"><p>74.3 (9.3)</p><p>[MCI: 50&#8211;97,</p><p>AD: 54&#8211;95]</p></td><td align="left" colspan="1" rowspan="1"><p>71.7 (7.5)</p><p>[MCI:55&#8211;85,</p><p>AD:55&#8211;85]</p></td><td align="left" colspan="1" rowspan="1"><p>73.9 (8.0)</p><p>[AD: 55&#8211;90]</p></td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Sex: male/female, n</td><td align="left" colspan="1" rowspan="1">357/374</td><td align="left" colspan="1" rowspan="1">90/83</td><td align="left" colspan="1" rowspan="1">178/187</td><td align="left" colspan="1" rowspan="1">89/104</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">APOE-&#949;4: non-carriers/carriers, n</td><td align="left" colspan="1" rowspan="1">242/478 (11*)</td><td align="left" colspan="1" rowspan="1">66/101 (6*)</td><td align="left" colspan="1" rowspan="1">121/243 (1*)</td><td align="left" colspan="1" rowspan="1">55/134 (4*)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Race</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Asian, n</td><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">41</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Black/African American, n</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">White, n</td><td align="left" colspan="1" rowspan="1">640 (24*)</td><td align="left" colspan="1" rowspan="1">169 (1*)</td><td align="left" colspan="1" rowspan="1">314 (3*)</td><td align="left" colspan="1" rowspan="1">157 (20*)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ethnicity</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hispanic or Latino, n</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Not Hispanic or Latino, n</td><td align="left" colspan="1" rowspan="1">597</td><td align="left" colspan="1" rowspan="1">91</td><td align="left" colspan="1" rowspan="1">337</td><td align="left" colspan="1" rowspan="1">169</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">Clinical Diagnosis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AD with mild dementia, n (%)</td><td align="left" colspan="1" rowspan="1">510 (69.76)</td><td align="left" colspan="1" rowspan="1">76 (43.93)</td><td align="left" colspan="1" rowspan="1">241 (66.02)</td><td align="left" colspan="1" rowspan="1">193 (100.00)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">MCI due to AD, n (%)</td><td align="left" colspan="1" rowspan="1">221 (30.23)</td><td align="left" colspan="1" rowspan="1">97 (56.06)</td><td align="left" colspan="1" rowspan="1">124 (33.97)</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cognitive composite scores at baseline</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Episodic memory (w-score), mean (SD)</td><td align="left" colspan="1" rowspan="1">1.85 (1.92)</td><td align="left" colspan="1" rowspan="1">1.64 (1.86)</td><td align="left" colspan="1" rowspan="1">1.93 (2.02)</td><td align="left" colspan="1" rowspan="1">1.91 (1.79)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Semantic memory (w-score), mean (SD)</td><td align="left" colspan="1" rowspan="1">0.78 (1.87)</td><td align="left" colspan="1" rowspan="1">0.95 (2.25)</td><td align="left" colspan="1" rowspan="1">0.59 (1.63)</td><td align="left" colspan="1" rowspan="1">0.98 (1.92)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Executive function (0&#8211;5 score), mean (SD)</td><td align="left" colspan="1" rowspan="1">2.58 (1.23)</td><td align="left" colspan="1" rowspan="1">---</td><td align="left" colspan="1" rowspan="1">2.56 (1.24)</td><td align="left" colspan="1" rowspan="1">2.60 (1.21)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Language (w-score), mean (SD)</td><td align="left" colspan="1" rowspan="1">2.92 (3.91)</td><td align="left" colspan="1" rowspan="1">2.61 (3.94)</td><td align="left" colspan="1" rowspan="1">2.84 (3.80)</td><td align="left" colspan="1" rowspan="1">3.34 (4.08)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Praxis (w-score), mean (SD)</td><td align="left" colspan="1" rowspan="1">1.18 (2.00)</td><td align="left" colspan="1" rowspan="1">0.96 (1.91)</td><td align="left" colspan="1" rowspan="1">1.29 (2.11)</td><td align="left" colspan="1" rowspan="1">1.18 (1.86)</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: AD, Alzheimer&#8217;s disease; APOE, apolipoprotein E; MCI, mild cognitive impairment; n, number of participants in the analysis; SD, standard deviation. Higher w-scores correspond to worse cognitive performance. The * indicates missing information</p></table-wrap-foot></table-wrap>
</p><p id="Par18">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Clinical, demographics, and genetic characteristics of the 221 participants included in prognostic analysis with longitudinal cognitive assessments</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinical and Genetic<break/>Characteristics</th><th align="left" colspan="1" rowspan="1">Complete Dataset<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;221)</th><th align="left" colspan="1" rowspan="1">A05<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;108)</th><th align="left" colspan="1" rowspan="1">AMARANTH<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;31)</th><th align="left" colspan="1" rowspan="1">EXPEDITION-3<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;82)</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age in years, mean (SD) [min-max]</td><td align="left" colspan="1" rowspan="1">74.47 (8.58)</td><td align="left" colspan="1" rowspan="1">75.35 (9.03)</td><td align="left" colspan="1" rowspan="1">72.29 (7.29)</td><td align="left" colspan="1" rowspan="1">74.14 (8.18)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Sex: male/female, n</td><td align="left" colspan="1" rowspan="1">113/108</td><td align="left" colspan="1" rowspan="1">61/47</td><td align="left" colspan="1" rowspan="1">16/15</td><td align="left" colspan="1" rowspan="1">36/46</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">APOE-&#949;4: non-carriers/carriers, n</td><td align="left" colspan="1" rowspan="1">76/137</td><td align="left" colspan="1" rowspan="1">42/62</td><td align="left" colspan="1" rowspan="1">12/19</td><td align="left" colspan="1" rowspan="1">22/56</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Race</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Asian, n</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Black/African American, n</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">White, n</td><td align="left" colspan="1" rowspan="1">199</td><td align="left" colspan="1" rowspan="1">105</td><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">68</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ethnicity</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hispanic or Latino, n</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Not Hispanic or Latino, n</td><td align="left" colspan="1" rowspan="1">156</td><td align="left" colspan="1" rowspan="1">58</td><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">Clinical Diagnosis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AD with mild dementia, n (%)</td><td align="left" colspan="1" rowspan="1">144 (65.16)</td><td align="left" colspan="1" rowspan="1">43 (39.81)</td><td align="left" colspan="1" rowspan="1">19 (61.29)</td><td align="left" colspan="1" rowspan="1">82 (100)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">MCI due to AD, n (%)</td><td align="left" colspan="1" rowspan="1">77 (34.84)</td><td align="left" colspan="1" rowspan="1">65 (60.19)</td><td align="left" colspan="1" rowspan="1">12 (38.71)</td><td align="left" colspan="1" rowspan="1">0 (0.00)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cognitive composite estimated slopes</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Episodic memory (w-score), mean (SD)</td><td align="left" colspan="1" rowspan="1">0.06 (0.60)</td><td align="left" colspan="1" rowspan="1">0.11 (0.59)</td><td align="left" colspan="1" rowspan="1">-0.04 (0.43)</td><td align="left" colspan="1" rowspan="1">0.03 (0.67)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Semantic memory (w-score), mean (SD)</td><td align="left" colspan="1" rowspan="1">0.02 (0.24)</td><td align="left" colspan="1" rowspan="1">0.02 (0.23)</td><td align="left" colspan="1" rowspan="1">0.01 (0.17)</td><td align="left" colspan="1" rowspan="1">0.02 (0.27)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Executive function (0&#8211;5 score), mean (SD)</td><td align="left" colspan="1" rowspan="1">0.03 (0.46)</td><td align="left" colspan="1" rowspan="1">--</td><td align="left" colspan="1" rowspan="1">0.03 (0.61)</td><td align="left" colspan="1" rowspan="1">0.03 (0.40)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Language (w-score), mean (SD)</td><td align="left" colspan="1" rowspan="1">0.04 (0.71)</td><td align="left" colspan="1" rowspan="1">0.02 (0.62)</td><td align="left" colspan="1" rowspan="1">0.10 (0.68)</td><td align="left" colspan="1" rowspan="1">0.05 (0.84)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Praxis (w-score), mean (SD)</td><td align="left" colspan="1" rowspan="1">0.04 (0.72)</td><td align="left" colspan="1" rowspan="1">0.04 (0.64)</td><td align="left" colspan="1" rowspan="1">0.14 (0.80)</td><td align="left" colspan="1" rowspan="1">0.00 (0.79)</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: AD, Alzheimer&#8217;s disease; APOE, apolipoprotein E; MCI, mild cognitive impairment; n, number of participants in the analysis; SD, standard deviation. Higher w-scores correspond to worse cognitive performance. The -- indicates missing of executive domain in A05 study</p></table-wrap-foot></table-wrap>
</p><sec id="Sec8"><title>Associations between domain-specific cognitive performance and tau-PET imaging at baseline</title><p id="Par19">Results from regional correlations between domain-specific cognitive performance and tau-PET SUVR are reported in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. Episodic memory deficits were associated with increased tau-PET uptake in the temporal, frontal lobes extensively, and in the supramarginal gyri, the precuneus and posterior cingulate cortex. Associations between semantic memory impairment and tau-PET uptake were much less widespread and involved anterior temporal regions only, on the left hemisphere more than the right hemisphere. Executive dysfunction was related to higher tau-PET uptake in bilateral fronto-parietal regions. The correlation analyses between language and tau-PET uptake showed significant associations in the left greater than right hemispheres, specifically in posterior superior temporal regions, parietal regions involving supramarginal gyrus and angular gyrus, and in inferior and middle frontal gyri. The correlation with praxis revealed significant associations with tau-PET uptake in right greater than left occipital, frontal and parietal regions extensively, and in temporal posterior regions. Adjusting the correlation analyses for global (average across all regions) tau-PET uptake, the core regions of the patterns remained the same (e.g., left temporal regions for semantic memory, left inferior frontal gyrus and temporal regions for language, and right inferior operculum and occipital regions for praxis; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>, bottom panel). Adding years of education as covariate in the correlation analyses did not change the results (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref>), as well as repeating the analyses after excluding young controls from the w-score computation (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par20">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Correlations between regional tau-PET SUVR values and domain-specific cognitive impairment at baseline. The surface maps display all the regional correlations assessed, while the bottom heatmap highlights only those correlations which have <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. The * indicates the correlations which survived stringent threshold of pFWE&#8201;&lt;&#8201;0.05. The x-axis of heatmap groups AAL brain regions by lobes, and the y-axis represents cognitive domains</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1028" position="float" orientation="portrait" xlink:href="13195_2025_1868_Fig1_HTML.jpg"/></fig>
</p><p id="Par21">Voxel-wise regression analysis identified similar patterns of tau-PET uptake associated with domain-specific cognitive performance as for the regional correlation analyses (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). The core regions of the patterns were the same, however the spatial extent was larger in regional analyses than in voxel-wise results. In particular, with the voxel-wise approach, the executive-related tau-PET pattern was limited to frontal/motor areas, and the left lateralization of the language-related pattern was more accentuated.</p><p id="Par22">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Voxel-wise correlation maps between tau-PET SUVR values and domain-specific cognitive impairment at baseline. The surface map indicates the correlations which survived stringent threshold of pFWE&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1043" position="float" orientation="portrait" xlink:href="13195_2025_1868_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec9"><title>Associations between tau-PET imaging at baseline and domain-specific cognitive decline over time</title><p id="Par23">The LGCM of longitudinal cognitive scores fit the data adequately (RMSEA&#8201;=&#8201;0.00, CFI&#8201;=&#8201;1, SRMR&#8201;=&#8201;0.00) for all cognitive domains. Next, we tested for associations between baseline tau-PET and domain-specific cognitive decline over time. Most patients experienced worsening across different domains as shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> (see Table&#160;<xref rid="Tab2" ref-type="table">2</xref> for summaries across cohorts). The results indicate that there is a global effect of tau, as tau-PET in specific brain regions is associated with cognitive decline across multiple domains. However, differential tau-PET patterns were associated with domain-specific cognitive decline (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Specifically, higher tau-PET uptake in fronto-temporal, parietal, cingulate and limbic regions was indicative of a faster decline in episodic memory. Higher tau-PET uptake in the left anterior and inferior temporal lobe was associated with greater decline in semantic memory. Executive decline exhibited minimal inter-individual variability, possibly due to low dynamic range in this domain (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>), thus correlations with baseline tau PET did not highlight strong association patterns. Additionally, a more extensive tau-PET uptake pattern in fronto-temporal and parietal regions (L&#8201;&gt;&#8201;R), and fronto-parietal and occipital regions was linked to accelerated decline in language and praxis domains, respectively. Adjusting the correlation analyses for global (average across all regions) tau-PET uptake, the domain-specific patterns were more spatially limited and reduced to core regions (e.g., left temporal regions for semantic memory and language, and parietal-occipital regions for praxis; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>, bottom panel). Voxel-wise regression analysis revealed similar patterns of tau-PET uptake associated with domain-specific cognitive decline (pFWE&#8201;&lt;&#8201;0.05, Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par24">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Longitudinal changes in domain-specific composite scores. Individual trajectories are represented using the intercepts (performance at baseline) and slopes (rate of change), estimated with the latent growth curve modelling approach on annualized w-scores. Blue indicates participants with MCI due to AD, and yellow indicates those with mild AD dementia</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1076" position="float" orientation="portrait" xlink:href="13195_2025_1868_Fig3_HTML.jpg"/></fig>
</p><p id="Par25">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Correlations between regional tau-PET SUVR values at baseline and domain-specific cognitive decline over time (slope). The surface maps display all the regional correlations assessed, while the bottom heatmaps highlights only those correlations which have <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 (with and without correcting for global Tau PET signal). The * indicates the correlations which survived stringent threshold of pFWE&#8201;&lt;&#8201;0.05. The x-axis of heatmap groups AAL brain regions by lobes, and the y-axis represents cognitive domains</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1090" position="float" orientation="portrait" xlink:href="13195_2025_1868_Fig4_HTML.jpg"/></fig>
</p><p id="Par26">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Voxel-wise correlation maps between baseline tau-PET SUVR values and domain-specific cognitive decline over time (slope). The surface map indicates the correlations which survived stringent threshold of pFWE&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1100" position="float" orientation="portrait" xlink:href="13195_2025_1868_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec10"><title>Associations between Gray matter volume at baseline and domain-specific cognitive decline over time</title><p id="Par27">Next, we examined the associations between baseline atrophy (gray matter volume) and domain-specific cognitive decline over time. The results (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>) indicate a common pattern of atrophy in temporoparietal regions associated with cognitive decline across all domains. However, unique differential atrophy patterns were also observed, showing associations with domain-specific cognitive decline. Adjusting the correlation analyses for global (sum across all regions) grey-matter volumes, the domain-specific patterns were spatially limited to core regions (e.g., left temporal pole for semantic memory and right parietal-occipital regions for praxis; Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>, bottom panel).</p><p id="Par28">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Correlations between regional gray matter volumes at baseline and domain-specific cognitive decline over time (slope). The surface maps display all the regional correlations assessed, while the bottom heatmap highlights only those correlations which have <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 (with and without correcting for global grey-matter volume). The * indicates the correlations which survived stringent threshold of pFWE&#8201;&lt;&#8201;0.05. The x-axis of heatmap groups AAL brain regions by lobes, and the y-axis represents cognitive domains</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1124" position="float" orientation="portrait" xlink:href="13195_2025_1868_Fig6_HTML.jpg"/></fig>
</p></sec><sec id="Sec11"><title>Association between baseline tau-PET and domain-specific cognitive decline controlling for atrophy</title><p id="Par29">To further examine whether grey matter atrophy mediates the relationship between baseline tau-PET and longitudinal cognitive decline, we created overlap maps that included regions showing significant association between cognitive performance and both tau-PET uptake and grey matter volume (at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 uncorrected). The threshold of these analyses was lowered as only a limited number of regions were obtained by associating cognition and grey matter volume. The top 10 regions were assessed from both the categories for assessment of overlap (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>). The mean tau-PET uptake and grey matter volume were then extracted in the overlap regions and included in mediation analyses, with grey matter volume as the mediator variable (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par30">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Overlapping regional patterns selected for the mediation analyses. Regions were selected based on the associations of tau-PET and gray matter volumes, respectively, with cognitive decline in each domain. Top-most 10 regions in terms of correlations (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) were selected for finding the overlap</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1151" position="float" orientation="portrait" xlink:href="13195_2025_1868_Fig7_HTML.jpg"/></fig>
</p><p id="Par31">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Summary of the mediation analyses in the brain areas where both flortaucipir tau-PET SUVR and grey matter volume were related to cognitive domain scores (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Cognitive domains</th><th align="left" colspan="2" rowspan="1">ACME</th><th align="left" colspan="2" rowspan="1">ADE</th></tr><tr><th align="left" colspan="1" rowspan="1">Estimates</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-values</th><th align="left" colspan="1" rowspan="1">Estimates</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-values</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Episodic memory</td><td char="." align="char" colspan="1" rowspan="1">0.0169</td><td char="." align="char" colspan="1" rowspan="1">0.12</td><td char="." align="char" colspan="1" rowspan="1">0.7076</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Semantic memory</td><td char="." align="char" colspan="1" rowspan="1">-0.0118</td><td char="." align="char" colspan="1" rowspan="1">0.34</td><td char="." align="char" colspan="1" rowspan="1">0.2268</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Executive function</td><td char="." align="char" colspan="1" rowspan="1">0.0300</td><td char="." align="char" colspan="1" rowspan="1">0.14</td><td char="." align="char" colspan="1" rowspan="1">0.2717</td><td char="." align="char" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" colspan="1" rowspan="1">Language</td><td char="." align="char" colspan="1" rowspan="1">0.0142</td><td char="." align="char" colspan="1" rowspan="1">0.50</td><td char="." align="char" colspan="1" rowspan="1">0.8191</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Praxis</td><td char="." align="char" colspan="1" rowspan="1">0.0271</td><td char="." align="char" colspan="1" rowspan="1">0.02*</td><td char="." align="char" colspan="1" rowspan="1">0.9644</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ACME&#8201;=&#8201;average causal mediation effect; ADE&#8201;=&#8201;average direct effect</p></table-wrap-foot></table-wrap>
</p><p id="Par32">We observed no mediation effect of gray matter atrophy on the association between baseline tau-PET and decline in cognitive domains (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>; episodic memory: ACME&#8201;=&#8201;0.02, <italic toggle="yes">P</italic>&#8201;=&#8201;0.12; ADE&#8201;=&#8201;0.71, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; semantic memory: ACME= -0.01, <italic toggle="yes">P</italic>&#8201;=&#8201;0.34; ADE&#8201;=&#8201;0.23, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; executive function: ACME&#8201;=&#8201;0.03; ADE&#8201;=&#8201;0.27, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; language: ACME&#8201;=&#8201;0.01, <italic toggle="yes">P</italic>&#8201;=&#8201;0.50; ADE&#8201;=&#8201;0.82, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), except praxis domain where marginal mediation effect of gray matter atrophy was observed (praxis: ACME&#8201;=&#8201;0.03, <italic toggle="yes">P</italic>&#8201;=&#8201;0.02; ADE&#8201;=&#8201;0.96, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par33">Our study corroborates the prognostic value of tau-PET regional distribution on cognitive decline in several domains, in a clinical trial cohort patients with MCI-to-mild dementia. Differential tau-PET patterns are associated with domain-specific cognitive performance and decline in symptomatic amyloid-positive patients, as shown by both regional correlation and voxel-wise regression analyses. Specifically, higher tau-PET SUVR in an extensive regional pattern encompassing fronto-temporal and parietal regions was predictive of faster decline in episodic memory. Higher tau-PET uptake in the left anterior temporal lobe related to worse semantic memory, while a more extensive and asymmetric tau-PET uptake pattern in (L&#8201;&gt;&#8201;R) fronto-temporal and parietal regions and (R&#8201;&gt;&#8201;L) fronto-parietal and occipital regions related to faster decline in language and praxis, respectively. Executive decline showed small inter-individual variability, leading to limited association patterns. Region-based analyses highlighted similar tau-PET uptake patterns as predictive of domain-specific decline.</p><p id="Par34">Previous cross-sectional studies on a similar but smaller cohort showed similar tau-PET uptake patterns associated with cross-sectional domain-specific impairment [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Thus, the current study replicates and extends previous evidence. Beyond cross-sectional studies, only a limited number of observational and smaller studies have shown associations between regional patterns of tau-PET and cognitive decline in patients on the spectrum of AD. In 152 individuals with CDR&#8201;&#8804;&#8201;0.5, with only a small portion of positive amyloid PET scans, retrospective longitudinal analyses indicated that tau-PET had the largest predictive value on episodic memory and executive functioning decline, as compared to amyloid-PET and structural MRI [<xref ref-type="bibr" rid="CR21">21</xref>]. Moving from pre-clinical to dementia stages on the AD spectrum, in a small cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;36) of amyloid-positive patients with AD, differential voxel-wise patterns of tau-PET at baseline were found to be strongly associated with subsequent cognitive decline in memory, executive and instrumental functions, while no associations were found with baseline amyloid load and regional cortical atrophy [<xref ref-type="bibr" rid="CR22">22</xref>]. In a larger cohort of amyloid-positive individuals (<italic toggle="yes">n</italic>&#8201;=&#8201;131) from the ADNI study, widespread associations between Flortaucipir PET patterns and cognitive decline were found in domain-related regions, as compared to limited cortical thickness-cognition associations [<xref ref-type="bibr" rid="CR23">23</xref>]. Another ADNI-based study on 140 amyloid-positive individuals confirmed the previous results, reporting that cognitive domain-specific tau-PET outperforms amyloid-PET and structural MRI, but also global and temporal lobe tau-PET, for predicting future cognitive decline in episodic memory, language, executive functioning, and visuospatial abilities [<xref ref-type="bibr" rid="CR24">24</xref>]. Overall, these observational studies indicated that domain-specific cognitive decline in patients with AD reflects underlying tau progression into associated brain circuits, and spatial patterns of tau-PET may have better sensitivity to capture differential decline than MRI-derived measures.</p><p id="Par35">Our study complements and expands on this series of reports. Specifically, our results point to similar tau-cognition spatial relationships in a larger and more diverse trial-based cohort of amyloid-positive patients with a clinical diagnosis of MCI or mild AD dementia. We focused on early stages of the disease as this may be the most efficacious time window to intervene with disease-modifying therapies, and prognostic biomarkers may be the most appropriate tools to stratify patients at these early stages of disease. Notably, our results showed that the observed asymmetry and spatial differences in the prognostic value of tau-PET for cognitive decline are more pronounced than in cross-sectional correlation patterns with cognitive domains. This aligns with recent evidence suggesting that asymmetric tau deposition is associated with earlier disease onset, greater pathological burden, and more rapid cognitive deterioration compared to symmetric patterns [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In addition, our results identify overlapping patters of tau-PET in correlation analyses with episodic memory and praxis performance. This overlap is consistent with evidence that tau pathology in regions such as frontal and parietal cortices is associated with decline across multiple cognitive domains, reflecting the interconnected nature of neural networks supporting memory and praxis. However, episodic memory deficits were related to tau-PET in temporal regions more extensively than praxis, while the latter was associated with a tau pattern involving posterior regions, including occipital cortex, that were not part of the episodic memory related patterns (Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig5" ref-type="fig">5</xref>). These findings highlight the importance of considering not only the overall burden but also differential spatial distributions and the lateralization of tau pathology when assessing prognosis and tailoring interventions in AD.</p><p id="Par36">Across domains, we observed overlapping regions where tau-PET uptake, grey matter volume, and cognition were significantly associated. This convergence, particularly in temporoparietal and medial temporal areas, highlights the close interplay between tau pathology, neurodegeneration, and cognitive decline. Such overlap supports the hypothesis that regional tau accumulation may drive local atrophy, which in turn contributes to domain-specific cognitive deficits [<xref ref-type="bibr" rid="CR27">27</xref>]. The associations between baseline gray matter volume and domain-specific cognitive decline, while showing some overlap, were less extensive and strong as compared to the associations between baseline tau-PET and domain-specific cognitive decline. This suggests that tau-PET may be a stronger predictor of domain-specific longitudinal cognitive decline than gray matter atrophy; and while structural brain changes are important, they may not capture the full extent of the neurodegenerative processes affecting cognitive functions. This aligns with cross-sectional multimodal imaging studies on the AD spectrum, showing tau-PET uptake in areas without overt neurodegeneration [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Tau pathology may locally precede neurodegeneration, as also suggested by significant associations of baseline tau-PET patterns with prospective atrophy as measured by structural MRI [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and retrospective longitudinal atrophy (years preceding tau-PET) in both cognitively unimpaired individuals and patients with clinical AD [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Moreover, our findings suggest that while there are regions where tau-PET signals and gray matter atrophy are both associated with cognitive decline, gray matter atrophy does not mediate the relationship between baseline tau-PET and cognitive decline. This indicates that tau-PET may be a robust and independent predictor of domain-specific cognitive decline. Baseline MRI may also capture more of the normal variation in brain structure, whereas tau-PET uptake is indicative of pathological process. Further research in clinical settings is necessary to confirm these findings and explore potential underlying mechanisms.</p><p id="Par37">Previous studies have described strong associations between baseline tau-PET and cognitive changes over time across the AD clinical spectrum. In head-to-head comparisons, tau-PET binding in temporo-parietal regions outperformed amyloid-PET and structural MRI measures in predicting global cognitive decline [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>], especially in patients at early AD stages [<xref ref-type="bibr" rid="CR12">12</xref>]. We relied on ADAS-cog as single tests with domain-specific sub-scores, rather than focusing on extensive cognitive batteries, in order to improve prognosis in clinical practice and trials in a feasible and pragmatic way while capturing different domains. Although a single test cannot fully assess patients&#8217; cognitive functioning and identify co-occurring deficits that a more extensive battery might reveal, it still holds value. Corroborating previous results by transitioning from composite scores to crude single-test sub-scores offers multiple advantages. First, administering a single test is quicker and less resource-intensive, making it suitable for settings with time constraints or limited access to testing materials, such as clinics that will soon start implementing disease modifying treatment delivery. Second, shorter testing time minimizes fatigue and stress for patients, which can result in more accurate and reliable performance. Third, a single-test assessment is easier to repeat over time for monitoring changes in cognitive function, such as in longitudinal studies or ongoing treatment assessments, reducing data missingness and subjective variability in multiple-test battery administration.</p><p id="Par38">As compared to previous reports, we also implemented a different approach to quantify cognitive changes over time, utilizing LGCM. This analytic approach offers several advantages over other previously used approaches, such as linear mixed effects models and the analysis of absolute differences for tracking changes over time, and has been successfully implemented in prognostic analysis in dementia [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>]. In particular, LGCM (i) explicitly models individual differences in initial status (intercept) and rate of change (slope), allowing for a detailed understanding of how individuals differ in their growth trajectories; (ii) handles missing data more robustly through full information maximum likelihood estimation, which uses all available data points and provides unbiased parameter estimates under the assumption that data are missing at random; (iii) offers a range of fit indices to assess model fit and compare alternative models, facilitating the identification of the best-fitting growth model over complex growth models [<xref ref-type="bibr" rid="CR36">36</xref>]. LGCM may be a powerful tool to implement in future AD clinical trials, as it provides a more nuanced, flexible, and robust approach to tracking changes over time compared to linear mixed effects models and the analysis of absolute differences.</p><p id="Par39">Notably, for both cross-sectional and longitudinal analyses in our cohort, after adjusting for global tau-PET uptake and global grey-matter volume, the observed domain-specific associations were spatially limited to core brain regions for each cognitive function. This spatial limitation highlights the importance of regional pathology over global disease burden in driving specific cognitive deficits, and the selective vulnerability of functionally specialized brain networks. Regional localized patterns of tau accumulation predict domain-specific cognitive decline and may inform both the timing and type of interventions. These findings reinforce the value of regional PET assessment and support the use of targeted approaches in both research and clinical interventions. Early detection of regionally restricted tau could enable targeted therapies and tailored clinical management, supporting a personalized medicine approach to delay or mitigate decline in specific cognitive domains.</p><p id="Par40">Our study has some limitations. First, the number of cancellation tests (part of ADAS-Cog13) was not available for participants in the A05 study, limiting our evaluation of executive domain to the AMARANTH and EXPEDITION studies. and we acknowledge that ADAS-Cog13 is able to evaluate more sensitively some cognitive domains (i.e., memory) than others. Additionally, w-scores for the executive domain were not calculated as controls had ADAS-Cog11 scores only available. Second, the control group was not age-matched, as it included participants across a wide age range. Notably, some control participants were younger than 50 years old (<italic toggle="yes">n</italic>&#8201;=&#8201;15, mean age&#8201;=&#8201;29.0), which may introduce some biases in the representativeness of the cohort. The inclusion of younger individuals could lead to an overestimation of cognitive differences between patients and controls, as younger participants are likely to perform better on cognitive assessments due to age-related advantages in processing speed and memory. Third, our mediation analyses were restricted to evaluating local relationships and did not account for potential distant relationships between tau-PET, gray matter atrophy, and domain-specific cognitive performance/decline. Finally, participants were recruited from expert clinical trial centers under highly controlled conditions, introducing selection bias. This might not accurately represent the broader patient population actually seen in the clinics. Additionally, the study population lacked racial and ethnic diversity, with over 90% of participants being white. The association between tau, neurodegeneration and cognition may vary based on race and ethnicity as proxies for social determinants of health [<xref ref-type="bibr" rid="CR37">37</xref>]. Other individual factors can also modify the relationship between tau accumulation and cognition, with younger age, female sex, higher education and cortical thickness being related to increased reserve and resistance against the effect of pathology on cognitive performance [<xref ref-type="bibr" rid="CR38">38</xref>]. Much more work in diverse cohorts is needed to validate our results in population-representative cohorts.</p><p id="Par41">In summary, we showed that differential regional patterns of tau-PET are associated with domain-specific cognitive decline in a large cohort of patients with MCI and early AD dementia. Implementing latent growth curve modelling approaches on single-test longitudinal changes may empower prognosis and outcome prediction. Tau-PET may be a good tool to stratify patients in clinical trials of disease-modifying therapies, with personalized predictions of neurodegeneration and cognitive trajectories, enhancing the chance to identify the best time window and cohort where a given therapy can be most effective.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1868_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Maura Malpetti and Saima Rathore contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank our participant volunteers for their participation in this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>MM designed the study, analyzed and interpreted the data, and drafted the manuscript. SR performed imaging analyses, analyzed and interpreted the data, and drafted the manuscript. LI, RLJ, GT, AMW, JRS contributed to the execution of the project. MJP and SS contributed to the design of the study. GDR was a major contributor in executing the project and writing the manuscript. All authors read, edited and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>M.M. was funded by Race Against Dementia Alzheimer&#8217;s Research UK (ARUK-RADF2021A-010), Parke Davis Exchange Fellowship in Biomedical Sciences (PD/2020/02) and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (NIHR203312: the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care).</p><p>Outside of this work, GDR receives funding from NIH/NIA P30-AG062422, R35 AG072362, U01-AG057195, U01-AG082350; Alzheimer&#8217;s Association, American College of Radiology, Rainwater Charitable Foundation, Laurel Foundation, Shenandoah Foundation.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par42">The protocols of the interventional and observational trials were reviewed and approved by appropriate ethics committees as required by global trials. All trials were conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization guideline on good clinical practice (World Medical Association, 1997). All patients provided written informed consent to participate in the trials.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par43">Unrelated to this work, M.M. provides consultancy to Astex Pharmaceuticals. G.D.R. receives research funding from Avid Radiopharmaceuticals and has served as a scientific consultant to Eli Lilly, which manufacture the FTP tau PET radiotracer evaluated in this manuscript. Unrelated to this work, he receives research funds from GE Healthcare, Genentech and Life Molecular Imaging; has served as a paid scientific consultant to Alector, C2N, Genentech, Johnson &amp; Johnson, Merck, Roche; serves as an Associate Editor for JAMA Neurology. MJP, LI and SS are employees and minor stockholders of Eli Lilly and Company. SR was an employee of Eli Lilly and Company when this work was conducted.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malpetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Joie</surname><given-names>R</given-names></name><name name-style="western"><surname>La, Rabinovici</surname><given-names>GD</given-names></name></person-group><article-title>Tau beats amyloid in predicting brain atrophy in alzheimer disease: implications for prognosis and clinical trials</article-title><source>J Nucl Med</source><year>2022</year><volume>63</volume><fpage>830</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.2967/jnumed.121.263694</pub-id><pub-id pub-id-type="pmid">35649659</pub-id><pub-id pub-id-type="pmcid">PMC9157718</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Malpetti M, Joie R, La, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in alzheimer disease: implications for prognosis and clinical trials. J Nucl Med. 2022;63:830&#8211;2.<pub-id pub-id-type="pmid">35649659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.121.263694</pub-id><pub-id pub-id-type="pmcid">PMC9157718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pontecorvo</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Devous</surname><given-names>MD</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>I</given-names></name><name name-style="western"><surname>Navitsky</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Galante</surname><given-names>N</given-names></name><etal/></person-group><article-title>A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and alzheimer&#8217;s disease dementia</article-title><source>Brain</source><year>2019</year><volume>142</volume><fpage>1723</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/brain/awz090</pub-id><pub-id pub-id-type="pmid">31009046</pub-id><pub-id pub-id-type="pmcid">PMC6536847</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and alzheimer&#8217;s disease dementia. Brain. 2019;142:1723&#8211;35.<pub-id pub-id-type="pmid">31009046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz090</pub-id><pub-id pub-id-type="pmcid">PMC6536847</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>PT</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I</given-names></name><name name-style="western"><surname>Bigio</surname><given-names>EH</given-names></name><name name-style="western"><surname>Bouras</surname><given-names>C</given-names></name><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Correlation of alzheimer disease neuropathologic changes with cognitive status: A review of the literature</article-title><source>J Neuropathol Exp Neurol</source><year>2012</year><volume>71</volume><fpage>362</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e31825018f7</pub-id><pub-id pub-id-type="pmid">22487856</pub-id><pub-id pub-id-type="pmcid">PMC3560290</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol. 2012;71:362&#8211;81.<pub-id pub-id-type="pmid">22487856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e31825018f7</pub-id><pub-id pub-id-type="pmcid">PMC3560290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>L</given-names></name><name name-style="western"><surname>Strom</surname><given-names>A</given-names></name><name name-style="western"><surname>Schonhaut</surname><given-names>DR</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><etal/></person-group><article-title>Spatial relationships between molecular pathology and neurodegeneration in the alzheimer&#8217;s disease continuum</article-title><source>Cereb Cortex</source><year>2021</year><volume>31</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhaa184</pub-id><pub-id pub-id-type="pmid">32808011</pub-id><pub-id pub-id-type="pmcid">PMC7727356</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Iaccarino L, La Joie R, Edwards L, Strom A, Schonhaut DR, Ossenkoppele R, et al. Spatial relationships between molecular pathology and neurodegeneration in the alzheimer&#8217;s disease continuum. Cereb Cortex. 2021;31:1&#8211;14.<pub-id pub-id-type="pmid">32808011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhaa184</pub-id><pub-id pub-id-type="pmcid">PMC7727356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><name name-style="western"><surname>Schonhaut</surname><given-names>DR</given-names></name><name name-style="western"><surname>Sch&#246;ll</surname><given-names>M</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>SN</given-names></name><name name-style="western"><surname>Ayakta</surname><given-names>N</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Tau PET patterns mirror clinical and neuroanatomical variability in alzheimer&#8217;s disease</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>1551</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1093/brain/aww027</pub-id><pub-id pub-id-type="pmid">26962052</pub-id><pub-id pub-id-type="pmcid">PMC5006248</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ossenkoppele R, Schonhaut DR, Sch&#246;ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in alzheimer&#8217;s disease. Brain. 2016;139:1551&#8211;67.<pub-id pub-id-type="pmid">26962052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww027</pub-id><pub-id pub-id-type="pmcid">PMC5006248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bejanin</surname><given-names>A</given-names></name><name name-style="western"><surname>Schonhaut</surname><given-names>DR</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>JH</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SL</given-names></name><name name-style="western"><surname>Sosa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Tau pathology and neurodegeneration contribute to cognitive impairment in alzheimer&#8217;s disease</article-title><source>Brain</source><year>2017</year><volume>140</volume><fpage>3286</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1093/brain/awx243</pub-id><pub-id pub-id-type="pmid">29053874</pub-id><pub-id pub-id-type="pmcid">PMC5841139</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in alzheimer&#8217;s disease. Brain. 2017;140:3286&#8211;300.<pub-id pub-id-type="pmid">29053874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awx243</pub-id><pub-id pub-id-type="pmcid">PMC5841139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name><name name-style="western"><surname>Ohlsson</surname><given-names>T</given-names></name><name name-style="western"><surname>Strandberg</surname><given-names>O</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></name><name name-style="western"><surname>Insel</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Associations between tau, A&#946;, and cortical thickness with cognition in alzheimer disease</article-title><source>Neurology</source><year>2019</year><volume>92</volume><fpage>e601</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000006875</pub-id><pub-id pub-id-type="pmid">30626656</pub-id><pub-id pub-id-type="pmcid">PMC6382060</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, A&#946;, and cortical thickness with cognition in alzheimer disease. Neurology. 2019;92:e601&#8211;12.<pub-id pub-id-type="pmid">30626656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000006875</pub-id><pub-id pub-id-type="pmcid">PMC6382060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanner</surname><given-names>JA</given-names></name><name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>L</given-names></name><name name-style="western"><surname>Asken</surname><given-names>BM</given-names></name><name name-style="western"><surname>Gorno-Tempini</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Amyloid, Tau and metabolic PET correlates of cognition in early and late-onset alzheimer&#8217;s disease</article-title><source>Brain</source><year>2022</year><volume>145</volume><fpage>4489</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1093/brain/awac229</pub-id><pub-id pub-id-type="pmid">35762829</pub-id><pub-id pub-id-type="pmcid">PMC10200306</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Tanner JA, Iaccarino L, Edwards L, Asken BM, Gorno-Tempini ML, Kramer JH, et al. Amyloid, Tau and metabolic PET correlates of cognition in early and late-onset alzheimer&#8217;s disease. Brain. 2022;145:4489&#8211;505.<pub-id pub-id-type="pmid">35762829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac229</pub-id><pub-id pub-id-type="pmcid">PMC10200306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><collab>Devous Sr</collab><name name-style="western"><surname>Fleisher</surname><given-names>MD</given-names></name><name name-style="western"><surname>Pontecorvo</surname><given-names>AS</given-names></name><name name-style="western"><surname>Lu</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Siderowf</surname><given-names>M</given-names></name><name name-style="western"><surname>Navitsky</surname><given-names>A</given-names></name></person-group><article-title>Relationships between cognition and neuropathological Tau in alzheimer&#8217;s disease assessed by 18F flortaucipir PET</article-title><source>JAD</source><year>2021</year><volume>80</volume><fpage>1091</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.3233/JAD-200808</pub-id><pub-id pub-id-type="pmid">33682705</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Devous Sr, Fleisher MD, Pontecorvo AS, Lu MJ, Siderowf M, Navitsky A. Relationships between cognition and neuropathological Tau in alzheimer&#8217;s disease assessed by 18F flortaucipir PET. JAD. 2021;80:1091&#8211;104.<pub-id pub-id-type="pmid">33682705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200808</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitwell</surname><given-names>JL</given-names></name><name name-style="western"><surname>Graff-Radford</surname><given-names>J</given-names></name><name name-style="western"><surname>Tosakulwong</surname><given-names>N</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>SD</given-names></name><name name-style="western"><surname>Machulda</surname><given-names>MM</given-names></name><name name-style="western"><surname>Senjem</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><year>2018</year><volume>14</volume><fpage>1005</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.020</pub-id><pub-id pub-id-type="pmid">29605222</pub-id><pub-id pub-id-type="pmcid">PMC6097955</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda MM, Senjem ML, et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical alzheimer&#8217;s disease. Alzheimer&#8217;s Dement. 2018;14:1005&#8211;14.<pub-id pub-id-type="pmid">29605222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.020</pub-id><pub-id pub-id-type="pmcid">PMC6097955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Josephs</surname><given-names>KA</given-names></name><name name-style="western"><surname>Tosakulwong</surname><given-names>N</given-names></name><name name-style="western"><surname>Graff-Radford</surname><given-names>J</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>SD</given-names></name><name name-style="western"><surname>Buciuc</surname><given-names>M</given-names></name><name name-style="western"><surname>Machulda</surname><given-names>MM</given-names></name><etal/></person-group><article-title>MRI and flortaucipir relationships in alzheimer&#8217;s phenotypes are heterogeneous</article-title><source>Ann Clin Transl Neurol</source><year>2020</year><volume>7</volume><fpage>707</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/acn3.51038</pub-id><pub-id pub-id-type="pmid">32293805</pub-id><pub-id pub-id-type="pmcid">PMC7261766</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Josephs KA, Tosakulwong N, Graff-Radford J, Weigand SD, Buciuc M, Machulda MM, et al. MRI and flortaucipir relationships in alzheimer&#8217;s phenotypes are heterogeneous. Ann Clin Transl Neurol. 2020;7:707&#8211;21.<pub-id pub-id-type="pmid">32293805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.51038</pub-id><pub-id pub-id-type="pmcid">PMC7261766</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name><name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N</given-names></name><name name-style="western"><surname>Groot</surname><given-names>C</given-names></name><name name-style="western"><surname>Leuzy</surname><given-names>A</given-names></name><name name-style="western"><surname>Strandberg</surname><given-names>O</given-names></name><etal/></person-group><article-title>Accuracy of Tau positron emission tomography as a prognostic marker in preclinical and prodromal alzheimer disease: A Head-to-Head comparison against amyloid positron emission tomography and magnetic resonance imaging</article-title><source>JAMA Neurol</source><year>2021</year><volume>78</volume><fpage>961</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.1858</pub-id><pub-id pub-id-type="pmid">34180956</pub-id><pub-id pub-id-type="pmcid">PMC8240013</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of Tau positron emission tomography as a prognostic marker in preclinical and prodromal alzheimer disease: A Head-to-Head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961&#8211;71.<pub-id pub-id-type="pmid">34180956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.1858</pub-id><pub-id pub-id-type="pmcid">PMC8240013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA et al. Association of amyloid and Tau with cognition in preclinical alzheimer disease A longitudinal study. 2019;02114:915&#8211;24.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.1424</pub-id><pub-id pub-id-type="pmcid">PMC6547132</pub-id><pub-id pub-id-type="pmid">31157827</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malpetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Kievit</surname><given-names>RA</given-names></name><name name-style="western"><surname>Passamonti</surname><given-names>L</given-names></name><name name-style="western"><surname>Jones</surname><given-names>PS</given-names></name><name name-style="western"><surname>Tsvetanov</surname><given-names>KA</given-names></name><name name-style="western"><surname>Rittman</surname><given-names>T</given-names></name><etal/></person-group><article-title>Microglial activation and Tau burden predict cognitive decline in alzheimer&#8217;s disease</article-title><source>Brain</source><year>2020</year><volume>143</volume><fpage>1588</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1093/brain/awaa088</pub-id><pub-id pub-id-type="pmid">32380523</pub-id><pub-id pub-id-type="pmcid">PMC7241955</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, et al. Microglial activation and Tau burden predict cognitive decline in alzheimer&#8217;s disease. Brain. 2020;143:1588&#8211;602.<pub-id pub-id-type="pmid">32380523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa088</pub-id><pub-id pub-id-type="pmcid">PMC7241955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><name name-style="western"><surname>Reimand</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name><name name-style="western"><surname>Leuzy</surname><given-names>A</given-names></name><name name-style="western"><surname>Strandberg</surname><given-names>O</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tau PET correlates with different alzheimer&#8217;s disease-related features compared to CSF and plasma p&#8208;tau biomarkers</article-title><source>EMBO Mol Med</source><year>2021</year><volume>13</volume><fpage>e14398</fpage><pub-id pub-id-type="doi">10.15252/emmm.202114398</pub-id><pub-id pub-id-type="pmid">34254442</pub-id><pub-id pub-id-type="pmcid">PMC8350902</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different alzheimer&#8217;s disease-related features compared to CSF and plasma p&#8208;tau biomarkers. EMBO Mol Med. 2021;13:e14398.<pub-id pub-id-type="pmid">34254442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202114398</pub-id><pub-id pub-id-type="pmcid">PMC8350902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honig</surname><given-names>LS</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>M</given-names></name><name name-style="western"><surname>Boada</surname><given-names>M</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>R</given-names></name><name name-style="western"><surname>Borrie</surname><given-names>M</given-names></name><etal/></person-group><article-title>Trial of Solanezumab for mild dementia due to alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>321</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1705971</pub-id><pub-id pub-id-type="pmid">29365294</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for mild dementia due to alzheimer&#8217;s disease. N Engl J Med. 2018;378:321&#8211;30.<pub-id pub-id-type="pmid">29365294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1705971</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wessels</surname><given-names>AM</given-names></name><name name-style="western"><surname>Tariot</surname><given-names>PN</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>JA</given-names></name><name name-style="western"><surname>Selzler</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Bragg</surname><given-names>SM</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Efficacy and safety of lanabecestat for treatment of early and mild alzheimer disease</article-title><source>JAMA Neurol</source><year>2020</year><volume>77</volume><fpage>199</fpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2019.3988</pub-id><pub-id pub-id-type="pmid">31764959</pub-id><pub-id pub-id-type="pmcid">PMC6902191</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, et al. Efficacy and safety of lanabecestat for treatment of early and mild alzheimer disease. JAMA Neurol. 2020;77:199.<pub-id pub-id-type="pmid">31764959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.3988</pub-id><pub-id pub-id-type="pmcid">PMC6902191</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pontecorvo</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Arora</surname><given-names>AK</given-names></name><name name-style="western"><surname>Devine</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Galante</surname><given-names>N</given-names></name><name name-style="western"><surname>Siderowf</surname><given-names>A</given-names></name><etal/></person-group><article-title>Quantitation of PET signal as an adjunct to visual interpretation of Florbetapir imaging</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2017</year><volume>44</volume><fpage>825</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s00259-016-3601-4</pub-id><pub-id pub-id-type="pmid">28064343</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Pontecorvo MJ, Arora AK, Devine M, Lu M, Galante N, Siderowf A, et al. Quantitation of PET signal as an adjunct to visual interpretation of Florbetapir imaging. Eur J Nucl Med Mol Imaging. 2017;44:825&#8211;37.<pub-id pub-id-type="pmid">28064343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-016-3601-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Pontecorvo</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Devous</surname><given-names>MD</given-names></name><name name-style="western"><surname>Arora</surname><given-names>AK</given-names></name><name name-style="western"><surname>Galante</surname><given-names>N</given-names></name><name name-style="western"><surname>McGeehan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Aggregated Tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and alzheimer disease: results from 2 phase III clinical trials</article-title><source>JAMA Neurol</source><year>2021</year><volume>78</volume><fpage>445</fpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2020.5505</pub-id><pub-id pub-id-type="pmid">33587110</pub-id><pub-id pub-id-type="pmcid">PMC7885097</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lu M, Pontecorvo MJ, Devous MD, Arora AK, Galante N, McGeehan A, et al. Aggregated Tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and alzheimer disease: results from 2 phase III clinical trials. JAMA Neurol. 2021;78:445.<pub-id pub-id-type="pmid">33587110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2020.5505</pub-id><pub-id pub-id-type="pmcid">PMC7885097</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schermelleh-Engel</surname><given-names>K</given-names></name><name name-style="western"><surname>Moosbrugger</surname><given-names>H</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>H</given-names></name></person-group><article-title>Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures</article-title><source>Methods Psychol Res Online</source><year>2003</year><volume>May 25</volume><fpage>23</fpage><lpage>74</lpage></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Schermelleh-Engel K, Moosbrugger H, M&#252;ller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures. Methods Psychol Res Online. 2003;25:23&#8211;74.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of Tau PET, amyloid PET, and hippocampal volume on cognition in alzheimer disease. Neurology. 2018;91.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000006075</pub-id><pub-id pub-id-type="pmcid">PMC6133625</pub-id><pub-id pub-id-type="pmid">30068637</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagarde</surname><given-names>J</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>P</given-names></name><name name-style="western"><surname>Tonietto</surname><given-names>M</given-names></name><name name-style="western"><surname>Tissot</surname><given-names>C</given-names></name><name name-style="western"><surname>Rivals</surname><given-names>I</given-names></name><name name-style="western"><surname>Gervais</surname><given-names>P</given-names></name><etal/></person-group><article-title>Tau-PET imaging predicts cognitive decline and brain atrophy progression in early alzheimer&#8217;s disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2022</year><volume>93</volume><fpage>459</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2021-328623</pub-id><pub-id pub-id-type="pmid">35228270</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Lagarde J, Olivieri P, Tonietto M, Tissot C, Rivals I, Gervais P, et al. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early alzheimer&#8217;s disease. J Neurol Neurosurg Psychiatry. 2022;93:459&#8211;67.<pub-id pub-id-type="pmid">35228270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2021-328623</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Digma</surname><given-names>LA</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>JR</given-names></name><name name-style="western"><surname>Reas</surname><given-names>ET</given-names></name><name name-style="western"><surname>Dale</surname><given-names>AM</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>JB</given-names></name><name name-style="western"><surname>Banks</surname><given-names>SJ</given-names></name></person-group><article-title>Tau and atrophy: domain-specific relationships with cognition</article-title><source>Alzheimer&#8217;s Res Therapy</source><year>2019</year><volume>11</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/s13195-019-0518-8</pub-id><pub-id pub-id-type="pmcid">PMC6661099</pub-id><pub-id pub-id-type="pmid">31351484</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Digma LA, Madsen JR, Reas ET, Dale AM, Brewer JB, Banks SJ. Tau and atrophy: domain-specific relationships with cognition. Alzheimer&#8217;s Res Therapy. 2019;11:65.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-019-0518-8</pub-id><pub-id pub-id-type="pmcid">PMC6661099</pub-id><pub-id pub-id-type="pmid">31351484</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biel</surname><given-names>D</given-names></name><name name-style="western"><surname>Luan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>M</given-names></name><name name-style="western"><surname>Hager</surname><given-names>P</given-names></name><name name-style="western"><surname>Dewenter</surname><given-names>A</given-names></name><name name-style="western"><surname>Moscoso</surname><given-names>A</given-names></name><etal/></person-group><article-title>Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Res Therapy</source><year>2022</year><volume>14</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01105-5</pub-id><pub-id pub-id-type="pmcid">PMC9639286</pub-id><pub-id pub-id-type="pmid">36345046</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Biel D, Luan Y, Brendel M, Hager P, Dewenter A, Moscoso A, et al. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in alzheimer&#8217;s disease. Alzheimer&#8217;s Res Therapy. 2022;14:1&#8211;12.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01105-5</pub-id><pub-id pub-id-type="pmcid">PMC9639286</pub-id><pub-id pub-id-type="pmid">36345046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><etal/></person-group><article-title>The heterogeneity of asymmetric Tau distribution is associated with an early age at onset and poor prognosis in alzheimer&#8217;s disease</article-title><source>NeuroImage: Clin</source><year>2023</year><volume>38</volume><fpage>103416</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2023.103416</pub-id><pub-id pub-id-type="pmid">37137254</pub-id><pub-id pub-id-type="pmcid">PMC10176076</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lu J, Zhang Z, Wu P, Liang X, Zhang H, Hong J, et al. The heterogeneity of asymmetric Tau distribution is associated with an early age at onset and poor prognosis in alzheimer&#8217;s disease. NeuroImage: Clin. 2023;38:103416.<pub-id pub-id-type="pmid">37137254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2023.103416</pub-id><pub-id pub-id-type="pmcid">PMC10176076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Anij&#228;rv TE, Ossenkoppele R, Smith R, Binette AP, Collij LE, Behjat HH et al. Hemispheric Asymmetry of Tau Pathology is Related to Asymmetric Amyloid Deposition in Alzheimer&#8217;s Disease. Neuroscience; 2025 [cited 2025 Jun 18]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://biorxiv.org/lookup/doi/">http://biorxiv.org/lookup/doi/</ext-link>10.1101/2025.04.15.648728<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-63564-2</pub-id><pub-id pub-id-type="pmcid">PMC12413461</pub-id><pub-id pub-id-type="pmid">40913038</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malpetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Joie</surname><given-names>RL</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></name></person-group><article-title>Tau beats amyloid in predicting brain atrophy in alzheimer disease: implications for prognosis and clinical trials</article-title><source>J Nucl Med</source><year>2022</year><volume>63</volume><fpage>830</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.2967/jnumed.121.263694</pub-id><pub-id pub-id-type="pmid">35649659</pub-id><pub-id pub-id-type="pmcid">PMC9157718</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Malpetti M, Joie RL, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in alzheimer disease: implications for prognosis and clinical trials. J Nucl Med. 2022;63:830&#8211;2.<pub-id pub-id-type="pmid">35649659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.121.263694</pub-id><pub-id pub-id-type="pmcid">PMC9157718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>TM</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R</given-names></name><name name-style="western"><surname>Maass</surname><given-names>A</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SL</given-names></name><name name-style="western"><surname>Swinnerton</surname><given-names>K</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>L</given-names></name><etal/></person-group><article-title>Longitudinal Tau accumulation and atrophy in aging and alzheimer disease</article-title><source>Ann Neurol</source><year>2019</year><volume>85</volume><fpage>229</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/ana.25406</pub-id><pub-id pub-id-type="pmid">30597624</pub-id><pub-id pub-id-type="pmcid">PMC6579738</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, et al. Longitudinal Tau accumulation and atrophy in aging and alzheimer disease. Ann Neurol. 2019;85:229&#8211;40.<pub-id pub-id-type="pmid">30597624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25406</pub-id><pub-id pub-id-type="pmcid">PMC6579738</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Joie</surname><given-names>R</given-names></name><name name-style="western"><surname>Visani</surname><given-names>AV</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SL</given-names></name><name name-style="western"><surname>Brown</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bourakova</surname><given-names>V</given-names></name><name name-style="western"><surname>Cha</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prospective longitudinal atrophy in alzheimer&#8217;s disease correlates with the intensity and topography of baseline tau-PET</article-title><source>Sci Transl Med</source><year>2020</year><volume>12</volume><fpage>5732</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aau5732</pub-id><pub-id pub-id-type="pmcid">PMC7035952</pub-id><pub-id pub-id-type="pmid">31894103</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in alzheimer&#8217;s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12:5732.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aau5732</pub-id><pub-id pub-id-type="pmcid">PMC7035952</pub-id><pub-id pub-id-type="pmid">31894103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Scott MR, Hampton OL, Buckley RF, Chhatwal JP, Hanseeuw BJ, Jacobs HIL et al. Inferior Temporal Tau is associated with accelerated prospective cortical thinning in clinically normal older adults. NeuroImage. 2020;220.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2020.116991</pub-id><pub-id pub-id-type="pmcid">PMC7572623</pub-id><pub-id pub-id-type="pmid">32512123</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaPoint</surname><given-names>MR</given-names></name><name name-style="western"><surname>Chhatwal</surname><given-names>JP</given-names></name><name name-style="western"><surname>Sepulcre</surname><given-names>J</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>AP</given-names></name></person-group><article-title>The association between Tau PET and retrospective cortical thinning in clinically normal elderly</article-title><source>NeuroImage</source><year>2017</year><volume>157</volume><fpage>612</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.05.049</pub-id><pub-id pub-id-type="pmid">28545932</pub-id><pub-id pub-id-type="pmcid">PMC5772972</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">LaPoint MR, Chhatwal JP, Sepulcre J, Johnson KA, Sperling RA, Schultz AP. The association between Tau PET and retrospective cortical thinning in clinically normal elderly. NeuroImage. 2017;157:612&#8211;22.<pub-id pub-id-type="pmid">28545932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2017.05.049</pub-id><pub-id pub-id-type="pmcid">PMC5772972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>SR</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Wisse</surname><given-names>LEM</given-names></name><name name-style="western"><surname>Ittyerah</surname><given-names>R</given-names></name><name name-style="western"><surname>Tustison</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake</article-title><source>Neurobiol Aging</source><year>2018</year><volume>66</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.01.024</pub-id><pub-id pub-id-type="pmid">29518752</pub-id><pub-id pub-id-type="pmcid">PMC5924615</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Das SR, Xie L, Wisse LEM, Ittyerah R, Tustison NJ, Dickerson BC, et al. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. Neurobiol Aging. 2018;66:49&#8211;58.<pub-id pub-id-type="pmid">29518752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2018.01.024</pub-id><pub-id pub-id-type="pmcid">PMC5924615</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malpetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>PS</given-names></name><name name-style="western"><surname>Tsvetanov</surname><given-names>KA</given-names></name><name name-style="western"><surname>Rittman</surname><given-names>T</given-names></name><name name-style="western"><surname>Swieten</surname><given-names>JC</given-names></name><name name-style="western"><surname>Borroni</surname><given-names>B</given-names></name><etal/></person-group><article-title>Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes</article-title><source>Alzheimer&#8217;s Dement</source><year>2021</year><volume>17</volume><fpage>969</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1002/alz.12252</pub-id><pub-id pub-id-type="pmid">33316852</pub-id><pub-id pub-id-type="pmcid">PMC8247340</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Malpetti M, Jones PS, Tsvetanov KA, Rittman T, Swieten JC, Borroni B, et al. Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer&#8217;s Dement. 2021;17:969&#8211;83.<pub-id pub-id-type="pmid">33316852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12252</pub-id><pub-id pub-id-type="pmcid">PMC8247340</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Clare L, Gamble LD, Martyr A, Sabatini S, Nelis SM, Quinn C et al. Longitudinal Trajectories of Quality of Life Among People With Mild-to-Moderate Dementia: A Latent Growth Model Approach With IDEAL Cohort Study Data. Isaacowitz DM, editor. The Journals of Gerontology: Series B. 2022;77:1037&#8211;50.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geronb/gbac022</pub-id><pub-id pub-id-type="pmcid">PMC9159063</pub-id><pub-id pub-id-type="pmid">35134935</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liew</surname><given-names>TM</given-names></name></person-group><article-title>Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia</article-title><source>Alzheimer&#8217;s Res Therapy</source><year>2020</year><volume>12</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1186/s13195-020-00699-y</pub-id><pub-id pub-id-type="pmcid">PMC7592368</pub-id><pub-id pub-id-type="pmid">33109275</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Liew TM. Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia. Alzheimer&#8217;s Res Therapy. 2020;12:135.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00699-y</pub-id><pub-id pub-id-type="pmcid">PMC7592368</pub-id><pub-id pub-id-type="pmid">33109275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duncan</surname><given-names>TE</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>SC</given-names></name></person-group><article-title>The abc&#8217;s of LGM: an introductory guide to latent variable growth curve modeling</article-title><source>Soc Pers Psychol Compass</source><year>2009</year><volume>3</volume><fpage>979</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/j.1751-9004.2009.00224.x</pub-id><pub-id pub-id-type="pmcid">PMC2888524</pub-id><pub-id pub-id-type="pmid">20577582</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Duncan TE, Duncan SC. The abc&#8217;s of LGM: an introductory guide to latent variable growth curve modeling. Soc Pers Psychol Compass. 2009;3:979&#8211;91.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1751-9004.2009.00224.x</pub-id><pub-id pub-id-type="pmcid">PMC2888524</pub-id><pub-id pub-id-type="pmid">20577582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Gleason CE, Zuelsdorff M, Gooding DC, Kind AJH, Johnson AL, James TT, et al. Alzheimer&#8217;s disease biomarkers in black and non-Hispanic white cohorts: A contextualized review of the evidence. Alzheimer&#8217;s &amp; Dementia; 2021.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12511</pub-id><pub-id pub-id-type="pmcid">PMC9543531</pub-id><pub-id pub-id-type="pmid">34870885</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><name name-style="western"><surname>Lyoo</surname><given-names>CH</given-names></name><name name-style="western"><surname>Jester-Broms</surname><given-names>J</given-names></name><name name-style="western"><surname>Sudre</surname><given-names>CH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological Tau in patients with alzheimer disease</article-title><source>JAMA Neurol</source><year>2020</year><volume>77</volume><fpage>632</fpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2019.5154</pub-id><pub-id pub-id-type="pmid">32091549</pub-id><pub-id pub-id-type="pmcid">PMC7042808</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu YH, et al. Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological Tau in patients with alzheimer disease. JAMA Neurol. 2020;77:632.<pub-id pub-id-type="pmid">32091549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.5154</pub-id><pub-id pub-id-type="pmcid">PMC7042808</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501345</article-id><article-id pub-id-type="pmcid-ver">PMC12501345.1</article-id><article-id pub-id-type="pmcaid">12501345</article-id><article-id pub-id-type="pmcaiid">12501345</article-id><article-id pub-id-type="pmid">40897577</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100332</article-id><article-id pub-id-type="pii">S2274-5807(25)00275-4</article-id><article-id pub-id-type="publisher-id">100332</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Preclinical detection of Alzheimer&#8217;s disease pathology using conceptual discrimination abilities</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Huyghe</surname><given-names initials="L">Lara</given-names></name><email>lara.huyghe@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Salman</surname><given-names initials="Y">Yasmine</given-names></name><email>yasmine.salman@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Colmant</surname><given-names initials="L">Lise</given-names></name><email>lise.colmant@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>G&#233;rard</surname><given-names initials="T">Thomas</given-names></name><email>thomas.gerard@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Malotaux</surname><given-names initials="V">Vincent</given-names></name><email>vincent.malotaux@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Besson</surname><given-names initials="G">Gabriel</given-names></name><email>gabriel.besson@gmail.com</email><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Delhaye</surname><given-names initials="E">Emma</given-names></name><email>emma.delhaye@uliege.be</email><xref rid="aff0005" ref-type="aff">e</xref><xref rid="aff0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0008"><name name-style="western"><surname>Bastin</surname><given-names initials="C">Christine</given-names></name><email>christine.bastin@uliege.be</email><xref rid="aff0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0009"><name name-style="western"><surname>Dessain</surname><given-names initials="Q">Quentin</given-names></name><email>quentin.dessain@uclouvain.be</email><xref rid="aff0007" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Dricot</surname><given-names initials="L">Laurence</given-names></name><email>laurence.dricot@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0011"><name name-style="western"><surname>Lhommel</surname><given-names initials="R">Renaud</given-names></name><email>renaud.lhommel@saintluc.uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0012"><name name-style="western"><surname>Ivanoiu</surname><given-names initials="A">Adrian</given-names></name><email>adrian.ivanoiu@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0013"><name name-style="western"><surname>Quenon</surname><given-names initials="L">Lisa</given-names></name><email>lisa.quenon@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0014"><name name-style="western"><surname>Hanseeuw</surname><given-names initials="B">Bernard</given-names></name><email>bernard.hanseeuw@uclouvain.be</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0008" ref-type="aff">h</xref><xref rid="aff0009" ref-type="aff">i</xref></contrib><aff id="aff0001"><label>a</label>Institute of Neuroscience (IoNS), UCLouvain, Brussels, Belgium</aff><aff id="aff0002"><label>b</label>Neurology Department, Saint-Luc University Hospital, Brussels, Belgium</aff><aff id="aff0003"><label>c</label>Nuclear Medicine Department, Saint-Luc University Hospital, Brussels, Belgium</aff><aff id="aff0004"><label>d</label>Psychiatry Department, Massachusetts General Hospital, Harvard Medical School, Boston, USA</aff><aff id="aff0005"><label>e</label>GIGA-Cyclotron Research Center Human Imaging, University of Li&#232;ge, Belgium</aff><aff id="aff0006"><label>f</label>CICPSI, Faculty of Psychology, University of Lisbon, Portugal</aff><aff id="aff0007"><label>g</label>ICTEAM, UCLouvain, Louvain-La-Neuve, Belgium</aff><aff id="aff0008"><label>h</label>Radiology Department, Massachusetts General Hospital, Harvard Medical School, Boston, USA</aff><aff id="aff0009"><label>i</label>WELBIO department, WEL Research Institute, avenue Pasteur, 6 1300 Wavre, Belgium</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author at: Avenue E. Mounier 53 1200 Brussels, Belgium. <email>lara.huyghe@uclouvain.be</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>9</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100332</elocation-id><history><date date-type="received"><day>17</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0001"><sec><title>Background</title><p>Performance on the Conceptual Matching Task (CMT), a measure of discrimination between conceptually confusable items, has been suggested as a cognitive marker of rhinal cortex atrophy, one of the first brain regions affected by Alzheimer&#8217;s disease (AD) pathology.</p></sec><sec><title>Objectives</title><p>We aimed to determine whether CMT can detect preclinical AD, and whether CMT performance is related to regional deposition of tau protein or other AD-associated lesions including amyloid (A&#946;) accumulation and white matter hyperintensities (WMH).</p></sec><sec><title>Design, setting and participants</title><p>This cross-sectional study include 101 participants from the UCL2016&#8211;121 cohorts in Brussels, Belgium, classified as 56 A&#946;-negative cognitively unimpaired (A&#946;-CU), 25 A&#946;-positive CU (A&#946;+CU, preclinical AD), and 20 A&#946;-positive mildly cognitively impaired (A&#946;+MCI, prodromal AD) individuals.</p></sec><sec><title>Measurements</title><p>Participants underwent CMT and a standard neuropsychological assessment that included the Preclinical Alzheimer Cognitive Composite (PACC5), an A&#946; status examination, a 3D-T1 MRI and a [<sup>18</sup>F]MK-6240 tau-PET scan.</p></sec><sec><title>Results</title><p>CMT performance was lower among A&#946;+MCI and A&#946;+CU than A&#946;-CU individuals. The effect of A&#946; on CMT performance was stronger in the presence of WMH, but rhinal tau burden did not explain CMT performance beyond the effects of A&#946; and WMH. CMT performance correlated with executive, memory, and language performance. Finally, CMT was more sensitive than PACC5 to detect CU individuals with A&#946; or tau pathology.</p></sec><sec><title>Conclusion</title><p>Given that impaired performance is observed earlier in the CMT than in standard neuropsychological tests, this test shows promise as an early diagnostic tool for AD and may offer significant utility in the context of clinical trials.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Preclinical Alzheimer's disease</kwd><kwd>Conceptual discrimination</kwd><kwd>Rhinal cortex</kwd><kwd>Tau</kwd><kwd>Amyloid</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0007">Alzheimer&#8217;s disease (AD) proteinopathies, including amyloid-beta (&#913;&#946;) plaques and tau neurofibrillary tangles [<xref rid="bib0001" ref-type="bibr">1</xref>,<xref rid="bib0002" ref-type="bibr">2</xref>], accumulate years before the onset of cognitive symptoms, defining a silent preclinical phase [<xref rid="bib0003" ref-type="bibr">3</xref>]. The risk of cognitive decline is higher among cognitively unimpaired (CU) individuals with an high A&#946; burden compared with those with low A&#946; levels [<xref rid="bib0004" ref-type="bibr">4</xref>,<xref rid="bib0005" ref-type="bibr">5</xref>]. Moreover, the combined impact of abnormal global A&#946; deposition and tau burden in the medial temporal lobe (A&#946;+Tau+MTL) in CU subjects increases the risk of short-term progression to symptomatic AD six-fold (risk=50 % within 3&#8211;5 years), compared with CU individuals with only a high A&#946; burden (A&#946;+Tau-, risk=8 %) [<xref rid="bib0006" ref-type="bibr">6</xref>]. Therefore, the identification of A&#946;+Tau+CU individuals could facilitate the enrichment of clinical trials with persons at risk for rapid cognitive decline [<xref rid="bib0006" ref-type="bibr">6</xref>]. However, a reliable, easy-to-use, rapid, and cost-effective method to identify AD progression at the preclinical stage remains a major research gap. Positron-emission-tomography (PET) imaging for A&#946; and tau is unsuitable for large-scale population screening due to its cost and invasiveness. On the other hand, cognitive assessments are good candidates for this purpose. However, the standard cognitive tests usually used clinically in Western Europe, were designed to optimally detect cognitive impairment in the prodromal and dementia stages of AD. Therefore, these tests (e.g., the Free and Cued Selective Reminding Test [<xref rid="bib0007" ref-type="bibr">7</xref>] or Verbal Fluency Test [<xref rid="bib0008" ref-type="bibr">8</xref>]) lack the requisite sensitivity to accurately capture the subtle cognitive correlates of the developing tau pathology in its earliest stages [<xref rid="bib0009" ref-type="bibr">9</xref>]. Various studies have attempted to implement new cognitive tasks to detect cognitive disorders earlier than the standard assessment. One the one hand, cognitive composite scores that aggregate standard measures, such as the Preclinical Alzheimer Cognitive Composite (PACC5, [<xref rid="bib0010" ref-type="bibr">10</xref>]), have been proposed as more sensitive instruments to detect early preclinical cognitive decline. However, cross-sectional performance between A&#946;-positive (A&#946;+) and A&#946;-negative (A&#946;-) CU individuals on this metric showed only small effect sizes (AUC between 0.580 and 0.630) [<xref rid="bib0011" ref-type="bibr">11</xref>]. The memory decline observed in AD during the standard neuropsychological assessment is linked primarily to hippocampal pathology [<xref rid="bib0012" ref-type="bibr">12</xref>]. However, deterioration of this region begins during Braak stage II or III whereas other regions such as the trans-entorhinal cortex are affected earlier in disease progression (Braak stage I) [<xref rid="bib0013" ref-type="bibr">13</xref>], which has been parcellated in a PET region-of-interest designated as the rhinal cortex (RC) [<xref rid="bib0014" ref-type="bibr">14</xref>]. One approach to detect subtle cognitive changes in preclinical AD would be to develop cognitive tasks that assess the function of this region [<xref rid="bib0015" ref-type="bibr">15</xref>].</p><p id="para0009">The RC receives inputs from multiple brain areas, establishing this region as a critical node for processing and storing representations of complex perceptual and semantic features [<xref rid="bib0016" ref-type="bibr">16</xref>]. More precisely, the RC has a conjunctive processing function, enabling precise distinctions between highly similar objects with overlapping features [<xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>]. Therefore, this region builds unique representations of objects [<xref rid="bib0019" ref-type="bibr">19</xref>] and is implicated in tasks involving discrimination of confusable objects [<xref rid="bib0020" ref-type="bibr">20</xref>,<xref rid="bib0021" ref-type="bibr">21</xref>]. The ability to discriminate conceptually confusable items can be evaluated with the Conceptual Matching Task (CMT, [<xref rid="bib0021" ref-type="bibr">21</xref>]). CMT performance is impaired in patients with mild AD and correlates with atrophy of the left perirhinal cortex (PrC, including the RC) [<xref rid="bib0022" ref-type="bibr">22</xref>]. However, performance of this task in the preclinical stage and its association with early tau protein deposition have not yet been studied. Nonetheless, these initial results and its brief administration time (maximum = 6 min) suggest its potential to facilitate the diagnosis of preclinical AD. Other studies assessing object memory have already shown, for instance, a difference in performance in SCI (Berron et al., 2022) or in Tau+CU subjects (Maass et al., 2019) compared with controls but those tasks are still waiting for validation in preclinical AD. The rhinal cortex is thought to be specific to the treatment of objects, whereas the processing of scenes and space is thought to be underpinned more by posterior-medial regions, and therefore affected later in the course of the disease (Ranganath et al., 2012; Berron et al., 2018). Apart from these studies, which focused on tasks underpinned by the trans-entorhinal cortex, other studies have looked at learning curves and have shown that these curves are reduced in A&#946;+CU subjects but only after several days of testing [<xref rid="bib0024" ref-type="bibr">[23]</xref>, <xref rid="bib0025" ref-type="bibr">[24]</xref>, <xref rid="bib0026" ref-type="bibr">[25]</xref>]. The absence of cross-sectional differences in these studies questioned the clinical utility of this testing method. Finally, very few studies have been able to demonstrate cross-sectional differences between CU individuals with and without A&#946; pathology [<xref rid="bib0027" ref-type="bibr">[26]</xref>, <xref rid="bib0028" ref-type="bibr">[27]</xref>, <xref rid="bib0029" ref-type="bibr">[28]</xref>, <xref rid="bib0030" ref-type="bibr">[29]</xref>]. In these studies, the effect sizes for predicting A&#946; status are greater than those observed for PACC5 (AUC between 0.63 and 0.77), but sensitivity to tau pathology is generally not assessed while the presence of this pathology is predictive of cognitive decline [<xref rid="bib0006" ref-type="bibr">6</xref>].</p><p id="para0010">The first aim of this study was to determine whether CMT can reveal cognitive decline earlier than the standard neuropsychological tests used in current clinical practice and trials (as early as the preclinical stage). Second, we assessed the association of CMT performance with early tau protein deposition and other AD-associated lesions such as &#913;&#946; deposition or white matter hyperintensities (WMH). Finally, we compared the sensitivities of CMT and standard cognitive assessment to detect the presence of &#913;&#946; and tau pathologies in CU individuals.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Participants</title><p id="para0011">Our study population comprised 112 individuals (aged 52&#8211;86), including 81 CU subjects and 31 patients with mild cognitive impairment (MCI; Mini Mental State Examination [MMSE] &#8805; 23 [<xref rid="bib0031" ref-type="bibr">30</xref>]). MCI patients were recruited at the Memory Clinic of the Cliniques Universitaires Saint-Luc in Brussels, Belgium. CU volunteers were enlisted via other academic studies through mailbox announcements and advertisements in the hospital&#8217;s vicinity. Volunteers were selected from this pool to participate in the current study. Volunteer selection was enriched in carriers of the apolipoprotein &#949;4 allele (<italic toggle="yes">APOE &#949;4</italic>) to match the prevalence of <italic toggle="yes">APOE &#949;4</italic> carriage observed in patients. Recruitment and examinations were conducted between June 2019 and January 2025. Exclusion criteria were focal brain lesions, major depression or other psychiatric diseases, and alcohol or drug abuse. Informed consent was obtained from all participants, adhering to the principles of the Declaration of Helsinki. The Ethical Committee of UCLouvain approved the study (UCL-2016&#8211;121, Date: 13/05/2019; Eudra-CT number: 2018&#8211;0034/73&#8211;94).</p><p id="para0012">All participants underwent the CMT [<xref rid="bib0022" ref-type="bibr">22</xref>], a standard neuropsychological assessment to determine their cognitive status, a [<sup>18</sup>F]MK-6240 Tau-PET scan, a 3D-T1 brain magnetic resonance imaging (MRI), and an assessment of &#913;&#946; status either by PET ([<sup>18</sup>F]Flutemetamol or [<sup>11</sup>C]PiB) or lumbar puncture. CMT was performed within a year relative to the tau-PET scan and the standard cognitive assessment.</p></sec><sec id="sec0004"><label>2.2</label><title>Conceptual matching task</title><p id="para0013">CMT [<xref rid="bib0022" ref-type="bibr">22</xref>] is composed of 120 trials in which a word and a picture are simultaneously presented for a maximum of 3 s on the screen (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>). In our sample, the average completion time was 229 s (min=163, max=320).<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Example of trials of the Conceptual Matching Task (CMT) [</bold><xref rid="bib0021" ref-type="bibr">21</xref><bold>].</bold></p><p>Legend: The participant was instructed to determine whether the word and the picture represented the same concept. The first example illustrates an item from matching trials, the second from the non-match distant trials, and the last one an item from the non-match close trials.</p></caption><alt-text id="alt0001">Fig 1:</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="para0014">In half of the trials, the picture and the word represented the same concept (matching trials), while in the other half, the word and picture did not match the exact same concept, although they belonged to the same superordinate semantic category (non-matching trials). We played on the distance between the concepts (distance condition): half of the non-matching word-picture pairs were very close semantically (close items), while the other half were more distant within the same semantic categories (distant items). Conceptual similarity was computed for each non-matching pair using the cosine between their production frequency vectors extracted from existing feature norms [<xref rid="bib0032" ref-type="bibr">31</xref>,<xref rid="bib0033" ref-type="bibr">32</xref>]. Moreover, each half of the trials utilized either living or non-living pairs (category-domain condition). Conceptual distance did not differ between living and non-living pairs (Living Pairs = 0.34 vs. Non-Living Pairs = 0.35, <italic toggle="yes">t</italic> = &#8722;0.25, df = 118, <italic toggle="yes">p</italic> = .892, see [<xref rid="bib0022" ref-type="bibr">22</xref>] for further details).</p><p id="para0015">Participants were instructed to indicate whether the word and the picture referred to the same concept by pressing either the far-right button on an Eprime Chronos device (on which we added a green label) if both items corresponded to the same concept, or the far-left button (on which we added a red label) otherwise.</p><p id="para0016">We calculated the accuracy score and the mean reaction time for the subset of items known by the participant among the 120 items comprising the task, and in each condition separately (close versus distant items for the distance condition, matching versus non match items for the matching condition and living versus non-living items in the category-domain condition). To assess the total number of known items, participants completed a prior knowledge questionnaire after the CMT. They were asked whether they had sufficient knowledge of each concept to have a mental representation upon reading it by circling &#8220;yes&#8221; or &#8220;no&#8221; next to each item. The total number of known items for each participant was determined by the number of concepts for which they answered &#8220;yes.&#8221; Responses and reaction times to unknown items were not considered. The average total number of known items was 114 words (min=96, max=120, SD= 3.9). The average numbers of known items were similar between groups (<italic toggle="yes">p</italic>=.351) and this variable did not impact CMT performance (<italic toggle="yes">p</italic>=.584).</p><p id="para0017">Each participant&#8217;s mean reaction time was divided by their accuracy score (higher scores indicating poorer efficiency) to compute a Speed-Accuracy Trade-Off (TO) metric. Because TO results were similar to those obtained separately for the accuracy score and the mean reaction time, we only present the TO results in the following sections.</p><p id="para0018">Finally, as in Frick and colleagues&#8217; study [<xref rid="bib0022" ref-type="bibr">22</xref>], we computed an &#8216;&#8216;accuracy sensitivity to conceptual similarity&#8217;&#8217; metric by correlating each participant&#8217;s accuracy to the conceptual distance value on a trial-by-trial level using Pearson correlations and a Fisher transformation to convert each Rho-value into a Z-score [<xref rid="bib0021" ref-type="bibr">21</xref>,<xref rid="bib0022" ref-type="bibr">22</xref>].</p></sec><sec id="sec0005"><label>2.3</label><title>Neuropsychological assessment</title><p id="para0019">The neuropsychological testing evaluated four cognitive domains: [<xref rid="bib0001" ref-type="bibr">1</xref>] verbal episodic memory (Free and Cued Selective Reminding Test, FCSRT, French version [<xref rid="bib0034" ref-type="bibr">33</xref>]), [<xref rid="bib0002" ref-type="bibr">2</xref>] language (Lexis Naming Test, Category and Letter Fluency Test for animals and letter &#8216;P&#8217;, [<xref rid="bib0008" ref-type="bibr">8</xref>]), [<xref rid="bib0003" ref-type="bibr">3</xref>] executive functions (Trail Making Test part A and B [<xref rid="bib0035" ref-type="bibr">34</xref>] and Luria&#8217;s Graphic Sequences [<xref rid="bib0036" ref-type="bibr">35</xref>]), and [<xref rid="bib0004" ref-type="bibr">4</xref>] visuospatial functions (Clock Drawing Test [<xref rid="bib0037" ref-type="bibr">36</xref>] and Praxis part of the CERAD battery [<xref rid="bib0038" ref-type="bibr">37</xref>]). Composite scores (<italic toggle="yes">Z</italic>-scores) were computed based on three measures for each cognitive domain, by referring to an independent sample of 32 A&#946;- individuals who remained globally cognitively stable (as defined by a MMSE &#8805; 26/30) over an 8-year period (data collected in UCL-2010&#8211;412 study, see [<xref rid="bib0039" ref-type="bibr">38</xref>] for more details). Our A&#946;-CN participants had a similar age and MMSE score that the independent sample. A cognitive domain was considered impaired when the corresponding <italic toggle="yes">Z</italic>-score fell below &#8722;1.5 SD. Patients were considered as having MCI if at least one cognitive domain was impaired, and as being CU when all z-scores were above the &#8722;1.5 SD threshold. The average of the Z-scores obtained in each of the four cognitive domains enables us to obtain the global cognitive Z-score.</p><p id="para0020">In addition to others tests mentioned above, volunteers also completed the Digit-Symbol Substitution test (WAIS-IV, [<xref rid="bib0040" ref-type="bibr">39</xref>]) and the Logical Memory test (MEM-III, [<xref rid="bib0041" ref-type="bibr">40</xref>]), allowing to calculate the PACC plus a semantic fluency measure (PACC5) [<xref rid="bib0042" ref-type="bibr">41</xref>]. In the current study, the PACC5 was computed as the average of five z-scores calculated based on the MMSE [0&#8211;30] [<xref rid="bib0043" ref-type="bibr">42</xref>], the Logical Memory Delayed Recall Story A [0&#8211;25] (MEM-III [<xref rid="bib0041" ref-type="bibr">40</xref>],), the Digit-Symbol Substitution Test [0&#8211;135] [<xref rid="bib0040" ref-type="bibr">39</xref>], the sums of free and total recalls from the French-version of the FCSRT [0&#8211;96] [<xref rid="bib0034" ref-type="bibr">33</xref>] and the category fluency (animals, 2 min, [<xref rid="bib0008" ref-type="bibr">8</xref>]). These <italic toggle="yes">Z</italic>-scores were calculated by referring to the performance obtained by all CU individuals (<italic toggle="yes">n</italic> = 81). The PACC5 was not available in MCI patients (because Logical Memory and Digit-Symbol Substitution Test was not administered in this group).</p></sec><sec id="sec0006"><label>2.4</label><title>MRI</title><p id="para0021">Participants underwent three-dimensional (3D) T1-weighted MRI examination at Saint-Luc University Hospital (UCLouvain, Belgium) using a 3 T head scanner (Signa&#8482; Premier; General Electric Company, USA) equipped with a 48-channel coil. 156 slices were acquired using the following parameters: TR = 2188 ms; TE = 2.9 ms; inversion time = 900 ms (MPRAGE), F = 8&#176;; slice thickness = 1 mm; FOV = 256 &#215; 256 mm<sup>2</sup>, acquisition matrix = 256 &#215; 256; acquired voxel size = 1 &#215; 1 &#215; 1 mm<sup>3</sup>. A 3D T2-weighted sequence was also acquired using the same scanner.</p><p id="para0022">Cortical parcellation of structural MRI data including rhinal cortex (RC, 13) parcellation were performed using FreeSurfer (version 7.2). WMH lesion load (mm<sup>3</sup>) was extracted from T1-weighted MRI. WMH was identified by using spatial intensity gradients across tissue classes [<xref rid="bib0044" ref-type="bibr">43</xref>].</p></sec><sec id="sec0007"><label>2.5</label><title>Tau [<sup>18</sup>F]MK-6240 PET</title><p id="para0023">[<sup>18</sup>F]MK-6240 (Lantheus Inc.) is an investigational drug studied as a second-generation cerebral tau tangles imaging agent. Radiosynthesis was performed at KULeuven and shipped to our clinic. Ninety minutes after intravenous administration of [<sup>18</sup>F]MK-6240 (target activity = 185&#177;5 MBq), a 30-min dynamic acquisition was performed on a Philips Vereos digital PET-CT. Images were reconstructed using manufacturer&#8217;s standard reconstruction algorithm (including attenuation, scatter, decay correction, and time-of-flight information). Point spread function (PSF) and 1 mm reslicing were also computed using the manufacturer&#8217;s algorithm to obtain a better resolution recovery.</p><p id="para0024">For all participants, tau-PET images were co-registrated with a 3D-T1 MRI using PetSurfer pipeline, a set of tools within FreeSurfer for end-to-end integrated MRI-PET analysis [<xref rid="bib0045" ref-type="bibr">44</xref>]. Standardized Uptake Value ratio (SUVr) values were extracted for the RC [<xref rid="bib0014" ref-type="bibr">14</xref>] using cerebellum gray matter as reference region. We selected the RC to test whether CMT performance could reflect tauopathy in the very first regions affected in AD.</p></sec><sec id="sec0008"><label>2.6</label><title>Amyloid status</title><p id="para0025">The &#913;&#946; status was determined either by lumbar puncture (<italic toggle="yes">n</italic> = 13) or &#913;&#946; PET-scan using [<sup>18</sup>F]Flutemetamol (Vizamyl&#8482;, GE Healthcare, <italic toggle="yes">n</italic> = 72) or [<sup>11</sup>C] Pittsburg compound B (PIB) (<italic toggle="yes">n</italic> = 26). The &#913;&#946;-PET burden was expressed in the Centiloid scale [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0046" ref-type="bibr">45</xref>]. In cerebral spinal fluid (CSF), measurements of A&#946;42 were conducted using Lumipulse automated assays. Participants were considered amyloid positive (A&#946;+) when Centiloid&gt;20 [<xref rid="bib0047" ref-type="bibr">46</xref>] or CSF A&#946;42 &lt; 437pg/ml [<xref rid="bib0048" ref-type="bibr">47</xref>].</p></sec><sec id="sec0009"><label>2.7</label><title>Bioclinical classification</title><p id="para0026">Based on cognitive and A&#946; statuses, four bioclinical groups were defined as follows: [1] amyloid-negative cognitively unimpaired individuals (A&#946;-CU, <italic toggle="yes">n</italic> = 56); [2] amyloid-positive cognitively unimpaired individuals (A&#946;+CU, <italic toggle="yes">n</italic> = 25); [3] amyloid-positive MCI participants (A&#946;+MCI, <italic toggle="yes">n</italic> = 20) and [4] amyloid-negative MCI participants (A&#946;-MCI, <italic toggle="yes">n</italic> = 11). As this research focused on early AD diagnosis, A&#946;-MCI participants were excluded from the analyses.</p><p id="para0027">Participants were also classified according to the visual read of tau-PET images. Individuals were classified as Tau+ when the Braak stage was rated as being superior to 0 on visual read by the nuclearists (T.G and R.L.). Based on the cognitive and the tau-PET statuses, groups were also defined as follows: Tau-CU (<italic toggle="yes">n</italic> = 66), Tau+CU (<italic toggle="yes">n</italic> = 15), Tau-MCI (<italic toggle="yes">n</italic> = 2) and Tau+MCI (<italic toggle="yes">n</italic> = 18).</p><p id="para0028">Among the 101 analyzed participants, one A&#946;+MCI participant had no available tau-PET data because he moved during the acquisition and was therefore only included in the behavioral analyses.</p></sec><sec id="sec0010"><label>2.8</label><title>Statistical analysis</title><p id="para0029">All analyses were computed using SPSS 29.0.2.0 Statistics for Windows (Armonk, NY: IBM Corp) with two-tailed <italic toggle="yes">p</italic>-values reported. <italic toggle="yes">P</italic>&lt;.05 was considered to be statistically significant. Data were tested for normality using Shapiro-Wilk test (data not shown). All analyses reported were corrected for the effect of age, sex and education.</p><p id="para0030">CMT performance was compared across bioclinical groups using parametric or non-parametric ANOVA&#8217;s, with post-hoc multiple comparisons tests adjusted using Bonferroni correction (<italic toggle="yes">n</italic> = 101). Second, linear mixed-effects regression was conducted with the bioclinical group as the between-subject factor and conceptual distance (close vs distant items) or the category-domain (living vs non-living items) as the within-subject factor (<italic toggle="yes">n</italic> = 101). Third, we realized multiple linear regression models to test whether tau burden in the RC predicted the CMT performance, first over the entire sample (<italic toggle="yes">n</italic> = 100) and then in CU participants only (A&#946;-CU and A&#946;+CU, <italic toggle="yes">n</italic> = 81). In addition to age, gender and education, these models were corrected for cognitive status and for the time between CMT and tau-PET scan. The A&#946; burden (as measured by PET and expressed in Centiloid) and WMH were introduced as covariates in separate models. Subjects who only underwent a lumbar puncture were therefore excluded from this analysis (<italic toggle="yes">n</italic> = 87 for the entire sample and <italic toggle="yes">n</italic> = 78 for CU sub-analysis). Fourth, mixed-effect models were used to determine whether the effect of RC tau burden on CMT performance varied by conditions (<italic toggle="yes">n</italic> = 100). Fifth, we performed partial correlations between CMT performance and cognitive composite z-scores in the entire sample (adjusted for the effect of age, sex, education and time between these examinations, <italic toggle="yes">n</italic> = 101). These correlations were corrected for multiple comparisons using Bonferroni correction. Then, we ran a linear regression model with all cognitive z-scores included as predictors to assess their independent contribution to CMT performance (<italic toggle="yes">n</italic> = 101). Finally, we computed ROC curve analyses to compare the sensitivity and the specificity of the CMT compared with PACC5, in the discrimination of A&#946;+CU (<italic toggle="yes">n</italic> = 56) from A&#946;-CU (<italic toggle="yes">n</italic> = 25) and Tau+CU (<italic toggle="yes">n</italic> = 66) from Tau-CU (<italic toggle="yes">n</italic> = 15) and we calculated whether the difference in AUC between these tests was significant using De Long test.</p></sec></sec><sec id="sec0011"><label>3</label><title>Results</title><sec id="sec0012"><label>3.1</label><title>Characteristics of participants</title><p id="para0031">The 101 participants included 56 A&#946;-CU (55.5 %), 25 A&#946;+CU (24.7 %) and 20 A&#946;+MCI (19.8 %) individuals. Groups did not differ in education (<italic toggle="yes">p</italic>=.315) or sex (<italic toggle="yes">p</italic>=.767; see <xref rid="tbl0001" ref-type="table">Table 1</xref>), but age was younger in A&#946;-CU than A&#946;+CU subjects (<italic toggle="yes">p</italic>=.017). MMSE and global cognitive composite scores were similar between A&#946;+CU and A&#946;-CU groups (<italic toggle="yes">p</italic>=.456 and <italic toggle="yes">p</italic>=.181, respectively), but PACC5 scores were worse in the A&#946;+CU than in the A&#946;-CU group (<italic toggle="yes">p</italic>=.019). As expected, global cognitive composite scores were worse in the A&#946;+MCI than both CU groups (all <italic toggle="yes">p</italic>&lt;.01). Centiloid values and RC tau burden were higher in the A&#946;+CU compared to the A&#946;-CU group (all <italic toggle="yes">p</italic>&lt;.001), while A&#946;+MCI patients exhibited higher centiloid values, WMH load, and RC tau burden than A&#946;-CU subjects (all <italic toggle="yes">p</italic>&lt;.05).<table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Demographic characteristics and biomarkers values.</p></caption><alt-text id="alt0005">Table 1:</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">A&#946;-CU (<italic toggle="yes">n</italic> = 56)</th><th valign="top" colspan="1" rowspan="1">A&#946;+CU (<italic toggle="yes">n</italic> = 25)</th><th valign="top" colspan="1" rowspan="1">A&#946;+MCI (<italic toggle="yes">n</italic> = 20)</th><th valign="top" colspan="1" rowspan="1">p-val</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Age &#8211; mean (SD)</td><td valign="top" colspan="1" rowspan="1">68.00 (7.91)</td><td valign="top" colspan="1" rowspan="1">72.83 (7.13) *</td><td valign="top" colspan="1" rowspan="1">71.41 (8.08)</td><td valign="top" colspan="1" rowspan="1">.016</td></tr><tr><td valign="top" colspan="1" rowspan="1">Education years &#8211; mean (SD)</td><td valign="top" colspan="1" rowspan="1">17.41 (2.82)</td><td valign="top" colspan="1" rowspan="1">16.92 (3.18)</td><td valign="top" colspan="1" rowspan="1">16.10 (4.60)</td><td valign="top" colspan="1" rowspan="1">.315</td></tr><tr><td valign="top" colspan="1" rowspan="1">Sex - % of women</td><td valign="top" colspan="1" rowspan="1">53 %</td><td valign="top" colspan="1" rowspan="1">54 %</td><td valign="top" colspan="1" rowspan="1">50 %</td><td valign="top" colspan="1" rowspan="1">.767</td></tr><tr><td valign="top" colspan="1" rowspan="1">APOE &#949;4 carriers &#8211; n ( %)</td><td valign="top" colspan="1" rowspan="1">25 (45.5 %)</td><td valign="top" colspan="1" rowspan="1">19 (76 %)</td><td valign="top" colspan="1" rowspan="1">9 (45 %)</td><td valign="top" colspan="1" rowspan="1">0.140</td></tr><tr><td valign="top" colspan="1" rowspan="1">MMSE - mean (SD)</td><td valign="top" colspan="1" rowspan="1">29.11 (0.88)</td><td valign="top" colspan="1" rowspan="1">28.75 (0.89)</td><td valign="top" colspan="1" rowspan="1">26.33 (1.88) <sup>*, **</sup></td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">PACC5 - mean (SD)</td><td valign="top" colspan="1" rowspan="1">0.11 (0.45)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.19 (0.49) *</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">.019</td></tr><tr><td valign="top" colspan="1" rowspan="1">Global cognitive z-score - mean (SD)</td><td valign="top" colspan="1" rowspan="1">0.17 (0.37)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.05 (0.42)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.25 (0.73) <sup>*, **</sup></td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">A&#946; method &#8211; CSF/PET (n)</td><td valign="top" colspan="1" rowspan="1">1/55</td><td valign="top" colspan="1" rowspan="1">2/23</td><td valign="top" colspan="1" rowspan="1">10/10</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1">Centiloid &#8211; mean (SD)</td><td valign="top" colspan="1" rowspan="1">6.05 (7.07)</td><td valign="top" colspan="1" rowspan="1">52.47 (28.27) *</td><td valign="top" colspan="1" rowspan="1">71.39 (29.36) *</td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">Tau rhinal SUVr - mean (SD)</td><td valign="top" colspan="1" rowspan="1">0.91 (0.12)</td><td valign="top" colspan="1" rowspan="1">1.17 (0.34) *</td><td valign="top" colspan="1" rowspan="1">1.81 (0.82) *</td><td valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">WMH &#8211; mean (SD)</td><td valign="top" colspan="1" rowspan="1">2423.80 (2204.99)</td><td valign="top" colspan="1" rowspan="1">3877.0 (4213.43)</td><td valign="top" colspan="1" rowspan="1">5139.92 (7324.62) *</td><td valign="top" colspan="1" rowspan="1">.017</td></tr></tbody></table><table-wrap-foot><fn><p><underline>Legend</underline>: SD= standard deviation; CU = cognitively unimpaired; MCI = mild cognitive impairment; A&#946; = amyloid-&#946;; CSF = cerebrospinal fluid; SUVr = standard uptake value ratio; WMH = white-matter hyperintensities volume (mm&#179;); * = significantly different from A&#946;- CU, ** = significantly different from A&#946;+CU.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0013"><label>3.2</label><title>Group differences in CMT performance</title><p id="para0032">A&#946;+CU participants performed worse (higher TO) than A&#946;-CU subjects over the entire task (<italic toggle="yes">p</italic>=.044, &#951;&#178;<italic toggle="yes">p</italic>=.054), in matching (<italic toggle="yes">p</italic>=.048, &#951;&#178;<italic toggle="yes">p</italic>=.052), and in non-living conditions (<italic toggle="yes">p</italic>=.035, &#951;&#178;<italic toggle="yes">p</italic>=.057). Performance was similar between those two groups in non-match (<italic toggle="yes">p</italic>=.138, &#951;&#178;<italic toggle="yes">p</italic>=.025), distant (<italic toggle="yes">p</italic>=.066, &#951;&#178;<italic toggle="yes">p</italic>=.024), close (<italic toggle="yes">p</italic>=.347, &#951;&#178;<italic toggle="yes">p</italic>=.023) or living (<italic toggle="yes">p</italic>=.133, &#951;&#178;<italic toggle="yes">p</italic>=.024) conditions. TO was worse in the A&#946;+MCI compared to the A&#946;-CU group in all conditions (all <italic toggle="yes">p</italic>&lt;.01) but similar between the A&#946;+MCI and A&#946;+CU groups (all <italic toggle="yes">p</italic>&gt;.05) (<xref rid="fig0002" ref-type="fig">Fig. 2A</xref>).<fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Boxplots of CMT performance in each group according to condition.</bold></p><p>Legend: A. Boxplots of CMT performance according to amyloid and cognitive status. B. Boxplots of CMT performance according to tau and cognitive status. In this analysis, we grouped Tau-MCI and Tau+MCI because of the small number of participants in the first subgroup (<italic toggle="yes">n</italic> = 2). All comparisons were corrected for the effect of age, sex and education.</p><p>TO= Trade-Off (higher score reflects poorer performance); A&#946; = amyloid; CU = cognitively unimpaired participants; MCI = mild cognitive impaired; *: <italic toggle="yes">p</italic>&lt;.05, **: <italic toggle="yes">p</italic>&lt;.01.</p></caption><alt-text id="alt0002">Fig 2:</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="para0033">After stratification by tau and cognitive statuses, performance did not differ between Tau+CU and MCI patients or between Tau-CU and Tau+CU in any CMT conditions (all <italic toggle="yes">p</italic>&gt;.05). However, MCI patients performed worse than Tau-CU subjects in all conditions (all <italic toggle="yes">p</italic>&lt;.05) (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>B). In this analysis, we combined Tau-MCI (<italic toggle="yes">n</italic> = 2) and Tau+MCI (<italic toggle="yes">n</italic> = 18) groups because of the small sample size of the first group. Excluding Tau-MCI subjects did not change the results.</p><p id="para0035">No intergroup differences in performance were observed when considering the accuracy sensitivity to similarity score (all <italic toggle="yes">p</italic>&gt;.100, Supplementary Material S1).</p></sec><sec id="sec0014"><label>3.3</label><title>Distance and domain effect</title><p id="para0036">To test the performance differences across the three groups according to A&#946; and cognitive status, distance conditions (distant vs close items), and category domains (living vs non-living items), we performed a 3 (group) x 2 (distance) x 2 (domain) ANOVA. This analysis revealed a distance effect (F(1,97)=59.59, <italic toggle="yes">p</italic>&lt;.001, &#951;&#178;<italic toggle="yes">p</italic>=.381) driven by a worse TO for close items; a domain effect (F(1,97)=23.97, <italic toggle="yes">p</italic>&lt;.001, &#951;&#178;<italic toggle="yes">p</italic>=.198) highlighting a better performance for living items; as well as a group effect (F(2,97)=7.71, <italic toggle="yes">p</italic>&lt;.001, &#951;&#178;<italic toggle="yes">p</italic>=.137) with worse performance in the MCI group. The analyses also revealed an interaction between distance and group (F(2,93)=4.74, <italic toggle="yes">p</italic>=.011, &#951;&#178;<italic toggle="yes">p</italic>=.079). Post-Hoc tests revealed a larger drop in performance in MCI patients compared to CU subjects for both distant and close items (all <italic toggle="yes">p</italic>&lt;.05), but this difference was even more pronounced for close items (<italic toggle="yes">B</italic> = &#8722;11.43, <italic toggle="yes">p</italic> &lt; 0.001, &#951;&#178;<italic toggle="yes">p</italic>=.141 and <italic toggle="yes">B</italic> = &#8722;8,09, <italic toggle="yes">p</italic>=.016, &#951;&#178;<italic toggle="yes">p</italic>=.059 for A&#946;-CU and A&#946;+CU, respectively) than for distant items (<italic toggle="yes">B</italic> = &#8722;4,68, <italic toggle="yes">p</italic> &lt; .001, &#951;&#178;<italic toggle="yes">p</italic> = .191 and <italic toggle="yes">B</italic> = &#8722;2,27, <italic toggle="yes">p</italic>=.046, &#951;&#178;<italic toggle="yes">p</italic> = .040 for A&#946;-CU and A&#946;+CU, respectively). Finally, there were no interactions between group and domain, domain and distance, or between domain, distance, and group (all <italic toggle="yes">p</italic>&gt;.170).</p></sec><sec id="sec0015"><label>3.4</label><title>Association between CMT performance and rhinal tau burden</title><p id="para0037">CMT performance was significantly associated with RC tau burden, in the model adjusted for age, sex, education and delay between CMT and tau-PET (<xref rid="tbl0002" ref-type="table">Table 2</xref>, Model 1, left side). This relationship did not survive when including cognitive status as a covariate (<xref rid="tbl0002" ref-type="table">Table 2</xref>, Model 2, left side). However, an interaction was observed between RC tau burden and cognitive status (<xref rid="tbl0002" ref-type="table">Table 2</xref>, Model 2, left side): RC tau burden had a higher predictive value of the CMT TO in CU subjects (<italic toggle="yes">B</italic> = 3.35 <italic toggle="yes">p</italic>=.028, &#951;&#178;<italic toggle="yes">p</italic>=.064) than in MCI participants (&#946;=&#8722;0.91 <italic toggle="yes">p</italic>=.601, &#951;&#178;<italic toggle="yes">p</italic>=.020). No interaction was found between RC tau and distance (F(1,94)=0.318, <italic toggle="yes">p</italic>=.574, &#951;&#178;<italic toggle="yes">p</italic>=.003) or category-domain (F(1,94)=0.329, <italic toggle="yes">p</italic>=.568, &#951;&#178;<italic toggle="yes">p</italic>=.003). There was no effect of the delay between CMT and tau-PET (<italic toggle="yes">B</italic>=&#8722;0.01 <italic toggle="yes">p</italic>=.169, &#951;&#178;<italic toggle="yes">p</italic>=.020) on performance nor between CMT and <italic toggle="yes">APOE</italic> status (all <italic toggle="yes">p</italic>&gt;.730). However, the accuracy sensitivity to similarity score was not explained by RC tau burden (<italic toggle="yes">B</italic>=&#8722;0.01 <italic toggle="yes">p</italic>=.758, &#951;&#178;<italic toggle="yes">p</italic>=.001, <bold>Supplementary Material S2, Model 1 and 2</bold>).<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Regression linear models explaining CMT performance.</p></caption><alt-text id="alt0006">Table 2:</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="4" align="center" valign="top" rowspan="1">Trade-off<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">&#946; (SE)</th><th valign="top" colspan="1" rowspan="1">p-val (&#951;&#178;p)</th><th valign="top" colspan="1" rowspan="1">&#946; (SE)</th><th valign="top" colspan="1" rowspan="1">p-val (&#951;&#178;p)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Model 1</td><td colspan="2" align="center" valign="top" rowspan="1"><italic toggle="yes">Entire sample (n</italic><italic toggle="yes">=</italic><italic toggle="yes">100)</italic><hr/></td><td colspan="2" align="center" valign="top" rowspan="1"><italic toggle="yes">CU only (n</italic><italic toggle="yes">=</italic><italic toggle="yes">81)</italic><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Intercept</td><td valign="top" colspan="1" rowspan="1">3.00 (3.89)</td><td valign="top" colspan="1" rowspan="1">.443 (0.006)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.85 (3.83)</td><td valign="top" colspan="1" rowspan="1">.825 (0.001)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;RC Tau (SUVr)</td><td valign="top" colspan="1" rowspan="1">1.53 (0.72)</td><td valign="top" colspan="1" rowspan="1">.037 (0.046)</td><td valign="top" colspan="1" rowspan="1">3.76 (1.51)</td><td valign="top" colspan="1" rowspan="1">.015 (0.078)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Age (y)</td><td valign="top" colspan="1" rowspan="1">.14 (0.05)</td><td valign="top" colspan="1" rowspan="1">.003 (0.091)</td><td valign="top" colspan="1" rowspan="1">.13 (0.04)</td><td valign="top" colspan="1" rowspan="1">.004 (0.108)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Education (y)</td><td valign="top" colspan="1" rowspan="1">.05 (0.12)</td><td valign="top" colspan="1" rowspan="1">.671 (0.002)</td><td valign="top" colspan="1" rowspan="1">.14 (0.12)</td><td valign="top" colspan="1" rowspan="1">.263 (0.017)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Sex</td><td valign="top" colspan="1" rowspan="1">&#8722;0.67 (0.76)</td><td valign="top" colspan="1" rowspan="1">.375 (0.009)</td><td valign="top" colspan="1" rowspan="1">.23 (0.68)</td><td valign="top" colspan="1" rowspan="1">.731 (0.002)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Delay between CMT and tau-PET</td><td valign="top" colspan="1" rowspan="1">.00 (0.00)</td><td valign="top" colspan="1" rowspan="1">.639 (0.002)</td><td valign="top" colspan="1" rowspan="1">.00 (0.00)</td><td valign="top" colspan="1" rowspan="1">.172 (0.025)</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Model 2</bold></td><td colspan="2" align="center" valign="top" rowspan="1"><italic toggle="yes">Entire sample (n</italic><italic toggle="yes">=</italic><italic toggle="yes">100)</italic></td><td colspan="2" align="center" valign="top" rowspan="1"><italic toggle="yes">CU only (n</italic><italic toggle="yes">=</italic><italic toggle="yes">81)</italic></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Intercept</td><td valign="top" colspan="1" rowspan="1">9.19 (3.93)</td><td valign="top" colspan="1" rowspan="1">.021 (0.057)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.85 (3.83)</td><td valign="top" colspan="1" rowspan="1">.825 (0.001)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;RC Tau (SUVr)</td><td valign="top" colspan="1" rowspan="1">&#8722;1.35 (0.98)</td><td valign="top" colspan="1" rowspan="1">.171 (0.021)</td><td valign="top" colspan="1" rowspan="1">3.76 (1.51)</td><td valign="top" colspan="1" rowspan="1">.015 (0.078)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Age (y)</td><td valign="top" colspan="1" rowspan="1">.13 (0.04)</td><td valign="top" colspan="1" rowspan="1">.004 (0.090)</td><td valign="top" colspan="1" rowspan="1">.13 (0.04)</td><td valign="top" colspan="1" rowspan="1">.004 (0.108)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Education (y)</td><td valign="top" colspan="1" rowspan="1">.12 (0.11)</td><td valign="top" colspan="1" rowspan="1">.271 (0.013)</td><td valign="top" colspan="1" rowspan="1">.14 (0.12)</td><td valign="top" colspan="1" rowspan="1">.263 (0.017)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Sex</td><td valign="top" colspan="1" rowspan="1">&#8722;0.12 (0.72)</td><td valign="top" colspan="1" rowspan="1">.869 (0.000)</td><td valign="top" colspan="1" rowspan="1">.23 (0.68)</td><td valign="top" colspan="1" rowspan="1">.731 (0.002)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Cognitive Status</td><td valign="top" colspan="1" rowspan="1">&#8722;9.60 (2.63)</td><td valign="top" colspan="1" rowspan="1">&lt;0.001 (0.129)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;RC Tau x Cognitive Status</td><td valign="top" colspan="1" rowspan="1">4.94 (1.93)</td><td valign="top" colspan="1" rowspan="1">.012 (0.068)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Delay between CMT and tau-PET</td><td valign="top" colspan="1" rowspan="1">.00 (0.00)</td><td valign="top" colspan="1" rowspan="1">.421 (0.007)</td><td valign="top" colspan="1" rowspan="1">.00 (0.00)</td><td valign="top" colspan="1" rowspan="1">.172 (0.025)</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Model 3</bold></td><td colspan="2" align="center" valign="top" rowspan="1"><italic toggle="yes">Entire sample (n</italic><italic toggle="yes">=</italic><italic toggle="yes">87)</italic></td><td colspan="2" align="center" valign="top" rowspan="1"><italic toggle="yes">CU only (n</italic><italic toggle="yes">=</italic><italic toggle="yes">78)</italic></td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Intercept</td><td valign="top" colspan="1" rowspan="1">12.82 (4.70)</td><td valign="top" colspan="1" rowspan="1">.019 (0.072)</td><td valign="top" colspan="1" rowspan="1">4.58 (3.98)</td><td valign="top" colspan="1" rowspan="1">.235 (0.021)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;RC Tau (SUVr)</td><td valign="top" colspan="1" rowspan="1">&#8722;3.16 (1.54)</td><td valign="top" colspan="1" rowspan="1">.511 (0.006)</td><td valign="top" colspan="1" rowspan="1">1.42 (1.65)</td><td valign="top" colspan="1" rowspan="1">.392 (0.011)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Age (y)</td><td valign="top" colspan="1" rowspan="1">.054 (0.044)</td><td valign="top" colspan="1" rowspan="1">.223 (0.020)</td><td valign="top" colspan="1" rowspan="1">.061 (0.05)</td><td valign="top" colspan="1" rowspan="1">.186 (0.026)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Education (y)</td><td valign="top" colspan="1" rowspan="1">.122 (0.103)</td><td valign="top" colspan="1" rowspan="1">.239 (0.018)</td><td valign="top" colspan="1" rowspan="1">.15 (0.11)</td><td valign="top" colspan="1" rowspan="1">.189 (0.026)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Sex</td><td valign="top" colspan="1" rowspan="1">.022 (0.647)</td><td valign="top" colspan="1" rowspan="1">.739 (0.001)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Cognitive Status</td><td valign="top" colspan="1" rowspan="1">&#8722;7.32 (3.53)</td><td valign="top" colspan="1" rowspan="1">.042 (0.054)</td><td valign="top" colspan="1" rowspan="1">.02 (0.66)</td><td valign="top" colspan="1" rowspan="1">.748 (0.002)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;A&#946;-PET (Centiloid)</td><td valign="top" colspan="1" rowspan="1">.024 (0.015)</td><td valign="top" colspan="1" rowspan="1">.119 (0.032)</td><td valign="top" colspan="1" rowspan="1">.03 (0.02)</td><td valign="top" colspan="1" rowspan="1">.057 (0.053)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;WMH</td><td valign="top" colspan="1" rowspan="1">.00 (0.00)</td><td valign="top" colspan="1" rowspan="1">.002 (0.125)</td><td valign="top" colspan="1" rowspan="1">.00 (0.00)</td><td valign="top" colspan="1" rowspan="1">.003 (0.125)</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;RC Tau x Cognitive Status</td><td valign="top" colspan="1" rowspan="1">4.78 (2.15)</td><td valign="top" colspan="1" rowspan="1">.029 (0.062)</td><td valign="top" colspan="1" rowspan="1">&#8211;</td><td valign="top" colspan="1" rowspan="1">&#8211;</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8195;Delay between CMT and tau-PET</td><td valign="top" colspan="1" rowspan="1">&#8722;0.01 (0.01)</td><td valign="top" colspan="1" rowspan="1">.230 (0.019)</td><td valign="top" colspan="1" rowspan="1">&#8722;0.01 (0.01)</td><td valign="top" colspan="1" rowspan="1">.418 (0.010)</td></tr></tbody></table><table-wrap-foot><fn id="spara015"><p>Legend: A. Regression linear model explaining CMT performance in the entire sample (models 1&#8211;3, left side) and in CU only (models 1&#8211;3, right side).</p></fn><fn id="spara016"><p>WMH = white matter hyperintensities volume (mm&#179;); A&#946; = amyloid-beta; CU= cognitively unimpaired participants; MCI= mild cognitively impaired; <italic toggle="yes">B</italic>= unstandardized beta; SE = standard error; p-val= <italic toggle="yes">p</italic>-value; &#951;&#178;<italic toggle="yes">p</italic> = partial eta square.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0016"><label>3.5</label><title>Association between CMT performance and rhinal tau after adjusting for amyloid load and white matter hyperintensities</title><p id="para0038">After adjusting for the effects of amyloid load and WMH, the association of RC tau burden with CMT performance did not remain significant (<xref rid="tbl0002" ref-type="table">Table 2</xref><bold>, Model 3, left side,</bold>
<italic toggle="yes">n</italic> = 87). CMT TO was predicted by WMH (<italic toggle="yes">B</italic>=&#8722;0.000, <italic toggle="yes">p</italic>=.002, &#951;&#178;<italic toggle="yes">p</italic>=.125), by the interaction between RC tau and cognitive status (<italic toggle="yes">B</italic> = 4.78, <italic toggle="yes">p</italic>=.029, &#951;&#178;<italic toggle="yes">p</italic>=.062), and by cognitive status (<italic toggle="yes">B</italic>=&#8722;7.32, <italic toggle="yes">p</italic>=.042, &#951;&#178;<italic toggle="yes">p</italic>=.054).</p><p id="para0039">No interaction was observed between tau and A&#946; (F(1,85)=0.492, <italic toggle="yes">p</italic>=.485, &#951;&#178;<italic toggle="yes">p</italic>=.007) or between tau and WMH (F(1,85)=1.91, <italic toggle="yes">p</italic>=.172, &#951;&#178;<italic toggle="yes">p</italic>=.025). However, we observed an interaction between A&#946; and WHM (F(1,87)=4.44, <italic toggle="yes">p</italic>=.038, &#951;&#178;<italic toggle="yes">p</italic>=.057). The effect of A&#946; on CMT performance was stronger in participants with high WMH (<italic toggle="yes">B</italic> = 0.073, <italic toggle="yes">p</italic>=.019, &#951;&#178;<italic toggle="yes">p</italic>=.314) than with low WMH (<italic toggle="yes">B</italic> = 0.018, <italic toggle="yes">p</italic>=.283, &#951;&#178;<italic toggle="yes">p</italic>=.023) (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>).<fig id="fig0003" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Illustration of the interaction effect between amyloid load and white matter hyperintensities in the entire sample.</bold></p><p>WMH = white matter hyperintensities volume (mm&#179;); A&#946; = amyloid-beta; CU= cognitively unimpaired participants; MCI= mild cognitively impaired.</p></caption><alt-text id="alt0003">Fig 3:</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="para0040">When restricting the analysis to CU participants (<xref rid="tbl0002" ref-type="table">Table 2</xref><bold>, Model 3, right side,</bold>
<italic toggle="yes">n</italic> = 78), CMT TO was predicted only by WMH (<italic toggle="yes">B</italic> = 0.00, <italic toggle="yes">p</italic>=.003, &#951;&#178;<italic toggle="yes">p</italic>=.125) and marginally by A&#946; load (<italic toggle="yes">B</italic> = 0.03, <italic toggle="yes">p</italic>=.057, &#951;&#178;<italic toggle="yes">p</italic>=.053).</p><p id="para0041">The accuracy sensitivity to similarity score was not explained by any biomarkers when considering the entire sample (Supplementary Material S2, Model 3).</p></sec><sec id="sec0017"><label>3.6</label><title>Association between CMT performance and cognitive z-scores in the entire sample</title><p id="para0042">Partial correlations were computed between cognitive z-scores and CMT performance in each condition (<bold>Supplementary Material S3</bold>). After correction for multiple comparisons, almost all correlations with memory, language, and the executive z-scores were significant (all <italic toggle="yes">p</italic>&lt;.05). We also observed a relation between close, non-living, and non-match items with the PACC5 as well as a correlation between the non-match items and visuo-constructive z-score (all <italic toggle="yes">p</italic>&lt;.05).</p><p id="para0043">The model including all cognitive composite scores as predictors highlighted that memory, executive, and language z-scores contributed independently to the total TO variance (&#946;=&#8722;0.58, <italic toggle="yes">p</italic>=.015, &#951;&#178;<italic toggle="yes">p</italic>=.064; &#946;=&#8722;1.12, <italic toggle="yes">p</italic>=.020, &#951;&#178;<italic toggle="yes">p</italic>=.059 and &#946;=&#8722;1.11, <italic toggle="yes">p</italic>=.039, &#951;&#178;<italic toggle="yes">p</italic>=.047, respectively).</p></sec><sec id="sec0018"><label>3.7</label><title>ROC curves</title><p id="para0044">To distinguish the A&#946;+CU from the A&#946;-CU group, CMT TO showed a marginally larger AUC compared to PACC5 (AUC=0.702, <italic toggle="yes">p</italic>=.001 and AUC =0.655, <italic toggle="yes">p</italic>=.039, respectively) (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>A). The DeLong test disclosed that the difference between these two AUCs was not significant (<italic toggle="yes">p</italic>=.770). To distinguish CU with a positive tau-PET visual read (Braak&gt;0) from CU with a negative tau-PET (Braak 0), CMT TO (AUC =0.733, <italic toggle="yes">p</italic>=.001) was more sensitive than PACC5 (AUC=0.663, <italic toggle="yes">p</italic>=.063) (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>B), but the difference between these AUCs was not significant (<italic toggle="yes">p</italic>=.460).<fig id="fig0004" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>ROC Curves comparing performance to distinguish A&#946;&#177; or Tau&#177; cognitively unimpaired individuals.</bold></p><p>ROC curves data table evaluating the cognitive metrics to distinguish A&#946;-CU vs A&#946;+CU (left side) and Tau-CU vs Tau+CU (right side). Amyloid positivity was defined as a CL value&gt;20 and Tau positivity was established on the basis of a Braak stage &gt;0. The best AUC curves for each comparison are in bold. Legend: CU = cognitively unimpaired; A&#946; = amyloid-&#946;; CMT = Conceptual Matching Task; TO= Trade-Off; PACC5 = preclinical Alzheimer cognitive composite; AUC = area under the curve; Sn = sensitivity; Sp = specificity.</p></caption><alt-text id="alt0004">Fig 4:</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0004" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec></sec><sec id="sec0019"><label>4</label><title>Discussion</title><p id="para0045">Detecting the initial cognitive changes of preclinical AD is essential for early diagnosis, prevention, and clinical trial enrolment. The present study investigated whether the CMT, a new short cognitive task that rapidly evaluates the ability to discriminate conceptually confusable items, may identify subtle cognitive impairment starting from the preclinical stage of AD, and whether impaired CMT performance may be associated with AD-related lesions. We found lower CMT performance in A&#946;+CU compared to A&#946;-CU individuals. This decline was explained primarily by the presence of WMH. Moreover, CMT performance correlated with memory, executive and language cognitive composites scores, and facilitated the identification of CU individuals with elevated A&#946; or tau-PET signals as well as than the PACC5 but with a much shorter administration time. Therefore, this test shows promise as a diagnostic tool for preclinical AD and may offer significant utility in the context of clinical trials.</p><p id="para0046">Our results are consistent with those of previous studies that demonstrated reduced CMT performance in samples including patients with AD or PrC lesions [<xref rid="bib0021" ref-type="bibr">21</xref>,<xref rid="bib0022" ref-type="bibr">22</xref>]. Nevertheless, our results evidenced lower performance at the preclinical stage of AD, before deficits become detectable in the standard neuropsychological assessment. To the best of our knowledge, this is one of the first studies showing a difference between A&#946;- and A&#946;+CU subjects using a cognitive task requiring a very brief completion time (&lt; 6 min) in a single testing session. The sensitivity of the CMT appears comparable to studies that have demonstrated difference between those groups using others remote cognitive tests [<xref rid="bib0027" ref-type="bibr">26</xref>,<xref rid="bib0028" ref-type="bibr">27</xref>].</p><p id="para0047">Moreover, our study showed that the CMT allows to predicts the tau-PET status in CU participants, a status that is all even more important given that, in the presence of high amyloid burden, it predicts a high risk of short-term (3&#8211;5 years) cognitive decline [<xref rid="bib0006" ref-type="bibr">6</xref>]. In an overlapping sample, we previously observed differences in perceptual discrimination performance between A- and <italic toggle="yes">A</italic>+ as well as between T- and <italic toggle="yes">T</italic>+ CU groups [<xref rid="bib0049" ref-type="bibr">48</xref>], supporting that fine-grained discrimination abilities are impaired as early as the preclinical stage, at both perceptual and conceptual levels. In this study, we highlighted associations between performance on these tasks and early tau protein deposition in the trans-entorhinal cortex. Assessing conceptual or perceptual discrimination abilities with a test of no more than 6 min duration seems a promising strategy for easy-to use, rapid, and cost-effective screening for preclinical AD pathology. Nevertheless, plasma biomarkers also hold promise as scalable screening tools [<xref rid="bib0051" ref-type="bibr">49</xref>], future studies should compare the individual and combined value of such cognitive measures and blood-based biomarkers to identify the individuals presenting a high risk of evolving to symptomatic AD.</p><p id="para0048">Although we highlighted a group, distance, and domain effect in this task [<xref rid="bib0021" ref-type="bibr">21</xref>,<xref rid="bib0022" ref-type="bibr">22</xref>], we did not observe a performance difference between A&#946;-CU and preclinical AD subjects in the conditions that were the most demanding in terms of conceptual discrimination (i.e. close and living conditions). We expected a performance difference under these conditions because those items are more difficult to distinguish conceptually as they share more co-occuring features (e.g., &#8220;has eyes&#8221;, &#8220;has four leg&#8221;, etc.) with less distinctive features, than distant or non-living concepts [<xref rid="bib0033" ref-type="bibr">32</xref>,<xref rid="bib0052" ref-type="bibr">50</xref>]. Given that the PrC is predominately involved in fine-grained discrimination of confusable items, and that this region is affected early in the course of AD, we expected lower performance in the close and living conditions in A&#946;+CU compared to A&#946;-CU individuals. Indeed, studies of patients at different stages of AD had shown the role of the PrC in distinguishing highly confusable compared to less confusable items [<xref rid="bib0053" ref-type="bibr">51</xref>,<xref rid="bib0054" ref-type="bibr">52</xref>]. A possible explanation is that the more difficult conditions were also challenging for low-amyloid participants, and that the difference in performance was therefore only noticeable in the easiest conditions (distant and non-living conditions). This hypothesis is supported by worse performance of A&#946;-CU individuals in living and close conditions than in non-living and distant conditions, respectively. Although all conditions were matched in terms of word length and lexical frequency, further studies should investigate the impact of other psycholinguistic variables (e.g. familiarity, age of acquisition, density of orthographic neighbourhood) on our results.</p><p id="para0049">Contrary to our hypothesis, CMT performance was more strongly related to WMH (and marginally linked to A&#946; deposition when considering CU individuals only) than to RC tau burden. This result is surprising because the literature has convincingly shown that cognition is more closely linked to tau burden than to A&#946; pathology [<xref rid="bib0001" ref-type="bibr">1</xref>,<xref rid="bib0055" ref-type="bibr">53</xref>] and that CMT is correlated with atrophy of the PrC [<xref rid="bib0021" ref-type="bibr">21</xref>,<xref rid="bib0022" ref-type="bibr">22</xref>], a site of early tau accumulation. Beyond differences in imaging methods (tau-PET vs MRI), Frick and colleagues [<xref rid="bib0022" ref-type="bibr">22</xref>] evaluated patients at more advanced disease stages, which may partially explain the discrepancy between their results and our findings. Because they studied patients with more advanced disease, PrC atrophy was probably more severe in their subjects than among our participants. On the other hand, we found that CMT performance correlated with several cognitive domains. These results underscore that this task is multi-determined and relies on widespread neural networks beyond the RC. It therefore makes sense that this task is more sensitive to biomarkers with a general impact on brain function, such as A&#946; load or WMH than to regional tau burden. CMT performance correlated primarily with memory and executive composite scores. Executive functions are largely underpinned by the fronto-parietal regions [<xref rid="bib0056" ref-type="bibr">54</xref>]. However, the fronto-parietal networks are less likely to be affected by tauopthy than by A&#946; and WMH during preclinical AD [<xref rid="bib0057" ref-type="bibr">55</xref>,<xref rid="bib0058" ref-type="bibr">56</xref>]. Previous studies have associated WMH with various executive tasks, and suggest that executive functioning may be impaired by WMH-induced disruption of neuronal transmission and intraneuronal connectivity [<xref rid="bib0059" ref-type="bibr">57</xref>,<xref rid="bib0060" ref-type="bibr">58</xref>].</p><p id="para0050">We also highlighted an interaction between A&#946; and WMH, which is consistent with the fact that WMH worsens cognitive impairment in AD [<xref rid="bib0061" ref-type="bibr">[59]</xref>, <xref rid="bib0062" ref-type="bibr">[60]</xref>, <xref rid="bib0063" ref-type="bibr">[61]</xref>]. Cognition, and episodic memory in particular, may be impaired by an interaction effect between these two biomarkers in CU individuals [<xref rid="bib0063" ref-type="bibr">61</xref>]. These findings underscore the importance of measuring WMH during the assessment of AD biomarkers.</p><p id="para0051">Finally, we observed a slightly higher AUCs for the CMT than the PACC5 for distinguishing A&#946;-CU from A&#946;+CU individuals and Tau-CU from Tau+CU subjects (using the tau-PET visual read to define tau positivity: Braak stage &gt;0), but these differences were not statistically significant. Of note, the PACC5 was designed initially to distinguish A&#946;- from A&#946;+CU individuals [<xref rid="bib0042" ref-type="bibr">41</xref>], but requires a longer administration time (30 vs. less than 6 min) and is less straightforward to implement remotely than the CMT. In addition, CMT performance appears to be more predictive of amyloid or tau status than PACC5 score, and correlates quite well with the different cognitive domains of the standard assessment.</p></sec><sec id="sec0020"><label>5</label><title>Limitations</title><p id="para0052">First, our sample was not representative of the general population, as it consisted primarily of white individuals with a high-level educational level and a high prevalence of <italic toggle="yes">APOE &#949;4</italic> carriage. Indeed, only 23 % of individuals in the general population carry at least one <italic toggle="yes">&#949;4</italic> allele [<xref rid="bib0064" ref-type="bibr">62</xref>] (versus 45 to 76 % across our groups, see <xref rid="tbl0001" ref-type="table">Table 1</xref>). Further research should be conducted in more diverse populations, although we have shown that <italic toggle="yes">APOE</italic> has no impact on performance.</p><p id="p1">Second, A&#946;-MCI participants were excluded from statistical analysis due to the small sample size. Therefore, this study did not determine the specificity of CMT performance to AD pathology.</p><p id="para0053">Third, this study was conducted in French. Translating the items into other languages would be ineffective because word frequency and length effects vary between languages. In addition, it has already been widely demonstrated that cultural differences between people speaking the same language can also have an impact on performance [<xref rid="bib0065" ref-type="bibr">63</xref>]. This would require item adjustement for each language and culture, which would obviously complicate the adaptation process compared with a non-verbal task. Relatedly, some items were unknown to some participants, despite their high educational level. Assessing the appropriateness of the task for participants from more diverse backgrounds and a broader range of French-speaking populations would require further studies using a novel set of stimuli that considers socio-economic and cultural factors. However, the results were only based on known items allowing adjustments for part of these variations and the study was conducted in a quite homogeneous French-Speaking Belgian population</p><p id="para0055">The fourth limitation was its cross-sectional design. Future work should determine how performance evolves over time in association with disease biomarkers, and test whether it is predictive of clinical progression.</p></sec><sec id="sec0021"><label>6</label><title>Perspectives</title><p id="para0056">While the CMT appears promising in identifying individuals with preclinical AD, further work is needed to validate this task as a screening tool (e.g., replication within larger preclinical samples, determination of the specificity of this task to screen for underlying AD pathology, standardization of task design and administration procedures, assessment of test-retest reliability, development of normative data, and longitudinal analysis). Future studies could compare the properties of this test with those of other rapid cognitive batteries and could also explore the benefits of combining this type of rapid test with biological measures such as plasma marker levels. Finally, our results were inconsistent with the hypothesis that we formulated based on previous studies that used this task. Indeed, Frick and colleagues [<xref rid="bib0022" ref-type="bibr">22</xref>] showed that CMT performance, in particular the accuracy sensitivity to similarity score, was related to RC pathology. However, we did not demonstrate a performance difference between A&#946;-CU and A&#946;+CU individuals when considering this score. Moreover, CMT performance was not correlated with RC tau burden, even before the correction for cognitive status or other biomarkers. Further work is therefore needed to better understand these discrepancies.</p></sec><sec id="sec0022"><title>Declaration of generative AI and AI-assisted technologies in the writing process</title><p id="para0057">I have not used any AI at all.</p></sec><sec id="sec0022a"><title>CRediT authorship contribution statement</title><p id="para0057a"><bold>Lara Huyghe:</bold> Writing &#8211; original draft, Visualization, Validation, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. <bold>Yasmine Salman:</bold> Writing &#8211; review &amp; editing, Validation, Data curation. <bold>Lise Colmant:</bold> Writing &#8211; review &amp; editing, Validation, Data curation. <bold>Thomas G&#233;rard:</bold> Writing &#8211; review &amp; editing, Validation, Data curation. <bold>Vincent Malotaux:</bold> Writing &#8211; review &amp; editing, Validation, Data curation. <bold>Gabriel Besson:</bold> Writing &#8211; review &amp; editing, Methodology, Conceptualization. <bold>Emma Delhaye:</bold> Writing &#8211; review &amp; editing, Validation, Methodology, Conceptualization. <bold>Christine Bastin:</bold> Writing &#8211; review &amp; editing, Validation, Supervision, Methodology, Conceptualization. <bold>Quentin Dessain:</bold> Writing &#8211; review &amp; editing, Methodology. <bold>Laurence Dricot:</bold> Writing &#8211; review &amp; editing, Software, Resources. <bold>Renaud Lhommel:</bold> Writing &#8211; review &amp; editing, Resources, Data curation. <bold>Adrian Ivanoiu:</bold> Writing &#8211; review &amp; editing, Supervision. <bold>Lisa Quenon:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Supervision, Resources, Methodology, Data curation, Conceptualization. <bold>Bernard Hanseeuw:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Supervision, Resources, Project administration, Methodology, Funding acquisition, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0063">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</p><p id="para0064">Bernard Hanseeuw reports equipment, drugs, or supplies was provided by Lantheus Medical Imaging Inc. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Hanseeuw</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Betensky</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>H.I.L.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Sepulcre</surname><given-names>J.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Association of amyloid and Tau with cognition in preclinical Alzheimer disease: a longitudinal study</article-title><source>JAMA Neurol</source><volume>76</volume><issue>8</issue><year>2019 Aug 1</year><fpage>915</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">31157827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.1424</pub-id><pub-id pub-id-type="pmcid">PMC6547132</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bigio</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Bouras</surname><given-names>C.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>N.J.</given-names></name><etal/></person-group><article-title>Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature</article-title><source>J Neuropathol Exp Neurol</source><volume>71</volume><issue>5</issue><year>2012 May</year><fpage>362</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">22487856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e31825018f7</pub-id><pub-id pub-id-type="pmcid">PMC3560290</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><etal/></person-group><article-title>Tracking pathophysiological processes in Alzheimer&#8217;s disease: an updated hypothetical model of dynamic biomarkers</article-title><source>Lancet Neurol</source><volume>12</volume><issue>2</issue><year>2013 Feb 1</year><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">23332364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(12)70291-0</pub-id><pub-id pub-id-type="pmcid">PMC3622225</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><etal/></person-group><article-title>Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons</article-title><source>JAMA</source><volume>317</volume><issue>22</issue><year>2017 Jun 13</year><fpage>2305</fpage><lpage>2316</lpage><pub-id pub-id-type="pmid">28609533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.6669</pub-id><pub-id pub-id-type="pmcid">PMC5736301</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Hanseeuw</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Malotaux</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dricot</surname><given-names>L.</given-names></name><name name-style="western"><surname>Quenon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sznajer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cerman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Defining a centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study</article-title><source>Eur J Nucl Med Mol Imaging</source><volume>48</volume><issue>1</issue><year>2021 Jan 1</year><fpage>302</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">32601802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-020-04942-4</pub-id><pub-id pub-id-type="pmcid">PMC7835306</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pichet Binette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Groot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Strandberg</surname><given-names>O.</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline</article-title><source>Nat Med</source><volume>28</volume><issue>11</issue><year>2022 Nov</year><fpage>2381</fpage><lpage>2387</lpage><pub-id pub-id-type="pmid">36357681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02049-x</pub-id><pub-id pub-id-type="pmcid">PMC9671808</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Grober</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lipton</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>H.</given-names></name></person-group><article-title>Memory impairment on free and cued selective reminding predicts dementia</article-title><source>Neurology</source><volume>54</volume><issue>4</issue><year>2000 Feb 22</year><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">10690971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.54.4.827</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="other" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>de Partz de Courtray</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Bilocq</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Wilde</surname><given-names>V.</given-names></name><name name-style="western"><surname>Seron</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lexis</surname><given-names>Pillon A.</given-names></name></person-group><article-title>Tests pour le diagnostic des troubles lexicaux chez le patient aphasique [Internet]</article-title><comment>[cited 2023 Feb 7]. Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dial.uclouvain.be/pr/boreal/object/boreal:90447" id="interref0002">https://dial.uclouvain.be/pr/boreal/object/boreal:90447</ext-link><year>2001</year></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Loewenstein</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Curiel</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Duara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Buschke</surname><given-names>H.</given-names></name></person-group><article-title>Novel cognitive paradigms for the detection of memory impairment in preclinical Alzheimer&#8217;s disease</article-title><source>Assessment</source><volume>25</volume><issue>3</issue><year>2018 Apr</year><fpage>348</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">29214859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1073191117691608</pub-id><pub-id pub-id-type="pmcid">PMC5729046</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Rentz</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>The preclinical Alzheimer cognitive composite: measuring amyloid-related decline</article-title><source>JAMA Neurol</source><volume>71</volume><issue>8</issue><year>2014 Aug 1</year><fpage>961</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">24886908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2014.803</pub-id><pub-id pub-id-type="pmcid">PMC4439182</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Papp</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Rofael</surname><given-names>H.</given-names></name><name name-style="western"><surname>Veroff</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Sensitivity of the preclinical Alzheimer&#8217;s cognitive composite (PACC), PACC5, and repeatable battery for neuropsychological status (RBANS) to amyloid status in preclinical Alzheimer&#8217;s Disease -Atabecestat Phase 2b/3 EARLY clinical trial</article-title><source>J Prev Alzheimers Dis</source><volume>9</volume><issue>2</issue><year>2022</year><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">35542998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.17</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Je</surname><given-names>Baker</given-names></name><name name-style="western"><surname>Bruns</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fripp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sr</surname><given-names>Rainey-Smith</given-names></name><etal/></person-group><article-title>Association of deficits in short-term learning and a&#946; and hippocampal volume in cognitively normal adults</article-title><source>Neurology [Internet]</source><volume>95</volume><issue>18</issue><year>2020 Mar 11</year><comment>[cited 2025 Feb 20]Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/32887774/" id="interref0003">https://pubmed.ncbi.nlm.nih.gov/32887774/</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000010728</pub-id><pub-id pub-id-type="pmid">32887774</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E.</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><volume>82</volume><issue>4</issue><year>1991 Sep 1</year><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>H.I.L.</given-names></name><name name-style="western"><surname>Hanseeuw</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#8217;s disease assessed with positron emission tomography</article-title><source>Sci Transl Med</source><volume>13</volume><issue>577</issue><year>2021 Jan 20</year><fpage>eabc0655</fpage><pub-id pub-id-type="pmid">33472953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abc0655</pub-id><pub-id pub-id-type="pmcid">PMC7978042</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Carlesimo</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>De Simone</surname><given-names>M.S.</given-names></name></person-group><article-title>Special issue on &#8220;novel neuropsychological instruments for the prodromal and preclinical diagnosis of Alzheimer&#8217;s disease</article-title><source>Neuropsychology</source><volume>37</volume><issue>6</issue><year>2023 Sep</year><fpage>623</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">37602995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/neu0000907</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Bussey</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Saksida</surname><given-names>L.M.</given-names></name></person-group><article-title>Memory, perception, and the ventral visual-perirhinal-hippocampal stream: thinking outside of the boxes</article-title><source>Hippocampus</source><volume>17</volume><issue>9</issue><year>2007</year><fpage>898</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">17636546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hipo.20320</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Barense</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Gaffan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>K.S.</given-names></name></person-group><article-title>The human medial temporal lobe processes online representations of complex objects</article-title><source>Neuropsychologia</source><volume>45</volume><issue>13</issue><year>2007 Oct 1</year><fpage>2963</fpage><lpage>2974</lpage><pub-id pub-id-type="pmid">17658561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2007.05.023</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Inhoff</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Heusser</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Tambini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>O&#8217;Neil</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Understanding perirhinal contributions to perception and memory: evidence through the lens of selective perirhinal damage</article-title><source>Neuropsychologia</source><volume>124</volume><year>2019 Feb 18</year><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">30594569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2018.12.020</pub-id><pub-id pub-id-type="pmcid">PMC6456260</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kravitz</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>C.I.</given-names></name></person-group><article-title>Disentangling visual imagery and perception of real-world objects</article-title><source>NeuroImage</source><volume>59</volume><issue>4</issue><year>2012 Feb 15</year><fpage>4064</fpage><lpage>4073</lpage><pub-id pub-id-type="pmid">22040738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.10.055</pub-id><pub-id pub-id-type="pmcid">PMC3288657</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Bruffaerts</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Deyne</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meersmans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liuzzi</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Storms</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>R.</given-names></name></person-group><article-title>Redefining the resolution of semantic knowledge in the brain: advances made by the introduction of models of semantics in neuroimaging</article-title><source>Neurosci Biobehav Rev</source><volume>103</volume><year>2019 Aug 1</year><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">31132379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2019.05.015</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>P.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>B.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>L.K.</given-names></name></person-group><article-title>The perirhinal cortex and conceptual processing: effects of feature-based statistics following damage to the anterior temporal lobes</article-title><source>Neuropsychologia</source><volume>76</volume><year>2015 Sep 1</year><fpage>192</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">25637774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2015.01.041</pub-id><pub-id pub-id-type="pmcid">PMC4582809</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Frick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Besson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>E.</given-names></name></person-group><article-title>Perirhinal cortex is associated with fine-grained discrimination of conceptually confusable objects in Alzheimer&#8217;s disease</article-title><source>Neurobiol Aging</source><volume>130</volume><year>2023 Oct</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">37419076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2023.06.003</pub-id></element-citation></ref><ref id="bib0024"><label>23</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Papp</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Jutten</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Soberanes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weizenbaum</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Molinare</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Early detection of amyloid-related changes in memory among cognitively unimpaired older adults with daily digital testing</article-title><source>Ann Neurol</source><volume>95</volume><issue>3</issue><year>2024</year><fpage>507</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">37991080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26833</pub-id><pub-id pub-id-type="pmcid">PMC10922126</pub-id></element-citation></ref><ref id="bib0025"><label>24</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Samaroo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amariglio</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>P.</given-names></name><name name-style="western"><surname>Properzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>Diminished learning over repeated exposures (LORE) in preclinical Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement Diagn Assess Dis Monit [Internet]</source><volume>12</volume><issue>1</issue><year>2020 Jan</year><comment>[cited 2025 Feb 20]Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/10.1002/dad2.12132" id="interref0004">https://onlinelibrary.wiley.com/doi/10.1002/dad2.12132</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12132</pub-id><pub-id pub-id-type="pmcid">PMC7784542</pub-id><pub-id pub-id-type="pmid">33426266</pub-id></element-citation></ref><ref id="bib0026"><label>25</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Weizenbaum</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Molinare</surname><given-names>C.</given-names></name><name name-style="western"><surname>Soberanes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Christiano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Viera</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Validation of the multi-day Boston remote assessment of neurocognitive health (BRANCH) among cognitively impaired &amp; unimpaired older adults</article-title><source>J Prev Alzheimers Dis</source><year>2025 Jan 13</year><object-id pub-id-type="publisher-id">100057</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tjpad.2025.100057</pub-id><pub-id pub-id-type="pmcid">PMC12183941</pub-id><pub-id pub-id-type="pmid">39809614</pub-id></element-citation></ref><ref id="bib0027"><label>26</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Stricker</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Stricker</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>W.Z.</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Stricker Learning Span criterion validity: a remote self-administered multi-device compatible digital word list memory measure shows similar ability to differentiate amyloid and tau PET-defined biomarker groups as in-person auditory verbal learning test</article-title><source>J Int Neuropsychol Soc JINS</source><volume>30</volume><issue>2</issue><year>2024 Feb</year><fpage>138</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">37385974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617723000322</pub-id><pub-id pub-id-type="pmcid">PMC10756923</pub-id></element-citation></ref><ref id="bib0028"><label>27</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Muurling</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vairavan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Chadha</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Tarnanas</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Augmented reality versus standard tests to assess cognition and function in early Alzheimer&#8217;s disease</article-title><source>NPJ Digit Med</source><volume>6</volume><issue>1</issue><year>2023 Dec 18</year><fpage>234</fpage><pub-id pub-id-type="pmid">38110486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-023-00978-6</pub-id><pub-id pub-id-type="pmcid">PMC10728213</pub-id></element-citation></ref><ref id="bib0029"><label>28</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Kunicki</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Emrani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Strenger</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Vito</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Britton</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Remote and in-clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults</article-title><source>Alzheimers Dement Diagn Assess Dis Monit</source><volume>15</volume><issue>4</issue><year>2023 Nov 27</year><object-id pub-id-type="publisher-id">e12500</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12500</pub-id><pub-id pub-id-type="pmcid">PMC10680059</pub-id><pub-id pub-id-type="pmid">38026761</pub-id></element-citation></ref><ref id="bib0030"><label>29</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Fristed</surname><given-names>E.</given-names></name><name name-style="western"><surname>Skirrow</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meszaros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lenain</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meepegama</surname><given-names>U.</given-names></name><name name-style="western"><surname>Cappa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A remote speech-based AI system to screen for early Alzheimer&#8217;s disease via smartphones</article-title><source>Alzheimers Dement Diagn Assess Dis Monit</source><volume>14</volume><issue>1</issue><year>2022 Nov 3</year><object-id pub-id-type="publisher-id">e12366</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12366</pub-id><pub-id pub-id-type="pmcid">PMC9632864</pub-id><pub-id pub-id-type="pmid">36348974</pub-id></element-citation></ref><ref id="bib0031"><label>30</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Ruchinskas</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Curyto</surname><given-names>K.J.</given-names></name></person-group><article-title>Cognitive screening in geriatric rehabilitation</article-title><source>Rehabil Psychol</source><volume>48</volume><issue>1</issue><year>2003</year><fpage>14</fpage><lpage>22</lpage></element-citation></ref><ref id="bib0032"><label>31</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>McRae</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cree</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Seidenberg</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>McNorgan</surname><given-names>C.</given-names></name></person-group><article-title>Semantic feature production norms for a large set of living and nonliving things</article-title><source>Behav Res Methods</source><volume>37</volume><issue>4</issue><year>2005</year><fpage>547</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">16629288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3758/bf03192726</pub-id></element-citation></ref><ref id="bib0033"><label>32</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Devereux</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Geertzen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>B.</given-names></name></person-group><article-title>The centre for speech, language and the brain (CSLB) concept property norms</article-title><source>Behav Res Methods</source><volume>46</volume><issue>4</issue><year>2014</year><fpage>1119</fpage><lpage>1127</lpage><pub-id pub-id-type="pmid">24356992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3758/s13428-013-0420-4</pub-id><pub-id pub-id-type="pmcid">PMC4237904</pub-id></element-citation></ref><ref id="bib0034"><label>33</label><element-citation publication-type="book" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Van der Linden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coyette</surname><given-names>F.</given-names></name><name name-style="western"><surname>Poitrenaud</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalafat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calicis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wyns</surname><given-names>C.</given-names></name><etal/></person-group><part-title>L&#8217;&#233;preuve de rappel libre /rappel indice &#224; 16 items (RL/RI-16)</part-title><comment>Baisset Mouly et les membres du GREMEM (Eds.)</comment><person-group person-group-type="editor"><name name-style="western"><surname>MVan der Linden</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agniel</surname><given-names>C.</given-names></name></person-group><source>L&#8217;&#233;valuation des troubles de la m&#233;moire: pr&#233;sentation de quatre tests de m&#233;moire &#233;pisodique (avec leur &#233;talonnage)</source><year>2004 Jan 1</year><publisher-name>Solal Editeur</publisher-name><fpage>25</fpage><lpage>47</lpage></element-citation></ref><ref id="bib0035"><label>34</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Reitan</surname><given-names>R.M.</given-names></name></person-group><article-title>The relation of the trail making test to organic brain damage</article-title><source>J Consult Psychol</source><volume>19</volume><issue>5</issue><year>1955 Oct</year><fpage>393</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">13263471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/h0044509</pub-id></element-citation></ref><ref id="bib0036"><label>35</label><element-citation publication-type="book" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Bianconi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Busigny</surname><given-names>T.</given-names></name></person-group><part-title>Validation M&#233;thodologique Et Normalisation D&#8217;un Test D&#8217;&#233;valuation Des Fonctions Ex&#233;cutives: Les S&#233;ries Graphiques</part-title><year>2005</year><publisher-name>Universit&#233; Cathologique de Louvain</publisher-name></element-citation></ref><ref id="bib0037"><label>36</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Rouleau</surname><given-names>I.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Butters</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>C.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>K.</given-names></name></person-group><article-title>Quantitative and qualitative analyses of clock drawings in Alzheimer&#8217;s and Huntington&#8217;s disease</article-title><source>Brain Cogn</source><volume>18</volume><issue>1</issue><year>1992 Jan</year><fpage>70</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">1543577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0278-2626(92)90112-y</pub-id></element-citation></ref><ref id="bib0038"><label>37</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Mohs</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fillenbaum</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heyman</surname><given-names>A.</given-names></name></person-group><article-title>Consortium to establish a registry for Alzheimer&#8217;s disease (CERAD) clinical and neuropsychological assessment of Alzheimer&#8217;s disease</article-title><source>Psychopharmacol Bull</source><volume>24</volume><issue>4</issue><year>1988</year><fpage>641</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">3249766</pub-id></element-citation></ref><ref id="bib0039"><label>38</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Ivanoiu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dricot</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gilis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grandin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lhommel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Quenon</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Classification of non-demented patients attending a memory clinic using the New diagnostic criteria for Alzheimer&#8217;s Disease with disease-related biomarkers</article-title><source>J Alzheimers Dis</source><volume>43</volume><issue>3</issue><year>2015 Jan 1</year><fpage>835</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">25114071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-140651</pub-id></element-citation></ref><ref id="bib0040"><label>39</label><element-citation publication-type="book" id="sbref0040"><person-group person-group-type="author"><collab>Wechlser</collab></person-group><part-title>MEM-IV - &#201;chelle Clinique De M&#233;moire De Wechsler - 4&#232;me &#201;dition</part-title><comment>[cited 2024 Sep 12]</comment><year>2011</year><publisher-name>Pearson Clinical &amp; Talent Assessment</publisher-name><comment>Available from</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pearsonclinical.fr/mem-iv" id="interref0005">https://www.pearsonclinical.fr/mem-iv</ext-link></element-citation></ref><ref id="bib0041"><label>40</label><element-citation publication-type="book" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Wechsler</surname><given-names>D.MEM-III</given-names></name></person-group><part-title>&#201;chelle Clinique De M&#233;moire De Wechsler: Manuel</part-title><year>2001</year><publisher-name>du Centre de psychologie appliqu&#233;e</publisher-name><publisher-loc>Paris, France</publisher-loc><fpage>449</fpage><comment>les &#201;d</comment></element-citation></ref><ref id="bib0042"><label>41</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Papp</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Rentz</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Orlovsky</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mormino</surname><given-names>E.C.</given-names></name></person-group><article-title>Optimizing the preclinical Alzheimer&#8217;s cognitive composite with semantic processing: the PACC5</article-title><source>Alzheimers Dement Transl Res Clin Interv</source><volume>3</volume><issue>4</issue><year>2017</year><fpage>668</fpage><lpage>677</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2017.10.004</pub-id><pub-id pub-id-type="pmcid">PMC5726754</pub-id><pub-id pub-id-type="pmid">29264389</pub-id></element-citation></ref><ref id="bib0043"><label>42</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Folstein</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>P.R.</given-names></name></person-group><article-title>&#8220;Mini-mental state&#8221;. A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><volume>12</volume><issue>3</issue><year>1975 Nov</year><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">1202204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-3956(75)90026-6</pub-id></element-citation></ref><ref id="bib0044"><label>43</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Salat</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>van der Kouwe</surname><given-names>A.J.W.</given-names></name><name name-style="western"><surname>Makris</surname><given-names>N.</given-names></name><name name-style="western"><surname>S&#233;gonne</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>B.T.</given-names></name><etal/></person-group><article-title>Sequence-independent segmentation of magnetic resonance images</article-title><source>NeuroImage</source><volume>23</volume><year>2004 Jan 1</year><fpage>S69</fpage><lpage>S84</lpage><pub-id pub-id-type="pmid">15501102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2004.07.016</pub-id></element-citation></ref><ref id="bib0045"><label>44</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Greve</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Salat</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Izquierdo-Garcia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Catana</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Different partial volume correction methods lead to different conclusions: an 18F-FDG-PET study of aging</article-title><source>NeuroImage</source><volume>132</volume><year>2016 May 15</year><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">26915497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2016.02.042</pub-id><pub-id pub-id-type="pmcid">PMC4851886</pub-id></element-citation></ref><ref id="bib0046"><label>45</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name name-style="western"><surname>Klunk</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Price</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Benzinger</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Devous</surname><given-names>Sr.</given-names><suffix>MD</suffix></name><name name-style="western"><surname>WJ</surname><given-names>Jagust</given-names></name><etal/></person-group><article-title>The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET</article-title><source>Alzheimers Dement</source><volume>11</volume><issue>1</issue><year>2015</year><fpage>1</fpage><lpage>15</lpage><comment>e4</comment><pub-id pub-id-type="pmid">25443857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.07.003</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id></element-citation></ref><ref id="bib0047"><label>46</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name name-style="western"><surname>Amadoru</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dor&#233;</surname><given-names>V.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Hinton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><volume>12</volume><issue>1</issue><year>2020 Mar 4</year><fpage>22</fpage><pub-id pub-id-type="pmid">32131891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00587-5</pub-id><pub-id pub-id-type="pmcid">PMC7057642</pub-id></element-citation></ref><ref id="bib0048"><label>47</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name name-style="western"><surname>Bayart</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hanseeuw</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ivanoiu</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Pesch</surname><given-names>V.</given-names></name></person-group><article-title>Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid A&#946;42 and T-tau assays for Alzheimer&#8217;s disease diagnosis</article-title><source>J Neurol</source><volume>266</volume><issue>9</issue><year>2019 Sep 1</year><fpage>2304</fpage><lpage>2311</lpage><pub-id pub-id-type="pmid">31179518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-019-09418-6</pub-id></element-citation></ref><ref id="bib0049"><label>48</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name name-style="western"><surname>Huyghe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Quenon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Salman</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Colmant</surname><given-names>L.</given-names></name><name name-style="western"><surname>G&#233;rard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Malotaux</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Entorhinal tau impairs short-term memory binding in preclinical Alzheimer&#8217;s disease</article-title><source>J Int Neuropsychol Soc</source><year>2025 May 22</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617725000165</pub-id><pub-id pub-id-type="pmid">40400392</pub-id></element-citation></ref><ref id="bib0051"><label>49</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name name-style="western"><surname>Yakoub</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gonzalez-Ortiz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>D&#233;ry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Strikwerda-Brown</surname><given-names>C.</given-names></name><name name-style="western"><surname>St-Onge</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window</article-title><source>Alzheimers Dement J Alzheimers Assoc</source><volume>21</volume><issue>2</issue><year>2025 Feb</year><object-id pub-id-type="publisher-id">e14537</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14537</pub-id><pub-id pub-id-type="pmcid">PMC11863240</pub-id><pub-id pub-id-type="pmid">40008832</pub-id></element-citation></ref><ref id="bib0052"><label>50</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name name-style="western"><surname>Tyler</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>H.E.</given-names></name></person-group><article-title>Towards a distributed account of conceptual knowledge</article-title><source>Trends Cogn Sci</source><volume>5</volume><issue>6</issue><year>2001 Jun 1</year><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">11390295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1364-6613(00)01651-x</pub-id></element-citation></ref><ref id="bib0053"><label>51</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name name-style="western"><surname>Bruffaerts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Shafto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsvetanov</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>A.</given-names></name></person-group><article-title>Perceptual and conceptual processing of visual objects across the adult lifespan</article-title><source>Sci Rep</source><volume>9</volume><issue>1</issue><year>2019 Sep 24</year><object-id pub-id-type="publisher-id">13771</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-50254-5</pub-id><pub-id pub-id-type="pmcid">PMC6760174</pub-id><pub-id pub-id-type="pmid">31551468</pub-id></element-citation></ref><ref id="bib0054"><label>52</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name name-style="western"><surname>Bastin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>E.</given-names></name></person-group><article-title>Targeting the function of the transentorhinal cortex to identify early cognitive markers of Alzheimer&#8217;s disease</article-title><source>Cogn Affect Behav Neurosci</source><volume>23</volume><issue>4</issue><year>2023 Aug 1</year><fpage>986</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">37024735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3758/s13415-023-01093-5</pub-id></element-citation></ref><ref id="bib0055"><label>53</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Lowe</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Bruinsma</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Wiste</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Min</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults</article-title><source>Neurology</source><volume>93</volume><issue>1</issue><year>2019 Jul 2</year><fpage>e29</fpage><lpage>e39</lpage><pub-id pub-id-type="pmid">31147421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000007728</pub-id><pub-id pub-id-type="pmcid">PMC6659005</pub-id></element-citation></ref><ref id="bib0056"><label>54</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Graff-Radford</surname><given-names>J.</given-names></name></person-group><article-title>Executive dysfunction and the prefrontal cortex</article-title><source>Contin Lifelong Learn Neurol</source><volume>27</volume><issue>6</issue><year>2021 Dec</year><fpage>1586</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CON.0000000000001009</pub-id><pub-id pub-id-type="pmid">34881727</pub-id></element-citation></ref><ref id="bib0057"><label>55</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name name-style="western"><surname>Thal</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>R&#252;b</surname><given-names>U.</given-names></name><name name-style="western"><surname>Orantes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name></person-group><article-title>Phases of A beta-deposition in the human brain and its relevance for the development of AD</article-title><source>Neurology</source><volume>58</volume><issue>12</issue><year>2002 Jun 25</year><fpage>1791</fpage><lpage>1800</lpage><pub-id pub-id-type="pmid">12084879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.58.12.1791</pub-id></element-citation></ref><ref id="bib0058"><label>56</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name name-style="western"><surname>Collij</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Salvad&#243;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shekari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopes Alves</surname><given-names>I.</given-names></name><name name-style="western"><surname>Reimand</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wink</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent</article-title><source>Eur J Nucl Med Mol Imaging</source><volume>48</volume><issue>7</issue><year>2021 Jul</year><fpage>2169</fpage><lpage>2182</lpage><pub-id pub-id-type="pmid">33615397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-020-05174-2</pub-id><pub-id pub-id-type="pmcid">PMC8175297</pub-id></element-citation></ref><ref id="bib0059"><label>57</label><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name name-style="western"><surname>Gunning-Dixon</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Raz</surname><given-names>N.</given-names></name></person-group><article-title>The cognitive correlates of white matter abnormalities in normal aging: a quantitative review</article-title><source>Neuropsychology</source><volume>14</volume><issue>2</issue><year>2000 Apr</year><fpage>224</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">10791862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037//0894-4105.14.2.224</pub-id></element-citation></ref><ref id="bib0060"><label>58</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Prins</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>van Dijk</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>den Heijer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vermeer</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Jolles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koudstaal</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Cerebral small-vessel disease and decline in information processing speed, executive function and memory</article-title><source>Brain J Neurol</source><volume>128</volume><issue>Pt 9</issue><year>2005 Sep</year><fpage>2034</fpage><lpage>2041</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awh553</pub-id><pub-id pub-id-type="pmid">15947059</pub-id></element-citation></ref><ref id="bib0061"><label>59</label><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name name-style="western"><surname>Breteler</surname><given-names>M.M.B.</given-names></name></person-group><article-title>Vascular risk factors for Alzheimer&#8217;s disease:: an epidemiologic perspective</article-title><source>Neurobiol Aging</source><volume>21</volume><issue>2</issue><year>2000 Mar 1</year><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">10867200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(99)00110-4</pub-id></element-citation></ref><ref id="bib0062"><label>60</label><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name name-style="western"><surname>Garnier-Crussard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bougacha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dautricourt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sherif</surname><given-names>S.</given-names></name><name name-style="western"><surname>Landeau</surname><given-names>B.</given-names></name><etal/></person-group><article-title>White matter hyperintensity topography in Alzheimer&#8217;s disease and links to cognition</article-title><source>Alzheimers Dement</source><volume>18</volume><issue>3</issue><year>2022 Mar</year><fpage>422</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">34322985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12410</pub-id><pub-id pub-id-type="pmcid">PMC9292254</pub-id></element-citation></ref><ref id="bib0063"><label>61</label><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>White matter hyperintensity volume and amyloid-PET synergistically impact memory independent of tau-PET in older adults without dementia</article-title><source>J Alzheimer&#8217;s Dis</source><volume>94</volume><issue>2</issue><year>2023 Jul 18</year><fpage>695</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">37302031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-221209</pub-id><pub-id pub-id-type="pmcid">PMC10357163</pub-id></element-citation></ref><ref id="bib0064"><label>62</label><element-citation publication-type="journal" id="sbref0064"><person-group person-group-type="author"><name name-style="western"><surname>R&#233;gy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dugravot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sabia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Helmer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tzourio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hanseeuw</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The role of dementia in the association between <italic toggle="yes">APOE4</italic> and all-cause mortality: pooled analyses of two population-based cohort studies</article-title><source>Lancet Healthy Longev</source><volume>5</volume><issue>6</issue><year>2024 Jun 1</year><fpage>e422</fpage><lpage>e430</lpage><pub-id pub-id-type="pmid">38824957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(24)00066-7</pub-id></element-citation></ref><ref id="bib0065"><label>63</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Bur&#233;-Reyes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hidalgo-Ruzzante</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vilar-L&#243;pez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gontier</surname><given-names>J.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>L.</given-names></name><name name-style="western"><surname>P&#233;rez-Garc&#237;a</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Neuropsychological test performance of Spanish speakers: is performance different across different Spanish-speaking subgroups?</article-title><source>J Clin Exp Neuropsychol</source><volume>35</volume><issue>4</issue><year>2013</year><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">23496164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803395.2013.778232</pub-id></element-citation></ref></ref-list><sec id="sec0027" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0058a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
<supplementary-material content-type="local-data" id="ecom0002" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.docx" position="float" orientation="portrait"><alt-text>Image, application 2</alt-text></media></supplementary-material>
<supplementary-material content-type="local-data" id="ecom0003" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc3.docx" position="float" orientation="portrait"><alt-text>Image, application 3</alt-text></media></supplementary-material>
<supplementary-material content-type="local-data" id="ecom0004" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc4.docx" position="float" orientation="portrait"><alt-text>Image, application 4</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><sec id="sec0024"><title>Acknowledgments</title><p id="para0065">We would like to extend our warmest thanks to the Belgian Alzheimer's research foundation for its support.</p><p id="para0066">We also thank Daniela Savina and Fiona Galande for their invaluable help in the practical organization of the various examinations as well as Jean Ferrier for contributing to data collection as part of his master's degree.</p></sec><sec id="sec0025"><title>Funding</title><p id="para0067">L.H. was funded by the <funding-source id="gs0001"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002661</institution-id><institution>Belgian Fund for Scientific Research</institution></institution-wrap></funding-source> (FNRS), grant number <award-id award-type="grant" rid="gs0001">FNRS40016560</award-id>. B.H. was funded by the <funding-source id="gs0002"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002661</institution-id><institution>FNRS</institution></institution-wrap></funding-source>, grant number <award-id award-type="grant" rid="gs0002">CCL40010417</award-id>, the FRFS-WELBIO, grant number 40010035, and the SAO grand number 2022/0026. CB is a senior research associate at the FNRS.</p></sec></ack><fn-group><fn id="sec0026" fn-type="supplementary-material"><p id="para0007a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100332" id="interref0001">doi:10.1016/j.tjpad.2025.100332</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Inflamm Res</journal-id><journal-id journal-id-type="iso-abbrev">J Inflamm Res</journal-id><journal-id journal-id-type="pmc-domain-id">1652</journal-id><journal-id journal-id-type="pmc-domain">jinres</journal-id><journal-id journal-id-type="publisher-id">jir</journal-id><journal-title-group><journal-title>Journal of Inflammation Research</journal-title></journal-title-group><issn pub-type="epub">1178-7031</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12503058</article-id><article-id pub-id-type="pmcid-ver">PMC12503058.1</article-id><article-id pub-id-type="pmcaid">12503058</article-id><article-id pub-id-type="pmcaiid">12503058</article-id><article-id pub-id-type="doi">10.2147/JIR.S544597</article-id><article-id pub-id-type="publisher-id">544597</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Identification of Mitophagy-Related Genes and Analysis of Immune Infiltration in Atherosclerosis</article-title><alt-title alt-title-type="running-authors">Zhang et al</alt-title><alt-title alt-title-type="running-title">Zhang et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jiaqi</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6072-6792</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="X">Xiting</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xiahuan</given-names></name><xref rid="aff0001" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="M">Meilin</given-names></name><xref rid="aff0001" ref-type="aff">1</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>Department of Geriatrics, First Hospital, Peking University</institution>, <addr-line>Beijing</addr-line>, <country>People&#8217;s Republic of China</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Meilin Liu, Email liumeilin@hotmail.com</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>18</volume><issue-id pub-id-type="pmc-issue-id">478868</issue-id><fpage>13689</fpage><lpage>13710</lpage><history><date date-type="received"><day>11</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 10:25:16.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Zhang et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhang et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v4.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jir-18-13689.pdf"/><abstract><sec><title>Background</title><p>Atherosclerosis is a chronic inflammatory disease involving mitophagy and immune dysregulation. Currently, there is no integrated diagnostic model for autophagy immune genes in mitochondria. This study aimed to identify potential diagnostic markers through integrated bioinformatics and experimental validation.</p></sec><sec><title>Methods</title><p>Two atherosclerosis-related datasets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>) were analyzed to identify differentially expressed mitophagy-related genes (MRGs), followed by enrichment analysis. Key genes were screened using LASSO, SVM-RFE, and random forest algorithms. A diagnostic nomogram was constructed and validated by ROC analysis. Immune infiltration was evaluated using CIBERSORT and ssGSEA. GSEA, GSVA, and unsupervised clustering were applied to explore biological pathways and molecular subtypes. qPCR validation was performed in ox-LDL-treated RAW264.7 and THP-1 cells.</p></sec><sec><title>Results</title><p>Thirteen upregulated and six downregulated MRGs were identified. Five hub genes (MNDA, CD163L1, NEXN, TC2N, SLC22A3) demonstrated strong diagnostic performance (AUC &gt; 0.85) and were closely associated with immune cell infiltration; two molecular subtypes with distinct immune profiles were identified; qPCR validation confirmed the differential expression of these genes under inflammatory stimulation.</p></sec><sec><title>Conclusion</title><p>MNDA, CD163L1, NEXN, TC2N, and SLC22A3 may serve as diagnostic biomarkers for atherosclerosis. This five-gene model can stratify patient risk and guide personalized anti-inflammatory/autophagic therapy.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>atherosclerosis</kwd><kwd>mitophagy</kwd><kwd>immune infiltration</kwd><kwd>bioinformatics</kwd><kwd>cardiovascular disease</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>High-Quality Clinical Research Project of Peking University First Hospital</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution>the PKU-Baidu Fund</institution></institution-wrap></funding-source></award-group><funding-statement>This research was funded by High-Quality Clinical Research Project of Peking University First Hospital (2023HQ04) and by the PKU-Baidu Fund (2019BD019).</funding-statement></funding-group><counts><fig-count count="12"/><table-count count="5"/><ref-count count="60"/><page-count count="22"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Atherosclerosis is a complex and chronic inflammatory disease of the arteries, characterized by the formation of atherosclerotic plaques.<xref rid="cit0001" ref-type="bibr">1</xref> Its pathogenesis involves a combination of endothelial injury, lipid accumulation, and dysregulated immune responses that promote plaque development within the arterial wall. These pathological processes are exacerbated by well-established risk factors such as hypercholesterolemia, hypertension, diabetes, obesity, and smoking.<xref rid="cit0002" ref-type="bibr">2</xref> Despite significant advances in diagnostic and therapeutic strategies, atherosclerosis remains the leading cause of cardiovascular-related morbidity and mortality worldwide.<xref rid="cit0003" ref-type="bibr">3</xref> Therefore, identifying precise molecular markers and elucidating their roles in atherogenesis are essential steps toward improving the clinical diagnosis, risk stratification, and treatment of atherosclerotic disease.</p><p>Mitophagy, the selective autophagic degradation of damaged mitochondria, is vital for maintaining cellular homeostasis, particularly in vascular endothelial cells, smooth muscle cells, and macrophages&#8212;key players in atherosclerotic plaque development. Increasing evidence indicates that impaired mitophagy contributes to mitochondrial dysfunction and oxidative stress, thereby exacerbating vascular injury and disease progression.<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0005" ref-type="bibr">5</xref> Meanwhile, chronic inflammation&#8212;a hallmark of atherosclerosis&#8212;is driven by immune cell infiltration into the vascular wall,<xref rid="cit0006" ref-type="bibr">6</xref> where macrophages and T lymphocytes release pro-inflammatory cytokines (eg, interferon-&#947;) that promote plaque growth.<xref rid="cit0007" ref-type="bibr">7</xref> Recent studies suggest that mitophagy and immune cell infiltration are interconnected processes in various diseases,<xref rid="cit0008" ref-type="bibr">8</xref> and this crosstalk may play a pivotal role in determining the initiation, progression, and stability of atherosclerotic plaques. For instance, mitophagy helps reduce inflammation by clearing dysfunctional mitochondria, which would otherwise serve as danger signals to activate immune pathways. It also modulates immune responses by promoting M2-type macrophage polarization and influencing T-cell activation and differentiation.<xref rid="cit0009" ref-type="bibr">9</xref> However, most studies to date have focused on mitophagy or immune mechanisms independently, leaving the interplay between these processes in the context of atherosclerosis largely unexplored. This gap highlights the need for an integrative approach that examines mitophagy and immune regulation concurrently to uncover new mechanistic insights and identify novel therapeutic targets.</p><p>In this study, we conducted an integrated bioinformatics analysis using two publicly available human gene expression datasets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>)<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref> to identify differentially expressed MRGs in atherosclerotic tissues. We further explored the relationship between these MRGs and immune cell infiltration. To validate our findings, we examined the expression of candidate genes in ox-LDL&#8211;stimulated macrophage models using quantitative PCR (qPCR). Collectively, our results provide new evidence that genes involved in mitophagy and immunity contribute to the pathogenesis of atherosclerosis and may serve as promising diagnostic biomarkers and therapeutic targets.</p></sec><sec id="s0002"><title>Materials and Methods</title><sec id="s0002-s2001"><title>Data Acquisition</title><p>Atherosclerosis-related microarray datasets <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link><xref rid="cit0010" ref-type="bibr">10</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link><xref rid="cit0011" ref-type="bibr">11</xref> were obtained from the NCBI Gene Expression Omnibus (GEO) database using the GEOquery package (version 2.76.0).<xref rid="cit0012" ref-type="bibr">12</xref> <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GPL6244">GPL6244</ext-link> platform) contained 64 samples (32 atherosclerotic lesions and 32 non-atherosclerotic controls), and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GPL17077">GPL17077</ext-link> platform) comprised 104 samples (69 atherosclerotic and 35 controls). A total of 2,414 MRGs were identified from GeneCards by searching the term &#8220;mitophagy&#8221;, and these are listed in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Table S1</ext-link></underline>.<xref rid="cit0013" ref-type="bibr">13</xref></p></sec><sec id="s0002-s2002"><title>Differential Analysis</title><p>The two GEO datasets were merged, and batch effects were corrected using the ComBat algorithm implemented in the sva package (version 3.56.0).<xref rid="cit0014" ref-type="bibr">14</xref> We verified successful batch effect removal by comparing sample expression distributions on boxplots before and after ComBat adjustment, which showed aligned medians across batches. Quantile normalization was applied as needed in conjunction with ComBat, following best-practice recommendations. After batch correction, differential expression analysis was performed using the limma package (version 3.64.1).<xref rid="cit0015" ref-type="bibr">15</xref> Genes with |log<sub>2</sub>FC| &gt; 1 and adjusted P &lt; 0.05 were considered differentially expressed genes (DEGs). Results were visualized with pheatmap (version 1.0.13) heatmaps and ggplot2 (version 3.5.2) volcano plots.</p></sec><sec id="s0002-s2003"><title>Enrichment Analysis</title><p>Gene Ontology (GO)<xref rid="cit0016" ref-type="bibr">16</xref> and Kyoto Encyclopedia of Genes and Genomes (KEGG)<xref rid="cit0017" ref-type="bibr">17</xref> pathway enrichment analyses were performed to investigate the biological functions of the identified MRGs. We utilized the WebGestalt toolkit<xref rid="cit0018" ref-type="bibr">18</xref> for GO and KEGG analyses, with statistical significance defined as P &lt; 0.05.</p></sec><sec id="s0002-s2004"><title>Selection of Feature Genes</title><p>Key diagnostic genes (hub genes) were identified using multiple machine-learning approaches. Least absolute shrinkage and selection operator (LASSO) regression, support vector machine-recursive feature elimination (SVM-RFE), and random forest algorithms were applied to the DEGs. These methods were implemented using the glmnet package (version 4.1&#8211;10) for LASSO, the e1071 package for SVM-RFE,<xref rid="cit0019" ref-type="bibr">19</xref> and the randomForest package (version 4.7&#8211;1.2) for random forest modeling.<xref rid="cit0020" ref-type="bibr">20</xref></p><p>The top-performing hub genes were further evaluated with a nomogram for diagnostic prediction. A nomogram was constructed using the rms package (version 8.0&#8211;0)<xref rid="cit0021" ref-type="bibr">21</xref> to illustrate the contribution of each hub gene to atherosclerosis risk. Calibration curves were plotted to assess the agreement between predicted risk and actual outcomes. The diagnostic performance was quantified by the area under the receiver operating characteristic curve (AUC), calculated using the pROC package (version 1.18.5).<xref rid="cit0022" ref-type="bibr">22</xref></p></sec><sec id="s0002-s2005"><title>Gene Set Enrichment and Variation Analysis</title><p>To explore pathway-level differences, gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were performed. Samples were stratified into high-risk and low-risk groups based on the median risk score derived from the diagnostic model. GSEA was conducted using the clusterProfiler package (version 4.16.0) with the c2.all.v7.2 curated gene set from the MSigDB database as the reference, and a significance threshold of P &lt; 0.05 was applied.<xref rid="cit0023" ref-type="bibr">23</xref>,<xref rid="cit0024" ref-type="bibr">24</xref> In parallel, GSVA (version 2.2.0) was used to estimate the variation in pathway activity across individual atherosclerotic samples based on their gene expression matrices.<xref rid="cit0025" ref-type="bibr">25</xref> Differentially enriched pathways between the high- and low-risk groups were identified using the limma package, with thresholds set at |log<sub>2</sub>FC| &gt; 1 and adjusted P &lt; 0.05.<xref rid="cit0015" ref-type="bibr">15</xref></p></sec><sec id="s0002-s2006"><title>Network Construction</title><p>Protein-protein interaction (PPI) networks were constructed using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins)<xref rid="cit0026" ref-type="bibr">26</xref> to explore interactions among hub genes. Additionally, mRNA&#8211;miRNA and mRNA&#8211;RBP regulatory networks were obtained from starBase.<xref rid="cit0027" ref-type="bibr">27</xref> Transcription factor (TF) binding predictions were conducted using the PROMO database,<xref rid="cit0028" ref-type="bibr">28</xref> resulting in comprehensive mRNA&#8211;miRNA, mRNA&#8211;RBP, and mRNA&#8211;TF interaction networks.</p></sec><sec id="s0002-s2007"><title>Immune Analysis</title><p>Immune cell infiltration was evaluated using the CIBERSORT algorithm<xref rid="cit0029" ref-type="bibr">29</xref> based on expression profiles of 22 immune cell types. Additionally, single-sample gene set enrichment analysis (ssGSEA)<xref rid="cit0030" ref-type="bibr">30</xref> was used to quantify 28 types of immune cells and immune response activities in individual samples. Visualizations of immune cell distributions were created using ggplot2. Correlations between hub gene expression and immune cell abundance were further analyzed, and differences in immune infiltration among atherosclerotic subtypes were explored.</p></sec><sec id="s0002-s2008"><title>Clustering Analysis</title><p>Unsupervised consensus clustering was performed using the ConsensusClusterPlus package (version 1.72.0)<xref rid="cit0031" ref-type="bibr">31</xref> to classify atherosclerotic samples into molecular subtypes.</p></sec><sec id="s0002-s2009"><title>Cell Culture and Treatment</title><p>RAW264.7 (mouse macrophage cell line) and THP-1 (human monocyte cell line) were purchased from Procell (Wuhan, China). RAW264.7 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), and THP-1 cells were cultured in RPMI1640 with 10% FBS. Both cell lines were maintained at 37&#176;C in a humidified atmosphere with 5% CO<sub>2</sub>. To induce macrophage differentiation, THP-1 cells were treated with 100 ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma) for 48&#160;hours.</p><p>To simulate the pro-inflammatory environment of atherosclerotic lesions in vitro, cells were divided into control and experimental groups. Experimental cells were treated with oxidized low-density lipoprotein (ox-LDL, 50&#160;&#181;g/mL; Yiyuan Biotech, Guangzhou, China) for 24&#160;h. This ox-LDL stimulation induces macrophage foam-cell formation and mimics atherosclerotic inflammatory conditions, as established in previous studies.<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0033" ref-type="bibr">33</xref> All cell experiments were performed in triplicate independent runs (n = 3) to ensure reproducibility.</p></sec><sec id="s0002-s2010"><title>RNA Extraction and cDNA Synthesis</title><p>Total RNA was extracted from treated cells using TRIzol reagent (Invitrogen, USA) according to the manufacturer&#8217;s protocol. RNA purity and concentration were assessed using NanoDrop spectrophotometer (Thermo Scientific). Reverse transcription was conducted using PrimeScript&#8482; RT Reagent Kit (TaKaRa, Japan) following manufacturer&#8217;s instructions, obtaining cDNA templates for subsequent qPCR analysis.</p></sec><sec id="s0002-s2011"><title>Quantitative Real-Time PCR (qPCR)</title><p>qPCR was performed with SYBR Green Master Mix (TaKaRa) on an ABI 7500 Real-Time PCR System. Cycling conditions were: 95&#176;C for 30s, followed by 40 cycles of 95&#176;C for 5&#8239;s and 60&#176;C for 30s. Relative gene expression was calculated by the 2^<sup>&#8722;&#916;&#916;Ct</sup> method using &#946;-actin (mouse) or GAPDH (human) as internal controls. Primer sequences are listed below:</p><p>Mouse primers: Mnda (forward 5&#8242;-GACAACCAAGAGCAATACACCA-3&#8242;, reverse 5&#8242;-ATCAGTTTGCCCAATCCAGAAT-3&#8242;), Cd163l1 (forward 5&#8242;-CTGGCCTCTGAGTTTAGGGTC-3&#8242;, reverse 5&#8242;-CCCTTGGTGTCGAACCAGC-3&#8242;), Nexn (forward 5&#8242;-ATGAATGACGTTTCGCAAAAGG-3&#8242;, reverse 5&#8242;-GCTAATTCGCGCTGTATTTTCC-3&#8242;), Tc2n (forward 5&#8242;-CCATTGGTATCCCTCCATTGAC-3&#8242;, reverse 5&#8242;-GGGCACCACAAATTGTACTTCTT-3&#8242;), Slc22a3 (forward 5&#8242;-CAGCCCGACTACTATTGGTGT-3&#8242;, reverse 5&#8242;-TGAGCTGGTATTAGTGGCTTCC-3&#8242;); &#946;-Actin (forward 5&#8242;-TCCGGCACTACCGAGTTATC-3&#8242;, reverse 5&#8242;-GATCCGGTGTAGCAGATCGC-3&#8242;).</p><p>Human primers: MNDA (forward 5&#8242;-GTTTACTCCGAATCAGGAAACCC-3&#8242;, reverse 5&#8242;-TAAATGGCGCTGTTGCTTTCA-3&#8242;), CD163L1 (forward 5&#8242;-GCTGTGGTAACTTGCATCCTG-3&#8242;, reverse 5&#8242;-GCAGTAGTGTTCCACCCATCA-3&#8242;), NEXN (forward 5&#8242;-ACTGTGAAGGGTAGATTTGCTG-3&#8242;, reverse 5&#8242;-TTCTGCGTTTTCGTTCCTCCT-3&#8242;), TC2N (forward 5&#8242;-TGGCTGTACTGAGGATTATTTGC-3&#8242;, reverse 5&#8242;-TGTGAAGGAGTTTCTTGTGTCC-3&#8242;), SLC22A3 (forward 5&#8242;-CTTCCGCTTCCTGCAAGGT-3&#8242;, reverse 5&#8242;-AAGTAGGCAATTCCAGGGAGA-3&#8242;); GAPDH (forward 5&#8242;-TGCACCACCAACTGCTTAGC-3&#8242;, reverse 5&#8242;-GGCATGGACTGTGGTCATGAG-3&#8242;).</p></sec><sec id="s0002-s2012"><title>Statistical Analysis</title><p>All statistical analyses were performed in R (version 3.6.3). Package versions used throughout the analysis are specified above to ensure reproducibility and statistical rigor.</p></sec></sec><sec id="s0003"><title>Results</title><sec id="s0003-s2001"><title>Overview of DEGs in Atherosclerosis</title><p>The workflow of this study is illustrated in <xref rid="f0001" ref-type="fig">Figure 1</xref>. The datasets used in this study are summarized in <xref rid="t0001" ref-type="table">Table 1</xref>. <xref rid="f0002" ref-type="fig">Figure 2A</xref> and <xref rid="f0002" ref-type="fig">B</xref> show the uncorrected and corrected boxplots of datasets <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>, respectively. Differential expression analysis between the Atherosclerotic and Control groups in the merged datasets identified 182 DEGs meeting the criteria |log<sub>2</sub>FC| &gt; 1 and P.adj &lt; 0.05, comprising 136 upregulated and 46 downregulated genes (<xref rid="f0002" ref-type="fig">Figure 2C</xref>). The most significantly upregulated genes were MMP9, IBSP, ACP5, MMP7, and MMP12, whereas the most significantly downregulated genes were PI16, CASQ2, DES, PLA2G2A, and MYOC (<xref rid="f0002" ref-type="fig">Figure 2D</xref>).<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1</label><caption><p>Dataset Information</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">GEO Data Set</th><th rowspan="1" colspan="1">Platform</th><th align="left" rowspan="1" colspan="1">Control</th><th align="left" rowspan="1" colspan="1">Atherosclerotic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link></td><td rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GPL6244">GPL6244</ext-link></td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">32</td></tr><tr><td rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link></td><td rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GPL17077">GPL17077</ext-link></td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">69</td></tr></tbody></table></table-wrap>
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>Research design flowchart.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0001.jpg"/><attrib><bold>Abbreviations</bold>: GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; LASSO, Least absolute shrinkage and selection operator; SVM-RFE, support vector machine-recursive feature elimination; GSEA, Gene set enrichment analysis; GSVA, Gene set variation analysis; ssGSEA, single-sample gene set enrichment analysis; CIBERSORT, cell-type identification by estimating relative subsets of RNA transcripts.</attrib></fig>
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>Comparative analysis of Atherosclerotic and Control samples. (<bold>A</bold>) Pre-normalization boxplot for datasets <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>. (<bold>B</bold>) Post-normalization boxplot for datasets <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>. (<bold>C</bold>) Volcano plot highlighting the differentially expressed genes (DEGs) between the Atherosclerotic and Control groups. (<bold>D</bold>) Heatmap representing the top five upregulated and downregulated DEGs in the Atherosclerotic and Control groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0002.jpg"/></fig></p></sec><sec id="s0003-s2002"><title>Identification of MRGs</title><p>A cross-analysis with 2,414 MRGs yielded 13 upregulated (HMOX1, FABP5, APOE, FBP1, C15orf48, MS4A4A, ITGAX, VAMP8, CD163L1, IL1B, CA2, CTSD, and MNDA) and six downregulated (SLC22A3, NEXN, MYOM1, FLNC, TC2N, and CASQ2) MRGs (<xref rid="f0003" ref-type="fig">Figure 3A</xref>). The chromosomal locations of these 19 genes are shown in <xref rid="f0003" ref-type="fig">Figure 3B</xref>. Their expression patterns are displayed in the heatmap (<xref rid="f0003" ref-type="fig">Figure 3C</xref>), volcano plot (<xref rid="f0003" ref-type="fig">Figure 3D</xref>), and boxplots (<xref rid="f0003" ref-type="fig">Figure 3E</xref>). Across all three visualization approaches, HMOX1, FABP5, APOE, FBP1, C15orf48, MS4A4A, ITGAX, VAMP8, CD163L1, IL1B, CA2, CTSD, and MNDA were markedly upregulated in the Atherosclerotic group, whereas SLC22A3, NEXN, MYOM1, FLNC, TC2N, and CASQ2 were significantly downregulated. Correlations among the 19 genes are presented in <xref rid="f0004" ref-type="fig">Figure 4A</xref>. ROC curves for MNDA, CD163L1, TC2N, and SLC22A3 showed AUC values above 0.85 in atherosclerotic tissue (<xref rid="f0004" ref-type="fig">Figure 4B&#8211;D</xref>).
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>Analysis of mitophagy-related gene expression in Atherosclerotic and Control samples. (<bold>A</bold>) Venn diagram illustrating the overlap between differentially expressed genes (DEGs) and mitophagy-related genes (MRGs). (<bold>B</bold>) Chromosomal localization of differentially expressed mitophagy genes. (<bold>C</bold>) Heatmap displaying the differential expression of mitophagy genes in the Atherosclerotic and Control groups (yellow = high expression and blue = low expression). (<bold>D</bold>) Volcano plot showing differential expression analysis of mitophagy genes between the Atherosclerotic and Control groups. (<bold>E</bold>) Expression profile of differentially expressed mitophagy genes in the Atherosclerotic and Control groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0003.jpg"/><attrib><bold>Note</bold>: (***<italic toggle="yes">P</italic> &lt; 0.001).</attrib></fig>
<fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4</label><caption><p>Correlation and diagnostic analysis of differentially expressed mitophagy genes in the combined dataset. (<bold>A</bold>) Heatmap illustrating the correlations between differentially expressed mitophagy genes in Atherosclerotic samples, with yellow indicating positive correlation and blue indicating negative correlation. (<bold>B-D</bold>) Diagnostic receiver operating characteristic (ROC) curves for selected differentially expressed mitophagy genes in the Atherosclerotic and Control groups: (<bold>B</bold>) MNDA, MS4A4A, CTSD, FABP5, CD163L1, C15orf48, ITGAX (<bold>C</bold>) APOE, VAMP8, IL1B, HMOX1, CA2, FBP1 (<bold>D</bold>) NEXN, CASQ2, TC2N, MYOM1, SLC22A3, FLNC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0004.jpg"/><attrib><bold>Note</bold>: (*<italic toggle="yes">P</italic> &lt; 0.05; **<italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">P</italic> &lt; 0.001).</attrib></fig></p></sec><sec id="s0003-s2003"><title>Enrichment Analyses of MRGs</title><p>In this study, functional enrichment analyses were performed using the GO and KEGG databases to understand the potential functions and pathways of MRGs in the development of atherosclerosis (<xref rid="t0002 t0003" ref-type="table">Tables 2, 3</xref> and <xref rid="f0005" ref-type="fig">Figure 5</xref>). GO enrichment analysis was performed to determine the biological characteristics of the DEGs, and the results were divided into three functional categories: biological processes (BP), cell components (CC), and molecular functions (MF). The MRGs were mainly associated with biological processes, such as response to stimulus, localization, biological regulation, cell communication, cellular component organization, multicellular organismal processes, developmental processes, and metabolic processes (<xref rid="f0005" ref-type="fig">Figure 5A&#8211;C</xref> and <xref rid="t0002" ref-type="table">Table 2</xref>). KEGG analysis identified enrichment in pathways, such as the pentose phosphate pathway, antifolate resistance, autophagy, fluid shear stress, and atherosclerosis (<xref rid="f0005" ref-type="fig">Figure 5D</xref> and <xref rid="t0003" ref-type="table">Table 3</xref>, <italic toggle="yes">P</italic> &lt; 0.05). The pathway maps are shown in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Figure S1</ext-link></underline>.<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2</label><caption><p>Gene Ontology Enrichment Analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Gene Set</th><th rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Size</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0050896</td><td rowspan="1" colspan="1">Response to stimulus</td><td rowspan="1" colspan="1">15</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0051179</td><td rowspan="1" colspan="1">Localization</td><td rowspan="1" colspan="1">15</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0065007</td><td rowspan="1" colspan="1">Biological regulation</td><td rowspan="1" colspan="1">13</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0007154</td><td rowspan="1" colspan="1">Cell communication</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0016043</td><td rowspan="1" colspan="1">Cellular component organization</td><td rowspan="1" colspan="1">10</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0032501</td><td rowspan="1" colspan="1">Multicellular organismal process</td><td rowspan="1" colspan="1">10</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0032502</td><td rowspan="1" colspan="1">Developmental process</td><td rowspan="1" colspan="1">10</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0008152</td><td rowspan="1" colspan="1">Metabolic process</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0051704</td><td rowspan="1" colspan="1">Multi-organism process</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0008283</td><td rowspan="1" colspan="1">Cell proliferation</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0040007</td><td rowspan="1" colspan="1">Growth</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">BP</td><td rowspan="1" colspan="1">GO:0000003</td><td rowspan="1" colspan="1">Reproduction</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0016020</td><td rowspan="1" colspan="1">Membrane</td><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005615</td><td rowspan="1" colspan="1">Extracellular space</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0012505</td><td rowspan="1" colspan="1">Endomembrane system</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0031982</td><td rowspan="1" colspan="1">Vesicle</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005634</td><td rowspan="1" colspan="1">Nucleus</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005829</td><td rowspan="1" colspan="1">Cytosol</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0031974</td><td rowspan="1" colspan="1">Membrane-enclosed lumen</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0032991</td><td rowspan="1" colspan="1">Protein-containing complex</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005773</td><td rowspan="1" colspan="1">Vacuole</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005783</td><td rowspan="1" colspan="1">Endoplasmic reticulum</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0042995</td><td rowspan="1" colspan="1">Cell projection</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005856</td><td rowspan="1" colspan="1">Cytoskeleton</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005768</td><td rowspan="1" colspan="1">Endosome</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0031012</td><td rowspan="1" colspan="1">Extracellular matrix</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005794</td><td rowspan="1" colspan="1">Golgi apparatus</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0005739</td><td rowspan="1" colspan="1">Mitochondrion</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">GO:0031975</td><td rowspan="1" colspan="1">Envelope</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0005515</td><td rowspan="1" colspan="1">Protein binding</td><td rowspan="1" colspan="1">16</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0043167</td><td rowspan="1" colspan="1">Ion binding</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0016787</td><td rowspan="1" colspan="1">Hydrolase activity</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0005198</td><td rowspan="1" colspan="1">Structural molecule activity</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0005215</td><td rowspan="1" colspan="1">Transporter activity</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0008289</td><td rowspan="1" colspan="1">Lipid binding</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0016209</td><td rowspan="1" colspan="1">Antioxidant activity</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0030234</td><td rowspan="1" colspan="1">Enzyme regulator activity</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0000166</td><td rowspan="1" colspan="1">Nucleotide binding</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0030246</td><td rowspan="1" colspan="1">Carbohydrate binding</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0009055</td><td rowspan="1" colspan="1">Electron transfer activity</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0060089</td><td rowspan="1" colspan="1">Molecular transducer activity</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">MF</td><td rowspan="1" colspan="1">GO:0003676</td><td rowspan="1" colspan="1">Nucleic acid binding</td><td rowspan="1" colspan="1">1</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3</label><caption><p>Kyoto Encyclopedia of Genes and Genomes Enrichment Analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Gene Set</th><th rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Size</th><th align="left" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">hsa00030</td><td rowspan="1" colspan="1">Pentose phosphate pathway</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">0.047134</td></tr><tr><td rowspan="1" colspan="1">hsa00910</td><td rowspan="1" colspan="1">Nitrogen metabolism</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">0.026963</td></tr><tr><td rowspan="1" colspan="1">hsa01523</td><td rowspan="1" colspan="1">Antifolate resistance</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">0.047134</td></tr><tr><td rowspan="1" colspan="1">hsa04140</td><td rowspan="1" colspan="1">Autophagy</td><td rowspan="1" colspan="1">127</td><td rowspan="1" colspan="1">0.01679</td></tr><tr><td rowspan="1" colspan="1">hsa04964</td><td rowspan="1" colspan="1">Proximal tubule bicarbonate reclamation</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">0.03632</td></tr><tr><td rowspan="1" colspan="1">hsa04966</td><td rowspan="1" colspan="1">Collecting duct acid secretion</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">0.042513</td></tr><tr><td rowspan="1" colspan="1">hsa05010</td><td rowspan="1" colspan="1">Alzheimer disease</td><td rowspan="1" colspan="1">170</td><td rowspan="1" colspan="1">0.029031</td></tr><tr><td rowspan="1" colspan="1">hsa05132</td><td rowspan="1" colspan="1">Salmonella infection</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">0.0074215</td></tr><tr><td rowspan="1" colspan="1">hsa05152</td><td rowspan="1" colspan="1">Tuberculosis</td><td rowspan="1" colspan="1">178</td><td rowspan="1" colspan="1">0.0024358</td></tr><tr><td rowspan="1" colspan="1">hsa05418</td><td rowspan="1" colspan="1">Fluid shear stress and atherosclerosis</td><td rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">0.019113</td></tr></tbody></table></table-wrap>
<fig position="float" id="f0005" fig-type="figure" orientation="portrait"><label>Figure 5</label><caption><p>GO and KEGG enrichment analysis of differentially expressed mitophagy genes in the combined dataset. (<bold>A-C</bold>) Enrichment analysis of differentially expressed mitophagy genes in the Atherosclerotic and Control groups, targeting (<bold>A</bold>) Biological Process, (<bold>B</bold>) Cellular Component, (<bold>C</bold>) Molecular Function. (<bold>D</bold>) Kyoto Encyclopedia of Genes and Genomes pathways.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0005.jpg"/><attrib><bold>Abbreviations</bold>: GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.</attrib></fig></p></sec><sec id="s0003-s2004"><title>Hub Gene Selection by Machine Learning</title><p>LASSO logistic regression analysis (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Figure S2A</ext-link></underline>) identified 18 genes from 19 MRGs (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Figure S2B</ext-link></underline>). The SVM-RFE algorithm further refined this to 16 genes with an accuracy of 0.923 (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Figure S2C</ext-link></underline>) and an error rate of 0.0774 (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Figure S2D</ext-link></underline>). The relationship between the number of decision trees and errors in RF model construction is shown in <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Figure S2E</ext-link></underline>, including the top six important MRGs (SLC22A3, TC2N, CD163L1, MNDA, HMOX1, and NEXN) (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Figure S2F</ext-link></underline>).</p><p>The intersection of the three algorithms yielded five diagnosis-related hub genes: MNDA, CD163L1, NEXN, TC2N, and SLC22A3 (<xref rid="f0006" ref-type="fig">Figure 6A</xref>). Individual gene AUCs showed high diagnostic efficiency (AUC &gt; 0.85), indicating high diagnostic value (<xref rid="f0006" ref-type="fig">Figure 6B</xref>). A line graph constructed using the hub genes is shown in <xref rid="f0006" ref-type="fig">Figure 6C</xref>. A calibration plot illustrated good agreement between the actual and predicted probabilities of atherosclerotic diagnosis (<xref rid="f0006" ref-type="fig">Figure 6D</xref>), demonstrating that the model possessed robust diagnostic efficacy.
<fig position="float" id="f0006" fig-type="figure" orientation="portrait"><label>Figure 6</label><caption><p>Analysis of hub genes derived from the combined dataset. (<bold>A</bold>) Venn diagram depicting the feature genes selected using the three distinct algorithms. (<bold>B</bold>) Forest plot illustrating the AUC for the identified hub genes. (<bold>C</bold>) Line plots constructed from the selected hub genes. (<bold>D</bold>) Calibration plot derived from the line plot model. Area Under the Curve, AUC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0006.jpg"/></fig></p></sec><sec id="s0003-s2005"><title>GSEA and GSVA Analyses</title><p>Patients with atherosclerosis were stratified into high- and low-risk groups based on the median risk score from the hub gene model. Differential expression analysis between these groups identified 26 DEGs (|log<sub>2</sub>FC| &gt; 1, P.adj &lt; 0.05), including 10 upregulated and 16 downregulated genes in the high-risk group (<xref rid="f0007" ref-type="fig">Figure 7A</xref>). The top five upregulated and downregulated genes are displayed in <xref rid="f0007" ref-type="fig">Figure 7B</xref>. GSEA identified pathways enriched in the high-risk group, including the WP IL-18 signaling pathway, KEGG chemokine signaling pathway, Alcala apoptosis, and WP B cell receptor signaling pathway (<xref rid="f0007" ref-type="fig">Figure 7C</xref> and <xref rid="t0004" ref-type="table">Table 4</xref>). GSVA revealed that the GO positive regulation of cardiac vascular smooth muscle cell differentiation pathway was enriched in the low-risk group (<xref rid="f0007" ref-type="fig">Figure 7D</xref> and <xref rid="t0005" ref-type="table">Table 5</xref>).<table-wrap position="float" id="t0004" orientation="portrait"><label>Table 4</label><caption><p>Gene Set Enrichment Analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Description</th><th rowspan="1" colspan="1">Setsize</th><th rowspan="1" colspan="1">NES</th><th rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">WP_IL18_SIGNALING_PATHWAY</td><td rowspan="1" colspan="1">254</td><td rowspan="1" colspan="1">1.910765637</td><td rowspan="1" colspan="1">0.001597444</td></tr><tr><td rowspan="1" colspan="1">KEGG_CHEMOKINE_SIGNALING_PATHWAY</td><td rowspan="1" colspan="1">172</td><td rowspan="1" colspan="1">1.979137305</td><td rowspan="1" colspan="1">0.001650165</td></tr><tr><td rowspan="1" colspan="1">ALCALA_APOPTOSIS</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">1.82034905</td><td rowspan="1" colspan="1">0.001712329</td></tr><tr><td rowspan="1" colspan="1">WP_B_CELL_RECEPTOR_SIGNALING_PATHWAY</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">1.866728646</td><td rowspan="1" colspan="1">0.001733102</td></tr><tr><td rowspan="1" colspan="1">WP_TNF_ALPHA_SIGNALING_PATHWAY</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">1.893610264</td><td rowspan="1" colspan="1">0.001748252</td></tr><tr><td rowspan="1" colspan="1">BIOCARTA_NFKB_PATHWAY</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">1.91215931</td><td rowspan="1" colspan="1">0.001845018</td></tr><tr><td rowspan="1" colspan="1">PID_PI3KCI_PATHWAY</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">1.961340656</td><td rowspan="1" colspan="1">0.001865672</td></tr><tr><td rowspan="1" colspan="1">WP_SENESCENCE_AND_AUTOPHAGY_IN_CANCER</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">1.438630285</td><td rowspan="1" colspan="1">0.010544815</td></tr><tr><td rowspan="1" colspan="1">PID_P53_DOWNSTREAM_PATHWAY</td><td rowspan="1" colspan="1">125</td><td rowspan="1" colspan="1">1.35248466</td><td rowspan="1" colspan="1">0.026132404</td></tr><tr><td rowspan="1" colspan="1">MOOTHA_MITOCHONDRIA</td><td rowspan="1" colspan="1">400</td><td rowspan="1" colspan="1">1.259252988</td><td rowspan="1" colspan="1">0.028963415</td></tr></tbody></table></table-wrap>
<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 5</label><caption><p>Gene Set Variation Analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Id</th><th align="center" rowspan="1" colspan="1">logFC</th><th align="center" rowspan="1" colspan="1">adj.P.Val</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">REACTOME_RHO_GTPASES_ACTIVATE_PAKS</td><td rowspan="1" colspan="1">&#8722;0.530450952</td><td rowspan="1" colspan="1">4.63E-13</td></tr><tr><td rowspan="1" colspan="1">PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN</td><td rowspan="1" colspan="1">&#8722;0.72754498</td><td rowspan="1" colspan="1">4.63E-13</td></tr><tr><td rowspan="1" colspan="1">GSE19198_CTRL_VS_IL21_TREATED_TCELL_6H_UP</td><td rowspan="1" colspan="1">0.402079877</td><td rowspan="1" colspan="1">3.45E-12</td></tr><tr><td rowspan="1" colspan="1">GO_BETA_2_MICROGLOBULIN_BINDING</td><td rowspan="1" colspan="1">0.791297562</td><td rowspan="1" colspan="1">7.05E-12</td></tr><tr><td rowspan="1" colspan="1">GO_DICHOTOMOUS_SUBDIVISION_OF_TERMINAL_UNITS_INVOLVED_IN_SALIVARY_GLAND_BRANCHING</td><td rowspan="1" colspan="1">0.799881156</td><td rowspan="1" colspan="1">7.05E-12</td></tr><tr><td rowspan="1" colspan="1">GO_REGULATION_OF_DENDRITIC_CELL_DIFFERENTIATION</td><td rowspan="1" colspan="1">0.659880403</td><td rowspan="1" colspan="1">7.05E-12</td></tr><tr><td rowspan="1" colspan="1">GO_COMPLEMENT_BINDING</td><td rowspan="1" colspan="1">0.502059467</td><td rowspan="1" colspan="1">7.78E-12</td></tr><tr><td rowspan="1" colspan="1">GO_POSITIVE_REGULATION_OF_CARDIAC_VASCULAR_SMOOTH_MUSCLE_CELL_DIFFERENTIATION</td><td rowspan="1" colspan="1">&#8722;1.03086206</td><td rowspan="1" colspan="1">7.78E-12</td></tr><tr><td rowspan="1" colspan="1">OCT1_03</td><td rowspan="1" colspan="1">&#8722;0.328112739</td><td rowspan="1" colspan="1">1.60E-11</td></tr><tr><td rowspan="1" colspan="1">GO_DICHOTOMOUS_SUBDIVISION_OF_AN_EPITHELIAL_TERMINAL_UNIT</td><td rowspan="1" colspan="1">0.655770191</td><td rowspan="1" colspan="1">1.69E-11</td></tr></tbody></table></table-wrap>
<fig position="float" id="f0007" fig-type="figure" orientation="portrait"><label>Figure 7</label><caption><p>Differential analysis between high- and low-risk groups in patients with atherosclerosis from the combined dataset. (<bold>A</bold>) Volcano plot illustrating differential gene expression between high- and low-risk groups; yellow indicates upregulated genes, and blue indicates downregulated genes. (<bold>B</bold>) Heatmap of the top five upregulated and downregulated differential genes, with yellow representing upregulated genes and blue representing downregulated genes. (<bold>C</bold>) Mountain plot of GSEA based on high- and low-risk groups. (<bold>D</bold>) Heatmap of GSVA based on high- and low-risk groups, where blue signifies log<sub>2</sub>FC &lt; 0 and yellow signifies log<sub>2</sub>FC &gt; 0.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0007.jpg"/><attrib><bold>Abbreviations</bold>: GSEA, Gene set enrichment analysis; GSVA, Gene set variation analysis.</attrib></fig></p></sec><sec id="s0003-s2006"><title>Network Construction</title><p>A PPI network of the hub genes was constructed using the STRING database (<xref rid="f0008" ref-type="fig">Figure 8A</xref>). Specifically, MNDA interacted with TYROBP and NCF2, whereas NEXN interacted with CTNNB1, CTTN, DBN1, and GRN, and CTNNB1 engaged with SLC22A3. Additionally, mRNA-miRNA interaction networks were derived from starBase (<xref rid="f0008" ref-type="fig">Figure 8B</xref> and <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/544597/544597%20Revised%20Supplementary_Material_1_1_1.docx" ext-link-type="uri">Table S2</ext-link></underline>). This network included interactions, such as CD163L1 with hsa-miR-146a-5p and hsa-miR-589-5p, and MNDA with hsa-miR-541-3p. The mRNA-RBP interaction network, predicted using the same database, is shown in <xref rid="f0008" ref-type="fig">Figure 8C</xref>. RPBs associated with CD163L1 included ACIN1, ADAR, BCCIP, BUD13, CNBP, whereas those associated with MNDA consisted of ELAVL1, FUS, HNRNPL, MSI2, TAF15, TROVE2. The predicted mRNA-TF network was based on the PROMO database (<xref rid="f0008" ref-type="fig">Figure 8D</xref>). TFs, such as Pax-5, p53, AP-2alphaA, NFI/CTF, TFII-I, GR-alpha, RXR-alpha, STAT4, ER-alpha, GCF, and Sp1, interacted with SLC22A3.
<fig position="float" id="f0008" fig-type="figure" orientation="portrait"><label>Figure 8</label><caption><p>Construction of interaction networks involving hub genes. (<bold>A</bold>) Protein-Protein Interaction (PPI) network of hub genes, constructed using the STRING database. (<bold>B</bold>) mRNA-miRNA regulatory network, with blue circles denoting mRNA and yellow triangles indicating miRNA. (<bold>C</bold>) mRNA-RNA-Binding Protein (RBP) regulatory network, where blue circles symbolize mRNA and yellow triangles symbolize RBPs. (<bold>D</bold>) mRNA-Transcription Factor (TF) network, where blue circles signify mRNA and yellow triangles signify TFs. RNA-Binding Protein, RBP; Transcription Factor, TF.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0008.jpg"/></fig></p></sec><sec id="s0003-s2007"><title>Immune Cell Infiltration Analysis</title><p>Using CIBERSORT, the abundance of 22 immune cell types was assessed in the Control, high-, and low-risk Atherosclerotic samples (<xref rid="f0009" ref-type="fig">Figure 9A</xref>). Notably, M0 macrophages were more abundant in Atherosclerotic samples than those in Control samples, and were also elevated in the high-risk versus low-risk Atherosclerotic groups. The heatmap in <xref rid="f0009" ref-type="fig">Figure 9B</xref> illustrates the correlations between hub genes and the infiltration levels of these immune cells in Atherosclerotic samples. Specifically, MNDA (<xref rid="f0009" ref-type="fig">Figure 9C</xref>) and CD163L1 (<xref rid="f0009" ref-type="fig">Figure 9D</xref>) were negatively correlated with plasma cells (R &lt; 0, <italic toggle="yes">P</italic> &lt; 0.05), whereas NEXN (<xref rid="f0009" ref-type="fig">Figure 9E</xref>) and CD163L1 (<xref rid="f0009" ref-type="fig">Figure 9F</xref>) were positively correlated with M2 macrophages and memory B cells, respectively (R &gt; 0, <italic toggle="yes">P</italic> &lt; 0.05).
<fig position="float" id="f0009" fig-type="figure" orientation="portrait"><label>Figure 9</label><caption><p>CIBERSORT immune analysis of atherosclerotic samples based on the combined dataset (<bold>A</bold>) Distribution of immune cells in Control, high-, and low-risk Atherosclerotic samples, as analyzed by CIBERSORT. (<bold>B</bold>) Heatmap illustrating the correlation between hub genes and varying levels of immune cell infiltration in Atherosclerotic samples, where blue denotes a negative correlation, and yellow denotes a positive correlation. (<bold>C-F</bold>) Scatter plots showing the correlation between specific genes and immune cell types: (<bold>C</bold>) Myeloid cell nuclear differentiation antigen (MNDA) and plasma cells, (<bold>D</bold>) CD163 molecule-like 1 (CD163L1) and plasma cells, (<bold>E</bold>) nexilin F-actin binding protein (NEXN) and M2 macrophages, and (<bold>F</bold>) CD163L1 and memory B cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0009.jpg"/><attrib><bold>Note</bold>: (*<italic toggle="yes">P</italic> &lt; 0.05; **<italic toggle="yes">P</italic> &lt; 0.01).</attrib></fig></p><p>ssGSEA was further used to assess the abundance of 28 immune cell types in the Control, high-, and low-risk Atherosclerotic groups (<xref rid="f0010" ref-type="fig">Figure 10A</xref>). There was an increased abundance of several immune cells in the Atherosclerotic samples compared to that in the Control, as well as in high-risk versus low-risk Atherosclerotic samples. The heatmap in <xref rid="f0010" ref-type="fig">Figure 10B</xref> shows significant positive correlations between MNDA, CD163L1, and several immune cells (R &gt; 0, <italic toggle="yes">P</italic> &lt; 0.05) and significant negative correlations between NEXN, TC2N, SLC22A3, and various immune cells (R &lt; 0, <italic toggle="yes">P</italic> &lt; 0.05).
<fig position="float" id="f0010" fig-type="figure" orientation="portrait"><label>Figure 10</label><caption><p>ssGSEA immune analysis of Atherosclerotic samples in the combined dataset. (<bold>A</bold>) Assessment of immune cell distribution in Control, high-, and low-risk Atherosclerotic samples using ssGSEA. (<bold>B</bold>) Heatmap illustrating the relationships between hub genes and various degrees of immune cell infiltration, as determined by ssGSEA.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0010.jpg"/><attrib><bold>Note</bold>: (*<italic toggle="yes">P</italic> &lt; 0.05; **<italic toggle="yes">P</italic> &lt; 0.01).</attrib><attrib><bold>Abbreviations</bold>: Single-sample gene-set enrichment analysis, ssGSEA.</attrib></fig></p></sec><sec id="s0003-s2008"><title>Consensus Clustering of Atherosclerosis</title><p>Unsupervised consensus clustering was employed to identify the molecular subtypes of atherosclerotic disease based on the expression profile data (<xref rid="f0011" ref-type="fig">Figure 11A</xref>). The expression profiles of the hub genes, differentiated into two unique atherosclerotic subtypes, are shown in <xref rid="f0011" ref-type="fig">Figure 11B</xref>. MNDA and CD163L1 were markedly overexpressed in cluster B, whereas TC2N and SLC22A3 were significantly underexpressed in the same cluster. Additionally, immune cell infiltration analysis across different clusters suggested variations in the presence of specific immune cells, such as M0 macrophages, among the different subtypes (<xref rid="f0011" ref-type="fig">Figure 11C</xref>).
<fig position="float" id="f0011" fig-type="figure" orientation="portrait"><label>Figure 11</label><caption><p>Unsupervised consensus clustering analysis of Atherosclerotic samples from the combined dataset (<bold>A</bold>) Distribution of sample clustering when segmented into two clusters. (<bold>B</bold>) Expression profiles of hub genes across atherosclerotic subtypes A and B, following division into two subtypes. (<bold>C</bold>) Status of immune cell infiltration in the two identified subtypes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0011.jpg"/><attrib><bold>Note</bold>: (**<italic toggle="yes">P</italic> &lt; 0.01; ***<italic toggle="yes">P</italic> &lt; 0.001).</attrib></fig></p></sec><sec id="s0003-s2009"><title>qPCR Validation of Candidate Genes</title><p>To validate the expression of candidate MRGs, qPCR was performed in RAW264.7 and THP-1 cells treated with ox-LDL to simulate an atherosclerosis-related inflammatory environment. In RAW264.7 cells, the expression of Mnda and Cd163l1 was significantly increased, while Nexn, Tc2n, and Slc22a3 were downregulated (<xref rid="f0012" ref-type="fig">Figure 12A</xref>). In THP-1 cells, MNDA expression was significantly elevated; CD163L1 showed no significant change. NEXN and SLC22A3 were downregulated, whereas TC2N expression remained unchanged (<xref rid="f0012" ref-type="fig">Figure 12B</xref>).
<fig position="float" id="f0012" fig-type="figure" orientation="portrait"><label>Figure 12</label><caption><p>Validation of expression levels of selected mitophagy-related genes by qPCR (<bold>A</bold>) Relative mRNA expression of Mnda, Cd163l1, Nexn, Tc2n, and Slc22a3 in RAW264.7 cells treated with ox-LDL. &#946;-actin was used as an internal control. (<bold>B</bold>) Relative mRNA expression of MNDA, CD163L1, NEXN, TC2N, and SLC22A3 in THP-1 cells treated with ox-LDL. GAPDH was used as an internal control. Data represent mean &#177; SD from three independent experiments. Statistical significance was determined by unpaired <italic toggle="yes">t</italic>-test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JIR-18-13689-g0012.jpg"/><attrib><bold>Note</bold>: (*<italic toggle="yes">P</italic> &lt; 0.05; **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.001).</attrib></fig></p></sec></sec><sec id="s0004"><title>Discussion</title><p>Our findings underscore the critical interplay between impaired mitophagy and immune dysregulation in atherosclerosis. In this study, we identified 19 differentially expressed MRGs in atherosclerotic lesions through integrated bioinformatic analysis. These genes were enriched in metabolism- and inflammation-related pathways &#8211; notably the pentose phosphate pathway, autophagy, and the &#8220;fluid shear stress and atherosclerosis&#8221; pathway &#8211; suggesting that disturbances in mitochondrial quality control can influence key atherogenic processes. For example, inhibiting the pentose phosphate pathway is known to alter macrophage metabolism and phenotype, thereby attenuating inflammatory responses and slowing plaque progression.<xref rid="cit0034" ref-type="bibr">34</xref> Similarly, aberrant mechanosensory signaling (as indicated by enrichment of the shear stress pathway) can exacerbate endothelial injury and inflammation via mechanisms such as bone morphogenetic protein-9/ALK1-mediated SMAD activation.<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0036" ref-type="bibr">36</xref> Thus, the enrichment analysis supports the concept that mitophagy-associated genes are functionally intertwined with the pathways driving atherosclerotic plaque development.</p><p>Using three machine-learning algorithms (LASSO, SVM-RFE, and random forest), we pinpointed five hub genes with high diagnostic value for atherosclerosis: MNDA, CD163L1, NEXN, TC2N, and SLC22A3. Each of these genes plays a distinct role in cellular function and immune regulation, shedding light on their potential contributions to atherogenesis.</p><p>MNDA (myeloid cell nuclear differentiation antigen) is expressed specifically in the nuclei of granulocyte-monocyte lineage cells and is involved in inflammation and apoptosis.<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0038" ref-type="bibr">38</xref> It can regulate interferon signaling in monocytes via interferon regulatory factor 7 (IRF7),<xref rid="cit0039" ref-type="bibr">39</xref> and it has been linked to autoimmune diseases such as rheumatoid arthritis.<xref rid="cit0040" ref-type="bibr">40</xref> In our analysis, MNDA was significantly up-regulated in atherosclerotic tissues and positively correlated with immune cell infiltration, suggesting that MNDA may promote pro-inflammatory activation within plaques.CD163L1 (CD163-like 1) is a membrane receptor mainly found on monocytes and macrophages,<xref rid="cit0041" ref-type="bibr">41</xref> closely related to the scavenger receptor CD163. CD163L1 and CD163 are known for their roles in immune regulation and the resolution of inflammation. High levels of CD163-positive macrophages have been observed in metabolic and fibrotic diseases.<xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0043" ref-type="bibr">43</xref> Moreover, modulating these macrophages can influence immune responses; for example, interferon-&#947; (IFN-&#947;) enhances CAR T-cell efficacy by affecting CD163<sup>+</sup> M2 macrophages.<xref rid="cit0044" ref-type="bibr">44</xref> The elevated expression of CD163L1 in atherosclerotic lesions in our study suggests a potential involvement in macrophage-driven inflammation or in feedback mechanisms that limit excessive inflammation within plaques.NEXN (Nexilin) is a cytoskeletal protein critical for cardiovascular cell integrity due to its F-actin binding and role in muscle development.<xref rid="cit0045" ref-type="bibr">45</xref> Notably, NEXN has an anti-inflammatory effect in the vasculature. For example, the long non-coding RNA NEXN-AS1 increases NEXN expression, which in turn inhibits Toll-like receptor 4 (TLR4)/NF-&#954;B signaling and reduces adhesion molecule and cytokine levels in endothelial cells; consequently, NEXN helps block monocyte adhesion and mitigates atherosclerosis.<xref rid="cit0046" ref-type="bibr">46</xref> Consistent with this protective role, we found NEXN to be significantly down-regulated in atherosclerotic tissues&#8212;a change that could remove an important brake on inflammatory cell recruitment and plaque formation.TC2N (tandem C2 domains, nuclear) encodes a nuclear protein containing two C2 domains. TC2N has been reported to influence cancer cell behavior (higher expression is linked to worse prognosis in gastric cancer),<xref rid="cit0047" ref-type="bibr">47</xref> although its function in cardiovascular or immune contexts is not well characterized. Our identification of TC2N as a down-regulated hub gene in atherosclerosis is novel, raising the possibility that TC2N normally participates in vesicular trafficking or autophagic processes that restrain inflammatory activation &#8211; a hypothesis that warrants further investigation.SLC22A3 is an organic cation transporter involved in the transmembrane transport of various metabolites.<xref rid="cit0048" ref-type="bibr">48</xref> Genetic polymorphisms in SLC22A3&#160;have been associated with altered risk of coronary heart disease,<xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0050" ref-type="bibr">50</xref> type 2 diabetes,<xref rid="cit0051" ref-type="bibr">51</xref> and hypertension,<xref rid="cit0052" ref-type="bibr">52</xref> and this transporter may also affect blood lipid levels.<xref rid="cit0049" ref-type="bibr">49</xref> We observed that SLC22A3 expression was down-regulated in atherosclerotic lesions, aligning with the notion that reduced transporter activity could influence macrophage lipid handling and vascular inflammation in the plaque microenvironment.</p><p>Collectively, these five diagnostic markers appear to play pivotal roles in processes such as inflammation, immune cell function, and cell signaling. Given that atherosclerosis is fundamentally a chronic inflammatory disease, perturbations in these genes could have significant impacts on its initiation and progression. Indeed, the involvement of NEXN and SLC22A3 in atherosclerosis and coronary artery disease has been noted previously, which is congruent with our findings. Importantly, our study newly implicates MNDA, CD163L1 and TC2N in atherosclerosis, opening up new avenues to explore their utility as biomarkers or therapeutic targets in this disease context.</p><p>Beyond individual genes, we constructed a diagnostic nomogram based on the five hub genes to stratify atherosclerotic patients into high-risk and low-risk groups according to their gene expression profiles. As expected, the high-risk group (with overall higher risk scores from the five-gene model) exhibited enrichment of pro-atherogenic pathways. GSEA and GSVA revealed that pathways related to immune signaling and inflammation were up-regulated in the high-risk subgroup, including pathways such as B cell receptor signaling and TNF-&#945; signaling, as well as biological processes like the positive regulation of vascular smooth muscle cell differentiation. These findings suggest that the identified gene signature captures a state of heightened immune activity and vascular remodeling, which are hallmarks of more advanced or active atherosclerotic disease.Furthermore, our network analysis of hub gene interactions provided additional context. The five hub genes were connected with numerous proteins, microRNAs (miRNAs), RNA-binding proteins (RBPs), and transcription factors known to regulate inflammation and apoptosis. For example, CTNNB1 (&#946;-catenin), a key component of the Wnt signaling pathway, was identified as a protein potentially interacting with the hub genes. CTNNB1 can modulate cytokine and chemokine production and thereby influence immune cell activation and recruitment; indeed, certain CTNNB1 mutations reduce chemokine expression via miRNA-mediated mechanisms, leading to decreased immune cell infiltration in tumors.<xref rid="cit0053" ref-type="bibr">53</xref> Likewise, miR-146a-5p emerged as part of the hub gene regulatory network. This miRNA is an important negative feedback regulator of inflammation: it is up-regulated in response to inflammatory stimuli to help dampen excessive immune reactions.<xref rid="cit0054" ref-type="bibr">54</xref> In cardiovascular contexts, miR-146a-5p has been shown to protect cardiac cells by modulating matrix metalloproteinases and muscle contractility pathways after myocardial infarction,<xref rid="cit0055" ref-type="bibr">55</xref> and aberrant miR-146a-5p signaling is implicated in the progression of autoimmune diseases such as rheumatoid arthritis.<xref rid="cit0056" ref-type="bibr">56</xref> The presence of CTNNB1, miR-146a-5p, and other such molecules in the hub gene interaction networks suggests that our five key genes are integrated into broader immunometabolic regulatory circuits. This systems-level perspective reinforces the idea that MRGs do not act in isolation, but rather influence atherosclerosis as part of complex gene&#8211;network interactions that govern inflammation and cell survival.</p><p>We also characterized immune cell infiltration patterns in atherosclerotic samples and found them to be closely linked with the expression of the hub genes. Immune profiling by CIBERSORT and ssGSEA confirmed that atherosclerotic lesions have significantly higher infiltration of macrophages (particularly undifferentiated M0 macrophages) compared to control arterial tissues, consistent with the chronic inflammatory nature of the disease. Notably, this macrophage elevation was even more pronounced in the high-risk patient subgroup defined by our gene model, indicating that the five-gene signature captures the extent of macrophage-driven inflammation. Correlation analyses further revealed that MNDA and CD163L1 expression levels were positively correlated with several immune cell types (including certain macrophage and lymphocyte populations), in line with their proposed pro-inflammatory roles. In contrast, NEXN, TC2N, and SLC22A3 levels were negatively correlated with immune cell abundance, consistent with the idea that lower expression of these genes accompanies a higher inflammatory state. Unsupervised clustering of the atherosclerotic samples further illustrated this immune imbalance. When samples were divided into two molecular subtypes, one subtype (Cluster&#160;B) was characterized by markedly higher MNDA and CD163L1 expression but lower TC2N and SLC22A3, and this subtype exhibited a greater accumulation of M0 macrophages and other immune cells. These results solidify the association between MRGs perturbations and immune cell dynamics in atherosclerosis. Our findings align with previous reports that mitophagy and immune activity are tightly interconnected.<xref rid="cit0007" ref-type="bibr">7</xref> In atherosclerotic plaques, macrophage-derived foam cells are pivotal drivers of disease progression,<xref rid="cit0057" ref-type="bibr">57</xref> and B cells and plasma cells can modulate autoimmune and inflammatory responses within lesions.<xref rid="cit0058" ref-type="bibr">58</xref> Mitophagy can influence these processes by removing damaged mitochondria from immune cells, thereby preventing excessive inflammation (for instance, by limiting NLRP3 inflammasome activation). Indeed, enhanced mitophagy is known to promote macrophage polarization toward an anti-inflammatory M2 phenotype,<xref rid="cit0059" ref-type="bibr">59</xref> which helps stabilize plaques, and it may also affect T-cell activation and differentiation,<xref rid="cit0060" ref-type="bibr">60</xref> thus altering adaptive immune responses in the plaque microenvironment. Therefore, the shifts in immune cell populations associated with specific mitophagy gene changes in our study provide a mechanistic clue: insufficient mitophagy (as indicated by down-regulation of certain MRGs) could exacerbate immune cell-driven inflammation in atherosclerosis, whereas boosting mitophagy-related pathways might help re-establish immune homeostasis in diseased arteries.</p><p>To further validate our computational findings, we performed in vitro experiments using macrophage models. Oxidized LDL (ox-LDL) stimulation was applied to mimic the pro-atherosclerotic, inflammatory environment in cultured cells.<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0033" ref-type="bibr">33</xref> In mouse RAW264.7 macrophages, ox-LDL exposure significantly up-regulated Mnda and Cd163l1 (the mouse homologs of MNDA and CD163L1), while Nexn, Tc2n, and Slc22a3 were down-regulated&#8212;changes fully consistent with the patterns observed in our human tissue analysis. Similarly, in phorbol ester-differentiated human THP-1 macrophages, MNDA transcript levels were markedly increased after ox-LDL treatment, and NEXN and SLC22A3 were decreased. (CD163L1 and TC2N in the THP-1 cells did not change significantly under ox-LDL, possibly reflecting differences between species or cell differentiation states). Despite these minor discrepancies, the overall concordance between our cell-based results and the bioinformatic predictions strengthens the validity of our findings.The observed up-regulation of MNDA and CD163L1 under inflammatory stress aligns with their roles in promoting macrophage activation and immune responses. Conversely, the down-regulation of NEXN, TC2N, and SLC22A3 in stimulated macrophages supports the idea that reduced expression of these genes accompanies the heightened inflammatory and metabolic activity characteristic of foam cell formation. By demonstrating that our hub genes respond to an atherogenic stimulus in two independent cell models (murine and human), these experiments suggest that the identified genes are not merely correlative markers but are actively involved in atherosclerosis-related cellular processes. However, we acknowledge that in vitro models are a simplification of the true disease environment, so further validation in vivo is needed.</p><p>This study has several limitations. First, our analyses relied on publicly available transcriptomic datasets which, despite careful batch correction and validation, may still contain intrinsic biases or offer limited clinical metadata. Because the data were retrospective, we could assess associations but not establish causation, and important clinical variables such as patient comorbidities or treatments could not be fully incorporated. Second, our experimental validation was limited to in vitro cell line models. Although ox-LDL-treated RAW264.7 and THP-1 macrophages helped substantiate the bioinformatic findings, these simplified systems cannot fully replicate the complexity of atherosclerotic lesions in vivo, which involve multiple cell types including endothelial cells and smooth muscle cells, intricate cell&#8211;cell interactions, and long-term processes such as plaque development and regression. These differences restrict the direct extrapolation of our results to clinical settings. Therefore, further in vivo investigations using animal models or patient samples will be essential to confirm the causative roles of the identified hub genes and to clarify their mechanistic connections to mitophagy and immunity in atherosclerosis. Despite these constraints, the study offers a valuable framework for elucidating the interplay between mitochondrial dysfunction and immune imbalance in atherosclerosis, and it provides a foundation for developing targeted diagnostic and therapeutic strategies.</p></sec><sec id="s0005"><title>Conclusions</title><p>In this study, we systematically investigated the relationship between mitophagy and immune infiltration in atherosclerosis and identified five hub genes&#8212;MNDA, CD163L1, NEXN, TC2N, and SLC22A3&#8212;as potential diagnostic biomarkers. These genes showed strong correlations with mitophagy-related pathways and immune cell infiltration profiles, indicating their potential roles in the interplay between mitochondrial homeostasis and immune dysregulation during atherogenesis. Experimental validation in ox-LDL&#8211;stimulated RAW264.7 and THP-1 macrophages confirmed expression patterns consistent with the bioinformatic predictions, strengthening the credibility of our integrative analysis. Overall, these findings provide new insights into the molecular links between mitophagy and immune imbalance in atherosclerosis and lay a foundation for future mechanistic research and the development of targeted diagnostic and therapeutic approaches.</p></sec></body><back><sec sec-type="data-availability" id="s0006"><title>Data Sharing Statement</title><p>All datasets analyzed in this study are publicly available. The raw data used in this investigation may be accessed via the public GEO database <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/geo/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/</ext-link></underline> (Accession numbers <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>).</p></sec><sec id="s0007"><title>Ethics Statement</title><p>This study was conducted using publicly available human gene expression datasets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE43292">GSE43292</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>) from the GEO database, all of which had been previously approved by their respective institutional ethics committees with informed consent obtained from participants. According to the Measures for Ethical Review of Life Science and Medical Research Involving Human Subjects (issued February 18, 2023, China), Article 32, Items 1 and 2, research using publicly available human data that cannot be linked to identifiable individuals is exempt from review by the Institutional Review Board (IRB). Therefore, this study was exempt from additional ethical approval by the Ethics Committee of Peking University First Hospital.</p></sec><sec sec-type="COI-statement" id="s0008"><title>Disclosure</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Popa-Fotea</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Ferdoschi</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Micheu</surname><given-names>MM</given-names></string-name>. <article-title>Molecular and cellular mechanisms of inflammation in atherosclerosis</article-title>. <source><italic toggle="yes">Front Cardiovasc Med</italic></source>. <year>2023</year>;<volume>10</volume>:<fpage>1200341</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcvm.2023.1200341</pub-id><pub-id pub-id-type="pmid">37600028</pub-id><pub-id pub-id-type="pmcid">PMC10434786</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Soehnlein</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Libby</surname><given-names>P</given-names></string-name>. <article-title>Targeting inflammation in atherosclerosis - from experimental insights to the clinic</article-title>. <source><italic toggle="yes">Nat Rev Drug Discov</italic></source>. <year>2021</year>;<volume>20</volume>(<issue>8</issue>):<fpage>589</fpage>&#8211;<lpage>610</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41573-021-00198-1</pub-id><pub-id pub-id-type="pmid">33976384</pub-id><pub-id pub-id-type="pmcid">PMC8112476</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Theofilis</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Oikonomou</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tsioufis</surname><given-names>K</given-names></string-name>, et al. <article-title>The role of macrophages in atherosclerosis: pathophysiologic mechanisms and treatment considerations</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2023</year>;<volume>24</volume>(<issue>11</issue>):<fpage>9568</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms24119568</pub-id><pub-id pub-id-type="pmid">37298518</pub-id><pub-id pub-id-type="pmcid">PMC10253295</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Weng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huan</surname><given-names>L</given-names></string-name>, et al. <article-title>Mitophagy in atherosclerosis: from mechanism to therapy</article-title>. <source><italic toggle="yes">Front Immunol</italic></source>. <year>2023</year>;<volume>14</volume>:<fpage>1165507</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2023.1165507</pub-id><pub-id pub-id-type="pmid">37261351</pub-id><pub-id pub-id-type="pmcid">PMC10228545</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Huynh</surname><given-names>DTN</given-names></string-name>, <string-name name-style="western"><surname>Heo</surname><given-names>KS</given-names></string-name>. <article-title>Role of mitochondrial dynamics and mitophagy of vascular smooth muscle cell proliferation and migration in progression of atherosclerosis</article-title>. <source><italic toggle="yes">Arch Pharm Res</italic></source>. <year>2021</year>;<volume>44</volume>(<issue>12</issue>):<fpage>1051</fpage>&#8211;<lpage>1061</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12272-021-01360-4</pub-id><pub-id pub-id-type="pmid">34743301</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>M</given-names></string-name>, et al. <article-title>Profiles of immune cell infiltration in carotid artery atherosclerosis based on gene expression data</article-title>. <source><italic toggle="yes">Front Immunol</italic></source>. <year>2021</year>;<volume>12</volume>:<fpage>599512</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2021.599512</pub-id><pub-id pub-id-type="pmid">33841393</pub-id><pub-id pub-id-type="pmcid">PMC8027089</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Engelen</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>B</surname><given-names>RAJ</given-names></string-name>, <string-name name-style="western"><surname>Zurke</surname><given-names>YX</given-names></string-name>, et al. <article-title>Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?</article-title><source><italic toggle="yes">Nat Rev Cardiol</italic></source>. <year>2022</year>;<volume>19</volume>(<issue>8</issue>):<fpage>522</fpage>&#8211;<lpage>542</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41569-021-00668-4</pub-id><pub-id pub-id-type="pmid">35102320</pub-id><pub-id pub-id-type="pmcid">PMC8802279</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhao</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>D</given-names></string-name>, et al. <article-title>Six mitophagy-related hub genes as peripheral blood biomarkers of Alzheimer&#8217;s disease and their immune cell infiltration correlation</article-title>. <source><italic toggle="yes">Front Neurosci</italic></source>. <year>2023</year>;<volume>17</volume>:<fpage>1125281</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnins.2023.1125281</pub-id><pub-id pub-id-type="pmid">37274215</pub-id><pub-id pub-id-type="pmcid">PMC10232817</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, et al. <article-title>Mitophagy: critical role in atherosclerosis progression</article-title>. <source><italic toggle="yes">DNA Cell Biol</italic></source>. <year>2022</year>;<volume>41</volume>(<issue>10</issue>):<fpage>851</fpage>&#8211;<lpage>860</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dna.2022.0249</pub-id><pub-id pub-id-type="pmid">36036955</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ayari</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bricca</surname><given-names>G</given-names></string-name>. <article-title>Identification of two genes potentially associated in iron-heme homeostasis in human carotid plaque using microarray analysis</article-title>. <source><italic toggle="yes">J Biosci</italic></source>. <year>2013</year>;<volume>38</volume>(<issue>2</issue>):<fpage>311</fpage>&#8211;<lpage>315</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12038-013-9310-2</pub-id><pub-id pub-id-type="pmid">23660665</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Steenman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Espitia</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Maurel</surname><given-names>B</given-names></string-name>, et al. <article-title>Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>3940</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-018-22292-y</pub-id><pub-id pub-id-type="pmid">29500419</pub-id><pub-id pub-id-type="pmcid">PMC5834518</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Davis</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Meltzer</surname><given-names>PS</given-names></string-name>. <article-title>GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>. <year>2007</year>;<volume>23</volume>(<issue>14</issue>):<fpage>1846</fpage>&#8211;<lpage>1847</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btm254</pub-id><pub-id pub-id-type="pmid">17496320</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Safran</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Shmueli</surname><given-names>O</given-names></string-name>, et al. <article-title>GeneCards 2002: towards a complete, object-oriented, human gene compendium</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>. <year>2002</year>;<volume>18</volume>(<issue>11</issue>):<fpage>1542</fpage>&#8211;<lpage>1543</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/18.11.1542</pub-id><pub-id pub-id-type="pmid">12424129</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Muller</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schillert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rothemeier</surname><given-names>C</given-names></string-name>, et al. <article-title>Removing batch effects from longitudinal gene expression - quantile normalization plus combat as best approach for microarray transcriptome data</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2016</year>;<volume>11</volume>(<issue>6</issue>):<fpage>e0156594</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0156594</pub-id><pub-id pub-id-type="pmid">27272489</pub-id><pub-id pub-id-type="pmcid">PMC4896498</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ritchie</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Phipson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, et al. <article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source><italic toggle="yes">Nucleic Acids Res</italic></source>. <year>2015</year>;<volume>43</volume>(<issue>7</issue>):<fpage>e47</fpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id><pub-id pub-id-type="pmcid">PMC4402510</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gene Ontology</surname><given-names>C</given-names></string-name>. <article-title>Gene Ontology Consortium: going forward</article-title>. <source><italic toggle="yes">Nucleic Acids Res</italic></source>. <year>2015</year>;<volume>43</volume>:<fpage>D1049</fpage>&#8211;<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gku1179</pub-id><pub-id pub-id-type="pmid">25428369</pub-id><pub-id pub-id-type="pmcid">PMC4383973</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kanehisa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goto</surname><given-names>S</given-names></string-name>. <article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title>. <source><italic toggle="yes">Nucleic Acids Res</italic></source>. <year>2000</year>;<volume>28</volume>(<issue>1</issue>):<fpage>27</fpage>&#8211;<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmid">10592173</pub-id><pub-id pub-id-type="pmcid">PMC102409</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>J</surname><given-names>JE</given-names></string-name>, et al. <article-title>WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs</article-title>. <source><italic toggle="yes">Nucleic Acids Res</italic></source>. <year>2019</year>;<volume>47</volume>(<issue>W1</issue>):<fpage>W199</fpage>&#8211;<lpage>W205</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkz401</pub-id><pub-id pub-id-type="pmid">31114916</pub-id><pub-id pub-id-type="pmcid">PMC6602449</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>L</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Hung</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>WM</given-names></string-name>, et al. <article-title>SVM-RFE based feature selection and Taguchi parameters optimization for multiclass SVM classifier [J]</article-title>. <source><italic toggle="yes">ScientificWorldJournal</italic></source>. <year>2014</year>;<volume>2014</volume>:<fpage>795624</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2014/795624</pub-id><pub-id pub-id-type="pmid">25295306</pub-id><pub-id pub-id-type="pmcid">PMC4175386</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rigatti</surname><given-names>SJ</given-names></string-name>. <article-title>Random Forest</article-title>. <source><italic toggle="yes">J Insur Med</italic></source>. <year>2017</year>;<volume>47</volume>(<issue>1</issue>):<fpage>31</fpage>&#8211;<lpage>39</lpage>. doi:<pub-id pub-id-type="doi">10.17849/insm-47-01-31-39.1</pub-id><pub-id pub-id-type="pmid">28836909</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Eng</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Schiller</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Morrell</surname><given-names>K</given-names></string-name>. <article-title>On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2015</year>;<volume>6</volume>(<issue>34</issue>):<fpage>36308</fpage>&#8211;<lpage>36318</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.6121</pub-id><pub-id pub-id-type="pmid">26486086</pub-id><pub-id pub-id-type="pmcid">PMC4742179</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Robin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Turck</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hainard</surname><given-names>A</given-names></string-name>, et al. <article-title>pROC: an open-source package for R and S+ to analyze and compare ROC curves</article-title>. <source><italic toggle="yes">BMC Bioinf</italic></source>. <year>2011</year>;<volume>12</volume>:<fpage>77</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2105-12-77</pub-id><pub-id pub-id-type="pmcid">PMC3068975</pub-id><pub-id pub-id-type="pmid">21414208</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liberzon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Birger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Thorvaldsdottir</surname><given-names>H</given-names></string-name>, et al. <article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title>. <source><italic toggle="yes">Cell Syst</italic></source>. <year>2015</year>;<volume>1</volume>(<issue>6</issue>):<fpage>417</fpage>&#8211;<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id><pub-id pub-id-type="pmcid">PMC4707969</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>Y</given-names></string-name>, et al. <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>. <source><italic toggle="yes">Omics</italic></source>. <year>2012</year>;<volume>16</volume>(<issue>5</issue>):<fpage>284</fpage>&#8211;<lpage>287</lpage>. doi:<pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id><pub-id pub-id-type="pmcid">PMC3339379</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hanzelmann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Castelo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Guinney</surname><given-names>J</given-names></string-name>. <article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title>. <source><italic toggle="yes">BMC Bioinf</italic></source>. <year>2013</year>;<volume>14</volume>:<fpage>7</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2105-14-7</pub-id><pub-id pub-id-type="pmcid">PMC3618321</pub-id><pub-id pub-id-type="pmid">23323831</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Szklarczyk</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gable</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Nastou</surname><given-names>KC</given-names></string-name>, et al. <article-title>The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>. <source><italic toggle="yes">Nucleic Acids Res</italic></source>. <year>2021</year>;<volume>49</volume>(<issue>D1</issue>):<fpage>D605</fpage>&#8211;<lpage>D12</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkaa1074</pub-id><pub-id pub-id-type="pmid">33237311</pub-id><pub-id pub-id-type="pmcid">PMC7779004</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>H</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, et al. <article-title>starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data</article-title>. <source><italic toggle="yes">Nucleic Acids Res</italic></source>. <year>2014</year>;<volume>42</volume>:<fpage>D92</fpage>&#8211;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkt1248</pub-id><pub-id pub-id-type="pmid">24297251</pub-id><pub-id pub-id-type="pmcid">PMC3964941</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Messeguer</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Escudero</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Farre</surname><given-names>D</given-names></string-name>, et al. <article-title>PROMO: detection of known transcription regulatory elements using species-tailored searches</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>. <year>2002</year>;<volume>18</volume>(<issue>2</issue>):<fpage>333</fpage>&#8211;<lpage>334</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/18.2.333</pub-id><pub-id pub-id-type="pmid">11847087</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Khodadoust</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>L</surname><given-names>LC</given-names></string-name>, et al. <article-title>Profiling Tumor Infiltrating Immune Cells with CIBERSORT</article-title>. <source><italic toggle="yes">Methods Mol Biol</italic></source>. <year>2018</year>;<volume>1711</volume>:<fpage>243</fpage>&#8211;<lpage>259</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-1-4939-7493-1_12</pub-id><pub-id pub-id-type="pmid">29344893</pub-id><pub-id pub-id-type="pmcid">PMC5895181</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xiao</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>A</given-names></string-name>, et al. <article-title>Identification and verification of immune-related gene prognostic signature based on ssGSEA for osteosarcoma</article-title>. <source><italic toggle="yes">Front Oncol</italic></source>. <year>2020</year>;<volume>10</volume>:<fpage>607622</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2020.607622</pub-id><pub-id pub-id-type="pmid">33384961</pub-id><pub-id pub-id-type="pmcid">PMC7771722</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wilkerson</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Hayes</surname><given-names>DN</given-names></string-name>. <article-title>ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source>. <year>2010</year>;<volume>26</volume>(<issue>12</issue>):<fpage>1572</fpage>&#8211;<lpage>1573</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btq170</pub-id><pub-id pub-id-type="pmid">20427518</pub-id><pub-id pub-id-type="pmcid">PMC2881355</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, et al. <article-title>Anti atherosclerosis effect and mechanism of a novel curcumin analogue CACN136: regulating macrophage M1/M2 polarization and lipid metabolism</article-title>. <source><italic toggle="yes">Front Pharmacol</italic></source>. <year>2025</year>;<volume>16</volume>:<fpage>1632647</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2025.1632647</pub-id><pub-id pub-id-type="pmid">40635740</pub-id><pub-id pub-id-type="pmcid">PMC12238012</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Moon</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>JM</given-names></string-name>. <article-title>Protective effect of Allium hookeri water extract and its main compound, Cycloalliin, on foam cell formation in THP-1-derived macrophages</article-title>. <source><italic toggle="yes">Food Nutr Res</italic></source>. <year>2025</year>;<fpage>69</fpage>. doi:<pub-id pub-id-type="doi">10.29219/fnr.v69.10763</pub-id><pub-id pub-id-type="pmcid">PMC12138981</pub-id><pub-id pub-id-type="pmid">40475061</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mei</surname><given-names>J</given-names></string-name>, et al. <article-title>Macrophage Dicer promotes tolerogenic apoptotic cell clearance and immune tolerance by inhibiting pentose phosphate pathway activity</article-title>. <source><italic toggle="yes">Cell Mol Immunol</italic></source>. <year>2021</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1841</fpage>&#8211;<lpage>1843</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41423-021-00693-w</pub-id><pub-id pub-id-type="pmid">34007029</pub-id><pub-id pub-id-type="pmcid">PMC8245631</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Baeyens</surname><given-names>N</given-names></string-name>. <article-title>Fluid shear stress sensing in vascular homeostasis and remodeling: towards the development of innovative pharmacological approaches to treat vascular dysfunction</article-title>. <source><italic toggle="yes">Biochem Pharmacol</italic></source>. <year>2018</year>;<volume>158</volume>:<fpage>185</fpage>&#8211;<lpage>191</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bcp.2018.10.023</pub-id><pub-id pub-id-type="pmid">30365948</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>L</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Obendorf</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jatzlau</surname><given-names>J</given-names></string-name>, et al. <article-title>Atheroprone fluid shear stress-regulated ALK1-Endoglin-SMAD signaling originates from early endosomes [J]</article-title>. <source><italic toggle="yes">BMC Biol</italic></source>. <year>2022</year>;<volume>20</volume>(<issue>1</issue>):<fpage>210</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12915-022-01396-y</pub-id><pub-id pub-id-type="pmid">36171573</pub-id><pub-id pub-id-type="pmcid">PMC9520843</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Johnson</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Natkunam</surname><given-names>Y</given-names></string-name>, et al. <article-title>Myeloid Cell Nuclear Differentiation Antigen (MNDA) expression distinguishes extramedullary presentations of myeloid leukemia from blastic plasmacytoid dendritic cell neoplasm</article-title>. <source><italic toggle="yes">Am J Surg Pathol</italic></source>. <year>2016</year>;<volume>40</volume>(<issue>4</issue>):<fpage>502</fpage>&#8211;<lpage>509</lpage>. doi:<pub-id pub-id-type="doi">10.1097/PAS.0000000000000595</pub-id><pub-id pub-id-type="pmid">26796502</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bottardi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guieze</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bourgoin</surname><given-names>V</given-names></string-name>, et al. <article-title>MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells</article-title>. <source><italic toggle="yes">Exp Hematol</italic></source>. <year>2020</year>;<volume>88</volume>:<fpage>68</fpage>&#8211;<lpage>82e5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exphem.2020.07.004</pub-id><pub-id pub-id-type="pmid">32682001</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Casserly</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Brady</surname><given-names>G</given-names></string-name>, et al. <article-title>Myeloid cell nuclear differentiation antigen controls the pathogen-stimulated type I interferon cascade in human monocytes by transcriptional regulation of IRF7</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>14</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-27701-x</pub-id><pub-id pub-id-type="pmid">35013241</pub-id><pub-id pub-id-type="pmcid">PMC8748983</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Van Beers</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schwarte</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Stammen-Vogelzangs</surname><given-names>J</given-names></string-name>, et al. <article-title>The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin</article-title>. <source><italic toggle="yes">Arthritis Rheum</italic></source>. <year>2013</year>;<volume>65</volume>(<issue>1</issue>):<fpage>69</fpage>&#8211;<lpage>80</lpage>. doi:<pub-id pub-id-type="doi">10.1002/art.37720</pub-id><pub-id pub-id-type="pmid">23044660</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gonz&#225;lez-Dom&#237;nguez</surname><given-names>&#201;</given-names></string-name>, <string-name name-style="western"><surname>Samaniego</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>L</surname><given-names>F-SJ</given-names></string-name>, et al. <article-title>CD163L1 and CLEC5A discriminate subsets of human resident and inflammatory macrophages in vivo</article-title>. <source><italic toggle="yes">J Leukoc Biol</italic></source>. <year>2015</year>;<volume>98</volume>(<issue>4</issue>):<fpage>453</fpage>&#8211;<lpage>466</lpage>. doi:<pub-id pub-id-type="doi">10.1189/jlb.3HI1114-531R</pub-id><pub-id pub-id-type="pmid">25877931</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Semnani-Azad</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Blanco Mejia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Connelly</surname><given-names>PW</given-names></string-name>, et al. <article-title>The association of soluble CD163, a novel biomarker of macrophage activation, with type 2 diabetes mellitus and its underlying physiological disorders: a systematic review</article-title>. <source><italic toggle="yes">Obes Rev</italic></source>. <year>2021</year>;<volume>22</volume>(<issue>9</issue>):<fpage>e13257</fpage>. doi:<pub-id pub-id-type="doi">10.1111/obr.13257</pub-id><pub-id pub-id-type="pmid">33913230</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yamashita</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Utsumi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nagashima</surname><given-names>H</given-names></string-name>, et al. <article-title>S100A9/CD163 expression profiles in classical monocytes as biomarkers to discriminate idiopathic pulmonary fibrosis from idiopathic nonspecific interstitial pneumonia</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>12135</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-91407-9</pub-id><pub-id pub-id-type="pmid">34108546</pub-id><pub-id pub-id-type="pmcid">PMC8190107</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gibson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>K</given-names></string-name>, et al. <article-title>PD-L1 blockade restores CAR T cell activity through IFN-&#947;-regulation of CD163+ M2 macrophages</article-title>. <source><italic toggle="yes">J Immunother Cancer</italic></source>. <year>2022</year>;<volume>10</volume>(<issue>6</issue>):<fpage>e004400</fpage>. doi:<pub-id pub-id-type="doi">10.1136/jitc-2021-004400</pub-id><pub-id pub-id-type="pmid">35738799</pub-id><pub-id pub-id-type="pmcid">PMC9226933</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>M</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Ezekian</surname><given-names>JE</given-names></string-name>, et al. <article-title>Determining the likelihood of disease pathogenicity among incidentally identified genetic variants in rare dilated cardiomyopathy-associated genes</article-title>. <source><italic toggle="yes">J Am Heart Assoc</italic></source>. <year>2022</year>;<volume>11</volume>(<issue>19</issue>):<fpage>e025257</fpage>. doi:<pub-id pub-id-type="doi">10.1161/JAHA.122.025257</pub-id><pub-id pub-id-type="pmid">36129056</pub-id><pub-id pub-id-type="pmcid">PMC9673717</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hu</surname><given-names>YW</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>FX</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>YJ</given-names></string-name>, et al. <article-title>Long noncoding RNA NEXN-AS1 mitigates atherosclerosis by regulating the actin-binding protein NEXN</article-title>. <source><italic toggle="yes">J Clin Invest</italic></source>. <year>2019</year>;<volume>129</volume>(<issue>3</issue>):<fpage>1115</fpage>&#8211;<lpage>1128</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI98230</pub-id><pub-id pub-id-type="pmid">30589415</pub-id><pub-id pub-id-type="pmcid">PMC6391138</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, et al. <article-title>Overexpression of TC2N is associated with poor prognosis in gastric cancer</article-title>. <source><italic toggle="yes">J Cancer</italic></source>. <year>2021</year>;<volume>12</volume>(<issue>3</issue>):<fpage>807</fpage>&#8211;<lpage>817</lpage>. doi:<pub-id pub-id-type="doi">10.7150/jca.50653</pub-id><pub-id pub-id-type="pmid">33403038</pub-id><pub-id pub-id-type="pmcid">PMC7778556</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>EC</given-names></string-name>, et al. <article-title>Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3</article-title>. <source><italic toggle="yes">Pharmacogenomics J</italic></source>. <year>2013</year>;<volume>13</volume>(<issue>2</issue>):<fpage>110</fpage>&#8211;<lpage>120</lpage>. doi:<pub-id pub-id-type="doi">10.1038/tpj.2011.60</pub-id><pub-id pub-id-type="pmid">22231567</pub-id><pub-id pub-id-type="pmcid">PMC3396779</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zheng</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>RX</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>XL</given-names></string-name>, et al. <article-title>Effect of SYTL3-SLC22A3 Variants, Their Haplotypes, and G x E interactions on serum lipid levels and the risk of coronary artery disease and ischaemic stroke</article-title>. <source><italic toggle="yes">Front Cardiovasc Med</italic></source>. <year>2021</year>;<volume>8</volume>:<fpage>713068</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcvm.2021.713068</pub-id><pub-id pub-id-type="pmid">34458338</pub-id><pub-id pub-id-type="pmcid">PMC8387813</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>L</given-names></string-name>, et al. <article-title>A solute carrier family 22 member 3 variant rs3088442 G--&gt;A associated with coronary heart disease inhibits lipopolysaccharide-induced inflammatory response</article-title>. <source><italic toggle="yes">J Biol Chem</italic></source>. <year>2015</year>;<volume>290</volume>(<issue>9</issue>):<fpage>5328</fpage>&#8211;<lpage>5340</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M114.584953</pub-id><pub-id pub-id-type="pmid">25561729</pub-id><pub-id pub-id-type="pmcid">PMC4342451</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, et al. <article-title>The Influence of SLC22A3 genetic polymorphisms on susceptibility to type 2 diabetes mellitus in chinese population</article-title>. <source><italic toggle="yes">Diabetes Metab Syndr Obes</italic></source>. <year>2023</year>;<volume>16</volume>:<fpage>1775</fpage>&#8211;<lpage>1781</lpage>. doi:<pub-id pub-id-type="doi">10.2147/DMSO.S412857</pub-id><pub-id pub-id-type="pmid">37342315</pub-id><pub-id pub-id-type="pmcid">PMC10278656</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sallinen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kaunisto</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Forsblom</surname><given-names>C</given-names></string-name>, et al. <article-title>Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension</article-title>. <source><italic toggle="yes">Ann Med</italic></source>. <year>2010</year>;<volume>42</volume>(<issue>4</issue>):<fpage>296</fpage>&#8211;<lpage>304</lpage>. doi:<pub-id pub-id-type="doi">10.3109/07853891003777109</pub-id><pub-id pub-id-type="pmid">20429798</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Xiao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>K</given-names></string-name>. <article-title>CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression</article-title>. <source><italic toggle="yes">Int Immunopharmacol</italic></source>. <year>2020</year>;<volume>89</volume>:<fpage>107043</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.intimp.2020.107043</pub-id><pub-id pub-id-type="pmid">33039961</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Iacona</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Lutz</surname><given-names>CS</given-names></string-name>. <article-title>miR-146a-5p: expression, regulation, and functions in cancer</article-title>. <source><italic toggle="yes">Wiley Interdiscip Rev RNA</italic></source>. <year>2019</year>;<volume>10</volume>(<issue>4</issue>):<fpage>e1533</fpage>. doi:<pub-id pub-id-type="doi">10.1002/wrna.1533</pub-id><pub-id pub-id-type="pmid">30895717</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, et al. <article-title>Impaired regulation of MMP2/16-MLCK3 by miR-146a-5p increased susceptibility to myocardial ischaemic injury in aging mice</article-title>. <source><italic toggle="yes">Cardiovasc Res</italic></source>. <year>2023</year>;<volume>119</volume>(<issue>3</issue>):<fpage>786</fpage>&#8211;<lpage>801</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cvr/cvac104</pub-id><pub-id pub-id-type="pmid">35727952</pub-id><pub-id pub-id-type="pmcid">PMC10153423</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, et al. <article-title>LCK, FOXC1 and hsa-miR-146a-5p as potential immune effector molecules associated with rheumatoid arthritis</article-title>. <source><italic toggle="yes">Biomarkers</italic></source>. <year>2023</year>;<volume>28</volume>(<issue>1</issue>):<fpage>130</fpage>&#8211;<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.1080/1354750X.2022.2150315</pub-id><pub-id pub-id-type="pmid">36420648</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kloc</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kubiak</surname><given-names>JZ</given-names></string-name>, <string-name name-style="western"><surname>Ghobrial</surname><given-names>RM</given-names></string-name>. <article-title>Macrophage-, dendritic-, smooth muscle-, endothelium-, and stem cells-derived foam cells in atherosclerosis</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2022</year>;<volume>23</volume>(<issue>22</issue>):<fpage>14154</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms232214154</pub-id><pub-id pub-id-type="pmid">36430636</pub-id><pub-id pub-id-type="pmcid">PMC9695208</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lux</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schwab</surname><given-names>I</given-names></string-name>, et al. <article-title>Targeting B cells and autoantibodies in the therapy of autoimmune diseases</article-title>. <source><italic toggle="yes">Semin Immunopathol</italic></source>. <year>2014</year>;<volume>36</volume>(<issue>3</issue>):<fpage>289</fpage>&#8211;<lpage>299</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00281-014-0427-7</pub-id><pub-id pub-id-type="pmid">24777745</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>H</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>S</given-names></string-name>, et al. <article-title>Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis</article-title>. <source><italic toggle="yes">Front Immunol</italic></source>. <year>2022</year>;<volume>13</volume>:<fpage>946832</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2022.946832</pub-id><pub-id pub-id-type="pmid">36275654</pub-id><pub-id pub-id-type="pmcid">PMC9583253</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dowling</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Macian</surname><given-names>F</given-names></string-name>. <article-title>Autophagy and T cell metabolism</article-title>. <source><italic toggle="yes">Cancer Lett</italic></source>. <year>2018</year>;<volume>419</volume>:<fpage>20</fpage>&#8211;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2018.01.033</pub-id><pub-id pub-id-type="pmid">29339212</pub-id><pub-id pub-id-type="pmcid">PMC5937942</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Behav Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Behav Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">644</journal-id><journal-id journal-id-type="pmc-domain">frontbehavneuro</journal-id><journal-id journal-id-type="publisher-id">Front. Behav. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Behavioral Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1662-5153</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12500559</article-id><article-id pub-id-type="pmcid-ver">PMC12500559.1</article-id><article-id pub-id-type="pmcaid">12500559</article-id><article-id pub-id-type="pmcaiid">12500559</article-id><article-id pub-id-type="doi">10.3389/fnbeh.2025.1648837</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Intranasal methylene blue administration confers neuroprotection in rats subjected to exhaustive exercise training</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Peng</surname><given-names initials="G">Guangcong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/2930865/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pan</surname><given-names initials="W">Wenxin</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cai</surname><given-names initials="Z">Ziheng</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lin</surname><given-names initials="L">Long</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1942134/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ma</surname><given-names initials="X">Xu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c002" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/3102286/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Institute for Brain Research and Rehabilitation, and Guangdong Key Laboratory of Mental Health and Cognitive Science, South China Normal University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Nanfang College Guangzhou</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2720/overview" ext-link-type="uri">Mart&#237;n Cammarota</ext-link>, Federal University of Rio Grande do Norte, Brazil</p></fn><fn fn-type="edited-by"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/189784/overview" ext-link-type="uri">Cynthia Katche</ext-link>, CONICET, Instituto de Biolog&#237;a Celular y Neurociencias (IBCN), Argentina</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/786823/overview" ext-link-type="uri">Andressa Radiske</ext-link>, Edmond and Lily Safra International Institute of Neuroscience (IIN-ELS/ISD), Brazil</p></fn><corresp id="c001">*Correspondence: Xu Ma, <email>max@nfu.edu.cn</email></corresp><corresp id="c002">Long Lin, <email>linl@nfu.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>19</volume><issue-id pub-id-type="pmc-issue-id">481077</issue-id><elocation-id>1648837</elocation-id><history><date date-type="received"><day>18</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Peng, Pan, Cai, Lin and Ma.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Peng, Pan, Cai, Lin and Ma</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnbeh-19-1648837.pdf"/><abstract><sec><title>Introduction</title><p>Emerging evidence suggests that exercise-induced fatigue negatively affects nervous system function, yet effective mitigation strategies are limited. This study aimed to determine whether intranasal methylene blue (MB) could prevent neurological deficits induced by exhaustive exercise in a rat model.</p></sec><sec><title>Methods</title><p>We utilized a rat exhaustive exercise training paradigm. Animal body weight was monitored, and a battery of behavioral tests was conducted to evaluate locomotor activity, anxiety-like behaviors, and spatial learning and memory. At the cellular level, we assessed neuron loss, apoptosis, synaptic proteins, myelin sheath, gliosis, and mitochondrial morphology in the hippocampal CA1 region and the striatum.</p></sec><sec><title>Results</title><p>Rats subjected to exhaustive exercise exhibited reduced locomotor activity, increased anxiety-like behaviors, and impaired spatial memory. This was associated with significant neuron loss, activation of apoptotic pathways, loss of synaptic proteins and myelin sheath, gliosis, and compromised mitochondrial morphology in the hippocampus and striatum. Notably, intranasal MB treatment significantly rescued these neuronal damages and improved performance in behavioral tests.</p></sec><sec><title>Discussion</title><p>Our findings demonstrate the neuroprotective effects of intranasal MB against exhaustive exercise-induced neurological deficits. This suggests that MB is a promising therapeutic agent for preventing the adverse neurological consequences of extreme physical exertion.</p></sec></abstract><abstract abstract-type="graphical" id="G1"><title>Graphical Abstract</title><p>
<fig position="float" id="d100e182" orientation="portrait"><caption><p>Intranasal methylene blue (MB) provides neuroprotection against exhaustive exercise-induced deficits by enhancing mitochondrial function and rescuing behavioral performance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g009.jpg"><alt-text content-type="machine-generated">A schematic illustration showing that intranasal methylene blue provides neuroprotection. The diagram depicts methylene blue being applied to a rat&#8217;s nose, with arrows pointing to the brain&#8217;s hippocampus and striatum. A magnified inset shows the chemical structure of methylene blue and details its role within a mitochondrion, visually explaining how it enhances mitochondrial function by interacting with the TCA cycle and ATP synthase.</alt-text></graphic></fig>
</p></abstract><kwd-group><kwd>exhaustive exercise</kwd><kwd>methylene blue</kwd><kwd>intranasal administration</kwd><kwd>mitochondria</kwd><kwd>neuroprotection</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the 2023 Guangdong Provincial Teaching Quality and Teaching Reform Construction Project - Yunkang School of Medicine and Health Industry (Project no: GDZL2303).</funding-statement></funding-group><counts><fig-count count="8"/><table-count count="0"/><equation-count count="0"/><ref-count count="78"/><page-count count="16"/><word-count count="11160"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Learning and Memory</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>1 Introduction</title><p>Exercise-induced fatigue is typically caused by prolonged duration or excessive intensity of physical activity. Based on the affected area, it can be categorized into peripheral fatigue and central fatigue (<xref rid="B6" ref-type="bibr">Carroll et al., 2017</xref>). Peripheral fatigue not only leads to muscle damage and increased cardiopulmonary stress but also results in bone and joint injuries (<xref rid="B54" ref-type="bibr">Shaktivesh et al., 2020</xref>). Additionally, exercise-induced fatigue involves central fatigue, which encompasses various mechanisms, including mitochondrial dynamics imbalance, neuronal apoptosis in certain brain regions, synaptic plasticity impairment, and inflammatory responses. Besides its adverse effects on athletic performance, prolonged exhaustive exercise has been shown to induce neurological deficits, including proprioceptive imbalances, temporary behavioral abnormalities, and changes in cognitive function (<xref rid="B21" ref-type="bibr">Gandevia, 2001</xref>; <xref rid="B39" ref-type="bibr">Lou et al., 2023</xref>). This collection of symptoms, usually associated with overtraining syndrome, not only impairs athletes&#8217; competitive performance but also affects their quality of life. Developing effective therapeutic strategies to mitigate the negative effects of prolonged exhaustive exercise, therefore, has become a key focus in the fields of sports medicine and neuroscience (<xref rid="B40" ref-type="bibr">Meeusen et al., 2013</xref>). Therefore, developing therapeutic strategies to mitigate the negative effects of prolonged exhaustive exercise on the central nervous system (CNS) is imperative (<xref rid="B28" ref-type="bibr">Jones et al., 2011</xref>).</p><p>After intense physical activity, blood circulation is redistributed, with skeletal muscles requiring more blood while the brain receives less, inevitably leading to cerebral F. This state following intense physical activity can result in damage to the CNS, including neuronal apoptosis and synaptic damage. Studies have revealed that after prolonged exhaustive exercise, certain brain regions in the CNS show increased expression of pro-apoptotic proteins like caspase-1, while expression of anti-apoptotic proteins is decreased, this triggers a cascade of responses in the caspase family of proteases, ultimately leading to apoptosis (<xref rid="B76" ref-type="bibr">Zhang et al., 2016</xref>; <xref rid="B24" ref-type="bibr">Han et al., 2018</xref>). Mitochondria play a crucial role in cellular energy supply and oxidative stress regulation. Maintaining mitochondrial dynamic balance involves processes such as mitochondrial fission, fusion, and autophagy (<xref rid="B78" ref-type="bibr">Zou et al., 2022</xref>; <xref rid="B55" ref-type="bibr">Singh and Singh, 2025</xref>). Highly dynamic mitochondria constantly oscillate between fission and fusion states, with the equilibrium achieved through these processes determining their morphology. Prolonged exhaustive exercise damages mitochondrial function, resulting in abnormal synaptic plasticity and neurological deficits (<xref rid="B17" ref-type="bibr">Davis et al., 2009</xref>; <xref rid="B37" ref-type="bibr">Liu et al., 2020</xref>). Consequently, mitochondrial dysfunction is a key indicator of unfavorable outcomes following exercise-induced fatigue. Prolonged intense exercise can activate microglia and astrocytes, prompting the secretion of large quantities of inflammatory factors, further exacerbating neuroinflammation. Iba-1 is specifically expressed in activated microglia, playing a role in immune response and regulation of neuroinflammation. Iba-1 also interacts with synapses to maintain the normal structure and function of the CNS (<xref rid="B31" ref-type="bibr">Kodali et al., 2021</xref>; <xref rid="B29" ref-type="bibr">Kann, 2024</xref>). GFAP is expressed in astrocytes, which tend to shift from a resting state to an enlarged, hypertrophic state when the CNS is diseased or under pathological conditions. GFAP can serve as a marker for astrocyte proliferation following exercise-induced fatigue.</p><p>The hippocampus and striatum play significant roles in the CNS. Through their respective functional specializations, they work in tandem to support memory formation and behavioral regulation, jointly sustaining the advanced functions of the CNS (<xref rid="B2" ref-type="bibr">Albouy et al., 2008</xref>). The hippocampus, as part of the brain&#8217;s limbic system, is critical for various cognitive functions, particularly learning, memory, and emotional regulation (<xref rid="B50" ref-type="bibr">Pronier et al., 2023</xref>). The striatum, as part of the basal ganglia, is located deep within the forebrain and is primarily associated with motor control, rewards, motivation, and habit learning. It contributes to the selection of complex behaviors and habits through the architecture of the basal ganglia (<xref rid="B32" ref-type="bibr">Kreitzer and Malenka, 2008</xref>; <xref rid="B19" ref-type="bibr">Fang and Creed, 2024</xref>). Given the critical functional significance of the hippocampus and striatum, alterations in physiological processes in these regions may underlie the adverse neurological consequences resulting from prolonged exhaustive exercise.</p><p>Originally introduced as a dye, methylene blue (MB) is now widely studied and applied for its diverse biological and medical functions (<xref rid="B53" ref-type="bibr">Schirmer et al., 2011</xref>). The drug initially played a significant role in malaria treatment, and it was later discovered to have antipsychotic effects when used in patients with psychiatric disorders. From the 1930s to the 1990s, the antifungal, antiparasitic, and antibiotic properties of MB and its derivatives, as well as their ability to reverse neurotoxicity in encephalopathy, were successively discovered (<xref rid="B45" ref-type="bibr">Ohlow and Moosmann, 2011</xref>). Recent studies have shown that MB exhibits significant neuroprotective effects in various neurological disorders, such as cerebral ischemia, Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and traumatic brain injury (<xref rid="B20" ref-type="bibr">Fenn et al., 2015</xref>; <xref rid="B34" ref-type="bibr">Li et al., 2018</xref>; <xref rid="B23" ref-type="bibr">Gureev et al., 2022</xref>). In summary, MB has demonstrated benefits in enhancing mitochondrial function, alleviating oxidative stress and inflammation, and improving cognitive functions in the CNS, and it has been utilized in clinical treatments and drug development. Meanwhile, intranasal administration allows small molecule drugs to bypass the blood-brain barrier and directly reach the brain via pathways like the olfactory and trigeminal nerves, enabling targeted CNS therapy. Given that MB is both hydrophilic and lipophilic, it can penetrate biological membranes effectively. Therefore, MB is well-suited for intranasal administration as a delivery method (<xref rid="B70" ref-type="bibr">Xue et al., 2021</xref>).</p><p>This study aims to investigate the effects of intranasal administration of MB on neuronal loss, synaptic plasticity damage, and mitochondrial dynamics in a rat model of exhaustive swimming exercise. In summary, this study aims to explore the neuroprotective effects of MB, providing a convenient approach to mitigate the negative impacts of exercise-induced fatigue.</p></sec><sec sec-type="materials|methods" id="S2"><title>2 Materials and methods</title><sec id="S2.SS1"><title>2.1 Animals and grouping</title><p>The rats used in this study were purchased from the Guangzhou Medical Laboratory Animal Center. The animal housing conditions were maintained at a temperature of 22 &#176;C &#177; 2 &#176;C, a humidity level of 60% &#177; 5%, with a normal light-dark cycle and quiet environment. After the rats arrived, all animals were housed in the animal facility and underwent a 14-days acclimatization period before any experimental procedures began. This critical stage aims to reduce stress caused by transportation and allow the animals to adapt to the new housing environment (constant temperature and humidity, 12-h light-dark cycle). During this period, the rats have free access to standard laboratory feed and water. The main purpose of this acclimatization period is to ensure that all animals reach a stable physiological and behavioral phenotype, thereby minimizing confounding variables and ensuring the validity of subsequent experimental data. After a 14-days acclimatization period, healthy 2-months-old male Sprague-Dawley (SD) rats were randomly divided into three groups: (a) the naive control group, which remained in a water environment without swimming (control group, <italic toggle="yes">n</italic> = 6), (b) the exhaustive exercise training group (EE, <italic toggle="yes">n</italic> = 7), and (c) the group treated with intranasal MB following exhaustive exercise training (EE + MB, <italic toggle="yes">n</italic> = 7). All animals involved in this experiment received approval from the Institutional Animal Care and Use Committee of South China Normal University and complied with the established animal welfare guidelines.</p></sec><sec id="S2.SS2"><title>2.2 Exhaustive swimming training</title><p>The exhaustive swimming training was performed as described previously with slight modifications (<xref rid="B49" ref-type="bibr">Pierce et al., 1984</xref>; <xref rid="B48" ref-type="bibr">Peng et al., 2021</xref>). The experimental design is illustrated in <xref rid="F1" ref-type="fig">Figure 1A</xref>. This study involved three experimental procedures for the animals: adaptive swimming phase, exhaustive swimming training, and behavioral testing. As shown in <xref rid="F1" ref-type="fig">Figure 1B</xref>, the swimming training was conducted in a 55 cm-diameter bucket filled with water to a depth of 50 cm. The water temperature was maintained at 30 &#176;C &#177; 2 &#176;C. To minimize water-induced stress on the animals, the rats underwent a 3-days adaptive swimming training before the experiment, with swimming durations of 10 min, 15 min, and 20 min on the first, second, and third days, respectively. During adaptive swimming, we observe the animals&#8217; condition after swimming, and proceed with swimming training if no obvious abnormalities are detected. Following the adaptive swimming training, the rats underwent exhaustive swimming training for 10 consecutive days. During this phase, weights equivalent to 3% of body weight were attached to the animals&#8217; tails, and the training lasted at least for 2 h daily, from 5:00 PM to 11:00 PM. To prevent the rats from floating or becoming overly stressed during swimming, a stationary brush was used to stir the water gently and continuously. To objectively and accurately determine fatigue points, we adopted a multi-component &#8220;Fatigue State Score,&#8221; which was refined based on our previous work (<xref rid="B48" ref-type="bibr">Peng et al., 2021</xref>). An animal was judged to have reached exhaustion, and its trial was immediately terminated, upon accumulating a cumulative score of two or more based on the following criteria, with each point assigned upon its first definitive observation: (1) Critical Submersion, defined as the animal remaining fully submerged for a continuous 10 s; (2) Loss of Coordinated Motor Control, characterized as a composite of inefficient and abnormal swimming postures such as pronounced upper-body torsion, a significant backward tilt from the normal swimming angle, or a clear shift to frantic and ineffective forelimb paddling; and (3) Onset of Sustained Vocalization, defined as the animal beginning to emit continuous and clearly audible &#8220;squeaking&#8221; sounds. This objective scoring system ensures a reproducible and ethically-sound endpoint for the determination of fatigue. Meanwhile, the control group animals were placed in shallow water environment (5 cm deep) at the same temperature for the same duration.</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Experimental timeline diagram, establishment of exhaustive exercise model and methylene blue administration schematic. <bold>(A)</bold> Rats underwent exhaustive exercise training for ten consecutive days (from day 16 to day 26), followed by MB nasal administration in the MB group after each training session. Behavioral tests were conducted from day 26 to day 30, and immediately after the tests, the animals were sacrificed to extract the whole brain for further analysis. <bold>(B)</bold> A schematic diagram of exhaustive swimming training in rats, with a timer used to measure the time it takes for the animals to reach a state of exhaustion during swimming. <bold>(C)</bold> Schematic of MB administration via the nasal cavity in rats. EE, exhaustive exercise; MB, methylene blue.</p></caption><alt-text>Diagram consisting of three panels. A: Experimental timeline showing different exercise and treatment protocols over 30 days for three groups: Control, EE, and EE+MB, with periods of adaptive swimming, exercise training, and behavioral testing. B: Illustration of a mouse swimming in a tank with a timer, indicating a swim test. C: Illustration of a mouse receiving an injection, labeled as Methylene Blue, from a syringe.</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g001.jpg"/></fig></sec><sec id="S2.SS3"><title>2.3 Methylene blue nasal administration</title><p>The dose and route of administration of MB were based on a previous study (<xref rid="B74" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B48" ref-type="bibr">Peng et al., 2021</xref>). In brief, a 1% MB solution (10 mg/ml) was prepared by dissolving and diluting MB in 0.9% saline. As shown in <xref rid="F1" ref-type="fig">Figure 1C</xref>, 1 h after each exhaustive swimming training session, rats were anesthetized with vaporized isoflurane and positioned on their backs. The MB solution (10 mg/ml) was administered intranasally using a pipette in a dropwise fashion (2.5 &#956;L/drop), alternating between the left and right nostrils every 2&#8211;3 min. Approximately 10 &#956;L was delivered into each nostril, with a total administration volume of about 20 &#956;L per session. Meanwhile, rats in both the Control (sedentary) and the EE groups were administered an identical volume of the vehicle (0.9% saline) using the same intranasal administration protocol.</p></sec><sec id="S2.SS4"><title>2.4 Monitoring animal weight and behavioral testing</title><p>The body weight of rats was measured throughout the exhaustive exercise training procedure. All rats underwent behavioral testing in a quiet environment with controlled light intensity after the final session of exhaustive exercise and MB administration. The order of the tests was as follows: the open field test (day 26), the elevated plus maze test (day 27), and the Barnes maze test (day 27&#8211;30). Before testing, the rats were acclimated to the laboratory for at least 4 h.</p></sec><sec id="S2.SS5"><title>2.5 Open field test</title><p>The open field test is commonly used to assess animals&#8217; exploratory behavior, locomotor ability, and anxiety levels (<xref rid="B77" ref-type="bibr">Zhao et al., 2024</xref>). In this experiment, a wooden open field box with dimensions of 60 cm in length, 60 cm in width, and 45 cm in height was used. The black floor of the box was evenly divided into nine equal squares with white paint. In a quiet environment, rats were placed in the open field and allowed to move freely for 5 min, while their movement trajectories were recorded and analyzed using ANY-maze software. After the test, 75% ethanol was used to clean the open field to eliminate any odors.</p></sec><sec id="S2.SS6"><title>2.6 Elevated plus maze (EPM)</title><p>The elevated plus maze is a classic method used to evaluate anxiety-like behavior in rodents, based on their conflicting tendencies to explore elevated open spaces and their fear of such environments (<xref rid="B66" ref-type="bibr">Wu et al., 2020</xref>). At the start of the experiment, rats are placed in the central area of the maze and allowed to move freely for 5 min. The number of entries into the open arms and the time spent in the open arms are negatively correlated with anxiety levels. After testing each animal, the maze platform is wiped thoroughly with 75% ethanol three times, and then allowed to dry for 5 min to remove any residual odors.</p></sec><sec id="S2.SS7"><title>2.7 Barnes maze</title><p>The Barnes maze experiment is a method used to assess spatial learning and memory in animals, as previously described by our laboratory (<xref rid="B73" ref-type="bibr">Yang et al., 2022</xref>). This experiment utilizes a black circular maze platform with 18 holes, one of which (located at the 2:00 position) has a black escape box underneath (13 cm &#215; 10 cm &#215; 11 cm). Rats undergo 3 days of spatial learning and memory training followed by 1 day of spatial memory testing. Training trial (Days 27&#8211;29): before training begins, one of the holes on the maze is designated as the target hole, with a black target box placed underneath it. Bright lighting serves as a stimulus, and the rats are allowed to freely explore the maze within a set time frame to locate the target box. Spatial memory testing (Day 30): On the probe test day, the black escape box was removed, and a camera recorded the rats&#8217; exploration paths on the platform for 90 s. The recorded data are analyzed using any maze video tracking software (Stoelting Co., Wood Dale, IL, USA). After each test, the platform is cleaned with 75% ethanol and air-dried. At the end of the testing, the time spent exploring the target zone is quantified to evaluate learning and memory performance.</p></sec><sec id="S2.SS8"><title>2.8 Sample collection</title><p>Following the behavioral testing, the animals were anesthetized and sampled as quickly as possible. In brief, after anesthetizing the animals with isoflurane, cardiac perfusion was carried out using ice-cold physiological saline. The brain tissues were removed promptly and divided into two halves. From one hemisphere, the hippocampus and striatum were dissected and preserved at &#8722;80 &#176;C for protein preparation. The other hemisphere was fixed overnight in 4% paraformaldehyde, then dehydrated in 30% sucrose solution until it sinks (<xref rid="B72" ref-type="bibr">Yang et al., 2019</xref>). Subsequently, the dehydrated brain tissues were embedded in OCT freezing compound and frozen at &#8722;80 &#176;C overnight. Finally, 20-&#956;m-thick coronal brain sections were prepared using a Leica cryostat (Leica Biosystems CM1850).</p></sec><sec id="S2.SS9"><title>2.9 Cresyl violet staining</title><p>Cresyl violet staining was used to quantify the number of surviving neurons. Briefly, 3&#8211;5 brain slices were randomly selected from each animal, rinsed with PBS for 30 min, mounted on slides, and air-dried. The slices were stained using tar violet staining solution for 12 min and then heated in a 37 &#176;C incubator. Gradual differentiation was performed as follows: decolorization in deionized water for 20 s, followed by sequential alcohol washes (70%, 80%, 90%, and 100%) for 3&#8211;4 s each. The slices were fixed with xylene for 5 min before coverslipping. A microscope was used to observe neuron density, capture images, and analyze the number of surviving neurons in the hippocampal CA1 pyramidal layer. Surviving neurons were identified by their rounded shape and distinctly stained nuclei, while abnormal or dead neurons appeared abnormally condensed and aggregated.</p></sec><sec id="S2.SS10"><title>2.10 Immunofluorescence staining</title><p>Immunofluorescence staining was performed as in our previous study (<xref rid="B67" ref-type="bibr">Wu et al., 2018</xref>). Briefly, floating brain sections (20 &#956;m) were incubated with 10% normal donkey serum at room temperature for 1 h, followed by overnight incubation with the appropriate primary antibodies. The primary antibodies used in this study were as follows: anti-NeuN (1:100, Abcam), anti-synaptophysin and spinophilin (1:100, Cell Signaling), anti-Iba1 (1:200, Abcam), anti-GFAP (1:200, Cell Signaling), anti-MBP (1:100, Abcam), anti-Annexin V (11060-1-AP, Proteintech), anti-cleaved Caspase-3 (1:300, CST) and anti-TOM20 (11802-1-AP, Proteintech). After 24 h of primary antibody incubation, brain sections were washed three times with 0.4% Triton for 40 min each time, followed by 2 h of incubation in the dark with matched Alexa Fluor donkey anti-mouse/rabbit secondary antibodies (555/488, Thermo Fisher). The sections were then stained for apoptosis using a TUNEL assay kit (Beyotime, C1088) and subsequently mounted and coverslipped using Vectashield mounting medium containing DAPI (Solarbio, China). More than one area per brain was quantified: 3 areas in the CA1 region/striatum were evenly selected on each slice, and 3 &#8211; 4 slices were chosen from each rat.</p></sec><sec id="S2.SS11"><title>2.11 Statistical analysis</title><p>All statistical analyses were performed using SigmaStat software (Systat Software; San Jose, CA, USA). All datasets passed the normality test. For comparisons among three groups at a single time point, one-way analysis of variance (ANOVA) followed by Tukey&#8217;s <italic toggle="yes">post-hoc</italic> test was used. For data involving repeated measurements over time, such as daily body weight, a two- way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons was performed to assess the effects of group and time, as well as their interaction. The Student&#8217;s <italic toggle="yes">T</italic>-test was used to analyze data between two groups. All data were presented as mean &#177; standard error (SE). <italic toggle="yes">P</italic>-values were calculated using GraphPad Prism 8 and SigmaStat 3.5 software. <italic toggle="yes">P</italic>-values &#8804; 0.05 are considered statistically significant.</p></sec></sec><sec sec-type="results" id="S3"><title>3 Results</title><sec id="S3.SS1"><title>3.1 MB improved time to exhaustion and physical condition of rats exposed to exhaustive exercise training</title><p>Time of exhaustion can comprehensively reflect the degree of exercise-induced fatigue in rats (<xref rid="B13" ref-type="bibr">Chen et al., 2022</xref>). To investigate the effect of intranasal MB administration on exercise-induced fatigue in rats, we recorded the time it took for rats in the EE group and MB group to swim to exhaustion under a weighted load on the 26th day. The state of swimming exhaustion is defined as the point when the rats repeatedly sank, showed a significant decline in motor coordination, and remained submerged at the bottom of the water for over 10 s without returning to the surface. As shown in <xref rid="F2" ref-type="fig">Figure 2A</xref>, compared to the EE group, the MB group demonstrated a significant increase in swimming time to exhaustion (<italic toggle="yes">P</italic> &lt; 0.05). This indicates that 10 days of intranasal MB administration can reduce the degree of exercise-induced fatigue in rats and promote recovery from fatigue.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Methylene blue (MB) improved time to exhaustion and physical condition of rats exposed to exhaustive exercise training. <bold>(A)</bold> On day 26, the time until exhaustion for rats in the EE group and MB group during swimming was recorded. <bold>(B)</bold> The weight gain changes in the three groups of rats from day 17 to day 26. <bold>(C)</bold> The schematic of the open field test (day 26). The movement trajectories of each group. <bold>(D)</bold> The number of line crossing of the rats in the open field test. <bold>(E)</bold> The total distance traveled of the rats during the open field test. <bold>(F)</bold> The average speed of the rats in the open field test. <bold>(G)</bold> The absolute turning angle of the rats in the open field test. <bold>(H)</bold> The freeing time of the rats in the open field test. Data represent mean &#177; SE (<italic toggle="yes">n</italic> = 6&#8211;7). *<italic toggle="yes">P</italic> &lt; 0.05 versus control group, #<italic toggle="yes">P</italic> &lt; 0.05 versus EE group. Statistical significance was determined using two-tailed <italic toggle="yes">t</italic>-tests, One-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons or Two-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons.</p></caption><alt-text>A composite image depicting multiple graphs and charts from an experiment. Panel A shows a bar graph of fatigue time on day 26 for two groups: EE, and EE + MB, with higher values for EE + MB. Panel B is a line graph showing average body weight from day 17 to 26, with three groups distinguished by color: Control (green), EE (red), and EE + MB (blue). Panel C includes three movement paths in square arenas for each group. Panels D to H display bar graphs for various metrics: line crossings, total distance, mean speed, absolute limb angle, and freezing time, each differentiated by group color. Data points and error bars are present in all graphs.</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g002.jpg"/></fig><p>Weight changes during periods of exhaustion can indirectly reflect the health status of an organism, when an organism experiences significant fatigue, noticeable fluctuations in body weight can occur (<xref rid="B27" ref-type="bibr">Jeukendrup, 2011</xref>). To investigate the effect of intranasal administration of MB on the body weight of rats, we recorded changes in their weight. As shown in <xref rid="F2" ref-type="fig">Figure 2B</xref>, we observed the dynamic changes in body weight during the 10-days exhaustive swimming scheme. Visually, a trend emerged where the EE group exhibited lower average body weights compared to the control group, while the EE + MB group&#8217;s weight trended in between the two groups. A two-way repeated measures ANOVA was conducted to analyze these changes. The analysis revealed a significant main effect for time (F (1.186, 20.15) = 141.9, <italic toggle="yes">P</italic> &lt; 0.0001), but the main effect for treatment group was not significant (F (2, 17) = 2.672, <italic toggle="yes">P</italic> = 0.0979). Crucially, there was a highly significant interaction effect between the treatment group and time (F (18, 153) = 4.044, <italic toggle="yes">P</italic> &lt; 0.0001), indicating that the weight-change trajectories over the 10 days were significantly different among the three groups. However, subsequent <italic toggle="yes">post-hoc</italic> tests comparing the groups at each individual time point did not find statistically significant differences (all <italic toggle="yes">P</italic> &gt; 0.05). This lack of significance at specific days, despite the overall differing trends, may be attributed to the notable individual variations within each group, as suggested by the error bars.</p><p>Therefore, while intranasal MB administration did not result in a statistically significant weight recovery on any single day within this experimental timeframe, the overall trend and the significant interaction effect suggest that MB may have a mitigating effect on weight loss induced by exhaustive exercise.</p><p>To investigate the effects of MB on the locomotor activity and exploratory behavior of rats exposed to exhaustive exercise training, the open field test was conducted 4 h after the last exhaustive swimming session. The representative movement trajectories of rats in each group are shown in <xref rid="F2" ref-type="fig">Figure 2C</xref>. The results indicate that the activity level of rats in the EE group was reduced compared to the other two groups. Compared to the performance of the control group in the open field, the EE group exhibited a significant reduction in line crossings, movement distance, average movement speed, and absolute turning angles (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F2" ref-type="fig">Figures 2D&#8211;G</xref>), along with a significant increase in freezing time (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F2" ref-type="fig">Figure 2H</xref>). These findings suggest that after 10 days of exhaustive swimming, the overall locomotor and exploratory activity of the EE group rats were significantly lower than those of the control group, indicating a pronounced state of fatigue. In contrast, the MB group showed a remarkable improvement in activity levels compared to the EE group (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F2" ref-type="fig">Figures 2D&#8211;G</xref>), with a significant reduction in freezing time (<italic toggle="yes">P</italic> &lt; 0.01, <xref rid="F2" ref-type="fig">Figure 2H</xref>). This indicates that intranasal administration of MB can promote recovery of exercise capacity in fatigued rats and enhance their activity levels.</p></sec><sec id="S3.SS2"><title>3.2 MB improved anxiety-like behavior and spatial memory ability in rats exposed to exhaustive exercise training</title><p>On day 27, the elevated plus maze was conducted. As shown in <xref rid="F3" ref-type="fig">Figure 3A</xref>, the movement trajectories of the three groups of rats in the elevated plus maze indicated that the EE group exhibited reduced exploratory activity in the open arms compared to the control group. The number of entries into the open arms, the percentage of entries, and the time spent in the open arms were all significantly decreased (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F3" ref-type="fig">Figures 3B&#8211;E</xref>), suggesting that rats subjected to exhaustive exercise training displayed anxiety-like behavior. Interestingly, the MB group showed a significant increase in the number of entries, the percentage of entries, and the time spent in the open arms compared to the EE group (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F3" ref-type="fig">Figures 3B&#8211;E</xref>), indicating that intranasal administration of MB can alleviate anxiety-like behavior induced by exhaustive exercise training.</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Methylene blue (MB) improved anxiety-like behavior and spatial memory ability in rats exposed to exhaustive exercise training. <bold>(A)</bold> Elevated plus maze (Day 27). Schematic of the elevated plus maze and representative activity diagrams of three groups of rats in the maze. <bold>(B)</bold> Number of times entered the open arm of the elevated cross maze. <bold>(C)</bold> The percentage (%) of rats entering the open arm of the elevated cross maze. <bold>(D)</bold> The time (seconds) that the rat stays in the open arm. <bold>(E)</bold> The percentage (%) of time rats stay in open arms. <bold>(F)</bold> Barnes Maze results, which assess animals&#8217; learning and memory abilities. Representative activity trajectories of three groups of animals on the third day of the Barnes maze. The time taken by animals on Days 27, 28, and 29 to locate the target box is shown in panel <bold>(G)</bold>. A memory test was conducted on Day 30, with representative movement trajectories of each group of rats illustrated. The time spent in the target quadrant (upper right corner) is displayed in panel <bold>(H)</bold>. Data represent mean &#177; SE (<italic toggle="yes">n</italic> = 6&#8211;7). *<italic toggle="yes">P</italic> &lt; 0.05 versus control group, #<italic toggle="yes">P</italic> &lt; 0.05 versus EE group. Statistical significance was determined using One-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons or Two-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons.</p></caption><alt-text>&#8220;Research data visualization showing results from elevated plus maze and Barnes maze tests. A: Diagram and path tracking in the elevated plus maze for control, EE, and EE + MB groups. B-E: Bar graphs display metrics on open arm entries and time spent, with significant differences marked. F: Path tracking in Barnes maze training (Day 29) and probe trials (Day 30) for all groups. G: Line graph of escape latency over days indicates decreasing escape time. H: Bar graph of quadrant occupancy shows group differences, with significant results marked.&#8221;</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g003.jpg"/></fig><p>To investigate the changes in spatial learning and memory abilities following exhaustive swimming training, the Barnes maze was conducted from day 27 to day 30. During the training trial (day 27&#8211;29), all three groups showed a reduction in the time taken to locate the hidden escape box. The representative search trajectories from the training trial (Day 29, <xref rid="F3" ref-type="fig">Figure 3F</xref>) and the subsequent probe trial (Day 30) visually summarize the patterns of spatial learning and memory retention, respectively. Although the EE group required more time to locate the hidden escape box compared to the control group and the MB group (<xref rid="F3" ref-type="fig">Figure 3G</xref>), the difference was not statistically significant (<italic toggle="yes">P</italic> &gt; 0.05). These results suggest that the exhaustive exercise training paradigm used in this study may not cause spatial learning deficits in rats. Nevertheless, in the probe trial (day 30), the EE group spent significantly less time in the target quadrant compared to the control animals, indicating that exhaustive exercise induced memory deficits (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F3" ref-type="fig">Figure 3H</xref>). Interestingly, this deficit was alleviated in the MB group, suggesting that MB treatment significantly improved spatial memory deficits following exhaustive exercise.</p></sec><sec id="S3.SS3"><title>3.3 MB prevented hippocampal neuron loss and inhibits activation of apoptotic pathways in rats exposed to exhaustive exercise training</title><p>To investigate whether exhaustive exercise training induces neuronal loss and whether this effect can be mitigated by MB treatment, Cresyl violet staining was used to quantify survival neurons in the hippocampal CA1 region. Cresyl violet has a high affinity for Nissl bodies in neurons and is widely used for observing the structure of neurons and Nissl bodies in neural tissue (<xref rid="B1" ref-type="bibr">Ahn et al., 2021</xref>). Additionally, neuronal nuclei protein (NeuN) is considered a reliable marker for mature neurons (<xref rid="B18" ref-type="bibr">Duan et al., 2016</xref>). As shown in <xref rid="F4" ref-type="fig">Figure 4A</xref>, subjected to exhaustive swimming exhibited significant neuron loss in the hippocampal CA1 region, as evidenced by a reduction in NeuN-positive neurons and decreased neuronal survival detected by Cresyl violet staining. Compared to the EE group, MB intervention significantly prevented EE-induced neuronal loss, indicated by a marked increase in NeuN labeling in the hippocampal CA1 region. Quantitative analysis of surviving positive neurons further confirmed that MB notably reversed EE-induced neuronal loss (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F4" ref-type="fig">Figures 4B, C</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Methylene blue (MB) prevented hippocampal neuron loss and inhibited activation of apoptotic pathways in rats exposed to exhaustive exercise training. <bold>(A)</bold> Representative images of Cresyl violet staining, NeuN staining (red), and cleaved caspase-3 and TUNEL staining (green) in the hippocampal region after MB intervention. Surviving neurons of CA1 <bold>(B)</bold>, NeuN positive cell <bold>(C)</bold>, TUNEL <bold>(D)</bold>, and cleaved caspase-3 <bold>(E)</bold> were quantified and expressed as percentage changes compared to the respective control group. Data represent mean &#177; SE (<italic toggle="yes">n</italic> = 6&#8211;7). *<italic toggle="yes">P</italic> &lt; 0.05 versus control group, #<italic toggle="yes">P</italic> &lt; 0.05 versus EE group. The scale bar = 10 &#956;m. Statistical significance was determined using One-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons.</p></caption><alt-text>Brain tissue analysis from hippocampal CA1, showing images from control, EE, and EE+MB groups. Staining includes cresyl violet, NeuN, TUNEL, and Cle-Caspase-3. Bar graphs (B-E) present quantitative analysis of surviving neurons, positive cells for NeuN, TUNEL, and Cle-Caspase-3 across conditions, showing statistical differences marked by symbols.</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g004.jpg"/></fig><p>To further elucidate whether MB can inhibit apoptosis resulting from exhaustive exercise, we performed immunofluorescence staining for cleaved caspase-3, a key executioner of apoptosis, and conducted a TUNEL assay to detect DNA fragmentation, a definitive hallmark of apoptotic cell death. As shown in <xref rid="F4" ref-type="fig">Figure 4A</xref> and quantified in <xref rid="F4" ref-type="fig">Figures 4D, E</xref>, EE significantly increased the immunoactivity of cleaved caspase-3 and TUNEL signal in the hippocampal CA1 region compared to the control group (<italic toggle="yes">P</italic> &lt; 0.05). Notably, MB treatment significantly reduced the activities of both cleaved caspase-3 and TUNEL signal (<italic toggle="yes">P</italic> &lt; 0.05).</p></sec><sec id="S3.SS4"><title>3.4 MB prevented loss of striatal neurons and myelin protein in rats exposed to exhaustive exercise training</title><p>To investigate the effects of intranasal MB administration on striatal neuron survival and myelin integrity in exercise-fatigued rats, we utilized neuronal marker NeuN, apoptotic protein marker Annexin V, and myelin protein marker MBP to stain and analyze brain sections of the rats. During apoptosis, the symmetry of the cell membrane is disrupted, causing phosphatidylserine (PS), normally located on the inner side of the membrane, to flip outward to the membrane&#8217;s exterior. Annexin V specifically binds to the exposed PS with high specificity, making it a classical marker for the early detection of apoptosis (<xref rid="B71" ref-type="bibr">Yagle et al., 2005</xref>; <xref rid="B5" ref-type="bibr">Brumatti et al., 2008</xref>). Myelin basic protein (MBP), the second most abundant protein in the CNS after proteolipid protein (PLP), is distributed on the cytoplasmic side of the myelin sheath, interacts with the cytoskeleton, and serves as an indicator of myelin structural functionality (<xref rid="B4" ref-type="bibr">Boggs, 2006</xref>; <xref rid="B26" ref-type="bibr">Haris et al., 2022</xref>). As shown in <xref rid="F5" ref-type="fig">Figure 5A</xref>, striatal neurons in rats subjected to exhaustive swimming exhibited a significant loss of NeuN-positive neurons. Compared to animals in the EE group, MB treatment significantly reduced EE-induced neuronal loss, as evidenced by a marked increase in NeuN labeling in this region. We conducted a quantitative analysis of surviving neurons and confirmed that MB could significantly reverse neuronal loss caused by EE (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F5" ref-type="fig">Figure 5B</xref>). To further elucidate the inhibitory effect of MB on EE-induced neuronal apoptosis, we assessed cleaved caspase-3, TUNEL signal, and Annexin V immunoactivity, which are involved in the apoptotic pathway. As shown in <xref rid="F5" ref-type="fig">Figure 5A</xref>, EE significantly increased the immunoactivity of cleaved caspase-3, TUNEL signal, and Annexin V in the striatal region compared to the control group. MB treatment led to a significant reduction in the activity levels of these markers. Quantitative analyses of cleaved TUNEL signal, caspase-3, and Annexin V activity confirmed that MB suppressed the activation of the apoptotic pathway (<italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F5" ref-type="fig">Figures 5C&#8211;E</xref>). Furthermore, as shown in <xref rid="F5" ref-type="fig">Figure 5F</xref>, compared to control rats, EE resulted in a fragmented and dispersed distribution of striatal MBP with reduced fluorescence intensity. However, MB treatment effectively prevented the decrease in MBP expression in animals subjected to exhaustive swimming (<italic toggle="yes">P</italic> &lt; 0.05).</p><fig position="float" id="F5" orientation="portrait"><label>FIGURE 5</label><caption><p>Methylene blue (MB) prevented loss of striatal neurons and myelin protein in rats exposed to exhaustive exercise training. <bold>(A)</bold> Representative images of NeuN staining (red), cleaved caspase-3, TUNEL staining (green), Annexin V staining (red) and MBP staining (green) in the striatum region after MB intervention. Number of surviving neurons <bold>(B)</bold>, TUNEL <bold>(C)</bold>, cleaved caspase-3 <bold>(D)</bold>, Annexin V <bold>(E)</bold> and MBP <bold>(F)</bold> were quantified and expressed as percentage changes compared to the respective control group. Data represent mean &#177; SE (<italic toggle="yes">n</italic> = 6&#8211;7). *<italic toggle="yes">P</italic> &lt; 0.05 versus control group, #<italic toggle="yes">P</italic> &lt; 0.05 versus EE group. The scale bar = 10 &#956;m. Statistical significance was determined using One-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons.</p></caption><alt-text>Diagram showing the effects of different treatments on brain tissue in the striatum area, indicated on a brain diagram. Panel A exhibits images of brain tissues under various conditions: Control, EE, and EE + MB, with staining for NeuN, TUNEL, Cle-Caspase-3, Annexin V, and MBP. Arrows point to positive cells. Panels B to F present bar graphs quantifying surviving neurons, TUNEL positive cells, Cle-Caspase-3 positive cells, Annexin V immunoreactivity, and MBP immunoreactivity across conditions, showing significant differences, marked by asterisks and hashes.</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g005.jpg"/></fig></sec><sec id="S3.SS5"><title>3.5 MB treatment significantly inhibited EE-induced loss of dendritic and synaptic proteins</title><p>Next, we examined expressions of spinophilin (a postsynaptic marker) and synaptophysin (a presynaptic marker) in the hippocampal and striatal regions. In the hippocampal region, as shown in <xref rid="F6" ref-type="fig">Figure 6A</xref>, the levels of synaptophysin and spinophilin in EE rats were significantly reduced compared to control animals (synaptophysin: <italic toggle="yes">P</italic> &lt; 0.0005, <xref rid="F6" ref-type="fig">Figure 6B</xref>; spinophilin: <italic toggle="yes">P</italic> &lt; 0.005, <xref rid="F6" ref-type="fig">Figure 6C</xref>). Conversely, the reduction in synaptophysin and spinophilin observed in EE rats was significantly alleviated following MB treatment (synaptophysin: <italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F6" ref-type="fig">Figure 6B</xref>; spinophilin: <italic toggle="yes">P</italic> &lt; 0.0001, <xref rid="F6" ref-type="fig">Figure 6C</xref>). Similarly, in the striatal region, as shown in <xref rid="F6" ref-type="fig">Figure 6D</xref>, the levels of synaptophysin and spinophilin in the EE group were significantly decreased compared to the control group (synaptophysin: <italic toggle="yes">P</italic> &lt; 0.0001, <xref rid="F6" ref-type="fig">Figure 6E</xref>; spinophilin: <italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F6" ref-type="fig">Figure 6F</xref>). This loss of dendritic and synaptic proteins was significantly rescued by MB treatment (synaptophysin: <italic toggle="yes">P</italic> &lt; 0.0001, <xref rid="F6" ref-type="fig">Figure 6E</xref>; spinophilin: <italic toggle="yes">P</italic> &lt; 0.05, <xref rid="F6" ref-type="fig">Figure 6F</xref>). These results indicate that MB provides effective therapeutic benefits against EE-induced synaptic atrophy.</p><fig position="float" id="F6" orientation="portrait"><label>FIGURE 6</label><caption><p>Methylene blue (MB) Treatment significantly inhibited EE-induced loss of dendritic and synaptic proteins. <bold>(A)</bold> Representative immunofluorescence images of the presynaptic (synaptophysin) and postsynaptic marker (spinophilin) in the hippocampal CA1 region, and the intensity of synaptophysin and spinophilin were quantified and expressed as percentage changes compared to the respective control group in panels <bold>(B&#8211;D)</bold> Representative immunofluorescence images of the presynaptic (synaptophysin) and postsynaptic marker (spinophilin) in the striatum region, and the intensity of synaptophysin and spinophilin were quantified and expressed as percentage changes compared to the respective control group in panels <bold>(E,F)</bold>. Data represent mean &#177; SE (<italic toggle="yes">n</italic> = 6&#8211;7). *<italic toggle="yes">P</italic> &lt; 0.05 versus control group, #<italic toggle="yes">P</italic> &lt; 0.05 versus EE group. The scale bar = 10 &#956;m. Statistical significance was determined using One-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons.</p></caption><alt-text>Fluorescence microscopy images and bar graphs showing synaptophysin and spinophilin expression in the hippocampus and striatum under different conditions: Control, EE (environmental enrichment), and EE+MB (methylene blue). Panels A, D display red synaptophysin staining. Panels C, F show green spinophilin staining. Panels B, E depict bar graphs quantifying presynaptic synaptophysin and panels C, F quantify dendritic spinophilin, with significant differences marked by symbols. Scale bars are present on the images.</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g006.jpg"/></fig></sec><sec id="S3.SS6"><title>3.6 MB suppressed EE-induced excessive activation of glial cells following exhaustive exercise</title><p>Excessive activation of glial cells can lead to further damage and apoptosis of neurons following injury (<xref rid="B56" ref-type="bibr">Speth et al., 2000</xref>; <xref rid="B14" ref-type="bibr">Choi et al., 2016</xref>). To explore the impact of MB intervention on glial cell activation in EE rats, we measured the fluorescence expression of GFAP (a classical marker of astrocytes) and Iba-1 (a marker of microglia/macrophages) in the hippocampus and striatum. As shown in <xref rid="F7" ref-type="fig">Figure 7A, B</xref>, the fluorescence expression of GFAP and Iba-1 within the hippocampus was significantly increased after EE (GFAP: <italic toggle="yes">P</italic> &lt; 0.0005, <xref rid="F7" ref-type="fig">Figure 7C</xref>; Iba-1: <italic toggle="yes">P</italic> &lt; 0.001, <xref rid="F7" ref-type="fig">Figure 7D</xref>), indicating that EE-induced excessive glial activation. Conversely, animals treated with MB exhibited a significant reduction in the GFAP and Iba-1 fluorescent expression (GFAP: <italic toggle="yes">P</italic> &lt; 0.0005, <xref rid="F7" ref-type="fig">Figure 7C</xref>; Iba-1: <italic toggle="yes">P</italic> &lt; 0.001, <xref rid="F7" ref-type="fig">Figure 7D</xref>). Interestingly, a similar pattern was observed in the striatum, as showed in <xref rid="F7" ref-type="fig">Figures 7E, F</xref>. A profound increase in GFAP and Iba-1 fluorescence expression was observed in the striatum following exhaustive exercise training (GFAP: <italic toggle="yes">P</italic> &lt; 0.0005, <xref rid="F7" ref-type="fig">Figure 7G</xref>; Iba-1: <italic toggle="yes">P</italic> &lt; 0.001, <xref rid="F7" ref-type="fig">Figure 7H</xref>). However, this increase in GFAP and Iba-1 expression was mitigated in animals treated with MB (GFAP: <italic toggle="yes">P</italic> &lt; 0.0005, <xref rid="F7" ref-type="fig">Figure 7G</xref>; Iba-1: <italic toggle="yes">P</italic> &lt; 0.001, <xref rid="F7" ref-type="fig">Figure 7H</xref>). In summary, EE induced excessive activation of glial cells in both the hippocampal and striatal regions, while MB significantly inhibited this effect.</p><fig position="float" id="F7" orientation="portrait"><label>FIGURE 7</label><caption><p>Methylene blue (MB) suppressed EE-induced excessive activation of glial cells following exhaustive exercise. Representative immunofluorescence images of GFAP <bold>(A)</bold> and Iba-1 <bold>(B)</bold> in the hippocampal CA1 region, and the immunoactivity of GFAP and Iba-1 were quantified and expressed as percentage changes compared to the respective control group in panels <bold>(C,D)</bold>. Representative immunofluorescence images of GFAP <bold>(E)</bold> and Iba-1 <bold>(F)</bold> in the striatum region, and the immunoactivity of GFAP and Iba-1 were quantified and expressed as percentage changes compared to the respective control group in panels <bold>(G,H)</bold>. Data represent mean &#177; SE (<italic toggle="yes">n</italic> = 6&#8211;7). *<italic toggle="yes">P</italic> &lt; 0.05 versus control group, #<italic toggle="yes">P</italic> &lt; 0.05 versus EE group. The scale bar = 10 &#956;m. Statistical significance was determined using One-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons.</p></caption><alt-text>Fluorescence microscopy images showing GFAP and Iba-1 immunoreactivity in hippocampus and striatum across control, enriched environment (EE), and EE with methylene blue (MB) groups. Panels A to D depict hippocampus: GFAP (green) intensity increases in EE and EE+MB. Iba-1 (red) intensity also increases with EE and EE+MB. Panels E to H depict striatum: similar trends for GFAP and Iba-1. Graphs C, D, G, and H show quantified immunoreactivity, indicating significant increases marked by asterisks. Nuclei counterstained with DAPI (blue) in all images. Scale bars are visible in each panel.</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g007.jpg"/></fig></sec><sec id="S3.SS7"><title>3.7 MB treatment protected mitochondrial morphology following exhaustive exercise training</title><p>We next evaluated the effects of MB treatment on mitochondrial morphology following EE in the hippocampus and striatum regions. In the hippocampus, as shown in <xref rid="F8" ref-type="fig">Figure 8A</xref>, animals in the EE group exhibit increased mitochondrial fragmentation and disrupted morphology compared to normal animals and those treated with MB. To further define and analyze these changes, we processed the TOM20 fluorescence images using ImageJ software by applying thresholding and binarization. Quantitative analyses of total mitochondrial particles, small particles, and large particles are shown in <xref rid="F8" ref-type="fig">Figures 8B&#8211;D</xref>. The results indicate that the reduction in mitochondrial structures was significantly greater in the EE group compared to the control group, whereas MB treatment attenuated mitochondrial fragmentation (<italic toggle="yes">P</italic> &lt; 0.05). Furthermore, similar results were observed in the striatum, as illustrated in <xref rid="F8" ref-type="fig">Figure 8E</xref>. The TOM20 signal in the control and MB groups was evenly distributed with intact structures, whereas the EE group displayed diminished TOM20 signal and pronounced structural fragmentation. Further quantitative analysis in <xref rid="F8" ref-type="fig">Figures 8F&#8211;H</xref> revealed that MB-treated EE rats exhibited more intact TOM20 particles, showing no significant difference from the control group. In contrast, EE rats showed notable mitochondrial fragmentation, with total and fragmented particles significantly decreased compared to the control and MB groups (<italic toggle="yes">P</italic> &lt; 0.05). These findings indicate that MB offers protective effects against exhaustive exercise-induced mitochondrial damage.</p><fig position="float" id="F8" orientation="portrait"><label>FIGURE 8</label><caption><p>Methylene blue (MB) treatment protected mitochondrial morphology following exhaustive exercise training. <bold>(A)</bold> Representative confocal microscopy images of the hippocampus showing DAPI (blue) and Tom 20 (red) are shown in figure. The confocal images of Tom 20 were thresholded, filtered (median), and binarized using image J software. As shown in figure, mitochondrial segments were separated into total particles, small particles (size: 0&#8211;2 &#956;m), and big particles (size: 3 &#956;m- infinity). The analysis of mitochondrial fragments involved counting, as shown in panels <bold>(B&#8211;D)</bold>. The total count of mitochondrial fragments <bold>(B)</bold>, the count of small mitochondrial fragments <bold>(C)</bold>, and the large mitochondrial structures <bold>(D)</bold> are normalized to the total mitochondrial area. <bold>(E)</bold> Representative confocal microscopy images of the striatum region showing DAPI (blue) and Tom 20 (red) are shown in figure. The confocal images of Tom 20 were thresholded, filtered (median), and binarized using image J software. As shown in figure, mitochondrial segments were separated into total particles, small particles (size: 0&#8211;2 &#956;m), and big particles (size: 3 &#956;m- infinity). The analysis of mitochondrial fragments involved counting, as shown in panels <bold>(F&#8211;H)</bold>. The total count of mitochondrial fragments <bold>(F)</bold>, the count of small mitochondrial fragments <bold>(G)</bold>, and the large mitochondrial structures <bold>(H)</bold> are normalized to the total mitochondrial area. Data represent mean &#177; SE (<italic toggle="yes">n</italic> = 6&#8211;7). *<italic toggle="yes">P</italic> &lt; 0.05 versus control group, #<italic toggle="yes">P</italic> &lt; 0.05 versus EE group. The scale bar = 10 &#956;m. Statistical significance was determined using One-way ANOVA analysis followed by the Tukey&#8217;s multiple comparisons.</p></caption><alt-text>Microscopy images and corresponding data charts compare the hippocampus and striatum under three conditions: Control, EE, and EE + MB. The images show TOM20/DAPI staining, highlighting cellular components in red and blue. Below the images are black and white particle analyses for total, small, and big particles. The charts (B, C, D, F, G, H) show bar graphs detailing fragmentation levels for each condition, with the Control, EE, and EE + MB groups differentiated by color. The data indicate variations in total fragmentation, small particle fragmentation, and big particle fragmentation across the conditions.</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnbeh-19-1648837-g008.jpg"/></fig></sec></sec><sec sec-type="discussion" id="S4"><title>4 Discussion</title><p>The adverse effects of prolonged exhaustive exercise have been investigated for many years, but research has primarily focused on its peripheral impact. In recent years, the adverse neurological consequences of prolonged exhaustive exercise have gained increasing research interest. Converging evidence suggests that prolonged exhaustive exercise may lead to slowed reaction times, impaired learning and memory, motor impairments, heightened anxiety, and other emotional disturbances (<xref rid="B3" ref-type="bibr">Ament and Verkerke, 2009</xref>; <xref rid="B69" ref-type="bibr">Xie et al., 2024</xref>). Currently, there are various anti-fatigue methods, each with its own advantages and disadvantages. For example, pre-cooling therapy, cold water immersion, electrical stimulation, and laser therapy have shown significant effectiveness but require external equipment, which can be costly. Nutritional supplementation, widely used in the sports industry, involves the intake of high-protein, high-carbohydrate foods, and energy supplements shortly after exercise. While this approach has demonstrated clear anti-fatigue benefits, it requires careful attention to dosage, consumption methods, and potential side effects (<xref rid="B43" ref-type="bibr">Nedelec et al., 2013</xref>; <xref rid="B51" ref-type="bibr">Querido et al., 2022</xref>). However, the above-mentioned interventions are often limited by the need for specialized equipment and narrow windows of application, and there is no emphasis on the protection of the CNS. Therefore, identifying strategies to promote rapid recovery after exhaustive exercise and prevent neural damage is critically important.</p><p>In this study, we investigated the effects of intranasal MB administration on neuronal apoptosis, synaptic structure damage, glial cell activation, and mitochondrial dynamics in the hippocampus and striatum of rats following exhaustive exercise training. Ten consecutive days of exhaustive swimming exercise represent a highly stressful state for the animals. High-intensity exercise has effects on the brain similar to ischemia/reperfusion, leading to central nervous oxidative stress and tissue necrosis (<xref rid="B68" ref-type="bibr">Wu et al., 2012</xref>; <xref rid="B48" ref-type="bibr">Peng et al., 2021</xref>). Moreover, studies have shown that physical activity alters the number of neurons in rats, involving the regulation of cell proliferation and apoptosis (<xref rid="B33" ref-type="bibr">Lattanzi et al., 2022</xref>). Related research has indicated that high-intensity exercises such as marathons and triathlons can trigger strong immune/inflammatory responses, causing vascular damage, respiratory diseases, and gastrointestinal disorders. Additionally, gene expression differences related to metabolism, DNA methylation, apoptosis, and brain function regulation can be detected shortly after high-intensity exercise (<xref rid="B25" ref-type="bibr">Hanke et al., 2010</xref>; <xref rid="B7" ref-type="bibr">Castell et al., 2019</xref>). Furthermore, overtraining can lead to increased cortisol levels in the blood of animals (<xref rid="B16" ref-type="bibr">da Rocha et al., 2017</xref>). For these reasons, metabolic imbalances and excessive oxidative stress responses can result in mitochondrial dysfunction, further leading to neuronal death and increasing the risk of developing mental disorders (<xref rid="B52" ref-type="bibr">Ren et al., 2023</xref>). Existing research indicates that MB plays a critical role in neuroprotection through mechanisms such as inhibiting oxidative stress, improving mitochondrial dysfunction, suppressing inflammatory responses, and regulating the expression of endocrine hormones like dopamine (<xref rid="B46" ref-type="bibr">Ou et al., 2023</xref>).</p><p>Methylene blue is characterized by its low dosage requirement, rapid efficacy, minimal side effects, and affordable price (<xref rid="B65" ref-type="bibr">Wu et al., 2024</xref>). Research has shown that MB solution provides significant neuroprotective effects in neonatal SD rat models of hypoxia-ischemia, with no notable side effects (<xref rid="B74" ref-type="bibr">Zhang et al., 2020</xref>). In this study, MB solution was used as an intervention, administered intranasally to address exhaustive exercise-induced neurological deficits. The present study observed that MB mitigated mitochondrial morphological changes induced by prolonged exhaustive exercise training, inhibiting apoptotic pathway activation and glial cell activation. This helped protect neuronal survival in the hippocampus and striatum regions, demonstrating its neuroprotective effects. Therefore, this study provides evidence supporting MB as a potential strategy to counteract neuronal deficits induced by exhaustive exercise. Many studies have shown that exhaustive exercise can lead to a decrease in the number of hippocampal neurons, and changes in microstructure (<xref rid="B11" ref-type="bibr">Chen et al., 2009</xref>; <xref rid="B38" ref-type="bibr">Liu et al., 2024</xref>). This research corroborates previous findings by observing, through cresyl violet staining, that neurons in the CA1 region of the hippocampus in rats appear smaller in volume, more sparsely distributed, and show signs of nuclear condensation, nuclear shrinkage, and blurred Nissl bodies. These findings suggest that high-intensity exercise causes cell necrosis and apoptosis in the hippocampal region. After 10 days of intranasal administration of MB, improvements were observed in the cresyl violet staining in the hippocampal CA1 region, with neuron volume returning to normal and distribution becoming denser. We further examined key markers of apoptosis and found that exhaustive exercise (EE) resulted in increased cleaved caspase-3 immunoreactivity and TUNEL signal in the hippocampal CA1 region. Notably, intranasal MB administration mitigated this neuronal apoptosis. This cellular-level protection was associated with functional improvements; in the Barnes maze, rats in the EE group exhibited memory deficits that were alleviated in the MB group. This cognitive improvement may be related to the restoration of synaptic structures in the hippocampal CA1 region, leading to enhanced synaptic plasticity.</p><p>The striatum, as a key area for motor regulation, can enhance neural activity and synaptic plasticity in the striatum with appropriate exercise intensity. However, intense or high load exercise has a negative impact on the survival of striatal neurons and synaptic structure (<xref rid="B58" ref-type="bibr">Tamakoshi et al., 2014</xref>; <xref rid="B64" ref-type="bibr">Wang Z. et al., 2019</xref>). This study examined the expression of neuronal nuclear protein NeuN, MBP, synaptophysin, and spinophilin in the striatum. The findings revealed that exhaustive exercise led to pathological alterations, including the loss of dorsolateral striatal neurons, reduced myelin sheath, and diminished spinophilin expression in rats. Synaptic plasticity is closely linked to learning and memory, and since the striatum is involved in motor regulation, synaptic function is likely associated with motor ability and performance in rats (<xref rid="B22" ref-type="bibr">Grillner et al., 2005</xref>; <xref rid="B9" ref-type="bibr">Chang et al., 2006</xref>; <xref rid="B32" ref-type="bibr">Kreitzer and Malenka, 2008</xref>). During the experiment, we observed a stark contrast in physical endurance. Rats in the exhaustive exercise (EE) group were progressively unable to sustain swimming, indicative of severe fatigue. In contrast, rats receiving intranasal MB showed markedly improved performance. To investigate a potential cellular basis for this exercise-induced central fatigue, we examined key apoptotic markers in the striatum. Analysis revealed that compared to the control group, the EE group exhibited a significant increase in the levels of cleaved caspase-3, as well as in TUNEL and Annexin V signals. Notably, 10 days of intranasal MB administration robustly reversed these pro-apoptotic changes.</p><p>Multiple research studies have shown that exhaustive exercise may disrupt the immune system, leading to immunosuppression and an excessive inflammatory response in athletes. These responses include the expression of pro-inflammatory factors such as TNF-&#945; and IL-6, which can further contribute to neurological disorders or negatively affect normal physiological states (<xref rid="B59" ref-type="bibr">Vargas and Marino, 2014</xref>; <xref rid="B15" ref-type="bibr">Clark and Mach, 2016</xref>; <xref rid="B36" ref-type="bibr">Li et al., 2019</xref>). Scientific studies indicate that abnormal activation of astrocytes and microglia not only produces more pro-inflammatory factors, such as IL-1&#946; and IL-6, causing more severe inflammatory responses, but also damages the CNS, further contributing to cognitive deficits in mice (<xref rid="B60" ref-type="bibr">Wang G. et al., 2019</xref>; <xref rid="B63" ref-type="bibr">Wang W. et al., 2024</xref>). Interestingly, exhaustive swimming exercises significantly increase the activation levels of GFAP and Iba-1 in the hippocampus and striatum, which can be reverse by MB treatment.</p><p>Mitochondria are essential organelles within cells, often referred to as the cell&#8217;s powerhouses, as they generate ATP through oxidative phosphorylation to provide energy for cellular activities (<xref rid="B44" ref-type="bibr">Nunnari and Suomalainen, 2012</xref>). Additionally, mitochondria participate in various metabolic processes, including glycolysis, amino acid metabolism, and fatty acid oxidation (<xref rid="B30" ref-type="bibr">Kelly and Pearce, 2020</xref>). Over the past decade, mitochondrial dysfunction has been closely linked to various CNS disorders (<xref rid="B41" ref-type="bibr">Morato et al., 2014</xref>; <xref rid="B61" ref-type="bibr">Wang H. et al., 2024</xref>). Studies have shown that restoring mitochondrial dynamics and inhibiting mitochondrial dysfunction to recover energy metabolism in different brain regions can significantly improve behavioral deficits in animal models of Alzheimer&#8217;s disease and Parkinson&#8217;s disease (<xref rid="B35" ref-type="bibr">Li et al., 2023</xref>). Previous research reports indicate that excessive exercise may alter the permeability of the mitochondrial inner membrane, with damaged mitochondria leading to excessive fragmentation, impaired mitochondrial enzyme complexes, reduced ATP levels, and the release of cytochrome c into the cytoplasm&#8211;an early apoptotic event during overexertion (<xref rid="B62" ref-type="bibr">Wang et al., 2023</xref>). Following the release of cytochrome c from mitochondria, caspase-3 and caspase-9 are activated, forming complexes with cytochrome c, thereby promoting subsequent apoptotic signaling pathways (<xref rid="B57" ref-type="bibr">Strobel et al., 2011</xref>; <xref rid="B75" ref-type="bibr">Zhang et al., 2022</xref>). Furthermore, studies have demonstrated that acute or high-intensity exercise can significantly increase apoptotic T cells and lymphocyte subsets CD4 and CD8 cells in human blood, with early apoptotic markers such as Annexin V, caspase-3, and caspase-9 activation further confirming that intense acute exercise accelerates apoptosis (<xref rid="B42" ref-type="bibr">Navalta et al., 2013</xref>; <xref rid="B47" ref-type="bibr">Palmowski et al., 2020</xref>). The findings of this study indicate that MB improves neural damage by inhibiting mitochondrial fragmentation in the hippocampus and striatum of rats and downregulating the expression levels of cleaved caspase-3, TUNEL and Annexin V signals. This further supports the potential of MB as a therapeutic agent for treating hippocampal and striatal neural damage caused by excessive exercise.</p><p>Overall, intranasal administration of MB demonstrated neuroprotective effects in a swim-exhaustion rat model. Although the detailed mechanisms of MB&#8217;s neuroprotective effects warrant further investigation, our findings suggest that MB can alleviate neuronal damage in the hippocampus and striatum while improving the physical condition of the exhausted rat model. Furthermore, this study did not measure oxidative reactions, inflammation, or hormone levels in the brain and plasma following intranasal MB administration. Future studies exploring the relationship between oxidative stress in the CNS, dosage, and treatment windows after intranasal MB administration would be particularly interesting. Additionally, the structural integrity of mitochondria relies on the regulation of mitochondrial fusion proteins. Mitochondrial fusion proteins Mfn1 and Mfn2 primarily mediate outer membrane fusion and play critical roles in maintaining normal mitochondrial morphology and function. Mitochondrial fusion can inhibit autophagy and protect mitochondrial functions by removing damaged mitochondrial proteins, highlighting the necessity for further investigation into mitochondrial-related proteins (<xref rid="B10" ref-type="bibr">Chen et al., 2003</xref>, <xref rid="B12" ref-type="bibr">2011</xref>; <xref rid="B8" ref-type="bibr">Chan, 2012</xref>). Future research should also consider the comprehensive effects of MB supplementation prior to exercise on extreme physical performance.</p><p>A key consideration is the nature of the exercise model itself. By omitting a gradual adaptation period, our protocol more closely represents an acute stress paradigm rather than a state of physiological fatigue from adapted exercise. This distinction is critical, as the observed cognitive deficits were likely driven by this acute stress, meaning the benefits of MB may stem from its known neuroprotective and stress-mitigating properties, rather than a direct role in physiological recovery. Future studies employing an adapted training protocol are therefore essential to disentangle these two potential mechanisms.</p><p>Further investigations are also warranted to fully elucidate MB&#8217;s effects. This should include measuring key biomarkers (oxidative stress, inflammation, hormone levels) and examining mitochondrial fusion proteins like Mfn1 and Mfn2. Exploring different dosages, treatment windows, and the effects of pre-exercise supplementation would also provide a more comprehensive understanding of MB&#8217;s therapeutic potential in this context.</p></sec></body><back><sec sec-type="data-availability" id="S5"><title>Data availability statement</title><p>The original contributions presented in this study are included in this article/supplementary material, further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="ethics-statement" id="S6"><title>Ethics statement</title><p>The animal study was approved by Animal Care and Use Committee of South China Normal University. The study was conducted in accordance with the local legislation and institutional requirements.</p></sec><sec sec-type="author-contributions" id="S7"><title>Author contributions</title><p>GP: Conceptualization, Writing &#8211; original draft, Data curation, Visualization, Validation, Formal analysis. WP: Methodology, Investigation, Writing &#8211; original draft, Data curation, Visualization. ZC: Formal analysis, Writing &#8211; original draft, Methodology, Visualization. LL: Writing &#8211; review &amp; editing, Funding acquisition, Supervision, Resources, Project administration. XM: Visualization, Software, Validation, Conceptualization, Supervision, Writing &#8211; review &amp; editing, Methodology.</p></sec><sec sec-type="COI-statement" id="S9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="S10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="S11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Tae</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Neuronal death in the CNS autonomic control center comes very early after cardiac arrest and is not significantly attenuated by prompt hypothermic treatment in rats.</article-title><source><italic toggle="yes">Cells</italic></source><volume>10</volume>:<fpage>60</fpage>. <pub-id pub-id-type="doi">10.3390/cells10010060</pub-id><pub-id pub-id-type="pmid">33401719</pub-id><pub-id pub-id-type="pmcid">PMC7824613</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albouy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sterpenich</surname><given-names>V.</given-names></name><name name-style="western"><surname>Balteau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vandewalle</surname><given-names>G.</given-names></name><name name-style="western"><surname>Desseilles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dang-Vu</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Both the hippocampus and striatum are involved in consolidation of motor sequence memory.</article-title><source><italic toggle="yes">Neuron</italic></source><volume>58</volume><fpage>261</fpage>&#8211;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.02.008</pub-id><pub-id pub-id-type="pmid">18439410</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ament</surname><given-names>W.</given-names></name><name name-style="western"><surname>Verkerke</surname><given-names>G. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Exercise and fatigue.</article-title><source><italic toggle="yes">Sports Med.</italic></source><volume>39</volume><fpage>389</fpage>&#8211;<lpage>422</lpage>. <pub-id pub-id-type="doi">10.2165/00007256-200939050-00005</pub-id><pub-id pub-id-type="pmid">19402743</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boggs</surname><given-names>J. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Myelin basic protein: a multifunctional protein.</article-title><source><italic toggle="yes">Cell. Mol. Life Sci.</italic></source><volume>63</volume><fpage>1945</fpage>&#8211;<lpage>1961</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-006-6094-7</pub-id><pub-id pub-id-type="pmid">16794783</pub-id><pub-id pub-id-type="pmcid">PMC11136439</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brumatti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Expression and purification of recombinant annexin V for the detection of membrane alterations on apoptotic cells.</article-title><source><italic toggle="yes">Methods</italic></source><volume>44</volume><fpage>235</fpage>&#8211;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymeth.2007.11.010</pub-id><pub-id pub-id-type="pmid">18314054</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Gandevia</surname><given-names>S. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Recovery of central and peripheral neuromuscular fatigue after exercise.</article-title><source><italic toggle="yes">J. Appl. Physiol.</italic></source><volume>122</volume><fpage>1068</fpage>&#8211;<lpage>1076</lpage>. <pub-id pub-id-type="doi">10.1152/japplphysiol.00775.2016</pub-id><pub-id pub-id-type="pmid">27932676</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castell</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Nieman</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Bermon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peeling</surname><given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>Exercise-induced illness and inflammation: Can immunonutrition and iron help?</article-title><source><italic toggle="yes">Int. J. Sport Nutr. Exerc. Metab.</italic></source><volume>29</volume><fpage>181</fpage>&#8211;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1123/ijsnem.2018-0288</pub-id><pub-id pub-id-type="pmid">30507260</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>D. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Fusion and fission: Interlinked processes critical for mitochondrial health.</article-title><source><italic toggle="yes">Annu. Rev. Genet.</italic></source><volume>46</volume><fpage>265</fpage>&#8211;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-genet-110410-132529</pub-id><pub-id pub-id-type="pmid">22934639</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>D. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Neural responses in multiple basal ganglia regions following unilateral dopamine depletion in behaving rats performing a treadmill locomotion task.</article-title><source><italic toggle="yes">Exp. Brain Res.</italic></source><volume>172</volume><fpage>193</fpage>&#8211;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1007/s00221-005-0312-7</pub-id><pub-id pub-id-type="pmid">16369786</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Detmer</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Ewald</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D. C.</given-names></name></person-group> (<year>2003</year>). <article-title>Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development.</article-title><source><italic toggle="yes">J. Cell. Biol.</italic></source><volume>160</volume><fpage>189</fpage>&#8211;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200211046</pub-id><pub-id pub-id-type="pmid">12527753</pub-id><pub-id pub-id-type="pmcid">PMC2172648</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y. J.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Fatigue reversibly reduced cortical and hippocampal dendritic spines concurrent with compromise of motor endurance and spatial memory.</article-title><source><italic toggle="yes">Neuroscience</italic></source><volume>161</volume><fpage>1104</fpage>&#8211;<lpage>1113</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.04.022</pub-id><pub-id pub-id-type="pmid">19376203</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>G. W.</given-names></name></person-group> (<year>2011</year>). <article-title>Mitochondrial fusion is essential for organelle function and cardiac homeostasis.</article-title><source><italic toggle="yes">Circ. Res.</italic></source><volume>109</volume><fpage>1327</fpage>&#8211;<lpage>1331</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.258723</pub-id><pub-id pub-id-type="pmid">22052916</pub-id><pub-id pub-id-type="pmcid">PMC3237902</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ordovas</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Anti-fatigue and anti-oxidant effects of curcumin supplementation in exhaustive swimming mice via Nrf2/Keap1 signal pathway.</article-title><source><italic toggle="yes">Curr. Res. Food Sci.</italic></source><volume>5</volume><fpage>1148</fpage>&#8211;<lpage>1157</lpage>. <pub-id pub-id-type="doi">10.1016/j.crfs.2022.07.006</pub-id><pub-id pub-id-type="pmid">35875345</pub-id><pub-id pub-id-type="pmcid">PMC9304720</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>E. O.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G. Y.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Baicalein protects C6 glial cells against hydrogen peroxide-induced oxidative stress and apoptosis through regulation of the Nrf2 signaling pathway.</article-title><source><italic toggle="yes">Int. J. Mol. Med.</italic></source><volume>37</volume><fpage>798</fpage>&#8211;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2016.2460</pub-id><pub-id pub-id-type="pmid">26796879</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mach</surname><given-names>N.</given-names></name></person-group> (<year>2016</year>). <article-title>Exercise-induced stress behavior, gut-microbiota-brain axis and diet: A systematic review for athletes.</article-title><source><italic toggle="yes">J. Int. Soc. Sports Nutr.</italic></source><volume>13</volume>:<fpage>43</fpage>. <pub-id pub-id-type="doi">10.1186/s12970-016-0155-6</pub-id><pub-id pub-id-type="pmid">27924137</pub-id><pub-id pub-id-type="pmcid">PMC5121944</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Rocha</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Frantz</surname><given-names>F. G.</given-names></name><name name-style="western"><surname>Elias</surname><given-names>L. L. K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Treadmill slope modulates inflammation, fiber type composition, androgen, and glucocorticoid receptors in the skeletal muscle of overtrained mice.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>8</volume>:<fpage>1378</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.01378</pub-id><pub-id pub-id-type="pmid">29163473</pub-id><pub-id pub-id-type="pmcid">PMC5669301</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance.</article-title><source><italic toggle="yes">Am. J. Physiol. Regul. Integr. Comp. Physiol.</italic></source><volume>296</volume><fpage>R1071</fpage>&#8211;<lpage>R1077</lpage>. <pub-id pub-id-type="doi">10.1152/ajpregu.90925.2008</pub-id><pub-id pub-id-type="pmid">19211721</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y. P.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C. Q.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Novel insights into neun: From neuronal marker to splicing regulator.</article-title><source><italic toggle="yes">Mol. Neurobiol.</italic></source><volume>53</volume><fpage>1637</fpage>&#8211;<lpage>1647</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-015-9122-5</pub-id><pub-id pub-id-type="pmid">25680637</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>L. Z.</given-names></name><name name-style="western"><surname>Creed</surname><given-names>M. C.</given-names></name></person-group> (<year>2024</year>). <article-title>Updating the striatal-pallidal wiring diagram.</article-title><source><italic toggle="yes">Nat. Neurosci.</italic></source><volume>27</volume><fpage>15</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-023-01518-x</pub-id><pub-id pub-id-type="pmid">38057614</pub-id><pub-id pub-id-type="pmcid">PMC11892008</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenn</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Skendelas</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Moussa</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Muccigrosso</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Popovich</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Lifshitz</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Methylene blue attenuates traumatic brain injury-associated neuroinflammation and acute depressive-like behavior in mice.</article-title><source><italic toggle="yes">J. Neurotrauma</italic></source><volume>32</volume><fpage>127</fpage>&#8211;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1089/neu.2014.3514</pub-id><pub-id pub-id-type="pmid">25070744</pub-id><pub-id pub-id-type="pmcid">PMC4291210</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandevia</surname><given-names>S. C.</given-names></name></person-group> (<year>2001</year>). <article-title>Spinal and supraspinal factors in human muscle fatigue.</article-title><source><italic toggle="yes">Physiol. Rev.</italic></source><volume>81</volume><fpage>1725</fpage>&#8211;<lpage>1789</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.2001.81.4.1725</pub-id><pub-id pub-id-type="pmid">11581501</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grillner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hellgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Menard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wikstrom</surname><given-names>M. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Mechanisms for selection of basic motor programs&#8211;roles for the striatum and pallidum.</article-title><source><italic toggle="yes">Trends Neurosci.</italic></source><volume>28</volume><fpage>364</fpage>&#8211;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2005.05.004</pub-id><pub-id pub-id-type="pmid">15935487</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gureev</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Sadovnikova</surname><given-names>I. S.</given-names></name><name name-style="western"><surname>Popov</surname><given-names>V. N.</given-names></name></person-group> (<year>2022</year>). <article-title>Molecular mechanisms of the neuroprotective effect of methylene blue.</article-title><source><italic toggle="yes">Biochemistry</italic></source><volume>87</volume><fpage>940</fpage>&#8211;<lpage>956</lpage>. <pub-id pub-id-type="doi">10.1134/S0006297922090073</pub-id><pub-id pub-id-type="pmid">36180986</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W. K.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Leucine and glycine dipeptides of porcine placenta ameliorate physical fatigue through enhancing dopaminergic systems.</article-title><source><italic toggle="yes">Mol. Med. Rep.</italic></source><volume>17</volume><fpage>4120</fpage>&#8211;<lpage>4130</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.8335</pub-id><pub-id pub-id-type="pmid">29286166</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanke</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Staib</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gorlinger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Perrey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dirkmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kienbaum</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Whole blood coagulation and platelet activation in the athlete: a comparison of marathon, triathlon and long distance cycling.</article-title><source><italic toggle="yes">Eur. J. Med. Res.</italic></source><volume>15</volume><fpage>59</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1186/2047-783x-15-2-59</pub-id><pub-id pub-id-type="pmid">20452885</pub-id><pub-id pub-id-type="pmcid">PMC3352046</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haris</surname><given-names>L.</given-names></name><name name-style="western"><surname>Biehl</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dulle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Radulescu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Holderer</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Variation of structural and dynamical flexibility of myelin basic protein in response to guanidinium chloride.</article-title><source><italic toggle="yes">Int. J. Mol. Sci.</italic></source><volume>23</volume>:<fpage>6969</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23136969</pub-id><pub-id pub-id-type="pmid">35805997</pub-id><pub-id pub-id-type="pmcid">PMC9266411</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeukendrup</surname><given-names>A. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Nutrition for endurance sports: Marathon, triathlon, and road cycling.</article-title><source><italic toggle="yes">J. Sports Sci.</italic></source><volume>29</volume><fpage>S91</fpage>&#8211;<lpage>S99</lpage>. <pub-id pub-id-type="doi">10.1080/02640414.2011.610348</pub-id><pub-id pub-id-type="pmid">21916794</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Haramizu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ranchordas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stear</surname><given-names>S.</given-names></name><name name-style="western"><surname>Castell</surname><given-names>L. M.</given-names></name></person-group> (<year>2011</year>). <article-title>A-Z of nutritional supplements: Dietary supplements, sports nutrition foods and ergogenic aids for health and performance&#8211;Part 27.</article-title><source><italic toggle="yes">Br. J. Sports Med.</italic></source><volume>45</volume><fpage>1246</fpage>&#8211;<lpage>1248</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2011-090669</pub-id><pub-id pub-id-type="pmid">22076991</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kann</surname><given-names>O.</given-names></name></person-group> (<year>2024</year>). <article-title>Lactate as a supplemental fuel for synaptic transmission and neuronal network oscillations: Potentials and limitations.</article-title><source><italic toggle="yes">J. Neurochem.</italic></source><volume>168</volume><fpage>608</fpage>&#8211;<lpage>631</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.15867</pub-id><pub-id pub-id-type="pmid">37309602</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>E. L.</given-names></name></person-group> (<year>2020</year>). <article-title>Amino assets: How amino acids support immunity.</article-title><source><italic toggle="yes">Cell. Metab.</italic></source><volume>32</volume><fpage>154</fpage>&#8211;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2020.06.010</pub-id><pub-id pub-id-type="pmid">32649859</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kodali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hattiangady</surname><given-names>B.</given-names></name><name name-style="western"><surname>Attaluri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Moderate, intermittent voluntary exercise in a model of Gulf War Illness improves cognitive and mood function with alleviation of activated microglia and astrocytes, and enhanced neurogenesis in the hippocampus.</article-title><source><italic toggle="yes">Brain Behav. Immun.</italic></source><volume>97</volume><fpage>135</fpage>&#8211;<lpage>149</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2021.07.005</pub-id><pub-id pub-id-type="pmid">34245811</pub-id><pub-id pub-id-type="pmcid">PMC9885810</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreitzer</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Malenka</surname><given-names>R. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Striatal plasticity and basal ganglia circuit function.</article-title><source><italic toggle="yes">Neuron</italic></source><volume>60</volume><fpage>543</fpage>&#8211;<lpage>554</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.11.005</pub-id><pub-id pub-id-type="pmid">19038213</pub-id><pub-id pub-id-type="pmcid">PMC2724179</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lattanzi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Savelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pagliarini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cuppini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ambrogini</surname><given-names>P.</given-names></name></person-group> (<year>2022</year>). <article-title>Short-term, voluntary exercise affects morpho-functional maturation of adult-generated neurons in rat hippocampus.</article-title><source><italic toggle="yes">Int. J. Mol. Sci.</italic></source><volume>23</volume>:<fpage>6866</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23126866</pub-id><pub-id pub-id-type="pmid">35743307</pub-id><pub-id pub-id-type="pmcid">PMC9224999</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Combination treatment with methylene blue and hypothermia in global cerebral ischemia.</article-title><source><italic toggle="yes">Mol. Neurobiol.</italic></source><volume>55</volume><fpage>2042</fpage>&#8211;<lpage>2055</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-017-0470-1</pub-id><pub-id pub-id-type="pmid">28271403</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Neuroprotective effects of morroniside from Cornus officinalis sieb. Et zucc against Parkinson&#8217;s disease via inhibiting oxidative stress and ferroptosis.</article-title><source><italic toggle="yes">BMC Complement Med. Ther.</italic></source><volume>23</volume>:<fpage>218</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-023-03967-0</pub-id><pub-id pub-id-type="pmid">37393274</pub-id><pub-id pub-id-type="pmcid">PMC10314491</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T. G.</given-names></name><name name-style="western"><surname>Shui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>D. Y.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Moxibustion reduces inflammatory response in the hippocampus of a chronic exercise-induced fatigue rat.</article-title><source><italic toggle="yes">Front. Integr. Neurosci.</italic></source><volume>13</volume>:<fpage>48</fpage>. <pub-id pub-id-type="doi">10.3389/fnint.2019.00048</pub-id><pub-id pub-id-type="pmid">31616260</pub-id><pub-id pub-id-type="pmcid">PMC6763602</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The preventive effects of pterostilbene on the exercise intolerance and circadian misalignment of mice subjected to sleep restriction.</article-title><source><italic toggle="yes">Mol. Nutr. Food Res.</italic></source><volume>64</volume>:<fpage>e1900991</fpage>. <pub-id pub-id-type="doi">10.1002/mnfr.201900991</pub-id><pub-id pub-id-type="pmid">32277569</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>W.</given-names></name></person-group> (<year>2024</year>). <article-title>Comparison of alterations in local field potentials and neuronal firing in mouse M1 and CA1 associated with central fatigue induced by high-intensity interval training and moderate-intensity continuous training.</article-title><source><italic toggle="yes">Front. Neurosci.</italic></source><volume>18</volume>:<fpage>1428901</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2024.1428901</pub-id><pub-id pub-id-type="pmid">39211437</pub-id><pub-id pub-id-type="pmcid">PMC11357951</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Q.</given-names></name></person-group> (<year>2023</year>). <article-title>Resveratrol promotes mitochondrial energy metabolism in exercise-induced fatigued rats.</article-title><source><italic toggle="yes">Nutr. Res. Pract.</italic></source><volume>17</volume><fpage>660</fpage>&#8211;<lpage>669</lpage>. <pub-id pub-id-type="doi">10.4162/nrp.2023.17.4.660</pub-id><pub-id pub-id-type="pmid">37529270</pub-id><pub-id pub-id-type="pmcid">PMC10375326</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meeusen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Duclos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gleeson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nieman</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Prevention, diagnosis, and treatment of the overtraining syndrome: joint consensus statement of the European College of sport science and the American college of sports medicine.</article-title><source><italic toggle="yes">Med. Sci. Sports Exerc.</italic></source><volume>45</volume><fpage>186</fpage>&#8211;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0b013e318279a10a</pub-id><pub-id pub-id-type="pmid">23247672</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morato</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Verrigni</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ardissone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Mitochondrial dysfunction in central nervous system white matter disorders.</article-title><source><italic toggle="yes">Glia</italic></source><volume>62</volume><fpage>1878</fpage>&#8211;<lpage>1894</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22670</pub-id><pub-id pub-id-type="pmid">24865954</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navalta</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prestes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arnett</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sobrero</surname><given-names>G. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Exercise intensity and lymphocyte subset apoptosis.</article-title><source><italic toggle="yes">Int. J. Sports Med.</italic></source><volume>34</volume><fpage>268</fpage>&#8211;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1055/s-0032-1312581</pub-id><pub-id pub-id-type="pmid">23041963</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedelec</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carling</surname><given-names>C.</given-names></name><name name-style="western"><surname>Legall</surname><given-names>F.</given-names></name><name name-style="western"><surname>Berthoin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>Recovery in soccer: Part ii-recovery strategies.</article-title><source><italic toggle="yes">Sports Med.</italic></source><volume>43</volume><fpage>9</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1007/s40279-012-0002-0</pub-id><pub-id pub-id-type="pmid">23315753</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunnari</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suomalainen</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Mitochondria: In sickness and in health.</article-title><source><italic toggle="yes">Cell</italic></source><volume>148</volume><fpage>1145</fpage>&#8211;<lpage>1159</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.02.035</pub-id><pub-id pub-id-type="pmid">22424226</pub-id><pub-id pub-id-type="pmcid">PMC5381524</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohlow</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Moosmann</surname><given-names>B.</given-names></name></person-group> (<year>2011</year>). <article-title>Phenothiazine: The seven lives of pharmacology&#8217;s first lead structure.</article-title><source><italic toggle="yes">Drug Discov. Today</italic></source><volume>16</volume><fpage>119</fpage>&#8211;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2011.01.001</pub-id><pub-id pub-id-type="pmid">21237283</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Che</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Methylene blue targets PHD3 expression in murine microglia to mitigate lipopolysaccharide-induced neuroinflammation and neurocognitive impairments.</article-title><source><italic toggle="yes">Int. Immunopharmacol.</italic></source><volume>120</volume>:<fpage>110349</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2023.110349</pub-id><pub-id pub-id-type="pmid">37210913</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmowski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reichel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bosslau</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>The effect of acute running and cycling exercise on T cell apoptosis in humans: A systematic review.</article-title><source><italic toggle="yes">Scand. J. Immunol.</italic></source><volume>91</volume>:<fpage>e12834</fpage>. <pub-id pub-id-type="doi">10.1111/sji.12834</pub-id><pub-id pub-id-type="pmid">31680301</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Intranasal administration of DHED protects against exhaustive exercise-induced brain injury in rats.</article-title><source><italic toggle="yes">Brain Res.</italic></source><volume>1772</volume><issue>147665</issue>. <pub-id pub-id-type="doi">10.1016/j.brainres.2021.147665</pub-id><pub-id pub-id-type="pmid">34562473</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierce</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Kutryk</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Dhalla</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Beamish</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Dhalla</surname><given-names>N. S.</given-names></name></person-group> (<year>1984</year>). <article-title>Biochemical alterations in heart after exhaustive swimming in rats.</article-title><source><italic toggle="yes">J. Appl. Physiol. Respir. Environ. Exerc. Physiol.</italic></source><volume>57</volume><fpage>326</fpage>&#8211;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1152/jappl.1984.57.2.326</pub-id><pub-id pub-id-type="pmid">6469802</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pronier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morici</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Girardeau</surname><given-names>G.</given-names></name></person-group> (<year>2023</year>). <article-title>The role of the hippocampus in the consolidation of emotional memories during sleep.</article-title><source><italic toggle="yes">Trends Neurosci.</italic></source><volume>46</volume><fpage>912</fpage>&#8211;<lpage>925</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2023.08.003</pub-id><pub-id pub-id-type="pmid">37714808</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Querido</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Radaelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vaz</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>S. R.</given-names></name></person-group> (<year>2022</year>). <article-title>Analysis of recovery methods&#8217; efficacy applied up to 72 hours postmatch in professional football: A systematic review with graded recommendations.</article-title><source><italic toggle="yes">Int. J. Sports Physiol. Perform.</italic></source><volume>17</volume><fpage>1326</fpage>&#8211;<lpage>1342</lpage>. <pub-id pub-id-type="doi">10.1123/ijspp.2022-0038</pub-id><pub-id pub-id-type="pmid">35961644</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Melatonin reduces radiation-induced ferroptosis in hippocampal neurons by activating the PKM2/NRF2/GPX4 signaling pathway.</article-title><source><italic toggle="yes">Prog. Neuropsychopharmacol. Biol. Psychiatry</italic></source><volume>126</volume>:<fpage>110777</fpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2023.110777</pub-id><pub-id pub-id-type="pmid">37100272</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schirmer</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pickhardt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Lest we forget you&#8211;methylene blue.</article-title><source><italic toggle="yes">Neurobiol. Aging</italic></source><volume>32</volume><fpage>2325.e7</fpage>-<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.12.012</pub-id><pub-id pub-id-type="pmid">21316815</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaktivesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malekipour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Whitton</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Hitchens</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P. V.</given-names></name></person-group> (<year>2020</year>). <article-title>Fatigue behavior of subchondral bone under simulated physiological loads of equine athletic training.</article-title><source><italic toggle="yes">J. Mech. Behav. Biomed. Mater.</italic></source><volume>110</volume>:<fpage>103920</fpage>. <pub-id pub-id-type="doi">10.1016/j.jmbbm.2020.103920</pub-id><pub-id pub-id-type="pmid">32957215</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R. K.</given-names></name></person-group> (<year>2025</year>). <article-title>Recent advancements in the understanding of the alterations in mitochondrial biogenesis in Alzheimer&#8217;s disease.</article-title><source><italic toggle="yes">Mol. Biol. Rep.</italic></source><volume>52</volume>:<fpage>173</fpage>. <pub-id pub-id-type="doi">10.1007/s11033-025-10297-6</pub-id><pub-id pub-id-type="pmid">39880979</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speth</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stockl</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wirleitner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Widner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wurzner</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Inflammation marker 7,8-dihydroneopterin induces apoptosis of neurons and glial cells: A potential contribution to neurodegenerative processes.</article-title><source><italic toggle="yes">Immunobiology</italic></source><volume>202</volume><fpage>460</fpage>&#8211;<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1016/S0171-2985(00)80104-7</pub-id><pub-id pub-id-type="pmid">11205375</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strobel</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Peake</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Coombes</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Wadley</surname><given-names>G. D.</given-names></name></person-group> (<year>2011</year>). <article-title>Antioxidant supplementation reduces skeletal muscle mitochondrial biogenesis.</article-title><source><italic toggle="yes">Med. Sci. Sports Exerc.</italic></source><volume>43</volume><fpage>1017</fpage>&#8211;<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0b013e318203afa3</pub-id><pub-id pub-id-type="pmid">21085043</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamakoshi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takamatsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hamakawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Motor skills training promotes motor functional recovery and induces synaptogenesis in the motor cortex and striatum after intracerebral hemorrhage in rats.</article-title><source><italic toggle="yes">Behav. Brain Res.</italic></source><volume>260</volume><fpage>34</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2013.11.034</pub-id><pub-id pub-id-type="pmid">24304717</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas</surname><given-names>N. T.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>A neuroinflammatory model for acute fatigue during exercise.</article-title><source><italic toggle="yes">Sports Med.</italic></source><volume>44</volume><fpage>1479</fpage>&#8211;<lpage>1487</lpage>. <pub-id pub-id-type="doi">10.1007/s40279-014-0232-4</pub-id><pub-id pub-id-type="pmid">25164464</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name></person-group> (<year>2019</year>). <article-title>Age-associated dopaminergic neuron loss and midbrain glia cell phenotypic polarization.</article-title><source><italic toggle="yes">Neuroscience</italic></source><volume>415</volume><fpage>89</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2019.07.021</pub-id><pub-id pub-id-type="pmid">31325563</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>CKLF induces microglial activation via triggering defective mitophagy and mitochondrial dysfunction.</article-title><source><italic toggle="yes">Autophagy</italic></source><volume>20</volume><fpage>590</fpage>&#8211;<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2023.2276639</pub-id><pub-id pub-id-type="pmid">37908119</pub-id><pub-id pub-id-type="pmcid">PMC10936627</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P. Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Son</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Syed</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U S A.</italic></source><volume>120</volume>:<fpage>e2302738120</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2302738120</pub-id><pub-id pub-id-type="pmid">37579159</pub-id><pub-id pub-id-type="pmcid">PMC10450651</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Gastrodin regulates the TLR4/TRAF6/NF-kappaB pathway to reduce neuroinflammation and microglial activation in an AD model.</article-title><source><italic toggle="yes">Phytomedicine</italic></source><volume>128</volume>:<fpage>155518</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2024.155518</pub-id><pub-id pub-id-type="pmid">38552431</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group> (<year>2019</year>). <article-title>Effects of exercise-induced fatigue on the morphology of asymmetric synapse and synaptic protein levels in rat striatum.</article-title><source><italic toggle="yes">Neurochem. Int.</italic></source><volume>129</volume>:<fpage>104476</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2019.104476</pub-id><pub-id pub-id-type="pmid">31145967</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name></person-group> (<year>2024</year>). <article-title>Methylene blue pretreatment protects against repeated neonatal isoflurane exposure-induced brain injury and memory loss.</article-title><source><italic toggle="yes">Mol. Neurobiol.</italic></source><volume>61</volume><fpage>5787</fpage>&#8211;<lpage>5801</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-024-03931-0</pub-id><pub-id pub-id-type="pmid">38233687</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>L. D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effects of exercise training on anxious-depressive-like behavior in Alzheimer rat.</article-title><source><italic toggle="yes">Med. Sci. Sports Exerc.</italic></source><volume>52</volume><fpage>1456</fpage>&#8211;<lpage>1469</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0000000000002294</pub-id><pub-id pub-id-type="pmid">32028456</pub-id><pub-id pub-id-type="pmcid">PMC8015320</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Beneficial effects of exercise pretreatment in a sporadic Alzheimer&#8217;s rat model.</article-title><source><italic toggle="yes">Med. Sci. Sports Exerc.</italic></source><volume>50</volume><fpage>945</fpage>&#8211;<lpage>956</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0000000000001519</pub-id><pub-id pub-id-type="pmid">29232315</pub-id><pub-id pub-id-type="pmcid">PMC5899011</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X. D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L. X.</given-names></name></person-group> (<year>2012</year>). <article-title>Exhaustive swimming exercise related kidney injury in rats - protective effects of acetylbritannilactone.</article-title><source><italic toggle="yes">Int. J. Sports Med.</italic></source><volume>33</volume><fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1055/s-0031-1284397</pub-id><pub-id pub-id-type="pmid">22105617</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group> (<year>2024</year>). <article-title>Effects of beta-asarone on spatial learning and memory impairment by exhaustive exercise-induced fatigue: Role of NR-CaMKII-ERK/CREB signal in hippocampus of rats.</article-title><source><italic toggle="yes">Behav. Brain Res.</italic></source><volume>471</volume>:<fpage>115076</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2024.115076</pub-id><pub-id pub-id-type="pmid">38825021</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thaivalappil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>The potentials of methylene blue as an anti-aging drug.</article-title><source><italic toggle="yes">Cells</italic></source><volume>10</volume>:<fpage>3379</fpage>. <pub-id pub-id-type="doi">10.3390/cells10123379</pub-id><pub-id pub-id-type="pmid">34943887</pub-id><pub-id pub-id-type="pmcid">PMC8699482</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yagle</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Eary</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Tait</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Grierson</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Link</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Lewellen</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis.</article-title><source><italic toggle="yes">J. Nucl. Med.</italic></source><volume>46</volume><fpage>658</fpage>&#8211;<lpage>666</lpage>.<pub-id pub-id-type="pmid">15809489</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Photobiomodulation preconditioning prevents cognitive impairment in a neonatal rat model of hypoxia-ischemia.</article-title><source><italic toggle="yes">J. Biophotonics</italic></source><volume>12</volume>:<fpage>e201800359</fpage>. <pub-id pub-id-type="doi">10.1002/jbio.201800359</pub-id><pub-id pub-id-type="pmid">30652418</pub-id><pub-id pub-id-type="pmcid">PMC6546525</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R. H.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Long-term exercise pre-training attenuates Alzheimer&#8217;s disease-related pathology in a transgenic rat model of Alzheimer&#8217;s disease.</article-title><source><italic toggle="yes">Geroscience</italic></source><volume>44</volume><fpage>1457</fpage>&#8211;<lpage>1477</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-022-00534-2</pub-id><pub-id pub-id-type="pmid">35229257</pub-id><pub-id pub-id-type="pmcid">PMC9213627</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Methylene blue post-treatment improves hypoxia-ischemic recovery in a neonatal rat model.</article-title><source><italic toggle="yes">Neurochem. Int.</italic></source><volume>139</volume>:<fpage>104782</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2020.104782</pub-id><pub-id pub-id-type="pmid">32628986</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Su</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Red ginseng extract improves skeletal muscle energy metabolism and mitochondrial function in chronic fatigue mice.</article-title><source><italic toggle="yes">Front. Pharmacol.</italic></source><volume>13</volume>:<fpage>1077249</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.1077249</pub-id><pub-id pub-id-type="pmid">36618917</pub-id><pub-id pub-id-type="pmcid">PMC9816794</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z. T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X. M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X. J.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C. L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Activation of the NLRP3 inflammasome in lipopolysaccharide-induced mouse fatigue and its relevance to chronic fatigue syndrome.</article-title><source><italic toggle="yes">J. Neuroinflammation</italic></source><volume>13</volume>:<fpage>71</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-016-0539-1</pub-id><pub-id pub-id-type="pmid">27048470</pub-id><pub-id pub-id-type="pmcid">PMC4822300</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>The potential related genes and mechanisms involved in improving the treadmill exercise ability of APP/PS1 mice.</article-title><source><italic toggle="yes">Int. J. Mol. Sci.</italic></source><volume>25</volume>:<fpage>10244</fpage>. <pub-id pub-id-type="doi">10.3390/ijms251910244</pub-id><pub-id pub-id-type="pmid">39408581</pub-id><pub-id pub-id-type="pmcid">PMC11476258</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Impacts of impaired mitochondrial dynamics in hearing loss: Potential therapeutic targets.</article-title><source><italic toggle="yes">Front. Neurosci.</italic></source><volume>16</volume>:<fpage>998507</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2022.998507</pub-id><pub-id pub-id-type="pmid">36278017</pub-id><pub-id pub-id-type="pmcid">PMC9579438</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="pmc-domain-id">798</journal-id><journal-id journal-id-type="pmc-domain">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>American Academy of Neurology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11379123</article-id><article-id pub-id-type="pmcid-ver">PMC11379123.1</article-id><article-id pub-id-type="pmcaid">11379123</article-id><article-id pub-id-type="pmcaiid">11379123</article-id><article-id pub-id-type="pmid">39236270</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000209861</article-id><article-id pub-id-type="publisher-id">WNL-2024-102464</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>21</subject><subject>52</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Methods in Neurology</subject></subj-group></article-categories><title-group><article-title>Common Critiques and Recommendations for Studies in Neurology Using Machine Learning Methods</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0679-8730</contrib-id><name name-style="western"><surname>Speiser</surname><given-names initials="JL">Jaime L.</given-names></name><degrees>PhD, MS</degrees></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5546-5951</contrib-id><name name-style="western"><surname>Kerr</surname><given-names initials="WT">Wesley T.</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8386-5397</contrib-id><name name-style="western"><surname>Ziegler</surname><given-names initials="A">Andreas</given-names></name><degrees>Dr rer nat</degrees></contrib><aff>From the Department of Biostatistics and Data Science (J.L.S.), Wake Forest University School of Medicine, Winston-Salem, NC; Department of Neurology and Biomedical Informatics (W.T.K.), University of Pittsburgh, PA; Cardio-CARE (A.Z.), Medizincampus Davos, Switzerland; Department of Cardiology and Population Health Innovation (A.Z.), University Medical Center Hamburg-Eppendorf, Germany; and Department of Mathematics, Statistics and Computer Science (A.Z.), University of KwaZulu-Natal, Berea, Durban, South Africa.</aff></contrib-group><author-notes><corresp><bold>Correspondence</bold> Dr. Speiser <email>jspeiser@wakehealth.edu</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000209861" ext-link-type="uri">Neurology.org/N</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p></fn><fn fn-type="other"><p>Submitted and externally peer reviewed. The handling editor was Editor-in-Chief Jos&#233; Merino, MD, MPhil, FAAN.</p></fn></author-notes><pub-date pub-type="ppub"><day>8</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>5</day><month>9</month><year>2024</year></pub-date><volume>103</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">469693</issue-id><elocation-id>e209861</elocation-id><history><date date-type="received"><day>02</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-released-under-embargo"><date><day>07</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 00:25:15.077"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 American Academy of Neurology</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="WNL-2024-102464.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="WNL-2024-102464.pdf"/><abstract><p>Machine learning (ML) methods are becoming more prevalent in the neurology literature as alternatives to traditional statistical methods to address challenges in the analysis of modern data sets. Despite the increase in the popularity of ML methods in neurology studies, some authors do not fully address all items recommended in reporting guidelines. The authors of this Research Methods article are members of the <italic toggle="yes">Neurology</italic>&#174; editorial board and have reviewed many studies using ML methods. In their review reports, several critiques often appear, which could be avoided if guidance were available. In this article, we detail common critiques found in ML research studies and make recommendations for how to avoid them. The first critique involves misalignment of the study goals and the analysis conducted. The second critique focuses on ML terminology being appropriately used. Critiques 3&#8211;6 are related to the study design: justifying sample sizes and the suitability of the data set for the study goals, describing the ML analysis pipeline sufficiently, quantifying the amount of missing data and providing information about missing data handling, and including uncertainty estimates for key metrics. The seventh critique focuses on fairly describing both strengths and limitations of the ML study, including the analysis methodology and results. We provide examples in neurology for each critique and guidance on how to avoid the critique. Overall, we recommend that authors use ML-specific checklists developed by research consortia for designing and reporting studies using ML. We also recommend that authors involve both a statistician and an ML expert in work that uses ML. Although our list of critiques is not exhaustive, our recommendations should help improve the quality and rigor of ML studies. ML has great potential to revolutionize neurology, but investigators need to conduct and report the results in a way that allows readers to fully evaluate the benefits and limitations of ML approaches.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuroimmunomodulation</journal-id><journal-id journal-id-type="iso-abbrev">Neuroimmunomodulation</journal-id><journal-id journal-id-type="pmc-domain-id">2985</journal-id><journal-id journal-id-type="pmc-domain">kargersd</journal-id><journal-id journal-id-type="publisher-id">NIM</journal-id><journal-title-group><journal-title>Neuroimmunomodulation</journal-title></journal-title-group><issn pub-type="ppub">1021-7401</issn><issn pub-type="epub">1423-0216</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Karger Author's Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12503459</article-id><article-id pub-id-type="pmcid-ver">PMC12503459.1</article-id><article-id pub-id-type="pmcaid">12503459</article-id><article-id pub-id-type="pmcaiid">12503459</article-id><article-id pub-id-type="pmid">40623398</article-id><article-id pub-id-type="doi">10.1159/000547243</article-id><article-id pub-id-type="publisher-id">547243</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Exosomes and microRNA: A New Form of Remote and Bidirectional Neuroimmunomodulation?</article-title><alt-title alt-title-type="short">microRNA-Accomplished Neuroimmunomodulation</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="relnr" authenticated="false">2793256</contrib-id><name name-style="western"><surname>Straub</surname><given-names initials="RH">Rainer H.</given-names></name></contrib><aff id="aff1">Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, <city>Regensburg</city>, <country>Germany</country></aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Rainer H. Straub, <email>rainer.straub@ukr.de</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2025</year></pub-date><volume>32</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">498495</issue-id><fpage>161</fpage><lpage>212</lpage><history><date date-type="received"><day>27</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2025</year></date><date date-type="subscription-year"><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by S. Karger AG, Basel</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://karger.com/Services/OpenAccessLicense">https://karger.com/Services/OpenAccessLicense</ext-link>). Usage and distribution for commercial purposes requires written permission.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nim-2025-0032-0001-547243.pdf"/><abstract><title>Abstract</title><sec><title>Background</title><p>There exists the well-known crosstalk between brain and immune system, which has much to do with energy regulation in the body. The selfish brain dominates energy distribution in the presence of threats like predators, wounding with hemorrhage, food scarcity, thirst, cold, and heat. The selfish immune system dominates energy allocation during infection and wounding with infection. Often, the two major organ systems selfishly inhibit each other to govern energy self-supply. However, sometimes they can help each other in early situation with threats (immediate mutual assistance). The brain influences the immune system by means of hard-wired nerve fibers and their neurotransmitters and through hormones from brain-controlled endocrine glands. The immune system influences structures of the brain through soluble factors like cytokines, migrating immune cells, and surface receptors (e.g., of cytokines) on sensory nerve fibers. After the appearance of microRNA, this classical view of neuroimmunomodulation needs some revision.</p></sec><sec><title>Summary</title><p>This view of neuroimmunomodulation has recently been expanded by experimental work in stress research [Semin Immunol. 2014;26(5):394&#8211;401 and Trends Immunol. 2017;38(10):768&#8211;76]. Next to classical connectors of brain and immune system, exosome microRNA may play an outstanding role in this bidirectional crosstalk. This review systematically analyzes sources of microRNA in the brain and effects of this microRNA on target immune function. Vice versa, microRNAs of distinct immune cells are demonstrated how they might interfere with various brain functions.</p></sec><sec><title>Key Messages</title><p>This review has the character of a theory that should stimulate new research in order to define &#8211; in a single publication &#8211; the origin of microRNA in the brain and its influence on the target in immune cells and vice versa. The field of neuroimmunomodulation should include these new microRNA pathways to obtain a full picture of bidirectional interactions between the two selfish organ systems.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>microRNA</kwd><kwd>Brain</kwd><kwd>Immune system</kwd><kwd>Crosstalk</kwd><kwd>Neuroimmunomodulation</kwd></kwd-group><funding-group><funding-statement>The work has been funded by institutional money of the University Hospital of Regensburg. The institute had no influence on study design, execution and analysis, manuscript conception, planning, writing, and decision to publish.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="12"/><ref-count count="798"/><page-count count="52"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>accessibilitySummary</meta-name><meta-value>WCAG 2.1 Level AA</meta-value></custom-meta><custom-meta><meta-name>accessibility-pdf-ua-compliance</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p>Neuroimmunomodulation discusses the bidirectional communication between the two supersystems of the central nervous system (mainly the brain) and the immune system. Usually, connectors like nerve fibers with neurotransmitters/neuropeptides and endocrine glands with hormones transmit the signals from brain to immune system. Vice versa, circulating immune cells that pass the blood-brain barrier as well as cytokines and other secreted solutes of immune cells connect the immune system to the brain. A detailed characterization of these bidirectional pathways has been given recently (e.g., newer reviews [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]).</p><p>Beyond neurotransmitters/neuropeptides and hormones, other pathways might connect brain and immune system independent of neuronal hard wiring, soluble hormones, or circulating cytokines/immune cells. These are extravesicles that can carry important molecules taken up at one location and transported to another &#8211; a cargo of hot activity.</p><p>One of the first papers, in 1985, described extravesicle release from a mother cell, which was a seminal work in the field of erythropoiesis [<xref rid="B3" ref-type="bibr">3</xref>]. The authors were interested in the known loss of the transferrin receptor from maturing reticulocytes, and they recognized that most of the transferrin receptor was lost through 50 nm-measuring vesicular elements locally released [<xref rid="B3" ref-type="bibr">3</xref>], later called exosomes [<xref rid="B4" ref-type="bibr">4</xref>]. The authors wrote: &#8220;&#8230; <italic toggle="yes">the data nonetheless argue that significant amounts of plasma membrane-bound activities may be released in vesicular form during maturation of reticulocytes &#8230;</italic>&#8221; [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>For a longer time, the focus on exosome molecules was on membrane-bound proteins, which has been studied in several immune cells like B and T lymphocytes, dendritic cells, mast cells, macrophages, and others (summarized in an early review of the year 2000 [<xref rid="B5" ref-type="bibr">5</xref>]). The functional role of these exosomes was soon discovered because B-cell-derived exosomes induced antigen-specific T-cell responses indicating exosome-triggered antigen presentation [<xref rid="B6" ref-type="bibr">6</xref>]. Similarly, exosomes were able to induce antigen-specific T-cell tolerance [<xref rid="B7" ref-type="bibr">7</xref>], and some authors called them &#8220;tolerosomes&#8221; [<xref rid="B7" ref-type="bibr">7</xref>]. These were the first indications that immunocyte-to-immunocyte transfer was possible through exosomes and a paracrine connection became visible.</p><p>At that time, not many solutes have been detected in exosomes, but some cytosolic proteins like heat shock protein 70 (Hsp70) [<xref rid="B8" ref-type="bibr">8</xref>] or heat shock protein hsc73 were already found [<xref rid="B9" ref-type="bibr">9</xref>]. With the advent of more systematic proteomic approaches, more and more soluble proteins surfaced, e.g., in dendritic cells [<xref rid="B10" ref-type="bibr">10</xref>] or B cells [<xref rid="B11" ref-type="bibr">11</xref>]. The putative therapeutic preclinical capabilities of dendritic cell-derived exosomes was memorably demonstrated when exosomes of tumor peptide-pulsed dendritic cells through interaction with cytotoxic T cells suppressed tumor growth in a murine model [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Soon, the rich content of exosomes occurred with hundreds of proteins but also mRNA and noncoding RNA [<xref rid="B13" ref-type="bibr">13</xref>]. In this early study on mast cells, the authors described that enough mRNA was present to support cDNA synthesis. Microarray analysis of mRNA demonstrated presence of transcripts of approximately 1,300 genes. In addition, 121 microRNAs emerged in these exosomes from mast cells [<xref rid="B13" ref-type="bibr">13</xref>]. Protein translation of exosome mRNA was demonstrated in the same study that showed the vehicle role of exosomes for cell-to-cell communication.</p><p>During psychological stress, these characteristics of exosomes and their impressive cargo prompted some authors to postulate a brain-to-target organ communication [<xref rid="B14" ref-type="bibr">14</xref>] and a brain-to-immune system interaction [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>], the latter of which is an entirely new form of neuroimmunomodulation independent of neuronal hard wiring and hormonal signaling. Since the contents of exosomes &#8211; due to encapsulation in a lipid bilayer &#8211; are perfectly protected from degradation in the circulating blood [<xref rid="B15" ref-type="bibr">15</xref>], exosome molecules might be perfect connectors between distant organs.</p><p>It is the intention of the author to demonstrate that exosomes, particularly with a look on microRNA, can be a perfect way to install another form of neuroimmunomodulation outside neuropeptide/neurotransmitter and hormonal pathways (<xref rid="F1" ref-type="fig">Fig. 1</xref>). In the author&#8217;s role as Editor-in-Chief of this journal, it is also an invitation to submit publications dealing with this new form of neuroimmunomodulation.</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p>Three pathways of the bidirectional crosstalk between brain and immune system. In an exemplary way, immune cells are given in the form of lymphocytes. Featured image declaration: modified from kjpargeter on Freepik and NIAID on Flickr.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nim-2025-0032-0001-547243_F01.jpg"/></fig></sec><sec sec-type="evolutionary perspective on the role of exosome microrna" id="s2"><title>Evolutionary Perspective on the Role of Exosome microRNA</title><p>Are exosomes and microRNAs evolutionarily old elements of life? Yes, they are very old, they are well conserved, and with growing complexity the number of microRNAs increases [<xref rid="B17" ref-type="bibr">17</xref>]. Some examples of this crosstalk are given below.</p><p>Release of exosomes between neighboring cells such as in bacterial biofilms or in a bacterial broth in the gut can be an important way of intercellular communication. For example, exosomes from the pathogenic protozoon <italic toggle="yes">Giardia lamblia</italic> can markedly change the function of neighboring <italic toggle="yes">Escherichia coli</italic>, which can be observed as a destruction of the bacterial biofilm [<xref rid="B18" ref-type="bibr">18</xref>]. Small noncoding RNA from exosomes stimulate the disease-inducing attack on the <italic toggle="yes">E. coli</italic> biofilm (10513) [<xref rid="B18" ref-type="bibr">18</xref>]. From an evolutionary medicine perspective, this information demonstrates that mechanisms related to exosomes and small RNA are evolutionarily old.</p><p>Exosomes in honeybee pollen, honey, and royal jelly have bacteriostatic, bactericidal, and biofilm-inhibiting effects on <italic toggle="yes">Staphylococcus aureus</italic> demonstrating inter-kingdom activity [<xref rid="B19" ref-type="bibr">19</xref>]. An organism can release a protective microRNA from exosomes to regulate protein expression and biofilm formation of <italic toggle="yes">Pseudomonas aeruginosa</italic> as demonstrated for the microRNA Let-7b-5p [<xref rid="B20" ref-type="bibr">20</xref>].</p><p>Although the synergistic or cooperative aspect of exosome microRNA signaling between neighboring cells has not been investigated often, positive collaboration of 2 cells might also be an important role of exosomes. For example, exosome microRNA can have a neurotrophic role after injury of the retina because they facilitate interactions between photoreceptors and M&#252;ller glia cells [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>From these illustrations, one recognizes that exosomes and their cargo have an outstanding role in antagonizing attacks from neighboring cells, but they also have collaborative function in cell-to-cell communication. The examples also show that exosomes with microRNA are evolutionarily very old (from bacteria over protozoon and insects to mammals). In a living being with distant organs, however, exosomes and their cargo might serve more remote communication (<xref rid="F1" ref-type="fig">Fig. 1</xref>).</p></sec><sec id="s2-1"><title>Briefing on Exosome Biology</title><p>Of the extracellular vesicles, the spheroid exosomes (endocytic origin) have a size of 30&#8211;200 nm, while irregular microvesicles (plasma membrane budding) have a diameter of 100&#8211;1,000 nm and variably shaped apoptotic bodies (blebbing) span more than 1,000 nm in diameter [<xref rid="B22" ref-type="bibr">22</xref>]. Exosomes and microvesicles contain nucleic acids such as microRNA while apoptotic bodies typically contain DNA fragments and histones [<xref rid="B22" ref-type="bibr">22</xref>]. Exosomes and microvesicles are relevant for cell-to-cell communication, while apoptotic bodies are relevant for clearance of material from dead cells.</p><p>It is not the aim to demonstrate detailed exosome biogenesis, exosome signaling, and exosome release because this has been extensively described by others [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B22" ref-type="bibr">22</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>]. Important molecules relevant in exosome biogenesis are demonstrated in Arya et al. [<xref rid="B24" ref-type="bibr">24</xref>]. The same review mentions the practical tools to study exosomes in the laboratory.</p><p>Exosomes contain tetraspanins (the cluster of differentiation [CD] molecules 9, 37, 53, 63, 81, 82), heat shock proteins (Hsp20, 27, 60, 90, Hsc70, 73), the major histocompatibility complex proteins (MHC class I and depending on cell type also MHC class II), cytoskeletal proteins (actin, cofilin, tubulin), adhesion molecules (integrins &#945; and &#946;, P-selectin), membrane transport and fusion proteins (GTPases, annexins, flotillin, RABs [members of RAS oncogene family], dynamin, syntaxin, syntenin), vesicle transport proteins (the endosomal sorting complexes required for transport, Alix [programmed cell death 6 interacting protein], TSG-101 [tumor susceptibility 101]), growth factors and cytokines (TNF [tumor necrosis factor], TGF-&#946; [transforming growth factor &#946;], TRAIL [TNF superfamily member 10]), signaling molecules (TNF receptor, Fas ligand, transferrin receptor), nucleic acids (mRNA, microRNA, DNA), and lipid molecules (cholesterol, ceramides, sphingomyelin, phosphatidylserine/-choline/-ethanolamine/-inositol, gangliosides) [<xref rid="B22" ref-type="bibr">22</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>]. Exosomes can also contain mitochondrial DNA [<xref rid="B24" ref-type="bibr">24</xref>].</p><p>One exosome can hold approximately 3,000 molecules [<xref rid="B24" ref-type="bibr">24</xref>], and it is controversially discussed whether, or not, sorting of exosome cargo is stochastic or selective. There are good arguments for both ways of cargo loading [<xref rid="B24" ref-type="bibr">24</xref>], which can be important for steered communication.</p><p>Exosomes exist in many different bodily liquids such as blood, serum, urine, saliva, amniotic liquor, cerebrospinal liquor, synovial fluid, pleural fluid, peritoneal fluid, ovarian follicular fluid, breast milk, and others [<xref rid="B22" ref-type="bibr">22</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>]. The biodistribution of exosomes given orally is enormous because they can reach a multitude of organs, tissues, and cells. Nasal exosome application targets specifically the brain. Macrophages in the periphery and microglia in the brain are the main up-taking cell populations for exosomes, but many other cells are also able to incorporate these extracellular vesicles [<xref rid="B22" ref-type="bibr">22</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>].</p><p>Most of the incorporated exosomes &#8211; the bulk uptake &#8211; ends in lysosomes to be degraded. This form of exosome degradation is &#8220;silent&#8221; because it does not activate the recipient cell [<xref rid="B24" ref-type="bibr">24</xref>]. The rest of the cargo is delivered intracellularly to endoplasmic reticulum, mitochondria, plasma membrane, cytosol but also back into the extracellular environment [<xref rid="B24" ref-type="bibr">24</xref>]. Delivery to the endoplasmic reticulum plays an important role for the function of microRNA because, there, microRNA-induced silencing of transcribed mRNA can happen using the RNA-induced silencing complex [<xref rid="B25" ref-type="bibr">25</xref>].</p></sec><sec sec-type="how can exosomes be targeted to a special cell or tissue?" id="s3"><title>How Can Exosomes Be Targeted to a Special Cell or Tissue?</title><p>In order to play a role as a connector between brain and immune system, in the sense of this review on remote and bidirectional neuroimmunomodulation, the exosome content must be specifically targetable. For example, surface proteins on exosomes can directly bind to receptors on the target cell, which can induce intracellular signaling. This has been demonstrated for the crosstalk of dendritic cell-derived exosomes and T cells, where peptide-loaded MHC class II molecules along with surface CD40 and DC-SIGN (CD209 molecule) on exosomes play decisive roles to stimulate IFN-&#947; secretion of CD4+ T cells [<xref rid="B26" ref-type="bibr">26</xref>].</p><p>Another perfect example of exosome targeting of a recipient cell was described in the following way. Exosomes of dendritic cells carry surface-bound TNF, Fas ligand, and TRAIL that bind to their surface receptors on tumor cells to induce caspase activation and apoptosis. In the same study, the authors also showed that exosome surface-bound TNF activates natural killer (NK) cells using the TNF receptor in order to stimulate IFN-&#947; secretion [<xref rid="B27" ref-type="bibr">27</xref>].</p><p>Exosomes of LPS-stimulated dendritic cells can carry intercellular adhesion molecule 1 (ICAM-1) and can, thus, bind to its ligand lymphocyte function-associated antigen 1 (LFA-1) on lymphocytes. This exosome-mediated signaling primes na&#239;ve T cells and triggers effector T-cell responses [<xref rid="B28" ref-type="bibr">28</xref>]. From these examples, one recognizes a kind of mutual relatedness of exosomes from immune cells toward target immune cells. However, this immunocyte-to-immunocyte crosstalk is not obligatory as the following results demonstrate.</p><p>Cargo can be delivered by selective endocytosis of the exosome through molecules on the surface of the recipient cell. For example, the T-cell immunoglobulin and mucin receptor 1 (TIM-1) on hepatocytes is the target structure of macrophage exosomes that carry IFN-&#945;, which is important to overcome the anti-hepatitis B virus. In this case, exosome entry to hepatitis B virus-replicating hepatocytes is dependent on clathrin-mediated endocytosis with the help of TIM-1 [<xref rid="B29" ref-type="bibr">29</xref>].</p><p>Exosomes that are specifically derived from intestinal epithelial cells carry the A33 antigen [<xref rid="B30" ref-type="bibr">30</xref>], and these A33 exosomes can be found in mesenteric lymph nodes showing epithelial cell exosome transfer toward immune cells [<xref rid="B31" ref-type="bibr">31</xref>]. Furthermore, intraperitoneal injection of A33 exosomes can decrease the antigen-induced immune response in a mouse model involving regulatory T (Treg) cells [<xref rid="B32" ref-type="bibr">32</xref>].</p><p>Another example of a wide-reaching effect can be recognized with exosomes positive for CD105 (endoglin, an auxiliary receptor to the TGF&#946; receptor), which are released from mesenchymal stem cell-like pancreatic cells in the peri-islet area, because these exosomes can directly stimulate autoreactive B and T cells to increase T-cell-mediated destruction of islets [<xref rid="B33" ref-type="bibr">33</xref>].</p><p>The neural cell adhesion molecule 1 (NCAM-1) plays a role in development of the nervous system by regulating neurogenesis, neurite outgrowth, and cell migration (e.g. [<xref rid="B34" ref-type="bibr">34</xref>]). It is also a typical surface molecule on neural cell exosomes [<xref rid="B35" ref-type="bibr">35</xref>]. Surface NCAM-1 binds surface NCAM-1 leading to homophilic interactions [<xref rid="B36" ref-type="bibr">36</xref>]. Beyond its role in the central nervous system, NCAM-1 &#8211; also called CD56 &#8211; is together with CD16, the identifying molecule of NK cells. Homophilic binding between NCAM-1-positive neuronal exosomes and NK cells in the periphery is a possible scenario that may lead to activation of NK cells, which might also involve the fibroblast growth factor receptor [<xref rid="B37" ref-type="bibr">37</xref>].</p><p>More general targeting might happen through widely expressed cell-surface markers like the tetraspanin CD81, which is present on most exosomes. This molecule can bind to a variety of different cell surface receptors or can interact with other surface receptors on immune cells and elsewhere [<xref rid="B38" ref-type="bibr">38</xref>]. This form of diffuse targeting reminds us to steroid hormone activities that can reach most cells in the body like cortisol, estrogens, and testosterone but also to the hormonal aspect of the circulating cytokine IL-6 that can induce variable effects in many tissues due to the abundance and ubiquity of the IL-6 receptor and its co-receptor gp130.</p><p>Although many different molecules in exosomes can be partners in cell-to-cell communication, the major focus of this review is on microRNA, whose discoverers Victor Ambros and Gary Ruvkun were awarded the 2024 Nobel Prize in Physiology or Medicine [<xref rid="B39" ref-type="bibr">39</xref>]. Exosomes are specifically enriched with a multitude of different microRNAs when compared to serum [<xref rid="B40" ref-type="bibr">40</xref>]. Compared to other molecules, microRNAs have the highest functional versatility by inhibiting target mRNA and protein output [<xref rid="B41" ref-type="bibr">41</xref>].</p></sec><sec id="s3-1"><title>Some General Energy-Related Concepts: Why the Selfish Brain Must Influence the Selfish Immune System and vice versa</title><p>These general principles are derived from the world of hormonal and neuronal interaction between the two supersystems and are part of a theory that has been presented in several publications [<xref rid="B42" ref-type="bibr">42</xref>&#8211;<xref rid="B49" ref-type="bibr">49</xref>]. In the network of energy consumers in the body, the brain and the immune system are selfish, because &#8211; in the presence of threats &#8211; they adopt the highest position in the hierarchy of energy regulation [<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B49" ref-type="bibr">49</xref>&#8211;<xref rid="B52" ref-type="bibr">52</xref>]. In the long process of evolution, these two organ systems obtained the selfish role depending on the type of immediate threat. For the brain, these threats occur as predators, wounding and hemorrhage, food scarcity, thirst, cold, and heat. For the immune system, infection and wounding with infection are the critical threats. The two organ systems control energy allocation in the body using self-supporting methods [<xref rid="B49" ref-type="bibr">49</xref>].</p><p>Under conditions of threats (for brain or immune system), anorexia is a dominant behavioral program in order to focus on the immediate energy-consuming problem (foraging or courtship behavior and body growth would be counterproductive). Under conditions with anorexia, the crosstalk with the energy-providing fat tissue is of outstanding importance to keep things running [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B53" ref-type="bibr">53</xref>]. Insulin resistance is one of the key factors stimulated by the brain and immune system in order to deviate energy-rich fuels to the two selfish organs [<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B52" ref-type="bibr">52</xref>]. In contrast, under conditions without threats, energy is available for foraging, reproduction, repair, and body growth.</p><p>In a situation with brain activation, usually the immune system is inhibited so that energy is available for brain activity and muscular work. In contrast, in the presence of an activated immune system the brain and muscular work are blocked so that energy is available for immune system activity. Brain and immune system inhibit each other by hormonal and neuronal pathways [<xref rid="B42" ref-type="bibr">42</xref>&#8211;<xref rid="B49" ref-type="bibr">49</xref>]. With respect to the new crosstalk between the brain and immune system by means of extracellular vesicles and microRNA, a similar picture of reciprocal inhibition might exist. The brain might restrain the immune system and, vice versa, the immune system might block the brain.</p></sec><sec id="s3-2"><title>Brain Exosome microRNA Modulates Immune Function</title><p>In this review, the author focuses on the typical locations of the central nervous system, which are involved in the normal hard-wired neuronal or hormonal crosstalk of brain and immune system. These central locations are the hypothalamus, pituitary gland, hippocampus, amygdala, sympathetic outflow pathways, parasympathetic outflow pathways, and the dorsal root ganglion. <xref rid="T1" ref-type="table">Table 1</xref> summarizes data on microRNA of these central nervous locations (=origin) with anti-inflammatory or proinflammatory effects on the immune system (=target). It is important to mention that 80&#8211;90% of the experiments were carried out in vitro in cell cultures so that the results may not apply to conditions in vivo. This situation prompts the research community to create new experiments of in vivo neuroimmunomodulation (see subsection below).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Exosome microRNA derived from distinct brain regions and effects on inflammation</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Organ and region of microRNA origin</th><th rowspan="1" colspan="1">microRNA in exosomal content</th><th rowspan="1" colspan="1">Function of microRNA on inflammatory pathways among other functions&#8230; (Refs.)</th></tr></thead><tbody><tr><td rowspan="7" colspan="1">Hypothalamus exosomes [<xref rid="B54" ref-type="bibr">54</xref>]</td><td rowspan="1" colspan="1">miR-15a-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B55" ref-type="bibr">55</xref>&#8211;<xref rid="B62" ref-type="bibr">62</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-17-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B63" ref-type="bibr">63</xref>&#8211;<xref rid="B65" ref-type="bibr">65</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-20a-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B66" ref-type="bibr">66</xref>&#8211;<xref rid="B69" ref-type="bibr">69</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-30e-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B70" ref-type="bibr">70</xref>&#8211;<xref rid="B72" ref-type="bibr">72</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-103a-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-146b-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B75" ref-type="bibr">75</xref>&#8211;<xref rid="B79" ref-type="bibr">79</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-378a-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B80" ref-type="bibr">80</xref>&#8211;<xref rid="B82" ref-type="bibr">82</xref>]</td></tr><tr><td rowspan="9" colspan="1">Hypothalamic adult neural stem/progenitor cells [<xref rid="B83" ref-type="bibr">83</xref>]</td><td rowspan="1" colspan="1">miR-15a-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B55" ref-type="bibr">55</xref>&#8211;<xref rid="B58" ref-type="bibr">58</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-20a-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B66" ref-type="bibr">66</xref>&#8211;<xref rid="B69" ref-type="bibr">69</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-30a-5p</td><td rowspan="1" colspan="1">Some anti-inflammatory effects [<xref rid="B84" ref-type="bibr">84</xref>&#8211;<xref rid="B86" ref-type="bibr">86</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-30e-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B70" ref-type="bibr">70</xref>&#8211;<xref rid="B72" ref-type="bibr">72</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-103a-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-106a-5p</td><td rowspan="1" colspan="1">Some anti-inflammatory effects [<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-146b-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B75" ref-type="bibr">75</xref>&#8211;<xref rid="B79" ref-type="bibr">79</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-378a-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B80" ref-type="bibr">80</xref>&#8211;<xref rid="B82" ref-type="bibr">82</xref>]</td></tr><tr><td colspan="2" rowspan="1">No data with respect to inflammation and immunoregulation for the following microRNAs: miR-320-3p, miR-421-3p, miR-466m-5p, miR-483-5p, miR-674-5p, miR-677-5p, miR-3072-5p, miR-3090-5p, miR-7044-5p, miR-7046-5p, miR-7118-5p</td></tr><tr><td rowspan="14" colspan="1">Pituitary gland anterior pituitary cells [<xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>]</td><td rowspan="2" colspan="1">miR-21-5p</td><td rowspan="1" colspan="1">Master regulator of innate immunity [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Mixed anti-inflammatory [<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B96" ref-type="bibr">96</xref>] and proinflammatory effects [<xref rid="B97" ref-type="bibr">97</xref>&#8211;<xref rid="B99" ref-type="bibr">99</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-129-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B100" ref-type="bibr">100</xref>&#8211;<xref rid="B106" ref-type="bibr">106</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-141-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B107" ref-type="bibr">107</xref>&#8211;<xref rid="B110" ref-type="bibr">110</xref>]</td></tr><tr><td rowspan="1" colspan="1">Th17 lineage support [<xref rid="B111" ref-type="bibr">111</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-183-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-200a-3p</td><td rowspan="1" colspan="1">Th17 lineage support [<xref rid="B111" ref-type="bibr">111</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-204-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B114" ref-type="bibr">114</xref>&#8211;<xref rid="B119" ref-type="bibr">119</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-340-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B120" ref-type="bibr">120</xref>&#8211;<xref rid="B123" ref-type="bibr">123</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-375-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B124" ref-type="bibr">124</xref>&#8211;<xref rid="B127" ref-type="bibr">127</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-497-5p</td><td rowspan="1" colspan="1">Pro-inflammatory [<xref rid="B128" ref-type="bibr">128</xref>&#8211;<xref rid="B131" ref-type="bibr">131</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-200b-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B132" ref-type="bibr">132</xref>&#8211;<xref rid="B142" ref-type="bibr">142</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-fibrotic [<xref rid="B143" ref-type="bibr">143</xref>&#8211;<xref rid="B145" ref-type="bibr">145</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibition of dendritic cell function [<xref rid="B146" ref-type="bibr">146</xref>]</td></tr><tr><td rowspan="3" colspan="1">Hippocampus after neurogenesis stimulation [<xref rid="B147" ref-type="bibr">147</xref>]</td><td rowspan="1" colspan="1">miR-339-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B148" ref-type="bibr">148</xref>, <xref rid="B149" ref-type="bibr">149</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-1298-5p</td><td rowspan="1" colspan="1">Proinflammatory [<xref rid="B150" ref-type="bibr">150</xref>, <xref rid="B151" ref-type="bibr">151</xref>]</td></tr><tr><td colspan="2" rowspan="1">No data with respect to inflammation and immunoregulation for the following microRNAs: miR-15b-3p, miR-187-5p, miR-411-3p, miR-3559-3p, miR-6319, miR-6324</td></tr><tr><td rowspan="1" colspan="1">Amygdala</td><td rowspan="1" colspan="1">No data</td><td rowspan="1" colspan="1">No data</td></tr><tr><td rowspan="1" colspan="1">Sympathetic ganglia neurons, rostral ventral lateral medulla neurons, sympathetic nerve ending</td><td rowspan="1" colspan="1">No data</td><td rowspan="1" colspan="1">No data</td></tr><tr><td rowspan="1" colspan="1">Parasympathetic ganglia neurons [<xref rid="B152" ref-type="bibr">152</xref>]</td><td rowspan="1" colspan="1">Exosomes</td><td rowspan="1" colspan="1">Inhibit apoptosis in glucose-stimulated cardiomyoblasts [<xref rid="B152" ref-type="bibr">152</xref>]</td></tr><tr><td rowspan="3" colspan="1">DRG lesioning [<xref rid="B153" ref-type="bibr">153</xref>&#8211;<xref rid="B155" ref-type="bibr">155</xref>]</td><td rowspan="3" colspan="1">miR-16-5p</td><td rowspan="1" colspan="1">Proinflammatory: induces M1 polarization of na&#239;ve or M2 murine macrophages and activates CD4+ T cells by downregulating PD-L1 [<xref rid="B156" ref-type="bibr">156</xref>], inhibition of PD-L1 in a co-culture cell model of human prostate cancer cells/T cells [<xref rid="B157" ref-type="bibr">157</xref>], stimulates cytotoxic CD8+ T cells in a prostate cancer model [<xref rid="B157" ref-type="bibr">157</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: induces M2 polarization of macrophages in the context of multiple myeloma [<xref rid="B158" ref-type="bibr">158</xref>], inhibits the IKKalpha/NF-kappaB pathway [<xref rid="B159" ref-type="bibr">159</xref>], inhibits macrophage TNF/IL-6/IFN-&#946; production [<xref rid="B160" ref-type="bibr">160</xref>], inhibits macrophage/foam cell TNF/IL-6 [<xref rid="B161" ref-type="bibr">161</xref>], inhibits macrophage Il-1&#946;/IL-6/TNF after lipopolysaccharide stimulation [<xref rid="B162" ref-type="bibr">162</xref>]</td></tr><tr><td rowspan="1" colspan="1">Important for IL-9 production in T-helper type 9 cells [<xref rid="B163" ref-type="bibr">163</xref>]</td></tr><tr><td rowspan="9" colspan="1">Neuropathic pain model [<xref rid="B164" ref-type="bibr">164</xref>, <xref rid="B165" ref-type="bibr">165</xref>]</td><td rowspan="3" colspan="1">miR-21-5p</td><td rowspan="1" colspan="1">Master regulator of innate immunity [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Mixed anti-inflammatory [<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B96" ref-type="bibr">96</xref>] and proinflammatory effects [<xref rid="B97" ref-type="bibr">97</xref>&#8211;<xref rid="B99" ref-type="bibr">99</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory and pro-pain: increase of macrophage inflammation and neuropathic hypersensitivity [<xref rid="B154" ref-type="bibr">154</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-142-3p</td><td rowspan="1" colspan="1">Involved in Treg biology [<xref rid="B166" ref-type="bibr">166</xref>]</td></tr><tr><td rowspan="1" colspan="1">Mixed anti-inflammatory [<xref rid="B167" ref-type="bibr">167</xref>&#8211;<xref rid="B170" ref-type="bibr">170</xref>] and proinflammatory effects [<xref rid="B171" ref-type="bibr">171</xref>&#8211;<xref rid="B173" ref-type="bibr">173</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-146b</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B75" ref-type="bibr">75</xref>&#8211;<xref rid="B79" ref-type="bibr">79</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-203-3p</td><td rowspan="1" colspan="1">Mixed anti-inflammatory [<xref rid="B174" ref-type="bibr">174</xref>] and proinflammatory effects [<xref rid="B175" ref-type="bibr">175</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-221</td><td rowspan="1" colspan="1">Mixed anti-inflammatory [<xref rid="B176" ref-type="bibr">176</xref>&#8211;<xref rid="B182" ref-type="bibr">182</xref>] and proinflammatory effects [<xref rid="B183" ref-type="bibr">183</xref>&#8211;<xref rid="B186" ref-type="bibr">186</xref>]</td></tr><tr><td rowspan="1" colspan="1">Key regulator of immunoglobulin class switch regulation [<xref rid="B187" ref-type="bibr">187</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn><fn><p>Th17, type 17 T-helper cell; Treg, regulatory T cells.</p></fn></table-wrap-foot></table-wrap><p>From <xref rid="T1" ref-type="table">Table 1</xref>, it becomes clear that almost all effects of hypothalamus-derived microRNAs have anti-inflammatory activities (<xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>a). Similarly, many microRNAs derived from the pituitary gland have anti-inflammatory effects, although some pathways are belonging to a proinflammatory cascade (<xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>). In contrast, hippocampal microRNAs and dorsal root ganglion microRNA have either mixed effects, anti- or proinflammatory (<xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>a). No specific data exist for microRNA from the amygdala and the sympathetic or parasympathetic outflow pathways (<xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>a).</p><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p>Number of references that support the anti- and proinflammatory role of a distinct microRNA. <bold>a</bold> Situation of microRNA secreted from brain origins and the adrenal gland. <bold>b</bold> Numbers of publications related to psychological stress, during which microRNAs are released that have effects on the immune system. For <bold>a</bold> and <bold>b</bold>, green means anti-inflammatory and red signifies proinflammatory influences on immune function. <bold>c</bold> Situation for microRNA secreted from distinct immune cells with effects on the central nervous system. Green, positive/protective effects on brain structures and function; red, negative/degenerative effects on brain structures and function.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nim-2025-0032-0001-547243_F02.jpg"/></fig><p>In the context of this review, the hormonal system is a mediator of the selfish brain to influence the selfish immune system, which is &#8211; for example &#8211; true for the adrenal glands and their major anti-inflammatory steroid hormone cortisol. Thus, the adrenal glands are discussed in this subchapter. Surprisingly, most of the microRNA derived from adrenal cells have anti-inflammatory activities. Of a total of 91 references, 78 references demonstrated anti-inflammatory effects of &#8220;adrenal microRNA&#8221; and only 13 showed proinflammatory effects (<xref rid="T2" ref-type="table">Table 2</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>a).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>MicroRNA derived from the adrenal glands and effects on inflammation</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Organ and region of microRNA origin</th><th rowspan="1" colspan="1">microRNA in exosomal or cellular content</th><th rowspan="1" colspan="1">Function of microRNA on inflammatory pathways among other functions&#8230; (Refs.)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">
<italic toggle="yes">Endocrine glands</italic>
</td></tr><tr><td rowspan="9" colspan="1">Adrenal gland derived from human adrenocortical adenoma tissue [<xref rid="B188" ref-type="bibr">188</xref>]</td><td rowspan="1" colspan="1">miR-15a</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B55" ref-type="bibr">55</xref>&#8211;<xref rid="B62" ref-type="bibr">62</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-29c</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B189" ref-type="bibr">189</xref>&#8211;<xref rid="B192" ref-type="bibr">192</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-195</td><td rowspan="1" colspan="1">Proinflammatory [<xref rid="B193" ref-type="bibr">193</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B194" ref-type="bibr">194</xref>&#8211;<xref rid="B197" ref-type="bibr">197</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-214</td><td rowspan="1" colspan="1">Anti- and proinflammatory (rev. in [<xref rid="B198" ref-type="bibr">198</xref>])</td></tr><tr><td rowspan="1" colspan="1">miR-335</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B199" ref-type="bibr">199</xref>&#8211;<xref rid="B203" ref-type="bibr">203</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-345</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B204" ref-type="bibr">204</xref>&#8211;<xref rid="B206" ref-type="bibr">206</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-497</td><td rowspan="1" colspan="1">Proinflammatory [<xref rid="B128" ref-type="bibr">128</xref>&#8211;<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B207" ref-type="bibr">207</xref>, <xref rid="B208" ref-type="bibr">208</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-708</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B209" ref-type="bibr">209</xref>&#8211;<xref rid="B212" ref-type="bibr">212</xref>]</td></tr><tr><td rowspan="4" colspan="1">Derived from adrenocortical tissue samples [<xref rid="B213" ref-type="bibr">213</xref>]</td><td rowspan="1" colspan="1">miR-379-5p</td><td rowspan="2" colspan="1">No data with respect to inflammation and immunoregulation</td></tr><tr><td rowspan="1" colspan="1">From ACTH-dependent Cushing syndrome</td></tr><tr><td rowspan="1" colspan="1">miR-1247-5p</td><td rowspan="2" colspan="1">No data with respect to inflammation and immunoregulation</td></tr><tr><td rowspan="1" colspan="1">From ACTH-independent Cushing syndrome</td></tr><tr><td rowspan="9" colspan="1">Normal adrenal gland [<xref rid="B214" ref-type="bibr">214</xref>, <xref rid="B215" ref-type="bibr">215</xref>]</td><td rowspan="1" colspan="1">miR-133b</td><td rowspan="1" colspan="1">Th17 induction [<xref rid="B216" ref-type="bibr">216</xref>], anti-inflammatory [<xref rid="B217" ref-type="bibr">217</xref>, <xref rid="B218" ref-type="bibr">218</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-146b</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B75" ref-type="bibr">75</xref>&#8211;<xref rid="B79" ref-type="bibr">79</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-200b-5p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B132" ref-type="bibr">132</xref>&#8211;<xref rid="B142" ref-type="bibr">142</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-fibrotic [<xref rid="B143" ref-type="bibr">143</xref>&#8211;<xref rid="B145" ref-type="bibr">145</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibition of dendritic cell function [<xref rid="B146" ref-type="bibr">146</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-203</td><td rowspan="1" colspan="1">Anti-inflammatory: inhibits VEGF expression [<xref rid="B219" ref-type="bibr">219</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B174" ref-type="bibr">174</xref>, <xref rid="B220" ref-type="bibr">220</xref>, <xref rid="B221" ref-type="bibr">221</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory [<xref rid="B175" ref-type="bibr">175</xref>, <xref rid="B222" ref-type="bibr">222</xref>, <xref rid="B223" ref-type="bibr">223</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-449</td><td rowspan="1" colspan="1">No data with respect to inflammation and immunoregulation</td></tr><tr><td rowspan="5" colspan="1">Cortisol-producing adrenocortical adenoma [<xref rid="B224" ref-type="bibr">224</xref>]</td><td rowspan="3" colspan="1">miR-22-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B225" ref-type="bibr">225</xref>&#8211;<xref rid="B235" ref-type="bibr">235</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits dendritic cell function [<xref rid="B236" ref-type="bibr">236</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits NLRP3 inflammasome [<xref rid="B229" ref-type="bibr">229</xref>, <xref rid="B234" ref-type="bibr">234</xref>, <xref rid="B237" ref-type="bibr">237</xref>, <xref rid="B238" ref-type="bibr">238</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-27a-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B239" ref-type="bibr">239</xref>&#8211;<xref rid="B244" ref-type="bibr">244</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory [<xref rid="B245" ref-type="bibr">245</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn></table-wrap-foot></table-wrap><p>In summary, of the 206 references that worked with microRNA of the central nervous system or the pituitary/adrenal glands 168 references showed anti-inflammatory immunosuppressive effects in inflammation or on immune function, and only 38 showed proinflammatory effects for the respective microRNAs (<xref rid="T1" ref-type="table">Tables 1</xref>, <xref rid="T2" ref-type="table">2</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>a). These data demonstrate an overwhelming preponderance of immunoinhibiting microRNAs released from the brain or pituitary/adrenal gland.</p><p>Nevertheless, some pathways from the selfish brain seem to support the immune system, which has been demonstrated in the context of stress research [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. The supportive effects of microvesicles and their cargo are directed toward innate immune pathways and wound healing (reviewed in [<xref rid="B16" ref-type="bibr">16</xref>]). In this field of inquiry, the bimodal effects of the brain on immune function is well known because either immunosupporting or immunoinhibiting effects were observed after different forms of stress [<xref rid="B246" ref-type="bibr">246</xref>]. Immunostimulatory effects are often seen with mild short-term stress [<xref rid="B247" ref-type="bibr">247</xref>] and, thus, we recognize that the brain can immediately support the selfish immune system. In an earlier publication, the author called it &#8220;immediate mutual assistance,&#8221; which may change over time with long-standing challenges [<xref rid="B248" ref-type="bibr">248</xref>]. This is opposite for long-standing severe stress during which the selfish role of the brain becomes very overwhelming [<xref rid="B247" ref-type="bibr">247</xref>]. <xref rid="T3" ref-type="table">Table 3</xref> gives an overview of microRNA detected in stress research that can influence immune function.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p>MicroRNA in stress research and influence on the immune system</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Type of stress</th><th rowspan="1" colspan="1">microRNA (up-/downregulation)</th><th rowspan="1" colspan="1">Function of microRNA on inflammatory pathways among other functions&#8230; (Refs.)</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">Social isolation [<xref rid="B219" ref-type="bibr">219</xref>]</td><td rowspan="1" colspan="1">miR-29a/c (high)</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B189" ref-type="bibr">189</xref>&#8211;<xref rid="B192" ref-type="bibr">192</xref>], inhibits vascular endothelial growth factor directly [<xref rid="B219" ref-type="bibr">219</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-203-3p (high)</td><td rowspan="1" colspan="1">Mixed anti-inflammatory [<xref rid="B174" ref-type="bibr">174</xref>] and proinflammatory effects [<xref rid="B175" ref-type="bibr">175</xref>]</td></tr><tr><td rowspan="3" colspan="1">Chronic social defeat [<xref rid="B249" ref-type="bibr">249</xref>]</td><td rowspan="3" colspan="1">miR-19b (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in epithelial cell lines [<xref rid="B250" ref-type="bibr">250</xref>], in an IL-1-stimulated murine chondrocyte cell line [<xref rid="B251" ref-type="bibr">251</xref>], in lipopolysaccharide-stimulated human umbilical veins endothelial cells [<xref rid="B252" ref-type="bibr">252</xref>], in a viral myocarditis model [<xref rid="B253" ref-type="bibr">253</xref>], in peripheral blood mononuclear cells of systemic lupus erythematosus patients [<xref rid="B254" ref-type="bibr">254</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in infection model of endothelial cells [<xref rid="B255" ref-type="bibr">255</xref>], in a high glucose model in retinal pigment epithelial cells [<xref rid="B256" ref-type="bibr">256</xref>], in murine primary microglial cells [<xref rid="B257" ref-type="bibr">257</xref>]</td></tr><tr><td rowspan="1" colspan="1">Decreases adrenoceptor &#946;1 mRNA [<xref rid="B249" ref-type="bibr">249</xref>]</td></tr><tr><td rowspan="9" colspan="1">Chronic social defeat [<xref rid="B258" ref-type="bibr">258</xref>]</td><td rowspan="1" colspan="1">miR-31-5p (high)</td><td rowspan="1" colspan="1">Proinflammatory [<xref rid="B259" ref-type="bibr">259</xref>, <xref rid="B260" ref-type="bibr">260</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-93-5p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory in a stroke model of ischemia [<xref rid="B261" ref-type="bibr">261</xref>, <xref rid="B262" ref-type="bibr">262</xref>], in a neuropathy model [<xref rid="B263" ref-type="bibr">263</xref>], in macrophages [<xref rid="B264" ref-type="bibr">264</xref>], in a sepsis model [<xref rid="B265" ref-type="bibr">265</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-193b-3p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B266" ref-type="bibr">266</xref>]: neuroprotective: in a model of cerebral ischemia-reperfusion injury in rats by inhibiting 5-lipoxygenase [<xref rid="B267" ref-type="bibr">267</xref>] and by reducing apoptosis/autophagy/ferroptosis [<xref rid="B268" ref-type="bibr">268</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-212-3p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in a macrophage cell line [<xref rid="B269" ref-type="bibr">269</xref>, <xref rid="B270" ref-type="bibr">270</xref>], in mouse monocyte macrophages [<xref rid="B271" ref-type="bibr">271</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in monocytes in a model of radiation-induced endothelial dysfunction [<xref rid="B272" ref-type="bibr">272</xref>], by inhibiting SIRT1 and NLRP3 inflammasome in a lipopolysaccharide-stimulated epithelial cell line [<xref rid="B273" ref-type="bibr">273</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-451a (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in a hepatitis model [<xref rid="B274" ref-type="bibr">274</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits signaling through TLR4 and has inhibitory effects on microglia activation [<xref rid="B275" ref-type="bibr">275</xref>], suppresses NLRP3-induced microglia activation [<xref rid="B276" ref-type="bibr">276</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-467b-3p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in chondrogenic cell line [<xref rid="B277" ref-type="bibr">277</xref>], in apolipoprotein E knockout mice [<xref rid="B278" ref-type="bibr">278</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-712-5p (high)</td><td rowspan="1" colspan="1">Mixed proinflammatory [<xref rid="B279" ref-type="bibr">279</xref>] and anti-inflammatory in macrophages [<xref rid="B280" ref-type="bibr">280</xref>]</td></tr><tr><td rowspan="2" colspan="1">Chronic social defeat [<xref rid="B281" ref-type="bibr">281</xref>]</td><td rowspan="2" colspan="1">miR-25-3p (high) (in the miR-106b&#8764;25 cluster)</td><td rowspan="1" colspan="1">Anti-inflammatory: in a sepsis-associated encephalopathy model by inhibiting TLR4 and the NLRP3 inflammasome [<xref rid="B282" ref-type="bibr">282</xref>], in a cardiomyocyte model [<xref rid="B283" ref-type="bibr">283</xref>, <xref rid="B284" ref-type="bibr">284</xref>], in a chondrocyte model [<xref rid="B285" ref-type="bibr">285</xref>], in a model of mesangial cells cultured with high glucose [<xref rid="B286" ref-type="bibr">286</xref>], in a model of neuronal stem cells [<xref rid="B287" ref-type="bibr">287</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a periodontitis model [<xref rid="B288" ref-type="bibr">288</xref>], in a macrophage cell line [<xref rid="B289" ref-type="bibr">289</xref>]</td></tr><tr><td rowspan="3" colspan="1">Chronic social defeat [<xref rid="B290" ref-type="bibr">290</xref>]</td><td rowspan="2" colspan="1">miR-29b-3p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in a model of cardiomyocytes [<xref rid="B291" ref-type="bibr">291</xref>], in human umbilical vein endothelial cells stimulated by lipopolysaccharide [<xref rid="B292" ref-type="bibr">292</xref>], in microvascular endothelial cells [<xref rid="B293" ref-type="bibr">293</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in particulate matter-induced human bronchial epithelial cells [<xref rid="B294" ref-type="bibr">294</xref>], in a cardiomyocyte cell line [<xref rid="B295" ref-type="bibr">295</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-340-5p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B120" ref-type="bibr">120</xref>&#8211;<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B296" ref-type="bibr">296</xref>]</td></tr><tr><td rowspan="15" colspan="1">Restraint stress [<xref rid="B297" ref-type="bibr">297</xref>&#8211;<xref rid="B299" ref-type="bibr">299</xref>]</td><td rowspan="3" colspan="1">miR-9 (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in different cell types by inhibition of the NFkB pathway [<xref rid="B300" ref-type="bibr">300</xref>&#8211;<xref rid="B303" ref-type="bibr">303</xref>], in neuron-like PC12 cells [<xref rid="B304" ref-type="bibr">304</xref>, <xref rid="B305" ref-type="bibr">305</xref>], in a rat pancreatic cell line [<xref rid="B306" ref-type="bibr">306</xref>], in radiation-induced human oral epithelial cells [<xref rid="B307" ref-type="bibr">307</xref>], in microglia by inhibiting TLR4 [<xref rid="B308" ref-type="bibr">308</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in microglia cells by stimulating the NFkB pathway [<xref rid="B309" ref-type="bibr">309</xref>]</td></tr><tr><td rowspan="1" colspan="1">Stimulatory of IL2 and IFN-&#947; in activated human CD4 T cells [<xref rid="B310" ref-type="bibr">310</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-18a (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in a chondrocyte cell line stimulated with IL-1&#946; [<xref rid="B311" ref-type="bibr">311</xref>], in a cardiomyocyte cell model by inhibiting gasdermin D [<xref rid="B312" ref-type="bibr">312</xref>], in a LPS-stimulated macrophage cell line [<xref rid="B313" ref-type="bibr">313</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in human-derived colonic epithelial NCM460 cells by increasing NFkB [<xref rid="B314" ref-type="bibr">314</xref>], in a cardiomyocyte cell model with hypoxia/reoxygenation [<xref rid="B315" ref-type="bibr">315</xref>]</td></tr><tr><td rowspan="1" colspan="1">Upregulated during wound repair in the miR-17&#8764;92 cluster* [<xref rid="B316" ref-type="bibr">316</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR 26a (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in different cell types by inhibition of the NFkB pathway [<xref rid="B317" ref-type="bibr">317</xref>&#8211;<xref rid="B320" ref-type="bibr">320</xref>], in cardiomyocytes by inhibition of ADAM17 [<xref rid="B321" ref-type="bibr">321</xref>], in lipopolysaccharide-treated microglia [<xref rid="B322" ref-type="bibr">322</xref>], in lipopolysaccharide-stimulated macrophages by inhibiting COX-2 [<xref rid="B323" ref-type="bibr">323</xref>], in lipopolysaccharide-stimulated pulmonary microvascular endothelial cells [<xref rid="B324" ref-type="bibr">324</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in epithelial cells infected with virus by upregulation of type I interferons [<xref rid="B325" ref-type="bibr">325</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-tuberculosis [<xref rid="B326" ref-type="bibr">326</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR 26b-5p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in an allergic cell model with a basophil cell line [<xref rid="B327" ref-type="bibr">327</xref>], in a macrophage cell line by inhibiting TGF&#946;-activated kinase-1 and NFkB [<xref rid="B328" ref-type="bibr">328</xref>], in a microglia cell line [<xref rid="B329" ref-type="bibr">329</xref>], in a myocardial infarction model [<xref rid="B330" ref-type="bibr">330</xref>], in a model of cerebral ischemia/reperfusion injury [<xref rid="B331" ref-type="bibr">331</xref>], in endothelial cells [<xref rid="B332" ref-type="bibr">332</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-124 (low)</td><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low: lack of the microRNA contributes to the M1 type macrophage [<xref rid="B333" ref-type="bibr">333</xref>] and microglia [<xref rid="B334" ref-type="bibr">334</xref>], lack of the microRNA increases MyD88 and NFkB [<xref rid="B335" ref-type="bibr">335</xref>&#8211;<xref rid="B337" ref-type="bibr">337</xref>], the lack of the microRNA increases several chemotactic factors [<xref rid="B338" ref-type="bibr">338</xref>], lack reduces differentiation of Treg cells [<xref rid="B339" ref-type="bibr">339</xref>], lack of the microRNA increases neuroinflammation [<xref rid="B340" ref-type="bibr">340</xref>&#8211;<xref rid="B342" ref-type="bibr">342</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-135a (low)</td><td rowspan="1" colspan="1">In general proinflammatory but anti-inflammatory when microRNA is low: in a macrophage cell line [<xref rid="B343" ref-type="bibr">343</xref>]</td></tr><tr><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low: lack of the microRNA increases injury-dependent inflammation [<xref rid="B344" ref-type="bibr">344</xref>], lack of this microRNA increases inflammatory markers in epithelial cell lines [<xref rid="B345" ref-type="bibr">345</xref>] and in a macrophage cell line [<xref rid="B346" ref-type="bibr">346</xref>], lack of this microRNA increases NFkB signaling [<xref rid="B347" ref-type="bibr">347</xref>]</td></tr><tr><td rowspan="2" colspan="1">let-7a (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in a hepatitis model [<xref rid="B348" ref-type="bibr">348</xref>] and in microglial cells [<xref rid="B349" ref-type="bibr">349</xref>], in macrophages activated by anti-citrullinated protein antibodies [<xref rid="B350" ref-type="bibr">350</xref>], in a neuroinflammation model [<xref rid="B351" ref-type="bibr">351</xref>], in a Parkinson disease model [<xref rid="B352" ref-type="bibr">352</xref>], in a mouse model of sclerosing cholangitis [<xref rid="B353" ref-type="bibr">353</xref>], in a model of acute lung injury [<xref rid="B354" ref-type="bibr">354</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a macrophage and mesangial cell line [<xref rid="B355" ref-type="bibr">355</xref>], in rat model of cerebral ischemia/reperfusion injury [<xref rid="B356" ref-type="bibr">356</xref>]</td></tr><tr><td rowspan="3" colspan="1">Electric tail shock [<xref rid="B357" ref-type="bibr">357</xref>]</td><td rowspan="2" colspan="1">miR-142-5p (low)</td><td rowspan="1" colspan="1">In general proinflammatory but anti-inflammatory when microRNA is low: inhibits SIRT 1 in microglia/macrophages [<xref rid="B358" ref-type="bibr">358</xref>], induces a shift to T-helper type 1 immunity [<xref rid="B359" ref-type="bibr">359</xref>], increases MHC class II expression on human umbilical vein endothelial cells [<xref rid="B360" ref-type="bibr">360</xref>], in lipopolysaccharide-treated PC12 cells [<xref rid="B361" ref-type="bibr">361</xref>]</td></tr><tr><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low: in a macrophage cell line by inhibiting IL-6 and TNF [<xref rid="B362" ref-type="bibr">362</xref>], induces a shift toward Treg cells by inhibition of phosphodiesterase 3B and increase of cAMP [<xref rid="B363" ref-type="bibr">363</xref>], in a rat model of post-traumatic stress disorder in the hippocampus by inhibiting IL-1&#946;, IL-6, TNF, and NFkB nucleus translocation [<xref rid="B364" ref-type="bibr">364</xref>], in keratinocyte cell line by inhibiting cyclin-dependent kinase 5 (CDK5) [<xref rid="B365" ref-type="bibr">365</xref>], in a IL-1&#946;-stimulated chondrocyte cell line [<xref rid="B366" ref-type="bibr">366</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-203-3p (low)</td><td rowspan="1" colspan="1">Mixed anti-inflammatory [<xref rid="B174" ref-type="bibr">174</xref>] and proinflammatory effects [<xref rid="B175" ref-type="bibr">175</xref>]</td></tr><tr><td rowspan="5" colspan="1">TSST in humans [<xref rid="B367" ref-type="bibr">367</xref>]</td><td rowspan="1" colspan="1">miR-20b (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in alveolar macrophages derived from asthmatic mice by increasing VEGF [<xref rid="B368" ref-type="bibr">368</xref>], by inhibiting the NLRP3 inflammasome/caspase-1/IL-1&#946; pathway [<xref rid="B369" ref-type="bibr">369</xref>], by inhibiting TXNIP and, thus, NLRP3 inflammasome [<xref rid="B370" ref-type="bibr">370</xref>], in chicken lymphocytes by inhibition of SIKE1 [<xref rid="B371" ref-type="bibr">371</xref>], in cerulean-lipopolysaccharide-treated pancreatic acinar cells [<xref rid="B372" ref-type="bibr">372</xref>], in an ovalbumin-induced airway inflammation model by inhibiting TXNIP and, thus, NLRP3 inflammasome [<xref rid="B373" ref-type="bibr">373</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-21-5p (low)</td><td rowspan="1" colspan="1">Master regulator of innate immunity [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">microRNA has mixed anti-inflammatory [<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B96" ref-type="bibr">96</xref>] and proinflammatory effects [<xref rid="B97" ref-type="bibr">97</xref>&#8211;<xref rid="B99" ref-type="bibr">99</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory and pro-pain: increase of macrophage inflammation and neuropathic hypersensitivity [<xref rid="B154" ref-type="bibr">154</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-26b-5p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in an allergic cell model with a basophil cell line [<xref rid="B327" ref-type="bibr">327</xref>], in a macrophage cell line by inhibiting TGF&#946;-activated kinase-1 and NFkB [<xref rid="B328" ref-type="bibr">328</xref>], in a microglia cell line [<xref rid="B329" ref-type="bibr">329</xref>], in a myocardial infarction model [<xref rid="B330" ref-type="bibr">330</xref>], in a model of cerebral ischemia/reperfusion injury [<xref rid="B331" ref-type="bibr">331</xref>], in endothelial cells [<xref rid="B332" ref-type="bibr">332</xref>]</td></tr><tr><td rowspan="6" colspan="1">Examen stress in humans [<xref rid="B374" ref-type="bibr">374</xref>]</td><td rowspan="3" colspan="1">miR-16 (high)</td><td rowspan="1" colspan="1">Proinflammatory: induces M1 polarization of na&#239;ve or M2 murine macrophages and activates CD4+ T cells by downregulating PD-L1 [<xref rid="B156" ref-type="bibr">156</xref>], inhibition of PD-L1 in a co-culture cell model of human prostate cancer cells/T cells [<xref rid="B157" ref-type="bibr">157</xref>], stimulates cytotoxic CD8+ T cells in a prostate cancer model [<xref rid="B157" ref-type="bibr">157</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: induces M2 polarization of macrophages in the context of multiple myeloma [<xref rid="B158" ref-type="bibr">158</xref>], inhibits the IKKalpha/NF-kappaB pathway [<xref rid="B159" ref-type="bibr">159</xref>], inhibits macrophage TNF/IL-6/IFN-&#946; production [<xref rid="B160" ref-type="bibr">160</xref>], inhibits macrophage/foam cell TNF/IL-6 [<xref rid="B161" ref-type="bibr">161</xref>], inhibits macrophage Il-1&#946;/IL-6/TNF after lipopolysaccharide stimulation [<xref rid="B162" ref-type="bibr">162</xref>]</td></tr><tr><td rowspan="1" colspan="1">Important for IL-9 production in T-helper type 9 cells [<xref rid="B163" ref-type="bibr">163</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-144 (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in mature dendritic cells by inhibiting proinflammatory cytokines [<xref rid="B375" ref-type="bibr">375</xref>], by polarization of macrophages toward M2 and inhibition of TNF and IL-1&#946; [<xref rid="B376" ref-type="bibr">376</xref>], in human synovial fibroblasts [<xref rid="B377" ref-type="bibr">377</xref>], in a trophoblast cell line [<xref rid="B378" ref-type="bibr">378</xref>], in CSE-induced bronchial epithelial cells [<xref rid="B379" ref-type="bibr">379</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a macrophage cell line [<xref rid="B380" ref-type="bibr">380</xref>], in endothelial cells by inhibiting Nrf2 [<xref rid="B381" ref-type="bibr">381</xref>], in CSE-induced bronchial epithelial cells [<xref rid="B382" ref-type="bibr">382</xref>], in lipopolysaccharide-induced periodontal ligament cells [<xref rid="B383" ref-type="bibr">383</xref>]</td></tr><tr><td rowspan="1" colspan="1">In an oxygen-glucose deprivation model [<xref rid="B384" ref-type="bibr">384</xref>] and in a model of cerebral ischemia-reperfusion injury [<xref rid="B385" ref-type="bibr">385</xref>]</td></tr><tr><td rowspan="14" colspan="1">Sleep deprivation stress in mice [<xref rid="B386" ref-type="bibr">386</xref>]</td><td rowspan="2" colspan="1">miR-29b-2 (high), precursor to miR-29b-3p and miR-29b-5p</td><td rowspan="1" colspan="1">Anti-inflammatory: in a model of cardiomyocytes [<xref rid="B291" ref-type="bibr">291</xref>], in human umbilical vein endothelial cells stimulated by lipopolysaccharide [<xref rid="B292" ref-type="bibr">292</xref>], in microvascular endothelial cells [<xref rid="B293" ref-type="bibr">293</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in particulate matter-induced human bronchial epithelial cells [<xref rid="B294" ref-type="bibr">294</xref>], in a cardiomyocyte cell line [<xref rid="B295" ref-type="bibr">295</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-29c (high)</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B189" ref-type="bibr">189</xref>&#8211;<xref rid="B192" ref-type="bibr">192</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-212-3p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in a macrophage cell line [<xref rid="B269" ref-type="bibr">269</xref>, <xref rid="B270" ref-type="bibr">270</xref>], in mouse monocyte-macrophages [<xref rid="B271" ref-type="bibr">271</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in monocytes in a model of radiation-induced endothelial dysfunction [<xref rid="B272" ref-type="bibr">272</xref>], by inhibiting SIRT1 and NLRP3 inflammasome in a lipopolysaccharide-stimulated epithelial cell line [<xref rid="B273" ref-type="bibr">273</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-212-5p (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in a neuroblastoma cell line [<xref rid="B387" ref-type="bibr">387</xref>], in lipopolysaccharide-stimulated human periodontal ligament cells [<xref rid="B388" ref-type="bibr">388</xref>], in bronchial epithelial cell line under CSE [<xref rid="B389" ref-type="bibr">389</xref>], in IL-1&#946;-stimulated chondrocytes [<xref rid="B390" ref-type="bibr">390</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-410 (high)</td><td rowspan="1" colspan="1">Anti-inflammatory: in an ovalbumin-induced murine model of asthma by inhibiting IL-4/Il-13 [<xref rid="B391" ref-type="bibr">391</xref>], in lipopolysaccharide-treated chondrocytes by inhibiting NFkB [<xref rid="B392" ref-type="bibr">392</xref>], in oxygen-glucose deprivation/reoxygenation-treated brain microvascular endothelial cells [<xref rid="B393" ref-type="bibr">393</xref>], in human fetal hepatocytes by inhibiting NFkB [<xref rid="B394" ref-type="bibr">394</xref>], in decidual macrophages at the maternal-fetal interface [<xref rid="B395" ref-type="bibr">395</xref>].</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a model of pulmonary fibrosis and a fibroblast cell line by stimulating SIRT1 and inhibiting NFkB [<xref rid="B396" ref-type="bibr">396</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-708 (high)</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B209" ref-type="bibr">209</xref>&#8211;<xref rid="B212" ref-type="bibr">212</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-22 (low)</td><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low [<xref rid="B225" ref-type="bibr">225</xref>&#8211;<xref rid="B235" ref-type="bibr">235</xref>], inhibits dendritic cell function [<xref rid="B236" ref-type="bibr">236</xref>], inhibits NLRP3 inflammasome [<xref rid="B229" ref-type="bibr">229</xref>, <xref rid="B234" ref-type="bibr">234</xref>, <xref rid="B237" ref-type="bibr">237</xref>, <xref rid="B238" ref-type="bibr">238</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-99a (low)</td><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low: in lipopolysaccharide-induced endothelial cell by inhibiting NFkB and mTOR [<xref rid="B397" ref-type="bibr">397</xref>], in macrophages by inhibiting M1 phenotype activation depending on TNF inhibition [<xref rid="B398" ref-type="bibr">398</xref>, <xref rid="B399" ref-type="bibr">399</xref>], by inducing Treg cells [<xref rid="B400" ref-type="bibr">400</xref>], in a neuron cell line stimulated with lipopolysaccharide [<xref rid="B401" ref-type="bibr">401</xref>], by inhibiting NLRP3 inflammasome and mTOR in macrophage cell line [<xref rid="B402" ref-type="bibr">402</xref>], by inhibiting TLR8 in chondrocytes [<xref rid="B403" ref-type="bibr">403</xref>]</td></tr><tr><td rowspan="1" colspan="1">In general proinflammatory but anti-inflammatory when microRNA is low: in <italic toggle="yes">S. aureus</italic>-infected monocytes by inhibition of mTOR [<xref rid="B404" ref-type="bibr">404</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-137 (low)</td><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low: in astrocytic and microglial cells [<xref rid="B405" ref-type="bibr">405</xref>], after ischemic injury after focal cerebral ischemia [<xref rid="B406" ref-type="bibr">406</xref>], in a spinal cord injury model [<xref rid="B407" ref-type="bibr">407</xref>], in a microglia cell line [<xref rid="B408" ref-type="bibr">408</xref>], in lipopolysaccharide-stimulated human nucleus pulposus cells [<xref rid="B409" ref-type="bibr">409</xref>], in a macrophage cell line [<xref rid="B410" ref-type="bibr">410</xref>]</td></tr><tr><td rowspan="1" colspan="1">let-7e (low)</td><td rowspan="1" colspan="1">In general proinflammatory but anti-inflammatory when microRNA is low: in vascular endothelial cells by stimulating the NFkB pathway [<xref rid="B411" ref-type="bibr">411</xref>], in a model of acute lung injury by supporting the NFkB pathway [<xref rid="B412" ref-type="bibr">412</xref>]</td></tr><tr><td rowspan="5" colspan="1">Sleep deprivation in humans [<xref rid="B413" ref-type="bibr">413</xref>]</td><td rowspan="2" colspan="1">miR-125a (low)</td><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low: reduces neuroinflammation [<xref rid="B414" ref-type="bibr">414</xref>, <xref rid="B415" ref-type="bibr">415</xref>], in mouse macrophages by inducing M2 polarization [<xref rid="B416" ref-type="bibr">416</xref>, <xref rid="B417" ref-type="bibr">417</xref>], stabilizes Treg cell immune homeostasis [<xref rid="B418" ref-type="bibr">418</xref>, <xref rid="B419" ref-type="bibr">419</xref>], suppresses neutrophil lung inflammation [<xref rid="B420" ref-type="bibr">420</xref>], in a model of diabetic cardiomyopathy [<xref rid="B421" ref-type="bibr">421</xref>], in fibroblast-like synovial cells in rheumatoid arthritis [<xref rid="B422" ref-type="bibr">422</xref>], in a psoriasis-like inflammatory cell model [<xref rid="B423" ref-type="bibr">423</xref>]</td></tr><tr><td rowspan="1" colspan="1">In general proinflammatory but anti-inflammatory when microRNA is low: induces microglia M1 polarization and neuroinflammation [<xref rid="B424" ref-type="bibr">424</xref>, <xref rid="B425" ref-type="bibr">425</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-126 (low)</td><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low: in monocytes [<xref rid="B426" ref-type="bibr">426</xref>], in a spinal cord injury model [<xref rid="B427" ref-type="bibr">427</xref>], in a cholestasis model [<xref rid="B428" ref-type="bibr">428</xref>], in endothelial cells [<xref rid="B429" ref-type="bibr">429</xref>, <xref rid="B430" ref-type="bibr">430</xref>], in lymphocytes of septic rats [<xref rid="B431" ref-type="bibr">431</xref>], in a rat model of chondrocyte inflammation [<xref rid="B432" ref-type="bibr">432</xref>], in cardiomyocytes under hypoxia-reoxygenation [<xref rid="B433" ref-type="bibr">433</xref>], in a chicken embryonic fibroblast cell line after virus infection [<xref rid="B434" ref-type="bibr">434</xref>], in lung fibroblasts infected with H1N1 influenza virus [<xref rid="B435" ref-type="bibr">435</xref>]</td></tr><tr><td rowspan="1" colspan="1">In general proinflammatory but anti-inflammatory when microRNA is low: in primary lipopolysaccharide-stimulated monocytes from chronic HIV-1 patients [<xref rid="B436" ref-type="bibr">436</xref>], in a IL-1&#946;-stimulated chondrocyte cell line [<xref rid="B437" ref-type="bibr">437</xref>], in monocytes in a model of radiation-induced endothelial dysfunction [<xref rid="B272" ref-type="bibr">272</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-146a (low)</td><td rowspan="1" colspan="1">In general anti-inflammatory but proinflammatory when microRNA is low: inhibits the NF-kB pathway [<xref rid="B438" ref-type="bibr">438</xref>&#8211;<xref rid="B440" ref-type="bibr">440</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn><fn><p>TXNIP, thioredoxin-interacting protein; SIKE1, suppressor of IKBKE 1; CSE, cigarette smoke extract.</p></fn><fn><p>*miR-17&#8764;92 cluster: miR-17, miR-18a, miR-19a/b, miR-20a, and miR-92.</p></fn></table-wrap-foot></table-wrap><p>Using the data in <xref rid="T3" ref-type="table">Table 3</xref>, one recognizes that &#8211; overall &#8211; a similar number of publications demonstrated anti- and proinflammatory effects for those microRNAs detected under the stress applied (<xref rid="F2" ref-type="fig">Fig. 2</xref>b). Looking on individual stress paradigms, stress with social isolation, with chronic social defeat, with bodily restraint, and during the Trier Social Stress Test (TSST) let to more publications of microRNA with anti-inflammatory effects (<xref rid="T3" ref-type="table">Table 3</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>b). In contrast, sleep deprivation gave rise to more publications of microRNAs with proinflammatory effects (<xref rid="T3" ref-type="table">Table 3</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>b). No big difference was observed for stress under tail shock in animals and exams in humans (<xref rid="T3" ref-type="table">Table 3</xref>; <xref rid="F2" ref-type="fig">Fig. 2</xref>b). These data confirm the contrasting effects of psychological stress on inflammation and immune function according to published data [<xref rid="B246" ref-type="bibr">246</xref>, <xref rid="B247" ref-type="bibr">247</xref>].</p></sec><sec id="s3-3"><title>Immune Cell Exosome microRNA Modulates Central and Peripheral Nervous Function</title><p>Immune cells produce a large amount of exosomes and microRNA, respectively. In this review, the author will focus on M1 macrophages, M2 macrophages, dendritic cells, neutrophils, monocytes, T cells in general, T-helper type 17 T cells (Th17 cells), Treg cells, and B cells in general. <xref rid="T4" ref-type="table">Tables 4</xref>&#8211;<xref rid="T12" ref-type="table">12</xref> demonstrate the microRNAs of these immune cells and their effects on the central nervous system. Again, most of these experiments have been performed in vitro and interpolation into an in vivo situation is problematic.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4.</label><caption><p>Exosome microRNA derived from M1 macrophages [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B441" ref-type="bibr">441</xref>&#8211;<xref rid="B446" ref-type="bibr">446</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">microRNA in exosomal content</th><th rowspan="1" colspan="1">Function of microRNA on brain and brain-dependent functions&#8230; (references)</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">miR-17&#8764;92 cluster</td><td rowspan="1" colspan="1">Pro-pain: increased the sensitivity to mechanical irritation [<xref rid="B155" ref-type="bibr">155</xref>], reduced expression of the gene encoding the delayed rectifier potassium channel Kv7.5 as well as the fast inactivating channel Kv1.4 [<xref rid="B155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supporting neurogenesis [<xref rid="B447" ref-type="bibr">447</xref>], supports oligodendrocyte proliferation [<xref rid="B447" ref-type="bibr">447</xref>]</td></tr><tr><td rowspan="1" colspan="1">Antidepressive in mice [<xref rid="B448" ref-type="bibr">448</xref>]</td></tr><tr><td rowspan="1" colspan="1">Rescues stress effects in hippocampus [<xref rid="B448" ref-type="bibr">448</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-21-5p</td><td rowspan="1" colspan="1">Master regulator of innate immunity [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: increases hypersensitivity and allodynia [<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B449" ref-type="bibr">449</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: downregulation of this microRNA is neuroprotective [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-33</td><td rowspan="1" colspan="1">Pro-pain: diabetic neuropathy [<xref rid="B450" ref-type="bibr">450</xref>]</td></tr><tr><td rowspan="1" colspan="1">Regulates synaptic plasticity [<xref rid="B451" ref-type="bibr">451</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative [<xref rid="B452" ref-type="bibr">452</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits hunger signals [<xref rid="B453" ref-type="bibr">453</xref>]</td></tr><tr><td rowspan="1" colspan="1">Maintains adaptive thermogenesis through SNS [<xref rid="B454" ref-type="bibr">454</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-34c-5p</td><td rowspan="1" colspan="1">Pro-pain: inhibits voltage-gated calcium channel Cav2.3, which leads to hypersensitivity [<xref rid="B155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory in neuroinflammation [<xref rid="B455" ref-type="bibr">455</xref>]</td></tr><tr><td rowspan="1" colspan="1">Regulates synaptic plasticity [<xref rid="B456" ref-type="bibr">456</xref>]</td></tr><tr><td rowspan="1" colspan="1">Has a role in human cognition relative to chimpanzee [<xref rid="B457" ref-type="bibr">457</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-125b-5p</td><td rowspan="1" colspan="1">Anti-pain: alleviates mechanical allodynia and thermal hyperalgesia [<xref rid="B458" ref-type="bibr">458</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: reduces neuroinflammation [<xref rid="B414" ref-type="bibr">414</xref>, <xref rid="B415" ref-type="bibr">415</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: induces microglia M1 polarization and neuroinflammation [<xref rid="B424" ref-type="bibr">424</xref>, <xref rid="B425" ref-type="bibr">425</xref>]</td></tr><tr><td rowspan="1" colspan="1">Role in neurodevelopment [<xref rid="B459" ref-type="bibr">459</xref>, <xref rid="B460" ref-type="bibr">460</xref>]</td></tr><tr><td rowspan="1" colspan="1">Involved in Alzheimer&#8217;s disease [<xref rid="B461" ref-type="bibr">461</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-133</td><td rowspan="1" colspan="1">Anti-inflammatory in neuroinflammation [<xref rid="B462" ref-type="bibr">462</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-146a-5p</td><td rowspan="1" colspan="1">Anti-inflammatory: inhibits the NF-kB pathway [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B439" ref-type="bibr">439</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B439" ref-type="bibr">439</xref>], protects blood-brain barrier [<xref rid="B439" ref-type="bibr">439</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-150</td><td rowspan="1" colspan="1">Anti-pain: alleviates mechanical allodynia by targeting NOTCH2 in microglial cells [<xref rid="B463" ref-type="bibr">463</xref>&#8211;<xref rid="B465" ref-type="bibr">465</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in a Parkinson disease model [<xref rid="B466" ref-type="bibr">466</xref>, <xref rid="B467" ref-type="bibr">467</xref>] but also neurodegenerative in a dementia model [<xref rid="B468" ref-type="bibr">468</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-155-5p</td><td rowspan="1" colspan="1">Proinflammatory: deletion of miR-155-5p prevented EAE and attenuated microgliosis and neuronal loss in an &#945;-synuclein-driven Parkinson model [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: inhibits the negative regulators of Toll-like receptor 4, increase of cytokine production [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Psychological stress-provoking: blocking the miR led to resilient phenotype [<xref rid="B469" ref-type="bibr">469</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroinflammatory: blocks BNDF, stimulates NF-kB [<xref rid="B470" ref-type="bibr">470</xref>, <xref rid="B471" ref-type="bibr">471</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: supports cancer pain and hypersensitivity [<xref rid="B472" ref-type="bibr">472</xref>]</td></tr><tr><td rowspan="6" colspan="1">miR-223-3p/5p</td><td rowspan="1" colspan="1">Pro- and anti-inflammatory roles [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B473" ref-type="bibr">473</xref>, <xref rid="B474" ref-type="bibr">474</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory in EAE [<xref rid="B475" ref-type="bibr">475</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in EAE [<xref rid="B476" ref-type="bibr">476</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: clearing of myelin debris through M2 microglia [<xref rid="B477" ref-type="bibr">477</xref>]</td></tr><tr><td rowspan="1" colspan="1">Nerve regeneration and anti-inflammatory: inhibits NLRP3 inflammasome [<xref rid="B478" ref-type="bibr">478</xref>, <xref rid="B479" ref-type="bibr">479</xref>] and IL-1&#946; [<xref rid="B473" ref-type="bibr">473</xref>], positive in nerve regeneration [<xref rid="B480" ref-type="bibr">480</xref>, <xref rid="B481" ref-type="bibr">481</xref>], particularly in female subjects [<xref rid="B482" ref-type="bibr">482</xref>]</td></tr><tr><td rowspan="1" colspan="1">Excitotoxic: inhibits NMDA effects through glutamate receptor subunits GluR2 and NR2B [<xref rid="B483" ref-type="bibr">483</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-495</td><td rowspan="1" colspan="1">Anti-addiction: downregulates addiction-related gene upregulation in specific substance-use-related biological pathways [<xref rid="B484" ref-type="bibr">484</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-epileptic in hippocampus [<xref rid="B485" ref-type="bibr">485</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: in high-glucose induced apoptosis of retinal ganglion cells [<xref rid="B486" ref-type="bibr">486</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroregenerative: in acute spinal cord injury model [<xref rid="B487" ref-type="bibr">487</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-641</td><td rowspan="1" colspan="1">No data</td></tr><tr><td rowspan="1" colspan="1">miR-let7b</td><td rowspan="1" colspan="1">Pro-pain: induces rapid inward currents and action potentials in sensory neurons in the DRG, mediators of sensitization, and nociceptive signaling [<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B444" ref-type="bibr">444</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete. A relatively complete list of microRNA from different human leukocytes can be derived from Juzenas et al. [<xref rid="B488" ref-type="bibr">488</xref>].</p></fn><fn><p>miR-17&#8764;92 cluster: miR-17, miR-18a, miR-19a/b, miR-20a, and miR-92.</p></fn><fn><p>BDNF, brain-derived neurotrophic factor; DRG, dorsal root ganglion; EAE, experimental autoimmune encephalomyelitis; NF-kB, nuclear factor kappa B; NMDA, N-methyl-D-aspartate; SNS, sympathetic nervous system.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5.</label><caption><p>Exosome microRNA derived from M2 macrophages [<xref rid="B489" ref-type="bibr">489</xref>&#8211;<xref rid="B491" ref-type="bibr">491</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">microRNA in exosomal content</th><th rowspan="1" colspan="1">Function of microRNA on brain and brain-dependent functions&#8230; (references)</th></tr></thead><tbody><tr><td rowspan="3" colspan="1">miR-24-3p</td><td rowspan="1" colspan="1">Anti-inflammatory: NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>] and in microglia in a spinal cord injury model [<xref rid="B493" ref-type="bibr">493</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits neuronal differentiation in SH-SY5Y cells (neuroblastoma) [<xref rid="B494" ref-type="bibr">494</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits the circadian Period2 gene oscillation [<xref rid="B495" ref-type="bibr">495</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-30b-5p</td><td rowspan="1" colspan="1">Anti-pain: anti-allodynic effect through inhibition of voltage-gated sodium ion channel, Nav1.7 [<xref rid="B155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in a spinal cord injury model [<xref rid="B496" ref-type="bibr">496</xref>], through NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-99a</td><td rowspan="1" colspan="1">Behavioral changes: overexpression leads to cognitive impairment in a menopause stress model [<xref rid="B497" ref-type="bibr">497</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: anti-apoptotic for astrocytes, rescues from hypoxia-induced injury [<xref rid="B498" ref-type="bibr">498</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-124</td><td rowspan="1" colspan="1">Neuroprotective: attenuating ischemic brain injury and promoting the survival of neurons [<xref rid="B489" ref-type="bibr">489</xref>], relevant for functional repair in the CNS [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B499" ref-type="bibr">499</xref>], in a model of traumatic brain injury [<xref rid="B500" ref-type="bibr">500</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-epileptic: suppresses seizure activity [<xref rid="B501" ref-type="bibr">501</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-137</td><td rowspan="1" colspan="1">Neuroprotective: attenuating ischemic brain injury and promoting the survival of neurons [<xref rid="B489" ref-type="bibr">489</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodevelopmental: important player in neural development and neoplastic transformation (as tumor suppressor), dysregulation is linked to major mental illnesses like schizophrenia [<xref rid="B502" ref-type="bibr">502</xref>, <xref rid="B503" ref-type="bibr">503</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory after spinal cord injury [<xref rid="B405" ref-type="bibr">405</xref>], after ischemic injury after focal cerebral ischemia [<xref rid="B406" ref-type="bibr">406</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-145-5p</td><td rowspan="1" colspan="1">Neurodegenerative: in a glaucoma model of apoptosis of retinal ganglion cells [<xref rid="B504" ref-type="bibr">504</xref>]</td></tr><tr><td rowspan="1" colspan="1">Demyelinating: prevents differentiation of oligodendrocyte progenitor cells [<xref rid="B505" ref-type="bibr">505</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: inhibits astrocyte proliferation related to spinal cord injury [<xref rid="B506" ref-type="bibr">506</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-inflammatory: in the microglia cell line BV2 after lipopolysaccharide [<xref rid="B507" ref-type="bibr">507</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in the microglia cell line BV2 after oxygen/glucose deprivation [<xref rid="B508" ref-type="bibr">508</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-146b</td><td rowspan="1" colspan="1">Anti-inflammatory: inhibits IRAK1 [<xref rid="B509" ref-type="bibr">509</xref>], inhibits microglia activation [<xref rid="B510" ref-type="bibr">510</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodevelopmental: supports neural commitment of pluripotent stem cells [<xref rid="B511" ref-type="bibr">511</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in an injury model of oligodendrocyte precursor cells [<xref rid="B512" ref-type="bibr">512</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-148a</td><td rowspan="1" colspan="1">Proinflammatory: in a human microglial cell line (CHME3) through lost stability of ATF3 [<xref rid="B513" ref-type="bibr">513</xref>] and through IRF9 [<xref rid="B514" ref-type="bibr">514</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-epileptic, neurodegenerative: in hippocampal neurons [<xref rid="B515" ref-type="bibr">515</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits microglia activation in a rat trauma injury model [<xref rid="B516" ref-type="bibr">516</xref>] or in an hypoxia-ischemia model [<xref rid="B517" ref-type="bibr">517</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-216a</td><td rowspan="1" colspan="1">Anti-inflammatory: inhibition of TLR4 [<xref rid="B518" ref-type="bibr">518</xref>], induces M2 microglia polarization [<xref rid="B518" ref-type="bibr">518</xref>], inhibition of HMGB1 and improved memory in an Alzheimer model [<xref rid="B519" ref-type="bibr">519</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroregenerative: in a traumatic brain injury model [<xref rid="B520" ref-type="bibr">520</xref>], anti-apoptotic in a Parkinson disease model [<xref rid="B521" ref-type="bibr">521</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: reduction of inflammatory response and microglia activation in spinal cord [<xref rid="B522" ref-type="bibr">522</xref>] and trigeminal ganglion [<xref rid="B523" ref-type="bibr">523</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-221-3p/5p</td><td rowspan="1" colspan="1">Peripheral nerve repair: promotes Schwann cell proliferation after sciatic nerve injury [<xref rid="B524" ref-type="bibr">524</xref>, <xref rid="B525" ref-type="bibr">525</xref>], inhibits Schwan cell myelination [<xref rid="B526" ref-type="bibr">526</xref>], in the presence of chondroitin sulfate proteoglycans in the model of sciatic nerve conditioning injury [<xref rid="B527" ref-type="bibr">527</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in brain-ischemic rats and hypoxia cell model by inhibiting apoptosis [<xref rid="B528" ref-type="bibr">528</xref>], in a Parkinson disease model [<xref rid="B529" ref-type="bibr">529</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in a cell model through the target gene TNFAIP2 [<xref rid="B177" ref-type="bibr">177</xref>] and in middle cerebral artery occlusion in rats [<xref rid="B178" ref-type="bibr">178</xref>]</td></tr><tr><td rowspan="1" colspan="1">Promotes depression-like behavior in mice [<xref rid="B530" ref-type="bibr">530</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-223-3p/5p</td><td rowspan="1" colspan="1">Pro- and anti-inflammatory roles [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B473" ref-type="bibr">473</xref>, <xref rid="B474" ref-type="bibr">474</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory in EAE [<xref rid="B475" ref-type="bibr">475</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: clearing of myelin debris through M2 microglia [<xref rid="B477" ref-type="bibr">477</xref>]</td></tr><tr><td rowspan="1" colspan="1">Nerve regeneration and anti-inflammatory: inhibits NLRP3 inflammasome [<xref rid="B478" ref-type="bibr">478</xref>, <xref rid="B479" ref-type="bibr">479</xref>] and IL-1&#946; [<xref rid="B473" ref-type="bibr">473</xref>]; positive in nerve regeneration [<xref rid="B480" ref-type="bibr">480</xref>, <xref rid="B481" ref-type="bibr">481</xref>]; particularly, in female subjects [<xref rid="B482" ref-type="bibr">482</xref>], in EAE [<xref rid="B476" ref-type="bibr">476</xref>], inhibits NMDA effects through glutamate receptor subunits GluR2 and NR2B [<xref rid="B483" ref-type="bibr">483</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-370</td><td rowspan="1" colspan="1">Neurodegenerative: in middle cerebral artery occlusion in rats [<xref rid="B531" ref-type="bibr">531</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increases blood-brain barrier permeability: in a model of oxygen-glucose deprivation/reperfusion in a cell line [<xref rid="B532" ref-type="bibr">532</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-378a</td><td rowspan="1" colspan="1">Neuroprotective: in the oxygen-glucose deprivation/reoxygenation cell model of primary hippocampal rat neurons [<xref rid="B533" ref-type="bibr">533</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in a mouse neuropathy model [<xref rid="B534" ref-type="bibr">534</xref>] and in cerebral ischemia neuroinflammation by inhibiting NLRP3 [<xref rid="B535" ref-type="bibr">535</xref>]</td></tr><tr><td rowspan="1" colspan="1">Interferes with morphine tolerance [<xref rid="B536" ref-type="bibr">536</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-615-5p</td><td rowspan="1" colspan="1">Proinflammatory: inhibition of oligodendrocyte precursor cells, worsening of inflammation in multiple sclerosis model [<xref rid="B537" ref-type="bibr">537</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn><fn><p>DRG, dorsal root ganglion.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T6" orientation="portrait"><label>Table 6.</label><caption><p>Exosome microRNA derived from dendritic cells [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B441" ref-type="bibr">441</xref>, <xref rid="B445" ref-type="bibr">445</xref>, <xref rid="B490" ref-type="bibr">490</xref>, <xref rid="B492" ref-type="bibr">492</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">microRNA in exosomal content</th><th rowspan="1" colspan="1">Function of microRNA on brain and brain-dependent functions&#8230; (references)</th></tr></thead><tbody><tr><td rowspan="3" colspan="1">miR-22-3p</td><td rowspan="1" colspan="1">Neuroprotective: in a Huntington disease neuronal cell model [<xref rid="B538" ref-type="bibr">538</xref>], in a cerebral ischemia model [<xref rid="B539" ref-type="bibr">539</xref>, <xref rid="B540" ref-type="bibr">540</xref>], in a Parkinson disease cell model [<xref rid="B541" ref-type="bibr">541</xref>], in an Alzheimer model [<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B542" ref-type="bibr">542</xref>], in a primary sensory neuron model [<xref rid="B543" ref-type="bibr">543</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodevelopmental role in cerebellum [<xref rid="B544" ref-type="bibr">544</xref>]</td></tr><tr><td rowspan="1" colspan="1">Hypertensive: in the rostral ventrolateral medulla through inhibition of &#946;-arrestin1 modified by microglia [<xref rid="B545" ref-type="bibr">545</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-24-3p</td><td rowspan="1" colspan="1">Anti-inflammatory: NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>], and in microglia in a spinal cord injury model [<xref rid="B493" ref-type="bibr">493</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits neuronal differentiation in SH-SY5Y cells (neuroblastoma) [<xref rid="B494" ref-type="bibr">494</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits the circadian Period2 gene oscillation [<xref rid="B495" ref-type="bibr">495</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-30b-5p</td><td rowspan="1" colspan="1">Anti-pain: anti-allodynic effect through inhibition of voltage-gated sodium ion channel, Nav1.7 [<xref rid="B155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in a spinal cord injury model [<xref rid="B496" ref-type="bibr">496</xref>], through NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-125b-5p</td><td rowspan="1" colspan="1">Anti-pain: alleviates mechanical allodynia and thermal hyperalgesia [<xref rid="B458" ref-type="bibr">458</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: reduces neuroinflammation [<xref rid="B414" ref-type="bibr">414</xref>, <xref rid="B415" ref-type="bibr">415</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-inflammatory: induces microglia M1 polarization and neuroinflammation [<xref rid="B424" ref-type="bibr">424</xref>, <xref rid="B425" ref-type="bibr">425</xref>]</td></tr><tr><td rowspan="1" colspan="1">Role in neurodevelopment [<xref rid="B459" ref-type="bibr">459</xref>, <xref rid="B460" ref-type="bibr">460</xref>]</td></tr><tr><td rowspan="1" colspan="1">Involved in Alzheimer&#8217;s disease [<xref rid="B461" ref-type="bibr">461</xref>]</td></tr><tr><td rowspan="8" colspan="1">miR-142-3p</td><td rowspan="1" colspan="1">Anti-inflammatory: NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: inhibits neuroinflammation through HMGB1 [<xref rid="B546" ref-type="bibr">546</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in the sciatic nerve transection model [<xref rid="B547" ref-type="bibr">547</xref>], in a Parkinson disease model [<xref rid="B548" ref-type="bibr">548</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: in a chronic compression injury model [<xref rid="B549" ref-type="bibr">549</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a model of choroidal neovascularization and inflammation [<xref rid="B550" ref-type="bibr">550</xref>]</td></tr><tr><td rowspan="1" colspan="1">Enhances glutamatergic neurotransmission through IL-1&#946;-dependent synaptopathy in neuroinflammation [<xref rid="B551" ref-type="bibr">551</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits dopamine D1 receptor signaling [<xref rid="B552" ref-type="bibr">552</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits circadian protein BMAL1 and abolishes circadian oscillation [<xref rid="B553" ref-type="bibr">553</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-146a-5p</td><td rowspan="1" colspan="1">Anti-inflammatory: inhibits the NF-kB pathway [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B439" ref-type="bibr">439</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B439" ref-type="bibr">439</xref>], protects blood-brain barrier [<xref rid="B439" ref-type="bibr">439</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-148a</td><td rowspan="1" colspan="1">Proinflammatory: in a human microglial cell line (CHME3) through lost stability of ATF3 [<xref rid="B513" ref-type="bibr">513</xref>] and through IRF9 [<xref rid="B514" ref-type="bibr">514</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-epileptic, neurodegenerative: in hippocampal neurons [<xref rid="B515" ref-type="bibr">515</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits microglia activation in a rat trauma injury model [<xref rid="B516" ref-type="bibr">516</xref>] or in an hypoxia-ischemia model [<xref rid="B517" ref-type="bibr">517</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-155-5p</td><td rowspan="1" colspan="1">Proinflammatory: deletion of miR-155-5p prevented EAE and attenuated microgliosis and neuronal loss in an &#945;-synuclein-driven Parkinson model [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: inhibits the negative regulators of Toll-like receptor 4, increase of cytokine production [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Psychological stress-provoking: blocking the miR led to resilient phenotype [<xref rid="B469" ref-type="bibr">469</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroinflammatory: blocks BNDF, stimulates NF-kB [<xref rid="B470" ref-type="bibr">470</xref>, <xref rid="B471" ref-type="bibr">471</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: supports cancer pain and hypersensitivity [<xref rid="B472" ref-type="bibr">472</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-451</td><td rowspan="1" colspan="1">Neurodegenerative: induces apoptotic pathways in a stretch model of cortical neurons [<xref rid="B554" ref-type="bibr">554</xref>], in a kainic acid-induced seizure model in hippocampal neurons [<xref rid="B555" ref-type="bibr">555</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits signaling through TLR4 and has inhibitory effects on microglia activation [<xref rid="B275" ref-type="bibr">275</xref>], suppresses NLRP3 inflammasome-induced microglia activation [<xref rid="B276" ref-type="bibr">276</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: in complete Freund&#8217;s adjuvant-induced inflammatory pain mice model [<xref rid="B275" ref-type="bibr">275</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-511</td><td rowspan="1" colspan="1">Involved in GDNF signaling in human neural progenitor cells [<xref rid="B556" ref-type="bibr">556</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-511 suppressed glucocorticoid-induced up-regulation of FKBP51 in HeLa cells and primary neurons [<xref rid="B557" ref-type="bibr">557</xref>]</td></tr><tr><td rowspan="1" colspan="1">Linked to depression-like behavior in rats without causal explanation [<xref rid="B558" ref-type="bibr">558</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn><fn><p>BDNF, brain-derived neurotrophic factor; EAE, experimental autoimmune encephalitis; GDNF, glial cell line-derived neurotrophic factor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T7" orientation="portrait"><label>Table 7.</label><caption><p>Exosome microRNA derived from neutrophils [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B445" ref-type="bibr">445</xref>, <xref rid="B491" ref-type="bibr">491</xref>, <xref rid="B559" ref-type="bibr">559</xref>&#8211;<xref rid="B562" ref-type="bibr">562</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1">miR-9</td><td rowspan="1" colspan="1">Neuroprotective: proliferation and differentiation of neural stem cells [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-21-5p</td><td rowspan="1" colspan="1">Master regulator of innate immunity [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: increases hypersensitivity and allodynia [<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B449" ref-type="bibr">449</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: downregulation of miR-21-5p is neuroprotective [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-29b</td><td rowspan="1" colspan="1">Protects blood-brain barrier integrity [<xref rid="B560" ref-type="bibr">560</xref>]</td></tr><tr><td rowspan="1" colspan="1">Necessary for proper motor function [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-30d-5p</td><td rowspan="1" colspan="1">Regulates survival programs of neural cells, increased infarct volume after hypoxia-ischemia model [<xref rid="B563" ref-type="bibr">563</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory in a stroke model [<xref rid="B564" ref-type="bibr">564</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-93</td><td rowspan="1" colspan="1">Role in neuroregeneration [<xref rid="B565" ref-type="bibr">565</xref>, <xref rid="B566" ref-type="bibr">566</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory in a stroke model of ischemia [<xref rid="B261" ref-type="bibr">261</xref>, <xref rid="B262" ref-type="bibr">262</xref>], in a neuropathy model [<xref rid="B263" ref-type="bibr">263</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain [<xref rid="B263" ref-type="bibr">263</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-122-5p</td><td rowspan="1" colspan="1">Plays a role in neurodevelopment [<xref rid="B567" ref-type="bibr">567</xref>] and myelin sheath repair [<xref rid="B568" ref-type="bibr">568</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: in neuropathic pain model [<xref rid="B569" ref-type="bibr">569</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a intracerebral hemorrhage model in mice [<xref rid="B570" ref-type="bibr">570</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits neuroinflammation in a sepsis model [<xref rid="B571" ref-type="bibr">571</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative in an Alzheimer model [<xref rid="B572" ref-type="bibr">572</xref>]</td></tr><tr><td rowspan="8" colspan="1">miR-142-3p</td><td rowspan="1" colspan="1">Anti-inflammatory: NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: inhibits neuroinflammation through HMGB1 [<xref rid="B546" ref-type="bibr">546</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in the sciatic nerve transection model [<xref rid="B547" ref-type="bibr">547</xref>], in a Parkinson disease model [<xref rid="B548" ref-type="bibr">548</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: in a chronic compression injury model [<xref rid="B549" ref-type="bibr">549</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a model of choroidal neovascularization and inflammation [<xref rid="B550" ref-type="bibr">550</xref>]</td></tr><tr><td rowspan="1" colspan="1">Enhances glutamatergic neurotransmission through IL-1&#946;-dependent synaptopathy in neuroinflammation [<xref rid="B551" ref-type="bibr">551</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits dopamine D1 receptor signaling [<xref rid="B552" ref-type="bibr">552</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits circadian protein BMAL1 and abolishes circadian oscillation [<xref rid="B553" ref-type="bibr">553</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-144-3p</td><td rowspan="1" colspan="1">Supportive role in fear extinction (in basolateral amygdala) [<xref rid="B573" ref-type="bibr">573</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory and neurodegenerative: in an oxygen-glucose deprivation model [<xref rid="B384" ref-type="bibr">384</xref>] and in a model of cerebral ischemia-reperfusion injury [<xref rid="B385" ref-type="bibr">385</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-150-5p</td><td rowspan="1" colspan="1">Anti-pain: alleviates mechanical allodynia by targeting NOTCH2 in microglial cells [<xref rid="B463" ref-type="bibr">463</xref>&#8211;<xref rid="B465" ref-type="bibr">465</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in a Parkinson disease model [<xref rid="B466" ref-type="bibr">466</xref>, <xref rid="B467" ref-type="bibr">467</xref>] but also neurodegenerative in a dementia model [<xref rid="B468" ref-type="bibr">468</xref>]</td></tr><tr><td rowspan="8" colspan="1">miR-218</td><td rowspan="1" colspan="1">Neuroprotective in a Parkinson disease model [<xref rid="B574" ref-type="bibr">574</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory and neuroprotective in a Parkinson disease model [<xref rid="B575" ref-type="bibr">575</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in an oxygen glucose deprivation/re-oxygenation neuronal injury model [<xref rid="B576" ref-type="bibr">576</xref>]</td></tr><tr><td rowspan="1" colspan="1">Protective in a stress model in mice [<xref rid="B577" ref-type="bibr">577</xref>]</td></tr><tr><td rowspan="1" colspan="1">Upregulated during chronic stress in the prefrontal cortex (corticosterone-treated rats) [<xref rid="B578" ref-type="bibr">578</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increases synaptic strength and function [<xref rid="B579" ref-type="bibr">579</xref>&#8211;<xref rid="B582" ref-type="bibr">582</xref>]</td></tr><tr><td rowspan="1" colspan="1">Important in neurodevelopmental processes of motor neurons [<xref rid="B583" ref-type="bibr">583</xref>&#8211;<xref rid="B585" ref-type="bibr">585</xref>]</td></tr><tr><td rowspan="1" colspan="1">Important for psychological resilience [<xref rid="B586" ref-type="bibr">586</xref>]</td></tr><tr><td rowspan="6" colspan="1">miR-223-3p/5p</td><td rowspan="1" colspan="1">Pro- and anti-inflammatory roles [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B473" ref-type="bibr">473</xref>, <xref rid="B474" ref-type="bibr">474</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory in EAE [<xref rid="B475" ref-type="bibr">475</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in EAE [<xref rid="B476" ref-type="bibr">476</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: clearing of myelin debris through M2 microglia [<xref rid="B477" ref-type="bibr">477</xref>]</td></tr><tr><td rowspan="1" colspan="1">Nerve regeneration and anti-inflammatory: inhibits NLRP3 inflammasome [<xref rid="B478" ref-type="bibr">478</xref>, <xref rid="B479" ref-type="bibr">479</xref>] and IL-1&#946; [<xref rid="B473" ref-type="bibr">473</xref>], positive in nerve regeneration [<xref rid="B480" ref-type="bibr">480</xref>, <xref rid="B481" ref-type="bibr">481</xref>], particularly in female subjects [<xref rid="B482" ref-type="bibr">482</xref>]</td></tr><tr><td rowspan="1" colspan="1">Excitotoxic: inhibits NMDA effects through glutamate receptor subunits GluR2 and NR2B [<xref rid="B483" ref-type="bibr">483</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-370-3p</td><td rowspan="1" colspan="1">Neurodegenerative: in middle cerebral artery occlusion in rats [<xref rid="B531" ref-type="bibr">531</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increases blood-brain barrier permeability: in a model of oxygen-glucose deprivation/reperfusion in a cell line [<xref rid="B532" ref-type="bibr">532</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-409-3p</td><td rowspan="1" colspan="1">Proinflammatory: in a model of EAE [<xref rid="B587" ref-type="bibr">587</xref>], in a cell model of BV-2 microglia [<xref rid="B588" ref-type="bibr">588</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective and anti-inflammatory: in a isoflurane-induced neurotoxicity model [<xref rid="B589" ref-type="bibr">589</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodevelopmental role [<xref rid="B590" ref-type="bibr">590</xref>]</td></tr><tr><td rowspan="1" colspan="1">Thought to play a role in altered blood-brain barrier integrity in the model of transient middle cerebral artery occlusion followed by reperfusion, which is used to study hemorrhagic transformation [<xref rid="B562" ref-type="bibr">562</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-451</td><td rowspan="1" colspan="1">Neurodegenerative: induces apoptotic pathways in a stretch model of cortical neurons [<xref rid="B554" ref-type="bibr">554</xref>], in a kainic acid-induced seizure model in hippocampal neurons [<xref rid="B555" ref-type="bibr">555</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits signaling through TLR4 and has inhibitory effects on microglia activation [<xref rid="B275" ref-type="bibr">275</xref>], suppresses NLRP3 inflammasome-induced microglia activation [<xref rid="B276" ref-type="bibr">276</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: in complete Freund&#8217;s adjuvant-induced inflammatory pain mice model [<xref rid="B275" ref-type="bibr">275</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-3473d</td><td rowspan="3" colspan="1">Thought to play a role in altered blood-brain barrier integrity in the model of transient middle cerebral artery occlusion followed by reperfusion, which is used to study hemorrhagic transformation [<xref rid="B562" ref-type="bibr">562</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-6904-5p</td></tr><tr><td rowspan="1" colspan="1">miR-6909-5p</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn><fn><p>EAE, experimental autoimmune encephalomyelitis; HMGB1, high mobility group box 1.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T8" orientation="portrait"><label>Table 8.</label><caption><p>Exosome microRNA derived from monocytes [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B441" ref-type="bibr">441</xref>, <xref rid="B491" ref-type="bibr">491</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1">miR-9</td><td rowspan="1" colspan="1">Neuroprotective: proliferation and differentiation of neural stem cells [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-17&#8764;92 cluster</td><td rowspan="1" colspan="1">Pro-pain: increased the sensitivity to mechanical irritation [<xref rid="B155" ref-type="bibr">155</xref>], reduced expression of the gene encoding the delayed rectifier potassium channel Kv7.5 as well as the fast inactivating channel Kv1.4 [<xref rid="B155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supporting neurogenesis [<xref rid="B447" ref-type="bibr">447</xref>], supports oligodendrocyte proliferation [<xref rid="B447" ref-type="bibr">447</xref>]</td></tr><tr><td rowspan="1" colspan="1">Antidepressive in mice [<xref rid="B448" ref-type="bibr">448</xref>]</td></tr><tr><td rowspan="1" colspan="1">Rescues stress effects in hippocampus [<xref rid="B448" ref-type="bibr">448</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-21-5p</td><td rowspan="1" colspan="1">Master regulator of innate immunity [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: increases hypersensitivity and allodynia [<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B449" ref-type="bibr">449</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: downregulation of miR-21-5p is neuroprotective [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-27</td><td rowspan="1" colspan="1">Neurodevelopmental [<xref rid="B591" ref-type="bibr">591</xref>]</td></tr><tr><td rowspan="1" colspan="1">Protective for the blood-brain barrier [<xref rid="B592" ref-type="bibr">592</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a rat stroke model [<xref rid="B593" ref-type="bibr">593</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-150</td><td rowspan="1" colspan="1">Anti-pain: alleviates mechanical allodynia by targeting NOTCH2 in microglial cells [<xref rid="B463" ref-type="bibr">463</xref>&#8211;<xref rid="B465" ref-type="bibr">465</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in a Parkinson disease model [<xref rid="B466" ref-type="bibr">466</xref>, <xref rid="B467" ref-type="bibr">467</xref>] but also neurodegenerative in a dementia model [<xref rid="B468" ref-type="bibr">468</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-155-5p</td><td rowspan="1" colspan="1">Proinflammatory: deletion of miR-155-5p prevented EAE and attenuated microgliosis and neuronal loss in an &#945;-synuclein-driven Parkinson model [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: inhibits the negative regulators of Toll-like receptor 4, increase of cytokine production [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Psychological stress-provoking: blocking the miR led to resilient phenotype [<xref rid="B469" ref-type="bibr">469</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroinflammatory: blocks BNDF, stimulates NF-kB [<xref rid="B470" ref-type="bibr">470</xref>, <xref rid="B471" ref-type="bibr">471</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: supports cancer pain and hypersensitivity [<xref rid="B472" ref-type="bibr">472</xref>]</td></tr><tr><td rowspan="6" colspan="1">miR-223-3p/5p</td><td rowspan="1" colspan="1">Pro- and anti-inflammatory roles [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B473" ref-type="bibr">473</xref>, <xref rid="B474" ref-type="bibr">474</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory in EAE [<xref rid="B475" ref-type="bibr">475</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in EAE [<xref rid="B476" ref-type="bibr">476</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: clearing of myelin debris through M2 microglia [<xref rid="B477" ref-type="bibr">477</xref>]</td></tr><tr><td rowspan="1" colspan="1">Nerve regeneration and anti-inflammatory: inhibits NLRP3 inflammasome [<xref rid="B478" ref-type="bibr">478</xref>, <xref rid="B479" ref-type="bibr">479</xref>] and IL-1&#946; [<xref rid="B473" ref-type="bibr">473</xref>], positive in nerve regeneration [<xref rid="B480" ref-type="bibr">480</xref>, <xref rid="B481" ref-type="bibr">481</xref>], particularly in female subjects [<xref rid="B482" ref-type="bibr">482</xref>]</td></tr><tr><td rowspan="1" colspan="1">Excitotoxic: inhibits NMDA effects through glutamate receptor subunits GluR2 and NR2B [<xref rid="B483" ref-type="bibr">483</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn><fn><p>miR-17&#8764;92 cluster: miR-17, miR-18a, miR-19a/b, miR-20a, and miR-92.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T9" orientation="portrait"><label>Table 9.</label><caption><p>Exosome microRNA derived from T cells [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B441" ref-type="bibr">441</xref>, <xref rid="B445" ref-type="bibr">445</xref>, <xref rid="B490" ref-type="bibr">490</xref>, <xref rid="B561" ref-type="bibr">561</xref>, <xref rid="B594" ref-type="bibr">594</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1">miR-9</td><td rowspan="1" colspan="1">Neuroprotective: proliferation and differentiation of neural stem cells [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-17&#8764;92 cluster</td><td rowspan="1" colspan="1">Pro-pain: increase the sensitivity to mechanical irritation [<xref rid="B155" ref-type="bibr">155</xref>], reduced expression of the gene encoding the delayed rectifier potassium channel Kv7.5 as well as the fast inactivating channel Kv1.4 [<xref rid="B155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supporting neurogenesis [<xref rid="B447" ref-type="bibr">447</xref>], supports oligodendrocyte proliferation [<xref rid="B447" ref-type="bibr">447</xref>]</td></tr><tr><td rowspan="1" colspan="1">Antidepressive in mice [<xref rid="B448" ref-type="bibr">448</xref>]</td></tr><tr><td rowspan="1" colspan="1">Rescues stress effects in hippocampus [<xref rid="B448" ref-type="bibr">448</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-20</td><td rowspan="1" colspan="1">Neurodevelopmental role [<xref rid="B447" ref-type="bibr">447</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in a model of ischemic brain injury [<xref rid="B595" ref-type="bibr">595</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory through inhibition of neurogenin 1 [<xref rid="B447" ref-type="bibr">447</xref>], in stroke models [<xref rid="B447" ref-type="bibr">447</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supports axonal growth and neuronal branching in primary hippocampal neurons [<xref rid="B447" ref-type="bibr">447</xref>], in a spinal cord dorsal column lesion model [<xref rid="B596" ref-type="bibr">596</xref>], and in the DRG [<xref rid="B597" ref-type="bibr">597</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative in a spinal cord injury model [<xref rid="B598" ref-type="bibr">598</xref>], in an Alzheimer disease model [<xref rid="B599" ref-type="bibr">599</xref>]</td></tr><tr><td rowspan="7" colspan="1">miR-25</td><td rowspan="1" colspan="1">Plays a role in hippocampal long-term potentiation [<xref rid="B600" ref-type="bibr">600</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in neurodevelopment [<xref rid="B601" ref-type="bibr">601</xref>&#8211;<xref rid="B604" ref-type="bibr">604</xref>]</td></tr><tr><td rowspan="1" colspan="1">neuroprotective: upregulation inhibits apoptosis in an oxygen-glucose deprivation cell model [<xref rid="B605" ref-type="bibr">605</xref>], in a cell model of epilepsy [<xref rid="B606" ref-type="bibr">606</xref>], in a stroke model</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: in a diabetic neuropathy model in mice [<xref rid="B607" ref-type="bibr">607</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B608" ref-type="bibr">608</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: in an Alzheimer mouse model [<xref rid="B609" ref-type="bibr">609</xref>]</td></tr><tr><td rowspan="1" colspan="1">Regulates circadian period 2 oscillation [<xref rid="B495" ref-type="bibr">495</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-31</td><td rowspan="1" colspan="1">Neuroprotective: in spinal cord injury [<xref rid="B610" ref-type="bibr">610</xref>, <xref rid="B611" ref-type="bibr">611</xref>], in an oxygen-glucose deprivation cell model [<xref rid="B612" ref-type="bibr">612</xref>], in a stroke model [<xref rid="B613" ref-type="bibr">613</xref>], in a model of traumatic neuron injury [<xref rid="B614" ref-type="bibr">614</xref>]</td></tr><tr><td rowspan="1" colspan="1">Role in neurodevelopment [<xref rid="B615" ref-type="bibr">615</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory in a model of EAE [<xref rid="B616" ref-type="bibr">616</xref>], in an oxygen-glucose deprivation cell model [<xref rid="B617" ref-type="bibr">617</xref>]</td></tr><tr><td rowspan="1" colspan="1">Relevant in terminal astrocyte differentiation [<xref rid="B618" ref-type="bibr">618</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-34c-5p</td><td rowspan="1" colspan="1">Pro-pain: inhibits voltage-gated calcium channel Cav2.3, which leads to hypersensitivity [<xref rid="B155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory in neuroinflammation [<xref rid="B455" ref-type="bibr">455</xref>]</td></tr><tr><td rowspan="1" colspan="1">Regulates synaptic plasticity [<xref rid="B456" ref-type="bibr">456</xref>]</td></tr><tr><td rowspan="1" colspan="1">Has a role in human cognition relative to chimpanzee [<xref rid="B457" ref-type="bibr">457</xref>]</td></tr><tr><td rowspan="8" colspan="1">miR-142-3p/5p</td><td rowspan="1" colspan="1">Anti-inflammatory: NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: inhibits neuroinflammation through HMGB1 [<xref rid="B546" ref-type="bibr">546</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in the sciatic nerve transection model [<xref rid="B547" ref-type="bibr">547</xref>], in a Parkinson disease model [<xref rid="B548" ref-type="bibr">548</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: in a chronic compression injury model [<xref rid="B549" ref-type="bibr">549</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a model of choroidal neovascularization and inflammation [<xref rid="B550" ref-type="bibr">550</xref>]</td></tr><tr><td rowspan="1" colspan="1">Enhances glutamatergic neurotransmission through IL-1&#946;-dependent synaptopathy in neuroinflammation [<xref rid="B551" ref-type="bibr">551</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits dopamine D1 receptor signaling [<xref rid="B552" ref-type="bibr">552</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits circadian protein BMAL1 and abolishes circadian oscillation [<xref rid="B553" ref-type="bibr">553</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-150</td><td rowspan="1" colspan="1">Anti-pain: alleviates mechanical allodynia by targeting NOTCH2 in microglial cells [<xref rid="B463" ref-type="bibr">463</xref>&#8211;<xref rid="B465" ref-type="bibr">465</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in a Parkinson disease model [<xref rid="B466" ref-type="bibr">466</xref>, <xref rid="B467" ref-type="bibr">467</xref>] but also neurodegenerative in a dementia model [<xref rid="B468" ref-type="bibr">468</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-155-5p</td><td rowspan="1" colspan="1">Proinflammatory: deletion of miR-155-5p prevented EAE and attenuated microgliosis and neuronal loss in an &#945;-synuclein-driven Parkinson model [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: inhibits the negative regulators of Toll-like receptor 4, increase of cytokine production [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Psychological stress-provoking: blocking the miR led to resilient phenotype [<xref rid="B469" ref-type="bibr">469</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroinflammatory: blocks BNDF, stimulates NF-kB [<xref rid="B470" ref-type="bibr">470</xref>, <xref rid="B471" ref-type="bibr">471</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: supports cancer pain and hypersensitivity [<xref rid="B472" ref-type="bibr">472</xref>]</td></tr><tr><td rowspan="6" colspan="1">miR-335</td><td rowspan="1" colspan="1">Neurodegenerative: proapoptotic, antimitogenic factor in a fetal mouse cerebral cortex-derived neurosphere culture model [<xref rid="B619" ref-type="bibr">619</xref>], in neuroinflammation [<xref rid="B620" ref-type="bibr">620</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in an oxygen-glucose deprivation neuronal cell model [<xref rid="B621" ref-type="bibr">621</xref>], in an Alzheimer cell model [<xref rid="B622" ref-type="bibr">622</xref>], in retinal ganglion cell model [<xref rid="B623" ref-type="bibr">623</xref>], in a spinal cord injury model [<xref rid="B624" ref-type="bibr">624</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in a microglia cell model through inhibition of the NLRP3 inflammasome [<xref rid="B625" ref-type="bibr">625</xref>]</td></tr><tr><td rowspan="1" colspan="1">Role in neurodevelopment [<xref rid="B626" ref-type="bibr">626</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-335 in the rostral ventrolateral medulla stimulates the sympathetic output/stress-induced hypertension [<xref rid="B627" ref-type="bibr">627</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-335-5p induces impairment in memory [<xref rid="B628" ref-type="bibr">628</xref>, <xref rid="B629" ref-type="bibr">629</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn><fn><p>miR-17&#8764;92 cluster: miR-17, miR-18a, miR-19a/b, miR-20a, and miR-92.</p></fn><fn><p>DRG, dorsal root ganglion; EAE, experimental autoimmune encephalomyelitis.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T10" orientation="portrait"><label>Table 10.</label><caption><p>Exosome microRNA derived from T-helper type 17 cells [<xref rid="B630" ref-type="bibr">630</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="5" colspan="1">miR-10b</td><td rowspan="1" colspan="1">Neurodegenerative: inhibits BDNF mRNA expression and protein and in an oxygen-glucose deprivation neuronal cell model [<xref rid="B631" ref-type="bibr">631</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in neuronal cells in a spinal cord injury model (inhibits apoptosis) [<xref rid="B632" ref-type="bibr">632</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in brain tumorigenesis [<xref rid="B633" ref-type="bibr">633</xref>&#8211;<xref rid="B636" ref-type="bibr">636</xref>]</td></tr><tr><td rowspan="1" colspan="1">Stimulates growth hormone secretion in pituitary cells of cattle [<xref rid="B637" ref-type="bibr">637</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits CYP11B1 (synthesis of cortisol) and CYP11B2 (synthesis of aldosterone) in adrenocortical cells [<xref rid="B638" ref-type="bibr">638</xref>]</td></tr><tr><td colspan="2" rowspan="1">
<italic toggle="yes">miR-96/182/183 cluster</italic>
</td></tr><tr><td rowspan="11" colspan="1">miR-96</td><td rowspan="1" colspan="1">Anti-inflammatory: in a model of spinal cord injury by inhibiting the NF-kB pathway [<xref rid="B639" ref-type="bibr">639</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a model of oxygen glucose deprivation and reperfusion in mouse astrocytes [<xref rid="B640" ref-type="bibr">640</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: in a neuropathic pain model (chronic constriction nerve injury) [<xref rid="B641" ref-type="bibr">641</xref>, <xref rid="B642" ref-type="bibr">642</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotection: in vivo in mice after intracerebroventricular injection of a mimic [<xref rid="B643" ref-type="bibr">643</xref>], in rats with status epilepticus [<xref rid="B644" ref-type="bibr">644</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: in a Parkinson disease cell model [<xref rid="B645" ref-type="bibr">645</xref>] and in mice with Parkinson disease in vivo [<xref rid="B646" ref-type="bibr">646</xref>] and in a model of chronic unpredictable stress by inhibiting BDNF [<xref rid="B647" ref-type="bibr">647</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in retinal photoreceptor integrity [<xref rid="B648" ref-type="bibr">648</xref>&#8211;<xref rid="B651" ref-type="bibr">651</xref>]</td></tr><tr><td rowspan="1" colspan="1">Important for proper synaptic transmission [<xref rid="B652" ref-type="bibr">652</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in hearing loss [<xref rid="B653" ref-type="bibr">653</xref>&#8211;<xref rid="B656" ref-type="bibr">656</xref>]</td></tr><tr><td rowspan="1" colspan="1">plays a role in cell-fate determination in the inner ear of the zebrafish [<xref rid="B657" ref-type="bibr">657</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in circadian rhythm generation in vitro and in vivo in mice [<xref rid="B658" ref-type="bibr">658</xref>]</td></tr><tr><td rowspan="1" colspan="1">Influences the serotonin pathway through inhibition of 5-HT 1B receptors and 5-HT 3E receptor subunits [<xref rid="B659" ref-type="bibr">659</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-182</td><td rowspan="1" colspan="1">Neurodegenerative: in a model of chronic unpredictable stress by inhibiting BDNF [<xref rid="B647" ref-type="bibr">647</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in retinal photoreceptor integrity [<xref rid="B648" ref-type="bibr">648</xref>, <xref rid="B649" ref-type="bibr">649</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in hearing loss [<xref rid="B655" ref-type="bibr">655</xref>, <xref rid="B656" ref-type="bibr">656</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in cell-fate determination in the inner ear of the zebrafish [<xref rid="B657" ref-type="bibr">657</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in circadian rhythm generation in vitro and in vivo in mice [<xref rid="B658" ref-type="bibr">658</xref>]</td></tr><tr><td rowspan="6" colspan="1">miR-183</td><td rowspan="1" colspan="1">Anti-pain: in a neuropathic pain model (L5 spinal nerve ligation model) [<xref rid="B660" ref-type="bibr">660</xref>, <xref rid="B661" ref-type="bibr">661</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in retinal photoreceptor integrity [<xref rid="B648" ref-type="bibr">648</xref>&#8211;<xref rid="B650" ref-type="bibr">650</xref>]</td></tr><tr><td rowspan="1" colspan="1">Important for proper synaptic transmission [<xref rid="B652" ref-type="bibr">652</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in hearing loss [<xref rid="B655" ref-type="bibr">655</xref>, <xref rid="B656" ref-type="bibr">656</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in cell-fate determination in the inner ear of the zebrafish [<xref rid="B657" ref-type="bibr">657</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in circadian rhythm generation in vitro and in vivo in mice [<xref rid="B658" ref-type="bibr">658</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-351</td><td rowspan="1" colspan="1">Neurodegenerative: overexpression in hippocampus aggravated impairment of spatial learning and memory in aluminum neurotoxicity in rats [<xref rid="B662" ref-type="bibr">662</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T11" orientation="portrait"><label>Table 11.</label><caption><p>Exosome microRNA derived from Treg cells [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B490" ref-type="bibr">490</xref>, <xref rid="B630" ref-type="bibr">630</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="4" colspan="1">miR-16</td><td rowspan="1" colspan="1">Neurodegenerative: downregulates BDNF [<xref rid="B663" ref-type="bibr">663</xref>, <xref rid="B664" ref-type="bibr">664</xref>], inhibits neurogenesis in mouse hippocampus [<xref rid="B665" ref-type="bibr">665</xref>], blocks function of BDNF [<xref rid="B666" ref-type="bibr">666</xref>], TNF/IL-1&#946;-stimulated astrocytic exosomes contain miR-16-5p that inhibits NTKR3 and downstream Bcl2 [<xref rid="B667" ref-type="bibr">667</xref>], in a model of prion disease [<xref rid="B668" ref-type="bibr">668</xref>], in a spinal cord injury model [<xref rid="B669" ref-type="bibr">669</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: in a neuropathy model of spinal nerve ligation with microglia activation [<xref rid="B165" ref-type="bibr">165</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in a cell model of Alzheimer disease [<xref rid="B670" ref-type="bibr">670</xref>&#8211;<xref rid="B672" ref-type="bibr">672</xref>]</td></tr><tr><td rowspan="1" colspan="1">Reduces serotonin transporter protein/is involved in function of selective serotonin reuptake inhibitors [<xref rid="B673" ref-type="bibr">673</xref>, <xref rid="B674" ref-type="bibr">674</xref>]</td></tr><tr><td rowspan="8" colspan="1">miR-142-3p/5p</td><td rowspan="1" colspan="1">Anti-inflammatory: NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: inhibits neuroinflammation through HMGB1 [<xref rid="B546" ref-type="bibr">546</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in the sciatic nerve transection model [<xref rid="B547" ref-type="bibr">547</xref>], in a Parkinson disease model [<xref rid="B548" ref-type="bibr">548</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: in a chronic compression injury model [<xref rid="B549" ref-type="bibr">549</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a model of choroidal neovascularization and inflammation [<xref rid="B550" ref-type="bibr">550</xref>]</td></tr><tr><td rowspan="1" colspan="1">Enhances glutamatergic neurotransmission through IL-1&#946;-dependent synaptopathy in neuroinflammation [<xref rid="B551" ref-type="bibr">551</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits dopamine D1 receptor signaling [<xref rid="B552" ref-type="bibr">552</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits circadian protein BMAL1 and abolishes circadian oscillation [<xref rid="B553" ref-type="bibr">553</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-150-5p</td><td rowspan="1" colspan="1">Anti-pain: alleviates mechanical allodynia by targeting NOTCH2 in microglial cells [<xref rid="B463" ref-type="bibr">463</xref>&#8211;<xref rid="B465" ref-type="bibr">465</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in a Parkinson disease model [<xref rid="B466" ref-type="bibr">466</xref>, <xref rid="B467" ref-type="bibr">467</xref>] but also neurodegenerative in a dementia model [<xref rid="B468" ref-type="bibr">468</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-155-5p</td><td rowspan="1" colspan="1">Proinflammatory: deletion of miR-155-5p prevented EAE and attenuated microgliosis and neuronal loss in an &#945;-synuclein-driven Parkinson model [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: inhibits the negative regulators of Toll-like receptor 4, increase of cytokine production [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Psychological stress-provoking: blocking the miR led to resilient phenotype [<xref rid="B469" ref-type="bibr">469</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroinflammatory: blocks BNDF, stimulates NF-kB [<xref rid="B470" ref-type="bibr">470</xref>, <xref rid="B471" ref-type="bibr">471</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: supports cancer pain and hypersensitivity [<xref rid="B472" ref-type="bibr">472</xref>]</td></tr><tr><td rowspan="6" colspan="1">miR-195</td><td rowspan="1" colspan="1">Neurodegenerative: targets/downregulates BDNF [<xref rid="B663" ref-type="bibr">663</xref>], in a model of Alzheimer disease [<xref rid="B675" ref-type="bibr">675</xref>], in mice in vivo leading to decreased memory function [<xref rid="B676" ref-type="bibr">676</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: in a neuropathy model of spinal nerve ligation by upregulation of IL-1&#946;, TNF, and iNOS in microglia [<xref rid="B193" ref-type="bibr">193</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in a cell model of Alzheimer disease through inhibition of BACE1 [<xref rid="B677" ref-type="bibr">677</xref>], in an animal model bilateral common carotid artery occlusion [<xref rid="B678" ref-type="bibr">678</xref>, <xref rid="B679" ref-type="bibr">679</xref>], in a cell model of Parkinson disease [<xref rid="B680" ref-type="bibr">680</xref>], in a model of intracerebral hemorrhage [<xref rid="B681" ref-type="bibr">681</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits microglia M1 polarization [<xref rid="B682" ref-type="bibr">682</xref>]</td></tr><tr><td rowspan="1" colspan="1">Role in neurodevelopment using adult neural stem/progenitor cells [<xref rid="B683" ref-type="bibr">683</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supports the integrity of the blood-brain barrier by inhibiting thrombospondin-1 effects [<xref rid="B684" ref-type="bibr">684</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-let7b</td><td rowspan="1" colspan="1">Pro-pain: induces rapid inward currents and action potentials in sensory neurons in the DRG, mediators of sensitization and nociceptive signaling [<xref rid="B155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-let7d</td><td rowspan="1" colspan="1">Attenuate Th1 phenotype of CD4+ T cells by Cox-2-mediated inhibition of IFN&#947; [<xref rid="B630" ref-type="bibr">630</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T12" orientation="portrait"><label>Table 12.</label><caption><p>Exosome microRNA derived from B cells [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B488" ref-type="bibr">488</xref>, <xref rid="B490" ref-type="bibr">490</xref>] and effects on brain and brain-dependent functions</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="5" colspan="1">miR-26a-5p</td><td rowspan="1" colspan="1">Anti-pain: inhibits neuropathic pain through inhibition of MAPK6 in a chronic sciatic nerve injury model [<xref rid="B685" ref-type="bibr">685</xref>] and using a nanoparticle-mediated therapy [<xref rid="B686" ref-type="bibr">686</xref>]</td></tr><tr><td rowspan="1" colspan="1">neuroprotective: in a model of ischemia-reperfusion brain injury [<xref rid="B687" ref-type="bibr">687</xref>], in a Parkinson disease cell model [<xref rid="B688" ref-type="bibr">688</xref>], in a model with sevoflurane anesthesia [<xref rid="B689" ref-type="bibr">689</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: in an astrocyte/hippocampal neuron model [<xref rid="B690" ref-type="bibr">690</xref>], in hippocampal neurons [<xref rid="B691" ref-type="bibr">691</xref>]</td></tr><tr><td rowspan="1" colspan="1">Downregulates the endogenous mRNA of the glutamate transporter SLC1A1 [<xref rid="B692" ref-type="bibr">692</xref>]</td></tr><tr><td rowspan="1" colspan="1">Protects from stress-induced effects in the hippocampus [<xref rid="B693" ref-type="bibr">693</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-28-3p</td><td rowspan="1" colspan="1">Social defeat stress-resilient rats demonstrate reduced levels of miR-28-3p in the blood [<xref rid="B694" ref-type="bibr">694</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-29a-3p</td><td rowspan="1" colspan="1">Neuroprotective: inhibits the expression of TNF receptor type I mRNA and is neuroprotective in an oxygen-glucose deprivation/reoxygenation-induced injury cell model [<xref rid="B695" ref-type="bibr">695</xref>] and in a model of intracerebral hemorrhage [<xref rid="B696" ref-type="bibr">696</xref>] and in a neuron cell model of intracerebral hemorrhage with hemin [<xref rid="B697" ref-type="bibr">697</xref>], in a hypoxia-ischemia model in neonatal mice [<xref rid="B698" ref-type="bibr">698</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in microglia mouse BV-2 cells after lipopolysaccharide by inhibiting the NLRP3 inflammasome [<xref rid="B699" ref-type="bibr">699</xref>], reduces phagocytosis of mouse BV-2 microglial cells [<xref rid="B700" ref-type="bibr">700</xref>]</td></tr><tr><td rowspan="1" colspan="1">Links to Alzheimer&#8217;s disease [<xref rid="B700" ref-type="bibr">700</xref>, <xref rid="B701" ref-type="bibr">701</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-apoptotic in a human brain microvascular endothelial cell model of glucose deprivation [<xref rid="B702" ref-type="bibr">702</xref>]</td></tr><tr><td rowspan="1" colspan="1">Protects from hypothalamic obesity [<xref rid="B703" ref-type="bibr">703</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-29b-3p</td><td rowspan="1" colspan="1">Protects blood-brain barrier integrity [<xref rid="B560" ref-type="bibr">560</xref>]</td></tr><tr><td rowspan="1" colspan="1">Necessary for proper motor function [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="9" colspan="1">miR-29c-3p</td><td rowspan="1" colspan="1">Anti-inflammatory [<xref rid="B189" ref-type="bibr">189</xref>&#8211;<xref rid="B192" ref-type="bibr">192</xref>]</td></tr><tr><td rowspan="1" colspan="1">Linked to the neurodegenerative disease of multiple system atrophy contributing to neuroinflammation [<xref rid="B704" ref-type="bibr">704</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in an astrocyte cell line by inhibiting IL-1&#946;, IL-6, and TNF [<xref rid="B189" ref-type="bibr">189</xref>], in lipopolysaccharide-stimulated microglial cells by inhibiting the NLRP3 inflammasome [<xref rid="B192" ref-type="bibr">192</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: for neuronal cells by supporting neurite outgrowth in PC12 cells [<xref rid="B705" ref-type="bibr">705</xref>], in an Alzheimer&#8217;s disease hippocampal cell model [<xref rid="B706" ref-type="bibr">706</xref>&#8211;<xref rid="B708" ref-type="bibr">708</xref>], in a neuroblastoma cell model by inhibiting expression of TNF receptor type I [<xref rid="B709" ref-type="bibr">709</xref>], in a model with mouse hippocampal cells [<xref rid="B710" ref-type="bibr">710</xref>], in a cell model of Parkinson disease [<xref rid="B711" ref-type="bibr">711</xref>], in an in vivo Parkinson disease model [<xref rid="B712" ref-type="bibr">712</xref>], in a cell model with hippocampal NT22 cells [<xref rid="B713" ref-type="bibr">713</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: in a model with DRG neurons by inhibiting axonal growth under hyperglycemia [<xref rid="B714" ref-type="bibr">714</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increased in a stress model in humans [<xref rid="B715" ref-type="bibr">715</xref>]</td></tr><tr><td rowspan="1" colspan="1">Important regulator of dopamine-induced reward behavior in the nucleus accumbens [<xref rid="B716" ref-type="bibr">716</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increased in mindfulness-based stress reduction in neuron-derived extracellular vesicles [<xref rid="B717" ref-type="bibr">717</xref>]</td></tr><tr><td rowspan="1" colspan="1">Relevant in drug induced behavioral sensitization [<xref rid="B718" ref-type="bibr">718</xref>] by regulating neuroplasticity [<xref rid="B719" ref-type="bibr">719</xref>]</td></tr><tr><td rowspan="6" colspan="1">miR-30e-3p</td><td rowspan="1" colspan="1">Pro-apoptotic by decreasing expression of Bcl-2 in HEK-293 and NIH/3T3 cells [<xref rid="B720" ref-type="bibr">720</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in a Parkinson disease model by inhibiting neuroinflammation through the NLRP3 inflammasome [<xref rid="B721" ref-type="bibr">721</xref>] and in a neuroblastoma cell model [<xref rid="B722" ref-type="bibr">722</xref>]</td></tr><tr><td rowspan="1" colspan="1">Relevant in depression: negative regulator of the serotonin 1A receptor through a palmitoyl acyltransferase [<xref rid="B723" ref-type="bibr">723</xref>]</td></tr><tr><td rowspan="1" colspan="1">Relevant in neurodevelopment [<xref rid="B724" ref-type="bibr">724</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-30e-5p is downregulated in the medial prefrontal cortex of high-fat dieted mice [<xref rid="B725" ref-type="bibr">725</xref>]</td></tr><tr><td rowspan="1" colspan="1">Stress-vulnerable rats demonstrated low blood levels of miR-30e-5p [<xref rid="B694" ref-type="bibr">694</xref>]</td></tr><tr><td rowspan="7" colspan="1">miR-140-3p</td><td rowspan="1" colspan="1">Degenerative: in normal human astrocyte culture by inhibiting brain-derived neurotrophic factor [<xref rid="B726" ref-type="bibr">726</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neurodegenerative: in an Alzheimer disease model through inhibition of ADAM10 [<xref rid="B572" ref-type="bibr">572</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in human cortical neuronal cells [<xref rid="B727" ref-type="bibr">727</xref>], in a model of intracerebral hemorrhage and studied in primary oligodendrocyte progenitor cells [<xref rid="B728" ref-type="bibr">728</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supportive role in neurodevelopment for pyramidal neurons [<xref rid="B729" ref-type="bibr">729</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: in neonatal rats partly through proinflammatory effects and inhibition of TGF-&#946;3 [<xref rid="B730" ref-type="bibr">730</xref>]</td></tr><tr><td rowspan="1" colspan="1">Nicotine stimulates and ethanol inhibits this microRNA in mouse fetal murine cerebral cortical-derived neurosphere cultures [<xref rid="B731" ref-type="bibr">731</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: dexamethasone increases this microRNA in microglia BV-2 cells and this inhibits TLR4 levels [<xref rid="B732" ref-type="bibr">732</xref>]</td></tr><tr><td rowspan="6" colspan="1">miR-141-3p</td><td rowspan="1" colspan="1">Neurodegenerative: in a cell model with neuronal stem cells exposed to propofol [<xref rid="B733" ref-type="bibr">733</xref>], in a mouse model of ischemic stroke [<xref rid="B734" ref-type="bibr">734</xref>, <xref rid="B735" ref-type="bibr">735</xref>], stimulates apoptosis in a cell model of retinal ganglion cells [<xref rid="B736" ref-type="bibr">736</xref>], stimulates apoptosis in PC12 cells treated with 1-methyl-4-phenylpyridinium (a Parkinson cell model) [<xref rid="B737" ref-type="bibr">737</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: in neuropathy model with chronic constriction injury by inhibiting HMGB1 [<xref rid="B738" ref-type="bibr">738</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in human retinal pigment epithelial cells and retinal ganglion cells under UV oxidative stress [<xref rid="B739" ref-type="bibr">739</xref>], in a model of intracerebral hemorrhage in mice [<xref rid="B740" ref-type="bibr">740</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: inhibits HMGB1 and inflammatory cytokines in bacterial meningitis model and in vitro in primary astrocytes [<xref rid="B108" ref-type="bibr">108</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supportive role in neurodevelopment [<xref rid="B741" ref-type="bibr">741</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits growth hormone from a pituitary tumor cell line [<xref rid="B742" ref-type="bibr">742</xref>]</td></tr><tr><td rowspan="8" colspan="1">miR-142-3p/5p</td><td rowspan="1" colspan="1">Anti-inflammatory: NF-kB downregulation [<xref rid="B492" ref-type="bibr">492</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-pain: inhibits neuroinflammation through HMGB1 [<xref rid="B546" ref-type="bibr">546</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in the sciatic nerve transection model [<xref rid="B547" ref-type="bibr">547</xref>], in a Parkinson disease model [<xref rid="B548" ref-type="bibr">548</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: in a chronic compression injury model [<xref rid="B549" ref-type="bibr">549</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a model of choroidal neovascularization and inflammation [<xref rid="B550" ref-type="bibr">550</xref>]</td></tr><tr><td rowspan="1" colspan="1">Enhances glutamatergic neurotransmission through IL-1&#946;-dependent synaptopathy in neuroinflammation [<xref rid="B551" ref-type="bibr">551</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits dopamine D1 receptor signaling [<xref rid="B552" ref-type="bibr">552</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits circadian protein BMAL1 and abolishes circadian oscillation [<xref rid="B553" ref-type="bibr">553</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-146a-5p</td><td rowspan="1" colspan="1">Anti-inflammatory: inhibits the NF-kB pathway [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B439" ref-type="bibr">439</xref>], reduces phagocytosis of mouse BV-2 microglial cells [<xref rid="B700" ref-type="bibr">700</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective [<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B439" ref-type="bibr">439</xref>]</td></tr><tr><td rowspan="1" colspan="1">Protects blood-brain barrier [<xref rid="B439" ref-type="bibr">439</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-150-5p</td><td rowspan="1" colspan="1">Anti-pain: alleviates mechanical allodynia by targeting NOTCH2 in microglial cells [<xref rid="B463" ref-type="bibr">463</xref>&#8211;<xref rid="B465" ref-type="bibr">465</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective in a Parkinson disease model [<xref rid="B466" ref-type="bibr">466</xref>, <xref rid="B467" ref-type="bibr">467</xref>] but also neurodegenerative in a dementia model [<xref rid="B468" ref-type="bibr">468</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-155-5p</td><td rowspan="1" colspan="1">Proinflammatory: deletion of miR-155-5p prevented EAE and attenuated microgliosis and neuronal loss in an &#945;-synuclein-driven Parkinson model [<xref rid="B438" ref-type="bibr">438</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: inhibits the negative regulators of Toll-like receptor 4, increase of cytokine production [<xref rid="B91" ref-type="bibr">91</xref>]</td></tr><tr><td rowspan="1" colspan="1">Psychological stress-provoking: blocking the miR led to resilient phenotype [<xref rid="B469" ref-type="bibr">469</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroinflammatory: blocks BNDF, stimulates NF-kB [<xref rid="B470" ref-type="bibr">470</xref>, <xref rid="B471" ref-type="bibr">471</xref>]</td></tr><tr><td rowspan="1" colspan="1">Pro-pain: supports cancer pain and hypersensitivity [<xref rid="B472" ref-type="bibr">472</xref>]</td></tr><tr><td rowspan="7" colspan="1">miR-181a-3p/5p</td><td rowspan="1" colspan="1">Neurodegenerative: increases injury in a model of ischemic stroke in the mouse and rat [<xref rid="B743" ref-type="bibr">743</xref>, <xref rid="B744" ref-type="bibr">744</xref>], pro-apoptotic in astrocytes [<xref rid="B745" ref-type="bibr">745</xref>], in a model of forebrain ischemia [<xref rid="B746" ref-type="bibr">746</xref>], in an epilepsy model [<xref rid="B747" ref-type="bibr">747</xref>&#8211;<xref rid="B749" ref-type="bibr">749</xref>], in transient focal cerebral ischemia in mice [<xref rid="B750" ref-type="bibr">750</xref>, <xref rid="B751" ref-type="bibr">751</xref>], in mitochondrial diseases [<xref rid="B752" ref-type="bibr">752</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in a neuroblastoma cell model of Parkinson disease by inhibiting apoptosis/autophagy [<xref rid="B753" ref-type="bibr">753</xref>], in an oxygen-glucose deprivation model with neuroblastoma cells [<xref rid="B754" ref-type="bibr">754</xref>], in an Alzheimer&#8217;s disease model in APP/PS1 mice [<xref rid="B755" ref-type="bibr">755</xref>], in a model of EAE by inhibiting inflammation [<xref rid="B756" ref-type="bibr">756</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supports cocaine addiction in the nucleus accumbens [<xref rid="B757" ref-type="bibr">757</xref>]</td></tr><tr><td rowspan="1" colspan="1">Supports hippocampus-dependent memory formation [<xref rid="B758" ref-type="bibr">758</xref>]</td></tr><tr><td rowspan="1" colspan="1">Has a key role in synaptic function in the hippocampus [<xref rid="B759" ref-type="bibr">759</xref>, <xref rid="B760" ref-type="bibr">760</xref>]</td></tr><tr><td rowspan="1" colspan="1">Plays a role in neurodevelopment and neuronal differentiation [<xref rid="B761" ref-type="bibr">761</xref>&#8211;<xref rid="B764" ref-type="bibr">764</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increases anxiety-like behavior and alcohol intake in mice [<xref rid="B765" ref-type="bibr">765</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-181b-5p</td><td rowspan="1" colspan="1">Neurodegenerative: in a model of cerebral ischemia in vivo [<xref rid="B766" ref-type="bibr">766</xref>], in a neuroblastoma cell line [<xref rid="B766" ref-type="bibr">766</xref>], in mitochondrial diseases [<xref rid="B752" ref-type="bibr">752</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in an epilepsy model in vivo in rats [<xref rid="B767" ref-type="bibr">767</xref>, <xref rid="B768" ref-type="bibr">768</xref>], in a cell model of intracerebral hemorrhage by inhibiting endoplasmic reticulum stress [<xref rid="B769" ref-type="bibr">769</xref>], in an in vivo model of intracerebral hemorrhage [<xref rid="B769" ref-type="bibr">769</xref>], in a mouse model of postoperative cognitive dysfunction [<xref rid="B770" ref-type="bibr">770</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in the hippocampus [<xref rid="B770" ref-type="bibr">770</xref>], in a cell model of lipopolysaccharide-stimulated microglia [<xref rid="B771" ref-type="bibr">771</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-193b</td><td rowspan="1" colspan="1">Neuroprotective: in a model of cerebral ischemia-reperfusion injury in rats by inhibiting 5-lipoxygenase [<xref rid="B267" ref-type="bibr">267</xref>] and by reducing apoptosis/autophagy/ferroptosis [<xref rid="B268" ref-type="bibr">268</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits sympathetic outflow and hypertension from the rostral ventrolateral medulla in hypertensive rats [<xref rid="B627" ref-type="bibr">627</xref>]</td></tr><tr><td rowspan="4" colspan="1">miR-221-3p/5p</td><td rowspan="1" colspan="1">Peripheral nerve repair: promotes Schwann cell proliferation after sciatic nerve injury [<xref rid="B524" ref-type="bibr">524</xref>, <xref rid="B525" ref-type="bibr">525</xref>], inhibits Schwan cell myelination [<xref rid="B526" ref-type="bibr">526</xref>], in the presence of chondroitin sulfate proteoglycans in the model of sciatic nerve conditioning injury [<xref rid="B527" ref-type="bibr">527</xref>]</td></tr><tr><td rowspan="1" colspan="1">Neuroprotective: in brain-ischemic rats and hypoxia cell model by inhibiting apoptosis [<xref rid="B528" ref-type="bibr">528</xref>], in a Parkinson disease model [<xref rid="B529" ref-type="bibr">529</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-inflammatory: in a cell model through the target gene TNFAIP2 [<xref rid="B177" ref-type="bibr">177</xref>] and in middle cerebral artery occlusion in rats [<xref rid="B178" ref-type="bibr">178</xref>]</td></tr><tr><td rowspan="1" colspan="1">Promotes depression-like behavior in mice [<xref rid="B530" ref-type="bibr">530</xref>]</td></tr><tr><td rowspan="5" colspan="1">miR-222a-3p</td><td rowspan="1" colspan="1">Neuroprotective: in DRG neurons [<xref rid="B772" ref-type="bibr">772</xref>, <xref rid="B773" ref-type="bibr">773</xref>], in a model of radiation-injury of auditory cells [<xref rid="B774" ref-type="bibr">774</xref>], in a neuronal cell model of spinal cord injury by inhibiting apoptosis [<xref rid="B775" ref-type="bibr">775</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: stimulating proinflammatory cytokines from lipopolysaccharide-activated microglia cells [<xref rid="B776" ref-type="bibr">776</xref>]</td></tr><tr><td rowspan="1" colspan="1">Reduces phosphodiesterase 3A expression and protein in cerebral microvascular endothelial cells [<xref rid="B777" ref-type="bibr">777</xref>]</td></tr><tr><td rowspan="1" colspan="1">Role in neurodevelopment [<xref rid="B778" ref-type="bibr">778</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits methamphetamine-induced addiction behavior [<xref rid="B779" ref-type="bibr">779</xref>, <xref rid="B780" ref-type="bibr">780</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-339-3p</td><td rowspan="1" colspan="1">Inhibits the &#181;-opioid receptor level in a cell line [<xref rid="B781" ref-type="bibr">781</xref>]</td></tr><tr><td rowspan="3" colspan="1">miR-342-3p</td><td rowspan="1" colspan="1">Neurodegenerative: in a mouse model of Alzheimer&#8217;s disease [<xref rid="B782" ref-type="bibr">782</xref>], in a coculture model of microglia and neuronal cells [<xref rid="B783" ref-type="bibr">783</xref>]</td></tr><tr><td rowspan="1" colspan="1">Proinflammatory: in a microglia cell line through upregulation of NFkB and TNF [<xref rid="B783" ref-type="bibr">783</xref>]</td></tr><tr><td rowspan="1" colspan="1">High levels of this microRNA are related to elevated TNF levels in hippocampal microglia and depressive-like behavior [<xref rid="B784" ref-type="bibr">784</xref>]</td></tr><tr><td rowspan="2" colspan="1">miR-361-3p</td><td rowspan="1" colspan="1">Neuroprotective: in an Alzheimer&#8217;s disease cell model [<xref rid="B785" ref-type="bibr">785</xref>]</td></tr><tr><td rowspan="1" colspan="1">Inhibits production of follicle-stimulating hormone in pig anterior pituitary cells [<xref rid="B786" ref-type="bibr">786</xref>]</td></tr><tr><td rowspan="1" colspan="1">miR-361-5p</td><td rowspan="1" colspan="1">Neurodegenerative: in a cell model of cerebral ischemia and reperfusion injury in PC12 cells [<xref rid="B787" ref-type="bibr">787</xref>], in a retinal ganglion precursor-like cell line [<xref rid="B788" ref-type="bibr">788</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The mentioned microRNAs are not complete.</p></fn><fn><p>DRG, dorsal root ganglion; EAE, experimental autoimmune encephalomyelitis.</p></fn></table-wrap-foot></table-wrap><p>Concerning these effects, the author distinguishes between positive (antidepressive, anti-inflammatory, anti-pain, neuroprotective, peripheral nerve repair, nerve regeneration, anti-addiction) and negative influences on the brain (pro-pain, proinflammatory or neuroinflammatory, demyelinating, increased permeability of blood-brain barrier, psychological stress provoking). Effects of immune cells on central nervous structures can be remote and initiated in secondary lymphoid organs in the periphery, but immune cell effects might also be local within the brain after passage of these cells through the blood-brain barrier.</p><p>The picture of positive and negative effects is much more variable as compared to the relative conclusive inhibitory effects of the brain on the immune system (<xref rid="F2" ref-type="fig">Fig. 2</xref>). It is impressive that M1 and M2 macrophages are clearly different since M2 macrophages are presented in publications more often with microRNAs that have positive effects on the CNS (<xref rid="F2" ref-type="fig">Fig. 2</xref>c). Most immune cells were demonstrated in more publications having microRNAs with positive effects than negative ones (<xref rid="F2" ref-type="fig">Fig. 2</xref>c). Particularly, B cells show a clear preponderance of publications that demonstrate microRNAs with positive effects.</p><p>Some microRNAs of immune cells have clear effects on stress such as the miR-17&#8764;92 cluster from M1 macrophages, monocytes, and T cells [<xref rid="B448" ref-type="bibr">448</xref>], the miR-218 from neutrophils [<xref rid="B577" ref-type="bibr">577</xref>, <xref rid="B578" ref-type="bibr">578</xref>, <xref rid="B586" ref-type="bibr">586</xref>], and the miR-26a-5p of B cells [<xref rid="B693" ref-type="bibr">693</xref>]. Some microRNAs from immune cells are stress provoking such as miR-155-5p of M1 macrophages, dendritic cells, monocytes, T cells, Treg cells, and B cells [<xref rid="B469" ref-type="bibr">469</xref>].</p><p>Some microRNAs of immune cells influence the circadian clock machinery such as miR-24-3p of M2 macrophages and dendritic cells [<xref rid="B495" ref-type="bibr">495</xref>], the miR-142-3p of dendritic cells, neutrophils, T cells, Treg cells, and B cells [<xref rid="B553" ref-type="bibr">553</xref>], the miR-25 of T cells [<xref rid="B495" ref-type="bibr">495</xref>], and the miR-96/182/183 cluster of T-helper type 17 cells [<xref rid="B658" ref-type="bibr">658</xref>].</p><p>In addition, microRNA of immune cells can manipulate the influence of the brain by indirect pathways through adrenocortical steroidogenesis [<xref rid="B638" ref-type="bibr">638</xref>, <xref rid="B789" ref-type="bibr">789</xref>], adrenergic receptor signaling [<xref rid="B790" ref-type="bibr">790</xref>&#8211;<xref rid="B796" ref-type="bibr">796</xref>], endogenous glucocorticoid regulation [<xref rid="B557" ref-type="bibr">557</xref>, <xref rid="B797" ref-type="bibr">797</xref>], central manipulation of the sympathetic nervous outflow [<xref rid="B454" ref-type="bibr">454</xref>, <xref rid="B627" ref-type="bibr">627</xref>], and sensory nervous signaling to the brain. Concerning sensory signaling, one can distinguish in microRNAs that support or inhibit pain pathways (literature is given in <xref rid="T4" ref-type="table">Tables 4</xref>&#8211;<xref rid="T12" ref-type="table">12</xref>).</p><p>Some microRNAs of immune cells can have direct effects on mental memory like the miR-17&#8764;92 cluster of monocytes and T cells [<xref rid="B448" ref-type="bibr">448</xref>], the miR-26a-5p of B cells [<xref rid="B693" ref-type="bibr">693</xref>], and the miR-335-5p of T cells [<xref rid="B628" ref-type="bibr">628</xref>, <xref rid="B629" ref-type="bibr">629</xref>]. Some have effects on cognition like miR-34c-5p of M1 macrophages [<xref rid="B457" ref-type="bibr">457</xref>] and miR-99a of M2 macrophages [<xref rid="B497" ref-type="bibr">497</xref>]. In summary, there may be enormous possibilities for crosstalk between immune cells and various cells in the CNS.</p></sec><sec id="s3-4"><title>Some Thoughts about Experiments in Neuroimmunomodulation</title><p>The following suggestions are certainly far away from complete, but they might give an idea how experiments with exosome microRNA in neuroimmunomodulation can look like. These suggestions stress the idea of the bidirectional interaction between brain and immune system. They might also touch the metabolic field to better understand the egoism of brain and immune system regarding energy distribution in the body.</p></sec><sec id="s3-5"><title>From the Brain to the Immune System</title><p>For a complete experiment, that shows in vivo neuroimmunomodulation, one needs to define the exact source of exosome microRNA under specific circumstances such as psychological stress, neurodegenerative disease, psychiatric disease, and brain tumor (the study of infection will be discussed in the next paragraph). The origin of exosome microRNA might be in the brain, in peripheral nerve endings, or in brain-dependent endocrine glands. In vivo, it needs to be studied that the specific exosome microRNA is released into the blood stream (from the brain), released from peripheral efferent nerve endings, or secreted from endocrine organs through the influence of the brain. If there are enough exosomes, separation of exosomes and characterization of cargo should be possible. Defined exosomes or their cargo microRNA are injected into genetically identical recipients with a normal or stimulated immune system (antigen [infections], autoantigen, or autoinflammatory). Readout parameters are on the side of the immune system in locations such as primary/secondary lymphoid organs or inflamed tissue. Studies on immune cells in vitro should complement these in vivo experiments. A respective study has been recently published [<xref rid="B798" ref-type="bibr">798</xref>].</p></sec><sec id="s3-6"><title>From the Immune System to the Brain</title><p>Vice versa, one needs to define the cellular source of exosome microRNA from activated immune cells (antigen [infection], autoantigen, or autoinflammatory). From these immune cells, exosomes and microRNA cargo can be easily characterized because numbers of immune cells are often high. Exosomes with known microRNA should be injected into genetically identical recipients. Now, the central nervous uptake of exosome microRNA should be studied in the recipient and the location of accumulation in the CNS should be detected. The recipients can have a normally functioning brain or a model brain disease (infectious brain disease, psychological stress, neurodegenerative disease, psychiatric disease, and brain tumor). Readout parameters are on the side of the CNS. These in vivo experiments should be complemented by studies on brain-derived cells in vitro.</p></sec><sec sec-type="conclusions" id="s4"><title>Conclusions</title><p>This review builds on former ideas of a bidirectional crosstalk of exosomal cargo including microRNA between the brain and the immune system contrived in stress research [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. It was the wish of the author to demonstrate possibilities of bidirectional interaction, while knowing that most of these interactions have not yet been studied in exact detail, particularly not in vivo. This review builds upon the logic that microRNA &#8211; in exosomes &#8211; can be easily transferred from brain structures to immune cells and vice versa. In most occasions given in <xref rid="T1" ref-type="table">Tables 1</xref>&#8211;<xref rid="T12" ref-type="table">12</xref>, these interactions are theoretical because respective experiments of origin and target of microRNA have never been carried out in one single study in vivo. Nevertheless, sometimes experiment follows theory such as in high-energy particle physics (e.g., Higgs boson). In summary, microRNA-accomplished bidirectional interactions can be a new fruitful way of neuroimmunomodulation.</p></sec><sec sec-type="COI-statement" id="s5"><title>Conflict of Interest Statement</title><p>Prof. Rainer H. Straub was a member of the journal&#8217;s Editorial Board at the time of submission.</p></sec><sec sec-type="funding sources" id="s6"><title>Funding Sources</title><p>The work has been funded by institutional money of the University Hospital of Regensburg. The institute had no influence on study design, execution and analysis, manuscript conception, planning, writing, and decision to publish.</p></sec><sec sec-type="author contributions" id="s7"><title>Author Contributions</title><p>The author has carried out all searches of the literature, has written the draft manuscript, provided all tables, and created the figures.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schiller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ben-Shaanan</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Rolls</surname><given-names>A</given-names></string-name></person-group>. <article-title>Neuronal regulation of immunity: why, how and where?</article-title><source>Nat Rev Immunol</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>20</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">32811994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0387-1</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dantzer</surname><given-names>R</given-names></string-name></person-group>. <article-title>Neuroimmune interactions: from the brain to the immune system and vice versa</article-title>. <source>Physiol Rev</source>. <year>2018</year>;<volume>98</volume>(<issue>1</issue>):<fpage>477</fpage>&#8211;<lpage>504</lpage>.<pub-id pub-id-type="pmid">29351513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00039.2016</pub-id><pub-id pub-id-type="pmcid">PMC5866360</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pan</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Johnstone</surname><given-names>RM</given-names></string-name></person-group>. <article-title>Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes</article-title>. <source>J Cell Biol</source>. <year>1985</year>;<volume>101</volume>(<issue>3</issue>):<fpage>942</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">2993317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.101.3.942</pub-id><pub-id pub-id-type="pmcid">PMC2113705</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Johnstone</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hammond</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Orr</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Turbide</surname><given-names>C</given-names></string-name></person-group>. <article-title>Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)</article-title>. <source>J Biol Chem</source>. <year>1987</year>;<volume>262</volume>(<issue>19</issue>):<fpage>9412</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">3597417</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Denzer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kleijmeer</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Heijnen</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Stoorvogel</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Geuze</surname><given-names>HJ</given-names></string-name></person-group>. <article-title>Exosome: from internal vesicle of the multivesicular body to intercellular signaling device</article-title>. <source>J Cell Sci</source>. <year>2000</year>;<volume>113 Pt 19</volume>(<issue>Pt 19</issue>):<fpage>3365</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">10984428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.113.19.3365</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raposo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nijman</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Stoorvogel</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liejendekker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Harding</surname><given-names>CV</given-names></string-name>, <string-name name-style="western"><surname>Melief</surname><given-names>CJ</given-names></string-name>, <etal/></person-group>. <article-title>B lymphocytes secrete antigen-presenting vesicles</article-title>. <source>J Exp Med</source>. <year>1996</year>;<volume>183</volume>(<issue>3</issue>):<fpage>1161</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">8642258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.183.3.1161</pub-id><pub-id pub-id-type="pmcid">PMC2192324</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karlsson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lundin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dahlgren</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Kahu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Pettersson</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Telemo</surname><given-names>E</given-names></string-name></person-group>. <article-title>&#8220;Tolerosomes&#8221; are produced by intestinal epithelial cells</article-title>. <source>Eur J Immunol</source>. <year>2001</year>;<volume>31</volume>(<issue>10</issue>):<fpage>2892</fpage>&#8211;<lpage>900</lpage>.<pub-id pub-id-type="pmid">11592064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-4141(2001010)31:10&lt;2892::aid-immu2892&gt;3.0.co;2-i</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mathew</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Johnstone</surname><given-names>RM</given-names></string-name></person-group>. <article-title>Hsp-70 is closely associated with the transferrin receptor in exosomes from maturing reticulocytes</article-title>. <source>Biochem J</source>. <year>1995</year>;<volume>308</volume>(<issue>Pt 3</issue>):<fpage>823</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">8948438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/bj3080823</pub-id><pub-id pub-id-type="pmcid">PMC1136798</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Th&#233;ry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Regnault</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Garin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wolfers</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zitvogel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73</article-title>. <source>J Cell Biol</source>. <year>1999</year>;<volume>147</volume>(<issue>3</issue>):<fpage>599</fpage>&#8211;<lpage>610</lpage>.<pub-id pub-id-type="pmid">10545503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.147.3.599</pub-id><pub-id pub-id-type="pmcid">PMC2151184</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Th&#233;ry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Boussac</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>V&#233;ron</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Raposo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Garin</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles</article-title>. <source>J Immunol</source>. <year>2001</year>;<volume>166</volume>(<issue>12</issue>):<fpage>7309</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">11390481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.166.12.7309</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wubbolts</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Leckie</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Veenhuizen</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Schwarzmann</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>M&#246;bius</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hoernschemeyer</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>13</issue>):<fpage>10963</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">12519789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M207550200</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zitvogel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Regnault</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lozier</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wolfers</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Flament</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tenza</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes</article-title>. <source>Nat Med</source>. <year>1998</year>;<volume>4</volume>(<issue>5</issue>):<fpage>594</fpage>&#8211;<lpage>600</lpage>.<pub-id pub-id-type="pmid">9585234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm0598-594</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Valadi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ekstr&#246;m</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bossios</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sj&#246;strand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>L&#246;tvall</surname><given-names>JO</given-names></string-name></person-group>. <article-title>Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells</article-title>. <source>Nat Cell Biol</source>. <year>2007</year>;<volume>9</volume>(<issue>6</issue>):<fpage>654</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17486113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncb1596</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Makrygianni</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Chrousos</surname><given-names>GP</given-names></string-name></person-group>. <article-title>Extracellular vesicles and the stress system</article-title>. <source>Neuroendocrinology</source>. <year>2023</year>;<volume>113</volume>(<issue>2</issue>):<fpage>120</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">36137504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000527182</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beninson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Fleshner</surname><given-names>M</given-names></string-name></person-group>. <article-title>Exosomes: an emerging factor in stress-induced immunomodulation</article-title>. <source>Semin Immunol</source>. <year>2014</year>;<volume>26</volume>(<issue>5</issue>):<fpage>394</fpage>&#8211;<lpage>401</lpage>.<pub-id pub-id-type="pmid">24405946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smim.2013.12.001</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fleshner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Crane</surname><given-names>CR</given-names></string-name></person-group>. <article-title>Exosomes, DAMPs and miRNA: features of stress physiology and immune homeostasis</article-title>. <source>Trends Immunol</source>. <year>2017</year>;<volume>38</volume>(<issue>10</issue>):<fpage>768</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">28838855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2017.08.002</pub-id><pub-id pub-id-type="pmcid">PMC5624844</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dexheimer</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Cochella</surname><given-names>L</given-names></string-name></person-group>. <article-title>MicroRNAs: from mechanism to organism</article-title>. <source>Front Cell Dev Biol</source>. <year>2020</year>;<volume>8</volume>:<fpage>409</fpage>.<pub-id pub-id-type="pmid">32582699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2020.00409</pub-id><pub-id pub-id-type="pmcid">PMC7283388</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siddiq</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Balan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Jex</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Olivier</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>A thermo-resistant and RNase-sensitive cargo from Giardia duodenalis extracellular vesicles modifies the behaviour of enterobacteria</article-title>. <source>J Extracell Biol</source>. <year>2023</year>;<volume>2</volume>(<issue>9</issue>):<fpage>e109</fpage>.<pub-id pub-id-type="pmid">38938375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jex2.109</pub-id><pub-id pub-id-type="pmcid">PMC11080815</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schuh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Aguayo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zavala</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Khoury</surname><given-names>M</given-names></string-name></person-group>. <article-title>Exosome-like vesicles in Apis mellifera bee pollen, honey and royal jelly contribute to their antibacterial and pro-regenerative activity</article-title>. <source>J Exp Biol</source>. <year>2019</year>;<volume>222</volume>(<issue>Pt 20</issue>):<fpage>jeb208702</fpage>.<pub-id pub-id-type="pmid">31537653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jeb.208702</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nymon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barnaby</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bashor</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hampton</surname><given-names>TH</given-names></string-name>, <etal/></person-group>. <article-title>Let-7b-5p in vesicles secreted by human airway cells reduces biofilm formation and increases antibiotic sensitivity of P. aeruginosa</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2021</year>;<volume>118</volume>(<issue>28</issue>):<fpage>e2105370118</fpage>.<pub-id pub-id-type="pmid">34260396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2105370118</pub-id><pub-id pub-id-type="pmcid">PMC8285967</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kalargyrou</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Guilfoyle</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Extracellular vesicles in the retina - putative roles in physiology and disease</article-title>. <source>Front Mol Neurosci</source>. <year>2022</year>;<volume>15</volume>:<fpage>1042469</fpage>.<pub-id pub-id-type="pmid">36710933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2022.1042469</pub-id><pub-id pub-id-type="pmcid">PMC9877344</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gurung</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Perocheau</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Touramanidou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Baruteau</surname><given-names>J</given-names></string-name></person-group>. <article-title>The exosome journey: from biogenesis to uptake and intracellular signalling</article-title>. <source>Cell Commun Signal</source>. <year>2021</year>;<volume>19</volume>(<issue>1</issue>):<fpage>47</fpage>.<pub-id pub-id-type="pmid">33892745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-021-00730-1</pub-id><pub-id pub-id-type="pmcid">PMC8063428</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Colombo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Raposo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Th&#233;ry</surname><given-names>C</given-names></string-name></person-group>. <article-title>Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles</article-title>. <source>Annu Rev Cell Dev Biol</source>. <year>2014</year>;<volume>30</volume>:<fpage>255</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">25288114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-cellbio-101512-122326</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arya</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Collie</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Parent</surname><given-names>CA</given-names></string-name></person-group>. <article-title>The ins-and-outs of exosome biogenesis, secretion, and internalization</article-title>. <source>Trends Cell Biol</source>. <year>2024</year>;<volume>34</volume>(<issue>2</issue>):<fpage>90</fpage>&#8211;<lpage>108</lpage>.<pub-id pub-id-type="pmid">37507251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2023.06.006</pub-id><pub-id pub-id-type="pmcid">PMC10811273</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heusermann</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hean</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Trojer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Steib</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>von Bueren</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Graff-Meyer</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER</article-title>. <source>J Cell Biol</source>. <year>2016</year>;<volume>213</volume>(<issue>2</issue>):<fpage>173</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">27114500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201506084</pub-id><pub-id pub-id-type="pmcid">PMC5084269</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tkach</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kowal</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zucchetti</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Enserink</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jouve</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lankar</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes</article-title>. <source>Embo J</source>. <year>2017</year>;<volume>36</volume>(<issue>20</issue>):<fpage>3012</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">28923825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.201696003</pub-id><pub-id pub-id-type="pmcid">PMC5641679</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Munich</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sobo-Vujanovic</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Buchser</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Beer-Stolz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vujanovic</surname><given-names>NL</given-names></string-name></person-group>. <article-title>Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands</article-title>. <source>Oncoimmunology</source>. <year>2012</year>;<volume>1</volume>(<issue>7</issue>):<fpage>1074</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">23170255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/onci.20897</pub-id><pub-id pub-id-type="pmcid">PMC3494621</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Segura</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Nicco</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lombard</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>V&#233;ron</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Raposo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Batteux</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming</article-title>. <source>Blood</source>. <year>2005</year>;<volume>106</volume>(<issue>1</issue>):<fpage>216</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">15790784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2005-01-0220</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Exosomes exploit the virus entry machinery and pathway to transmit alpha interferon-induced antiviral activity</article-title>. <source>J Virol</source>. <year>2018</year>;<volume>92</volume>(<issue>24</issue>):<fpage>e01578-18</fpage>.<pub-id pub-id-type="pmid">30282711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01578-18</pub-id><pub-id pub-id-type="pmcid">PMC6258946</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Niel</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Raposo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Candalh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Boussac</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hershberg</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cerf-Bensussan</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Intestinal epithelial cells secrete exosome-like vesicles</article-title>. <source>Gastroenterology</source>. <year>2001</year>;<volume>121</volume>(<issue>2</issue>):<fpage>337</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">11487543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/gast.2001.26263</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Van Niel</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mallegol</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bevilacqua</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Candalh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Brugi&#232;re</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tomaskovic-Crook</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice</article-title>. <source>Gut</source>. <year>2003</year>;<volume>52</volume>(<issue>12</issue>):<fpage>1690</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">14633944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.52.12.1690</pub-id><pub-id pub-id-type="pmcid">PMC1773888</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shin</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YK</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JG</given-names></string-name></person-group>. <article-title>Extracellular vesicles derived from small intestinal lamina propria reduce antigen-specific immune response</article-title>. <source>Korean J Intern Med</source>. <year>2022</year>;<volume>37</volume>(<issue>1</issue>):<fpage>85</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">34425655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3904/kjim.2020.510</pub-id><pub-id pub-id-type="pmcid">PMC8747917</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rahman</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Regn</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bashratyan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>YD</given-names></string-name></person-group>. <article-title>Exosomes released by islet-derived mesenchymal stem cells trigger autoimmune responses in NOD mice</article-title>. <source>Diabetes</source>. <year>2014</year>;<volume>63</volume>(<issue>3</issue>):<fpage>1008</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">24170696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db13-0859</pub-id><pub-id pub-id-type="pmcid">PMC3931393</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cesca</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Loers</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Schweizer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Buck</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Benfenati</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Synapsin I is an oligomannose-carrying glycoprotein, acts as an oligomannose-binding lectin, and promotes neurite outgrowth and neuronal survival when released via glia-derived exosomes</article-title>. <source>J Neurosci</source>. <year>2011</year>;<volume>31</volume>(<issue>20</issue>):<fpage>7275</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21593312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.6476-10.2011</pub-id><pub-id pub-id-type="pmcid">PMC6622588</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fiandaca</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Kapogiannis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mapstone</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Boxer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Eitan</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>JB</given-names></string-name>, <etal/></person-group>. <article-title>Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>(<issue>6</issue>):<fpage>600</fpage>&#8211;<lpage>7.e1</lpage>.<pub-id pub-id-type="pmid">25130657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.06.008</pub-id><pub-id pub-id-type="pmcid">PMC4329112</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dall&#233;rac</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rampon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Doy&#232;re</surname><given-names>V</given-names></string-name></person-group>. <article-title>NCAM function in the adult brain: lessons from mimetic peptides and therapeutic potential</article-title>. <source>Neurochem Res</source>. <year>2013</year>;<volume>38</volume>(<issue>6</issue>):<fpage>1163</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">23494903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-013-1007-2</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kiselyov</surname><given-names>VV</given-names></string-name></person-group>. <article-title>NCAM and the FGF-receptor</article-title>. <source>Adv Exp Med Biol</source>. <year>2010</year>;<volume>663</volume>:<fpage>67</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">20017015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4419-1170-4_4</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Levy</surname><given-names>S</given-names></string-name></person-group>. <article-title>Function of the tetraspanin molecule CD81 in B and T cells</article-title>. <source>Immunol Res</source>. <year>2014</year>;<volume>58</volume>(<issue>2&#8211;3</issue>):<fpage>179</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">24522698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-014-8490-7</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>The Nobel Assembly at Karolinska Institutet</collab></person-group>. <source>The Nobel prize in physiology or medicine 2024 stoickholm, Sweden: karolinska institutet</source>; <year>2024</year>. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nobelprize.org/prizes/medicine/2024/press-release/" ext-link-type="uri">https://www.nobelprize.org/prizes/medicine/2024/press-release/</ext-link></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gallo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tandon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alevizos</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Illei</surname><given-names>GG</given-names></string-name></person-group>. <article-title>The majority of microRNAs detectable in serum and saliva is concentrated in exosomes</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>e30679</fpage>.<pub-id pub-id-type="pmid">22427800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0030679</pub-id><pub-id pub-id-type="pmcid">PMC3302865</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ingolia</surname><given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Weissman</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></string-name></person-group>. <article-title>Mammalian microRNAs predominantly act to decrease target mRNA levels</article-title>. <source>Nature</source>. <year>2010</year>;<volume>466</volume>(<issue>7308</issue>):<fpage>835</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">20703300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature09267</pub-id><pub-id pub-id-type="pmcid">PMC2990499</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Cutolo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Buttgereit</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pongratz</surname><given-names>G</given-names></string-name></person-group>. <article-title>Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases</article-title>. <source>J Intern Med</source>. <year>2010</year>;<volume>267</volume>(<issue>6</issue>):<fpage>543</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">20210843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2796.2010.02218.x</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases</article-title>. <source>Brain Behav Immun</source>. <year>2011</year>;<volume>25</volume>:<fpage>1</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">20705130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2010.08.002</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Evolutionary medicine and chronic inflammatory state &#8211; known and new concepts in pathophysiology</article-title>. <source>J Mol Med</source>. <year>2012</year>;<volume>90</volume>(<issue>5</issue>):<fpage>523</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">22271169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-012-0861-8</pub-id><pub-id pub-id-type="pmcid">PMC3354326</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Interaction of the endocrine system with inflammation: a function of energy and volume regulation</article-title>. <source>Arthritis Res Ther</source>. <year>2014</year>;<volume>16</volume>(<issue>1</issue>):<fpage>203</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">24524669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/ar4484</pub-id><pub-id pub-id-type="pmcid">PMC3978663</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name></person-group>. <article-title>Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases</article-title>. <source>Arthritis Res Ther</source>. <year>2014</year>;<volume>16</volume>(<issue>Suppl 2</issue>):<fpage>S4</fpage>.<pub-id pub-id-type="pmid">25608958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/ar4688</pub-id><pub-id pub-id-type="pmcid">PMC4249495</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name></person-group><source>The origin of chronic inflammatory systemic diseases and their sequelae(Hrsg.)</source>. <publisher-loc>San Diego</publisher-loc>: <publisher-name>Academic Press</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Schradin</surname><given-names>C</given-names></string-name></person-group>. <article-title>Chronic inflammatory systemic diseases: an evolutionary trade-off between acutely beneficial but chronically harmful programs</article-title>. <source>Evol Med Public Health</source>. <year>2016</year>;<volume>2016</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">26817483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/emph/eow001</pub-id><pub-id pub-id-type="pmcid">PMC4753361</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name></person-group>. <article-title>The brain and immune system prompt energy shortage in chronic inflammation and ageing</article-title>. <source>Nat Rev Rheumatol</source>. <year>2017</year>;<volume>13</volume>(<issue>12</issue>):<fpage>743</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">29021568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrrheum.2017.172</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peters</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schweiger</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Pellerin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hubold</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Oltmanns</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Conrad</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>The selfish brain: competition for energy resources</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2004</year>;<volume>28</volume>(<issue>2</issue>):<fpage>143</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">15172762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2004.03.002</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fenckov&#225;</surname><given-names>M</given-names></string-name></person-group>. <article-title>When the &#8220;selfish&#8221; brain and the &#8220;selfish&#8221; immune system clash</article-title>. <source>Nat Rev Neurosci</source>. <year>2025</year>;<volume>26</volume>(<issue>3</issue>):<fpage>140</fpage>.<pub-id pub-id-type="pmid">39695246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-024-00900-3</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yamagata</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Mansur</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Rizzo</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Rosenstock</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McIntyre</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Brietzke</surname><given-names>E</given-names></string-name></person-group>. <article-title>Selfish brain and selfish immune system interplay: a theoretical framework for metabolic comorbidities of mood disorders</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2017</year>;<volume>72</volume>:<fpage>43</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27871787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2016.11.010</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name></person-group>. <article-title>The memory of the fatty acid system</article-title>. <source>Prog Lipid Res</source>. <year>2020</year>;<volume>79</volume>:<fpage>101049</fpage>.<pub-id pub-id-type="pmid">32589906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.plipres.2020.101049</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krarup</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Araya</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>&#193;lvarez</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>B&#243;rquez</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Urrutia</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>A brain anti-senescence transcriptional program triggered by hypothalamic-derived exosomal microRNAs</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>10</issue>):<fpage>5467</fpage>.<pub-id pub-id-type="pmid">38791505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25105467</pub-id><pub-id pub-id-type="pmcid">PMC11122052</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nie</surname><given-names>M</given-names></string-name></person-group>. <article-title>LncRNA ARFRP1 knockdown inhibits LPS-induced the injury of chondrocytes by regulation of NF-&#954;B pathway through modulating miR-15a-5p/TLR4 axis</article-title>. <source>Life Sci</source>. <year>2020</year>;<volume>261</volume>:<fpage>118429</fpage>.<pub-id pub-id-type="pmid">32931797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.118429</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonz&#225;lez-L&#243;pez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>&#193;lvarez-Villarreal</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ruiz-Sim&#243;n</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez-Pastor</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>de Ceniga</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Esparza</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Role of miR-15a-5p and miR-199a-3p in the inflammatory pathway regulated by NF-&#954;B in experimental and human atherosclerosis</article-title>. <source>Clin Transl Med</source>. <year>2023</year>;<volume>13</volume>(<issue>8</issue>):<fpage>e1363</fpage>.<pub-id pub-id-type="pmid">37605307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ctm2.1363</pub-id><pub-id pub-id-type="pmcid">PMC10442475</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name></person-group>. <article-title>ADRB2 suppresses IL-13-induced allergic rhinitis inflammatory cytokine regulated by miR-15a-5p</article-title>. <source>Hum Cell</source>. <year>2019</year>;<volume>32</volume>(<issue>3</issue>):<fpage>306</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">31104300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13577-019-00259-z</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>miR-15a-5p suppresses inflammation and fibrosis of peritoneal mesothelial cells induced by peritoneal dialysis via targeting VEGFA</article-title>. <source>J Cell Physiol</source>. <year>2019</year>;<volume>234</volume>(<issue>6</issue>):<fpage>9746</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">30362573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.27660</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Coactivator-associated arginine methyltransferase 1 targeted by miR-15a regulates inflammation in acute coronary syndrome</article-title>. <source>Atherosclerosis</source>. <year>2014</year>;<volume>233</volume>(<issue>2</issue>):<fpage>349</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">24530761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2014.01.039</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moon</surname><given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>Y</given-names></string-name></person-group>. <article-title>miR-15a/16 regulates macrophage phagocytosis after bacterial infection</article-title>. <source>J Immunol</source>. <year>2014</year>;<volume>193</volume>(<issue>9</issue>):<fpage>4558</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">25261473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1401372</pub-id><pub-id pub-id-type="pmcid">PMC4216178</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>miR-15a/16 are upreuglated in the serum of neonatal sepsis patients and inhibit the LPS-induced inflammatory pathway</article-title>. <source>Int J Clin Exp Med</source>. <year>2015</year>;<volume>8</volume>(<issue>4</issue>):<fpage>5683</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">26131152</pub-id><pub-id pub-id-type="pmcid">PMC4483976</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Increased M1 macrophages in young miR-15a/16(-/-) mice with tumour grafts or dextran sulphate sodium-induced colitis</article-title>. <source>Scand J Immunol</source>. <year>2018</year>;<volume>88</volume>(<issue>3</issue>):<fpage>e12703</fpage>.<pub-id pub-id-type="pmid">30047999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/sji.12703</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gamdzyk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Doycheva</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Travis</surname><given-names>ZD</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>GW0742 activates miR-17-5p and inhibits TXNIP/NLRP3-mediated inflammation after hypoxic-ischaemic injury in rats and in PC12 cells</article-title>. <source>J Cell Mol Med</source>. <year>2020</year>;<volume>24</volume>(<issue>21</issue>):<fpage>12318</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">33034416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.15698</pub-id><pub-id pub-id-type="pmcid">PMC7686982</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>ZR</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schisandrin</surname><given-names>B</given-names></string-name></person-group>. <article-title>Schisandrin B attenuates inflammation in LPS-induced sepsis through miR-17-5p downregulating TLR4</article-title>. <source>Inflammation</source>. <year>2019</year>;<volume>42</volume>(<issue>2</issue>):<fpage>731</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30506107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-018-0931-3</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pimenta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Camargo</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Ghazarian</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Candido</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Guimar&#227;es</surname><given-names>VR</given-names></string-name>, <etal/></person-group>. <article-title>Overexpression of miR-17-5p may negatively impact p300/CBP factor-associated inflammation in a hypercholesterolemic advanced prostate cancer model</article-title>. <source>Mol Biol Rep</source>. <year>2023</year>;<volume>50</volume>(<issue>9</issue>):<fpage>7333</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">37439896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-023-08638-4</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Men</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>miR-20a-5p ameliorates ovalbumin (OVA)-induced mouse model of allergic asthma through targeting ATG7-regulated cell death, fibrosis and inflammation</article-title>. <source>Int Immunopharmacol</source>. <year>2021</year>;<volume>95</volume>:<fpage>107342</fpage>.<pub-id pub-id-type="pmid">33684878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.107342</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-20a-5p overexpression prevented diabetic cardiomyopathy via inhibition of cardiomyocyte apoptosis, hypertrophy, fibrosis and JNK/NF-&#954;B signalling pathway</article-title>. <source>J Biochem</source>. <year>2021</year>;<volume>170</volume>(<issue>3</issue>):<fpage>349</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">33837411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jb/mvab047</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>PLGA microspheres carrying miR-20a-5p improved intestinal epithelial barrier function in patients with Crohn's disease through STAT3-mediated inhibition of Th17 differentiation</article-title>. <source>Int Immunopharmacol</source>. <year>2022</year>;<volume>110</volume>:<fpage>109025</fpage>.<pub-id pub-id-type="pmid">35853280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2022.109025</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Exosomes from adipose-derived mesenchymal stem cells improve liver fibrosis by regulating the miR-20a-5p/TGFBR2 axis to affect the p38 MAPK/NF-&#954;B pathway</article-title>. <source>Cytokine</source>. <year>2023</year>;<volume>172</volume>:<fpage>156386</fpage>.<pub-id pub-id-type="pmid">37852157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2023.156386</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miranda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mehrpouya-Bahrami</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Nagarkatti</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Nagarkatti</surname><given-names>M</given-names></string-name></person-group>. <article-title>Cannabinoid receptor 1 blockade attenuates obesity and adipose tissue type 1 inflammation through miR-30e-5p regulation of delta-like-4 in macrophages and consequently downregulation of Th1 cells</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1049</fpage>.<pub-id pub-id-type="pmid">31134094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01049</pub-id><pub-id pub-id-type="pmcid">PMC6523050</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>H</given-names></string-name></person-group>. <article-title>miR-30e-5p alleviates inflammation and cardiac dysfunction after myocardial infarction through targeting PTEN</article-title>. <source>Inflammation</source>. <year>2021</year>;<volume>44</volume>(<issue>2</issue>):<fpage>769</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">33180227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01376-w</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>S</given-names></string-name></person-group>. <article-title>miR-30e-5p attenuates neuronal deficit and inflammation of rats with intracerebral hemorrhage by regulating TLR4</article-title>. <source>Exp Ther Med</source>. <year>2022</year>;<volume>24</volume>(<issue>2</issue>):<fpage>492</fpage>.<pub-id pub-id-type="pmid">35837037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2022.11419</pub-id><pub-id pub-id-type="pmcid">PMC9257744</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>miR-103a-3p could attenuate sepsis-induced liver injury by targeting HMGB1</article-title>. <source>Inflammation</source>. <year>2020</year>;<volume>43</volume>(<issue>6</issue>):<fpage>2075</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">32556802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01275-0</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>F</given-names></string-name></person-group>. <article-title>Exosomal miR-103a-3p ameliorates lipopolysaccharide-induced immune response in BEAS-2B cells via NF-&#954;B pathway by targeting transducin &#946;-like 1X related protein 1</article-title>. <source>Clin Exp Pharmacol Physiol</source>. <year>2020</year>;<volume>47</volume>(<issue>4</issue>):<fpage>620</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31876003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1440-1681.13241</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Hepatitis A virus-induced hsa-miR-146a-5p attenuates IFN-&#946; signaling by targeting adaptor protein TRAF6</article-title>. <source>Arch Virol</source>. <year>2021</year>;<volume>166</volume>(<issue>3</issue>):<fpage>789</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="pmid">33459883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00705-021-04952-z</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name></person-group>. <article-title>miR-146a-5p negatively regulates the IL-1&#946;-stimulated inflammatory response via downregulation of the IRAK1/TRAF6 signaling pathway in human intestinal epithelial cells</article-title>. <source>Exp Ther Med</source>. <year>2022</year>;<volume>24</volume>(<issue>4</issue>):<fpage>615</fpage>.<pub-id pub-id-type="pmid">36160881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2022.11552</pub-id><pub-id pub-id-type="pmcid">PMC9468834</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis</article-title>. <source>Hum Cell</source>. <year>2021</year>;<volume>34</volume>(<issue>5</issue>):<fpage>1360</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">34052997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13577-021-00547-7</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bhaumik</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>GK</given-names></string-name>, <string-name name-style="western"><surname>Schokrpur</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Orjalo</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Rodier</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8</article-title>. <source>Aging</source>. <year>2009</year>;<volume>1</volume>(<issue>4</issue>):<fpage>402</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">20148189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.100042</pub-id><pub-id pub-id-type="pmcid">PMC2818025</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></string-name></person-group>. <article-title>MicroRNA-146a-5p attenuates irradiation-induced and LPS-induced hepatic stellate cell activation and hepatocyte apoptosis through inhibition of TLR4 pathway</article-title>. <source>Cell Death Dis</source>. <year>2018</year>;<volume>9</volume>(<issue>2</issue>):<fpage>22</fpage>.<pub-id pub-id-type="pmid">29348414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-017-0038-z</pub-id><pub-id pub-id-type="pmcid">PMC5833436</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dubois-Camacho</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Diaz-Jimenez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>De la Fuente</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Quera</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Simian</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;nez</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Inhibition of miR-378a-3p by inflammation enhances IL-33 levels: a novel mechanism of alarmin modulation in ulcerative colitis</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>2449</fpage>.<pub-id pub-id-type="pmid">31824476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02449</pub-id><pub-id pub-id-type="pmcid">PMC6879552</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Targeting M2 macrophages alleviates airway inflammation and remodeling in asthmatic mice via miR-378a-3p/GRB2 pathway</article-title>. <source>Front Mol Biosci</source>. <year>2021</year>;<volume>8</volume>:<fpage>717969</fpage>.<pub-id pub-id-type="pmid">34589519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2021.717969</pub-id><pub-id pub-id-type="pmcid">PMC8473897</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>JZ</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>WQ</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Mesenchymal stem cells-derived extracellular vesicles containing miR-378a-3p inhibit the occurrence of inflammatory bowel disease by targeting GATA2</article-title>. <source>J Cell Mol Med</source>. <year>2022</year>;<volume>26</volume>(<issue>11</issue>):<fpage>3133</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">35582765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.17176</pub-id><pub-id pub-id-type="pmcid">PMC9170824</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zuniga-Hertz</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Hypothalamic stem cells control ageing speed partly through exosomal miRNAs</article-title>. <source>Nature</source>. <year>2017</year>;<volume>548</volume>(<issue>7665</issue>):<fpage>52</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28746310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature23282</pub-id><pub-id pub-id-type="pmcid">PMC5999038</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Choi</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Ha</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>MiR-30a-5p and miR-153-3p regulate LPS-induced neuroinflammatory response and neuronal apoptosis by targeting NeuroD1</article-title>. <source>BMB Rep</source>. <year>2022</year>;<volume>55</volume>(<issue>9</issue>):<fpage>447</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">35651331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5483/BMBRep.2022.55.9.061</pub-id><pub-id pub-id-type="pmcid">PMC9537026</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-30a-5p ameliorates LPS-induced inflammatory injury in human A549 cells and mice via targeting RUNX2</article-title>. <source>Innate Immun</source>. <year>2021</year>;<volume>27</volume>(<issue>1</issue>):<fpage>41</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">33232195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1753425920971347</pub-id><pub-id pub-id-type="pmcid">PMC7780354</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name></person-group>. <article-title>MiR-30a-5p ameliorates spinal cord injury-induced inflammatory responses and oxidative stress by targeting Neurod 1 through MAPK/ERK signalling</article-title>. <source>Clin Exp Pharmacol Physiol</source>. <year>2018</year>;<volume>45</volume>:<fpage>68</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">28925510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1440-1681.12856</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname><given-names>H</given-names></string-name></person-group>. <article-title>Combination of baicalein and miR-106a-5p mimics significantly alleviates IL-1&#946;-induced inflammatory injury in CHON-001 cells</article-title>. <source>Exp Ther Med</source>. <year>2021</year>;<volume>21</volume>(<issue>4</issue>):<fpage>345</fpage>.<pub-id pub-id-type="pmid">33732318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2021.9776</pub-id><pub-id pub-id-type="pmcid">PMC7903477</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>MiR-106a-5p targets PFKFB3 and improves sepsis through regulating macrophage pyroptosis and inflammatory response</article-title>. <source>J Biol Chem</source>. <year>2024</year>;<volume>300</volume>(<issue>6</issue>):<fpage>107334</fpage>.<pub-id pub-id-type="pmid">38705396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2024.107334</pub-id><pub-id pub-id-type="pmcid">PMC11190718</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Moran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Marb&#225;n</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Melmed</surname><given-names>S</given-names></string-name></person-group>. <article-title>Pituitary somatotroph adenoma-derived exosomes: characterization of nonhormonal actions</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2022</year>;<volume>107</volume>(<issue>2</issue>):<fpage>379</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">34467411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgab651</pub-id><pub-id pub-id-type="pmcid">PMC8764361</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Exosomal hsa-miR-21-5p derived from growth hormone-secreting pituitary adenoma promotes abnormal bone formation in acromegaly</article-title>. <source>Transl Res</source>. <year>2020</year>;<volume>215</volume>:<fpage>1</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">31469974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2019.07.013</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Momen-Heravi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bala</surname><given-names>S</given-names></string-name></person-group>. <article-title>miRNA regulation of innate immunity</article-title>. <source>J Leukoc Biol</source>. <year>2018</year>;<volume>103</volume>(<issue>6</issue>):<fpage>1205</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.3MIR1117-459R</pub-id><pub-id pub-id-type="pmid">29656417</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ge</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>miR-21-5p alleviates leakage of injured brain microvascular endothelial barrier in vitro through suppressing inflammation and apoptosis</article-title>. <source>Brain Res</source>. <year>2016</year>;<volume>1650</volume>:<fpage>31</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">27421180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2016.07.015</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cui</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Brucella Omp25 upregulates miR-155, miR-21-5p, and miR-23b to inhibit interleukin-12 production via modulation of programmed death-1 signaling in human monocyte/macrophages</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>8</volume>:<fpage>708</fpage>.<pub-id pub-id-type="pmid">28694807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00708</pub-id><pub-id pub-id-type="pmcid">PMC5483987</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>CH</given-names></string-name></person-group>. <article-title>Myostatin promotes interleukin-1&#946; expression in rheumatoid arthritis synovial fibroblasts through inhibition of miR-21-5p</article-title>. <source>Front Immunol</source>. <year>2017</year>;<volume>8</volume>:<fpage>1747</fpage>.<pub-id pub-id-type="pmid">29276516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.01747</pub-id><pub-id pub-id-type="pmcid">PMC5727021</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>X</given-names></string-name></person-group>. <article-title>MiR-21-5p regulates mycobacterial survival and inflammatory responses by targeting Bcl-2 and TLR4 in Mycobacterium tuberculosis-infected macrophages</article-title>. <source>FEBS Lett</source>. <year>2019</year>;<volume>593</volume>(<issue>12</issue>):<fpage>1326</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">31090056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1873-3468.13438</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xue</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>miR-21-5p inhibits inflammation injuries in LPS-treated H9c2 cells by regulating PDCD4</article-title>. <source>Am J Transl Res</source>. <year>2021</year>;<volume>13</volume>(<issue>10</issue>):<fpage>11450</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">34786071</pub-id><pub-id pub-id-type="pmcid">PMC8581922</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Neuron-derived exosomes with high miR-21-5p expression promoted polarization of M1 microglia in culture</article-title>. <source>Brain Behav Immun</source>. <year>2020</year>;<volume>83</volume>:<fpage>270</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">31707083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2019.11.004</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>S</given-names></string-name></person-group>. <article-title>The role of the miR-21-5p-mediated inflammatory pathway in ulcerative colitis</article-title>. <source>Exp Ther Med</source>. <year>2020</year>;<volume>19</volume>(<issue>2</issue>):<fpage>981</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">32010260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2019.8277</pub-id><pub-id pub-id-type="pmcid">PMC6966149</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name></person-group>. <article-title>Knockdown of long noncoding RNA GAS5 protects human cardiomyocyte-like AC16 cells against high glucose-induced inflammation by inhibiting miR-21-5p-mediated TLR4/NF-&#954;B signaling</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source>. <year>2020</year>;<volume>393</volume>(<issue>8</issue>):<fpage>1541</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31865425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00210-019-01795-z</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Hua</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>YL</given-names></string-name>, <etal/></person-group>. <article-title>Bone marrow-derived mesenchymal stem cell-derived exosome-loaded miR-129-5p targets high-mobility group box 1 attenuates neurological-impairment after diabetic cerebral hemorrhage</article-title>. <source>World J Diabetes</source>. <year>2024</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1979</fpage>&#8211;<lpage>2001</lpage>.<pub-id pub-id-type="pmid">39280179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4239/wjd.v15.i9.1979</pub-id><pub-id pub-id-type="pmcid">PMC11372641</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>X</given-names></string-name></person-group>. <article-title>Effects of miR-129-5p on inflammation and nucleus pulposus cell apoptosis in rats with intervertebral disc degeneration through JNK signaling pathway</article-title>. <source>Cell Mol Biol</source>. <year>2024</year>;<volume>70</volume>(<issue>4</issue>):<fpage>164</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.14715/cmb/2024.70.4.26</pub-id><pub-id pub-id-type="pmid">38678607</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kuang</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Circ_0001714 knockdown alleviates lipopolysaccharide-induced apoptosis and inflammation in renal tubular epithelial cells via miR-129-5p/TRAF6 axis in septic acute kidney injury</article-title>. <source>J Bioenerg Biomembr</source>. <year>2023</year>;<volume>55</volume>(<issue>4</issue>):<fpage>289</fpage>&#8211;<lpage>300</lpage>.<pub-id pub-id-type="pmid">37526815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10863-023-09975-6</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wei</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wiredu Ocansey</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis</article-title>. <source>J Nanobiotechnology</source>. <year>2023</year>;<volume>21</volume>(<issue>1</issue>):<fpage>188</fpage>.<pub-id pub-id-type="pmid">37303049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-01951-x</pub-id><pub-id pub-id-type="pmcid">PMC10259042</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name></person-group>. <article-title>MiR-129-5p prevents depressive-like behaviors by targeting MAPK1 to suppress inflammation</article-title>. <source>Exp Brain Res</source>. <year>2021</year>;<volume>239</volume>(<issue>11</issue>):<fpage>3359</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">34482419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00221-021-06203-8</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeng</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>miR-129-5p targets Wnt5a to block PKC/ERK/NF-&#954;B and JNK pathways in glioblastoma</article-title>. <source>Cell Death Dis</source>. <year>2018</year>;<volume>9</volume>(<issue>3</issue>):<fpage>394</fpage>.<pub-id pub-id-type="pmid">29531296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-018-0343-1</pub-id><pub-id pub-id-type="pmcid">PMC5847604</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chuan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>miR-129-5p alleviates LPS-induced acute kidney injury via targeting HMGB1/TLRs/NF-kappaB pathway</article-title>. <source>Int Immunopharmacol</source>. <year>2020</year>;<volume>89</volume>(<issue>Pt A</issue>):<fpage>107016</fpage>.<pub-id pub-id-type="pmid">33039954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.107016</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wa</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Downregulation of miR-141-3p promotes bone metastasis via activating NF-&#954;B signaling in prostate cancer</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2017</year>;<volume>36</volume>(<issue>1</issue>):<fpage>173</fpage>.<pub-id pub-id-type="pmid">29202848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-017-0645-7</pub-id><pub-id pub-id-type="pmcid">PMC5716366</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhuo</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>miR-141-3p inhibits the activation of astrocytes and the release of inflammatory cytokines in bacterial meningitis through down-regulating HMGB1</article-title>. <source>Brain Res</source>. <year>2021</year>;<volume>1770</volume>:<fpage>147611</fpage>.<pub-id pub-id-type="pmid">34403663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2021.147611</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name></person-group>. <article-title>miR-141-3p alleviates ulcerative colitis by targeting SUGT1 to inhibit colonic epithelial cell pyroptosis</article-title>. <source>Autoimmunity</source>. <year>2023</year>;<volume>56</volume>(<issue>1</issue>):<fpage>2220988</fpage>.<pub-id pub-id-type="pmid">37317573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08916934.2023.2220988</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>C</given-names></string-name></person-group>. <article-title>miR-141-3p attenuates inflammation and oxidative stress-induced pulmonary fibrosis in ARDS via the Keap1/Nrf2/ARE signaling pathway</article-title>. <source>Immunol Res</source>. <year>2024</year>;<volume>72</volume>(<issue>5</issue>):<fpage>1003</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">38865000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-024-09503-7</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bahmani</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Baghi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peymani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Javeri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ghaedi</surname><given-names>K</given-names></string-name></person-group>. <article-title>MiR-141-3p and miR-200a-3p are involved in Th17 cell differentiation by negatively regulating RARB expression</article-title>. <source>Hum Cell</source>. <year>2021</year>;<volume>34</volume>(<issue>5</issue>):<fpage>1375</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">34086186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13577-021-00558-4</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hua</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>miR-183-5p alleviates early injury after intracerebral hemorrhage by inhibiting heme oxygenase-1 expression</article-title>. <source>Aging</source>. <year>2020</year>;<volume>12</volume>(<issue>13</issue>):<fpage>12869</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">32602850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103343</pub-id><pub-id pub-id-type="pmcid">PMC7377845</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ding</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name></person-group>. <article-title>Extracellular vesicles derived from bone marrow mesenchymal stem cells alleviate neuroinflammation after diabetic intracerebral hemorrhage via the miR-183-5p/PDCD4/NLRP3 pathway</article-title>. <source>J Endocrinol Investig</source>. <year>2021</year>;<volume>44</volume>(<issue>12</issue>):<fpage>2685</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">34024028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40618-021-01583-8</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>D</given-names></string-name></person-group>. <article-title>LPS promotes the progression of sepsis by activation of lncRNA HULC/miR-204-5p/TRPM7 network in HUVECs</article-title>. <source>Biosci Rep</source>. <year>2020</year>;<volume>40</volume>(<issue>6</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20200740</pub-id><pub-id pub-id-type="pmcid">PMC7295636</pub-id><pub-id pub-id-type="pmid">32484206</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>Z</given-names></string-name></person-group>. <article-title>LncRNA NEAT1 regulates the proliferation and production of the inflammatory cytokines in rheumatoid arthritis fibroblast-like synoviocytes by targeting miR-204-5p</article-title>. <source>Hum Cell</source>. <year>2021</year>;<volume>34</volume>(<issue>2</issue>):<fpage>372</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">33394349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13577-020-00461-4</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Ko</surname><given-names>CY</given-names></string-name>, <etal/></person-group>. <article-title>Nesfatin-1 facilitates IL-1&#946; production in osteoarthritis synovial fibroblasts by suppressing miR-204-5p synthesis through the AP-1 and NF-&#954;B pathways</article-title>. <source>Aging</source>. <year>2021</year>;<volume>13</volume>(<issue>18</issue>):<fpage>22490</fpage>&#8211;<lpage>501</lpage>.<pub-id pub-id-type="pmid">34560673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.203559</pub-id><pub-id pub-id-type="pmcid">PMC8507299</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Silencing long non-coding RNA Kcnq1ot1 limits acute kidney injury by promoting miR-204-5p and blocking the activation of NLRP3 inflammasome</article-title>. <source>Front Physiol</source>. <year>2021</year>;<volume>12</volume>:<fpage>721524</fpage>.<pub-id pub-id-type="pmid">34858199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2021.721524</pub-id><pub-id pub-id-type="pmcid">PMC8632456</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>miR-204-5p is sponged by TUG1 to aggravate neuron damage induced by focal cerebral ischemia and reperfusion injury through upregulating COX2</article-title>. <source>Cell Death Discov</source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>89</fpage>.<pub-id pub-id-type="pmid">35228515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-022-00885-x</pub-id><pub-id pub-id-type="pmcid">PMC8885635</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>L</given-names></string-name></person-group>. <article-title>miR-204-5p inhibits inflammation of synovial fibroblasts in osteoarthritis by suppressing FOXC1</article-title>. <source>J Orthop Sci</source>. <year>2022</year>;<volume>27</volume>(<issue>4</issue>):<fpage>921</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">34045139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jos.2021.03.014</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name></person-group>. <article-title>Protective effect of miR-340-5p against brain injury after intracerebral hemorrhage by targeting PDCD4</article-title>. <source>Cerebrovasc Dis</source>. <year>2020</year>;<volume>49</volume>(<issue>6</issue>):<fpage>593</fpage>&#8211;<lpage>600</lpage>.<pub-id pub-id-type="pmid">33176298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000508210</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qian</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Excess administration of miR-340-5p ameliorates spinal cord injury-induced neuroinflammation and apoptosis by modulating the P38-MAPK signaling pathway</article-title>. <source>Brain Behav Immun</source>. <year>2020</year>;<volume>87</volume>:<fpage>531</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">32014577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2020.01.025</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-340-5p inhibits M&#252;ller cell activation and pro-inflammatory cytokine production by targeting BMP4 in experimental diabetic retinopathy</article-title>. <source>Cytokine</source>. <year>2022</year>;<volume>149</volume>:<fpage>155745</fpage>.<pub-id pub-id-type="pmid">34689058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2021.155745</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>P</given-names></string-name></person-group>. <article-title>MiR-340-5p alleviates neuroinflammation and neuronal injury via suppressing STING in subarachnoid hemorrhage</article-title>. <source>Brain Behav</source>. <year>2022</year>;<volume>12</volume>(<issue>9</issue>):<fpage>e2687</fpage>.<pub-id pub-id-type="pmid">35957622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.2687</pub-id><pub-id pub-id-type="pmcid">PMC9480905</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Di</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hirman</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Duo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhai</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>MiR-375-3p alleviates the severity of inflammation through targeting YAP1/LEKTI pathway in HaCaT cells</article-title>. <source>Biosci Biotechnol Biochem</source>. <year>2020</year>;<volume>84</volume>(<issue>10</issue>):<fpage>2005</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">32564679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09168451.2020.1783196</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name></person-group>. <article-title>Calycosin attenuates lipopolysaccharide-induced acute lung injury in mice through the miR-375-3p/ROCK2 Axis</article-title>. <source>J Invest Surg</source>. <year>2023</year>;<volume>36</volume>(<issue>1</issue>):<fpage>2211166</fpage>.<pub-id pub-id-type="pmid">37400250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08941939.2023.2211166</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kaisi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mengzhen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiaming</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huirong</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>miR-375-3p targets YWHAB to attenuate intestine injury in neonatal necrotizing enterocolitis</article-title>. <source>Pediatr Surg Int</source>. <year>2024</year>;<volume>40</volume>(<issue>1</issue>):<fpage>63</fpage>.<pub-id pub-id-type="pmid">38431920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00383-024-05653-9</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bian</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name></person-group>. <article-title>SNHG14 elevates NFAT5 expression through sequestering miR-375-3p to promote MPP + -induced neuronal apoptosis, inflammation, and oxidative stress in Parkinson's disease</article-title>. <source>Neurochem Res</source>. <year>2024</year>;<volume>49</volume>(<issue>5</issue>):<fpage>1212</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">38381247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-024-04106-y</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Downregulation of miR-497-5p prevents liver ischemia-reperfusion injury in association with MED1/TIMP-2 axis and the NF-&#954;B pathway</article-title>. <source>Faseb j</source>. <year>2021</year>;<volume>35</volume>(<issue>4</issue>):<fpage>e21180</fpage>.<pub-id pub-id-type="pmid">33715222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202001029R</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name></person-group>. <article-title>Downregulation of miR-497-5p improves sepsis-induced acute lung injury by targeting IL2RB</article-title>. <source>BioMed Res Int</source>. <year>2021</year>;<volume>2021</volume>:<fpage>6624702</fpage>.<pub-id pub-id-type="pmid">33954185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/6624702</pub-id><pub-id pub-id-type="pmcid">PMC8057895</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>A</given-names></string-name></person-group>. <article-title>Mesenchymal stem cells-derived exosomes prevent sepsis-induced myocardial injury by a CircRTN4/miR-497-5p/MG53 pathway</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2022</year>;<volume>618</volume>:<fpage>133</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">35724457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2022.05.094</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name></person-group>. <article-title>MiR-497-5p regulates ox-LDL-induced dysfunction in vascular endothelial cells by targeting VEGFA/p38/MAPK pathway in atherosclerosis</article-title>. <source>Heliyon</source>. <year>2024</year>;<volume>10</volume>(<issue>7</issue>):<fpage>e28887</fpage>.<pub-id pub-id-type="pmid">38601630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e28887</pub-id><pub-id pub-id-type="pmcid">PMC11004747</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wendlandt</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Graff</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Gioannini</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>McCaffrey</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>ME</given-names></string-name></person-group>. <article-title>The role of microRNAs miR-200b and miR-200c in TLR4 signaling and NF-&#954;B activation</article-title>. <source>Innate Immun</source>. <year>2012</year>;<volume>18</volume>(<issue>6</issue>):<fpage>846</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">22522429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1753425912443903</pub-id><pub-id pub-id-type="pmcid">PMC3733339</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hillman</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mazkereth</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Farberov</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shomron</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fishelson</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Regulation of complement-dependent cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217</article-title>. <source>J Immunol</source>. <year>2016</year>;<volume>196</volume>(<issue>12</issue>):<fpage>5156</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">27183614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1502701</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>miR-200b inhibits TNF-&#945;-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitro</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2017</year>;<volume>312</volume>(<issue>2</issue>):<fpage>G123</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27979826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpgi.00316.2016</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>XT</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>XL</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>XH</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>WZ</given-names></string-name>, <etal/></person-group>. <article-title>Inhibition of miR-200b/miR-429 contributes to neuropathic pain development through targeting zinc finger E box binding protein-1</article-title>. <source>J Cell Physiol</source>. <year>2018</year>;<volume>233</volume>(<issue>6</issue>):<fpage>4815</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">29150958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.26284</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matsui</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nakayama</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mezawa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>MiR-200b attenuates IL-6 production through IKK&#946; and ZEB1 in human gingival fibroblasts</article-title>. <source>Inflamm Res</source>. <year>2018</year>;<volume>67</volume>(<issue>11&#8211;12</issue>):<fpage>965</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">30306207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00011-018-1192-1</pub-id><pub-id pub-id-type="pmcid">PMC6223877</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>MiR-200b in heme oxygenase-1-modified bone marrow mesenchymal stem cell-derived exosomes alleviates inflammatory injury of intestinal epithelial cells by targeting high mobility group box 3</article-title>. <source>Cell Death Dis</source>. <year>2020</year>;<volume>11</volume>(<issue>6</issue>):<fpage>480</fpage>.<pub-id pub-id-type="pmid">32587254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-2685-8</pub-id><pub-id pub-id-type="pmcid">PMC7316799</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duan</surname><given-names>XJ</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YP</given-names></string-name></person-group>. <article-title>MiR-200a and miR-200b restrain inflammation by targeting ORMDL3 to regulate the ERK/MMP-9 pathway in asthma</article-title>. <source>Exp Lung Res</source>. <year>2020</year>;<volume>46</volume>(<issue>9</issue>):<fpage>321</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">32820688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01902148.2020.1778816</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Z</given-names></string-name></person-group>. <article-title>miR-200b-3p alleviates TNF-&#945;-induced apoptosis and inflammation of intestinal epithelial cells and ulcerative colitis progression in rats via negatively regulating KHDRBS1</article-title>. <source>Cytotechnology</source>. <year>2021</year>;<volume>73</volume>(<issue>5</issue>):<fpage>727</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">34629748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10616-021-00490-3</pub-id><pub-id pub-id-type="pmcid">PMC8492882</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chang</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Tzang</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Tzang</surname><given-names>BS</given-names></string-name></person-group>. <article-title>Unraveling the role of miR-200b-3p in attention-deficit/hyperactivity disorder (ADHD) and its therapeutic potential in spontaneously hypertensive rats (SHR)</article-title>. <source>Biomedicines</source>. <year>2024</year>;<volume>12</volume>(<issue>1</issue>):<fpage>144</fpage>.<pub-id pub-id-type="pmid">38255250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines12010144</pub-id><pub-id pub-id-type="pmcid">PMC10813109</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wei</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gou</surname><given-names>W</given-names></string-name></person-group>. <article-title>miR-200b-3p relieved inflammation in patients with heart failure by regulating ZEB1 expression</article-title>. <source>J Cardiothorac Surg</source>. <year>2024</year>;<volume>19</volume>(<issue>1</issue>):<fpage>271</fpage>.<pub-id pub-id-type="pmid">38702771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13019-024-02628-8</pub-id><pub-id pub-id-type="pmcid">PMC11067240</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Sin</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Hsueh</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>WY</given-names></string-name></person-group>. <article-title>miR-200b-3p accelerates diabetic wound healing through anti-inflammatory and pro-angiogenic effects</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2024</year>;<volume>731</volume>:<fpage>150388</fpage>.<pub-id pub-id-type="pmid">39024974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2024.150388</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>CZ</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>XX</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>XY</given-names></string-name>, <etal/></person-group>. <article-title>miR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2017</year>;<volume>32</volume>(<issue>12</issue>):<fpage>1966</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">28370348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.13797</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ping</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name></person-group>. <article-title>miR-200b/c attenuates lipopolysaccharide-induced early pulmonary fibrosis by targeting ZEB1/2 via p38 MAPK and TGF-&#946;/smad3 signaling pathways</article-title>. <source>Lab Invest</source>. <year>2018</year>;<volume>98</volume>(<issue>3</issue>):<fpage>339</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">29200203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/labinvest.2017.123</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>YN</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>GH</given-names></string-name></person-group>. <article-title>MiR-200b/c family inhibits renal fibrosis through modulating epithelial-to-mesenchymal transition via targeting fascin-1/CD44 axis</article-title>. <source>Life Sci</source>. <year>2020</year>;<volume>252</volume>:<fpage>117589</fpage>.<pub-id pub-id-type="pmid">32220622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.117589</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>MiR-200b modulates the properties of human monocyte-derived dendritic cells by targeting WASF3</article-title>. <source>Life Sci</source>. <year>2015</year>;<volume>122</volume>:<fpage>26</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">25510861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2014.11.023</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>The role of hippocampal niche exosomes in rat hippocampal neurogenesis after fimbria-fornix transection</article-title>. <source>J Biol Chem</source>. <year>2021</year>;<volume>296</volume>:<fpage>100188</fpage>.<pub-id pub-id-type="pmid">33334882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.RA120.015561</pub-id><pub-id pub-id-type="pmcid">PMC7948408</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Di</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name></person-group>. <article-title>miR-339-5p inhibits alcohol-induced brain inflammation through regulating NF-&#954;B pathway</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2014</year>;<volume>452</volume>(<issue>3</issue>):<fpage>450</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">25172655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2014.08.092</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Paeonol attenuates inflammation by targeting HMGB1 through upregulating miR-339-5p</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>19370</fpage>.<pub-id pub-id-type="pmid">31852965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-55980-4</pub-id><pub-id pub-id-type="pmcid">PMC6920373</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>LY</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>QH</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>XY</given-names></string-name>; <collab>BingLi</collab></person-group>. <article-title>Inhibition of miR-1298-5p attenuates sepsis lung injury by targeting SOCS6</article-title>. <source>Mol Cell Biochem</source>. <year>2021</year>;<volume>476</volume>(<issue>10</issue>):<fpage>3745</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">34100174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11010-021-04170-w</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>J</given-names></string-name></person-group>. <article-title>LncRNA OSER1-AS1 regulates the inflammation and apoptosis of rheumatoid arthritis fibroblast like synoviocytes via regulating miR-1298-5p/E2F1 axis</article-title>. <source>Bioengineered</source>. <year>2022</year>;<volume>13</volume>(<issue>3</issue>):<fpage>4951</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">35164656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21655979.2022.2037854</pub-id><pub-id pub-id-type="pmcid">PMC8974142</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singla</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Garner</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Samsam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Singla</surname><given-names>DK</given-names></string-name></person-group>. <article-title>Exosomes derived from cardiac parasympathetic ganglionic neurons inhibit apoptosis in hyperglycemic cardiomyoblasts</article-title>. <source>Mol Cell Biochem</source>. <year>2019</year>;<volume>462</volume>(<issue>1&#8211;2</issue>):<fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">31468244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11010-019-03604-w</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hori</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Narita</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yamashita</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Horiuchi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hamada</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kondo</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Changes in the expression of IL-6-Mediated MicroRNAs in the dorsal root ganglion under neuropathic pain in mice</article-title>. <source>Synapse</source>. <year>2016</year>;<volume>70</volume>(<issue>8</issue>):<fpage>317</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">26990296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.21902</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simeoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Montague</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Castaldi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chambers</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kelleher</surname><given-names>JH</given-names></string-name>, <etal/></person-group>. <article-title>Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma</article-title>. <source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1778</fpage>.<pub-id pub-id-type="pmid">29176651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-01841-5</pub-id><pub-id pub-id-type="pmcid">PMC5701122</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montague-Cardoso</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Malcangio</surname><given-names>M</given-names></string-name></person-group>. <article-title>The role of microRNAs in neurons and neuroimmune communication in the dorsal root ganglia in chronic pain</article-title>. <source>Neurosci Lett</source>. <year>2020</year>;<volume>735</volume>:<fpage>135230</fpage>.<pub-id pub-id-type="pmid">32621949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2020.135230</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation</article-title>. <source>J Cell Mol Med</source>. <year>2016</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1898</fpage>&#8211;<lpage>907</lpage>.<pub-id pub-id-type="pmid">27241533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.12882</pub-id><pub-id pub-id-type="pmcid">PMC5020626</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ruan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>MiR-195/-16 family enhances radiotherapy via T cell activation in the tumor microenvironment by blocking the PD-L1 immune checkpoint</article-title>. <source>Cell Physiol Biochem</source>. <year>2018</year>;<volume>48</volume>(<issue>2</issue>):<fpage>801</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">30032144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000491909</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khalife</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ghose</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Martella</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Viola</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rocci</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Troadec</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>MiR-16 regulates crosstalk in NF-&#954;B tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages</article-title>. <source>JCI insight</source>. <year>2019</year>;<volume>4</volume>(<issue>21</issue>):<fpage>e129348</fpage>.<pub-id pub-id-type="pmid">31593552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.129348</pub-id><pub-id pub-id-type="pmcid">PMC6948777</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Choksi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>ZG</given-names></string-name></person-group>. <article-title>MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation</article-title>. <source>Nat Immunol</source>. <year>2010</year>;<volume>11</volume>(<issue>9</issue>):<fpage>799</fpage>&#8211;<lpage>805</lpage>.<pub-id pub-id-type="pmid">20711193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.1918</pub-id><pub-id pub-id-type="pmcid">PMC2926307</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Talari</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kapadia</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kain</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Seshadri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Prajapati</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rajput</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-16 modulates macrophage polarization leading to improved insulin sensitivity in myoblasts</article-title>. <source>Biochimie</source>. <year>2015</year>;<volume>119</volume>:<fpage>16</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">26453808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biochi.2015.10.004</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-16 suppresses the activation of inflammatory macrophages in atherosclerosis by targeting PDCD4</article-title>. <source>Int J Mol Med</source>. <year>2016</year>;<volume>37</volume>(<issue>4</issue>):<fpage>967</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">26936421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2016.2497</pub-id><pub-id pub-id-type="pmcid">PMC4790696</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yamada</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Takizawa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ohgaku</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Asami</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Furuya</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA 16-5p is upregulated in calorie-restricted mice and modulates inflammatory cytokines of macrophages</article-title>. <source>Gene</source>. <year>2020</year>;<volume>725</volume>:<fpage>144191</fpage>.<pub-id pub-id-type="pmid">31654705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gene.2019.144191</pub-id></mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singh</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Garden</surname><given-names>OA</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cobb</surname><given-names>BS</given-names></string-name></person-group>. <article-title>MicroRNAs regulate T-cell production of interleukin-9 and identify hypoxia-inducible factor-2&#945; as an important regulator of T helper 9 and regulatory T-cell differentiation</article-title>. <source>Immunology</source>. <year>2016</year>;<volume>149</volume>(<issue>1</issue>):<fpage>74</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">27278750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.12631</pub-id><pub-id pub-id-type="pmcid">PMC4981607</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ikuma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sakai</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sakamoto</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></string-name></person-group>. <article-title>Increased extracellular release of microRNAs from dorsal root ganglion cells in a rat model of neuropathic pain caused by peripheral nerve injury</article-title>. <source>PLoS One</source>. <year>2023</year>;<volume>18</volume>(<issue>1</issue>):<fpage>e0280425</fpage>.<pub-id pub-id-type="pmid">36662897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0280425</pub-id><pub-id pub-id-type="pmcid">PMC9858844</pub-id></mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xing</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name></person-group>. <article-title>Dorsal root ganglion-derived exosomes deteriorate neuropathic pain by activating microglia via the microRNA-16-5p/HECTD1/HSP90 axis</article-title>. <source>Biol Res</source>. <year>2024</year>;<volume>57</volume>(<issue>1</issue>):<fpage>28</fpage>.<pub-id pub-id-type="pmid">38750549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40659-024-00513-1</pub-id><pub-id pub-id-type="pmcid">PMC11094882</pub-id></mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Haupt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Prots</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Th&#252;mmler</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kremmer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lipsky</surname><given-names>PE</given-names></string-name>, <etal/></person-group>. <article-title>miR-142-3p is involved in CD25+ CD4 T cell proliferation by targeting the expression of glycoprotein A repetitions predominant</article-title>. <source>J Immunol</source>. <year>2013</year>;<volume>190</volume>(<issue>12</issue>):<fpage>6579</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">23650616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1202993</pub-id></mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naqvi</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Fordham</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Nares</surname><given-names>S</given-names></string-name></person-group>. <article-title>miR-24, miR-30b, and miR-142-3p regulate phagocytosis in myeloid inflammatory cells</article-title>. <source>J Immunol</source>. <year>2015</year>;<volume>194</volume>(<issue>4</issue>):<fpage>1916</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">25601927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1401893</pub-id><pub-id pub-id-type="pmcid">PMC4323870</pub-id></mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuhn</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Splith</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ballschuh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Feldbr&#252;gge</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Krenzien</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Atanasov</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Mononuclear-cell-derived microparticles attenuate endothelial inflammation by transfer of miR-142-3p in a CD39 dependent manner</article-title>. <source>Purinergic Signal</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>423</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">30244433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11302-018-9624-5</pub-id><pub-id pub-id-type="pmcid">PMC6298922</pub-id></mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>X</given-names></string-name></person-group>. <article-title>gga-miR-142-3p negatively regulates Mycoplasma gallisepticum (HS strain)-induced inflammatory cytokine production via the NF-&#954;B and MAPK signaling by targeting TAB2</article-title>. <source>Inflamm Res</source>. <year>2021</year>;<volume>70</volume>(<issue>10&#8211;12</issue>):<fpage>1217</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">34554275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00011-021-01499-2</pub-id></mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pang</surname><given-names>XL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name></person-group>. <article-title>MiR-142-3p regulates ILC1s by targeting HMGB1 via the NF-&#954;B pathway in a mouse model of early pregnancy loss</article-title>. <source>Curr Med Sci</source>. <year>2024</year>;<volume>44</volume>(<issue>1</issue>):<fpage>195</fpage>&#8211;<lpage>211</lpage>.<pub-id pub-id-type="pmid">38393528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11596-024-2833-y</pub-id></mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yamada</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kosaka</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Miyazawa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kurata-Miura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname><given-names>T</given-names></string-name></person-group>. <article-title>miR-142-3p enhances Fc&#949;RI-mediated degranulation in mast cells</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2014</year>;<volume>443</volume>(<issue>3</issue>):<fpage>980</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">24361879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2013.12.078</pub-id></mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE</article-title>. <source>Arthritis Res Ther</source>. <year>2016</year>;<volume>18</volume>(<issue>1</issue>):<fpage>263</fpage>.<pub-id pub-id-type="pmid">27852285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-016-1158-z</pub-id><pub-id pub-id-type="pmcid">PMC5112667</pub-id></mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>M</given-names></string-name></person-group>. <article-title>Downregulated expression of miR-142-3p in macrophages contributes to increased IL-6 levels in aged mice</article-title>. <source>Mol Immunol</source>. <year>2016</year>;<volume>80</volume>:<fpage>11</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">27788393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2016.10.009</pub-id></mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hua</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>MiR-203-3p inhibits the oxidative stress, inflammatory responses and apoptosis of mice podocytes induced by high glucose through regulating Sema3A expression</article-title>. <source>Open Life Sci</source>. <year>2020</year>;<volume>15</volume>(<issue>1</issue>):<fpage>939</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">33817280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/biol-2020-0088</pub-id><pub-id pub-id-type="pmcid">PMC7874591</pub-id></mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cai</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name></person-group>. <article-title>Suppression of miR-203-3p inhibits lipopolysaccharide induced human intervertebral disc inflammation and degeneration through upregulating estrogen receptor &#945;</article-title>. <source>Gene Ther</source>. <year>2020</year>;<volume>27</volume>(<issue>9</issue>):<fpage>417</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">31896759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41434-019-0118-z</pub-id></mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>XM</given-names></string-name></person-group>. <article-title>miR-221 suppresses ICAM-1 translation and regulates interferon-gamma-induced ICAM-1 expression in human cholangiocytes</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2010</year>;<volume>298</volume>(<issue>4</issue>):<fpage>G542</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">20110463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpgi.00490.2009</pub-id><pub-id pub-id-type="pmcid">PMC2853302</pub-id></mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>ZH</given-names></string-name></person-group>. <article-title>miR-221 alleviates the inflammatory response and cell apoptosis of neuronal cell through targeting TNFAIP2 in spinal cord ischemia-reperfusion</article-title>. <source>Neuroreport</source>. <year>2018</year>;<volume>29</volume>(<issue>8</issue>):<fpage>655</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">29596155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001013</pub-id></mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Di</surname><given-names>W</given-names></string-name></person-group>. <article-title>miR-221 exerts neuroprotective effects in ischemic stroke by inhibiting the proinflammatory response</article-title>. <source>J Stroke Cerebrovasc Dis</source>. <year>2021</year>;<volume>30</volume>(<issue>2</issue>):<fpage>105489</fpage>.<pub-id pub-id-type="pmid">33276305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2020.105489</pub-id></mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name></person-group>. <article-title>MiR-221-5p is involved in the regulation of inflammatory responses in acute gouty arthritis by targeting IL-1&#946;</article-title>. <source>Int J Rheum Dis</source>. <year>2021</year>;<volume>24</volume>(<issue>3</issue>):<fpage>335</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">33201565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1756-185X.14028</pub-id></mixed-citation></ref><ref id="B180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lai</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>SW</given-names></string-name>, <etal/></person-group>. <article-title>Nanocurcumin reduces high glucose and particulate matter-induced endothelial inflammation: mitochondrial function and involvement of miR-221/222</article-title>. <source>Int J Nanomedicine</source>. <year>2023</year>;<volume>18</volume>:<fpage>7379</fpage>&#8211;<lpage>402</lpage>.<pub-id pub-id-type="pmid">38084125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S433658</pub-id><pub-id pub-id-type="pmcid">PMC10710795</pub-id></mixed-citation></ref><ref id="B181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gui</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name></person-group>. <article-title>miR-221-3p as a potential biomarker of chronic periodontitis and its regulatory effect on inflammatory response</article-title>. <source>Am J Dent</source>. <year>2024</year>;<volume>37</volume>(<issue>3</issue>):<fpage>131</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">38899992</pub-id></mixed-citation></ref><ref id="B182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>miR-9-5p and miR-221-3p promote human mesenchymal stem cells to alleviate carbon tetrachloride-induced liver injury by enhancing human mesenchymal stem cell engraftment and inhibiting hepatic stellate cell activation</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>13</issue>):<fpage>7235</fpage>.<pub-id pub-id-type="pmid">39000343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25137235</pub-id><pub-id pub-id-type="pmcid">PMC11241704</pub-id></mixed-citation></ref><ref id="B183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhuang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>L</given-names></string-name></person-group>. <article-title>MiR-221 activates the NF-&#954;B pathway by targeting A20</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2016</year>;<volume>472</volume>(<issue>1</issue>):<fpage>11</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26549234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2015.11.009</pub-id></mixed-citation></ref><ref id="B184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quero</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tiaden</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Hanser</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Roux</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Laski</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>miR-221-3p drives the shift of M2-macrophages to a pro-inflammatory function by suppressing JAK3/STAT3 activation</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>3087</fpage>.<pub-id pub-id-type="pmid">32047494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.03087</pub-id><pub-id pub-id-type="pmcid">PMC6996464</pub-id></mixed-citation></ref><ref id="B185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Mammary epithelial cell derived exosomal MiR-221 mediates M1 macrophage polarization via SOCS1/STATs to promote inflammatory response</article-title>. <source>Int Immunopharmacol</source>. <year>2020</year>;<volume>83</volume>:<fpage>106493</fpage>.<pub-id pub-id-type="pmid">32289739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106493</pub-id></mixed-citation></ref><ref id="B186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Do-Umehara</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>miR-221-5p-Mediated downregulation of JNK2 aggravates acute lung injury</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>700933</fpage>.<pub-id pub-id-type="pmid">34899681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.700933</pub-id><pub-id pub-id-type="pmcid">PMC8656235</pub-id></mixed-citation></ref><ref id="B187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wigton</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Mikami</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>McMonigle</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Castellanos</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Wade-Vallance</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>SK</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-directed pathway discovery elucidates an miR-221/222-mediated regulatory circuit in class switch recombination</article-title>. <source>J Exp Med</source>. <year>2021</year>;<volume>218</volume>(<issue>11</issue>):<fpage>e20201422</fpage>.<pub-id pub-id-type="pmid">34586363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20201422</pub-id><pub-id pub-id-type="pmcid">PMC8485858</pub-id></mixed-citation></ref><ref id="B188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feinmesser</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Benbassat</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Meiri</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Benjamin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lebanony</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lebenthal</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Specific MicroRNAs differentiate adrenocortical adenomas from carcinomas and correlate with weiss histopathologic system</article-title>. <source>Appl Immunohistochem Mol Morphol</source>. <year>2015</year>;<volume>23</volume>(<issue>7</issue>):<fpage>522</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">25265426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAI.0000000000000117</pub-id></mixed-citation></ref><ref id="B189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name></person-group>. <article-title>Long noncoding RNA X-inactive-specific transcript promotes the secretion of inflammatory cytokines in LPS stimulated astrocyte cell via sponging miR-29c-3p and regulating nuclear factor of activated T cell 5 expression</article-title>. <source>Front Endocrinol</source>. <year>2021</year>;<volume>12</volume>:<fpage>573143</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2021.573143</pub-id><pub-id pub-id-type="pmcid">PMC7995889</pub-id><pub-id pub-id-type="pmid">33776905</pub-id></mixed-citation></ref><ref id="B190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name></person-group>. <article-title>miR-29c-3p accelerates mucosal repair in dextran sodium sulfateinduced ulcerative colitis mice through the KDM6B/H3K27me3/LDHA Axis</article-title>. <source>Protein Pept Lett</source>. <year>2023</year>;<volume>30</volume>(<issue>6</issue>):<fpage>459</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">37171009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929866530666230511115213</pub-id></mixed-citation></ref><ref id="B191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name></person-group>. <article-title>MiR-29c alleviates hyperglycemia-induced inflammation via targeting TGF-&#946; in cardiomyocytes</article-title>. <source>Mol Cell Biochem</source>. <year>2024</year>;<volume>479</volume>(<issue>8</issue>):<fpage>2047</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">37589861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11010-023-04813-0</pub-id></mixed-citation></ref><ref id="B192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name></person-group>. <article-title>miR-29c-3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson's disease</article-title>. <source>Genes Cells</source>. <year>2020</year>;<volume>25</volume>(<issue>6</issue>):<fpage>364</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">32160394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/gtc.12764</pub-id></mixed-citation></ref><ref id="B193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Increased miR-195 aggravates neuropathic pain by inhibiting autophagy following peripheral nerve injury</article-title>. <source>Glia</source>. <year>2013</year>;<volume>61</volume>(<issue>4</issue>):<fpage>504</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">23361941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.22451</pub-id></mixed-citation></ref><ref id="B194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bras</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Calin</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Barbosa</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Almeida</surname><given-names>MI</given-names></string-name></person-group>. <article-title>miR-195 inhibits macrophages pro-inflammatory profile and impacts the crosstalk with smooth muscle cells</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>11</issue>):<fpage>e0188530</fpage>.<pub-id pub-id-type="pmid">29166412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0188530</pub-id><pub-id pub-id-type="pmcid">PMC5699821</pub-id></mixed-citation></ref><ref id="B195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bai</surname><given-names>XS</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name></person-group>. <article-title>MiR-195 alleviates ulcerative colitis in rats via MAPK signaling pathway</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2020</year>;<volume>24</volume>(<issue>5</issue>):<fpage>2640</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">32196614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202003_20533</pub-id></mixed-citation></ref><ref id="B196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>HT</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>JH</given-names></string-name></person-group>. <article-title>MiR-195 regulates CD40 to maintain Th17/Treg balance in rats with non-alcoholic fatty liver disease</article-title>. <source>Biomed Pharmacother</source>. <year>2020</year>;<volume>124</volume>:<fpage>109930</fpage>.<pub-id pub-id-type="pmid">31991386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2020.109930</pub-id></mixed-citation></ref><ref id="B197"><label>197.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>T</given-names></string-name></person-group>. <article-title>Effects of miR-195 on diabetic nephropathy rats through targeting TLR4 and blocking NF-&#954;B pathway</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2021</year>;<volume>25</volume>(<issue>3</issue>):<fpage>1522</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">33629321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202102_24860</pub-id></mixed-citation></ref><ref id="B198"><label>198.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Man</surname><given-names>C</given-names></string-name></person-group>. <article-title>Immune function of miR-214 and its application prospects as molecular marker</article-title>. <source>PeerJ</source>. <year>2021</year>;<volume>9</volume>:<fpage>e10924</fpage>.<pub-id pub-id-type="pmid">33628646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.10924</pub-id><pub-id pub-id-type="pmcid">PMC7894119</pub-id></mixed-citation></ref><ref id="B199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Potential roles of miR-335-5p on pathogenesis of experimental periodontitis</article-title>. <source>J Periodontal Res</source>. <year>2020</year>;<volume>55</volume>(<issue>2</issue>):<fpage>191</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">31541471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jre.12701</pub-id><pub-id pub-id-type="pmcid">PMC7680696</pub-id></mixed-citation></ref><ref id="B200"><label>200.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>XH</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>ZC</given-names></string-name>, <etal/></person-group>. <article-title>Upregulation of miR-335 reduces myocardial injury following myocardial infarction via targeting MAP3K2</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2021</year>;<volume>25</volume>(<issue>1</issue>):<fpage>344</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">33506923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202101_24401</pub-id></mixed-citation></ref><ref id="B201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>B</given-names></string-name></person-group>. <article-title>Overexpressed miR-335-5p reduces atherosclerotic vulnerable plaque formation in acute coronary syndrome</article-title>. <source>J Clin Lab Anal</source>. <year>2021</year>;<volume>35</volume>(<issue>2</issue>):<fpage>e23608</fpage>.<pub-id pub-id-type="pmid">33277957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcla.23608</pub-id><pub-id pub-id-type="pmcid">PMC7891542</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC12459215"/></mixed-citation></ref><ref id="B202"><label>202.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Upregulation of miR-335 exerts protective effects against sepsis-induced myocardial injury</article-title>. <source>Mol Med Rep</source>. <year>2021</year>;<volume>24</volume>(<issue>5</issue>):<fpage>806</fpage>.<pub-id pub-id-type="pmid">34542164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2021.12446</pub-id><pub-id pub-id-type="pmcid">PMC8477184</pub-id></mixed-citation></ref><ref id="B203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Melatonin promotes the restoration of bone defects via enhancement of miR-335-5p combined with inhibition of TNF&#945;/NF-&#954;B signaling</article-title>. <source>FASEB J</source>. <year>2023</year>;<volume>37</volume>(<issue>1</issue>):<fpage>e22711</fpage>.<pub-id pub-id-type="pmid">36520091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202200572RRR</pub-id></mixed-citation></ref><ref id="B204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wei</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MiR-345-3p attenuates apoptosis and inflammation caused by oxidized low-density lipoprotein by targeting TRAF6 via TAK1/p38/NF-kB signaling in endothelial cells</article-title>. <source>Life Sci</source>. <year>2020</year>;<volume>241</volume>:<fpage>117142</fpage>.<pub-id pub-id-type="pmid">31825793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2019.117142</pub-id></mixed-citation></ref><ref id="B205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>miR-345-3p modulates M1/M2 macrophage polarization to inhibit inflammation in bone infection via targeting MAP3K1 and NF-&#954;B pathway</article-title>. <source>J Immunol</source>. <year>2024</year>;<volume>212</volume>(<issue>5</issue>):<fpage>844</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">38231123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2300561</pub-id></mixed-citation></ref><ref id="B206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name></person-group>. <article-title>CircRSU1 contributes to the development of osteoarthritis via the miR-345-3p/TRAF6 signaling</article-title>. <source>Arch Gerontol Geriatr</source>. <year>2025</year>;<volume>129</volume>:<fpage>105696</fpage>.<pub-id pub-id-type="pmid">39586158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.archger.2024.105696</pub-id></mixed-citation></ref><ref id="B207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name></person-group>. <article-title>Inhibition of miR-497-3p downregulates the expression of procalcitonin and ameliorates bacterial pneumonia in mice</article-title>. <source>Inflammation</source>. <year>2020</year>;<volume>43</volume>(<issue>6</issue>):<fpage>2119</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">32591941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01279-w</pub-id></mixed-citation></ref><ref id="B208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhai</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>J</given-names></string-name></person-group>. <article-title>MiR-497 promotes microglia activation and proinflammatory cytokines production in chronic unpredictable stress-induced depression via targeting FGF2</article-title>. <source>J Chem Neuroanat</source>. <year>2020</year>;<volume>110</volume>:<fpage>101872</fpage>.<pub-id pub-id-type="pmid">33068702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jchemneu.2020.101872</pub-id></mixed-citation></ref><ref id="B209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>X</given-names></string-name></person-group>. <article-title>miR-708-5p promotes fibroblast-like synoviocytes&#8217; cell apoptosis and ameliorates rheumatoid arthritis by the inhibition of Wnt3a/&#946;-catenin pathway</article-title>. <source>Drug Des Devel Ther</source>. <year>2018</year>;<volume>12</volume>:<fpage>3439</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S177128</pub-id><pub-id pub-id-type="pmcid">PMC6186895</pub-id><pub-id pub-id-type="pmid">30349197</pub-id></mixed-citation></ref><ref id="B210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Xuan</surname><given-names>J</given-names></string-name></person-group>. <article-title>miR-708 affords protective efficacy in anoxia/reoxygenation-stimulated cardiomyocytes by blocking the TLR4 signaling via targeting HMGB1</article-title>. <source>Mol Cell Probes</source>. <year>2020</year>;<volume>54</volume>:<fpage>101653</fpage>.<pub-id pub-id-type="pmid">32866662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcp.2020.101653</pub-id></mixed-citation></ref><ref id="B211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Monteleone</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Lutz</surname><given-names>CS</given-names></string-name></person-group>. <article-title>miR-708 negatively regulates TNF&#945;/IL-1&#946; signaling by suppressing NF-&#954;B and arachidonic acid pathways</article-title>. <source>Mediators Inflamm</source>. <year>2021</year>;<volume>2021</volume>:<fpage>5595520</fpage>.<pub-id pub-id-type="pmid">33776573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/5595520</pub-id><pub-id pub-id-type="pmcid">PMC7969122</pub-id></mixed-citation></ref><ref id="B212"><label>212.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>W</given-names></string-name></person-group>. <article-title>MiR-708-3p alleviates inflammation and myocardial injury after myocardial infarction by suppressing ADAM17 expression</article-title>. <source>Inflammation</source>. <year>2021</year>;<volume>44</volume>(<issue>3</issue>):<fpage>1083</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">33492555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01404-9</pub-id></mixed-citation></ref><ref id="B213"><label>213.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vetrivel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Engel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>O&#223;wald</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Watts</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Characterization of adrenal miRNA-based dysregulations in cushing's syndrome</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>14</issue>):<fpage>7676</fpage>.<pub-id pub-id-type="pmid">35887024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23147676</pub-id><pub-id pub-id-type="pmcid">PMC9320303</pub-id></mixed-citation></ref><ref id="B214"><label>214.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iliopoulos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bimpaki</surname><given-names>EI</given-names></string-name>, <string-name name-style="western"><surname>Nesterova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stratakis</surname><given-names>CA</given-names></string-name></person-group>. <article-title>MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>(<issue>8</issue>):<fpage>3278</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">19351815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-09-0155</pub-id><pub-id pub-id-type="pmcid">PMC3124768</pub-id></mixed-citation></ref><ref id="B215"><label>215.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bimpaki</surname><given-names>EI</given-names></string-name>, <string-name name-style="western"><surname>Iliopoulos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Moraitis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stratakis</surname><given-names>CA</given-names></string-name></person-group>. <article-title>MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis</article-title>. <source>Clin Endocrinol</source>. <year>2010</year>;<volume>72</volume>(<issue>6</issue>):<fpage>744</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2265.2009.03725.x</pub-id><pub-id pub-id-type="pmcid">PMC3003432</pub-id><pub-id pub-id-type="pmid">19849700</pub-id></mixed-citation></ref><ref id="B216"><label>216.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haas</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Nistala</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Petermann</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Saran</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chennupati</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Schmitz</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Expression of miRNAs miR-133b and miR-206 in the Il17a/f locus is co-regulated with IL-17 production in &#945;&#946; and &#947;&#948; T cells</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>5</issue>):<fpage>e20171</fpage>.<pub-id pub-id-type="pmid">21637854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0020171</pub-id><pub-id pub-id-type="pmcid">PMC3102691</pub-id></mixed-citation></ref><ref id="B217"><label>217.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>BY</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Mou</surname><given-names>XZ</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>miR-133b downregulation reduces vulnerable plaque formation in mice with AS through inhibiting macrophage immune responses</article-title>. <source>Mol Ther Nucleic Acids</source>. <year>2019</year>;<volume>16</volume>:<fpage>745</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">31146256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2019.04.024</pub-id><pub-id pub-id-type="pmcid">PMC6539412</pub-id></mixed-citation></ref><ref id="B218"><label>218.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>J</given-names></string-name></person-group>. <article-title>Effects of PM2.5 on mucus hypersecretion in airway through miR-133b-5p/EGFR/Claudin1/MUC5AC axis</article-title>. <source>Aging</source>. <year>2024</year>;<volume>16</volume>(<issue>10</issue>):<fpage>8472</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">38809424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.205785</pub-id><pub-id pub-id-type="pmcid">PMC11164504</pub-id></mixed-citation></ref><ref id="B219"><label>219.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Engeland</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>B</given-names></string-name></person-group>. <article-title>Social isolation impairs oral palatal wound healing in sprague-dawley rats: a role for miR-29 and miR-203 via VEGF suppression</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e72359</fpage>.<pub-id pub-id-type="pmid">23951316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0072359</pub-id><pub-id pub-id-type="pmcid">PMC3739786</pub-id></mixed-citation></ref><ref id="B220"><label>220.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>B</given-names></string-name></person-group>. <article-title>miR-203 protects microglia mediated brain injury by regulating inflammatory responses via feedback to MyD88 in ischemia</article-title>. <source>Mol Immunol</source>. <year>2015</year>;<volume>65</volume>(<issue>2</issue>):<fpage>293</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="pmid">25723469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2015.01.019</pub-id></mixed-citation></ref><ref id="B221"><label>221.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name></person-group>. <article-title>Downregulated miR-203 attenuates IL-&#946;, IL-6, and TNF-&#945; activation in TRAF6-treated human renal mesangial and tubular epithelial cells</article-title>. <source>Int J Clin Exp Pathol</source>. <year>2020</year>;<volume>13</volume>(<issue>2</issue>):<fpage>324</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">32211116</pub-id><pub-id pub-id-type="pmcid">PMC7061798</pub-id></mixed-citation></ref><ref id="B222"><label>222.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Groome</surname><given-names>LJ</given-names></string-name></person-group>. <article-title>Up-regulation of miR-203 expression induces endothelial inflammatory response: potential role in preeclampsia</article-title>. <source>Am J Reprod Immunol</source>. <year>2016</year>;<volume>76</volume>(<issue>6</issue>):<fpage>482</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">27753461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/aji.12589</pub-id><pub-id pub-id-type="pmcid">PMC5118090</pub-id></mixed-citation></ref><ref id="B223"><label>223.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>P</given-names></string-name></person-group>. <article-title>LncRNA UCA1 suppresses the inflammation via modulating miR-203-mediated regulation of MEF2C/NF-&#954;B signaling pathway in epilepsy</article-title>. <source>Neurochem Res</source>. <year>2020</year>;<volume>45</volume>(<issue>4</issue>):<fpage>783</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">32056051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-019-02952-9</pub-id></mixed-citation></ref><ref id="B224"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perge</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Decmann</surname><given-names>&#193;</given-names></string-name>, <string-name name-style="western"><surname>Pezzani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bancos</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Fassina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Luconi</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors</article-title>. <source>Endocrine</source>. <year>2018</year>;<volume>59</volume>(<issue>2</issue>):<fpage>280</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29299796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-017-1506-z</pub-id></mixed-citation></ref><ref id="B225"><label>225.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>F</given-names></string-name></person-group>. <article-title>NEAT1 aggravates sepsis-induced acute kidney injury by sponging miR-22-3p</article-title>. <source>Open Med</source>. <year>2020</year>;<volume>15</volume>(<issue>1</issue>):<fpage>333</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/med-2020-0401</pub-id><pub-id pub-id-type="pmcid">PMC7712373</pub-id><pub-id pub-id-type="pmid">33335994</pub-id></mixed-citation></ref><ref id="B226"><label>226.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name></person-group>. <article-title>MiR-22-3p suppresses sepsis-induced acute kidney injury by targeting PTEN</article-title>. <source>Biosci Rep</source>. <year>2020</year>;<volume>40</volume>(<issue>6</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20200527</pub-id><pub-id pub-id-type="pmcid">PMC7268257</pub-id><pub-id pub-id-type="pmid">32412059</pub-id></mixed-citation></ref><ref id="B227"><label>227.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>RR</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-22-3p alleviates spinal cord ischemia/reperfusion injury by modulating M2 macrophage polarization via IRF5</article-title>. <source>J Neurochem</source>. <year>2021</year>;<volume>156</volume>(<issue>1</issue>):<fpage>106</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">32406529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15042</pub-id></mixed-citation></ref><ref id="B228"><label>228.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MiR-223-3p and miR-22-3p inhibit monosodium urate-induced gouty inflammation by targeting NLRP3</article-title>. <source>Int J Rheum Dis</source>. <year>2021</year>;<volume>24</volume>(<issue>4</issue>):<fpage>599</fpage>&#8211;<lpage>607</lpage>.<pub-id pub-id-type="pmid">33650318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1756-185X.14089</pub-id></mixed-citation></ref><ref id="B229"><label>229.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-22-3p plays a protective role in a murine asthma model through the inhibition of the NLRP3-caspase-1-IL-1&#946; axis</article-title>. <source>Exp Physiol</source>. <year>2021</year>;<volume>106</volume>(<issue>8</issue>):<fpage>1829</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">33932961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/EP089575</pub-id></mixed-citation></ref><ref id="B230"><label>230.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xue</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>ZJ</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>P</given-names></string-name></person-group>. <article-title>H19 is involved in the regulation of inflammatory responses in acute gouty arthritis by targeting miR-2-3p</article-title>. <source>Immunol Res</source>. <year>2022</year>;<volume>70</volume>(<issue>3</issue>):<fpage>392</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">35314952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-022-09276-x</pub-id></mixed-citation></ref><ref id="B231"><label>231.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xia</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zong</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-22-3p ameliorates Alzheimer's disease by targeting SOX9 through the NF-&#954;B signaling pathway in the hippocampus</article-title>. <source>J Neuroinflammation</source>. <year>2022</year>;<volume>19</volume>(<issue>1</issue>):<fpage>180</fpage>.<pub-id pub-id-type="pmid">35821145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02548-1</pub-id><pub-id pub-id-type="pmcid">PMC9277852</pub-id></mixed-citation></ref><ref id="B232"><label>232.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name></person-group>. <article-title>miR-22 alleviates sepsis-induced acute kidney injury via targeting the HMGB1/TLR4/NF-&#954;B signaling pathway</article-title>. <source>Int Urol Nephrol</source>. <year>2022</year>;<volume>55</volume>(<issue>2</issue>):<fpage>409</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">35960478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11255-022-03321-2</pub-id><pub-id pub-id-type="pmcid">PMC9859886</pub-id></mixed-citation></ref><ref id="B233"><label>233.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>G</given-names></string-name></person-group>. <article-title>MicroRNA-22-3p alleviates atherosclerosis by mediating macrophage M2 polarization as well as inhibiting NLRP3 activation</article-title>. <source>J Int Med Res</source>. <year>2023</year>;<volume>51</volume>(<issue>10</issue>):<fpage>3000605231197071</fpage>.<pub-id pub-id-type="pmid">37824732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/03000605231197071</pub-id><pub-id pub-id-type="pmcid">PMC10571701</pub-id></mixed-citation></ref><ref id="B234"><label>234.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>MSC-derived small extracellular vesicles alleviate diabetic retinopathy by delivering miR-22-3p to inhibit NLRP3 inflammasome activation</article-title>. <source>Stem Cell</source>. <year>2024</year>;<volume>42</volume>(<issue>1</issue>):<fpage>64</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/stmcls/sxad078</pub-id><pub-id pub-id-type="pmid">37847598</pub-id></mixed-citation></ref><ref id="B235"><label>235.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Pig milk exosome packaging ssc-miR-22-3p alleviates pig intestinal epithelial cell injury and inflammatory response by targeting MAPK14</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>19</issue>):<fpage>10715</fpage>.<pub-id pub-id-type="pmid">39409044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms251910715</pub-id><pub-id pub-id-type="pmcid">PMC11476862</pub-id></mixed-citation></ref><ref id="B236"><label>236.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>JA</given-names></string-name></person-group>. <article-title>MicroRNA-22-3p as a novel regulator and therapeutic target for autoimmune diseases</article-title>. <source>Int Rev Immunol</source>. <year>2017</year>;<volume>36</volume>(<issue>3</issue>):<fpage>176</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">28471251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08830185.2017.1281272</pub-id></mixed-citation></ref><ref id="B237"><label>237.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fransisca</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Protective effects of microRNA-22-3p against retinal pigment epithelial inflammatory damage by targeting NLRP3 inflammasome</article-title>. <source>J Cell Physiol</source>. <year>2019</year>;<volume>234</volume>(<issue>10</issue>):<fpage>18849</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">30927257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.28523</pub-id></mixed-citation></ref><ref id="B238"><label>238.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Resveratrol attenuates pulmonary embolism associated cardiac injury by suppressing activation of the inflammasome via the MALAT1-miR-22-3p signaling pathway</article-title>. <source>Int J Mol Med</source>. <year>2019</year>;<volume>44</volume>(<issue>6</issue>):<fpage>2311</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">31573048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2019.4358</pub-id></mixed-citation></ref><ref id="B239"><label>239.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>LQ</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Over-expressed miR-27a-3p inhibits inflammatory response to spinal cord injury by decreasing TLR4</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2018</year>;<volume>22</volume>(<issue>17</issue>):<fpage>5416</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">30229811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201809_15800</pub-id></mixed-citation></ref><ref id="B240"><label>240.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name></person-group>. <article-title>MiR-27a-3p downregulation contributes to the development of occlusive bronchiolitis</article-title>. <source>Cell Stress Chaperones</source>. <year>2019</year>;<volume>24</volume>(<issue>5</issue>):<fpage>883</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31452017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12192-019-01026-7</pub-id><pub-id pub-id-type="pmcid">PMC6717216</pub-id></mixed-citation></ref><ref id="B241"><label>241.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MiR-27a-3p overexpression mitigates inflammation and apoptosis of lipopolysaccharides-induced alveolar epithelial cells by targeting FOXO3 and suppressing the activation of NAPDH/ROS</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2020</year>;<volume>533</volume>(<issue>4</issue>):<fpage>723</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">32993961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2020.07.126</pub-id></mixed-citation></ref><ref id="B242"><label>242.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Biliverdin protects against cerebral ischemia/reperfusion injury by regulating the miR-27a-3p/rgs1 Axis</article-title>. <source>Neuropsychiatr Dis Treat</source>. <year>2021</year>;<volume>17</volume>:<fpage>1165</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">33911865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S300773</pub-id><pub-id pub-id-type="pmcid">PMC8075361</pub-id></mixed-citation></ref><ref id="B243"><label>243.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>C</given-names></string-name></person-group>. <article-title>Upregulating miR-27a-3p inhibits cell proliferation and inflammation of rheumatoid arthritis synovial fibroblasts through targeting toll-like receptor 5</article-title>. <source>Exp Ther Med</source>. <year>2021</year>;<volume>22</volume>:<fpage>1227</fpage>.<pub-id pub-id-type="pmid">34539823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2021.10661</pub-id><pub-id pub-id-type="pmcid">PMC8438689</pub-id></mixed-citation></ref><ref id="B244"><label>244.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Activated hepatic stellate cell-derived small extracellular vesicles facilitate M2 macrophage polarization and hepatoma progression via miR-27a-3p</article-title>. <source>Front Immunol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1489679</fpage>.<pub-id pub-id-type="pmid">39742261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1489679</pub-id><pub-id pub-id-type="pmcid">PMC11685157</pub-id></mixed-citation></ref><ref id="B245"><label>245.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>H</given-names></string-name></person-group>. <article-title>miR-27a-3p promotes inflammatory response in infectious endophthalmitis via targeting TSC1</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>19353</fpage>.<pub-id pub-id-type="pmid">39169069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-69964-6</pub-id><pub-id pub-id-type="pmcid">PMC11339321</pub-id></mixed-citation></ref><ref id="B246"><label>246.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dhabhar</surname><given-names>FS</given-names></string-name></person-group>. <article-title>Effects of stress on immune function: the good, the bad, and the beautiful</article-title>. <source>Immunol Res</source>. <year>2014</year>;<volume>58</volume>(<issue>2&#8211;3</issue>):<fpage>193</fpage>&#8211;<lpage>210</lpage>.<pub-id pub-id-type="pmid">24798553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-014-8517-0</pub-id></mixed-citation></ref><ref id="B247"><label>247.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dhabhar</surname><given-names>FS</given-names></string-name></person-group>. <article-title>The short-term stress response - mother nature&#8217;s mechanism for enhancing protection and performance under conditions of threat, challenge, and opportunity</article-title>. <source>Front Neuroendocrinol</source>. <year>2018</year>;<volume>49</volume>:<fpage>175</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">29596867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yfrne.2018.03.004</pub-id><pub-id pub-id-type="pmcid">PMC5964013</pub-id></mixed-citation></ref><ref id="B248"><label>248.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Straub</surname><given-names>RH</given-names></string-name></person-group>. <source>Understanding aging, fatigue, and inflammation - when the immune system and brain compete for energy in the body(Hrsg.)</source>. <publisher-loc>Berlin Heidelberg</publisher-loc>: <publisher-name>Springer-Verlag GmbH, DE, part of Springer Nature</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="B249"><label>249.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Volk</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Paul</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Haramati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Eitan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fields</surname><given-names>BKK</given-names></string-name>, <string-name name-style="western"><surname>Zwang</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-19b associates with Ago2 in the amygdala following chronic stress and regulates the adrenergic receptor beta 1</article-title>. <source>J Neurosci</source>. <year>2014</year>;<volume>34</volume>(<issue>45</issue>):<fpage>15070</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">25378171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0855-14.2014</pub-id><pub-id pub-id-type="pmcid">PMC6608371</pub-id></mixed-citation></ref><ref id="B250"><label>250.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>miR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn&#8217;s disease</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>:<fpage>10397</fpage>.<pub-id pub-id-type="pmid">25997679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep10397</pub-id><pub-id pub-id-type="pmcid">PMC4441154</pub-id></mixed-citation></ref><ref id="B251"><label>251.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>MiR-19b-3p attenuates IL-1&#946; induced extracellular matrix degradation and inflammatory injury in chondrocytes by targeting GRK6</article-title>. <source>Mol Cell Biochem</source>. <year>2019</year>;<volume>459</volume>(<issue>1&#8211;2</issue>):<fpage>205</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">31227976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11010-019-03563-2</pub-id></mixed-citation></ref><ref id="B252"><label>252.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>H</given-names></string-name></person-group>. <article-title>Clinical significance of miR-19b-3p in patients with sepsis and its regulatory role in the LPS-induced inflammatory response</article-title>. <source>Eur J Med Res</source>. <year>2020</year>;<volume>25</volume>(<issue>1</issue>):<fpage>9</fpage>.<pub-id pub-id-type="pmid">32188465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40001-020-00408-3</pub-id><pub-id pub-id-type="pmcid">PMC7079357</pub-id></mixed-citation></ref><ref id="B253"><label>253.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiahui</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jiadai</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Nan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Rui</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lipin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jian</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>miR-19b-3p/PKNOX1 regulates viral myocarditis by regulating macrophage polarization</article-title>. <source>Front Genet</source>. <year>2022</year>;<volume>13</volume>:<fpage>902453</fpage>.<pub-id pub-id-type="pmid">35812737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.902453</pub-id><pub-id pub-id-type="pmcid">PMC9264346</pub-id></mixed-citation></ref><ref id="B254"><label>254.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name></person-group>. <article-title>UC-BSCs exosomes regulate Th17/treg balance in patients with systemic lupus erythematosus via miR-19b/KLF13</article-title>. <source>Cells</source>. <year>2022</year>;<volume>11</volume>(<issue>24</issue>):<fpage>4123</fpage>.<pub-id pub-id-type="pmid">36552891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11244123</pub-id><pub-id pub-id-type="pmcid">PMC9777319</pub-id></mixed-citation></ref><ref id="B255"><label>255.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amjad</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Decrease of miR-19b-3p in brain microvascular endothelial cells attenuates meningitic Escherichia coli-induced neuroinflammation via TNFAIP3-mediated NF-&#954;B inhibition</article-title>. <source>Pathogens</source>. <year>2019</year>;<volume>8</volume>(<issue>24</issue>):<fpage>268</fpage>.<pub-id pub-id-type="pmid">31783671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens8040268</pub-id><pub-id pub-id-type="pmcid">PMC6963872</pub-id></mixed-citation></ref><ref id="B256"><label>256.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>YX</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>F</given-names></string-name></person-group>. <article-title>LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression</article-title>. <source>Kaohsiung J Med Sci</source>. <year>2021</year>;<volume>37</volume>(<issue>2</issue>):<fpage>101</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">33022863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/kjm2.12302</pub-id><pub-id pub-id-type="pmcid">PMC11896425</pub-id></mixed-citation></ref><ref id="B257"><label>257.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sahebdel</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Quinta</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Morse</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Olson</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Battaglino</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Transcriptomic profiling of primary microglia: effects of miR-19a-3p and miR-19b-3p on microglia activation</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>19</issue>):<fpage>10601</fpage>.<pub-id pub-id-type="pmid">39408930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms251910601</pub-id><pub-id pub-id-type="pmcid">PMC11477266</pub-id></mixed-citation></ref><ref id="B258"><label>258.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sakamoto</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mallah</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Medeiros</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Dohi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Imai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>IVL</given-names></string-name>, <etal/></person-group>. <article-title>Alterations in circulating extracellular vesicles underlie social stress-induced behaviors in mice</article-title>. <source>FEBS Open Bio</source>. <year>2021</year>;<volume>11</volume>(<issue>10</issue>):<fpage>2678</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/2211-5463.13204</pub-id><pub-id pub-id-type="pmcid">PMC8487053</pub-id><pub-id pub-id-type="pmid">34043886</pub-id></mixed-citation></ref><ref id="B259"><label>259.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>GL</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-31-5p exacerbates lipopolysaccharide-induced acute lung injury via inactivating cab39/ampk&#945; pathway</article-title>. <source>Oxid Med Cell Longev</source>. <year>2020</year>;<volume>2020</volume>:<fpage>8822361</fpage>.<pub-id pub-id-type="pmid">33101593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/8822361</pub-id><pub-id pub-id-type="pmcid">PMC7568166</pub-id></mixed-citation></ref><ref id="B260"><label>260.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname><given-names>LQ</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>SM</given-names></string-name></person-group>. <article-title>MiR-31 aggravates inflammation and apoptosis in COPD rats via activating the NF-&#954;B signaling pathway</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2020</year>;<volume>24</volume>(<issue>18</issue>):<fpage>9626</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">33015806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202009_23051</pub-id></mixed-citation></ref><ref id="B261"><label>261.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>J</given-names></string-name></person-group>. <article-title>MicroRNA-93 downregulation ameliorates cerebral ischemic injury through the Nrf2/HO-1 defense pathway</article-title>. <source>Neurochem Res</source>. <year>2016</year>;<volume>41</volume>(<issue>10</issue>):<fpage>2627</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">27300700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-016-1975-0</pub-id></mixed-citation></ref><ref id="B262"><label>262.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Mesenchymal stem cell-derived extracellular vesicle-enclosed microRNA-93 prevents hypoxic-ischemic brain damage in rats</article-title>. <source>Neuroscience</source>. <year>2022</year>;<volume>500</volume>:<fpage>12</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">35803492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2022.06.037</pub-id></mixed-citation></ref><ref id="B263"><label>263.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>XT</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-93 alleviates neuropathic pain through targeting signal transducer and activator of transcription 3</article-title>. <source>Int Immunopharmacol</source>. <year>2017</year>;<volume>46</volume>:<fpage>156</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">28284149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2017.01.027</pub-id></mixed-citation></ref><ref id="B264"><label>264.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-93 inhibits inflammatory cytokine production in LPS-stimulated murine macrophages by targeting IRAK4</article-title>. <source>FEBS Lett</source>. <year>2014</year>;<volume>588</volume>(<issue>9</issue>):<fpage>1692</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24642374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.febslet.2014.03.013</pub-id></mixed-citation></ref><ref id="B265"><label>265.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yue</surname><given-names>L</given-names></string-name></person-group>. <article-title>Endothelial progenitor cells-secreted extracellular vesicles containing microRNA-93-5p confer protection against sepsis-induced acute kidney injury via the KDM6B/H3K27me3/TNF-&#945; axis</article-title>. <source>Exp Cell Res</source>. <year>2020</year>;<volume>395</volume>(<issue>2</issue>):<fpage>112173</fpage>.<pub-id pub-id-type="pmid">32679234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexcr.2020.112173</pub-id></mixed-citation></ref><ref id="B266"><label>266.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lai</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Systemic exosomal miR-193b-3p delivery attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage in mice</article-title>. <source>J Neuroinflammation</source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>74</fpage>.<pub-id pub-id-type="pmid">32098619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-020-01745-0</pub-id><pub-id pub-id-type="pmcid">PMC7041199</pub-id></mixed-citation></ref><ref id="B267"><label>267.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-193b-3p alleviates focal cerebral ischemia and reperfusion-induced injury in rats by inhibiting 5-lipoxygenase expression</article-title>. <source>Exp Neurol</source>. <year>2020</year>;<volume>327</volume>:<fpage>113223</fpage>.<pub-id pub-id-type="pmid">32032565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2020.113223</pub-id></mixed-citation></ref><ref id="B268"><label>268.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>GATA6 inhibits neuronal autophagy and ferroptosis in cerebral ischemia-reperfusion injury through a miR-193b/ATG7 axis-dependent mechanism</article-title>. <source>Neurochem Res</source>. <year>2023</year>;<volume>48</volume>(<issue>8</issue>):<fpage>2552</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">37059928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-023-03918-8</pub-id></mixed-citation></ref><ref id="B269"><label>269.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name></person-group>. <article-title>MiR-212-3p inhibits LPS-induced inflammatory response through targeting HMGB1 in murine macrophages</article-title>. <source>Exp Cell Res</source>. <year>2017</year>;<volume>350</volume>(<issue>2</issue>):<fpage>318</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">27940320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexcr.2016.12.008</pub-id></mixed-citation></ref><ref id="B270"><label>270.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name></person-group>. <article-title>Silencing LncRNA SNHG16 suppresses the diabetic inflammatory response by targeting the miR-212-3p/NF-&#954;B signaling pathway</article-title>. <source>Diabetol Metab Syndr</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>119</fpage>.<pub-id pub-id-type="pmid">37280692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13098-023-01070-5</pub-id><pub-id pub-id-type="pmcid">PMC10245462</pub-id></mixed-citation></ref><ref id="B271"><label>271.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name></person-group>. <article-title>Regulatory mechanisms of miR-212-3p on the secretion of inflammatory factors in monocyte-macrophages and the directed differentiation into osteoclasts in ankylosing spondylitis</article-title>. <source>Aging</source>. <year>2023</year>;<volume>15</volume>(<issue>22</issue>):<fpage>13411</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">38019469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.205249</pub-id><pub-id pub-id-type="pmcid">PMC10713416</pub-id></mixed-citation></ref><ref id="B272"><label>272.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Choi</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>The miR-126-5p and miR-212-3p in the extracellular vesicles activate monocytes in the early stage of radiation-induced vascular inflammation implicated in atherosclerosis</article-title>. <source>J Extracell Vesicles</source>. <year>2023</year>;<volume>12</volume>(<issue>5</issue>):<fpage>e12325</fpage>.<pub-id pub-id-type="pmid">37140946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jev2.12325</pub-id><pub-id pub-id-type="pmcid">PMC10158827</pub-id></mixed-citation></ref><ref id="B273"><label>273.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Lipopolysaccharide upregulates miR-132/212 in Hirschsprung-associated enterocolitis, facilitating pyroptosis by activating NLRP3 inflammasome via targeting Sirtuin 1 (SIRT1)</article-title>. <source>Aging</source>. <year>2020</year>;<volume>12</volume>(<issue>18</issue>):<fpage>18588</fpage>&#8211;<lpage>602</lpage>.<pub-id pub-id-type="pmid">32950974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103852</pub-id><pub-id pub-id-type="pmcid">PMC7585123</pub-id></mixed-citation></ref><ref id="B274"><label>274.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>XH</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>HF</given-names></string-name></person-group>. <article-title>MiR-451a ameliorates alcoholic hepatitis via repressing HDAC8-mediated proinflammatory response</article-title>. <source>Kaohsiung J Med Sci</source>. <year>2020</year>;<volume>36</volume>(<issue>11</issue>):<fpage>904</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">32643864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/kjm2.12272</pub-id><pub-id pub-id-type="pmcid">PMC11896153</pub-id></mixed-citation></ref><ref id="B275"><label>275.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name></person-group>. <article-title>miR-451 elevation relieves inflammatory pain by suppressing microglial activation-evoked inflammatory response via targeting TLR4</article-title>. <source>Cell Tissue Res</source>. <year>2018</year>;<volume>374</volume>(<issue>3</issue>):<fpage>487</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">30069596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00441-018-2898-7</pub-id></mixed-citation></ref><ref id="B276"><label>276.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name></person-group>. <article-title>MicroRNA-451 attenuates the inflammatory response of activated microglia by downregulating nucleotide binding oligomerization domain-like receptor protein 3</article-title>. <source>World Neurosurg</source>. <year>2022</year>;<volume>167</volume>:<fpage>e1128</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">36087911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2022.08.139</pub-id></mixed-citation></ref><ref id="B277"><label>277.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-467b alleviates lipopolysaccharide-induced inflammation through targeting STAT1 in chondrogenic ATDC5 cells</article-title>. <source>Int J Immunogenet</source>. <year>2021</year>;<volume>48</volume>(<issue>5</issue>):<fpage>435</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">33650224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/iji.12534</pub-id></mixed-citation></ref><ref id="B278"><label>278.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tian</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Ouyang</surname><given-names>XP</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>GJ</given-names></string-name>, <etal/></person-group>. <article-title>The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein E knockout mice</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2014</year>;<volume>443</volume>(<issue>2</issue>):<fpage>428</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">24309104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2013.11.109</pub-id></mixed-citation></ref><ref id="B279"><label>279.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Son</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Takabe</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Alberts-Grill</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis</article-title>. <source>Nat Commun</source>. <year>2013</year>;<volume>4</volume>:<fpage>3000</fpage>.<pub-id pub-id-type="pmid">24346612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms4000</pub-id><pub-id pub-id-type="pmcid">PMC3923891</pub-id></mixed-citation></ref><ref id="B280"><label>280.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Talari</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nayak</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Kain</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Babu</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Misra</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Parsa</surname><given-names>KV</given-names></string-name></person-group>. <article-title>MicroRNA-712 restrains macrophage pro-inflammatory responses by targeting LRRK2 leading to restoration of insulin stimulated glucose uptake by myoblasts</article-title>. <source>Mol Immunol</source>. <year>2017</year>;<volume>82</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27992764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2016.12.014</pub-id></mixed-citation></ref><ref id="B281"><label>281.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pfau</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Menard</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cathomas</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Desland</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kana</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>KL</given-names></string-name>, <etal/></person-group>. <article-title>Role of monocyte-derived MicroRNA106b&#8764;25 in resilience to social stress</article-title>. <source>Biol Psychiatry</source>. <year>2019</year>;<volume>86</volume>(<issue>6</issue>):<fpage>474</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">31101319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2019.02.023</pub-id><pub-id pub-id-type="pmcid">PMC6717005</pub-id></mixed-citation></ref><ref id="B282"><label>282.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luo</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>QS</given-names></string-name></person-group>. <article-title>miR-25-3p ameliorates SAE by targeting the TLR4/NLRP3 axis</article-title>. <source>Metab Brain Dis</source>. <year>2022</year>;<volume>37</volume>(<issue>6</issue>):<fpage>1803</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">35704145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-022-01017-1</pub-id><pub-id pub-id-type="pmcid">PMC9198415</pub-id></mixed-citation></ref><ref id="B283"><label>283.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>H</given-names></string-name></person-group>. <article-title>Suppression of lncRNA OIP5-AS1 attenuates apoptosis and inflammation, and promotes proliferation by mediating miR-25-3p expression in lipopolysaccharide-induced myocardial injury</article-title>. <source>Anal Cell Pathol</source>. <year>2023</year>;<volume>2023</volume>:<fpage>3154223</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2023/3154223</pub-id><pub-id pub-id-type="pmcid">PMC10042636</pub-id><pub-id pub-id-type="pmid">36994450</pub-id></mixed-citation></ref><ref id="B284"><label>284.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shui</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>BMSC-derived exosome-mediated miR-25-3p delivery protects against myocardial ischemia/reperfusion injury by constraining M1-like macrophage polarization</article-title>. <source>Mol Med Rep</source>. <year>2024</year>;<volume>30</volume>(<issue>2</issue>):<fpage>142</fpage>.<pub-id pub-id-type="pmid">38904206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2024.13266</pub-id><pub-id pub-id-type="pmcid">PMC11208993</pub-id></mixed-citation></ref><ref id="B285"><label>285.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>T</given-names></string-name></person-group>. <article-title>Mir-25-3p in extracellular vesicles from fibroblast-like synoviocytes alleviates pyroptosis of chondrocytes in knee osteoarthritis</article-title>. <source>J Bioenerg Biomembr</source>. <year>2023</year>;<volume>55</volume>(<issue>5</issue>):<fpage>365</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">37725203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10863-023-09964-9</pub-id></mixed-citation></ref><ref id="B286"><label>286.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name></person-group>. <article-title>Dysregulation of miR-25-3p in diabetic nephropathy and its role in inflammatory response</article-title>. <source>Biochem Genet</source>. <year>2025</year>;<volume>63</volume>(<issue>2</issue>):<fpage>1635</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">38602597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10528-024-10781-x</pub-id></mixed-citation></ref><ref id="B287"><label>287.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>M2 microglia-derived small extracellular vesicles modulate NSC fate after ischemic stroke via miR-25-3p/miR-93-5p-TGFBR/PTEN/FOXO3 axis</article-title>. <source>J Nanobiotechnology</source>. <year>2025</year>;<volume>23</volume>(<issue>1</issue>):<fpage>311</fpage>.<pub-id pub-id-type="pmid">40270025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-025-03390-2</pub-id><pub-id pub-id-type="pmcid">PMC12020034</pub-id></mixed-citation></ref><ref id="B288"><label>288.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Byun</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Moon</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SH</given-names></string-name>, <etal/></person-group>. <article-title>Effect of salivary exosomal miR-25-3p on periodontitis with insulin resistance</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>775046</fpage>.<pub-id pub-id-type="pmid">35069547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.775046</pub-id><pub-id pub-id-type="pmcid">PMC8777127</pub-id></mixed-citation></ref><ref id="B289"><label>289.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Suk</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>WH</given-names></string-name></person-group>. <article-title>Regulation of inflammatory response by LINC00346 via miR-25-3p-mediated modulation of the PTEN/PI3K/AKT/NF-&#954;B pathway</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2024</year>;<volume>709</volume>:<fpage>149828</fpage>.<pub-id pub-id-type="pmid">38537596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2024.149828</pub-id></mixed-citation></ref><ref id="B290"><label>290.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jung</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tarr</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Reader</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Molecular mechanisms of repeated social defeat-induced glucocorticoid resistance: role of microRNA</article-title>. <source>Brain Behav Immun</source>. <year>2015</year>;<volume>44</volume>:<fpage>195</fpage>&#8211;<lpage>206</lpage>.<pub-id pub-id-type="pmid">25317829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2014.09.015</pub-id><pub-id pub-id-type="pmcid">PMC4275324</pub-id></mixed-citation></ref><ref id="B291"><label>291.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>miR-29b-3p protects cardiomyocytes against endotoxin-induced apoptosis and inflammatory response through targeting FOXO3A</article-title>. <source>Cell Signal</source>. <year>2020</year>;<volume>74</volume>:<fpage>109716</fpage>.<pub-id pub-id-type="pmid">32707074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellsig.2020.109716</pub-id></mixed-citation></ref><ref id="B292"><label>292.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Q</given-names></string-name></person-group>. <article-title>MiR-29b-3p inhibits the inflammation injury in human umbilical vein endothelial cells by regulating SEC23A</article-title>. <source>Biochem Genet</source>. <year>2022</year>;<volume>60</volume>(<issue>6</issue>):<fpage>2000</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">35190931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10528-022-10194-8</pub-id></mixed-citation></ref><ref id="B293"><label>293.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Z</given-names></string-name></person-group>. <article-title>CIRCKLHL2 knockdown alleviates sepsis-induced acute lung injury by regulating miR-29b-3p mediated ROCK1 expression down-regulation</article-title>. <source>Shock</source>. <year>2023</year>;<volume>59</volume>(<issue>1</issue>):<fpage>99</fpage>&#8211;<lpage>107</lpage>.<pub-id pub-id-type="pmid">36476974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000002034</pub-id></mixed-citation></ref><ref id="B294"><label>294.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>She</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-29b-3p promotes particulate matter-induced inflammatory responses by regulating the C1QTNF6/AMPK pathway</article-title>. <source>Aging</source>. <year>2020</year>;<volume>12</volume>(<issue>2</issue>):<fpage>1141</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">31955152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.102672</pub-id><pub-id pub-id-type="pmcid">PMC7053628</pub-id></mixed-citation></ref><ref id="B295"><label>295.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>L</given-names></string-name></person-group>. <article-title>MiR-29b-3p aggravates cardiac hypoxia/reoxygenation injury via targeting PTX3</article-title>. <source>Cytotechnology</source>. <year>2021</year>;<volume>73</volume>(<issue>1</issue>):<fpage>91</fpage>&#8211;<lpage>100</lpage>.<pub-id pub-id-type="pmid">33505117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10616-020-00446-z</pub-id><pub-id pub-id-type="pmcid">PMC7817735</pub-id></mixed-citation></ref><ref id="B296"><label>296.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>microRNA-340-5p inhibits hypoxia/reoxygenation-induced apoptosis and oxidative stress in cardiomyocytes by regulating the Act1/NF-&#954;B pathway</article-title>. <source>J Cell Biochem</source>. <year>2019</year>;<volume>120</volume>(<issue>9</issue>):<fpage>14618</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">30989715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.28723</pub-id></mixed-citation></ref><ref id="B297"><label>297.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mannironi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Camon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>De Vito</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Biundo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>De Stefano</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Persiconi</surname><given-names>I</given-names></string-name>, <etal/></person-group>. <article-title>Acute stress alters amygdala microRNA miR-135a and miR-124 expression: inferences for corticosteroid dependent stress response</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>9</issue>):<fpage>e73385</fpage>.<pub-id pub-id-type="pmid">24023867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0073385</pub-id><pub-id pub-id-type="pmcid">PMC3762773</pub-id></mixed-citation></ref><ref id="B298"><label>298.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rinaldi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vincenti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>De Vito</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bozzoni</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Oliverio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Presutti</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Stress induces region specific alterations in microRNAs expression in mice</article-title>. <source>Behav Brain Res</source>. <year>2010</year>;<volume>208</volume>(<issue>1</issue>):<fpage>265</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19913057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2009.11.012</pub-id></mixed-citation></ref><ref id="B299"><label>299.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Uchida</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nishida</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hara</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kamemoto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Suetsugi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fujimoto</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor</article-title>. <source>Eur J Neurosci</source>. <year>2008</year>;<volume>27</volume>(<issue>9</issue>):<fpage>2250</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">18445216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1460-9568.2008.06218.x</pub-id></mixed-citation></ref><ref id="B300"><label>300.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bazzoni</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rossato</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fabbri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gaudiosi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mirolo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mori</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2009</year>;<volume>106</volume>(<issue>13</issue>):<fpage>5282</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19289835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0810909106</pub-id><pub-id pub-id-type="pmcid">PMC2664036</pub-id></mixed-citation></ref><ref id="B301"><label>301.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chakraborty</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zawieja</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Muthuchamy</surname><given-names>M</given-names></string-name></person-group>. <article-title>MicroRNA signature of inflamed lymphatic endothelium and role of miR-9 in lymphangiogenesis and inflammation</article-title>. <source>Am J Physiol Cell Physiol</source>. <year>2015</year>;<volume>309</volume>(<issue>10</issue>):<fpage>C680</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">26354749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpcell.00122.2015</pub-id><pub-id pub-id-type="pmcid">PMC4652079</pub-id></mixed-citation></ref><ref id="B302"><label>302.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yue</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jing</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>J</given-names></string-name></person-group>. <article-title>Down-regulation of taurine-up-regulated gene 1 attenuates inflammation by sponging miR-9-5p via targeting NF-&#954;B1/p50 in multiple sclerosis</article-title>. <source>Life Sci</source>. <year>2019</year>;<volume>233</volume>:<fpage>116731</fpage>.<pub-id pub-id-type="pmid">31394128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2019.116731</pub-id></mixed-citation></ref><ref id="B303"><label>303.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>miR-9 targeting RUNX1 improves LPS-induced alveolar hypercoagulation and fibrinolysis inhibition through NF-&#954;B inactivation in ARDS</article-title>. <source>Int Immunopharmacol</source>. <year>2023</year>;<volume>120</volume>:<fpage>110318</fpage>.<pub-id pub-id-type="pmid">37201407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2023.110318</pub-id></mixed-citation></ref><ref id="B304"><label>304.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name></person-group>. <article-title>Matrine protects PC12 cells from lipopolysaccharide-evoked inflammatory injury via upregulation of miR-9</article-title>. <source>Pharm Biol</source>. <year>2020</year>;<volume>58</volume>(<issue>1</issue>):<fpage>314</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">32297823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13880209.2020.1719165</pub-id><pub-id pub-id-type="pmcid">PMC7178860</pub-id></mixed-citation></ref><ref id="B305"><label>305.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>D</given-names></string-name></person-group>. <article-title>Exosomal miR-9-5p derived from BMSCs alleviates apoptosis, inflammation and endoplasmic reticulum stress in spinal cord injury by regulating the HDAC5/FGF2 axis</article-title>. <source>Mol Immunol</source>. <year>2022</year>;<volume>145</volume>:<fpage>97</fpage>&#8211;<lpage>108</lpage>.<pub-id pub-id-type="pmid">35316648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2022.03.007</pub-id></mixed-citation></ref><ref id="B306"><label>306.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name></person-group>. <article-title>miR-9 alleviated the inflammatory response and apoptosis in caerulein-induced acute pancreatitis by regulating FGF10 and the NF-&#954;B signaling pathway</article-title>. <source>Exp Ther Med</source>. <year>2021</year>;<volume>22</volume>(<issue>2</issue>):<fpage>795</fpage>.<pub-id pub-id-type="pmid">34093751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2021.10227</pub-id><pub-id pub-id-type="pmcid">PMC8170642</pub-id></mixed-citation></ref><ref id="B307"><label>307.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Que</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Thalidomide attenuates oral epithelial cell apoptosis and pro-inflammatory cytokines secretion induced by radiotherapy via the miR-9-3p/NFATC2/NF-&#954;B axis</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2022</year>;<volume>603</volume>:<fpage>102</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">35279460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2022.03.030</pub-id></mixed-citation></ref><ref id="B308"><label>308.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cui</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Bi</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MiR-9-enriched mesenchymal stem cells derived exosomes prevent cystitis-induced bladder pain via suppressing TLR4/NLRP3 pathway in interstitial cystitis mice</article-title>. <source>Immun Inflamm Dis</source>. <year>2024</year>;<volume>12</volume>(<issue>2</issue>):<fpage>e1140</fpage>.<pub-id pub-id-type="pmid">38415918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/iid3.1140</pub-id><pub-id pub-id-type="pmcid">PMC10836038</pub-id></mixed-citation></ref><ref id="B309"><label>309.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>MiR-9 promotes microglial activation by targeting MCPIP1</article-title>. <source>Nat Commun</source>. <year>2014</year>;<volume>5</volume>:<fpage>4386</fpage>.<pub-id pub-id-type="pmid">25019481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms5386</pub-id><pub-id pub-id-type="pmcid">PMC4104446</pub-id></mixed-citation></ref><ref id="B310"><label>310.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thiele</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wittmann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>J&#228;ck</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Pahl</surname><given-names>A</given-names></string-name></person-group>. <article-title>miR-9 enhances IL-2 production in activated human CD4(+) T cells by repressing Blimp-1</article-title>. <source>Eur J Immunol</source>. <year>2012</year>;<volume>42</volume>:<fpage>2100</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22585398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.201142203</pub-id></mixed-citation></ref><ref id="B311"><label>311.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name></person-group>. <article-title>MiR-18a-3p improves cartilage matrix remodeling and inhibits inflammation in osteoarthritis by suppressing PDP1</article-title>. <source>J Physiol Sci</source>. <year>2022</year>;<volume>72</volume>(<issue>1</issue>):<fpage>3</fpage>.<pub-id pub-id-type="pmid">35148687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12576-022-00827-3</pub-id><pub-id pub-id-type="pmcid">PMC10717587</pub-id></mixed-citation></ref><ref id="B312"><label>312.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>ZF</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>XJ</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>SQ</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>SY</given-names></string-name>, <etal/></person-group>. <article-title>Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR-18a-3p/Gsdmd pathway</article-title>. <source>Int J Mol Med</source>. <year>2023</year>;<volume>51</volume>(<issue>6</issue>):<fpage>49</fpage>.<pub-id pub-id-type="pmid">37114562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2023.5252</pub-id></mixed-citation></ref><ref id="B313"><label>313.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>L</given-names></string-name></person-group>. <article-title>LncRNA CYP1B1-AS1 as a clinical biomarker exacerbates sepsis inflammatory response via targeting miR- 18a- 5p</article-title>. <source>BMC Immunol</source>. <year>2025</year>;<volume>26</volume>(<issue>1</issue>):<fpage>32</fpage>.<pub-id pub-id-type="pmid">40234801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12865-025-00712-9</pub-id><pub-id pub-id-type="pmcid">PMC12001399</pub-id></mixed-citation></ref><ref id="B314"><label>314.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Circulating exosomal microRNA-18a-5p accentuates intestinal inflammation in Hirschsprung-associated enterocolitis by targeting RORA</article-title>. <source>Am J Transl Res</source>. <year>2021</year>;<volume>13</volume>(<issue>5</issue>):<fpage>4182</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">34150007</pub-id><pub-id pub-id-type="pmcid">PMC8205693</pub-id></mixed-citation></ref><ref id="B315"><label>315.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Piao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name></person-group>. <article-title>Propofol synergizes with circAPBB2 to protect against hypoxia/reoxygenation-induced oxidative stress, inflammation, and apoptosis of human cardiomyocytes</article-title>. <source>Immun Inflamm Dis</source>. <year>2023</year>;<volume>11</volume>(<issue>8</issue>):<fpage>e952</fpage>.<pub-id pub-id-type="pmid">37647434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/iid3.952</pub-id><pub-id pub-id-type="pmcid">PMC10408373</pub-id></mixed-citation></ref><ref id="B316"><label>316.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sommar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>miR-19a/b and miR-20a promote wound healing by regulating the inflammatory response of keratinocytes</article-title>. <source>J Invest Dermatol</source>. <year>2021</year>;<volume>141</volume>(<issue>3</issue>):<fpage>659</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">32949564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2020.06.037</pub-id></mixed-citation></ref><ref id="B317"><label>317.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Quan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Reciprocal inhibition between miR-26a and NF-&#954;B regulates obesity-related chronic inflammation in chondrocytes</article-title>. <source>Biosci Rep</source>. <year>2015</year>;<volume>35</volume>(<issue>3</issue>):<fpage>e00204</fpage>.<pub-id pub-id-type="pmid">26182366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20150071</pub-id><pub-id pub-id-type="pmcid">PMC4613702</pub-id></mixed-citation></ref><ref id="B318"><label>318.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yue</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Downregulation of growth arrest-specific transcript 5 alleviates palmitic acid-induced myocardial inflammatory injury through the miR-26a/HMGB1/NF-&#954;B axis</article-title>. <source>Mol Med Rep</source>. <year>2018</year>;<volume>18</volume>(<issue>6</issue>):<fpage>5742</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">30365114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2018.9593</pub-id></mixed-citation></ref><ref id="B319"><label>319.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Inhibiting Rab27a in renal tubular epithelial cells attenuates the inflammation of diabetic kidney disease through the miR-26a-5p/CHAC1/NF-kB pathway</article-title>. <source>Life Sci</source>. <year>2020</year>;<volume>261</volume>:<fpage>118347</fpage>.<pub-id pub-id-type="pmid">32853650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.118347</pub-id></mixed-citation></ref><ref id="B320"><label>320.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></string-name></person-group>. <article-title>miR-26a-5p attenuates oxidative stress and inflammation in diabetic retinopathy through the USP14/NF-&#954;B signaling pathway</article-title>. <source>J Ophthalmol</source>. <year>2024</year>;<volume>2024</volume>:<fpage>1470898</fpage>.<pub-id pub-id-type="pmid">38282961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2024/1470898</pub-id><pub-id pub-id-type="pmcid">PMC10817816</pub-id></mixed-citation></ref><ref id="B321"><label>321.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Effect of miR-26a-5p targeting ADAM17 gene on apoptosis, inflammatory factors and oxidative stress response of myocardial cells in hypoxic model</article-title>. <source>J Bioenerg Biomembr</source>. <year>2020</year>;<volume>52</volume>(<issue>2</issue>):<fpage>83</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">32170604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10863-020-09829-5</pub-id></mixed-citation></ref><ref id="B322"><label>322.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-26a inhibits the inflammatory response of microglia by targeting HMGA2 in intracerebral hemorrhage</article-title>. <source>J Int Med Res</source>. <year>2020</year>;<volume>48</volume>(<issue>6</issue>):<fpage>300060520929615</fpage>.<pub-id pub-id-type="pmid">32588686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300060520929615</pub-id><pub-id pub-id-type="pmcid">PMC7325462</pub-id></mixed-citation></ref><ref id="B323"><label>323.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>MiR-26a reduces inflammatory responses via inhibition of PGE2 production by targeting COX-2</article-title>. <source>Inflammation</source>. <year>2022</year>;<volume>45</volume>(<issue>4</issue>):<fpage>1484</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">35083625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-022-01631-2</pub-id><pub-id pub-id-type="pmcid">PMC8791555</pub-id></mixed-citation></ref><ref id="B324"><label>324.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Bone mesenchymal stem cell-derived exosomal miR-26a-3p promotes autophagy to attenuate LPS-induced apoptosis and inflammation in pulmonary microvascular endothelial cells</article-title>. <source>Cell Mol Biol</source>. <year>2024</year>;<volume>70</volume>(<issue>2</issue>):<fpage>104</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.14715/cmb/2024.70.2.15</pub-id><pub-id pub-id-type="pmid">38430034</pub-id></mixed-citation></ref><ref id="B325"><label>325.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Bi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name></person-group>. <article-title>Cellular microRNA miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by activating innate antiviral immunity</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>:<fpage>10651</fpage>.<pub-id pub-id-type="pmid">26013676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep10651</pub-id><pub-id pub-id-type="pmcid">PMC4445041</pub-id></mixed-citation></ref><ref id="B326"><label>326.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sahu</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chakraborty</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Banerjee</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA 26a (miR-26a)/KLF4 and CREB-C/EBP&#946; regulate innate immune signaling, the polarization of macrophages and the trafficking of Mycobacterium tuberculosis to lysosomes during infection</article-title>. <source>PLoS Pathog</source>. <year>2017</year>;<volume>13</volume>(<issue>5</issue>):<fpage>e1006410</fpage>.<pub-id pub-id-type="pmid">28558034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1006410</pub-id><pub-id pub-id-type="pmcid">PMC5466338</pub-id></mixed-citation></ref><ref id="B327"><label>327.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwon</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Eom</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-26a/-26b-COX-2-MIP-2 loop regulates allergic inflammation and allergic inflammation-promoted enhanced tumorigenic and metastatic potential of cancer cells</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>(<issue>22</issue>):<fpage>14245</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">25907560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M115.645580</pub-id><pub-id pub-id-type="pmcid">PMC4447993</pub-id></mixed-citation></ref><ref id="B328"><label>328.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MicroRNA-26b inhibits the immune response to Mycobacterium tuberculosis (M.tb) infection in THP-1 cells via targeting TGF&#946;-activated kinase-1 (TAK1), a promoter of the NF-&#954;B pathway</article-title>. <source>Int J Clin Exp Pathol</source>. <year>2018</year>;<volume>11</volume>(<issue>3</issue>):<fpage>1218</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">31938216</pub-id><pub-id pub-id-type="pmcid">PMC6958124</pub-id></mixed-citation></ref><ref id="B329"><label>329.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kang</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>WS</given-names></string-name></person-group>. <article-title>MicroRNA-26b regulates the microglial inflammatory response in hypoxia/ischemia and affects the development of vascular cognitive impairment</article-title>. <source>Front Cell Neurosci</source>. <year>2018</year>;<volume>12</volume>:<fpage>154</fpage>.<pub-id pub-id-type="pmid">29937716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2018.00154</pub-id><pub-id pub-id-type="pmcid">PMC6002499</pub-id></mixed-citation></ref><ref id="B330"><label>330.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ge</surname><given-names>ZW</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>XL</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-26b relieves inflammatory response and myocardial remodeling of mice with myocardial infarction by suppression of MAPK pathway through binding to PTGS2</article-title>. <source>Int J Cardiol</source>. <year>2019</year>;<volume>280</volume>:<fpage>152</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30679074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2018.12.077</pub-id></mixed-citation></ref><ref id="B331"><label>331.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shangguan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>H</given-names></string-name></person-group>. <article-title>GAS5 knockdown ameliorates apoptosis and inflammatory response by modulating miR-26b-5p/Smad1 axis in cerebral ischaemia/reperfusion injury</article-title>. <source>Behav Brain Res</source>. <year>2020</year>;<volume>379</volume>:<fpage>112370</fpage>.<pub-id pub-id-type="pmid">31751592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2019.112370</pub-id></mixed-citation></ref><ref id="B332"><label>332.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Decoction of heat-clearing, detoxifying and blood stasis removing relieves acute soft tissue injury via modulating MiR-26b-5p/COX2 Axis to inhibit inflammation</article-title>. <source>Biosci Rep</source>. <year>2020</year>;<volume>40</volume>(<issue>12</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20201981</pub-id><pub-id pub-id-type="pmcid">PMC7753743</pub-id><pub-id pub-id-type="pmid">33270831</pub-id></mixed-citation></ref><ref id="B333"><label>333.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veremeyko</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Siddiqui</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sotnikov</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Yung</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ponomarev</surname><given-names>ED</given-names></string-name></person-group>. <article-title>IL-4/IL-13-dependent and independent expression of miR-124 and its contribution to M2 phenotype of monocytic cells in normal conditions and during allergic inflammation</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>12</issue>):<fpage>e81774</fpage>.<pub-id pub-id-type="pmid">24358127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0081774</pub-id><pub-id pub-id-type="pmcid">PMC3864800</pub-id></mixed-citation></ref><ref id="B334"><label>334.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>MiR-124 contributes to M2 polarization of microglia and confers brain inflammatory protection via the C/EBP-&#945; pathway in intracerebral hemorrhage</article-title>. <source>Immunol Lett</source>. <year>2017</year>;<volume>182</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">28025043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imlet.2016.12.003</pub-id></mixed-citation></ref><ref id="B335"><label>335.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Mycobacterium bovis BCG triggered MyD88 induces miR-124 feedback negatively regulates immune response in alveolar epithelial cells</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>4</issue>):<fpage>e92419</fpage>.<pub-id pub-id-type="pmid">24705038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0092419</pub-id><pub-id pub-id-type="pmcid">PMC3976256</pub-id></mixed-citation></ref><ref id="B336"><label>336.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>miR-124a inhibits the proliferation and inflammation in rheumatoid arthritis fibroblast-like synoviocytes via targeting PIK3/NF-&#954;B pathway</article-title>. <source>Cell Biochem Funct</source>. <year>2019</year>;<volume>37</volume>(<issue>4</issue>):<fpage>208</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">30941802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbf.3386</pub-id></mixed-citation></ref><ref id="B337"><label>337.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>K</given-names></string-name></person-group>. <article-title>miR-124-5p/NOX2 Axis modulates the ROS production and the inflammatory microenvironment to protect against the cerebral I/R injury</article-title>. <source>Neurochem Res</source>. <year>2020</year>;<volume>45</volume>(<issue>2</issue>):<fpage>404</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">31950451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-019-02931-0</pub-id></mixed-citation></ref><ref id="B338"><label>338.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manoharan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Basford</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Pilcher-Roberts</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Neumann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hui</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Lingrel</surname><given-names>JB</given-names></string-name></person-group>. <article-title>Reduced levels of microRNAs miR-124a and miR-150 are associated with increased proinflammatory mediator expression in Kr&#252;ppel-like factor 2 (KLF2)-deficient macrophages</article-title>. <source>J Biol Chem</source>. <year>2014</year>;<volume>289</volume>(<issue>45</issue>):<fpage>31638</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25248747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.579763</pub-id><pub-id pub-id-type="pmcid">PMC4223359</pub-id></mixed-citation></ref><ref id="B339"><label>339.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heyn</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luchting</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hinske</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>H&#252;bner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Azad</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Kreth</surname><given-names>S</given-names></string-name></person-group>. <article-title>miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain</article-title>. <source>J Neuroinflammation</source>. <year>2016</year>;<volume>13</volume>(<issue>1</issue>):<fpage>248</fpage>.<pub-id pub-id-type="pmid">27646435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-016-0712-6</pub-id><pub-id pub-id-type="pmcid">PMC5029065</pub-id></mixed-citation></ref><ref id="B340"><label>340.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name></person-group>. <article-title>miR-124-3p ameliorates isoflurane-induced learning and memory impairment via targeting STAT3 and inhibiting neuroinflammation</article-title>. <source>Neuroimmunomodulation</source>. <year>2021</year>;<volume>28</volume>(<issue>4</issue>):<fpage>248</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">34392240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000515661</pub-id></mixed-citation></ref><ref id="B341"><label>341.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>X</given-names></string-name></person-group>. <article-title>miR-124-3p inhibits microglial secondary inflammation after basal ganglia hemorrhage by targeting TRAF6 and repressing the activation of NLRP3 inflammasome</article-title>. <source>Front Neurol</source>. <year>2021</year>;<volume>12</volume>:<fpage>653321</fpage>.<pub-id pub-id-type="pmid">34413820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.653321</pub-id><pub-id pub-id-type="pmcid">PMC8369369</pub-id></mixed-citation></ref><ref id="B342"><label>342.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mavroudis</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Balmus</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Ciobica</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nicoara</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Luca</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Palade</surname><given-names>DO</given-names></string-name></person-group>. <article-title>The role of microglial exosomes and miR-124-3p in neuroinflammation and neuronal repair after traumatic brain injury</article-title>. <source>Life (Basel, Switz</source>. <year>2023</year>;<volume>13</volume>(<issue>9</issue>):<fpage>1924</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life13091924</pub-id><pub-id pub-id-type="pmcid">PMC10532687</pub-id><pub-id pub-id-type="pmid">37763327</pub-id></mixed-citation></ref><ref id="B343"><label>343.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name></person-group>. <article-title>MiR-135a is highly expressed and aggravates inflammatory response in sepsis by targeting MYOM1</article-title>. <source>Acta Biochim Pol</source>. <year>2022</year>;<volume>69</volume>(<issue>3</issue>):<fpage>587</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">35977075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18388/abp.2020_5882</pub-id></mixed-citation></ref><ref id="B344"><label>344.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MiR-135a protects vascular endothelial cells against ventilator-induced lung injury by inhibiting PHLPP2 to activate PI3K/akt pathway</article-title>. <source>Cell Physiol Biochem</source>. <year>2018</year>;<volume>48</volume>(<issue>3</issue>):<fpage>1245</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">30045018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000492010</pub-id></mixed-citation></ref><ref id="B345"><label>345.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>Q</given-names></string-name></person-group>. <article-title>miR-135a protects dextran sodium sulfate-induced inflammation in human colorectal cell lines by activating STAT3 signal</article-title>. <source>Cell Physiol Biochem</source>. <year>2018</year>;<volume>51</volume>(<issue>3</issue>):<fpage>1001</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30476915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000495481</pub-id></mixed-citation></ref><ref id="B346"><label>346.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>XJ</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>JM</given-names></string-name></person-group>. <article-title>MiR-135a represses oxidative stress and vascular inflammatory events via targeting toll-like receptor 4 in atherogenesis</article-title>. <source>J Cell Biochem</source>. <year>2018</year>;<volume>119</volume>(<issue>7</issue>):<fpage>6154</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">29663503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.26819</pub-id></mixed-citation></ref><ref id="B347"><label>347.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Z</given-names></string-name></person-group>. <article-title>miR-135a alleviates silica-induced pulmonary fibrosis by targeting NF-&#954;B/Inflammatory signaling pathway</article-title>. <source>Mediators Inflamm</source>. <year>2020</year>;<volume>2020</volume>:<fpage>1231243</fpage>.<pub-id pub-id-type="pmid">32617074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/1231243</pub-id><pub-id pub-id-type="pmcid">PMC7317310</pub-id></mixed-citation></ref><ref id="B348"><label>348.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Suo</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>K</given-names></string-name></person-group>. <article-title>MicroRNA let-7a ameliorates con A-induced hepatitis by inhibiting IL-6-dependent Th17 cell differentiation</article-title>. <source>J Clin Immunol</source>. <year>2013</year>;<volume>33</volume>(<issue>3</issue>):<fpage>630</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23184091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10875-012-9840-7</pub-id></mixed-citation></ref><ref id="B349"><label>349.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cho</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JE</given-names></string-name></person-group>. <article-title>MicroRNA-Let-7a regulates the function of microglia in inflammation</article-title>. <source>Mol Cell Neurosci</source>. <year>2015</year>;<volume>68</volume>:<fpage>167</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">26221772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcn.2015.07.004</pub-id></mixed-citation></ref><ref id="B350"><label>350.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MiR-let-7a regulates anti-citrullinated protein antibody-induced macrophage activation and correlates with the development of experimental rheumatoid arthritis</article-title>. <source>Int Immunopharmacol</source>. <year>2017</year>;<volume>51</volume>:<fpage>40</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">28802150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2017.08.001</pub-id></mixed-citation></ref><ref id="B351"><label>351.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Let-7a promotes microglia M2 polarization by targeting CKIP-1 following ICH</article-title>. <source>Immunol Lett</source>. <year>2018</year>;<volume>202</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">30053453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imlet.2018.07.007</pub-id></mixed-citation></ref><ref id="B352"><label>352.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dongwei</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xinhui</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Kunwang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Guohui</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>miR-let-7a suppresses &#945;-Synuclein-induced microglia inflammation through targeting STAT3 in Parkinson's disease</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2019</year>;<volume>519</volume>(<issue>4</issue>):<fpage>740</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">31547989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2019.08.140</pub-id></mixed-citation></ref><ref id="B353"><label>353.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hua</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>QQ</given-names></string-name>, <string-name name-style="western"><surname>Kalagbor</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>GZ</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bian</surname><given-names>ZR</given-names></string-name>, <etal/></person-group>. <article-title>Recombinant adeno-associated virus 8-mediated inhibition of microRNA let-7a ameliorates sclerosing cholangitis in a clinically relevant mouse model</article-title>. <source>World J Gastroenterol</source>. <year>2024</year>;<volume>30</volume>(<issue>5</issue>):<fpage>471</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">38414587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v30.i5.471</pub-id><pub-id pub-id-type="pmcid">PMC10895596</pub-id></mixed-citation></ref><ref id="B354"><label>354.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>YS</given-names></string-name>, <etal/></person-group>. <article-title>Engineered extracellular vesicles carrying let-7a-5p for alleviating inflammation in acute lung injury</article-title>. <source>J Biomed Sci</source>. <year>2024</year>;<volume>31</volume>(<issue>1</issue>):<fpage>30</fpage>.<pub-id pub-id-type="pmid">38500170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-024-01019-4</pub-id><pub-id pub-id-type="pmcid">PMC10949767</pub-id></mixed-citation></ref><ref id="B355"><label>355.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chafin</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Regna</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Caudell</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Reilly</surname><given-names>CM</given-names></string-name></person-group>. <article-title>MicroRNA-let-7a promotes E2F-mediated cell proliferation and NF&#954;B activation in vitro</article-title>. <source>Cell Mol Immunol</source>. <year>2014</year>;<volume>11</volume>(<issue>1</issue>):<fpage>79</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">24240124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cmi.2013.51</pub-id><pub-id pub-id-type="pmcid">PMC3947333</pub-id></mixed-citation></ref><ref id="B356"><label>356.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>ZK</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>FF</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>XM</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>XF</given-names></string-name></person-group>. <article-title>Let-7a gene knockdown protects against cerebral ischemia/reperfusion injury</article-title>. <source>Neural Regen Res</source>. <year>2016</year>;<volume>11</volume>(<issue>2</issue>):<fpage>262</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27073379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.177734</pub-id><pub-id pub-id-type="pmcid">PMC4810990</pub-id></mixed-citation></ref><ref id="B357"><label>357.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beninson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>PN</given-names></string-name>, <string-name name-style="western"><surname>Loughridge</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Saludes</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Maslanik</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hills</surname><given-names>AK</given-names></string-name>, <etal/></person-group>. <article-title>Acute stressor exposure modifies plasma exosome-associated heat shock protein 72 (Hsp72) and microRNA (miR-142-5p and miR-203)</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>:<fpage>e108748</fpage>.<pub-id pub-id-type="pmid">25259839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0108748</pub-id><pub-id pub-id-type="pmcid">PMC4178201</pub-id></mixed-citation></ref><ref id="B358"><label>358.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chaudhuri</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Yelamanchili</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Marcondes</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Up-regulation of microRNA-142 in simian immunodeficiency virus encephalitis leads to repression of sirtuin1</article-title>. <source>Faseb J</source>. <year>2013</year>;<volume>27</volume>:<fpage>3720</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23752207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.13-232678</pub-id><pub-id pub-id-type="pmcid">PMC3752547</pub-id></mixed-citation></ref><ref id="B359"><label>359.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Talebi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ghorbani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Boghozian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Masoumi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ghasemi</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis</article-title>. <source>J Neuroinflammation</source>. <year>2017</year>;<volume>14</volume>(<issue>1</issue>):<fpage>55</fpage>.<pub-id pub-id-type="pmid">28302134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-017-0832-7</pub-id><pub-id pub-id-type="pmcid">PMC5356264</pub-id></mixed-citation></ref><ref id="B360"><label>360.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Han</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Ahn</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Ha</surname><given-names>CH</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-142-5p is up-regulated on allogeneic immune responses and up-regulates MHC class II expression in human umbilical vein endothelial cells</article-title>. <source>Transpl Proc</source>. <year>2021</year>;<volume>53</volume>(<issue>1</issue>):<fpage>408</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.transproceed.2020.05.024</pub-id><pub-id pub-id-type="pmid">32616346</pub-id></mixed-citation></ref><ref id="B361"><label>361.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name></person-group>. <article-title>Clinical significance of miR-142-5p in spinal cord injury caused by spinal trauma and its functional role in the regulation of inflammation</article-title>. <source>J Spinal Cord Med</source>. <year>2022</year>;<volume>45</volume>(<issue>6</issue>):<fpage>957</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">33905318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10790268.2021.1911505</pub-id><pub-id pub-id-type="pmcid">PMC9662015</pub-id></mixed-citation></ref><ref id="B362"><label>362.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wong</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Au</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pinello</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kwok</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Thoeng</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever</article-title>. <source>Nucleic Acids Res</source>. <year>2016</year>;<volume>44</volume>(<issue>6</issue>):<fpage>2888</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">26825461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkw041</pub-id><pub-id pub-id-type="pmcid">PMC4824108</pub-id></mixed-citation></ref><ref id="B363"><label>363.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anandagoda</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Willis</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Hertweck</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>G&#246;kmen</surname><given-names>MR</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-142-mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance</article-title>. <source>J Clin Investig</source>. <year>2019</year>;<volume>129</volume>(<issue>3</issue>):<fpage>1257</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">30741720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI124725</pub-id><pub-id pub-id-type="pmcid">PMC6391082</pub-id></mixed-citation></ref><ref id="B364"><label>364.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nie</surname><given-names>PY</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>LL</given-names></string-name></person-group>. <article-title>miR-142 downregulation alleviates rat PTSD-like behaviors, reduces the level of inflammatory cytokine expression and apoptosis in hippocampus, and upregulates the expression of fragile X mental retardation protein</article-title>. <source>J Neuroinflammation</source>. <year>2021</year>;<volume>18</volume>(<issue>1</issue>):<fpage>17</fpage>.<pub-id pub-id-type="pmid">33407653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-020-02064-0</pub-id><pub-id pub-id-type="pmcid">PMC7788709</pub-id></mixed-citation></ref><ref id="B365"><label>365.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sui</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>MiR-142-5p directly targets cyclin-dependent kinase 5-mediated upregulation of the inflammatory process in acquired middle ear cholesteatoma</article-title>. <source>Mol Immunol</source>. <year>2022</year>;<volume>141</volume>:<fpage>236</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">34875451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2021.11.017</pub-id></mixed-citation></ref><ref id="B366"><label>366.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name></person-group>. <article-title>CircSEC24A promotes IL-1&#946;-induced apoptosis and inflammation in chondrocytes by regulating miR-142-5p/SOX5 axis</article-title>. <source>Biotechnol Appl Biochem</source>. <year>2022</year>;<volume>69</volume>(<issue>2</issue>):<fpage>701</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">33751650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bab.2145</pub-id></mixed-citation></ref><ref id="B367"><label>367.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wiegand</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Heusser</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Klinger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cysarz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>B&#252;ssing</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ostermann</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Stress-associated changes in salivary microRNAs can be detected in response to the Trier Social Stress Test: an exploratory study</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>7112</fpage>.<pub-id pub-id-type="pmid">29740073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-25554-x</pub-id><pub-id pub-id-type="pmcid">PMC5940676</pub-id></mixed-citation></ref><ref id="B368"><label>368.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>H</given-names></string-name></person-group>. <article-title>Alveolar macrophage-derived vascular endothelial growth factor contributes to allergic airway inflammation in a mouse asthma model</article-title>. <source>Scand J Immunol</source>. <year>2012</year>;<volume>75</volume>(<issue>6</issue>):<fpage>599</fpage>&#8211;<lpage>605</lpage>.<pub-id pub-id-type="pmid">22324377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-3083.2012.02693.x</pub-id></mixed-citation></ref><ref id="B369"><label>369.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>W</given-names></string-name></person-group>. <article-title>MiR-20b inhibits mycobacterium tuberculosis induced inflammation in the lung of mice through targeting NLRP3</article-title>. <source>Exp Cell Res</source>. <year>2017</year>;<volume>358</volume>(<issue>2</issue>):<fpage>120</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28606793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexcr.2017.06.007</pub-id></mixed-citation></ref><ref id="B370"><label>370.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name></person-group>. <article-title>Elevated microRNA-20b-3p and reduced thioredoxin-interacting protein ameliorate diabetic retinopathy progression by suppressing the NLRP3 inflammasomes</article-title>. <source>IUBMB life</source>. <year>2020</year>;<volume>72</volume>(<issue>7</issue>):<fpage>1433</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">32150340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/iub.2267</pub-id></mixed-citation></ref><ref id="B371"><label>371.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Analysis of miRNA and mRNA reveals core interaction networks and pathways of dexamethasone-induced immunosuppression in chicken bursa of Fabricius</article-title>. <source>Mol Immunol</source>. <year>2021</year>;<volume>134</volume>:<fpage>34</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">33711668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2021.02.022</pub-id></mixed-citation></ref><ref id="B372"><label>372.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tang</surname><given-names>GX</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>ZL</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>SP</given-names></string-name></person-group>. <article-title>MiR-20b-5p modulates inflammation, apoptosis and angiogenesis in severe acute pancreatitis through autophagy by targeting AKT3</article-title>. <source>Autoimmunity</source>. <year>2021</year>;<volume>54</volume>(<issue>7</issue>):<fpage>460</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">34402705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08916934.2021.1953484</pub-id></mixed-citation></ref><ref id="B373"><label>373.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ruan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name></person-group>. <article-title>miR-20b attenuates airway inflammation by regulating TXNIP and NLRP3 inflammasome in ovalbumin-induced asthmatic mice</article-title>. <source>J Asthma</source>. <year>2023</year>;<volume>60</volume>(<issue>11</issue>):<fpage>2040</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">37167014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02770903.2023.2213332</pub-id></mixed-citation></ref><ref id="B374"><label>374.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Katsuura</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kuwano</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yamagishi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kurokawa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kajita</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Akaike</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNAs miR-144/144* and miR-16 in peripheral blood are potential biomarkers for naturalistic stress in healthy Japanese medical students</article-title>. <source>Neurosci Lett</source>. <year>2012</year>;<volume>516</volume>(<issue>1</issue>):<fpage>79</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">22484483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2012.03.062</pub-id></mixed-citation></ref><ref id="B375"><label>375.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>XF</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>QB</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>ZY</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-144 suppresses the expression of cytokines through targeting RANKL in the matured immune cells</article-title>. <source>Cytokine</source>. <year>2018</year>;<volume>108</volume>:<fpage>197</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="pmid">29684757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2018.03.043</pub-id></mixed-citation></ref><ref id="B376"><label>376.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MiR-144-5p limits experimental abdominal aortic aneurysm formation by mitigating M1 macrophage-associated inflammation: suppression of TLR2 and OLR1</article-title>. <source>J Mol Cell Cardiol</source>. <year>2020</year>;<volume>143</volume>:<fpage>1</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">32278833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yjmcc.2020.04.008</pub-id></mixed-citation></ref><ref id="B377"><label>377.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name></person-group>. <article-title>LncRNA TM1-3P regulates proliferation, apoptosis and inflammation of fibroblasts in osteoarthritis through miR-144-3p/ONECUT2 Axis</article-title>. <source>Orthop Surg</source>. <year>2022</year>;<volume>14</volume>(<issue>11</issue>):<fpage>3078</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">36178080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/os.13530</pub-id><pub-id pub-id-type="pmcid">PMC9627084</pub-id></mixed-citation></ref><ref id="B378"><label>378.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name></person-group>. <article-title>Huc-MSC-derived exosomal miR-144 alleviates inflammation in LPS-induced preeclampsia-like pregnant rats via the FosB/Flt-1 pathway</article-title>. <source>Heliyon</source>. <year>2024</year>;<volume>10</volume>(<issue>2</issue>):<fpage>e24575</fpage>.<pub-id pub-id-type="pmid">38304844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e24575</pub-id><pub-id pub-id-type="pmcid">PMC10830578</pub-id></mixed-citation></ref><ref id="B379"><label>379.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name></person-group>. <article-title>The role of MicroRNA-144 in regulating airway immune dysfunction in COPD through the transforming growth factor-beta/polymeric immunoglobulin receptor pathway: an in vitro study</article-title>. <source>Chronic Obstr Pulm Dis</source>. <year>2025</year>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15326/jcopdf.2024.0592</pub-id><pub-id pub-id-type="pmcid">PMC12429530</pub-id><pub-id pub-id-type="pmid">40338977</pub-id></mixed-citation></ref><ref id="B380"><label>380.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>YW</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>YR</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>SG</given-names></string-name>, <etal/></person-group>. <article-title>An agomir of miR-144-3p accelerates plaque formation through impairing reverse cholesterol transport and promoting pro-inflammatory cytokine production</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>4</issue>):<fpage>e94997</fpage>.<pub-id pub-id-type="pmid">24733347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0094997</pub-id><pub-id pub-id-type="pmcid">PMC3986368</pub-id></mixed-citation></ref><ref id="B381"><label>381.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Csiszar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gautam</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sosnowska</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tarantini</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Banki</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tucsek</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Caloric restriction confers persistent anti-oxidative, pro-angiogenic, and anti-inflammatory effects and promotes anti-aging miRNA expression profile in cerebromicrovascular endothelial cells of aged rats</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2014</year>;<volume>307</volume>(<issue>3</issue>):<fpage>H292</fpage>&#8211;<lpage>306</lpage>.<pub-id pub-id-type="pmid">24906921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpheart.00307.2014</pub-id><pub-id pub-id-type="pmcid">PMC4121647</pub-id></mixed-citation></ref><ref id="B382"><label>382.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name></person-group>. <article-title>LncRNA LOC729178 acts as a sponge of miR-144-3p to mitigate cigarette smoke extract-induced inflammatory injury via regulating PHLPP2 in 16HBE cells</article-title>. <source>J Mol Histol</source>. <year>2021</year>;<volume>52</volume>(<issue>3</issue>):<fpage>437</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">33847879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10735-021-09972-2</pub-id></mixed-citation></ref><ref id="B383"><label>383.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Circ_0066881 targets miR-144-5p/RORA axis to alleviate LPS-induced apoptotic and inflammatory damages in human periodontal ligament cells</article-title>. <source>Innate Immun</source>. <year>2022</year>;<volume>28</volume>(<issue>5</issue>):<fpage>164</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">35635221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17534259221079812</pub-id><pub-id pub-id-type="pmcid">PMC9189553</pub-id></mixed-citation></ref><ref id="B384"><label>384.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Suppression of microRNA-144-3p attenuates oxygen-glucose deprivation/reoxygenation-induced neuronal injury by promoting Brg1/Nrf2/ARE signaling</article-title>. <source>J Biochem Mol Toxicol</source>. <year>2018</year>;<volume>32</volume>(<issue>4</issue>):<fpage>e22044</fpage>.<pub-id pub-id-type="pmid">29457851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jbt.22044</pub-id></mixed-citation></ref><ref id="B385"><label>385.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>WH</given-names></string-name></person-group>. <article-title>Overexpression of long non-coding RNA Rian attenuates cell apoptosis from cerebral ischemia-reperfusion injury via Rian/miR-144-3p/GATA3 signaling</article-title>. <source>Gene</source>. <year>2020</year>;<volume>737</volume>:<fpage>144411</fpage>.<pub-id pub-id-type="pmid">32006596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gene.2020.144411</pub-id></mixed-citation></ref><ref id="B386"><label>386.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mongrain</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Hernandez</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Pradervand</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dorsaz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Curie</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hagiwara</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Separating the contribution of glucocorticoids and wakefulness to the molecular and electrophysiological correlates of sleep homeostasis</article-title>. <source>Sleep</source>. <year>2010</year>;<volume>33</volume>(<issue>9</issue>):<fpage>1147</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">20857860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/sleep/33.9.1147</pub-id><pub-id pub-id-type="pmcid">PMC2938796</pub-id></mixed-citation></ref><ref id="B387"><label>387.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name></person-group>. <article-title>Long noncoding RNA NEAT1 knockdown inhibits MPP<sup>+</sup>-induced apoptosis, inflammation and cytotoxicity in SK-N-SH cells by regulating miR-212-5p/RAB3IP axis</article-title>. <source>Neurosci Lett</source>. <year>2020</year>;<volume>731</volume>:<fpage>135060</fpage>.<pub-id pub-id-type="pmid">32442477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2020.135060</pub-id></mixed-citation></ref><ref id="B388"><label>388.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hua</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>D</given-names></string-name></person-group>. <article-title>MicroRNA-212-5p regulates the inflammatory response of periodontal ligament cells by targeting myeloid differentiation factor 88</article-title>. <source>Arch Oral Biol</source>. <year>2020</year>;<volume>118</volume>:<fpage>104831</fpage>.<pub-id pub-id-type="pmid">32707140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.archoralbio.2020.104831</pub-id></mixed-citation></ref><ref id="B389"><label>389.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Z</given-names></string-name></person-group>. <article-title>LINC00599 influences smoke-related chronic obstructive pulmonary disease and regulates CSE-induced epithelial cell apoptosis and inflammation by targeting miR-212-5p/BASP1 axis</article-title>. <source>Hum Exp Toxicol</source>. <year>2022</year>;<volume>41</volume>:<fpage>9603271221146790</fpage>.<pub-id pub-id-type="pmid">36541900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/09603271221146790</pub-id></mixed-citation></ref><ref id="B390"><label>390.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>M</given-names></string-name></person-group>. <article-title>Exosomes derived from miR-212-5p overexpressed human synovial mesenchymal stem cells suppress chondrocyte degeneration and inflammation by targeting ELF3</article-title>. <source>Front Bioeng Biotechnol</source>. <year>2022</year>;<volume>10</volume>:<fpage>816209</fpage>.<pub-id pub-id-type="pmid">35284413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2022.816209</pub-id><pub-id pub-id-type="pmcid">PMC8908902</pub-id></mixed-citation></ref><ref id="B391"><label>391.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>R</given-names></string-name></person-group>. <article-title>Intranasal instillation of miR-410 targeting IL-4/IL-13 attenuates airway inflammation in OVA-induced asthmatic mice</article-title>. <source>Mol Med Rep</source>. <year>2019</year>;<volume>19</volume>(<issue>2</issue>):<fpage>895</fpage>&#8211;<lpage>900</lpage>.<pub-id pub-id-type="pmid">30535486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2018.9703</pub-id><pub-id pub-id-type="pmcid">PMC6323201</pub-id></mixed-citation></ref><ref id="B392"><label>392.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-410-3p modulates chondrocyte apoptosis and inflammation by targeting high mobility group box 1 (HMGB1) in an osteoarthritis mouse model</article-title>. <source>BMC Musculoskelet Disord</source>. <year>2020</year>;<volume>21</volume>:<fpage>486</fpage>.<pub-id pub-id-type="pmid">32709223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12891-020-03489-7</pub-id><pub-id pub-id-type="pmcid">PMC7379779</pub-id></mixed-citation></ref><ref id="B393"><label>393.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>F</given-names></string-name></person-group>. <article-title>Interfering TUG1 attenuates cerebrovascular endothelial apoptosis and inflammatory injury after cerebral ischemia/reperfusion via TUG1/miR-410/FOXO3 ceRNA Axis</article-title>. <source>Neurotox Res</source>. <year>2022</year>;<volume>40</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">34851489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12640-021-00446-7</pub-id></mixed-citation></ref><ref id="B394"><label>394.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname><given-names>ZJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Catapol attenuates the aseptic inflammatory response to hepatic I/R injury in vivo and in vitro by inhibiting the HMGB1/TLR-4/NF-&#954;B signaling pathway via the microRNA-410-3p</article-title>. <source>Mol Immunol</source>. <year>2023</year>;<volume>164</volume>:<fpage>66</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">37979473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2023.11.004</pub-id></mixed-citation></ref><ref id="B395"><label>395.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Trophoblast-derived miR-410-5p induces M2 macrophage polarization and mediates immunotolerance at the fetal-maternal interface by targeting the STAT1 signaling pathway</article-title>. <source>J Transl Med</source>. <year>2024</year>;<volume>22</volume>(<issue>1</issue>):<fpage>19</fpage>.<pub-id pub-id-type="pmid">38178171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04831-y</pub-id><pub-id pub-id-type="pmcid">PMC10768263</pub-id></mixed-citation></ref><ref id="B396"><label>396.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Downregulation of miR-410-3p via the METRNL-mediated AMPK/SIRT1/NF-&#954;B signaling axis inhibits oxidative stress and inflammation in idiopathic pulmonary fibrosis</article-title>. <source>Cell Signal</source>. <year>2025</year>;<volume>130</volume>:<fpage>111667</fpage>.<pub-id pub-id-type="pmid">39971221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellsig.2025.111667</pub-id></mixed-citation></ref><ref id="B397"><label>397.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bao</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>HQ</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>QL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>GY</given-names></string-name>, <etal/></person-group>. <article-title>NF-&#954;B-Regulated miR-99a modulates endothelial cell inflammation</article-title>. <source>Mediators Inflamm</source>. <year>2016</year>;<volume>2016</volume>:<fpage>5308170</fpage>.<pub-id pub-id-type="pmid">27403035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/5308170</pub-id><pub-id pub-id-type="pmcid">PMC4923609</pub-id></mixed-citation></ref><ref id="B398"><label>398.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jaiswal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Maurya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maurya</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Barthwal</surname><given-names>MK</given-names></string-name></person-group>. <article-title>Lin28B regulates angiotensin II-mediated let-7c/miR-99a MicroRNA formation consequently affecting macrophage polarization and allergic inflammation</article-title>. <source>Inflammation</source>. <year>2020</year>;<volume>43</volume>(<issue>5</issue>):<fpage>1846</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">32458348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01258-1</pub-id></mixed-citation></ref><ref id="B399"><label>399.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jaiswal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Maurya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maurya</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Barthwal</surname><given-names>MK</given-names></string-name></person-group>. <article-title>MicroRNA-99a mimics inhibit M1 macrophage phenotype and adipose tissue inflammation by targeting TNF&#945;</article-title>. <source>Cell Mol Immunol</source>. <year>2019</year>;<volume>16</volume>(<issue>5</issue>):<fpage>495</fpage>&#8211;<lpage>507</lpage>.<pub-id pub-id-type="pmid">29849090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-018-0038-7</pub-id><pub-id pub-id-type="pmcid">PMC6474300</pub-id></mixed-citation></ref><ref id="B400"><label>400.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hua</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Aberrant expression of microRNA in CD4(+) cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia</article-title>. <source>Thromb Res</source>. <year>2019</year>;<volume>177</volume>:<fpage>70</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30856381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.thromres.2019.03.005</pub-id></mixed-citation></ref><ref id="B401"><label>401.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jing</surname><given-names>L</given-names></string-name></person-group>. <article-title>MiRNA-99a alleviates inflammation and oxidative stress in lipopolysaccharide-stimulated PC-12 cells and rats post spinal cord injury</article-title>. <source>Bioengineered</source>. <year>2022</year>;<volume>13</volume>(<issue>2</issue>):<fpage>4248</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">35135443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21655979.2022.2031386</pub-id><pub-id pub-id-type="pmcid">PMC8974123</pub-id></mixed-citation></ref><ref id="B402"><label>402.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jing</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>XJ</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>XL</given-names></string-name>, <etal/></person-group>. <article-title>miR-99a-5p: a potential new therapy for atherosclerosis by targeting mTOR and then inhibiting NLRP3 inflammasome activation and promoting macrophage autophagy</article-title>. <source>Dis Markers</source>. <year>2022</year>;<volume>2022</volume>:<fpage>7172583</fpage>.<pub-id pub-id-type="pmid">35968506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/7172583</pub-id><pub-id pub-id-type="pmcid">PMC9374553</pub-id></mixed-citation></ref><ref id="B403"><label>403.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sui</surname><given-names>C</given-names></string-name></person-group>. <article-title>The experimental study of mir-99a-5p negative regulation of TLR8 receptor mediated-mediated innate immune response in rabbit knee cartilage injury</article-title>. <source>Immun Inflamm Dis</source>. <year>2024</year>;<volume>12</volume>(<issue>4</issue>):<fpage>e1211</fpage>.<pub-id pub-id-type="pmid">38602270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/iid3.1211</pub-id><pub-id pub-id-type="pmcid">PMC11007787</pub-id></mixed-citation></ref><ref id="B404"><label>404.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fitzpatrick</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nader</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Watkin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>McCoy</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Curley</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Kerrigan</surname><given-names>SW</given-names></string-name></person-group>. <article-title>Human endothelial cell-derived exosomal microRNA-99a/b drives a sustained inflammatory response during sepsis by inhibiting mTOR expression</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2022</year>;<volume>12</volume>:<fpage>854126</fpage>.<pub-id pub-id-type="pmid">36061862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2022.854126</pub-id><pub-id pub-id-type="pmcid">PMC9434345</pub-id></mixed-citation></ref><ref id="B405"><label>405.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name></person-group>. <article-title>MiR-137 inhibited inflammatory response and apoptosis after spinal cord injury via targeting of MK2</article-title>. <source>J Cell Biochem</source>. <year>2018</year>;<volume>119</volume>(<issue>4</issue>):<fpage>3280</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">29125882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.26489</pub-id></mixed-citation></ref><ref id="B406"><label>406.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>B</given-names></string-name></person-group>. <article-title>miR-137 alleviates focal cerebral ischemic injury in rats by regulating JAK1/STAT1 signaling pathway</article-title>. <source>Hum Exp Toxicol</source>. <year>2020</year>;<volume>39</volume>(<issue>6</issue>):<fpage>816</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">31961204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0960327119897103</pub-id></mixed-citation></ref><ref id="B407"><label>407.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>HT</given-names></string-name>, <etal/></person-group>. <article-title>MiR-137 attenuates spinal cord injury by modulating NEUROD4 through reducing inflammation and oxidative stress</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2018</year>;<volume>22</volume>(<issue>7</issue>):<fpage>1884</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">29687839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201804_14709</pub-id></mixed-citation></ref><ref id="B408"><label>408.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>H</given-names></string-name></person-group>. <article-title>Curcumin alleviates LPS-induced inflammation and oxidative stress in mouse microglial BV2 cells by targeting miR-137-3p/NeuroD1</article-title>. <source>RSC Adv</source>. <year>2019</year>;<volume>9</volume>(<issue>66</issue>):<fpage>38397</fpage>&#8211;<lpage>406</lpage>.<pub-id pub-id-type="pmid">35540218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9ra07266g</pub-id><pub-id pub-id-type="pmcid">PMC9075845</pub-id></mixed-citation></ref><ref id="B409"><label>409.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-137 inhibits the inflammatory response and extracellular matrix degradation in lipopolysaccharide-stimulated human nucleus pulposus cells by targeting activin a receptor type I</article-title>. <source>Bioengineered</source>. <year>2022</year>;<volume>13</volume>(<issue>3</issue>):<fpage>6396</fpage>&#8211;<lpage>408</lpage>.<pub-id pub-id-type="pmid">35236255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21655979.2022.2042987</pub-id><pub-id pub-id-type="pmcid">PMC8973860</pub-id></mixed-citation></ref><ref id="B410"><label>410.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>J</given-names></string-name></person-group>. <article-title>LncRNA KCNQ1OT1 knockdown inhibits ox-LDL-induced inflammatory response and oxidative stress in THP-1 macrophages through the miR-137/TNFAIP1 axis</article-title>. <source>Cytokine</source>. <year>2022</year>;<volume>155</volume>:<fpage>155912</fpage>.<pub-id pub-id-type="pmid">35598525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2022.155912</pub-id></mixed-citation></ref><ref id="B411"><label>411.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Let-7e modulates the inflammatory response in vascular endothelial cells through ceRNA crosstalk</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>42498</fpage>.<pub-id pub-id-type="pmid">28195197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep42498</pub-id><pub-id pub-id-type="pmcid">PMC5307339</pub-id></mixed-citation></ref><ref id="B412"><label>412.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Down-regulation of miR-let-7e attenuates LPS-induced acute lung injury in mice via inhibiting pulmonary inflammation by targeting SCOS1/NF-&#954;B pathway</article-title>. <source>Biosci Rep</source>. <year>2021</year>;<volume>41</volume>(<issue>1</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20201089</pub-id><pub-id pub-id-type="pmcid">PMC7785041</pub-id><pub-id pub-id-type="pmid">33392621</pub-id></mixed-citation></ref><ref id="B413"><label>413.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hijmans</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lincenberg</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Diehl</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Greiner</surname><given-names>JJ</given-names></string-name>, <etal/></person-group>. <article-title>Insufficient sleep is associated with a pro-atherogenic circulating microRNA signature</article-title>. <source>Exp Physiol</source>. <year>2019</year>;<volume>104</volume>(<issue>6</issue>):<fpage>975</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">31016755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/EP087469</pub-id><pub-id pub-id-type="pmcid">PMC6544492</pub-id></mixed-citation></ref><ref id="B414"><label>414.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yue</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>T</given-names></string-name></person-group>. <article-title>Upregulated miR-125b mitigates inflammation, astrocyte activation, and dysfunction of spinal cord injury by inactivating the MAPK pathway</article-title>. <source>Histol Histopathol</source>. <year>2024</year>;<volume>39</volume>(<issue>2</issue>):<fpage>225</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">37166139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14670/HH-18-624</pub-id></mixed-citation></ref><ref id="B415"><label>415.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>XQ</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>ZL</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>H</given-names></string-name></person-group>. <article-title>MicroRNA-125b mimic inhibits ischemia reperfusion-induced neuroinflammation and aberrant p53 apoptotic signalling activation through targeting TP53INP1</article-title>. <source>Brain Behav Immun</source>. <year>2018</year>;<volume>74</volume>:<fpage>154</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">30193876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2018.09.002</pub-id></mixed-citation></ref><ref id="B416"><label>416.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Banerjee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Icyuz</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>miR-125a-5p regulates differential activation of macrophages and inflammation</article-title>. <source>J Biol Chem</source>. <year>2013</year>;<volume>288</volume>(<issue>49</issue>):<fpage>35428</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">24151079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M112.426866</pub-id><pub-id pub-id-type="pmcid">PMC3853290</pub-id></mixed-citation></ref><ref id="B417"><label>417.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>ZH</given-names></string-name></person-group>. <article-title>Downregulation of lncRNA NEAT1 ameliorates LPS-induced inflammatory responses by promoting macrophage M2 polarization via miR-125a-5p/TRAF6/TAK1 Axis</article-title>. <source>Inflammation</source>. <year>2020</year>;<volume>43</volume>(<issue>4</issue>):<fpage>1548</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">32388658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01231-y</pub-id></mixed-citation></ref><ref id="B418"><label>418.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis</article-title>. <source>Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>7096</fpage>.<pub-id pub-id-type="pmid">25963922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms8096</pub-id></mixed-citation></ref><ref id="B419"><label>419.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhan</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>QW</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>XS</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Anti-inflammatory effect of miR-125a-5p on experimental optic neuritis by promoting the differentiation of Treg cells</article-title>. <source>Neural Regen Res</source>. <year>2023</year>;<volume>18</volume>(<issue>2</issue>):<fpage>451</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">35900445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.346462</pub-id><pub-id pub-id-type="pmcid">PMC9396506</pub-id></mixed-citation></ref><ref id="B420"><label>420.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>PW</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Fernando</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Contreras</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation</article-title>. <source>JCI insight</source>. <year>2018</year>;<volume>3</volume>(<issue>15</issue>):<fpage>e120798</fpage>.<pub-id pub-id-type="pmid">30089723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.120798</pub-id><pub-id pub-id-type="pmcid">PMC6129123</pub-id></mixed-citation></ref><ref id="B421"><label>421.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name></person-group>. <article-title>NORAD lentivirus shRNA mitigates fibrosis and inflammatory responses in diabetic cardiomyopathy via the ceRNA network of NORAD/miR-125a-3p/Fyn</article-title>. <source>Inflamm Res</source>. <year>2021</year>;<volume>70</volume>(<issue>10&#8211;12</issue>):<fpage>1113</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">34591118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00011-021-01500-y</pub-id></mixed-citation></ref><ref id="B422"><label>422.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MiR-125a-3p inhibits cell proliferation and inflammation responses in fibroblast-like synovial cells in rheumatoid arthritis by mediating the Wnt/&#946;-catenin and NF-&#954;B pathways via targeting MAST3</article-title>. <source>J Musculoskelet Neuronal Interact</source>. <year>2021</year>;<volume>21</volume>(<issue>4</issue>):<fpage>560</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">34854396</pub-id><pub-id pub-id-type="pmcid">PMC8672414</pub-id></mixed-citation></ref><ref id="B423"><label>423.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>MiR-125a-3p alleviates hyperproliferation of keratinocytes and psoriasis-like inflammation by targeting TLR4/NF-&#954;B pathway</article-title>. <source>Postepy Dermatol Alergol</source>. <year>2023</year>;<volume>40</volume>(<issue>3</issue>):<fpage>447</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">37545827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/ada.2023.129155</pub-id><pub-id pub-id-type="pmcid">PMC10399661</pub-id></mixed-citation></ref><ref id="B424"><label>424.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Long non-coding RNA MALAT1 protects against spinal cord injury via suppressing microRNA-125b-5p mediated microglial M1 polarization, neuroinflammation, and neural apoptosis</article-title>. <source>Mol Neurobiol</source>. <year>2024</year>;<volume>61</volume>(<issue>4</issue>):<fpage>2136</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">37858031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03664-6</pub-id></mixed-citation></ref><ref id="B425"><label>425.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parisi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Napoli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pelegrin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Volont&#233;</surname><given-names>C</given-names></string-name></person-group>. <article-title>M1 and M2 functional imprinting of primary microglia: role of P2X7 activation and miR-125b</article-title>. <source>Mediators Inflamm</source>. <year>2016</year>;<volume>2016</volume>:<fpage>2989548</fpage>.<pub-id pub-id-type="pmid">28090150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/2989548</pub-id><pub-id pub-id-type="pmcid">PMC5206439</pub-id></mixed-citation></ref><ref id="B426"><label>426.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Rui</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis</article-title>. <source>Nat Cell Biol</source>. <year>2013</year>;<volume>15</volume>(<issue>3</issue>):<fpage>284</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">23396050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncb2690</pub-id><pub-id pub-id-type="pmcid">PMC3672398</pub-id></mixed-citation></ref><ref id="B427"><label>427.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name></person-group>. <article-title>miR-126 promotes angiogenesis and attenuates inflammation after contusion spinal cord injury in rats</article-title>. <source>Brain Res</source>. <year>2015</year>;<volume>1608</volume>:<fpage>191</fpage>&#8211;<lpage>202</lpage>.<pub-id pub-id-type="pmid">25724143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2015.02.036</pub-id></mixed-citation></ref><ref id="B428"><label>428.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Deletion of miR-126a promotes hepatic aging and inflammation in a mouse model of cholestasis</article-title>. <source>Mol Ther Nucleic Acids</source>. <year>2019</year>;<volume>16</volume>:<fpage>494</fpage>&#8211;<lpage>504</lpage>.<pub-id pub-id-type="pmid">31051334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2019.04.002</pub-id><pub-id pub-id-type="pmcid">PMC6495079</pub-id></mixed-citation></ref><ref id="B429"><label>429.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Cooper</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>McCathran</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Downregulation of vitamin D receptor and miR-126-3p expression contributes to increased endothelial inflammatory response in preeclampsia</article-title>. <source>Am J Reprod Immunol</source>. <year>2019</year>;<volume>82</volume>(<issue>4</issue>):<fpage>e13172</fpage>.<pub-id pub-id-type="pmid">31323164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/aji.13172</pub-id></mixed-citation></ref><ref id="B430"><label>430.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>miR-126 overexpression attenuates oxygen-glucose deprivation/reperfusion injury by inhibiting oxidative stress and inflammatory response via the activation of SIRT1/Nrf2 signaling pathway in human umbilical vein endothelial cells</article-title>. <source>Mol Med Rep</source>. <year>2021</year>;<volume>23</volume>(<issue>2</issue>):<fpage>165</fpage>.<pub-id pub-id-type="pmid">33355373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2020.11804</pub-id><pub-id pub-id-type="pmcid">PMC7789090</pub-id></mixed-citation></ref><ref id="B431"><label>431.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zou</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name></person-group>. <article-title>Influences of regulation of miR-126 on inflammation,Th17/treg subpopulation differentiation, and lymphocyte apoptosis through caspase signaling pathway in sepsis</article-title>. <source>Inflammation</source>. <year>2020</year>;<volume>43</volume>(<issue>6</issue>):<fpage>2287</fpage>&#8211;<lpage>300</lpage>.<pub-id pub-id-type="pmid">32748275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01298-7</pub-id></mixed-citation></ref><ref id="B432"><label>432.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ming</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Exosomes derived from miR-126-3p-overexpressing synovial fibroblasts suppress chondrocyte inflammation and cartilage degradation in a rat model of osteoarthritis</article-title>. <source>Cell Death Discov</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>37</fpage>.<pub-id pub-id-type="pmid">33627637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-021-00418-y</pub-id><pub-id pub-id-type="pmcid">PMC7904758</pub-id></mixed-citation></ref><ref id="B433"><label>433.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name></person-group>. <article-title>Mechanism of miR-126 in hypoxia-reoxygenation-induced cardiomyocyte pyroptosis by regulating HMGB1 and NLRP3 inflammasome</article-title>. <source>Immunopharmacol Immunotoxicol</source>. <year>2022</year>;<volume>44</volume>(<issue>4</issue>):<fpage>500</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">35297734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08923973.2022.2054819</pub-id></mixed-citation></ref><ref id="B434"><label>434.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Chicken miR-126-5p negatively regulates antiviral innate immunity by targeting TRAF3</article-title>. <source>Vet Res</source>. <year>2022</year>;<volume>53</volume>(<issue>1</issue>):<fpage>82</fpage>.<pub-id pub-id-type="pmid">36224663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13567-022-01098-x</pub-id><pub-id pub-id-type="pmcid">PMC9559812</pub-id></mixed-citation></ref><ref id="B435"><label>435.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>miR-126a-5p inhibits H1N1-induced inflammation and matrix protease secretion in lung fibroblasts by targeting ADAMTS-4</article-title>. <source>Arch Virol</source>. <year>2024</year>;<volume>169</volume>(<issue>8</issue>):<fpage>164</fpage>.<pub-id pub-id-type="pmid">38990242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00705-024-06086-4</pub-id></mixed-citation></ref><ref id="B436"><label>436.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA miR-126-5p enhances the inflammatory responses of monocytes to lipopolysaccharide stimulation by suppressing cylindromatosis in chronic HIV-1 infection</article-title>. <source>J Virol</source>. <year>2017</year>;<volume>91</volume>(<issue>10</issue>):<fpage>e02048-16</fpage>.<pub-id pub-id-type="pmid">28250134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02048-16</pub-id><pub-id pub-id-type="pmcid">PMC5411609</pub-id></mixed-citation></ref><ref id="B437"><label>437.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>XF</given-names></string-name></person-group>. <article-title>Inhibition of miR-126 protects chondrocytes from IL-1&#946; induced inflammation via upregulation of Bcl-2</article-title>. <source>Bone Jt Res</source>. <year>2018</year>;<volume>7</volume>(<issue>6</issue>):<fpage>414</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1302/2046-3758.76.BJR-2017-0138.R1</pub-id><pub-id pub-id-type="pmcid">PMC6035362</pub-id><pub-id pub-id-type="pmid">30034795</pub-id></mixed-citation></ref><ref id="B438"><label>438.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ju&#378;wik</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>S Drake</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Paradis-Isler</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sylvester</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Amar-Zifkin</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>microRNA dysregulation in neurodegenerative diseases: a systematic review</article-title>. <source>Prog Neurobiol</source>. <year>2019</year>;<volume>182</volume>:<fpage>101664</fpage>.<pub-id pub-id-type="pmid">31356849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2019.101664</pub-id></mixed-citation></ref><ref id="B439"><label>439.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Efendizade</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>Y</given-names></string-name></person-group>. <article-title>The role of microRNA in neuronal inflammation and survival in the post ischemic brain: a review</article-title>. <source>Neurol Res</source>. <year>2023</year>;<volume>45</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01616412.2017.1327505</pub-id><pub-id pub-id-type="pmid">28552032</pub-id></mixed-citation></ref><ref id="B440"><label>440.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Olivieri</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Prattichizzo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Giuliani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Matacchione</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rippo</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Sabbatinelli</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>miR-21 and miR-146a: the microRNAs of inflammaging and age-related diseases</article-title>. <source>Ageing Res Rev</source>. <year>2021</year>;<volume>70</volume>:<fpage>101374</fpage>.<pub-id pub-id-type="pmid">34082077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2021.101374</pub-id></mixed-citation></ref><ref id="B441"><label>441.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hulsmans</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Holvoet</surname><given-names>P</given-names></string-name></person-group>. <article-title>MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease</article-title>. <source>Cardiovasc Res</source>. <year>2013</year>;<volume>100</volume>(<issue>1</issue>):<fpage>7</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">23774505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvt161</pub-id></mixed-citation></ref><ref id="B442"><label>442.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>SU</given-names></string-name>, <string-name name-style="western"><surname>Zhai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>M1 macrophages-derived exosomes miR-34c-5p regulates interstitial cells of Cajal through targeting SCF</article-title>. <source>J Biosci</source>. <year>2021</year>;<volume>46</volume>(<issue>4</issue>):<fpage>90</fpage>.<pub-id pub-id-type="pmid">34544909</pub-id></mixed-citation></ref><ref id="B443"><label>443.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ismail</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dakhlallah</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Moldovan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Batte</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Macrophage microvesicles induce macrophage differentiation and miR-223 transfer</article-title>. <source>Blood</source>. <year>2013</year>;<volume>121</volume>(<issue>6</issue>):<fpage>984</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">23144169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-08-374793</pub-id><pub-id pub-id-type="pmcid">PMC3567345</pub-id></mixed-citation></ref><ref id="B444"><label>444.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Donnelly</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>RR</given-names></string-name></person-group>. <article-title>Regulation of pain by neuro-immune interactions between macrophages and nociceptor sensory neurons</article-title>. <source>Curr Opin Neurobiol</source>. <year>2020</year>;<volume>62</volume>:<fpage>17</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">31809997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.conb.2019.11.006</pub-id><pub-id pub-id-type="pmcid">PMC7266706</pub-id></mixed-citation></ref><ref id="B445"><label>445.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Modulators of MicroRNA function in the immune system</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>7</issue>):<fpage>2357</fpage>.<pub-id pub-id-type="pmid">32235299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21072357</pub-id><pub-id pub-id-type="pmcid">PMC7177468</pub-id></mixed-citation></ref><ref id="B446"><label>446.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eichm&#252;ller</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Osen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mandelboim</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Seliger</surname><given-names>B</given-names></string-name></person-group>. <article-title>Immune modulatory microRNAs involved in tumor attack and tumor immune escape</article-title>. <source>J Natl Cancer Inst</source>. <year>2017</year>;<volume>109</volume>(<issue>10</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djx034</pub-id><pub-id pub-id-type="pmid">28383653</pub-id></mixed-citation></ref><ref id="B447"><label>447.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arzhanov</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sintakova</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Romanyuk</surname><given-names>N</given-names></string-name></person-group>. <article-title>The role of miR-20 in health and disease of the central nervous system</article-title>. <source>Cells</source>. <year>2022</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1525</fpage>.<pub-id pub-id-type="pmid">35563833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11091525</pub-id><pub-id pub-id-type="pmcid">PMC9100679</pub-id></mixed-citation></ref><ref id="B448"><label>448.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname><given-names>JS</given-names></string-name>, <etal/></person-group>. <article-title>miR-17-92 cluster regulates adult hippocampal neurogenesis, anxiety, and depression</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>16</volume>(<issue>6</issue>):<fpage>1653</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">27477270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.06.101</pub-id><pub-id pub-id-type="pmcid">PMC4981532</pub-id></mixed-citation></ref><ref id="B449"><label>449.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeboudj</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sideris-Lampretsas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Al-Mudaris</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Picco</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Silencing miR-21-5p in sensory neurons reverses neuropathic allodynia via activation of TGF-&#946;-related pathway in macrophages</article-title>. <source>J Clin Investig</source>. <year>2023</year>;<volume>133</volume>(<issue>11</issue>):<fpage>e164472</fpage>.<pub-id pub-id-type="pmid">37071481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI164472</pub-id><pub-id pub-id-type="pmcid">PMC10232007</pub-id></mixed-citation></ref><ref id="B450"><label>450.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bali</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Gandla</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rangel</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Castaldi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mouritzen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>A genome-wide screen reveals microRNAs in peripheral sensory neurons driving painful diabetic neuropathy</article-title>. <source>Pain</source>. <year>2021</year>;<volume>162</volume>(<issue>5</issue>):<fpage>1334</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">33492037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000002159</pub-id></mixed-citation></ref><ref id="B451"><label>451.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-33 regulates the synaptic plasticity-related gene ARC in temporal lobe epilepsy</article-title>. <source>Neurosci Res</source>. <year>2025</year>;<volume>210</volume>:<fpage>19</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">39214315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neures.2024.08.003</pub-id></mixed-citation></ref><ref id="B452"><label>452.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tate</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wijeratne</surname><given-names>HRS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Philtjens</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>DH</given-names></string-name>, <etal/></person-group>. <article-title>Deletion of miR-33, a regulator of the ABCA1-APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>11</issue>):<fpage>7805</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">39345217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14243</pub-id><pub-id pub-id-type="pmcid">PMC11567857</pub-id></mixed-citation></ref><ref id="B453"><label>453.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Price</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez-Tussy</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Varela</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cardelo</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Shanabrough</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aryal</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-33 controls hunger signaling in hypothalamic AgRP neurons</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2131</fpage>.<pub-id pub-id-type="pmid">38459068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-46427-0</pub-id><pub-id pub-id-type="pmcid">PMC10923783</pub-id></mixed-citation></ref><ref id="B454"><label>454.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Horie</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nakao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Miyasaka</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nishino</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Matsumura</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nakazeki</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-33 maintains adaptive thermogenesis via enhanced sympathetic nerve activity</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>843</fpage>.<pub-id pub-id-type="pmid">33594062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21107-5</pub-id><pub-id pub-id-type="pmcid">PMC7886914</pub-id></mixed-citation></ref><ref id="B455"><label>455.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Downregulation of MicroRNA-34c-5p facilitated neuroinflammation in drug-resistant epilepsy</article-title>. <source>Brain Res</source>. <year>2020</year>;<volume>1749</volume>:<fpage>147130</fpage>.<pub-id pub-id-type="pmid">32950487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2020.147130</pub-id></mixed-citation></ref><ref id="B456"><label>456.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Early life stress enhances the susceptibility to depression and interferes with neuroplasticity in the hippocampus of adolescent mice via regulating miR-34c-5p/SYT1 axis</article-title>. <source>J Psychiatr Res</source>. <year>2024</year>;<volume>170</volume>:<fpage>262</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">38181539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2023.12.030</pub-id></mixed-citation></ref><ref id="B457"><label>457.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA expression and regulation in human, chimpanzee, and macaque brains</article-title>. <source>Plos Genet</source>. <year>2011</year>;<volume>7</volume>(<issue>10</issue>):<fpage>e1002327</fpage>.<pub-id pub-id-type="pmid">22022286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1002327</pub-id><pub-id pub-id-type="pmcid">PMC3192836</pub-id></mixed-citation></ref><ref id="B458"><label>458.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-125b-5p alleviated CCI-induced neuropathic pain and modulated neuroinflammation via targeting SOX11</article-title>. <source>Synapse</source>. <year>2024</year>;<volume>78</volume>(<issue>5</issue>):<fpage>e22306</fpage>.<pub-id pub-id-type="pmid">39135278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.22306</pub-id></mixed-citation></ref><ref id="B459"><label>459.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cui</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MiR-125b orchestrates cell proliferation, differentiation and migration in neural stem/progenitor cells by targeting Nestin</article-title>. <source>BMC Neurosci</source>. <year>2012</year>;<volume>13</volume>:<fpage>116</fpage>.<pub-id pub-id-type="pmid">23016664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2202-13-116</pub-id><pub-id pub-id-type="pmcid">PMC3507862</pub-id></mixed-citation></ref><ref id="B460"><label>460.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Le</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chia</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>Rizk</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Um</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets</article-title>. <source>Mol Cell Biol</source>. <year>2009</year>;<volume>29</volume>(<issue>19</issue>):<fpage>5290</fpage>&#8211;<lpage>305</lpage>.<pub-id pub-id-type="pmid">19635812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MCB.01694-08</pub-id><pub-id pub-id-type="pmcid">PMC2747988</pub-id></mixed-citation></ref><ref id="B461"><label>461.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Swarbrick</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wragg</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stolzing</surname><given-names>A</given-names></string-name></person-group>. <article-title>Systematic review of miRNA as biomarkers in alzheimer's disease</article-title>. <source>Mol Neurobiol</source>. <year>2019</year>;<volume>56</volume>(<issue>9</issue>):<fpage>6156</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">30734227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-019-1500-y</pub-id><pub-id pub-id-type="pmcid">PMC6682547</pub-id></mixed-citation></ref><ref id="B462"><label>462.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dai</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Downregulation of circular RNA HECTD1 induces neuroprotection against ischemic stroke through the microRNA-133b/TRAF3 pathway</article-title>. <source>Life Sci</source>. <year>2021</year>;<volume>264</volume>:<fpage>118626</fpage>.<pub-id pub-id-type="pmid">33148417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.118626</pub-id></mixed-citation></ref><ref id="B463"><label>463.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Bone marrow mesenchymal stem cell-derived exosomes shuttling miR-150-5p alleviates mechanical allodynia in rats by targeting NOTCH2 in microglia</article-title>. <source>Mol Med</source>. <year>2022</year>;<volume>28</volume>(<issue>1</issue>):<fpage>133</fpage>.<pub-id pub-id-type="pmid">36348269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10020-022-00561-x</pub-id><pub-id pub-id-type="pmcid">PMC9644547</pub-id></mixed-citation></ref><ref id="B464"><label>464.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Effects of miR-150 on neuropathic pain process via targeting AKT3</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2019</year>;<volume>517</volume>(<issue>3</issue>):<fpage>532</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31376943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2019.07.061</pub-id></mixed-citation></ref><ref id="B465"><label>465.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>QM</given-names></string-name></person-group>. <article-title>MiR-150 alleviates neuropathic pain via inhibiting toll-like receptor 5</article-title>. <source>J Cell Biochem</source>. <year>2018</year>;<volume>119</volume>(<issue>1</issue>):<fpage>1017</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">28685867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.26269</pub-id></mixed-citation></ref><ref id="B466"><label>466.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>The long noncoding RNA GAS5 potentiates neuronal injury in Parkinson's disease by binding to microRNA-150 to regulate Fosl1 expression</article-title>. <source>Exp Neurol</source>. <year>2022</year>;<volume>347</volume>:<fpage>113904</fpage>.<pub-id pub-id-type="pmid">34755654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2021.113904</pub-id></mixed-citation></ref><ref id="B467"><label>467.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-150 serves as a diagnostic biomarker and is involved in the inflammatory pathogenesis of Parkinson's disease</article-title>. <source>Mol Genet Genomic Med</source>. <year>2020</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e1189</fpage>.<pub-id pub-id-type="pmid">32077254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mgg3.1189</pub-id><pub-id pub-id-type="pmcid">PMC7196454</pub-id></mixed-citation></ref><ref id="B468"><label>468.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wei</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Promotive role of microRNA-150 in hippocampal neurons apoptosis in vascular dementia model rats</article-title>. <source>Mol Med Rep</source>. <year>2021</year>;<volume>23</volume>(<issue>4</issue>):<fpage>257</fpage>.<pub-id pub-id-type="pmid">33576461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2021.11896</pub-id><pub-id pub-id-type="pmcid">PMC7893740</pub-id></mixed-citation></ref><ref id="B469"><label>469.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Solich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kolasa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Faron-G&#243;recka</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pabian</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Latocha</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Korlatowicz</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Modulating stress susceptibility and resilience: insights from miRNA manipulation and neural mechanisms in mice</article-title>. <source>Mol Neurobiol</source>. <year>2024</year>;<volume>61</volume>(<issue>9</issue>):<fpage>6135</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">38280111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-024-03922-1</pub-id></mixed-citation></ref><ref id="B470"><label>470.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hou</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name></person-group>. <article-title>The effect of miR-155-5p on long-term memory of sleep-deprived mice through the BDNF/NF-&#954;B pathway</article-title>. <source>Acta Neurobiol Exp</source>. <year>2024</year>;<volume>84</volume>(<issue>2</issue>):<fpage>203</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.55782/ane-2024-2586</pub-id><pub-id pub-id-type="pmid">39087835</pub-id></mixed-citation></ref><ref id="B471"><label>471.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MiR-155-5p aggravated astrocyte activation and glial scarring in a spinal cord injury model by inhibiting Ndfip1 expression and PTEN nuclear translocation</article-title>. <source>Neurochem Res</source>. <year>2023</year>;<volume>48</volume>(<issue>6</issue>):<fpage>1912</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">36750528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-023-03862-7</pub-id><pub-id pub-id-type="pmcid">PMC10119073</pub-id></mixed-citation></ref><ref id="B472"><label>472.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>miR-155-5p in the spinal cord regulates hypersensitivity in a rat model of bone cancer pain</article-title>. <source>Mol Pain</source>. <year>2022</year>;<volume>18</volume>:<fpage>17448069221127811</fpage>.<pub-id pub-id-type="pmid">36069070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17448069221127811</pub-id><pub-id pub-id-type="pmcid">PMC9536109</pub-id></mixed-citation></ref><ref id="B473"><label>473.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haneklaus</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gerlic</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kurowska-Stolarska</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rainey</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Pich</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>McInnes</surname><given-names>IB</given-names></string-name>, <etal/></person-group>. <article-title>Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1&#946; production</article-title>. <source>J Immunol</source>. <year>2012</year>;<volume>189</volume>(<issue>8</issue>):<fpage>3795</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22984081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1200312</pub-id></mixed-citation></ref><ref id="B474"><label>474.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname><given-names>YZ</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>XL</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>FZ</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>MiR-223-5p inhibitor suppresses microglia inflammation and promotes Nrg-1 in rats of spinal cord injury</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2019</year>;<volume>23</volume>(<issue>22</issue>):<fpage>9746</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">31799641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201911_19537</pub-id></mixed-citation></ref><ref id="B475"><label>475.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cantoni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cignarella</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ghezzi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mikesell</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bollman</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Berrien-Elliott</surname><given-names>MM</given-names></string-name>, <etal/></person-group>. <article-title>Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis</article-title>. <source>Acta Neuropathol</source>. <year>2017</year>;<volume>133</volume>(<issue>1</issue>):<fpage>61</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">27704281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-016-1621-6</pub-id><pub-id pub-id-type="pmcid">PMC5423756</pub-id></mixed-citation></ref><ref id="B476"><label>476.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morquette</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ju&#378;wik</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Drake</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Charabati</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>L&#233;cuyer</surname><given-names>MA</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis</article-title>. <source>Brain</source>. <year>2019</year>;<volume>142</volume>(<issue>10</issue>):<fpage>2979</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">31412103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz245</pub-id></mixed-citation></ref><ref id="B477"><label>477.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Galloway</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Blandford</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Stefanelli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ploughman</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>miR-223 promotes regenerative myeloid cell phenotype and function in the demyelinated central nervous system</article-title>. <source>Glia</source>. <year>2019</year>;<volume>67</volume>(<issue>5</issue>):<fpage>857</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">30548333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.23576</pub-id></mixed-citation></ref><ref id="B478"><label>478.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name></person-group>. <article-title>Long noncoding RNA GAS5 promotes microglial inflammatory response in Parkinson's disease by regulating NLRP3 pathway through sponging miR-223-3p</article-title>. <source>Int Immunopharmacol</source>. <year>2020</year>;<volume>85</volume>:<fpage>106614</fpage>.<pub-id pub-id-type="pmid">32470877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106614</pub-id></mixed-citation></ref><ref id="B479"><label>479.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Galloway</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Carew</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Blandford</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Benoit</surname><given-names>RY</given-names></string-name>, <string-name name-style="western"><surname>Fudge</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Investigating the NLRP3 inflammasome and its regulator miR-223-3p in multiple sclerosis and experimental demyelination</article-title>. <source>J Neurochem</source>. <year>2022</year>;<volume>163</volume>(<issue>2</issue>):<fpage>94</fpage>&#8211;<lpage>112</lpage>.<pub-id pub-id-type="pmid">35633501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15650</pub-id></mixed-citation></ref><ref id="B480"><label>480.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qing</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>X</given-names></string-name></person-group>. <article-title>Exosomes and their MicroRNA cargo: new players in peripheral nerve regeneration</article-title>. <source>Neurorehabil Neural Repair</source>. <year>2018</year>;<volume>32</volume>(<issue>9</issue>):<fpage>765</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">30223738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968318798955</pub-id><pub-id pub-id-type="pmcid">PMC6146407</pub-id></mixed-citation></ref><ref id="B481"><label>481.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>BY</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Macrophage-derived microvesicles promote proliferation and migration of Schwann cell on peripheral nerve repair</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2015</year>;<volume>468</volume>(<issue>1&#8211;2</issue>):<fpage>343</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26499078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2015.10.097</pub-id></mixed-citation></ref><ref id="B482"><label>482.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prajapati</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>WX</given-names></string-name>, <string-name name-style="western"><surname>Pesina</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Geleta</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Springer</surname><given-names>JE</given-names></string-name></person-group>. <article-title>Sex-specific alterations in inflammatory MicroRNAs in mouse brain and bone marrow CD11b+ cells following traumatic brain injury</article-title>. <source>Cell Mol Neurobiol</source>. <year>2023</year>;<volume>43</volume>(<issue>1</issue>):<fpage>423</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">34761332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-021-01164-6</pub-id><pub-id pub-id-type="pmcid">PMC11415165</pub-id></mixed-citation></ref><ref id="B483"><label>483.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harraz</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Eacker</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>VL</given-names></string-name></person-group>. <article-title>MicroRNA-223 is neuroprotective by targeting glutamate receptors</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2012</year>;<volume>109</volume>(<issue>46</issue>):<fpage>18962</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23112146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1121288109</pub-id><pub-id pub-id-type="pmcid">PMC3503176</pub-id></mixed-citation></ref><ref id="B484"><label>484.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bastle</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Oliver</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Gardiner</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Pentkowski</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Bolognani</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Allan</surname><given-names>AM</given-names></string-name>, <etal/></person-group>. <article-title>In silico identification and in vivo validation of miR-495 as a novel regulator of motivation for cocaine that targets multiple addiction-related networks in the nucleus accumbens</article-title>. <source>Mol Psychiatry</source>. <year>2018</year>;<volume>23</volume>(<issue>2</issue>):<fpage>434</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">28044061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mp.2016.238</pub-id><pub-id pub-id-type="pmcid">PMC5495632</pub-id></mixed-citation></ref><ref id="B485"><label>485.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Geng</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>XZ</given-names></string-name></person-group>. <article-title>LncRNA UCA1 inhibits epilepsy and seizure-induced brain injury by regulating miR-495/Nrf2-ARE signal pathway</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2018</year>;<volume>99</volume>:<fpage>133</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29608952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2018.03.021</pub-id></mixed-citation></ref><ref id="B486"><label>486.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Suppression of microRNA-495 alleviates high-glucose-induced retinal ganglion cell apoptosis by regulating Notch/PTEN/Akt signaling</article-title>. <source>Biomed Pharmacother</source>. <year>2018</year>;<volume>106</volume>:<fpage>923</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30119264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2018.07.018</pub-id></mixed-citation></ref><ref id="B487"><label>487.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name></person-group>. <article-title>miR-495 reduces neuronal cell apoptosis and relieves acute spinal cord injury through inhibiting PRDM5</article-title>. <source>J Mol Histol</source>. <year>2021</year>;<volume>52</volume>(<issue>2</issue>):<fpage>385</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">33630203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10735-021-09959-z</pub-id></mixed-citation></ref><ref id="B488"><label>488.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Juzenas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Venkatesh</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>H&#252;benthal</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hoeppner</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>ZG</given-names></string-name>, <string-name name-style="western"><surname>Paulsen</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>A comprehensive, cell specific microRNA catalogue of human peripheral blood</article-title>. <source>Nucleic Acids Res</source>. <year>2017</year>;<volume>45</volume>(<issue>16</issue>):<fpage>9290</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="pmid">28934507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkx706</pub-id><pub-id pub-id-type="pmcid">PMC5766192</pub-id></mixed-citation></ref><ref id="B489"><label>489.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name></person-group>. <article-title>Research advances and application progress on miRNAs in exosomes derived from M2 macrophage for tissue injury repairing</article-title>. <source>Int J Nanomedicine</source>. <year>2025</year>;<volume>20</volume>:<fpage>1543</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">39925680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S508781</pub-id><pub-id pub-id-type="pmcid">PMC11806736</pub-id></mixed-citation></ref><ref id="B490"><label>490.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bauer</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Round</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connell</surname><given-names>RM</given-names></string-name></person-group>. <article-title>No small matter: emerging roles for exosomal miRNAs in the immune system</article-title>. <source>FEBS J</source>. <year>2022</year>;<volume>289</volume>(<issue>14</issue>):<fpage>4021</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">34087046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.16052</pub-id><pub-id pub-id-type="pmcid">PMC9545694</pub-id></mixed-citation></ref><ref id="B491"><label>491.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name></person-group>. <article-title>Exosome-derived microRNA: potential target for diagnosis and treatment of sepsis</article-title>. <source>J Immunol Res</source>. <year>2024</year>;<volume>2024</volume>:<fpage>4481452</fpage>.<pub-id pub-id-type="pmid">39104595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2024/4481452</pub-id><pub-id pub-id-type="pmcid">PMC11300089</pub-id></mixed-citation></ref><ref id="B492"><label>492.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kikete</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bian</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Endogenous and tumour-derived microRNAs regulate cross-presentation in dendritic cells and consequently cytotoxic T cell function</article-title>. <source>Cytotechnology</source>. <year>2016</year>;<volume>68</volume>(<issue>6</issue>):<fpage>2223</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">27193424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10616-016-9975-0</pub-id><pub-id pub-id-type="pmcid">PMC5101325</pub-id></mixed-citation></ref><ref id="B493"><label>493.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>F</given-names></string-name></person-group>. <article-title>MicroRNA-24-3p inhibits microglia inflammation by regulating MK2 following spinal cord injury</article-title>. <source>Neurochem Res</source>. <year>2021</year>;<volume>46</volume>(<issue>4</issue>):<fpage>843</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">33439430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-020-03211-y</pub-id></mixed-citation></ref><ref id="B494"><label>494.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kang</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>JS</given-names></string-name></person-group>. <article-title>MicroRNA-24-3p regulates neuronal differentiation by controlling hippocalcin expression</article-title>. <source>Cell Mol Life Sci</source>. <year>2019</year>;<volume>76</volume>(<issue>22</issue>):<fpage>4569</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">31486848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-019-03290-3</pub-id><pub-id pub-id-type="pmcid">PMC6841749</pub-id></mixed-citation></ref><ref id="B495"><label>495.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Choe</surname><given-names>HK</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-25 as a novel modulator of circadian Period2 gene oscillation</article-title>. <source>Exp Mol Med</source>. <year>2020</year>;<volume>52</volume>(<issue>9</issue>):<fpage>1614</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">32968200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-020-00496-5</pub-id><pub-id pub-id-type="pmcid">PMC8080691</pub-id></mixed-citation></ref><ref id="B496"><label>496.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Z</given-names></string-name></person-group>. <article-title>MiR-30b-5p attenuates the inflammatory response and facilitates the functional recovery of spinal cord injury by targeting the NEFL/mTOR pathway</article-title>. <source>Brain Behav</source>. <year>2022</year>;<volume>12</volume>:<fpage>e2788</fpage>.<pub-id pub-id-type="pmid">36282532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.2788</pub-id><pub-id pub-id-type="pmcid">PMC9759133</pub-id></mixed-citation></ref><ref id="B497"><label>497.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>X</given-names></string-name></person-group>. <article-title>Overexpression of miR-99a in hippocampus leads to impairment of reversal learning in mice</article-title>. <source>Behav Brain Res</source>. <year>2022</year>;<volume>416</volume>:<fpage>113542</fpage>.<pub-id pub-id-type="pmid">34425183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2021.113542</pub-id></mixed-citation></ref><ref id="B498"><label>498.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Exosomal circCNOT6L regulates astrocyte apoptotic signals induced by hypoxia exposure through miR99a-5p/SERPINE1 and alleviates ischemic stroke injury</article-title>. <source>Mol Neurobiol</source>. <year>2023</year>;<volume>60</volume>(<issue>12</issue>):<fpage>7118</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">37531026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03518-1</pub-id></mixed-citation></ref><ref id="B499"><label>499.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Molecular mechanisms involved in the regulation of neurodevelopment by miR-124</article-title>. <source>Mol Neurobiol</source>. <year>2023</year>;<volume>60</volume>(<issue>7</issue>):<fpage>3569</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">36840845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03271-5</pub-id></mixed-citation></ref><ref id="B500"><label>500.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-124 reduced neuroinflammation after traumatic brain injury by inhibiting TRAF6</article-title>. <source>Neuroimmunomodulation</source>. <year>2023</year>;<volume>30</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">36858024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000528502</pub-id></mixed-citation></ref><ref id="B501"><label>501.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>The microRNA miR-124 suppresses seizure activity and regulates CREB1 activity</article-title>. <source>Expert Rev Mol Med</source>. <year>2016</year>;<volume>18</volume>:<fpage>e4</fpage>.<pub-id pub-id-type="pmid">26996991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/erm.2016.3</pub-id><pub-id pub-id-type="pmcid">PMC4836211</pub-id></mixed-citation></ref><ref id="B502"><label>502.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mahmoudi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cairns</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>MiR-137: an important player in neural development and neoplastic transformation</article-title>. <source>Mol Psychiatry</source>. <year>2017</year>;<volume>22</volume>(<issue>1</issue>):<fpage>44</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">27620842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mp.2016.150</pub-id><pub-id pub-id-type="pmcid">PMC5414082</pub-id></mixed-citation></ref><ref id="B503"><label>503.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pergola</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rampino</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sportelli</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Borcuk</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Passiatore</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Di Carlo</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>A miR-137-related biological pathway of risk for schizophrenia is associated with human brain emotion processing</article-title>. <source>Biol Psychiatry Cogn Neurosci Neuroimaging</source>. <year>2024</year>;<volume>9</volume>(<issue>3</issue>):<fpage>356</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">38000716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpsc.2023.11.001</pub-id></mixed-citation></ref><ref id="B504"><label>504.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-145-5p targeting of TRIM2 mediates the apoptosis of retinal ganglion cells via the PI3K/AKT signaling pathway in glaucoma</article-title>. <source>J Gene Med</source>. <year>2021</year>;<volume>23</volume>(<issue>11</issue>):<fpage>e3378</fpage>.<pub-id pub-id-type="pmid">34291866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jgm.3378</pub-id></mixed-citation></ref><ref id="B505"><label>505.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kornfeld</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Fathi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bonin</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Kothary</surname><given-names>R</given-names></string-name></person-group>. <article-title>MiRNA-145-5p prevents differentiation of oligodendrocyte progenitor cells by regulating expression of myelin gene regulatory factor</article-title>. <source>J Cell Physiol</source>. <year>2021</year>;<volume>236</volume>(<issue>2</issue>):<fpage>997</fpage>&#8211;<lpage>1012</lpage>.<pub-id pub-id-type="pmid">32602617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29910</pub-id></mixed-citation></ref><ref id="B506"><label>506.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ye</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Downregulation of MicroRNA-145-5p in activated microglial exosomes promotes astrocyte proliferation by removal of Smad3 inhibition</article-title>. <source>Neurochem Res</source>. <year>2022</year>;<volume>47</volume>(<issue>2</issue>):<fpage>382</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">34623564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-021-03446-3</pub-id></mixed-citation></ref><ref id="B507"><label>507.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>ZC</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name></person-group>. <article-title>Inhibition of miR-145-5p reduces spinal cord injury-induced inflammatory and oxidative stress responses via affecting nurr1-TNF-&#945; signaling Axis</article-title>. <source>Cell Biochem Biophys</source>. <year>2021</year>;<volume>79</volume>(<issue>4</issue>):<fpage>791</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">34133012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12013-021-00992-z</pub-id></mixed-citation></ref><ref id="B508"><label>508.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qi</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Huo</surname><given-names>W</given-names></string-name></person-group>. <article-title>Long non-coding RNA SNHG14 promotes microglia activation by regulating miR-145-5p/PLA2G4A in cerebral infarction</article-title>. <source>Neuroscience</source>. <year>2017</year>;<volume>348</volume>:<fpage>98</fpage>&#8211;<lpage>106</lpage>.<pub-id pub-id-type="pmid">28215748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2017.02.002</pub-id></mixed-citation></ref><ref id="B509"><label>509.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hsu</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mukai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Karayiorgou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gogos</surname><given-names>JA</given-names></string-name></person-group>. <article-title>The BDNF Val66Met variant affects gene expression through miR-146b</article-title>. <source>Neurobiol Dis</source>. <year>2015</year>;<volume>77</volume>:<fpage>228</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">25771167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2015.03.004</pub-id><pub-id pub-id-type="pmcid">PMC5579022</pub-id></mixed-citation></ref><ref id="B510"><label>510.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bokobza</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Schang</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Csaba</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Faivre</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Montan&#233;</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>miR-146b protects the perinatal brain against microglia-induced hypomyelination</article-title>. <source>Ann Neurol</source>. <year>2022</year>;<volume>91</volume>(<issue>1</issue>):<fpage>48</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">34741343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26263</pub-id><pub-id pub-id-type="pmcid">PMC9298799</pub-id></mixed-citation></ref><ref id="B511"><label>511.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lyu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xuan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>miR-146b-5p promotes the neural conversion of pluripotent stem cells by targeting Smad4</article-title>. <source>Int J Mol Med</source>. <year>2017</year>;<volume>40</volume>(<issue>3</issue>):<fpage>814</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">28713933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2017.3064</pub-id><pub-id pub-id-type="pmcid">PMC5548013</pub-id></mixed-citation></ref><ref id="B512"><label>512.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-146b-5p protects oligodendrocyte precursor cells from oxygen/glucose deprivation-induced injury through regulating Keap1/Nrf2 signaling via targeting bromodomain-containing protein 4</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2019</year>;<volume>513</volume>:<fpage>875</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">31003769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2019.04.045</pub-id></mixed-citation></ref><ref id="B513"><label>513.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mishra</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lahon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Banerjea</surname><given-names>AC</given-names></string-name></person-group>. <article-title>Dengue virus degrades USP33-ATF3 Axis via extracellular vesicles to activate human microglial cells</article-title>. <source>J Immunol</source>. <year>2020</year>;<volume>205</volume>(<issue>7</issue>):<fpage>1787</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">32848034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2000411</pub-id></mixed-citation></ref><ref id="B514"><label>514.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mishra</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Banerjea</surname><given-names>AC</given-names></string-name></person-group>. <article-title>SARS-CoV-2 spike targets USP33-IRF9 Axis via exosomal miR-148a to activate human microglia</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>656700</fpage>.<pub-id pub-id-type="pmid">33936086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.656700</pub-id><pub-id pub-id-type="pmcid">PMC8079643</pub-id></mixed-citation></ref><ref id="B515"><label>515.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name></person-group>. <article-title>Febrile seizure-related miR-148a-3p exerts neuroprotection by promoting the proliferation of hippocampal neurons in children with temporal lobe epilepsy</article-title>. <source>Dev Neurosci</source>. <year>2021</year>;<volume>43</volume>(<issue>5</issue>):<fpage>312</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">34348296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000518352</pub-id></mixed-citation></ref><ref id="B516"><label>516.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qian</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Astrocyte-derived exosomal miR-148a-3p suppresses neuroinflammation and restores neurological function in traumatic brain injury by regulating the microglial phenotype</article-title>. <source>eNeuro</source>. <year>2024</year>;<volume>11</volume>(<issue>2</issue>):<fpage>ENEURO.0336-23.2024</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/ENEURO.0336-23.2024</pub-id><pub-id pub-id-type="pmcid">PMC10860656</pub-id><pub-id pub-id-type="pmid">38272675</pub-id></mixed-citation></ref><ref id="B517"><label>517.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>H</given-names></string-name></person-group>. <article-title>Dexmedetomidine suppresses hippocampal astrocyte pyroptosis in cerebral hypoxic-ischemic neonatal rats by upregulating microRNA-148a-3p to inactivate the STAT/JMJD3 axis</article-title>. <source>Int Immunopharmacol</source>. <year>2023</year>;<volume>121</volume>:<fpage>110440</fpage>.<pub-id pub-id-type="pmid">37327511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2023.110440</pub-id></mixed-citation></ref><ref id="B518"><label>518.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization</article-title>. <source>J Neuroinflammation</source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>47</fpage>.<pub-id pub-id-type="pmid">32019561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-020-1726-7</pub-id><pub-id pub-id-type="pmcid">PMC7001326</pub-id></mixed-citation></ref><ref id="B519"><label>519.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shao</surname><given-names>P</given-names></string-name></person-group>. <article-title>MiR-216a-5p ameliorates learning-memory deficits and neuroinflammatory response of Alzheimer's disease mice via regulation of HMGB1/NF-&#954;B signaling</article-title>. <source>Brain Res</source>. <year>2021</year>;<volume>1766</volume>:<fpage>147511</fpage>.<pub-id pub-id-type="pmid">33957091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2021.147511</pub-id></mixed-citation></ref><ref id="B520"><label>520.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Protective effect of BMSCs-derived exosomes mediated by BDNF on TBI via miR-216a-5p</article-title>. <source>Med Sci Monit</source>. <year>2020</year>;<volume>26</volume>:<fpage>e920855</fpage>.<pub-id pub-id-type="pmid">32150531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.920855</pub-id><pub-id pub-id-type="pmcid">PMC7081927</pub-id></mixed-citation></ref><ref id="B521"><label>521.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>H</given-names></string-name></person-group>. <article-title>MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax</article-title>. <source>Metab Brain Dis</source>. <year>2020</year>;<volume>35</volume>(<issue>4</issue>):<fpage>627</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">32140823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-020-00546-x</pub-id></mixed-citation></ref><ref id="B522"><label>522.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhenzhen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fenghao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Meina</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rui</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wenbo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>W</given-names></string-name></person-group>. <article-title>Targeting HMGB1-TLR4 signaling by miR-216a-5p elevation alleviates the inflammatory behavioral hypersensitivity</article-title>. <source>Neurosci Lett</source>. <year>2021</year>;<volume>759</volume>:<fpage>136043</fpage>.<pub-id pub-id-type="pmid">34118309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2021.136043</pub-id></mixed-citation></ref><ref id="B523"><label>523.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>H3K27 trimethylation-mediated downregulation of miR-216a-3p in sensory neurons regulates neuropathic pain behaviors via targeting STIM1</article-title>. <source>J Neurosci</source>. <year>2025</year>;<volume>45</volume>(<issue>1</issue>):<fpage>e0607242024</fpage>.<pub-id pub-id-type="pmid">39592234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0607-24.2024</pub-id><pub-id pub-id-type="pmcid">PMC11694406</pub-id></mixed-citation></ref><ref id="B524"><label>524.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>miR-221 and miR-222 promote Schwann cell proliferation and migration by targeting LASS2 after sciatic nerve injury</article-title>. <source>J Cell Sci</source>. <year>2012</year>;<volume>125</volume>(<issue>Pt 11</issue>):<fpage>2675</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">22393241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.098996</pub-id></mixed-citation></ref><ref id="B525"><label>525.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Che</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Biodegradable and biocompatible cationic polymer delivering microRNA-221/222 promotes nerve regeneration after sciatic nerve crush</article-title>. <source>Int J Nanomedicine</source>. <year>2017</year>;<volume>12</volume>:<fpage>4195</fpage>&#8211;<lpage>208</lpage>.<pub-id pub-id-type="pmid">28652727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S132190</pub-id><pub-id pub-id-type="pmcid">PMC5473607</pub-id></mixed-citation></ref><ref id="B526"><label>526.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>miR-221-3p inhibits schwann cell myelination</article-title>. <source>Neuroscience</source>. <year>2018</year>;<volume>379</volume>:<fpage>239</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">29577996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2018.03.019</pub-id></mixed-citation></ref><ref id="B527"><label>527.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yuan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Inhibition of miR-221-3p promotes axonal regeneration and repair of primary sensory neurons via regulating p27 expression</article-title>. <source>Neuroreport</source>. <year>2023</year>;<volume>34</volume>(<issue>9</issue>):<fpage>471</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">37161985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001912</pub-id><pub-id pub-id-type="pmcid">PMC10292576</pub-id></mixed-citation></ref><ref id="B528"><label>528.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>XB</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>LncRNAGAS5 sponges miRNA-221 to promote neurons apoptosis by up-regulated PUMA under hypoxia condition</article-title>. <source>Neurol Res</source>. <year>2020</year>;<volume>42</volume>(<issue>1</issue>):<fpage>8</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">31878844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01616412.2019.1672382</pub-id></mixed-citation></ref><ref id="B529"><label>529.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-221 rescues the loss of dopaminergic neurons in a mouse model of Parkinson's disease</article-title>. <source>Brain Behav</source>. <year>2023</year>;<volume>13</volume>(<issue>3</issue>):<fpage>e2921</fpage>.<pub-id pub-id-type="pmid">36795044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.2921</pub-id><pub-id pub-id-type="pmcid">PMC10013949</pub-id></mixed-citation></ref><ref id="B530"><label>530.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lian</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>X</given-names></string-name></person-group>. <article-title>MiR-221 is involved in depression by regulating Wnt2/CREB/BDNF axis in hippocampal neurons</article-title>. <source>Cell CycleGeorget</source>. <year>2018</year>;<volume>17</volume>(<issue>24</issue>):<fpage>2745</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15384101.2018.1556060</pub-id><pub-id pub-id-type="pmcid">PMC6343714</pub-id><pub-id pub-id-type="pmid">30589396</pub-id></mixed-citation></ref><ref id="B531"><label>531.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruan</surname><given-names>ZF</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gui</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-370 accelerated cerebral ischemia reperfusion injury via targeting SIRT6 and regulating Nrf2/ARE signal pathway</article-title>. <source>Kaohsiung J Med Sci</source>. <year>2020</year>;<volume>36</volume>:<fpage>741</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">32311231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/kjm2.12219</pub-id><pub-id pub-id-type="pmcid">PMC11896186</pub-id></mixed-citation></ref><ref id="B532"><label>532.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Exosomal miR-370-3p increases the permeability of blood-brain barrier in ischemia/reperfusion stroke of brain by targeting MPK1</article-title>. <source>Aging</source>. <year>2023</year>;<volume>15</volume>(<issue>6</issue>):<fpage>1931</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">37000151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.204573</pub-id><pub-id pub-id-type="pmcid">PMC10085611</pub-id></mixed-citation></ref><ref id="B533"><label>533.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>C</given-names></string-name></person-group>. <article-title>miR-378a-5p regulates CAMKK2/AMPK pathway to contribute to cerebral ischemia/reperfusion injury-induced neuronal apoptosis</article-title>. <source>Folia Histochem Cytobiol</source>. <year>2021</year>;<volume>59</volume>(<issue>1</issue>):<fpage>57</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">33651374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5603/FHC.a2021.0007</pub-id></mixed-citation></ref><ref id="B534"><label>534.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>LncRNA-PCat19 acts as a ceRNA of miR-378a-3p to facilitate microglia activation and accelerate chronic neuropathic pain in rats by promoting KDM3A-mediated BDNF demethylation</article-title>. <source>Mol Immunol</source>. <year>2024</year>;<volume>170</volume>:<fpage>88</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">38643689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2024.04.003</pub-id></mixed-citation></ref><ref id="B535"><label>535.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jiao</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Astrocyte-derived exosomal miR-378a-5p mitigates cerebral ischemic neuroinflammation by modulating NLRP3-mediated pyroptosis</article-title>. <source>Front Immunol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1454116</fpage>.<pub-id pub-id-type="pmid">39176087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1454116</pub-id><pub-id pub-id-type="pmcid">PMC11338813</pub-id></mixed-citation></ref><ref id="B536"><label>536.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>YX</given-names></string-name></person-group>. <article-title>Morphine modulates the expression of mu-opioid receptor exon 5-associated full-length C-terminal splice variants by upregulating miR-378a-3p</article-title>. <source>FASEB J</source>. <year>2020</year>;<volume>34</volume>(<issue>3</issue>):<fpage>4540</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">31999011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201901879RR</pub-id><pub-id pub-id-type="pmcid">PMC7060099</pub-id></mixed-citation></ref><ref id="B537"><label>537.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>YX</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>JQ</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Microglia-derived exosomes modulate myelin regeneration via miR-615-5p/MYRF axis</article-title>. <source>J Neuroinflammation</source>. <year>2024</year>;<volume>21</volume>(<issue>1</issue>):<fpage>29</fpage>.<pub-id pub-id-type="pmid">38246987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03019-5</pub-id><pub-id pub-id-type="pmcid">PMC10801965</pub-id></mixed-citation></ref><ref id="B538"><label>538.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jovicic</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zaldivar Jolissaint</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Moser</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Silva Santos</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Luthi-Carter</surname><given-names>R</given-names></string-name></person-group>. <article-title>MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e54222</fpage>.<pub-id pub-id-type="pmid">23349832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0054222</pub-id><pub-id pub-id-type="pmcid">PMC3547907</pub-id></mixed-citation></ref><ref id="B539"><label>539.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>W</given-names></string-name></person-group>. <article-title>Neuroprotective effects of viral overexpression of microRNA-22 in rat and cell models of cerebral ischemia-reperfusion injury</article-title>. <source>J Cell Biochem</source>. <year>2015</year>;<volume>116</volume>(<issue>2</issue>):<fpage>233</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">25186498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.24960</pub-id></mixed-citation></ref><ref id="B540"><label>540.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>F</given-names></string-name></person-group>. <article-title>MicroRNA-22 exerts its neuroprotective and angiogenic functions via regulating PI3K/Akt signaling pathway in cerebral ischemia-reperfusion rats</article-title>. <source>J Neural Transm</source>. <year>2020</year>;<volume>127</volume>(<issue>1</issue>):<fpage>35</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">31883035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-019-02124-7</pub-id></mixed-citation></ref><ref id="B541"><label>541.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>ZH</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Rui</surname><given-names>HC</given-names></string-name></person-group>. <article-title>Neuroprotective role of MicroRNA-22 in a 6-hydroxydopamine-induced cell model of Parkinson's disease via regulation of its target gene TRPM7</article-title>. <source>J Mol Neurosci</source>. <year>2016</year>;<volume>60</volume>(<issue>4</issue>):<fpage>445</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">27631550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-016-0828-2</pub-id></mixed-citation></ref><ref id="B542"><label>542.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name></person-group>. <article-title>MiR-22-3p regulates amyloid &#946; deposit in mice model of alzheimer's disease by targeting mitogen-activated protein kinase 14</article-title>. <source>Curr Neurovasc Res</source>. <year>2019</year>;<volume>16</volume>(<issue>5</issue>):<fpage>473</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">31713484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567202616666191111124516</pub-id></mixed-citation></ref><ref id="B543"><label>543.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>miR-22-3p enhances the intrinsic regenerative abilities of primary sensory neurons via the CBL/p-EGFR/p-STAT3/GAP43/p-GAP43 axis</article-title>. <source>J Cell Physiol</source>. <year>2020</year>;<volume>235</volume>(<issue>5</issue>):<fpage>4605</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">31663116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29338</pub-id></mixed-citation></ref><ref id="B544"><label>544.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Berenguer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Herrera</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vuolo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Torroba</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Llorens</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sumoy</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA 22 regulates cell cycle length in cerebellar granular neuron precursors</article-title>. <source>Mol Cell Biol</source>. <year>2013</year>;<volume>33</volume>(<issue>14</issue>):<fpage>2706</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">23671190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MCB.00338-13</pub-id><pub-id pub-id-type="pmcid">PMC3700129</pub-id></mixed-citation></ref><ref id="B545"><label>545.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>miR-22-3p in the rostral ventrolateral medulla promotes hypertension through inhibiting &#946;-arrestin-1</article-title>. <source>J Physiol</source>. <year>2024</year>;<volume>602</volume>(<issue>2</issue>):<fpage>317</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">38152023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/JP283960</pub-id></mixed-citation></ref><ref id="B546"><label>546.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>H</given-names></string-name></person-group>. <article-title>MicroRNA-142-3p relieves neuropathic pain by targeting high mobility group box 1</article-title>. <source>Int J Mol Med</source>. <year>2018</year>;<volume>41</volume>:<fpage>501</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">29115575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2017.3222</pub-id></mixed-citation></ref><ref id="B547"><label>547.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>XR</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>MiR-142-3p enhances cell viability and inhibits apoptosis by targeting CDKN1B and TIMP3 following sciatic nerve injury</article-title>. <source>Cell Physiol Biochem</source>. <year>2018</year>;<volume>46</volume>(<issue>6</issue>):<fpage>2347</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">29742504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000489626</pub-id></mixed-citation></ref><ref id="B548"><label>548.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>miR-142-3p alleviates neuronal apoptosis in Parkinson's disease via negatively regulating C9orf72</article-title>. <source>Neurosci Lett</source>. <year>2024</year>;<volume>836</volume>:<fpage>137887</fpage>.<pub-id pub-id-type="pmid">38942112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2024.137887</pub-id></mixed-citation></ref><ref id="B549"><label>549.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>H</given-names></string-name></person-group>. <article-title>miR-142-3p targets AC9 to regulate sciatic nerve injury-induced neuropathic pain by regulating the cAMP/AMPK signalling pathway</article-title>. <source>Int J Mol Med</source>. <year>2021</year>;<volume>47</volume>(<issue>2</issue>):<fpage>561</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">33416140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2020.4824</pub-id><pub-id pub-id-type="pmcid">PMC7797458</pub-id></mixed-citation></ref><ref id="B550"><label>550.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Roblain</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Louis</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yip</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baudin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Struman</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Caolo</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization</article-title>. <source>Aging</source>. <year>2021</year>;<volume>13</volume>(<issue>9</issue>):<fpage>12359</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">33952723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.203035</pub-id><pub-id pub-id-type="pmcid">PMC8148470</pub-id></mixed-citation></ref><ref id="B551"><label>551.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mandolesi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>De Vito</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Musella</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gentile</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bullitta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fresegna</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>miR-142-3p is a key regulator of IL-1&#946;-dependent synaptopathy in neuroinflammation</article-title>. <source>J Neurosci</source>. <year>2017</year>;<volume>37</volume>(<issue>3</issue>):<fpage>546</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">28100738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0851-16.2016</pub-id><pub-id pub-id-type="pmcid">PMC6596761</pub-id></mixed-citation></ref><ref id="B552"><label>552.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tob&#243;n</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kuzhikandathil</surname><given-names>EV</given-names></string-name></person-group>. <article-title>MicroRNA 142-3p mediates post-transcriptional regulation of D1 dopamine receptor expression</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>11</issue>):<fpage>e49288</fpage>.<pub-id pub-id-type="pmid">23152889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0049288</pub-id><pub-id pub-id-type="pmcid">PMC3495858</pub-id></mixed-citation></ref><ref id="B553"><label>553.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shende</surname><given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>Neuendorff</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Earnest</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>Role of miR-142-3p in the post-transcriptional regulation of the clock gene Bmal1 in the mouse SCN</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e65300</fpage>.<pub-id pub-id-type="pmid">23755214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0065300</pub-id><pub-id pub-id-type="pmcid">PMC3673942</pub-id></mixed-citation></ref><ref id="B554"><label>554.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Truettner</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Motti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dietrich</surname><given-names>WD</given-names></string-name></person-group>. <article-title>MicroRNA overexpression increases cortical neuronal vulnerability to injury</article-title>. <source>Brain Res</source>. <year>2013</year>;<volume>1533</volume>:<fpage>122</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">23948100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2013.08.011</pub-id><pub-id pub-id-type="pmcid">PMC3829616</pub-id></mixed-citation></ref><ref id="B555"><label>555.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kuang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-451 aggravates kainic acid-induced seizure and neuronal apoptosis by targeting GDNF</article-title>. <source>Curr Neurovasc Res</source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>50</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31870266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567202617666191223150510</pub-id></mixed-citation></ref><ref id="B556"><label>556.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maheu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Crapper</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Davoli</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Turecki</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mechawar</surname><given-names>N</given-names></string-name></person-group>. <article-title>MicroRNA regulation of central glial cell line-derived neurotrophic factor (GDNF) signalling in depression</article-title>. <source>Transl Psychiatry</source>. <year>2015</year>;<volume>5</volume>(<issue>2</issue>):<fpage>e511</fpage>.<pub-id pub-id-type="pmid">25689572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tp.2015.11</pub-id><pub-id pub-id-type="pmcid">PMC4445749</pub-id></mixed-citation></ref><ref id="B557"><label>557.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sabbagh</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Blair</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Darling</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dickey</surname><given-names>CA</given-names></string-name></person-group>. <article-title>MicroRNA-511 binds to FKBP5 mRNA, which encodes a chaperone protein, and regulates neuronal differentiation</article-title>. <source>J Biol Chem</source>. <year>2016</year>;<volume>291</volume>(<issue>34</issue>):<fpage>17897</fpage>&#8211;<lpage>906</lpage>.<pub-id pub-id-type="pmid">27334923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M116.727941</pub-id><pub-id pub-id-type="pmcid">PMC5016178</pub-id></mixed-citation></ref><ref id="B558"><label>558.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Short- and long-term alterations of FKBP5-GR and specific microRNAs in the prefrontal cortex and hippocampus of male rats induced by adolescent stress contribute to depression susceptibility</article-title>. <source>Psychoneuroendocrinology</source>. <year>2019</year>;<volume>101</volume>:<fpage>204</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">30469088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psyneuen.2018.11.008</pub-id></mixed-citation></ref><ref id="B559"><label>559.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hirschberger</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hinske</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Kreth</surname><given-names>S</given-names></string-name></person-group>. <article-title>MiRNAs: dynamic regulators of immune cell functions in inflammation and cancer</article-title>. <source>Cancer Lett</source>. <year>2018</year>;<volume>431</volume>:<fpage>11</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">29800684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2018.05.020</pub-id></mixed-citation></ref><ref id="B560"><label>560.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Burlacu</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Ciobanu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Badulescu</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Chelaru</surname><given-names>VF</given-names></string-name>, <string-name name-style="western"><surname>Mitre</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Capitanescu</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Circulating MicroRNAs and extracellular vesicle-derived MicroRNAs as predictors of functional recovery in ischemic stroke patients: a systematic review and meta-analysis</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>24</volume>(<issue>1</issue>):<fpage>251</fpage>.<pub-id pub-id-type="pmid">36613694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24010251</pub-id><pub-id pub-id-type="pmcid">PMC9820088</pub-id></mixed-citation></ref><ref id="B561"><label>561.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nail</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Chiu</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Leung</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>MMM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>HMD</given-names></string-name></person-group>. <article-title>Exosomal miRNA-mediated intercellular communications and immunomodulatory effects in tumor microenvironments</article-title>. <source>J Biomed Sci</source>. <year>2023</year>;<volume>30</volume>(<issue>1</issue>):<fpage>69</fpage>.<pub-id pub-id-type="pmid">37605155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-023-00964-w</pub-id><pub-id pub-id-type="pmcid">PMC10440907</pub-id></mixed-citation></ref><ref id="B562"><label>562.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>XR</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>Q</given-names></string-name></person-group>. <article-title>Activated neutrophil-derived exosomes contribute to blood-brain barrier damage and hemorrhagic transformation after cerebral ischemia/reperfusion</article-title>. <source>Brain Res</source>. <year>2023</year>;<volume>1810</volume>:<fpage>148374</fpage>.<pub-id pub-id-type="pmid">37116559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2023.148374</pub-id></mixed-citation></ref><ref id="B563"><label>563.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>miR-30d-5p plays an important role in autophagy and apoptosis in developing rat brains after hypoxic-ischemic injury</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2017</year>;<volume>76</volume>(<issue>8</issue>):<fpage>709</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">28789480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlx052</pub-id></mixed-citation></ref><ref id="B564"><label>564.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Exosomes from MiR-30d-5p-ADSCs reverse acute ischemic stroke-induced, autophagy-mediated brain injury by promoting M2 microglial/macrophage polarization</article-title>. <source>Cell Physiol Biochem</source>. <year>2018</year>;<volume>47</volume>(<issue>2</issue>):<fpage>864</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">29807362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000490078</pub-id></mixed-citation></ref><ref id="B565"><label>565.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name></person-group>. <article-title>MiR-93 targeting EphA4 promotes neurite outgrowth from spinal cord neurons</article-title>. <source>J Mol Neurosci</source>. <year>2016</year>;<volume>58</volume>(<issue>4</issue>):<fpage>517</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">26798048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-015-0709-0</pub-id></mixed-citation></ref><ref id="B566"><label>566.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ouyang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Transforming growth factor-&#946;1 functions as a competitive endogenous RNA that ameliorates intracranial hemorrhage injury by sponging microRNA-93-5p</article-title>. <source>Mol Med Rep</source>. <year>2021</year>;<volume>24</volume>(<issue>1</issue>):<fpage>499</fpage>.<pub-id pub-id-type="pmid">33955515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2021.12138</pub-id><pub-id pub-id-type="pmcid">PMC8127068</pub-id></mixed-citation></ref><ref id="B567"><label>567.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name></person-group>. <article-title>The role of miR-122-5p in negatively regulating T-box brain 1 expression on the differentiation of mouse bone mesenchymal stem cells</article-title>. <source>Neuroreport</source>. <year>2017</year>;<volume>28</volume>(<issue>7</issue>):<fpage>367</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">28240720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000000752</pub-id></mixed-citation></ref><ref id="B568"><label>568.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Study on the role and mechanism of exosomes derived from dental pulp stem cells in promoting regeneration of myelin sheath in rats with sciatic nerve injury</article-title>. <source>Mol Neurobiol</source>. <year>2024</year>;<volume>61</volume>(<issue>9</issue>):<fpage>6175</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">38285287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-024-03960-9</pub-id></mixed-citation></ref><ref id="B569"><label>569.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name></person-group>. <article-title>MiR-122-5p suppresses neuropathic pain development by targeting PDK4</article-title>. <source>Neurochem Res</source>. <year>2021</year>;<volume>46</volume>(<issue>4</issue>):<fpage>957</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">33566299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-020-03213-w</pub-id></mixed-citation></ref><ref id="B570"><label>570.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nan</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>miR-122-5p promotes peripheral and central nervous system inflammation in a mouse model of intracerebral hemorrhage via disruption of the MLLT1/PI3K/AKT signaling</article-title>. <source>Neurochem Res</source>. <year>2023</year>;<volume>48</volume>(<issue>12</issue>):<fpage>3665</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">37594575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-023-04014-7</pub-id></mixed-citation></ref><ref id="B571"><label>571.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>LncRNA xist regulates sepsis associated neuroinflammation in the periventricular white matter of CLP rats by miR-122-5p/PKC&#951; Axis</article-title>. <source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1225482</fpage>.<pub-id pub-id-type="pmid">38115999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1225482</pub-id><pub-id pub-id-type="pmcid">PMC10728298</pub-id></mixed-citation></ref><ref id="B572"><label>572.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Song</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Dysregulated expression of miR-140 and miR-122 compromised microglial chemotaxis and led to reduced restriction of AD pathology</article-title>. <source>J Neuroinflammation</source>. <year>2024</year>;<volume>21</volume>(<issue>1</issue>):<fpage>167</fpage>.<pub-id pub-id-type="pmid">38956605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03162-z</pub-id><pub-id pub-id-type="pmcid">PMC11218311</pub-id></mixed-citation></ref><ref id="B573"><label>573.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murphy</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Maurer</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Oberhauser</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gstir</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wearick-Silva</surname><given-names>LE</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-mediated rescue of fear extinction memory by miR-144-3p in extinction-impaired mice</article-title>. <source>Biol Psychiatry</source>. <year>2017</year>;<volume>81</volume>(<issue>12</issue>):<fpage>979</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">28104225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2016.12.021</pub-id></mixed-citation></ref><ref id="B574"><label>574.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Up-regulated microRNA-218-5p ameliorates the damage of dopaminergic neurons in rats with Parkinson&#8217;s disease via suppression of LASP1</article-title>. <source>Brain Res Bull</source>. <year>2021</year>;<volume>166</volume>:<fpage>92</fpage>&#8211;<lpage>101</lpage>.<pub-id pub-id-type="pmid">33144090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2020.10.019</pub-id></mixed-citation></ref><ref id="B575"><label>575.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-218-5p-Ddx41 axis restrains microglia-mediated neuroinflammation through downregulating type I interferon response in a mouse model of Parkinson's disease</article-title>. <source>J Transl Med</source>. <year>2024</year>;<volume>22</volume>(<issue>1</issue>):<fpage>63</fpage>.<pub-id pub-id-type="pmid">38229084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-024-04881-w</pub-id><pub-id pub-id-type="pmcid">PMC10792813</pub-id></mixed-citation></ref><ref id="B576"><label>576.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xia</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>LncRNA CCAT1 protects astrocytes against OGD/R-Induced damage by targeting the miR-218/NFAT5-signaling Axis</article-title>. <source>Cell Mol Neurobiol</source>. <year>2020</year>;<volume>40</volume>(<issue>8</issue>):<fpage>1383</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">32239388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-020-00824-3</pub-id><pub-id pub-id-type="pmcid">PMC11448959</pub-id></mixed-citation></ref><ref id="B577"><label>577.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Torres-Berr&#237;o</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nouel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cuesta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Parise</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Restrepo-Lozano</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Larochelle</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>MiR-218: a molecular switch and potential biomarker of susceptibility to stress</article-title>. <source>Mol Psychiatry</source>. <year>2020</year>;<volume>25</volume>(<issue>5</issue>):<fpage>951</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">30980043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-019-0421-5</pub-id><pub-id pub-id-type="pmcid">PMC6790160</pub-id></mixed-citation></ref><ref id="B578"><label>578.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yoshino</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dwivedi</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Corticosterone-mediated regulation and functions of miR-218-5p in rat brain</article-title>. <source>Sci Rep</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>194</fpage>.<pub-id pub-id-type="pmid">34996981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-03863-y</pub-id><pub-id pub-id-type="pmcid">PMC8742130</pub-id></mixed-citation></ref><ref id="B579"><label>579.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rocchi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Moretti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lignani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Colombo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Scholz-Starke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Baldelli</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Neurite-enriched MicroRNA-218 stimulates translation of the GluA2 subunit and increases excitatory synaptic strength</article-title>. <source>Mol Neurobiol</source>. <year>2019</year>;<volume>56</volume>(<issue>8</issue>):<fpage>5701</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">30671783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-019-1492-7</pub-id></mixed-citation></ref><ref id="B580"><label>580.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Antoniou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Auderset</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kaurani</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sebastian</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Allahham</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Neuronal extracellular vesicles and associated microRNAs induce circuit connectivity downstream BDNF</article-title>. <source>Cell Rep</source>. <year>2023</year>;<volume>42</volume>(<issue>2</issue>):<fpage>112063</fpage>.<pub-id pub-id-type="pmid">36753414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.112063</pub-id></mixed-citation></ref><ref id="B581"><label>581.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>QW</given-names></string-name>, <etal/></person-group>. <article-title>miR-218-2 regulates cognitive functions in the hippocampus through complement component 3-dependent modulation of synaptic vesicle release</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2021</year>;<volume>118</volume>(<issue>14</issue>):<fpage>e2021770118</fpage>.<pub-id pub-id-type="pmid">33782126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2021770118</pub-id><pub-id pub-id-type="pmcid">PMC8040660</pub-id></mixed-citation></ref><ref id="B582"><label>582.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pulcrano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>De Gregorio</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>De Sanctis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Volpicelli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Piscitelli</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Speranza</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>miR-218 promotes dopaminergic differentiation and controls neuron excitability and neurotransmitter release through the regulation of a synaptic-related genes network</article-title>. <source>J Neurosci</source>. <year>2023</year>;<volume>43</volume>(<issue>48</issue>):<fpage>8104</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">37816598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0431-23.2023</pub-id><pub-id pub-id-type="pmcid">PMC10697421</pub-id></mixed-citation></ref><ref id="B583"><label>583.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thiebes</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Nam</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cambronne</surname><given-names>XA</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Glasgow</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>HH</given-names></string-name>, <etal/></person-group>. <article-title>miR-218 is essential to establish motor neuron fate as a downstream effector of Isl1-Lhx3</article-title>. <source>Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>7718</fpage>.<pub-id pub-id-type="pmid">26212498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms8718</pub-id><pub-id pub-id-type="pmcid">PMC4518464</pub-id></mixed-citation></ref><ref id="B584"><label>584.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amin</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Klug</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Bonanomi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pankratz</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Gifford</surname><given-names>WD</given-names></string-name>, <etal/></person-group>. <article-title>Loss of motoneuron-specific microRNA-218 causes systemic neuromuscular failure</article-title>. <source>Science</source>. <year>2015</year>;<volume>350</volume>(<issue>6267</issue>):<fpage>1525</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26680198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad2509</pub-id><pub-id pub-id-type="pmcid">PMC4913787</pub-id></mixed-citation></ref><ref id="B585"><label>585.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reichenstein</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Eitan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Diaz-Garcia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Haim</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Magen</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Siany</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology</article-title>. <source>Sci Transl Med</source>. <year>2019</year>;<volume>11</volume>(<issue>523</issue>):<fpage>eaav5264</fpage>.<pub-id pub-id-type="pmid">31852800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aav5264</pub-id><pub-id pub-id-type="pmcid">PMC7057809</pub-id></mixed-citation></ref><ref id="B586"><label>586.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Torres-Berr&#237;o</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Bagot</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Nouel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dal Bo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cuesta</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>DCC confers susceptibility to depression-like behaviors in humans and mice and is regulated by miR-218</article-title>. <source>Biol Psychiatry</source>. <year>2017</year>;<volume>81</volume>(<issue>4</issue>):<fpage>306</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">27773352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2016.08.017</pub-id><pub-id pub-id-type="pmcid">PMC5239724</pub-id></mixed-citation></ref><ref id="B587"><label>587.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>MiR-409-3p and MiR-1896 co-operatively participate in IL-17-induced inflammatory cytokine production in astrocytes and pathogenesis of EAE mice via targeting SOCS3/STAT3 signaling</article-title>. <source>Glia</source>. <year>2019</year>;<volume>67</volume>(<issue>1</issue>):<fpage>101</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30294880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.23530</pub-id></mixed-citation></ref><ref id="B588"><label>588.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Si</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Exosomal miR-409-3p secreted from activated mast cells promotes microglial migration, activation and neuroinflammation by targeting Nr4a2 to activate the NF-&#954;B pathway</article-title>. <source>J Neuroinflammation</source>. <year>2021</year>;<volume>18</volume>(<issue>1</issue>):<fpage>68</fpage>.<pub-id pub-id-type="pmid">33750404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-021-02110-5</pub-id><pub-id pub-id-type="pmcid">PMC7945321</pub-id></mixed-citation></ref><ref id="B589"><label>589.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nie</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Vitexin improves neuron apoptosis and memory impairment induced by isoflurane via regulation of miR-409 expression</article-title>. <source>Adv Clin Exp Med</source>. <year>2020</year>;<volume>29</volume>(<issue>1</issue>):<fpage>135</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">32011832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17219/acem/104556</pub-id></mixed-citation></ref><ref id="B590"><label>590.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Diaz</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Siththanandan</surname><given-names>VB</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez-Nava</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pasquina</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>MacDonald</surname><given-names>JL</given-names></string-name>, <etal/></person-group>. <article-title>An evolutionarily acquired microRNA shapes development of mammalian cortical projections</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2020</year>;<volume>117</volume>(<issue>46</issue>):<fpage>29113</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">33139574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2006700117</pub-id><pub-id pub-id-type="pmcid">PMC7682328</pub-id></mixed-citation></ref><ref id="B591"><label>591.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tung</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Yen</surname><given-names>YP</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>YL</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA filters Hox temporal transcription noise to confer boundary formation in the spinal cord</article-title>. <source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>:<fpage>14685</fpage>.<pub-id pub-id-type="pmid">28337978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14685</pub-id><pub-id pub-id-type="pmcid">PMC5376671</pub-id></mixed-citation></ref><ref id="B592"><label>592.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harati</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hammad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tlili</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mahfood</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mabondzo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hamoudi</surname><given-names>R</given-names></string-name></person-group>. <article-title>miR-27a-3p regulates expression of intercellular junctions at the brain endothelium and controls the endothelial barrier permeability</article-title>. <source>PLoS One</source>. <year>2022</year>;<volume>17</volume>(<issue>1</issue>):<fpage>e0262152</fpage>.<pub-id pub-id-type="pmid">35025943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0262152</pub-id><pub-id pub-id-type="pmcid">PMC8758013</pub-id></mixed-citation></ref><ref id="B593"><label>593.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ye</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Serum exosomal microRNA-27-3p aggravates cerebral injury and inflammation in patients with acute cerebral infarction by targeting PPAR&#947;</article-title>. <source>Inflammation</source>. <year>2021</year>;<volume>44</volume>(<issue>3</issue>):<fpage>1035</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">33394189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01399-3</pub-id></mixed-citation></ref><ref id="B594"><label>594.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amaral</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Andrade</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Foxall</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Matoso</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Matos</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Soares</surname><given-names>RS</given-names></string-name>, <etal/></person-group>. <article-title>miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication</article-title>. <source>EMBO J</source>. <year>2017</year>;<volume>36</volume>(<issue>3</issue>):<fpage>346</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">27993935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.201694335</pub-id><pub-id pub-id-type="pmcid">PMC5286376</pub-id></mixed-citation></ref><ref id="B595"><label>595.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>L</given-names></string-name></person-group>. <article-title>HDAC9 silencing exerts neuroprotection against ischemic brain injury via miR-20a-dependent downregulation of NeuroD1</article-title>. <source>Front Cell Neurosci</source>. <year>2020</year>;<volume>14</volume>:<fpage>544285</fpage>.<pub-id pub-id-type="pmid">33584204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2020.544285</pub-id><pub-id pub-id-type="pmcid">PMC7873949</pub-id></mixed-citation></ref><ref id="B596"><label>596.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MiR-20a plays a key regulatory role in the repair of spinal cord dorsal column lesion via PDZ-RhoGEF/RhoA/GAP43 Axis in rat</article-title>. <source>Cell Mol Neurobiol</source>. <year>2019</year>;<volume>39</volume>(<issue>1</issue>):<fpage>87</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">30426336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-018-0635-0</pub-id><pub-id pub-id-type="pmcid">PMC11469850</pub-id></mixed-citation></ref><ref id="B597"><label>597.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>miR-20a promotes the axon regeneration of DRG neurons by targeting Nr4a3</article-title>. <source>Neurosci Bull</source>. <year>2021</year>;<volume>37</volume>(<issue>6</issue>):<fpage>569</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">33683649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12264-021-00647-2</pub-id><pub-id pub-id-type="pmcid">PMC8055734</pub-id></mixed-citation></ref><ref id="B598"><label>598.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jee</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Im</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>SK</given-names></string-name></person-group>. <article-title>Silencing of miR20a is crucial for Ngn1-mediated neuroprotection in injured spinal cord</article-title>. <source>Hum Gene Ther</source>. <year>2012</year>;<volume>23</volume>(<issue>5</issue>):<fpage>508</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">22182208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2011.121</pub-id></mixed-citation></ref><ref id="B599"><label>599.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tian</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>J</given-names></string-name></person-group>. <article-title>MicroRNA-20b-5p aggravates neuronal apoptosis induced by &#946;-Amyloid via down-regulation of Ras homolog family member C in Alzheimer's disease</article-title>. <source>Neurosci Lett</source>. <year>2021</year>;<volume>742</volume>:<fpage>135542</fpage>.<pub-id pub-id-type="pmid">33278507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2020.135542</pub-id></mixed-citation></ref><ref id="B600"><label>600.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Earls</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Fricke</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Zakharenko</surname><given-names>SS</given-names></string-name></person-group>. <article-title>Age-dependent microRNA control of synaptic plasticity in 22q11 deletion syndrome and schizophrenia</article-title>. <source>J Neurosci</source>. <year>2012</year>;<volume>32</volume>(<issue>41</issue>):<fpage>14132</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">23055483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1312-12.2012</pub-id><pub-id pub-id-type="pmcid">PMC3486522</pub-id></mixed-citation></ref><ref id="B601"><label>601.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodr&#237;guez-Aznar</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Barrallo-Gimeno</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nieto</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Scratch2 prevents cell cycle re-entry by repressing miR-25 in postmitotic primary neurons</article-title>. <source>J Neurosci</source>. <year>2013</year>;<volume>33</volume>(<issue>12</issue>):<fpage>5095</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="pmid">23516276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4459-12.2013</pub-id><pub-id pub-id-type="pmcid">PMC6704984</pub-id></mixed-citation></ref><ref id="B602"><label>602.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Repetitive transcranial magnetic stimulation promotes neural stem cell proliferation via the regulation of MiR-25 in a rat model of focal cerebral ischemia</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>10</issue>):<fpage>e109267</fpage>.<pub-id pub-id-type="pmid">25302788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0109267</pub-id><pub-id pub-id-type="pmcid">PMC4193773</pub-id></mixed-citation></ref><ref id="B603"><label>603.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wohl</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Hooper</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Reh</surname><given-names>TA</given-names></string-name></person-group>. <article-title>MicroRNAs miR-25, let-7 and miR-124 regulate the neurogenic potential of M&#252;ller glia in mice</article-title>. <source>Development</source>. <year>2019</year>;<volume>146</volume>(<issue>17</issue>):<fpage>dev179556</fpage>.<pub-id pub-id-type="pmid">31383796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dev.179556</pub-id><pub-id pub-id-type="pmcid">PMC6765125</pub-id></mixed-citation></ref><ref id="B604"><label>604.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>MircoRNA-25-3p in skin precursor cell-induced Schwann cell-derived extracellular vesicles promotes axon regeneration by targeting Tgif1</article-title>. <source>Exp Neurol</source>. <year>2024</year>;<volume>376</volume>:<fpage>114750</fpage>.<pub-id pub-id-type="pmid">38492636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2024.114750</pub-id></mixed-citation></ref><ref id="B605"><label>605.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>ZH</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-25 negatively regulates cerebral ischemia/reperfusion injury-induced cell apoptosis through fas/FasL pathway</article-title>. <source>J Mol Neurosci</source>. <year>2016</year>;<volume>58</volume>(<issue>4</issue>):<fpage>507</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">26768135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-016-0712-0</pub-id></mixed-citation></ref><ref id="B606"><label>606.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-25-3p suppresses epileptiform discharges through inhibiting oxidative stress and apoptosis via targeting OXSR1 in neurons</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2020</year>;<volume>523</volume>(<issue>4</issue>):<fpage>859</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">31954517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2020.01.050</pub-id></mixed-citation></ref><ref id="B607"><label>607.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name></person-group>. <article-title>Inhibition of miR-25 aggravates diabetic peripheral neuropathy</article-title>. <source>Neuroreport</source>. <year>2018</year>;<volume>29</volume>(<issue>11</issue>):<fpage>945</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">29877948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001058</pub-id><pub-id pub-id-type="pmcid">PMC6045951</pub-id></mixed-citation></ref><ref id="B608"><label>608.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MicroRNA-25-5p negatively regulates TXNIP expression and relieves inflammatory responses of brain induced by lipopolysaccharide</article-title>. <source>Sci Rep</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>17915</fpage>.<pub-id pub-id-type="pmid">36289253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-21169-5</pub-id><pub-id pub-id-type="pmcid">PMC9605969</pub-id></mixed-citation></ref><ref id="B609"><label>609.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Si</surname><given-names>E</given-names></string-name></person-group>. <article-title>MicroRNA-25 aggravates A&#946;1-42-induced hippocampal neuron injury in Alzheimer's disease by downregulating KLF2 via the Nrf2 signaling pathway in a mouse model</article-title>. <source>J Cell Biochem</source>. <year>2019</year>;<volume>120</volume>(<issue>9</issue>):<fpage>15891</fpage>&#8211;<lpage>905</lpage>.<pub-id pub-id-type="pmid">31144355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.28861</pub-id></mixed-citation></ref><ref id="B610"><label>610.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-31 regulating apoptosis by mediating the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in treatment of spinal cord injury</article-title>. <source>Brain Dev</source>. <year>2019</year>;<volume>41</volume>(<issue>8</issue>):<fpage>649</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">31036380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.braindev.2019.04.010</pub-id></mixed-citation></ref><ref id="B611"><label>611.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>miR-31 promotes neural stem cell proliferation and restores motor function after spinal cord injury</article-title>. <source>Exp Biol Med</source>. <year>2021</year>;<volume>246</volume>(<issue>11</issue>):<fpage>1274</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1535370221997071</pub-id><pub-id pub-id-type="pmcid">PMC8371310</pub-id><pub-id pub-id-type="pmid">33715531</pub-id></mixed-citation></ref><ref id="B612"><label>612.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wei</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Inhibition of the BCL6/miR-31/PKD1 axis attenuates oxidative stress-induced neuronal damage</article-title>. <source>Exp Neurol</source>. <year>2021</year>;<volume>335</volume>:<fpage>113528</fpage>.<pub-id pub-id-type="pmid">33189730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2020.113528</pub-id></mixed-citation></ref><ref id="B613"><label>613.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lv</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Che</surname><given-names>Y</given-names></string-name></person-group>. <article-title>miR-31 from adipose stem cell-derived extracellular vesicles promotes recovery of neurological function after ischemic stroke by inhibiting TRAF6 and IRF5</article-title>. <source>Exp Neurol</source>. <year>2021</year>;<volume>342</volume>:<fpage>113611</fpage>.<pub-id pub-id-type="pmid">33460643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2021.113611</pub-id></mixed-citation></ref><ref id="B614"><label>614.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qian</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-31 inhibits traumatic brain injury-triggered neuronal cell apoptosis by regulating hypoxia-inducible factor-1A/vascular endothelial growth factor A axis</article-title>. <source>Neuroreport</source>. <year>2022</year>;<volume>33</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">34874324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001741</pub-id></mixed-citation></ref><ref id="B615"><label>615.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>mRNA and miRNA expression profile reveals the role of miR-31 overexpression in neural stem cell</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>17537</fpage>.<pub-id pub-id-type="pmid">33067542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-74541-8</pub-id><pub-id pub-id-type="pmcid">PMC7568549</pub-id></mixed-citation></ref><ref id="B616"><label>616.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ke</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-31 negatively regulates peripherally derived regulatory T-cell generation by repressing retinoic acid-inducible protein 3</article-title>. <source>Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>7639</fpage>.<pub-id pub-id-type="pmid">26165721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms8639</pub-id><pub-id pub-id-type="pmcid">PMC4510656</pub-id></mixed-citation></ref><ref id="B617"><label>617.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cai</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name></person-group>. <article-title>Up-regulation of circARF3 reduces blood-brain barrier damage in rat subarachnoid hemorrhage model via miR-31-5p/MyD88/NF-&#954;B axis</article-title>. <source>Aging</source>. <year>2021</year>;<volume>13</volume>(<issue>17</issue>):<fpage>21345</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">34511434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.203468</pub-id><pub-id pub-id-type="pmcid">PMC8457610</pub-id></mixed-citation></ref><ref id="B618"><label>618.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meares</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Rajbhandari</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gerigk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tien</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fehling</surname><given-names>SC</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-31 is required for astrocyte specification</article-title>. <source>Glia</source>. <year>2018</year>;<volume>66</volume>(<issue>5</issue>):<fpage>987</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">29380422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.23296</pub-id><pub-id pub-id-type="pmcid">PMC5851835</pub-id></mixed-citation></ref><ref id="B619"><label>619.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sathyan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Golden</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Miranda</surname><given-names>RC</given-names></string-name></person-group>. <article-title>Competing interactions between micro-RNAs determine neural progenitor survival and proliferation after ethanol exposure: evidence from an ex vivo model of the fetal cerebral cortical neuroepithelium</article-title>. <source>J Neurosci</source>. <year>2007</year>;<volume>27</volume>(<issue>32</issue>):<fpage>8546</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">17687032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1269-07.2007</pub-id><pub-id pub-id-type="pmcid">PMC2915840</pub-id></mixed-citation></ref><ref id="B620"><label>620.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carvalho</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Dos Santos Sanna</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Dos Santos Afonso</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Bondan</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>da Silva Feltran</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>MR</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA biogenesis machinery activation and lncRNA and REST overexpression as neuroprotective responses to fight inflammation in the hippocampus</article-title>. <source>J Neuroimmunol</source>. <year>2023</year>;<volume>382</volume>:<fpage>578149</fpage>.<pub-id pub-id-type="pmid">37481910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2023.578149</pub-id></mixed-citation></ref><ref id="B621"><label>621.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Circular RNA TLK1 aggravates neuronal injury and neurological deficits after ischemic stroke via miR-335-3p/TIPARP</article-title>. <source>J Neurosci</source>. <year>2019</year>;<volume>39</volume>(<issue>37</issue>):<fpage>7369</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">31311824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0299-19.2019</pub-id><pub-id pub-id-type="pmcid">PMC6759031</pub-id></mixed-citation></ref><ref id="B622"><label>622.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fei</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name></person-group>. <article-title>MiR-335-5p inhibits &#946;-amyloid (a&#946;) accumulation to attenuate cognitive deficits through targeting c-jun-N-terminal kinase 3 in alzheimer's disease</article-title>. <source>Curr Neurovasc Res</source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>93</fpage>&#8211;<lpage>101</lpage>.<pub-id pub-id-type="pmid">32003672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567202617666200128141938</pub-id></mixed-citation></ref><ref id="B623"><label>623.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ke</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name></person-group>. <article-title>miR-708 and miR-335-3p inhibit the apoptosis of retinal ganglion cells through suppressing autophagy</article-title>. <source>J Mol Neurosci</source>. <year>2021</year>;<volume>71</volume>(<issue>2</issue>):<fpage>284</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">32683666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-020-01648-y</pub-id></mixed-citation></ref><ref id="B624"><label>624.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Rong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>MiR-335 improves functional recovery in rats after spinal cord injury and protects PC12 cells against injury via the SPI-Bax/Caspase-3 Axis</article-title>. <source>Spine</source>. <year>2024</year>;<volume>49</volume>(<issue>8</issue>):<fpage>583</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">38167229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0000000000004862</pub-id></mixed-citation></ref><ref id="B625"><label>625.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name></person-group>. <article-title>METTL3 mediates microglial activation and blood-brain barrier permeability in cerebral ischemic stroke by regulating NLRP3 inflammasomes through m6A methylation modification</article-title>. <source>Neurotox Res</source>. <year>2024</year>;<volume>42</volume>(<issue>1</issue>):<fpage>15</fpage>.<pub-id pub-id-type="pmid">38349604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12640-024-00687-2</pub-id></mixed-citation></ref><ref id="B626"><label>626.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bishayee</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sadra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Moon</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Defective neuronal migration and inhibition of bipolar to multipolar transition of migrating neural cells by Mesoderm-Specific Transcript, Mest, in the developing mouse neocortex</article-title>. <source>Neuroscience</source>. <year>2017</year>;<volume>355</volume>:<fpage>126</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">28501506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2017.05.003</pub-id></mixed-citation></ref><ref id="B627"><label>627.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>D</given-names></string-name></person-group>. <article-title>Up-regulation of miR-335 and miR-674-3p in the rostral ventrolateral medulla contributes to stress-induced hypertension</article-title>. <source>J Neurochem</source>. <year>2022</year>;<volume>161</volume>(<issue>5</issue>):<fpage>387</fpage>&#8211;<lpage>404</lpage>.<pub-id pub-id-type="pmid">35152434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15589</pub-id></mixed-citation></ref><ref id="B628"><label>628.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Capitano</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Camon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Licursi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ferretti</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Maggi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Scianni</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-335-5p modulates spatial memory and hippocampal synaptic plasticity</article-title>. <source>Neurobiol Learn Mem</source>. <year>2017</year>;<volume>139</volume>:<fpage>63</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28039088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nlm.2016.12.019</pub-id></mixed-citation></ref><ref id="B629"><label>629.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raihan</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Brishti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Molla</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>The age-dependent elevation of miR-335-3p leads to reduced cholesterol and impaired memory in brain</article-title>. <source>Neuroscience</source>. <year>2018</year>;<volume>390</volume>:<fpage>160</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">30125687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2018.08.003</pub-id></mixed-citation></ref><ref id="B630"><label>630.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naqvi</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Datta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Naqvi</surname><given-names>AR</given-names></string-name></person-group>. <article-title>Regulatory roles of MicroRNA in shaping T cell function, differentiation and polarization</article-title>. <source>Semin Cell Dev Biol</source>. <year>2022</year>;<volume>124</volume>:<fpage>34</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">34446356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcdb.2021.08.003</pub-id><pub-id pub-id-type="pmcid">PMC11661912</pub-id></mixed-citation></ref><ref id="B631"><label>631.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Dexmedetomidine had neuroprotective effects on hippocampal neuronal cells via targeting lncRNA SHNG16 mediated microRNA-10b-5p/BDNF axis</article-title>. <source>Mol Cell Biochem</source>. <year>2020</year>;<volume>469</volume>(<issue>1&#8211;2</issue>):<fpage>41</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">32323054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11010-020-03726-6</pub-id><pub-id pub-id-type="pmcid">PMC7244615</pub-id></mixed-citation></ref><ref id="B632"><label>632.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>MiR-10b-5p regulates neuronal autophagy and apoptosis induced by spinal cord injury through UBR7</article-title>. <source>Neuroscience</source>. <year>2024</year>;<volume>543</volume>:<fpage>13</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">38382692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2024.02.013</pub-id></mixed-citation></ref><ref id="B633"><label>633.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chai</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Oblinger</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Prahalad</surname><given-names>AK</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1</article-title>. <source>Cancer Sci</source>. <year>2010</year>;<volume>101</volume>(<issue>9</issue>):<fpage>1997</fpage>&#8211;<lpage>2004</lpage>.<pub-id pub-id-type="pmid">20550523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1349-7006.2010.01616.x</pub-id><pub-id pub-id-type="pmcid">PMC11159772</pub-id></mixed-citation></ref><ref id="B634"><label>634.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Foley</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Bray</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Watters</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bryan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bernas</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2</article-title>. <source>Cell Death Differ</source>. <year>2011</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1089</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">21212796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cdd.2010.172</pub-id><pub-id pub-id-type="pmcid">PMC3114164</pub-id></mixed-citation></ref><ref id="B635"><label>635.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guessous</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Alvarado-Velez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Marcinkiewicz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heister</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Oncogenic effects of miR-10b in glioblastoma stem cells</article-title>. <source>J Neuro Oncol</source>. <year>2013</year>;<volume>112</volume>(<issue>2</issue>):<fpage>153</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-013-1047-0</pub-id><pub-id pub-id-type="pmcid">PMC3609924</pub-id><pub-id pub-id-type="pmid">23307328</pub-id></mixed-citation></ref><ref id="B636"><label>636.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aguennouz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Polito</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Visalli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vita</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Raffa</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Oteri</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors</article-title>. <source>Cancer Treat Res Commun</source>. <year>2020</year>;<volume>24</volume>:<fpage>100203</fpage>.<pub-id pub-id-type="pmid">32777750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctarc.2020.100203</pub-id></mixed-citation></ref><ref id="B637"><label>637.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>The effect of miR-10b on growth hormone in pituitary cells of Yanbian yellow cattle by somatostatin receptor 2</article-title>. <source>Anim Sci J</source>. <year>2020</year>;<volume>91</volume>(<issue>1</issue>):<fpage>e13420</fpage>.<pub-id pub-id-type="pmid">32618083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/asj.13420</pub-id></mixed-citation></ref><ref id="B638"><label>638.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nusrin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Chaturvedi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Giesy</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>RY</given-names></string-name></person-group>. <article-title>Regulation of CYP11B1 and CYP11B2 steroidogenic genes by hypoxia-inducible miR-10b in H295R cells</article-title>. <source>Mar Pollut Bull</source>. <year>2014</year>;<volume>85</volume>(<issue>2</issue>):<fpage>344</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">24768260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.marpolbul.2014.04.002</pub-id></mixed-citation></ref><ref id="B639"><label>639.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Triptolide suppressed the microglia activation to improve spinal cord injury through miR-96/IKK&#946;/NF-&#954;B pathway</article-title>. <source>Spine</source>. <year>2019</year>;<volume>44</volume>(<issue>12</issue>):<fpage>E707</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">31150368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BRS.0000000000002989</pub-id></mixed-citation></ref><ref id="B640"><label>640.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>C</given-names></string-name></person-group>. <article-title>CircRNA CTNNB1 (circCTNNB1) ameliorates cerebral ischemia/reperfusion injury by sponging miR-96-5p to up-regulate scavenger receptor class B type 1 (SRB1) expression</article-title>. <source>Bioengineered</source>. <year>2022</year>;<volume>13</volume>(<issue>4</issue>):<fpage>10258</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">35435123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21655979.2022.2061304</pub-id><pub-id pub-id-type="pmcid">PMC9162012</pub-id></mixed-citation></ref><ref id="B641"><label>641.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>HP</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>BH</given-names></string-name>, <etal/></person-group>. <article-title>Intrathecal miR-96 inhibits Nav1.3 expression and alleviates neuropathic pain in rat following chronic construction injury</article-title>. <source>Neurochem Res</source>. <year>2014</year>;<volume>39</volume>(<issue>1</issue>):<fpage>76</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">24234845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-013-1192-z</pub-id></mixed-citation></ref><ref id="B642"><label>642.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-96 is required to prevent allodynia by repressing voltage-gated sodium channels in spinal cord</article-title>. <source>Prog Neurobiol</source>. <year>2021</year>;<volume>202</volume>:<fpage>102024</fpage>.<pub-id pub-id-type="pmid">33636225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2021.102024</pub-id></mixed-citation></ref><ref id="B643"><label>643.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kinoshita</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Aoyama</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Matsumura</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kikuchi-Utsumi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Watabe</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nakaki</surname><given-names>T</given-names></string-name></person-group>. <article-title>Rhythmic oscillations of the microRNA miR-96-5p play a neuroprotective role by indirectly regulating glutathione levels</article-title>. <source>Nat Commun</source>. <year>2014</year>;<volume>5</volume>:<fpage>3823</fpage>.<pub-id pub-id-type="pmid">24804999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms4823</pub-id><pub-id pub-id-type="pmcid">PMC4024755</pub-id></mixed-citation></ref><ref id="B644"><label>644.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>miR-96 attenuates status epilepticus-induced brain injury by directly targeting Atg7 and Atg16L1</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>10270</fpage>.<pub-id pub-id-type="pmid">28860495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-10619-0</pub-id><pub-id pub-id-type="pmcid">PMC5579030</pub-id></mixed-citation></ref><ref id="B645"><label>645.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>ZX</given-names></string-name></person-group>. <article-title>Suppressed microRNA-96 inhibits iNOS expression and dopaminergic neuron apoptosis through inactivating the MAPK signaling pathway by targeting CACNG5 in mice with Parkinson's disease</article-title>. <source>Mol Med</source>. <year>2018</year>;<volume>24</volume>(<issue>1</issue>):<fpage>61</fpage>.<pub-id pub-id-type="pmid">30486773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10020-018-0059-9</pub-id><pub-id pub-id-type="pmcid">PMC6263543</pub-id></mixed-citation></ref><ref id="B646"><label>646.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>DX</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>XS</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>HX</given-names></string-name>, <etal/></person-group>. <article-title>Pramipexole attenuates neuronal injury in Parkinson's disease by targeting miR-96 to activate BNIP3-mediated mitophagy</article-title>. <source>Neurochem Int</source>. <year>2021</year>;<volume>146</volume>:<fpage>104972</fpage>.<pub-id pub-id-type="pmid">33493581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2021.104972</pub-id></mixed-citation></ref><ref id="B647"><label>647.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>miR-182 mediated the inhibitory effects of NF-&#954;B on the GPR39/CREB/BDNF pathway in the hippocampus of mice with depressive-like behaviors</article-title>. <source>Behav Brain Res</source>. <year>2022</year>;<volume>418</volume>:<fpage>113647</fpage>.<pub-id pub-id-type="pmid">34743948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2021.113647</pub-id></mixed-citation></ref><ref id="B648"><label>648.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loscher</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Hokamp</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Humphries</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Farrar</surname><given-names>GJ</given-names></string-name>, <etal/></person-group>. <article-title>A common microRNA signature in mouse models of retinal degeneration</article-title>. <source>Exp Eye Res</source>. <year>2008</year>;<volume>87</volume>(<issue>6</issue>):<fpage>529</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">18834879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exer.2008.08.016</pub-id><pub-id pub-id-type="pmcid">PMC4030402</pub-id></mixed-citation></ref><ref id="B649"><label>649.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Okano</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Maeda</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Sponge transgenic mouse model reveals important roles for the microRNA-183 (miR-183)/96/182 cluster in postmitotic photoreceptors of the retina</article-title>. <source>J Biol Chem</source>. <year>2011</year>;<volume>286</volume>(<issue>36</issue>):<fpage>31749</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">21768104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.259028</pub-id><pub-id pub-id-type="pmcid">PMC3173082</pub-id></mixed-citation></ref><ref id="B650"><label>650.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>XJ</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>GH</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>JN</given-names></string-name>, <etal/></person-group>. <article-title>miR-183/96 plays a pivotal regulatory role in mouse photoreceptor maturation and maintenance</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2017</year>;<volume>114</volume>(<issue>24</issue>):<fpage>6376</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">28559309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1618757114</pub-id><pub-id pub-id-type="pmcid">PMC5474811</pub-id></mixed-citation></ref><ref id="B651"><label>651.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Overexpression of miR-96 leads to retinal degeneration in mice</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2024</year>;<volume>719</volume>:<fpage>150048</fpage>.<pub-id pub-id-type="pmid">38763044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2024.150048</pub-id></mixed-citation></ref><ref id="B652"><label>652.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krohs</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>K&#246;rber</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ebbers</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Altaf</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hollje</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hoppe</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Loss of miR-183/96 alters synaptic strength via presynaptic and postsynaptic mechanisms at a central synapse</article-title>. <source>J Neurosci</source>. <year>2021</year>;<volume>41</volume>(<issue>32</issue>):<fpage>6796</fpage>&#8211;<lpage>811</lpage>.<pub-id pub-id-type="pmid">34193555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0139-20.2021</pub-id><pub-id pub-id-type="pmcid">PMC8360680</pub-id></mixed-citation></ref><ref id="B653"><label>653.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Menc&#237;a</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Modamio-H&#248;ybj&#248;r</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Redshaw</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mor&#237;n</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mayo-Merino</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Olavarrieta</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss</article-title>. <source>Nat Genet</source>. <year>2009</year>;<volume>41</volume>(<issue>5</issue>):<fpage>609</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">19363479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.355</pub-id></mixed-citation></ref><ref id="B654"><label>654.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuhn</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Furness</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ingham</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hilton</surname><given-names>JM</given-names></string-name>, <etal/></person-group>. <article-title>miR-96 regulates the progression of differentiation in mammalian cochlear inner and outer hair cells</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2011</year>;<volume>108</volume>(<issue>6</issue>):<fpage>2355</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">21245307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1016646108</pub-id><pub-id pub-id-type="pmcid">PMC3038748</pub-id></mixed-citation></ref><ref id="B655"><label>655.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weston</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Pierce</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Jensen-Smith</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Fritzsch</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rocha-Sanchez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Beisel</surname><given-names>KW</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-183 family expression in hair cell development and requirement of microRNAs for hair cell maintenance and survival</article-title>. <source>Dev Dyn</source>. <year>2011</year>;<volume>240</volume>(<issue>4</issue>):<fpage>808</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">21360794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dvdy.22591</pub-id><pub-id pub-id-type="pmcid">PMC3072272</pub-id></mixed-citation></ref><ref id="B656"><label>656.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weston</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Tarang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pierce</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Pyakurel</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Rocha-Sanchez</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>McGee</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>A mouse model of miR-96, miR-182 and miR-183 misexpression implicates miRNAs in cochlear cell fate and homeostasis</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>3569</fpage>.<pub-id pub-id-type="pmid">29476110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-21811-1</pub-id><pub-id pub-id-type="pmcid">PMC5824881</pub-id></mixed-citation></ref><ref id="B657"><label>657.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kloosterman</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Fekete</surname><given-names>DM</given-names></string-name></person-group>. <article-title>MicroRNA-183 family members regulate sensorineural fates in the inner ear</article-title>. <source>J Neurosci</source>. <year>2010</year>;<volume>30</volume>(<issue>9</issue>):<fpage>3254</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">20203184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4948-09.2010</pub-id><pub-id pub-id-type="pmcid">PMC2848753</pub-id></mixed-citation></ref><ref id="B658"><label>658.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Miraglia</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Romero</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mure</surname><given-names>LS</given-names></string-name>, <etal/></person-group>. <article-title>A genome-wide microRNA screen identifies the microRNA-183/96/182 cluster as a modulator of circadian rhythms</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2021</year>;<volume>118</volume>(<issue>1</issue>):<fpage>118</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2020454118</pub-id><pub-id pub-id-type="pmcid">PMC7817116</pub-id><pub-id pub-id-type="pmid">33443164</pub-id></mixed-citation></ref><ref id="B659"><label>659.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Millan</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues</article-title>. <source>Curr Opin Pharmacol</source>. <year>2011</year>;<volume>11</volume>(<issue>1</issue>):<fpage>11</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">21345728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coph.2011.01.008</pub-id></mixed-citation></ref><ref id="B660"><label>660.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Sheen-Chen</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Intrathecal miR-183 delivery suppresses mechanical allodynia in mononeuropathic rats</article-title>. <source>Eur J Neurosci</source>. <year>2014</year>;<volume>39</volume>(<issue>10</issue>):<fpage>1682</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24612023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ejn.12522</pub-id></mixed-citation></ref><ref id="B661"><label>661.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>HP</given-names></string-name></person-group>. <article-title>MiR-183-5p alleviates chronic constriction injury-induced neuropathic pain through inhibition of TREK-1</article-title>. <source>Neurochem Res</source>. <year>2018</year>;<volume>43</volume>(<issue>6</issue>):<fpage>1143</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29736614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-018-2529-4</pub-id></mixed-citation></ref><ref id="B662"><label>662.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>miR-351-5p regulation of CPEB3 affecting aluminium-induced learning and memory impairment in SD rats</article-title>. <source>Environ Pollut</source>. <year>2024</year>;<volume>362</volume>:<fpage>124973</fpage>.<pub-id pub-id-type="pmid">39307336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.envpol.2024.124973</pub-id></mixed-citation></ref><ref id="B663"><label>663.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mellios</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Grigorenko</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rogaev</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Akbarian</surname><given-names>S</given-names></string-name></person-group>. <article-title>A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex</article-title>. <source>Hum Mol Genet</source>. <year>2008</year>;<volume>17</volume>(<issue>19</issue>):<fpage>3030</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">18632683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddn201</pub-id><pub-id pub-id-type="pmcid">PMC2722882</pub-id></mixed-citation></ref><ref id="B664"><label>664.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Abnormal hippocampal BDNF and miR-16 expression is associated with depression-like behaviors induced by stress during early life</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>10</issue>):<fpage>e46921</fpage>.<pub-id pub-id-type="pmid">23056528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0046921</pub-id><pub-id pub-id-type="pmcid">PMC3466179</pub-id></mixed-citation></ref><ref id="B665"><label>665.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Launay</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Mouillet-Richard</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baudry</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pietri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kellermann</surname><given-names>O</given-names></string-name></person-group>. <article-title>Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16</article-title>. <source>Transl Psychiatry</source>. <year>2011</year>;<volume>1</volume>(<issue>11</issue>):<fpage>e56</fpage>.<pub-id pub-id-type="pmid">22833211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tp.2011.54</pub-id><pub-id pub-id-type="pmcid">PMC3309472</pub-id></mixed-citation></ref><ref id="B666"><label>666.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Antoniou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Khudayberdiev</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Idziak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bicker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jacob</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schratt</surname><given-names>G</given-names></string-name></person-group>. <article-title>The dynamic recruitment of TRBP to neuronal membranes mediates dendritogenesis during development</article-title>. <source>EMBO Rep</source>. <year>2018</year>;<volume>19</volume>(<issue>3</issue>):<fpage>e44853</fpage>.<pub-id pub-id-type="pmid">29263199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.201744853</pub-id><pub-id pub-id-type="pmcid">PMC5835843</pub-id></mixed-citation></ref><ref id="B667"><label>667.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chaudhuri</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Dastgheyb</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Trout</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Talbot</surname><given-names>CC</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>TNF&#945; and IL-1&#946; modify the miRNA cargo of astrocyte shed extracellular vesicles to regulate neurotrophic signaling in neurons</article-title>. <source>Cell Death Dis</source>. <year>2018</year>;<volume>9</volume>(<issue>3</issue>):<fpage>363</fpage>.<pub-id pub-id-type="pmid">29507357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-018-0369-4</pub-id><pub-id pub-id-type="pmcid">PMC5838212</pub-id></mixed-citation></ref><ref id="B668"><label>668.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Burak</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lamoureux</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Boese</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Majer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Saba</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-16 targets mRNA involved in neurite extension and branching in hippocampal neurons during presymptomatic prion disease</article-title>. <source>Neurobiol Dis</source>. <year>2018</year>;<volume>112</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">29277556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2017.12.011</pub-id></mixed-citation></ref><ref id="B669"><label>669.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>QC</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>ZW</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>QM</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>ZY</given-names></string-name></person-group>. <article-title>Enhancement of miR-16-5p on spinal cord injury-induced neuron apoptosis and inflammatory response through inactivating ERK1/2 pathway</article-title>. <source>J Neurosurg Sci</source>. <year>2024</year>;<volume>68</volume>(<issue>1</issue>):<fpage>101</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32043849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23736/S0390-5616.20.04880-8</pub-id></mixed-citation></ref><ref id="B670"><label>670.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>QF</given-names></string-name></person-group>. <article-title>MiR-16 regulates cell death in Alzheimer&#8217;s disease by targeting amyloid precursor protein</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2015</year>;<volume>19</volume>(<issue>21</issue>):<fpage>4020</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26592823</pub-id></mixed-citation></ref><ref id="B671"><label>671.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>MiR-16 attenuates &#946;-amyloid-induced neurotoxicity through targeting &#946;-site amyloid precursor protein-cleaving enzyme 1 in an Alzheimer&#8217;s disease cell model</article-title>. <source>Neuroreport</source>. <year>2018</year>;<volume>29</volume>(<issue>16</issue>):<fpage>1365</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">30142113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001118</pub-id></mixed-citation></ref><ref id="B672"><label>672.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>YW</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>XL</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name></person-group>. <article-title>miR-16-5p and miR-19b-3p prevent amyloid &#946;-induced injury by targeting BACE1 in SH-SY5Y cells</article-title>. <source>Neuroreport</source>. <year>2020</year>;<volume>31</volume>(<issue>3</issue>):<fpage>205</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">31876684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001379</pub-id></mixed-citation></ref><ref id="B673"><label>673.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baudry</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mouillet-Richard</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Launay</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Kellermann</surname><given-names>O</given-names></string-name></person-group>. <article-title>miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants</article-title>. <source>Science</source>. <year>2010</year>;<volume>329</volume>(<issue>5998</issue>):<fpage>1537</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">20847275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1193692</pub-id></mixed-citation></ref><ref id="B674"><label>674.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moya</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Wendland</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Salemme</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fried</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>DL</given-names></string-name></person-group>. <article-title>miR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells</article-title>. <source>Int J Neuropsychopharmacol</source>. <year>2013</year>;<volume>16</volume>(<issue>3</issue>):<fpage>621</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22564678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1461145712000454</pub-id></mixed-citation></ref><ref id="B675"><label>675.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>MiR-195 dependent roles of mitofusin2 in the mitochondrial dysfunction of hippocampal neurons in SAMP8 mice</article-title>. <source>Brain Res</source>. <year>2016</year>;<volume>1652</volume>:<fpage>135</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">27693395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2016.09.047</pub-id></mixed-citation></ref><ref id="B676"><label>676.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Administration of miR-195 inhibitor enhances memory function through improving synaptic degradation and mitochondrial dysfunction of the hippocampal neurons in SAMP8 mice</article-title>. <source>J Alzheimers Dis</source>. <year>2022</year>;<volume>85</volume>(<issue>4</issue>):<fpage>1495</fpage>&#8211;<lpage>509</lpage>.<pub-id pub-id-type="pmid">34924391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215301</pub-id></mixed-citation></ref><ref id="B677"><label>677.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>JF</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-195 downregulates Alzheimer's disease amyloid-&#946; production by targeting BACE1</article-title>. <source>Brain Res Bull</source>. <year>2012</year>;<volume>88</volume>(<issue>6</issue>):<fpage>596</fpage>&#8211;<lpage>601</lpage>.<pub-id pub-id-type="pmid">22721728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2012.05.018</pub-id></mixed-citation></ref><ref id="B678"><label>678.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Che</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>TZ</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>WC</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats</article-title>. <source>J Neurosci</source>. <year>2013</year>;<volume>33</volume>(<issue>9</issue>):<fpage>3989</fpage>&#8211;<lpage>4001</lpage>.<pub-id pub-id-type="pmid">23447608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1997-12.2013</pub-id><pub-id pub-id-type="pmcid">PMC6619292</pub-id></mixed-citation></ref><ref id="B679"><label>679.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>XM</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-195 prevents dendritic degeneration and neuron death in rats following chronic brain hypoperfusion</article-title>. <source>Cell Death Dis</source>. <year>2017</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e2850</fpage>.<pub-id pub-id-type="pmid">28569780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2017.243</pub-id><pub-id pub-id-type="pmcid">PMC5520902</pub-id></mixed-citation></ref><ref id="B680"><label>680.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ren</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name></person-group>. <article-title>MicroRNA&#8209;195 triggers neuroinflammation in Parkinson&#8217;s disease in a Rho&#8209;associated kinase&#160;1&#8209;dependent manner</article-title>. <source>Mol Med Rep</source>. <year>2019</year>;<volume>19</volume>(<issue>6</issue>):<fpage>5153</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">31059087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2019.10176</pub-id></mixed-citation></ref><ref id="B681"><label>681.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsai</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Chong</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>HP</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>TL</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-195-5p inhibits intracerebral hemorrhage-induced inflammatory response and neuron cell apoptosis</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>19</issue>):<fpage>10321</fpage>.<pub-id pub-id-type="pmid">39408651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms251910321</pub-id><pub-id pub-id-type="pmcid">PMC11476780</pub-id></mixed-citation></ref><ref id="B682"><label>682.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>XB</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-195 prevents hippocampal microglial/macrophage polarization towards the M1 phenotype induced by chronic brain hypoperfusion through regulating CX3CL1/CX3CR1 signaling</article-title>. <source>J Neuroinflammation</source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>244</fpage>.<pub-id pub-id-type="pmid">32819407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-020-01919-w</pub-id><pub-id pub-id-type="pmcid">PMC7439693</pub-id></mixed-citation></ref><ref id="B683"><label>683.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>ZQ</given-names></string-name>, <string-name name-style="western"><surname>McQuate</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Jobe</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Christ</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>von Hoyningen-Huene</surname><given-names>SJ</given-names></string-name>, <etal/></person-group>. <article-title>An epigenetic feedback regulatory loop involving microRNA-195 and MBD1 governs neural stem cell differentiation</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e51436</fpage>.<pub-id pub-id-type="pmid">23349673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0051436</pub-id><pub-id pub-id-type="pmcid">PMC3547917</pub-id></mixed-citation></ref><ref id="B684"><label>684.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Chao</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>JL</given-names></string-name>, <etal/></person-group>. <article-title>miR-195 reduces age-related blood-brain barrier leakage caused by thrombospondin-1-mediated selective autophagy</article-title>. <source>Aging Cell</source>. <year>2020</year>;<volume>19</volume>(<issue>11</issue>):<fpage>e13236</fpage>.<pub-id pub-id-type="pmid">33029941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13236</pub-id><pub-id pub-id-type="pmcid">PMC7681043</pub-id></mixed-citation></ref><ref id="B685"><label>685.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>DJ</given-names></string-name>, <etal/></person-group>. <article-title>Effects of miR-26a-5p on neuropathic pain development by targeting MAPK6 in in CCI rat models</article-title>. <source>Biomed Pharmacother</source>. <year>2018</year>;<volume>107</volume>:<fpage>644</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30118880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2018.08.005</pub-id></mixed-citation></ref><ref id="B686"><label>686.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>A novel microglia-targeting strategy based on nanoparticle-mediated delivery of miR-26a-5p for long-lasting analgesia in chronic pain</article-title>. <source>J Nanobiotechnology</source>. <year>2024</year>;<volume>22</volume>(<issue>1</issue>):<fpage>128</fpage>.<pub-id pub-id-type="pmid">38519978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-024-02420-9</pub-id><pub-id pub-id-type="pmcid">PMC10960380</pub-id></mixed-citation></ref><ref id="B687"><label>687.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>MSCs-derived exosomes attenuate ischemia-reperfusion brain injury and inhibit microglia apoptosis might via exosomal miR-26a-5p mediated suppression of CDK6</article-title>. <source>Mol Med</source>. <year>2021</year>;<volume>27</volume>(<issue>1</issue>):<fpage>67</fpage>.<pub-id pub-id-type="pmid">34215174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10020-021-00324-0</pub-id><pub-id pub-id-type="pmcid">PMC8254277</pub-id></mixed-citation></ref><ref id="B688"><label>688.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name></person-group>. <article-title>Circular RNA circTLK1 regulates dopaminergic neuron injury during Parkinson's disease by targeting miR-26a-5p/DAPK1</article-title>. <source>Neurosci Lett</source>. <year>2022</year>;<volume>782</volume>:<fpage>136638</fpage>.<pub-id pub-id-type="pmid">35447224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2022.136638</pub-id></mixed-citation></ref><ref id="B689"><label>689.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Astrocyte-derived exosomes-transported miRNA-26a-5p ameliorates sevoflurane-induced cognitive dysfunction in aged mice</article-title>. <source>Transl Res</source>. <year>2024</year>;<volume>268</volume>:<fpage>79</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">38246343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2024.01.007</pub-id></mixed-citation></ref><ref id="B690"><label>690.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luarte</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Henzi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gaete</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cisternas</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pizarro</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Astrocyte-derived small extracellular vesicles regulate dendritic complexity through miR-26a-5p activity</article-title>. <source>Cells</source>. <year>2020</year>;<volume>9</volume>(<issue>4</issue>):<fpage>930</fpage>.<pub-id pub-id-type="pmid">32290095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9040930</pub-id><pub-id pub-id-type="pmcid">PMC7226994</pub-id></mixed-citation></ref><ref id="B691"><label>691.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Nrf2 improves hippocampal synaptic plasticity, learning and memory through the circ-Vps41/miR-26a-5p/CaMKIV regulatory network</article-title>. <source>Exp Neurol</source>. <year>2022</year>;<volume>351</volume>:<fpage>113998</fpage>.<pub-id pub-id-type="pmid">35143833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2022.113998</pub-id></mixed-citation></ref><ref id="B692"><label>692.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Potenza</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mosca</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mondola</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Damiano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Russo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>De Felice</surname><given-names>B</given-names></string-name></person-group>. <article-title>Human miR-26a-5p regulates the glutamate transporter SLC1A1 (EAAT3) expression. Relevance in multiple sclerosis</article-title>. <source>Biochim Biophys Acta Mol Basis Dis</source>. <year>2018</year>;<volume>1864</volume>(<issue>1</issue>):<fpage>317</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">28962897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2017.09.024</pub-id></mixed-citation></ref><ref id="B693"><label>693.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lafourcade</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ram&#237;rez</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Corval&#225;n</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Carrasco</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iturriaga</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>A role for mir-26a in stress: a potential sEV biomarker and modulator of excitatory neurotransmission</article-title>. <source>Cells</source>. <year>2020</year>;<volume>9</volume>(<issue>6</issue>):<fpage>1364</fpage>.<pub-id pub-id-type="pmid">32492799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9061364</pub-id><pub-id pub-id-type="pmcid">PMC7349773</pub-id></mixed-citation></ref><ref id="B694"><label>694.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sengupta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Heydendael</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Nicholas</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Beltrami</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNAs as biomarkers of resilience or vulnerability to stress</article-title>. <source>Neuroscience</source>. <year>2015</year>;<volume>305</volume>:<fpage>36</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">26208845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2015.07.045</pub-id></mixed-citation></ref><ref id="B695"><label>695.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>XZ</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>ZX</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>GL</given-names></string-name></person-group>. <article-title>MiR-29a-3p enhances the viability of rat neuronal cells that injured by oxygen-glucose deprivation/reoxygenation treatment through targeting TNFRSF1A and regulating NF-&#954;B signaling pathway</article-title>. <source>J Stroke Cerebrovasc Dis</source>. <year>2020</year>;<volume>29</volume>(<issue>11</issue>):<fpage>105210</fpage>.<pub-id pub-id-type="pmid">33066952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2020.105210</pub-id></mixed-citation></ref><ref id="B696"><label>696.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Elevated miR-29a contributes to axonal outgrowth and neurological recovery after intracerebral hemorrhage via targeting PTEN/PI3K/akt pathway</article-title>. <source>Cell Mol Neurobiol</source>. <year>2021</year>;<volume>41</volume>(<issue>8</issue>):<fpage>1759</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">32889668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-020-00945-9</pub-id><pub-id pub-id-type="pmcid">PMC11444011</pub-id></mixed-citation></ref><ref id="B697"><label>697.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>W</given-names></string-name></person-group>. <article-title>Mechanism of SOX10 in ferroptosis of hippocampal neurons after intracerebral hemorrhage via the miR-29a-3p/ACSL4 axis</article-title>. <source>J Neurophysiol</source>. <year>2023</year>;<volume>129</volume>(<issue>4</issue>):<fpage>862</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">36919939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00374.2022</pub-id></mixed-citation></ref><ref id="B698"><label>698.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luo</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>MiR-29a-3p ameliorate behavioral deficiency in hypoxia-ischemia brain damage in neonatal mice by inhibiting BTG2</article-title>. <source>Behav Brain Res</source>. <year>2025</year>;<volume>486</volume>:<fpage>115552</fpage>.<pub-id pub-id-type="pmid">40147793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2025.115552</pub-id></mixed-citation></ref><ref id="B699"><label>699.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pan</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>LY</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>QZ</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>miR-29a-3p promotes the regulatory role of eicosapentaenoic acid in the NLRP3 inflammasome and autophagy in microglial cells</article-title>. <source>Kaohsiung J Med Sci</source>. <year>2023</year>;<volume>39</volume>(<issue>6</issue>):<fpage>565</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">36974975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/kjm2.12670</pub-id><pub-id pub-id-type="pmcid">PMC11895928</pub-id></mixed-citation></ref><ref id="B700"><label>700.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scoyni</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Giudice</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>V&#228;&#228;n&#228;nen</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Downes</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Korhonen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Choo</surname><given-names>XY</given-names></string-name>, <etal/></person-group>. <article-title>Alzheimer's disease-induced phagocytic microglia express a specific profile of coding and non-coding RNAs</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>2</issue>):<fpage>954</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">37828821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13502</pub-id><pub-id pub-id-type="pmcid">PMC10916983</pub-id></mixed-citation></ref><ref id="B701"><label>701.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>H&#233;bert</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Horr&#233;</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nicola&#239;</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Papadopoulou</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Mandemakers</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Silahtaroglu</surname><given-names>AN</given-names></string-name>, <etal/></person-group>. <article-title>Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer&#8217;s disease correlates with increased BACE1/&#946;-secretase expression</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2008</year>;<volume>105</volume>(<issue>17</issue>):<fpage>6415</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">18434550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0710263105</pub-id><pub-id pub-id-type="pmcid">PMC2359789</pub-id></mixed-citation></ref><ref id="B702"><label>702.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name></person-group>. <article-title>CircSEC11A knockdown alleviates oxidative stress and apoptosis and promotes cell proliferation and angiogenesis by regulating miR-29a-3p/SEMA3A axis in OGD-induced human brain microvascular endothelial cells (HBMECs)</article-title>. <source>Clin Hemorheol Microcirc</source>. <year>2023</year>;<volume>84</volume>(<issue>3</issue>):<fpage>247</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">36872771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/CH-221689</pub-id></mixed-citation></ref><ref id="B703"><label>703.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Murgia</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sirakawin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Konovalov</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Neuronal miR-29a protects from obesity in adult mice</article-title>. <source>Mol Metab</source>. <year>2022</year>;<volume>61</volume>:<fpage>101507</fpage>.<pub-id pub-id-type="pmid">35490865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2022.101507</pub-id><pub-id pub-id-type="pmcid">PMC9114687</pub-id></mixed-citation></ref><ref id="B704"><label>704.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Valera</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Desplats</surname><given-names>P</given-names></string-name></person-group>. <article-title>Alterations in striatal microRNA-mRNA networks contribute to neuroinflammation in multiple system atrophy</article-title>. <source>Mol Neurobiol</source>. <year>2019</year>;<volume>56</volume>(<issue>10</issue>):<fpage>7003</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">30968343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-019-1577-3</pub-id><pub-id pub-id-type="pmcid">PMC7216788</pub-id></mixed-citation></ref><ref id="B705"><label>705.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-29c/PTEN pathway is involved in mice brain development and modulates neurite outgrowth in PC12 cells</article-title>. <source>Cell Mol Neurobiol</source>. <year>2015</year>;<volume>35</volume>(<issue>3</issue>):<fpage>313</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">25352418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-014-0126-x</pub-id><pub-id pub-id-type="pmcid">PMC11486311</pub-id></mixed-citation></ref><ref id="B706"><label>706.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Weng</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>DNA methyltransferase 3, a target of microRNA-29c, contributes to neuronal proliferation by regulating the expression of brain-derived neurotrophic factor</article-title>. <source>Mol Med Rep</source>. <year>2015</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1435</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">25815896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2015.3531</pub-id></mixed-citation></ref><ref id="B707"><label>707.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Weng</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-29c targets &#946;-site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo</article-title>. <source>Mol Med Rep</source>. <year>2015</year>;<volume>12</volume>(<issue>2</issue>):<fpage>3081</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25955795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2015.3728</pub-id></mixed-citation></ref><ref id="B708"><label>708.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>L</given-names></string-name></person-group>. <article-title>Mesenchymal stem cells-derived extracellular vesicles ameliorate Alzheimer&#8217;s disease in rat models via the microRNA-29c-3p/BACE1 axis and the Wnt/&#946;-catenin pathway</article-title>. <source>Aging</source>. <year>2021</year>;<volume>13</volume>(<issue>11</issue>):<fpage>15285</fpage>&#8211;<lpage>306</lpage>.<pub-id pub-id-type="pmid">34086603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.203088</pub-id><pub-id pub-id-type="pmcid">PMC8221351</pub-id></mixed-citation></ref><ref id="B709"><label>709.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>JP</given-names></string-name></person-group>. <article-title>Cerebellar fastigial nucleus stimulation in a chronic unpredictable mild stress rat model reduces post-stroke depression by suppressing brain inflammation via the microRNA-29c/TNFRSF1A signaling pathway</article-title>. <source>Med Sci Monit</source>. <year>2019</year>;<volume>25</volume>:<fpage>5594</fpage>&#8211;<lpage>605</lpage>.<pub-id pub-id-type="pmid">31352465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.911835</pub-id><pub-id pub-id-type="pmcid">PMC6683727</pub-id></mixed-citation></ref><ref id="B710"><label>710.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>S</given-names></string-name></person-group>. <article-title>Circ_016719 plays a critical role in neuron cell apoptosis induced by I/R via targeting miR-29c/Map2k6</article-title>. <source>Mol Cell Probes</source>. <year>2020</year>;<volume>49</volume>:<fpage>101478</fpage>.<pub-id pub-id-type="pmid">31698040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcp.2019.101478</pub-id></mixed-citation></ref><ref id="B711"><label>711.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>circSAMD4A participates in the apoptosis and autophagy of dopaminergic neurons via the miR-29c-3p-mediated AMPK/mTOR pathway in Parkinson's disease</article-title>. <source>Mol Med Rep</source>. <year>2021</year>;<volume>24</volume>(<issue>1</issue>):<fpage>540</fpage>.<pub-id pub-id-type="pmid">34080649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2021.12179</pub-id><pub-id pub-id-type="pmcid">PMC8170871</pub-id></mixed-citation></ref><ref id="B712"><label>712.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>miR-29c-3p regulates TET2 expression and inhibits autophagy process in Parkinson's disease models</article-title>. <source>Genes Cells</source>. <year>2021</year>;<volume>26</volume>(<issue>9</issue>):<fpage>684</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">34086379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/gtc.12877</pub-id></mixed-citation></ref><ref id="B713"><label>713.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>MiR-29c inhibits TNF-&#945;-induced ROS production and apoptosis in mouse hippocampal HT22 cell line</article-title>. <source>Neurochem Res</source>. <year>2023</year>;<volume>48</volume>(<issue>2</issue>):<fpage>519</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">36309937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-022-03776-w</pub-id></mixed-citation></ref><ref id="B714"><label>714.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chopp</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Szalad</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>MiR-29c/PRKCI regulates axonal growth of dorsal root ganglia neurons under hyperglycemia</article-title>. <source>Mol Neurobiol</source>. <year>2018</year>;<volume>55</volume>(<issue>1</issue>):<fpage>851</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28070856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-016-0374-5</pub-id><pub-id pub-id-type="pmcid">PMC5577385</pub-id></mixed-citation></ref><ref id="B715"><label>715.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vaisvaser</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Modai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Farberov</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sharon</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gilam</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Neuro-Epigenetic indications of acute stress response in humans: the case of MicroRNA-29c</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>1</issue>):<fpage>e0146236</fpage>.<pub-id pub-id-type="pmid">26730965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0146236</pub-id><pub-id pub-id-type="pmcid">PMC4711717</pub-id></mixed-citation></ref><ref id="B716"><label>716.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Dopamine D3 receptor mediates natural and methamphetamine rewards via regulating the expression of miR-29c in the nucleus accumbens of mice</article-title>. <source>Neuropharmacology</source>. <year>2025</year>;<volume>262</volume>:<fpage>110200</fpage>.<pub-id pub-id-type="pmid">39490406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2024.110200</pub-id></mixed-citation></ref><ref id="B717"><label>717.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hashizume</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nakano</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kubota</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Himuro</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kobayashi</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Mindfulness intervention improves cognitive function in older adults by enhancing the level of miRNA-29c in neuron-derived extracellular vesicles</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>21848</fpage>.<pub-id pub-id-type="pmid">34750393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-01318-y</pub-id><pub-id pub-id-type="pmcid">PMC8575875</pub-id></mixed-citation></ref><ref id="B718"><label>718.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Regulation of microRNA-29c in the nucleus accumbens modulates methamphetamine -induced locomotor sensitization in mice</article-title>. <source>Neuropharmacology</source>. <year>2019</year>;<volume>148</volume>:<fpage>160</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">30639389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2019.01.007</pub-id></mixed-citation></ref><ref id="B719"><label>719.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Impact of miR-29c-3p in the nucleus accumbens on methamphetamine-induced behavioral sensitization and neuroplasticity-related proteins</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>2</issue>):<fpage>942</fpage>.<pub-id pub-id-type="pmid">38256016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25020942</pub-id><pub-id pub-id-type="pmcid">PMC10815255</pub-id></mixed-citation></ref><ref id="B720"><label>720.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khanna</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Muthusamy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sarojini</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>E</given-names></string-name></person-group>. <article-title>Gain of survival signaling by down-regulation of three key miRNAs in brain of calorie-restricted mice</article-title>. <source>Aging</source>. <year>2011</year>;<volume>3</volume>:<fpage>223</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">21415464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.100276</pub-id><pub-id pub-id-type="pmcid">PMC3091518</pub-id></mixed-citation></ref><ref id="B721"><label>721.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Q</given-names></string-name></person-group>. <article-title>MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3</article-title>. <source>Hum Cell</source>. <year>2018</year>;<volume>31</volume>(<issue>2</issue>):<fpage>106</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">29274035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13577-017-0187-5</pub-id><pub-id pub-id-type="pmcid">PMC5852205</pub-id></mixed-citation></ref><ref id="B722"><label>722.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Circulating miR-30e-3p induces disruption of neurite development in SH-SY5Y cells by targeting ABI1, a novel biomarker for schizophrenia</article-title>. <source>J Psychiatr Res</source>. <year>2024</year>;<volume>174</volume>:<fpage>84</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">38626565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2024.04.005</pub-id></mixed-citation></ref><ref id="B723"><label>723.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gorinski</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bijata</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wirth</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abdel Galil</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zeug</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Attenuated palmitoylation of serotonin receptor 5-HT1A affects receptor function and contributes to depression-like behaviors</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>3924</fpage>.<pub-id pub-id-type="pmid">31477731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-11876-5</pub-id><pub-id pub-id-type="pmcid">PMC6718429</pub-id></mixed-citation></ref><ref id="B724"><label>724.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nigro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Menon</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bergamaschi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Clovis</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Baldi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ehrmann</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>MiR-30e and miR-181d control radial glia cell proliferation via HtrA1 modulation</article-title>. <source>Cell Death Dis</source>. <year>2012</year>;<volume>3</volume>(<issue>8</issue>):<fpage>e360</fpage>.<pub-id pub-id-type="pmid">22854828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2012.98</pub-id><pub-id pub-id-type="pmcid">PMC3434671</pub-id></mixed-citation></ref><ref id="B725"><label>725.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Labouesse</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Polesel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Clementi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Markkanen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mouttet</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA expression profiling in the prefrontal cortex: putative mechanisms for the cognitive effects of adolescent high fat feeding</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>8344</fpage>.<pub-id pub-id-type="pmid">29844565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-26631-x</pub-id><pub-id pub-id-type="pmcid">PMC5974184</pub-id></mixed-citation></ref><ref id="B726"><label>726.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>I</given-names></string-name>, <etal/></person-group>. <article-title>MiR-140/BDNF axis regulates normal human astrocyte proliferation and LPS-induced IL-6 and TNF-&#945; secretion</article-title>. <source>Biomed Pharmacother</source>. <year>2017</year>;<volume>91</volume>:<fpage>899</fpage>&#8211;<lpage>905</lpage>.<pub-id pub-id-type="pmid">28501777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2017.05.016</pub-id></mixed-citation></ref><ref id="B727"><label>727.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Kuo</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>PH</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNAs serve as prediction and treatment-response biomarkers of attention-deficit/hyperactivity disorder and promote the differentiation of neuronal cells by repressing the apoptosis pathway</article-title>. <source>Transl Psychiatry</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>67</fpage>.<pub-id pub-id-type="pmid">35184133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-022-01832-1</pub-id><pub-id pub-id-type="pmcid">PMC8858317</pub-id></mixed-citation></ref><ref id="B728"><label>728.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Mo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>L</given-names></string-name></person-group>. <article-title>Circ-AGTPBP1 promotes white matter injury through miR-140-3p/Pcdh17 axis role of Circ-AGTPBP1 in white matter injury</article-title>. <source>J Bioenerg Biomembr</source>. <year>2024</year>;<volume>56</volume>:<fpage>1</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">37994971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10863-023-09984-5</pub-id></mixed-citation></ref><ref id="B729"><label>729.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ambrozkiewicz</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Schwark</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kishimoto-Suga</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Borisova</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hori</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Salazar-L&#225;zaro</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Polarity acquisition in cortical neurons is driven by synergistic action of sox9-regulated Wwp1 and Wwp2 E3 ubiquitin ligases and intronic miR-140</article-title>. <source>Neuron</source>. <year>2018</year>;<volume>100</volume>(<issue>5</issue>):<fpage>1097</fpage>&#8211;<lpage>115.e15</lpage>.<pub-id pub-id-type="pmid">30392800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2018.10.008</pub-id></mixed-citation></ref><ref id="B730"><label>730.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Down-regulation of miR-140-3p can alleviate neonatal repetitive pain in rats via inhibiting TGF-&#946;3</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2019</year>;<volume>515</volume>(<issue>4</issue>):<fpage>627</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">31176490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2019.05.133</pub-id></mixed-citation></ref><ref id="B731"><label>731.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Balaraman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Winzer-Serhan</surname><given-names>UH</given-names></string-name>, <string-name name-style="western"><surname>Miranda</surname><given-names>RC</given-names></string-name></person-group>. <article-title>Opposing actions of ethanol and nicotine on microRNAs are mediated by nicotinic acetylcholine receptors in fetal cerebral cortical-derived neural progenitor cells</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2012</year>;<volume>36</volume>(<issue>10</issue>):<fpage>1669</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">22458409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1530-0277.2012.01793.x</pub-id><pub-id pub-id-type="pmcid">PMC3390449</pub-id></mixed-citation></ref><ref id="B732"><label>732.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Dexmedetomidine attenuates neuroinflammation and microglia activation in LPS-stimulated BV2 microglia cells through targeting circ-Shank3/miR-140-3p/TLR4 axis</article-title>. <source>Eur J Histochem</source>. <year>2023</year>;<volume>67</volume>(<issue>3</issue>):<fpage>3766</fpage>.<pub-id pub-id-type="pmid">37491974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4081/ejh.2023.3766</pub-id><pub-id pub-id-type="pmcid">PMC10476535</pub-id></mixed-citation></ref><ref id="B733"><label>733.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>X</given-names></string-name></person-group>. <article-title>Propofol inhibits neurogenesis of rat neural stem cells by upregulating MicroRNA-141-3p</article-title>. <source>Stem Cell Dev</source>. <year>2017</year>;<volume>26</volume>(<issue>3</issue>):<fpage>189</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/scd.2016.0257</pub-id><pub-id pub-id-type="pmid">27796156</pub-id></mixed-citation></ref><ref id="B734"><label>734.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verma</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ritzel</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pandi</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Inhibition of miR-141-3p ameliorates the negative effects of poststroke social isolation in aged mice</article-title>. <source>Stroke</source>. <year>2018</year>;<volume>49</volume>:<fpage>1701</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29866755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.118.020627</pub-id><pub-id pub-id-type="pmcid">PMC6019570</pub-id></mixed-citation></ref><ref id="B735"><label>735.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dhuri</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Vyas</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Blumenfeld</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bahal</surname><given-names>R</given-names></string-name></person-group>. <article-title>Nanoparticle delivered anti-miR-141-3p for stroke therapy</article-title>. <source>Cells</source>. <year>2021</year>;<volume>10</volume>(<issue>5</issue>):<fpage>1011</fpage>.<pub-id pub-id-type="pmid">33922958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10051011</pub-id><pub-id pub-id-type="pmcid">PMC8145654</pub-id></mixed-citation></ref><ref id="B736"><label>736.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>LQ</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>HQ</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>MicroRNA-141-3p inhibits retinal neovascularization and retinal ganglion cell apoptosis in glaucoma mice through the inactivation of Docking protein 5-dependent mitogen-activated protein kinase signaling pathway</article-title>. <source>J Cell Physiol</source>. <year>2019</year>;<volume>234</volume>(<issue>6</issue>):<fpage>8873</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">30515784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.27549</pub-id></mixed-citation></ref><ref id="B737"><label>737.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Mir-141-3p regulates apoptosis and mitochondrial membrane potential via targeting Sirtuin1 in a 1-methyl-4-phenylpyridinium in vitro model of Parkinson's disease</article-title>. <source>BioMed Res Int</source>. <year>2020</year>;<volume>2020</volume>:<fpage>7239895</fpage>.<pub-id pub-id-type="pmid">33204711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/7239895</pub-id><pub-id pub-id-type="pmcid">PMC7666638</pub-id></mixed-citation></ref><ref id="B738"><label>738.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zi</surname><given-names>T</given-names></string-name></person-group>. <article-title>Overexpression of microRNA-141 relieves chronic constriction injury-induced neuropathic pain via targeting high-mobility group box 1</article-title>. <source>Int J Mol Med</source>. <year>2015</year>;<volume>36</volume>(<issue>5</issue>):<fpage>1433</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26398163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2015.2342</pub-id></mixed-citation></ref><ref id="B739"><label>739.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>XM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>miRNA-141 attenuates UV-induced oxidative stress via activating Keap1-Nrf2 signaling in human retinal pigment epithelium cells and retinal ganglion cells</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>:<fpage>13186</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">28061435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.14489</pub-id><pub-id pub-id-type="pmcid">PMC5355087</pub-id></mixed-citation></ref><ref id="B740"><label>740.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>T</given-names></string-name></person-group>. <article-title>miR-141-3p protects against blood-brain barrier disruption and brain injury after intracerebral hemorrhage by targeting ZEB2</article-title>. <source>J Clin Neurosci</source>. <year>2022</year>;<volume>99</volume>:<fpage>253</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">35306455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jocn.2022.03.010</pub-id></mixed-citation></ref><ref id="B741"><label>741.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Svetoni</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>De Paola</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>La Rosa</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mercatelli</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Caporossi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sette</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Post-transcriptional regulation of FUS and EWS protein expression by miR-141 during neural differentiation</article-title>. <source>Hum Mol Genet</source>. <year>2017</year>;<volume>26</volume>(<issue>14</issue>):<fpage>2732</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">28453628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddx160</pub-id></mixed-citation></ref><ref id="B742"><label>742.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xi</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></string-name>, <etal/></person-group>. <article-title>Age-related changes in MicroRNA in the rat pituitary and potential role in GH regulation</article-title>. <source>Int J Mol Sci</source>. <year>2018</year>;<volume>19</volume>(<issue>7</issue>):<fpage>2058</fpage>.<pub-id pub-id-type="pmid">30011963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19072058</pub-id><pub-id pub-id-type="pmcid">PMC6073141</pub-id></mixed-citation></ref><ref id="B743"><label>743.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ouyang</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yue</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>XX</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>RE</given-names></string-name>, <etal/></person-group>. <article-title>miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo</article-title>. <source>Neurobiol Dis</source>. <year>2012</year>;<volume>45</volume>(<issue>1</issue>):<fpage>555</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">21983159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2011.09.012</pub-id><pub-id pub-id-type="pmcid">PMC3251314</pub-id></mixed-citation></ref><ref id="B744"><label>744.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>M</given-names></string-name></person-group>. <article-title>Hypoxia-specific anti-RAGE exosomes for nose-to-brain delivery of anti-miR-181a oligonucleotide in an ischemic stroke model</article-title>. <source>Nanoscale</source>. <year>2021</year>;<volume>13</volume>(<issue>33</issue>):<fpage>14166</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">34477698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0nr07516g</pub-id></mixed-citation></ref><ref id="B745"><label>745.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ouyang</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yue</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Giffard</surname><given-names>RG</given-names></string-name></person-group>. <article-title>miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes</article-title>. <source>Mitochondrion</source>. <year>2012</year>;<volume>12</volume>(<issue>2</issue>):<fpage>213</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21958558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mito.2011.09.001</pub-id><pub-id pub-id-type="pmcid">PMC3250561</pub-id></mixed-citation></ref><ref id="B746"><label>746.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moon</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Giffard</surname><given-names>RG</given-names></string-name></person-group>. <article-title>Inhibition of microRNA-181 reduces forebrain ischemia-induced neuronal loss</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2013</year>;<volume>33</volume>(<issue>12</issue>):<fpage>1976</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">24002437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2013.157</pub-id><pub-id pub-id-type="pmcid">PMC3851907</pub-id></mixed-citation></ref><ref id="B747"><label>747.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MiR-181a influences the cognitive function of epileptic rats induced by pentylenetetrazol</article-title>. <source>Int J Clin Exp Pathol</source>. <year>2015</year>;<volume>8</volume>(<issue>10</issue>):<fpage>12861</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26722477</pub-id><pub-id pub-id-type="pmcid">PMC4680422</pub-id></mixed-citation></ref><ref id="B748"><label>748.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ren</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name></person-group>. <article-title>Silencing miR-181a produces neuroprotection against hippocampus neuron cell apoptosis post-status epilepticus in a rat model and in children with temporal lobe epilepsy</article-title>. <source>Genet Mol Res</source>. <year>2016</year>;<volume>15</volume>(<issue>1</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.4238/gmr.15017798</pub-id><pub-id pub-id-type="pmid">26910006</pub-id></mixed-citation></ref><ref id="B749"><label>749.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhuo</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Inhibition of miR-181a-5p reduces astrocyte and microglia activation and oxidative stress by activating SIRT1 in immature rats with epilepsy</article-title>. <source>Lab Invest</source>. <year>2020</year>;<volume>100</volume>(<issue>9</issue>):<fpage>1223</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">32461588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41374-020-0444-1</pub-id></mixed-citation></ref><ref id="B750"><label>750.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stary</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ouyang</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Inhibition of miR-181a protects female mice from transient focal cerebral ischemia by targeting astrocyte estrogen receptor-&#945;</article-title>. <source>Mol Cell Neurosci</source>. <year>2017</year>;<volume>82</volume>:<fpage>118</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">28522364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcn.2017.05.004</pub-id><pub-id pub-id-type="pmcid">PMC5561665</pub-id></mixed-citation></ref><ref id="B751"><label>751.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Griffiths</surname><given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Ouyang</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Giffard</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Stary</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Postinjury inhibition of miR-181a promotes restoration of hippocampal CA1 neurons after transient forebrain ischemia in rats</article-title>. <source>eNeuro</source>. <year>2019</year>;<volume>6</volume>(<issue>4</issue>):<fpage>ENEURO.0002-19.2019</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/ENEURO.0002-19.2019</pub-id><pub-id pub-id-type="pmcid">PMC6727148</pub-id><pub-id pub-id-type="pmid">31427401</pub-id></mixed-citation></ref><ref id="B752"><label>752.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Indrieri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Carrella</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Romano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Spaziano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Marrocco</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fernandez-Vizarra</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>miR-181a/b downregulation exerts a protective action on mitochondrial disease models</article-title>. <source>EMBO Mol Med</source>. <year>2019</year>;<volume>11</volume>(<issue>5</issue>):<fpage>e8734</fpage>.<pub-id pub-id-type="pmid">30979712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201708734</pub-id><pub-id pub-id-type="pmcid">PMC6505685</pub-id></mixed-citation></ref><ref id="B753"><label>753.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name></person-group>. <article-title>MicroRNA-181a regulates apoptosis and autophagy process in Parkinson&#8217;s disease by inhibiting p38 mitogen-activated protein kinase (MAPK)/c-Jun N-terminal kinases (JNK) signaling pathways</article-title>. <source>Med Sci Monit</source>. <year>2017</year>;<volume>23</volume>:<fpage>1597</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="pmid">28365714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.900218</pub-id><pub-id pub-id-type="pmcid">PMC5386441</pub-id></mixed-citation></ref><ref id="B754"><label>754.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name></person-group>. <article-title>The neuroprotective effect of miR-181a after oxygen-glucose deprivation/reperfusion and the associated mechanism</article-title>. <source>J Mol Neurosci</source>. <year>2019</year>;<volume>68</volume>(<issue>2</issue>):<fpage>261</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">30949956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-019-01300-4</pub-id></mixed-citation></ref><ref id="B755"><label>755.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-181a protects against pericyte apoptosis via directly targeting FOXO1: implication for ameliorated cognitive deficits in APP/PS1 mice</article-title>. <source>Aging</source>. <year>2019</year>;<volume>11</volume>(<issue>16</issue>):<fpage>6120</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">31467256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.102171</pub-id><pub-id pub-id-type="pmcid">PMC6738434</pub-id></mixed-citation></ref><ref id="B756"><label>756.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Extracellular vesicles containing miR-181a-5p as a novel therapy for experimental autoimmune encephalomyelitis-induced demyelination</article-title>. <source>Int Immunopharmacol</source>. <year>2024</year>;<volume>135</volume>:<fpage>112326</fpage>.<pub-id pub-id-type="pmid">38796967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2024.112326</pub-id></mixed-citation></ref><ref id="B757"><label>757.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chandrasekar</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Dreyer</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Regulation of MiR-124, Let-7d, and MiR-181a in the accumbens affects the expression, extinction, and reinstatement of cocaine-induced conditioned place preference</article-title>. <source>Neuropsychopharmacology</source>. <year>2011</year>;<volume>36</volume>(<issue>6</issue>):<fpage>1149</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">21307844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2010.250</pub-id><pub-id pub-id-type="pmcid">PMC3079833</pub-id></mixed-citation></ref><ref id="B758"><label>758.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>JG</given-names></string-name></person-group>. <article-title>miR-181a involves in the hippocampus-dependent memory formation via targeting PRKAA1</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>8480</fpage>.<pub-id pub-id-type="pmid">28814760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-09095-3</pub-id><pub-id pub-id-type="pmcid">PMC5559581</pub-id></mixed-citation></ref><ref id="B759"><label>759.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saba</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>St&#246;rchel</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>Aksoy-Aksel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kepura</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lippi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Plant</surname><given-names>TD</given-names></string-name>, <etal/></person-group>. <article-title>Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons</article-title>. <source>Mol Cell Biol</source>. <year>2012</year>;<volume>32</volume>(<issue>3</issue>):<fpage>619</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">22144581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MCB.05896-11</pub-id><pub-id pub-id-type="pmcid">PMC3266602</pub-id></mixed-citation></ref><ref id="B760"><label>760.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodriguez-Ortiz</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Prieto</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Martini</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Forner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Trujillo-Estrada</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>LaFerla</surname><given-names>FM</given-names></string-name>, <etal/></person-group>. <article-title>miR-181a negatively modulates synaptic plasticity in hippocampal cultures and its inhibition rescues memory deficits in a mouse model of Alzheimer's disease</article-title>. <source>Aging Cell</source>. <year>2020</year>;<volume>19</volume>(<issue>3</issue>):<fpage>e13118</fpage>.<pub-id pub-id-type="pmid">32087004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13118</pub-id><pub-id pub-id-type="pmcid">PMC7059142</pub-id></mixed-citation></ref><ref id="B761"><label>761.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stappert</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Borghese</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Roese-Koerner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Weinhold</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Koch</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Terstegge</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-based promotion of human neuronal differentiation and subtype specification</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>3</issue>):<fpage>e59011</fpage>.<pub-id pub-id-type="pmid">23527072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0059011</pub-id><pub-id pub-id-type="pmcid">PMC3601127</pub-id></mixed-citation></ref><ref id="B762"><label>762.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>Y</given-names></string-name></person-group>. <article-title>microRNA-181a is involved in insulin-like growth factor-1-mediated regulation of the transcription factor CREB1</article-title>. <source>J Neurochem</source>. <year>2013</year>;<volume>126</volume>(<issue>6</issue>):<fpage>771</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">23865718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.12370</pub-id></mixed-citation></ref><ref id="B763"><label>763.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sasaki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Goshima</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bassell</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>Identification of axon-enriched microRNAs localized to growth cones of cortical neurons</article-title>. <source>Dev Neurobiol</source>. <year>2014</year>;<volume>74</volume>(<issue>3</issue>):<fpage>397</fpage>&#8211;<lpage>406</lpage>.<pub-id pub-id-type="pmid">23897634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dneu.22113</pub-id><pub-id pub-id-type="pmcid">PMC4111797</pub-id></mixed-citation></ref><ref id="B764"><label>764.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Loh</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Law</surname><given-names>PY</given-names></string-name></person-group>. <article-title>Morphine modulates mouse hippocampal progenitor cell lineages by upregulating miR-181a level</article-title>. <source>Stem Cell</source>. <year>2014</year>;<volume>32</volume>(<issue>11</issue>):<fpage>2961</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/stem.1774</pub-id><pub-id pub-id-type="pmcid">PMC4198488</pub-id><pub-id pub-id-type="pmid">24964978</pub-id></mixed-citation></ref><ref id="B765"><label>765.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bahi</surname><given-names>A</given-names></string-name></person-group>. <article-title>Hippocampal microRNA-181a overexpression participates in anxiety and ethanol related behaviors via regulating the expression of SIRT-1</article-title>. <source>Physiol Behav</source>. <year>2025</year>;<volume>292</volume>:<fpage>114839</fpage>.<pub-id pub-id-type="pmid">39920909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.physbeh.2025.114839</pub-id></mixed-citation></ref><ref id="B766"><label>766.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Downregulation of miR-181b in mouse brain following ischemic stroke induces neuroprotection against ischemic injury through targeting heat shock protein A5 and ubiquitin carboxyl-terminal hydrolase isozyme L1</article-title>. <source>J Neurosci Res</source>. <year>2013</year>;<volume>91</volume>(<issue>10</issue>):<fpage>1349</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">23900885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.23255</pub-id></mixed-citation></ref><ref id="B767"><label>767.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>X</given-names></string-name></person-group>. <article-title>Mir-181b functions as anti-apoptotic gene in post-status epilepticus via modulation of nrarp and notch signaling pathway</article-title>. <source>Ann Clin Lab Sci</source>. <year>2015</year>;<volume>45</volume>:<fpage>550</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">26586707</pub-id></mixed-citation></ref><ref id="B768"><label>768.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Suo</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>JH</given-names></string-name>, <etal/></person-group>. <article-title>MiR-181b inhibits P38/JNK signaling pathway to attenuate autophagy and apoptosis in juvenile rats with kainic acid-induced epilepsy via targeting TLR4</article-title>. <source>CNS Neurosci Ther</source>. <year>2019</year>;<volume>25</volume>(<issue>1</issue>):<fpage>112</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">29808547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.12991</pub-id><pub-id pub-id-type="pmcid">PMC6436603</pub-id></mixed-citation></ref><ref id="B769"><label>769.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name></person-group>. <article-title>miR-181b regulates ER stress induced neuron death through targeting Heat Shock Protein A5 following intracerebral haemorrhage</article-title>. <source>Immunol Lett</source>. <year>2019</year>;<volume>206</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">30503822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imlet.2018.11.014</pub-id></mixed-citation></ref><ref id="B770"><label>770.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-181b-5p attenuates early postoperative cognitive dysfunction by suppressing hippocampal neuroinflammation in mice</article-title>. <source>Cytokine</source>. <year>2019</year>;<volume>120</volume>:<fpage>41</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">31003188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2019.04.005</pub-id></mixed-citation></ref><ref id="B771"><label>771.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name></person-group>. <article-title>LncRNA p21, downregulating miR-181b, aggravates neuropathic pain by upregulating Tnfaip1 and inhibit the AKT/CREB axis</article-title>. <source>Brain Res Bull</source>. <year>2021</year>;<volume>171</volume>:<fpage>150</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">33774143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2021.03.005</pub-id></mixed-citation></ref><ref id="B772"><label>772.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>microRNA-222 targeting PTEN promotes neurite outgrowth from adult dorsal root ganglion neurons following sciatic nerve transection</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>9</issue>):<fpage>e44768</fpage>.<pub-id pub-id-type="pmid">23028614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0044768</pub-id><pub-id pub-id-type="pmcid">PMC3441418</pub-id></mixed-citation></ref><ref id="B773"><label>773.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>MiR-21 and miR-222 inhibit apoptosis of adult dorsal root ganglion neurons by repressing TIMP3 following sciatic nerve injury</article-title>. <source>Neurosci Lett</source>. <year>2015</year>;<volume>586</volume>:<fpage>43</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25484256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2014.12.006</pub-id></mixed-citation></ref><ref id="B774"><label>774.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>GY</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>XX</given-names></string-name></person-group>. <article-title>MicroRNA-222 alleviates radiation-induced apoptosis by targeting BCL2L11 in cochlea hair cells</article-title>. <source>Biosci Rep</source>. <year>2021</year>;<volume>41</volume>(<issue>6</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20201397</pub-id><pub-id pub-id-type="pmcid">PMC8182987</pub-id><pub-id pub-id-type="pmid">33942856</pub-id></mixed-citation></ref><ref id="B775"><label>775.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name></person-group>. <article-title>miR-222-3p reduces neuronal cell apoptosis and alleviates spinal cord injury by inhibiting Bbc3 and Bim</article-title>. <source>Neurosci Res</source>. <year>2023</year>;<volume>188</volume>:<fpage>39</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">36328305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neures.2022.10.008</pub-id></mixed-citation></ref><ref id="B776"><label>776.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>S</given-names></string-name></person-group>. <article-title>Propofol ameliorates microglia activation by targeting MicroRNA-221/222-IRF2 Axis</article-title>. <source>J Immunol Res</source>. <year>2021</year>;<volume>2021</volume>:<fpage>3101146</fpage>.<pub-id pub-id-type="pmid">34423051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/3101146</pub-id><pub-id pub-id-type="pmcid">PMC8373515</pub-id></mixed-citation></ref><ref id="B777"><label>777.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yasmeen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mirza</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Brodin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pociot</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kruuse</surname><given-names>C</given-names></string-name></person-group>. <article-title>miRNA-27a-3p and miRNA-222-3p as novel modulators of phosphodiesterase 3a (PDE3A) in cerebral microvascular endothelial cells</article-title>. <source>Mol Neurobiol</source>. <year>2019</year>;<volume>56</volume>(<issue>8</issue>):<fpage>5304</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">30603956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-018-1446-5</pub-id></mixed-citation></ref><ref id="B778"><label>778.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Decembrini</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bressan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vignali</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pitto</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mariotti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rainaldi</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNAs couple cell fate and developmental timing in retina</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2009</year>;<volume>106</volume>(<issue>50</issue>):<fpage>21179</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">19965369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0909167106</pub-id><pub-id pub-id-type="pmcid">PMC2781736</pub-id></mixed-citation></ref><ref id="B779"><label>779.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Mechanisms underlying microRNA-222-3p modulation of methamphetamine-induced conditioned place preference in the nucleus accumbens in mice</article-title>. <source>Psychopharmacology</source>. <year>2022</year>;<volume>239</volume>(<issue>9</issue>):<fpage>2997</fpage>&#8211;<lpage>3008</lpage>.<pub-id pub-id-type="pmid">35881147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-022-06183-9</pub-id></mixed-citation></ref><ref id="B780"><label>780.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>MiR-222-3p regulates methamphetamine-induced behavioral sensitization through PP2A-AKT signaling pathway in the dorsal striatum of male mice</article-title>. <source>Neurosci Lett</source>. <year>2025</year>;<volume>852</volume>:<fpage>138181</fpage>.<pub-id pub-id-type="pmid">40032211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2025.138181</pub-id></mixed-citation></ref><ref id="B781"><label>781.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wagley</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>DK</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA 339 down-regulates &#956;-opioid receptor at the post-transcriptional level in response to opioid treatment</article-title>. <source>FASEB J</source>. <year>2013</year>;<volume>27</volume>(<issue>2</issue>):<fpage>522</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">23085997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.12-213439</pub-id><pub-id pub-id-type="pmcid">PMC3545525</pub-id></mixed-citation></ref><ref id="B782"><label>782.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Intrahippocampal miR-342-3p inhibition reduces &#946;-amyloid plaques and ameliorates learning and memory in Alzheimer's disease</article-title>. <source>Metab Brain Dis</source>. <year>2019</year>;<volume>34</volume>(<issue>5</issue>):<fpage>1355</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">31134481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-019-00438-9</pub-id></mixed-citation></ref><ref id="B783"><label>783.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Br&#225;s</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Bravo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Freitas</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Barbosa</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Summavielle</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>TNF-alpha-induced microglia activation requires miR-342: impact on NF-kB signaling and neurotoxicity</article-title>. <source>Cell Death Dis</source>. <year>2020</year>;<volume>11</volume>(<issue>6</issue>):<fpage>415</fpage>.<pub-id pub-id-type="pmid">32488063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-2626-6</pub-id><pub-id pub-id-type="pmcid">PMC7265562</pub-id></mixed-citation></ref><ref id="B784"><label>784.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Br&#225;s</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Guillot de Suduiraut</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Zanoletti</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Monari</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Meijer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Grosse</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Stress-induced depressive-like behavior in male rats is associated with microglial activation and inflammation dysregulation in the hippocampus in adulthood</article-title>. <source>Brain Behav Immun</source>. <year>2022</year>;<volume>99</volume>:<fpage>397</fpage>&#8211;<lpage>408</lpage>.<pub-id pub-id-type="pmid">34793941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2021.10.018</pub-id></mixed-citation></ref><ref id="B785"><label>785.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name></person-group>. <article-title>lncRNA SNHG1 knockdown alleviates amyloid-&#946;-induced neuronal injury by regulating ZNF217 via sponging miR-361-3p in alzheimer&#8217;s disease</article-title>. <source>J Alzheimers Dis</source>. <year>2020</year>;<volume>77</volume>(<issue>1</issue>):<fpage>85</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">32741808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-191303</pub-id></mixed-citation></ref><ref id="B786"><label>786.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ye</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>QE</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>miR-361-3p regulates FSH by targeting FSHB in a porcine anterior pituitary cell model</article-title>. <source>Reproduction</source>. <year>2017</year>;<volume>153</volume>(<issue>3</issue>):<fpage>341</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27998941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/REP-16-0373</pub-id></mixed-citation></ref><ref id="B787"><label>787.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></string-name></person-group>. <article-title>MiR-361-5p promotes oxygen-glucose deprivation/re-oxygenation induced neuronal injury by negatively regulating SQSTM1 in vitro</article-title>. <source>Metab Brain Dis</source>. <year>2021</year>;<volume>36</volume>(<issue>8</issue>):<fpage>2359</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">34581931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-021-00845-x</pub-id></mixed-citation></ref><ref id="B788"><label>788.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Transcriptome sequencing reveals tgf-&#946;-mediated noncoding RNA regulatory mechanisms involved in DNA damage in the 661W photoreceptor cell line</article-title>. <source>Genes</source>. <year>2022</year>;<volume>13</volume>(<issue>11</issue>):<fpage>2140</fpage>.<pub-id pub-id-type="pmid">36421815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes13112140</pub-id><pub-id pub-id-type="pmcid">PMC9691224</pub-id></mixed-citation></ref><ref id="B789"><label>789.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Azhar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Kraemer</surname><given-names>FB</given-names></string-name></person-group>. <article-title>The role of miRNAs in regulating adrenal and gonadal steroidogenesis</article-title>. <source>J Mol Endocrinol</source>. <year>2020</year>;<volume>64</volume>(<issue>1</issue>):<fpage>R21</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">31671401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/JME-19-0105</pub-id><pub-id pub-id-type="pmcid">PMC7202133</pub-id></mixed-citation></ref><ref id="B790"><label>790.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Over-expression of microRNA-145 drives alterations in &#946;-adrenergic signaling and attenuates cardiac remodeling in heart failure post myocardial infarction</article-title>. <source>Aging</source>. <year>2020</year>;<volume>12</volume>:<fpage>11603</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">32554856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103320</pub-id><pub-id pub-id-type="pmcid">PMC7343449</pub-id></mixed-citation></ref><ref id="B791"><label>791.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Woo</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Liggett</surname><given-names>SB</given-names></string-name></person-group>. <article-title>A CREB-mediated increase in miRNA let-7f during prolonged &#946;-agonist exposure: a novel mechanism of &#946;(2)-adrenergic receptor down-regulation in airway smooth muscle</article-title>. <source>FASEB J</source>. <year>2018</year>;<volume>32</volume>(<issue>7</issue>):<fpage>3680</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">29455573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201701278R</pub-id><pub-id pub-id-type="pmcid">PMC5998966</pub-id></mixed-citation></ref><ref id="B792"><label>792.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Suppression of microRNA-16 protects against acute myocardial infarction by reversing beta2-adrenergic receptor down-regulation in rats</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>(<issue>12</issue>):<fpage>20122</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">28423616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.15391</pub-id><pub-id pub-id-type="pmcid">PMC5386749</pub-id></mixed-citation></ref><ref id="B793"><label>793.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>YW</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>SS</given-names></string-name>, <etal/></person-group>. <article-title>The mutual regulation between miR-214 and A2AR signaling plays an important role in inflammatory response</article-title>. <source>Cell Signal</source>. <year>2015</year>;<volume>27</volume>(<issue>10</issue>):<fpage>2026</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">26171727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellsig.2015.07.007</pub-id></mixed-citation></ref><ref id="B794"><label>794.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Castaldi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zaglia</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Di Mauro</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Carullo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Viggiani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Borile</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>MicroRNA-133 modulates the &#946;1-adrenergic receptor transduction cascade</article-title>. <source>Circ Res</source>. <year>2014</year>;<volume>115</volume>(<issue>2</issue>):<fpage>273</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">24807785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.115.303252</pub-id></mixed-citation></ref><ref id="B795"><label>795.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>let-7e replacement yields potent anti-arrhythmic efficacy via targeting beta 1-adrenergic receptor in rat heart</article-title>. <source>J Cell Mol Med</source>. <year>2014</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1334</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">24758696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.12288</pub-id><pub-id pub-id-type="pmcid">PMC4124018</pub-id></mixed-citation></ref><ref id="B796"><label>796.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Juan</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Panebra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Liggett</surname><given-names>SB</given-names></string-name></person-group>. <article-title>MicroRNA let-7 establishes expression of beta2-adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2011</year>;<volume>108</volume>(<issue>15</issue>):<fpage>6246</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">21447718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1101439108</pub-id><pub-id pub-id-type="pmcid">PMC3076830</pub-id></mixed-citation></ref><ref id="B797"><label>797.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Riester</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Issler</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Spyroglou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rodrig</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Beuschlein</surname><given-names>F</given-names></string-name></person-group>. <article-title>ACTH-dependent regulation of microRNA as endogenous modulators of glucocorticoid receptor expression in the adrenal gland</article-title>. <source>Endocrinology</source>. <year>2012</year>;<volume>153</volume>(<issue>1</issue>):<fpage>212</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">22128032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2011-1285</pub-id></mixed-citation></ref><ref id="B798"><label>798.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Primary sensory neuron-derived miR-let-7b underlies stress-elicited psoriasis</article-title>. <source>Brain Behav Immun</source>. <year>2025</year>;<volume>123</volume>:<fpage>997</fpage>&#8211;<lpage>1010</lpage>.<pub-id pub-id-type="pmid">39510418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2024.11.005</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70704" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12504051</article-id><article-id pub-id-type="pmcid-ver">PMC12504051.1</article-id><article-id pub-id-type="pmcaid">12504051</article-id><article-id pub-id-type="pmcaiid">12504051</article-id><article-id pub-id-type="pmid">41057918</article-id><article-id pub-id-type="doi">10.1002/alz.70704</article-id><article-id pub-id-type="publisher-id">ALZ70704</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD</article-title><alt-title alt-title-type="left-running-head">ERICHSEN <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="alz70704-cr-0001" contrib-type="author"><name name-style="western"><surname>Erichsen</surname><given-names initials="JM">Jennifer M.</given-names></name><xref rid="alz70704-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70704-cr-0002" contrib-type="author"><name name-style="western"><surname>Register</surname><given-names initials="TC">Thomas C.</given-names></name><xref rid="alz70704-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70704-cr-0003" contrib-type="author"><name name-style="western"><surname>Sutphen</surname><given-names initials="C">Courtney</given-names></name><xref rid="alz70704-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70704-cr-0004" contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="D">Da</given-names></name><xref rid="alz70704-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70704-cr-0005" contrib-type="author"><name name-style="western"><surname>Gaussoin</surname><given-names initials="SA">Sarah A.</given-names></name><xref rid="alz70704-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70704-cr-0006" contrib-type="author"><name name-style="western"><surname>Rudolph</surname><given-names initials="M">Marc</given-names></name><xref rid="alz70704-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70704-cr-0007" contrib-type="author"><name name-style="western"><surname>Rundle</surname><given-names initials="M">Melissa</given-names></name><xref rid="alz70704-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70704-cr-0008" contrib-type="author"><name name-style="western"><surname>Bateman</surname><given-names initials="JT">James T.</given-names></name><xref rid="alz70704-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70704-cr-0009" contrib-type="author"><name name-style="western"><surname>Lockhart</surname><given-names initials="SN">Samuel N.</given-names></name><xref rid="alz70704-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70704-cr-0010" contrib-type="author"><name name-style="western"><surname>Sai</surname><given-names initials="KKS">Kiran K. Solingapuram</given-names></name><xref rid="alz70704-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70704-cr-0011" contrib-type="author"><name name-style="western"><surname>Whitlow</surname><given-names initials="C">Christopher</given-names></name><xref rid="alz70704-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70704-cr-0012" contrib-type="author" corresp="yes"><name name-style="western"><surname>Craft</surname><given-names initials="S">Suzanne</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0591-8657</contrib-id><xref rid="alz70704-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>suzcraft@wakehealth.edu</email></address></contrib></contrib-group><aff id="alz70704-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Section on Gerontology and Geriatric Medicine</institution>
<institution>Wake Forest University School of Medicine</institution>
<city>Winston&#8208;Salem</city>
<named-content content-type="country-part">North Carolina</named-content>
<country country="US">USA</country>
</aff><aff id="alz70704-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Wake Forest University School of Medicine</institution>
<city>Winston&#8208;Salem</city>
<named-content content-type="country-part">North Carolina</named-content>
<country country="US">USA</country>
</aff><aff id="alz70704-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Biostatistics and Data Science</named-content>
<institution>Wake Forest University School of Medicine</institution>
<city>Winston&#8208;Salem</city>
<named-content content-type="country-part">North Carolina</named-content>
<country country="US">USA</country>
</aff><aff id="alz70704-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Wake Forest University School of Medicine</institution>
<city>Winston&#8208;Salem</city>
<named-content content-type="country-part">North Carolina</named-content>
<country country="US">USA</country>
</aff><aff id="alz70704-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>Wake Forest University School of Medicine</institution>
<city>Winston&#8208;Salem</city>
<named-content content-type="country-part">North Carolina</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Suzanne Craft, Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston&#8208;Salem, NC 27157, USA.<break/> Email: <email>suzcraft@wakehealth.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="390">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70704</elocation-id><history><date date-type="rev-recd"><day>15</day><month>7</month><year>2025</year></date><date date-type="received"><day>18</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70704.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70704.pdf"/><abstract><title>Abstract</title><sec id="alz70704-sec-0010"><title>INTRODUCTION</title><p>Agents targeting metabolic/vascular disorders are promising candidates to treat Alzheimer's disease (AD) and enhance safety and efficacy of other therapies.</p></sec><sec id="alz70704-sec-0020"><title>METHODS</title><p>In a 2&#215;2 factorial double&#8208;blinded randomized trial, participants with mild cognitive impairment (MCI), early AD, or who were amyloid positive received intranasal insulin (INI; 40 IU q.i.d.), the sodium&#8211;glucose cotransporter&#8208;2 inhibitor empagliflozin (10&#160;mg q.d. oral tablet), both, or placebo for 4&#160;weeks. The primary outcome was treatment&#8208;related adverse events (TRAEs). Secondary outcomes included the modified Preclinical Alzheimer's Cognitive Composite&#8208;5 (mPACC5), fluid biomarkers, cerebral blood flow (CBF), and fractional anisotropy (FA).</p></sec><sec id="alz70704-sec-0030"><title>RESULTS</title><p>TRAEs were mild and similar for all groups. INI increased mPACC5, modulated FA and CBF, and reduced plasma glial fibrillary acidic protein. Empagliflozin lowered cerebrospinal fluid tau and modulated CBF. Both agents moderated immune/inflammatory/neurovascular markers.</p></sec><sec id="alz70704-sec-0040"><title>DISCUSSION</title><p>INI and empagliflozin treatment was safe with promising effects on cognition, fluid, and imaging biomarkers. A longer and larger trial is needed to confirm these results.</p></sec><sec id="alz70704-sec-0050"><title>CLINICAL TRIAL REGISTRATION</title><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05081219">NCT05081219</ext-link></p></sec><sec id="alz70704-sec-0060"><title>Highlights</title><p>
<list list-type="bullet" id="alz70704-list-0001"><list-item><p>Agents targeting metabolic or vascular disorders are promising candidates to prevent or treat Alzheimer's disease (AD).</p></list-item><list-item><p>Intranasal insulin and empagliflozin were safe alone or in combination for mild cognitive impairment/AD.</p></list-item><list-item><p>Insulin improved cognition and markers of inflammation and immune function.</p></list-item><list-item><p>Empagliflozin reduced markers of vascular injury and neurodegeneration.</p></list-item><list-item><p>A longer, larger trial is needed to validate these results.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70704-kwd-0001">Alzheimer's disease</kwd><kwd id="alz70704-kwd-0002">empagliflozin</kwd><kwd id="alz70704-kwd-0003">immune function</kwd><kwd id="alz70704-kwd-0004">insulin</kwd><kwd id="alz70704-kwd-0005">metabolism</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Wake Forest University School of Medicine Alzheimer's Disease Research Center</institution></institution-wrap></funding-source><award-id>P30 AG072947</award-id><award-id>T32 AG033534</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Kulynych Center for Memory and Cognition</institution></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Aptar Pharma</institution></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Kulynych Cente for Memory and and Cognition</institution></institution-wrap></funding-source></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>T32 AG0333534</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>National Institute of Aging</institution></institution-wrap></funding-source></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>Alzheimer's Association</institution><institution-id institution-id-type="doi">10.13039/100000957</institution-id></institution-wrap></funding-source><award-id>PTC&#8208;22&#8208;975243</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="5"/><page-count count="13"/><word-count count="8249"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:07.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70704-cite-0001"><string-name name-style="western"><surname>Erichsen</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Register</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Sutphen</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70704</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70704</pub-id><pub-id pub-id-type="pmid">41057918</pub-id><pub-id pub-id-type="pmcid">PMC12504051</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70704-sec-0070"><label>1</label><title>BACKGROUND</title><p>There is an urgent need for effective strategies to treat Alzheimer's disease (AD), given its toll on individual and public health, and increasing prevalence in an aging society. The recent approval of anti&#8208;amyloid monoclonal antibodies (AAmAbs) represents a major advance in AD therapeutics. However, their clinical benefits are modest, and they are unavailable to many individuals with AD due to contraindications. Moreover, they do not address upstream causes of amyloid aggregation or induce repair mechanisms that restore cognition. Their association with amyloid&#8208;related imaging abnormalities (ARIAs) must also be weighed against their benefits. Thus, interventions targeting other disease mechanisms are needed. Agents used to treat comorbid conditions associated with increased risk of AD such as metabolic and vascular disorders are promising therapeutic candidates. As described in recent reviews, central nervous system (CNS) effects of vascular and metabolic disorders may involve insulin resistance, bioenergetic deficits, inflammation and immune dysfunction, impaired cerebrovascular function, and reduced clearance of protein aggregates, all of which have cumulative adverse effects on brain health.<xref rid="alz70704-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> This body of research offers a strong biological basis for the repurposing of agents proven effective in treating metabolic and vascular disorders as AD therapies.</p><p>Sodium&#8211;glucose cotransporter&#8208;2 inhibitors (SGLT2is), widely used for type 2 diabetes (T2D) and cardiovascular disease, have emerged as promising candidates. In the periphery, SGLT2is block resorption of glucose and sodium by SGLT2 transporters in the kidneys, leading to increased excretion in urine, reducing hyperglycemia and sodium levels. These effects have been proposed to lead to improving insulin sensitivity and vascular function in periphery and CNS; additional effects on CNS oxidative stress, neuroinflammation and plasticity, and mitochondrial bioenergetics have been proposed.<xref rid="alz70704-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70704-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70704-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> CNS effects have not been extensively investigated, although in AD models, the SGLT2i empagliflozin (EMPA) reduced amyloid beta (A&#946;) plaques, microhemorrhages, and inflammation in the brain, as well as improved memory.<xref rid="alz70704-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Observational data from large T2D cohorts further suggest that SGLT2i use is associated with reduced dementia risk.<xref rid="alz70704-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> They have an excellent safety profile and do not induce hypoglycemia in non&#8208;diabetic adults.<xref rid="alz70704-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>Intranasal insulin (INI) delivery allows insulin to directly access the CNS,<xref rid="alz70704-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> providing another approach to correcting brain, metabolic, and vascular dysfunction in AD. Previous AD trials have shown that INI administered daily for 4 months preserved or enhanced cerebral glucose metabolism assessed with fluorodeoxyglucose positron emission tomography (PET),<xref rid="alz70704-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> and that 12 months of INI treatment with an effective delivery device enhanced cognition, improved AD and inflammatory cerebrospinal fluid (CSF) biomarker profiles, and reduced white matter hyperintensity (WMH) progression indicating preserved CNS vascular integrity.<xref rid="alz70704-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70704-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70704-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> This method of insulin delivery also likely activates the nasal&#8211;olfactory plexus, a glymphatic and immune hub connecting the CNS and periphery.<xref rid="alz70704-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><p>SGLT2is and INI improve peripheral and CNS bioenergetics and vascular function through different mechanisms; they also have pleiotropic actions on other targets of importance in AD, heightening their potential impact.<xref rid="alz70704-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> SGLT2is reduce peripheral hyperglycemia and sodium and thereby improve insulin resistance in the periphery, and vascular/endothelial health in both peripheral and CNS; other CNS effects have been proposed but remain to be fully elucidated.<xref rid="alz70704-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70704-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> In contrast, INI likely raises CNS insulin levels and works directly through insulin receptors in the nasal&#8211;olfactory plexus and brain to promote synaptic viability, neurogenesis, endothelial function, white matter integrity, and inflammation/immune homeostasis.<xref rid="alz70704-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Both interventions may have downstream benefits for amyloid and tau pathology.</p><p>The present trial evaluated the safety and efficacy of INI and EMPA, alone and in combination in older adults with mild cognitive impairment (MCI) and early AD. We used a higher dose of insulin than in prior trials (40 IU q.i.d. Humulin R&#8208;100) delivered via a device validated with PET.<xref rid="alz70704-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70704-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Empagliflozin has not been previously evaluated in non&#8208;diabetic older adults with MCI or AD. The primary outcome for the study was treatment&#8208;related adverse events. Secondary outcomes included cognition, metabolic and fluid biomarkers, and magnetic resonance imaging (MRI). Both INI and empagliflozin were found to be safe, with promising effects on key outcomes, warranting further evaluation in larger and longer term studies.</p></sec><sec id="alz70704-sec-0080"><label>2</label><title>METHODS</title><sec id="alz70704-sec-0090"><label>2.1</label><title>Participants</title><p>The study was approved by the Wake Forest School of Medicine Institutional Review Board (IRB00075245) and performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and later amendments. As specified in the protocol (see supporting information), eligibility criteria included: (1) clinical MCI/dementia (DEM) diagnosis (MCI <italic toggle="yes">n</italic>&#160;=&#160;33, DEM&#160;=&#160;5) or cognitively normal with amyloid positivity (CSF A&#946;42/40 ratio &#160;&#8804; 0.058<xref rid="alz70704-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> or <sup>11</sup>C&#8208;Pittsburgh compound B PET standardized uptake value &#8805; 1.21, <italic toggle="yes">n</italic>&#160;=&#160;4; CSF phosphorylated tau [p&#8208;tau]181 was not used as a criterion);<xref rid="alz70704-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> clinical diagnosis was adjudicated using National Institute on Aging&#8211;Alzheimer's Association Research Framework criteria;<xref rid="alz70704-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> (2) age 55 to 85 years; (3) Mini&#8208;Mental State Examination (MMSE) 21 to 30; (4) no unstable illness; (5) no diabetic medications or loop diuretics; (6) no large vessel stroke or other relevant neurological disease; (7) normal renal function. Participants with elevated blood glucose were eligible for the study, although no participant had hemoglobin A1c (HbA1c) values in the diabetic range. Participants were recruited from the Wake Forest School of Medicine Alzheimer's Disease Research Center (ADRC, P30 AG072947) and its affiliated registry from April 2022 through July 2024, with final participant visits occurring in September 2024.</p></sec><sec id="alz70704-sec-0100"><label>2.2</label><title>Study design</title><p>We conducted a phase IIA/B 2&#160;&#215;&#160;2 factorial, double&#8208;blinded, placebo&#8208;controlled trial in which participants were randomized with a random number generator program on a 1:1:1:1 basis by an registered nurse clinician who assigned participants to receive INI (40 IU Humulin U&#8208;100 q.i.d./Eli Lilly), EMPA (10&#160;mg q.d. oral tablet/Jardiance, Boehringer Ingelheim), both agents, or placebo (IN diluent and matched placebo pill) for 4&#160;weeks. The 10&#160;mg dose chosen for EMPA is the standard dose used for adults who do not have T2D, but have other indications such as cardiovascular disease.<xref rid="alz70704-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The 40 IU insulin dose was based on preliminary work showing that this dose raised insulin more reliably in CSF than did a 20 IU dose after administration with the INI device described below (data not shown). Each participant took an oral dose of EMPA or placebo in the morning, and an intranasal dose of insulin or placebo four times daily, 30 minutes before breakfast, lunch, dinner, and bedtime. All participants, care providers, and study personnel collecting study outcomes were blinded to intervention assignment.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70704-sec-0110"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70704-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors interrogated PubMed using the following search terms or combinations thereof: nasal, insulin, empagliflozin, sodium&#8211;glucose cotransporter&#8208;2 inhibitors, Alzheimer's disease (AD), mild cognitive impairment, proteomics, NULISA, inflammation, immune system, glymphatic, neurovascular, pseudo&#8208;continuous arterial spin label, and fractional anisotropy.</p></list-item><list-item><p>
<bold>Interpretation</bold>: We verified the safety of 4 weeks of treatment with empagliflozin, which has not been tested previously in AD, and of a higher dose of intranasal insulin (INI) than used in past AD trials. Effects on cognition, imaging, and fluid biomarkers suggested that INI enhanced astrocytic and neurovascular function whereas empagliflozin enhanced tau&#8208;related pathways. Both agents moderated plasma and cerebrospinal fluid markers of inflammation and immune function.</p></list-item><list-item><p>
<bold>Future directions</bold>: These findings suggest that INI and empagliflozin are promising therapeutic candidates either individually or in combination with other agents. Given the brief duration and small sample size of this initial trial, longer, larger trials are warranted to confirm our results.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70704-sec-0120"><label>2.3</label><title>Intranasal delivery protocol</title><p>The Aptar Pharma's Cartridge Pump System (CPS) provides precise dose control at volumes from 50 to 140 &#181;L, reliable stability, and ease of use, targeting nasal areas with non&#8208;inhalable droplets to minimize nasopharyngeal and lung deposition. Successful delivery of insulin to the CNS with the CPS device was verified in preliminary studies using [<sup>68</sup>Ga]Ga&#8208;NOTA&#8208;insulin PET in non&#8208;human primates<xref rid="alz70704-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> and in cognitively normal older adults and adults with MCI.<xref rid="alz70704-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> The CPS device was used to administer a total volume of 2&#160;mL of insulin or placebo four times per day, 30&#160;minutes before breakfast, lunch, dinner, and bedtime; participants administered 0.5 mL into each nostril, waited 2&#160;minutes, then repeated. Participants and study partners were extensively trained in device use and participants were supervised in administering intranasal treatment if deemed necessary by study partners or study staff. Compliance was calculated as percent of target doses assessed with a daily dosing diary, and validated with pill counts, and measurement of residual insulin/placebo. Participants were asked to rate feasibility of device use and dosing schedule on a 1 to 5 scale, with 5 being the most feasible.</p></sec><sec id="alz70704-sec-0130"><label>2.4</label><title>Primary outcome</title><p>Treatment&#8208;related adverse events (TRAEs) were assessed throughout the study intervention period, either by formal structured assessment at the week 2 and 4 study visits, or through notification from study participants, at which time structured assessment was implemented. For all AEs, severity and treatment relatedness was determined by qualified study clinicians blinded to treatment assignment.</p></sec><sec id="alz70704-sec-0140"><label>2.5</label><title>Secondary outcomes</title><p>These outcomes were assessed at baseline and after 4&#160;weeks of treatment.</p><sec id="alz70704-sec-0150"><label>2.5.1</label><title>Clinical outcomes included</title><p>(1) The modified Preclinical Alzheimer's Cognitive Composite 5 (MPACC5), a composite scale consisting of the average of <italic toggle="yes">Z</italic> scores calculated using baseline MMSE, delayed logical memory, delayed Rey Auditory Verbal Learning Test (instead of the Free and Cued Selective Reminding Test), digit symbol coding, and category fluency. <italic toggle="yes">Z</italic> score averages were created at baseline, and post&#8208;intervention <italic toggle="yes">Z</italic> scores were calculated using the baseline group mean and standard deviation, as described in Papp et&#160;al.;<xref rid="alz70704-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> (2) Alzheimer's Disease Assessment Scale Cognitive subscale V14 (ADAS14);<xref rid="alz70704-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> and (3) Activities of Daily Living Scale&#8211;MCI (ADL&#8211;MCI).<xref rid="alz70704-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</p></sec><sec id="alz70704-sec-0160"><label>2.5.2</label><title>CSF/plasma biomarker outcomes</title><p>A fasting lumbar puncture and blood draw were conducted in the morning at baseline and after 4 weeks of treatment. AD markers (CSF A&#946;40, 42, p&#8208;tau181, total tau, neurofilament light chain [NfL], and plasma A&#946;40, A&#946;42, p&#8208;tau181, p&#8208;tau217, NfL, and glial fibrillary acidic protein [GFAP]) were measured from first thawed samples using a Lumipulse G1200 Chemiluminescence Enzyme Immunoassay (CLEIA) System and reagents and calibrators from the manufacturer (Fujirebio Diagnostics Inc.). For a subset of participants, CSF (<italic toggle="yes">n</italic>&#160;=&#160;26) and blood (<italic toggle="yes">n&#160;</italic>=&#160;23) were assayed with the Alamar NULISAseq CNS Panel 120 and Inflammation Panel 250; these are high specificity, ultrasensitive panels providing broad coverage of proteins involved in key immune function/inflammation and CNS disease pathways.<xref rid="alz70704-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p></sec><sec id="alz70704-sec-0170"><label>2.5.3</label><title>MRI outcomes</title><p>Participants were scanned on a research&#8208;dedicated 3T Siemens Skyra MRI (32&#8208;channel head coil) scanner. Detailed MRI acquisition parameters have been described previously.<xref rid="alz70704-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> High&#8208;resolution T1&#8208;weighted images were obtained with a magnetization prepared rapid gradient echo (MP&#8208;RAGE) sequence. Whole&#8208;brain cerebral blood flow (CBF) was captured via pseudo&#8208;continuous arterial spin labeling (PCASL) scans performed with a whole brain MP&#8208;PCASL sequence.<xref rid="alz70704-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Diffusion tensor imaging (DTI) fractional anisotropy (FA) was used to assess white matter microstructure. Image processing procedures have been described in detail previously.<xref rid="alz70704-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Briefly, global average DTI FA values were computed using the average signal across all white matter tracts from the Johns Hopkins University (JHU) DTI atlas overlaid on FA images in template space.<xref rid="alz70704-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> For PCASL CBF, supratentorial gray matter (GM) regions of interest (ROIs) from the automated anatomical labelling (AAL) atlas were overlaid on GM CBF images to calculate mean global GM CBF for each participant; JHU white matter (WM) tracts were overlaid on WM CBF images to calculate mean global WM CBF for each participant. PCASL CBF and DTI FA were also each assessed in five a priori defined GM (global, frontal, parietal, temporal, insula/cingulum, and hippocampus) ROIs and in global and hippocampal WM ROIs. Weighted values were obtained for each ROI by dividing the average signal by the number of voxels for a given ROI.</p></sec><sec id="alz70704-sec-0180"><label>2.5.4</label><title>Compliance and feasibility</title><p>Compliance was assessed at weeks 2 and 4 and was calculated as percent of target doses according to participant report, verified with pill count and volumetric assessment of remaining liquid. Feasibility ratings were obtained for device use and dosing schedule each of which was rated on a scale of 1 (not feasible) to 5 (very feasible).</p></sec><sec id="alz70704-sec-0190"><label>2.5.5</label><title>Cardiometabolic outcomes</title><p>We examined change in fasting glucose and insulin levels, HbA1c, low&#8208;density lipoprotein (LDL) and high&#8208;density lipoprotein (HDL) cholesterol, and systolic/diastolic blood pressure over the 4 week treatment period.</p></sec></sec><sec id="alz70704-sec-0200"><label>2.6</label><title>Statistical analysis</title><p>Prespecified initial analyses for all clinical and imaging outcomes used a 2&#160;&#215;&#160;2 approach comparing (1) INI&#8208;treated (INI and INI+EMPA) versus non&#8211;INI&#8208;treated (EMPA+placebo) groups and (2) EMPA&#8208;treated (EMPA and INI+EMPA) versus non&#8211;EMPA&#8208;treated (INI and placebo) groups. Subsequent prespecified sensitivity analyses compared each individual arm to placebo. For the primary outcome, TRAE, all randomized participants were included in the analysis, regardless of whether they completed the intervention (<italic toggle="yes">n</italic>&#160;=&#160;47). Poisson models assessed differences in number of TRAEs between 2&#160;&#215;&#160;2 groups with age, sex, diagnosis, and education as covariates, and in sensitivity analyses compared individual arms (INI, EMPA, INI+EMPA) to placebo. For clinical and imaging secondary outcomes, the modified intent&#8208;to&#8208;treat (mITT) group referred to eligible participants with baseline and one post&#8208;treatment measure (<italic toggle="yes">n</italic>&#160;=&#160;42). For secondary outcomes, generalized linear models with age, sex, diagnosis, and education as covariates were used to compare change from baseline to week 4 for participants with baseline and one post&#8208;treatment measure for each analyte. Due to the exploratory nature of the study, no adjustments were made for multiple comparisons. For MRI measures, weighted log&#8208;transformed ROI values were analyzed.</p><p>For AD fluid biomarkers, due to the exploratory nature of the analyses and to most clearly determine specific treatment effects, change in levels for each individual active treatment arm was compared to change in the placebo&#8208;only group, with age, sex, and diagnosis as covariates. For the NULISA panel we applied differential expression analysis (DEA) using the linear mixed&#8208;effect models (LMM) for each of the NULISA markers across the whole panel of analytes (i.e., for both inflammation and CSF panels).<xref rid="alz70704-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> The log&#8208;transformed protein expression level of the measured quantification for each NULISA marker was used as the predictor for the LMM. The &#8220;differential expression level&#8221; between each intervention arm and the placebo arm is represented by the log<sub>2</sub> fold change (LFC) contrasting the pre&#8208; and post&#8208;intervention, formally defined as the coefficient of the interaction term between the intervention group and intervention time (i.e., baseline and 4 weeks post&#8208;treatment) in the LMM. Given the exploratory nature of the experiments, multiple test corrections were not conducted. As noted, analyses for secondary outcomes were pre&#8208;specified; however, given the fact that the trial was not powered to detect a difference in these outcomes and no corrections were made for multiple comparisons, all effects with <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 are considered nominally significant, and effects <italic toggle="yes">p&#160;</italic>&lt;&#160;0.10 but &#8805; 0.05 are considered trends.</p></sec></sec><sec id="alz70704-sec-0210"><label>3</label><title>RESULTS</title><sec id="alz70704-sec-0220"><label>3.1</label><title>Participants</title><p>Participant flow is depicted in the Consolidated Standards of Reporting Trials (CONSORT) diagram in Figure&#160;<xref rid="alz70704-fig-0001" ref-type="fig">1</xref>. Forty&#8208;nine participants enrolled in the study, 47 of whom were randomized on a 1:1:1:1 basis to one of four arms: placebo&#8211;placebo (<italic toggle="yes">n</italic>&#160;=&#160;10), EMPA+placebo (<italic toggle="yes">n</italic>&#160;=&#160;12), INI+placebo (<italic toggle="yes">n</italic>&#160;=&#160;14), INI+EMPA (<italic toggle="yes">n</italic>&#160;=&#160;11). Forty&#8208;two participants provided baseline and one post&#8208;treatment assessment and thus were included in the mITT sample. Demographic information for the individual treatment groups as well as the combined 2&#160;&#215;&#160;2 analysis groups (INI&#8208;treated vs. non&#8208;INI treated, and EMPA&#8208;treated and non&#8208;EMPA treated) for mITT participants is shown in Table&#160;<xref rid="alz70704-tbl-0001" ref-type="table">1</xref>, and all enrolled participants in Table <xref rid="alz70704-supinfo-0001" ref-type="">S1</xref> in supporting information. No significant differences were observed between individual groups and 2&#160;&#215;&#160;2 groups on any demographic variable for enrolled or mITT groups.</p><fig position="float" fig-type="FIGURE" id="alz70704-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Consolidated Standards of Reporting Trials (CONSORT) diagram. EMPA, empagliflozin; INI, intranasal insulin; LP, lumbar puncture; TRAE, treatment&#8208;related adverse event.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70704-g001.jpg"/></fig><table-wrap position="float" id="alz70704-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographic characteristics for the mITT group.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">PBO</th><th align="left" rowspan="1" colspan="1">INI</th><th align="left" rowspan="1" colspan="1">EMPA</th><th align="left" rowspan="1" colspan="1">INI+EMPA</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N (F/M)</td><td align="left" rowspan="1" colspan="1">9 (4/5)</td><td align="left" rowspan="1" colspan="1">10 (5/5)</td><td align="left" rowspan="1" colspan="1">12 (5/7)</td><td align="left" rowspan="1" colspan="1">11 (5/6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dx (CN, MCI, DEM)</td><td align="left" rowspan="1" colspan="1">0/8/1</td><td align="left" rowspan="1" colspan="1">1/8/1</td><td align="left" rowspan="1" colspan="1">2/8/2</td><td align="left" rowspan="1" colspan="1">1/9/1</td></tr><tr><td align="left" rowspan="1" colspan="1">Amyloid+ (Y/N)*</td><td align="left" rowspan="1" colspan="1">5/4</td><td align="left" rowspan="1" colspan="1">5/5</td><td align="left" rowspan="1" colspan="1">8/4</td><td align="left" rowspan="1" colspan="1">7/4</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years, mean, SD)</td><td align="left" rowspan="1" colspan="1">71.7 (6.6)</td><td align="left" rowspan="1" colspan="1">71.0 (4.7)</td><td align="left" rowspan="1" colspan="1">67.4 (7.6)</td><td align="left" rowspan="1" colspan="1">71.2 (6.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">MMSE</td><td align="left" rowspan="1" colspan="1">28.3 (1.6)</td><td align="left" rowspan="1" colspan="1">27.3 (3.3)</td><td align="left" rowspan="1" colspan="1">27.7 (2.6)</td><td align="left" rowspan="1" colspan="1">26.4 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years, mean, SD)</td><td align="left" rowspan="1" colspan="1">16.0 (2.2)</td><td align="left" rowspan="1" colspan="1">15.4 (3.3)</td><td align="left" rowspan="1" colspan="1">16.8 (2.4)</td><td align="left" rowspan="1" colspan="1">14.7 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> (&#949;4&#8211;/&#949;4+)</td><td align="left" rowspan="1" colspan="1">4/5</td><td align="left" rowspan="1" colspan="1">7/3</td><td align="left" rowspan="1" colspan="1">7/5</td><td align="left" rowspan="1" colspan="1">6/5</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">INI TX</th><th align="left" rowspan="1" colspan="1">NON&#8208;INI TX</th><th align="left" rowspan="1" colspan="1">EMPA TX</th><th align="left" rowspan="1" colspan="1">NON&#8208;EMPA TX</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N (F/M)</td><td align="left" rowspan="1" colspan="1">21 (10/11)</td><td align="left" rowspan="1" colspan="1">21 (9/12)</td><td align="left" rowspan="1" colspan="1">23 (10/13)</td><td align="left" rowspan="1" colspan="1">19 (9/10)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dx (CN, MCI, DEM)</td><td align="left" rowspan="1" colspan="1">2/17/2</td><td align="left" rowspan="1" colspan="1">2/16/3</td><td align="left" rowspan="1" colspan="1">3/17/3</td><td align="left" rowspan="1" colspan="1">1/16/2</td></tr><tr><td align="left" rowspan="1" colspan="1">Amyloid+ (Y/N)*</td><td align="left" rowspan="1" colspan="1">12/9</td><td align="left" rowspan="1" colspan="1">13/8</td><td align="left" rowspan="1" colspan="1">15/8</td><td align="left" rowspan="1" colspan="1">10/9</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years, mean, SD)</td><td align="left" rowspan="1" colspan="1">71.1 (5.5)</td><td align="left" rowspan="1" colspan="1">69.2 (7.3)</td><td align="left" rowspan="1" colspan="1">69.2 (7.1)</td><td align="left" rowspan="1" colspan="1">71.3 (5.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">MMSE</td><td align="left" rowspan="1" colspan="1">26.8 (3.2)</td><td align="left" rowspan="1" colspan="1">28.0 (2.2)</td><td align="left" rowspan="1" colspan="1">27.0 (3.0)</td><td align="left" rowspan="1" colspan="1">27.8 (2.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years, mean, SD)</td><td align="left" rowspan="1" colspan="1">15.0 (3.2)</td><td align="left" rowspan="1" colspan="1">16.4 (2.3)</td><td align="left" rowspan="1" colspan="1">15.8 (3.0)</td><td align="left" rowspan="1" colspan="1">15.7 (2.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> (&#949;4&#8211;/&#949;4+)</td><td align="left" rowspan="1" colspan="1">13/8</td><td align="left" rowspan="1" colspan="1">11/10</td><td align="left" rowspan="1" colspan="1">13/10</td><td align="left" rowspan="1" colspan="1">11/8</td></tr></tbody></table><table-wrap-foot><fn id="alz70704-tbl1-note-0001"><label>*</label><p>Amyloid positivity was defined as CSF A&#946;42/40 ratio &#8804; 0.058<xref rid="alz70704-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> or 11C&#8208;Pittsburgh compound B positron emission tomography standardized uptake value &#8805; 1.21.<xref rid="alz70704-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>.</p></fn><fn id="alz70704-tbl1-note-0002"><p>Abbreviations: A&#946;, amyloid beta; <italic toggle="yes">APOE</italic>, apolipoprotein E; CN, cognitively normal; CSF, cerebrospinal fluid; DEM, dementia; Dx, diagnosis; EMPA, empagliflozin; INI, intranasal insulin; MCI, mild cognitive impairment; mITT, modified intention to treat; MMSE, Mini&#8208;Mental State Examination; PBO, placebo; SD, standard deviation; TX, treatment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70704-sec-0230"><label>3.2</label><title>Primary outcome: TRAEs</title><p>Numbers of TRAE are depicted in Table&#160;<xref rid="alz70704-tbl-0002" ref-type="table">2</xref>. No differences were observed between INI&#8208;treated and non&#8211;INI&#8208;treated groups (ratio&#160;=&#160;1.81, 95% confidence interval [CI] 0.62, 5.34, <italic toggle="yes">p</italic>&#160;=&#160;0.2728). Similarly, no differences were observed between EMPA&#8208;treated and non&#8211;EMPA&#8208;treated groups (ratio&#160;=&#160;1.09, 95% CI 0.38, 3.08, <italic toggle="yes">p</italic>&#160;=&#160;0.8744). TRAEs for combined treatment compared to individual active treatment arms or placebo also did not differ. All TRAEs were rated mild, with full recovery. As shown in Table&#160;<xref rid="alz70704-tbl-0003" ref-type="table">3</xref>, the most common TRAEs were nasal irritation (<italic toggle="yes">n</italic>&#160;=&#160;5) and vaginal yeast infections (<italic toggle="yes">n</italic>&#160;=&#160;4), the rate of occurrence of which did not differ between groups in any comparisons.</p><table-wrap position="float" id="alz70704-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Total number of treatment&#8208;related adverse events (TRAEs).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Groups</th><th align="left" rowspan="1" colspan="1">TRAE (<italic toggle="yes">n</italic>)</th><th align="left" rowspan="1" colspan="1">Ratio (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">INI TX versus NON&#8208;INI TX</td><td align="left" rowspan="1" colspan="1">6&#160;vs 10</td><td align="left" rowspan="1" colspan="1">1.81 (0.62, 5.34)</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">EMPA TX versus NON&#8208;EMPA TX</td><td align="left" rowspan="1" colspan="1">7&#160;vs 9</td><td align="left" rowspan="1" colspan="1">1.09 (0.38,3.08)</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">INI+EMPA versus EMPA</td><td align="left" rowspan="1" colspan="1">2&#160;vs 5</td><td align="left" rowspan="1" colspan="1">0.40 (0.07, 2.37)</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">INI+EMPA versus INI</td><td align="left" rowspan="1" colspan="1">2&#160;vs 4</td><td align="left" rowspan="1" colspan="1">0.65 (0.12, 3.62)</td><td align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">INI+EMPA versus PLACEBO</td><td align="left" rowspan="1" colspan="1">2&#160;vs 5</td><td align="left" rowspan="1" colspan="1">0.43 (0.08, 2.43)</td><td align="left" rowspan="1" colspan="1">0.34</td></tr></tbody></table><table-wrap-foot><fn id="alz70704-tbl2-note-0001"><p>Abbreviations: CI, confidence interval; EMPA, empagliflozin; INI, intranasal insulin; TX, treatment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70704-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Types of treatment&#8208;related adverse events (TRAEs).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">TRAE</th><th align="left" rowspan="1" colspan="1">PBO</th><th align="left" rowspan="1" colspan="1">INI</th><th align="left" rowspan="1" colspan="1">EMPA</th><th align="left" rowspan="1" colspan="1">INI+EMPA</th><th align="left" rowspan="1" colspan="1">INI TX</th><th align="left" rowspan="1" colspan="1">NON&#8208;INI TX</th><th align="left" rowspan="1" colspan="1">EMPA TX</th><th align="left" rowspan="1" colspan="1">NON&#8208;EMPA TX</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">Hoarseness</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Nasal irritation</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Vaginal yeast infection</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Lethargy</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Myalgia</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="alz70704-tbl3-note-0001"><p>Abbreviations: EMPA, empagliflozin; INI, intranasal insulin; PBO, placebo; SD, standard deviation; TX, treatment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70704-sec-0240"><label>3.3</label><title>Secondary outcomes</title><p>Analyses for secondary outcomes were pre&#8208;specified; however, given the fact that the trial was not powered to detect a difference in these outcomes and no corrections were made for multiple comparisons, all effects with <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 are considered nominally significant, and effects <italic toggle="yes">p</italic>&#160;&lt;&#160;0.10 but &#8805; 0.05 are considered trends. There were no baseline differences between groups for any secondary outcome (Table <xref rid="alz70704-supinfo-0001" ref-type="">S2</xref> in supporting information).</p><sec id="alz70704-sec-0250"><label>3.3.1</label><title>Compliance/feasibility</title><p>Ratings were high for reliability and ease of use for the CPS device (4.6/5.0) and dosing regimen feasibility (4.0/5.0). IN and oral drug compliance was also high (97.4% of target doses for IN administration, 98.0% for oral administration). No differences in compliance or feasibility were noted between groups.</p></sec><sec id="alz70704-sec-0260"><label>3.3.2</label><title>Cognitive and clinical outcomes</title><p>As shown in Figure&#160;<xref rid="alz70704-fig-0002" ref-type="fig">2A</xref>, mPACC5 performance improved for the INI&#8208;treated group compared to the non&#8211;INI&#8208;treated group (mean change 0.10 [95% CI &#8211;0.05, 0.26] vs. &#8722;0.08 [&#8722;0.25, 0.09], <italic toggle="yes">p</italic>&#160;=&#160;0.0432). In sensitivity analyses, comparisons of each of the three active treatment arms to the placebo showed that both INI alone and INI+EMPA arms had greater mPACC5 scores after treatment (INI alone vs. placebo <italic toggle="yes">p</italic>&#160;=&#160;0.0305, INI+EMPA vs. placebo <italic toggle="yes">p</italic>&#160;=&#160;0.0395, Table <xref rid="alz70704-supinfo-0001" ref-type="">S3</xref> in supporting information). No differences in mPACC5 performance were noted between EMPA&#8208;treated and non&#8211;EMPA&#8208;treated groups (Figure&#160;<xref rid="alz70704-fig-0002" ref-type="fig">2A</xref>). No difference in change was noted for either of the 2&#160;&#215;&#160;2 groups for the ADAS14 (Table&#160;<xref rid="alz70704-tbl-0004" ref-type="table">4</xref>). For ADL&#8208;MCI, no changes were observed with EMPA treatment (Table&#160;<xref rid="alz70704-tbl-0004" ref-type="table">4</xref>). ADL&#8208;MCI scores were essentially unchanged for the INI&#8208;treated group, and improved slightly for the non&#8211;INI&#8208;treated group (Table&#160;<xref rid="alz70704-tbl-0004" ref-type="table">4</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70704-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>A, mPACC5 change scores for the non&#8208;INI&#8208;treated versus INI&#8208;treated and non&#8211;EMPA&#8208;treated versus EMPA&#8208;treated groups. B, Change in plasma GFAP (pg/mL) for the placebo, INI&#8208;only, EMPA&#8208;only, and INI+EMPA groups. C, Change in CSF total tau (pg/mL) for the placebo, INI&#8208;only, EMPA&#8208;only, and INI+EMPA groups. <bold>*</bold> Nominal <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05. CSF, cerebrospinal fluid; EMPA, empagliflozin; GFAP, glial fibrillary acidic protein; INI, intranasal insulin; mPACC5, modified Preclinical Alzheimer's Cognitive Composite 5.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70704-g003.jpg"/></fig><table-wrap position="float" id="alz70704-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Mean change with 95% confidence limits for clinical, cognitive, vascular, and metabolic outcomes for INI&#8208;treated and non&#8211;INI&#8208;treated groups, and for EMPA&#8208;treated and non&#8211;EMPA&#8208;treated groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Outcome</th><th align="left" rowspan="1" colspan="1">INI TX</th><th align="left" rowspan="1" colspan="1">Non&#8208;INI TX</th><th align="left" rowspan="1" colspan="1">EMPA TX</th><th align="left" rowspan="1" colspan="1">Non&#8208;EMPA TX</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MPACC5 *</td><td align="char" rowspan="1" colspan="1">
<bold>0.10 (&#8211;0.05, 0.26)*</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.08 (&#8211;0.25, 0.09)*</bold>
</td><td align="char" rowspan="1" colspan="1">0.05 (&#8211;0.11, 0.21)</td><td align="char" rowspan="1" colspan="1">&#8722;0.01 (&#8211;0.19, 0.16)</td></tr><tr><td align="left" rowspan="1" colspan="1">ADL&#8208;MCI *</td><td align="char" rowspan="1" colspan="1">
<bold>0.39 (&#8211;1.25, 2.03)*</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>2.56 (0.59, 4.52)*</bold>
</td><td align="char" rowspan="1" colspan="1">1.47 (&#8211;0.25, 3.18)</td><td align="char" rowspan="1" colspan="1">0.64 (&#8211;1.40, 2.68)</td></tr><tr><td align="left" rowspan="1" colspan="1">ADAS14</td><td align="char" rowspan="1" colspan="1">0.52 (&#8211;1.87, 2.90)</td><td align="char" rowspan="1" colspan="1">1.15 (&#8211;1.47, 3.76)</td><td align="char" rowspan="1" colspan="1">1.46 (&#8211;0.86, 3.77)</td><td align="char" rowspan="1" colspan="1">&#8722;0.16 (&#8211;2.70, 2.38)</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP</td><td align="char" rowspan="1" colspan="1">&#8722;7.70 (&#8211;15.7, 0.29)</td><td align="char" rowspan="1" colspan="1">&#8722;8.48 (&#8211;17.4, 0.45)</td><td align="char" rowspan="1" colspan="1">&#8722;10.1 (&#8211;17.8, &#8211;2.34)</td><td align="char" rowspan="1" colspan="1">&#8722;&#8208;5.09 (&#8211;13.6, 3.47)</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP</td><td align="char" rowspan="1" colspan="1">&#8722;2.29 (&#8211;6.55, 1.98)</td><td align="char" rowspan="1" colspan="1">&#8722;3.41 (&#8211;8.17, 1.36)</td><td align="char" rowspan="1" colspan="1">&#8722;3.35 (&#8211;7.56, 0.85)</td><td align="char" rowspan="1" colspan="1">&#8722;1.88 (&#8211;6.52, 2.76)</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose</td><td align="char" rowspan="1" colspan="1">1.48 (&#8211;3.13, 6.08)</td><td align="char" rowspan="1" colspan="1">&#8722;1.53 (&#8211;6.58, 3.53)</td><td align="char" rowspan="1" colspan="1">0.51 (&#8211;4.12, 5.15)</td><td align="char" rowspan="1" colspan="1">&#8722;0.21 (&#8211;&#8208;5.30, 4.88)</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin</td><td align="char" rowspan="1" colspan="1">&#8722;1.10 (&#8211;3.99, 1.79)</td><td align="char" rowspan="1" colspan="1">&#8722;0.44 (&#8211;3.61, 2.73)</td><td align="char" rowspan="1" colspan="1">&#8722;0.93 (&#8211;3.80, 1.93)</td><td align="char" rowspan="1" colspan="1">&#8722;0.66 (&#8211;3.81, 2.48)</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c *</td><td align="char" rowspan="1" colspan="1">
<bold>0.05 (&#8211;0.08, 0.18)*</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.10 (&#8211;0.25, 0.04)*</bold>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.00 (&#8211;0.14, 0.13)</td><td align="char" rowspan="1" colspan="1">&#8722;0.03 (&#8211;0.18, 0.13)</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL*</td><td align="char" rowspan="1" colspan="1">&#8722;1.21 (&#8211;5.73, 3.31)</td><td align="char" rowspan="1" colspan="1">1.95 (&#8211;3.01, 6.91)</td><td align="char" rowspan="1" colspan="1">
<bold>2.36 (&#8211;1.89, 6.62)*</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;3.02 (&#8211;7.70, 1.66)*</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL</td><td align="char" rowspan="1" colspan="1">&#8722;5.06 (&#8211;20.2, 10.04)</td><td align="char" rowspan="1" colspan="1">&#8722;16.0 (&#8211;32.6, 0.56)</td><td align="char" rowspan="1" colspan="1">&#8722;4.26 (&#8211;19.0, 10.49)</td><td align="char" rowspan="1" colspan="1">&#8722;17.3 (&#8211;33.5, &#8211;1.07)</td></tr></tbody></table><table-wrap-foot><fn id="alz70704-tbl4-note-0001"><p>Abbreviations: ADAS14, Alzheimer's Disease Assessment Scale Cognitive subscale V14; ADL&#8208;MCI, Activities of Daily Living Scale&#8211;Mild Cognitive Impairment; DBP, diastolic blood pressure; EMPA, empagliflozin; INI, intranasal insulin; HbAIc, hemoglobin A1c, HDL, high&#8208;density lipoprotein; LDL, low&#8208;density lipoprotein; MPACC5, mPACC5, modified Preclinical Alzheimer's Cognitive Composite 5; SBP, systolic blood pressure; TX, treatment.</p></fn><fn id="alz70704-tbl4-note-0002"><p>Bolded values differ between groups, * nominal <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70704-sec-0270"><label>3.3.3</label><title>Metabolic outcomes</title><p>Metabolic outcomes are shown in Table&#160;<xref rid="alz70704-tbl-0004" ref-type="table">4</xref>. The EMPA&#8208;treated group showed increased HDL (<italic toggle="yes">p</italic>&#160;=&#160;0.0275); no other changes were noted. HbA1c increased slightly for the INI&#8208;treated group and decreased for the non&#8208;INI group (<italic toggle="yes">p</italic>&#160;=&#160;0.0436), with no other changes noted.</p></sec><sec id="alz70704-sec-0280"><label>3.3.4</label><title>Imaging outcomes</title><p>INI&#8208;treated participants showed increased DTI GM FA in frontal and parietal ROIs (Table&#160;<xref rid="alz70704-tbl-0005" ref-type="table">5</xref>, <italic toggle="yes">p</italic>s&#160;=&#160;0.0409, 0.0207), and in global WM relative to the non&#8208;treated group (<italic toggle="yes">p</italic>&#160;=&#160;0.0085). No changes were observed for the EMPA&#8208;treated group. On PCASL, insulin&#8208;treated participants showed reduced CBF in the GM hippocampal ROI (Table&#160;<xref rid="alz70704-tbl-0005" ref-type="table">5</xref>, <italic toggle="yes">p</italic>&#160;=&#160;0.0451). EMPA&#8208;treated participants showed reduced CBF relative to non&#8208;EMPA treated participants in the GM insula&#8208;cingulate ROI, and in the global WM ROI (Table&#160;<xref rid="alz70704-tbl-0005" ref-type="table">5</xref>, <italic toggle="yes">p</italic>s&#160;=&#160;0.0489, 0.0425).</p><table-wrap position="float" id="alz70704-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Mean change with 95% confidence limits for DTI FA and PCASL outcomes for INI treated and non&#8208;INI treated groups, and for EMPA&#8208;treated and non&#8211;EMPA&#8208;treated groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">INI TX</th><th align="left" rowspan="1" colspan="1">NON&#8208;INI TX</th><th align="left" rowspan="1" colspan="1">EMPA TX</th><th align="left" rowspan="1" colspan="1">NON&#8208;EMPA TX</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DTI FA</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Frontal GM*</td><td align="char" rowspan="1" colspan="1">
<bold>0.02 (&#8722;0</bold>.<bold>002, 0.04)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.006 (&#8722;0.03,0.02)</bold>
</td><td align="char" rowspan="1" colspan="1">0.002 (&#8722;0.02, 0.02)</td><td align="char" rowspan="1" colspan="1">0.01 (&#8722;0.009, 0.04)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Parietal GM*</td><td align="char" rowspan="1" colspan="1">
<bold>0.03 (0.007, 0.06)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.002 (&#8722;0.02, 0.02)</bold>
</td><td align="char" rowspan="1" colspan="1">0.009 (&#8722;0.15, 0.03)</td><td align="char" rowspan="1" colspan="1">0.02 (&#8722;0.004, 0.05)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Global WM**</td><td align="char" rowspan="1" colspan="1">
<bold>0.01 (0.005, 0.02)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.0009 (&#8722;0.01, 0.01)</bold>
</td><td align="char" rowspan="1" colspan="1">0.004 (&#8722;0.003, 0.01)</td><td align="char" rowspan="1" colspan="1">0.01 (0.003, 0.02)</td></tr><tr><td align="left" rowspan="1" colspan="1">PCASL CBF</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hippocampal GM*</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.05 (&#8722;0.13, 0.04)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.05 (&#8722;0.03, 0.14)</bold>
</td><td align="char" rowspan="1" colspan="1">&#8722;0.03 (&#8722;0.11, 0.06)</td><td align="char" rowspan="1" colspan="1">0.04 (&#8722;0.05, 0.13)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Insula/Cingulum GM*</td><td align="char" rowspan="1" colspan="1">&#8722;0.04 (&#8722;0.13, 0.04)</td><td align="char" rowspan="1" colspan="1">0.02 (&#8722;0.06, 0.10)</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.05 (&#8722;0.13, 0.02)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.04 (&#8722;0.04, 0.13)</bold>
</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Global WM*</td><td align="char" rowspan="1" colspan="1">0.03 (&#8722;0.03, 0.09)</td><td align="char" rowspan="1" colspan="1">0.02 (&#8722;0.04, 0.08)</td><td align="char" rowspan="1" colspan="1">
<bold>&#8722;0.002 (&#8722;0.06, 0.05)</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.06 (0.00, 0.13)</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="alz70704-tbl5-note-0001"><p>Notes: Bolded values differ between groups, * nominal <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 or ** nominal <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01.</p></fn><fn id="alz70704-tbl5-note-0002"><p>Abbreviations: CBF, cerebral blood flow; DTI diffusion tensor imaging; EMPA, empagliflozin; FA, fractional anisotropy; INI, intranasal insulin; GM, gray matter; PCASL, pseudo&#8208;continuous arterial spin labeling; TX, treatment; WM, white matter.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70704-sec-0290"><label>3.3.5</label><title>Fluid biomarker outcomes</title><p>For the INI&#8208;only group, plasma GFAP levels were lowered compared to the placebo&#8208;only group (Figure&#160;<xref rid="alz70704-fig-0002" ref-type="fig">2B</xref>, <italic toggle="yes">p</italic>&#160;=&#160;0.0402). Compared to the placebo&#8208;only group, EMPA&#8208;only treatment lowered CSF tau levels (Figure&#160;<xref rid="alz70704-fig-0002" ref-type="fig">2C</xref>, <italic toggle="yes">p&#160;</italic>=&#160;0.0416). No other differences were noted among groups for blood or CSF AD markers (Table <xref rid="alz70704-supinfo-0001" ref-type="">S4</xref> in supporting information).</p><p>INI treatment alone compared to placebo was associated with change in several CSF analytes (Figure&#160;3A&#160;and&#160;<xref rid="alz70704-fig-0003" ref-type="fig">3B</xref>), including increased neurotrophic factor fibroblast growth factor 2 (FGF2), cytokines interleukin (IL)&#8208;11, and IL 2 receptor &#946; (IL2RB), and immune regulator programmed cell death 1 ligand 2 (PDCD1LG2), and decreased IL&#8208;4 and thrombopoietin (THPO). In plasma, INI&#8208;only treatment was associated with increased immune/inflammatory regulators tissue inhibitor of metalloproteinases 3 (TIMP3), C&#8208;reactive protein (CRP), C&#8211;X&#8211;C motif chemokine ligand 6 (CXCL6), CD40 ligand (CD40LG), and growth factor platelet&#8208;derived growth factor subunit A (PDGFA). Plasma I4, tumor necrosis factor superfamily member 14 (TNFSF14), and Wnt family member 7A (WNT7A) decreased after INI treatment (Figure&#160;3C&#160;and&#160;<xref rid="alz70704-fig-0003" ref-type="fig">3D</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70704-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Change in CSF (A) CNS and (B) inflammation biomarkers; change in plasma (C) CNS and (D) inflammation biomarkers for INI&#8208;only, EMPA&#8208;only and INI+EMPA groups versus placebo. The <italic toggle="yes">x</italic> axis of each volcano plot shows the magnitude and direction of the intervention effect, represented by the LFC (with the sign of the LFC reflecting the direction of the effect). The <italic toggle="yes">y</italic> axis shows the statistical significance of the group difference in change, represented by the minus log<sub>10</sub>&#8208;transformed <italic toggle="yes">p</italic> value (i.e. &#8211;log<sub>10</sub>[p]), with smaller <italic toggle="yes">p</italic> values appearing higher on the plot. A threshold of nominal <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 and log2 fold change of&#160;&gt;&#160;0.05 and&#160;&#8592;&#160;0.05 (trend) was used for the exploratory analysis to identify significant analytes as potential biomarkers in each treatment arm. CNS, central nervous system; CSF, cerebrospinal fluid; EMPA, empagliflozin; INI, intranasal insulin; LFC, log fold change; PBO, placebo.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70704-g002.jpg"/></fig><p>Multiple markers were reduced after EMPA&#8208;only treatment in CSF, including immune/inflammatory regulators IL&#8208;2, IL&#8208;7, IL&#8208;4 receptor (IL&#8208;4R), IL&#8208;12 subunit beta (IL&#8208;12B), and C&#8211;C motif chemokine ligand 8 (CCL8). CSF vascular modulators were also lowered, including cardiotrophin 1 (CTF1) platelet&#8208;derived growth factor receptor beta (PDGFR&#946;), erythropoietin (EPO), vascular cell adhesion molecule 1 (VCAM1), and TEK receptor tyrosine kinase (TEK). Neurotrophic modulators neurogranin (NRGN), secreted frizzled&#8208;related protein 1 (SFRP1), and fibroblast growth factor 19 (FGF19) were also lowered (Figure&#160;3A&#160;and&#160;<xref rid="alz70704-fig-0003" ref-type="fig">3B</xref>). In plasma, EMPA&#8208;only treatment increased immune/inflammation/lipid modulators serum amyloid A1 (SAA1), IL&#8208;1 receptor antagonist (IL&#8208;1RN) and IL&#8208;36&#947;, and decreased IL&#8208;4 and CXCL12 (Figure&#160;3C&#160;and&#160;<xref rid="alz70704-fig-0003" ref-type="fig">3D</xref>).</p><p>In CSF, combined INI+EMPA&#8208;treated group increased CSF inhibitor of nuclear factor kappa&#8208;B kinase subunit gamma (IKBKG) and lymphotoxin alpha and beta (LTA/LB), and decreased IL&#8208;2, V&#8208;set and transmembrane domain&#8208;containing protein 1 (VSTM1), and CCL8 (Figure&#160;3A&#160;and&#160;<xref rid="alz70704-fig-0003" ref-type="fig">3B</xref>). In plasma, interferon gamma (IFN&#947;), IL&#8208;22, and CD3 epsilon chain (CD3E) were decreased (Figure&#160;3C&#160;and&#160;<xref rid="alz70704-fig-0003" ref-type="fig">3D</xref>).</p></sec></sec></sec><sec id="alz70704-sec-0300"><label>4</label><title>DISCUSSION</title><p>This phase IIA/B trial investigated the safety and explored the efficacy of 4 weeks of treatment with two immuno&#8208;metabolic modulators: empagliflozin, an SGLT2i not previously investigated in AD clinical trials, and high&#8208;dose INI, which has shown promising but variable effects at lower doses. The trial also assessed safety of combining both interventions using an innovative 2&#160;&#215;&#160;2 design to enhance efficiency. Results supported the primary hypothesis: both treatments were safe, with no differences in TRAEs, the primary outcome, for the combined EMPA&#8208;treated or INI&#8208;treated groups, or for individual arms versus placebo.</p><p>In secondary and exploratory analyses, INI improved cognition, moderated MRI FA and CBF, and reduced plasma GFAP. EMPA treatment lowered CSF tau and modulated CBF. Both agents influenced multiple immune/inflammatory markers. A larger, longer trial is needed to validate these promising results.</p><sec id="alz70704-sec-0310"><label>4.1</label><title>Safety of EMPA and INI treatment</title><p>TRAE rates were equal for EMPA and non&#8208;EMPA treated groups, suggesting that EMPA is safe for non&#8208;diabetic adults with MCI/early AD. SGLT2is are a promising class of therapeutics which have been shown to improve glucose metabolism and vascular function in diabetes and cardiovascular disease.<xref rid="alz70704-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Empagliflozin (Jardiance) is the most widely prescribed agent in this class. Its effects have not been reported in AD, marking an important innovation of our study. SGLT2is reduce peripheral hyperglycemia by preventing glucose reabsorption in the kidneys,<xref rid="alz70704-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> without causing hypoglycemia, even in non&#8208;diabetic adults; a meta&#8208;analysis of 20 trials (&gt;&#160;15,000 patients) found similar adverse event (AE) rates for EMPA and placebo.<xref rid="alz70704-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> AEs included volume depletion with loop diuretic use, and genital yeast infections. Loop diuretics were excluded from our trial and no group differences in yeast infections were noted. Large trials show SGLT2is improve peripheral and CNS vascular health, reducing myocardial infarction and stroke risk.<xref rid="alz70704-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70704-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70704-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Mechanisms include improved sodium handling, blood pressure and endothelial function, and reduced arterial stiffness. SGLT2is also reduce inflammation and oxidative stress.<xref rid="alz70704-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> SGLT2i improvement of multiple vascular indices make them a promising class of agents for combination therapy in AD.</p><p>SGLT2i effects on the brain have been less studied than peripheral metabolic/vascular outcomes. SGLT2 is expressed in the hippocampus and choroid plexus, and increases in the brain after traumatic injury and cerebral ischemia.<xref rid="alz70704-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70704-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="alz70704-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> Preclinical studies show that SGLT2is enhance mitochondrial function, shift metabolism from glycolysis to fatty acids, increase hippocampal plasticity, and reduce oxidative stress.<xref rid="alz70704-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="alz70704-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> In rodent models, EMPA reduced A&#946;, inflammation, and microhemorrhages; preserved cortical volume; and improved memory.<xref rid="alz70704-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> In humans, EMPA reduces hyperglycemia, insulin resistance, and vascular dysfunction and other mechanisms which may drive or exacerbate AD pathology. In a study of&#160;&gt;&#160;11,000 diabetic patients, SGLT2i treatment reduced dementia risk by 42%.<xref rid="alz70704-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> In prediabetic cognitively normal adults, 8&#160;weeks of EMPA enhanced brain insulin sensitivity assessed with functional MRI.<xref rid="alz70704-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> A recent trial showed that the SGLT2i dapagliflozin improved peripheral metabolism and brain glutathione in 46 adults with probable AD.<xref rid="alz70704-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</p><p>INI safety has been well characterized. A meta&#8208;analysis of 18 studies (<italic toggle="yes">n</italic>&#160;=&#160;832, INI doses of 20 to 160 IU for up to 9.7 years) revealed no cases of symptomatic hypoglycemia or serious AEs.<xref rid="alz70704-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> In a study of 18 months of 40 IU INI treatment in AD, no differences were observed in rates of AEs between insulin&#8208;treated and placebo&#8208;assigned groups.<xref rid="alz70704-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In the present trial (160 IU/day), we saw no TRAE differences between INI and non&#8208;INI groups, supporting feasibility of a longer trial.</p></sec><sec id="alz70704-sec-0320"><label>4.2</label><title>Clinical outcomes</title><p>INI improved performance on the mPACC5, a composite sensitive to preclinical AD and MCI.<xref rid="alz70704-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Sensitivity analyses also confirmed better mPACC5 performance for INI&#8208;only and INI+EMPA treated groups versus placebo. The mPACC5 contains three memory tests; INI has been shown to improve memory in acute and short&#8208;term studies.<xref rid="alz70704-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> Given the relatively brief inter&#8208;test interval, it is possible the practice effects may have influenced results, although both INI and non&#8208;INI groups had similar baseline mPACC5 scores and a similar opportunity to benefit from practice. INI did not affect the ADAS14, which may require longer treatment; improvement was noted after 6 months for a subgroup in a previous study.<xref rid="alz70704-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> EMPA did not change cognition, but did increase HDL cholesterol, a known SGLT2i effect.<xref rid="alz70704-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="alz70704-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</p></sec><sec id="alz70704-sec-0330"><label>4.3</label><title>Fluid biomarker changes</title><p>To identify specific effects of INI and EMPA and their combination on biomarkers, exploratory analyses compared change in each of the three individual treatment arms to placebo. For AD biomarkers, EMPA&#8208;only treatment lowered CSF tau, consistent with preclinical studies showing that SGLT2is inhibit tau hyperphosphorylation by moderating GSK3&#946; and mTOR signaling.<xref rid="alz70704-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="alz70704-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> INI&#8208;only treatment reduced plasma GFAP, a marker of astrocyte activation elevated in AD.<xref rid="alz70704-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> Astrocytic&#8208;derived GFAP may also be sensitive to therapeutic effects; in a clinical trial of the AAmAb donanemab, GFAP decreased in the first 12&#160;weeks.<xref rid="alz70704-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Astrocytes are critical for intact neurovascular and glymphatic function.<xref rid="alz70704-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Insulin is key to astrocytic function; reduced astrocytic insulin signaling is linked to increased AD pathology in rodents and the human brain.<xref rid="alz70704-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70704-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> No other differences were noted for blood or CSF AD markers.</p><sec id="alz70704-sec-0340"><label>4.3.1</label><title>Exploratory proteomic analyses</title><p>INI moderated proteins associated with immune/inflammatory dysregulation; INI&#8208;only treatment increased CSF IL&#8208;11, IL&#8208;2RB, and PDCD1, and decreased plasma CXCL6 and TNFSF14, which participate in protective immune responses to AD pathology.<xref rid="alz70704-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="alz70704-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>, <xref rid="alz70704-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>, <xref rid="alz70704-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> INI's immune effects may be mediated in part by a newly identified pathway, the nasal&#8211;olfactory plexus, a critical hub connecting the brain's glymphatic system to the peripheral and CNS immune systems.<xref rid="alz70704-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> CSF&#8208;associated glymphatic agents pass through the cribriform plate to submucosal vessels in olfactory epithelium, continuing to deep cervical lymph nodes and triggering bidirectional activation of CNS and peripheral immune systems.<xref rid="alz70704-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>, <xref rid="alz70704-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>
</p><p>INI&#8208;only treatment increased proteostasis regulators plasma TIMP3 and CSF FGF2,<xref rid="alz70704-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="alz70704-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> and reduced vascular markers plasma PDGF&#945; and CSF THPO. THPO is elevated in stroke, and exacerbates hypoxic injury.<xref rid="alz70704-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>, <xref rid="alz70704-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> PDGF&#945; and its receptor operate via the PI3K insulin signaling pathway, affecting inflammation, oligodendrocyte proliferation, and neurovascular/blood&#8211;brain barrier function.<xref rid="alz70704-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> Notably, most proteins affected by INI have extensive interactions with insulin signaling pathways.</p><p>Like INI, EMPA&#8208;only treatment reduced CSF IL&#8208;4 and increased CSF PDCD1. It lowered CSF neurogranin, a synaptic protein that predicts AD clinical progression and correlates highly with tau;<xref rid="alz70704-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> as noted EMPA lowered CSF tau. EMPA lowered CSF PDGFR&#946; and VCAM1, proteins related to plasticity and cerebrovascular integrity; both are correlated with CSF tau, elevated in AD, and predict clinical progression.<xref rid="alz70704-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="alz70704-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>, <xref rid="alz70704-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> EMPA also lowered multiple pro&#8208;inflammatory/immune proteins (IL&#8208;4, IL&#8208;2, IL&#8208;7, IL&#8208;12B, and CCL8), and CSF SFRP1, which promotes amyloidogenesis, and is elevated in AD.<xref rid="alz70704-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>
</p><p>Combined INI and EMPA treatment decreased T cell&#8211;derived modulators plasma IFN&#947; and CD3&#949;. Plasma IL&#8208;22 was reduced, reversing a pattern associated with AD.<xref rid="alz70704-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> INI+EMPA increased IKBKG, which reduces nuclear factor kappa beta activation and AD pathology.<xref rid="alz70704-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> Combined INI+EMPA treatment resulted in fewer changes than individual treatments, with only two overlapping markers (CSF IL&#8208;2 and CCL8). Combined therapy may lead to more variable responses across participants, impeding our ability to detect significant changes in our small sample.</p></sec></sec><sec id="alz70704-sec-0350"><label>4.4</label><title>Imaging biomarkers</title><p>We examined CBF with PCASL MRI, which reflects capillary blood flow and neural function. A U&#8208;shaped ASL pattern has been reported in AD: early hippocampal and limbic hyperactivation linked to a compensatory response to pathology, transitioning to hypometabolism in later stages.<xref rid="alz70704-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>, <xref rid="alz70704-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> INI reduced hippocampal CBF and improved cognition, suggesting attenuation of compensatory hyperactivation. Similarly, EMPA reduced insular and global WM CBF. WM CBF has not been extensively investigated in AD; in multiple sclerosis WM hyperperfusion is associated with inflammation.<xref rid="alz70704-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref>
</p><p>DTI FA measures water diffusion directionality, reflecting myelin and microstructural integrity. AD is associated with progressive FA reduction in numerous WM tracts.<xref rid="alz70704-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> INI increased FA globally in WM. FA is also influenced by inflammation and edema.<xref rid="alz70704-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> INI&#8208;related FA increases may reflect improved astrocytic function, given that INI reduced GFAP, a marker of astrocytic integrity. Higher GFAP correlates with reduced FA in AD&#8208;vulnerable regions in MCI and AD.<xref rid="alz70704-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> Further, insulin receptors on astrocytes are necessary for intact neurovascular coupling; lack of astrocytic insulin receptors produces a U shaped abnormality in blood flow, with initial hyperperfusion followed by progressive hypoperfusion.<xref rid="alz70704-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> As noted, hyperperfusion has been observed in preclinical and early AD, followed by hypoperfusion with disease progression. Thus, INI may impact ASL, FA, and GFAP via astrocytic pathways.</p></sec><sec id="alz70704-sec-0360"><label>4.5</label><title>Limitations</title><p>The primary outcome for this trial was safety of EMPA and high&#8208;dose INI, and their combined administration, which have not been previously investigated in AD. As such the trial duration was brief and the sample size small. The between&#8208;group differences for most outcomes were modest. Further, given the exploratory nature of the trial, no corrections for multiple comparisons were made. A larger trial with a longer treatment period is needed to confirm these results.</p></sec></sec><sec id="alz70704-sec-0370"><label>5</label><title>SUMMARY AND CONCLUSIONS</title><p>Four weeks of treatment with EMPA and INI was safe, with good feasibility and compliance. Our clinical, imaging, and biomarker results suggest pathways through which these agents may act. INI influenced astrocytic, immune, and neurovascular pathways, possibly contributing to cognitive benefits. EMPA lowered tau, as well as neurogranin and vascular modulators tied to tau, suggesting potential effects on tau&#8208;related processes. Both INI and EMPA moderated numerous immune/inflammatory regulators. Our results reinforce the potential therapeutic benefit of INI and EMPA for AD, either individually or in combination with other treatments, and provide a foundation for a longer, larger trial.</p></sec><sec sec-type="COI-statement" id="alz70704-sec-0390"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors have no conflicts to report. Author disclosures are available in the <xref rid="alz70704-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70704-sec-0400"><title>CONSENT STATEMENT</title><p>All participants in this study signed informed consent as overseen by the Wake Forest University School of Medicine/Atrium/Advocate Health Institutional Review Board.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70704-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70704-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70704-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70704-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70704-s004.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70704-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70704-s003.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70704-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70704-s002.doc" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70704-sec-0380"><title>ACKNOWLEDGMENTS</title><p>The authors would like to acknowledge the assistance of the Translational Imaging Program of Wake Forest University School of Medicine. This work was supported by the Alzheimer's Association Part the Cloud program (PTC&#8208;22&#8208;975243; S.C.), Wake Forest University School of Medicine Alzheimer's Disease Research Center (P30 AG072947; S.C., K.S., T.R., C.S., C.W., M.R.), T32 AG033534 (J.E., M.R.), and the Kulynych Center for Memory and Cognition (S.C.). Aptar Pharma provided all devices for the study; they had no input into study design, data analysis, or interpretation of results.</p></ack><ref-list id="alz70704-bibl-0001"><title>REFERENCES</title><ref id="alz70704-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70704-cite-0002"><string-name name-style="western"><surname>Kellar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Craft</surname><given-names>S</given-names></string-name>. <article-title>Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches</article-title>. <source>The Lancet Neurol</source>. <year>2020</year>;<volume>19</volume>(<issue>9</issue>):<fpage>758</fpage>&#8208;<lpage>766</lpage>.<pub-id pub-id-type="pmid">32730766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30231-3</pub-id><pub-id pub-id-type="pmcid">PMC9661919</pub-id></mixed-citation></ref><ref id="alz70704-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70704-cite-0003"><string-name name-style="western"><surname>Rizzo</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Di Meo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Polito</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment</article-title>. <source>Pharmacol Res</source>. <year>2022</year>;<volume>176</volume>:<elocation-id>106062</elocation-id>.<pub-id pub-id-type="pmid">35017046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2022.106062</pub-id></mixed-citation></ref><ref id="alz70704-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70704-cite-0004"><string-name name-style="western"><surname>Scheen</surname><given-names>AJ</given-names></string-name>. <article-title>Sodium&#8211;glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>. <year>2020</year>;<volume>16</volume>(<issue>10</issue>):<fpage>556</fpage>&#8208;<lpage>577</lpage>.<pub-id pub-id-type="pmid">32855502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-020-0392-2</pub-id></mixed-citation></ref><ref id="alz70704-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70704-cite-0005"><string-name name-style="western"><surname>Pawlos</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Broncel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wo&#378;niak</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gorzelak&#8208;Pabi&#347;</surname><given-names>P</given-names></string-name>. <article-title>Neuroprotective effect of SGLT2 inhibitors</article-title>. <source>Molecules</source>. <year>2021</year>;<volume>26</volume>(<issue>23</issue>):<fpage>7213</fpage>.<pub-id pub-id-type="pmid">34885795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules26237213</pub-id><pub-id pub-id-type="pmcid">PMC8659196</pub-id></mixed-citation></ref><ref id="alz70704-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70704-cite-0006"><string-name name-style="western"><surname>Hierro&#8208;Bujalance</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Infante&#8208;Garcia</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Del Marco</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes</article-title>. <source>Alzheimer's Research &amp; Therapy</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>40</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00607-4</pub-id><pub-id pub-id-type="pmcid">PMC7140573</pub-id><pub-id pub-id-type="pmid">32264944</pub-id></mixed-citation></ref><ref id="alz70704-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70704-cite-0007"><string-name name-style="western"><surname>Wium&#8208;Andersen</surname><given-names>IK</given-names></string-name>, <string-name name-style="western"><surname>Osler</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>J&#248;rgensen</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Rungby</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wium&#8208;Andersen</surname><given-names>MK</given-names></string-name>. <article-title>Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case&#8211;control study</article-title>. <source>Eur J Endocrinol</source>. <year>2019</year>;<volume>181</volume>(<issue>5</issue>):<fpage>499</fpage>&#8208;<lpage>507</lpage>.<pub-id pub-id-type="pmid">31437816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EJE-19-0259</pub-id></mixed-citation></ref><ref id="alz70704-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70704-cite-0008"><string-name name-style="western"><surname>Cowie</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Fisher</surname><given-names>M</given-names></string-name>. <article-title>SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control</article-title>. <source>Nat Rev Cardiol</source>. <year>2020</year>;<volume>17</volume>(<issue>12</issue>):<fpage>761</fpage>&#8208;<lpage>772</lpage>.<pub-id pub-id-type="pmid">32665641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-020-0406-8</pub-id></mixed-citation></ref><ref id="alz70704-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70704-cite-0009"><string-name name-style="western"><surname>Hallschmid</surname><given-names>M</given-names></string-name>. <article-title>Intranasal insulin for Alzheimer's disease</article-title>. <source>CNS Drugs</source>. <year>2021</year>;<volume>35</volume>(<issue>1</issue>):<fpage>21</fpage>&#8208;<lpage>37</lpage>.<pub-id pub-id-type="pmid">33515428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40263-020-00781-x</pub-id><pub-id pub-id-type="pmcid">PMC7873098</pub-id></mixed-citation></ref><ref id="alz70704-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70704-cite-0010"><string-name name-style="western"><surname>Craft</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></string-name>, et&#160;al. <article-title>Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment</article-title>. <source>Arch Neurol</source>. <year>2012</year>;<volume>69</volume>(<issue>1</issue>):<fpage>29</fpage>.<pub-id pub-id-type="pmid">21911655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2011.233</pub-id><pub-id pub-id-type="pmcid">PMC3260944</pub-id></mixed-citation></ref><ref id="alz70704-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70704-cite-0011"><string-name name-style="western"><surname>Craft</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Raman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>TW</given-names></string-name>, et&#160;al. <article-title>Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia</article-title>. <source>JAMA Neurol</source>. <year>2020</year>;<volume>77</volume>(<issue>9</issue>):<fpage>1099</fpage>.<pub-id pub-id-type="pmid">32568367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2020.1840</pub-id><pub-id pub-id-type="pmcid">PMC7309571</pub-id></mixed-citation></ref><ref id="alz70704-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70704-cite-0012"><string-name name-style="western"><surname>Kellar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Register</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lockhart</surname><given-names>SN</given-names></string-name>, et&#160;al. <article-title>Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial</article-title>. <source>Sci Rep</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1346</fpage>.<pub-id pub-id-type="pmid">35079029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-05165-3</pub-id><pub-id pub-id-type="pmcid">PMC8789895</pub-id></mixed-citation></ref><ref id="alz70704-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70704-cite-0013"><string-name name-style="western"><surname>Kellar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lockhart</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Intranasal insulin reduces white matter hyperintensity progression in association with improvements in cognition and CSF biomarker profiles in mild cognitive impairment and Alzheimer's disease</article-title>. <source>J Prevent Alzheimer's Dis</source>. <year>2021</year>;<volume>8</volume>(<issue>3</issue>):<fpage>240</fpage>&#8208;<lpage>248</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2021.14</pub-id><pub-id pub-id-type="pmcid">PMC10233712</pub-id><pub-id pub-id-type="pmid">34101779</pub-id></mixed-citation></ref><ref id="alz70704-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70704-cite-0014"><string-name name-style="western"><surname>Wellford</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Moseman</surname><given-names>EA</given-names></string-name>. <article-title>Olfactory immunology: the missing piece in airway and CNS defence</article-title>. <source>Nat Rev Immunol</source>. <year>2024</year>;<volume>24</volume>(<issue>6</issue>):<fpage>381</fpage>&#8208;<lpage>398</lpage>.<pub-id pub-id-type="pmid">38097777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-023-00972-9</pub-id><pub-id pub-id-type="pmcid">PMC11560121</pub-id></mixed-citation></ref><ref id="alz70704-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70704-cite-0015"><string-name name-style="western"><surname>Erichsen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Craft</surname><given-names>S</given-names></string-name>. <article-title>Targeting immuno&#8208;metabolic pathways for combination therapy in Alzheimer's disease</article-title>. <source>Alzheimer's Dement: TranslRes Clin Intervent</source>. <year>2023</year>;<volume>9</volume>(<issue>4</issue>):<elocation-id>e12423</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12423</pub-id><pub-id pub-id-type="pmcid">PMC10541802</pub-id><pub-id pub-id-type="pmid">37786483</pub-id></mixed-citation></ref><ref id="alz70704-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70704-cite-0016"><string-name name-style="western"><surname>Alami</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Morvaridzadeh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>El Khayari</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Reducing Alzheimer's disease risk with SGLT2 inhibitors: from glycemic control to neuroprotection</article-title>. <source>Ageing Res Rev</source>. <year>2025</year>;<volume>108</volume>:<elocation-id>102751</elocation-id>.<pub-id pub-id-type="pmid">40204129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2025.102751</pub-id></mixed-citation></ref><ref id="alz70704-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70704-cite-0017"><string-name name-style="western"><surname>Vaziri</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Saleki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Aram</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Empagliflozin treatment of cardiotoxicity: a comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications</article-title>. <source>Biomed Pharmacother</source>. <year>2023</year>;<volume>168</volume>:<elocation-id>115686</elocation-id>.<pub-id pub-id-type="pmid">37839109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.115686</pub-id></mixed-citation></ref><ref id="alz70704-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70704-cite-0018"><string-name name-style="western"><surname>Solingapuram Sai</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Erichsen</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Gollapelli</surname><given-names>KK</given-names></string-name>, et&#160;al. <article-title>First biodistribution study of [68Ga]Ga&#8208;NOTA&#8208;insulin following intranasal administration in adult vervet monkeys</article-title>. <source>JAlzheimer's Dis</source>. <year>2024</year>;<volume>101</volume>(<issue>1</issue>):<fpage>309</fpage>&#8208;<lpage>320</lpage>.<pub-id pub-id-type="pmid">39213084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-240484</pub-id></mixed-citation></ref><ref id="alz70704-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70704-cite-0077"><string-name name-style="western"><surname>Sai</surname><given-names>KKS</given-names></string-name>, <string-name name-style="western"><surname>Erichsen</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Gollapelli</surname><given-names>KK</given-names></string-name>, et&#160;al. <article-title>First&#8208;in&#8208;human positron emission tomography study of intranasal insulin in aging and MCI</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>11</volume>(<issue>3</issue>):<elocation-id>e70123</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.70123</pub-id><pub-id pub-id-type="pmcid">PMC12284729</pub-id><pub-id pub-id-type="pmid">40703476</pub-id></mixed-citation></ref><ref id="alz70704-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70704-cite-0019"><string-name name-style="western"><surname>Willemse</surname><given-names>EAJ</given-names></string-name>. <article-title>Prediction of amyloid PET status using the LUMIPULSE G &#946;&#8208;amyloid ratio (1&#8208;42/1&#8208;40)</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2020</year>;<volume>16</volume>(<issue>S4</issue>):<elocation-id>e046006</elocation-id>.</mixed-citation></ref><ref id="alz70704-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70704-cite-0020"><string-name name-style="western"><surname>Villeneuve</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Cohn&#8208;Sheehy</surname><given-names>BI</given-names></string-name>, et&#160;al. <article-title>Existing Pittsburgh compound&#8208;B positron emission tomography thresholds are too high: statistical and pathological evaluation</article-title>. <source>Brain</source>. <year>2015</year>;<volume>138</volume>(<issue>Pt 7</issue>):<fpage>2020</fpage>&#8208;<lpage>2033</lpage>.<pub-id pub-id-type="pmid">25953778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv112</pub-id><pub-id pub-id-type="pmcid">PMC4806716</pub-id></mixed-citation></ref><ref id="alz70704-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70704-cite-0021"><string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, et&#160;al. <article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2024</year>;<volume>20</volume>(<issue>8</issue>):<fpage>5143</fpage>&#8208;<lpage>5169</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id><pub-id pub-id-type="pmid">38934362</pub-id></mixed-citation></ref><ref id="alz70704-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70704-cite-0022"><string-name name-style="western"><surname>Packer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Anker</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Cardiovascular and renal outcomes with empagliflozin in heart failure</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>(<issue>15</issue>):<fpage>1413</fpage>&#8208;<lpage>1424</lpage>.<pub-id pub-id-type="pmid">32865377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022190</pub-id></mixed-citation></ref><ref id="alz70704-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70704-cite-0023"><string-name name-style="western"><surname>Papp</surname><given-names>KV</given-names></string-name>, <string-name name-style="western"><surname>Rentz</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Orlovsky</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Mormino</surname><given-names>EC</given-names></string-name>. <article-title>Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5</article-title>. <source>Alzheimer's Dement: Transl Res Clin Interv</source>. <year>2017</year>;<volume>3</volume>(<issue>4</issue>):<fpage>668</fpage>&#8208;<lpage>677</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2017.10.004</pub-id><pub-id pub-id-type="pmcid">PMC5726754</pub-id><pub-id pub-id-type="pmid">29264389</pub-id></mixed-citation></ref><ref id="alz70704-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70704-cite-0024"><string-name name-style="western"><surname>Kueper</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Speechley</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Montero&#8208;Odasso</surname><given-names>M</given-names></string-name>. <article-title>The Alzheimer's Disease Assessment Scale&#8211;Cognitive Subscale (ADAS&#8208;Cog): modifications and responsiveness in&#160;pre&#8208;dementia populations. a narrative review</article-title>. <source>J Alzheimer's Dis</source>. <year>2018</year>;<volume>63</volume>(<issue>2</issue>):<fpage>423</fpage>&#8208;<lpage>444</lpage>.<pub-id pub-id-type="pmid">29660938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170991</pub-id><pub-id pub-id-type="pmcid">PMC5929311</pub-id></mixed-citation></ref><ref id="alz70704-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70704-cite-0025"><string-name name-style="western"><surname>Potashman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tahir</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Psychometric properties of the Alzheimer's Disease Cooperative Study&#8212;Activities of Daily Living for Mild Cognitive Impairment (ADCS&#8208;MCI&#8208;ADL) scale: a post hoc analysis of the ADCS ADC&#8208;008 trial</article-title>. <source>BMC Geriatrics</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>124</fpage>.<pub-id pub-id-type="pmid">36879199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12877-022-03527-0</pub-id><pub-id pub-id-type="pmcid">PMC9990271</pub-id></mixed-citation></ref><ref id="alz70704-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70704-cite-0026"><string-name name-style="western"><surname>Feng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Beer</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>Q</given-names></string-name>, et&#160;al. <article-title>NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing</article-title>. <source>Nat Commun</source>. <year>2023</year>;<volume>14</volume>(<issue>1</issue>):<fpage>7238</fpage>.<pub-id pub-id-type="pmid">37945559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-42834-x</pub-id><pub-id pub-id-type="pmcid">PMC10636041</pub-id></mixed-citation></ref><ref id="alz70704-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70704-cite-0027"><string-name name-style="western"><surname>Coffin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Suerken</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Bateman</surname><given-names>JR</given-names></string-name>, et&#160;al. <article-title>Vascular and microstructural markers of cognitive pathology</article-title>. <source>Alzheimer's Dement: Diagn Assessm Dis Monit</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<elocation-id>e12332</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12332</pub-id><pub-id pub-id-type="pmcid">PMC9257520</pub-id><pub-id pub-id-type="pmid">35814618</pub-id></mixed-citation></ref><ref id="alz70704-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70704-cite-0028"><string-name name-style="western"><surname>Jung</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>TT</given-names></string-name>. <article-title>Multiphase pseudocontinuous arterial spin labeling (MP&#8208;PCASL) for robust quantification of cerebral blood flow</article-title>. <source>Magn Reson Med</source>. <year>2010</year>;<volume>64</volume>(<issue>3</issue>):<fpage>799</fpage>&#8208;<lpage>810</lpage>.<pub-id pub-id-type="pmid">20578056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.22465</pub-id></mixed-citation></ref><ref id="alz70704-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70704-cite-0029"><string-name name-style="western"><surname>Hughes</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Lockhart</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Suerken</surname><given-names>CK</given-names></string-name>, et&#160;al. <article-title>Hypertensive aspects of cardiometabolic disorders are associated with lower brain microstructure, perfusion, and cognition</article-title>. <source>J Alzheimers Dis</source>. <year>2022</year>;<volume>90</volume>(<issue>4</issue>):<fpage>1589</fpage>&#8208;<lpage>1599</lpage>.<pub-id pub-id-type="pmid">36314205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220646</pub-id><pub-id pub-id-type="pmcid">PMC9764872</pub-id></mixed-citation></ref><ref id="alz70704-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70704-cite-0030"><string-name name-style="western"><surname>Oishi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Faria</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Atlas&#8208;based whole brain white matter analysis using large deformation diffeomorphic metric mapping: application to normal elderly and Alzheimer's disease participants</article-title>. <source>Neuroimage</source>. <year>2009</year>;<volume>46</volume>(<issue>2</issue>):<fpage>486</fpage>&#8208;<lpage>499</lpage>.<pub-id pub-id-type="pmid">19385016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2009.01.002</pub-id><pub-id pub-id-type="pmcid">PMC2885858</pub-id></mixed-citation></ref><ref id="alz70704-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70704-cite-0031"><string-name name-style="western"><surname>Huang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Staniak</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Veiga Leprevost</surname><given-names>FD</given-names></string-name>, et&#160;al. <article-title>Statistical detection of differentially abundant proteins in experiments with repeated measures designs and isobaric labeling</article-title>. <source>J Proteome Res</source>. <year>2023</year>;<volume>22</volume>(<issue>8</issue>):<fpage>2641</fpage>&#8208;<lpage>2659</lpage>.<pub-id pub-id-type="pmid">37467362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jproteome.3c00155</pub-id><pub-id pub-id-type="pmcid">PMC11090052</pub-id></mixed-citation></ref><ref id="alz70704-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70704-cite-0032"><string-name name-style="western"><surname>Kinduryte Schorling</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zwiener</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kaspers</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Iliev</surname><given-names>H</given-names></string-name>. <article-title>Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus</article-title>. <source>Adv Ther</source>. <year>2020</year>;<volume>37</volume>(<issue>8</issue>):<fpage>3463</fpage>&#8208;<lpage>3484</lpage>.<pub-id pub-id-type="pmid">32372290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-020-01329-7</pub-id><pub-id pub-id-type="pmcid">PMC7370973</pub-id></mixed-citation></ref><ref id="alz70704-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70704-cite-0033"><string-name name-style="western"><surname>Lopaschuk</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>S</given-names></string-name>. <article-title>Mechanisms of cardiovascular benefits of sodium glucose co&#8208;transporter 2 (SGLT2) inhibitors</article-title>. <source>JACC: Basic Translat Sci</source>. <year>2020</year>;<volume>5</volume>(<issue>6</issue>):<fpage>632</fpage>&#8208;<lpage>644</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacbts.2020.02.004</pub-id><pub-id pub-id-type="pmcid">PMC7315190</pub-id><pub-id pub-id-type="pmid">32613148</pub-id></mixed-citation></ref><ref id="alz70704-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70704-cite-0034"><string-name name-style="western"><surname>Verma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McMurray</surname><given-names>JJV</given-names></string-name>. <article-title>SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state&#8208;of&#8208;the&#8208;art review</article-title>. <source>Diabetologia</source>. <year>2018</year>;<volume>61</volume>(<issue>10</issue>):<fpage>2108</fpage>&#8208;<lpage>2117</lpage>.<pub-id pub-id-type="pmid">30132036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-018-4670-7</pub-id></mixed-citation></ref><ref id="alz70704-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70704-cite-0035"><string-name name-style="western"><surname>Garvey</surname><given-names>WT</given-names></string-name>, <string-name name-style="western"><surname>Van Gaal</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leiter</surname><given-names>LA</given-names></string-name>, et&#160;al. <article-title>Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes</article-title>. <source>Metabolism</source>. <year>2018</year>;<volume>85</volume>:<fpage>32</fpage>&#8208;<lpage>37</lpage>.<pub-id pub-id-type="pmid">29452178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2018.02.002</pub-id></mixed-citation></ref><ref id="alz70704-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70704-cite-0036"><string-name name-style="western"><surname>Yamazaki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Harada</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tokuyama</surname><given-names>S</given-names></string-name>. <article-title>Sodium&#8211;glucose transporter as a novel therapeutic target in disease</article-title>. <source>Eur J Pharmacol</source>. <year>2018</year>;<volume>822</volume>:<fpage>25</fpage>&#8208;<lpage>31</lpage>.<pub-id pub-id-type="pmid">29329760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2018.01.003</pub-id></mixed-citation></ref><ref id="alz70704-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70704-cite-0037"><string-name name-style="western"><surname>Wici&#324;ski</surname><given-names>M</given-names></string-name>. <article-title>Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: focus on Alzheimer's disease and ischemia&#8208;related brain injury</article-title>. <source>Pharmaceuticals (Basel)</source>. <year>2020</year>;<volume>13</volume>(<issue>11</issue>):<fpage>379</fpage>.<pub-id pub-id-type="pmid">33187206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph13110379</pub-id><pub-id pub-id-type="pmcid">PMC7697611</pub-id></mixed-citation></ref><ref id="alz70704-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70704-cite-0038"><string-name name-style="western"><surname>Oerter</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>F&#246;rster</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bohnert</surname><given-names>M</given-names></string-name>. <article-title>Validation of sodium/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation</article-title>. <source>Int J Legal Med</source>. <year>2019</year>;<volume>133</volume>(<issue>4</issue>):<fpage>1107</fpage>&#8208;<lpage>1114</lpage>.<pub-id pub-id-type="pmid">30073510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00414-018-1893-6</pub-id></mixed-citation></ref><ref id="alz70704-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70704-cite-0039"><string-name name-style="western"><surname>Esterline</surname><given-names>R</given-names>,</string-name> , <string-name name-style="western"><surname>Oscarsson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>J</given-names></string-name>. <article-title>A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?</article-title>. <source>Int Rev Neurobiol</source>. <year>2020</year>;<volume>155</volume>:<fpage>113</fpage>&#8208;<lpage>140</lpage>.<pub-id pub-id-type="pmid">32854852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.irn.2020.03.018</pub-id></mixed-citation></ref><ref id="alz70704-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70704-cite-0040"><string-name name-style="western"><surname>Sa&#8208;Nguanmoo</surname><given-names>P</given-names></string-name>. <article-title>SGLT2&#8208;inhibitor and DPP&#8208;4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD&#8208;induced obese rats</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2017</year>;<volume>333</volume>:<fpage>43</fpage>&#8208;<lpage>50</lpage>.<pub-id pub-id-type="pmid">28807765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.taap.2017.08.005</pub-id></mixed-citation></ref><ref id="alz70704-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70704-cite-0041"><string-name name-style="western"><surname>Kullmann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hummel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Empagliflozin improves insulin sensitivity of the hypothalamus in humans With prediabetes: a randomized, double&#8208;blind, placebo&#8208;controlled, phase 2 trial</article-title>. <source>Diabetes Care</source>. <year>2021</year>;<volume>45</volume>(<issue>2</issue>):<fpage>398</fpage>&#8208;<lpage>406</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc21-1136</pub-id><pub-id pub-id-type="pmcid">PMC8914418</pub-id><pub-id pub-id-type="pmid">34716213</pub-id></mixed-citation></ref><ref id="alz70704-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70704-cite-0078"><string-name name-style="western"><surname>Burns</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Vidoni</surname><given-names>ED</given-names></string-name>, et&#160;al. <article-title>Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>6</issue>):<elocation-id>e70416</elocation-id>.<pub-id pub-id-type="pmid">40566796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70416</pub-id><pub-id pub-id-type="pmcid">PMC12198475</pub-id></mixed-citation></ref><ref id="alz70704-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70704-cite-0042"><string-name name-style="western"><surname>Schmid</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kullmann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gfr&#246;rer</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Safety of intranasal human insulin: a review</article-title>. <source>Diabetes, Obesity and Metabolism</source>. <year>2018</year>;<volume>20</volume>(<issue>7</issue>):<fpage>1563</fpage>&#8208;<lpage>1577</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13279</pub-id><pub-id pub-id-type="pmid">29508509</pub-id></mixed-citation></ref><ref id="alz70704-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70704-cite-0043"><string-name name-style="western"><surname>Reger</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Green</surname><given-names>PS</given-names></string-name>, et&#160;al. <article-title>Intranasal insulin administration dose&#8208;dependently modulates verbal memory and plasma amyloid&#8208;&#946; in memory&#8208;impaired older adults</article-title>. <source>J Alzheimers Dis</source>. <year>2008</year>;<volume>13</volume>(<issue>3</issue>):<fpage>323</fpage>&#8208;<lpage>331</lpage>.<pub-id pub-id-type="pmid">18430999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/jad-2008-13309</pub-id><pub-id pub-id-type="pmcid">PMC2804944</pub-id></mixed-citation></ref><ref id="alz70704-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70704-cite-0044"><string-name name-style="western"><surname>Bonnet</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Scheen</surname><given-names>AJ</given-names></string-name>. <article-title>Effects of SGLT2 inhibitors on systemic and tissue low&#8208;grade inflammation: the potential contribution to diabetes complications and cardiovascular disease</article-title>. <source>Diabetes Metab</source>. <year>2018</year>;<volume>44</volume>(<issue>6</issue>):<fpage>457</fpage>&#8208;<lpage>464</lpage>.<pub-id pub-id-type="pmid">30266577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabet.2018.09.005</pub-id></mixed-citation></ref><ref id="alz70704-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70704-cite-0045"><string-name name-style="western"><surname>Pang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L&#8208;L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>F&#8208;X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z&#8208;D</given-names></string-name>. <article-title>The sodium glucose co&#8208;transporter 2 inhibitor ertugliflozin for Alzheimer's disease: inhibition of brain insulin signaling disruption&#8208;induced tau hyperphosphorylation</article-title>. <source>Physiol Behav</source>. <year>2023</year>;<volume>263</volume>:<elocation-id>114134</elocation-id>.<pub-id pub-id-type="pmid">36809844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.physbeh.2023.114134</pub-id></mixed-citation></ref><ref id="alz70704-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70704-cite-0046"><string-name name-style="western"><surname>Ramakrishan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rajangam</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mahinoor</surname><given-names>SS</given-names></string-name>, et&#160;al. <article-title>Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer's disease in type 2 diabetes</article-title>. <source>Metab Brain Dis</source>. <year>2025</year>;<volume>40</volume>(<issue>3</issue>):<fpage>132</fpage>.<pub-id pub-id-type="pmid">40009301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-025-01555-4</pub-id></mixed-citation></ref><ref id="alz70704-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70704-cite-0047"><string-name name-style="western"><surname>Elahi</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Casaletto</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>La Joie</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Plasma biomarkers of astrocytic and neuronal dysfunction in early&#8208; and late&#8208;onset Alzheimer's disease</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2020</year>;<volume>16</volume>(<issue>4</issue>):<fpage>681</fpage>&#8208;<lpage>695</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.09.004</pub-id><pub-id pub-id-type="pmcid">PMC7138729</pub-id><pub-id pub-id-type="pmid">31879236</pub-id></mixed-citation></ref><ref id="alz70704-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70704-cite-0048"><string-name name-style="western"><surname>Pontecorvo</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Burnham</surname><given-names>SC</given-names></string-name>, et&#160;al. <article-title>Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>12</issue>):<fpage>1250</fpage>.<pub-id pub-id-type="pmid">36251300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2022.3392</pub-id><pub-id pub-id-type="pmcid">PMC9577883</pub-id></mixed-citation></ref><ref id="alz70704-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70704-cite-0049"><string-name name-style="western"><surname>Ferrer</surname><given-names>I</given-names></string-name>. <article-title>Diversity of astroglial responses across human neurodegenerative disorders and brain aging</article-title>. <source>Brain Pathol</source>. <year>2017</year>;<volume>27</volume>(<issue>5</issue>):<fpage>645</fpage>&#8208;<lpage>674</lpage>.<pub-id pub-id-type="pmid">28804999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.12538</pub-id><pub-id pub-id-type="pmcid">PMC8029391</pub-id></mixed-citation></ref><ref id="alz70704-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70704-cite-0050"><string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lazdon</surname><given-names>EK</given-names></string-name>, et&#160;al. <article-title>Loss of insulin signaling in astrocytes exacerbates Alzheimer&#8208;like phenotypes in a 5xFAD mouse model</article-title>. <source>Proc Natl Acad Sci</source>. <year>2023</year>;<volume>120</volume>(<issue>21</issue>):<elocation-id>e2220684120</elocation-id>.<pub-id pub-id-type="pmid">37186836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2220684120</pub-id><pub-id pub-id-type="pmcid">PMC10214134</pub-id></mixed-citation></ref><ref id="alz70704-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70704-cite-0051"><string-name name-style="western"><surname>Simpson</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Ince</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>PJ</given-names></string-name>, et&#160;al. <article-title>Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer's pathology and APOE genotype</article-title>. <source>Neurobiol Aging</source>. <year>2011</year>;<volume>32</volume>(<issue>10</issue>):<fpage>1795</fpage>&#8208;<lpage>1807</lpage>.<pub-id pub-id-type="pmid">21705112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2011.04.013</pub-id></mixed-citation></ref><ref id="alz70704-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70704-cite-0052"><string-name name-style="western"><surname>Galimberti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Venturelli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fenoglio</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Intrathecal levels of IL&#8208;6, IL&#8208;11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration</article-title>. <source>J Neurol</source>. <year>2008</year>;<volume>255</volume>(<issue>4</issue>):<fpage>539</fpage>&#8208;<lpage>544</lpage>.<pub-id pub-id-type="pmid">18204920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-008-0737-6</pub-id></mixed-citation></ref><ref id="alz70704-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70704-cite-0053"><string-name name-style="western"><surname>Alves</surname><given-names>S</given-names></string-name>. <article-title>Interleukin&#8208;2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice</article-title>. <source>Brain</source>. <year>2017</year>;<volume>140</volume>(<issue>3</issue>):<fpage>826</fpage>&#8208;<lpage>842</lpage>.<pub-id pub-id-type="pmid">28003243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww330</pub-id></mixed-citation></ref><ref id="alz70704-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70704-cite-0054"><string-name name-style="western"><surname>Zeng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lafferty</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Sehrawat</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Multi&#8208;analyte&#160;proteomic analysis identifies blood&#8208;based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease</article-title>. <source>Molecular Neurodegen</source>. <year>2024</year>;<volume>19</volume>(<issue>1</issue>):<fpage>68</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-024-00753-5</pub-id><pub-id pub-id-type="pmcid">PMC11465638</pub-id><pub-id pub-id-type="pmid">39385222</pub-id></mixed-citation></ref><ref id="alz70704-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz70704-cite-0055"><string-name name-style="western"><surname>Rosenzweig</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dvir&#8208;Szternfeld</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tsitsou&#8208;Kampeli</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>PD&#8208;1/PD&#8208;L1 checkpoint blockade harnesses monocyte&#8208;derived macrophages to combat cognitive impairment in a tauopathy mouse model</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>465</fpage>.<pub-id pub-id-type="pmid">30692527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-08352-5</pub-id><pub-id pub-id-type="pmcid">PMC6349941</pub-id></mixed-citation></ref><ref id="alz70704-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz70704-cite-0056"><string-name name-style="western"><surname>Chae</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>S&#8208;J</given-names></string-name>. <article-title>The nasal lymphatic route of CSF outflow: implications for neurodegenerative disease diagnosis and monitoring</article-title>. <source>Animal Cells and Systems</source>. <year>2024</year>;<volume>28</volume>(<issue>1</issue>):<fpage>45</fpage>&#8208;<lpage>54</lpage>.<pub-id pub-id-type="pmid">38292931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19768354.2024.2307559</pub-id><pub-id pub-id-type="pmcid">PMC10826790</pub-id></mixed-citation></ref><ref id="alz70704-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz70704-cite-0057"><string-name name-style="western"><surname>Pawelec</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ziemka&#8208;Nalecz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sypecka</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zalewska</surname><given-names>T</given-names></string-name>. <article-title>The impact of the CX3CL1/CX3CR1 axis in neurological disorders</article-title>. <source>Cells</source>. <year>2020</year>;<volume>9</volume>(<issue>10</issue>):<fpage>2277</fpage>.<pub-id pub-id-type="pmid">33065974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9102277</pub-id><pub-id pub-id-type="pmcid">PMC7600611</pub-id></mixed-citation></ref><ref id="alz70704-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz70704-cite-0058"><string-name name-style="western"><surname>Zhai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>J</given-names></string-name>. <article-title>The fibroblast growth factor system in cognitive disorders and dementia</article-title>. <source>Front Neurosci</source>. <year>2023</year>;<volume>17</volume>:<elocation-id>1136266</elocation-id>.<pub-id pub-id-type="pmid">37214403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1136266</pub-id><pub-id pub-id-type="pmcid">PMC10196031</pub-id></mixed-citation></ref><ref id="alz70704-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz70704-cite-0059"><string-name name-style="western"><surname>Park</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>S&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Jo</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Altered TIMP&#8208;3 levels in the cerebrospinal fluid and plasma of patients with Alzheimer's disease</article-title>. <source>J PersonalizeMed</source>. <year>2022</year>;<volume>12</volume>(<issue>5</issue>):<fpage>827</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm12050827</pub-id><pub-id pub-id-type="pmcid">PMC9144624</pub-id><pub-id pub-id-type="pmid">35629249</pub-id></mixed-citation></ref><ref id="alz70704-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="alz70704-cite-0060"><string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>c&#8208;Mpl and TPO expression in the human central nervous system neurons inhibits neuronal apoptosis</article-title>. <source>Aging</source>. <year>2020</year>;<volume>12</volume>(<issue>8</issue>):<fpage>7397</fpage>&#8208;<lpage>7410</lpage>.<pub-id pub-id-type="pmid">32341206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103086</pub-id><pub-id pub-id-type="pmcid">PMC7202501</pub-id></mixed-citation></ref><ref id="alz70704-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz70704-cite-0061"><string-name name-style="western"><surname>Ehrenreich</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hasselblatt</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Knerlich</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain</article-title>. <source>Proc Natl Acad Sci</source>. <year>2005</year>;<volume>102</volume>(<issue>3</issue>):<fpage>862</fpage>&#8208;<lpage>867</lpage>.<pub-id pub-id-type="pmid">15642952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0406008102</pub-id><pub-id pub-id-type="pmcid">PMC545528</pub-id></mixed-citation></ref><ref id="alz70704-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="alz70704-cite-0062"><string-name name-style="western"><surname>Li</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Smyth</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Dragunow</surname><given-names>M</given-names></string-name>. <article-title>Platelet&#8208;derived growth factor signalling in neurovascular function and disease</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2022</year>;<volume>145</volume>:<elocation-id>106187</elocation-id>.<pub-id pub-id-type="pmid">35217189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2022.106187</pub-id></mixed-citation></ref><ref id="alz70704-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="alz70704-cite-0063"><string-name name-style="western"><surname>Portelius</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Skillb&#228;ck</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease</article-title>. <source>Brain</source>. <year>2015</year>;<volume>138</volume>(<issue>Pt 11</issue>):<fpage>3373</fpage>&#8208;<lpage>3385</lpage>.<pub-id pub-id-type="pmid">26373605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv267</pub-id><pub-id pub-id-type="pmcid">PMC4643642</pub-id></mixed-citation></ref><ref id="alz70704-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="alz70704-cite-0064"><string-name name-style="western"><surname>Miners</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Kehoe</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Love</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>. <article-title>CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood&#8208;brain barrier dysfunction and disease pathology</article-title>. <source>Alzheimer's Res Therap</source>. <year>2019</year>;<volume>11</volume>(<issue>1</issue>):<fpage>81</fpage>.<pub-id pub-id-type="pmid">31521199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-019-0534-8</pub-id><pub-id pub-id-type="pmcid">PMC6745071</pub-id></mixed-citation></ref><ref id="alz70704-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="alz70704-cite-0065"><string-name name-style="western"><surname>Montagne</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nation</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Sagare</surname><given-names>AP</given-names></string-name>, et&#160;al. <article-title>APOE4 leads to blood&#8211;brain barrier dysfunction predicting cognitive decline</article-title>. <source>Nature</source>. <year>2020</year>;<volume>581</volume>(<issue>7806</issue>):<fpage>71</fpage>&#8208;<lpage>76</lpage>.<pub-id pub-id-type="pmid">32376954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2247-3</pub-id><pub-id pub-id-type="pmcid">PMC7250000</pub-id></mixed-citation></ref><ref id="alz70704-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="alz70704-cite-0066"><string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>91</volume>(<issue>9</issue>):<fpage>e867</fpage>&#8208;<lpage>e877</lpage>.<pub-id pub-id-type="pmid">30054439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000006082</pub-id><pub-id pub-id-type="pmcid">PMC6133624</pub-id></mixed-citation></ref><ref id="alz70704-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="alz70704-cite-0067"><string-name name-style="western"><surname>Esteve</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rueda&#8208;Carrasco</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>In&#233;s Mateo</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Elevated levels of Secreted&#8208;Frizzled&#8208;Related&#8208;Protein 1 contribute to Alzheimer's disease pathogenesis</article-title>. <source>Nat Neurosci</source>. <year>2019</year>;<volume>22</volume>(<issue>8</issue>):<fpage>1258</fpage>&#8208;<lpage>1268</lpage>.<pub-id pub-id-type="pmid">31308530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-019-0432-1</pub-id></mixed-citation></ref><ref id="alz70704-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="alz70704-cite-0068"><string-name name-style="western"><surname>Saresella</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Calabrese</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Marventano</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Increased activity of Th&#8208;17 and Th&#8208;9 lymphocytes and a skewing of the post&#8208;thymic differentiation pathway are seen in Alzheimer's disease</article-title>. <source>Brain Behav Immun</source>. <year>2011</year>;<volume>25</volume>(<issue>3</issue>):<fpage>539</fpage>&#8208;<lpage>547</lpage>.<pub-id pub-id-type="pmid">21167930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2010.12.004</pub-id></mixed-citation></ref><ref id="alz70704-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="alz70704-cite-0069"><string-name name-style="western"><surname>Rangasamy</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Corbett</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Intranasal delivery of NEMO&#8208;binding domain peptide prevents memory loss in&#160;a&#160;mouse model of Alzheimer's disease</article-title>. <source>J Alzheimers Dis</source>. <year>2015</year>;<volume>47</volume>(<issue>2</issue>):<fpage>385</fpage>&#8208;<lpage>402</lpage>.<pub-id pub-id-type="pmid">26401561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150040</pub-id><pub-id pub-id-type="pmcid">PMC4582676</pub-id></mixed-citation></ref><ref id="alz70704-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="alz70704-cite-0070"><string-name name-style="western"><surname>Thomas</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Osuna</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Weigand</surname><given-names>AJ</given-names></string-name>, et&#160;al. <article-title>Regional hyperperfusion in older adults with objectively&#8208;defined subtle cognitive decline</article-title>. <source>J Cerebral Blood Flow &amp; Metabol</source>. <year>2021</year>;<volume>41</volume>(<issue>5</issue>):<fpage>1001</fpage>&#8208;<lpage>1012</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X20935171</pub-id><pub-id pub-id-type="pmcid">PMC8054731</pub-id><pub-id pub-id-type="pmid">32615887</pub-id></mixed-citation></ref><ref id="alz70704-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="alz70704-cite-0071"><string-name name-style="western"><surname>Hays</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Zlatar</surname><given-names>ZZ</given-names></string-name>, <string-name name-style="western"><surname>Wierenga</surname><given-names>CE</given-names></string-name>. <article-title>The utility of cerebral blood flow as a biomarker of preclinical Alzheimer's disease</article-title>. <source>Cell Mol Neurobiol</source>. <year>2016</year>;<volume>36</volume>(<issue>2</issue>):<fpage>167</fpage>&#8208;<lpage>179</lpage>.<pub-id pub-id-type="pmid">26898552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-015-0261-z</pub-id><pub-id pub-id-type="pmcid">PMC5278904</pub-id></mixed-citation></ref><ref id="alz70704-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="alz70704-cite-0072"><string-name name-style="western"><surname>Lapointe</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>DKB</given-names></string-name>, <string-name name-style="western"><surname>Traboulsee</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Rauscher</surname><given-names>A</given-names></string-name>. <article-title>What have we learned from perfusion MRI in multiple sclerosis?</article-title>. <source>Am J Neuroradiol</source>. <year>2018</year>;<volume>39</volume>(<issue>6</issue>):<fpage>994</fpage>&#8208;<lpage>1000</lpage>.<pub-id pub-id-type="pmid">29301779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A5504</pub-id><pub-id pub-id-type="pmcid">PMC7410640</pub-id></mixed-citation></ref><ref id="alz70704-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="alz70704-cite-0073"><string-name name-style="western"><surname>Mayo</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Mazerolle</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Ritchie</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fisk</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Gawryluk</surname><given-names>JR</given-names></string-name>. <article-title>Longitudinal changes in microstructural white matter metrics in Alzheimer's disease</article-title>. <source>NeuroImage: Clinical</source>. <year>2017</year>;<volume>13</volume>:<fpage>330</fpage>&#8208;<lpage>338</lpage>.<pub-id pub-id-type="pmid">28066707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2016.12.012</pub-id><pub-id pub-id-type="pmcid">PMC5200876</pub-id></mixed-citation></ref><ref id="alz70704-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="alz70704-cite-0074"><string-name name-style="western"><surname>Caranova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Soares</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Batista</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Castelo&#8208;Branco</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Duarte</surname><given-names>JV</given-names></string-name>. <article-title>A systematic review of microstructural abnormalities in multiple sclerosis detected with NODDI and DTI models of diffusion&#8208;weighted magnetic resonance imaging</article-title>. <source>Magn Reson Imaging</source>. <year>2023</year>;<volume>104</volume>:<fpage>61</fpage>&#8208;<lpage>71</lpage>.<pub-id pub-id-type="pmid">37775062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mri.2023.09.010</pub-id></mixed-citation></ref><ref id="alz70704-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="alz70704-cite-0075"><string-name name-style="western"><surname>Bettcher</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Olson</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Carlson</surname><given-names>NE</given-names></string-name>, et&#160;al. <article-title>Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>2021</year>;<volume>103</volume>:<fpage>68</fpage>&#8208;<lpage>77</lpage>.<pub-id pub-id-type="pmid">33845398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.02.012</pub-id><pub-id pub-id-type="pmcid">PMC8313091</pub-id></mixed-citation></ref><ref id="alz70704-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="alz70704-cite-0076"><string-name name-style="western"><surname>Fernandez</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Martinez&#8208;Rachadell</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Navarrete</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Insulin regulates neurovascular coupling through astrocytes</article-title>. <source>Proc Natl Acad Sci</source>. <year>2022</year>;<volume>119</volume>(<issue>29</issue>):<elocation-id>e2204527119</elocation-id>.<pub-id pub-id-type="pmid">35858325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2204527119</pub-id><pub-id pub-id-type="pmcid">PMC9304019</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">4759</journal-id><journal-id journal-id-type="pmc-domain">jpad</journal-id><journal-title-group><journal-title>The Journal of Prevention of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12501320</article-id><article-id pub-id-type="pmcid-ver">PMC12501320.1</article-id><article-id pub-id-type="pmcaid">12501320</article-id><article-id pub-id-type="pmcaiid">12501320</article-id><article-id pub-id-type="pmid">40716973</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100316</article-id><article-id pub-id-type="pii">S2274-5807(25)00259-6</article-id><article-id pub-id-type="publisher-id">100316</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Pregnancy hypertension is associated with higher p-tau217 in healthy midlife women</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name name-style="western"><surname>Yong</surname><given-names initials="EL">Eu-Leong</given-names></name><email>obgyel@nus.edu.sg</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref><xref rid="cor0001" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0002"><name name-style="western"><surname>Wong</surname><given-names initials="BWX">Beverly Wen Xin</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0003"><name name-style="western"><surname>Tan</surname><given-names initials="DYZ">Darren Yuen Zhang</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0004"><name name-style="western"><surname>Shen</surname><given-names initials="L">Liang</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Thia</surname><given-names initials="BWQ">Benecia Wan Qing</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0006"><name name-style="western"><surname>Chong</surname><given-names initials="JR">Joyce Ruifen</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0007"><name name-style="western"><surname>Chen</surname><given-names initials="CLH">Christopher Li-Hsian</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><aff id="aff0001"><label>a</label>Department of Obstetrics and Gynecology, Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower Block, 1E Kent Ridge Road, 119228, Singapore</aff><aff id="aff0002"><label>b</label>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, MD1, Tahir Foundation Building, 12 Science Drive 2 117549, Singapore</aff><aff id="aff0003"><label>c</label>Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower Block, 1E Kent Ridge Road 119228, Singapore</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#8270;</label>Corresponding author. <email>obgyel@nus.edu.sg</email></corresp><fn id="fn1"><label>1</label><p id="notep0001">Joint first authors.</p></fn></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>7</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498449</issue-id><elocation-id>100316</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>3</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="abs0001"><title>Highlights</title><p><list list-type="simple" id="celist0001"><list-item id="celistitem0001"><label>&#8226;</label><p id="para0002">Does pregnancy hypertension increase risk for Alzheimer's disease (AD) pathology?.</p></list-item><list-item id="celistitem0002"><label>&#8226;</label><p id="para0003">P-tau217 is a sensitive and specific biomarker of AD pathology.</p></list-item><list-item id="celistitem0003"><label>&#8226;</label><p id="para0004">Pregnancy hypertension was associated with higher serum p-tau217 decades later.</p></list-item><list-item id="celistitem0004"><label>&#8226;</label><p id="para0005">Hypertension in pregnancy is a risk factor for AD pathology.</p></list-item></list></p></abstract><abstract id="abs0002"><sec><title>Introduction</title><p>There is very limited knowledge on the relationship between pregnancy hypertension and the occurrence of pre-clinical Alzheimer's disease (AD).</p></sec><sec><title>Methods</title><p>Community-dwelling midlife women without dementia were enrolled from well-woman clinics of the National University Hospital, Singapore. Sociodemographic parameters and history of pregnancy hypertension were obtained. Cognition was assessed using the Montreal Cognitive Assessment-Basic tool. Fasted blood samples were stored for batched analysis of renal function, APOE genotyping and p-tau217 levels using Simoa&#174; ALZpath p-tau217 Advantage PLUS (Quanterix, MA, USA). General linear modelling was used to examine the association between pregnancy hypertension and p-tau217.</p></sec><sec><title>Results</title><p>Among 743 women (mean age 62.9 &#177; 6.0; range: 50.7 to 76.6 years) enrolled, 68 (9.2%) reported pregnancy hypertension. General linear modelling showed that an older age [mean difference: 0.002 (95% CI: 0.001, 0.003)], mild cognitive impairment [0.016 (0.001, 0.032)], lower BMI [0.068 (0.027, 0.109)], eGFR&lt;60 mL/min/1.73 m<sup>2</sup> [0.132 (0.072, 0.193)] and the <italic toggle="yes">APOE4</italic> carrier genotype [0.038 (0.018, 0.058)] were independently associated with higher serum p-tau217 levels. History of pregnancy hypertension remained significantly associated with subsequent higher serum p-tau217 [0.040 (0.013, 0.067)], after adjustment for age, mild cognitive impairment, hypertension, BMI, renal function, and <italic toggle="yes">APOE4</italic> genotype status<bold>.</bold></p></sec><sec><title>Discussion</title><p>Pregnancy hypertension was associated with AD pathology with mean differences similar to high risk APOE4 carrier genotypes. Information on pregnancy hypertension could help physicians to identify women who might benefit from early p-tau217 screening for Alzheimer&#8217;s disease, allowing for early clinical intervention.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Pregnancy hypertension</kwd><kwd>P-tau217</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>Midlife women</kwd><kwd>Longitudinal cohort</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0001"><label>1</label><title>Introduction</title><p id="para0010">Women have approximately twice the incidence of Alzheimer's disease compared to men, and most people living with dementia are women [<xref rid="bib0001" ref-type="bibr">1</xref>]. Although selective survival may account for a portion of sex differences in dementia incidence [<xref rid="bib0002" ref-type="bibr">2</xref>], simulations indicate that biological differences could contribute up to 20 % higher risk in women [<xref rid="bib0003" ref-type="bibr">3</xref>]. Although not unanimous [<xref rid="bib0004" ref-type="bibr">4</xref>], limited epidemiological evidence suggests a link between pregnancy hypertension and later development of Alzheimer&#8217;s disease, with a meta-analysis indicating a 40 % to 92 % higher risk among women with pregnancy hypertension, compared to those without [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0006" ref-type="bibr">6</xref>]. A population study from Utah indicated that pregnancy hypertension and its severe manifestation, pre-eclampsia, was associated with 3.44-fold excess risk for mortality from Alzheimer disease, greater than that observed for diabetes, ischemic heart disease, and stroke [<xref rid="bib0007" ref-type="bibr">7</xref>].</p><p id="para0011">Despite pregnancy hypertension and Alzheimer's disease having no common clinical features, striking parallels exist in their pathogenesis [<xref rid="bib0008" ref-type="bibr">8</xref>]. The urine of women with pre-eclampsia have been noted to contain amyloid-like aggregates, reminiscent of the protein conformational disorders noted in Alzheimer's and prion disease [<xref rid="bib0009" ref-type="bibr">9</xref>,<xref rid="bib0010" ref-type="bibr">10</xref>]. Defective clearance of aggregation of misfolded proteins, including the amyloid beta peptide (A&#946;), have been reported [<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0011" ref-type="bibr">11</xref>]. Cerebrospinal fluid levels of A&#946; peptides and tau protein concentrations were observed to be higher in women who developed severe pregnancy hypertension [<xref rid="bib0012" ref-type="bibr">12</xref>,<xref rid="bib0013" ref-type="bibr">13</xref>]. The pre-eclampsia susceptibility gene STOX1 is abundantly expressed in the brain and is involved in A&#946; protein precursor processing and Alzheimer&#8217;s disease, suggesting a conserved pathway for protein processing shared between the placenta and the brain [<xref rid="bib0014" ref-type="bibr">14</xref>].</p><p id="para0012">In recent years, elevated blood-based phosphorylated-tau217 (p-tau217) has been shown to reflect abnormal amyloid and tau positron emission tomography burden [<xref rid="bib0015" ref-type="bibr">15</xref>,<xref rid="bib0016" ref-type="bibr">16</xref>]. P-tau217 correlated with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorated murine tauopathy [<xref rid="bib0017" ref-type="bibr">17</xref>]. The cost-effective and accessible blood-based biomarker, p-tau217, correlated with post-mortem Alzheimer's disease pathology, differentiated Alzheimer's disease from other types of dementia, and predicted future progression from normal cognition and mild cognitive impairment (MCI) to Alzheimer's disease [<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0019" ref-type="bibr">19</xref>]. There is only a very limited knowledge on the relationship between pregnancy hypertension and the occurrence of AD pathology decades later in midlife. We postulate that women with a history of pregnancy hypertension would have higher serum p-tau217 levels and increased risk for Alzheimer&#8217;s Disease.</p><p id="para0013">In this study, we measured serum p-tau217 to examine the relationship between pregnancy hypertension and subsequent development of AD pathology in community dwelling midlife women without dementia.</p></sec><sec id="sec0002"><label>2</label><title>Methods</title><sec id="sec0003"><label>2.1</label><title>Study setting and population</title><p id="para0014">Between February 2021 and June 2024, women from the Integrated Women&#8217;s Health Program were contacted via phone calls, emails, and text messages to attend a follow-up visit 6.8 years after their baseline visit in 2014 to 2016 [<xref rid="bib0020" ref-type="bibr">20</xref>]. Eligibility criteria at baseline included an age range of 45 to 69 years, being of Chinese, Malay and Indian ethnicities, and having no diagnosis of life-threatening or terminal illnesses. Participants were recruited from four well-women clinics at the National University Hospital (NUH), Singapore. This study utilized cross-sectional data from the 2021 to 2024 follow-up visit and was approved by the Domain Specific Review Board of the National Healthcare Group, Singapore (Reference number: 2020/00,201). All participants provided written informed consent.</p></sec><sec id="sec0004"><label>2.2</label><title>Outcome: serum p-tau217</title><p id="para0015">Blood (30 ml) was drawn following an overnight fast at the study visit and processed within 6 h of collection. The blood was first left at room temperature to clot for 30 min to an hour. Next, the tubes were centrifuged at 3000x<italic toggle="yes">g</italic> in 4 &#176;C, before the serum was aliquoted and stored at &#8722;80 &#176;C for analyses.</p><p id="para0016">Serum p-tau217 was analyzed using the Simoa&#174; ALZpath p-tau217 Advantage PLUS (Quanterix, MA, USA). This digital immunoassay for the quantitative determination of p-tau217 has been validated as a serum biomarker of AD comparable with CSF biomarkers and correlating highly with PET imaging [<xref rid="bib0016" ref-type="bibr">16</xref>], and is one of two commercially available p-tau217 assays found to have similarly high diagnostic performance [<xref rid="bib0021" ref-type="bibr">21</xref>]. The assay was performed by analysts from the Agency for Science, Technology and Research, Singapore Immunology Network Multiplex Analysis of Proteins platform, who were blinded to clinical backgrounds of the samples. Median centric normalization was used to normalize each plate to a common median to reduce plate to plate variations. The functional lower limit of p-tau217 quantification was 0.00978 pg/mL. All samples were within the limit of quantification range, although 6 samples were excluded due to sample matrix issues preventing data collection. The intra- and inter-assay coefficients of variation were 0.12&#8211;6.85 % and 8.65 % for p-tau 217.</p></sec><sec id="sec0005"><label>2.3</label><title>Exposure: hypertension during pregnancy</title><p id="para0017">Pregnancy hypertension was self-reported using the question: &#8220;Did you develop high blood pressure during your pregnancy?&#8221; Participants who answered <italic toggle="yes">yes</italic> were considered to have the condition. Participants who reported pregnancy hypertension were subsequently re-contacted by phone to obtain additional data including dates of each pregnancy, number of pregnancies with hypertension, and hospital admissions. Latency period between pregnancy hypertension and p-tau217 testing was calculated by subtracting age at first hypertensive pregnancy from age at follow-up.</p></sec><sec id="sec0006"><label>2.4</label><title>Covariates</title><p id="para0018">Demographic characteristics, including age, ethnicity (Chinese, Malay, Indian), and highest education attainment (no formal or primary, secondary or post-secondary, university) were self-reported via a questionnaire. Reproductive information such as gestational diabetes (yes, no), breastfeeding status (yes, no), and parity (nulliparous, parous) were also self-reported.</p><p id="para0019">MCI was ascertained using the 30-question Montreal Cognitive Assessment-Basic (MoCA-B), a tool with high sensitivity and specificity for detecting MCI in patients who are performing in the normal range on the widely used Mini-Mental State Examination [<xref rid="bib0022" ref-type="bibr">22</xref>]. The assessment was administered by trained and certified study coordinators. MOCA-B evaluated six cognitive domains, including executive functioning, memory, orientation, language, attention and visual perception with a maximum (best) score of 30. A cut-off score of &#8804;25 gave high sensitivity (86 %) and specificity (86 %) in detecting individuals with MCI [<xref rid="bib0022" ref-type="bibr">22</xref>].</p><p id="para0020">Blood pressure was measured thrice using the OMRON IntelliSense (HEM-7211), in a seated position, with one-minute intervals between each measurement. Participants were instructed to bring all medications and supplements consumed in the past two weeks to the study visit, and study coordinators recorded their dosage and frequency [<xref rid="bib0020" ref-type="bibr">20</xref>]. Hypertension was defined as having an average systolic blood pressure &#8805;140 mmHg and/or diastolic blood pressure &#8805;90 mmHg, use of anti-hypertensive medication, or a self-reported physician diagnosis. Height and weight were measured once, and twice, respectively using the SECA 769 Electronic Measuring Station, with footwear removed and pockets emptied. Body mass index (BMI) was calculated as weight divided by average height squared and categorized into underweight (&lt;18.5 kg/m<sup>2</sup>), healthy weight (18.5&#8211;22.9 kg/m<sup>2</sup>), overweight (23.0&#8211;27.49 kg/m<sup>2</sup>), and obese (&#8805;27.5 kg/m<sup>2</sup>) according to Asian standards [<xref rid="bib0023" ref-type="bibr">23</xref>].</p><p id="para0021">Serum creatinine was quantified using the Alinity C Creatinine (Enzymatic) Reagent kit (Abbott Laboratories, USA) at NUH&#8217;s Referral Laboratory, accredited by the Joint Commission International. Renal function was assessed using the estimated glomerular filtration rate (eGFR), which was calculated using the CKD-EPI 2021 equation [<xref rid="bib0024" ref-type="bibr">24</xref>]. Values were categorized into &#8805;90 mL/min/1.73 m<sup>2</sup>, 60&#8211;89 mL/min/1.73 m<sup>2</sup>, and &lt;60 mL/min/1.73 m<sup>2</sup>, in accordance with clinical practice guidelines [<xref rid="bib0025" ref-type="bibr">25</xref>,<xref rid="bib0026" ref-type="bibr">26</xref>]. No participant had readings &lt;15 mL/min/1.73 m<sup>2</sup>. Genetic testing was conducted to phenotype apolipoprotein &#603;2 (<italic toggle="yes">APOE2</italic>), &#603;3 (<italic toggle="yes">APOE3</italic>), and &#603;4 alleles (<italic toggle="yes">APOE4</italic>), as previously described [<xref rid="bib0027" ref-type="bibr">27</xref>]. To examine the contribution of &#603;4 alleles on p-tau217 levels, participants with one or two &#603;4 alleles were grouped together.</p></sec><sec id="sec0007"><label>2.5</label><title>Statistical analysis</title><p id="para0022">Descriptive statistics were used to examine the relationship between characteristics and pregnancy hypertension using the independent samples <italic toggle="yes">t</italic>-test or Pearson&#8217;s chi-square test. Univariate associations between participant characteristics and serum p-tau217 levels were evaluated using general linear modelling for continuous variables (such as age) or the independent samples <italic toggle="yes">t</italic>-test or one-way analysis of variance (ANOVA) for categorical variables (such as pregnancy hypertension, ethnicity, or highest education attainment). The results were presented as mean difference and 95 % confidence intervals (CI) or mean and standard deviation (SD).</p><p id="para0023">General linear modelling was used to examine the association between pregnancy hypertension and p-tau217 levels. Variables known to be associated with Alzheimer's disease <italic toggle="yes">a-priori</italic> [<xref rid="bib0028" ref-type="bibr">[28]</xref>, <xref rid="bib0029" ref-type="bibr">[29]</xref>, <xref rid="bib0030" ref-type="bibr">[30]</xref>] or had a univariate result of <italic toggle="yes">p</italic> &lt; 0.10 in <xref rid="tbl0002" ref-type="table">Table 2</xref> were added as covariates into the same model. Covariates included age, MCI, hypertension, BMI, renal function, and <italic toggle="yes">APOE4</italic> genetic status. Time since pregnancy was not included as a covariate due to small numbers.</p><p id="para0024">All results were analyzed using IBM SPSS statistics software (version 29.0; IBM Corp., Armonk, NY) and GraphPad Prism (version 10.0; GraphPad software, Boston, MA). A two-sided p-value&lt;0.05 indicated statistical significance.</p></sec></sec><sec id="sec0008"><label>3</label><title>RESULTS</title><p id="para0025">Among 998 participants enrolled at the 6.8-year follow-up visit, 255 with missing p-tau217 (<italic toggle="yes">n</italic> = 108) and/or pregnancy hypertension data (<italic toggle="yes">n</italic> = 147) were excluded, resulting in an analytical sample of 743 (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>). The mean age of study participants was 62.9 &#177; 6.0 years (range: 50.7 to 76.6 years). The majority were of Chinese ethnicity (82.3 %) and had at least secondary education (87.7 %) (<xref rid="tbl0001" ref-type="table">Table 1</xref>). 58.5 % were overweight or obese, 48.0 % had hypertensive disease at midlife, 42.3 % had MCI (MOCA scores &#8804;25), 22.0 % had reduced renal function (eGFR &lt;90 mL/min/1.73 m<sup>2</sup>) and 16.7 % were carriers of the high risk <italic toggle="yes">APOE4</italic> genotype.<fig id="fig0001" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Participant flow chart.</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0001" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Participant characteristics by pregnancy hypertension status (<italic toggle="yes">n</italic> = 743).</p></caption><alt-text id="alt0004">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1">Characteristics<hr/></th><th valign="top" colspan="1" rowspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">Pregnancy hypertension<hr/></th><th valign="top" colspan="1" rowspan="1"/></tr><tr><th valign="top" colspan="1" rowspan="1">N ( %)</th><th valign="top" colspan="1" rowspan="1">Yes (<italic toggle="yes">n</italic> = 68, 9.2 %)</th><th valign="top" colspan="1" rowspan="1">No (<italic toggle="yes">n</italic> = 675, 90.8 %)</th><th valign="top" colspan="1" rowspan="1">P-value</th></tr><tr><th valign="top" colspan="1" rowspan="1"/><th colspan="4" align="left" valign="top" rowspan="1">Mean &#177; SD or n ( %)</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Age, years</td><td valign="top" colspan="1" rowspan="1">743 (100.0)</td><td valign="top" colspan="1" rowspan="1">62.6 &#177; 5.9</td><td valign="top" colspan="1" rowspan="1">62.9 &#177; 6.0</td><td valign="top" colspan="1" rowspan="1">0.668</td></tr><tr><td valign="top" colspan="1" rowspan="1">Ethnicity</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.092</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Chinese</td><td valign="top" colspan="1" rowspan="1">591 (82.3)</td><td valign="top" colspan="1" rowspan="1">48 (8.1)</td><td valign="top" colspan="1" rowspan="1">543 (91.9)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Malay</td><td valign="top" colspan="1" rowspan="1">47 (6.5)</td><td valign="top" colspan="1" rowspan="1">6 (12.8)</td><td valign="top" colspan="1" rowspan="1">41 (87.2)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Indian</td><td valign="top" colspan="1" rowspan="1">80 (11.1)</td><td valign="top" colspan="1" rowspan="1">12 (15.0)</td><td valign="top" colspan="1" rowspan="1">68 (85.0)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Highest education attainment</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.117</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No formal or primary</td><td valign="top" colspan="1" rowspan="1">90 (12.3)</td><td valign="top" colspan="1" rowspan="1">4 (4.4)</td><td valign="top" colspan="1" rowspan="1">86 (95.6)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Secondary or post-secondary</td><td valign="top" colspan="1" rowspan="1">501 (68.5)</td><td valign="top" colspan="1" rowspan="1">53 (10.6)</td><td valign="top" colspan="1" rowspan="1">448 (89.4)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;University</td><td valign="top" colspan="1" rowspan="1">140 (19.2)</td><td valign="top" colspan="1" rowspan="1">10 (7.1)</td><td valign="top" colspan="1" rowspan="1">130 (92.9)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Gestational diabetes</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">93 (12.7)</td><td valign="top" colspan="1" rowspan="1">18 (19.4)</td><td valign="top" colspan="1" rowspan="1">75 (80.6)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">641 (87.3)</td><td valign="top" colspan="1" rowspan="1">48 (7.5)</td><td valign="top" colspan="1" rowspan="1">593 (92.5)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Breastfed</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.284</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">517 (71.3)</td><td valign="top" colspan="1" rowspan="1">44 (8.5)</td><td valign="top" colspan="1" rowspan="1">473 (91.5)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">208 (28.7)</td><td valign="top" colspan="1" rowspan="1">23 (11.1)</td><td valign="top" colspan="1" rowspan="1">185 (88.9)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Parity</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.684</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Nulliparous</td><td valign="top" colspan="1" rowspan="1">16 (2.2)</td><td valign="top" colspan="1" rowspan="1">1 (6.3)</td><td valign="top" colspan="1" rowspan="1">15 (93.8)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Parous</td><td valign="top" colspan="1" rowspan="1">727 (97.8)</td><td valign="top" colspan="1" rowspan="1">67 (9.2)</td><td valign="top" colspan="1" rowspan="1">660 (90.8)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Mild cognitive impairment</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.175</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">314 (42.3)</td><td valign="top" colspan="1" rowspan="1">34 (10.8)</td><td valign="top" colspan="1" rowspan="1">280 (89.2)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">429 (57.7)</td><td valign="top" colspan="1" rowspan="1">34 (7.9)</td><td valign="top" colspan="1" rowspan="1">395 (92.1)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Hypertension</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">355 (48.0)</td><td valign="top" colspan="1" rowspan="1">53 (14.9)</td><td valign="top" colspan="1" rowspan="1">302 (85.1)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">384 (52.0)</td><td valign="top" colspan="1" rowspan="1">14 (3.6)</td><td valign="top" colspan="1" rowspan="1">370 (96.4)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Body mass index, kg/m<sup>2</sup></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&lt;18.5</td><td valign="top" colspan="1" rowspan="1">27 (3.6)</td><td valign="top" colspan="1" rowspan="1">0 (0.0)</td><td valign="top" colspan="1" rowspan="1">27 (100.0)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;18.5&#8211;23.0</td><td valign="top" colspan="1" rowspan="1">281 (37.9)</td><td valign="top" colspan="1" rowspan="1">21 (7.5)</td><td valign="top" colspan="1" rowspan="1">260 (92.5)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&gt;23.0&#8211;27.4</td><td valign="top" colspan="1" rowspan="1">270 (36.4)</td><td valign="top" colspan="1" rowspan="1">15 (5.6)</td><td valign="top" colspan="1" rowspan="1">255 (94.4)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8805;27.5</td><td valign="top" colspan="1" rowspan="1">164 (22.1)</td><td valign="top" colspan="1" rowspan="1">32 (19.5)</td><td valign="top" colspan="1" rowspan="1">132 (80.5)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Renal function (eGFR)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.008</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&lt;60</td><td valign="top" colspan="1" rowspan="1">12 (1.6)</td><td valign="top" colspan="1" rowspan="1">4 (33.3)</td><td valign="top" colspan="1" rowspan="1">8 (66.7)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;60&#8211;89</td><td valign="top" colspan="1" rowspan="1">151 (20.4)</td><td valign="top" colspan="1" rowspan="1">10 (6.6)</td><td valign="top" colspan="1" rowspan="1">141 (93.4)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8805;90</td><td valign="top" colspan="1" rowspan="1">578 (78.0)</td><td valign="top" colspan="1" rowspan="1">54 (9.3)</td><td valign="top" colspan="1" rowspan="1">524 (90.7)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">APOE4</italic> genotype</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">0.638</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Carriers</td><td valign="top" colspan="1" rowspan="1">124 (16.7)</td><td valign="top" colspan="1" rowspan="1">10 (8.1)</td><td valign="top" colspan="1" rowspan="1">114 (91.9)</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Non-carriers</td><td valign="top" colspan="1" rowspan="1">617 (83.3)</td><td valign="top" colspan="1" rowspan="1">58 (9.4)</td><td valign="top" colspan="1" rowspan="1">559 (90.6)</td><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Results were analyzed using the independent samples <italic toggle="yes">t</italic>-test or Pearson&#8217;s chi-square test and presented as mean &#177; SD or frequencies and percentages, n ( %). Missing data accounted for 0.1 % to 3.4 % of the overall data.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec0009"><label>3.1</label><title>Characteristics of women by the exposure variable, pregnancy hypertension (<xref rid="tbl0001" ref-type="table">Table 1</xref>)</title><p id="para0026">Among 743 women, 68 (9.2 %) reported pregnancy hypertension. Women with a history of pregnancy hypertension were more likely to report gestational diabetes (<xref rid="tbl0001" ref-type="table">Table 1</xref>). In contrast, ethnicity, educational attainment, breastfeeding and parity were not associated with pregnancy hypertension. Some decades later in midlife, participants with a history of pregnancy hypertension were more likely to have higher body mass index, hypertensive disease and poorer renal function. Pregnancy hypertension was not associated with MCI or <italic toggle="yes">APOE4</italic> genotype.</p><p id="para0027">Women with pregnancy hypertension were recontacted and the characteristics of those pregnancy episodes were shown in <bold>Supplementary Table</bold>. Mean age at onset for pregnancy hypertension was 29.3 &#177; 5.6 years, and mean latency period between pregnancy and p-tau analysis was 32.1 &#177; 8.3 years. 28.2 % of pregnancy hypertension cases occurred more than once, 27.3 % required admission to hospital, and about three quarters of pregnancies with hypertension occurred in the 1st pregnancy (74.4 %).</p></sec><sec id="sec0010"><label>3.2</label><title>Unadjusted risk factors for AD pathology in midlife (<xref rid="tbl0002" ref-type="table">Table 2</xref>)</title><p id="para0028">Univariate analysis indicated that pregnancy hypertension was associated with a trend towards higher serum p-tau217 (<italic toggle="yes">p</italic> = 0.085) (<xref rid="tbl0002" ref-type="table">Table 2</xref>). Boxplots were generated to examine the distribution of serum p-tau217 levels of the participants with pregnancy hypertension (<italic toggle="yes">n</italic> = 68), and those without (<italic toggle="yes">n</italic> = 675) (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>). For subjects with pregnancy hypertension, the 25th percentile was 0.21 pg/ml, 50th percentile was 0.24 pg/ml and the 75th percentile was 0.31 pg/ml, whilst corresponding values for women without pregnancy hypertension were 0.21, 0.24, and 0.28 pg/ml respectively. Mean values for p-tau217 in women with pregnancy hypertension were 0.30 pg/ml compared to 0.26 pg/ml for those without.<table-wrap position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Participant characteristics by serum p-tau217 levels (<italic toggle="yes">n</italic> = 743).</p></caption><alt-text id="alt0005">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1">Characteristics</th><th colspan="3" align="left" valign="top" rowspan="1">P-tau217 (pg/ml)<hr/></th></tr><tr><th valign="top" colspan="1" rowspan="1">N ( %)</th><th valign="top" colspan="1" rowspan="1">Mean difference (95 % CI) or mean &#177; SD</th><th align="left" valign="top" colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Age, years</td><td valign="top" colspan="1" rowspan="1">743 (100.0)</td><td valign="top" colspan="1" rowspan="1">0.003 (0.002, 0.005)</td><td align="left" valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">Ethnicity</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.702</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Chinese</td><td valign="top" colspan="1" rowspan="1">591 (82.3)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.12</td><td rowspan="3" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Malay</td><td valign="top" colspan="1" rowspan="1">47 (6.5)</td><td valign="top" colspan="1" rowspan="1">0.25 &#177; 0.08</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Indian</td><td valign="top" colspan="1" rowspan="1">80 (11.1)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.08</td></tr><tr><td valign="top" colspan="1" rowspan="1">Highest education attainment</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.489</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No formal or primary</td><td valign="top" colspan="1" rowspan="1">90 (12.3)</td><td valign="top" colspan="1" rowspan="1">0.28 &#177; 0.13</td><td rowspan="3" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Secondary or post-secondary</td><td valign="top" colspan="1" rowspan="1">501 (68.5)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.11</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;University</td><td valign="top" colspan="1" rowspan="1">140 (19.2)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.11</td></tr><tr><td valign="top" colspan="1" rowspan="1">Gestational diabetes</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.583</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">93 (12.7)</td><td valign="top" colspan="1" rowspan="1">0.27 &#177; 0.10</td><td rowspan="2" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">641 (87.3)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.11</td></tr><tr><td valign="top" colspan="1" rowspan="1">Pregnancy hypertension</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.085</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">68 (9.2)</td><td valign="top" colspan="1" rowspan="1">0.30 &#177; 0.19</td><td rowspan="2" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">675 (90.8)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.10</td></tr><tr><td valign="top" colspan="1" rowspan="1">Breastfed</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.188</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">517 (71.3)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.10</td><td rowspan="2" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">208 (28.7)</td><td valign="top" colspan="1" rowspan="1">0.27 &#177; 0.13</td></tr><tr><td valign="top" colspan="1" rowspan="1">Parity</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.381</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Nulliparous</td><td valign="top" colspan="1" rowspan="1">16 (2.2)</td><td valign="top" colspan="1" rowspan="1">0.29 &#177; 0.10</td><td rowspan="2" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Parous</td><td valign="top" colspan="1" rowspan="1">727 (97.8)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.11</td></tr><tr><td valign="top" colspan="1" rowspan="1">Mild cognitive impairment</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.004</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">314 (42.3)</td><td valign="top" colspan="1" rowspan="1">0.28 &#177; 0.14</td><td align="left" valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">429 (57.7)</td><td valign="top" colspan="1" rowspan="1">0.25 &#177; 0.07</td><td align="left" valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Hypertension</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.009</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Yes</td><td valign="top" colspan="1" rowspan="1">355 (48.0)</td><td valign="top" colspan="1" rowspan="1">0.27 &#177; 0.13</td><td align="left" valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;No</td><td valign="top" colspan="1" rowspan="1">384 (52.0)</td><td valign="top" colspan="1" rowspan="1">0.25 &#177; 0.09</td><td align="left" valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Body mass index, kg/m<sup>2</sup></td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.004</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&lt;18.5</td><td valign="top" colspan="1" rowspan="1">27 (3.6)</td><td valign="top" colspan="1" rowspan="1">0.33 &#177; 0.18</td><td rowspan="4" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;18.5&#8211;23.0</td><td valign="top" colspan="1" rowspan="1">281 (37.9)</td><td valign="top" colspan="1" rowspan="1">0.27 &#177; 0.11</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&gt;23.0&#8211;27.4</td><td valign="top" colspan="1" rowspan="1">270 (36.4)</td><td valign="top" colspan="1" rowspan="1">0.25 &#177; 0.10</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8805;27.5</td><td valign="top" colspan="1" rowspan="1">164 (22.1)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.09</td></tr><tr><td valign="top" colspan="1" rowspan="1">Renal function (eGFR)</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&lt;60</td><td valign="top" colspan="1" rowspan="1">12 (1.6)</td><td valign="top" colspan="1" rowspan="1">0.42 &#177; 0.18</td><td rowspan="3" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;60&#8211;89</td><td valign="top" colspan="1" rowspan="1">151 (20.4)</td><td valign="top" colspan="1" rowspan="1">0.28 &#177; 0.11</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;&#8805;90</td><td valign="top" colspan="1" rowspan="1">578 (78.0)</td><td valign="top" colspan="1" rowspan="1">0.25 &#177; 0.11</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">APOE4</italic> genotype</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">0.004</td></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Carriers</td><td valign="top" colspan="1" rowspan="1">124 (16.7)</td><td valign="top" colspan="1" rowspan="1">0.29 &#177; 0.13</td><td rowspan="2" align="left" valign="top" colspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">&#160;Non-carriers</td><td valign="top" colspan="1" rowspan="1">617 (83.3)</td><td valign="top" colspan="1" rowspan="1">0.26 &#177; 0.10</td></tr></tbody></table><table-wrap-foot><fn><p>Results were analyzed using the general linear model, independent samples <italic toggle="yes">t</italic>-test or one-way ANOVA and presented as mean difference (95 % CI) or mean &#177; SD. Missing data accounted for 0.1 % to 3.4 % of the overall data.</p></fn></table-wrap-foot></table-wrap><fig id="fig0002" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Serum p-tau217 levels in the total cohort (<italic toggle="yes">n</italic> = 743), and in participants with (<italic toggle="yes">n</italic> = 68) and without pregnancy hypertension (<italic toggle="yes">n</italic> = 675). Boxplots reflect the minimum value, 25th, 50th, 75th percentiles, and maximum value. <sup>+</sup>indicates the mean values in each of the three groups.</p></caption><alt-text id="alt0002">Fig 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0002" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="para0029">In unadjusted analyses, contemporaneous factors associated with higher serum p-tau217 levels were older age, MCI, hypertension, <italic toggle="yes">lower</italic> body mass index, poorer renal function, and the <italic toggle="yes">APOE4</italic> genotype (<xref rid="tbl0002" ref-type="table">Table 2</xref>)<bold>.</bold> Ethnicity, educational attainment, gestational diabetes, breastfeeding and parity were not associated with serum p-tau217 levels.</p></sec><sec id="sec0011"><label>3.3</label><title>General linear modelling for independent factors associated with p-tau217 (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>)</title><p id="para0030"><xref rid="fig0003" ref-type="fig">Fig. 3</xref> shows independent factors associated with higher p-tau217 levels. General linear modelling showed that an older age [mean difference: 0.002 (95 % CI: 0.001, 0.003)], MCI [0.016 (0.001, 0.032)], lower BMI (&lt;18.5 kg/m<sup>2</sup>) [0.068 (0.027, 0.109)], and eGFR&lt;60 mL/min/1.73 m<sup>2</sup> [0.132 (0.072, 0.193)] were independently associated with higher serum p-tau217 levels. Subjects with <italic toggle="yes">APOE4</italic> carrier genotype had higher serum p-tau217 levels [0.038 (0.018, 0.058)]. History of pregnancy hypertension was significantly associated with subsequent higher serum p-tau217 [0.040 (0.013, 0.067)], after adjustment for age, MCI, hypertension, BMI, renal function, and <italic toggle="yes">APOE4</italic> genotype status (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>)<bold>.</bold><fig id="fig0003" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>General linear modelling showing the association between pregnancy hypertension and p-tau217 levels. Forest plot depicts the mean difference in p-tau217 (pg/ml) after mutual adjustment for age, MCI, hypertension, BMI, renal function, and <italic toggle="yes">APOE4</italic> genotype status in the same model. Results are presented as mean difference (95 % CI).</p></caption><alt-text id="alt0003">Fig 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="celink0003" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec></sec><sec id="sec0012"><label>4</label><title>Discussion</title><p id="para0031">We report that in community dwelling midlife women without dementia, a history of pregnancy hypertension increased risk for AD pathology many decades later. Higher serum p-tau217 levels were still observed in women with pregnancy hypertension after adjustment for age, MCI, hypertension, BMI, renal function, and <italic toggle="yes">APOE4</italic> carrier status. Our findings merit consideration that a history of hypertensive disorders in pregnancy is a potential risk factor for Alzheimer&#8217;s disease.</p><p id="para0032">To our knowledge, this is the first investigation into the relationship between the history of pregnancy hypertension and AD pathology many decades later. Pregnancy hypertension is a multisystemic disorder unmasked by the gravid state. Starting with hypertension in the second half of pregnancy, the disease progresses to pre-eclampsia and eclampsia, resulting in greater risk for the subsequent development of hypertension, ischemic heart disease, stroke, and dementia [<xref rid="bib0031" ref-type="bibr">31</xref>]. Cerebral blood velocity responses can be altered in women with a history of preeclampsia, linking impairments in cerebrovascular regulation to the structural and functional changes in the brain [<xref rid="bib0032" ref-type="bibr">32</xref>].</p><p id="para0033">Although cardiovascular disease, ministrokes and reduced cerebrovascular blood flow are recognized pathogenic mechanisms for Alzheimer&#8217;s disease [<xref rid="bib0033" ref-type="bibr">33</xref>], it has been postulated that disorders of pregnancy hypertension may contribute more directly to AD pathology in the brain [<xref rid="bib0034" ref-type="bibr">34</xref>]. Tau hyperphosphorylation has been observed in animal models of preeclampsia and may be early etiological drivers for both pregnancy hypertension and pre-clinical Alzheimer's disease [<xref rid="bib0035" ref-type="bibr">35</xref>]. Cis p-tau, an early etiological driver and blood biomarker in pre-clinical Alzheimer's have been reported to be higher in the placenta and serum of pre-eclampsia patients [<xref rid="bib0035" ref-type="bibr">35</xref>]. Concentrations for p-tau181 in cerebro-spinal fluid obtained following regional anesthesia during pregnancy were higher in subjects with severe pregnancy hypertension compared to those with normal blood pressure [<xref rid="bib0036" ref-type="bibr">36</xref>]. Women with preeclampsia demonstrated 2.18-fold higher plasma concentrations of neurofilament light chain, 2.17-fold higher tau and 2.77-fold higher glial fibrillary acidic protein compared to women with normotensive pregnancies [<xref rid="bib0037" ref-type="bibr">37</xref>]. These diverse lines of evidence suggest abnormalities of protein processing in preeclampsia that may increase risk for Alzheimer&#8217;s disease in later life.</p><p id="para0034">MCI is conceptualized as a transitional stage between normal aging and dementia. The MoCA-B tool, an instrument with good test&#8211;retest reliability and internal consistency [<xref rid="bib0022" ref-type="bibr">22</xref>], indicated a MCI prevalence of 42.3 % in our cohort of midlife women (mean age 62.9 &#177; 6.0 years), consistent with 36.2 % for subjects &#8805;55 years from a large Chinese study using MOCA [<xref rid="bib0038" ref-type="bibr">38</xref>]. Although a portion of these cases with MCI may be due to cerebral small vessel disease [<xref rid="bib0039" ref-type="bibr">39</xref>], our study suggests that Alzheimer's pathology contributes to MCI. Anticipating increased Alzheimer&#8217;s disease risk will allow women with a history of pregnancy hypertension to receive additional support, early intervention, and close monitoring.</p><p id="para0035">Our study needs to be interpreted considering several limitations. Firstly, pregnancy history was self-reported, which might be prone to recall bias since the events had a latency period of 32.1 years on average. Nevertheless, a study on low-birth-weight babies indicated 96.5 % sensitivity for pregnancy hypertension recall compared to that documented in obstetric case records [<xref rid="bib0040" ref-type="bibr">40</xref>]. Next, about 40 % of our cohort had MCI, which might have influenced reporting of pregnancy events. To address this, we have accounted for MCI as a covariate in adjusted analyses. We found that pregnancy hypertension was significantly associated with p-tau217 levels, independent of MCI. Thirdly, the cross-sectional design of this study makes it difficult to determine causality or temporality, although from a biological standpoint, pregnancy hypertension would naturally precede AD pathology. Fourth, although we have adjusted for current hypertension, MCI, renal function and <italic toggle="yes">APOE4</italic> carrier status; subjects with pregnancy hypertension may have other co-morbid conditions or residual confounders not considered in this study that increase risk for Alzheimer's disease. Fifth, the latency period (time since pregnancy) was not included as a covariate due to small numbers. Finally, our single center study identified only a relatively small number of subjects with pregnancy hypertension, which limit generalizability to other populations. There is a need to replicate our findings in other cohorts.</p><p id="para0036">A key strength of this study was the use of a serum p-tau217 immunoassay that has been validated to accurately identify Alzheimer&#8217;s disease, comparable with results using cerebral spinal fluid biomarkers and superior to brain atrophy assessments, with reproducible cut-offs across cohorts that can detect longitudinal changes at the preclinical stage [<xref rid="bib0016" ref-type="bibr">16</xref>,<xref rid="bib0041" ref-type="bibr">41</xref>,<xref rid="bib0042" ref-type="bibr">42</xref>]. Furthermore, key confounders such as age, MCI, hypertension, BMI, renal function, <italic toggle="yes">APOE4</italic> genotype, were accurately and rigorously quantified. If our findings are validated in other populations, one key implication is that obstetricians and primary care physicians should pay more attention to pregnancy hypertension as a risk factor for Alzheimer&#8217;s Disease and brain health.</p></sec><sec id="sec0013"><label>5</label><title>Conclusion</title><p id="para0037">In summary, pregnancy hypertension was associated with AD pathology with mean differences similar to high risk <italic toggle="yes">APOE4</italic> carrier genotypes. Premature placental aging underlies early-onset preeclampsia [<xref rid="bib0043" ref-type="bibr">43</xref>] and pregnancy may be a stress factor that unmasks a latent inability to clear misfolded A&#946; amyloid proteins, resulting in deposition of protein aggregates in the placenta and brain [<xref rid="bib0044" ref-type="bibr">44</xref>]. Abnormal dysregulation of protein homeostasis may be common to the development of both pregnancy hypertension and Alzheimer's disease [<xref rid="bib0044" ref-type="bibr">44</xref>]. Information on history of preeclampsia could help physicians to identify women who might benefit from early p-tau217 screening for Alzheimer&#8217;s disease, allowing for early clinical intervention [<xref rid="bib0035" ref-type="bibr">35</xref>].</p></sec><sec id="sec0014"><title>Author contributions</title><p id="para0038">Prof. Yong has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. <italic toggle="yes">Concept and design:</italic> Yong, Wong, Chong, Chen. <italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Yong, Wong, Tan, Shen, Thia. <italic toggle="yes">Drafting of the manuscript:</italic> Yong, Wong, Shen. <italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Yong, Wong, Tan, Shen, Chong, Chen. <italic toggle="yes">Statistical analysis:</italic> Wong, Shen, Thia. <italic toggle="yes">Obtained funding:</italic> Yong. <italic toggle="yes">Administrative, technical, or material support:</italic> Wong, Tan. <italic toggle="yes">Supervision:</italic> Yong, Chen.</p></sec><sec id="sec0015"><title>Funding</title><p id="para0039">This study was supported by the Singapore National Medical Research Council Grant (reference numbers: NMRC/CSASI/ 0010/2017 and NMRC/CSASI20nov-0006) to Eu-Leong Yong. The funders had no role in the study design, collection, analysis or interpretation of data.</p></sec><sec id="sec0016"><title>DATA sharing statement</title><p id="para0040">Data cannot be shared publicly because of ethical-legal considerations and consent was not sought from study participants for public data sharing. However, data is available from the corresponding author for researchers who meet the criteria for access to confidential data at obgyel@nus.edu.sg.</p></sec><sec id="sec0017"><title>Declaration of generative AI</title><p id="para0041">We declare that no generative AI and AI-assisted technologies were used in this manuscript.</p></sec><sec id="sec0017a"><title>CRediT authorship contribution statement</title><p id="para0041a"><bold>Eu-Leong Yong:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Funding acquisition, Conceptualization. <bold>Beverly Wen Xin Wong:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Project administration, Formal analysis, Conceptualization. <bold>Darren Yuen Zhang Tan:</bold> Writing &#8211; review &amp; editing, Project administration, Formal analysis. <bold>Liang Shen:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Formal analysis. <bold>Benecia Wan Qing Thia:</bold> Formal analysis. <bold>Joyce Ruifen Chong:</bold> Writing &#8211; review &amp; editing, Conceptualization. <bold>Christopher Li-Hsian Chen:</bold> Writing &#8211; review &amp; editing, Supervision, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0001"><title>Declaration of competing interest</title><p id="para0043">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Alzheimer's disease</article-title><source>Lancet</source><volume>397</volume><issue>10284</issue><year>Apr 24 2021</year><fpage>1577</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name name-style="western"><surname>Mielke</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ferretti</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Iulita</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khachaturian</surname><given-names>A.S.</given-names></name></person-group><article-title>Sex and gender in Alzheimer's disease - does it matter?</article-title><source>Alzheimers Dement</source><volume>14</volume><issue>9</issue><year>Sep 2018</year><fpage>1101</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.08.003</pub-id><pub-id pub-id-type="pmid">30196887</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Evaluation of selective survival and sex/gender differences in dementia incidence using a simulation model</article-title><source>JAMA Netw Open</source><volume>4</volume><issue>3</issue><year>Mar 1 2021</year><object-id pub-id-type="publisher-id">e211001</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.1001</pub-id><pub-id pub-id-type="pmcid">PMC7944377</pub-id><pub-id pub-id-type="pmid">33687445</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name name-style="western"><surname>Abheiden</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>van Doornik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aukes</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>C.J.</given-names></name></person-group><article-title>Hypertensive disorders of pregnancy appear not to be associated with Alzheimer's disease later in life</article-title><source>Dement Geriatr Cogn Dis Extra</source><volume>5</volume><issue>3</issue><year>2015</year><fpage>375</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">26557136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000439043</pub-id><pub-id pub-id-type="pmcid">PMC4637816</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Carey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mulcahy</surname><given-names>E.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kublickiene</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khashan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>P.</given-names></name></person-group><article-title>Hypertensive disorders of pregnancy and the risk of maternal dementia: a systematic review and meta-analysis</article-title><source>Am J Obstet Gynecol</source><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2024.01.013</pub-id><pub-id pub-id-type="pmid">38278201</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name name-style="western"><surname>Schliep</surname><given-names>K.C.</given-names></name><etal/></person-group><article-title>Association between hypertensive disorders of pregnancy and dementia: a systematic review and meta-analysis</article-title><source>Hypertension</source><volume>80</volume><issue>2</issue><year>2023</year><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">36345823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.122.19399</pub-id><pub-id pub-id-type="pmcid">PMC9851987</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name name-style="western"><surname>Theilen</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hollingshaus</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Schliep</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Varner</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Esplin</surname><given-names>M.S.</given-names></name></person-group><article-title>All-cause and cause-specific mortality after hypertensive disease of pregnancy</article-title><source>Obstetr Gynecol</source><volume>128</volume><issue>2</issue><year>2016</year><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0000000000001534</pub-id><pub-id pub-id-type="pmcid">PMC4961555</pub-id><pub-id pub-id-type="pmid">27400006</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name></person-group><article-title>Understanding pre-eclampsia using Alzheimer's etiology: an intriguing viewpoint</article-title><source>Am J Reproduct Immunol</source><volume>75</volume><issue>3</issue><year>2016</year><fpage>372</fpage><lpage>381</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/aji.12446</pub-id><pub-id pub-id-type="pmid">26585303</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name name-style="western"><surname>Sergeeva</surname><given-names>V.A.</given-names></name><etal/></person-group><article-title>The high-resolution mass spectrometry study of the protein composition of amyloid-like urine aggregates associated with preeclampsia</article-title><source>Eur J Mass Spectrometry</source><volume>26</volume><issue>2</issue><year>2020</year><fpage>158</fpage><lpage>161</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1469066719860076</pub-id><pub-id pub-id-type="pmid">31291787</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Valtanen</surname><given-names>R.S.</given-names></name><etal/></person-group><article-title>Conformation-dependent anti-A&#946; monoclonal antibody signatures of disease status and severity in urine of women with preeclampsia</article-title><source>Pregnancy Hypertens</source><volume>28</volume><year>2022</year><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">35183929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.preghy.2022.01.007</pub-id><pub-id pub-id-type="pmcid">PMC9133023</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name name-style="western"><surname>Buhimschi</surname><given-names>I.A.</given-names></name><etal/></person-group><article-title>Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia</article-title><source>Sci Transl Med</source><volume>6</volume><issue>245</issue><year>2014</year><fpage>245ra92</fpage><comment>-245ra92</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3008808</pub-id><pub-id pub-id-type="pmid">25031267</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name name-style="western"><surname>Alomar-Dominguez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lederer</surname><given-names>W.</given-names></name></person-group><article-title>High beta-amyloid (1&#8211;40) cerebrospinal fluid concentrations precede increase of serum biomarkers in a case with severe HELLP syndrome</article-title><source>Placenta</source><volume>158</volume><year>2024</year><fpage>102</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">39418969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.placenta.2024.10.005</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name name-style="western"><surname>Lederer</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Cerebrospinal beta-amyloid peptides (1-40) and (1-42) in severe preeclampsia and HELLP syndrome&#8211;a pilot study</article-title><source>Sci Rep</source><volume>10</volume><issue>1</issue><year>2020</year><fpage>5783</fpage><pub-id pub-id-type="pmid">32238862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-62805-2</pub-id><pub-id pub-id-type="pmcid">PMC7113242</pub-id></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name name-style="western"><surname>Van Dijk</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The pre-eclampsia gene STOX1 controls a conserved pathway in placenta and brain upregulated in late-onset Alzheimer's disease</article-title><source>Journal of Alzheimer&#8217;s Disease</source><volume>19</volume><issue>2</issue><year>2010</year><fpage>673</fpage><lpage>679</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2010-1265</pub-id><pub-id pub-id-type="pmid">20110611</pub-id></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Blood biomarkers to detect Alzheimer disease in primary care and secondary care</article-title><source>JAMA</source><volume>332</volume><issue>15</issue><year>2024</year><fpage>1245</fpage><lpage>1257</lpage><pub-id pub-id-type="pmid">39068545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.13855</pub-id><pub-id pub-id-type="pmcid">PMC11284636</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><etal/></person-group><article-title>Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology</article-title><source>JAMA Neurol</source><volume>81</volume><issue>3</issue><year>2024</year><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">38252443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.5319</pub-id><pub-id pub-id-type="pmcid">PMC10804282</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><etal/></person-group><article-title>P-tau217 correlates with neurodegeneration in Alzheimer&#8217;s disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy</article-title><source>Neuron</source><volume>112</volume><issue>10</issue><year>2024</year><fpage>1676</fpage><lpage>1693.e12</lpage><pub-id pub-id-type="pmid">38513667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2024.02.017</pub-id></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>van der Kant</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O.</given-names></name></person-group><article-title>Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials</article-title><source>Lancet Neurol</source><volume>21</volume><issue>8</issue><year>2022</year><fpage>726</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">35643092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(22)00168-5</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease</article-title><source>Alzheimers Dement</source><volume>21</volume><issue>2</issue><year>2025</year><object-id pub-id-type="publisher-id">e14502</object-id><pub-id pub-id-type="doi">10.1002/alz.14502</pub-id><pub-id pub-id-type="pmcid">PMC11848187</pub-id><pub-id pub-id-type="pmid">39807654</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Thu</surname><given-names>W.P.P.</given-names></name><name name-style="western"><surname>Logan</surname><given-names>S.J.S.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Cauley</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>E.L.</given-names></name></person-group><article-title>Cohort Profile: the Integrated Women's Health Programme (IWHP): a study of key health issues of midlife Singaporean women</article-title><source>Int J Epidemiol</source><volume>47</volume><issue>2</issue><year>2018</year><fpage>389</fpage><lpage>390f</lpage><pub-id pub-id-type="doi">10.1093/ije/dyx278</pub-id><pub-id pub-id-type="pmid">29415269</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name name-style="western"><surname>Therriault</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology</article-title><source>EBioMedicine</source><volume>102</volume><year>2024</year><object-id pub-id-type="publisher-id">105046</object-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2024.105046</pub-id><pub-id pub-id-type="pmcid">PMC10943661</pub-id><pub-id pub-id-type="pmid">38471397</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name name-style="western"><surname>Julayanont</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The montreal cognitive assessment&#8212;Basic: a screening tool for mild cognitive impairment in illiterate and low-educated elderly adults</article-title><source>J Am Geriatr Soc</source><volume>63</volume><issue>12</issue><year>2015</year><fpage>2550</fpage><lpage>2554</lpage><pub-id pub-id-type="pmid">26648041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.13820</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>K.</given-names></name></person-group><article-title>Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies</article-title><source>The lancet</source><year>2004</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(03)15268-3</pub-id><pub-id pub-id-type="pmid">14726171</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name name-style="western"><surname>Inker</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>New creatinine-and cystatin C&#8211;based equations to estimate GFR without race</article-title><source>New England Journal of Medicine</source><volume>385</volume><issue>19</issue><year>2021</year><fpage>1737</fpage><lpage>1749</lpage><pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Knicely</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Grams</surname><given-names>M.E.</given-names></name></person-group><article-title>Chronic kidney disease diagnosis and management: a review</article-title><source>JAMA</source><volume>322</volume><issue>13</issue><year>2019</year><fpage>1294</fpage><lpage>1304</lpage><pub-id pub-id-type="pmid">31573641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.14745</pub-id><pub-id pub-id-type="pmcid">PMC7015670</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Kidney disease: improving global outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease</article-title><source>Kidney Int Suppl (2011)</source><volume>3</volume><issue>1</issue><year>2013</year><fpage>1</fpage><lpage>150</lpage></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name name-style="western"><surname>Chai</surname><given-names>Y.L.</given-names></name><etal/></person-group><article-title>Apolipoprotein &#603;4 is associated with dementia and cognitive impairment predominantly due to Alzheimer&#8217;s disease and not with vascular cognitive impairment: a Singapore-based cohort</article-title><source>J Alzheimer's Disease</source><volume>51</volume><issue>4</issue><year>2016</year><fpage>1111</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">26923016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150902</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name name-style="western"><surname>Koutsodendris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name></person-group><article-title>Apolipoprotein E and Alzheimer's disease: findings, hypotheses, and potential mechanisms</article-title><source>Annu Rev Pathol</source><volume>17</volume><year>2022</year><fpage>73</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-030421-112756</pub-id><pub-id pub-id-type="pmid">34460318</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name name-style="western"><surname>Bornhorst</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Quantitative assessment of the effect of chronic kidney disease on plasma P-Tau217 concentrations</article-title><source>Neurology</source><volume>104</volume><issue>3</issue><year>2025</year><object-id pub-id-type="publisher-id">e210287</object-id><pub-id pub-id-type="doi">10.1212/WNL.0000000000210287</pub-id><pub-id pub-id-type="pmcid">PMC11744813</pub-id><pub-id pub-id-type="pmid">39823562</pub-id></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Nianogo</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Rosenwohl-Mack</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>D.E.</given-names></name></person-group><article-title>Risk factors associated with Alzheimer disease and related dementias by sex and race and ethnicity in the US</article-title><source>JAMA Neurol</source><volume>79</volume><issue>6</issue><year>2022</year><fpage>584</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.0976</pub-id><pub-id pub-id-type="pmid">35532912</pub-id><pub-id pub-id-type="pmcid">PMC9086930</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name name-style="western"><surname>Erez</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Preeclampsia and eclampsia: the conceptual evolution of a syndrome</article-title><source>Am J Obstet Gynecol</source><volume>226</volume><issue>2</issue><year>2022</year><fpage>S786</fpage><lpage>S803</lpage><pub-id pub-id-type="pmid">35177220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2021.12.001</pub-id><pub-id pub-id-type="pmcid">PMC8941666</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>J.N.</given-names></name></person-group><article-title>Pregnancy history, hypertension, and cognitive impairment in postmenopausal women</article-title><source>Curr Hypertens Rep</source><volume>21</volume><issue>12</issue><year>2019</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11906-019-0997-9</pub-id><pub-id pub-id-type="pmcid">PMC6861362</pub-id><pub-id pub-id-type="pmid">31741134</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name name-style="western"><surname>Beckett</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>McFadden</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Warrington</surname><given-names>J.P.</given-names></name></person-group><article-title>Preeclampsia history and postpartum risk of cerebrovascular disease and cognitive impairment: potential mechanisms</article-title><source>Front Physiol</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1141002</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2023.1141002</pub-id><pub-id pub-id-type="pmcid">PMC10102351</pub-id><pub-id pub-id-type="pmid">37064920</pub-id></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name name-style="western"><surname>Puri</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Galea</surname><given-names>L.A.</given-names></name></person-group><article-title>Beyond sex differences: short-and long-term effects of pregnancy on the brain</article-title><source>Trends Neurosci</source><volume>46</volume><issue>6</issue><year>2023</year><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">37120339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tins.2023.03.010</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Jash</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Cis P-tau is a central circulating and placental etiologic driver and therapeutic target of preeclampsia</article-title><source>Nat Commun</source><volume>14</volume><issue>1</issue><year>2023</year><fpage>5414</fpage><pub-id pub-id-type="pmid">37669931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-41144-6</pub-id><pub-id pub-id-type="pmcid">PMC10480164</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name name-style="western"><surname>Lederer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dominguez</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Popovscaia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Putz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Humpel</surname><given-names>C.</given-names></name></person-group><article-title>Cerebrospinal fluid levels of tau and phospho-tau-181 proteins during pregnancy</article-title><source>Pregnancy Hypertension: Int J Women's Cardiovascular Health</source><volume>6</volume><issue>4</issue><year>2016</year><fpage>384</fpage><lpage>387</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.preghy.2016.08.243</pub-id><pub-id pub-id-type="pmid">27939487</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name name-style="western"><surname>Bergman</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Cerebral biomarkers in neurologic complications of preeclampsia</article-title><source>Am J Obstet Gynecol</source><volume>227</volume><issue>2</issue><year>2022</year><fpage>298.e1</fpage><lpage>298.e10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2022.02.036</pub-id><pub-id pub-id-type="pmid">35257666</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A comparison of the mini-mental state examination (MMSE) with the montreal cognitive assessment (MOCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study</article-title><source>BMC Psychiatry</source><volume>21</volume><issue>1</issue><year>2021</year><fpage>485</fpage><pub-id pub-id-type="doi">10.1186/s12888-021-03495-6</pub-id><pub-id pub-id-type="pmid">34607584</pub-id><pub-id pub-id-type="pmcid">PMC8489046</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name name-style="western"><surname>Hilal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>V.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.L.-H.</given-names></name></person-group><article-title>Prevalence, risk factors and consequences of cerebral small vessel diseases: data from three Asian countries</article-title><source>J Neurol, Neurosurg Psychiatry</source><volume>88</volume><issue>8</issue><year>2017</year><fpage>669</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">28600443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2016-315324</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Delgado-Rodr&#237;guez</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#243;mez-Olmedo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bueno-Cavanillas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mart&#237;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#225;lvez-Vargas</surname><given-names>R.</given-names></name></person-group><article-title>Recall bias in a `1`case-control study of low birth weight</article-title><source>J Clin Epidemiol</source><volume>48</volume><issue>9</issue><year>1995</year><fpage>1133</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">7636515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0895-4356(94)00241-h</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name name-style="western"><surname>Kirsebom</surname><given-names>B.E.</given-names></name><etal/></person-group><article-title>Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity</article-title><source>Alzheimers Dement</source><volume>21</volume><issue>5</issue><year>2025</year><object-id pub-id-type="publisher-id">e70319</object-id><pub-id pub-id-type="doi">10.1002/alz.70319</pub-id><pub-id pub-id-type="pmcid">PMC12122256</pub-id><pub-id pub-id-type="pmid">40442871</pub-id></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name name-style="western"><surname>Selma-Gonzalez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Association of plasma phosphorylated Tau 217 with clinical deterioration across Alzheimer disease stages</article-title><source>Neurology</source><volume>105</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">e213769</object-id><pub-id pub-id-type="doi">10.1212/WNL.0000000000213769</pub-id><pub-id pub-id-type="pmid">40472304</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name name-style="western"><surname>Maiti</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Evidence that fetal death is associated with placental aging</article-title><source>Am J Obstet Gynecol</source><volume>217</volume><issue>4</issue><year>2017</year><fpage>441.e1</fpage><lpage>441.e14</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2017.06.015</pub-id><pub-id pub-id-type="pmid">28645573</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name name-style="western"><surname>Cater</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Human pregnancy zone protein stabilizes misfolded proteins including preeclampsia-and Alzheimer&#8217;s-associated amyloid beta peptide</article-title><source>Proc National Acad Sci</source><volume>116</volume><issue>13</issue><year>2019</year><fpage>6101</fpage><lpage>6110</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1817298116</pub-id><pub-id pub-id-type="pmcid">PMC6442606</pub-id><pub-id pub-id-type="pmid">30850528</pub-id></element-citation></ref></ref-list><sec id="sec0019" sec-type="supplementary-material"><label>Appendix</label><title>Supplementary materials</title><p id="para0042a">
<supplementary-material content-type="local-data" id="ecom0001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Image, application 1</alt-text></media></supplementary-material>
</p></sec><ack id="ack0001"><title>Acknowledgements</title><p id="para0044">The authors thank the Agency for Science, Technology and Research (A*STAR)'s Singapore Immunology Network (SIgN) Multiplex Analysis of Proteins (MAP) platform for enabling the Luminex work for this publication. A*STAR's SIgN MAP platform is supported by research grants including the Biomedical Research Council (BMRC) grant and the <funding-source id="gs00001"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000964</institution-id><institution>National Research Foundation</institution></institution-wrap></funding-source> (NRF), Immunomonitoring Service Platform (Ref: <award-id award-type="grant" rid="gs00001">ISP: NRF2017_SISFP09</award-id>) grant.</p></ack><fn-group><fn id="sec0018" fn-type="supplementary-material"><p id="para0010a">Supplementary material associated with this article can be found, in the online version, at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tjpad.2025.100316" id="interref0001">doi:10.1016/j.tjpad.2025.100316</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>